collection_id	dataset_id	subjectkey	src_subject_id	interview_date	interview_age	gender	visitid	visit	truncvis	phase_ct	visday	qol01a	qol01b	qol01c	qol01d	qol01e	qol01f	qol01g	qol02	qol03	qol04	qol05	qol06	qol07	qol08	qol09	qol10	qol11	qol12	qol13	qol14	qol15	qol16	qol17	qol18	qol19	qol20	qol21	qol22	qol23a	qol23b	qol23c	qol23d	qol24a	qol24b	qol24c	qol24d	qol25a	qol25b	qol25c	qol25d	qol25e	qol25f	qol25g	qol25h	qol25ia	qol25ib	qol25ic	qol25id	qol25ie	qol25if	qol25ig	qol25j1	qol25j2	qol25j3	qol25j4	qol26a	qol26aa	qol26b	qol26ba	qol26c	qol26ca	qol26d	qol26da	qol26e	qol26ea	qol27a	qol27b	qol27c	qol28a	qol28b	qol28c	qol28d	qol28e	qol29a	qol29b	qol29c	qol29d	qol30a	qol30b	qol30c	qol30d	qol31	intr_rel	inst_rol	intr_fou	com_obj	qol_tot	base1	last1	b1_qol	b1_qrel	b1_qins	b1_qpsy	b1_qobj	c1_qol	c1_qrel	c1_qins	c1_qpsy	c1_qobj	visitday	fseqno	version_form	daysrz	bliwqlpf	iwql_pf	chiwqlpf	bliwqlse	iwql_se	chiwqlse	bliwqlsl	iwql_sl	chiwqlsl	bliwqlpd	iwql_pd	chiwqlpd	bliwqlwk	iwql_wk	chiwqlwk	bliwqlt	iwql_t	chiwqlt	iwqa1	iwqa2	iwqa3	iwqa4	iwqa5	iwqa6	iwqa7	iwqa8	iwqa9	iwqa10	iwqa11	iwqa12	iwqa13	iwqa14	iwqa15	iwqa16	iwqa17	iwqa18	iwqa19	iwqa20	iwqa21	iwqa22	iwqa23	iwqa24	iwqa25	iwqa26	iwqa27	iwqa28	iwqa29	iwqa30	iwqa31	week_psych	mpdat	vis_type	health1	hlth_sat	esteem	est_sat	goal	goal_sat	money	mon_sat	work	work_sat	play	play_sat	learn	lrn_sat	creat	cre_sat	help1	help_sat	love	love_sat	friends1	frnd_sat	children	chld_sat	relativs	rel_sat	home	home_sat	neighbor	nbr_sat	commty	comm_sat	site	comments	doa_futdt	dode	dode_futdt	form_completed	form_explain	other_reason_nc	assessment_complete	protocol_summary	d1reltsx	d2roltsx	d3foutsx	d4comtsx	qlstsx	a1reltsx	a2roltsx	a3foutsx	a1relts	a2rolts	a3fouts	days_baseline	monthsbl	treatment_name	rand_num	ql_play	ql_vocnotapp	ql_mtravel	collection_title	promoted_subjectkey
collection_id	dataset_id	The NDAR Global Unique Identifier (GUID) for research subject	Subject ID how it's defined in lab/project	Date on which the interview/genetic test/sampling/imaging was completed. MM/DD/YYYY	Age in months at the time of the interview/test/sampling/imaging.	Sex of the subject	MetaTrial Visit ID	Visit name	Truncated Visit Number	Current Phase. Phase patient was in at the time of the assessment Phase 4 refers to the follow-up phase.	Number of days from study baseline to date of visit	Currently live with parent	Currently live with a spouse/girlfriend/boyfriend	Currently live with a sibling	Currently live with a son or daughter	Currently live with other relatives	Currently live with other people not related and not friends	Lives alone	2. Intimate relationship with household members	3. Intimate relationships	4. Active acquaintances	5. Level of social activity	6. Involved social network	7. Social initiatives	8. Social withdrawal	9. Sociosexual relations	10. Extent of occupational role function	11. Level of accomplishment	12. Degree of underemployment	13. Satisfaction with occupational funct	14. Sense of purpose	15. Degree of motivation	16. Curiosity	17. Anhedonia	18. Time utilization	19. Commonplace objects	20. Commonplace activities	21. Capacity for empathy	22. Capacity for engagement and interact	23a. Shopping	23b. Go to restaurant/coffee shop	23c. Prepare meal	23d. Hobby	24a. Wash two or more times	24b. Clean room/apartment	24c. Do own laundry	24d. Help with chores	25a. Spend time with one or more family	25b. Feel listened to	25c. Close friends who are not family me	25d. Do anything with these close friend	25e. Visit with someone not living with	25f. Do something with another person that you planned ahead of time	25g. Spend time with boyfriend/girlfriend	25h. Someone who helps with mental treatment	25i. Who helps you? spouse/boyfriend/girlfriend	Who helps you? Parent/grandparent	Who helps you? Sibling	Who helps you?Other relative	Who helps you? Friend	Who helps you? Other	Who helps you? No one	25j1. Remind you of appointments	25j2. Take you to appointments	25j3. Remind you to take medication	25j4. Give you medication to take	26a. Independent living	26aa. Days	26b. Minimally structured residence	26ba. Days	26c. Moderately restrictive residence	26ca. Days	26d. Extremely restrictive residence	26da. Days	26e. Homeless	26ea. Days	27a. Attend college full or part time	27b. Work on GED	27c. Formal worksite/vocational training	28a. Competitive vocational activity	28b. Substantial vocational activity	28c. Moderate vocational activity	28d. Prevocational activity	28e. No vocational activity	29a. violent crime	29b. non-violent crime	29c. arrest or picked up for any crime	29d. spend any nights in jail	30a. food	30b. clothing	30c. housing	30d. transportation	31. How do you feel about your life in g	Interpersonal Relations Subscale	Instrumental Role Subscale	Intrapsychic Foundations Subscale	Common Objects and Activities Subscale	QOL Total Score by Mean of 21 items	Flag Baseline Phase 1/1A Visit	Flag Last Phase 1/1A Visit	Phase 1 Baseline QOL Total Score	Phase 1 Baseline QOL Interpersonal Relation	Phase 1 Baseline QOL Instrumental Role Score	Phase 1 Baseline QOL Intrapsychic Foundation	Phase 1 Baseline QOL Common Objects and Activities	Phase 1 CFB QOL Total Score	Phase 1 CFB QOL Interpersonal Relations	Phase 1 CFB QOL Instrumental Role Score	Phase 1 CFB QOL Intrapsychic Foundations	Phase 1 CFB QOL Common Objects and Activities	day of visit	Sequence Number	Form used	days since randomization	Baseline IWQOL Physical Function Score	IWQOL-Physical Function Score	Change from baseline in IWQOL Physical Function Score	Baseline IWQOL Self Esteem Score	IWQOL-Self Esteem Score	Change from baseline in IWQOL Self Esteem Score	Baseline IWQOL Sexual Life Score	IWQOL-Sexual Life Score	Change from baseline in IWQOL Sexual Life Score	Baseline IWQOL Public Distress Score	IWQOL-Public Distress Score	Change from baseline in IWQOL Public Distress Score	Baseline IWQOL Work Score	IWQOL-Work Score	Change from baseline in IWQOL Work Score	Baseline IWQOL Total Score	IWQOL-Total Score	Change from baseline in IWQOL Total Score	Because of my weight I have trouble picking up objects	Because of my weight I have trouble tying my shoes	Because of my weight I have difficulty getting up from chairs	Because of my weight I have trouble using stairs	Because of my weight I have difficulty putting on or taking off my clothing	Because of my weight I have trouble with mobility	Because of my weight I have trouble crossing my legs	I feel short of breath with only mild exertion	I am troubled by painful or stiff joints	My ankles and lower legs are swollen at the end of the day	I am worried about my health	Because of my weight I am self-conscious	Because of my weight my self-esteem is not what it could be	Because of my weight I feel unsure of myself	Because of my weight I don't like myself	Because of my weight I am afraid of being rejected	Because of my weight I avoid looking in mirrors or seeing myself in photographs	Because of my weight I am embarrassed to be seen in public places	Because of my weight I do not enjoy sexual activity	Because of my weight I have little or no sexual desire	Because of my weight I have difficulty with sexual performance	Because of my weight I avoid sexual encounters whenever possible	Because of my weight I experience ridicule, teasing, or unwanted attention	Because of my weight I worry about fitting into seats in public places (e.g., theaters, restaurants, cars, or airplanes)	Because of my weight I worry about fitting through aisles or turnstiles	Because of my weight I worry about finding chairs that are strong enough to hold my weight	Because of my weight I experience discrimination by others	Because of my weight I have trouble getting things accomplished or meeting my responsibilities	Because of my weight I am less productive than I could be	Because of my weight I don't receive appropriate raises, promotions or recognition at work	Because of my weight I am afraid to go on job interviews	Week	days from enrollment	Visit type	Importance of health	Health satisfaction	Importance of self-esteem	Self-esteem satisfaction	Importance of goals and values	Goals and values satisfaction	Importance of money	Money satisfaction	Importance of work	Work satisfaction	Importance of play	Play satisfaction	Importance of learning	Learning satisfaction	Importance of creativity	Creativity satisfaction	Importance of helping	Helping satisfaction	Importance of love	Love satisfaction	Importance of friends	Friends satisfaction	Importance of children	Children satisfaction	Importance of relatives	Relative satisfaction	Importance of home	Home satisfaction	Importance of neighborhood	Neighborhood satisfaction	Importance of community	Community satisfaction	Site	Comments about assessment	Future date entered (Assessment)	Date of Data Entry	Future date entered (Data Entry)	Was the form completed?	Why was this form not completed?	Other reason form was not completed	Complete?	Protocol summary	Interpersonal Relations Subscale Mean score	Instrumental Role Subscale Mean score	Intrapsychic Foundations Subscale Mean score	Common Objects and Activities Subscale  Mean score	Mean Total Score	Alternative Interpersonal Relations Subscale Mean score	Alternative Instrumental Role Subscale Mean score	Alternative Intrapsychic Foundations Subscale Mean score	Alternative Interpersonal Relations Subscale	Alternative Instrumental Role Subscale	Alternative Intrapsychic Foundations Subscale	Days since baseline	Actual number of months from Baseline	treatment name	Randomization Number	QOL 23c: leisure activities, play	QOL 28f: work activity, not developmentally appropriate	QOL 30d: finances, enough money for traveling around	collection_title	promoted_subjectkey
2081	8976	NDAR_INVAA412BBY	2341			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	0	0	1	2	0	0	0	0	0	0	9	0	6	4	4	4	5	4	5	5	0	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	14	0		0		1	16	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1	0	4	4.5	2.25	1		2.25	1	0	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAA412BBY
2081	8976	NDAR_INVAB125GA8	2667			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	4	5	6	6	6	0	1	5	6	9	6	6	4	6	0	5	4	6	6	1	0	1	1	1	1	1	1	1	1	1	3	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.75	3	4.857143	4.5	4.65	1		4.65	4.75	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB125GA8
2081	8976	NDAR_INVAB125GA8	2667			M	1600	Visit6	6	Phase 3	147	1	0	0	0	0	0	0	6	6	6	6	6	6	5	0	2	5	6	9	3	6	2	6	4	5	4	6	6	1	1	1	0	1	1	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		2	2	2	0	0	0	1	0	0	0	0	0	1	1	1	1	5	5.125	3.25	4.714286	4.5	4.8			4.65	4.75	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB125GA8
2081	8976	NDAR_INVAB125GA8	2667			M	2800	Visit12	12	Phase 3	314	1	0	0	0	0	0	0	6	6	6	6	5	6	6	0	4	6	6	6	4	6	2	6	5	5	4	6	6	1	1	1	1	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	6	5.125	5.5	5	4.5	5.095238			4.65	4.75	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB125GA8
2081	8976	NDAR_INVAB125GA8	2667			M	5200	EndofPhase1_1a	1	Phase 1/1A	19	1	0	0	0	0	0	0	6	5	4	4	5	4	5	0	4	4	6	6	3	5	3	4	4	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	3	2	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.125	5	4.428571	5	4.4761906		1	4.65	4.75	3	4.857143	4.5	-0.17380953	-0.625	2	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB125GA8
2081	8976	NDAR_INVAB125GA8	2667			M	5800	EndofPhase2	5	Phase 2	117	1	0	0	0	0	0	0	6	5	5	5	4	5	6	2	3	2	1	3	0	3	4	3	4	5	4	5	4	0	1	1	0	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.75	2.25	3.2857144	4.5	3.7619047			4.65	4.75	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB125GA8
2081	8976	NDAR_INVAB125GA8	2667			M	6000	EndofPhase3	18	Phase 3	489	1	0	0	0	0	0	0	6	6	6	6	5	6	6	0	4	6	6	6	5	6	4	6	5	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	4	1	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	5	5.125	5.5	5.428571	5.5	5.3333335			4.65	4.75	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB125GA8
2081	8976	NDAR_INVAB164FVP	2808			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	2	0	6	2	2	2	0	4	3	9	6	5	3	4	4	6	4	6	6	0	0	1	1	1	1	1	1	1	1	1	3	2	3	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	1.75	4.857143	5	3.75	1		3.75	3	1.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB164FVP
2081	8976	NDAR_INVAB164FVP	2808			F	1600	Visit6	6	Phase 1B	167	1	0	0	0	0	0	0	6	4	4	5	4	5	5	2	4	5	4	4	4	4	6	5	5	6	4	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	4.25	5.142857	5	4.6666665			3.75	3	1.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB164FVP
2081	8976	NDAR_INVAB164FVP	2808			F	2800	Visit12	12	Phase 1B	336	1	0	0	0	0	0	0	5	5	5	5	5	6	5	6	5	5	4	3	4	4	5	5	5	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	5.25	4.25	5	5	4.952381			3.75	3	1.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB164FVP
2081	8976	NDAR_INVAB164FVP	2808			F	5200	EndofPhase1_1a	2	Phase 1/1A	42	1	0	0	0	0	0	0	6	2	2	3	6	1	1	1	1	0	1	9	1	3	3	2	4	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	3	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.75	0.5	3.5714285	5.5	3		1	3.75	3	1.75	4.857143	5	-0.75	-0.25	-1.25	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB164FVP
2081	8976	NDAR_INVAB164FVP	2808			F	5400	EndofPhase1b	18	Phase 1B	505	1	0	0	0	0	0	0	6	3	3	3	3	3	3	3	5	5	5	6	4	4	4	6	5	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.375	5.25	5	6	4.5238094			3.75	3	1.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB164FVP
2081	8976	NDAR_INVAB580MK8	2748			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	2	1	0	0	2	2	0	0	0	9	0	0	2	2	2	3	2	5	5	0	0	0	0	1	0	2	2	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	7	1.625	0	2.2857144	2.5	1.7	1		1.7	1.625	0	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB580MK8
2081	8976	NDAR_INVAB580MK8	2748			M	1600	Visit6	6	Phase 1/1A	187	0	0	0	0	0	1	0	5	6	4	5	5	5	6	5	0	0	0	9	2	3	2	4	1	3	1	5	5	0	1	0	0	1	1	0	0	3	1	1	2	1	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.125	0	3.142857	2	3.35			1.7	1.625	0	2.2857144	2.5	1.65	3.5	0	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB580MK8
2081	8976	NDAR_INVAB580MK8	2748			M	2800	Visit12	12	Phase 1/1A	362	0	0	0	0	0	1	0	4	3	3	3	2	3	3	1	0	0	0	9	2	1	2	2	1	2	2	3	2	1	1	0	0	1	2	1	2	3	2	1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	0	1.8571428	2	1.95			1.7	1.625	0	2.2857144	2.5	0.25	1.125	0	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB580MK8
2081	8976	NDAR_INVAB580MK8	2748			M	5200	EndofPhase1_1a	18	Phase 1/1A	558	0	0	0	0	0	1	0	4	3	4	4	3	3	3	1	0	0	0	9	2	1	2	5	1	4	2	4	3	1	1	0	0	1	1	1	1	3	2	1	3	1	2	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.125	0	2.5714285	3	2.45		1	1.7	1.625	0	2.2857144	2.5	0.75	1.5	0	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB580MK8
2081	8976	NDAR_INVAB636BG0	1117			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	0	3	2	0	2	2	0	2	6	9	4	3	4	2	2	4	3	4	4	1	1	1	0	1	1	1	2	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	3	1.375	2	3.2857144	3.5	2.45	1		2.45	1.375	2	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB636BG0
2081	8976	NDAR_INVAB636BG0	1117			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	5	0	0	2	2	2	2	1	1	3	4	9	0	2	2	5	4	6	4	5	5	1	1	0	1	1	1	1	1	2	1	0	4	4	3	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	2	3.2857144	5	2.75			2.45	1.375	2	3.2857144	3.5	0.3	0.375	0	0	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB636BG0
2081	8976	NDAR_INVAB636BG0	1117			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	0	1	6	0	2	2	2	2	2	1	6	4	6	4	4	2	4	5	5	6	6	5	4	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	1	0	0	0	0	1	1	1	1	5	2.125	5	4.142857	6	3.7142856			2.45	1.375	2	3.2857144	3.5	1.2642857	0.75	3	0.85714287	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB636BG0
2081	8976	NDAR_INVAB636BG0	1117			M	4000	Visit18	18	Phase 1/1A	530	0	0	0	0	0	0	1	6	2	4	5	4	4	4	2	5	2	6	6	4	3	3	5	4	6	5	4	5	1	1	1	1	1	1	1	1	2	1	1	2	3	4	2	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.875	4.75	4	5.5	4.2380953		1	2.45	1.375	2	3.2857144	3.5	1.7880952	2.5	2.75	0.71428573	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAB636BG0
2081	8976	NDAR_INVAC199RGN	2676			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	3	0	3	3	2	3	2	0	2	4	5	9	3	3	3	1	3	3	2	2	2	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1		2	2.75	2.4285715	2.5	2.45	1		2.45	2	2.75	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAC199RGN
2081	8976	NDAR_INVAC199RGN	2676			F	5200	EndofPhase1_1a	17	Phase 1/1A	486	0	0	0	1	0	0	0	6	5	6	3	4	5	5	2	2	5	4	9	0	3	1	4	4	2	1	1	3									1		1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0						4.5	2.75	2.2857144	1.5	3.3		1	2.45	2	2.75	2.4285715	2.5	0.85	2.5	0	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAC199RGN
2081	8976	NDAR_INVAC503FLF	2343			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	2	0	2	2	3	1	1	1	3	9	1	2	0	2	2	3	2	4	4	2	2	2	1	1	1	0	1	2	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2	1.25	2.142857	2.5	2.05	1		2.05	2	1.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAC503FLF
2081	8976	NDAR_INVAC503FLF	2343			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	1	0	4	6	4	6	2	4	6	4	1	1	1	9	3	2	0	4	4	3	2	4	4	0	1	0	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.5	0.75	3	2.5	3.25			2.05	2	1.25	2.142857	2.5	1.2	2.5	-0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAC503FLF
2081	8976	NDAR_INVAC503FLF	2343			M	2800	Visit12	12	Phase 1/1A	331	1	0	0	0	0	0	0	6	4	4	5	5	4	5	2	2	2	1	9	3	5	3	4	2	3	3	5	4	0	1	1	0	1	1	0	1	2	1	1	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.375	1.25	3.7142856	3	3.6			2.05	2	1.25	2.142857	2.5	1.55	2.375	0	1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAC503FLF
2081	8976	NDAR_INVAC503FLF	2343			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	1	0	0	0	0	0	0	5	3	2	5	5	3	5	2	1	1	1	9	2	5	1	5	2	3	3	4	6	1	0	0	1	1	1	0	1	1	1	1	3	3	3	3	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	0.75	3.5714285	3	3.2		1	2.05	2	1.25	2.142857	2.5	1.15	1.75	-0.5	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAC503FLF
2081	8976	NDAR_INVAD098BRG	1395			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	4	5	4	2	6	2	0	5	1	9	2	2	5	2	4	5	3	6	6	1	0	1	1	1	0	1	1	1	1	1	3	4	2	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	2	4.125	1.5	3.857143	4	3.7	1		3.7	4.125	1.5	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD098BRG
2081	8976	NDAR_INVAD098BRG	1395			F	1600	Visit6	6	Phase 1/1A	169	1	0	0	1	1	0	0	6	6	5	4	6	4	6	4	4	5	4	3	5	6	6	6	6	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	2	3	3	1	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	5	5.125	4	5.857143	5.5	5.1904764			3.7	4.125	1.5	3.857143	4	1.4904761	1	2.5	2	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD098BRG
2081	8976	NDAR_INVAD098BRG	1395			F	2800	Visit12	12	Phase 1/1A	345	0	0	0	1	0	0	0	4	4	5	5	5	5	4	3	2	2	3	9	4	4	4	4	4	3	4	2	3	1	1	1	1	1	1	1	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	1.75	3.5714285	3.5	3.7			3.7	4.125	1.5	3.857143	4	0	0.25	0.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD098BRG
2081	8976	NDAR_INVAD098BRG	1395			F	5200	EndofPhase1_1a	12	Phase 1/1A	345	0	0	0	1	0	0	0	4	4	5	5	5	5	4	3	2	2	3	9	4	4	4	4	4	3	4	2	3	1	1	1	1	1	1	1	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	1.75	3.5714285	3.5	3.7		1	3.7	4.125	1.5	3.857143	4	0	0.25	0.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD098BRG
2081	8976	NDAR_INVAD165ECX	1174			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	6	6	4	6	6	0	0	0	9	3	4	5	6	5	6	5	4	6	1	1	1	1	1	1	1	1	3	1	1	2	3	1	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.75	0	4.714286	5.5	4.5	1		4.5	5.75	0	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD165ECX
2081	8976	NDAR_INVAD286JDE	2342			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	6	6	6	6	6	5	1	2	3	4	9	1	4	4	5	5	6	5	5	6	1	1	1	0	1	0	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	17	0		0		1	13	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	3	4.875	2.25	4.285714	5.5	4.45	1		4.45	4.875	2.25	4.285714	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD286JDE
2081	8976	NDAR_INVAD286JDE	2342			M	5200	EndofPhase1_1a	1	Phase 1/1A	16	1	0	0	0	0	0	0	3	6	6	6	6	6	5	1	2	3	4	9	1	4	4	5	5	6	5	5	6	1	1	1	0	1	0	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.875	2.25	4.285714	5.5	4.45		1	4.45	4.875	2.25	4.285714	5.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD286JDE
2081	8976	NDAR_INVAD286JDE	2342			M	5800	EndofPhase2	3	Phase 2	55																																													0	0	0	0	0	0	0																															2								4.45	4.875	2.25	4.285714	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD286JDE
2081	8976	NDAR_INVAD465YGX	1106			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	4	2	2	2	2	2	4	2	2	2	9	2	2	3	2	3	4	3	3	3	0	1	0	0	1	1	0	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.5	2.5714285	3.5	2.65	1		2.65	2.75	1.5	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD465YGX
2081	8976	NDAR_INVAD465YGX	1106			M	1600	Visit6	6	Phase 1/1A	171	0	1	0	0	0	0	0	3	3	3	3	3	3	3	3	1	3	3	9	3	3	3	3	2	3	3	4	3	1	0	0	0	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	1.75	3	3	2.9			2.65	2.75	1.5	2.5714285	3.5	0.25	0.25	0.25	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD465YGX
2081	8976	NDAR_INVAD465YGX	1106			M	2800	Visit12	12	Phase 1/1A	365	0	1	0	0	0	0	0	3	3	3	3	3	3	2	3	2	2	2	9	2	2	3	2	2	4	3	4	4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.875	1.5	2.7142856	3.5	2.75			2.65	2.75	1.5	2.5714285	3.5	0.1	0.125	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD465YGX
2081	8976	NDAR_INVAD465YGX	1106			M	5200	EndofPhase1_1a	18	Phase 1/1A	543	0	1	0	0	0	0	0	3	3	3	3	2	3	3	3	3	2	2	9	2	2	3	2	2	6	4	3	3	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	1.75	2.4285715	5	2.85		1	2.65	2.75	1.5	2.5714285	3.5	0.2	0.125	0.25	-0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD465YGX
2081	8976	NDAR_INVAD713UKY	1438			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	1	1	4	4	2	2	1	3	2	1	6	3	2	0	3	1	5	3	4	3	1	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	28	0		0		1	2	0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	7	2.5	3	2.2857144	4	2.6666667	1		2.6666667	2.5	3	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD713UKY
2081	8976	NDAR_INVAD713UKY	1438			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	1	0	2	3	2	0	2	0	0	1	0	9	0	1	0	3	0	6	3	1	1	0	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	1.25	0.25	0.85714287	4.5	1.3			2.6666667	2.5	3	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD713UKY
2081	8976	NDAR_INVAD713UKY	1438			M	2800	Visit12	12	Phase 3	344	1	0	0	0	0	0	0	4	0	4	3	2	1	4	0	0	0	1	9	1	2	3	4	2	5	4	3	4	1	1	1	1	1	1	0	1	1	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	0.25	2.7142856	4.5	2.35			2.6666667	2.5	3	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD713UKY
2081	8976	NDAR_INVAD713UKY	1438			M	5200	EndofPhase1_1a	5	Phase 1/1A	139	1	0	0	0	0	0	0	4	0	0	2	2	1	4	0	2	1	2	9	0	3	0	4	3	4	2	1	2	1	0	0	0	1	1	0	1	1	2	0	4	4	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	0	6	1.625	1.25	1.8571428	3	1.85		1	2.6666667	2.5	3	2.2857144	4	-0.81666666	-0.875	-1.75	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD713UKY
2081	8976	NDAR_INVAD713UKY	1438			M	5800	EndofPhase2	9	Phase 2	231	1	0	0	0	0	0	0	5	0	4	4	5	0	5	0	0	1	1	9	1	2	3	1	1	4	4	3	2	1	1	0	1	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	29	0		0		1	1	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.875	0.5	1.8571428	4	2.3			2.6666667	2.5	3	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD713UKY
2081	8976	NDAR_INVAD713UKY	1438			M	6000	EndofPhase3	18	Phase 3	506	1	0	0	0	0	0	0	3	0	0	3	2	2	2	0	2	3	1	9	0	2	3	2	2	3	4	2	2	1	1	1	1	1	1	1	1	1	1	0	4	3	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	29	0		0		1	1	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	1.5	1.8571428	3.5	1.9			2.6666667	2.5	3	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD713UKY
2081	8976	NDAR_INVAD778FDA	1284			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	0	0	0	1	0	0	1	9	0	0	0	0	0	2	0	2	2	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	0.375	0.25	0.5714286	1	0.5	1		0.5	0.375	0.25	0.5714286	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD778FDA
2081	8976	NDAR_INVAD778FDA	1284			M	1600	Visit6	6	Phase 2	169	1	0	0	1	0	0	0	6	0	0	0	0	0	0	0	0	0	0	9	2	0	0	2	0	2	1	2	2	0	0	0	0	1	0	0	0	2	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	0.75	0	1.1428572	1.5	0.85			0.5	0.375	0.25	0.5714286	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD778FDA
2081	8976	NDAR_INVAD778FDA	1284			M	2800	Visit12	12	Phase 2	340	1	0	0	1	0	0	0	6	0	0	0	2	0	1	1	0	0	0	9	0	0	0	2	0	2	1	2	2	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	0	0.85714287	1.5	0.95			0.5	0.375	0.25	0.5714286	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD778FDA
2081	8976	NDAR_INVAD778FDA	1284			M	5200	EndofPhase1_1a	1	Phase 1/1A	11	1	0	0	0	0	0	0	4	2	0	0	0	0	0	1	0	0	0	9	0	0	0	4	0	1	0	2	4	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	1	0.875	0	1.4285715	0.5	0.9		1	0.5	0.375	0.25	0.5714286	1	0.4	0.5	-0.25	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD778FDA
2081	8976	NDAR_INVAD778FDA	1284			M	5800	EndofPhase2	18	Phase 2	509	1	0	0	1	0	0	0	2	1	1	2	2	1	2	2	3	1	2	2	3	2	1	2	1	3	1	3	3	0	0	0	0	1	0	0	0	1	1	0	4	4	1	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.625	2	2.142857	2	1.9047619			0.5	0.375	0.25	0.5714286	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAD778FDA
2081	8976	NDAR_INVAE861TMH	1997			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	3	3	5	4	4	4	2	0	0	0	9	0	3	4	6	5	6	5	5	5	1	1	2	1	1	1	2	2	2	2	1	4	3	3	4	1	0	0	1	0	0	0	0	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	3.75	0	4	5.5	3.45	1		3.45	3.75	0	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAE861TMH
2081	8976	NDAR_INVAE861TMH	1997			M	5200	EndofPhase1_1a	3	Phase 1/1A	81	0	0	0	0	0	1	0	5	2	2	2	3	3	4	2	0	0	0	9	0	3	3	5	4	4	3	4	5	2	2	2	2	1	2	2	2	3	1	1	4	4	4	4	1	0	0	1	0	0	0	0	2	2	2	2	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	0	3.4285715	3.5	2.7		1	3.45	3.75	0	4	5.5	-0.75	-0.875	0	-0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAE861TMH
2081	8976	NDAR_INVAE861TMH	1997			M	5800	EndofPhase2	4	Phase 2	109	0	0	0	0	0	1	0	5	4	2	2	4	3	6	3	0	0	6	9	1	5	5	6	3	4	4	4	5	1	2	2	2	1	1	2	2	2	1	1	4	3	4	4	1	0	0	1	0	0	0	0	2	2	2	2	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.625	1.5	4.142857	4	3.6			3.45	3.75	0	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAE861TMH
2081	8976	NDAR_INVAF213GPT	1910			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	1	1	0	2	0	2	2	0	0	1	9	1	0	0	3	2	5	2	2	4	0	0	0	0	1	0	1	1	1	1	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.25	1.7142857	3.5	1.5	1		1.5	1.25	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF213GPT
2081	8976	NDAR_INVAF213GPT	1910			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	0	1	0	6	0	0	0	0	4	2	0	4	2	9	2	0	0	6	2	2	2	0	2	0	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1.5	1.5	1.7142857	2	1.7		1	1.5	1.25	0.25	1.7142857	3.5	0.2	0.25	1.25	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF213GPT
2081	8976	NDAR_INVAF433XKU	1759			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	2	1	2	2	2	2	0	1	1	6	9	1	1	0	2	1	5	5	4	4	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.125	2	1.8571428	5	2.4	1		2.4	2.125	2	1.8571428	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF433XKU
2081	8976	NDAR_INVAF433XKU	1759			F	1600	Visit6	6	Phase 1B	170	0	0	0	1	0	0	0	3	0	0	2	2	2	2	0	0	2	6	9	0	0	0	2	0	2	1	2	2	0	1	1	0	1	1	1	1	1	2	0	4	3	4	4	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.375	2	0.85714287	1.5	1.4			2.4	2.125	2	1.8571428	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF433XKU
2081	8976	NDAR_INVAF433XKU	1759			F	2800	Visit12	12	Phase 2	332	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	6	9	0	1	0	2	0	3	1	2	2	0	0	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	0.25	1.5	1	2	0.95			2.4	2.125	2	1.8571428	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF433XKU
2081	8976	NDAR_INVAF433XKU	1759			F	5200	EndofPhase1_1a	3	Phase 1/1A	100	0	0	0	0	0	1	0	2	1	1	2	2	2	2	0	0	1	6	9	0	0	0	2	0	3	0	4	3	2	2	2	2	1	0	2	0	3	3	0	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	7	1	4	0		1	19	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.5	1.75	1.2857143	1.5	1.55		1	2.4	2.125	2	1.8571428	5	-0.85	-0.625	-0.25	-0.5714286	-3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF433XKU
2081	8976	NDAR_INVAF433XKU	1759			F	5400	EndofPhase1b	10	Phase 1B	283	0	0	0	1	0	0	0	4	4	0	0	0	2	2	0	0	2	6	9	1	1	0	2	0	3	2	4	2	1	1	0	0	1	0	0	1	1	2	0	4	3	4	4	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.5	2	1.4285715	2.5	1.75			2.4	2.125	2	1.8571428	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF433XKU
2081	8976	NDAR_INVAF433XKU	1759			F	5800	EndofPhase2	18	Phase 2	507	0	0	0	1	0	0	0	3	0	0	0	2	2	2	0	0	1	6	9	0	1	0	1	0	3	2	2	4	1	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	1.125	1.75	1.1428572	2.5	1.45			2.4	2.125	2	1.8571428	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF433XKU
2081	8976	NDAR_INVAF531WD0	1495			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	1	1	0	2	0	2	1	0	0	2	9	3	3	3	3	2	4	2	4	5	0	1	0	0	1	0	1	0	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.5	0.5	3.2857144	3	2.15	1		2.15	1.5	0.5	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF531WD0
2081	8976	NDAR_INVAF531WD0	1495			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	5	0	0	2	2	2	2	2	0	0	2	9	3	4	4	5	3	4	3	5	5	1	1	1	1	1	1	1	1	1	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.875	0.5	4.142857	3.5	2.65		1	2.15	1.5	0.5	3.2857144	3	0.5	0.375	0	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAF531WD0
2081	8976	NDAR_INVAG103CW4	1510			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	0	0	0	2	0	0	2	0	9	1	0	2	2	1	2	4	4	2	1	1	0	1	1	0	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	0.75	0.5	1.7142857	3	1.3	1		1.3	0.75	0.5	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG103CW4
2081	8976	NDAR_INVAG103CW4	1510			M	1600	Visit6	6	Phase 3	162	1	0	0	0	0	0	0	4	0	0	0	2	0	0	0	0	0	0	9	0	1	1	1	0	1	1	0	1	0	0	0	0	1	1	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	0.75	0	0.5714286	1	0.6			1.3	0.75	0.5	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG103CW4
2081	8976	NDAR_INVAG103CW4	1510			M	2800	Visit12	12	Phase 3	341	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	9	0	0	0	0	0	1	0	0	0	1	0	0	0	1	1	1	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	7	0.25	0	0	0.5	0.15			1.3	0.75	0.5	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG103CW4
2081	8976	NDAR_INVAG103CW4	1510			M	4000	Visit18	18	Phase 3	502	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	9	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	2	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	21	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	0.25	0	0	0	0.1			1.3	0.75	0.5	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG103CW4
2081	8976	NDAR_INVAG103CW4	1510			M	5200	EndofPhase1_1a	3	Phase 1/1A	69	1	0	0	0	0	0	0	4	0	0	0	3	0	1	0	0	0	1	9	2	2	0	2	0	1	0	1	3	0	0	0	0	1	2	2	2	1	3	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	24	0		0		1	6	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	7	1	0.25	1.4285715	0.5	1		1	1.3	0.75	0.5	1.7142857	3	-0.3	0.25	-0.25	-0.2857143	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG103CW4
2081	8976	NDAR_INVAG103CW4	1510			M	5800	EndofPhase2	4	Phase 2	92	1	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	9	1	1	1	1	0	1	1	0	2	0	0	0	0	1	1	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		1	21	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	0.375	0	0.85714287	1	0.55			1.3	0.75	0.5	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG103CW4
2081	8976	NDAR_INVAG525AK1	1476			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	6	6	6	6	4	4	0	4	4	6	6	4	6	4	4	6	2	4	4	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	4	1	0	1	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	5	4.857143	3	4.3809524	1		4.3809524	4	5	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG525AK1
2081	8976	NDAR_INVAG525AK1	1476			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	9	2	2	4	2	4	4	0	4	2	5	2	3	4	6	2	5	5	6	4	6	1	1	1	1	1	1	1	1	3	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5714285	3.25	4.285714	5.5	3.6			4.3809524	4	5	4.857143	3	-0.7809524	-1.4285715	-1.75	-0.5714286	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG525AK1
2081	8976	NDAR_INVAG525AK1	1476			M	2800	Visit12	12	Phase 2	346	0	0	0	0	0	0	1		2	4	4	4	4	5	0	5	2	5	6	4	4	6	4	6	6	5	4	6	1	1	1	1	1	1	1	1	2	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.2857144	4.5	4.857143	5.5	4.3			4.3809524	4	5	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG525AK1
2081	8976	NDAR_INVAG525AK1	1476			M	4000	Visit18	18	Phase 2	514	0	0	0	0	0	0	1	9	2	2	4	2	2	2	0	2	2	2	9	3	2	5	4	4	4	4	4	5	1	1	1	1	1	1	1	1	3	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.5	3.857143	4	2.8947368			4.3809524	4	5	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG525AK1
2081	8976	NDAR_INVAG525AK1	1476			M	5200	EndofPhase1_1a	10	Phase 1/1A	287	0	0	0	0	0	0	1	9	2	4	2	4	4	4	0	4	2	4	6	4	4	6	4	5	4	5	4	4	1	1	1	1	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	2.857143	4	4.428571	4.5	3.8		1	4.3809524	4	5	4.857143	3	-0.5809524	-1.1428572	-1	-0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG525AK1
2081	8976	NDAR_INVAG751YU1	2846			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	5	4	4	3	4	4	4	4	2	9	3	3	4	4	4	6	6	5	6	1	1	1	0	1	1	1	1	1	1	1	2	2	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	2.5	4.142857	6	4.25	1		4.25	4.25	2.5	4.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG751YU1
2081	8976	NDAR_INVAG751YU1	2846			F	1600	Visit6	6	Phase 1/1A	172	0	0	0	1	0	0	0	6	4	5	4	4	3	4	4	4	4	2	9	3	3	4	4	4	6	6	5	6	0	1	1	0	1	1	1	1	1	1	1	2	2	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	2.5	4.142857	6	4.25			4.25	4.25	2.5	4.142857	6	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG751YU1
2081	8976	NDAR_INVAG751YU1	2846			F	5200	EndofPhase1_1a	10	Phase 1/1A	312	0	1	1	1	0	0	0	5	5	5	3	2	3	2	3	2	2	3	9	4	2	4	4	5	5	4	4	1	1	1	1	2	1	1	0	1	1	2	0	4	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	1.75	3.4285715	4.5	3.4		1	4.25	4.25	2.5	4.142857	6	-0.85	-0.75	-0.75	-0.71428573	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG751YU1
2081	8976	NDAR_INVAG751YU1	2846			F	5800	EndofPhase2	10	Phase 2	315	0	0	1	1	1	0	0	5	5	5	3	2	3	2	3	2	2	3	9	4	2	4	4	5	5	4	4	1	1	1	1	2	1	1	0	1	1	2	0	4	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	1.75	3.4285715	4.5	3.4			4.25	4.25	2.5	4.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAG751YU1
2081	8976	NDAR_INVAH218TDV	1170			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	1	2	2	2	1	2	1	1	1	2	9	1	1	2	2	1	2	1	1	3	0	0	1	1	1	1	0	1	1	1	1	3	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	1.75	1	1.5714285	1.5	1.6	1		1.6	1.75	1	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH218TDV
2081	8976	NDAR_INVAH218TDV	1170			M	1600	Visit6	6	Phase 1B	169	1	0	0	0	0	0	0	2	0	1	2	2	3	2	0	1	0	0	9	2	1	2	2	1	2	1	3	4	0	0	1	0	1	1	0	1	1	2	0	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.5	0.25	2.142857	1.5	1.55			1.6	1.75	1	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH218TDV
2081	8976	NDAR_INVAH218TDV	1170			M	2800	Visit12	12	Phase 2	337	1	0	1	0	0	0	0	3	0	0	1	3	0	0	1	0	0	1	9	1	1	1	1	2	2	2	2	1	0	0	0	0	1	1	0	0	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1	0.25	1.2857143	2	1.1			1.6	1.75	1	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH218TDV
2081	8976	NDAR_INVAH218TDV	1170			M	5200	EndofPhase1_1a	5	Phase 1/1A	149	1	0	0	0	0	0	0	2	2	0	1	2	1	2	0	0	1	1	9	1	2	2	2	0	1	1	2	3	0	0	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.25	0.5	1.7142857	1	1.3		1	1.6	1.75	1	1.5714285	1.5	-0.3	-0.5	-0.5	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH218TDV
2081	8976	NDAR_INVAH218TDV	1170			M	5400	EndofPhase1b	11	Phase 1B	309	1	0	1	0	0	0	0	2	1	1	1	2	2	1	1	0	0	0	9	1	0	0	1	1	1	2	3	2	2	0	1	1	0	1	0	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.375	0	1.1428572	1.5	1.1			1.6	1.75	1	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH218TDV
2081	8976	NDAR_INVAH218TDV	1170			M	5800	EndofPhase2	18	Phase 2	520	1	0	1	0	0	0	0	3	1	1	2	3	1	1	1	1	1	1	9	2	1	1	1	1	2	1	2	3	1	0	0	0	0	0	0	1	1	2	0	4	3	3	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.625	0.75	1.5714285	1.5	1.5			1.6	1.75	1	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH218TDV
2081	8976	NDAR_INVAH389ZPX	2760			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	0	1	2	2	2	1	1	0	1	9	1	2	3	6	4	6	4	4	5	1	1	1	1	1	0	0	1	3	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	1.25	0.5	3.5714285	5	2.35	1		2.35	1.25	0.5	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH389ZPX
2081	8976	NDAR_INVAH389ZPX	2760			M	1600	Visit6	6	Phase 2	160	0	0	0	0	0	0	1	6	1	2	0	2	1	2	0	0	0	4	9	2	2	2	4	1	5	3	4	4	1	1	1	1	1	1	0	1	3	1	0	4	3	4	4	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1	2.7142856	4	2.25			2.35	1.25	0.5	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH389ZPX
2081	8976	NDAR_INVAH389ZPX	2760			M	2800	Visit12	12	Phase 2	336	0	0	0	0	0	0	1	2	1	0	1	1	2	5	0	1	0	0	9	1	3	3	2	4	6	4	4	4	1	1	0	1	1	0	0	1	3	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.25	3	5	2.2			2.35	1.25	0.5	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH389ZPX
2081	8976	NDAR_INVAH389ZPX	2760			M	5200	EndofPhase1_1a	3	Phase 1/1A	83	0	0	0	0	0	0	1	4	1	0	0	2	2	2	0	1	2	1	9	3	4	4	4	2	6	3	4	5	1	1	1	1	1	1	0	1	3	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.375	1	3.7142856	4.5	2.5		1	2.35	1.25	0.5	3.5714285	5	0.15	0.125	0.5	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH389ZPX
2081	8976	NDAR_INVAH389ZPX	2760			M	5800	EndofPhase2	18	Phase 2	490	0	0	0	0	0	0	1	4	3	3	1	3	1	4	2	1	1	1	9	1	2	4	2	2	6	3	5	5	1	1	1	1	1	1	0	1	3	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.625	0.75	3	4.5	2.7			2.35	1.25	0.5	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAH389ZPX
2081	8976	NDAR_INVAJ121PYR	1103			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	1	2	4	3	2	2	2	2	3	9	1	2	1	3	1	6	5	1	3	1	1	1	1	1	0	1	1	2	2	1	3	3	3	3	1	0	1	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	5	2.5	1.75	1.7142857	5.5	2.5	1		2.5	2.5	1.75	1.7142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAJ121PYR
2081	8976	NDAR_INVAJ121PYR	1103			F	1600	Visit6	6	Phase 1/1A	180	1	0	0	0	0	0	0	6	5	2	4	6	3	4	2	0	5	2	9	3	3	1	3	3	5	4	5	5	1	1	1	0	1	1	0	1	1	1	1	4	3	3	3	1	1	1	1	1	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	4	1.75	3.2857144	4.5	3.55			2.5	2.5	1.75	1.7142857	5.5	1.05	1.5	0	1.5714285	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAJ121PYR
2081	8976	NDAR_INVAJ121PYR	1103			F	2800	Visit12	12	Phase 1/1A	343	1	0	0	0	0	0	0	6	4	4	4	4	4	4	2	5	4	4	5	5	5	2	4	5	5	4	5	6	1	1	1	1	1	1	0	1	1	2	1	3	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	4	4.5	4.571429	4.5	4.3333335			2.5	2.5	1.75	1.7142857	5.5	1.8333334	1.5	2.75	2.857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAJ121PYR
2081	8976	NDAR_INVAJ121PYR	1103			F	5200	EndofPhase1_1a	18	Phase 1/1A	512	1	0	0	0	0	0	0	5	5	5	4	5	4	4	4	5	5	4	6	5	4	4	4	6	5	4	5	5	1	1	2	1	1	1	0	1	1	1	1	3	2	2	3	1	0	1	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	6	4.5	5	4.714286	4.5	4.6666665		1	2.5	2.5	1.75	1.7142857	5.5	2.1666667	2	3.25	3	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAJ121PYR
2081	8976	NDAR_INVAJ790CT2	2130			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	1	2	0	0	0	4	2	6	2	2	2	0	1	2	3	2	0	2	0	1	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	0.625	3.5	1.2857143	2.5	1.5714285	1		1.5714285	0.625	3.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAJ790CT2
2081	8976	NDAR_INVAJ790CT2	2130			M	5200	EndofPhase1_1a	5	Phase 1/1A	188	0	0	0	0	0	1	0	9	2	0	0	0	0	0	0	2	2	5	9	0	2	0	0	4	3	1	0	2	0	1	1	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	0.2857143	2.25	1.1428572	2	1.2105263		1	1.5714285	0.625	3.5	1.2857143	2.5	-0.36090225	-0.3392857	-1.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAJ790CT2
2081	8976	NDAR_INVAK200YD8	1948			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	5	5	5	5	4	3	4	5	4	6	6	6	5	4	5	5	4	3	5	5	1	0	1	0	1	1	1	1	1	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.625	5.25	5	3.5	4.7619047	1		4.7619047	4.625	5.25	5	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK200YD8
2081	8976	NDAR_INVAK200YD8	1948			F	2800	Visit12	12	Phase 3	342	0	1	0	0	0	0	0	5	4	3	2	4	3	4	4	4	5	6	6	4	5	4	4	5	4	3	5	5	1	0	1	0	1	1	1	1	2	2	1	3	3	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.625	5.25	4.571429	3.5	4.2380953			4.7619047	4.625	5.25	5	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK200YD8
2081	8976	NDAR_INVAK200YD8	1948			F	5200	EndofPhase1_1a	9	Phase 1/1A	254	0	1	0	0	0	0	0	6	4	2	4	4	2	5	5	6	6	6	5	5	4	3	4	5	4	3	5	4	1	0	1	0	1	1	1	1	1	3	1	2	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4	5.75	4.285714	3.5	4.3809524		1	4.7619047	4.625	5.25	5	3.5	-0.3809524	-0.625	0.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK200YD8
2081	8976	NDAR_INVAK200YD8	1948			F	5800	EndofPhase2	11	Phase 2	314	0	1	0	0	0	0	0	6	3	4	4	4	3	3	5	6	5	6	6	5	4	4	4	5	4	2	5	5	1	0	1	0	1	1	1	1	1	2	1	3	2	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4	5.75	4.571429	3	4.428571			4.7619047	4.625	5.25	5	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK200YD8
2081	8976	NDAR_INVAK200YD8	1948			F	6000	EndofPhase3	18	Phase 3	510	0	1	0	0	0	0	0	6	3	2	3	3	3	2	5	6	5	6	6	4	4	3	4	4	5	4	4	5	1	0	1	0	1	1	1	1	1	1	1	2	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	5.75	4	4.5	4.142857			4.7619047	4.625	5.25	5	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK200YD8
2081	8976	NDAR_INVAK341YL1	2576			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	4	2	4	1	2	2	3	1	1	4	1	2	4	2	2	3	2	5	6	0	0	1	1	1	1	1	1	1	2	1	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	25	0		0		1	5	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	2.25	3.142857	2.5	2.6190476	1		2.6190476	2.375	2.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK341YL1
2081	8976	NDAR_INVAK395MXX	1034			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	3	0	4	2	4	1	0	3	0	9	4	5	4	5	2	4	3	6	6	1	0	1	1	1	0	1	1	3		1	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	2.5714285	0.75	4.571429	3.5	3.1578948	1		3.1578948	2.5714285	0.75	4.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK395MXX
2081	8976	NDAR_INVAK395MXX	1034			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	0	1	4	1	4	3	2	3	4	1	0	1	2	9	4	5	4	5	2	4	3	6	6	1	0	1	1	1	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	2.75	0.75	4.571429	3.5	3.2			3.1578948	2.5714285	0.75	4.571429	3.5	0.04210526	0.17857143	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK395MXX
2081	8976	NDAR_INVAK395MXX	1034			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	0	1	4	2	4	0	2	2	5	1	1	2	2	9	2	2	2	3	0	4	3	6	6	1	0	1	1	1	0	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	1	1	0	4	2.5	1.25	3	3.5	2.65			3.1578948	2.5714285	0.75	4.571429	3.5	-0.50789475	-0.071428575	0.5	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK395MXX
2081	8976	NDAR_INVAK395MXX	1034			M	5200	EndofPhase1_1a	18	Phase 1/1A	495	0	0	0	0	0	0	1	3	2	0	0	2	0	3	2	0	0	1	9	2	1	2	5	0	4	3	4	4	0	0	1	1	1	1	0	0	2	1	1	4	3	3	3	1	0	1	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	6	1.5	0.25	2.5714285	3.5	1.9		1	3.1578948	2.5714285	0.75	4.571429	3.5	-1.2578948	-1.0714285	-0.5	-2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK395MXX
2081	8976	NDAR_INVAK871FL6	1864			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	1	0	0	6	4	1	4	2	1	5	6	5	5	1	5	2	2	1	4	4	0	1	3	5	0	0	0	0	1	1	1	1	3	3	1	2	1	1	1	0	0	0	0	0	0	0	0					1	20	0		0		1	10	0		0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	7	3.625	4	3	0.5	3.1904762	1		3.1904762	3.625	4	3	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAK871FL6
2081	8976	NDAR_INVAL145DJ8	1528			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	4	4	0	0	4	2	3	6	4	1	2	4	5	5	5	3	2	5	3	0	0	2	0	1	1	1	2	3	3	1	3	3	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	5	2.5	3.5	4.142857	2.5	3.2380953	1		3.2380953	2.5	3.5	4.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL145DJ8
2081	8976	NDAR_INVAL145DJ8	1528			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	1	0	0	2	0	1	3	3	4	2	0	0	0	9	2	2	2	5	3	2	3	4	2	0	0	0	0	1	0	2	2	3		0	4	2	2	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	0	2.857143	2.5	2			3.2380953	2.5	3.5	4.142857	2.5	-1.2380953	-0.625	-3.5	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL145DJ8
2081	8976	NDAR_INVAL145DJ8	1528			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	1	0	0	4	4	3	0	4	5	3	0	2	1	9	1	2	4	5	3	3	3	4	4	1	1	0	0	1	1	1	0	3		1	3	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	0.75	3.2857144	3	2.75			3.2380953	2.5	3.5	4.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL145DJ8
2081	8976	NDAR_INVAL145DJ8	1528			M	5200	EndofPhase1_1a	8	Phase 1/1A	212	0	0	0	0	0	1	0	2	2	4	3	1	4	5	3	0	1	1	9	2	2	2	4	4	2	2	4	3	0	0	0	0	1	1	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0.5	3	2	2.55		1	3.2380953	2.5	3.5	4.142857	2.5	-0.6880952	0.5	-3	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL145DJ8
2081	8976	NDAR_INVAL189LXL	1616			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	5	5	4	4	2	3	4	1	1	1	9	1	2	1	3	1	2	1	4	3	0	0	0	0	1	1	1	1	3	2	1	4	2	4	1	1	1	1	0	1	1	0	0	1	0	1	1	1	30	1	30	1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	4	0.75	2.142857	1.5	2.65	1		2.65	4	0.75	2.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL189LXL
2081	8976	NDAR_INVAL356EFE	1240			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	1	0	0	1	1	1	1	1	9	0	1	0	2	0	2	1	2	2	0	0	0	0	1	2	0	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	14	1	16	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	0.42857143	0.75	1	1.5	0.84210527	1		0.84210527	0.42857143	0.75	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356EFE
2081	8976	NDAR_INVAL356RRK	2551			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	1	0	0	5	0	0	1	1	1	0	1	2	5	9	4	2	1	2	0	1	1	4	6	0	0	0	0	1	1	1	1	3	3	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	1	0	0	0	0	1	1	2	2.7142856	1	1.85	1		1.85	1	2	2.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356RRK
2081	8976	NDAR_INVAL356RRK	2551			F	1600	Visit6	6	Phase 2	157	1	1	0	1	0	0	0	2	5	0	2	1	1	3	0	1	2	5	9	3	2	0	2	1	2	2	4	4	1	0	0	0	1	1	1	1	1	3	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	1.75	2	2.2857144	2	2.1			1.85	1	2	2.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356RRK
2081	8976	NDAR_INVAL356RRK	2551			F	2800	Visit12	12	Phase 2	336	1	1	0	1	0	0	0	4	5	0	2	4	4	5	0	3	2	5	9	1	2	0	2	0	3	2	4	5	0	0	1	0	1	1	1	1	1	3	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	3	2.5	2	2.5	2.65			1.85	1	2	2.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356RRK
2081	8976	NDAR_INVAL356RRK	2551			F	4000	Visit18	18	Phase 2	506	1	1	0	1	0	0	0	1	2	0	2	2	1	2	0	4	2	6	6	1	2	3	2	2	4	3	5	6	1	0	1	0	1	1	1	1	1	3	1	4	2	3	4	0	0	0	0	0	0	0	0					1	28	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.25	4.5	3	3.5	2.6666667			1.85	1	2	2.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356RRK
2081	8976	NDAR_INVAL356RRK	2551			F	5200	EndofPhase1_1a	3	Phase 1/1A	73	0	0	0	1	0	1	0	0	5	0	1	1	1	2	0	1	2	5	9	4	2	1	2	0	1	2	4	6	0	1	0	0	1	1	1	1	3	3	1	2	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	1	1.25	2	2.7142856	1.5	2		1	1.85	1	2	2.7142856	1	0.15	0.25	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356RRK
2081	8976	NDAR_INVAL356RRK	2551			F	5800	EndofPhase2	20	Phase 2	554	1	1	0	1	0	0	0	1	2	0	2	2	2	3	0	5	3	6	6	4	5	4	3	4	4	3	5	6	1	1	1	0	1	1	1	1	1	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	20	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	3	1.5	5	4.428571	3.5	3.3333333			1.85	1	2	2.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAL356RRK
2081	8976	NDAR_INVAM181DG3	1480			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	4	1	1	2	2	1	3	2	4	4	5	3	4	4	3	3	5	4	3	4	4	1	1	1	0	1	1	0	1	0	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2	4	3.857143	3.5	3.142857	1		3.142857	2	4	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM181DG3
2081	8976	NDAR_INVAM181DG3	1480			M	1600	Visit6	6	Phase 1/1A	193	0	1	0	0	0	0	0	4	0	0	4	1	0	0	4	6	5	5	6	4	5	0	5	6	4	1	5	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	5.5	4.142857	2.5	3.2857144			3.142857	2	4	3.857143	3.5	0.14285715	-0.375	1.5	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM181DG3
2081	8976	NDAR_INVAM181DG3	1480			M	2800	Visit12	12	Phase 1/1A	370	0	1	0	1	0	0	0	5	3	4	4	2	0	3	4	6	5	6	6	2	4	4	5	6	4	0	5	5	0	0	0	1	1	1	0	1	1	2	1	2	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	4	3.125	5.75	4.428571	2	3.952381			3.142857	2	4	3.857143	3.5	0.8095238	1.125	1.75	0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM181DG3
2081	8976	NDAR_INVAM181DG3	1480			M	4000	Visit18	18	Phase 1/1A	545	0	1	0	1	0	0	0	4	2	5	0	2	0	0	5	2	3	5	9	3	5	5	6	5	4	1	5	5	2	2	1	1	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	2.25	2.5	4.857143	2.5	3.35		1	3.142857	2	4	3.857143	3.5	0.20714286	0.25	-1.5	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM181DG3
2081	8976	NDAR_INVAM863KJQ	2869			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	2	2	1	3	2	2	4	5	5	4	4	4	3	2	4	4	1	1	4	4	0	0	0	0	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.625	4.5	3.5714285	1	3.142857	1		3.142857	2.625	4.5	3.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM863KJQ
2081	8976	NDAR_INVAM863KJQ	2869			F	1600	Visit6	6	Phase 1/1A	190	0	1	0	1	0	0	0	3	1	1	2	2	2	4	4	5	2	3	4	3	3	1	2	4	3	2	3	5	1	1	1	0	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	3.5	3	2.5	2.8095238			3.142857	2.625	4.5	3.5714285	1	-0.33333334	-0.25	-1	-0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM863KJQ
2081	8976	NDAR_INVAM863KJQ	2869			F	2800	Visit12	12	Phase 1/1A	351	0	1	0	0	0	0	0	5	4	4	4	3	3	4	4	5	3	3	4	3	2	1	3	3	3	2	3	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	3.875	3.75	2.7142856	2.5	3.3333333			3.142857	2.625	4.5	3.5714285	1	0.1904762	1.25	-0.75	-0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM863KJQ
2081	8976	NDAR_INVAM863KJQ	2869			F	5200	EndofPhase1_1a	18	Phase 1/1A	539	0	1	0	0	0	0	0	4	1	1	1	2	1	4	4	4	2	3	4	4	3	1	1	3	1	1	3	4	0	0	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.25	3.25	2.7142856	1	2.4761906		1	3.142857	2.625	4.5	3.5714285	1	-0.6666667	-0.375	-1.25	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM863KJQ
2081	8976	NDAR_INVAM943HVB	1289			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	3	4	4	4	3	6	5	2	4	6	9	3	6	3	6	5	5	4	2	6	1	0	1	1	1	1	0	1	0	2	1	2	4	3	4	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	0	1	1	6	4.25	3	4.428571	4.5	4.3	1		4.3	4.25	3	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM943HVB
2081	8976	NDAR_INVAM943HVB	1289			M	1600	Visit6	6	Phase 1/1A	157	0	1	0	0	0	0	0	6	4	4	3	4	3	6	5	2	2	2	9	4	2	4	6	4	5	4	4	6	1	1	1	1	1	1	1	1	1	2	1	3	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.375	1.5	4.285714	4.5	4			4.3	4.25	3	4.428571	4.5	-0.3	0.125	-1.5	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM943HVB
2081	8976	NDAR_INVAM943HVB	1289			M	2800	Visit12	12	Phase 1/1A	346	0	1	0	0	0	0	0	5	2	2	3	1	1	5	6	2	5	5	9	4	1	4	6	2	5	4	4	5	0	1	1	0	1	1	1	1	2	2	1	4	2	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.125	3	3.7142856	4.5	3.6			4.3	4.25	3	4.428571	4.5	-0.7	-1.125	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM943HVB
2081	8976	NDAR_INVAM943HVB	1289			M	4000	Visit18	18	Phase 1/1A	505	0	1	0	0	0	0	0	5	3	0	4	2	1	2	6	3	5	5	1	0	2	2	6	5	5	4	5	6	1	1	1	0	0	1	1	0	3	1	1	4	4	4	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	5	2.875	3.5	3.7142856	4.5	3.4285715			4.3	4.25	3	4.428571	4.5	-0.87142855	-1.375	0.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM943HVB
2081	8976	NDAR_INVAM943HVB	1289			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	0	0	5	3	0	4	2	1	2	6	3	5	5	1	0	2	2	6	5	5	4	5	6	1	1	1	0	0	1	1	0	3	1	1	4	4	4	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	5	2.875	3.5	3.7142856	4.5	3.4285715		1	4.3	4.25	3	4.428571	4.5	-0.87142855	-1.375	0.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAM943HVB
2081	8976	NDAR_INVAN082WVM	2886			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	5	2	2	0	5	0	4	4	0	0	0	9	0	1	2	3	2	4	2	4	6	1	0	0	0	0	1	0	0	1	1	0	4	3	4	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	0	2.5714285	3	2.3	1		2.3	2.75	0	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN082WVM
2081	8976	NDAR_INVAN447DJ2	1782			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	1	1	1	2	2	2	4	4	1	4	3	5	5	5	6	4	3	6	6	1	1	2	1	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	1.25	3.25	5.142857	3.5	3.142857	1		3.142857	1.25	3.25	5.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN447DJ2
2081	8976	NDAR_INVAN564XRU	2617			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	2	4	2	3	0	4	0	1	2	4	9	3	3	0	3	0	3	3	0	2	1	0	1	0	1	1	1	1	1	1	1	3	3	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	1.75	1.5714285	3	1.95	1		1.95	1.875	1.75	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN564XRU
2081	8976	NDAR_INVAN564XRU	2617			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	0	0	6	5	2	6	5	0	2	2	0	9	2	4	4	4	4	3	2	6	4	0	0	1	0	1	1	1	1	3		1	4	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	3	1	4	2.5	3.05			1.95	1.875	1.75	1.5714285	3	1.1	1.125	-0.75	2.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN564XRU
2081	8976	NDAR_INVAN564XRU	2617			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	9	4	4	6	6	6	6	2	2	4	6	9	2	2	4	4	2	4	2	2	6	1	0	1	0	1	1	1	1	3	1	1	2	1	4	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4.857143	3	3.142857	3	3.8947368			1.95	1.875	1.75	1.5714285	3	1.9447368	2.982143	1.25	1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN564XRU
2081	8976	NDAR_INVAN564XRU	2617			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	0	4	2	4	3	4	4	0	2	4	4	9	3	2	2	4	2	4	3	0	2	1	0	1	0	1	1	1	1	3		1	2	1	1	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.625	2.5	2.142857	3.5	2.65		1	1.95	1.875	1.75	1.5714285	3	0.7	0.75	0.75	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN564XRU
2081	8976	NDAR_INVAN586HFB	1755			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	3	2	2	0	0	0	0	0	9	1	3	1	3	4	4	3	5	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	0	3.2857144	3.5	2.15	1		2.15	1.625	0	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN586HFB
2081	8976	NDAR_INVAN586HFB	1755			M	1600	Visit6	6	Phase 1/1A	174	1	0	0	0	0	0	0	6	1	1	1	2	2	2	0	1	1	1	9	3	4	4	2	4	5	4	5	6	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.875	0.75	4	4.5	2.75			2.15	1.625	0	3.2857144	3.5	0.6	0.25	0.75	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN586HFB
2081	8976	NDAR_INVAN586HFB	1755			M	5200	EndofPhase1_1a	12	Phase 1/1A	338	1	0	0	0	0	0	0	2	0	0	0	3	0	0	0	1	1	1	9	1	2	2	3	4	5	4	4	5	1	0	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	1	0.625	0.75	3	4.5	1.9		1	2.15	1.625	0	3.2857144	3.5	-0.25	-1	0.75	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN586HFB
2081	8976	NDAR_INVAN586HFB	1755			M	5800	EndofPhase2	17	Phase 2	471	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	1	3	4	9	1	3	4	4	4	5	3	5	6	1	0	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	2	3.857143	4	2.85			2.15	1.625	0	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN586HFB
2081	8976	NDAR_INVAN586HFB	1755			M	6000	EndofPhase3	18	Phase 3	498	1	0	0	0	0	0	0	5	0	0	0	2	0	0	1	1	2	3	9	1	3	4	4	4	4	5	5	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	1.5	3.7142856	4.5	2.45			2.15	1.625	0	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN586HFB
2081	8976	NDAR_INVAN945BHU	1093			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	0	1	2	2	3	2	1	1	2	9	1	2	3	2	3	3	2	4	4	1	1	0	0	1	0	0	1	1	3	1	3	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	3	2	1	2.7142856	2.5	2.2	1		2.2	2	1	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN945BHU
2081	8976	NDAR_INVAN945BHU	1093			M	1600	Visit6	6	Phase 1/1A	193	0	1	0	0	0	0	0	1	0	4	0	3	3	2	3	2	1	1	9	2	2	4	1	1	3	3	4	4	1	1	0	0	1	1	0	1	1	3	0	4	1	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	1	2.5714285	3	2.2			2.2	2	1	2.7142856	2.5	0	0	0	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN945BHU
2081	8976	NDAR_INVAN945BHU	1093			M	2800	Visit12	12	Phase 1/1A	338	0	1	0	0	0	0	0	4	1	2	2	5	2	2	1	4	3	1	5	2	2	4	2	2	4	3	5	5	2	1	1	2	1	1	0	1	1	2	0	4	4	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.375	3.25	3.142857	3.5	2.9047618			2.2	2	1	2.7142856	2.5	0.7047619	0.375	2.25	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN945BHU
2081	8976	NDAR_INVAN945BHU	1093			M	4000	Visit18	18	Phase 1/1A	501	0	1	0	0	0	0	0	2	0	2	3	2	1	2	0	0	0	0	9	0	1	0	1	2	2	2	4	4	2	1	1	0	1	1	1	0	1	3	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	1.5	0	1.7142857	2	1.4		1	2.2	2	1	2.7142856	2.5	-0.8	-0.5	-1	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAN945BHU
2081	8976	NDAR_INVAP621APQ	1223			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	2	2	2	2	2	3	1	1	3	4	9	2	2	1	4	2	3	2	3	5	0	1	0	0	1	1	1	0	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	2	2.7142856	2.5	2.6	1		2.6	2.5	2	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAP621APQ
2081	8976	NDAR_INVAP621APQ	1223			M	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	0	1	5	0	1	4	4	4	4	2	4	2	5	5	4	3	3	4	5	4	4	5	5	1	1	0	1	1	1	1	1	1	1	1	3	3	3	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3	4	4.142857	4	3.6666667			2.6	2.5	2	2.7142856	2.5	1.0666667	0.5	2	1.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAP621APQ
2081	8976	NDAR_INVAP621APQ	1223			M	2800	Visit12	12	Phase 1/1A	349	0	0	0	0	0	0	1	5	2	3	3	5	4	5	3	5	4	5	5	4	4	4	6	6	6	5	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	3		1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.75	4.75	4.857143	5.5	4.4761906			2.6	2.5	2	2.7142856	2.5	1.8761904	1.25	2.75	2.142857	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAP621APQ
2081	8976	NDAR_INVAP621APQ	1223			M	4000	Visit18	18	Phase 1/1A	551	0	0	0	0	0	0	1	5	1	1	1	2	2	2	1	6	4	5	6	1	3	2	6	5	4	1	5	5	0	0	0	0	1	1	1	1	1	1	1	4	4	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	1.875	5.25	3.857143	2.5	3.2380953		1	2.6	2.5	2	2.7142856	2.5	0.63809526	-0.625	3.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAP621APQ
2081	8976	NDAR_INVAP988FM7	1126			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	2	4	0	0	1	1	0	0	0	9	1	2	1	2	4	4	3	4	3	0	0	0	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	21	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0	2.4285715	3.5	1.6	1		1.6	1	0	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAP988FM7
2081	8976	NDAR_INVAR165VGY	1915			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	2	2	2	2	2	2	0	2	2	9	2	2	2	2	0	4	0	2	4	2	2	2	2	1	1	1	2	3	1	1	4	3	3	3	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	1	2	2	2	1		2	2.25	1	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAR165VGY
2081	8976	NDAR_INVAR460KRP	1342			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	2	4	2	2	4	3	3	4	6	4	2	4	4	4	5	5	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	20	0		0		0		0		2	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.5	4	3.7142856	5	3.8095238	1		3.8095238	3.5	4	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAR460KRP
2081	8976	NDAR_INVAR460KRP	1342			F	1600	Visit6	6	Phase 1/1A	197	0	0	0	1	0	0	0	4	4	4	4	4	4	4	4	2	2	2	9	3	2	4	2	2	6	5	3	4	1	1	1	0	1	1	1	1	2	2	1	3	2	2	2	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4	1.5	2.857143	5.5	3.45			3.8095238	3.5	4	3.7142856	5	-0.3595238	0.5	-2.5	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAR460KRP
2081	8976	NDAR_INVAR460KRP	1342			F	2800	Visit12	12	Phase 1/1A	386	0	0	0	0	0	0	1	2	4	4	4	4	4	4	0	3	3	2	9	2	4	4	4	5	5	5	4	6	1	1	1	1	1	1	1	1	3	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	3.25	2	4.142857	5	3.65		1	3.8095238	3.5	4	3.7142856	5	-0.15952381	-0.25	-2	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAR460KRP
2081	8976	NDAR_INVAR599PRH	1398			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	2	2	2	9	1	1	1	2	1	4	2	4	2	2	2	2	1	1	2	2	2	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	22	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2	1.5	1.7142857	3	2	1		2	2	1.5	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAR599PRH
2081	8976	NDAR_INVAT008DV3	2881			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	0	0	2	2	0	2	2	0	1	1	9	0	2	0	2	2	2	2	1	2	1	1	1	0	1	1	1	0	1	2	0	4	3	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	1.25	0.5	1.2857143	2	1.25	1		1.25	1.25	0.5	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT008DV3
2081	8976	NDAR_INVAT008DV3	2881			M	5200	EndofPhase1_1a	2	Phase 1/1A	51	0	1	0	0	0	0	0	2	1	1	2	1	1	2	2	0	2	5	9	0	1	0	3	0	3	2	2	2	1	1	0	0	1	0	1	0	1	3	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.5	1.75	1.1428572	2.5	1.6		1	1.25	1.25	0.5	1.2857143	2	0.35	0.25	1.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT008DV3
2081	8976	NDAR_INVAT148VZ5	1175			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	0	0	2	2	2	2	1	1	1	1	9	2	2	2	2	2	4	3	4	4	0	1	0	1	1	0	1	1	1	1	0	4	2	2	4	1	0	1	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	1	1	1	1	1	1.625	0.75	2.5714285	3.5	2.05	1		2.05	1.625	0.75	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT148VZ5
2081	8976	NDAR_INVAT148VZ5	1175			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	1	0	1	0	0	0	0	1	0	0	1	2	0	2	0	0	0	0	9	0	0	0	2	0	3	6	0	2	0	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	1	1	1	4	0.75	0	0.5714286	4.5	0.95		1	2.05	1.625	0.75	2.5714285	3.5	-1.1	-0.875	-0.75	-2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT148VZ5
2081	8976	NDAR_INVAT148VZ5	1175			M	5800	EndofPhase2	7	Phase 2	190	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	2	0	0	2	0	0	0	0	1	1	1	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0	0	0.2857143	1	0.2			2.05	1.625	0.75	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT148VZ5
2081	8976	NDAR_INVAT391PB6	2173			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	4	4	4	3	4	6	4	5	5	5	6	5	3	3	5	4	3	3	1	1	0	1	0	1	1	1	1	1	1	1	4	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	1	0	0	1	1	1	1	3	3.625	4.75	3.7142856	3.5	3.857143	1		3.857143	3.625	4.75	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT391PB6
2081	8976	NDAR_INVAT391PB6	2173			F	1600	Visit6	6	Phase 1/1A	180	1	0	0	0	0	0	0	5	1	3	4	3	1	2	3	1	1	2	9	4	3	1	1	2	3	3	2	1	1	1	1	0	1	1	1	1	1	1	1	4	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	2	2.75	1	2	3	2.3			3.857143	3.625	4.75	3.7142856	3.5	-1.5571429	-0.875	-3.75	-1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT391PB6
2081	8976	NDAR_INVAT391PB6	2173			F	2800	Visit12	12	Phase 1/1A	365	0	0	0	0	0	1	0	5	0	1	2	2	2	2	3	3	3	2	9	5	5	4	4	4	4	3	3	3	1	1	1	1	1	1	1	1	2	2	0	4	3	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		1	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	4	2.125	2	4	3.5	3			3.857143	3.625	4.75	3.7142856	3.5	-0.85714287	-1.5	-2.75	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT391PB6
2081	8976	NDAR_INVAT391PB6	2173			F	5200	EndofPhase1_1a	18	Phase 1/1A	548	0	0	0	0	0	0	1	3	0	4	3	2	6	6	5	4	5	2	2	5	6	6	3	5	4	4	6	5	1	1	1	1	1	1	1	1	3	2	0	4	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	1	0	1	1	1	0	0	0	0	0	1	1	1	1	5	3.625	3.25	5.142857	4	4.095238		1	3.857143	3.625	4.75	3.7142856	3.5	0.23809524	0	-1.5	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT391PB6
2081	8976	NDAR_INVAT849XBP	2594			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	2	1	2	1	1	0	2	0	9	1	1	1	2	1	5	4	3	0	1	0	1	0	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.5714285	0.5	1.2857143	4.5	1.6315789	1		1.6315789	1.5714285	0.5	1.2857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT849XBP
2081	8976	NDAR_INVAT849XBP	2594			F	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	9	2	0	0	4	0	0	0	0	0	0	9	0	0	0	2	0	5	2	4	2	1	0	0	0	1	0	0	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.85714287	0	1.1428572	3.5	1.1052631			1.6315789	1.5714285	0.5	1.2857143	4.5	-0.5263158	-0.71428573	-0.5	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT849XBP
2081	8976	NDAR_INVAT849XBP	2594			F	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	0	1	9	0	0	0	2	0	0	0	0	0	0	9	0	0	0	2	0	4	3	2	2	1	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.2857143	0	0.85714287	3.5	0.7894737			1.6315789	1.5714285	0.5	1.2857143	4.5	-0.84210527	-1.2857143	-0.5	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT849XBP
2081	8976	NDAR_INVAT849XBP	2594			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	0	0	0	4	0	1	0	2	1	0	9	1	2	0	2	1	4	2	5	2	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.71428573	0.75	1.8571428	3	1.4210526		1	1.6315789	1.5714285	0.5	1.2857143	4.5	-0.21052632	-0.85714287	0.25	0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT849XBP
2081	8976	NDAR_INVAT911GMV	2877			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	6	6	6	6	2	2	0	4	9	4	1	4	5	6	4	1	6	5	2	2	2	2	1	1	1	2	2	2	1	4	2	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.5	1.5	4.428571	2.5	4.3	1		4.3	5.5	1.5	4.428571	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAT911GMV
2081	8976	NDAR_INVAU202MHY	1698			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	1	3	2	1	1	1	2	1	9	2	2	0	2	2	2	2	1	3	0	0	1	0	1	0	0	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	17	0		1	21	0		0		0	0	1	1	1	0	0	1	0	0	0	0	1	1	1	1	5	1.5	1	1.7142857	2	1.6	1		1.6	1.5	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU202MHY
2081	8976	NDAR_INVAU202MHY	1698			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	1	0	1	1	1	2	1	2	1	6	9	1	1	2	2	4	3	3	2	5	0	0	1	1	1	0	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1.625	2.25	2.4285715	3	2.25			1.6	1.5	1	1.7142857	2	0.65	0.125	1.25	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU202MHY
2081	8976	NDAR_INVAU202MHY	1698			M	5200	EndofPhase1_1a	12	Phase 1/1A	370	1	0	0	0	0	0	0	3	2	3	3	3	3	4	3	2	2	3	9	3	2	3	4	3	3	2	3	5	0	0	1	0	1	1	1	0	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	3	1.75	3.2857144	2.5	2.95		1	1.6	1.5	1	1.7142857	2	1.35	1.5	0.75	1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU202MHY
2081	8976	NDAR_INVAU600NPZ	1798			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	3	3	2	1	3	2	2	3	0	0	2	9	1	1	2	2	2	4	3	4	4	1	1	0	0	1	1	0	0	1	3	1	3	2	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	0.5	2.2857144	3.5	2.2	1		2.2	2.375	0.5	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU600NPZ
2081	8976	NDAR_INVAU621JJL	2519			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	2	2	2	3	3	0	0	1	1	9	2	2	2	2	0	2	0	3	4	0	0	1	0	1	1	1	1	3		0	4	3	3	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	0	3	1.75	0.5	2.142857	1	1.65	1		1.65	1.75	0.5	2.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU621JJL
2081	8976	NDAR_INVAU621JJL	2519			M	5200	EndofPhase1_1a	6	Phase 1/1A	111	1	0	0	0	0	0	0	5	0	0	2	3	3	5	1	0	0	0	9	2	2	4	4	2	3	1	2	2	0	0	1	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	0	2.5714285	2	2.05		1	1.65	1.75	0.5	2.142857	1	0.4	0.625	-0.5	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU621JJL
2081	8976	NDAR_INVAU621JJL	2519			M	5800	EndofPhase2	7	Phase 2	147	1	0	0	0	0	0	0	4	1	1	2	4	4	3	3	0	0	0	9	2	1	2	4	0	1	1	3	0	1	0	0	0	1	1	1	0	2	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	0	1.7142857	1	1.8			1.65	1.75	0.5	2.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU621JJL
2081	8976	NDAR_INVAU749CKG	2193			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	5	4	5	4	6	6	6	4	6	6	5	4	2	6	6	5	5	5	6	1	1	0	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.25	5.5	4.857143	5	5.142857	1		5.142857	5.25	5.5	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAU749CKG	2193			M	1600	Visit6	6	Phase 1/1A	172	1	0	0	0	0	0	0	6	6	6	6	4	4	6	4	6	4	5	6	4	4	5	4	6	6	6	6	6	1	1	1	1	1	1	2	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.25	5.25	5	6	5.2380953			5.142857	5.25	5.5	4.857143	5	0.0952381	0	-0.25	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAU749CKG	2193			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	0	1	6	6	6	5	5	5	5	4	6	6	6	9	6	6	6	6	6	6	6	6	6	1	0	0	1	1	0	1	1	1	1	1	2	2	2	2	1	1	1	1	1	1	0	0	1	1	1	1	1	30	0		0		0		0		0	1	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.25	4.5	6	6	5.7			5.142857	5.25	5.5	4.857143	5	0.55714285	0	-1	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAU749CKG	2193			M	4000	Visit18	18	Phase 3	512	0	0	0	0	0	0	1	0	6	5	5	5	4	6	4	6	4	5	6	5	5	3	5	5	5	3	4	4	0	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	5.25	4.428571	4	4.5238094			5.142857	5.25	5.5	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAU749CKG	2193			M	5200	EndofPhase1_1a	14	Phase 1/1A	385	0	0	0	0	0	0	1	6	6	6	4	4	4	5	4	6	4	5	6	4	5	3	4	5	6	6	4	5	1	1	1	1	1	1	1	0	1	1	1	2	2	2	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	5.25	4.285714	6	4.857143		1	5.142857	5.25	5.5	4.857143	5	-0.2857143	-0.375	-0.25	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAU749CKG	2193			M	5800	EndofPhase2	15	Phase 2	421	0	0	0	0	0	0	1	6	6	4	4	4	5	4	6	4	5	6	4	4	5	3	4	5	6	6	4	5	1	1	1	1	1	1	1	0	1	1	1	2	2	2	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	4.75	4.285714	6	4.7619047			5.142857	5.25	5.5	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAU749CKG	2193			M	6000	EndofPhase3	23	Phase 3	645	1	0	0	0	0	0	0	6	6	4	5	4	4	4	4	6	4	6	6	5	4	1	6	6	6	6	2	2	1	1	1	0	1	1	0	1	1	1	1	4	1	2	2	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.625	5.5	3.7142856	6	4.6190476			5.142857	5.25	5.5	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAU749CKG
2081	8976	NDAR_INVAV767HKY	1164			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	5	4	4	5	5	5	1	1	1	2	9	2	3	0	6	2	2	2	6	6	1	0	1	0	1	1	1	1	2	1	1	4	2	3	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4.375	1	3.5714285	2	3.4	1		3.4	4.375	1	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAV767HKY
2081	8976	NDAR_INVAV767HKY	1164			M	1600	Visit6	6	Phase 1/1A	185	0	0	1	0	1	0	0	6	5	4	4	6	6	6	2	0	2	3	9	2	2	3	6	6	3	3	5	6	1	1	1	0	1	1	1	1	1	2	1	3	2	2	2	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	1.25	4.285714	3	4			3.4	4.375	1	3.5714285	2	0.6	0.5	0.25	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAV767HKY
2081	8976	NDAR_INVAV767HKY	1164			M	2800	Visit12	12	Phase 1/1A	362	0	0	1	0	1	0	0	6	6	6	4	5	2	5	0	0	0	3	9	2	4	5	4	0	3	3	6	5	0	1	1	2	1	1	1	1	1	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	0.75	3.7142856	3	3.45			3.4	4.375	1	3.5714285	2	0.05	-0.125	-0.25	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAV767HKY
2081	8976	NDAR_INVAV767HKY	1164			M	5200	EndofPhase1_1a	18	Phase 1/1A	541	0	0	0	0	0	0	1	6	4	4	2	4	0	5	1	0	0	3	9	4	4	4	6	3	4	4	5	5	1	1	1	1	1	1	1	1	2	1	1	4	2	3	2	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	0.75	4.428571	4	3.4		1	3.4	4.375	1	3.5714285	2	0	-1.125	-0.25	0.85714287	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAV767HKY
2081	8976	NDAR_INVAW503EEC	1258			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	4	5	3	4	3	1	1	1	9	1	3	4	4	1	2	3	3	4	0	1	1	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.125	0.75	2.857143	2.5	3.05	1		3.05	4.125	0.75	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW503EEC
2081	8976	NDAR_INVAW503EEC	1258			M	5200	EndofPhase1_1a	6	Phase 1/1A	165	1	0	0	0	0	0	0	4	2	3	3	2	2	4	2	1	1	2	9	2	2	3	4	2	4	3	3	4	1	1	1	0	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	2.75	1	2.857143	3.5	2.65		1	3.05	4.125	0.75	2.857143	2.5	-0.4	-1.375	0.25	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW503EEC
2081	8976	NDAR_INVAW744NMK	1957			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	1	4	4	4	5	3	2	2	1	1	9	5	5	6	5	5	4	6	4	5	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	29	0		0		0		1	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	2.875	1	5	5	3.6	1		3.6	2.875	1	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW744NMK
2081	8976	NDAR_INVAW744NMK	1957			M	1600	Visit6	6	Phase 1/1A	174	1	0	0	0	0	0	0	6	5	4	2	5	6	6	4	4	5	5	5	5	5	6	5	5	5	4	5	5	1	1	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.75	4.75	5.142857	4.5	4.857143			3.6	2.875	1	5	5	1.2571429	1.875	3.75	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW744NMK
2081	8976	NDAR_INVAW744NMK	1957			M	2800	Visit12	12	Phase 2	333	1	0	0	0	0	0	0	6	6	5	6	5	5	6	5	6	6	6	6	6	6	6	6	6	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	2	4	1	0	1	0	0	0	0	0	1	1	0	1	1	30	0		0		0		0		1	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	5	5.5	6	6	5.5	5.7619047			3.6	2.875	1	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW744NMK
2081	8976	NDAR_INVAW744NMK	1957			M	5200	EndofPhase1_1a	7	Phase 1/1A	193	1	0	0	0	0	0	0	6	2	5	2	5	2	5	4	4	5	5	5	5	5	5	5	5	5	4	5	5	1	1	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.875	4.75	5	4.5	4.4761906		1	3.6	2.875	1	5	5	0.8761905	1	3.75	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW744NMK
2081	8976	NDAR_INVAW744NMK	1957			M	5800	EndofPhase2	18	Phase 2	495	1	0	0	0	0	0	0	6	6	6	6	6	4	6	6	4	5	4	4	4	5	6	6	5	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	4	3	3	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	5.75	4.25	5.428571	6	5.3809524			3.6	2.875	1	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW744NMK
2081	8976	NDAR_INVAW872RRD	1497			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	1	1	1	2	2	2	1	0	2	2	9	2	2	2	4	1	4	2	4	4	1	0	1	0	0	0	0	1	1	1	0		3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	1.875	1	2.7142856	3	2.2	1		2.2	1.875	1	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW872RRD
2081	8976	NDAR_INVAW872RRD	1497			M	5200	EndofPhase1_1a	1	Phase 1/1A	26	1	0	0	0	0	0	0	4	1	1	1	2	0	0	0	0	2	1	9	2	2	2	2	0	3	3	2	3	1	1	0	0	1	1	1	1	1	1	1	3	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.125	0.75	1.8571428	3	1.55		1	2.2	1.875	1	2.7142856	3	-0.65	-0.75	-0.25	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAW872RRD
2081	8976	NDAR_INVAX038HMQ	2157			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	2	0	0	4	1	0	0	1	9	0	4	3	4	2	2	2	4	5	0	0	2	0	1	0	2	0	3		1	3	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0.25	3.142857	2	1.8	1		1.8	1.125	0.25	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX038HMQ
2081	8976	NDAR_INVAX038HMQ	2157			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	1	0	3	2	0	2	2	1	3	1	0	1	1	9	0	2	3	4	2	2	2	3	4	1	1	2	0	1	0	0	0	3		1	3	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.75	0.5	2.5714285	2	1.9			1.8	1.125	0.25	3.142857	2	0.1	0.625	0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX038HMQ
2081	8976	NDAR_INVAX038HMQ	2157			M	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	1	0	4	0	4	2	3	2	5	2	0	2	1	9	2	3	3	5	2	2	2	4	5	0	1	2	0	1	0	0	0	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	0.75	3.4285715	2	2.65			1.8	1.125	0.25	3.142857	2	0.85	1.625	0.5	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX038HMQ
2081	8976	NDAR_INVAX038HMQ	2157			M	5200	EndofPhase1_1a	18	Phase 1/1A	508	0	0	0	0	0	1	0	5	4	5	5	4	3	5	1	1	1	1	9	2	3	3	5	3	3	3	4	4	1	1	0	0	1	0	0	0	3	2	1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	4	0.75	3.4285715	3	3.25		1	1.8	1.125	0.25	3.142857	2	1.45	2.875	0.5	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX038HMQ
2081	8976	NDAR_INVAX090YW2	1544			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	6	6	6	6	5	4	4	4	6	6	5	4	6	3	4	4	6	6	1	1	1	0	1	1	1	1	1	1	1	2	1	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.875	4.5	5.142857	4	5.1904764	1		5.1904764	5.875	4.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX090YW2
2081	8976	NDAR_INVAX090YW2	1544			F	2800	Visit12	12	Phase 3	336	1	0	0	0	0	0	0	6	5	2	4	5	5	5	4	1	0	1	9	4	3	5	5	4	5	5	4	6	1	1	1	1	1	1	1	0	1	1	1	3	2	4	1	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.5	0.5	4.428571	5	3.95			5.1904764	5.875	4.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX090YW2
2081	8976	NDAR_INVAX090YW2	1544			F	5200	EndofPhase1_1a	6	Phase 1/1A	177	1	0	0	0	0	0	0	6	5	6	6	5	5	6	4	3	2	2	2	4	2	3	6	4	5	5	5	5	1	1	0	1	1	1	1	1	1	1	1	2	1	2	4	1	0	1	0	0	0	0	0	1	0	0	1	1	30	0		0		0		0		0	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.375	2.25	4.142857	5	4.3333335		1	5.1904764	5.875	4.5	5.142857	4	-0.85714287	-0.5	-2.25	-1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX090YW2
2081	8976	NDAR_INVAX090YW2	1544			F	6000	EndofPhase3	15	Phase 3	428	1	0	0	0	0	0	0	5	5	3	4	4	5	6	5	1	1	2	9	5	3	1	5	2	5	5	5	6	1	1	1	0	1	1	1	1	1	1	1	3	1	3	1	1	0	1	0	0	0	0	0	1	1	1	1	1	29	0		1	1	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.625	1	3.857143	5	3.9			5.1904764	5.875	4.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX090YW2
2081	8976	NDAR_INVAX120VGC	1394			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	2	0	2	0	0	4	5	4	5	6	3	3	4	4	2	5	2	5	6	0	0	1	0	1	1	1	1	1	1	0	4	4	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.75	5	3.857143	3.5	3.2380953	1		3.2380953	1.75	5	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX120VGC
2081	8976	NDAR_INVAX120VGC	1394			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	1	0	0	0	0	0	6	0	0	0	2	4	2	6	2	4	4	9	0	2	2	5	6	5	1	6	6	0	0	0	0	1	1	1	1	3	3	0	4	3	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.5	2.5	3.857143	3	3.15		1	3.2380953	1.75	5	3.857143	3.5	-0.08809524	0.75	-2.5	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX120VGC
2081	8976	NDAR_INVAX120VGC	1394			F	5800	EndofPhase2	6	Phase 2	169	0	1	0	0	0	0	0	6	0	0	0	2	2	2	6	2	4	4	9	0	2	2	4	4	5	2	4	5	0	0	1	0	1	1	1	1	2	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.25	2.5	3	3.5	2.8			3.2380953	1.75	5	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX120VGC
2081	8976	NDAR_INVAX120VGC	1394			F	6000	EndofPhase3	12	Phase 3	338	0	1	0	0	0	0	0	6	0	0	0	2	2	2	6	2	2	4	9	0	2	0	2	3	4	2	4	4	0	0	1	0	1	1	1	1	2	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2.25	2	2.142857	3	2.35			3.2380953	1.75	5	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX120VGC
2081	8976	NDAR_INVAX242UGL	2554			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	2	0	0	2	0	0	0	6	4	2	2	2	2	4	2	4	3	1	4	5	0	0	1	0	0	1	1	1	2	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.25	3.5	3.2857144	2	2.4285715	1		2.4285715	1.25	3.5	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX242UGL
2081	8976	NDAR_INVAX242UGL	2554			F	1600	Visit6	6	Phase 1B	172	0	0	0	0	0	0	1	6	0	4	2	3	2	2	0	3	4	4	3	3	4	6	6	4	4	4	6	6	1	0	1	0	1	1	1	1	1	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2.375	3.5	5	4	3.6190476			2.4285715	1.25	3.5	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX242UGL
2081	8976	NDAR_INVAX242UGL	2554			F	2800	Visit12	12	Phase 1B	326	0	0	0	0	0	0	1	6	0	0	2	2	2	2	0	2	4	1	9	3	3	2	3	4	5	2	4	5	1	0	1	1	1	1	1	1	1	1	0	4	4	2	4	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	5	1.75	1.75	3.4285715	3.5	2.6			2.4285715	1.25	3.5	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX242UGL
2081	8976	NDAR_INVAX242UGL	2554			F	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	0	0	0	0	0	1	6	2	0	0	2	0	0	0	0	3	1	9	2	2	0	3	4	4	2	4	5	0	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	1.25	1	2.857143	3	2		1	2.4285715	1.25	3.5	3.2857144	2	-0.42857143	0	-2.5	-0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX242UGL
2081	8976	NDAR_INVAX242UGL	2554			F	5400	EndofPhase1b	18	Phase 1B	491	0	0	0	0	0	0	1	6	0	4	3	2	2	2	0	3	4	4	4	3	4	4	5	6	4	5	5	6	1	1	1	1	1	1	1	1	1	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.375	3.75	4.714286	4.5	3.6190476			2.4285715	1.25	3.5	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAX242UGL
2081	8976	NDAR_INVAY258HBN	1709			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	0	0	2	0	2	2	1	1	1	2	9	3	4	4	2	2	5	2	4	4	0	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.25	1	3.2857144	3.5	2.2	1		2.2	1.25	1	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAY258HBN
2081	8976	NDAR_INVAY258HBN	1709			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	5	0	3	2	0	2	2	1	1	1	2	9	3	4	4	4	4	5	3	4	5	0	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.875	1	4	4	2.75			2.2	1.25	1	3.2857144	3.5	0.55	0.625	0	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAY258HBN
2081	8976	NDAR_INVAY258HBN	1709			M	2800	Visit12	12	Phase 1/1A	346	1	0	0	0	0	0	0	5	2	0	3	3	2	3	2	3	3	3	4	4	5	6	5	5	5	3	5	5	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.5	3.25	5	4	3.6190476			2.2	1.25	1	3.2857144	3.5	1.4190476	1.25	2.25	1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAY258HBN
2081	8976	NDAR_INVAY258HBN	1709			M	5200	EndofPhase1_1a	18	Phase 1/1A	522	1	0	0	0	0	0	0	6	4	0	1	4	4	3	4	5	4	4	2	4	4	4	4	5	5	2	4	4	1	1	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	3.75	4.142857	3.5	3.6666667		1	2.2	1.25	1	3.2857144	3.5	1.4666667	2	2.75	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAY258HBN
2081	8976	NDAR_INVAZ173YPF	2713			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	0	1	1	1	2	1	2			9	2	2	2	2	4	6	5	1	2	1	1	1	1	1	1	1	1	3	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1		0	0	0	0	1	1	1	0	5	0.75		2.142857	5.5	1.8888888	1		1.8888888	0.75		2.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ173YPF
2081	8976	NDAR_INVAZ173YPF	2713			M	1600	Visit6	6	Phase 1/1A	167	1	0	0	0	0	0	0	0	0	0	1	1	1	2	1	2	0	0	9	2	2	2	2	4	6	5	1	2	1	1	1	1	1	1	1	1	3	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	0	5	0.75	0.5	2.142857	5.5	1.7			1.8888888	0.75		2.142857	5.5	-0.18888889	0		0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ173YPF
2081	8976	NDAR_INVAZ173YPF	2713			M	2800	Visit12	12	Phase 2	342	1	0	0	0	0	0	0	4	2	4	2	5	1	3	2	3	6	6	6	4	6	6	6	5	5	6	6	4	1	1	0	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	4	2.875	5.25	5.285714	5.5	4.3809524			1.8888888	0.75		2.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ173YPF
2081	8976	NDAR_INVAZ173YPF	2713			M	5200	EndofPhase1_1a	7	Phase 1/1A	183	1	0	0	0	0	0	0	0	0	0	1	1	1	2	1	2			9	2	2	2	2	4	6	5	1	2	1	1	1	1	1	1	1	1	3	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	0	5	0.75		2.142857	5.5	1.8888888		1	1.8888888	0.75		2.142857	5.5	0	0		0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ173YPF
2081	8976	NDAR_INVAZ173YPF	2713			M	5400	EndofPhase1b	9	Phase 1B	232	1	0	0	0	0	0	0	0	0	0	1	1	1	2	1	2	0	0	9	2	2	2	2	4	6	4	1	2	1	1	1	1	1	1	1	1	3	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	0	5	0.75	0.5	2.142857	5	1.65			1.8888888	0.75		2.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ173YPF
2081	8976	NDAR_INVAZ173YPF	2713			M	5800	EndofPhase2	18	Phase 2	503	1	0	0	0	0	0	0	6	2	2	2	4	3	2	3	5	5	5	6	6	5	6	5	4	6	4	6	6	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	5	3	5.25	5.428571	5	4.428571			1.8888888	0.75		2.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ173YPF
2081	8976	NDAR_INVAZ390BM3	2464			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	3	3	3	2	4	1	1	2	5	9	1	3	3	3	4	6	4	3	4	0	1	0	0	1	0	1	1	3		1	3	1	1	4	0	0	0	0	0	0	0	0					1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	2	3	5	2.8	1		2.8	2.125	2	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ390BM3
2081	8976	NDAR_INVAZ390BM3	2464			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	2	2	3	2	1	2	2	0	1	2	3	9	1	2	2	2	4	6	4	2	2	1	1	0	0	1	0	1	0	3	2	1	3	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.5	2.142857	5	2.25			2.8	2.125	2	3	5	-0.55	-0.375	-0.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ390BM3
2081	8976	NDAR_INVAZ390BM3	2464			M	2800	Visit12	12	Phase 1/1A	334	0	0	0	0	0	0	1	2	0	2	1	1	1	2	1	0	0	0	9	0	2	0	0	1	6	3	1	1	1	1	1	1	1	1	1	1	3		1	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.25	0	0.71428573	4.5	1.2			2.8	2.125	2	3	5	-1.6	-0.875	-2	-2.2857144	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ390BM3
2081	8976	NDAR_INVAZ390BM3	2464			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	0	1	2	1	3	3	2	1	2	1	0	0	0	9	1	2	2	2	3	6	4	1	2	1	1	0	1	1	0	1	0	3	3	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1.875	0	1.8571428	5	1.9		1	2.8	2.125	2	3	5	-0.9	-0.25	-2	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ390BM3
2081	8976	NDAR_INVAZ664YV0	1726			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	2	0	1	2	1	1	1	3	2	5	9	2	2	1	2	1	2	0	3	2	0	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	2	1.625	2.5	1.8571428	1	1.9	1		1.9	1.625	2.5	1.8571428	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ664YV0
2081	8976	NDAR_INVAZ664YV0	1726			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	1	0	0	5	3	3	2	3	2	2	3	4	3	6	2	2	3	2	2	1	2	3	5	5	0	0	1	0	1	1	1	1	2	2	1	3	2	4	2	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	4	2.875	3.75	2.857143	2.5	3			1.9	1.625	2.5	1.8571428	1	1.1	1.25	1.25	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ664YV0
2081	8976	NDAR_INVAZ664YV0	1726			M	2800	Visit12	12	Phase 1/1A	337	0	0	1	0	0	0	0	4	4	3	2	4	1	2	3	5	4	6	4	3	4	2	5	2	4	1	4	5	0	0	1	0	1	1	1	1	1	1	1	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	4	2.875	4.75	3.5714285	2.5	3.4285715			1.9	1.625	2.5	1.8571428	1	1.5285715	1.25	2.25	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ664YV0
2081	8976	NDAR_INVAZ664YV0	1726			M	4000	Visit18	18	Phase 1/1A	518	0	0	1	0	0	0	0	5	3	2	3	3	3	4	2	3	4	4	9	3	4	4	4	2	3	1	4	4	0	0	1	0	1	1	1	1	1	1	1	3	3	2	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.125	2.75	3.5714285	2	3.25		1	1.9	1.625	2.5	1.8571428	1	1.35	1.5	0.25	1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ664YV0
2081	8976	NDAR_INVAZ854VLT	1521			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	4	2	4	4	4	4	1	2	1	9	3	0	4	4	0	6	4	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	3	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.25	1	2.7142856	5	2.95	1		2.95	3.25	1	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ854VLT
2081	8976	NDAR_INVAZ854VLT	1521			M	1600	Visit6	6	Phase 1/1A	162	1	0	0	0	0	0	0	6	6	6	4	4	6	6	2	2	4	2	9	2	4	4	4	2	6	3	4	6	0	1	1	0	1	0	1	0	1	1	1	4	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	2	3.7142856	4.5	4.15			2.95	3.25	1	2.7142856	5	1.2	1.75	1	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ854VLT
2081	8976	NDAR_INVAZ854VLT	1521			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	5	5	5	5	5	5	5	4	2	4	4	9	4	5	4	4	5	5	4	5	5	1	1	1	0	1	0	1	0	2	1	1	4	2	3	3	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4.875	2.5	4.571429	4.5	4.5			2.95	3.25	1	2.7142856	5	1.55	1.625	1.5	1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ854VLT
2081	8976	NDAR_INVAZ854VLT	1521			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	0	0	1	6	6	5	6	6	4	6	5	2	4	4	9	6	5	4	6	4	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	1	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.5	2.5	5.285714	5.5	5.1		1	2.95	3.25	1	2.7142856	5	2.15	2.25	1.5	2.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVAZ854VLT
2081	8976	NDAR_INVBA923RJR	2828			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	9	0	0	6	2	4	6	3	3	3	0	0	0	0	1	0	0	1	2	3	1	4	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.125	0	2.5714285	4.5	1.4	1		1.4	0.125	0	2.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBA923RJR
2081	8976	NDAR_INVBA926NYH	2268			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	4	2	1	5	1	3	3	2	2	4	9	6	3	0	2	2	3	3	2	6	0	1	0	0	1	0	0	1	2	3	1	2	2	3	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	5	2.625	2	3	3	2.8	1		2.8	2.625	2	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBA926NYH
2081	8976	NDAR_INVBA926NYH	2268			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	0	1	6	6	4	5	5	5	5	4	4	3	3	4	3	4	4	4	4	4	4	5	6	0	1	1	0	1	1	1	1	2	3	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	5	3.5	4.285714	4	4.3809524			2.8	2.625	2	3	3	1.5809524	2.375	1.5	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBA926NYH
2081	8976	NDAR_INVBA926NYH	2268			M	2800	Visit12	12	Phase 2	316	0	0	0	0	0	0	1	6	6	6	6	6	6	6	3	3	6	6	4	4	6	6	6	3	4	3	5	6	0	0	1	0	1	0	0	1	3	2	1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	4	5.625	4.75	5.142857	3.5	5.095238			2.8	2.625	2	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBA926NYH
2081	8976	NDAR_INVBA926NYH	2268			M	5200	EndofPhase1_1a	7	Phase 1/1A	190	0	0	0	0	0	0	1	6	6	4	5	5	5	5	4	4	3	3	4	3	4	4	4	4	4	4	5	6	0	1	1	0	1	1	1	1	2	3	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	5	3.5	4.285714	4	4.3809524		1	2.8	2.625	2	3	3	1.5809524	2.375	1.5	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBA926NYH
2081	8976	NDAR_INVBA926NYH	2268			M	5800	EndofPhase2	18	Phase 2	484	0	0	0	0	0	0	1	5	3	3	4	4	2	5	4	3	2	3	9	4	4	4	5	2	4	3	6	6	0	0	1	0	1	0	0	1	3	2	1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	2	4.428571	3.5	3.8			2.8	2.625	2	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBA926NYH
2081	8976	NDAR_INVBB928ALU	1509			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	6	2	2	4	4	2	4	2	3	5	9	4	3	5	4	1	3	4	6	6	1	1	1	1	1	0	0	1	2	2	1	3	2	2	3	1	0	0	0	0	1	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.5	2.5	4.142857	3.5	3.7	1		3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB928ALU
2081	8976	NDAR_INVBB928ALU	1509			M	1600	Visit6	6	Phase 3	182	0	0	0	0	0	0	1	6	5	4	3	2	4	4	4	3	3	2	5	5	4	6	5	3	3	4	5	6	1	1	1	0	1	1	1	1	2	3	1	3	2	2	4	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4	3.25	4.857143	3.5	4.095238			3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB928ALU
2081	8976	NDAR_INVBB928ALU	1509			M	2800	Visit12	12	Phase 3	338	0	0	0	0	0	0	1	4	4	0	2	2	4	4	0	1	2	4	3	3	3	3	3	2	3	4	3	5	1	1	1	0	1	1	1	1	3	2	1	3	4	2	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	2.5	2.5	3.142857	3.5	2.8095238			3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB928ALU
2081	8976	NDAR_INVBB928ALU	1509			M	5200	EndofPhase1_1a	3	Phase 1/1A	64	0	0	0	0	0	0	1	2	6	2	5	5	5	3	4	1	3	4	9	3	2	4	3	2	4	3	6	5	1	1	0	1	1	1	1	1	1	3	1	3	2	2	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	1	0	0	1	1	1	1	4	4	2	3.5714285	3.5	3.6		1	3.7	3.5	2.5	4.142857	3.5	-0.1	0.5	-0.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB928ALU
2081	8976	NDAR_INVBB928ALU	1509			M	5800	EndofPhase2	4	Phase 2	100	0	0	0	0	0	0	1	4	3	4	3	4	3	2	4	2	1	3	9	1	2	2	2	1	3	4	2	4	1	0	1	0	0	1	0	0	2	3	1	4	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.375	1.5	2	3.5	2.7			3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB928ALU
2081	8976	NDAR_INVBB928ALU	1509			M	6000	EndofPhase3	18	Phase 3	529	0	0	0	0	0	0	1	0	3	2	2	2	3	3	0	0	2	5	9	3	2	3	4	2	4	4	5	6	1	1	1	1	1	1	0	1	1	3	1	3	1	2	4	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	1.75	3.5714285	4	2.75			3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB928ALU
2081	8976	NDAR_INVBB995NKV	2444			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	3	4	3	3	4	3	3	4	4	5	4	3	3	4	5	6	6	6	5	1	0	1	1	1	1	1	1	2	3	0	4	2	2	2	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.2857144	4	4.285714	6	4.05	1		4.05	3.2857144	4	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB995NKV
2081	8976	NDAR_INVBB995NKV	2444			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	2	2	5	2	1	6	3	1	3	6	9	6	6	1	6	6	6	4	6	6	1	0	1	0	1	1	1	2	2	1	1	4	3	2	3	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3	2.5	5.285714	5	4.105263			4.05	3.2857144	4	4.285714	6	0.055263158	-0.2857143	-1.5	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB995NKV
2081	8976	NDAR_INVBB995NKV	2444			F	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	9	4	4	3	4	4	3	3	2	4	2	9	5	5	4	6	4	4	4	4	6	1	1	1	1	1	1	1	1	2	1	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	5	3.5714285	2	4.857143	4	3.9473684			4.05	3.2857144	4	4.285714	6	-0.10263158	0.2857143	-2	0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB995NKV
2081	8976	NDAR_INVBB995NKV	2444			F	5200	EndofPhase1_1a	13	Phase 1/1A	366	0	0	0	0	0	0	1	4	3	4	2	4	2	6	1	2	3	2	9	4	4	4	5	4	4	4	5	6	1	1	1	0	1	1	1	1	2	2	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.25	1.75	4.571429	4	3.65		1	4.05	3.2857144	4	4.285714	6	-0.4	-0.035714287	-2.25	0.2857143	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBB995NKV
2081	8976	NDAR_INVBD176VUG	2033			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	1	1	1	1	1	1	2	0	0	0	9	2	2	2	2	3	4	3	4	4	1	0	0	0	1	1	0	0	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.125	0	2.7142856	3.5	1.75	1		1.75	1.125	0	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD176VUG
2081	8976	NDAR_INVBD176VUG	2033			M	5200	EndofPhase1_1a	1	Phase 1/1A	21	1	0	0	0	0	0	0	4	3	0	0	3	2	0	1	1	1	2	9	0	1	2	1	0	3	2	3	2	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	1.625	1	1.2857143	2.5	1.55		1	1.75	1.125	0	2.7142856	3.5	-0.2	0.5	1	-1.4285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD176VUG
2081	8976	NDAR_INVBD202YDD	1706			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	3	3	2	6	2	3	2	4	4	6	6	3	4	6	4	3	6	4	4	6	1	1	1	0	1	1	1	1	2	3	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	5	4.285714	5	4.142857	1		4.142857	3.375	5	4.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD202YDD
2081	8976	NDAR_INVBD202YDD	1706			M	1600	Visit6	6	Phase 1/1A	192	0	0	0	0	0	0	1	9	1	2	2	5	6	6	3	4	6	6	5	6	6	6	6	6	6	4	6	6	1	1	1	0	1	1	1	1	2	1	0	4	2	2	4	1	0	0	0	0	0	1	0	0	0	0	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5714285	5.25	6	5	4.9			4.142857	3.375	5	4.285714	5	0.75714284	0.19642857	0.25	1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD202YDD
2081	8976	NDAR_INVBD202YDD	1706			M	2800	Visit12	12	Phase 1/1A	378	0	0	0	0	0	0	1	6	6	6	6	6	6	6	4	4	6	6	6	4	6	4	6	6	6	6	5	6	1	1	1	0	1	1	1	1	2	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	5.75	5.5	5.285714	6	5.571429			4.142857	3.375	5	4.285714	5	1.4285715	2.375	0.5	1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD202YDD
2081	8976	NDAR_INVBD202YDD	1706			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	0	1	6	2	2	2	6	2	2	2	4	3	6	5	2	2	4	2	4	6	5	5	5	1	1	1	0	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3	4.5	3.4285715	5.5	3.6666667		1	4.142857	3.375	5	4.285714	5	-0.47619048	-0.375	-0.5	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD202YDD
2081	8976	NDAR_INVBD974GTH	1347			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	5	4	2	3	2	1	0	0	1	1	9	1	1	1	0	1	5	4	1	1	0	1	0	1	1	1	1	1	3	2	1	3	2	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	0.5	0.85714287	4.5	1.9	1		1.9	2.625	0.5	0.85714287	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBD974GTH	1347			M	1600	Visit6	6	Phase 2	165	0	0	0	0	0	0	1	0	0	2	2	2	1	2	1	1	2	1	9	2	2	2	4	3	5	3	2	3	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	1	2.5714285	4	2			1.9	2.625	0.5	0.85714287	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBD974GTH	1347			M	2800	Visit12	12	Phase 3	335	0	0	0	0	0	0	1	1	1	2	2	2	1	2	2	1	2	1	9	2	2	2	2	2	5	4	3	3	0	0	1	0	1	1	1	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.625	1	2.2857144	4.5	2.1			1.9	2.625	0.5	0.85714287	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBD974GTH	1347			M	4000	Visit18	18	Phase 3	516	0	0	0	0	0	0	1	4	6	2	4	6	2	6	0	0	2	4	9	2	2	4	2	2	2	2	4	4	1	1	1	0	1	1	1	1	2	1	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.75	1.5	2.857143	2	3			1.9	2.625	0.5	0.85714287	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBD974GTH	1347			M	5200	EndofPhase1_1a	1	Phase 1/1A	18	0	0	0	0	0	0	1	4	5	4	2	3	2	1	0	0	1	1	9	1	1	1	0	1	5	4	1	1	0	1	0	1	1	1	1	1	3	2	1	3	2	4	4	1	0	0	0	0	1	0	0	0	0	0	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.625	0.5	0.85714287	4.5	1.9		1	1.9	2.625	0.5	0.85714287	4.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBD974GTH	1347			M	5400	EndofPhase1b	4	Phase 1B	89	0	0	0	0	0	0	1	4	5	4	2	3	2	1	0	0	1	1	9	1	1	1	0	1	5	4	1	1	0	1	0	1	1	0	1	1	3		1	4	3	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	0.5	0.85714287	4.5	1.9			1.9	2.625	0.5	0.85714287	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBD974GTH	1347			M	5800	EndofPhase2	7	Phase 2	174	0	0	0	0	0	0	1	0	0	2	2	2	1	2	1	1	2	1	9	2	2	2	4	3	5	3	2	3	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	1	2.5714285	4	2			1.9	2.625	0.5	0.85714287	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBD974GTH
2081	8976	NDAR_INVBE385MVG	1310			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	4	0	2	4	2	2	1	2	1	1	9	4	3	2	4	0	6	4	4	4	0	0	1	1	1	0	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1	3	5	2.55	1		2.55	2	1	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE385MVG
2081	8976	NDAR_INVBE408EHN	1314			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	2	2	0	5	2	4	5	5	4	6	6	0	6	4	2	2	4	5	6	5	5	1	1	0	0	1	0	2	1	2	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	5	3.125	4	4	5.5	3.8095238	1		3.8095238	3.125	4	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE408EHN
2081	8976	NDAR_INVBE408EHN	1314			M	2800	Visit12	12	Phase 3	337	1	0	0	0	0	0	0	4	5	3	5	2	3	4	2	4	3	5	2	4	4	2	4	5	5	5	2	4	1	1	1	0	1	1	0	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.5	3.5	3.5714285	5	3.6666667			3.8095238	3.125	4	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE408EHN
2081	8976	NDAR_INVBE408EHN	1314			M	4000	Visit18	18	Phase 3	505	1	0	0	0	0	0	0	3	3	1	4	4	4	5	2	4	4	4	2	5	5	3	4	4	5	4	4	4	1	1	1	1	1	0	0	1	2	2	1	3	2	2	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	4	3.25	3.5	4.142857	4.5	3.7142856			3.8095238	3.125	4	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE408EHN
2081	8976	NDAR_INVBE408EHN	1314			M	5200	EndofPhase1_1a	6	Phase 1/1A	168	1	0	1	0	0	0	0	1	2	0	6	2	3	5	2	3	6	6	1	5	5	4	4	3	5	5	6	6	1	1	1	1	1	1	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.625	4	4.714286	5	3.8095238		1	3.8095238	3.125	4	4	5.5	0	-0.5	0	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE408EHN
2081	8976	NDAR_INVBE408EHN	1314			M	5400	EndofPhase1b	8	Phase 1B	220	1	0	0	0	0	0	0	3	2	1	5	3	2	5	2	4	4	5	3	3	3	3	6	4	5	4	4	6	1	1	1	1	1	1	0	1	2	2	1	3	2	2	2	1	0	1	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.875	4	4.142857	4.5	3.6666667			3.8095238	3.125	4	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE408EHN
2081	8976	NDAR_INVBE408EHN	1314			M	5800	EndofPhase2	10	Phase 2	273	1	0	1	0	0	0	0	2	4	0	5	2	2	0	0	3	4	5	4	3	4	4	4	4	5	4	2	4	1	1	1	1	1	0	0	1	2	2	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	5	1.875	4	3.5714285	4.5	3.0952382			3.8095238	3.125	4	4	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE408EHN
2081	8976	NDAR_INVBE738UC3	1558			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	6	3	4	5	4	4	1	1	4	4	9	4	4	0	6	6	5	5	5	6	1	1	1	1	1	1	1	1	2	2	1	4	2	3	4	1	0	0	0	1	1	0	0	1	1	1	0	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4	2.25	4.428571	5	4.1	1		4.1	4	2.25	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE738UC3
2081	8976	NDAR_INVBE738UC3	1558			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	2	3	1	3	2	3	4	4	1	3	4	9	3	2	2	3	4	5	3	6	6	0	1	0	0	0	0	1	0	1	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	1	1	1	1	1	1	1	5	2.75	2	3.7142856	4	3.2			4.1	4	2.25	4.428571	5	-0.9	-1.25	-0.25	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE738UC3
2081	8976	NDAR_INVBE738UC3	1558			F	2800	Visit12	12	Phase 1/1A	338	0	0	0	1	0	0	0	4	5	2	4	3	3	6	0	1	3	4	9	3	4	0	4	3	4	4	6	6	1	0	1	0	0	1	1	1	1	2	1	3	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.375	2	3.7142856	4	3.45			4.1	4	2.25	4.428571	5	-0.65	-0.625	-0.25	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE738UC3
2081	8976	NDAR_INVBE738UC3	1558			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	1	0	0	0	4	4	0	4	4	3	5	0	1	2	3	9	4	2	1	3	1	5	3	5	4	1	1	1	0	1	1	0	1	1	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	3	1.5	2.857143	4	2.9		1	4.1	4	2.25	4.428571	5	-1.2	-1	-0.75	-1.5714285	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE738UC3
2081	8976	NDAR_INVBE946TPN	1408			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	6	6	5	5	4	5	2	1	3	1	9	4	4	6	6	5	4	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.875	1.25	5.285714	4	4.45	1		4.45	4.875	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBE946TPN	1408			M	1600	Visit6	6	Phase 1B	171	0	0	0	1	0	0	0	6	6	4	6	6	5	5	2	0	1	2	9	5	4	5	5	3	5	3	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5	0.75	4.571429	4	4.15			4.45	4.875	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBE946TPN	1408			M	4000	Visit18	18	Phase 3	512	0	0	1	0	0	0	0	4	1	1	1	3	0	2	1	0	0	1	9	2	0	2	2	0	1	2	4	3	1	1	0	1	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.25	1.8571428	1.5	1.5			4.45	4.875	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBE946TPN	1408			M	5200	EndofPhase1_1a	4	Phase 1/1A	98	0	0	1	1	0	0	0	6	4	4	2	4	2	3	1	3	4	4	9	4	2	5	5	4	5	4	6	6	1	1	1	2	1	1	1	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	2.75	4.571429	4.5	3.9		1	4.45	4.875	1.25	5.285714	4	-0.55	-1.625	1.5	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBE946TPN	1408			M	5400	EndofPhase1b	9	Phase 1B	247	0	0	0	1	0	0	0	6	4	4	4	6	4	6	2	0	2	2	9	6	6	4	6	1	4	3	4	6	1	1	1	0	1	1	1	1	1	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.5	1	4.714286	3.5	4			4.45	4.875	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBE946TPN	1408			M	5800	EndofPhase2	12	Phase 2	336	0	0	0	1	0	0	0	6	4	4	2	0	2	6	4	1	1	1	9	4	4	4	6	1	4	4	5	6	1	1	0	1	1	1	1	1	2	1	1	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.5	0.75	4.285714	4	3.45			4.45	4.875	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBE946TPN	1408			M	6000	EndofPhase3	18	Phase 3	512	0	0	1	0	0	0	0	4	3	1	1	3	0	2	1	0	0	1	9	2	0	2	2	0	1	2	4	3	1	1	2	1	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0.25	1.8571428	1.5	1.6			4.45	4.875	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBE946TPN
2081	8976	NDAR_INVBF033CUH	1079			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	5	4	5	5	4	6	4	0	0	0	9	4	2	4	5	1	5	4	4	4	1	1	0	1	0	0	0	1	2	1	1	2	1	2	1	1	1	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	4.625	0	3.4285715	4.5	3.5	1		3.5	4.625	0	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF033CUH
2081	8976	NDAR_INVBF033CUH	1079			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	3	3	3	2	1	4	5	4	0	0	0	9	4	2	6	4	4	5	4	5	5	1	1	1	1	0	1	1	1	1	1	1	3	1	1	1	1	1	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	5	3.125	0	4.285714	4.5	3.2			3.5	4.625	0	3.4285715	4.5	-0.3	-1.5	0	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF033CUH
2081	8976	NDAR_INVBF033CUH	1079			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	4	2	2	2	2	1	4	3	0	0	0	9	6	4	4	5	3	5	4	5	6	1	1	1	1	0	0	1	1	1	2	1	2	1	2	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	6	2.5	0	4.714286	4.5	3.1			3.5	4.625	0	3.4285715	4.5	-0.4	-2.125	0	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF033CUH
2081	8976	NDAR_INVBF033CUH	1079			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	1	0	0	0	0	0	6	4	2	4	6	4	5	4	1	3	1	9	4	4	6	6	2	6	4	4	6	1	1	1	1	0	0	0	1	1	1	1	2	1	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	6	4.375	1.25	4.571429	5	4.1		1	3.5	4.625	0	3.4285715	4.5	0.6	-0.25	1.25	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF033CUH
2081	8976	NDAR_INVBF815JL0	2261			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	1	4	6	5	6	2	5	5	3	6	4	5	5	5	5	6	4	5	5	1	1	1	1	1	1	1	1	2	1	1	4	1	1	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	4.75	4.857143	5	4.6190476	1		4.6190476	4.25	4.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF815JL0
2081	8976	NDAR_INVBF815JL0	2261			M	2800	Visit12	12	Phase 3	374	0	0	0	0	0	0	1	5	3	2	2	2	2	3	0	1	1	2	9	2	2	5	4	2	5	4	4	4	1	1	0	1	1	1	0	0	1	2	0	4	1	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	1	3.2857144	4.5	2.75			4.6190476	4.25	4.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF815JL0
2081	8976	NDAR_INVBF815JL0	2261			M	5200	EndofPhase1_1a	5	Phase 1/1A	147	0	0	0	0	0	0	1	6	2	0	3	5	2	4	1	2	2	2	9	4	3	4	3	4	5	3	4	4	0	1	1	1	1	1	1	1	1	1	0	4	1	3	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	1.5	3.7142856	4	3.15		1	4.6190476	4.25	4.75	4.857143	5	-1.4690477	-1.375	-3.25	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF815JL0
2081	8976	NDAR_INVBF815JL0	2261			M	5800	EndofPhase2	6	Phase 2	179	0	0	0	0	0	0	1	5	3	0	2	2	2	4	0	1	0	2	9	2	2	4	4	2	3	3	3	2	1	1	1	0	1	1	0	1	1	2	0	4	1	2	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0.75	2.7142856	3	2.3			4.6190476	4.25	4.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF815JL0
2081	8976	NDAR_INVBF815JL0	2261			M	6000	EndofPhase3	18	Phase 3	534	0	0	0	0	0	0	1	5	1	1	2	2	2	2	1	1	1	1	9	2	2	4	4	4	5	5	4	5	1	1	0	1	1	1	1	1	2	1	0	4	1	1	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.75	3.5714285	5	2.7			4.6190476	4.25	4.75	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBF815JL0
2081	8976	NDAR_INVBG070VNE	2677			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	0	4	2	0	2	0	0	4	6	9	0	2	2	2	0	4	2	3	4	1	0	1	1	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2	2.5	1.8571428	3	2.25	1		2.25	2	2.5	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG070VNE
2081	8976	NDAR_INVBG070VNE	2677			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	6	4	0	4	4	4	5	0	0	4	2	9	4	6	4	5	4	5	2	5	6	1	0	1	0	1	1	1	1	1	2	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	3.375	1.5	4.857143	3.5	3.7			2.25	2	2.5	1.8571428	3	1.45	1.375	-1	3	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG070VNE
2081	8976	NDAR_INVBG070VNE	2677			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	1	0	0	0	6	5	3	3	3	2	4	3	4	5	6	6	3	4	2	4	5	5	2	5	5	1	1	1	0	1	1	1	1	1	1	1	3	3	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	7	3.625	5.25	4	3.5	4.047619			2.25	2	2.5	1.8571428	3	1.7976191	1.625	2.75	2.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG070VNE
2081	8976	NDAR_INVBG070VNE	2677			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	0	1	6	6	5	4	4	4	5	2	6	5	6	6	3	3	4	5	6	5	4	5	6	1	1	1	1	1	0	1	0	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	4.5	5.75	4.571429	4.5	4.7619047		1	2.25	2	2.5	1.8571428	3	2.5119047	2.5	3.25	2.7142856	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG070VNE
2081	8976	NDAR_INVBG113KYW	2103			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	2	2	1	2	1	3	1	0	0	1	9	2	2	5	4	2	1	1	6	6	1	0	0	0	1	1	0	0	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.125	0.25	3.857143	1	2.35	1		2.35	2.125	0.25	3.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG113KYW
2081	8976	NDAR_INVBG113KYW	2103			M	1600	Visit6	6	Phase 2	176	0	0	0	0	0	1	0	6	6	4	3	6	6	6	3	0	2	4	9	3	2	5	5	2	2	1	6	6	1	0	0	0	1	1	0	0	2	1	1	2	4	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	1	0	0	0	1	1	1	1		5	1.5	4.142857	1.5	3.9			2.35	2.125	0.25	3.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG113KYW
2081	8976	NDAR_INVBG113KYW	2103			M	2800	Visit12	12	Phase 3	309	0	0	0	0	0	1	0	5	5	2	1	4	3	3	0	1	1	3	9	3	3	4	3	3	1	3	6	6	1	0	0	0	1	1	0	0	2	1	1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.25	4	2	3			2.35	2.125	0.25	3.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG113KYW
2081	8976	NDAR_INVBG113KYW	2103			M	5200	EndofPhase1_1a	3	Phase 1/1A	82	0	0	0	0	0	1	0	6	6	4	2	5	2	3	1	2	2	4	9	3	3	4	4	3	2	1	5	6	0	0	0	0	1	1	0	0	2	2	1	2	4	4	4	1	0	0	0	0	0	1	0	0	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.625	2	4	1.5	3.4		1	2.35	2.125	0.25	3.857143	1	1.05	1.5	1.75	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG113KYW
2081	8976	NDAR_INVBG113KYW	2103			M	5800	EndofPhase2	8	Phase 2	216	0	0	0	0	0	1	0	6	2	2	4	6	3	6	3	3	3	4	9	6	3	6	4	1	1	2	5	6	2	2	2	2	1	2	2	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	25	0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	0	4	4	2.5	4.428571	1.5	3.8			2.35	2.125	0.25	3.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG113KYW
2081	8976	NDAR_INVBG113KYW	2103			M	6000	EndofPhase3	18	Phase 3	484	0	0	0	0	0	1	0	6	4	4	4	4	4	5	3	1	2	1	9	2	2	3	3	1	2	3	3	5	1	0	0	0	1	1	0	0	3	1	1	2	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	1	2.7142856	2.5	3.1			2.35	2.125	0.25	3.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG113KYW
2081	8976	NDAR_INVBG594NRZ	1934			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	1	2	2	0	0	1	9	2	3	2	2	1	1	2	2	2	0	1	0	0	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	13	0		0		0		1	17	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	4	0.625	0.25	2	1.5	1.15	1		1.15	0.625	0.25	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG594NRZ
2081	8976	NDAR_INVBG849NYU	1236			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	0	2	4	4	4	4	0	2	4	6	9	4	2	4	4	3	3	4	4	5	2	1	1	2	1	1	0	1	2	1	0		2	2	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3	3	3.7142856	3.5	3.45	1		3.45	3	3	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG849NYU
2081	8976	NDAR_INVBG849NYU	1236			F	1600	Visit6	6	Phase 1/1A	189	0	0	0	0	0	0	1	9	4	4	6	6	6	3	3	4	4	4	9	4	2	4	4	4	3	4	4	6	0	0	1	0	0	0	0	0	2	2	0	4	2	2	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.571429	3	4	3.5	4.1578946		1	3.45	3	3	3.7142856	3.5	0.70789474	1.5714285	0	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBG849NYU
2081	8976	NDAR_INVBH357BP1	2399			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	0	2	2	2	2	0	2	2	5	9	3	2	1	2	1	5	2	4	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	1	4	1.5	2.25	2.4285715	3.5	2.25	1		2.25	1.5	2.25	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH357BP1
2081	8976	NDAR_INVBH357BP1	2399			M	1600	Visit6	6	Phase 1/1A	162	0	0	1	0	0	0	0	6	2	1	2	2	4	2	1	6	6	5	6	5	6	6	5	6	6	2	6	6	1	0	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	5.75	5.714286	4	4.3333335			2.25	1.5	2.25	2.4285715	3.5	2.0833333	1	3.5	3.2857144	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH357BP1
2081	8976	NDAR_INVBH357BP1	2399			M	2800	Visit12	12	Phase 1/1A	330	0	0	1	0	0	0	0	6	5	5	3	2	2	2	3	6	4	5	6	4	4	4	5	5	6	5	4	4	1	1	1	0	1	1	1	1	1	1	0	4	4	3	4	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.5	5.25	4.285714	5.5	4.285714			2.25	1.5	2.25	2.4285715	3.5	2.0357144	2	3	1.8571428	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH357BP1
2081	8976	NDAR_INVBH357BP1	2399			M	5200	EndofPhase1_1a	18	Phase 1/1A	510	0	0	1	0	0	0	0	6	4	5	4	4	4	4	3	6	6	5	6	3	5	4	5	5	5	4	6	5	1	1	1	2	1	1	1	1	1	1	1	3	2	2	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	5.75	4.714286	4.5	4.714286		1	2.25	1.5	2.25	2.4285715	3.5	2.4642856	2.75	3.5	2.2857144	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH357BP1
2081	8976	NDAR_INVBH433JG4	2345			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	1	1	2	1	0	0	1	0	9	1	1	1	2	1	2	2	1	2	0	0	0	0	0	1	0	2	3	3	1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		2	0	2	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.125	0.25	1.2857143	2	1.15	1		1.15	1.125	0.25	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH433JG4
2081	8976	NDAR_INVBH433JG4	2345			M	5200	EndofPhase1_1a	6	Phase 1/1A	165	0	0	0	0	0	1	0	2	1	1	2	1	1	1	2	0	0	0	9	1	1	1	1	1	4	4	2	2	2	2	2	1	1	1	2	2	3	3	0	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	0	1.2857143	4	1.4		1	1.15	1.125	0.25	1.2857143	2	0.25	0.25	-0.25	0	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH433JG4
2081	8976	NDAR_INVBH921KAQ	1676			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	0	0	2	2	0	2	2	0	0	2	9	3	1	0	4	0	4	2	4	5	1	0	1	0	0	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.5	2.4285715	3	1.85	1		1.85	1.5	0.5	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH921KAQ
2081	8976	NDAR_INVBH921KAQ	1676			M	1600	Visit6	6	Phase 1/1A	167	1	0	1	0	0	0	0	4	0	0	0	2	0	1	1	0	0	0	9	1	0	0	2	0	4	1	4	3	0	0	0	0	0	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0	1.4285715	2.5	1.15			1.85	1.5	0.5	2.4285715	3	-0.7	-0.5	-0.5	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH921KAQ
2081	8976	NDAR_INVBH921KAQ	1676			M	2800	Visit12	12	Phase 1/1A	341	1	0	0	0	0	0	0	4	0	0	0	2	0	3	1	0	0	0	9	1	0	0	6	0	4	1	4	3	0	0	1	0	0	0	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0	2	2.5	1.45			1.85	1.5	0.5	2.4285715	3	-0.4	-0.25	-0.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH921KAQ
2081	8976	NDAR_INVBH921KAQ	1676			M	5200	EndofPhase1_1a	18	Phase 1/1A	501	1	0	1	0	0	0	0	6	0	0	0	0	0	1	1	0	0	1	9	1	0	0	0	0	4	1	4	4	1	0	0	0	0	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0.25	1.2857143	2.5	1.15		1	1.85	1.5	0.5	2.4285715	3	-0.7	-0.5	-0.25	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBH921KAQ
2081	8976	NDAR_INVBJ073HKT	1588			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	1	2	1	2	0	2	0	2	1	1	9	0	1	0	2	0	2	1	2	2	0	0	0	0	1	1	1	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.125	1	1	1.5	1.15	1		1.15	1.125	1	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ073HKT
2081	8976	NDAR_INVBJ073HKT	1588			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	1	9	0	1	0	0	0	3	3	0	1	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	6	0.25	0.75	0.2857143	3	0.65		1	1.15	1.125	1	1	1.5	-0.5	-0.875	-0.25	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ073HKT
2081	8976	NDAR_INVBJ229NV6	1367			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	4	2	2	0	2	0	1	2	1	9	4	2	3	2	1	3	3	5	6	1	0	1	1	1	1	0	1	3	3	1	1	4	3	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	7	1.25	1	3.2857144	3	2.15	1		2.15	1.25	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ229NV6
2081	8976	NDAR_INVBJ229NV6	1367			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	4	0	0	4	0	0	2	1	0	0	3	9	3	4	2	5	5	3	2	5	6	1	0	1	1	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.375	0.75	4.285714	2.5	2.45			2.15	1.25	1	3.2857144	3	0.3	0.125	-0.25	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ229NV6
2081	8976	NDAR_INVBJ229NV6	1367			M	2800	Visit12	12	Phase 2	335	0	0	0	0	0	0	1	4	0	0	0	3	0	0	2	0	0	0	9	2	4	4	6	5	4	3	6	6	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.125	0	4.714286	3.5	2.45			2.15	1.25	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ229NV6
2081	8976	NDAR_INVBJ229NV6	1367			M	4000	Visit18	18	Phase 2	513	0	0	0	0	0	0	1	1	3	1	0	2	0	0	2	0	0	0	9	1	1	4	1	3	3	2	5	5	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.125	0	2.857143	2.5	1.7			2.15	1.25	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ229NV6
2081	8976	NDAR_INVBJ229NV6	1367			M	5200	EndofPhase1_1a	11	Phase 1/1A	316	0	0	0	0	0	0	1	4	0	0	0	3	0	0	2	0	0	0	9	2	4	4	6	5	5	3	6	6	1	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.125	0	4.714286	4	2.5		1	2.15	1.25	1	3.2857144	3	0.35	-0.125	-1	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ229NV6
2081	8976	NDAR_INVBJ258LJ7	2335			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	3	4	3	3	5	5	0	3	4	4	3	4	4	2	2	4	4	3	5	4	0	1	0	0	0	0	0	1	3	1	1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.625	3.5	3.5714285	3.5	3.5714285	1		3.5714285	3.625	3.5	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ258LJ7
2081	8976	NDAR_INVBJ258LJ7	2335			F	2800	Visit12	12	Phase 1/1A	393	0	0	0	0	0	1	0	6	4	4	4	4	2	3	0	3	3	6	9	3	2	1	2	4	4	3	4	3	1	1	0	0	0	0	1	0	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.375	3	2.7142856	3.5	3.25		1	3.5714285	3.625	3.5	3.5714285	3.5	-0.32142857	-0.25	-0.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ258LJ7
2081	8976	NDAR_INVBJ566NYA	1269			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	0	1	2	2	3	2	2	0	0	0	9	4	1	2	2	2	3	4	4	3	2	2	2	2	1	1	0	0	1	1	1	3	2	3	2	1	0	1	0	0	0	0	0	2	1	1	1	1	4	1	5	0		1	21	0		2	0	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	2.5714285	3.5	2.1	1		2.1	2.125	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ566NYA
2081	8976	NDAR_INVBJ566NYA	1269			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	2	0	0	2	2	2	2	1	0	0	0	9	3	0	0	4	2	0	1	4	5	0	0	0	0	1	1	1	1	2	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	3	1.375	0	2.5714285	0.5	1.5			2.1	2.125	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ566NYA
2081	8976	NDAR_INVBJ566NYA	1269			M	2800	Visit12	12	Phase 2	346	0	0	0	0	0	1	0	4	3	2	3	3	3	3	3	2	4	3	9	3	3	3	3	5	0	0	3	4	0	0	0	0	1	1	0	1	3	1	0	4	4	4	4	1	0	1	0	0	0	1	0	1	0	1	1	0		0		0		1	30	0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	5	3	2.25	3.4285715	0	2.85			2.1	2.125	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ566NYA
2081	8976	NDAR_INVBJ566NYA	1269			M	5200	EndofPhase1_1a	2	Phase 1/1A	51	0	0	0	0	0	1	0	4	3	1	2	4	2	3	2	2	2	1	9	3	2	4	3	3	2	3	4	4	0	0	0	0	1	1	0	2	2	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	28	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	5	2.625	1.25	3.2857144	2.5	2.7		1	2.1	2.125	0	2.5714285	3.5	0.6	0.5	1.25	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ566NYA
2081	8976	NDAR_INVBJ566NYA	1269			M	5800	EndofPhase2	15	Phase 2	416	0	0	0	0	0	1	0	3	1	0	1	2	0	2	1	0	0	0	9	0	0	0	2	0	0	0	1	4	2	2	2	2	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.25	0	1	0	0.85			2.1	2.125	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ566NYA
2081	8976	NDAR_INVBJ566NYA	1269			M	6000	EndofPhase3	16	Phase 3	441	0	0	0	0	0	1	0	3	2	1	1	2	0	3	1	0	0	0	9	1	0	1	3	0	1	2	1	4	2	2	2	2	1	1	1	1	3	2	1	4	3	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	0	1	6	1.625	0	1.4285715	1.5	1.3			2.1	2.125	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ566NYA
2081	8976	NDAR_INVBJ775APM	2374			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	2	1	1	2	2	1	0	0	0	1	2	0	2	3	1	2	3	3	4	1	1	2	1	1	1	2	2	3	3	0	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		1	2	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	0.25	2.142857	2.5	1.5714285	1		1.5714285	1.5	0.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBJ775APM
2081	8976	NDAR_INVBK235DJB	1966			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	4	3	3	3	0	1	2	0	0	3	9	6	5	6	3	2	3	2	6	6	2	2	2	1	0	0	1	1	2	1	1	3	3	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	3	0		0		1	27	0		2	2	2	0	0	0	0	1	0	0	0	0	1	0	1	1	1	2.625	0.75	4.857143	2.5	3.15	1		3.15	2.625	0.75	4.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK235DJB
2081	8976	NDAR_INVBK235DJB	1966			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	1	0	3	3	0	3	4	1	3	4	1	3	3	5	4	4	5	5	5	3	3	4	5	1	0	0	1	1	1	1	1	2	1	1	3	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	0		0		0		1	30	0		2	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.625	3	4.571429	3	3.3809524			3.15	2.625	0.75	4.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK235DJB
2081	8976	NDAR_INVBK235DJB	1966			M	5200	EndofPhase1_1a	3	Phase 1/1A	81	0	0	0	0	0	1	0	3	3	2	2	2	2	2	2	2	4	3	9	3	3	5	3	4	2	2	4	5	2	2	2	1	1	1	1	1	1	1	1	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	0		0		0		1	30	0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.25	2.25	3.857143	2	2.9		1	3.15	2.625	0.75	4.857143	2.5	-0.25	-0.375	1.5	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK235DJB
2081	8976	NDAR_INVBK235DJB	1966			M	5800	EndofPhase2	12	Phase 2	345	0	0	0	0	0	1	0	4	3	3	2	2	2	3	3	1	3	3	9	4	3	5	3	3	2	2	3	5	2	2	2	0	1	1	1	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.75	1.75	3.7142856	2	2.95			3.15	2.625	0.75	4.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK235DJB
2081	8976	NDAR_INVBK235DJB	1966			M	6000	EndofPhase3	18	Phase 3	504	0	0	0	0	0	1	0	4	4	3	3	4	0	0	2	5	4	3	5	3	3	1	5	5	6	5	4	5	1	1	1	1	1	1	0	1	3		1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.5	4.25	3.7142856	5.5	3.5238094			3.15	2.625	0.75	4.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK235DJB
2081	8976	NDAR_INVBK367VDZ	1778			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	1	0	0	1	0	2	0	2	0	0	2	0	0	0	9	2	1	4	2	0	3	3	5	5	0	1	0	0	1	0	0	1	3	1	0	4	2	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	4	0.875	0	2.7142856	3	1.6	1		1.6	0.875	0	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK367VDZ
2081	8976	NDAR_INVBK367VDZ	1778			M	5200	EndofPhase1_1a	6	Phase 1/1A	177	1	0	0	0	0	0	0	2	0	0	0	2	0	2	2	0	0	0	9	1	0	4	1	0	3	1	0	6	1	0	0	0	1	0	0	1	1	2	1	2	4	2	1	0	0	0	0	0	0	0	0					1	14	0		0		1	16	0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	3	1	0	1.7142857	2	1.2		1	1.6	0.875	0	2.7142856	3	-0.4	0.125	0	-1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK367VDZ
2081	8976	NDAR_INVBK841LCL	2154			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	0	0	0	0	0	2	0	0	0	0	9	0	1	2	2	2	4	1	3	5	0	0	0	0	1	1	1	1	3	3	0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	0.75	0	2.142857	2.5	1.3	1		1.3	0.75	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK841LCL
2081	8976	NDAR_INVBK841LCL	2154			F	2800	Visit12	12	Phase 2	365	0	0	0	1	0	0	0	3	3	1	1	2	1	1	1	1	1	1	9	1	1	2	2	1	4	1	4	3	0	0	0	0	1	1	1	1	3	3	0	4	4	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	1.625	0.75	2	2.5	1.75			1.3	0.75	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK841LCL
2081	8976	NDAR_INVBK841LCL	2154			F	5200	EndofPhase1_1a	6	Phase 1/1A	175	0	0	0	1	0	0	0	3	0	1	3	0	2	1	0	1	0	1	9	0	1	1	1	1	5	3	3	3	1	1	0	0	1	1	1	1	1	3	0	4	1	4	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.5	1.4285715	4	1.5		1	1.3	0.75	0	2.142857	2.5	0.2	0.5	0.5	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK841LCL
2081	8976	NDAR_INVBK841LCL	2154			F	5800	EndofPhase2	18	Phase 2	527	0	0	0	1	0	0	0	1	1	1	1	1	1	2	0	1	1	1	9	1	1	1	2	2	5	4	1	3	1	1	1	0	1	1	1	1	1	3	0	4	2	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1	0.75	1.5714285	4.5	1.55			1.3	0.75	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBK841LCL
2081	8976	NDAR_INVBL029PEE	2416			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	4	4	4	4	6	6	4	4	4	3	4	4	4	6	6	5	4	6	6	1	1	0	0	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5	3.75	5.142857	4.5	4.7619047	1		4.7619047	5	3.75	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL029PEE
2081	8976	NDAR_INVBL029PEE	2416			M	5200	EndofPhase1_1a	3	Phase 1/1A	77	0	1	0	0	0	0	0	5	4	4	5	4	5	5	5	5	4	4	4	4	4	4	4	4	4	4	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.625	4.25	4.285714	4	4.3809524		1	4.7619047	5	3.75	5.142857	4.5	-0.3809524	-0.375	0.5	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL029PEE
2081	8976	NDAR_INVBL029PEE	2416			M	5400	EndofPhase1b	5	Phase 1B	133	0	1	0	0	0	0	0	6	4	4	4	4	4	4	4	4	4	4	6	4	4	4	4	6	3	4	4	6	1	1	1	0	1	0	1	1	1	1	1	3	2	2	2	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	4.5	4.571429	3.5	4.3333335			4.7619047	5	3.75	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL029PEE
2081	8976	NDAR_INVBL536PAX	1358			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	1	2	3	2	5	3	1	1	1	9	2	2	4	4	3	6	4	4	4	1	1	0	0	1	1	0	0	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.5	0.75	3.2857144	5	2.8	1		2.8	2.5	0.75	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL536PAX
2081	8976	NDAR_INVBL626TPV	2430			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	1	1	2	1	9	2	1	2	1	2	2	2	3	3	0	0	0	0	2	2	1	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.875	1	2	2	1.85	1		1.85	1.875	1	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL626TPV
2081	8976	NDAR_INVBL739EY4	2201			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	3	0	2	0	3	3	0	0	0	9	2	2	2	2	0	3	1	2	3	0	0	1	0	1	1	0	1	1	1	1	2	2	4	3	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	2.375	0	1.8571428	2	1.8	1		1.8	2.375	0	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL739EY4
2081	8976	NDAR_INVBL739EY4	2201			F	1600	Visit6	6	Phase 1/1A	171	0	0	1	0	0	0	0	6	2	2	1	2	1	2	4	0	0	0	9	0	2	2	4	1	3	2	5	2	0	0	0	0	1	1	1	1	2	1	1	4	2	3	3	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	7	2.5	0	2.2857144	2.5	2.05			1.8	2.375	0	1.8571428	2	0.25	0.125	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL739EY4
2081	8976	NDAR_INVBL739EY4	2201			F	5200	EndofPhase1_1a	9	Phase 1/1A	309	0	0	0	0	0	1	0	4	4	2	0	2	6	5	2	0	4	5	9	5	1	3	6	2	4	1	2	2	1	0	1	0	1	1	1	1	2	3	1	4	1	4	4	1	0	0	0	0	1	1	0	1	0	1	0	1	30	0		0		1	16	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	3.125	2.25	3	2.5	3		1	1.8	2.375	0	1.8571428	2	1.2	0.75	2.25	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL739EY4
2081	8976	NDAR_INVBL772UYA	1287			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	3	3	2	1	2	3	2	2	4	4	2	1	2	4	3	1	4	3	4	4	5	1	1	1	1	1	1	1	1	1	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	0	4	2.25	2.75	3.2857144	3.5	2.8095238	1		2.8095238	2.25	2.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL772UYA
2081	8976	NDAR_INVBL772UYA	1287			M	1600	Visit6	6	Phase 1/1A	169	1	0	1	0	0	0	0	6	1	4	4	4	4	6	4	6	5	3	3	2	2	4	6	6	5	3	4	6	1	1	1	1	1	1	1	1	1	1	1	3	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	1	0	0	1	1	1	1	4	4.125	4.25	4.285714	4	4.1904764			2.8095238	2.25	2.75	3.2857144	3.5	1.3809524	1.875	1.5	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL772UYA
2081	8976	NDAR_INVBL772UYA	1287			M	2800	Visit12	12	Phase 1/1A	344	1	0	1	0	0	0	0	5	4	2	1	2	1	2	1	2	2	3	9	2	1	2	2	4	4	3	4	4	1	1	1	0	1	1	1	0	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	1.75	2.7142856	3.5	2.55			2.8095238	2.25	2.75	3.2857144	3.5	-0.2595238	0	-1	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL772UYA
2081	8976	NDAR_INVBL772UYA	1287			M	4000	Visit18	18	Phase 1/1A	504	1	0	0	0	0	0	0	4	2	3	3	4	4	4	1	2	4	5	9	3	3	4	4	5	6	6	4	5	1	1	0	0	1	1	0	0	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.125	2.75	4	6	3.8		1	2.8095238	2.25	2.75	3.2857144	3.5	0.9904762	0.875	0	0.71428573	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL772UYA
2081	8976	NDAR_INVBL806MLE	1086			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	1	2	5	2	5	1	5	4	4	6	4	4	0	3	5	3	4	4	4	1	1	2	2	1	1	1	1	1	3	0	4	1	3	4	1	0	1	0	0	0	0	0	1	1	1	2	0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	6	2.75	4.75	3.4285715	3.5	3.4285715	1		3.4285715	2.75	4.75	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL806MLE
2081	8976	NDAR_INVBL806MLE	1086			M	1600	Visit6	6	Phase 1/1A	209	1	0	0	0	0	0	0	4	4	5	4	4	1	2	4	4	2	2	5	2	3	3	2	3	5	5	4	2	1	1	1	1	1	1	1	1	1	2	1	2	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	3.5	3.25	2.7142856	5	3.3333333			3.4285715	2.75	4.75	3.4285715	3.5	-0.0952381	0.75	-1.5	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL806MLE
2081	8976	NDAR_INVBL806MLE	1086			M	2800	Visit12	12	Phase 1/1A	399	1	0	0	0	0	0	0	4	4	3	4	4	4	2	3	4	4	2	5	3	3	1	4	2	5	4	4	2	1	1	1	0	1	1	1	1	1	1	1	3	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1		3.5	3.75	2.7142856	4.5	3.3809524			3.4285715	2.75	4.75	3.4285715	3.5	-0.04761905	0.75	-1	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL806MLE
2081	8976	NDAR_INVBL806MLE	1086			M	5200	EndofPhase1_1a	18	Phase 1/1A	544	1	0	0	0	0	0	0	4	4	4	4	4	4	2	3	4	3	2	5	3	3	2	4	3	5	5	4	2	1	1	1	1	1	1	1	1	1	2	1	3	2	2		0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0		0	0	0		0	0	0	0	1	1	1	1		3.625	3.5	3	5	3.5238094		1	3.4285715	2.75	4.75	3.4285715	3.5	0.0952381	0.875	-1.25	-0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBL806MLE
2081	8976	NDAR_INVBM553XKE	2385			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	6	4	4	5	2	2	2	1	1	2	2	2	1	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	16	0		0		1	14	0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	4	3.125	3.25	3.4285715	5	3.4285715	1		3.4285715	3.125	3.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM553XKE
2081	8976	NDAR_INVBM553XKE	2385			M	1600	Visit6	6	Phase 1/1A	181	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	2	1	1	9	1	1	1	1	1	2	1	2	3	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1	1	1.4285715	1.5	1.25			3.4285715	3.125	3.25	3.4285715	5	-2.1785715	-2.125	-2.25	-2	-3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM553XKE
2081	8976	NDAR_INVBM553XKE	2385			M	5200	EndofPhase1_1a	8	Phase 1/1A	229	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	1	2	2	9	2	2	2	2	2	1	1	2	2	1	0	1	0	1	1	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2	1.25	2	1	1.85		1	3.4285715	3.125	3.25	3.4285715	5	-1.5785714	-1.125	-2	-1.4285715	-4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM553XKE
2081	8976	NDAR_INVBM553XKE	2385			M	5800	EndofPhase2	10	Phase 2	280	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	2	2	2	9	2	2	1	2	2	2	1	3	2	2	2	2	1	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1		0		1		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	2	1.5	2	1.5	1.95			3.4285715	3.125	3.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM553XKE
2081	8976	NDAR_INVBM742EZ2	1850			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	2	0	1	1	1	2	2	5	3	5	5	2	5	2	4	1	4	2	4	5	1	0	1	0	1	1	1	1	1	2	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	1.625	4.5	3.2857144	3	2.857143	1		2.857143	1.625	4.5	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM742EZ2
2081	8976	NDAR_INVBM742EZ2	1850			F	5200	EndofPhase1_1a	2	Phase 1/1A	105	0	0	0	1	0	0	0	2	0	2	1	2	1	1	3	0	4	5	9	2	1	1	3	1	3	2	3	5	1	0	1	0	1	1	1	1	1	2	1	4	3	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	1.5	2.25	2.2857144	2.5	2.1		1	2.857143	1.625	4.5	3.2857144	3	-0.75714284	-0.125	-2.25	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM742EZ2
2081	8976	NDAR_INVBM759BC4	2740			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	2	0	2	0	0	0	1	0	0	9	2	1	2	4	1	5	5	4	5	1	1	0	1	1	0	1	1	2	3	0	4	1	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.75	0.25	2.7142856	5	1.8	1		1.8	0.75	0.25	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM759BC4
2081	8976	NDAR_INVBM759BC4	2740			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	4	2	4	4	2	2	5	4	1	0	0	9	2	4	4	4	2	5	5	5	6	1	1	1	0	1	1	1	1	2	3	1	3	2	2	2	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	0.25	3.857143	5	3.25			1.8	0.75	0.25	2.7142856	5	1.45	2.625	0	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM759BC4
2081	8976	NDAR_INVBM759BC4	2740			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	0	1	0	0	0	2	2	1	0	0	1	0	0	9	2	2	0	2	0	5	4	0	2	1	1	1	0	1	0	0	1	3		0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.625	0.25	1.1428572	4.5	1.15			1.8	0.75	0.25	2.7142856	5	-0.65	-0.125	0	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM759BC4
2081	8976	NDAR_INVBM759BC4	2740			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	0	1	0	0	0	2	2	0	0	0	0	2	0	9	2	2	3	4	1	5	4	2	4	1	1	1	1	1	1	1	1	2	3	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.5	0.5	2.5714285	4.5	1.65		1	1.8	0.75	0.25	2.7142856	5	-0.15	-0.25	0.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM759BC4
2081	8976	NDAR_INVBM981LV1	2326			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	0	0	0	2	2	2	0	1	2	1	9	3	2	2	2	1	3	4	3	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	26	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.5	1	2.7142856	3.5	2.1	1		2.1	1.5	1	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM981LV1
2081	8976	NDAR_INVBM981LV1	2326			F	1600	Visit6	6	Phase 2	168	0	0	0	0	1	0	0	6	4	0	5	6	3	3	2	3	3	1	2	3	3	1	4	4	5	5	2	6	1	1	1	2	1	1	1	1	1	1	1	4	3	3	3	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.625	2.25	3.2857144	5	3.3809524			2.1	1.5	1	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM981LV1
2081	8976	NDAR_INVBM981LV1	2326			F	5200	EndofPhase1_1a	2	Phase 1/1A	42	0	0	0	0	1	0	0	6	0	0	2	2	2	2	1	1	2	1	9	3	2	2	4	1	5	2	4	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	1.875	1	3.142857	3.5	2.4		1	2.1	1.5	1	2.7142856	3.5	0.3	0.375	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM981LV1
2081	8976	NDAR_INVBM981LV1	2326			F	5800	EndofPhase2	12	Phase 2	313	0	0	0	0	1	0	0	6	0	0	2	2	2	3	1	0	0	1	9	2	0	3	2	3	5	1	4	2	1	0	1	0	1	1	1	1	1	1	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	2	0.25	2.2857144	3	1.95			2.1	1.5	1	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM981LV1
2081	8976	NDAR_INVBM981LV1	2326			F	6000	EndofPhase3	18	Phase 3	496	0	0	0	0	0	0	1	6	4	1	4	2	3	3	2	3	4	4	5	4	4	3	4	3	5	3	4	6	1	0	1	0	1	1	1	1	2	1	1	4	2	2	3	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	4	4	4	3.6666667			2.1	1.5	1	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBM981LV1
2081	8976	NDAR_INVBN024ZXL	1775			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	5	5	5	5	5	6	5	2	4	4	9	3	5	4	5	4	4	4	5	5	1	1	0	1	1	1	1	1	3	1	1	2	3	1	3	1	0	1	0	1	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	5.25	2.5	4.428571	4	4.55	1		4.55	5.25	2.5	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN024ZXL
2081	8976	NDAR_INVBN024ZXL	1775			M	1600	Visit6	6	Phase 1/1A	161	0	0	0	0	0	1	0	6	5	5	5	5	5	6	2	1	2	1	9	3	4	4	5	5	4	4	4	4	1	1	2	0	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	1	1	0	1	0	1	1	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.875	1	4.142857	4	4			4.55	5.25	2.5	4.428571	4	-0.55	-0.375	-1.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN024ZXL
2081	8976	NDAR_INVBN024ZXL	1775			M	2800	Visit12	12	Phase 1/1A	333	0	0	0	0	0	1	0	6	3	3	4	4	5	5	3	2	4	5	9	3	5	3	4	6	5	3	4	4	1	1	2	1	1	1	1	1	3	1	1	3	2	2	2	1	0	0	0	0	1	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.125	2.75	4.142857	4	4.05			4.55	5.25	2.5	4.428571	4	-0.5	-1.125	0.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN024ZXL
2081	8976	NDAR_INVBN024ZXL	1775			M	5200	EndofPhase1_1a	18	Phase 1/1A	494	0	0	0	0	0	1	0	6	3	3	5	4	5	6	3	2	4	5	9	3	6	3	4	5	5	5	4	5	1	1	0	0	1	1	1	1	3	1	1	2	3	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	5	4.375	2.75	4.285714	5	4.3		1	4.55	5.25	2.5	4.428571	4	-0.25	-0.875	0.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN024ZXL
2081	8976	NDAR_INVBN414VWW	2671			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	2	2	1	2	2	0	0	0	1	1	1	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	16	0		0		1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	4	1	0.75	1.4285715	1.5	1.2	1		1.2	1	0.75	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN414VWW
2081	8976	NDAR_INVBN414VWW	2671			M	5200	EndofPhase1_1a	1	Phase 1/1A	28	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	3	1	1	1	3	3	0	0	0	1	1	0	0	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1		1		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	2	1	0.75	1.8571428	1	1.3		1	1.2	1	0.75	1.4285715	1.5	0.1	0	0	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN414VWW
2081	8976	NDAR_INVBN631VT5	2062			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	1	1	1	1	2	1	0	0	0	9	1	2	2	2	0	3	2	1	1	2	2	2	2	1	1	1	0	3		0	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.25	0	1.2857143	2.5	1.2	1		1.2	1.25	0	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBN631VT5
2081	8976	NDAR_INVBR723EU0	1563			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	5	3	3	4	3	5	5	2	4	4	9	2	4	2	6	5	5	4	5	6	1	1	1	0	1	1	1	1	1	1	1	2	2	4	3	0	0	0	0	0	0	0	1	2	2	2	2	1	25	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	6	4.125	2.5	4.285714	4.5	4.1	1		4.1	4.125	2.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR723EU0
2081	8976	NDAR_INVBR723EU0	1563			M	1600	Visit6	6	Phase 2	162	0	0	0	0	0	0	1	4	4	3	2	3	2	5	3	1	1	1	9	2	2	2	6	1	2	1	4	3	1	0	1	0	1	1	1	1	2	3	1	3	2	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	6	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	7	3.25	0.75	2.857143	1.5	2.6			4.1	4.125	2.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR723EU0
2081	8976	NDAR_INVBR723EU0	1563			M	2800	Visit12	12	Phase 2	341	0	0	0	0	0	0	1	9	3	1	1	2	0	5	4	2	2	4	9	0	4	2	6	6	4	4	5	6	1	1	1	0	1	1	1	1	3		0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	2.2857144	2	4.142857	4	3.2105262			4.1	4.125	2.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR723EU0
2081	8976	NDAR_INVBR723EU0	1563			M	5200	EndofPhase1_1a	3	Phase 1/1A	65	0	0	1	0	0	0	0	4	5	5	5	5	5	5	5	1	2	1	9	1	1	2	5	4	5	2	4	4	1	1	1	0	1	1	1	1	3	1	1	3	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	6	4.875	1	3	3.5	3.55		1	4.1	4.125	2.5	4.285714	4.5	-0.55	0.75	-1.5	-1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR723EU0
2081	8976	NDAR_INVBR723EU0	1563			M	5800	EndofPhase2	13	Phase 2	373	0	1	0	0	0	0	0	5	4	4	5	4	3	6	3	2	4	5	9	3	3	2	6	6	5	2	4	4	1	1	1	0	1	1	1	1	3		1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4.25	2.75	4	3.5	4			4.1	4.125	2.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR723EU0
2081	8976	NDAR_INVBR723EU0	1563			M	6000	EndofPhase3	18	Phase 3	509	0	0	0	0	0	0	1	9	3	3	3	5	5	4	5	1	1	2	9	1	2	1	6	4	5	3	4	6	1	0	1	0	1	1	1	1	3		1	3	3	2	1	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4	1	3.4285715	4	3.368421			4.1	4.125	2.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR723EU0
2081	8976	NDAR_INVBR926MB7	1543			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	5	4	4	5	3	3	1	0	0	0	9	2	3	6	4	4	4	5	3	6	1	1	1	1	1	1	1	1	2	1	1	2	1	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.875	0	4	4.5	3.4	1		3.4	3.875	0	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR926MB7
2081	8976	NDAR_INVBR926MB7	1543			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	5	5	0	2	3	0	3	0	0	0	0	9	3	2	3	3	1	5	5	4	2	1	1	1	1	1	1	1	0	1	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	0	2.5714285	5	2.3			3.4	3.875	0	4	4.5	-1.1	-1.625	0	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR926MB7
2081	8976	NDAR_INVBR926MB7	1543			M	2800	Visit12	12	Phase 1/1A	354	0	0	0	0	0	0	1	5	2	0	0	2	0	2	1	0	0	0	9	2	1	2	3	0	5	4	2	5	1	1	1	1	1	1	1	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	4	1.5	0	2.142857	4.5	1.8			3.4	3.875	0	4	4.5	-1.6	-2.375	0	-1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR926MB7
2081	8976	NDAR_INVBR926MB7	1543			M	4000	Visit18	18	Phase 1/1A	508	0	0	0	0	0	0	1	4	2	0	0	2	0	1	0	0	0	0	9	0	0	4	3	2	4	5	1	3	1	1	1	0	1	0	0	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0	1.8571428	4.5	1.55		1	3.4	3.875	0	4	4.5	-1.85	-2.75	0	-2.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBR926MB7
2081	8976	NDAR_INVBT484UVR	2703			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	2	3	2	4	3	2	2	1	1	1	9	2	1	1	2	1	4	4	1	1	0	1	1	0	1	1	1	1	1	3	1	2	2	2	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.5	0.75	1.2857143	4	2	1		2	2.5	0.75	1.2857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBT484UVR
2081	8976	NDAR_INVBT956VMC	1839			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	2	4	6	5	6	4	2	0	1	1	9	2	2	6	4	5	4	4	6	6	1	1	0	1	1	1	1	1	1	2	1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.375	0.5	4.428571	4	3.8	1		3.8	4.375	0.5	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBT956VMC
2081	8976	NDAR_INVBU258BZE	2693			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	1	0	1	0	0	2	0	0	0	9	2	2	3	3	1	5	4	4	5	1	1	1	1	1	0	0	1	3		0	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	3	0.5714286	0	2.857143	4.5	1.7368422	1		1.7368422	0.5714286	0	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBU258BZE
2081	8976	NDAR_INVBU258BZE	2693			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	5	5	6	2	4	2	4	4	6	6	6	6	6	6	6	6	6	6	4	6	6	1	1	0	1	1	1	1	1	3		1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3	4	6	6	5	5.142857			1.7368422	0.5714286	0	2.857143	4.5	3.406015	3.4285715	6	3.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBU258BZE
2081	8976	NDAR_INVBU258BZE	2693			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	9	0	6	1	0	1	2	3	2	2	1	9	6	4	4	3	2	5	3	5	5	1	0	0	1	1	1	2	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.8571428	1.25	4.142857	4	2.8947368			1.7368422	0.5714286	0	2.857143	4.5	1.1578947	1.2857143	1.25	1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBU258BZE
2081	8976	NDAR_INVBU258BZE	2693			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	0	2	0	0	0	1	3	1	1	1	9	0	1	1	2	1	4	4	4	4	1	1	0	1	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	2	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0.85714287	0.75	1.8571428	4	1.5789474		1	1.7368422	0.5714286	0	2.857143	4.5	-0.15789473	0.2857143	0.75	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBU258BZE
2081	8976	NDAR_INVBU451RPQ	2025			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	4	4	4	6	6	0	4	1	9	2	3	4	3	5	4	5	6	5	1	1	1	1	1	1	1	1	3	1	1	4	3	3	3	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.75	1.25	4	4.5	4	1		4	4.75	1.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBU451RPQ
2081	8976	NDAR_INVBV511WN3	2222			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	6	5	5	2	6	2	2	3	0	0	2	9	3	2	2	6	4	2	3	3	6	1	0	1	0	1	0	0	1	1	1	1	2	1	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.875	0.5	3.7142856	2.5	3.2	1		3.2	3.875	0.5	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV511WN3
2081	8976	NDAR_INVBV511WN3	2222			M	1600	Visit6	6	Phase 1/1A	168	1	0	1	0	1	0	0	6	5	5	4	6	4	4	5	0	0	1	9	4	0	4	4	3	2	3	5	6	0	1	0	0	1	1	0	1	1	1	1	3	1	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	0.25	3.7142856	2.5	3.55			3.2	3.875	0.5	3.7142856	2.5	0.35	1	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV511WN3
2081	8976	NDAR_INVBV511WN3	2222			M	2800	Visit12	12	Phase 1/1A	338	1	0	1	0	1	0	0	6	3	3	4	6	0	3	3	2	3	4	9	2	3	6	2	2	2	2	5	6	1	0	0	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	5	3.5	2.25	3.7142856	2	3.35			3.2	3.875	0.5	3.7142856	2.5	0.15	-0.375	1.75	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV511WN3
2081	8976	NDAR_INVBV511WN3	2222			M	5200	EndofPhase1_1a	18	Phase 1/1A	520	1	0	1	0	1	0	0	6	5	4	6	4	3	5	5	4	4	4	6	4	4	4	6	5	3	3	5	6	1	1	1	0	1	1	1	1	1	1	1	3	1	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5	4.75	4.5	4.857143	3	4.571429		1	3.2	3.875	0.5	3.7142856	2.5	1.3714286	0.875	4	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV511WN3
2081	8976	NDAR_INVBV732BBY	2738			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	3	1	1	3	4	2	2	4	2	2	2	2	2	2	2	1	1	0	1	4	0	0	0	0	1	1	1	1	1	3	1	2	2	4	1	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.25	2.5	2	0.5	2.047619	1		2.047619	2.25	2.5	2	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV732BBY
2081	8976	NDAR_INVBV732BBY	2738			M	1600	Visit6	6	Phase 2	164	0	0	0	0	0	0	1	1	4	2	1	2	4	2	2	4	3	3	3	2	1	1	1	2	1	1	3	4	1	0	1	0	1	1	0	1	3		1	3	1	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	3.25	2	1	2.2380953			2.047619	2.25	2.5	2	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV732BBY
2081	8976	NDAR_INVBV732BBY	2738			M	2800	Visit12	12	Phase 2	332	0	0	0	0	0	0	1	3	2	3	3	3	3	3	2	3	2	3	3	2	3	1	2	4	2	0	3	4	0	0	1	0	1	1	1	1	2	2	1	2	1	3	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.75	2.75	2.7142856	1	2.5714285			2.047619	2.25	2.5	2	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV732BBY
2081	8976	NDAR_INVBV732BBY	2738			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	0	0	0	0	0	1	1	3	2	2	2	2	2	1	1	2	2	9	3	2	1	2	2	3	3	2	2	1	1	1	0	1	1	1	1	3	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.875	1.25	2	3	2		1	2.047619	2.25	2.5	2	0.5	-0.04761905	-0.375	-1.25	0	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV732BBY
2081	8976	NDAR_INVBV732BBY	2738			M	5800	EndofPhase2	18	Phase 2	498	0	0	0	0	0	0	1	2	4	3	3	3	3	3	3	3	3	2	3	1	3	2	3	4	1	0	4	5	0	0	0	0	1	1	0	1	2	1	1	2	1	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	2.75	3.142857	0.5	2.7619047			2.047619	2.25	2.5	2	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV732BBY
2081	8976	NDAR_INVBV733GVC	1037			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	0	4	5	5	4	6	1	1	0	9	2	5	3	4	2	3	3	6	5	1	1	1	1	1	1	1	1	1	1	1	4	1	4	1	1	1	1	1	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	1	1	1	1	5	4.25	0.5	3.857143	3	3.45	1		3.45	4.25	0.5	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV733GVC
2081	8976	NDAR_INVBV733GVC	1037			M	5200	EndofPhase1_1a	0	Phase 1/1A	9	0	1	0	0	0	0	0	6	4	0	5	6	2	5	6	1	0	0	9	3	2	4	4	1	4	3	6	6	1	1	0	1	1	1	1	1	2	2	1	4	1	4	1	1	1	1	1	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	6	4.25	0.25	3.7142856	3.5	3.4		1	3.45	4.25	0.5	3.857143	3	-0.05	0	-0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV733GVC
2081	8976	NDAR_INVBV733GVC	1037			M	5800	EndofPhase2	2	Phase 2	37	0	1	0	0	0	0	0	6	6	5	4	6	4	6	5	2	1	0	9	3	0	4	6	4	3	2	6	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	1	1	1	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	4	5.25	0.75	4	2.5	3.9			3.45	4.25	0.5	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV733GVC
2081	8976	NDAR_INVBV733GVC	1037			M	6000	EndofPhase3	4	Phase 3	112	0	1	0	0	0	0	0	5	2	1	2	2	3	2	5	0	0	1	9	2	2	2	4	0	3	3	4	5	1	1	1	0	0	0	1	1	1	1	0	4	1	3	1	1	1	1	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	3	2.75	0.25	2.7142856	3	2.4			3.45	4.25	0.5	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBV733GVC
2081	8976	NDAR_INVBW552GFF	1147			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	5	5	4	4	2	4	2	2	2	1	9	3	3	4	4	3	3	1	4	5	1	1	1	0	1	1	1	1	1	2	1	3	3	2	4	1	0	1	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.875	1.25	3.7142856	2	3.3	1		3.3	3.875	1.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBW552GFF
2081	8976	NDAR_INVBW552GFF	1147			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	2	2	1	3	3	3	2	0	1	2	9	4	4	4	4	2	3	3	4	4	1	1	1	2	1	1	1	1	1	2	1	3	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	0.75	3.7142856	3	2.85			3.3	3.875	1.25	3.7142856	2	-0.45	-1.125	-0.5	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBW552GFF
2081	8976	NDAR_INVBW552GFF	1147			M	5200	EndofPhase1_1a	12	Phase 1/1A	338	1	0	0	0	0	0	0	2	0	0	0	0	1	0	1	0	1	0	9	2	1	2	1	1	3	2	1	2	0	0	1	1	1	1	1	1	1	3	0	4	3	3	4	1	0	0	1	0	0	0	0	1	1	1	1	1	21	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	4	0.5	0.25	1.4285715	2.5	1		1	3.3	3.875	1.25	3.7142856	2	-2.3	-3.375	-1	-2.2857144	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBW552GFF
2081	8976	NDAR_INVBW909MRX	1282			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	6	5	4	6	3	4	3	4	4	6	6	5	6	4	6	5	3	3	5	6	1	1	1	1	1	1	1	1	3		1	2	1	1	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	1	0	1	1	0	0	0	0	0	0	1	1	1	1	7	4.428571	5	5.285714	3	4.7	1		4.7	4.428571	5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBW909MRX
2081	8976	NDAR_INVBW909MRX	1282			M	5200	EndofPhase1_1a	1	Phase 1/1A	33	0	0	0	0	0	0	1	9	4	0	4	2	3	4	0	2	6	4	9	3	6	0	6	6	3	3	6	6	1	1	1	1	1	1	1	1	3	1	1	2	1	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	1	0	0	0	1	0	0	0	1	1	1	1	6	2.4285715	3	4.714286	3	3.5789473		1	4.7	4.428571	5	5.285714	3	-1.1210526	-2	-2	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBW909MRX
2081	8976	NDAR_INVBY476AE8	2023			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	3	2	2	2	2	2	2	0	0	1	9	3	2	4	3	0	3	2	3	4	0	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2.625	0.25	2.7142856	2.5	2.3	1		2.3	2.625	0.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBY476AE8
2081	8976	NDAR_INVBY476AE8	2023			M	1600	Visit6	6	Phase 2	168	1	0	0	0	0	0	0	6	4	3	3	3	3	3	2	0	0	1	9	2	2	2	3	2	3	2	3	5	0	1	1	1	1	1	0	0	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.375	0.25	2.7142856	2.5	2.6			2.3	2.625	0.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBY476AE8
2081	8976	NDAR_INVBY476AE8	2023			M	2800	Visit12	12	Phase 3	318	1	0	0	0	0	0	0	6	3	2	2	2	2	2	1	0	0	0	9	3	2	3	4	1	4	2	4	4	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	0	3	3	2.35			2.3	2.625	0.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBY476AE8
2081	8976	NDAR_INVBY476AE8	2023			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	6	3	2	2	2	2	2	2	0	0	1	9	2	2	2	2	2	3	2	3	4	0	1	0	0	1	1	0	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.625	0.25	2.4285715	2.5	2.2		1	2.3	2.625	0.25	2.7142856	2.5	-0.1	0	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBY476AE8
2081	8976	NDAR_INVBY476AE8	2023			M	6000	EndofPhase3	18	Phase 3	486	1	0	0	0	0	0	0	5	3	3	2	2	2	2	2	0	0	1	9	2	2	3	3	2	3	1	3	4	1	1	0	0	1	1	1	1	1	2	1	3	3	4	4	1	0	1	0	0	0	1	0	1	0	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.625	0.25	2.7142856	2	2.25			2.3	2.625	0.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVBY476AE8
2081	8976	NDAR_INVCA163DRV	1049			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	2	2	0	2	6	0	0	0	9	3	2	0	6	2	2	2	4	6	1	2	2	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	0	4	1.75	0	3.2857144	2	2.05	1		2.05	1.75	0	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA163DRV
2081	8976	NDAR_INVCA163DRV	1049			F	1600	Visit6	6	Phase 2	168	1	0	1	0	0	0	0	5	4	0	2	3	0	3	4	0	0	0	9	0	2	4	6	1	3	3	5	6	1	1	1	0	1	1	1	1	1	1	1	2	1	4	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.625	0	3.4285715	3	2.55			2.05	1.75	0	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA163DRV
2081	8976	NDAR_INVCA163DRV	1049			F	5200	EndofPhase1_1a	2	Phase 1/1A	49	1	0	1	0	0	0	0	6	4	0	4	4	4	4	6	0	0	0	9	6	3	6	6	1	3	3	5	6	1	1	1	0	1	1	1	1	1	1	1	2	1	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	6	4	0	4.714286	3	3.55		1	2.05	1.75	0	3.2857144	2	1.5	2.25	0	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA163DRV
2081	8976	NDAR_INVCA189MFB	1087			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	1	2	1	1	1	0	0	3	1	9	2	0	0	0	0	6	6	6	2	1	1	1	0	1	1	1	1	3	1	1	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	21	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	0.75	1	1.4285715	6	1.6	1		1.6	0.75	1	1.4285715	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA189MFB
2081	8976	NDAR_INVCA189MFB	1087			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	0	2	4	4	4	0	4	2	0	0	0	9	4	4	6	5	5	6	5	5	5	1	1	1	1	1	1	1	1	2	2	1	3	3	2	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.5	0	4.857143	5.5	3.25			1.6	0.75	1	1.4285715	6	1.65	1.75	-1	3.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA189MFB
2081	8976	NDAR_INVCA189MFB	1087			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	0	0	2	2	4	1	3	0	0	0	0	9	6	4	6	6	5	6	5	6	6	1	1	1	1	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.5	0	5.571429	5.5	3.1			1.6	0.75	1	1.4285715	6	1.5	0.75	-1	4.142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA189MFB
2081	8976	NDAR_INVCA189MFB	1087			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	0	6	6	6	6	6	6	0	4	4	5	2	6	6	6	6	5	6	6	6	6	1	1	1	1	1	1	1	1	2	2	1	3	2	1	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.5	3.75	5.857143	6	4.952381		1	1.6	0.75	1	1.4285715	6	3.352381	3.75	2.75	4.428571	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA189MFB
2081	8976	NDAR_INVCA280VLE	1455			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	4	4	4	3	3	3	1	1	2	1	9	1	4	4	4	2	5	4	3	4	1	1	1	0	1	1	1	1	3	3	1	3	2	3	4	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	2	2.75	1	3.142857	4.5	2.85	1		2.85	2.75	1	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA280VLE
2081	8976	NDAR_INVCA280VLE	1455			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	0	1	4	4	1	4	2	3	3	0	1	2	1	9	2	2	1	2	1	4	4	4	4	1	1	1	0	1	1	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.625	1	2.2857144	4	2.45			2.85	2.75	1	3.142857	4.5	-0.4	-0.125	0	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA280VLE
2081	8976	NDAR_INVCA280VLE	1455			M	2800	Visit12	12	Phase 1/1A	350	0	0	0	0	0	0	1	2	4	1	4	2	3	3	0	0	2	1	9	0	2	0	0	1	4	3	2	2	0	1	0	1	1	1	0	2	3		0	4	2	4	4	0	0	0	0	0	0	0	0					1	10	0		0		1	1	1	19	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	2	2.375	0.75	1	3.5	1.8			2.85	2.75	1	3.142857	4.5	-1.05	-0.375	-0.25	-2.142857	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA280VLE
2081	8976	NDAR_INVCA280VLE	1455			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	0	0	0	0	0	0	1	9	4	4	4	4	2	3	1	1	1	2	9	4	4	1	4	2	3	2	4	5	1	0	2	0	1	1	0	0	3		1	2	1	3	4	1	0	0	0	0	1	0	0	1	0	1	0	0		0		0		0		1	30	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	7	3.142857	1	3.4285715	2.5	2.8947368		1	2.85	2.75	1	3.142857	4.5	0.044736844	0.39285713	0	0.2857143	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA280VLE
2081	8976	NDAR_INVCA367ETV	1292			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	1	2	1	2	1	1	1	1	1	1	9	0	1	2	2	1	3	4	3	3	1	1	0	1	1	1	0	1	1	1	1	4	2	2	2	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	1	1	1	1	1	1	6	1.375	0.75	1.7142857	3.5	1.65	1		1.65	1.375	0.75	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA367ETV
2081	8976	NDAR_INVCA367ETV	1292			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	2	3	2	3	2	2	3	2	3	2	9	2	2	3	2	3	2	2	4	5	1	1	1	0	1	1	0	1	1	1	1	4	2	4	2	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.875	1.75	3	2	2.75			1.65	1.375	0.75	1.7142857	3.5	1.1	1.5	1	1.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA367ETV
2081	8976	NDAR_INVCA367ETV	1292			M	2800	Visit12	12	Phase 1/1A	350	1	0	1	0	0	0	0	6	1	2	3	5	2	3	3	3	3	3	3	4	3	4	3	2	3	3	4	5	2	1	1	1	1	1	1	1	1	2	1	3	2	2	2	1	0	1	1	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	6	3.125	3	3.5714285	3	3.2380953			1.65	1.375	0.75	1.7142857	3.5	1.5880952	1.75	2.25	1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA367ETV
2081	8976	NDAR_INVCA367ETV	1292			M	5200	EndofPhase1_1a	18	Phase 1/1A	533	1	0	1	0	0	0	0	6	5	5	4	5	4	4	5	5	4	4	5	5	4	3	5	3	5	4	5	5	1	1	1	1	1	1	0	1	1	1	1	2	2	2	1	1	1	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	4.5	4.285714	4.5	4.5238094		1	1.65	1.375	0.75	1.7142857	3.5	2.8738096	3.375	3.75	2.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA367ETV
2081	8976	NDAR_INVCA544WCZ	2479			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	2	0	4	5	5	5	0	2	3	1	9	1	5	0	4	2	4	3	5	6	1	1	0	0	1	1	1	1	2	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.375	1.5	3.2857144	3.5	3.15	1		3.15	3.375	1.5	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA544WCZ
2081	8976	NDAR_INVCA544WCZ	2479			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	6	1	0	2	2	2	3	0	2	3	1	9	0	2	1	4	2	3	3	4	6	1	0	0	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.5	2.7142856	3	2.35			3.15	3.375	1.5	3.2857144	3.5	-0.8	-1.375	0	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA544WCZ
2081	8976	NDAR_INVCA544WCZ	2479			M	5200	EndofPhase1_1a	9	Phase 1/1A	257	0	0	0	0	0	1	0	6	0	0	2	2	2	3	0	2	3	1	9	0	2	3	4	2	3	2	4	6	1	1	0	1	1	1	1	1	3	1	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	1.5	3	2.5	2.35		1	3.15	3.375	1.5	3.2857144	3.5	-0.8	-1.5	0	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA544WCZ
2081	8976	NDAR_INVCA799MUJ	2636			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	5	4	4	2	4	1	0	0	0	0	1	0	0	4	3	5	5	5	4	1	1	1	1	1	1	0	1	2	1	0	4	2	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.5	0	2.4285715	5	2.6190476	1		2.6190476	3.5	0	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA799MUJ
2081	8976	NDAR_INVCA799MUJ	2636			M	1600	Visit6	6	Phase 1/1A	162	0	0	0	0	0	0	1	4	3	5	3	3	2	1	1	3	2	2	2	1	2	3	2	2	6	5	2	6	1	1	0	0	1	1	0	0	3	1	1	3	3	2	3	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	2.25	2.5714285	5.5	2.857143			2.6190476	3.5	0	2.4285715	5	0.23809524	-0.75	2.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA799MUJ
2081	8976	NDAR_INVCA799MUJ	2636			M	2800	Visit12	12	Phase 1/1A	334	0	0	0	0	0	0	1	3	3	4	2	1	2	2	1	1	1	1	9	2	1	2	3	2	5	5	4	5	1	1	1	0	1	1	1	1	2	2	1	3	2	2	2	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0.75	2.7142856	5	2.5			2.6190476	3.5	0	2.4285715	5	-0.11904762	-1.25	0.75	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA799MUJ
2081	8976	NDAR_INVCA799MUJ	2636			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	0	1	0	6	3	4	2	2	4	2	0	0	1	9	3	2	3	2	4	4	4	4	3	1	1	0	1	1	1	0	0	2	1	1	4	3	3	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	0.25	3	4	2.65		1	2.6190476	3.5	0	2.4285715	5	0.030952381	-0.625	0.25	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA799MUJ
2081	8976	NDAR_INVCA959YGL	2216			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	1	1	2	4	1	2	2	2	2	0	9	2	1	2	2	2	2	2	4	2	1	1	1	0	1	1	1	1	2	1	0	4	1	4	2	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	1.8571428	1	2.142857	2	1.8947369	1		1.8947369	1.8571428	1	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCA959YGL
2081	8976	NDAR_INVCB171GLT	1516			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	0	0	0	0	2	0	0	0	0	0	9	0	4	6	4	6	6	4	6	6	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1	0	4.571429	5	2.5	1		2.5	1	0	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB171GLT
2081	8976	NDAR_INVCB171GLT	1516			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	1	0	0	0	6	0	0	2	0	2	1	0	1	0	0	9	1	4	4	5	5	5	3	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.375	0.25	4.428571	4	2.55			2.5	1	0	4.571429	5	0.05	0.375	0.25	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB171GLT
2081	8976	NDAR_INVCB171GLT	1516			M	2800	Visit12	12	Phase 1/1A	359	0	0	0	0	0	0	1	6	0	0	2	2	2	2	0	0	0	0	9	0	3	0	5	6	5	3	6	6	1	1	1	1	1	1	1	1	1	1	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.75	0	3.7142856	4	2.4			2.5	1	0	4.571429	5	-0.1	0.75	0	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB171GLT
2081	8976	NDAR_INVCB171GLT	1516			M	5200	EndofPhase1_1a	18	Phase 1/1A	522	0	0	0	1	0	0	0	6	0	0	0	0	2	0	0	0	0	0	9	0	4	6	4	6	5	5	5	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1	0	4.285714	5	2.4		1	2.5	1	0	4.571429	5	-0.1	0	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB171GLT
2081	8976	NDAR_INVCB189WH9	1467			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	4	4	3	2	5	4	1	5	3	9	3	4	5	4	4	4	3	6	5	0	0	0	1	1	1	1	1	3		1	2	1	4	4	0	0	0	0	0	0	0	1					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.7142856	2.25	4.428571	3.5	3.8421052	1		3.8421052	3.7142856	2.25	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB189WH9
2081	8976	NDAR_INVCB189WH9	1467			M	1600	Visit6	6	Phase 1/1A	218	0	0	0	0	0	0	1	9	0	1	0	1	1	3	1	2	4	4	9	3	6	5	3	4	4	3	5	5	0	0	0	1	1	1	0	1	3		0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	5	1	2.5	4.428571	3.5	2.8947368			3.8421052	3.7142856	2.25	4.428571	3.5	-0.94736844	-2.7142856	0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB189WH9
2081	8976	NDAR_INVCB189WH9	1467			M	2800	Visit12	12	Phase 1/1A	366	0	0	0	0	0	1	0	1	1	4	4	0	2	4	1	2	5	4	9	2	4	4	3	2	4	3	5	4	0	0	0	1	1	1	0	1	3		0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0		1	1	1	5	2.125	2.75	3.4285715	3.5	2.95			3.8421052	3.7142856	2.25	4.428571	3.5	-0.8921053	-1.5892857	0.5	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB189WH9
2081	8976	NDAR_INVCB189WH9	1467			M	5200	EndofPhase1_1a	18	Phase 1/1A	551	0	0	0	0	0	1	0	4	4	1	2	1	2	4	0	2	4	5	9	0	5	3	2	4	4	3	5	4	1	0	1	1	1	1	1	1	3		1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.25	2.75	3.2857144	3.5	2.95		1	3.8421052	3.7142856	2.25	4.428571	3.5	-0.8921053	-1.4642857	0.5	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB189WH9
2081	8976	NDAR_INVCB708FN4	1083			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	0	0	0	6	2	3	2	2	0	0	9	0	1	0	0	0	5	1	6	6	0	1	1	0	1	1	1	1	1	1	0	4	4	3	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.25	0.5	1.8571428	3	1.95	1		1.95	2.25	0.5	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB708FN4
2081	8976	NDAR_INVCB708FN4	1083			M	1600	Visit6	6	Phase 1/1A	161	0	0	1	0	0	0	0	6	3	2	5	6	4	0	0	2	0	2	9	3	6	6	6	1	5	4	6	6	1	1	1	0	1	1	1	1	1	1	1	4	2	2	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	1	4.857143	4.5	3.65			1.95	2.25	0.5	1.8571428	3	1.7	1	0.5	3	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB708FN4
2081	8976	NDAR_INVCB708FN4	1083			M	4000	Visit18	18	Phase 1/1A	498	0	0	1	0	0	0	0	6	0	4	2	6	0	2	0	0	0	0	9	2	2	6	2	4	6	2	6	6	1	1	1	1	1	1	1	1	1	1	0	4	3	3	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0	4	4	2.8		1	1.95	2.25	0.5	1.8571428	3	0.85	0.25	-0.5	2.142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB708FN4
2081	8976	NDAR_INVCB944PY4	2075			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	1	0	0	0	1	1	1	0	2	0	2	9	1	1	1	1	0	3	0	0	1	0	0	0	0	0	1	0	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.5	1	0.71428573	1.5	0.8	1		0.8	0.5	1	0.71428573	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB944PY4
2081	8976	NDAR_INVCB944PY4	2075			M	2800	Visit12	12	Phase 3	353	1	0	0	0	0	0	0	3	4	4	4	3	4	4	1	3	2	2	2	1	4	3	2	2	3	2	4	4	1	0	1	1	1	1	0	1	1	2	1	2	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5	3.375	2.25	2.857143	2.5	2.9047618			0.8	0.5	1	0.71428573	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB944PY4
2081	8976	NDAR_INVCB944PY4	2075			M	5200	EndofPhase1_1a	3	Phase 1/1A	101	1	0	1	0	0	0	0	2	1	1	1	2	1	1	1	2	2	2	9	1	1	1	3	2	2	1	2	1	1	2	1	1	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	1.25	1.5	1.5714285	1.5	1.5		1	0.8	0.5	1	0.71428573	1.5	0.7	0.75	0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB944PY4
2081	8976	NDAR_INVCB944PY4	2075			M	5800	EndofPhase2	6	Phase 2	184	1	0	1	0	0	0	0	1	1	1	1	0	1	1	0	2	1	1	9	1	1	1	1	1	3	2	1	1	1	1	1	0	1	1	0	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	3	0.75	1	1	2.5	1.1			0.8	0.5	1	0.71428573	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB944PY4
2081	8976	NDAR_INVCB944PY4	2075			M	6000	EndofPhase3	13	Phase 3	379	1	0	1	0	0	0	0	5	4	3	5	3	3	5	0	2	1	1	9	1	2	2	2	1	3	2	2	4	1	0	1	1	1	1	0	1	1	2	1	3	3	4	4	1	0	1	1	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	3.5	1	2	2.5	2.55			0.8	0.5	1	0.71428573	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCB944PY4
2081	8976	NDAR_INVCC028GXB	2767			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	0	2	0	1	0	2	4	0	2	0	9	3	2	0	1	0	6	2	5	5	0	0	1	0	1	2	0	1	3		1	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	1.75	0.5	2.2857144	4	2	1		2	1.75	0.5	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC028GXB
2081	8976	NDAR_INVCC028GXB	2767			F	1600	Visit6	6	Phase 1/1A	182	0	1	0	0	0	0	0	6	1	2	0	2	0	2	3	0	0	0	9	0	2	2	2	0	6	1	1	4	0	0	0	0	1	0	0	1	2	3	1	4	3	4	2	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	0	1.5714285	3.5	1.7		1	2	1.75	0.5	2.2857144	4	-0.3	0.25	-0.5	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC028GXB
2081	8976	NDAR_INVCC028GXB	2767			F	2800	Visit12	12	Phase 2	370	0	1	0	0	0	0	0	3	1	0	0	2	0	0	3	1	1	0	9	2	2	1	2	0	5	1	5	4	0	0	0	0	1	1	2	1	2	1	1	4	4	4	4	1	0	0	0	0	1	0	0	0	1	0	0	1	27	0		0		1	3	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0.5	2.2857144	3	1.65			2	1.75	0.5	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC028GXB
2081	8976	NDAR_INVCC662ZFE	1241			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	0	0	6	0	2	2	0	0	5	9	0	3	0	3	2	4	2	5	3	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	1.25	2.2857144	3	2.25	1		2.25	2.25	1.25	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC662ZFE
2081	8976	NDAR_INVCC662ZFE	1241			M	1600	Visit6	6	Phase 1/1A	226	1	0	1	0	0	0	0	1	1	1	1	1	1	1	1	1	0	1	9	1	1	4	3	3	4	3	4	4	2	2	2	2	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0.5	2.857143	3.5	1.85			2.25	2.25	1.25	2.2857144	3	-0.4	-1.25	-0.75	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC662ZFE
2081	8976	NDAR_INVCC662ZFE	1241			M	2800	Visit12	12	Phase 1/1A	394	1	0	1	0	0	0	0	6	4	4	4	4	4	4	3	4	4	4	4	2	4	4	4	6	5	5	4	4	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.125	4	4	5	4.142857		1	2.25	2.25	1.25	2.2857144	3	1.8928572	1.875	2.75	1.7142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC662ZFE
2081	8976	NDAR_INVCC858LCG	1061			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	3	1	1	1	1	1	3	1	1	1	9	1	1	1	2	1	3	3	3	3	0	0	2	2	1	1	2	1	3	3	1	4	4	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	20	0		0		0		1	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.5	0.75	1.7142857	3	1.65	1		1.65	1.5	0.75	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC858LCG
2081	8976	NDAR_INVCC858LCG	1061			M	1600	Visit6	6	Phase 1/1A	168	0	1	0	0	0	0	0	3	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	2	2	2	2	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.25	0.75	1.2857143	2	1.3			1.65	1.5	0.75	1.7142857	3	-0.35	-0.25	0	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC858LCG
2081	8976	NDAR_INVCC858LCG	1061			M	2800	Visit12	12	Phase 1/1A	370	0	0	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	9	1	2	2	1	1	1	1	1	1	1	0	1	0	1	0	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1	0.75	1.2857143	1	1.1			1.65	1.5	0.75	1.7142857	3	-0.55	-0.5	0	-0.42857143	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC858LCG
2081	8976	NDAR_INVCC858LCG	1061			M	5200	EndofPhase1_1a	18	Phase 1/1A	525	0	0	1	0	0	0	0	4	2	2	2	2	2	2	1	1	2	2	9	2	2	2	2	3	3	2	3	2	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	2.125	1.25	2.2857144	2.5	2.15		1	1.65	1.5	0.75	1.7142857	3	0.5	0.625	0.5	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCC858LCG
2081	8976	NDAR_INVCD286UDX	2059			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	2	1	2	4	3	4	2	1	1	3	9	2	2	2	4	2	4	3	3	4	1	1	2	0	1	1	2	1	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	1.25	2.7142856	3.5	2.75	1		2.75	3	1.25	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD286UDX
2081	8976	NDAR_INVCD336JWW	1204			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	2	1	0	2	0	0	0	0	0	0	9	1	0	2	2	0	5	2	2	0	0	0	1	0	1	1	1	1	1	2	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	5	0.625	0	1	3.5	0.95	1		0.95	0.625	0	1	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD336JWW
2081	8976	NDAR_INVCD336JWW	1204			M	2800	Visit12	12	Phase 3	361	1	0	0	0	0	0	0	0	4	5	0	4	0	4	0	0	0	0	9	4	4	6	5	2	5	3	6	6	0	1	2	2	1	2	1	1	1	2	1	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	7	1	8	0		1	15	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.125	0	4.714286	4	2.9			0.95	0.625	0	1	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD336JWW
2081	8976	NDAR_INVCD336JWW	1204			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	1	0	0	0	0	0	0	4	2	5	6	6	3	1	0	0	0	0	9	4	2	4	3	2	5	3	5	5	1	0	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3.375	0	3.5714285	4	3		1	0.95	0.625	0	1	3.5	2.05	2.75	0	2.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD336JWW
2081	8976	NDAR_INVCD336JWW	1204			M	5800	EndofPhase2	11	Phase 2	309	1	0	0	0	0	0	0	5	3	2	3	4	0	1	0	0	0	0	9	2	1	4	4	0	5	4	5	4	0	0	1	0	1	1	1	1	1	2	1	3	4	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	28	1	2	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2.25	0	2.857143	4.5	2.35			0.95	0.625	0	1	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD336JWW
2081	8976	NDAR_INVCD336JWW	1204			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	6	0	2	2	4	2	3	2	0	3	4	9	4	6	6	6	4	6	4	4	6	1	1	1	2	1	1	1	1	1	2	1	3	2	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	1.75	5.142857	5	3.7			0.95	0.625	0	1	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD336JWW
2081	8976	NDAR_INVCD653CCA	2865			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	4	2	2	2	2	5	6	2	6	2	2	2	2	2	4	5	1	4	4	1	0	0	0	1	0	0	1	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	4	2.857143	3	3	1		3	2.625	4	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD653CCA
2081	8976	NDAR_INVCD653CCA	2865			M	1600	Visit6	6	Phase 1/1A	176	0	1	0	0	0	0	0	4	0	0	2	2	1	2	3	6	2	6	2	2	2	0	2	4	5	3	2	4	1	0	0	0	1	2	2	1	1	2	0	4	3	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	4	2.2857144	4	2.5714285			3	2.625	4	2.857143	3	-0.42857143	-0.875	0	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD653CCA
2081	8976	NDAR_INVCD653CCA	2865			M	2800	Visit12	12	Phase 1/1A	365	0	1	0	0	0	0	0	4	0	0	2	2	1	2	2	6	2	6	6	2	2	0	2	4	4	3	4	4	1	1	0	0	1	0	0	1	1	2	0	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	5	2.5714285	3.5	2.7619047			3	2.625	4	2.857143	3	-0.23809524	-1	1	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD653CCA
2081	8976	NDAR_INVCD653CCA	2865			M	5200	EndofPhase1_1a	18	Phase 1/1A	535	0	1	0	0	0	0	0	4	0	0	2	2	2	2	4	0	0	0	9	0	2	4	2	2	4	4	4	4	1	1	2	0	1	2	2	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	0	2.5714285	4	2.1		1	3	2.625	4	2.857143	3	-0.9	-0.625	-4	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD653CCA
2081	8976	NDAR_INVCD867YBU	1453			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	1	2	2	2	2	5	6	4	6	6	6	6	6	4	6	6	6	3	5	5	1	0	1	1	1	1	1	1	1	1	0		4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.25	5.5	5.428571	4.5	4.5238094	1		4.5238094	3.25	5.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD867YBU
2081	8976	NDAR_INVCD867YBU	1453			F	1600	Visit6	6	Phase 2	172	0	0	0	0	0	0	1	9	3	4	5	5	6	6	0	5	6	6	6	4	5	4	6	6	6	3	6	3	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.142857	5.75	4.857143	4.5	4.75			4.5238094	3.25	5.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD867YBU
2081	8976	NDAR_INVCD867YBU	1453			F	2800	Visit12	12	Phase 2	337	0	0	0	0	0	0	1	6	6	0	3	5	3	4	3	4	6	4	6	6	5	5	4	6	6	4	5	5	1	1	1	0	1	0	1	1	2	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	7	3.75	5	5.142857	5	4.571429			4.5238094	3.25	5.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD867YBU
2081	8976	NDAR_INVCD867YBU	1453			F	4000	Visit18	18	Phase 2	513	0	0	0	0	0	0	1	6	2	4	6	4	6	6	0	4	5	6	5	6	6	4	6	6	6	3	6	5	1	0	1	0	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.25	5	5.571429	4.5	4.857143			4.5238094	3.25	5.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD867YBU
2081	8976	NDAR_INVCD867YBU	1453			F	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	0	0	0	0	0	1	6	3	2	3	5	3	3	0	4	6	5	6	1	6	3	6	6	6	3	5	3	1	0	1	0	1	1	1	1	2	1	1	4	3	3	4	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.125	5.25	4.285714	4.5	4.047619		1	4.5238094	3.25	5.5	5.428571	4.5	-0.47619048	-0.125	-0.25	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCD867YBU
2081	8976	NDAR_INVCE287HWX	2237			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	0	0	0	0	2	0	0	0	6	9	0	0	2	0	0	4	3	4	4	1	1	2	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	24	1	6	0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.5	1.5	1.4285715	3.5	1.35	1		1.35	0.5	1.5	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE287HWX
2081	8976	NDAR_INVCE656JB3	1833			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	4	2	3	2	1	2	3	9	0	4	4	6	5	5	4	6	6	1	1	1	1	1	1	1	1	2	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1	5	2.375	1.5	4.428571	4.5	3.25	1		3.25	2.375	1.5	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE656JB3
2081	8976	NDAR_INVCE656JB3	1833			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	6	6	5	5	5	5	5	2	6	4	6	6	3	4	5	5	5	5	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	5.5	4.857143	4.5	4.952381			3.25	2.375	1.5	4.428571	4.5	1.7023809	2.5	4	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE656JB3
2081	8976	NDAR_INVCE656JB3	1833			M	2800	Visit12	12	Phase 1/1A	348	0	0	0	0	0	0	1	4	1	2	2	3	3	2	2	0	0	1	9	3	4	6	4	4	1	3	4	6	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0.25	4.428571	2	2.75			3.25	2.375	1.5	4.428571	4.5	-0.5	0	-1.25	0	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE656JB3
2081	8976	NDAR_INVCE656JB3	1833			M	4000	Visit18	18	Phase 1/1A	545	0	0	0	0	0	0	1	9	2	2	2	4	4	4	2	2	3	4	9	4	3	3	4	5	1	3	6	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.857143	2.25	4.285714	2	3.3157895		1	3.25	2.375	1.5	4.428571	4.5	0.065789476	0.48214287	0.75	-0.14285715	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE656JB3
2081	8976	NDAR_INVCE728WPZ	1051			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	2	0	2	0	3	0	0	1	2	9	2	2	2	4	2	2	1	0	2	0	0	0	0	1	1	0	1	3	1	0	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1	0.75	2	1.5	1.4210526	1		1.4210526	1	0.75	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE728WPZ
2081	8976	NDAR_INVCE728WPZ	1051			M	5200	EndofPhase1_1a	2	Phase 1/1A	57	0	0	0	0	0	0	1	0	0	1	0	2	0	3	1	0	0	1	9	1	0	1	2	0	3	1	1	2	0	1	0	0	1	1	1	1	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	2	0	0	0	0	1	1	0	0	0	1	1	1	1	3	0.875	0.25	1	2	0.95		1	1.4210526	1	0.75	2	1.5	-0.47105265	-0.125	-0.5	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE728WPZ
2081	8976	NDAR_INVCE980MLP	1685			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	4	4	5	3	4	5	4	4	1	1	4	5	6	3	2	4	2	6	6	1	0	1	1	1	1	1	1	1	2	1	4	2	1	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	1	0	0	0	0	1	1	1	1	5	4.25	2.5	4.571429	3	3.9047618	1		3.9047618	4.25	2.5	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE980MLP
2081	8976	NDAR_INVCE980MLP	1685			M	1600	Visit6	6	Phase 1/1A	182	1	0	0	0	0	0	0	6	6	4	6	5	5	4	5	5	4	1	4	4	4	5	4	6	5	3	6	6	1	1	1	1	1	1	1	1	1	2	1	3	2	2	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.125	3.5	5	4	4.6666665			3.9047618	4.25	2.5	4.571429	3	0.7619048	0.875	1	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE980MLP
2081	8976	NDAR_INVCE980MLP	1685			M	2800	Visit12	12	Phase 1/1A	351	1	0	0	0	0	0	0	6	4	2	4	4	4	4	5	2	2	1	9	3	4	4	4	1	5	4	4	6	1	1	0	1	1	1	1	1	1	1	1	3	3	1	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	4.125	1.25	3.7142856	4.5	3.65			3.9047618	4.25	2.5	4.571429	3	-0.2547619	-0.125	-1.25	-0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE980MLP
2081	8976	NDAR_INVCE980MLP	1685			M	5200	EndofPhase1_1a	18	Phase 1/1A	524	1	0	0	0	0	0	0	6	4	2	4	4	4	4	5	2	2	1	9	3	4	4	4	1	5	4	4	6	1	1	0	1	1	1	1	1	1	1	1	3	3	1	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0		4.125	1.25	3.7142856	4.5	3.65		1	3.9047618	4.25	2.5	4.571429	3	-0.2547619	-0.125	-1.25	-0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE980MLP
2081	8976	NDAR_INVCE986TWM	1573			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	0	0	0	0	0	2	1	0	0	1	9	1	1	0	2	4	6	2	5	3	1	0	1	1	1	1	0	1	1	2	0	4	2	4	4	1	0	0	1	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	0.625	0.25	2.2857144	4	1.5	1		1.5	0.625	0.25	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE986TWM
2081	8976	NDAR_INVCE986TWM	1573			M	5200	EndofPhase1_1a	6	Phase 1/1A	189	0	0	0	0	0	0	1	1	1	0	0	2	0	2	0	1	1	1	9	2	2	1	0	1	5	2	3	2	1	0	1	1	1	1	1	1	1	3	0	4	1	4	4	1	0	0	1	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	5	0.75	0.75	1.5714285	3.5	1.35		1	1.5	0.625	0.25	2.2857144	4	-0.15	0.125	0.5	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE986TWM
2081	8976	NDAR_INVCE986TWM	1573			M	5800	EndofPhase2	12	Phase 2	350	0	0	0	0	0	0	1	2	2	1	0	0	0	0	1	0	0	0		0	0	0	5	0	4	2	4	2	1	0	0	1	1	1	0	1	3		0	4				1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.75		1.5714285	3	1.15			1.5	0.625	0.25	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCE986TWM
2081	8976	NDAR_INVCF093XM6	1561			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	6	3	4	5	5	5	3	4	0	0	9	4	2	2	4	2	2	1	4	1	0	0	0	1	1	1	1	1	1	1	1	3	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.125	1	2.7142856	1.5	2.95	1		2.95	4.125	1	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF093XM6
2081	8976	NDAR_INVCF455KKU	2596			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	6	6	6	2	5	6	0	2	3	5	9	4	5	4	4	6	3	4	5	5	1	1	0	1	1	1	0	1	3	1	1	2	4	2	4	1	0	0	1	0	0	0	0	1	0	1	0	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	1	0	0	1	1	1	1	6	4.5	2.5	4.714286	3.5	4.3	1		4.3	4.5	2.5	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF455KKU
2081	8976	NDAR_INVCF455KKU	2596			M	1600	Visit6	6	Phase 1/1A	221	0	0	0	0	0	1	0	6	6	4	6	5	6	6	0	0	3	5	9	3	5	4	4	2	3	3	6	6	0	1	0	1	1	1	1	1	3	1	1	2	4	3	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	2	4.285714	3	4.15			4.3	4.5	2.5	4.714286	3.5	-0.15	0.375	-0.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF455KKU
2081	8976	NDAR_INVCF455KKU	2596			M	2800	Visit12	12	Phase 1/1A	389	0	0	0	0	0	1	0	6	6	4	6	5	6	6	0	0	3	6	9	3	5	4	4	2	2	2	3	5	1	1	1	1	1	1	1	1	3	1	1	2	4	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.875	2.25	3.7142856	2	3.9			4.3	4.5	2.5	4.714286	3.5	-0.4	0.375	-0.25	-1	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF455KKU
2081	8976	NDAR_INVCF455KKU	2596			M	5200	EndofPhase1_1a	18	Phase 1/1A	550	0	0	0	0	0	1	0	6	6	4	6	6	6	6	0	1	3	6	9	3	5	4	5	3	3	3	4	5	1	1	0	1	1	1	1	1	3	1	1	2	3	3	4	0	0	0	0	0	0	0	0					0		1	3	0		1	27	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5	2.5	4.142857	3	4.25		1	4.3	4.5	2.5	4.714286	3.5	-0.05	0.5	0	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF455KKU
2081	8976	NDAR_INVCF841RW2	2088			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	4	4	5	4	4	5	5	0	4	0	9	3	3	5	5	4	4	2	4	5	1	1	1	1	1	1	1	1	3	1	1	4	1	4	1	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.625	1	4.142857	3	3.8	1		3.8	4.625	1	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF841RW2
2081	8976	NDAR_INVCF841RW2	2088			M	1600	Visit6	6	Phase 1/1A	177	1	0	1	0	0	0	0	6	4	4	5	4	4	5	5	1	4	1	9	3	3	5	5	4	4	4	4	5	1	1	1	1	1	0	1	1	3	1	1	4	2	4	4	1	0	1	1	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	1	1	1	0	4	4.625	1.5	4.142857	4	4			3.8	4.625	1	4.142857	3	0.2	0	0.5	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF841RW2
2081	8976	NDAR_INVCF841RW2	2088			M	2800	Visit12	12	Phase 1B	343	1	0	0	0	0	0	0	3	3	2	3	4	2	2	4	2	2	2	9	3	4	2	2	3	3	2	2	2	0	0	0	0	1	1	1	1	3	2	1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.875	1.5	2.5714285	2.5	2.6			3.8	4.625	1	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF841RW2
2081	8976	NDAR_INVCF841RW2	2088			M	5200	EndofPhase1_1a	9	Phase 1/1A	255	0	0	0	0	0	0	1	2	2	3	2	4	2	2	4	2	2	2	9	3	4	2	2	3	3	2	2	2	0	0	0	0	1	1	1	1	3	2	1	3	4	4	4	0	0	0	0	0	0	0	0					1	21	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.625	1.5	2.5714285	2.5	2.5		1	3.8	4.625	1	4.142857	3	-1.3	-2	0.5	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF841RW2
2081	8976	NDAR_INVCF841RW2	2088			M	5400	EndofPhase1b	18	Phase 1B	560	1	0	0	0	0	0	0	3	3	3	2	4	2	2	4	2	2	2	9	3	4	2	2	3	3	2	2	2	0	0	0	0	1	1	1	1	3	2	1	3	4	4	4	0	0	0	0	0	0	0	0					1	9	0		0		0		1	21	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.875	1.5	2.5714285	2.5	2.6			3.8	4.625	1	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCF841RW2
2081	8976	NDAR_INVCG148UBX	2715			F	400	Baseline	0	Pre-Rand	1	1	1	1	0	0	0	0	4	0	0	0	2	0	0	3	4	4	1	3	2	2	0	3	4	2	2	4	2	1	0	1	1	1	1	1	1	1	3	0	4	4	4	4	1	1	1	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	3	2.4285715	2	2	1		2	1.125	3	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG148UBX
2081	8976	NDAR_INVCG148UBX	2715			F	1600	Visit6	6	Phase 1/1A	169	1	1	0	0	0	0	0	5	0	0	2	2	2	2	4	4	4	1	9	2	3	2	3	4	2	3	4	2	1	1	1	1	1	1	1	1	1	2	0	4	3	4	4	1	1	1	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	2.25	2.857143	2.5	2.55		1	2	1.125	3	2.4285715	2	0.55	1	-0.75	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG148UBX
2081	8976	NDAR_INVCG495CP9	1520			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	3	4	4	2	1	4	1	0	0	5	9	1	3	4	6	2	5	5	5	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	2	3.125	1.25	3.857143	5	3.35	1		3.35	3.125	1.25	3.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG495CP9
2081	8976	NDAR_INVCG495CP9	1520			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	6	0	0	1	2	0	2	0	0	0	4	9	0	2	4	1	2	5	4	4	6	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	1.375	1	2.7142856	4.5	2.15			3.35	3.125	1.25	3.857143	5	-1.2	-1.75	-0.25	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG495CP9
2081	8976	NDAR_INVCG495CP9	1520			M	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	6	0	3	3	2	0	3	2	0	0	4	9	1	2	3	2	1	4	3	4	5	1	0	0	0	1	1	1	1	1	2	0	4	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2.375	1	2.5714285	3.5	2.4			3.35	3.125	1.25	3.857143	5	-0.95	-0.75	-0.25	-1.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG495CP9
2081	8976	NDAR_INVCG495CP9	1520			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	4	0	3	1	2	0	2	2	0	0	4	9	1	2	3	2	1	3	3	4	4	1	1	0	0	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	23	1	7	0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	6	1.75	1	2.4285715	3	2.05		1	3.35	3.125	1.25	3.857143	5	-1.3	-1.375	-0.25	-1.4285715	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG495CP9
2081	8976	NDAR_INVCG709UFX	2547			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	1	1	1	3	2	2	1	5	1	3	6	4	4	4	3	4	5	3	4	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	4	1.75	3.75	4	4	3.0952382	1		3.0952382	1.75	3.75	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG709UFX
2081	8976	NDAR_INVCG709UFX	2547			M	1600	Visit6	6	Phase 1/1A	183	1	0	1	0	1	0	0	2	0	0	1	0	1	1	2	0	2	1	9	3	2	2	3	2	6	4	2	2	1	0	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	0.875	0.75	2.2857144	5	1.8			3.0952382	1.75	3.75	4	4	-1.2952381	-0.875	-3	-1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG709UFX
2081	8976	NDAR_INVCG709UFX	2547			M	2800	Visit12	12	Phase 1/1A	348	1	0	1	0	1	0	0	2	0	0	2	2	1	2	2	2	2	4	3	2	2	3	2	2	2	3	2	2	1	1	0	0	1	1	1	1	1	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	3	1.375	2.75	2.142857	2.5	2			3.0952382	1.75	3.75	4	4	-1.0952381	-0.375	-1	-1.8571428	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG709UFX
2081	8976	NDAR_INVCG709UFX	2547			M	5200	EndofPhase1_1a	18	Phase 1/1A	537	1	0	1	0	1	0	0	1	1	0	1	0	0	2	2	0	1	1	9	1	1	0	4	0	4	3	2	4	0	0	0	1	1	0	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	3	0.875	0.5	1.7142857	3.5	1.4		1	3.0952382	1.75	3.75	4	4	-1.6952381	-0.875	-3.25	-2.2857144	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCG709UFX
2081	8976	NDAR_INVCH073PE5	1462			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	9	1	0	0	3	1	2	1	3	2	0	0	0	0	1	0	2	2	3	3	1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	0.25	0	1.4285715	1.5	0.75	1		0.75	0.25	0	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCH073PE5
2081	8976	NDAR_INVCH073PE5	1462			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	9	1	0	0	3	1	2	1	3	2	0	0	0	0	1	0	2	2	3		1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	0.25	0	1.4285715	1.5	0.75			0.75	0.25	0	1.4285715	1.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCH073PE5
2081	8976	NDAR_INVCH073PE5	1462			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	9	1	0	0	3	1	2	1	3	2	0	0	0	0	1	0	2	2	3		1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	0.25	0	1.4285715	1.5	0.75			0.75	0.25	0	1.4285715	1.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCH073PE5
2081	8976	NDAR_INVCH073PE5	1462			M	5200	EndofPhase1_1a	18	Phase 1/1A	537	0	0	0	0	0	1	0	0	0	1	2	1	2	1	1	0	0	0	9	0	1	1	1	0	3	3	2	1	2	2	2	2	1	1	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	28	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0	0.85714287	3	1		1	0.75	0.25	0	1.4285715	1.5	0.25	0.75	0	-0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCH073PE5
2081	8976	NDAR_INVCH728KZY	1693			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	3	4	5	3	6	5	4	0	0	0	9	5	4	4	5	4	6	4	5	6	1	1	1	1	1	1	1	1	2	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.375	0	4.714286	5	3.9	1		3.9	4.375	0	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCH728KZY
2081	8976	NDAR_INVCJ432ZDG	2139			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	2	2	2	3	2	2	5	3	3	2	2	4	3	3	3	2	5	4	3	4	1	1	1	1	1	1	1	1	1	1	0	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	2.625	2.5	3.142857	4.5	2.952381	1		2.952381	2.625	2.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ432ZDG
2081	8976	NDAR_INVCJ432ZDG	2139			M	1600	Visit6	6	Phase 1B	177	0	1	0	0	0	0	0	6	4	3	3	4	4	4	5	4	2	2	3	4	3	4	3	4	6	3	4	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	4.125	2.75	3.857143	4.5	3.8095238			2.952381	2.625	2.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ432ZDG
2081	8976	NDAR_INVCJ432ZDG	2139			M	5200	EndofPhase1_1a	1	Phase 1/1A	27	0	1	0	0	0	0	0	4	2	2	2	3	1	2	4	2	2	1	9	3	2	1	1	2	5	3	3	2	1	1	1	1	1	0	1	1	1	2	1	3	2	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	24	0		0		1	6	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2.5	1.25	2	4	2.35		1	2.952381	2.625	2.5	3.142857	4.5	-0.60238093	-0.125	-1.25	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ432ZDG
2081	8976	NDAR_INVCJ432ZDG	2139			M	5400	EndofPhase1b	12	Phase 1B	338	0	1	0	0	0	0	0	4	4	4	2	4	2	3	4	2	2	2	9	2	1	1	2	3	4	3	3	5	1	1	1	1	1	1	0	1	1	2	1	3	2	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	5	3.375	1.5	2.4285715	3.5	2.85			2.952381	2.625	2.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ432ZDG
2081	8976	NDAR_INVCJ432ZDG	2139			M	5800	EndofPhase2	18	Phase 2	518	0	1	0	0	0	0	0	5	4	2	2	4	4	3	2	1	2	2	9	3	3	1	4	3	6	3	4	5	1	1	1	1	1	1	1	1	1	2	1	2	1	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	3.25	1.25	3.2857144	4.5	3.15			2.952381	2.625	2.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ432ZDG
2081	8976	NDAR_INVCJ681GF3	2051			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	4	4	2	2	0	4	2	0	2	5	9	2	5	4	5	1	4	4	5	5	1	1	0	1	1	1	1	1	1	3	1	3	3	3	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	1.75	3.857143	4	3.3	1		3.3	3	1.75	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ681GF3
2081	8976	NDAR_INVCJ923TE4	2822			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	2	1	2	2	2	2	2	4	3	3	3	3	3	3	3	4	4	4	2	3	1	1	1	0	1	1	0	1	1	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.75	3.25	3	4	2.6666667	1		2.6666667	1.75	3.25	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ923TE4
2081	8976	NDAR_INVCJ923TE4	2822			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	4	2	2	2	4	1	2	2	2	3	2	9	2	3	4	3	4	3	3	3	4	1	1	1	0	1	1	1	1	2	1	1	3	4	3	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.375	1.75	3.2857144	3	2.75			2.6666667	1.75	3.25	3	4	0.083333336	0.625	-1.5	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ923TE4
2081	8976	NDAR_INVCJ923TE4	2822			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	0	1	3	2	2	2	3	2	2	3	3	2	2	2	3	2	2	4	3	4	4	3	4	1	1	1	0	1	1	1	1	2	2	1	4	2	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	4	2.375	2.25	3	4	2.7142856			2.6666667	1.75	3.25	3	4	0.04761905	0.625	-1	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ923TE4
2081	8976	NDAR_INVCJ923TE4	2822			M	5200	EndofPhase1_1a	15	Phase 1/1A	448	0	0	0	0	0	0	1	2	4	3	3	3	2	3	2	3	2	2	2	2	3	3	2	2	5	5	4	4	1	1	1	1	1	1	1	1	2	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	2.75	2.25	2.857143	5	2.9047618		1	2.6666667	1.75	3.25	3	4	0.23809524	1	-1	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ923TE4
2081	8976	NDAR_INVCJ923TE4	2822			M	5800	EndofPhase2	18	Phase 2	539	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	1	2	9	2	3	1	3	1	4	4	3	3	1	1	1	1	1	1	1	1	2	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	4	2	1.25	2.2857144	4	2.25			2.6666667	1.75	3.25	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ923TE4
2081	8976	NDAR_INVCJ990GAT	2229			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	3	2	3	2	2	1	2	3	9	3	2	4	4	1	3	2	3	3	0	1	0	0	1	1	1	1	3		0	4	2	2	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	2.25	1.5	2.857143	2.5	2.45	1		2.45	2.25	1.5	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCJ990GAT
2081	8976	NDAR_INVCK075WY4	1926			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	1	4	5	4	5	1	4	0	0	2	1	9	2	1	1	1	1	5	5	2	4	0	1	0	0	1	1	1	1	3	3	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	3	0.75	1.7142857	5	2.45	1		2.45	3	0.75	1.7142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCK075WY4
2081	8976	NDAR_INVCK339BPM	1262			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	5	3	2	0	4	1	4	2	3	1	0	2	0	4	2	3	2	3	4	0	1	0	0	0	1	0	0	1	2	0	4	1	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	2.125	2.5	2.142857	2.5	2.2380953	1		2.2380953	2.125	2.5	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCK339BPM
2081	8976	NDAR_INVCK339BPM	1262			M	1600	Visit6	6	Phase 1/1A	184	0	0	0	0	0	1	0	1	0	1	4	1	2	2	1	0	0	0	9	0	1	1	2	1	3	2	3	4	0	1	0	0	1	0	0	0	2	1	1	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0	1.7142857	2.5	1.45			2.2380953	2.125	2.5	2.142857	2.5	-0.78809524	-0.625	-2.5	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCK339BPM
2081	8976	NDAR_INVCK339BPM	1262			M	2800	Visit12	12	Phase 1/1A	371	0	0	0	0	0	1	0	0	0	2	2	1	1	1	1	0	0	0	9	1	0	0	2	2	1	2	0	4	1	1	2	0	1	1	2	2	3	1	1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0	1.2857143	1.5	1			2.2380953	2.125	2.5	2.142857	2.5	-1.2380953	-1.125	-2.5	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCK339BPM
2081	8976	NDAR_INVCK339BPM	1262			M	5200	EndofPhase1_1a	18	Phase 1/1A	551	0	0	0	0	0	1	0	0	0	2	1	0	0	1	1	0	0	0	9	0	0	0	2	1	2	2	1	1	1	1	0	0	1	2	2	2	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.625	0	0.71428573	2	0.7		1	2.2380953	2.125	2.5	2.142857	2.5	-1.5380952	-1.5	-2.5	-1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCK339BPM
2081	8976	NDAR_INVCK744UR3	1716			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	1	0	0	4	0	0	2	4	3	2	3	3	3	3	1	3	3	3	3	4	3	1	5	5	1	0	1	0	1	1	1	1	1	1	0	4	2	2	1	1	1	1	0	0	0	0	0	1	1	1	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.25	2.5	3.7142856	2	2.7619047	1		2.7619047	2.25	2.5	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCK744UR3
2081	8976	NDAR_INVCL031JZD	2559			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	1	1	1	1	2	1	0	0	0	9	1	2	2	2	2	3	1	2	2	1	1	0	1	1	1	1	2	3		1	4	3	4	4	0	0	0	0	0	0	0	0					0		0		1	26	1	4	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0	1.8571428	2	1.3	1		1.3	1.125	0	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL031JZD
2081	8976	NDAR_INVCL031JZD	2559			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	3	2	2	2	2	2	3	0	3	2	4	4	2	2	2	2	2	4	4	2	3	1	1	1	1	1	1	1	1	3		1	3	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	3.25	2.142857	4	2.4761906			1.3	1.125	0	1.8571428	2	1.1761905	0.875	3.25	0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL031JZD
2081	8976	NDAR_INVCL031JZD	2559			F	5200	EndofPhase1_1a	7	Phase 1/1A	197	0	0	0	0	0	1	0	3	2	2	2	2	2	3	0	3	2	4	4	2	2	2	2	2	4	4	2	3	1	1	1	1	1	1	1	1	3		1	3	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	3.25	2.142857	4	2.4761906		1	1.3	1.125	0	1.8571428	2	1.1761905	0.875	3.25	0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL031JZD
2081	8976	NDAR_INVCL303HEL	1904			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	0	0	5	4	0	0	1	1	1	9	0	2	2	2	1	5	2	4	2	1	1	0	0	0	1	1	1	1	1	0	4	2	4	4	1	0	0	0	1	0	0	0	1	2	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	0.75	1.8571428	3.5	2.1	1		2.1	2.375	0.75	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL303HEL
2081	8976	NDAR_INVCL303HEL	1904			F	1600	Visit6	6	Phase 2	102	0	0	0	1	0	0	0	6	4	0	0	5	4	0	0	1	1	1	9	0	2	2	2	1	5	4	4	2	1	1	0	0	0	1	1	1	1	1	0	4	2	4	4	1	0	0	0	1	0	0	0	1	2	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	0.75	1.8571428	4.5	2.2			2.1	2.375	0.75	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL303HEL
2081	8976	NDAR_INVCL303HEL	1904			F	2800	Visit12	12	Phase 2	266	0	0	0	1	0	0	0	3	0	0	0	1	1	1	0	1	2	1	9	4	1	1	2	1	3	1	3	2	1	0	1	0	0	0	1	1	2	3	1	3	4	4	4	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	2	0.75	1	2	2	1.4			2.1	2.375	0.75	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL303HEL
2081	8976	NDAR_INVCL303HEL	1904			F	5800	EndofPhase2	18	Phase 2	434	0	0	0	1	0	0	0	5	4	4	0	0	1	3	0	0	0	0	9	2	2	2	2	2	5	5	2	2	1	1	1	1	1	1	1	1	1	1	0	4	2	2	4	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	2	5	2.05			2.1	2.375	0.75	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL303HEL
2081	8976	NDAR_INVCL362JXY	2290			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	3	4	4	6	2	0	0	0	9	3	6	2	5	6	3	0	3	6	0	0	0	0	1	1	1	2	3		1	2	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	2	2	2	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.875	0	4.428571	1.5	2.85	1		2.85	2.875	0	4.428571	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCL362JXY
2081	8976	NDAR_INVCM006VLM	1736			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	2	1	2	2	2	2	0	0	0	9	2	1	1	1	1	2	3	4	5	1	1	1	0	1	1	1	1	1	2	0	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0	2.142857	2.5	1.8	1		1.8	2	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM006VLM
2081	8976	NDAR_INVCM006VLM	1736			M	1600	Visit6	6	Phase 1/1A	163	1	0	0	0	0	0	0	5	0	0	0	5	1	2	0	0	0	0	9	0	2	1	3	5	3	4	4	4	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0	2.7142856	3.5	1.95		1	1.8	2	0	2.142857	2.5	0.15	-0.375	0	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM006VLM
2081	8976	NDAR_INVCM080VG4	1244			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	3	1	1	1	1	2	0	1	1	9	2	1	2	2	1	3	2	5	4	0	0	0	0	1	0	0	0	3	3	1	3	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0.5	2.4285715	2.5	2	1		2	2	0.5	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM080VG4
2081	8976	NDAR_INVCM487UTQ	1192			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	1	2	4	2	2	2	0	1	0	9	4	4	3	3	1	5	4	2	3	2	1	2	0	1	1	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	0.25	2.857143	4.5	2.25	1		2.25	1.875	0.25	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM487UTQ
2081	8976	NDAR_INVCM487UTQ	1192			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	1	0	2	0	1	2	4	2	2	2	0	1	0	9	4	4	3	3	5	4	4	2	3	2	1	2	0	1	1	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	1.875	0.25	3.4285715	4	2.4			2.25	1.875	0.25	2.857143	4.5	0.15	0	0	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM487UTQ
2081	8976	NDAR_INVCM487UTQ	1192			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	1	0	2	0	1	2	4	2	2	2	0	1	0	9	4	4	3	3	1	5	4	2	3	2	1	2	0	1	1	1	0	3	1	0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	1.875	0.25	2.857143	4.5	2.25			2.25	1.875	0.25	2.857143	4.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM487UTQ
2081	8976	NDAR_INVCM487UTQ	1192			M	4000	Visit18	18	Phase 1/1A	513	0	0	0	0	0	1	0	2	0	0	4	2	0	4	2	0	0	1	9	2	4	4	3	2	6	4	2	4	1	1	2	0	1	1	1	2	3		0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	0.25	3	5	2.3			2.25	1.875	0.25	2.857143	4.5	0.05	-0.125	0	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM487UTQ
2081	8976	NDAR_INVCM487UTQ	1192			M	5200	EndofPhase1_1a	20	Phase 1/1A	600	0	0	0	0	0	1	0	4	1	4	4	4	2	3	2	0	1	0	9	4	3	4	4	0	6	4	5	5	1	1	1	0	1	1	1	1	2	1	0	4	4	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	0.25	3.5714285	5	3		1	2.25	1.875	0.25	2.857143	4.5	0.75	1.125	0	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM487UTQ
2081	8976	NDAR_INVCM947TPH	1191			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	0	2	0	0	6	0	0	0	6	9	0	2	2	2	4	2	2	3	3	0	0	0	0	1	0	0	1	3	3	1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2.25	1.5	2.2857144	2	2.2	1		2.2	2.25	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM947TPH
2081	8976	NDAR_INVCM947TPH	1191			M	1600	Visit6	6	Phase 2	182	0	0	0	0	0	1	0	6	6	2	5	4	0	5	2	0	1	0	9	0	2	2	2	0	2	3	2	2	0	1	0	0	1	1	0	0	3		1	4	3	2	4	1	0	0	0	0	1	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.75	0.25	1.4285715	2.5	2.3			2.2	2.25	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM947TPH
2081	8976	NDAR_INVCM947TPH	1191			M	2800	Visit12	12	Phase 2	370	0	0	0	0	0	1	0	1	1	1	2	3	1	1	0	0	0	1	9	1	1	1	1	0	2	1	2	2	1	1	0	0	1	1	0	0	3		0	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.25	0.25	1.1428572	1.5	1.1			2.2	2.25	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM947TPH
2081	8976	NDAR_INVCM947TPH	1191			M	5200	EndofPhase1_1a	5	Phase 1/1A	131	0	0	0	0	0	1	0	4	4	4	4	3	3	2	1	0	1	1	9	0	0	4	4	2	1	1	1	4	0	1	2	0	0	0	0	0	3		1	3	4	4	4	1	0	0	0	0	1	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	3.125	0.5	2.142857	1	2.2		1	2.2	2.25	1.5	2.2857144	2	0	0.875	-1	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCM947TPH
2081	8976	NDAR_INVCN023RVT	1788			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	5	3	5	2	4	2	0	0	0	9	2	3	5	5	4	6	4	5	4	1	1	1	1	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.125	0	4	5	3.55	1		3.55	4.125	0	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN023RVT
2081	8976	NDAR_INVCN023RVT	1788			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	4	4	3	4	4	4	4	2	2	4	2	9	3	3	4	4	4	5	3	4	3	1	0	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3.625	2	3.5714285	4	3.5		1	3.55	4.125	0	4	5	-0.05	-0.5	2	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN023RVT
2081	8976	NDAR_INVCN216XUW	2802			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	0	2	2	2	0	0	2	6	9	4	3	3	2	0	5	1	2	3	0	0	1	0	1	1	1	1	1	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	2	2.4285715	3	2.15	1		2.15	1.5	2	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN216XUW
2081	8976	NDAR_INVCN216XUW	2802			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	0	0	2	4	2	2	4	0	6	6	6	6	3	5	0	5	6	5	4	2	6	1	1	1	0	1	1	1	0	2	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1.75	6	3.857143	4.5	3.5238094		1	2.15	1.5	2	2.4285715	3	1.3738096	0.25	4	1.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN216XUW
2081	8976	NDAR_INVCN295TZG	1302			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	3	2	4	4	4	5	5	4	6	1	1	3	0	4	5	6	4	2	3	1	1	1	1	1	1	1	1	2	1	1	4	4	4	2	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		2	2	2	1	0	0	0	1	0	0	0	0	1	0	1	0	1	3.75	4	2.5714285	5	3.5238094	1		3.5238094	3.75	4	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN295TZG
2081	8976	NDAR_INVCN295TZG	1302			F	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	3	3	4	3	3	4	4	3	5	2	4	2	4	4	4	5	4	5	4	3	5	1	1	1	0	1	1	1	1	3	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	3.25	4.142857	4.5	3.7142856			3.5238094	3.75	4	2.5714285	5	0.1904762	-0.375	-0.75	1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN295TZG
2081	8976	NDAR_INVCN295TZG	1302			F	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	5	4	4	4	5	4	5	5	4	3	4	4	4	4	4	5	4	6	4	4	5	1	1	1	0	1	1	1	1	3	1	1	4	3	3	1	1	1	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.5	3.75	4.285714	5	4.3333335			3.5238094	3.75	4	2.5714285	5	0.8095238	0.75	-0.25	1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN295TZG
2081	8976	NDAR_INVCN295TZG	1302			F	5200	EndofPhase1_1a	18	Phase 1/1A	500	0	1	0	0	0	0	0	4	4	4	5	4	4	5	5	6	6	6	6	5	5	4	5	5	6	5	5	6	1	0	1	0	1	1	1	1	2	1	1	4	3	3	1	1	1	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.375	6	5	5.5	5		1	3.5238094	3.75	4	2.5714285	5	1.4761904	0.625	2	2.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN295TZG
2081	8976	NDAR_INVCN401LND	2252			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	6	0	2	6	6	5	0	2	2	6	9	6	0	6	0	6	4	1	6	4	1	0	1	1	1	1	1	1	2	1	1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	0	1	1	1	2	3.875	2.5	4	2.5	3.7	1		3.7	3.875	2.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN401LND	2252			F	1600	Visit6	6	Phase 1B	171	0	0	1	0	0	0	0	6	6	6	4	2	0	2	0	0	0	0	9	4	0	0	4	0	4	2	6	5	0	0	1	0	1	1	1	1	1	1	1	3	1	3	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	6	3.25	0	2.7142856	3	2.55			3.7	3.875	2.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN401LND	2252			F	2800	Visit12	12	Phase 3	336	1	0	0	0	0	0	0	2	0	0	2	1	0	2	0	0	0	0	9	4	1	3	4	0	4	3	4	4	1	0	1	0	1	1	1	1	1	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	0.875	0	2.857143	3.5	1.7			3.7	3.875	2.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN401LND	2252			F	5200	EndofPhase1_1a	1	Phase 1/1A	24	0	0	1	0	0	0	0	6	0	2	1	0	0	0	0	0	5	1	9	3	3	0	2	0	4	2	1	4	0	0	0	0	1	1	0	1	2	3	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.125	1.5	1.8571428	3	1.7		1	3.7	3.875	2.5	4	2.5	-2	-2.75	-1	-2.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN401LND	2252			F	5400	EndofPhase1b	8	Phase 1B	228	1	0	0	0	0	0	0	3	0	0	0	2	0	2	0	0	0	0	9	1	6	4	4	0	2	4	4	5	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0.875	0	3.4285715	3	1.85			3.7	3.875	2.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN401LND	2252			F	5800	EndofPhase2	10	Phase 2	303	0	0	1	0	0	0	0	4	0	0	0	1	0	2	0	0	0	0	9	0	2	0	0	0	4	3	1	4	1	0	1	0	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	0.875	0	1	3.5	1.05			3.7	3.875	2.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN401LND	2252			F	6000	EndofPhase3	18	Phase 3	500	1	0	0	0	0	0	0	6	0	0	0	0	0	0	0	0	0	0	9	3	0	6	5	0	5	3	4	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	0.75	0	3.142857	4	1.8			3.7	3.875	2.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN401LND
2081	8976	NDAR_INVCN551URH	2584			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	0	0	0	2	0	2	0	0	0	0	9	0	0	2	2	0	5	1	2	2	1	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0	1.1428572	3	1.2	1		1.2	1.25	0	1.1428572	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN551URH
2081	8976	NDAR_INVCN621NUC	2889			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	2	5	5	5	4	3	2	2	3	9	3	5	5	5	4	4	3	6	6	1	1	1	1	1	1	0	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.25	1.75	4.857143	3.5	4.1	1		4.1	4.25	1.75	4.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN621NUC
2081	8976	NDAR_INVCN621NUC	2889			M	1600	Visit6	6	Phase 1/1A	165	0	0	0	0	0	0	1	6	6	4	4	4	6	6	1	4	2	1	9	3	4	4	4	4	4	3	4	6	1	0	1	1	1	1	0	1	2	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.625	1.75	4.142857	3.5	4			4.1	4.25	1.75	4.857143	3.5	-0.1	0.375	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN621NUC
2081	8976	NDAR_INVCN621NUC	2889			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	9	4	4	5	5	3	3	2	0	0	0	9	5	5	0	6	2	5	3	5	6	1	0	1	1	1	0	1	1	2	1	1	3	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.7142856	0	4.142857	4	3.3157895			4.1	4.25	1.75	4.857143	3.5	-0.7842105	-0.53571427	-1.75	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN621NUC
2081	8976	NDAR_INVCN621NUC	2889			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	5	4	3	4	2	3	1	0	0	0	9	1	2	2	3	2	5	2	4	5	1	1	1	0	1	1	1	1	1	3	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.142857	0	2.7142856	3.5	2.5263157		1	4.1	4.25	1.75	4.857143	3.5	-1.5736842	-1.1071428	-1.75	-2.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN621NUC
2081	8976	NDAR_INVCN852HGZ	1914			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	2	2	2	0	3	0	1	3	1	9	4	2	4	4	1	5	3	5	5	0	0	0	0	1	1	0	1	3	2	0	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	1	1	1	1	1	0	4	1.625	1.25	3.5714285	4	2.55	1		2.55	1.625	1.25	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN852HGZ
2081	8976	NDAR_INVCN852HGZ	1914			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	3	5	0	2	2	4	4	0	1	2	5	9	4	3	3	4	5	4	4	5	2	1	1	0	0	1	1	1	2	3	1	1	3	2	2	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	2	3.7142856	4	3.1			2.55	1.625	1.25	3.5714285	4	0.55	0.875	0.75	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN852HGZ
2081	8976	NDAR_INVCN852HGZ	1914			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	0	1	3	1	2	2	2	4	3	2	1	3	3	9	4	3	3	4	1	5	2	4	3	0	0	0	0	1	0	0	0	3		1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	2.375	1.75	3.142857	3.5	2.75			2.55	1.625	1.25	3.5714285	4	0.2	0.75	0.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN852HGZ
2081	8976	NDAR_INVCN852HGZ	1914			M	5200	EndofPhase1_1a	18	Phase 1/1A	496	0	0	0	0	0	0	1	2	4	1	4	3	3	3	1	3	4	4	5	6	4	5	6	4	5	2	4	6	1	0	1	1	1	1	0	0	3		1	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	1	0	0	0	0	1	0	1	0	0	1	1	1	1	6	2.625	4	5	3.5	3.7619047		1	2.55	1.625	1.25	3.5714285	4	1.2119048	1	2.75	1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCN852HGZ
2081	8976	NDAR_INVCP239PKC	1249			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	3	2	1	2	2	0	0	0	9	0	0	1	3	2	2	0	2	2	0	2	2	2	1	1	0	0	3	3	0	4	4	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2	0	1.4285715	1	1.4	1		1.4	2	0	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCP239PKC
2081	8976	NDAR_INVCP239PKC	1249			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	2	2	2	2	4	2	2	2	0	0	0	9	0	0	0	2	0	2	2	4	4	1	1	2	1	1	2	2	2	3	2	1	3	3	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	0	1.4285715	2	1.6			1.4	2	0	1.4285715	1	0.2	0.25	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCP239PKC
2081	8976	NDAR_INVCP239PKC	1249			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	1	0	2	2	2	2	4	2	2	2	0	0	0	9	0	0	0	2	0	2	2	4	4	1	1	2	1	1	2	2	2	3	2	1	3	3	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	0	1.4285715	2	1.6			1.4	2	0	1.4285715	1	0.2	0.25	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCP239PKC
2081	8976	NDAR_INVCP239PKC	1249			M	4000	Visit18	18	Phase 3	540	0	0	0	0	0	0	1	4	0	1	1	1	2	1	1	0	1	1	9	1	0	0	1	1	1	1	4	1	1	1	2	0	1	1	2	1	3		0	4					0	0	0	0	0	0	0					0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	1.375	0.5	1.1428572	1	1.15			1.4	2	0	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCP239PKC
2081	8976	NDAR_INVCP239PKC	1249			M	5200	EndofPhase1_1a	12	Phase 1/1A	340	0	0	0	0	0	1	0	2	2	2	2	4	2	2	2	0	0	0	9	0	0	0	2	0	2	2	4	4	1	1	2	1	1	2	2	2	3	2	1	3	3	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	0	1.4285715	2	1.6		1	1.4	2	0	1.4285715	1	0.2	0.25	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCP239PKC
2081	8976	NDAR_INVCP239PKC	1249			M	5800	EndofPhase2	15	Phase 2	456	0	0	0	0	0	1	0	2	2	2	2	4	2	2	2	0	0	0	9	0	0	0	2	0	2	2	4	4	1	1	2	1	1	2	1	2	3	2	1	3	3	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	0	1.4285715	2	1.6			1.4	2	0	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCP239PKC
2081	8976	NDAR_INVCR239XD0	2819			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	4	0	3	4	3	4	4	0	4	4	9	5	5	2	4	4	2	1	4	4	0	0	2	0	1	1	1	0	3		1	3	2	2	4	1	0	0	0	0	1	0	0	2	2	2	2	0		0		0		1	30	0		0	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0	5	2.75	2	4	1.5	3.05	1		3.05	2.75	2	4	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR239XD0
2081	8976	NDAR_INVCR239XD0	2819			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	9	3	0	1	1	1	2	1	1	1	5	9	2	2	0	1	0	4	1	3	5	0	0	1	1	1	1	1	1	3		1	3	4	3	4	1	0	0	0	0	1	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	5	1.2857143	1.75	1.8571428	2.5	1.7894737			3.05	2.75	2	4	1.5	-1.2605263	-1.4642857	-0.25	-2.142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR239XD0
2081	8976	NDAR_INVCR239XD0	2819			M	2800	Visit12	12	Phase 1/1A	342	0	0	0	0	0	0	1	1	2	2	3	2	1	2	1	0	0	1	9	1	1	1	3	0	4	2	3	4	1	0	1	0	1	1	0	1	3		1	3	2	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0.25	1.8571428	3	1.7			3.05	2.75	2	4	1.5	-1.35	-1	-1.75	-2.142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR239XD0
2081	8976	NDAR_INVCR239XD0	2819			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	0	1	0	2	2	2	2	0	2	1	0	0	1	9	1	2	0	2	2	4	3	3	4	1	1	1	1	1	0	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.375	0.25	2	3.5	1.65		1	3.05	2.75	2	4	1.5	-1.4	-1.375	-1.75	-2	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR239XD0
2081	8976	NDAR_INVCR316AZ4	1598			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	0	2	2	0	2	4	2	2	2	9	0	2	2	2	0	5	2	4	4	0	0	1	1	0	0	1	1	3	1	1	4	4	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2	1.5	2	3.5	2.15	1		2.15	2	1.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR316AZ4
2081	8976	NDAR_INVCR316AZ4	1598			M	1600	Visit6	6	Phase 1/1A	192	0	1	0	0	0	0	0	6	0	4	2	2	2	3	1	3	2	4	4	3	4	4	2	1	5	2	4	5	0	0	1	0	1	1	1	1	3	1	0	4	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.5	3.25	3.2857144	3.5	3			2.15	2	1.5	2	3.5	0.85	0.5	1.75	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR316AZ4
2081	8976	NDAR_INVCR316AZ4	1598			M	2800	Visit12	12	Phase 1/1A	340	0	1	0	0	0	0	0	6	0	4	2	2	2	3	1	3	2	4	4	3	4	1	2	2	5	3	5	3	1	0	1	0	1	1	1	1	1	1	1	3	3	2	1	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.5	3.25	2.857143	4	2.9047618			2.15	2	1.5	2	3.5	0.75476193	0.5	1.75	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR316AZ4
2081	8976	NDAR_INVCR316AZ4	1598			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	1	0	0	0	0	0	5	4	4	4	4	3	4	4	2	3	4	9	2	3	2	3	2	5	2	4	4	0	0	1	0	1	0	1	1	1	2	0	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	4	2.25	2.857143	3.5	3.4		1	2.15	2	1.5	2	3.5	1.25	2	0.75	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR316AZ4
2081	8976	NDAR_INVCR681DKJ	1286			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	0	0	2	0	1	1	0	9	1	0	3	0	2	5	5	2	3	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.5	0.5	1.5714285	5	1.35	1		1.35	0.5	0.5	1.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR681DKJ
2081	8976	NDAR_INVCR681DKJ	1286			M	1600	Visit6	6	Phase 2	176	1	0	0	0	0	0	0	2	0	1	2	1	0	1	1	1	0	1	9	2	1	2	1	1	5	4	0	4	1	1	1	0	0	0	1	1	3	1	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1	0.5	1.5714285	4.5	1.5			1.35	0.5	0.5	1.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR681DKJ
2081	8976	NDAR_INVCR681DKJ	1286			M	2800	Visit12	12	Phase 3	351	1	0	0	0	0	0	0	2	2	2	4	3	3	3	0	2	4	2	9	2	4	4	3	2	5	2	2	5	0	0	0	0	0	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	27	1	3	0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	2	3.142857	3.5	2.8			1.35	0.5	0.5	1.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR681DKJ
2081	8976	NDAR_INVCR681DKJ	1286			M	5200	EndofPhase1_1a	2	Phase 1/1A	60	0	0	0	0	1	0	0	2	0	0	0	2	0	0	1	0	0	0	9	0	0	2	0	0	5	4	1	3	1	1	1	0	0	1	1	1	3	1	1	4	4	3	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	4	0.625	0	0.85714287	4.5	1		1	1.35	0.5	0.5	1.5714285	5	-0.35	0.125	-0.5	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR681DKJ
2081	8976	NDAR_INVCR681DKJ	1286			M	5800	EndofPhase2	11	Phase 2	305	1	0	0	0	0	0	0	2	3	3	2	2	2	2	1	4	2	3	2	3	3	3	3	3	4	3	4	2	1	1	1	0	0	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.125	2.75	3	3.5	2.6666667			1.35	0.5	0.5	1.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR681DKJ
2081	8976	NDAR_INVCR886XJL	2459			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	5	4	6	6	6	0	0	5	5	9	5	6	6	6	6	6	5	6	6	1	1	1	1	1	0	1	1	3		1	2	1	2	3	0	0	0	0	0	0	0	0					1	23	0		1	7	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	4.125	2.5	5.857143	5.5	4.75	1		4.75	4.125	2.5	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR886XJL
2081	8976	NDAR_INVCR886XJL	2459			F	5200	EndofPhase1_1a	2	Phase 1/1A	68	0	0	0	0	0	0	1	5	6	6	4	6	6	6	6	6	6	6	6	3	6	6	6	6	6	6	4	5	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.625	6	5.142857	6	5.571429		1	4.75	4.125	2.5	5.857143	5.5	0.8214286	1.5	3.5	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCR886XJL
2081	8976	NDAR_INVCT059BWV	1280			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	6	0	0	4	0	1	0	0	0	0	9	1	2	4	0	2	4	2	3	3	1	0	0	0	1	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1.5714285	0	2.142857	3	1.6842105	1		1.6842105	1.5714285	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT059BWV
2081	8976	NDAR_INVCT059BWV	1280			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	9	2	0	1	2	2	2	0	0	0	0	9	3	2	4	6	0	5	3	6	6	1	0	1	1	1	1	1	1	3	3	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	4	1.2857143	0	3.857143	4	2.3157895			1.6842105	1.5714285	0	2.142857	3	0.6315789	-0.2857143	0	1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT059BWV
2081	8976	NDAR_INVCT059BWV	1280			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	0	1	9	1	0	1	1	1	2	0	0	0	0	9	0	2	4	6	2	4	3	6	6	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	0.85714287	0	3.7142856	3.5	2.0526316			1.6842105	1.5714285	0	2.142857	3	0.36842105	-0.71428573	0	1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT059BWV
2081	8976	NDAR_INVCT059BWV	1280			M	5200	EndofPhase1_1a	13	Phase 1/1A	368	0	0	0	0	0	0	1	9	2	0	1	2	1	2	0	0	0	0	9	0	2	2	6	2	4	3	6	6	1	1	1	0	1	1	0	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	1.1428572	0	3.4285715	3.5	2.0526316		1	1.6842105	1.5714285	0	2.142857	3	0.36842105	-0.42857143	0	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT059BWV
2081	8976	NDAR_INVCT059BWV	1280			M	5800	EndofPhase2	15	Phase 2	419	0	0	0	0	0	0	1	9	2	0	1	2	0	1	0	0	0	0	9	0	2	2	6	2	4	2	6	6	1	0	1	1	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	0.85714287	0	3.4285715	3	1.8947369			1.6842105	1.5714285	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT059BWV
2081	8976	NDAR_INVCT059BWV	1280			M	6000	EndofPhase3	18	Phase 3	505	0	0	0	0	0	0	1	9	3	2	1	2	0	2	2	0	0	0	9	0	2	3	6	2	4	3	6	6	1	1	1	1	1	1	0	1	3		1	3	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.7142857	0	3.5714285	3.5	2.3157895			1.6842105	1.5714285	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT059BWV
2081	8976	NDAR_INVCT319RXW	1882			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	1	0	0	6	4	5	5	5	5	6	6	4	5	3	6	5	6	4	6	4	3	5	5	6	0	1	1	1	1	1	1	1	1	1	1	4	2	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.25	4.5	5.142857	4	4.952381	1		4.952381	5.25	4.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT319RXW
2081	8976	NDAR_INVCT319RXW	1882			F	1600	Visit6	6	Phase 2	197	0	1	0	0	0	1	0	5	4	4	5	2	5	5	4	2	4	4	9	4	4	2	5	2	5	5	4	6	1	1	1	0	1	1	1	1	1	1	0	4	4	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	2.5	3.857143	5	4.05			4.952381	5.25	4.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT319RXW
2081	8976	NDAR_INVCT319RXW	1882			F	5200	EndofPhase1_1a	4	Phase 1/1A	119	0	0	0	0	0	1	0	5	2	2	5	5	5	5	4	4	4	4	6	5	5	2	5	4	3	5	5	5	1	1	1	0	1	1	1	1	1	1	0	4	1	2	3	0	0	0	0	0	0	0	0					0		1	3	1	27	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	4.125	4.5	4.428571	4	4.285714		1	4.952381	5.25	4.5	5.142857	4	-0.6666667	-1.125	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT319RXW
2081	8976	NDAR_INVCT439MJW	1981			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	2	2	2	2	4	3	5	4	6	6	3	3	2	4	5	4	3	4	3	0	0	2	0	1	1	2	0	3		1	2	2	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.875	5.25	3.4285715	3.5	3.5714285	1		3.5714285	2.875	5.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT439MJW
2081	8976	NDAR_INVCT439MJW	1981			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	1	0	4	4	3	2	2	1	4	4	3	4	6	5	2	2	3	3	4	4	2	4	4	1	1	2	1	1	1	2	0	3	1	1	2	3	2	1	1	0	0	0	0	0	1	0	1	1	1	1	1	5	1	31	0		1	9	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3	4.5	3.142857	3	3.3333333			3.5714285	2.875	5.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT439MJW
2081	8976	NDAR_INVCT439MJW	1981			M	2800	Visit12	12	Phase 3	341	0	0	0	0	0	0	1	4	4	4	4	4	4	5	4	5	6	3	6	5	6	5	5	6	4	5	6	5	1	1	2	1	1	1	2	2	3	1	1	2	3	3	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5	5.428571	4.5	4.7619047			3.5714285	2.875	5.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT439MJW
2081	8976	NDAR_INVCT439MJW	1981			M	5200	EndofPhase1_1a	5	Phase 1/1A	126	0	0	0	0	0	0	1	4	4	4	2	4	2	5	4	5	3	6	6	2	5	6	5	5	4	1	4	5	0	0	2	0	1	1	2	2	3	1	1	3	4	4	1	0	0	0	0	0	0	0	0					0		1	25	0		1	5	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	5	4.571429	2.5	4.095238		1	3.5714285	2.875	5.25	3.4285715	3.5	0.52380955	0.75	-0.25	1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT439MJW
2081	8976	NDAR_INVCT439MJW	1981			M	5800	EndofPhase2	10	Phase 2	261	0	0	0	0	0	0	1	4	0	3	2	3	3	5	4	2	2	4	9	2	0	3	3	1	5	3	5	4	0	0	2	1	1	1	2	2	3		1	3	2	2	1	0	0	0	0	0	0	0	0					0		1	29	1	1	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	3	2	2.5714285	4	2.9			3.5714285	2.875	5.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT439MJW
2081	8976	NDAR_INVCT439MJW	1981			M	6000	EndofPhase3	18	Phase 3	513	0	0	0	0	0	0	1	4	5	4	3	4	5	5	3	3	3	4	5	2	3	4	3	5	5	3	5	5	1	1	2	1	1	1	0	2	3		1	2	4	2	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	3	4.125	3.75	3.857143	4	3.952381			3.5714285	2.875	5.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT439MJW
2081	8976	NDAR_INVCT757DCE	2151			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	2	2	2	4	4	9	4	6	3	6	6	6	4	2	5	1	1	0	0	1	1	0	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	2.5	4.571429	5	3.4	1		3.4	2	2.5	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCT757DCE
2081	8976	NDAR_INVCU554RPB	1514			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	3	2	4	3	3	2	6	5	4	2	4	4	0	2	5	5	3	4	4	0	1	1	1	1	0	1	1	3	3	1	3	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	4.25	3.2857144	4	3.4761906	1		3.4761906	3.125	4.25	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU554RPB
2081	8976	NDAR_INVCU554RPB	1514			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	4	5	2	1	4	5	5	2	6	5	6	6	5	4	3	5	6	5	5	4	5	1	1	1	1	1	1	1	1	2	1	1	3	2	1	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	5.75	4.571429	5	4.428571			3.4761906	3.125	4.25	3.2857144	4	0.95238096	0.375	1.5	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU554RPB
2081	8976	NDAR_INVCU554RPB	1514			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	1	0	2	1	1	0	2	0	0	2	0	0	0	9	0	0	0	1	0	2	0	0	0	2	2	2	2	1	0	0	2	3	3	1	4	3	4	4	1	0	0	0	0	0	1	0	2	2	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	1	0	0.14285715	1	0.55			3.4761906	3.125	4.25	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU554RPB
2081	8976	NDAR_INVCU554RPB	1514			M	5200	EndofPhase1_1a	11	Phase 1/1A	288	0	0	0	0	0	1	0	3	3	3	3	3	3	3	3	4	4	4	4	3	2	2	4	5	5	4	2	2	1	0	1	1	1	0	0	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	27	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	4	3	4	2.857143	4.5	3.2857144		1	3.4761906	3.125	4.25	3.2857144	4	-0.1904762	-0.125	-0.25	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU554RPB
2081	8976	NDAR_INVCU554RPB	1514			M	5800	EndofPhase2	18	Phase 2	506	0	0	0	0	0	1	0	5	5	5	5	5	5	5	4	4	4	4	5	5	5	4	5	5	4	5	5	6	1	1	0	1	1	1	1	1	2	1	1	3	2	3	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.875	4.25	5	4.5	4.7619047			3.4761906	3.125	4.25	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU554RPB
2081	8976	NDAR_INVCU577NZD	2565			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	2	3	6	4	4	2	1	1	1	9	2	2	4	2	2	2	1	4	5	2	2	2	2	1	2	2	2	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	0.75	3	1.5	2.95	1		2.95	4	0.75	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU577NZD
2081	8976	NDAR_INVCU610FYT	1835			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	1	4	4	3	4	4	1	0	1	0	9	2	2	2	5	1	3	3	4	5	1	1	0	0	1	0	0	0	1	2	0	4	1	1	4	1	0	1	0	0	0	0	0	1	0	0	0	1	15	0		0		0		1	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2.875	0.25	3	3	2.55	1		2.55	2.875	0.25	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU610FYT
2081	8976	NDAR_INVCU610FYT	1835			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	4	0	3	5	2	3	2	2	0	2	0	9	2	2	4	5	4	5	4	5	5	1	1	2	0	1	0	1	0	3	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	0.5	3.857143	4.5	2.95			2.55	2.875	0.25	3	3	0.4	-0.25	0.25	0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU610FYT
2081	8976	NDAR_INVCU610FYT	1835			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	4	0	2	5	2	2	4	2	0	0	1	9	2	2	2	5	4	5	5	5	5	1	0	1	1	1	1	0	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.625	0.25	3.5714285	5	2.85			2.55	2.875	0.25	3	3	0.3	-0.25	0	0.5714286	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU610FYT
2081	8976	NDAR_INVCU610FYT	1835			M	5200	EndofPhase1_1a	18	Phase 1/1A	522	0	0	0	0	0	0	1	2	0	4	4	4	1	4	2	0	1	1	9	2	1	4	5	4	5	4	4	4	1	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	2.625	0.5	3.4285715	4.5	2.8		1	2.55	2.875	0.25	3	3	0.25	-0.25	0.25	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU610FYT
2081	8976	NDAR_INVCU820KFD	1082			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	5	2	4	3	4	4	4	2	0	1	9	3	2	3	3	2	4	3	4	2	1	1	2	1	1	1	1	2	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	2	1	0	1	1	0		0		1	29	0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	4	3.75	0.75	2.7142856	3.5	2.95	1		2.95	3.75	0.75	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU820KFD
2081	8976	NDAR_INVCU820KFD	1082			M	1600	Visit6	6	Phase 1/1A	210	1	0	0	0	0	0	0	3	4	5	5	5	4	4	2	1	1	1	9	2	3	0	5	2	3	1	2	2	0	1	0	1	1	1	1	1	1	2	1	2	1	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4	0.75	2.2857144	2	2.75			2.95	3.75	0.75	2.7142856	3.5	-0.2	0.25	0	-0.42857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU820KFD
2081	8976	NDAR_INVCU820KFD	1082			M	2800	Visit12	12	Phase 1/1A	343	0	1	0	0	0	0	0	5	5	2	3	4	3	3	5	4	4	4	6	2	4	3	4	2	1	5	4	2	1	1	1	1	1	1	1	1	1	1	1	3	1	2	1	1	1	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.75	4.5	3	3	3.5714285			2.95	3.75	0.75	2.7142856	3.5	0.62142855	0	3.75	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU820KFD
2081	8976	NDAR_INVCU820KFD	1082			M	5200	EndofPhase1_1a	18	Phase 1/1A	575	0	1	0	0	0	0	0	6	3	4	3	2	0	3	4	4	4	6	5	1	2	3	5	4	4	4	3	1	1	1	1	0	1	1	1	1	1	1	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.125	4.75	2.7142856	4	3.3809524		1	2.95	3.75	0.75	2.7142856	3.5	0.43095237	-0.625	4	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCU820KFD
2081	8976	NDAR_INVCV549UGK	2421			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	2	2	2	2	1	2	0	2	3	4	9	2	3	4	3	2	5	2	4	2	1	0	1	0	1	0	0	1	3	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.625	2.25	2.857143	3.5	2.45	1		2.45	1.625	2.25	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV549UGK
2081	8976	NDAR_INVCV549UGK	2421			M	2800	Visit12	12	Phase 3	336	1	0	0	0	0	0	0	4	3	4	3	3	2	3	0	2	4	4	9	3	4	3	5	4	5	4	4	2	0	0	1	0	1	0	0	1	2	2	0	4	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.75	2.5	3.5714285	4.5	3.3			2.45	1.625	2.25	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV549UGK
2081	8976	NDAR_INVCV549UGK	2421			M	5200	EndofPhase1_1a	2	Phase 1/1A	57	1	0	0	0	0	0	0	2	1	1	1	1	2	2	0	1	1	1	9	2	2	2	3	1	6	2	4	3	0	0	1	0	1	0	0	1	1	2	0	4	3	3	4	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	1.25	0.75	2.4285715	4	1.9		1	2.45	1.625	2.25	2.857143	3.5	-0.55	-0.375	-1.5	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV549UGK
2081	8976	NDAR_INVCV549UGK	2421			M	5800	EndofPhase2	6	Phase 2	169	1	0	0	0	0	0	0	4	3	3	3	3	2	2	0	3	2	4	4	3	4	4	4	4	5	5	4	4	0	0	1	1	1	1	0	1	1	2	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.5	3.25	3.857143	5	3.3333333			2.45	1.625	2.25	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV549UGK
2081	8976	NDAR_INVCV549UGK	2421			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	5	3	2	4	4	3	3	5	2	4	4	9	4	3	4	5	4	6	4	4	4	1	1	1	0	1	0	0	1	2	1	1	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.625	2.5	4	5	3.85			2.45	1.625	2.25	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV549UGK
2081	8976	NDAR_INVCV668ED6	2704			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	1	9	1	1	2	1	1	3	1	2	4	0	0	1	1	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0		0.5	0.25	1.7142857	2	1.05	1		1.05	0.5	0.25	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV668ED6
2081	8976	NDAR_INVCV668ED6	2704			M	1600	Visit6	6	Phase 1/1A	181	1	0	0	0	0	0	0	0	2	2	0	1	0	0	2	0	2	0	9	0	2	2	2	0	0	1	2	2	0	0	0	0	1	0	1	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0.875	0.5	1.4285715	0.5	1			1.05	0.5	0.25	1.7142857	2	-0.05	0.375	0.25	-0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV668ED6
2081	8976	NDAR_INVCV668ED6	2704			M	2800	Visit12	12	Phase 1/1A	345	1	0	0	0	0	0	0	0	2	2	1	1	0	1	0	0	0	0	9	0	2	1	1	0	3	1	2	2	0	0	0	0	1	0	0	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	1	1	0	0	0	0	2	0.875	0	1.1428572	2	0.95			1.05	0.5	0.25	1.7142857	2	-0.1	0.375	-0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV668ED6
2081	8976	NDAR_INVCV668ED6	2704			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	1	0	0	0	0	0	0	4	2	4	2	5	1	1	1	0	1	1	9	3	4	2	4	1	6	2	2	4	1	0	1	1	1	1	0	1	1	2	1	3	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	0.5	2.857143	4	2.5		1	1.05	0.5	0.25	1.7142857	2	1.45	2	0.25	1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCV668ED6
2081	8976	NDAR_INVCW710BLV	2845			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	6	6	6	6	1	0	0	2	9	4	3	2	6	1	6	3	6	6	1	1	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.875	0.5	4	4.5	3.5	1		3.5	3.875	0.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW710BLV
2081	8976	NDAR_INVCW710BLV	2845			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	4	0	0	3	5	3	4	0	0	0	0	9	1	3	0	2	2	5	3	3	2	1	1	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0	1.8571428	4	2			3.5	3.875	0.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW710BLV
2081	8976	NDAR_INVCW710BLV	2845			M	5200	EndofPhase1_1a	3	Phase 1/1A	77	1	0	0	0	0	0	0	4	0	0	0	5	0	2	1	0	0	0	9	2	0	0	0	0	4	4	0	2	0	0	0	0	1	1	1	1	3	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.5	0	0.5714286	4	1.2		1	3.5	3.875	0.5	4	4.5	-2.3	-2.375	-0.5	-3.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW710BLV
2081	8976	NDAR_INVCW710BLV	2845			M	5400	EndofPhase1b	5	Phase 1B	127	1	0	0	0	0	0	0	0	0	2	2	2	1	0	0	0	0	0	9	1	1	3	2	4	3	6	0	1	1	1	1	1	1	1	1	1	1	3	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	0.875	0	1.7142857	4.5	1.4			3.5	3.875	0.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW710BLV
2081	8976	NDAR_INVCW710BLV	2845			M	5800	EndofPhase2	12	Phase 2	341	1	0	0	0	0	0	0	4	0	0	0	2	2	1	1	0	0	5	9	1	2	4	4	1	5	3	4	4	1	1	1	1	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.25	1.25	2.857143	4	2.15			3.5	3.875	0.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW710BLV
2081	8976	NDAR_INVCW710BLV	2845			M	6000	EndofPhase3	14	Phase 3	371	1	0	0	0	0	0	0	4	0	0	1	2	2	2	1	0	1	0	9	1	0	0	2	4	0	3	1	2	1	1	0	0	1	0	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	1	1	28	0		0		1	2	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	0.25	1.4285715	1.5	1.3			3.5	3.875	0.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW710BLV
2081	8976	NDAR_INVCW724BHY	1644			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	4	5	4	6	5	5	0	0	1	9	1	0	4	5	2	4	4	5	6	1	1	1	0	1	1	1	1	1	1	1	3	2	4	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.875	0.25	3.2857144	4	3.55	1		3.55	4.875	0.25	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCW724BHY
2081	8976	NDAR_INVCX062HDC	1189			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	2	2	0	3	6	0	0	0	9	3	2	0	2	0	3	1	6	6	0	0	0	0	1	1	0	1	1	1	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	1	2.375	0	2.7142856	2	2.1	1		2.1	2.375	0	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCX062HDC
2081	8976	NDAR_INVCX062HDC	1189			M	1600	Visit6	6	Phase 1/1A	178	0	1	0	1	1	0	0	6	0	0	0	2	0	2	4	0	0	1	9	0	4	0	5	0	2	1	6	5	0	0	0	0	1	1	0	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.75	0.25	2.857143	1.5	1.9			2.1	2.375	0	2.7142856	2	-0.2	-0.625	0.25	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCX062HDC
2081	8976	NDAR_INVCX062HDC	1189			M	5200	EndofPhase1_1a	8	Phase 1/1A	232	0	1	0	1	0	0	0	6	0	3	2	2	0	3	5	0	1	1	9	0	4	3	2	3	2	1	6	4	0	0	0	0	1	1	0	1	1	1	0	4	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	2.625	0.5	3.142857	1.5	2.4		1	2.1	2.375	0	2.7142856	2	0.3	0.25	0.5	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCX062HDC
2081	8976	NDAR_INVCX409EG0	2631			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	6	6	0	1	5	5	0	2	1	9	4	4	0	6	6	3	2	6	6	1	0	0	0	1	1	1	1	2	2	1	2	1	2	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	1	1	4.375	0.75	4.571429	2.5	3.75	1		3.75	4.375	0.75	4.571429	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCX409EG0
2081	8976	NDAR_INVCY218XDY	2141			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	4	1	2	2	3	2	0	1	1	1	9	2	2	2	3	1	4	3	3	4	1	1	0	1	1	0	0	0	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	0.75	2.4285715	3.5	2.15	1		2.15	2	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY218XDY
2081	8976	NDAR_INVCY218XDY	2141			M	1600	Visit6	6	Phase 2	161	0	0	0	0	0	0	1	9	2	0	0	2	2	2	1	0	0	0	9	4	3	5	4	2	5	4	4	5	1	1	0	1	1	0	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.2857143	0	3.857143	4.5	2.368421			2.15	2	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY218XDY
2081	8976	NDAR_INVCY218XDY	2141			M	2800	Visit12	12	Phase 2	338	0	0	0	0	0	0	1	4	3	3	2	2	3	4	1	0	0	1	9	4	3	4	3	2	6	5	4	5	1	1	1	1	1	0	0	0	3	1	1	4	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	0.25	3.5714285	5.5	2.95			2.15	2	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY218XDY
2081	8976	NDAR_INVCY218XDY	2141			M	5200	EndofPhase1_1a	5	Phase 1/1A	126	0	0	0	0	0	0	1	2	2	0	0	1	0	0	0	0	0	0	9	0	0	0	0	0	4	3	3	2	1	1	0	0	0	0	1	0	3		1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	0.625	0	0.71428573	3.5	0.85		1	2.15	2	0.75	2.4285715	3.5	-1.3	-1.375	-0.75	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY218XDY
2081	8976	NDAR_INVCY218XDY	2141			M	5800	EndofPhase2	18	Phase 2	507	0	0	0	0	0	0	1	5	5	2	5	5	3	2	2	2	1	1	9	2	2	2	3	4	5	4	4	4	1	1	1	1	1	1	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	26	0		0		1	4	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	3.625	1	3	4.5	3.15			2.15	2	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY218XDY
2081	8976	NDAR_INVCY245RXR	2544			F	2800	Visit12	12	Phase 1/1A	343	0	0	0	1	0	0	0	2	2	0	0	2	1	1	2	1	0	0	9	0	0	2	0	4	5	3	2	2	1	0	1	0	1	1	0	1	3	2	1	4	3	3	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	4	1.25	0.25	1.4285715	4	1.45		1																																																																																																																															Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY245RXR
2081	8976	NDAR_INVCY633JDE	1955			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	3	2	0	3	0	6	6	6	6	6	6	6	6	6	6	4	6	6	1	0	1	1	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	6	6	5	4.6666665	1		4.6666665	2.75	6	6	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY633JDE
2081	8976	NDAR_INVCY760HYF	2348			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	5	5	4	4	5	3	2	3	2	9	0	5	4	6	4	6	5	4	4	1	1	1	1	1	1	1	1	2	1	1	2	2	1	2	1	0	1	0	0	1	0	0	0	0	1	0	1	24	0		0		1	6	0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	7	4.375	1.75	3.857143	5.5	4	1		4	4.375	1.75	3.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY760HYF
2081	8976	NDAR_INVCY760HYF	2348			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	1	0	4	2	6	4	2	5	5	2	5	5	4	5	1	4	3	6	5	5	5	4	5	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	5	3.75	4.75	4	5	4.142857			4	4.375	1.75	3.857143	5.5	0.14285715	-0.625	3	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY760HYF
2081	8976	NDAR_INVCY760HYF	2348			M	2800	Visit12	12	Phase 1/1A	358	1	0	0	0	0	0	0	5	1	4	2	2	4	4	2	5	6	5	6	4	6	5	6	5	6	5	4	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3	5.5	5.142857	5.5	4.428571			4	4.375	1.75	3.857143	5.5	0.42857143	-1.375	3.75	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY760HYF
2081	8976	NDAR_INVCY760HYF	2348			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	1	0	0	0	0	0	0	5	2	5	3	2	4	5	3	6	6	5	6	4	5	4	6	5	6	5	5	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.625	5.75	5	5.5	4.6666665		1	4	4.375	1.75	3.857143	5.5	0.6666667	-0.75	4	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCY760HYF
2081	8976	NDAR_INVCZ178YJ9	2731			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	1	0	2	0	0	2	0	3	1	9	0	0	0	3	2	2	0	2	5	0	0	0	0	1	0	2	0	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.875	1	1.7142857	1	1.65	1		1.65	1.875	1	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCZ178YJ9
2081	8976	NDAR_INVCZ178YJ9	2731			F	2800	Visit12	12	Phase 2	337	1	0	0	0	0	0	0	4	4	2	3	2	2	0	0	0	0	0	9	2	2	0	2	0	3	0	4	4	0	0	0	0	1	1	1	1	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.125	0	2	1.5	1.7			1.65	1.875	1	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCZ178YJ9
2081	8976	NDAR_INVCZ178YJ9	2731			F	5200	EndofPhase1_1a	6	Phase 1/1A	189	1	0	0	0	0	0	0	4	0	0	0	2	0	0	0	2	2	0	9	0	2	0	4	2	3	2	4	4	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.75	1	2.2857144	2.5	1.55		1	1.65	1.875	1	1.7142857	1	-0.1	-1.125	0	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCZ178YJ9
2081	8976	NDAR_INVCZ178YJ9	2731			F	5800	EndofPhase2	18	Phase 2	504	1	0	0	0	0	0	0	2	1	2	0	2	2	2	0	2	2	0	9	0	2	0	2	0	3	1	4	4	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	1	1.7142857	2	1.55			1.65	1.875	1	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVCZ178YJ9
2081	8976	NDAR_INVDA060BEG	2714			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	3	2	3	4	3	3	1	0	2	4	9	5	1	4	2	0	3	2	5	4	1	1	1	0	1	1	1	1	1	3	1	3	2	2	2	0	0	0	0	0	0	0	0					1	16	0		0		0		1	14	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	2.875	1.5	3	2.5	2.75	1		2.75	2.875	1.5	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA060BEG
2081	8976	NDAR_INVDA299KLD	1469			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	0	0	9	1	0	2	1	0	1	2	4	5	0	1	0	0	1	0	0	0	3		0	4	4	3	4	0	0	0	0	0	0	0	0	1	1	1	1	0		1	20	0		1	3	0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	3	1	0.25	1.8571428	1.5	1.25	1		1.25	1	0.25	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA299KLD
2081	8976	NDAR_INVDA522JTA	1420			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	0	2	4	6	6	2	0	0	0	9	0	6	4	4	2	6	6	6	6	1	1	1	0	1	1	1	1	2	1	1	3	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	0	4	6	3.5	1		3.5	3.75	0	4	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA522JTA
2081	8976	NDAR_INVDA522JTA	1420			M	1600	Visit6	6	Phase 1/1A	165	0	0	0	0	0	0	1	5	0	3	2	2	1	2	0	0	0	0	9	0	3	2	6	6	6	3	6	5	1	0	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	0	4	4.5	2.6			3.5	3.75	0	4	6	-0.9	-1.875	0	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA522JTA
2081	8976	NDAR_INVDA522JTA	1420			M	2800	Visit12	12	Phase 1/1A	331	0	0	0	0	0	0	1	9	2	2	2	2	0	2	0	0	0	0	9	0	2	4	2	2	5	4	6	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.4285715	0	3.142857	4.5	2.1578948			3.5	3.75	0	4	6	-1.3421053	-2.3214285	0	-0.85714287	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA522JTA
2081	8976	NDAR_INVDA522JTA	1420			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	0	0	1	6	2	2	2	2	2	2	2	0	0	0	9	0	0	4	4	1	5	4	5	5	1	0	1	0	1	1	1	1	1	1	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0	2.7142856	4.5	2.4		1	3.5	3.75	0	4	6	-1.1	-1.25	0	-1.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA522JTA
2081	8976	NDAR_INVDA570EN8	2769			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	1	0	2	1	2	1	1	2	2	2	4	9	2	2	3	3	2	3	1	0	3	1	0	1	1	1	1	0	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1.25	2	2.142857	2	1.85	1		1.85	1.25	2	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA570EN8
2081	8976	NDAR_INVDA586VRT	1735			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	1	0	6	2	0	0	2	3	3	4	0	0	0	9	4	5	5	4	5	5	4	6	4	1	1	1	1	1	1	1	1	2	2	1	3	1	2	1	1	1	0	0	0	0	0	0	1	0	2	2	1	24	0		0		1	6	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.5	0	4.714286	4.5	3.1	1		3.1	2.5	0	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDA586VRT
2081	8976	NDAR_INVDB022BB1	1096			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	0	0	2	0	0	4	0	0	0	9	3	2	0	2	0	4	3	4	2	1	0	1	0	1	1	1	1	1	3	1	4	2	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	1.75	0	1.8571428	3.5	1.7	1		1.7	1.75	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB022BB1
2081	8976	NDAR_INVDB022BB1	1096			F	1600	Visit6	6	Phase 2	174	0	1	0	1	0	0	0	5	1	0	2	2	0	2	1	0	0	0	9	2	0	0	1	0	5	3	5	3	1	0	1	0	1	1	1	1	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1.625	0	1.5714285	4	1.6			1.7	1.75	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB022BB1
2081	8976	NDAR_INVDB022BB1	1096			F	5200	EndofPhase1_1a	4	Phase 1/1A	111	0	1	0	1	0	0	0	4	1	1	2	2	0	2	3	0	0	0	9	2	2	3	1	0	5	2	5	4	1	0	1	0	1	1	1	1	1	3	1	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1.875	0	2.4285715	3.5	1.95		1	1.7	1.75	0	1.8571428	3.5	0.25	0.125	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB022BB1
2081	8976	NDAR_INVDB022BB1	1096			F	5800	EndofPhase2	12	Phase 2	334	0	1	0	1	0	0	0	2	0	1	2	2	0	1	4	0	0	0	9	2	1	2	2	2	5	2	4	5	1	1	1	0	1	0	1	1	3	3	1	4	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	5	1.5	0	2.5714285	3.5	1.85			1.7	1.75	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB022BB1
2081	8976	NDAR_INVDB022BB1	1096			F	6000	EndofPhase3	18	Phase 3	502	0	1	0	1	0	0	0	6	0	2	2	2	0	2	4	2	2	0	9	3	3	3	3	4	5	4	6	5	1	0	1	0	1	1	1	1	1	2	0	4	2	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.25	1	3.857143	4.5	2.9			1.7	1.75	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB022BB1
2081	8976	NDAR_INVDB091WNZ	2297			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	2	2	2	4	1	3	0	5	4	5	3	5	5	4	3	5	5	1	5	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	4.25	4.571429	3	3.5714285	1		3.5714285	2.5	4.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB091WNZ
2081	8976	NDAR_INVDB091WNZ	2297			F	1600	Visit6	6	Phase 3	162	0	0	1	0	0	0	0	6	4	3	4	5	2	4	1	4	6	6	6	5	6	4	5	5	4	3	5	5	1	0	1	1	1	1	1	1	1	1	0	4	3	3	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.625	5.5	5	3.5	4.428571			3.5714285	2.5	4.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB091WNZ
2081	8976	NDAR_INVDB091WNZ	2297			F	2800	Visit12	12	Phase 3	337	0	0	0	0	1	0	0	5	2	4	2	2	2	2	1	6	5	6	5	3	5	4	4	5	5	2	5	5	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	5.5	4.428571	3.5	3.8095238			3.5714285	2.5	4.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB091WNZ
2081	8976	NDAR_INVDB091WNZ	2297			F	5200	EndofPhase1_1a	1	Phase 1/1A	33	0	0	0	0	1	0	0	6	1	1	2	3	2	3	0	6	6	5	5	6	6	4	5	5	5	2	5	5	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.25	5.5	5.142857	3.5	3.952381		1	3.5714285	2.5	4.25	4.571429	3	0.3809524	-0.25	1.25	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB091WNZ
2081	8976	NDAR_INVDB091WNZ	2297			F	5800	EndofPhase2	4	Phase 2	103	0	0	1	0	0	0	0	6	2	4	3	4	3	4	0	4	4	6	6	5	4	5	4	6	5	2	4	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	5	4.714286	3.5	4.095238			3.5714285	2.5	4.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB091WNZ
2081	8976	NDAR_INVDB091WNZ	2297			F	6000	EndofPhase3	18	Phase 3	504	0	0	1	0	0	0	0	6	3	2	3	4	2	2	1	6	6	6	3	5	6	3	4	6	4	2	5	6	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	5.25	5	3	4.047619			3.5714285	2.5	4.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB091WNZ
2081	8976	NDAR_INVDB594BZU	2720			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	1	1	0	0	0	3	0	0	0	0	9	0	0	0	0	1	1	1	0	4	1	1	0	0	0	1	1	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0	0.71428573	1	0.75	1		0.75	1	0	0.71428573	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB594BZU
2081	8976	NDAR_INVDB594BZU	2720			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	1	0	1	1	2	2	2	0	2	1	0	0	0	9	0	0	0	1	0	3	2	0	0	1	1	2	0	1	0	1	0	3		0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	0	0.14285715	2.5	0.85			0.75	1	0	0.71428573	1	0.1	0.375	0	-0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB594BZU
2081	8976	NDAR_INVDB594BZU	2720			M	2800	Visit12	12	Phase 1/1A	377	0	0	0	0	0	1	0	3	3	2	1	2	1	1	2	0	1	0	9	2	2	1	2	4	2	2	0	2	1	1	0	0	1	0	0	0	3		0	4	4	4	3	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	0.25	1.8571428	2	1.65			0.75	1	0	0.71428573	1	0.9	0.875	0.25	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB594BZU
2081	8976	NDAR_INVDB594BZU	2720			M	5200	EndofPhase1_1a	18	Phase 1/1A	562	0	0	0	0	0	1	0	3	3	3	2	2	2	2	2	0	0	0	9	1	2	2	2	2	3	2	0	3	1	1	2	0	1	0	1	0	3		0	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0	1.7142857	2.5	1.8		1	0.75	1	0	0.71428573	1	1.05	1.375	0	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB594BZU
2081	8976	NDAR_INVDB884XGF	1602			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	1	2	2	2	2	0	6	2	2	4	2	2	4	3	3	4	2	2	2	0	1	2	1	1	0	2	0	1	2	1	2	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	3.5	2.5714285	3	2.2380953	1		2.2380953	1.125	3.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB884XGF
2081	8976	NDAR_INVDB884XGF	1602			M	1600	Visit6	6	Phase 1B	175	1	0	1	0	1	0	0	1	2	0	2	2	1	2	0	6	4	5	4	4	6	6	6	4	3	2	6	6	0	0	2	1	1	1	2	2	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	4.75	5.428571	2.5	3.4285715			2.2380953	1.125	3.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB884XGF
2081	8976	NDAR_INVDB884XGF	1602			M	2800	Visit12	12	Phase 1B	340	1	0	0	0	0	0	0	0	2	0	4	3	4	4	0	0	0	0	9	3	4	6	5	0	3	3	6	6	1	1	1	1	1	0	2	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	2.125	0	4.285714	3	2.65			2.2380953	1.125	3.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB884XGF
2081	8976	NDAR_INVDB884XGF	1602			M	5200	EndofPhase1_1a	3	Phase 1/1A	81	1	0	1	0	1	0	0	0	0	1	3	3	5	3	0	6	4	6	6	3	4	4	6	2	3	2	3	4	0	0	0	0	1	2	2	2	1	1	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	5.5	3.7142856	2.5	3.2380953		1	2.2380953	1.125	3.5	2.5714285	3	1	0.75	2	1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB884XGF
2081	8976	NDAR_INVDB884XGF	1602			M	5400	EndofPhase1b	18	Phase 1B	505	1	0	1	0	1	0	0	6	4	0	4	4	4	4	0	2	4	4	9	2	0	3	4	4	3	3	6	6	1	1	2	1	1	0	2	0	1	3	1	3	1	2	4	1	0	1	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	2.5	3.5714285	3	3.35			2.2380953	1.125	3.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDB884XGF
2081	8976	NDAR_INVDC187XCC	1481			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	4	4	4	2	2	4	0	0	0	0	9	0	0	1	2	1	5	4	3	6	1	1	1	1	1	1	1	1	3		1	2	2	2	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2.5	0	1.8571428	4.5	2.1	1		2.1	2.5	0	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC187XCC
2081	8976	NDAR_INVDC187XCC	1481			M	1600	Visit6	6	Phase 1/1A	187	0	0	0	0	0	0	1	9	4	4	4	3	3	5	2	0	0	6	9	0	0	3	2	2	6	4	4	6	1	1	1	0	1	1	1	1	3	3	1	2	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5714285	1.5	2.4285715	5	3.0526316			2.1	2.5	0	1.8571428	4.5	0.9526316	1.0714285	1.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC187XCC
2081	8976	NDAR_INVDC187XCC	1481			M	2800	Visit12	12	Phase 1/1A	362	0	0	0	0	0	0	1	9	3	2	1	1	1	2	2	2	2	6	9	0	2	1	2	1	6	4	4	4	1	1	1	1	1	1	0	1	3		1	3	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	1.7142857	2.5	2	5	2.4210527			2.1	2.5	0	1.8571428	4.5	0.32105264	-0.78571427	2.5	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC187XCC
2081	8976	NDAR_INVDC187XCC	1481			M	5200	EndofPhase1_1a	18	Phase 1/1A	548	0	0	0	0	0	0	1	9	4	4	4	3	2	2	3	1	1	6	9	1	1	2	2	2	6	3	4	4	1	1	1	0	1	1	1	1	3		0	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3.142857	2	2.2857144	4.5	2.8947368		1	2.1	2.5	0	1.8571428	4.5	0.79473686	0.64285713	2	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC187XCC
2081	8976	NDAR_INVDC201EP9	1629			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	4	3	3	3	5	5	2	2	2	9	2	1	3	4	2	5	3	4	3	1	1	1	0	1	1	1	1	1	2	1	2	1	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	3.625	1.5	2.7142856	4	3.1	1		3.1	3.625	1.5	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC201EP9
2081	8976	NDAR_INVDC201EP9	1629			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	3	3	3	3	3	3	3	3	1	2	2	9	2	2	2	3	1	3	4	3	2	1	1	1	0	1	1	1	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	3	1.25	2.142857	3.5	2.55		1	3.1	3.625	1.5	2.7142856	4	-0.55	-0.625	-0.25	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC201EP9
2081	8976	NDAR_INVDC925MYP	1154			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	0	0	3	5	2	3	2	4	3	2	9	4	4	4	5	2	6	5	5	5	1	1	1	0	1	1	1	1	1	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	5	2.5	2.25	4.142857	5.5	3.45	1		3.45	2.5	2.25	4.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC925MYP
2081	8976	NDAR_INVDC925MYP	1154			M	2800	Visit12	12	Phase 2	358	1	0	0	0	0	0	0	5	2	4	2	2	2	4	2	2	1	2	9	3	1	3	4	3	5	5	4	4	1	1	0	0	1	1	1	1	2	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.875	1.25	3.142857	5	3			3.45	2.5	2.25	4.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC925MYP
2081	8976	NDAR_INVDC925MYP	1154			M	5800	EndofPhase2	13	Phase 2	389	1	0	0	0	0	0	0	2	0	1	2	2	2	1	1	0	2	3	9	2	2	4	4	2	5	5	4	4	1	1	1	0	1	1	1	1	1	2	0	4	3	2	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	0	0		0	0	0	0	0	0	0	1	1	1	1		1.375	1.25	3.142857	5	2.4			3.45	2.5	2.25	4.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDC925MYP
2081	8976	NDAR_INVDD412RU3	1916			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	1	0	2	5	2	2	4	0	0	1	9	2	2	4	2	0	5	1	4	3	0	1	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.75	0.25	2.4285715	3	2.3	1		2.3	2.75	0.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD412RU3
2081	8976	NDAR_INVDD412RU3	1916			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	6	5	3	4	6	3	3	2	1	2	2	9	2	3	3	3	4	5	2	4	4	1	0	1	1	1	1	0	1	1	2	1	3	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4	1.25	3.2857144	3.5	3.35			2.3	2.75	0.25	2.4285715	3	1.05	1.25	1	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD412RU3
2081	8976	NDAR_INVDD412RU3	1916			M	5200	EndofPhase1_1a	8	Phase 1/1A	226	1	0	0	0	0	0	0	6	5	2	4	6	2	2	3	1	2	2	9	2	3	3	3	3	6	3	4	3	1	1	1	1	1	0	0	1	1	2	0	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.75	1.25	3	4.5	3.25		1	2.3	2.75	0.25	2.4285715	3	0.95	1	1	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD412RU3
2081	8976	NDAR_INVDD412RU3	1916			M	5800	EndofPhase2	12	Phase 2	342	1	0	0	0	0	0	0	5	1	4	3	4	3	4	1	3	4	3	4	2	2	3	2	3	5	3	4	4	1	0	1	0	1	1	0	1	1	2	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	3.125	3.5	2.857143	4	3.1904762			2.3	2.75	0.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD412RU3
2081	8976	NDAR_INVDD412RU3	1916			M	6000	EndofPhase3	14	Phase 3	412	1	0	0	0	0	0	0	6	2	3	3	5	2	3	1	3	3	3	3	3	3	4	3	4	6	2	4	4	1	1	0	0	1	1	0	0	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	2	1	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.125	3	3.5714285	4	3.3333333			2.3	2.75	0.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD412RU3
2081	8976	NDAR_INVDD936FCK	1785			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	3	2	4	3	1	3	1	1	1	0	9	1	2	3	2	2	2	2	2	3	0	1	2	1	0	1	1	0	3	3	1	3	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	0		1	19	0		1	11	0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	2	2.625	0.5	2.142857	2	2.1	1		2.1	2.625	0.5	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD936FCK
2081	8976	NDAR_INVDD936FCK	1785			M	1600	Visit6	6	Phase 1/1A	162	0	0	0	0	0	1	0	5	4	4	4	4	1	5	2	1	3	1	9	3	2	4	4	1	3	4	2	4	1	1	0	0	1	1	1	1	3	2	1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.625	1.25	2.857143	3.5	3.05			2.1	2.625	0.5	2.142857	2	0.95	1	0.75	0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD936FCK
2081	8976	NDAR_INVDD936FCK	1785			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	4	2	1	2	2	3	4	2	1	2	4	9	2	2	3	4	1	2	1	4	3	0	0	2	0	1	1	1	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.5	1.75	2.7142856	1.5	2.45			2.1	2.625	0.5	2.142857	2	0.35	-0.125	1.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD936FCK
2081	8976	NDAR_INVDD936FCK	1785			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	1	0	3	2	0	3	2	3	3	2	1	2	4	9	2	3	3	3	1	1	1	3	3	1	0	2	0	1	0	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.25	1.75	2.5714285	1	2.25		1	2.1	2.625	0.5	2.142857	2	0.15	-0.375	1.25	0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDD936FCK
2081	8976	NDAR_INVDE112CRX	2117			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	2	3	9	2	3	3	2	5	4	1	5	6	2	2	2	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	16	0		0		1	14	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2.75	3.7142856	2.5	2.1	1		2.1	0	2.75	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE112CRX
2081	8976	NDAR_INVDE112CRX	2117			M	1600	Visit6	6	Phase 1/1A	182	0	0	0	0	0	1	0	2	3	0	2	2	5	0	3	2	3	5	9	4	1	0	5	5	4	1	5	5	0	0	0	0	1	0	1	0	3	1	1	3	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		2	2	2	0	1	0	1	0	0	0	0	0	1	0	1	1	5	2.125	2.5	3.5714285	2.5	2.85			2.1	0	2.75	3.7142856	2.5	0.75	2.125	-0.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE112CRX
2081	8976	NDAR_INVDE112CRX	2117			M	2800	Visit12	12	Phase 1/1A	350	0	0	0	0	0	1	0	2	0	0	0	2	2	3	0	0	0	0	9	3	3	0	3	5	2	1	3	4	1	1	0	0	1	0	0	0	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.125	0	3	1.5	1.65			2.1	0	2.75	3.7142856	2.5	-0.45	1.125	-2.75	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE112CRX
2081	8976	NDAR_INVDE112CRX	2117			M	5200	EndofPhase1_1a	18	Phase 1/1A	525	0	0	0	0	0	1	0	4	0	0	3	2	1	4	1	5	4	5	2	3	3	0	3	4	4	3	4	5	1	0	1	1	1	0	0	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	4	3.142857	3.5	2.857143		1	2.1	0	2.75	3.7142856	2.5	0.75714284	1.875	1.25	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE112CRX
2081	8976	NDAR_INVDE443GD1	1276			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	2	1	2	2	0	1	2	0	1	1	9	1	3	2	2	1	1	2	1	2	0	0	1	1	1	0	0	0	2	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.5	0.5	1.7142857	1.5	1.45	1		1.45	1.5	0.5	1.7142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE443GD1
2081	8976	NDAR_INVDE443GD1	1276			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	1	0	0	2	2	1	1	2	2	2	3	4	3	3	3	4	4	2	4	3	3	4	3	3	0	1	1	1	1	1	1	1	1	2	1	3	4	4	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	3.25	3.2857144	3.5	2.7619047			1.45	1.5	0.5	1.7142857	1.5	1.3119048	0.375	2.75	1.5714285	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE443GD1
2081	8976	NDAR_INVDE443GD1	1276			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	1	0	0	4	4	2	3	3	2	3	3	2	2	2	9	4	2	1	2	1	4	1	2	2	0	0	1	1	0	1	0	1	1	2	1	3	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	3	1.5	2	2.5	2.45			1.45	1.5	0.5	1.7142857	1.5	1	1.5	1	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE443GD1
2081	8976	NDAR_INVDE443GD1	1276			M	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	1	0	0	3	3	2	3	4	2	2	1	1	1	1	9	2	3	4	3	2	2	4	2	3	1	1	1	1	1	1	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0.75	2.7142856	3	2.4		1	1.45	1.5	0.5	1.7142857	1.5	0.95	1	0.25	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE443GD1
2081	8976	NDAR_INVDE669KLZ	1553			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	5	5	3	4	4	2	0	0	0	9	2	2	3	4	2	3	4	3	2	1	1	0	1	1	0	1	0	2	3	1	2	1	1	1	1	0	1	1	0	0	0	0	1	1	1	2	1	3	1	13	0		1	14	0		0	0	0	0	0	0	1	1	1	1	1	0	1	0	1	1	4	3	0	2.5714285	3.5	2.45	1		2.45	3	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE669KLZ
2081	8976	NDAR_INVDE669KLZ	1553			M	1600	Visit6	6	Phase 2	189	0	0	0	0	0	1	0	2	1	3	2	4	3	4	4	1	2	2	9	3	3	3	3	4	3	3	1	4	1	1	1	1	1	1	0	0	2	3	1	3	2	2	2	1	0	1	0	0	0	0	0	0	1	1	0	0		1	10	0		1	20	0		0	0	0	0	0	0	0	0	0	1	1	0	1	1	1	1	5	2.875	1.25	3	3	2.75			2.45	3	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE669KLZ
2081	8976	NDAR_INVDE669KLZ	1553			M	2800	Visit12	12	Phase 2	349	0	0	0	0	0	1	0	0	3	1	4	5	3	4	4	1	1	1	9	3	4	4	4	3	3	5	5	4	1	1	2	1	1	1	2	2	3	3	1	2	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	5	3	0.75	3.857143	4	3.1			2.45	3	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE669KLZ
2081	8976	NDAR_INVDE669KLZ	1553			M	4000	Visit18	18	Phase 2	533	0	0	0	0	0	1	0	3	2	3	3	4	3	4	3	1	1	1	9	3	3	4	4	3	3	4	4	4	1	1	1	1	1	1	2	2	2	3	0	4	2	2	3	1	0	0	0	0	0	1	0	0	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.125	0.75	3.5714285	3.5	3			2.45	3	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE669KLZ
2081	8976	NDAR_INVDE669KLZ	1553			M	5200	EndofPhase1_1a	5	Phase 1/1A	161	0	0	0	0	0	1	0	2	2	4	4	3	3	4	3	3	3	5	6	4	4	1	4	4	4	4	1	4	1	1	1	0	1	1	0	1	2	3	1	2	1	1	1	1	0	1	0	0	0	0	0	1	0	1	1	0		1	25	0		1	5	0		0	0	0	0	0	0	0	1	0	1	1	0	1	1	1	1	6	3.125	4.25	3.142857	4	3.4285715		1	2.45	3	0	2.5714285	3.5	0.9785714	0.125	4.25	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE669KLZ
2081	8976	NDAR_INVDE780NDL	2857			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	4	2	4	4	5	2	1	4	4	9	3	4	1	4	4	3	2	4	6	1	0	1	1	1	1	1	1	3		1	4	4	1	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.625	2.25	3.7142856	2.5	3.45	1		3.45	3.625	2.25	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE780NDL
2081	8976	NDAR_INVDE780NDL	2857			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	9	5	4	2	4	5	5	2	0	4	4	9	2	5	2	4	4	4	2	4	6	1	0	1	0	1	1	1	1	3		1	3	1	3	2	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.857143	2	3.857143	3	3.5789473			3.45	3.625	2.25	3.7142856	2.5	0.12894736	0.23214285	-0.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE780NDL
2081	8976	NDAR_INVDE780NDL	2857			M	2800	Visit12	12	Phase 2	309	0	0	0	0	0	0	1	9	6	5	4	3	2	3	4	2	2	1	9	1	2	1	3	1	4	2	5	5	1	0	1	0	1	1	1	1	3		1	2	2	2	1	1	1	0	0	0	0	0	0	1	1	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.857143	1.25	2.5714285	3	2.9473684			3.45	3.625	2.25	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE780NDL
2081	8976	NDAR_INVDE780NDL	2857			M	5200	EndofPhase1_1a	10	Phase 1/1A	268	0	0	0	0	0	1	0	1	5	4	2	4	5	5	4	0	2	1	9	1	3	1	2	1	6	6	4	6	1	0	1	0	1	1	1	1	3		1	3	1	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.75	0.75	2.5714285	6	3.15		1	3.45	3.625	2.25	3.7142856	2.5	-0.3	0.125	-1.5	-1.1428572	3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE780NDL
2081	8976	NDAR_INVDE780NDL	2857			M	5400	EndofPhase1b	11	Phase 1B	275	0	0	0	0	0	0	1	2	2	2	2	2	2	2	4	1	3	3	9	2	5	2	3	1	5	5	4	6	1	1	1	0	1	1	1	0	3		1	2	3	2	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	1	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	1.75	3.2857144	5	2.9			3.45	3.625	2.25	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE780NDL
2081	8976	NDAR_INVDE780NDL	2857			M	5800	EndofPhase2	18	Phase 2	499	0	0	0	0	0	0	1	9	6	5	5	5	5	5	5	4	5	3	5	2	4	2	6	2	5	4	3	6	1	1	1	0	1	0	1	1	3		1	2	3	1	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	5.142857	4.25	3.5714285	4.5	4.35			3.45	3.625	2.25	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE780NDL
2081	8976	NDAR_INVDE930TAR	1950			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	2	2	5	4	2	2	4	5	1	5	3	6	4	4	6	5	4	4	4	1	0	1	1	1	0	0	0	2	1	1	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	0	1	1	7	3.625	3.75	4.428571	4.5	4	1		4	3.625	3.75	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDE930TAR
2081	8976	NDAR_INVDF290JFD	1278			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	6	4	5	5	4	3	4	2	4	2	9	6	6	4	5	5	1	3	6	5	1	1	1	1	1	1	0	1	1	2	1	3	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.5	2	5.285714	2	4.25	1		4.25	4.5	2	5.285714	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF290JFD
2081	8976	NDAR_INVDF290JFD	1278			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	6	2	1	2	2	2	4	4	0	1	0	9	2	2	2	3	3	1	2	2	4	0	1	1	1	1	0	0	1	1	1	1	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	0.25	2.5714285	1.5	2.25			4.25	4.5	2	5.285714	2	-2	-1.625	-1.75	-2.7142856	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF290JFD
2081	8976	NDAR_INVDF290JFD	1278			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	3	6	0	4	2	0	2	2	0	0	1	9	2	2	2	4	1	2	4	1	2	1	0	1	1	1	1	0	1	2	2	1	2	2	2	4	1	0	1	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.375	0.25	2	3	2		1	4.25	4.5	2	5.285714	2	-2.25	-2.125	-1.75	-3.2857144	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF290JFD
2081	8976	NDAR_INVDF805DXT	1461			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	4	3	4	4	4	2	1	2	3	9	3	3	2	2	3	2	2	3	4	1	0	1	1	1	1	1	1	2	1	0	4	2	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	1.5	2.857143	2	2.8	1		2.8	3.25	1.5	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF805DXT
2081	8976	NDAR_INVDF805DXT	1461			F	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	1	3	2	4	2	2	2	6	4	6	1	5	5	2	4	0	5	4	6	6	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	4.25	4	4.5	3.6190476			2.8	3.25	1.5	2.857143	2	0.81904763	-0.5	2.75	1.1428572	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF805DXT
2081	8976	NDAR_INVDF805DXT	1461			F	2800	Visit12	12	Phase 1/1A	336	1	0	1	0	0	0	0	6	1	1	1	2	3	4	1	4	4	3	5	4	4	4	5	5	5	4	4	6	1	0	0	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	6	2.375	4	4.571429	4.5	3.6190476			2.8	3.25	1.5	2.857143	2	0.81904763	-0.875	2.5	1.7142857	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF805DXT
2081	8976	NDAR_INVDF805DXT	1461			F	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	1	0	0	0	0	4	3	3	1	3	3	4	2	5	5	4	2	4	3	3	3	5	5	4	4	5	1	0	0	1	0	1	1	1	1	1	0	4	4	3	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	6	2.875	4	3.857143	4.5	3.5714285		1	2.8	3.25	1.5	2.857143	2	0.7714286	-0.375	2.5	1	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDF805DXT
2081	8976	NDAR_INVDG306KHE	1429			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	0	0	0	0	0	0	5	0	9	2	4	4	2	6	6	4	4	6	1	1	1	1	1	1	1	1	3	2	0	4	1	1	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	1.25	4	5	2.2631578	1		2.2631578	0	1.25	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG306KHE
2081	8976	NDAR_INVDG306KHE	1429			F	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0	0	9	2	2	4	4	0	5	2	6	6	1	0	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	0.25	0	3.4285715	3.5	1.65			2.2631578	0	1.25	4	5	-0.61315787	0.25	-1.25	-0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG306KHE
2081	8976	NDAR_INVDG306KHE	1429			F	5200	EndofPhase1_1a	11	Phase 1/1A	333	0	0	0	0	0	0	1	2	4	4	0	3	0	2	4	0	4	4	9	2	2	4	4	2	4	2	6	6	1	0	1	0	0	0	0	0	3	3	1	3	1	2	2	1	0	0	0	0	0	1	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2.375	2	3.7142856	3	2.95		1	2.2631578	0	1.25	4	5	0.6868421	2.375	0.75	-0.2857143	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG306KHE
2081	8976	NDAR_INVDG306KHE	1429			F	5800	EndofPhase2	12	Phase 2	354	0	0	0	0	0	0	1	0	6	4	2	2	2	4	6	0	0	0	9	5	4	6	3	2	5	2	4	6	1	0	1	0	1	1	0	1	3	3	1	2	2	2	2	1	0	0	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	3.25	0	4.285714	3.5	3.15			2.2631578	0	1.25	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG306KHE
2081	8976	NDAR_INVDG315FFH	1895			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	4	3	3	3	3	3	3	3	3	1	9	2	2	3	3	2	4	4	4	3	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1.75	2.7142856	4	3	1		3	3.25	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG315FFH
2081	8976	NDAR_INVDG315FFH	1895			M	1600	Visit6	6	Phase 1/1A	200	0	0	0	0	1	0	0	2	2	2	2	2	2	2	2	1	2	2	9	2	2	2	2	2	3	3	4	4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2	1.25	2.5714285	3	2.25			3	3.25	1.75	2.7142856	4	-0.75	-1.25	-0.5	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG315FFH
2081	8976	NDAR_INVDG315FFH	1895			M	2800	Visit12	12	Phase 2	449	0	0	0	0	1	0	0	2	2	2	2	2	2	2	2	2	2	2	9	1	2	2	2	2	3	3	2	2	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	6	2	1.5	1.8571428	3	2.05			3	3.25	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG315FFH
2081	8976	NDAR_INVDG315FFH	1895			M	5200	EndofPhase1_1a	8	Phase 1/1A	271	0	0	0	0	1	0	0	3	2	3	3	3	3	3	3	1	2	2	9	2	3	3	3	3	4	3	4	3	1	1	1	0	1	1	0	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.875	1.25	3	3.5	2.8		1	3	3.25	1.75	2.7142856	4	-0.2	-0.375	-0.5	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG315FFH
2081	8976	NDAR_INVDG315FFH	1895			M	5800	EndofPhase2	18	Phase 2	536	0	0	0	0	1	0	0	3	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	4	2	4	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	6	2.125	1.5	2.5714285	3	2.35			3	3.25	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG315FFH
2081	8976	NDAR_INVDG379KA7	2787			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	1	0	0	0	1	0	1	2	0	0	0	9	1	0	4	1	0	5	1	6	4	0	0	2	0	1	1	0	0	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	0.625	0	2.2857144	3	1.35	1		1.35	0.625	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG379KA7
2081	8976	NDAR_INVDG670LLC	1732			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	3	2	4	4	4	5	2	2	3	4	9	4	4	4	5	4	5	3	4	4	1	1	1	0	1	1	1	1	2	2	1	3	2	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.625	2.25	4.142857	4	3.75	1		3.75	3.625	2.25	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG670LLC
2081	8976	NDAR_INVDG912JG1	1104			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	2	0	1	2	2	2	1	3	3	5	4	1	2	2	3	2	5	2	3	5	1	1	1	0	1	0	0	1	1	2	1	2	2	4	4	1	0	1	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2	3.75	2.5714285	3.5	2.6666667	1		2.6666667	2	3.75	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG912JG1
2081	8976	NDAR_INVDG912JG1	1104			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	6	4	0	2	2	2	2	1	2	3	5	9	2	2	0	2	2	4	3	2	5	1	1	1	0	1	0	1	1	3	2	1	2	2	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	2.375	2.5	2.142857	3.5	2.55			2.6666667	2	3.75	2.5714285	3.5	-0.11666667	0.375	-1.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG912JG1
2081	8976	NDAR_INVDG912JG1	1104			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	4	2	1	3	2	2	1	2	2	2	3	9	2	2	0	1	2	4	3	2	4	1	1	1	0	1	0	0	1	2	2	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2.125	1.75	1.8571428	3.5	2.2			2.6666667	2	3.75	2.5714285	3.5	-0.46666667	0.125	-2	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG912JG1
2081	8976	NDAR_INVDG912JG1	1104			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	4	3	3	2	4	1	2	1	2	4	4	9	3	3	3	2	4	5	3	2	4	1	1	1	0	1	0	0	1	2	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	7	2.5	2.5	3	4	2.95		1	2.6666667	2	3.75	2.5714285	3.5	0.28333333	0.5	-1.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG912JG1
2081	8976	NDAR_INVDG960HPT	2784			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	2	3	2	3	2	6	6	6	6	5	5	2	4	6	4	2	6	6	0	1	0	1	1	1	1	1	1	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	3.25	6	4.857143	3	4.285714	1		4.285714	3.25	6	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG960HPT
2081	8976	NDAR_INVDG960HPT	2784			F	5200	EndofPhase1_1a	2	Phase 1/1A	51	1	0	1	0	0	0	0	5	6	3	5	4	5	5	3	6	6	6	6	6	6	5	2	5	4	3	6	6	1	0	0	1	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	4.5	6	5.142857	3.5	4.904762		1	4.285714	3.25	6	4.857143	3	0.61904764	1.25	0	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG960HPT
2081	8976	NDAR_INVDG960HPT	2784			F	5400	EndofPhase1b	5	Phase 1B	127	1	0	0	0	0	0	0	6	5	4	2	4	4	5	2	6	6	6	2	3	6	6	2	6	6	4	5	6	1	1	1	1	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	4	5	4.857143	5	4.571429			4.285714	3.25	6	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG960HPT
2081	8976	NDAR_INVDG960HPT	2784			F	5800	EndofPhase2	6	Phase 2	155	1	0	0	0	0	0	0	6	4	1	2	5	4	5	2	6	2	3	3	3	5	5	6	3	4	3	6	6	1	1	2	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	3.625	3.5	4.857143	3.5	4			4.285714	3.25	6	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG960HPT
2081	8976	NDAR_INVDG960HPT	2784			F	6000	EndofPhase3	7	Phase 3	178	1	0	0	0	0	0	0	3	5	4	5	5	4	4	1	2	2	2	9	1	1	1	1	2	2	3	4	4	1	0	0	0	1	1	1	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	1	3.875	1.5	2	2.5	2.8			4.285714	3.25	6	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDG960HPT
2081	8976	NDAR_INVDH022ZTQ	2219			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	4	4	4	4	4	5	4	4	4	4	4	4	4	4	4	5	5	5	4	1	1	1	0	1	1	1	1	2	2	1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4	4.125	4	4.142857	5	4.1904764	1		4.1904764	4.125	4	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH022ZTQ
2081	8976	NDAR_INVDH022ZTQ	2219			M	5200	EndofPhase1_1a	2	Phase 1/1A	68	0	0	0	0	0	1	0	4	4	3	4	3	3	3	4	2	2	3	9	3	3	4	4	3	5	4	4	4	1	1	1	1	1	1	1	1	3	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	4	3.5	1.75	3.5714285	4.5	3.45		1	4.1904764	4.125	4	4.142857	5	-0.7404762	-0.625	-2.25	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH022ZTQ
2081	8976	NDAR_INVDH063EBQ	2294			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	2	2	2	2	2	2	2	0	0	0	9	2	2	4	5	4	5	3	4	5	1	1	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2.375	0	3.7142856	4	2.65	1		2.65	2.375	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH063EBQ
2081	8976	NDAR_INVDH063EBQ	2294			M	5200	EndofPhase1_1a	1	Phase 1/1A	70	0	0	0	0	0	1	0	4	0	1	2	2	1	2	0	0	0	0	9	1	2	4	4	2	5	2	2	4	1	2	1	0	1	1	1	1	1	1	0	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0	2.7142856	3.5	1.9		1	2.65	2.375	0	3.7142856	4	-0.75	-0.875	0	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH063EBQ
2081	8976	NDAR_INVDH192EKB	2564			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	6	6	6	6	5	6	2	3	4	9	5	4	4	6	3	5	5	5	5	0	1	1	1	1	1	0	1	3	1	1	2	1	1	4	1	0	0	0	1	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	7	5.875	2.25	4.571429	5	4.9	1		4.9	5.875	2.25	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH192EKB
2081	8976	NDAR_INVDH192EKB	2564			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	3	3	3	4	3	4	3	2	2	1	9	2	2	3	4	1	2	4	4	5	1	1	1	1	1	1	1	1	3		1	2	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	3.625	1.25	3	3	3.05		1	4.9	5.875	2.25	4.571429	5	-1.85	-2.25	-1	-1.5714285	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH192EKB
2081	8976	NDAR_INVDH354RMH	1545			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	1	2	2	2	2	3	2	2	4	9	3	4	6	4	2	5	4	5	6	1	1	1	1	1	1	1	1	1	2	1	2	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	1	0	0	0	0	1	0	2	2.75	2	4.285714	4.5	3.45	1		3.45	2.75	2	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH354RMH
2081	8976	NDAR_INVDH720BEE	2539			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	1	0	1	0	0	0	0	0	1	2	0	0	0	9	0	0	0	1	0	1	1	4	6	0	0	1	0	1	0	0	1	2	3	0	4	2	4	2	0	0	0	0	0	0	0	0					1	17	0		0		1	13	0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	3	0.5	0	1.5714285	1	0.85	1		0.85	0.5	0	1.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH720BEE
2081	8976	NDAR_INVDH720BEE	2539			F	5200	EndofPhase1_1a	5	Phase 1/1A	133	0	0	0	0	0	0	1	0	2	1	2	2	2	2	0	1	2	5	9	0	3	2	1	1	4	2	3	4	0	1	0	1	1	1	0	1	3	3	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1.375	2	2	3	1.95		1	0.85	0.5	0	1.5714285	1	1.1	0.875	2	0.42857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH720BEE
2081	8976	NDAR_INVDH720BEE	2539			F	5800	EndofPhase2	6	Phase 2	172	0	0	0	0	0	0	1	3	2	2	3	1	2	2	2	2	1	0	9	1	1	2	2	1	4	1	4	4	0	0	0	0	1	0	0	0	2	3	0	4	2	4	3	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	2.125	0.75	2.142857	2.5	2			0.85	0.5	0	1.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDH720BEE
2081	8976	NDAR_INVDJ176LRR	1656			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	0	0	2	2	2	0	5	4	5	6	0	4	0	0	5	2	1	1	3	0	0	0	1	0	0	0	2	1	3	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	0.875	5	1.8571428	1.5	2.047619	1		2.047619	0.875	5	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176LRR
2081	8976	NDAR_INVDJ176LRR	1656			F	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	1	0	1	0	0	0	2	2	2	0	5	3	5	5	0	4	0	0	4	2	1	1	2	0	0	0	0	1	1	1	0	1	3	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	0.875	4.5	1.5714285	1.5	1.8571428			2.047619	0.875	5	1.8571428	1.5	-0.1904762	0	-0.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176LRR
2081	8976	NDAR_INVDJ176LRR	1656			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	5	2	1	2	4	2	2	1	3	3	5	5	1	3	3	2	3	3	0	4	4	0	0	0	0	1	1	1	0	1	1	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	2.375	4	2.857143	1.5	2.7619047			2.047619	0.875	5	1.8571428	1.5	0.71428573	1.5	-1	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176LRR
2081	8976	NDAR_INVDJ176LRR	1656			F	5200	EndofPhase1_1a	18	Phase 1/1A	502	0	0	0	0	0	0	1	2	0	3	1	4	1	2	1	6	5	5	6	2	2	4	4	6	4	0	1	4	0	0	0	0	1	1	1	2	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1.75	5.5	3.2857144	2	3		1	2.047619	0.875	5	1.8571428	1.5	0.95238096	0.875	0.5	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176LRR
2081	8976	NDAR_INVDJ176RZJ	1094			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	0	1	1	2	0	0	0	1	2	2	0	3	2	3	2	4	6	3	4	4	1	0	1	0	1	0	1	1	1	2	0	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	1	2	1.125	1.25	3.142857	4.5	2.142857	1		2.142857	1.125	1.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176RZJ
2081	8976	NDAR_INVDJ176RZJ	1094			F	1600	Visit6	6	Phase 1/1A	174	1	0	1	0	0	0	0	5	0	1	4	2	0	6	0	6	5	4	4	3	4	4	3	6	6	3	4	5	1	1	1	0	1	1	1	1	1	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	2.25	4.75	4.142857	4.5	3.5714285			2.142857	1.125	1.25	3.142857	4.5	1.4285715	1.125	3.5	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176RZJ
2081	8976	NDAR_INVDJ176RZJ	1094			F	2800	Visit12	12	Phase 1/1A	358	1	0	1	0	0	0	0	6	3	0	1	2	0	2	1	5	4	5	0	2	4	6	3	5	6	2	5	3	0	0	1	0	1	1	1	1	1	3	1	3	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	3.5	4	4	3.0952382			2.142857	1.125	1.25	3.142857	4.5	0.95238096	0.75	2.25	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176RZJ
2081	8976	NDAR_INVDJ176RZJ	1094			F	5200	EndofPhase1_1a	18	Phase 1/1A	524	1	0	1	0	0	0	0	6	1	1	3	5	2	5	3	6	4	2	0	5	4	6	4	5	5	3	6	5	0	1	1	0	1	1	1	1	1	3	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	3.25	3	5	4	3.857143		1	2.142857	1.125	1.25	3.142857	4.5	1.7142857	2.125	1.75	1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ176RZJ
2081	8976	NDAR_INVDJ369WWU	1729			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	0	2	2	0	3	5	3	4	1	4	0	1	2	2	2	3	2	4	2	1	0	1	1	1	1	0	1	3		1	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	3	1.8571428	2.5	2.3333333	1		2.3333333	2.375	3	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ369WWU
2081	8976	NDAR_INVDJ369WWU	1729			M	1600	Visit6	6	Phase 1/1A	192	0	0	0	0	0	0	1	9	0	0	0	2	0	2	5	2	2	1	9	3	3	2	2	3	2	1	3	3	1	0	1	0	1	1	1	1	3		1	3	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1	5	1.2857143	1.25	2.7142856	1.5	1.8947369			2.3333333	2.375	3	1.8571428	2.5	-0.4385965	-1.0892857	-1.75	0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ369WWU
2081	8976	NDAR_INVDJ369WWU	1729			M	2800	Visit12	12	Phase 1/1A	346	0	0	0	0	0	1	0	1	0	0	0	1	0	1	2	0	0	1	9	0	0	0	1	0	2	3	2	2	1	1	1	1	1	0	1	0	3		0	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	0.625	0.25	0.71428573	2.5	0.8			2.3333333	2.375	3	1.8571428	2.5	-1.5333333	-1.75	-2.75	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ369WWU
2081	8976	NDAR_INVDJ369WWU	1729			M	5200	EndofPhase1_1a	12	Phase 1/1A	346	0	0	0	0	0	1	0	1	0	0	0	1	0	1	2	0	0	1	9	0	0	0	1	0	2	3	2	2	1	1	1	1	1	0	1	0	3		0	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	0.625	0.25	0.71428573	2.5	0.8		1	2.3333333	2.375	3	1.8571428	2.5	-1.5333333	-1.75	-2.75	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ369WWU
2081	8976	NDAR_INVDJ369WWU	1729			M	5800	EndofPhase2	17	Phase 2	464	0	0	0	0	0	1	0	2	3	0	3	2	2	2	2	1	3	2	9	4	4	4	3	1	2	2	3	4	1	0	0	0	1	0	1	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		2	0	1	0	0	0	1	0	0	0	0	0	0	0	1	1	6	2	1.5	3.2857144	2	2.45			2.3333333	2.375	3	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ369WWU
2081	8976	NDAR_INVDJ369WWU	1729			M	6000	EndofPhase3	18	Phase 3	535	0	0	0	0	0	1	0	4	3	2	2	3	0	3	4	0	1	1	9	3	0	0	1	2	3	2	3	2	1	0	1	0	1	1	1	1	3		1	4	2			1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	2.625	0.5	1.5714285	2.5	1.95			2.3333333	2.375	3	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ369WWU
2081	8976	NDAR_INVDJ683HL4	2244			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	4	2	2	3	3	2	3	0	1	1	3	1	3	5	5	4	5	5	4	4	1	1	1	1	1	1	1	1	1	2	0	3	3	2	2	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		1	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.25	3.7142856	5	3.047619	1		3.047619	2.875	1.25	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ683HL4
2081	8976	NDAR_INVDJ683HL4	2244			M	2800	Visit12	12	Phase 1B	337	0	0	0	0	0	0	1	2	2	2	2	2	1	2	1	1	1	1	9	2	4	3	4	3	5	5	5	5	1	1	1	1	1	1	1	1	2	2	0	4	2	2	2	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	0.75	3.7142856	5	2.65			3.047619	2.875	1.25	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ683HL4
2081	8976	NDAR_INVDJ683HL4	2244			M	4000	Visit18	18	Phase 1B	511	0	0	1	0	0	0	0	6	3	4	2	2	3	4	2	2	1	2	2	1	3	3	3	2	5	5	3	5	1	1	1	0	1	1	1	1	1	1	1	3	1	2	2	0	0	0	0	0	0	0	0					1	1	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	1.75	2.857143	5	3			3.047619	2.875	1.25	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ683HL4
2081	8976	NDAR_INVDJ683HL4	2244			M	5200	EndofPhase1_1a	6	Phase 1/1A	151	0	0	1	0	0	0	0	4	1	2	1	1	1	1	0	0	1	1	0	0	1	6	4	0	4	4	2	5	1	1	1	1	1	1	1	1	1	2	1	3	3	3	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.375	0.5	2.5714285	4	1.8571428		1	3.047619	2.875	1.25	3.7142856	5	-1.1904762	-1.5	-0.75	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ683HL4
2081	8976	NDAR_INVDJ740PFV	1348			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	0	4	4	4	4	6	2	4	4	9	4	6	4	6	5	6	5	6	5	1	1	0	0	1	0	1	1	1	2	1	4	1	2	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	5	4	2.5	5.142857	5.5	4.45	1		4.45	4	2.5	5.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ740PFV
2081	8976	NDAR_INVDJ740PFV	1348			M	2800	Visit12	12	Phase 1B	236	0	1	0	0	0	0	0	5	1	3	4	4	3	3	3	0	0	1	9	2	2	2	4	3	6	4	5	5	1	1	1	0	0	1	0	1	1	1	1	2	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	0.25	3.2857144	5	3			4.45	4	2.5	5.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ740PFV
2081	8976	NDAR_INVDJ740PFV	1348			M	5200	EndofPhase1_1a	2	Phase 1/1A	56	0	1	0	0	0	0	0	5	1	1	2	6	1	1	5	3	1	1	9	1	2	4	1	5	3	3	6	4	0	1	1	0	1	1	1	1	1	2	1	3	1	4	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	4	2.75	1.25	3.2857144	3	2.8		1	4.45	4	2.5	5.142857	5.5	-1.65	-1.25	-1.25	-1.8571428	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ740PFV
2081	8976	NDAR_INVDJ740PFV	1348			M	5400	EndofPhase1b	18	Phase 1B	411	0	1	0	0	0	0	0	5	1	2	4	3	2	3	3	2	3	5	9	3	3	2	4	5	5	5	4	5	1	0	1	0	0	0	1	1	1	1	1	2	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.875	2.5	3.7142856	5	3.45			4.45	4	2.5	5.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ740PFV
2081	8976	NDAR_INVDJ965ECX	2400			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	6	6	6	6	6	2	5	4	2	6	3	4	4	5	6	4	2	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	4.25	4.857143	3	4.714286	1		4.714286	5.25	4.25	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ965ECX
2081	8976	NDAR_INVDJ965ECX	2400			F	1600	Visit6	6	Phase 1/1A	194	0	0	0	1	0	0	0	6	6	4	6	6	6	6	6	2	6	4	9	2	3	4	6	6	4	4	6	6	1	1	0	0	1	0	0	0	1	1	1	2	1	1	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.75	3	4.714286	4	4.95		1	4.714286	5.25	4.25	4.857143	3	0.23571429	0.5	-1.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDJ965ECX
2081	8976	NDAR_INVDK494ABT	1869			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	0	2	1	0	4	0	9	3	4	4	2	1	6	3	4	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	3	1.625	1	3.2857144	4.5	2.45	1		2.45	1.625	1	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK494ABT
2081	8976	NDAR_INVDK494ABT	1869			M	5200	EndofPhase1_1a	1	Phase 1/1A	63	1	0	0	0	0	0	0	3	0	0	2	2	0	0	1	0	0	0	9	0	2	3	4	1	6	3	3	4	1	0	1	0	1	1	1	1	1	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	2	0	0	0	0	1	1	0	0	0	1	1	1	1	3	1	0	2.4285715	4.5	1.7		1	2.45	1.625	1	3.2857144	4.5	-0.75	-0.625	-1	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK494ABT
2081	8976	NDAR_INVDK562XZG	1288			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	3	2	0	2	1	1	1	2	2	1	9	3	3	5	2	2	5	5	4	5	1	1	1	0	1	1	1	1	2	3	1	4	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	1.25	3.4285715	5	2.65	1		2.65	1.75	1.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK562XZG
2081	8976	NDAR_INVDK562XZG	1288			M	5200	EndofPhase1_1a	6	Phase 1/1A	172	0	0	0	0	0	1	0	3	3	3	1	2	2	3	2	2	4	1	9	2	5	1	2	5	4	4	4	3	1	1	1	0	1	1	1	1	3	1	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.375	1.75	3.142857	4	2.8		1	2.65	1.75	1.25	3.4285715	5	0.15	0.625	0.5	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK562XZG
2081	8976	NDAR_INVDK789KGF	2733			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	1	0	0	2	1	2	2	4	1	2	2	4	2	1	4	2	4	2	4	5	1	0	1	0	1	1	1	1	1	2	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.375	2.25	3.142857	3	2.2857144	1		2.2857144	1.375	2.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK789KGF
2081	8976	NDAR_INVDK789KGF	2733			F	1600	Visit6	6	Phase 1/1A	156	1	0	0	0	0	0	0	6	5	2	3	2	2	4	5	1	1	1	9	1	2	4	5	2	4	3	5	4	1	0	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.625	0.75	3.2857144	3.5	3.1			2.2857144	1.375	2.25	3.142857	3	0.8142857	2.25	-1.5	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK789KGF
2081	8976	NDAR_INVDK789KGF	2733			F	5200	EndofPhase1_1a	7	Phase 1/1A	179	1	0	0	0	0	0	0	6	5	2	2	1	2	3	2	1	1	1	9	1	1	3	2	1	4	3	5	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.875	0.75	2.4285715	3.5	2.5		1	2.2857144	1.375	2.25	3.142857	3	0.21428572	1.5	-1.5	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK789KGF
2081	8976	NDAR_INVDK789KGF	2733			F	5800	EndofPhase2	12	Phase 2	332	1	0	1	0	0	0	0	6	5	4	3	4	3	4	3	5	5	5	5	4	4	3	4	4	6	4	5	5	1	0	1	0	1	1	1	1	1	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4	5	4.142857	5	4.3333335			2.2857144	1.375	2.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK789KGF
2081	8976	NDAR_INVDK916LZP	2210			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	5	0	0	4	0	4	0	0	6	5	9	4	5	6	5	2	5	1	6	6	2	2	1	1	1	1	1	1	2	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	3	2.125	2.75	4.857143	3	3.4	1		3.4	2.125	2.75	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK916LZP
2081	8976	NDAR_INVDK916LZP	2210			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	6	2	1	4	6	4	4	0	6	6	5	9	4	4	5	6	6	6	6	4	6	1	1	1	1	1	1	1	1	2	1	1	4	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	4.25	5	6	4.55			3.4	2.125	2.75	4.857143	3	1.15	1.25	1.5	0.14285715	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK916LZP
2081	8976	NDAR_INVDK916LZP	2210			F	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	0	1	4	3	2	5	5	5	5	0	0	5	5	9	4	5	5	4	5	6	6	4	5	1	1	1	0	1	1	1	1	1	2	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	3.625	2.5	4.571429	6	4.15			3.4	2.125	2.75	4.857143	3	0.75	1.5	-0.25	-0.2857143	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK916LZP
2081	8976	NDAR_INVDK916LZP	2210			F	5200	EndofPhase1_1a	15	Phase 1/1A	408	0	0	0	0	1	0	0	5	4	4	5	4	6	6	0	1	2	5	9	5	6	6	4	6	6	6	4	6	1	1	1	1	1	1	1	1	1	3	0	4	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	7	4.25	2	5.285714	6	4.55		1	3.4	2.125	2.75	4.857143	3	1.15	2.125	-0.75	0.42857143	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDK916LZP
2081	8976	NDAR_INVDL011DR9	1445			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	6	6	6	6	6	2	1	2	1	9	4	2	2	6	5	1	2	5	6	1	1	0	0	1	1	0	0	3	3	1	2	3	3	4	0	0	0	0	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	5.5	1	4.285714	1.5	4.05	1		4.05	5.5	1	4.285714	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL011DR9
2081	8976	NDAR_INVDL011DR9	1445			M	1600	Visit6	6	Phase 1/1A	184	0	0	0	0	0	1	0	6	6	6	6	6	6	6	4	4	6	5	4	6	5	5	5	5	2	2	6	6	1	1	2	1	1	1	1	1	3	1	1	2	4	2	4	1	0	1	1	0	1	0	0	1	1	0	2	0		1	30	0		0		0		2	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	7	5.75	4.75	5.428571	2	5.095238			4.05	5.5	1	4.285714	1.5	1.0452381	0.25	3.75	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL011DR9
2081	8976	NDAR_INVDL011DR9	1445			M	2800	Visit12	12	Phase 1/1A	347	0	0	0	0	0	1	0	5	6	6	6	6	6	6	3	3	4	6	6	3	6	4	5	5	3	2	6	6	1	1	2	1	1	1	1	1	3	1	1	2	3	2	4	1	0	1	1	0	1	0	0	1	1	1	0	0		1	30	0		0		0		2	0	0	0	0	1	1	0	0	1	0	0	1	1	1	1	7	5.5	4.75	5	2.5	4.904762			4.05	5.5	1	4.285714	1.5	0.8547619	0	3.75	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL011DR9
2081	8976	NDAR_INVDL011DR9	1445			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	6	0	1	2	2	4	4	0	2	4	5	9	4	3	4	4	1	2	2	5	6	0	1	2	1	1	1	1	1	3	1	1	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.375	2.75	3.857143	2	3.05		1	4.05	5.5	1	4.285714	1.5	-1	-3.125	1.75	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL011DR9
2081	8976	NDAR_INVDL420JN1	2061			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	3	5	2	5	2	3	2	3	2	4	5	4	5	4	6	4	5	3	5	6	1	0	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		1	0	1	0	0	0	1	1	0	0	1	1	1	0	1	1	7	3.5	3.5	4.857143	4	4	1		4	3.5	3.5	4.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL420JN1
2081	8976	NDAR_INVDL420JN1	2061			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	1	0	0	5	4	4	4	4	1	3	1	0	0	0	9	3	2	4	4	2	5	4	4	4	0	0	1	1	1	1	1	1	1	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	0	3.2857144	4.5	2.9			4	3.5	3.5	4.857143	4	-1.1	-0.25	-3.5	-1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL420JN1
2081	8976	NDAR_INVDL420JN1	2061			M	2800	Visit12	12	Phase 1/1A	351	0	0	0	0	0	0	1	2	4	3	3	3	2	5	1	0	1	1	9	1	3	2	2	3	3	4	4	5	1	1	0	0	1	1	1	1	3	2	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	1	1	1	0	1	1	6	2.875	0.5	2.857143	3.5	2.6			4	3.5	3.5	4.857143	4	-1.4	-0.625	-3	-2	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL420JN1
2081	8976	NDAR_INVDL420JN1	2061			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	1	0	0	5	3	4	2	2	3	5	4	0	0	1	9	2	4	1	5	5	3	5	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	1	1	1	1	1	1	5	3.5	0.25	3.857143	4	3.2		1	4	3.5	3.5	4.857143	4	-0.8	0	-3.25	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL420JN1
2081	8976	NDAR_INVDL891WTC	1580			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	2	0	2	2	0	0	2	9	0	4	0	4	1	4	3	5	5	1	1	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	0.75	0.5	2.7142856	3.5	1.7	1		1.7	0.75	0.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL891WTC
2081	8976	NDAR_INVDL891WTC	1580			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	1	1	2	1	1	1	2	1	0	1	1	9	1	1	1	2	3	4	2	3	3	0	0	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	4	1.25	0.5	2	3	1.6			1.7	0.75	0.5	2.7142856	3.5	-0.1	0.5	0	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL891WTC
2081	8976	NDAR_INVDL891WTC	1580			M	5200	EndofPhase1_1a	12	Phase 1/1A	350	0	0	0	0	0	0	1	1	0	0	2	3	2	2	0	0	0	1	9	0	3	3	2	2	4	4	3	3	1	0	1	0	0	0	1	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	0.25	2.2857144	4	1.75		1	1.7	0.75	0.5	2.7142856	3.5	0.05	0.5	-0.25	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL891WTC
2081	8976	NDAR_INVDL891WTC	1580			M	5400	EndofPhase1b	18	Phase 1B	517	0	0	0	0	0	0	1	4	3	2	2	4	3	4	2	0	2	4	9	3	2	3	4	4	4	3	3	4	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3	1.5	3.2857144	3.5	3			1.7	0.75	0.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL891WTC
2081	8976	NDAR_INVDL996CWK	2495			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	0	0	3	0	0	1	0	0	0	9	2	0	0	2	1	3	0	3	1	1	0	0	0	1	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	1	0	1.2857143	1.5	1	1		1	1	0	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL996CWK
2081	8976	NDAR_INVDL996CWK	2495			M	5200	EndofPhase1_1a	6	Phase 1/1A	178	0	0	0	0	0	0	1	5	2	0	0	0	0	4	4	0	2	0	9	4	4	2	2	0	3	3	5	4	0	1	1	1	1	1	1	1	1	2	1	3	4	4	1	0	0	0	0	0	0	0	0					1	9	0		0		1	21	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.875	0.5	3	3	2.2		1	1	1	0	1.2857143	1.5	1.2	0.875	0.5	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDL996CWK
2081	8976	NDAR_INVDM438YZQ	1324			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	3	5	4	4	4	4	3	3	3	4	6	2	2	4	4	6	4	4	4	2	0	0	1	1	1	1	1	1	3	3	1	2	4	2	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3.75	4	3.4285715	4	3.7142856	1		3.7142856	3.75	4	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDM438YZQ
2081	8976	NDAR_INVDM438YZQ	1324			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	1	0	1	0	2	1	2	0	2	1	2	1	1	9	0	1	2	2	2	5	6	4	4	1	0	1	1	1	1	1	1	3	3	1	2	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.125	1	2.142857	5.5	1.95			3.7142856	3.75	4	3.4285715	4	-1.7642857	-2.625	-3	-1.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDM438YZQ
2081	8976	NDAR_INVDM438YZQ	1324			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	4	5	4	4	1	5	5	1	3	4	4	0	0	2	4	2	4	5	5	4	4	1	0	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	3	3.625	2.75	2.857143	5	3.3333333			3.7142856	3.75	4	3.4285715	4	-0.3809524	-0.125	-1.25	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDM438YZQ
2081	8976	NDAR_INVDM438YZQ	1324			M	4000	Visit18	18	Phase 1/1A	498	0	0	0	0	0	1	0	4	0	0	1	0	0	0	2	1	1	1	9	2	2	1	2	3	4	4	2	1	0	0	1	1	1	1	1	1	1	1	1	3	2	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		0		1	30	0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	0.875	0.75	1.8571428	4	1.55		1	3.7142856	3.75	4	3.4285715	4	-2.1642857	-2.875	-3.25	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDM438YZQ
2081	8976	NDAR_INVDN591GNG	2873			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	0	0	2	1	0	2	0	2	2	0	9	2	2	0	4	4	1	2	4	1	2	2	2	2	1	2	2	2	1	3	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	0	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	0.75	1	2.4285715	1.5	1.5	1		1.5	0.75	1	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN591GNG
2081	8976	NDAR_INVDN591GNG	2873			M	1600	Visit6	6	Phase 3	172	0	0	0	0	0	1	0	2	0	1	0	2	0	2	1	0	3	1	9	2	2	0	3	2	3	2	3	4	0	0	0	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	0		0		1	30	0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1	1	2.2857144	2.5	1.65			1.5	0.75	1	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN591GNG
2081	8976	NDAR_INVDN591GNG	2873			M	2800	Visit12	12	Phase 3	334	0	0	0	0	0	0	1	9	0	0	2	2	2	2	1	2	4	3	9	3	4	2	4	1	4	3	5	5	1	0	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	0	1	1	6	1.2857143	2.25	3.4285715	3.5	2.5789473			1.5	0.75	1	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN591GNG
2081	8976	NDAR_INVDN591GNG	2873			M	5200	EndofPhase1_1a	2	Phase 1/1A	47	0	1	0	0	0	0	0	4	0	0	0	4	2	3	1	0	2	0	9	2	2	2	4	2	2	2	2	6	0	0	1	0	0	0	1	1	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	1.75	0.5	2.857143	2	2		1	1.5	0.75	1	2.4285715	1.5	0.5	1	-0.5	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN591GNG
2081	8976	NDAR_INVDN591GNG	2873			M	5800	EndofPhase2	4	Phase 2	106	0	0	0	0	0	1	0	4	0	0	0	2	0	1	0	0	0	0	9	2	3	1	4	1	4	5	1	2	0	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	1	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.875	0	2	4.5	1.5			1.5	0.75	1	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN591GNG
2081	8976	NDAR_INVDN591GNG	2873			M	6000	EndofPhase3	17	Phase 3	498	0	0	0	0	0	0	1	4	2	0	0	5	2	2	1	2	4	1	9	2	4	0	4	2	4	3	4	5	0	0	1	1	1	1	1	1	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	1.75	3	3.5	2.55			1.5	0.75	1	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN591GNG
2081	8976	NDAR_INVDN815MEM	2123			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	4	4	4	4	5	6	6	5	6	6	6	4	5	5	6	6	5	4	6	5	1	1	1	1	1	1	0	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.625	5.75	5.285714	4.5	5.047619	1		5.047619	4.625	5.75	5.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN815MEM
2081	8976	NDAR_INVDN815MEM	2123			M	1600	Visit6	6	Phase 1/1A	181	1	0	0	0	0	0	0	6	5	4	4	4	5	5	5	1	1	2	9	4	5	2	6	5	5	4	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	5	4.75	1	4.571429	4.5	4.15		1	5.047619	4.625	5.75	5.285714	4.5	-0.89761907	0.125	-4.75	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDN815MEM
2081	8976	NDAR_INVDP204WY0	2310			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	1	2	2	2	0	2	1	2	9	3	2	3	6	4	5	4	4	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	1.25	4	4.5	2.65	1		2.65	1.375	1.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDP204WY0
2081	8976	NDAR_INVDP204WY0	2310			M	1600	Visit6	6	Phase 3	182	1	0	0	0	0	0	0	4	0	0	2	2	0	0	1	0	0	1	9	3	1	0	2	1	4	1	4	4	0	0	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.125	0.25	2.142857	2.5	1.5			2.65	1.375	1.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDP204WY0
2081	8976	NDAR_INVDP204WY0	2310			M	5800	EndofPhase2	4	Phase 2	122	1	0	0	0	0	0	0	6	0	0	0	2	2	3	2	0	0	3	9	2	3	6	3	5	5	2	6	6	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	2	1.875	0.75	4.428571	3.5	2.8			2.65	1.375	1.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDP204WY0
2081	8976	NDAR_INVDP204WY0	2310			M	6000	EndofPhase3	14	Phase 3	415	0	0	0	0	0	1	0	0	0	0	2	2	0	2	2	6	4	6	6	1	6	2	6	4	5	4	3	4	1	0	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	1	5.5	3.7142856	4.5	3.0952382			2.65	1.375	1.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDP204WY0
2081	8976	NDAR_INVDR332TH0	1884			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	3	4	1	2	2	0	2	1	0	0	3	9	2	2	0	2	2	5	3	4	3	1	1	1	0	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	7	1.875	0.75	2.142857	4	2.05	1		2.05	1.875	0.75	2.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR332TH0
2081	8976	NDAR_INVDR332TH0	1884			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	1	0	0	0	5	0	0	2	2	1	2	1	0	4	4	9	2	2	4	2	1	4	2	4	5	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.625	2	2.857143	3	2.35		1	2.05	1.875	0.75	2.142857	4	0.3	-0.25	1.25	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR332TH0
2081	8976	NDAR_INVDR479NPM	1095			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	5	4	5	4	5	2	5	1	3	4	3	4	6	5	5	4	5	4	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	4	1	0	1	0	1	0	0	0	1	1	1	0	1	19	0		1	8	1	3	0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	4	4.375	3.25	4.714286	4.5	4.285714	1		4.285714	4.375	3.25	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR479NPM
2081	8976	NDAR_INVDR479NPM	1095			M	5200	EndofPhase1_1a	2	Phase 1/1A	55	1	0	0	0	0	0	0	6	4	4	2	6	3	5	2	0	0	1	9	4	3	4	2	1	5	4	1	2	2	2	2	2	1	1	1	2	2	1	1	3	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4	0.25	2.4285715	4.5	2.95		1	4.285714	4.375	3.25	4.714286	4.5	-1.3357143	-0.375	-3	-2.2857144	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR479NPM
2081	8976	NDAR_INVDR479NPM	1095			M	5400	EndofPhase1b	3	Phase 1B	65	1	0	0	0	0	0	0	5	3	2	2	3	3	5	2	1	0	2	9	2	1	3	4	2	5	4	2	2	0	1	0	1	1	1	0	0	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	0	5	3.125	0.75	2.2857144	4.5	2.65			4.285714	4.375	3.25	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR479NPM
2081	8976	NDAR_INVDR898LGE	2159			M	400	Baseline	0	Pre-Rand	1	1	1	0	0	0	0	0	4	0	0	1	2	3	2	5	2	4	3	9	1	2	1	2	0	3	1	4	2	1	0	0	0	1	0	0	0	1	3	0	4	4	4	4	1	1	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	2.125	2.25	1.7142857	2	2.1	1		2.1	2.125	2.25	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR898LGE
2081	8976	NDAR_INVDR898LGE	2159			M	5200	EndofPhase1_1a	6	Phase 1/1A	170	0	1	0	0	0	0	0	5	3	1	2	2	2	3	4	3	2	4	3	2	2	3	3	4	1	1	4	3	0	0	1	0	1	1	0	1	1	2	1	3	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	2.75	3	3	1	2.7142856		1	2.1	2.125	2.25	1.7142857	2	0.6142857	0.625	0.75	1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR898LGE
2081	8976	NDAR_INVDR954BZF	1366			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	2	2	2	2	3	3	4	4	4	3	5	4	3	4	2	4	4	5	5	1	1	1	0	1	1	1	1	1	2	1	4	3	3	4	1	0	1	1	0	0	0	0	1	0	0	0	1	16	0		0		1	14	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	3.75	4	4	3.4761906	1		3.4761906	2.75	3.75	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR954BZF
2081	8976	NDAR_INVDR954BZF	1366			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	0	1	6	4	4	2	2	3	2	2	4	4	4	5	4	4	3	4	4	5	4	5	4	1	1	1	0	1	1	1	1	2	1	1	3	2	3	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	1	0	0	0	0	0	0	0	1	1	1	1	5	3.125	4.25	4	4.5	3.7619047			3.4761906	2.75	3.75	4	4	0.2857143	0.375	0.5	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR954BZF
2081	8976	NDAR_INVDR954BZF	1366			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	6	5	3	3	3	3	5	1	4	3	4	4	3	2	4	4	4	5	4	4	4	1	1	1	1	1	1	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.625	3.75	3.5714285	4.5	3.7142856			3.4761906	2.75	3.75	4	4	0.23809524	0.875	0	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR954BZF
2081	8976	NDAR_INVDR954BZF	1366			M	5200	EndofPhase1_1a	18	Phase 1/1A	520	0	0	0	0	0	0	1	3	3	3	3	3	3	3	2	2	3	3	9	2	2	4	4	2	5	3	3	4	1	1	1	1	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.875	2	3	4	3		1	3.4761906	2.75	3.75	4	4	-0.47619048	0.125	-1.75	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDR954BZF
2081	8976	NDAR_INVDT014YFK	1513			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	3	4	3	3	3	2	2	4	4	9	3	3	6		3	5	3		5	1	1	0	0	1	1	1	1	3	2	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	2.5		4	3.4444444	1		3.4444444	3	2.5		4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT014YFK
2081	8976	NDAR_INVDT014YFK	1513			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	1	0	4	3	2	2	4	2	3	1	2	4	4	9	3	3	6	4	3	5	4	5	6	1	1	0	1	1	1	1	1	3	2	0	4	3	3	4		0	0	0	0	0	0	0									0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	2.5	4.285714	4.5	3.5			3.4444444	3	2.5		4	0.055555556	-0.375	0		0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT014YFK
2081	8976	NDAR_INVDT014YFK	1513			M	2800	Visit12	12	Phase 1/1A	372	0	0	0	0	0	1	0	4	0	2	2	2	0	3	1	2	3	4	9	3	3	6	5	2	5	2	5	6	1	0	1	1	1	1	1	1	3	1	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	2.25	4.285714	3.5	3		1	3.4444444	3	2.5		4	-0.44444445	-1.25	-0.25		-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT014YFK
2081	8976	NDAR_INVDT014YFK	1513			M	5200	EndofPhase1_1a	17	Phase 1/1A	500	0	0	0	0	0	1	0	3	0	2	2				1										3	3			1	0	1	1	1	1	1	1	3		0	4	4	3	4	0	0	0	0	0	0	0	0																							0	0	0	0	1	1	1	1	4				3				3.4444444	3	2.5		4					-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT014YFK
2081	8976	NDAR_INVDT112TXG	1218			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	0	0	2	2	2	0	0	0	0	9	0	0	2	2	2	3	2	4	6	1	1	1	0	1	1	0	1	1	1	1	1	4	3	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0	4	2	0	2.2857144	2.5	1.85	1		1.85	2	0	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT112TXG
2081	8976	NDAR_INVDT112TXG	1218			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	1	0	2	4	2	1	3	1	6	0	0	0	6	9	1	1	1	2	0	4	1	2	4	1	1	1	0	1	1	0	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	1.5	1.5714285	2.5	2.05			1.85	2	0	2.2857144	2.5	0.2	0.375	1.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT112TXG
2081	8976	NDAR_INVDT112TXG	1218			M	2800	Visit12	12	Phase 1/1A	365	0	0	0	0	0	1	0	2	0	0	1	2	0	2	1	0	0	6	9	1	1	2	2	0	3	2	4	6	1	0	1	0	0	0	0	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	1.5	2.2857144	2.5	1.75			1.85	2	0	2.2857144	2.5	-0.1	-1	1.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT112TXG
2081	8976	NDAR_INVDT112TXG	1218			M	5200	EndofPhase1_1a	18	Phase 1/1A	548	0	0	0	0	0	0	1	4	0	0	2	2	1	2	0	0	0	6	9	0	0	0	0	0	4	3	4	3	1	1	0	0	0	0	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.375	1.5	1	3.5	1.55		1	1.85	2	0	2.2857144	2.5	-0.3	-0.625	1.5	-1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT112TXG
2081	8976	NDAR_INVDT522YDZ	2020			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	2	4	4	4	4	1	4	2	2	4	2	2	3	3	2	4	3	4	3	0	1	1	0	1	0	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.75	3	2.7142856	3.5	3.2380953	1		3.2380953	3.75	3	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT522YDZ
2081	8976	NDAR_INVDT522YDZ	2020			M	5200	EndofPhase1_1a	2	Phase 1/1A	61	1	0	0	0	0	0	0	6	5	2	4	4	4	4	1	4	2	2	4	2	2	3	3	2	4	4	4	3	1	0	1	0	1	0	1	1	1	1	1	4	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.75	3	2.7142856	4	3.2857144		1	3.2380953	3.75	3	2.7142856	3.5	0.04761905	0	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDT522YDZ
2081	8976	NDAR_INVDU138LEC	1296			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	6	6	6	6	6	6	6	6	5	6	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.875	5.75	6	6	5.904762	1		5.904762	5.875	5.75	6	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU138LEC
2081	8976	NDAR_INVDU138LEC	1296			F	1600	Visit6	6	Phase 1/1A	172	1	0	0	0	0	0	0	6	5	5	6	6	5	6	6	6	6	4	6	5	5	6	6	6	6	6	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.625	5.5	5.571429	6	5.6190476			5.904762	5.875	5.75	6	6	-0.2857143	-0.25	-0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU138LEC
2081	8976	NDAR_INVDU138LEC	1296			F	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	6	5	5	5	5	5	5	6	5	6	6	6	5	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	4	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.25	5.75	5.857143	6	5.6190476			5.904762	5.875	5.75	6	6	-0.2857143	-0.625	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU138LEC
2081	8976	NDAR_INVDU138LEC	1296			F	5200	EndofPhase1_1a	18	Phase 1/1A	514	1	0	0	0	0	0	0	6	6	5	6	6	6	6	6	6	5	4	6	6	5	5	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.875	5.25	5.714286	6	5.714286		1	5.904762	5.875	5.75	6	6	-0.1904762	0	-0.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU138LEC
2081	8976	NDAR_INVDU141EYX	2586			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	3	3	2	2	2	2	3	0	0	0	9	4	4	4	4	4	6	5	5	4	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.875	0	4.142857	5.5	3.15	1		3.15	2.875	0	4.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU141EYX
2081	8976	NDAR_INVDU141EYX	2586			F	5200	EndofPhase1_1a	3	Phase 1/1A	88	1	0	0	1	0	0	0	5	0	0	2	4	2	2	1	1	2	1	9	1	3	1	4	3	4	2	3	4	1	0	0	0	1	1	1	1	2	1	0	4	3	3	4	1	0	1	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1	2.7142856	3	2.25		1	3.15	2.875	0	4.142857	5.5	-0.9	-0.875	1	-1.4285715	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU141EYX
2081	8976	NDAR_INVDU581MRW	1621			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	2	2	1	5	2	4	5	0	0	0	9	1	4	2	3	1	2	2	4	3	1	1	2	2	1	1	1	2	2	1	1	4	4	3	3	1	0	0	1	0	0	0	0	1	1	1	0	1	5	0		0		1	25	0		2	2	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3.25	0	2.5714285	2	2.4	1		2.4	3.25	0	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU581MRW
2081	8976	NDAR_INVDU857YYA	1765			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	1	0	0	5	6	2	6	5	5	6	4	2	2	4	9	2	2	2	6	5	4	3	5	6	2	2	2	1	1	0	1	1	2	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	16	0		0		1	14	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	4.875	2	4	3.5	4.1	1		4.1	4.875	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU857YYA
2081	8976	NDAR_INVDU857YYA	1765			M	5200	EndofPhase1_1a	1	Phase 1/1A	38	1	0	0	0	1	0	0	3	4	2	4	4	4	6	4	2	4	4	9	4	3	3	5	5	5	3	6	6	1	1	1	1	1	1	1	1	2	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	13	0		0		1	17	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	2.5	4.571429	4	4.05		1	4.1	4.875	2	4	3.5	-0.05	-1	0.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU857YYA
2081	8976	NDAR_INVDU857YYA	1765			M	5400	EndofPhase1b	2	Phase 1B	56	1	0	1	0	1	0	0	3	4	2	4	4	4	6	4	2	4	4	9	4	3	3	5	5	5	3	6	6	1	1	0	1	1	1	1	1	2	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	18	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	2.5	4.571429	4	4.05			4.1	4.875	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDU857YYA
2081	8976	NDAR_INVDV165JNJ	2721			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	0	2	2	2	2	6	0	0	0	9	0	6	4	6	2	5	4	6	6	1	1	1	0	1	1	1	1	1	1	1	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	0	4.285714	4.5	3.15	1		3.15	3	0	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDV165JNJ
2081	8976	NDAR_INVDV533YD9	2329			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	0	2	2	1	2	4	2	0	4	2	2	0	3	4	4	2	4	4	3	5	6	1	1	1	0	1	1	1	1	1	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	3	1.625	2	4	3.5	2.6666667	1		2.6666667	1.625	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDV533YD9
2081	8976	NDAR_INVDW094NA3	1161			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	1	1	1	4	0	1	1	0	0	0	9	4	2	4	5	4	4	4	5	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0	4	4	2.5	1		2.5	1.75	0	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW094NA3
2081	8976	NDAR_INVDW342JD4	1595			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	4	4	4	2	4	2	0	0	0	9	2	2	2	4	0	2	3	4	6	1	1	1	0	1	1	1	1	3	3	1	4	3	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	3.25	0	2.857143	2.5	2.55	1		2.55	3.25	0	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW342JD4
2081	8976	NDAR_INVDW342JD4	1595			F	1600	Visit6	6	Phase 1/1A	212	0	0	0	0	0	1	0	4	2	4	4	4	2	4	2	0	0	0	9	2	2	2	4	0	2	3	3	5	1	1	0	0	1	1	1	1	3	3	1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	3.25	0	2.5714285	2.5	2.45			2.55	3.25	0	2.857143	2.5	-0.1	0	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW342JD4
2081	8976	NDAR_INVDW342JD4	1595			F	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	1	0	4	4	4	2	4	2	4	2	0	0	0	9	3	2	2	4	2	2	2	4	4	1	1	2	2	1	1	1	2	3	3	1	2	3	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	3.25	0	3	2	2.55			2.55	3.25	0	2.857143	2.5	0	0	0	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW342JD4
2081	8976	NDAR_INVDW342JD4	1595			F	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	2	2	4	4	4	4	5	2	2	2	2	9	2	2	2	4	2	3	3	4	4	1	1	0	0	1	1	1	0	3	3	1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	7	3.375	1.5	2.857143	3	2.95		1	2.55	3.25	0	2.857143	2.5	0.4	0.125	1.5	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW342JD4
2081	8976	NDAR_INVDW380AUM	2214			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	1	2	2	2	3	3	0	0	1	9	2	2	4	4	4	3	2	3	5	0	0	2	0	1	1	1	2	2	1	1	4	2	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	0.25	3.4285715	2.5	2.45	1		2.45	2.375	0.25	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW380AUM
2081	8976	NDAR_INVDW380AUM	2214			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	3	1	3	2	0	3	2	3	0	2	0	9	2	3	2	4	1	3	3	3	4	1	0	1	0	0	1	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2.125	0.5	2.7142856	3	2.2			2.45	2.375	0.25	3.4285715	2.5	-0.25	-0.25	0.25	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW380AUM
2081	8976	NDAR_INVDW380AUM	2214			M	5200	EndofPhase1_1a	9	Phase 1/1A	262	0	0	0	0	0	0	1	0	2	2	0	1	2	3	2	1	1	1	9	1	2	3	3	2	5	4	3	3	1	1	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.5	0.75	2.4285715	4.5	2.05		1	2.45	2.375	0.25	3.4285715	2.5	-0.4	-0.875	0.5	-1	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW380AUM
2081	8976	NDAR_INVDW810WBQ	2067			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	4	1	4	2	2	5	0	0	4	9	4	3	5	4	3	4	3	5	6	1	1	0	1	1	1	1	1	1	2	1	4	4	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.375	1	4.285714	3.5	3.4	1		3.4	3.375	1	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW810WBQ
2081	8976	NDAR_INVDW810WBQ	2067			M	1600	Visit6	6	Phase 2	168	0	1	0	0	0	0	0	3	0	0	1	0	1	1	5	6	3	4	5	3	4	0	3	5	4	2	0	5	1	0	1	0	1	2	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1.375	4.5	2.857143	3	2.6190476			3.4	3.375	1	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW810WBQ
2081	8976	NDAR_INVDW810WBQ	2067			M	5200	EndofPhase1_1a	4	Phase 1/1A	126	0	1	0	0	0	0	0	5	1	2	2	2	3	3	3	5	3	4	5	2	4	5	4	5	4	3	4	4	1	1	0	1	1	1	1	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	6	2.625	4.25	4	3.5	3.4761906		1	3.4	3.375	1	4.285714	3.5	0.07619048	-0.75	3.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW810WBQ
2081	8976	NDAR_INVDW868YVX	2885			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	3	3	3	3	4	2	2	0	0	0	1	9	3	1	4	2	2	5	2	4	5	1	0	1	1	1	1	1	1	1	2	1	4	3	3	2	1	0	0	1	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	0.25	3	3.5	2.45	1		2.45	2.5	0.25	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDW868YVX
2081	8976	NDAR_INVDX073LA8	1363			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	3	2	3	1	2	0	2	4	1	9	1	3	1	1	2	2	2	1	2	1	1	1	0	1	1	1	1	3	3	0		4	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	1.75	1.5714285	2	1.75	1		1.75	1.625	1.75	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX073LA8
2081	8976	NDAR_INVDX073LA8	1363			F	1600	Visit6	6	Phase 1/1A	178	0	0	0	0	0	1	0	5	2	4	3	3	2	5	1	3	4	5	9	1	4	2	4	4	3	2	3	2	1	1	1	1	1	1	1	1	3	1	0	4	4	4	3	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.125	3	2.857143	2.5	3.1			1.75	1.625	1.75	1.5714285	2	1.35	1.5	1.25	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX073LA8
2081	8976	NDAR_INVDX073LA8	1363			F	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	1	0	6	2	4	4	3	4	4	0	3	4	5	9	3	3	4	5	4	4	1	3	5	0	0	1	0	1	1	0	1	3	1	0	4	3	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		3.375	3	3.857143	2.5	3.55		1	1.75	1.625	1.75	1.5714285	2	1.8	1.75	1.25	2.2857144	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX073LA8
2081	8976	NDAR_INVDX855LK5	2241			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	4	4	2	3	4	4	2	2	1	9	5	4	4	6	4	5	4	5	6	1	1	0	1	1	1	0	1	3		1	3	2	3	2	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	0	1	1	0	4	3.7142856	1.25	4.857143	4.5	3.8947368	1		3.8947368	3.7142856	1.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX855LK5
2081	8976	NDAR_INVDX855LK5	2241			F	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	9	4	2	3	4	4	4	4	1	3	2	9	4	3	4	4	3	6	4	4	4	1	1	1	0	1	1	0	1	3		1	2	1	1	1	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5714285	1.5	3.7142856	5	3.5263157			3.8947368	3.7142856	1.25	4.857143	4.5	-0.36842105	-0.14285715	0.25	-1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX855LK5
2081	8976	NDAR_INVDX855LK5	2241			F	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	5	3	2	3	4	4	6	3	4	4	5	5	5	6	5	4	4	5	4	5	4	1	1	1	1	1	1	1	1	3		1	2	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	1	0	0	0	1	0	0	0	0	0	0	0	1	1	6	3.75	4.5	4.714286	4.5	4.285714			3.8947368	3.7142856	1.25	4.857143	4.5	0.39097744	0.035714287	3.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX855LK5
2081	8976	NDAR_INVDX855LK5	2241			F	5200	EndofPhase1_1a	17	Phase 1/1A	510	0	0	0	0	0	0	1	4	3	3	4	4	5	5	4	3	4	4	4	4	5	4	5	3	6	4	3	3	1	1	1	1	1	1	0	1	3	1	1	4	3	4	3	1	0	1	0	0	0	0	0	1	0	0	0	0		0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	3.75	3.857143	5	4		1	3.8947368	3.7142856	1.25	4.857143	4.5	0.10526316	0.2857143	2.5	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX855LK5
2081	8976	NDAR_INVDX959PXW	2202			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	3	4	3	5	3	1	1	3	9	1	3	4	5	5	5	2	2	5	1	1	2	0	1	1	2	2	3	2	1	4	3	3	3	1	0	0	1	1	0	0	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.25	3.5714285	3.5	2.95	1		2.95	2.75	1.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX959PXW
2081	8976	NDAR_INVDX959PXW	2202			M	2800	Visit12	12	Phase 1B	342	0	0	0	0	0	1	0	1	1	0	4	0	1	5	2	1	2	5	9	1	5	4	4	6	5	4	5	6	1	1	1	1	1	1	0	1	3	1	1	2	4	4	3	1	1	0	0	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.75	2	4.428571	4.5	3.1			2.95	2.75	1.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX959PXW
2081	8976	NDAR_INVDX959PXW	2202			M	5200	EndofPhase1_1a	6	Phase 1/1A	168	0	0	0	0	0	1	0	2	0	0	2	1	1	3	0	0	2	2	9	0	2	3	4	3	4	2	2	4	1	1	2	0	1	0	2	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.125	1	2.5714285	3	1.85		1	2.95	2.75	1.25	3.5714285	3.5	-1.1	-1.625	-0.25	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX959PXW
2081	8976	NDAR_INVDX959PXW	2202			M	5400	EndofPhase1b	18	Phase 1B	496	0	0	0	0	0	1	0	6	6	6	6	5	5	6	2	1	2	1	9	1	5	5	6	5	3	2	4	5	0	1	0	1	1	1	0	1	3	2	1	2	1	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	5.25	1	4.428571	2.5	4.1			2.95	2.75	1.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVDX959PXW
2081	8976	NDAR_INVEA098LRX	2083			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	1	2	2	2	2	1	0	0	4	9	2	4	0	2	2	3	4	4	4	1	0	0	1	1	0	0	1	1	1	0	4	3	2	3	1	0	0	0	1	0	0	0	1	1	1	0	1	28	0		1	2	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	2.375	1	2.5714285	3.5	2.4	1		2.4	2.375	1	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEA098LRX
2081	8976	NDAR_INVEA146UV7	1054			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	5	6	6	6	6	6	4	0	2	3	9	2	2	2	4	4	6	5	4	5	1	1	1	1	1	1	1	1	3	3	1	2	1	1	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	5.125	1.25	3.2857144	5.5	4	1		4	5.125	1.25	3.2857144	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEA146UV7
2081	8976	NDAR_INVEA784ANX	1058			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	1	1	4	3	0	0	0	0	1	1	0	0	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	1.5	2.4285715	1	2.05	1		2.05	2	1.5	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEA784ANX
2081	8976	NDAR_INVEA784ANX	1058			M	1600	Visit6	6	Phase 1/1A	180	0	0	0	0	0	1	0	1	1	1	1	1	1	1	0	1	1	1	9	2	2	2	2	1	2	2	4	3	0	0	0	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	0.875	0.75	2.2857144	2	1.5		1	2.05	2	1.5	2.4285715	1	-0.55	-1.125	-0.75	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEA784ANX
2081	8976	NDAR_INVEA919VVK	1364			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	2	2	0	3	4	0	0	0	2	9	2	0	2	6	3	2	2	3	4	1	1	0	0	1	1	1	1	2	1	1	3	4	4	1	0	0	0	0	0	0	0	1	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.375	0.5	2.857143	2	2.25	1		2.25	2.375	0.5	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEA919VVK
2081	8976	NDAR_INVEB483YXE	1017			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	6	0	6	6	6	6	0	4	6	5	6	5	6	2	5	6	6	6	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.5	5.25	5.142857	6	5	1		5	4.5	5.25	5.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEB483YXE
2081	8976	NDAR_INVEB483YXE	1017			M	1600	Visit6	6	Phase 3	166	0	0	0	0	0	0	1	6	6	6	6	2	6	6	0	6	4	4	6	3	6	4	5	5	6	4	6	6	1	1	1	0	1	1	0	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	5	5	5	4.904762			5	4.5	5.25	5.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEB483YXE
2081	8976	NDAR_INVEB483YXE	1017			M	2800	Visit12	12	Phase 3	337	0	0	0	0	0	0	1	6	5	5	6	5	6	6	3	4	4	6	5	3	5	3	6	5	6	5	5	6	1	0	1	0	1	1	0	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.25	4.75	4.714286	5.5	5			5	4.5	5.25	5.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEB483YXE
2081	8976	NDAR_INVEB483YXE	1017			M	4000	Visit18	18	Phase 3	505	0	0	0	0	0	0	1	6	6	5	6	5	6	5	2	1	1	1	9	2	4	2	5	4	5	4	5	6	1	1	1	0	1	1	0	1	2	1	1	3	2	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	5.125	0.75	4	4.5	4.05			5	4.5	5.25	5.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEB483YXE
2081	8976	NDAR_INVEB483YXE	1017			M	5200	EndofPhase1_1a	4	Phase 1/1A	113	0	0	1	0	0	0	0	6	6	6	6	6	6	6	5	6	6	5	6	4	6	2	6	6	6	4	6	6	1	1	1	0	1	1	1	1	3	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	1	1	1	1	1	1	1	1	6	5.875	5.75	5.142857	5	5.5238094		1	5	4.5	5.25	5.142857	6	0.52380955	1.375	0.5	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEB483YXE
2081	8976	NDAR_INVEB483YXE	1017			M	5800	EndofPhase2	5	Phase 2	132	0	0	1	0	0	0	0	6	6	6	6	2	6	5	5	6	6	4	6	4	6	3	5	6	6	5	5	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.25	5.5	5	5.5	5.2380953			5	4.5	5.25	5.142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEB483YXE
2081	8976	NDAR_INVEC049BGK	1668			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	3	4	4	6	5	6	6	6	6	4	3	5	5	1	0	1	1	1	1	1	1	1	2	1	4	2	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	6	4.25	5.571429	3.5	5.285714	1		5.285714	6	4.25	5.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEC049BGK
2081	8976	NDAR_INVEC049BGK	1668			M	5200	EndofPhase1_1a	6	Phase 1/1A	153	0	1	0	0	0	0	0	6	5	6	6	5	6	6	6	4	6	6	6	3	6	6	6	5	4	5	5	6	1	0	1	0	1	1	1	1	1	2	1	3	2	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	5.75	5.5	5.285714	4.5	5.428571		1	5.285714	6	4.25	5.571429	3.5	0.14285715	-0.25	1.25	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEC049BGK
2081	8976	NDAR_INVEC578GFB	1838			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	3	6	2	3	4	6	2	2	4	3	9	3	3	6	6	1	3	2	5	5	1	1	0	0	1	0	0	1	3		1	4	2	4	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	2.25	4.142857	2.5	3.7	1		3.7	3.875	2.25	4.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEC578GFB
2081	8976	NDAR_INVEC621KTU	1986			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	4	1	3	2	3	0	1	2	1	9	0	1	4	2	2	4	2	5	4	1	0	1	0	1	1	0	1	1	2	1	2	1	2	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	1	2.5714285	3	2.35	1		2.35	2.375	1	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEC621KTU
2081	8976	NDAR_INVEC621KTU	1986			M	5800	EndofPhase2	2	Phase 2	35	0	0	0	0	0	0	1	2	3	2	2	4	2	3	2	2	3	1	9	1	1	1	3	2	2	1	2	1	1	0	1	0	1	1	1	1	2	2	1	2	1	1	4	1	0	0	0	0	0	1	0	1	0	0	1	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.5	1.5	1.5714285	1.5	2			2.35	2.375	1	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEC621KTU
2081	8976	NDAR_INVED286CJX	1059			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	2	1	2	1	2	0	0	0	0	9	2	2	0	6	2	1	2	5	6	1	0	1	0	0	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	0	3.2857144	1.5	2	1		2	1.75	0	3.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED286CJX
2081	8976	NDAR_INVED286CJX	1059			M	1600	Visit6	6	Phase 1/1A	174	1	0	0	0	0	0	0	6	6	6	2	4	3	4	3	0	0	0	9	0	2	0	6	4	2	3	6	6	1	1	1	0	1	1	1	1	1	1	1	3	3	3	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	0	3.4285715	2.5	3.15			2	1.75	0	3.2857144	1.5	1.15	2.5	0	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED286CJX
2081	8976	NDAR_INVED286CJX	1059			M	2800	Visit12	12	Phase 1/1A	348	1	0	0	0	0	0	0	6	4	2	2	2	2	2	2	0	0	0	9	0	2	2	6	1	2	1	6	5	1	0	1	0	1	1	1	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	0	3.142857	1.5	2.35			2	1.75	0	3.2857144	1.5	0.35	1	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED286CJX
2081	8976	NDAR_INVED286CJX	1059			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	1	0	0	0	0	0	0	6	6	0	4	5	3	6	2	0	0	0	9	2	4	4	5	2	3	3	6	6	1	1	1	0	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	5	4	0	4.142857	3	3.35		1	2	1.75	0	3.2857144	1.5	1.35	2.25	0	0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED286CJX
2081	8976	NDAR_INVED579KEG	1071			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	0	0	0	0	0	0	0	6	4	5	2	3	2	1	3	0	5	3	5	3	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	0.5	4.25	2.4285715	4	2.1904762	1		2.1904762	0.5	4.25	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED579KEG
2081	8976	NDAR_INVED579KEG	1071			F	1600	Visit6	6	Phase 3	169	0	0	0	1	0	0	0	4	4	0	3	3	2	3	2	2	3	3	9	0	2	3	3	1	4	3	5	5	1	2	1	0	1	0	1	1	1	2	1	2	1	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2	2.7142856	3.5	2.75			2.1904762	0.5	4.25	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED579KEG
2081	8976	NDAR_INVED579KEG	1071			F	2800	Visit12	12	Phase 3	337	0	0	0	1	0	0	0	4	0	3	1	2	1	2	0	2	2	3	9	0	2	3	3	1	3	4	5	3	1	1	1	0	1	1	1	1	1	1	0	4	1	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.625	1.75	2.4285715	3.5	2.2			2.1904762	0.5	4.25	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED579KEG
2081	8976	NDAR_INVED579KEG	1071			F	5200	EndofPhase1_1a	1	Phase 1/1A	19	0	0	0	1	0	0	0	3	0	0	0	0	0	0	0	6	2	3	2	3	2	1	3	0	4	2	5	3	1	0	1	0	1	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	0.375	3.25	2.4285715	3	1.8571428		1	2.1904762	0.5	4.25	2.4285715	4	-0.33333334	-0.125	-1	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED579KEG
2081	8976	NDAR_INVED579KEG	1071			F	5800	EndofPhase2	3	Phase 2	84	0	0	0	1	0	0	0	4	0	0	0	2	0	0	0	2	2	3	9	0	2	4	3	0	3	2	5	4	1	2	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.75	1.75	2.5714285	2.5	1.8			2.1904762	0.5	4.25	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED579KEG
2081	8976	NDAR_INVED579KEG	1071			F	6000	EndofPhase3	18	Phase 3	506	0	0	0	1	0	0	0	6	4	0	2	3	0	2	0	2	2	3	9	0	2	3	3	0	4	1	5	4	1	0	1	0	1	1	1	1	2	2	1	2	1	4	4	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1.75	2.4285715	2.5	2.3			2.1904762	0.5	4.25	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVED579KEG
2081	8976	NDAR_INVEE008KMX	2064			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	4	4	4	4	6	4	6	5	6	6	6	6	6	6	6	6	5	6	5	1	1	1	2	1	1	1	1	2	2	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5.75	5.857143	5.5	5.142857	1		5.142857	4.125	5.75	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE008KMX
2081	8976	NDAR_INVEE008KMX	2064			M	2800	Visit12	12	Phase 3	336	0	0	0	0	0	0	1	2	4	3	4	1	2	3	2	0	0	4	9	2	2	4	4	3	4	4	2	2	1	1	1	1	1	1	1	1	3		1	4	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.625	1	2.7142856	4	2.6			5.142857	4.125	5.75	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE008KMX
2081	8976	NDAR_INVEE008KMX	2064			M	5200	EndofPhase1_1a	5	Phase 1/1A	161	0	0	0	0	0	0	1	3	4	4	3	3	2	4	3	6	6	6	6	6	6	4	6	6	6	6	2	5	1	1	1	1	1	1	1	1	3	2	1	3	2	2	2	1	0	1	1	0	0	0	0	2	2	1	2	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	6	5	6	4.6190476		1	5.142857	4.125	5.75	5.857143	5.5	-0.52380955	-0.875	0.25	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE008KMX
2081	8976	NDAR_INVEE008KMX	2064			M	5800	EndofPhase2	6	Phase 2	162	0	0	0	0	0	0	1	3	4	4	3	3	2	4	3	6	6	6	6	6	6	4	6	6	6	6	2	5	1	1	1	1	1	1	1	1	3	2	1	3	2	3	2	1	0	1	1	0	0	0	0	2	2	1	2	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	6	5	6	4.6190476			5.142857	4.125	5.75	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE008KMX
2081	8976	NDAR_INVEE008KMX	2064			M	6000	EndofPhase3	18	Phase 3	518	0	0	0	0	0	0	1	2	4	3	4	1	2	3	2	0	0	4	9	2	2	4	4	3	4	4	2	2	1	1	1	1	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	1	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.625	1	2.7142856	4	2.6			5.142857	4.125	5.75	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE008KMX
2081	8976	NDAR_INVEE411HBL	2638			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	2	0	1	1	1	1	0	2	2	4	9	4	2	1	2	1	5	4	1	6	1	1	0	2	1	1	1	0	2	2	1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	0.875	2	2.4285715	4.5	2.05	1		2.05	0.875	2	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE411HBL
2081	8976	NDAR_INVEE769PLH	1294			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	6	4	4	5	6	3	3	2	6	4	6	5	4	4	4	5	5	6	5	5	5	1	1	0	0	1	1	1	1	1	2	1	2	2	3	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5.25	4.571429	5.5	4.6190476	1		4.6190476	4.125	5.25	4.571429	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE769PLH
2081	8976	NDAR_INVEE769PLH	1294			M	5200	EndofPhase1_1a	2	Phase 1/1A	128	1	0	0	0	0	0	0	5	6	5	5	6	4	6	4	6	6	6	6	6	4	3	4	5	5	4	4	6	1	1	2	1	1	0	1	1	1	1	1	2	1	2	2	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.125	6	4.571429	4.5	5.047619		1	4.6190476	4.125	5.25	4.571429	5.5	0.42857143	1	0.75	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE769PLH
2081	8976	NDAR_INVEE780LER	1040			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	0	4	1	9	4	2	3	6	3	3	3	2	2	1	0	1	1	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0.375	1.25	3.142857	3	1.8	1		1.8	0.375	1.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE780LER
2081	8976	NDAR_INVEE780LER	1040			F	5200	EndofPhase1_1a	1	Phase 1/1A	17	0	0	0	0	0	0	1	0	0	1	0	0	2	1	0	0	4	1	9	4	2	3	6	3	5	3	2	3	1	1	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0.5	1.25	3.2857144	4	2		1	1.8	0.375	1.25	3.142857	3	0.2	0.125	0	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE780LER
2081	8976	NDAR_INVEE780LER	1040			F	5800	EndofPhase2	2	Phase 2	30	0	0	0	0	0	0	1	4	2	2	1	1	1	2	0	1	3	1	9	3	2	2	1	3	4	4	3	2	1	1	1	0	1	1	1	1	3	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.625	1.25	2.2857144	4	2.1			1.8	0.375	1.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEE780LER
2081	8976	NDAR_INVEF085TJ9	1215			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	5	5	3	6	4	5	2	4	4	3	5	3	3	5	4	1	6	4	5	5	1	1	1	1	1	1	1	1	3	1	1	3	2	4	2	1	0	0	0	0	1	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.25	4	3.7142856	5	4.095238	1		4.095238	4.25	4	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF085TJ9
2081	8976	NDAR_INVEF085TJ9	1215			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	4	5	4	2	4	1	2	2	5	3	1	6	3	4	4	2	1	1	3	5	5	1	0	1	1	1	1	1	1	2	1	1	3	3	4	3	1	0	1	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3	3.75	3.4285715	2	3.1904762			4.095238	4.25	4	3.7142856	5	-0.9047619	-1.25	-0.25	-0.2857143	-3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF085TJ9
2081	8976	NDAR_INVEF085TJ9	1215			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	5	4	5	5	5	5	5	5	5	6	5	6	5	5	4	5	4	6	5	5	5	1	1	1	1	1	1	1	1	3		1	4	3	3	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.875	5.5	4.714286	5.5	5			4.095238	4.25	4	3.7142856	5	0.9047619	0.625	1.5	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF085TJ9
2081	8976	NDAR_INVEF085TJ9	1215			M	5200	EndofPhase1_1a	18	Phase 1/1A	511	0	0	0	0	0	0	1	9	3	4	4	5	2	5	2	5	4	4	5	5	5	3	4	5	6	3	4	4	1	2	1	1	1	1	1	1	3	3	1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.5714285	4.5	4.285714	4.5	4.1		1	4.095238	4.25	4	3.7142856	5	0.004761905	-0.6785714	0.5	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF085TJ9
2081	8976	NDAR_INVEF559ZVH	1321			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	1	0	5	5	4	4	2	2	3	2	6	4	0	4	0	5	5	4	5	6	3	4	3	1	0	1	1	1	0	0	1	1	2	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	1	0	0	0	0	0	0	1	1	1	1	4	3.375	3.5	3.7142856	4.5	3.6190476	1		3.6190476	3.375	3.5	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF559ZVH
2081	8976	NDAR_INVEF559ZVH	1321			M	5200	EndofPhase1_1a	5	Phase 1/1A	139	1	0	0	0	0	0	0	5	4	0	4	4	2	4	3	6	5	5	4	1	5	6	4	4	6	3	4	6	1	0	1	0	1	1	0	1	1	2	1	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	1	0	0	0	0	0	0	1	1	1	1	4	3.25	5	4.285714	4.5	4.047619		1	3.6190476	3.375	3.5	3.7142856	4.5	0.42857143	-0.125	1.5	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF559ZVH
2081	8976	NDAR_INVEF867MKT	1883			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	2	1	2	2	0	2	0	0	0	0	9	2	2	2	4	2	2	2	4	5	2	1	1	0	1	1	1	1	2	2	0	4	3	4	4	1	0	0	1	0	0	0	0	1	1	2	2	0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.5	0	3	2	1.85	1		1.85	1.5	0	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF867MKT
2081	8976	NDAR_INVEF867MKT	1883			M	1600	Visit6	6	Phase 1B	189	0	0	1	0	0	0	0	2	1	0	1	2	2	2	2	0	0	0	9	1	0	1	2	2	3	2	2	4	1	1	1	0	1	1	1	1	1	3	0	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.5	0	1.7142857	2.5	1.45			1.85	1.5	0	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF867MKT
2081	8976	NDAR_INVEF867MKT	1883			M	2800	Visit12	12	Phase 1B	357	0	0	1	0	0	0	0	4	2	0	0	2	0	2	2	0	0	0	9	1	1	0	2	1	1	2	4	4	1	0	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	0	0	1	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.5	0	1.8571428	1.5	1.4			1.85	1.5	0	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF867MKT
2081	8976	NDAR_INVEF867MKT	1883			M	5200	EndofPhase1_1a	3	Phase 1/1A	86	0	0	1	0	0	0	0	5	0	0	0	0	2	2	0	0	0	0	9	1	0	0	4	2	5	1	2	4	0	0	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.125	0	1.8571428	3	1.4		1	1.85	1.5	0	3	2	-0.45	-0.375	0	-1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF867MKT
2081	8976	NDAR_INVEF867MKT	1883			M	5400	EndofPhase1b	18	Phase 1B	541	0	0	0	0	0	0	1	4	3	4	2	2	2	4	2	0	0	0	0	0	2	3	5	4	5	2	4	5	1	0	1	0	1	1	1	1	2	2	1	3	2	2	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	2.875	0	3.2857144	3.5	2.5238094			1.85	1.5	0	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEF867MKT
2081	8976	NDAR_INVEG019BKF	1190			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	3	4	4	5	3	4	5	3	3	2	5	4	4	4	4	2	5	2	5	5	1	0	0	1	1	0	1	1	1	1	1	4	3	3	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	3.25	4	3.5	3.9047618	1		3.9047618	4.25	3.25	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG019BKF
2081	8976	NDAR_INVEG019BKF	1190			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	6	4	4	2	2	2	2	2	0	0	0	9	0	1	2	2	2	4	3	5	5	1	0	1	0	1	1	1	0	1	2	1	4	3	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3	0	2.4285715	3.5	2.4			3.9047618	4.25	3.25	4	3.5	-1.5047619	-1.25	-3.25	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG019BKF
2081	8976	NDAR_INVEG019BKF	1190			M	2800	Visit12	12	Phase 1/1A	332	0	0	1	0	0	0	0	4	4	2	2	2	2	2	2	0	4	4	9	2	2	2	3	2	3	3	4	5	1	0	1	0	1	1	1	1	1	2	1	4	2	3	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	2	2.857143	3	2.7			3.9047618	4.25	3.25	4	3.5	-1.2047619	-1.75	-1.25	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG019BKF
2081	8976	NDAR_INVEG019BKF	1190			M	4000	Visit18	18	Phase 1/1A	512	0	0	1	0	0	0	0	5	4	4	4	4	1	2	1	0	2	4	9	1	2	0	2	2	3	2	3	4	1	0	1	0	1	1	0	1	1	2	1	4	3	3	3	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.5	2	2.5	2.5			3.9047618	4.25	3.25	4	3.5	-1.4047619	-1.125	-1.75	-2	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG019BKF
2081	8976	NDAR_INVEG019BKF	1190			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	1	0	0	0	0	5	4	4	4	4	1	2	1	0	2	4	9	1	2	0	2	2	3	2	3	4	1	0	1	0	1	1	0	1	1	2	1	4	3	3	3	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.5	2	2.5	2.5		1	3.9047618	4.25	3.25	4	3.5	-1.4047619	-1.125	-1.75	-2	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG019BKF
2081	8976	NDAR_INVEG124CPA	2717			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	1	1	1	0	5	1	0	1	1	9	0	2	4	6	5	5	3	4	4	1	0	1	1	1	0	1	1	3		1	3	3	4	4	0	0	0	0	0	0	0	0					1	24	0		0		1	6	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.5	3.5714285	4	2.4	1		2.4	1.625	0.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG124CPA
2081	8976	NDAR_INVEG124CPA	2717			F	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	0	1	2	4	6	5	2	5	6	1	2	4	1	9	2	4	6	6	4	5	3	4	6	1	0	1	0	1	1	1	1	3		1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	1.75	4.571429	4	3.9			2.4	1.625	0.5	3.5714285	4	1.5	2.25	1.25	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG124CPA
2081	8976	NDAR_INVEG124CPA	2717			F	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	0	1	4	4	3	4	3	3	4	1	4	4	3	9	3	4	4	4	4	5	4	4	5	1	2	1	1	1	1	1	1	3		1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	2.75	4	4.5	3.7			2.4	1.625	0.5	3.5714285	4	1.3	1.625	2.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG124CPA
2081	8976	NDAR_INVEG124CPA	2717			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	4	4	4	4	4	5	5	1	4	4	5	9	4	4	4	5	5	4	3	5	5	1	0	1	0	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.875	3.25	4.571429	3.5	4.15		1	2.4	1.625	0.5	3.5714285	4	1.75	2.25	2.75	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG124CPA
2081	8976	NDAR_INVEG508UXC	2177			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	4	4	3	4	3	0	4	6	9	4	2	0	6	6	5	4	4	6	1	1	1	0	1	1	0	1	1	2	1	3	3	4	2	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4	2.5	4	4.5	3.95	1		3.95	4	2.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG508UXC
2081	8976	NDAR_INVEG533GFY	2872			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	3	3	3	3	2	3	5	4	3	3	6	4	4	4	4	5	5	5	5	3	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.375	4	4.142857	5	3.9047618	1		3.9047618	3.375	4	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG533GFY
2081	8976	NDAR_INVEG533GFY	2872			M	1600	Visit6	6	Phase 1/1A	188	0	1	0	0	0	0	0	4	3	3	2	3	2	3	4	3	2	2	3	3	3	3	4	4	4	1	5	4	2	1	1	1	1	1	1	1	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	3	2.5	3.7142856	2.5	3.0952382			3.9047618	3.375	4	4.142857	5	-0.8095238	-0.375	-1.5	-0.42857143	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG533GFY
2081	8976	NDAR_INVEG533GFY	2872			M	2800	Visit12	12	Phase 3	371	0	1	0	0	0	0	0	5	2	3	3	4	2	4	5	5	4	3	4	5	5	5	4	5	2	3	4	4	0	0	1	1	1	1	1	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	22	1	8	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.5	4	4.571429	2.5	3.857143			3.9047618	3.375	4	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG533GFY
2081	8976	NDAR_INVEG533GFY	2872			M	5200	EndofPhase1_1a	9	Phase 1/1A	268	0	0	0	0	0	0	1	4	1	3	2	2	2	2	3	2	1	2	9	3	2	4	3	3	3	2	4	4	0	1	0	1	1	0	0	1	2	2	1	4	3	3	2	1	1	0	0	0	0	0	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.375	1.25	3.2857144	2.5	2.6		1	3.9047618	3.375	4	4.142857	5	-1.3047619	-1	-2.75	-0.85714287	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG533GFY
2081	8976	NDAR_INVEG533GFY	2872			M	5800	EndofPhase2	10	Phase 2	316	0	0	0	0	0	0	1	3	1	3	2	2	1	2	3	1	1	2	9	2	2	3	2	2	4	3	3	2	0	1	0	0	1	1	0	1	2	3	1	4	4	4	3	1	1	0	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	2.125	1	2.2857144	3.5	2.2			3.9047618	3.375	4	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG533GFY
2081	8976	NDAR_INVEG533GFY	2872			M	6000	EndofPhase3	18	Phase 3	553	0	1	0	0	0	0	0	4	2	3	3	4	2	4	5	5	5	3	4	3	4	5	4	5	3	3	4	5	1	1	1	1	1	1	1	1	1	1	0	4	2	2	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.375	4.25	4.285714	3	3.8095238			3.9047618	3.375	4	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG533GFY
2081	8976	NDAR_INVEG968FJG	1069			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	4	4	4	2	3	1	1	1	1	9	3	2	3	2	3	2	3	4	5	1	1	0	2	1	1	0	0	3	2	1	4	4	1	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	5	3.125	0.75	3.142857	2.5	2.75	1		2.75	3.125	0.75	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG968FJG
2081	8976	NDAR_INVEG968FJG	1069			M	5200	EndofPhase1_1a	2	Phase 1/1A	70	0	0	0	0	0	1	0	0	0	2	0	2	2	2	1	0	0	1	9	2	4	3	3	2	1	2	2	5	2	1	2	2	1	1	2	2	3	2	0	4	4	4	3	1	0	1	0	0	0	0	0	0	0	1	0	0		1	24	0		1	6	0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	0	4	1.125	0.25	3	1.5	1.7		1	2.75	3.125	0.75	3.142857	2.5	-1.05	-2	-0.5	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEG968FJG
2081	8976	NDAR_INVEH036KBL	1465			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	2	1	1	5	4	1	4	4	6	1	4	5	4	4	6	3	3	3	6	0	1	0	1	1	1	1	0	3		1	2	1	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	0	5	2	3.75	4.571429	3	3.2857144	1		3.2857144	2	3.75	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH036KBL
2081	8976	NDAR_INVEH036KBL	1465			M	1600	Visit6	6	Phase 2	174	0	0	0	0	0	1	0	4	2	1	0	2	2	3	1	0	0	0	9	2	2	5	3	2	3	4	4	4	1	1	1	1	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	1	4	1.875	0	3.142857	3.5	2.2			3.2857144	2	3.75	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH036KBL
2081	8976	NDAR_INVEH036KBL	1465			M	5200	EndofPhase1_1a	1	Phase 1/1A	34	0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	2	1	9	2	2	3	6	2	3	4	3	5	1	1	1	1	1	1	1	1	3		1	3	1	4	4	0	0	0	0	0	0	0	0					1	29	1	1	0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	5	0.5	1	3.2857144	3.5	1.9		1	3.2857144	2	3.75	4.571429	3	-1.3857143	-1.5	-2.75	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH036KBL
2081	8976	NDAR_INVEH390PB5	1439			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	2	1	1	2	0	9	1	1	2	6	1	3	3	2	3	1	1	1	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	0.75	2.2857144	3	2	1		2	1.875	0.75	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH390PB5	1439			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	6	0	0	2	2	2	2	2	1	2	0	9	1	0	2	4	1	4	2	2	4	0	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.75	2	3	1.95			2	1.875	0.75	2.2857144	3	-0.05	0.125	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH390PB5	1439			M	2800	Visit12	12	Phase 2	336	1	0	0	0	0	0	0	4	0	0	2	2	2	2	2	1	2	0	9	2	2	2	4	4	4	3	4	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	1.75	0.75	3.142857	3.5	2.3			2	1.875	0.75	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH390PB5	1439			M	4000	Visit18	18	Phase 3	505	1	0	0	0	0	0	0	5	0	0	2	2	2	2	2	1	1	0	9	2	3	2	4	4	5	3	4	5	0	1	1	0	1	1	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.875	0.5	3.4285715	4	2.45			2	1.875	0.75	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH390PB5	1439			M	5200	EndofPhase1_1a	9	Phase 1/1A	252	1	0	0	0	0	0	0	4	0	0	2	2	2	4	2	1	2	1	9	2	2	2	4	2	5	3	3	4	0	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2	1	2.7142856	4	2.35		1	2	1.875	0.75	2.2857144	3	0.35	0.125	0.25	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH390PB5	1439			M	5800	EndofPhase2	14	Phase 2	393	1	0	0	0	0	0	0	2	0	0	2	2	2	2	2	0	1	0	9	2	2	2	4	1	5	3	4	4	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	0.25	2.7142856	4	2			2	1.875	0.75	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH390PB5	1439			M	6000	EndofPhase3	19	Phase 3	574	1	0	0	0	0	0	0	3	0	0	2	2	2	3	2	1	1	0	9	2	2	2	5	1	5	3	4	5	1	1	0	0	1	1	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.75	0.5	3	4	2.25			2	1.875	0.75	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH390PB5
2081	8976	NDAR_INVEH395APT	2560			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	0	2	4	4	4	5	6	6	6	6	6	6	6	6	5	6	5	5	3	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	2	2	1	2	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	3.875	6	5.428571	5	4.904762	1		4.904762	3.875	6	5.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH395APT
2081	8976	NDAR_INVEH395APT	2560			M	5200	EndofPhase1_1a	3	Phase 1/1A	129	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	5	6	5	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	6	6	5.857143	5.5	5.904762		1	4.904762	3.875	6	5.428571	5	1	2.125	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH395APT
2081	8976	NDAR_INVEH415HZU	2318			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	3	2	3	3	2	2	3	2	3	3	9	2	3	2	2	2	6	4	4	3	0	1	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	2	2.5714285	5	2.85	1		2.85	2.625	2	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH415HZU
2081	8976	NDAR_INVEH548CM2	1231			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	0	0	0	0	0	0	0	4	9	0	1	0	0	0	3	3	6	6	0	1	1	0	1	0	0	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	0	1	1.8571428	3	1.2105263	1		1.2105263	0	1	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH548CM2
2081	8976	NDAR_INVEH548CM2	1231			M	1600	Visit6	6	Phase 1/1A	187	0	0	0	0	0	0	1	9	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	3	1	6	6	0	0	0	0	1	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	0	0	1.7142857	2	0.84210527			1.2105263	0	1	1.8571428	3	-0.36842105	0	-1	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH548CM2
2081	8976	NDAR_INVEH548CM2	1231			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	9	0	4	2	0	0	2	1	0	0	0	9	0	0	1	0	4	4	3	0	0	1	1	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.2857143	0	0.71428573	3.5	1.1052631			1.2105263	0	1	1.8571428	3	-0.10526316	1.2857143	-1	-1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH548CM2
2081	8976	NDAR_INVEH548CM2	1231			M	5200	EndofPhase1_1a	18	Phase 1/1A	520	0	0	0	0	0	0	1	9	0	0	2	2	2	2	0	0	0	0	9	2	2	2	1	2	5	2	6	6	0	0	1	0	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.1428572	0	3	3.5	1.8947369		1	1.2105263	0	1	1.8571428	3	0.68421054	1.1428572	-1	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEH548CM2
2081	8976	NDAR_INVEJ603JCV	1532			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	0	1	2	2	0	2	2	3	3	9	3	4	3	1	2	2	1	4	4	0	1	1	0	1	1	0	1	3	2	1	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	5	1.75	2	3	1.5	2.3	1		2.3	1.75	2	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEJ603JCV
2081	8976	NDAR_INVEJ603JCV	1532			M	5200	EndofPhase1_1a	1	Phase 1/1A	13	1	0	0	0	0	0	0	2	0	2	1	2	1	1	2	0	0	2	9	2	2	1	2	1	2	2	3	3	0	1	1	0	1	1	1	1	1	2	1	4	4	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	6	1.375	0.5	2	2	1.55		1	2.3	1.75	2	3	1.5	-0.75	-0.375	-1.5	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEJ603JCV
2081	8976	NDAR_INVEK026ELQ	2379			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	1	0	2	1	0	0	5	1	0	0	9	4	2	0	2	0	4	3	5	4	1	1	1	0	1	1	0	1	2	1	1	2	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	0	0	0	5	1.625	0.25	2.4285715	3.5	1.9	1		1.9	1.625	0.25	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK026ELQ
2081	8976	NDAR_INVEK026ELQ	2379			F	1600	Visit6	6	Phase 1/1A	184	0	0	0	0	1	0	0	5	0	0	0	5	0	4	5	0	0	0	9	3	2	2	6	0	4	3	1	4	0	0	0	0	1	1	1	1	1	3	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	2.375	0	2.5714285	3.5	2.2			1.9	1.625	0.25	2.4285715	3.5	0.3	0.75	-0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK026ELQ
2081	8976	NDAR_INVEK026ELQ	2379			F	5200	EndofPhase1_1a	11	Phase 1/1A	365	0	0	0	0	1	0	0	6	0	0	0	2	2	3	3	0	0	0	9	4	0	0	4	0	3	3	4	6	1	0	1	1	1	1	1	1	1	3	0	4	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2	0	2.5714285	3	2		1	1.9	1.625	0.25	2.4285715	3.5	0.1	0.375	-0.25	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK026ELQ
2081	8976	NDAR_INVEK257YWW	1247			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	5	2	2	0	6	5	4	9	4	4	2	5	1	5	2	2	3	0	1	0	0	1	0	0	0	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.125	3.75	3	3.5	3	1		3	2.125	3.75	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK257YWW
2081	8976	NDAR_INVEK257YWW	1247			M	1600	Visit6	6	Phase 1/1A	183	1	0	0	0	0	0	0	5	2	1	2	3	1	1	1	5	3	4	3	3	2	2	3	3	5	4	4	4	1	0	1	0	1	1	1	1	1	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2	3.75	3	4.5	2.9047618			3	2.125	3.75	3	3.5	-0.0952381	-0.125	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK257YWW
2081	8976	NDAR_INVEK257YWW	1247			M	2800	Visit12	12	Phase 1/1A	351	1	0	0	0	0	0	0	4	2	1	1	3	2	2	1	4	3	3	4	2	2	2	4	2	4	4	4	4	1	2	1	0	0	1	0	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2	3.5	2.857143	4	2.7619047		1	3	2.125	3.75	3	3.5	-0.23809524	-0.125	-0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK257YWW
2081	8976	NDAR_INVEK396PZZ	1852			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	4	2	4	5	3	4	0	0	1	9	3	3	4	5	2	5	4	6	5	1	1	1	0	1	1	1	1	3		1	2	1	2	1	1	1	0	1	1	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	0.25	4	4.5	3.6	1		3.6	4.25	0.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK396PZZ
2081	8976	NDAR_INVEK396PZZ	1852			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	2	4	2	4	4	4	6	6	0	0	0	9	2	3	0	6	1	5	3	6	6	1	1	1	1	1	0	0	1	3		1	2	2	3	1	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	0	3.4285715	4	3.2			3.6	4.25	0.25	4	4.5	-0.4	-0.25	-0.25	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK396PZZ
2081	8976	NDAR_INVEK396PZZ	1852			M	5200	EndofPhase1_1a	9	Phase 1/1A	262	0	1	0	0	0	0	0	6	6	2	4	2	0	3	6	0	0	0	9	2	4	2	6	3	5	3	6	4	1	0	1	1	1	1	1	1	3	3	1	2	3	3	1	1	1	0	0	0	0	0	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.625	0	3.857143	4	3.2		1	3.6	4.25	0.25	4	4.5	-0.4	-0.625	-0.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK396PZZ
2081	8976	NDAR_INVEK396PZZ	1852			M	5800	EndofPhase2	12	Phase 2	337	0	0	0	0	0	0	1	4	6	1	2	4	2	1	6	0	0	3	9	1	2	3	6	3	4	4	5	4	1	1	1	1	1	1	1	1	3		1	2	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	0.75	3.4285715	4	3.05			3.6	4.25	0.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK396PZZ
2081	8976	NDAR_INVEK396PZZ	1852			M	6000	EndofPhase3	13	Phase 3	350	0	1	0	0	0	0	0	5	4	0	4	2	0	4	6	0	0	6	9	2	3	0	6	4	6	3	4	5	0	1	1	0	1	1	1	1	3		1	2	2	3	1	1	1	0	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.5	3.4285715	4.5	3.2			3.6	4.25	0.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK396PZZ
2081	8976	NDAR_INVEK675HU4	2569			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	3	3	2	2	3	3	0	1	0	9	2	3	2	5	2	6	3	4	5	1	1	1	2	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.75	0.25	3.2857144	4.5	2.75	1		2.75	2.75	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK675HU4
2081	8976	NDAR_INVEK675HU4	2569			M	1600	Visit6	6	Phase 2	162	0	0	0	0	0	1	0	4	0	0	0	0	0	2	1	0	0	0	9	1	2	4	2	2	5	3	5	6	1	1	1	1	0	0	0	1	3		1	2	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.875	0	3.142857	4	1.85			2.75	2.75	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK675HU4
2081	8976	NDAR_INVEK675HU4	2569			M	2800	Visit12	12	Phase 2	330	0	0	0	0	0	1	0	2	2	2	3	2	2	3	0	0	0	0	9	2	2	2	2	1	5	4	4	4	1	1	1	2	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0	2.4285715	4.5	2.1			2.75	2.75	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK675HU4
2081	8976	NDAR_INVEK675HU4	2569			M	5200	EndofPhase1_1a	4	Phase 1/1A	107	0	0	0	0	0	1	0	3	3	3	3	2	2	2	2	0	0	0	9	2	3	3	3	2	6	3	4	2	1	1	1	0	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	0	2.7142856	4.5	2.4		1	2.75	2.75	0.25	3.2857144	4.5	-0.35	-0.25	-0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK675HU4
2081	8976	NDAR_INVEK675HU4	2569			M	5800	EndofPhase2	14	Phase 2	386	0	0	0	0	0	0	1	6	0	2	1	2	2	3	1	0	1	1	9	1	1	4	2	5	5	4	5	3	1	1	1	1	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.125	0.5	3	4.5	2.45			2.75	2.75	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK675HU4
2081	8976	NDAR_INVEK675HU4	2569			M	6000	EndofPhase3	18	Phase 3	517	0	0	0	0	0	0	1	3	2	4	3	3	3	3	2	0	0	0	9	3	3	3	3	1	5	3	4	5	1	1	1	0	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	0	3.142857	4	2.65			2.75	2.75	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEK675HU4
2081	8976	NDAR_INVEL195MK3	2408			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	5	4	5	5	6	6	4	4	3	4	3	4	4	2	6	5	4	3	5	6	0	1	0	0	1	1	1	0	1	1	1	2	1	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	6	5.125	3.5	4.571429	3.5	4.4761906	1		4.4761906	5.125	3.5	4.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL195MK3
2081	8976	NDAR_INVEL195MK3	2408			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	4	4	2	4	4	4	6	4	4	4	4	4	4	4	0	6	5	4	3	0	6	1	1	1	0	1	1	1	1	3		1	2	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	7	4	4	3.5714285	3.5	3.8095238			4.4761906	5.125	3.5	4.571429	3.5	-0.6666667	-1.125	0.5	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL195MK3
2081	8976	NDAR_INVEL195MK3	2408			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	1	0	0	4	3	5	4	4	4	4	3	2	2	2	9	2	2	3	5	3	5	3	3	6	1	0	0	0	1	1	1	1	1	2	1	3	2	4	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	0	0	5	3.875	1.5	3.4285715	4	3.45			4.4761906	5.125	3.5	4.571429	3.5	-1.0261905	-1.25	-2	-1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL195MK3
2081	8976	NDAR_INVEL195MK3	2408			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	1	0	0	6	4	4	2	2	2	2	3	2	2	3	9	2	3	1	2	6	4	2	4	4	1	0	1	0	1	0	0	1	2	1	1	3	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.125	1.75	3.142857	3	3		1	4.4761906	5.125	3.5	4.571429	3.5	-1.4761904	-2	-1.75	-1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL195MK3
2081	8976	NDAR_INVEL339YN3	1865			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	1	3	4	4	6	5	6	4	4	6	1	2	3	4	5	2	3	5	3	0	1	1	0	1	1	1	1	2	1	1	2	2	2	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	1	0	0	0	0	1	0	0	0	1	1	1	1	5	4	5	3.2857144	2.5	3.8095238	1		3.8095238	4	5	3.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL339YN3
2081	8976	NDAR_INVEL339YN3	1865			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	5	4	4	3	4	4	6	4	6	5	5	5	5	5	0	6	4	3	4	3	4	1	1	1	0	1	1	1	1	2	1	1	3	2	1	3	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	5.25	3.857143	3.5	4.2380953			3.8095238	4	5	3.2857144	2.5	0.42857143	0.25	0.25	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL339YN3
2081	8976	NDAR_INVEL339YN3	1865			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	4	4	4	4	3	5	6	3	6	1	4	2	2	2	4	3	2	4	4	4	4	1	1	1	0	1	1	1	1	2	1	1	4	3	2	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	1	0	0	1	1	1	1	6	4.125	3.25	3	4	3.5714285			3.8095238	4	5	3.2857144	2.5	-0.23809524	0.125	-1.75	-0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL339YN3
2081	8976	NDAR_INVEL339YN3	1865			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	0	1	4	5	4	4	4	5	6	3	2	3	4	9	3	5	4	4	5	3	5	4	4	0	1	1	1	1	1	1	1	2	1	1	4	2	2	3	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.375	2.25	4.142857	4	4.05		1	3.8095238	4	5	3.2857144	2.5	0.24047619	0.375	-2.75	0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL339YN3
2081	8976	NDAR_INVEL454JAE	1878			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	3	0	2	4	2	2	5	5	4	4	6	5	5	1	2	4	6	4	6	4	1	1	1	0	1	1	1	1	1	2	1	3	2	4	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5	2.75	4.75	3.857143	5	3.7142856	1		3.7142856	2.75	4.75	3.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL454JAE
2081	8976	NDAR_INVEL454JAE	1878			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	1	0	0	0	6	0	0	5	5	4	6	3	4	3	2	5	3	4	0	4	4	6	3	5	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	3.625	3.5	3.5714285	4.5	3.6666667		1	3.7142856	2.75	4.75	3.857143	5	-0.04761905	0.875	-1.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL454JAE
2081	8976	NDAR_INVEL646EVW	2228			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	1	2	0	1	5	4	3	4	5	0	0	0	1	3	2	1	5	4	0	0	1	0	1	0	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	1.875	4	1.8571428	1.5	2.2380953	1		2.2380953	1.875	4	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL646EVW
2081	8976	NDAR_INVEL756JUP	2299			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	2	4	6	4	6	6	0	0	0	9	3	2	4	6	1	4	2	3	5	1	0	1	0	1	1	1	1	3	1	1	3	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	5	0	3.4285715	3	3.5	1		3.5	5	0	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL756JUP
2081	8976	NDAR_INVEL756JUP	2299			F	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	1	0	0	0	0	0	6	6	2	4	6	4	6	6	0	0	0	9	0	2	3	6	1	4	3	3	5	1	0	1	0	1	1	1	1	2	1	1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	5	0	2.857143	3.5	3.35		1	3.5	5	0	3.4285715	3	-0.15	0	0	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL756JUP
2081	8976	NDAR_INVEL756JUP	2299			F	5800	EndofPhase2	2	Phase 2	57	0	1	0	0	0	0	0	6	6	2	4	6	4	6	6	0	0	0	9	0	2	3	6	1	3	2	3	5	1	0	1	0	1	1	1	1	2	3	1	3	2	4	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	5	0	2.857143	2.5	3.25			3.5	5	0	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL756JUP
2081	8976	NDAR_INVEL756JUP	2299			F	6000	EndofPhase3	4	Phase 3	100	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	0	0	0	9	0	0	6	6	6	5	3	6	6	1	0	1	0	1	1	1	1	1	1	1	2	2	4	1	1	1	0	0	0	0	0	0	2	2	1	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	6	0	4.285714	4	4.3			3.5	5	0	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEL756JUP
2081	8976	NDAR_INVEM147JJW	1113			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	0	0	2	4	2	5	0	1	4	2	9	4	3	4	6	4	5	2	5	5	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.375	1.75	4.428571	3.5	3.2	1		3.2	2.375	1.75	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM147JJW
2081	8976	NDAR_INVEM147JJW	1113			F	1600	Visit6	6	Phase 1/1A	221	0	0	0	1	0	0	0	6	0	0	0	2	2	2	2	0	2	2	9	2	2	2	2	0	6	2	4	6	1	0	1	0	1	0	1	0	1	1	0	4	4	4	4	1	0	1	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	1.75	1	2.5714285	4	2.2		1	3.2	2.375	1.75	4.428571	3.5	-1	-0.625	-0.75	-1.8571428	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM147JJW
2081	8976	NDAR_INVEM147JJW	1113			F	2800	Visit12	12	Phase 1B	363	0	0	0	1	0	0	0	6	2	4	2	2	2	2	2	1	2	4	9	2	1	4	4	2	4	3	4	3	1	1	1	0	1	1	1	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2.75	1.75	2.857143	3.5	2.8			3.2	2.375	1.75	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM147JJW
2081	8976	NDAR_INVEM147JJW	1113			F	5400	EndofPhase1b	18	Phase 1B	513	0	0	0	1	0	0	0	6	4	5	4	5	4	6	6	3	3	4	4	4	4	4	4	4	3	4	5	5	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	3.5	4.285714	3.5	4.3333335			3.2	2.375	1.75	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM147JJW
2081	8976	NDAR_INVEM262ZMQ	2302			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	2	2	4	1	3	3	6	4	5	6	6	6	6	5	5	3	3	6	6	2	2	2	2	1	0	1	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3.125	5.25	5.714286	3	4.3809524	1		4.3809524	3.125	5.25	5.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM262ZMQ
2081	8976	NDAR_INVEM262ZMQ	2302			M	5200	EndofPhase1_1a	5	Phase 1/1A	121	1	0	0	0	0	0	0	6	2	3	3	5	1	4	3	3	3	2	9	6	5	6	6	3	4	3	4	6	1	1	0	1	1	0	0	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	0	0	5	3.375	2	5.142857	3.5	3.9		1	4.3809524	3.125	5.25	5.714286	3	-0.48095238	0.25	-3.25	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM262ZMQ
2081	8976	NDAR_INVEM266FVL	2572			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	3	2	0	1	2	0	1	2	5	9	1	1	3	0	2	2	2	2	3	1	1	1	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.25	2	1.7142857	2	1.7	1		1.7	1.25	2	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM266FVL
2081	8976	NDAR_INVEM351NJK	2366			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	0	0	2	2	0	1	2	1	9	1	2	1	3	1	4	3	3	3	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1	1	2	3.5	1.65	1		1.65	1	1	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM351NJK
2081	8976	NDAR_INVEM468NHZ	2027			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	1	1	0	2	1	0	0	1	9	1	2	2	2	0	3	4	4	4	0	0	2	0	1	1	1	1	3		1	2	4	4	2	0	0	0	0	0	0	0	0					0		1	29	0		1	1	0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	4	0.875	0.25	2.142857	3.5	1.5	1		1.5	0.875	0.25	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM468NHZ
2081	8976	NDAR_INVEM468NHZ	2027			M	5200	EndofPhase1_1a	3	Phase 1/1A	79	0	0	0	0	0	0	1	0	1	3	3	2	2	3	4	2	4	2	9	1	4	3	2	4	5	3	4	4	1	0	1	0	1	1	1	1	3		1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	1	1	1	1	1	1	1	4	2.25	2	3.142857	4	2.8		1	1.5	0.875	0.25	2.142857	3.5	1.3	1.375	1.75	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM468NHZ
2081	8976	NDAR_INVEM498VU0	2497			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	4	4	0	0	5	1	0	1	1	9	3	3	3	4	2	4	3	2	3	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	4	2.5	0.5	2.857143	3.5	2.45	1		2.45	2.5	0.5	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM498VU0
2081	8976	NDAR_INVEM498VU0	2497			F	5200	EndofPhase1_1a	3	Phase 1/1A	76	1	0	0	0	0	0	0	3	0	0	3	2	0	5	1	0	0	1	9	3	2	2	2	0	4	3	4	2	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	1.75	0.25	2.142857	3.5	1.85		1	2.45	2.5	0.5	2.857143	3.5	-0.6	-0.75	-0.25	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM498VU0
2081	8976	NDAR_INVEM498VU0	2497			F	5800	EndofPhase2	6	Phase 2	160	1	0	0	0	0	0	0	5	2	1	3	2	0	3	0	0	0	1	9	3	2	3	3	0	4	2	2	4	1	1	1	0	1	1	1	1	1	2	0	4	4	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.25	2.4285715	3	2			2.45	2.5	0.5	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM498VU0
2081	8976	NDAR_INVEM556WEZ	1207			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	6	6	4	2	2	4	2	2	5	5	9	6	5	2	4	6	4	4	6	5	0	1	0	1	1	1	1	1	3		1	3	2	2	4	1	0	0	0	0	1	0	0	1	1	1	1	0		0		1	30	0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3.625	3	4.857143	4	4.15	1		4.15	3.625	3	4.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM556WEZ
2081	8976	NDAR_INVEM556WEZ	1207			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	4	5	0	2	4	6	5	2	1	3	4	9	4	4	3	4	4	4	4	5	6	0	1	2	0	1	1	1	1	3		1	4	3	3	4	1	0	0	0	0	0	1	0	0	0	0	0	0		0		1	30	0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	3	3.5	2	4.285714	4	3.7			4.15	3.625	3	4.857143	4	-0.45	-0.125	-1	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM556WEZ
2081	8976	NDAR_INVEM556WEZ	1207			M	5200	EndofPhase1_1a	7	Phase 1/1A	195	0	0	0	0	0	1	0	2	1	0	2	1	1	1	0	4	3	3	4	4	2	4	2	2	5	4	1	5	0	1	0	1	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	30	0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1	3.5	2.857143	4.5	2.4285715		1	4.15	3.625	3	4.857143	4	-1.7214285	-2.625	0.5	-2	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM556WEZ
2081	8976	NDAR_INVEM556WEZ	1207			M	5800	EndofPhase2	12	Phase 2	334	0	0	0	0	0	1	0	2	1	0	2	1	2	4	1	3	4	5	4	4	4	0	5	2	4	3	2	6	1	0	1	0	1	1	1	1	3		1	3	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	1	0	0	0	1	1	1	1	0	0	0	0	6	1.625	4	3.2857144	3.5	2.8095238			4.15	3.625	3	4.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM556WEZ
2081	8976	NDAR_INVEM556WEZ	1207			M	6000	EndofPhase3	13	Phase 3	354	0	0	0	0	0	1	0	2	1	0	2	0	2	3	0	2	3	5	9	4	3	0	3	2	4	3	1	6	1	0	1	0	1	1	1	1	3		1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.25	2.5	2.7142856	3.5	2.3			4.15	3.625	3	4.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM556WEZ
2081	8976	NDAR_INVEM709PTV	1256			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	2	1	2	2	0	0	0	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.875	1.5	2	1.5	1.9	1		1.9	1.875	1.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM709PTV
2081	8976	NDAR_INVEM709PTV	1256			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	2	2	2	2	2	3	3	3	3	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	5	1	0.75	2.2857144	3	1.65			1.9	1.875	1.5	2	1.5	-0.25	-0.875	-0.75	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM709PTV
2081	8976	NDAR_INVEM709PTV	1256			M	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	0	1	0	2	2	2	2	2	2	2	1	2	2	2	9	2	2	2	3	3	4	3	4	2	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.875	1.5	2.5714285	3.5	2.3		1	1.9	1.875	1.5	2	1.5	0.4	0	0	0.5714286	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM709PTV
2081	8976	NDAR_INVEM710PGL	1877			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	3	3	5	3	3	4	0	0	1	9	4	1	2	1	1	4	2	4	4	1	1	1	0	1	2	2	0	3	2	1	3	3	3	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	0.25	2.4285715	3	2.8	1		2.8	4	0.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM710PGL
2081	8976	NDAR_INVEM710PGL	1877			M	1600	Visit6	6	Phase 1/1A	165	0	0	0	0	1	0	0	4	4	0	1	2	2	4	2	0	1	0	9	0	2	0	2	0	4	2	0	5	1	1	0	0	1	0	0	0	1	1	1	2	4	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	0.25	1.2857143	3	1.75			2.8	4	0.25	2.4285715	3	-1.05	-1.625	0	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM710PGL
2081	8976	NDAR_INVEM710PGL	1877			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	1	0	0	2	4	2	1	1	0	3	2	0	0	0	9	1	1	3	3	3	2	1	3	2	1	0	1	0	1	0	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1.875	0	2.2857144	1.5	1.7			2.8	4	0.25	2.4285715	3	-1.1	-2.125	-0.25	-0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM710PGL
2081	8976	NDAR_INVEM710PGL	1877			M	5200	EndofPhase1_1a	14	Phase 1/1A	390	0	0	0	0	1	0	0	3	4	4	2	3	2	2	4	0	2	0	9	1	1	1	1	2	3	0	1	2	0	0	0	0	1	0	1	0	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0.5	1.2857143	1.5	1.9		1	2.8	4	0.25	2.4285715	3	-0.9	-1	0.25	-1.1428572	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM710PGL
2081	8976	NDAR_INVEM710PGL	1877			M	5800	EndofPhase2	16	Phase 2	439	0	0	0	0	0	1	0	3	2	2	2	3	2	3	2	0	0	0	9	0	1	1	2	0	2	2	1	4	0	0	0	0	0	0	0	0	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	5	2.375	0	1.2857143	2	1.6			2.8	4	0.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM710PGL
2081	8976	NDAR_INVEM710PGL	1877			M	6000	EndofPhase3	18	Phase 3	505	0	0	0	0	1	0	0	6	0	0	0	4	3	2	2	0	0	0	9	0	1	1	1	0	3	2	1	4	0	0	1	0	1	0	1	0	1	3	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2.125	0	1.1428572	2.5	1.5			2.8	4	0.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM710PGL
2081	8976	NDAR_INVEM743VP3	2635			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	2	2	2	2	6	6	4	4	5	6	3	4	4	4	4	6	5	6	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.75	4.75	4.428571	5.5	4.3333335	1		4.3333335	3.75	4.75	4.428571	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM743VP3
2081	8976	NDAR_INVEM743VP3	2635			M	1600	Visit6	6	Phase 2	179	0	0	0	0	1	0	0	6	6	6	2	2	2	2	6	4	4	6	4	4	5	3	5	5	6	4	5	6	1	1	1	1	1	1	1	1	1	1	0	4	4	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4	4.5	4.714286	5	4.428571			4.3333335	3.75	4.75	4.428571	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM743VP3
2081	8976	NDAR_INVEM743VP3	2635			M	2800	Visit12	12	Phase 2	351	0	1	0	0	0	0	0	6	6	4	2	2	4	4	6	4	5	5	6	6	5	5	5	5	6	5	6	6	1	1	1	1	1	1	1	1	3	1	0	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.25	5	5.428571	5.5	4.904762			4.3333335	3.75	4.75	4.428571	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM743VP3
2081	8976	NDAR_INVEM743VP3	2635			M	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	1	0	0	0	0	0	6	5	5	3	3	3	4	5	4	4	5	4	5	5	4	4	1	6	6	4	4	1	1	1	1	1	1	1	1	2	1	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	4.25	3.857143	6	4.285714		1	4.3333335	3.75	4.75	4.428571	5.5	-0.04761905	0.5	-0.5	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM743VP3
2081	8976	NDAR_INVEM743VP3	2635			M	5800	EndofPhase2	18	Phase 2	551	0	1	0	0	0	0	0	6	6	6	5	3	3	3	6	5	4	6	4	4	5	4	4	1	6	6	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.75	4.75	4	6	4.6190476			4.3333335	3.75	4.75	4.428571	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM743VP3
2081	8976	NDAR_INVEM909BCN	2568			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	3	1	3	2	2	3	4	3	3	4	2	3	2	3	5	3	3	4	5	1	1	0	1	1	1	0	1	2	2	1	4	2	4	1	1	0	1	0	0	0	0	0	1	0	1	0	1	22	0		0		1	8	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	4	2.875	3.5	3.4285715	3	3.1904762	1		3.1904762	2.875	3.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM909BCN
2081	8976	NDAR_INVEM909BCN	2568			M	1600	Visit6	6	Phase 1/1A	191	0	1	0	0	0	0	0	5	4	2	2	3	2	2	5	6	3	5	2	2	4	4	4	6	4	3	4	4	0	1	0	1	1	1	1	1	1	1	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	1	4	3.125	4	4	3.5	3.6190476			3.1904762	2.875	3.5	3.4285715	3	0.42857143	0.25	0.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM909BCN
2081	8976	NDAR_INVEM909BCN	2568			M	2800	Visit12	12	Phase 2	372	0	1	0	0	0	0	0	6	3	2	2	2	2	6	6	6	3	5	2	1	3	3	4	5	5	4	4	4	0	1	0	0	1	1	1	1	2	1	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	4	3.625	4	3.4285715	4.5	3.7142856			3.1904762	2.875	3.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM909BCN
2081	8976	NDAR_INVEM909BCN	2568			M	5200	EndofPhase1_1a	10	Phase 1/1A	309	0	1	0	0	0	0	0	5	4	2	3	2	3	5	6	6	4	5	2	1	2	2	3	6	4	4	2	4	1	1	0	0	1	1	0	1	2	1	1	4	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	4	3.75	4.25	2.857143	4	3.5714285		1	3.1904762	2.875	3.5	3.4285715	3	0.3809524	0.875	0.75	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM909BCN
2081	8976	NDAR_INVEM909BCN	2568			M	5800	EndofPhase2	13	Phase 2	380	0	1	0	0	0	0	0	4	2	2	1	2	2	4	6	6	2	4	0	1	2	3	2	4	5	3	2	6	0	1	0	0	1	0	0	0	2	1	1	2	2	2	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	2.875	3	2.857143	4	3			3.1904762	2.875	3.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM909BCN
2081	8976	NDAR_INVEM909BCN	2568			M	6000	EndofPhase3	18	Phase 3	520	0	1	0	0	0	0	0	4	2	1	2	2	0	2	4	2	1	2	9	2	5	2	2	2	3	3	3	5	1	1	1	0	1	1	0	1	2	1	1	4	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.125	1.25	3	3	2.45			3.1904762	2.875	3.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM909BCN
2081	8976	NDAR_INVEM912FU1	2205			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	3	2	2	3	2	3	2	3	3	9	3	2	4	3	3	4	3	3	2	1	1	1	1	1	1	1	1	2	2	0	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.875	2	2.857143	3.5	2.9	1		2.9	2.875	2	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM912FU1
2081	8976	NDAR_INVEM912FU1	2205			M	5200	EndofPhase1_1a	5	Phase 1/1A	144	1	0	0	0	0	0	0	5	3	3	3	3	3	3	3	0	1	2	9	3	3	4	4	4	5	3	3	3	1	1	1	0	1	1	1	1	1	2	1	2	1	3	1	0	0	0	0	0	0	0	0					1	26	0		0		1	4	0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	5	3.25	0.75	3.4285715	4	3.05		1	2.9	2.875	2	2.857143	3.5	0.15	0.375	-1.25	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEM912FU1
2081	8976	NDAR_INVEN612TX2	1661			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	0	0	2	0	2						3	3	0	4	0	4	4			1	1	1	1	1	1	1	1	1	2	1	3	2	3	4		0	0	0	0	0	0	0					1		0		1		1				0	0	0						0	1	0	0	1	1	0	1	4	1.1428572			4		1			1.1428572			4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEN612TX2
2081	8976	NDAR_INVEP854MB5	1952			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	0	2	1	2	2	1	1	1	1	2	9	2	2	2	3	1	1	1	4	4	1	1	1	0	1	0	1	1	2	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.5	1	2.5714285	1	1.8	1		1.8	1.5	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEP854MB5
2081	8976	NDAR_INVEP854MB5	1952			M	1600	Visit6	6	Phase 1/1A	185	0	0	0	0	0	0	1	3	0	3	0	2	2	2	2	1	0	1	9	0	2	1	2	1	0	2	2	2	1	0	1	0	1	0	1	0	2	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0.5	1.4285715	1	1.4			1.8	1.5	1	2.5714285	1	-0.4	0.25	-0.5	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEP854MB5
2081	8976	NDAR_INVEP854MB5	1952			M	2800	Visit12	12	Phase 1/1A	360	0	0	0	0	0	0	1	3	0	3	1	2	2	2	2	1	1	3	9	1	2	1	3	1	1	2	2	3	1	0	1	0	0	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	1.25	1.8571428	1.5	1.8			1.8	1.5	1	2.5714285	1	0	0.375	0.25	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEP854MB5
2081	8976	NDAR_INVEP854MB5	1952			M	4000	Visit18	18	Phase 2	521	0	0	0	0	0	0	1	3	2	3	1	2	2	2	1	1	1	3	9	0	2	2	4	1	0	2	2	4	0	0	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.25	2.142857	1	1.9			1.8	1.5	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEP854MB5
2081	8976	NDAR_INVEP854MB5	1952			M	5200	EndofPhase1_1a	14	Phase 1/1A	416	0	0	0	0	0	0	1	2	2	3	2	2	3	2	2	1	1	4	9	1	2	4	3	2	1	3	2	2	1	0	1	0	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	1.5	2.2857144	2	2.2		1	1.8	1.5	1	2.5714285	1	0.4	0.75	0.5	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEP854MB5
2081	8976	NDAR_INVEP854MB5	1952			M	5800	EndofPhase2	20	Phase 2	591	0	0	0	0	0	0	1	2	2	2	1	2	2	2	1	1	1	3	9	2	2	4	4	1	1	2	3	4	1	1	1	0	1	0	1	0	3	3	1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.75	1.25	2.857143	1.5	2.1			1.8	1.5	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEP854MB5
2081	8976	NDAR_INVER218LNE	2575			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	6	6	6	6	2	2	0	4	2	9	4	6	4	6	4	6	6	6	4	1	1	1	1	1	1	1	1	1	1	1	2	2	2	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	5	4.25	1.5	4.857143	6	4.3	1		4.3	4.25	1.5	4.857143	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER218LNE
2081	8976	NDAR_INVER218LNE	2575			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	0	4	6	6	6	6	5	0	6	4	5	4	6	6	6	6	6	4	4	6	6	0	0	1	0	1	1	0	1	2	2	1	2	2	2	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	4.75	6	4	4.857143			4.3	4.25	1.5	4.857143	6	0.55714285	-0.125	3.25	1.1428572	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER218LNE
2081	8976	NDAR_INVER218LNE	2575			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	0	6	4	6	6	4	5	1	4	4	4	6	4	4	6	6	6	5	3	6	6	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4	4.5	5.428571	4	4.571429			4.3	4.25	1.5	4.857143	6	0.27142859	-0.25	3	0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER218LNE
2081	8976	NDAR_INVER218LNE	2575			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	1	0	6	6	2	6	6	4	6	6	4	4	6	6	6	6	4	6	6	4	4	6	6	1	0	1	1	1	1	1	1	1	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	6	5.25	5	5.714286	4	5.2380953		1	4.3	4.25	1.5	4.857143	6	0.9380952	1	3.5	0.85714287	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER218LNE
2081	8976	NDAR_INVER280TET	2065			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	1	2	1	2	2	1	2	1	9	2	2	1	4	1	3	1	1	1	0	0	0	0	1	0	1	0	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.75	1	1.7142857	2	1.7	1		1.7	1.75	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER280TET
2081	8976	NDAR_INVER280TET	2065			F	1600	Visit6	6	Phase 1/1A	140	0	1	0	0	0	0	0	6	0	0	1	2	1	2	2	1	2	1	9	2	2	1	4	1	3	1	1	1	0	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.75	1	1.7142857	2	1.7			1.7	1.75	1	1.7142857	2	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER280TET
2081	8976	NDAR_INVER280TET	2065			F	2800	Visit12	12	Phase 3	346	0	1	0	0	0	0	0	5	2	6	4	5	3	4	5	0	0	0	9	2	2	4	3	2	2	2	4	5	1	1	1	1	1	1	1	1	2	1	1	3	3	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	4.25	0	3.142857	2	3			1.7	1.75	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER280TET
2081	8976	NDAR_INVER280TET	2065			F	5200	EndofPhase1_1a	8	Phase 1/1A	205	0	1	0	0	0	0	0	6	0	0	1	2	1	4	4	1	0	1	9	0	0	1	2	1	3	2	2	4	1	1	0	0	1	1	1	1	2	2	1	3	3	4	4	1	1	0	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.25	0.5	1.4285715	2.5	1.75		1	1.7	1.75	1	1.7142857	2	0.05	0.5	-0.5	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER280TET
2081	8976	NDAR_INVER280TET	2065			F	5800	EndofPhase2	9	Phase 2	217	0	1	0	0	0	0	0	6	0	0	1	2	1	4	4	1	0	1	9	0	0	1	2	1	3	3	2	4	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.25	0.5	1.4285715	3	1.8			1.7	1.75	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER280TET
2081	8976	NDAR_INVER280TET	2065			F	6000	EndofPhase3	18	Phase 3	553	0	0	0	0	0	0	1	5	2	6	4	5	3	4	5	0	0	0	9	2	2	4	3	2	2	2	4	5	1	1	1	2	1	1	1	1	1	1	1	3	3	3	2	1	1	0	0	0	0	0	0	1	1	1	1	1	9	0		0		1	21	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	0	3.142857	2	3			1.7	1.75	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER280TET
2081	8976	NDAR_INVER371JMR	1077			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	4	3	3	3	3	3	2	3	2	9	4	4	1	6	4	4	3	5	5	1	1	1	0	1	1	1	1	2	1	0	4	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	5	3.25	1.75	4.142857	3.5	3.45	1		3.45	3.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER371JMR
2081	8976	NDAR_INVER371JMR	1077			F	1600	Visit6	6	Phase 3	154	0	0	0	0	0	0	1	4	3	2	2	3	4	4	3	1	2	2	9	4	2	2	4	1	4	3	5	6	1	0	1	0	1	1	1	1	3	1	1	4	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	5	3.125	1.25	3.4285715	3.5	3.05			3.45	3.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER371JMR
2081	8976	NDAR_INVER371JMR	1077			F	5200	EndofPhase1_1a	2	Phase 1/1A	49	0	0	0	0	0	0	1	3	1	4	2	3	3	3	2	2	1	2	9	3	3	1	2	2	4	3	3	4	1	1	1	0	1	1	1	1	3	1	1	3	2	3	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	6	2.625	1.25	2.5714285	3.5	2.55		1	3.45	3.25	1.75	4.142857	3.5	-0.9	-0.625	-0.5	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER371JMR
2081	8976	NDAR_INVER371JMR	1077			F	5800	EndofPhase2	4	Phase 2	105	0	0	0	0	0	0	1	4	2	4	2	2	3	3	4	2	2	3	9	3	3	4	5	3	5	5	5	5	1	1	1	1	1	1	1	1	3	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3	1.75	4	5	3.45			3.45	3.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER371JMR
2081	8976	NDAR_INVER411YRZ	2663			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	0	0	0	0	6	0	0	0	9	0	0	0	3	0	5	2	5	5	1	0	0	0	0	0	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	0	1.8571428	3.5	1.6	1		1.6	1.5	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER411YRZ
2081	8976	NDAR_INVER411YRZ	2663			M	1600	Visit6	6	Phase 2	165	0	1	0	0	0	0	0	6	2	0	4	4	4	6	6	4	4	6	5	4	6	5	6	4	5	2	5	5	1	0	0	1	1	1	1	1	3		0	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	4	4.75	5	3.5	4.428571			1.6	1.5	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER411YRZ
2081	8976	NDAR_INVER411YRZ	2663			M	5200	EndofPhase1_1a	2	Phase 1/1A	53	0	1	0	0	0	0	0	6	1	0	0	0	0	0	6	0	0	0	9	0	0	0	4	0	5	3	5	5	1	0	0	0	1	0	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0	2	4	1.75		1	1.6	1.5	0	1.8571428	3.5	0.15	0.125	0	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER411YRZ
2081	8976	NDAR_INVER411YRZ	2663			M	5800	EndofPhase2	12	Phase 2	330	0	1	0	0	0	0	0	6	2	3	6	2	6	6	6	4	4	6	9	3	4	3	6	2	6	2	5	4	1	0	1	0	1	1	1	1	1	1	0	4	4	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.625	3.5	3.857143	4	4.3			1.6	1.5	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER411YRZ
2081	8976	NDAR_INVER411YRZ	2663			M	6000	EndofPhase3	18	Phase 3	508	0	1	0	0	0	0	0	6	3	3	3	3	2	6	5	3	4	6	9	3	3	4	4	4	5	3	5	6	1	1	0	0	1	1	0	1	1	1	0	4	4	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	3.25	4.142857	4	4.05			1.6	1.5	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER411YRZ
2081	8976	NDAR_INVER469ZUU	1308			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	4		5				2									4	3		4	0	0	1	0	1	1	1	1	2	1	1	3	2	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0									3.5		1						3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER469ZUU
2081	8976	NDAR_INVER469ZUU	1308			M	1600	Visit6	6	Phase 1/1A	187	0	0	0	0	0	0	1	4	1	3	2	4	1	4	1	3	4	3	3	3	4	4	5	2	4	4	4	4	0	1	0	0	1	1	1	1	2	2	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	5	2.5	3.25	3.7142856	4	3.1904762							3.5					0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER469ZUU
2081	8976	NDAR_INVER469ZUU	1308			M	5200	EndofPhase1_1a	7	Phase 1/1A	221	0	0	0	0	0	0	1	4	3	4	2	2	4	5	1	1	2	1	9	1	2	4	4	1	4	3	4	4	0	1	1	0	1	1	1	1	2	1	1	3	2	4	4		0	0	0	0	0	0	0					1	25	0		0		1	6	0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	6	3.125	1	2.857143	3.5	2.8		1					3.5					0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER469ZUU
2081	8976	NDAR_INVER731LMC	1172			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	2	2	2	2	2	0	0	6	2	0	2	2	0	4	4	2	4	2	4	4	1	1	1	0	1	1	0	1	1	2	0	4	1	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	2.5	2.857143	3	2.1904762	1		2.1904762	1.25	2.5	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER731LMC
2081	8976	NDAR_INVER749TJ0	2651			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	2	1	4	0	1	1	0	0	0	9	1	0	4	4	0	3	2	4	4	1	0	0	0	1	1	0	1	1	2	1	3	2	4	4	1	0	1	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	4	1.875	0	2.4285715	2.5	1.85	1		1.85	1.875	0	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER749TJ0
2081	8976	NDAR_INVER766RTL	2368			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	3	2	1	1	0	0	0	2	1	9	1	1	2	2	2	4	3	4	4	1	0	1	0	0	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.75	2.2857144	3.5	2.15	1		2.15	2.125	0.75	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER766RTL
2081	8976	NDAR_INVER803ZG6	2136			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	9	2	4	2	2	4	3	3	0	4	0	0	2	0	1	1	1	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	15	0		1	15	0		0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	3	0.25	0	2.5714285	3	1.3	1		1.3	0.25	0	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVER803ZG6
2081	8976	NDAR_INVET024AVQ	2894			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	1	0	0									4	2			6	4	6	2	2	6	0	2	6	1	0	1	1	1	1	1	1	1	2	1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2			4	3		1					4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET024AVQ
2081	8976	NDAR_INVET024AVQ	2894			F	1600	Visit6	6	Phase 2	164	1	0	0	0	0	0	0	6	0	1	0	4	2	6	4	2	5	4	9	6	2	4	3	0	2	3	3	5	1	1	1	0	1	1	1	1	1	2	1	2	4	4	1	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		2	0	1	1	0	0	0	0	0	1	0	0	1	0	0	0	3	2.875	2.75	3.2857144	2.5	3.1						4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET024AVQ
2081	8976	NDAR_INVET024AVQ	2894			F	5800	EndofPhase2	9	Phase 2	243	1	0	0	0	1	0	0	1	0	2	2	2	2	2	4	3	2	3	3	3	2	4	4	4	2	2	4	3	1	0	1	0	1	0	1	1	2	2	0	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	1	1.875	2.75	3.4285715	2	2.5714285						4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET024AVQ
2081	8976	NDAR_INVET024AVQ	2894			F	6000	EndofPhase3	12	Phase 3	326	1	0	0	0	1	0	0	2	0	0	1	2	1	2	4	0	0	0	9	2	0	2	2	1	2	3	3	2	1	1	1	1	1	1	1	1	2	2	1	2	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.5	0	1.7142857	2.5	1.45						4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET024AVQ
2081	8976	NDAR_INVET037ZA7	2766			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	6	6	6	6	3	6	4	1	2	1	9	0	4	2	4	0	3	3	5	4	1	1	1	1	1	1	1	1	1	1	1	2	2	3	1	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.375	1	2.7142856	3	3.6	1		3.6	5.375	1	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET037ZA7
2081	8976	NDAR_INVET037ZA7	2766			M	5200	EndofPhase1_1a	12	Phase 1/1A	337	0	0	1	0	0	0	0	6	4	4	4	4	5	6	4	1	2	1	9	2	2	0	5	0	3	3	4	2	1	0	0	1	1	1	0	1	1	1	1	3	2	3	1	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.625	1	2.142857	3	3.1		1	3.6	5.375	1	2.7142856	3	-0.5	-0.75	0	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET037ZA7
2081	8976	NDAR_INVET037ZA7	2766			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	1	0	0	6	2	0	4	3	3	4	4	1	2	1	9	2	2	2	4	1	3	4	4	2	1	1	0	0	1	1	1	1	1	1	1	3	3	3	1	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1	2.4285715	3.5	2.7			3.6	5.375	1	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET037ZA7
2081	8976	NDAR_INVET431XM0	1146			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	4	0	3	4	2	1	1	2	4	1	9	2	2	4	2	1	6	3	3	3	1	1	1	1	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	1.75	2.4285715	4.5	2.45	1		2.45	2	1.75	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET431XM0
2081	8976	NDAR_INVET431XM0	1146			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	5	5	1	2	3	4	1	6	5	4	5	4	6	6	6	6	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		2	2	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	5	5.714286	5.5	4.6666665			2.45	2	1.75	2.4285715	4.5	2.2166667	1.375	3.25	3.2857144	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET431XM0
2081	8976	NDAR_INVET431XM0	1146			M	2800	Visit12	12	Phase 1/1A	332	1	0	0	0	0	0	0	6	3	4	2	4	0	6	0	4	2	2	9	3	1	4	6	2	5	4	4	3	1	1	1	1	1	1	1	1	1	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	2	3.2857144	4.5	3.25			2.45	2	1.75	2.4285715	4.5	0.8	1.125	0.25	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET431XM0
2081	8976	NDAR_INVET431XM0	1146			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	1	0	0	0	0	0	0	6	2	3	2	2	2	6	0	4	4	3	6	2	3	4	6	5	4	4	5	2	0	0	1	2	1	1	1	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	4.25	3.857143	4	3.5714285		1	2.45	2	1.75	2.4285715	4.5	1.1214286	0.875	2.5	1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET431XM0
2081	8976	NDAR_INVET886NU4	1443			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	4	1	4	3	6	6	3	5	6	5	6	2	4	3	3	6	4	3	3	5	1	1	1	0	1	1	1	1	1	1	1	3	2	1	2	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	3.875	5.5	3.7142856	3.5	4.095238	1		4.095238	3.875	5.5	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET886NU4
2081	8976	NDAR_INVET886NU4	1443			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	1	0	0	0	6	2	2	2	4	2	5	2	2	6	3	9	5	5	6	2	6	4	2	3	3	1	1	1	1	1	1	1	1	1	1	1	3	2	3	1	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.125	2.75	4.285714	3	3.6			4.095238	3.875	5.5	3.7142856	3.5	-0.4952381	-0.75	-2.75	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET886NU4
2081	8976	NDAR_INVET886NU4	1443			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	1	0	0	0	6	6	6	5	4	5	5	6	6	6	5	6	6	5	5	6	6	5	4	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	5.375	5.75	5.714286	4.5	5.4761906			4.095238	3.875	5.5	3.7142856	3.5	1.3809524	1.5	0.25	2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET886NU4
2081	8976	NDAR_INVET886NU4	1443			F	4000	Visit18	18	Phase 1/1A	512	0	0	0	1	0	0	0	6	5	3	3	4	3	4	2	2	4	4	9	4	4	4	6	6	5	4	4	4	1	0	1	1	1	1	1	1	1	2	1	3	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	4	3.75	2.5	4.571429	4.5	4.05		1	4.095238	3.875	5.5	3.7142856	3.5	-0.045238096	-0.125	-3	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVET886NU4
2081	8976	NDAR_INVEU255FHP	1903			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	2	2	2	1	2	0	0	3	5	9	2	2	2	2	2	3	3	2	2	1	1	1	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	1.125	2	2	3	1.85	1		1.85	1.125	2	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEU255FHP
2081	8976	NDAR_INVEU255FHP	1903			F	1600	Visit6	6	Phase 1/1A	184	0	0	1	0	0	0	0	2	2	4	4	2	2	2	0	0	3	0	9	3	3	2	4	2	3	3	3	4	1	0	1	0	1	1	0	1	1	3	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	2.25	0.75	3	3	2.4			1.85	1.125	2	2	3	0.55	1.125	-1.25	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEU255FHP
2081	8976	NDAR_INVEU255FHP	1903			F	2800	Visit12	12	Phase 1/1A	357	0	0	0	0	0	0	1	2	2	3	2	2	2	2	0	2	4	0	9	2	2	2	2	2	4	2	2	2	1	0	1	0	1	1	0	1	2	2	1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.875	1.5	2	3	2.05			1.85	1.125	2	2	3	0.2	0.75	-0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEU255FHP
2081	8976	NDAR_INVEU255FHP	1903			F	5200	EndofPhase1_1a	18	Phase 1/1A	513	0	0	0	0	0	0	1	3	3	0	2	2	0	2	0	0	2	0	9	0	2	2	4	2	4	1	4	4	0	0	1	0	1	1	0	0	3	2	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.5	0.5	2.5714285	2.5	1.85		1	1.85	1.125	2	2	3	0	0.375	-1.5	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEU255FHP
2081	8976	NDAR_INVEV176YT5	2832			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	2	2	4	2	3	2	3	3	2	3	3	9	4	3	3	4	5	4	4	3	6	1	1	0	1	1	0	1	1	1	3	1	2	2	2	1	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.625	2	4	4	3.25	1		3.25	2.625	2	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV176YT5
2081	8976	NDAR_INVEV176YT5	2832			M	5200	EndofPhase1_1a	3	Phase 1/1A	85	1	0	0	0	0	0	0	3	4	4	2	4	3	3	2	1	1	1	9	4	4	5	4	5	6	5	4	5	1	1	1	1	1	0	1	1	1	3	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	4	3.125	0.75	4.428571	5.5	3.5		1	3.25	2.625	2	4	4	0.25	0.5	-1.25	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV176YT5
2081	8976	NDAR_INVEV392KH4	2323			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	5	4	2	6	4	3	3	0	0	1	9	3	4	3	4	1	4	2	6	6	1	1	0	0	1	1	0	1	2	1	1	4	4	4	1	1	0	0	0	1	0	0	0	1	1	1	0	1	27	0		0		1	3	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	0.25	3.857143	3	3.3	1		3.3	4	0.25	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV392KH4
2081	8976	NDAR_INVEV392KH4	2323			M	2800	Visit12	12	Phase 3	328	0	1	0	0	0	0	0	6	6	4	2	4	4	2	6	0	0	1	9	0	3	2	3	2	5	3	5	3	0	0	0	0	1	1	0	1	2	1	1	3	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.25	0.25	2.5714285	4	3.05			3.3	4	0.25	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV392KH4
2081	8976	NDAR_INVEV392KH4	2323			M	5200	EndofPhase1_1a	4	Phase 1/1A	116	0	1	0	0	0	0	0	6	5	4	2	6	4	2	3	0	0	1	9	3	2	2	6	1	5	3	5	6	0	1	1	0	1	1	0	1	3	1	1	4	4	4	1	1	1	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	0.25	3.5714285	4	3.3		1	3.3	4	0.25	3.857143	3	0	0	0	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV392KH4
2081	8976	NDAR_INVEV392KH4	2323			M	5800	EndofPhase2	6	Phase 2	165	0	1	0	0	0	0	0	6	6	4	2	4	4	2	6	0	0	1	9	0	2	2	2	0	4	3	5	4	1	1	1	0	1	1	0	1	2	1	1	4	2	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.25	0.25	2.142857	3.5	2.85			3.3	4	0.25	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV392KH4
2081	8976	NDAR_INVEV392KH4	2323			M	6000	EndofPhase3	18	Phase 3	508	0	1	0	0	0	0	0	6	3	3	2	2	2	3	4	1	2	1	9	2	4	1	4	3	6	2	4	5	1	1	1	0	1	1	0	1	2	1	1	2	3	4	1	1	1	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	1	3.2857144	4	3			3.3	4	0.25	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV392KH4
2081	8976	NDAR_INVEV446AAR	1493			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	0	0	1	6	3	5	5	0	2	2	9	3	2	4	4	4	4	2	6	6	1	0	1	0	1	1	2	1	3	1	0	4	3	3	4	1	0	0	1	0	0	0	0	1	1	1	1	1	8	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	4	3.25	1	4.142857	3	3.25	1		3.25	3.25	1	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV446AAR
2081	8976	NDAR_INVEV446AAR	1493			M	1600	Visit6	6	Phase 1/1A	174	1	0	0	0	0	0	0	6	0	0	0	5	2	2	2	0	0	0	9	2	2	4	4	0	4	2	2	4	0	0	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	1	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.125	0	2.5714285	3	2.05			3.25	3.25	1	4.142857	3	-1.2	-1.125	-1	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV446AAR
2081	8976	NDAR_INVEV446AAR	1493			M	2800	Visit12	12	Phase 1/1A	342	0	0	1	0	0	0	0	6	0	0	0	2	2	2	2	2	1	1	9	1	1	2	0	0	4	1	1	2	0	0	0	0	1	0	0	1	1	1	0	4	2	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1	1	2.5	1.5			3.25	3.25	1	4.142857	3	-1.75	-1.5	0	-3.142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV446AAR
2081	8976	NDAR_INVEV446AAR	1493			M	5200	EndofPhase1_1a	18	Phase 1/1A	496	1	0	1	0	0	0	0	4	0	2	0	2	0	2	0	1	1	1	9	0	0	4	2	0	5	2	2	4	0	0	1	0	1	1	0	1	1	1	0	4	2	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.75	1.7142857	3.5	1.6		1	3.25	3.25	1	4.142857	3	-1.65	-2	-0.25	-2.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV446AAR
2081	8976	NDAR_INVEV490HBK	1743			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	1	0	0	0	1	1	2	1	1	5	9	2	0	1	1	1	3	2	4	2	2	2	2	2	1	1	1	1	2	2	0	4	2	4	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	6	1.25	1.75	1.5714285	2.5	1.65	1		1.65	1.25	1.75	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV490HBK
2081	8976	NDAR_INVEV490HBK	1743			M	1600	Visit6	6	Phase 1/1A	161	0	0	1	0	0	0	0	1	0	0	0	0	0	2	0	0	1	0	9	1	2	1	0	0	2	1	1	1	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	4	0.375	0.25	0.85714287	1.5	0.65			1.65	1.25	1.75	1.5714285	2.5	-1	-0.875	-1.5	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV490HBK
2081	8976	NDAR_INVEV490HBK	1743			M	2800	Visit12	12	Phase 1/1A	344	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	5	9	1	0	0	1	1	0	0	0	0	0	1	1	0	1	1	1	1	1	3	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	0.125	1.25	0.42857143	0	0.45		1	1.65	1.25	1.75	1.5714285	2.5	-1.2	-1.125	-0.5	-1.1428572	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV490HBK
2081	8976	NDAR_INVEV605NTH	2542			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	4	4	2	1	2	2	0	2	2	3	9	5	3	4	2	2	4	3	4	5	1	1	1	1	0	1	0	1	3	1	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	2	2.25	1.75	3.5714285	3.5	2.85	1		2.85	2.25	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV605NTH
2081	8976	NDAR_INVEV605NTH	2542			F	1600	Visit6	6	Phase 2	193	0	0	0	0	0	0	1	4	4	5	4	3	4	3	0	2	4	2	9	1	2	3	2	3	4	3	4	5	0	0	1	1	1	1	0	1	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	2	3.375	2	2.857143	3.5	3.1			2.85	2.25	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV605NTH
2081	8976	NDAR_INVEV605NTH	2542			F	2800	Visit12	12	Phase 2	364	0	0	0	0	0	0	1	3	0	2	2	1	1	2	0	2	2	2	9	0	0	3	2	2	4	3	2	4	1	0	1	1	1	1	1	1	3	1	0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.375	1.5	1.8571428	3.5	1.85			2.85	2.25	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV605NTH
2081	8976	NDAR_INVEV605NTH	2542			F	5200	EndofPhase1_1a	2	Phase 1/1A	78	0	0	0	0	0	0	1	2	3	4	3	3	3	2	0	2	3	3	9	1	1	2	1	2	3	4	4	4	0	0	1	1	0	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	2.5	2	2.142857	3.5	2.5		1	2.85	2.25	1.75	3.5714285	3.5	-0.35	0.25	0.25	-1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV605NTH
2081	8976	NDAR_INVEV605NTH	2542			F	5800	EndofPhase2	18	Phase 2	518	0	0	0	0	0	0	1	4	1	3	2	2	2	2	0	2	2	1	9	0	3	4	3	2	4	3	2	4	0	1	1	1	1	1	1	1	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.25	2.5714285	3.5	2.3			2.85	2.25	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEV605NTH
2081	8976	NDAR_INVEW075KYL	1468			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	0	0	2	2	2	2	0	2	4	2	9	0	2	0	4	1	5	2	4	3	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	2	2	3.5	2.15	1		2.15	1.75	2	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW075KYL
2081	8976	NDAR_INVEW075KYL	1468			M	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	0	0	1	0	0	0	6	0	0	2	2	2	2	0	2	4	2	9	0	2	0	4	1	5	2	4	3	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	2	2	3.5	2.15		1	2.15	1.75	2	2	3.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW075KYL
2081	8976	NDAR_INVEW075KYL	1468			M	5800	EndofPhase2	4	Phase 2	114	0	0	0	1	0	0	0	4	0	0	0	2	0	2	0	2	4	6	9	4	4	4	4	2	5	2	5	4	1	0	1	0	1	1	1	1	1	1	0	4	3	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1	3	3.857143	3.5	2.7			2.15	1.75	2	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW075KYL
2081	8976	NDAR_INVEW075KYL	1468			M	6000	EndofPhase3	5	Phase 3	127	0	0	0	1	0	0	0	4	0	0	0	2	0	2	0	2	4	5	9	4	4	3	4	2	5	2	5	4	1	0	1	0	1	1	1	1	1	1	0	4	3	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	2.75	3.7142856	3.5	2.6			2.15	1.75	2	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW075KYL
2081	8976	NDAR_INVEW387JPR	1139			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	2	1	2	1	2	5	2	2	1	9	1	2	3	2	0	5	2	4	4	1	1	1	1	1	0	0	1	1	2	1	2	4	4	1	1	1	1	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	1.25	2.2857144	3.5	2.35	1		2.35	2.375	1.25	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW387JPR
2081	8976	NDAR_INVEW387JPR	1139			M	1600	Visit6	6	Phase 1B	189	0	1	0	0	0	0	0	5	1	2	2	2	2	2	4	1	2	1	9	0	2	0	3	1	3	1	3	4	1	1	1	0	1	1	1	1	2	1	1	3	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	1	1.8571428	2	2.05			2.35	2.375	1.25	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW387JPR
2081	8976	NDAR_INVEW387JPR	1139			M	2800	Visit12	12	Phase 1B	350	0	1	0	0	0	0	0	6	5	5	5	5	4	5	5	3	3	4	2	3	3	3	4	2	5	2	4	5	1	1	1	1	1	1	0	1	1	1	1	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	3	3.4285715	3.5	3.952381			2.35	2.375	1.25	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW387JPR
2081	8976	NDAR_INVEW387JPR	1139			M	5200	EndofPhase1_1a	3	Phase 1/1A	78	0	1	0	0	0	0	0	6	0	2	2	4	1	2	5	1	2	1	9	1	2	3	2	1	4	3	5	5	0	0	1	1	1	0	0	1	3	1	1	2	4	4	1	1	1	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.75	1	2.7142856	3.5	2.6		1	2.35	2.375	1.25	2.2857144	3.5	0.25	0.375	-0.25	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW387JPR
2081	8976	NDAR_INVEW387JPR	1139			M	5400	EndofPhase1b	18	Phase 1B	511	0	1	0	0	0	0	0	6	5	4	4	4	2	4	5	0	2	1	9	0	2	3	2	0	4	2	3	5	1	0	1	1	1	1	1	1	2	1	1	2	2	4	1	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	0.75	2.142857	3	2.9			2.35	2.375	1.25	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW387JPR
2081	8976	NDAR_INVEW387JPR	1139			M	5800	EndofPhase2	23	Phase 2	659	0	1	0	0	0	0	0	6	6	6	5	6	5	6	6	2	4	6	9	2	6	0	6	5	4	2	5	6	1	0	0	1	1	1	1	1	2	1	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	5.75	3	4.285714	3	4.7			2.35	2.375	1.25	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW387JPR
2081	8976	NDAR_INVEW452HZB	1752			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	1	2	2	2	1	3	1	1	2	9	4	3	2	4	0	2	5	3	6	1	1	0	0	1	1	1	1	1	2	0	4	3	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	2	1	3.142857	3.5	2.45	1		2.45	2	1	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW452HZB
2081	8976	NDAR_INVEW452HZB	1752			M	1600	Visit6	6	Phase 2	172	1	0	0	0	0	0	0	2	0	4	4	2	2	4	0	0	2	1	9	0	2	0	3	0	4	3	6	3	1	1	1	0	1	1	1	1	2	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0.75	2	3.5	2.1			2.45	2	1	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW452HZB
2081	8976	NDAR_INVEW452HZB	1752			M	2800	Visit12	12	Phase 2	339	1	0	0	0	0	0	0	3	0	2	2	2	2	2	0	0	2	3	9	2	3	0	4	0	4	4	5	4	1	1	0	0	1	1	0	1	2	1	1	3	4	2	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	1.25	2.5714285	4	2.2			2.45	2	1	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW452HZB
2081	8976	NDAR_INVEW452HZB	1752			M	5200	EndofPhase1_1a	1	Phase 1/1A	32	1	0	1	0	0	0	0	4	0	2	0	2	0	2	0	1	1	4	9	2	2	1	2	1	4	3	6	3	0	1	0	0	1	1	0	1	1	3	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	1.5	2.4285715	3.5	2		1	2.45	2	1	3.142857	3.5	-0.45	-0.75	0.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW452HZB
2081	8976	NDAR_INVEW452HZB	1752			M	5800	EndofPhase2	18	Phase 2	507	1	0	0	0	0	0	0	6	5	5	5	6	4	5	2	1	2	2	9	3	4	4	5	2	5	4	4	3	1	1	1	0	1	1	1	1	1	1	1	3	1	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	1.25	3.5714285	4.5	3.85			2.45	2	1	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW452HZB
2081	8976	NDAR_INVEW970LLD	1618			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	6	6	5	6	6	6	3	5	2	2	3	5	4	4	2	6	5	5	6	6	1	1	1	1	1	1	1	1	1	3	1	4	2	3	2	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	5	5.25	3	4.714286	5	4.6190476	1		4.6190476	5.25	3	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW970LLD
2081	8976	NDAR_INVEW970LLD	1618			F	1600	Visit6	6	Phase 1/1A	170	0	1	0	0	0	0	0	4	5	2	2	4	2	2	3	2	2	1	9	3	5	4	2	6	6	5	4	5	1	1	1	1	1	1	1	1	2	1	1	4	2	4	4	1	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3	1.25	4.142857	5.5	3.45			4.6190476	5.25	3	4.714286	5	-1.1690476	-2.25	-1.75	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW970LLD
2081	8976	NDAR_INVEW970LLD	1618			F	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	2	4	4	3	4	3	4	2	2	4	2	9	3	2	4	2	4	4	4	4	4	1	0	1	0	1	1	1	1	1	3	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	3.25	2	3.2857144	4	3.25			4.6190476	5.25	3	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW970LLD
2081	8976	NDAR_INVEW970LLD	1618			F	5200	EndofPhase1_1a	10	Phase 1/1A	275	0	1	0	0	0	0	0	3	3	5	5	4	3	1	3	5	2	1	1	3	5	4	2	6	6	5	6	4	1	1	1	1	1	1	1	1	2	3	1	3	2	2	1	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	1	0	0	1	1	1	1	5	3.375	2.25	4.285714	5.5	3.6666667		1	4.6190476	5.25	3	4.714286	5	-0.95238096	-1.875	-0.75	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW970LLD
2081	8976	NDAR_INVEW970LLD	1618			F	5800	EndofPhase2	18	Phase 2	527	0	1	0	0	0	0	0	2	0	4	2	2	2	2	2	2	4	2	9	2	2	3	2	3	4	5	4	4	0	0	1	0	1	1	1	1	1	3	0	4	4	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	2	2.857143	4.5	2.65			4.6190476	5.25	3	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEW970LLD
2081	8976	NDAR_INVEX008ZA4	2702			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	5	6	4	5	5	6	1	1	4	5	9	4	3	4	3	4	4	4	4	5	1	1	1	1	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.75	2.5	3.857143	4	4.15	1		4.15	4.75	2.5	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX008ZA4
2081	8976	NDAR_INVEX008ZA4	2702			M	5200	EndofPhase1_1a	18	Phase 1/1A	521	0	0	0	0	0	1	0	6	2	2	2	2	2	2	6	5	5	6	6	6	4	4	6	5	4	4	5	5	1	1	1	1	1	1	1	1	2	1	0	4	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3	5.5	5	4	4.2380953		1	4.15	4.75	2.5	3.857143	4	0.08809524	-1.75	3	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX008ZA4
2081	8976	NDAR_INVEX068AV0	1123			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	5	5	5	2	6	6	4	3	5	5	6	4	6	4	6	6	4	5	5	5	1	1	1	1	1	1	1	1	2	1	1	2	2	3	2	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.75	4.75	5.142857	4.5	4.857143	1		4.857143	4.75	4.75	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX068AV0
2081	8976	NDAR_INVEX068AV0	1123			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	0	4	4	5	6	6	2	2	2	2	9	3	3	2	4	3	3	4	2	4	1	1	1	1	1	1	1	1	3	2	1	3	2	3	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.125	1.5	3	3.5	3.35			4.857143	4.75	4.75	5.142857	4.5	-1.5071429	-0.625	-3.25	-2.142857	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX068AV0
2081	8976	NDAR_INVEX068AV0	1123			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	6	5	5	4	5	6	4	5	4	2	6	6	5	6	6	6	6	4	4	6	6	1	1	1	1	1	1	1	1	3		1	3	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5	4.5	5.857143	4	5.095238			4.857143	4.75	4.75	5.142857	4.5	0.23809524	0.25	-0.25	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX068AV0
2081	8976	NDAR_INVEX068AV0	1123			M	4000	Visit18	18	Phase 1/1A	492	0	0	0	0	0	1	0	6	6	6	6	6	6	6	2	2	4	6	9	4	6	4	6	6	5	3	6	6	1	1	1	1	1	1	1	1	3		1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	5.5	3	5.428571	4	5.1			4.857143	4.75	4.75	5.142857	4.5	0.24285714	0.75	-1.75	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX068AV0
2081	8976	NDAR_INVEX068AV0	1123			M	5200	EndofPhase1_1a	18	Phase 1/1A	492	0	0	0	0	0	1	0	6	6	6	6	6	6	6	2	2	4	6	9	4	6	4	6	6	5	3	6	6	1	1	1	1	1	1	1	1	3		1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	5.5	3	5.428571	4	5.1		1	4.857143	4.75	4.75	5.142857	4.5	0.24285714	0.75	-1.75	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX068AV0
2081	8976	NDAR_INVEX218GCQ	2673			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	0	0	0	0	0	0	0	0	1	9	0	0	0	0	0	3	1	0	0	1	0	1	0	1	1	1	1	1	1	1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.25	0	2	0.75	1		0.75	1.25	0.25	0	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEX218GCQ
2081	8976	NDAR_INVEY283XXR	1245			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	0	2	2	1	2	0	0	0	1	9	0	2	2	2	1	4	3	3	2	0	1	1	1	1	1	0	0	3	1	1	2	4	1	4	0	0	0	0	0	0	0	1					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.2857143	0.25	1.7142857	3.5	1.5263158	1		1.5263158	1.2857143	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY283XXR
2081	8976	NDAR_INVEY283XXR	1245			M	1600	Visit6	6	Phase 1/1A	165	0	0	0	0	0	0	1	9	2	2	1	1	2	3	0	1	1	3	9	1	2	4	3	2	3	3	3	4	1	1	1	1	1	1	1	0	3		1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5714285	1.25	2.7142856	3	2.1578948			1.5263158	1.2857143	0.25	1.7142857	3.5	0.6315789	0.2857143	1	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY283XXR
2081	8976	NDAR_INVEY283XXR	1245			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	9	3	3	1	2	1	2	0	4	6	5	6	4	5	4	3	5	5	4	4	6	0	1	1	1	1	1	0	1	3		1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	2	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.7142857	5.25	4.428571	4.5	3.65			1.5263158	1.2857143	0.25	1.7142857	3.5	2.1236842	0.42857143	5	2.7142856	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY283XXR
2081	8976	NDAR_INVEY283XXR	1245			M	4000	Visit18	18	Phase 1/1A	491	0	0	0	0	0	0	1	4	3	3	1	2	2	2	0	4	4	5	4	1	4	4	2	4	4	3	4	6	1	0	1	1	1	0	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	2.125	4.25	3.5714285	3.5	3.142857			1.5263158	1.2857143	0.25	1.7142857	3.5	1.6165414	0.83928573	4	1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY283XXR
2081	8976	NDAR_INVEY283XXR	1245			M	5200	EndofPhase1_1a	18	Phase 1/1A	491	0	0	0	0	0	1	0	4	3	3	1	2	2	2	0	4	4	5	4	1	4	4	2	4	4	3	4	6	1	0	1	1	1	0	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	2.125	4.25	3.5714285	3.5	3.142857		1	1.5263158	1.2857143	0.25	1.7142857	3.5	1.6165414	0.83928573	4	1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY283XXR
2081	8976	NDAR_INVEY411VH4	1734			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	6	0	4	2	4	4	4	0	0	0	9	2	0	4	0	4	6	3	4	6	1	1	1	1	1	1	1	1	1	3	1	3	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	3.375	0	2.857143	4.5	2.8	1		2.8	3.375	0	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY411VH4
2081	8976	NDAR_INVEY411VH4	1734			F	5200	EndofPhase1_1a	1	Phase 1/1A	36	0	1	0	0	0	0	0	4	6	6	6	6	6	4	6	6	6	6	9	2	3	6	4	3	6	3	4	6	1	1	1	1	1	1	1	1	1	2	1	3	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	5.5	4.5	4	4.5	4.95		1	2.8	3.375	0	2.857143	4.5	2.15	2.125	4.5	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVEY411VH4
2081	8976	NDAR_INVFA114VBR	1038			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	2	2	2	0	2	5	6	5	5	6	5	6	4	4	6	5	2	5	5	1	0	1	0	1	1	1	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	1	1	1	1	1	1	1	1	4	2.5	5.5	5	3.5	4	1		4	2.5	5.5	5	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA114VBR
2081	8976	NDAR_INVFA114VBR	1038			M	1600	Visit6	6	Phase 1/1A	174	0	1	0	0	0	0	0	6	0	2	2	2	0	6	5	6	5	5	6	4	4	0	5	6	6	2	5	6	1	0	1	0	1	1	1	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	5.5	4.285714	4	3.952381			4	2.5	5.5	5	3.5	-0.04761905	0.375	0	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA114VBR
2081	8976	NDAR_INVFA114VBR	1038			M	2800	Visit12	12	Phase 1/1A	359	0	1	0	0	0	0	0	5	0	2	2	2	0	0	5	5	4	5	6	2	3	2	4	6	6	1	3	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2	5	3.5714285	3.5	3.2380953		1	4	2.5	5.5	5	3.5	-0.7619048	-0.5	-0.5	-1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA114VBR
2081	8976	NDAR_INVFA190VV8	2433			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	0	0	1	0	1	0	1	2	1	9	2	2	0	2	2	3	3	3	6	1	1	0	0	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	0.625	1	2.4285715	3	1.6	1		1.6	0.625	1	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA190VV8
2081	8976	NDAR_INVFA190VV8	2433			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	1	0	4	0	1	0	1	2	2	0	2	5	6	9	4	5	0	2	0	4	2	4	5	0	1	0	0	1	1	1	1	3	1	0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.25	3.25	2.857143	3	2.45			1.6	0.625	1	2.4285715	3	0.85	0.625	2.25	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA190VV8
2081	8976	NDAR_INVFA190VV8	2433			F	2800	Visit12	12	Phase 1/1A	348	0	0	0	0	0	1	0	4	1	1	0	1	1	2	0	1	5	6	9	4	5	0	2	0	4	2	4	6	1	1	0	0	1	1	1	1	3	1	0	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.25	3	3	3	2.45			1.6	0.625	1	2.4285715	3	0.85	0.625	2	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA190VV8
2081	8976	NDAR_INVFA190VV8	2433			F	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	1	0	4	1	1	0	1	1	2	0	1	4	6	9	3	4	0	2	0	3	2	4	6	0	0	0	1	1	1	1	1	3	1	0	4	3	3	4	0	0	0	0	0	0	0	0					0		1	22	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	1.25	2.75	2.7142856	2.5	2.25		1	1.6	0.625	1	2.4285715	3	0.65	0.625	1.75	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA190VV8
2081	8976	NDAR_INVFA700LY3	2640			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	2	2	2	2	2	1	2	1	1	1	9	2	2	2	2	1	4	5	4	4	1	1	1	0	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	0.75	2.4285715	4.5	2.15	1		2.15	1.75	0.75	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA700LY3
2081	8976	NDAR_INVFA700LY3	2640			M	1600	Visit6	6	Phase 2	170	0	0	0	0	0	0	1	4	4	2	4	4	2	2	1	2	2	2	9	2	3	0	2	1	4	5	2	3	1	1	0	0	1	1	1	0	3		1	2	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.875	1.5	1.8571428	4.5	2.55			2.15	1.75	0.75	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA700LY3
2081	8976	NDAR_INVFA700LY3	2640			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	0	1	2	2	2	4	4	3	2	1	5	2	3	4	3	2	2	3	2	5	4	2	2	1	0	1	1	1	1	1	1	2	2	0	4	2	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.5	3.5	2.2857144	4.5	2.8095238			2.15	1.75	0.75	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA700LY3
2081	8976	NDAR_INVFA700LY3	2640			M	5200	EndofPhase1_1a	5	Phase 1/1A	140	0	0	0	0	0	0	1	6	5	4	1	2	2	2	2	1	1	1	9	3	2	3	4	2	5	2	5	5	1	1	1	0	0	0	1	0	3		1	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	4	3	0.75	3.4285715	3.5	2.9		1	2.15	1.75	0.75	2.4285715	4.5	0.75	1.25	0	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA700LY3
2081	8976	NDAR_INVFA700LY3	2640			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	0	0	1	4	1	2	4	4	2	4	3	3	3	2	3	2	2	2	1	2	4	4	3	4	1	1	1	0	1	0	0	1	3	2	1	3	2	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3	2.75	2.2857144	4	2.8095238			2.15	1.75	0.75	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFA700LY3
2081	8976	NDAR_INVFB106JZK	2771			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	1	2	1	3	1	0	2	0	0	0	9	1	1	0	0	1	1	4	3	3	1	0	0	0	1	0	0	0	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.875	0	1.2857143	2.5	1.45	1		1.45	1.875	0	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB106JZK
2081	8976	NDAR_INVFB106JZK	2771			M	1600	Visit6	6	Phase 1/1A	185	0	1	0	0	0	0	0	4	2	2	2	2	2	2	2	0	0	0	9	1	0	4	2	0	1	2	2	4	1	1	0	0	1	0	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0	1.8571428	1.5	1.7			1.45	1.875	0	1.2857143	2.5	0.25	0.375	0	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB106JZK
2081	8976	NDAR_INVFB106JZK	2771			M	2800	Visit12	12	Phase 1/1A	367	0	1	0	0	0	0	0	4	0	0	0	3	1	1	2	0	0	0	9	2	1	1	2	3	2	4	2	6	1	1	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	0	2.4285715	3	1.7			1.45	1.875	0	1.2857143	2.5	0.25	-0.5	0	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB106JZK
2081	8976	NDAR_INVFB106JZK	2771			M	5200	EndofPhase1_1a	18	Phase 1/1A	548	0	1	0	0	0	0	0	2	0	0	1	2	0	2	2	0	0	0	9	3	2	3	3	5	1	3	3	6	1	0	1	0	0	0	0	1	1	2	0	4	4	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0	3.5714285	2	1.9		1	1.45	1.875	0	1.2857143	2.5	0.45	-0.75	0	2.2857144	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB106JZK
2081	8976	NDAR_INVFB525EHZ	1546			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	4	2	2	3	2	2	1	1	4	1	9	0	2	2	3	1	5	3	6	5	1	0	1	0	1	1	1	1	2	1	1	3	1	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.75	1.5	2.7142856	4	2.75	1		2.75	2.75	1.5	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB525EHZ
2081	8976	NDAR_INVFB525EHZ	1546			M	1600	Visit6	6	Phase 1/1A	198	0	0	1	0	0	0	0	6	4	4	0	4	2	4	0	1	2	1	9	0	2	2	2	1	5	3	4	4	1	1	1	0	1	1	1	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	1	2.142857	4	2.55			2.75	2.75	1.5	2.7142856	4	-0.2	0.25	-0.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB525EHZ
2081	8976	NDAR_INVFB525EHZ	1546			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	9	0	4	4	3	6	5	1	1	5	5	9	0	4	0	2	4	5	3	6	6	1	1	1	0	1	1	1	1	2	2	0	4	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.2857144	2.75	3.142857	4	3.368421			2.75	2.75	1.5	2.7142856	4	0.6184211	0.53571427	1.25	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB525EHZ
2081	8976	NDAR_INVFB525EHZ	1546			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	0	4	4	3	6	5	1	1	5	5	9	0	3	3	2	4	5	3	6	6	1	0	1	0	1	1	1	1	2	2	1	3	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.2857144	2.75	3.4285715	4	3.4736843		1	2.75	2.75	1.5	2.7142856	4	0.7236842	0.53571427	1.25	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFB525EHZ
2081	8976	NDAR_INVFC014VBM	1577			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	4	4	4	1	5	3	4	2	1	4	9	1	4	4	3	4	2	2	2	4	0	0	0	0	1	1	0	1	3	3	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	3.375	1.75	3.142857	2	3	1		3	3.375	1.75	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC014VBM
2081	8976	NDAR_INVFC014VBM	1577			F	1600	Visit6	6	Phase 2	168	0	0	0	0	0	1	0	3	2	3	2	2	1	2	3	3	2	1	3	1	3	4	1	5	3	3	2	2	2	0	0	0	1	1	2	2	3	3	1	3	2	4	2	0	0	0	0	0	0	0	1	2	2	2	2	0		0		1	30	0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	3	2.25	2.25	2.5714285	3	2.4285715			3	3.375	1.75	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC014VBM
2081	8976	NDAR_INVFC014VBM	1577			F	2800	Visit12	12	Phase 2	336	0	0	0	0	0	1	0	2	0	1	2	1	2	2	3	0	0	2	9	2	2	2	2	0	2	0	0	2	0	1	0	0	0	0	0	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	1.625	0.5	1.4285715	1	1.35			3	3.375	1.75	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC014VBM
2081	8976	NDAR_INVFC014VBM	1577			F	4000	Visit18	18	Phase 3	468	0	0	0	0	0	1	0	2	0	0	0	1	0	0	2	0	0	0	9	0	1	1	2	0	3	2	1	1	1	0	0	0	1	1	0	0	3		0	4	2	2	2	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	0.625	0	0.85714287	2.5	0.8			3	3.375	1.75	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC014VBM
2081	8976	NDAR_INVFC014VBM	1577			F	5200	EndofPhase1_1a	5	Phase 1/1A	140	0	0	0	0	0	1	0	2	2	3	2	2	0	2	2	1	1	1	9	3	3	1	2	2	3	2	2	4	1	0	2	2	1	1	0	1	3	3	1	4	4	4	2	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		2	2	2	0	0	0	1	0	0	0	0	1	1	1	1	1	4	1.875	0.75	2.4285715	2.5	2		1	3	3.375	1.75	3.142857	2	-1	-1.5	-1	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC014VBM
2081	8976	NDAR_INVFC014VBM	1577			F	5800	EndofPhase2	14	Phase 2	371	0	0	0	0	0	1	0	0	0	1	1	1	0	2	0	0	0	0	9	0	1	0	2	0	3	2	0	2	1	1	0	0	1	1	1	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	0.625	0	0.71428573	2.5	0.75			3	3.375	1.75	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC014VBM
2081	8976	NDAR_INVFC408CBV	1517			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	2	1	2	3	4	9	2	2	3	4	2	5	5	4	4	1	1	1	0	1	0	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	2.25	3	5	2.75	1		2.75	1.875	2.25	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC408CBV
2081	8976	NDAR_INVFC408CBV	1517			M	1600	Visit6	6	Phase 2	168	1	0	0	0	0	0	0	5	2	2	2	2	2	2	0	3	4	6	5	3	2	3	4	2	6	5	4	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.125	4.5	3.142857	5.5	3.2380953			2.75	1.875	2.25	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC408CBV
2081	8976	NDAR_INVFC408CBV	1517			M	2800	Visit12	12	Phase 2	336	1	0	0	0	0	0	0	5	0	0	0	2	2	2	1	4	3	6	2	2	2	4	3	2	6	5	4	4	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	0	5	1.5	3.75	3	5.5	2.8095238			2.75	1.875	2.25	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC408CBV
2081	8976	NDAR_INVFC408CBV	1517			M	5200	EndofPhase1_1a	1	Phase 1/1A	27	1	0	0	0	0	0	0	4	0	0	2	2	2	2	0	3	2	5	4	2	2	3	2	2	6	5	3	3	1	1	1	1	1	1	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	1.5	3.5	2.4285715	5.5	2.5714285		1	2.75	1.875	2.25	3	5	-0.17857143	-0.375	1.25	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC408CBV
2081	8976	NDAR_INVFC408CBV	1517			M	5800	EndofPhase2	18	Phase 2	505	1	0	0	0	0	0	0	6	4	4	4	2	3	4	3	4	4	6	4	2	2	3	4	2	5	4	3	5	1	1	1	1	1	1	1	1	3	2	1	3	2	3	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	3.75	4.5	3	4.5	3.7142856			2.75	1.875	2.25	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC408CBV
2081	8976	NDAR_INVFC775WR9	2735			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	2	2	0	2	0	0	2	6	9	2	1	0	4	0	4	2	4	4	0	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1	2	2.142857	3	1.85	1		1.85	1	2	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFC775WR9
2081	8976	NDAR_INVFD288JZ1	2679			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	6	2	2	4	6	4	1	6	5	6	4	6	6	4	4	4	4	4	5	6	1	1	1	1	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	5.25	5	4	4.2380953	1		4.2380953	3.125	5.25	5	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD288JZ1
2081	8976	NDAR_INVFD288JZ1	2679			F	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	9	6	6	6	6	5	6	6	6	6	6	6	6	5	5	5	6	5	4	5	6	1	1	1	1	1	0	0	1	3		1	3	2	2	2	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.857143	6	5.428571	4.5	5.6			4.2380953	3.125	5.25	5	4	1.3619047	2.732143	0.75	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD288JZ1
2081	8976	NDAR_INVFD288JZ1	2679			F	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	0	1	0	0	0	4	4	2	4	2	6	6	5	6	4	6	6	6	6	6	6	6	6	1	1	1	1	1	0	1	1	3		1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	2	5.75	5.714286	6	4.3333335			4.2380953	3.125	5.25	5	4	0.0952381	-1.125	0.5	0.71428573	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD288JZ1
2081	8976	NDAR_INVFD288JZ1	2679			F	5200	EndofPhase1_1a	18	Phase 1/1A	520	0	0	0	0	0	0	1	9	4	0	1	0	1	1	0	6	5	5	3	5	2	4	4	5	5	3	3	6	1	0	1	1	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	1	1	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1	4.75	4.142857	4	3.15		1	4.2380953	3.125	5.25	5	4	-1.0880952	-2.125	-0.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD288JZ1
2081	8976	NDAR_INVFD366KRE	2212			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	1	0	2	2	2	1	3	4	4	4	4	5	1	3	5	6	4	4	4	1	0	1	0	1	1	0	1	2	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	1.75	3.75	3.7142856	5	3.0952382	1		3.0952382	1.75	3.75	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD366KRE
2081	8976	NDAR_INVFD366KRE	2212			F	1600	Visit6	6	Phase 2	129	0	0	0	0	0	0	1	4	3	0	2	1	2	2	0	3	3	3	5	4	4	2	4	5	6	4	5	4	1	1	1	1	1	1	1	1	2	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	5	1.75	3.5	4	5	3.142857			3.0952382	1.75	3.75	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD366KRE
2081	8976	NDAR_INVFD366KRE	2212			F	5800	EndofPhase2	8	Phase 2	173	0	0	0	0	0	0	1	4	3	1	2	1	2	2	0	3	4	4	5	4	4	2	4	5	6	3	5	4	1	1	1	0	1	1	1	1	2	1	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	1.875	4	4	4.5	3.2380953			3.0952382	1.75	3.75	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFD366KRE
2081	8976	NDAR_INVFE685JVP	2449			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	6	4	6	6	4	4	0	0	0	0	9	2	4	4	6	6	6	4	6	6	1	0	1	0	1	1	1	1	2	2	1	3	4	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	1	0	1	0	0	1	1	1	1	4	3.75	0	4.857143	5	3.7	1		3.7	3.75	0	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFE685JVP
2081	8976	NDAR_INVFE685JVP	2449			F	5200	EndofPhase1_1a	1	Phase 1/1A	102	0	0	0	0	0	0	1	9	6	6	6	6	6	6	0	0	0	1	9	2	4	4	6	6	5	3	6	6	1	0	1	0	1	1	0	1	2	2	1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	5.142857	0.25	4.857143	4	4.1578946		1	3.7	3.75	0	4.857143	5	0.45789474	1.3928572	0.25	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFE685JVP
2081	8976	NDAR_INVFE862RVR	2668			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	2	1	1	2	1	2	2	1	1	1	9	1	2	2	2	2	6	1	3	3	2	2	2	1	1	2	2	2	3		0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0.75	2.142857	3.5	1.95	1		1.95	1.75	0.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFE862RVR
2081	8976	NDAR_INVFE862RVR	2668			M	1600	Visit6	6	Phase 2	193	0	1	0	0	0	0	0	4	3	2	2	2	2	2	3	1	2	2	9	2	2	2	2	2	6	1	4	2	0	0	0	0	1	1	0	0	1	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	15	0		0		1	15	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	1.25	2.2857144	3.5	2.4			1.95	1.75	0.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFE862RVR
2081	8976	NDAR_INVFE862RVR	2668			M	5200	EndofPhase1_1a	3	Phase 1/1A	75	0	1	0	0	0	0	0	3	2	3	2	2	2	2	4	2	2	2	9	2	2	2	3	2	5	1	3	3	0	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1.5	2.4285715	3	2.45		1	1.95	1.75	0.75	2.142857	3.5	0.5	0.75	0.75	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFE862RVR
2081	8976	NDAR_INVFF105HRL	1902			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	3	3	2	1	1	1	1	0	1	9	2	2	3	4	1	6	3	4	6	1	1	1	0	1	1	1	1	2	1	0	4	2	2	2	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0.5	3.142857	4.5	2.5	1		2.5	2.125	0.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF105HRL
2081	8976	NDAR_INVFF105HRL	1902			M	1600	Visit6	6	Phase 1B	168	0	0	0	0	0	0	1	6	3	4	3	4	3	2	1	1	1	1	9	2	2	4	3	2	4	5	5	4	1	0	1	0	1	0	1	1	2	2	1	4	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	0.75	3.142857	4.5	3			2.5	2.125	0.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF105HRL
2081	8976	NDAR_INVFF105HRL	1902			M	5200	EndofPhase1_1a	2	Phase 1/1A	43	0	0	0	0	0	0	1	4	2	3	3	2	1	1	1	1	0	1	9	2	2	3	4	1	5	2	4	6	1	1	1	0	1	1	1	1	2	1	0	4	2	2	2	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0.5	3.142857	3.5	2.4		1	2.5	2.125	0.5	3.142857	4.5	-0.1	0	0	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF105HRL
2081	8976	NDAR_INVFF105HRL	1902			M	5400	EndofPhase1b	9	Phase 1B	253	0	0	0	0	0	0	1	5	5	3	3	4	2	3	1	0	1	1	9	2	4	4	5	2	6	3	4	5	1	0	1	0	1	1	1	1	2	1	1	4	3	2	4	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	0.5	3.7142856	4.5	3.15			2.5	2.125	0.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF105HRL
2081	8976	NDAR_INVFF105HRL	1902			M	5800	EndofPhase2	11	Phase 2	300	0	0	0	0	0	0	1	4	2	2	3	4	3	4	1	0	0	0	9	3	4	4	5	4	5	3	4	5	1	0	1	0	1	0	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	0	4.142857	4	3			2.5	2.125	0.5	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF105HRL
2081	8976	NDAR_INVFF185LGD	2213			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	1	3	1	2	0	2	4	0	0	0	9	4	3	2	3	2	2	2	2	3	0	0	0	0	1	1	1	1	1	2	1	2	4	4	1	1	0	0	0	0	0	1	0	0	0	1	0	1	10	0		0		1	20	0		0	1	0	0	0	0	0	1	0	0	1	0	1	1	1	1	7	2.25	0	2.7142856	2	2.05	1		2.05	2.25	0	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF185LGD
2081	8976	NDAR_INVFF185LGD	2213			M	1600	Visit6	6	Phase 2	169	0	1	0	0	0	0	0	4	0	0	0	1	0	2	4	0	0	0	9	0	0	0	3	2	4	3	3	3	1	1	1	0	1	1	0	1	1	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	0	1.5714285	3.5	1.45			2.05	2.25	0	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF185LGD
2081	8976	NDAR_INVFF185LGD	2213			M	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	1	0	0	0	0	0	2	0	0	0	1	0	2	3	1	0	0	9	1	0	0	3	2	2	2	2	4	1	0	0	0	1	2	2	2	3	2	0	4	4	4	1	1	0	0	0	0	0	1	0	1	0	0	0	1	6	0		0		0		1	11	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	4	1	0.25	1.7142857	2	1.25		1	2.05	2.25	0	2.7142856	2	-0.8	-1.25	0.25	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF185LGD
2081	8976	NDAR_INVFF185LGD	2213			M	5800	EndofPhase2	6	Phase 2	201	0	1	0	0	0	0	0	2	0	0	0	1	0	0	2	0	0	0	9	0	0	0	2	2	4	2	1	2	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	22	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.625	0	1	3	0.9			2.05	2.25	0	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF185LGD
2081	8976	NDAR_INVFF260EBV	2349			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	2	1	3	3	2	2	2	1	1	2	2	2	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	8	0		0		1	22	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2	1.5	2.2857144	1.5	2.05	1		2.05	2	1.5	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF260EBV
2081	8976	NDAR_INVFF572DXB	1055			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	1	2	2	2	4	0	0	0	9	2	6	4	6	6	3	3	4	6	1	1	2	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	28	0		1	2	0	2	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.375	0	4.857143	3	2.55	1		2.55	1.375	0	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF572DXB
2081	8976	NDAR_INVFF572DXB	1055			M	5200	EndofPhase1_1a	1	Phase 1/1A	12	0	0	0	0	0	0	1	0	0	0	1	1	0	1	2	0	0	1	9	2	2	4	3	0	3	3	2	6	1	0	2	1	1	1	1	1	3		1	2	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	5	0.625	0.25	2.7142856	3	1.55		1	2.55	1.375	0	4.857143	3	-1	-0.75	0.25	-2.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF572DXB
2081	8976	NDAR_INVFF641KMM	2223			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	4	0	3	2	0	0	2	5	4	9	3	4	4	0	4	5	2	4	4	1	0	1	0	1	1	0	0	1	1	1	3	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	3	1.875	2.75	3.2857144	3.5	2.8	1		2.8	1.875	2.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF641KMM
2081	8976	NDAR_INVFF641KMM	2223			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	4	4	4	3	1	0	2	1	1	1	3	9	2	2	4	3	4	5	3	2	5	1	1	1	0	1	1	0	0	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	1.25	3.142857	4	2.7			2.8	1.875	2.75	3.2857144	3.5	-0.1	0.5	-1.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF641KMM
2081	8976	NDAR_INVFF641KMM	2223			M	5200	EndofPhase1_1a	10	Phase 1/1A	269	1	0	0	0	0	0	0	4	0	3	0	2	0	3	1	0	1	3	9	2	2	4	1	2	5	2	3	5	1	0	0	1	1	1	0	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.625	1	2.7142856	3.5	2.15		1	2.8	1.875	2.75	3.2857144	3.5	-0.65	-0.25	-1.75	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF641KMM
2081	8976	NDAR_INVFF888HC8	2000			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	2	2	4	3	5	2	0	5	6	9	5	5	1	5	5	3	1	6	5	2	2	2	2	1	1	1	1	3	1	1	4	4	4	4	1	0	1	0	0	0	0	0	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.5	2.75	4.571429	2	3.75	1		3.75	3.5	2.75	4.571429	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF888HC8
2081	8976	NDAR_INVFF888HC8	2000			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	6	6	4	5	5	5	5	4	5	4	4	3	5	4	4	4	5	2	2	4	4	2	2	2	2	1	1	1	1	3	1	1	4	3	3	3	1	0	1	0	0	0	0	0	0	0	0	0	0		0		0		1	30	0		0	0	0	0	1	0	0	1	0	0	0	0	0	1	1	0	7	5	4	4.285714	2	4.285714			3.75	3.5	2.75	4.571429	2	0.53571427	1.5	1.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF888HC8
2081	8976	NDAR_INVFF888HC8	2000			M	2800	Visit12	12	Phase 2	322	0	0	0	0	0	1	0	6	1	1	4	2	3	4	3	5	2	3	9	5	5	4	4	4	1	3	4	3	2	2	2	2	1	1	1	1	3	1	1	4	4	4	4	1	0	1	0	0	0	0	0	2	2	2	2	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3	2.5	4.142857	2	3.35			3.75	3.5	2.75	4.571429	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF888HC8
2081	8976	NDAR_INVFF888HC8	2000			M	5200	EndofPhase1_1a	9	Phase 1/1A	244	0	0	0	0	0	1	0	6	1	1	1	4	1	6	6	4	4	5	9	6	3	3	4	5	3	0	6	5	2	2	2	2	1	1	1	1	3		1	4	4	4	4	1	0	1	0	0	0	0	0	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.25	3.25	4.571429	1.5	3.7		1	3.75	3.5	2.75	4.571429	2	-0.05	-0.25	0.5	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF888HC8
2081	8976	NDAR_INVFF888HC8	2000			M	5800	EndofPhase2	13	Phase 2	336	0	0	0	0	0	1	0	6	2	3	3	4	4	3	3	1	2	1	9	3	3	3	3	4	4	2	3	3	2	2	2	2	1	1	1	1	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	2	0	0	1	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.5	1	3.142857	3	3			3.75	3.5	2.75	4.571429	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF888HC8
2081	8976	NDAR_INVFF888HC8	2000			M	6000	EndofPhase3	18	Phase 3	495	0	0	0	0	0	1	0	3	5	3	3	3	1	3	2	1	1	3	9	1	2	3	2	3	2	1	3	1	2	2	2	2	1	1	1	1	3	1	1	2	4	4	4	1	0	0	0	0	0	1	0	1	2	1	1	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.875	1.25	2.142857	1.5	2.3			3.75	3.5	2.75	4.571429	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFF888HC8
2081	8976	NDAR_INVFG064XXW	1026			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	2	0	9	0	2	4	2	0	1	2	1	4	2	1	0	0	1	0	0	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0	0.5	1.8571428	1.5	0.9	1		0.9	0	0.5	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG064XXW
2081	8976	NDAR_INVFG064XXW	1026			M	5200	EndofPhase1_1a	2	Phase 1/1A	75	0	0	0	1	0	1	0	4	0	0	1	2	1	2	0	0	1	0	9	0	2	4	0	0	3	2	2	4	1	0	0	0	0	1	0	1	1	2	0	4	4	4	4	1	0	1	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.25	1.7142857	2.5	1.4		1	0.9	0	0.5	1.8571428	1.5	0.5	1.25	-0.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG064XXW
2081	8976	NDAR_INVFG252HVR	2142			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	0	2	0	0	0	0	9	1	2	4	6	0	4	3	2	3	1	0	1	1	1	1	1	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.5	0	2.5714285	3.5	1.85	1		1.85	1.5	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG252HVR
2081	8976	NDAR_INVFG252HVR	2142			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	0	1	6	6	6	4	4	6	6	4	0	0	0	9	0	2	2	6	0	5	3	4	6	1	0	1	0	1	1	1	1	2	1	1	3	1	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.25	0	2.857143	4	3.5			1.85	1.5	0	2.5714285	3.5	1.65	3.75	0	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG252HVR
2081	8976	NDAR_INVFG252HVR	2142			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	6	6	4	4	5	4	6	6	2	4	4	9	4	4	4	6	3	4	3	4	6	1	1	1	1	1	1	0	1	1	1	1	3	1	3	1	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	5.125	2.5	4.428571	3.5	4.45			1.85	1.5	0	2.5714285	3.5	2.6	3.625	2.5	1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG252HVR
2081	8976	NDAR_INVFG252HVR	2142			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	0	0	0	0	1	6	4	2	4	4	2	2	6	3	4	4	4	4	4	4	4	2	4	2	4	5	1	0	1	1	1	0	0	0	1	2	1	3	3	3	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	4	3.75	3.75	3.857143	3	3.7142856		1	1.85	1.5	0	2.5714285	3.5	1.8642857	2.25	3.75	1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG252HVR
2081	8976	NDAR_INVFG255EWG	2153			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	6	2	1	2	0	0	3	0	0	1	9	2	2	1	4	0	6	4	6	6	1	0	1	0	1	1	1	1	3	1	1	4	1	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	6	2.375	0.25	3	5	2.55	1		2.55	2.375	0.25	3	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG255EWG
2081	8976	NDAR_INVFG255EWG	2153			F	1600	Visit6	6	Phase 1/1A	182	0	0	0	0	0	0	1	5	4	5	4	2	6	5	2	2	4	6	9	3	3	0	6	2	6	3	5	5	1	0	1	0	1	1	1	1	3		1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	6	4.125	3	3.4285715	4.5	3.9			2.55	2.375	0.25	3	5	1.35	1.75	2.75	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG255EWG
2081	8976	NDAR_INVFG255EWG	2153			F	5200	EndofPhase1_1a	7	Phase 1/1A	197	0	0	0	0	0	0	1	6	4	3	4	6	1	6	3	2	2	6	9	0	3	0	6	2	6	3	3	4	1	0	1	0	1	1	0	1	2	1	1	3	1	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	6	4.125	2.5	2.5714285	4.5	3.5		1	2.55	2.375	0.25	3	5	0.95	1.75	2.25	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG255EWG
2081	8976	NDAR_INVFG705FDW	1007			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	2	1	5	2	2	2	0	0	2	9	2	2	2	4	1	3	1	4	3	0	0	1	0	1	1	1	1	1	2	1	3	2	3	4	1	0	1	1	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.75	0.5	2.5714285	2	2.3	1		2.3	2.75	0.5	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG705FDW
2081	8976	NDAR_INVFG705FDW	1007			M	1600	Visit6	6	Phase 1/1A	177	1	0	0	0	0	0	0	6	0	0	2	2	0	2	1	1	1	1	9	0	0	2	2	0	4	3	2	6	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	0.75	1.7142857	3.5	1.75			2.3	2.75	0.5	2.5714285	2	-0.55	-1.125	0.25	-0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG705FDW
2081	8976	NDAR_INVFG705FDW	1007			M	2800	Visit12	12	Phase 1/1A	392	1	0	0	0	0	0	0	6	6	6	6	6	4	4	1	0	0	2	9	2	3	2	2	2	4	3	4	5	1	1	0	0	1	1	1	1	1	1	1	2	2	2	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	0.5	2.857143	3.5	3.4		1	2.3	2.75	0.5	2.5714285	2	1.1	2.125	0	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG705FDW
2081	8976	NDAR_INVFG756JHZ	1265			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	6	6	6	6	6	0	0	6	9	0	6	4	6	4	4	4	3	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	6	1.5	4.142857	4	4.55	1		4.55	6	1.5	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG756JHZ
2081	8976	NDAR_INVFG756JHZ	1265			M	1600	Visit6	6	Phase 1/1A	179	1	0	0	0	0	0	0	6	4	4	4	4	4	4	4	4	3	6	5	3	4	4	6	3	4	4	6	5	1	1	0	1	1	1	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.25	4.5	4.428571	4	4.3333335			4.55	6	1.5	4.142857	4	-0.21666667	-1.75	3	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG756JHZ
2081	8976	NDAR_INVFG756JHZ	1265			M	2800	Visit12	12	Phase 1/1A	353	1	0	0	0	0	0	0	4	4	4	3	4	4	3	4	4	4	6	6	4	4	4	6	4	3	4	4	6	1	1	1	0	1	1	1	1	1	1	1	4	4	4	3	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	3.75	5	4.571429	3.5	4.2380953			4.55	6	1.5	4.142857	4	-0.31190476	-2.25	3.5	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG756JHZ
2081	8976	NDAR_INVFG756JHZ	1265			M	5200	EndofPhase1_1a	18	Phase 1/1A	492	1	0	0	0	0	0	0	5	4	5	6	5	5	5	4	4	4	6	4	3	4	4	6	5	4	2	5	4	1	1	1	0	1	1	1	1	1	1	1	2	1	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	4.875	4.5	4.428571	3	4.4761906		1	4.55	6	1.5	4.142857	4	-0.07380953	-1.125	3	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG756JHZ
2081	8976	NDAR_INVFG996LA6	2809			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	5	4	4	5	6	5	3	0	0	2	9	3	2	3	4	1	3	2	5	4	0	0	1	1	1	1	0	1	3	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	4.5	0.5	3.142857	2.5	3.25	1		3.25	4.5	0.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG996LA6
2081	8976	NDAR_INVFG996LA6	2809			M	1600	Visit6	6	Phase 1/1A	181	0	1	0	0	0	0	0	3	1	4	1	2	0	2	3	0	0	0	9	0	0	1	2	1	3	2	4	2	0	1	1	0	1	1	1	1	2	2	1	4	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2	0	1.4285715	2.5	1.55			3.25	4.5	0.5	3.142857	2.5	-1.7	-2.5	-0.5	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG996LA6
2081	8976	NDAR_INVFG996LA6	2809			M	5200	EndofPhase1_1a	9	Phase 1/1A	280	0	1	0	0	0	0	0	6	3	0	1	4	2	5	3	3	3	1	3	1	4	4	2	4	2	2	2	4	1	0	1	0	1	1	0	1	1	1	1	3	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	3	3	2.5	3	2	2.8095238		1	3.25	4.5	0.5	3.142857	2.5	-0.44047618	-1.5	2	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFG996LA6
2081	8976	NDAR_INVFH529HX9	1874			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	4	1	0	2	3	2	2	0	1	2	9	0	2	3	3	6	4	1	5	6	2	0	0	2	1	1	1	1	3		1	4	2	2	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	1	1.875	0.75	3.5714285	2.5	2.4	1		2.4	1.875	0.75	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFH529HX9
2081	8976	NDAR_INVFJ190ZUF	1584			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	2	3	4	5	6	3	0	2	1	9	3	3	6	5	2	3	4	4	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	0.75	4.142857	3.5	3.7	1		3.7	4.375	0.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ190ZUF
2081	8976	NDAR_INVFJ190ZUF	1584			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	6	6	5	5	6	5	5	2	2	3	5	9	3	5	4	5	5	4	4	5	5	1	1	1	1	1	1	1	1	1	1	1	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	5	2.5	4.571429	4	4.5			3.7	4.375	0.75	4.142857	3.5	0.8	0.625	1.75	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ190ZUF
2081	8976	NDAR_INVFJ190ZUF	1584			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	6	6	6	6	6	6	6	3	5	3	3	9	5	4	6	5	6	5	5	6	6	1	1	0	1	1	1	0	1	1	1	1	3	2	1	2	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	5.625	2.75	5.428571	5	5.2			3.7	4.375	0.75	4.142857	3.5	1.5	1.25	2	1.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ190ZUF
2081	8976	NDAR_INVFJ190ZUF	1584			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	1	0	0	0	0	0	0	6	6	6	6	6	6	6	6	6	6	6	6	6	6	3	6	6	4	4	6	6	0	1	1	1	1	1	1	1	1	2	1	2	1	1	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	6	6	5.571429	4	5.6666665		1	3.7	4.375	0.75	4.142857	3.5	1.9666667	1.625	5.25	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ190ZUF
2081	8976	NDAR_INVFJ285HT0	1537			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	0	2	4	3	0	0	2	4	9	0	2	4	4	4	3	3	4	5	0	0	0	1	1	1	1	1	1	3	1	4	4	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.625	1.5	3.2857144	3	2.4	1		2.4	1.625	1.5	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ285HT0
2081	8976	NDAR_INVFJ285HT0	1537			M	4000	Visit18	18	Phase 2	382	1	0	0	0	0	0	0	2	2	0	0	1	2	0	0	0	0	0	9	2	2	0	2	0	3	1	4	4	0	0	0	0	1	1	1	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.875	0	2	2	1.25			2.4	1.625	1.5	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ285HT0
2081	8976	NDAR_INVFJ285HT0	1537			M	5200	EndofPhase1_1a	6	Phase 1/1A	156	1	0	0	0	0	0	0	2	0	0	0	2	2	2	0	2	2	4	9	2	2	2	2	4	3	2	4	4	1	0	1	0	1	1	1	1	1	3	1	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	2	2.857143	2.5	2.05		1	2.4	1.625	1.5	3.2857144	3	-0.35	-0.625	0.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ285HT0
2081	8976	NDAR_INVFJ285HT0	1537			M	5800	EndofPhase2	21	Phase 2	458	1	0	0	0	0	0	0	2	0	0	0	0	0	2	0	1	0	0	9	2	2	2	2	4	3	2	2	4	0	0	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	0.5	0.25	2.5714285	2.5	1.4			2.4	1.625	1.5	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ285HT0
2081	8976	NDAR_INVFJ435WLH	1047			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	2	0	6	2	6	1	2	0	1	5	2	3	4	6	2	2	4	5	5	1	1	2	0	1	1	1	2	1	2	1	4	3	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	17	0		0		1	13	0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	3	2	3.857143	3	3.0952382	1		3.0952382	3	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ435WLH
2081	8976	NDAR_INVFJ435WLH	1047			M	2800	Visit12	12	Phase 3	336	1	0	0	0	0	0	0	4	0	0	0	2	1	5	1	4	4	4	5	3	4	3	4	4	4	2	2	5	1	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1.625	4.25	3.5714285	3	2.9047618			3.0952382	3	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ435WLH
2081	8976	NDAR_INVFJ435WLH	1047			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	0	0	0	0	0	1	0	2	1	3	2	2	0	5	2	2	2	1	9	2	4	4	4	1	3	2	3	3	1	1	1	2	1	1	1	1	3	1	1	4	1	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.125	1.25	3	2.5	2.4		1	3.0952382	3	2	3.857143	3	-0.6952381	-0.875	-0.75	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ435WLH
2081	8976	NDAR_INVFJ435WLH	1047			M	5800	EndofPhase2	10	Phase 2	283	1	0	0	0	0	0	0	2	0	0	2	2	0	5	1	3	4	4	5	3	4	3	3	4	4	2	3	3	1	1	0	1	1	1	0	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.5	4	3.2857144	3	2.7142856			3.0952382	3	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ435WLH
2081	8976	NDAR_INVFJ435WLH	1047			M	6000	EndofPhase3	18	Phase 3	504	1	0	0	0	0	0	0	3	2	4	2	2	1	6	1	4	4	4	9	3	4	4	4	5	4	4	3	4	1	1	2	1	1	1	2	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.625	3	3.857143	4	3.4			3.0952382	3	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ435WLH
2081	8976	NDAR_INVFJ584WFN	1673			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	1	1	2	0	1	0	0	0	0	9	0	0	2	0	0	5	1	1	2	1	0	1	0	1	1	1	1	2	1	0	4	4	3	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0	0.71428573	3	1	1		1	1.125	0	0.71428573	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ584WFN
2081	8976	NDAR_INVFJ584WFN	1673			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	0	0	0	9	0	0	0	2	1	2	2	2	2	1	0	1	0	1	1	1	1	1	2	1	3	4	4	3	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.375	0	1	2	0.7			1	1.125	0	0.71428573	3	-0.3	-0.75	0	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ584WFN
2081	8976	NDAR_INVFJ584WFN	1673			M	5200	EndofPhase1_1a	18	Phase 1/1A	526	0	0	0	0	0	0	1	1	2	2	2	1	2	2	2	2	1	1	9	1	2	2	2	2	5	5	2	2	1	2	1	0	0	0	1	1	2	2	1	4	3	3	4	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1	1.8571428	5	2.05		1	1	1.125	0	0.71428573	3	1.05	0.625	1	1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFJ584WFN
2081	8976	NDAR_INVFK153TFZ	1940			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	0	0	0	0	2	0	0	4	4	6	3	3	2	0	2	2	3	1	2	3	0	0	0	0	1	0	0	1	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	5	1	4.25	2	2	2.047619	1		2.047619	1	4.25	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK153TFZ
2081	8976	NDAR_INVFK153TFZ	1940			M	1600	Visit6	6	Phase 2	169	1	0	1	0	0	0	0	6	0	0	2	2	0	2	2	0	0	0	9	0	2	0	6	0	2	2	3	4	1	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.75	0	2.142857	2	1.65			2.047619	1	4.25	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK153TFZ
2081	8976	NDAR_INVFK153TFZ	1940			M	2800	Visit12	12	Phase 2	351	1	0	0	0	0	0	0	6	3	4	4	2	2	2	0	0	0	0	9	2	2	3	4	2	3	1	4	3	0	1	1	1	1	1	1	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.875	0	2.857143	2	2.35			2.047619	1	4.25	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK153TFZ
2081	8976	NDAR_INVFK153TFZ	1940			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	1	0	0	0	0	6	2	2	0	2	0	2	0	4	4	4	2	2	3	2	3	2	3	2	3	2	0	0	0	0	1	1	1	0	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	3.5	2.4285715	2.5	2.3809524		1	2.047619	1	4.25	2	2	0.33333334	0.75	-0.75	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK153TFZ
2081	8976	NDAR_INVFK153TFZ	1940			M	5800	EndofPhase2	18	Phase 2	522	1	0	0	0	0	0	0	6	0	0	2	2	2	4	0	0	0	0	9	2	2	2	2	0	2	2	4	4	0	1	1	0	1	0	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	5	2	0	2.2857144	2	1.8			2.047619	1	4.25	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK153TFZ
2081	8976	NDAR_INVFK259LWB	1435			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	1	1	2	1	2	3	5	4	3	5	4	4	4	4	4	5	4	5	5	1	1	0	1	1	1	1	1	1	2	1	4	4	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	16	0		0		1	14	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	4.25	4.285714	4.5	3.5714285	1		3.5714285	2.375	4.25	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK259LWB
2081	8976	NDAR_INVFK259LWB	1435			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	6	2	2	3	3	1	3	2	0	0	1	9	2	2	1	2	3	5	4	3	3	1	1	0	0	1	0	1	0	1	1	0	4	2	3	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.75	0.25	2.2857144	4.5	2.4			3.5714285	2.375	4.25	4.285714	4.5	-1.1714286	0.375	-4	-2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK259LWB
2081	8976	NDAR_INVFK259LWB	1435			M	2800	Visit12	12	Phase 1/1A	350	1	0	0	0	0	0	0	3	3	4	3	3	3	3	2	0	1	1	9	4	3	4	4	3	5	4	5	4	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0.5	3.857143	4.5	3.1			3.5714285	2.375	4.25	4.285714	4.5	-0.47142857	0.625	-3.75	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK259LWB
2081	8976	NDAR_INVFK259LWB	1435			M	5200	EndofPhase1_1a	18	Phase 1/1A	516	1	0	0	0	0	0	0	5	4	4	5	4	4	4	4	0	0	1	9	4	4	4	5	4	6	4	4	5	1	1	1	0	1	1	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	0.25	4.285714	5	3.75		1	3.5714285	2.375	4.25	4.285714	4.5	0.17857143	1.875	-4	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK259LWB
2081	8976	NDAR_INVFK650RWP	1433			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	3	0	2	2	1	2	2	1	1	4	9	2	0	2	1	0	2	3	1	3	0	0	1	0	1	1	0	1	2	2	1	4	2	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.5	1.2857143	2.5	1.8	1		1.8	2	1.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK650RWP
2081	8976	NDAR_INVFK650RWP	1433			M	1600	Visit6	6	Phase 2	170	0	0	0	0	0	0	1	4	4	3	1	2	2	1	3	0	0	4	9	1	2	2	0	1	4	4	4	4	0	0	1	0	1	1	1	1	2	1	1	3	2	4	2	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	4	2.5	1	2	4	2.3			1.8	2	1.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK650RWP
2081	8976	NDAR_INVFK650RWP	1433			M	2800	Visit12	12	Phase 3	337	0	0	0	0	0	0	1	4	4	0	1	2	1	2	4	0	1	4	9	4	3	3	2	1	3	3	3	5	1	0	1	1	1	1	0	1	2	1	1	4	3	3	3	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.25	1.25	3	3	2.5			1.8	2	1.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK650RWP
2081	8976	NDAR_INVFK650RWP	1433			M	4000	Visit18	18	Phase 3	505	0	0	0	0	0	0	1	2	4	0	2	2	0	2	4	0	2	4	9	3	2	4	4	1	4	3	4	4	1	0	1	0	1	1	1	1	2	2	1	4	3	4	3	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.5	3.142857	3.5	2.55			1.8	2	1.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK650RWP
2081	8976	NDAR_INVFK650RWP	1433			M	5200	EndofPhase1_1a	1	Phase 1/1A	35	0	0	0	0	1	0	0	3	3	0	0	0	2	0	2	2	2	6	9	0	2	1	2	3	2	1	1	2	1	0	1	1	0	1	0	1	1	1	1	4	3	4	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.25	2.5	1.5714285	1.5	1.7		1	1.8	2	1.5	1.2857143	2.5	-0.1	-0.75	1	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK650RWP
2081	8976	NDAR_INVFK650RWP	1433			M	5800	EndofPhase2	8	Phase 2	217	0	0	0	0	0	0	1	9	4	0	2	3	0	2	4	0	0	4	9	1	3	2	2	1	3	4	4	4	0	0	1	0	1	1	0	1	1	2	1	3	2	4	2	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.142857	1	2.4285715	3.5	2.2631578			1.8	2	1.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFK650RWP
2081	8976	NDAR_INVFL285LWJ	1441			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	0	0	0	2	0	0	0	0	9	0	1	0	1	0	2	2	0	4	1	2	1	1	1	0	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	0	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0	0.85714287	2	0.9	1		0.9	1	0	0.85714287	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL285LWJ
2081	8976	NDAR_INVFL285LWJ	1441			M	5200	EndofPhase1_1a	2	Phase 1/1A	63	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	3	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	20	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	4	0	0	0.14285715	0	0.05		1	0.9	1	0	0.85714287	2	-0.85	-1	0	-0.71428573	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL285LWJ
2081	8976	NDAR_INVFL285LWJ	1441			M	5800	EndofPhase2	4	Phase 2	117	1	0	0	0	0	0	0	0	0	0	1	1	0	2	0	0	1	0	9	2	2	1	1	0	3	1	2	2	0	0	0	0	1	1	1	1	1	1	1	3	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1		0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	3	0.5	0.25	1.4285715	2	0.95			0.9	1	0	0.85714287	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL285LWJ
2081	8976	NDAR_INVFL458KWF	2096			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0								0	0	0	0	9	0	2			1	4			1	1	1	1	1	1	1	0	1	1	1	1	3	3	3	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7		0				1				0																																																																																																																												Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL458KWF
2081	8976	NDAR_INVFL479VZ4	2101			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	3	4	3	6	6	1	1	1	2	9	5	5	6	6	3	6	4	6	6	0	1	1	0	1	0	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	3.375	1	5.285714	5	3.9	1		3.9	3.375	1	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL479VZ4
2081	8976	NDAR_INVFL479VZ4	2101			M	1600	Visit6	6	Phase 2	183	0	0	0	0	0	1	0	6	0	3	3	3	5	6	1	1	0	2	9	3	3	6	4	2	5	4	6	6	1	1	1	1	1	0	1	1	2	1	0	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	3.375	0.75	4.285714	4.5	3.45			3.9	3.375	1	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL479VZ4
2081	8976	NDAR_INVFL479VZ4	2101			M	2800	Visit12	12	Phase 2	340	0	0	0	0	0	1	0	6	4	4	2	4	4	6	3	2	1	2	9	3	6	6	6	5	5	4	4	6	1	1	1	1	1	1	1	1	2	1	1	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.125	1.25	5.142857	4.5	4.15			3.9	3.375	1	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL479VZ4
2081	8976	NDAR_INVFL479VZ4	2101			M	5200	EndofPhase1_1a	2	Phase 1/1A	52	0	0	0	0	0	1	0	6	0	2	2	3	2	6	1	4	1	1	9	5	6	6	6	4	5	4	6	6	1	1	1	1	1	0	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	1	0	0	1	1	1	1	5	2.75	1.5	5.571429	4.5	3.8		1	3.9	3.375	1	5.285714	5	-0.1	-0.625	0.5	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL479VZ4
2081	8976	NDAR_INVFL479VZ4	2101			M	5800	EndofPhase2	18	Phase 2	514	0	0	0	0	0	1	0	6	4	2	4	4	3	4	1	1	2	2	9	2	6	6	6	4	5	4	5	6	1	1	1	1	1	1	1	1	2	1	1	2	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	3.5	1.25	5	4.5	3.85			3.9	3.375	1	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL479VZ4
2081	8976	NDAR_INVFL961FTN	2874			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	3	1	1	5	6	6	3	5	4	1	5	5	5	5	5	5	4	4	6	6	1	2	1	0	1	1	1	1	1	1	1	3	3	4	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.875	3.75	5.285714	4	4.3333335	1		4.3333335	3.875	3.75	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFL961FTN
2081	8976	NDAR_INVFM359CA1	1298			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	1	0	4	4	4	3	2	0	4	3	2	4	4	9	6	5	5	6	3	4	3	6	6	1	0	1	1	1	1	0	1	1	3	1	3	2	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	7	3	2.5	5.285714	3.5	3.9	1		3.9	3	2.5	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM359CA1
2081	8976	NDAR_INVFM392EL1	2090			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	5	4	4	5	5	5	5	1	2	4	9	3	2	4	4	1	1	3	5	6	1	1	2	1	1	0	1	0	3	1	1	2	4	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	0	0	6	4.75	1.75	3.5714285	2	3.7	1		3.7	4.75	1.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM392EL1
2081	8976	NDAR_INVFM392EL1	2090			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	6	6	2	6	5	5	4	2	2	4	5	9	4	4	4	5	4	1	2	5	6	1	1	0	1	1	1	1	0	3		1	3	4	2	4	1	0	0	0	0	1	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.5	2.75	4.571429	1.5	4.1			3.7	4.75	1.75	3.5714285	2	0.4	-0.25	1	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM392EL1
2081	8976	NDAR_INVFM392EL1	2090			M	5200	EndofPhase1_1a	8	Phase 1/1A	240	0	0	0	0	0	1	0	6	6	3	6	5	6	4	2	2	4	5	9	4	4	4	5	6	1	4	5	6	1	1	0	1	1	1	1	1	3		1	3	4	2	4	1	0	0	0	0	1	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	2.75	4.857143	2.5	4.4		1	3.7	4.75	1.75	3.5714285	2	0.7	0	1	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM392EL1
2081	8976	NDAR_INVFM522XE7	2600			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	4	3	4	4	2	0	1	2	5	0	0	0	0	1	1	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	3.4285715	0.5	1.25	1		1.25	0	0	3.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM522XE7
2081	8976	NDAR_INVFM522XE7	2600			M	1600	Visit6	6	Phase 2	163	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	2	2	2	9	2	4	4	4	4	1	1	4	3	0	0	0	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.25	1.5	3.5714285	1	1.75			1.25	0	0	3.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM522XE7
2081	8976	NDAR_INVFM522XE7	2600			M	2800	Visit12	12	Phase 3	323	0	0	0	0	0	1	0	2	2	0	0	1	1	2	1	2	3	1	9	2	2	2	1	4	2	0	2	4	2	2	2	2	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.125	1.5	2.4285715	1	1.7			1.25	0	0	3.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM522XE7
2081	8976	NDAR_INVFM522XE7	2600			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	9	4	2	2	2	2	0	1	4	4	2	2	2	2	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	0	0	2.857143	0.5	1.05		1	1.25	0	0	3.4285715	0.5	-0.2	0	0	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM522XE7
2081	8976	NDAR_INVFM522XE7	2600			M	5800	EndofPhase2	9	Phase 2	253	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	2	4	0	9	1	2	4	0	4	1	1	2	3	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	7	0.25	1.5	2.2857144	1	1.3			1.25	0	0	3.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM522XE7
2081	8976	NDAR_INVFM522XE7	2600			M	6000	EndofPhase3	18	Phase 3	500	0	0	0	0	0	1	0	0	0	0	2	0	2	2	0	3	4	0	6	2	4	4	4	4	2	1	4	4	2	2	2	2	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	0.75	3.25	3.7142856	1.5	2.2857144			1.25	0	0	3.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM522XE7
2081	8976	NDAR_INVFM531ULK	2298			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	3	4	0	2	2	2	1	0	2	4	9	4	2	2	4	2	3	2	4	4	1	1	1	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.25	1.5	3.142857	2.5	2.55	1		2.55	2.25	1.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM531ULK
2081	8976	NDAR_INVFM531ULK	2298			F	1600	Visit6	6	Phase 2	175	1	0	0	0	0	0	0	2	2	0	0	2	2	2	0	0	3	6	9	0	2	2	3	0	5	4	4	1	1	1	1	0	1	1	1	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	1.25	2.25	1.7142857	4.5	2			2.55	2.25	1.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM531ULK
2081	8976	NDAR_INVFM531ULK	2298			F	2800	Visit12	12	Phase 2	337	1	0	0	0	0	0	0	3	2	0	0	2	1	2	0	0	2	5	9	2	2	2	3	0	2	4	4	5	1	0	1	1	1	1	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.25	1.75	2.5714285	3	2.05			2.55	2.25	1.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM531ULK
2081	8976	NDAR_INVFM531ULK	2298			F	5200	EndofPhase1_1a	5	Phase 1/1A	141	1	0	0	0	0	0	0	4	0	4	4	2	2	2	0	0	4	4	9	0	4	3	4	1	6	3	4	5	0	0	1	0	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.25	2	3	4.5	2.8		1	2.55	2.25	1.5	3.142857	2.5	0.25	0	0.5	-0.14285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM531ULK
2081	8976	NDAR_INVFM531ULK	2298			F	5800	EndofPhase2	18	Phase 2	507	1	0	0	0	0	0	0	3	1	0	0	2	1	2	0	0	2	4	9	2	2	2	3	0	2	3	4	4	1	0	1	1	1	1	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.125	1.5	2.4285715	2.5	1.85			2.55	2.25	1.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM531ULK
2081	8976	NDAR_INVFM934MZ4	2493			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	2	2	2	2	2	0	0	1	1	9	1	2	1	2	2	2	1	2	2	0	0	0	0	1	1	0	1	2	2	0	4	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		1.625	0.5	1.7142857	1.5	1.5	1		1.5	1.625	0.5	1.7142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM934MZ4
2081	8976	NDAR_INVFM934MZ4	2493			M	1600	Visit6	6	Phase 1/1A	186	1	1	0	0	0	0	0	6	2	2	1	2	1	2	4	0	0	0	9	2	2	3	2	0	3	1	4	3	0	1	2	1	1	1	1	0	1	1	1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	0	2.2857144	2	2			1.5	1.625	0.5	1.7142857	1.5	0.5	0.875	-0.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM934MZ4
2081	8976	NDAR_INVFM934MZ4	2493			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	1	0	0	2	2	2	4	2	2	6	1	2	4	9	0	2	0	3	2	5	2	5	4	0	1	0	1	1	1	0	1	2	1	0	4	4	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.5	1.75	2.2857144	3.5	2.5			1.5	1.625	0.5	1.7142857	1.5	1	0.875	1.25	0.5714286	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM934MZ4
2081	8976	NDAR_INVFM934MZ4	2493			M	4000	Visit18	18	Phase 1/1A	527	0	0	0	0	0	1	0	0	2	2	2	3	2	2	6	1	2	2	9	0	2	0	3	2	5	2	4	4	0	1	0	0	1	1	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.375	1.25	2.142857	3.5	2.3		1	1.5	1.625	0.5	1.7142857	1.5	0.8	0.75	0.75	0.42857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM934MZ4
2081	8976	NDAR_INVFM962PD0	2701			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	0	2	2	2	1	4	2	3	9	3	3	0	3	3	3	2	6	6	1	1	1	1	1	1	1	1	1	3	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.625	2.25	3.4285715	2.5	2.55	1		2.55	1.625	2.25	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM962PD0
2081	8976	NDAR_INVFM962PD0	2701			F	2800	Visit12	12	Phase 3	312	0	1	0	0	0	0	0	6	5	4	6	5	5	5	5	3	2	3	9	4	4	5	5	3	5	4	6	6	1	1	1	0	1	1	1	1	2	1	0	4	1	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.125	2	4.714286	4.5	4.55			2.55	1.625	2.25	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM962PD0
2081	8976	NDAR_INVFM962PD0	2701			F	5200	EndofPhase1_1a	1	Phase 1/1A	19	0	0	0	0	1	0	0	6	5	3	1	4	3	3	1	3	3	3	9	4	3	6	4	5	4	3	6	6	1	1	1	1	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.25	2.25	4.857143	3.5	3.8		1	2.55	1.625	2.25	3.4285715	2.5	1.25	1.625	0	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM962PD0
2081	8976	NDAR_INVFM962PD0	2701			F	5800	EndofPhase2	6	Phase 2	143	0	1	0	0	0	0	0	6	6	3	4	5	5	5	6	3	3	3	9	4	4	4	5	3	3	2	6	6	1	1	1	1	1	1	1	1	1	3	0	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	5	2.25	4.571429	2.5	4.3			2.55	1.625	2.25	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM962PD0
2081	8976	NDAR_INVFM962PD0	2701			F	6000	EndofPhase3	18	Phase 3	494	0	1	0	0	0	0	0	6	5	4	4	5	3	5	4	0	2	1	9	3	3	4	5	3	4	3	6	6	1	0	1	1	1	1	1	1	2	1	1	2	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.5	0.75	4.285714	3.5	3.8			2.55	1.625	2.25	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFM962PD0
2081	8976	NDAR_INVFN167BKZ	2486			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	2	1	1	1	4	0	1	0	0	1	2	1	2	2	1	3	2	2	4	0	1	0	0	1	0	0	0	3		0	3	4	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.5	2	2.5	1.5714285	1		1.5714285	1.5	0.5	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN167BKZ
2081	8976	NDAR_INVFN167BKZ	2486			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	1	0	1	1	3	1	1	1	1	0	1	1	1	9	2	2	2	2	1	3	3	4	4	1	1	0	0	1	0	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0.75	2.4285715	3	1.75			1.5714285	1.5	0.5	2	2.5	0.17857143	-0.375	0.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN167BKZ
2081	8976	NDAR_INVFN167BKZ	2486			M	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	1	0	1	1	1	1	1	1	2	1	0	1	0	9	1	1	0	0	2	1	2	2	1	2	2	2	0	1	1	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	1.125	0.25	1	1.5	1			1.5714285	1.5	0.5	2	2.5	-0.5714286	-0.375	-0.25	-1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN167BKZ
2081	8976	NDAR_INVFN167BKZ	2486			M	4000	Visit18	18	Phase 1/1A	508	0	0	0	0	0	1	0	1	1	3	1	1	1	1	0	1	1	1	9	2	2	2	2	1	3	3	4	4	1	1	0	0	1	0	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0.75	2.4285715	3	1.75			1.5714285	1.5	0.5	2	2.5	0.17857143	-0.375	0.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN167BKZ
2081	8976	NDAR_INVFN167BKZ	2486			M	5200	EndofPhase1_1a	18	Phase 1/1A	508	0	0	0	0	0	1	0	1	1	3	1	1	1	1	0	1	1	1	9	2	2	2	2	1	3	3	4	4	1	1	0	0	1	0	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0.75	2.4285715	3	1.75		1	1.5714285	1.5	0.5	2	2.5	0.17857143	-0.375	0.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN167BKZ
2081	8976	NDAR_INVFN226EVK	2337			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	2	2	3	2	2	2	2	4	4	5	5	4	4	4	3	3	5	4	4	5	1	1	1	1	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.5	4.5	3.857143	4.5	3.5238094	1		3.5238094	2.5	4.5	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN226EVK
2081	8976	NDAR_INVFN882TCD	2502			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	3	3	3	3	3	3	2	2	2	9	2	2	2	2	2	4	4	4	4	1	1	1	1	1	1	2	2	2	2	1	3	2	2	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	19	0		1	11	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3	1.5	2.5714285	4	2.8	1		2.8	3	1.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN882TCD
2081	8976	NDAR_INVFN882TCD	2502			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	1	0	3	2	2	2	3	2	2	3	1	2	2	9	2	2	2	2	3	6	4	4	3	1	1	0	0	1	1	1	1	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.375	1.25	2.5714285	5	2.6			2.8	3	1.5	2.5714285	4	-0.2	-0.625	-0.25	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN882TCD
2081	8976	NDAR_INVFN882TCD	2502			M	2800	Visit12	12	Phase 1/1A	379	0	0	0	0	0	1	0	3	3	3	3	3	3	3	4	1	2	2	9	2	2	4	3	1	5	3	3	3	1	1	1	1	1	1	1	1	3	2	1	3	2	2	2	1	0	0	1	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.25	2.5714285	4	2.8			2.8	3	1.5	2.5714285	4	0	0.125	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN882TCD
2081	8976	NDAR_INVFN882TCD	2502			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	3	2	2	3	2	2	3	1	2	2	2	9	2	2	2	3	2	6	4	3	3	1	1	1	0	1	1	1	1	1	2	1	4	2	2	2	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	1.5	2.4285715	5	2.55		1	2.8	3	1.5	2.5714285	4	-0.25	-0.75	0	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN882TCD
2081	8976	NDAR_INVFN914PW3	2855			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	3	3	3	2	2	2	2	6	5	5	6	4	4	3	4	5	5	4	3	4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	5.5	3.857143	4.5	3.8095238	1		3.8095238	2.75	5.5	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFN914PW3
2081	8976	NDAR_INVFR442UTU	2360			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	0	1	0	2	0	2	0	2	1	1	9	0	0	0	0	2	4	0	1	0	1	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	0.75	1	0.42857143	2	0.85	1		0.85	0.75	1	0.42857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFR442UTU
2081	8976	NDAR_INVFR442UTU	2360			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	6	6	5	4	4	4	4	6	6	4	5	6	5	6	5	5	6	6	6	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.875	5.25	5.428571	6	5.2380953			0.85	0.75	1	0.42857143	2	4.3880954	4.125	4.25	5	4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFR442UTU
2081	8976	NDAR_INVFR442UTU	2360			M	2800	Visit12	12	Phase 1/1A	343	1	0	0	0	0	0	0	2	3	4	4	4	4	4	3	3	4	5	6	4	3	4	4	6	6	6	4	4	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	4.5	4.142857	6	4.142857			0.85	0.75	1	0.42857143	2	3.2928572	2.75	3.5	3.7142856	4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFR442UTU
2081	8976	NDAR_INVFR442UTU	2360			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	1	0	0	0	0	0	0	6	6	6	6	6	5	6	5	6	6	6	6	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		1	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.75	6	6	6	5.904762		1	0.85	0.75	1	0.42857143	2	5.054762	5	5	5.571429	4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFR442UTU
2081	8976	NDAR_INVFT510FGU	2264			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	1	0	4	5	4	2	2	1	2	0	2	4	6	9	2	2	3	4	4	3	4	6	6	1	1	0	1	1	1	1	1	3		1	4	2	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	2.5	3	3.857143	3.5	3.3	1		3.3	2.5	3	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT510FGU
2081	8976	NDAR_INVFT510FGU	2264			M	1600	Visit6	6	Phase 1/1A	168	0	1	0	0	0	1	0	4	5	4	2	2	2	2	0	3	4	6	4	3	4	4	4	4	4	3	6	6	1	1	0	1	1	1	1	1	3	2	1	4	2	3	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.625	4.25	4.428571	3.5	3.6190476			3.3	2.5	3	3.857143	3.5	0.31904763	0.125	1.25	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT510FGU
2081	8976	NDAR_INVFT510FGU	2264			M	2800	Visit12	12	Phase 1/1A	343	0	1	0	0	0	1	0	4	3	4	2	2	2	2	0	3	4	6	5	3	4	4	4	4	4	4	6	6	1	1	2	1	1	1	1	1	3	2	1	4	2	3	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.375	4.5	4.428571	4	3.6190476			3.3	2.5	3	3.857143	3.5	0.31904763	-0.125	1.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT510FGU
2081	8976	NDAR_INVFT510FGU	2264			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	1	0	4	5	4	2	2	2	2	2	3	4	6	6	3	4	4	4	4	5	4	6	6	1	1	0	1	1	1	1	1	3		1	4	1	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.875	4.75	4.428571	4.5	3.9047618		1	3.3	2.5	3	3.857143	3.5	0.6047619	0.375	1.75	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT510FGU
2081	8976	NDAR_INVFT523DFX	1446			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	2	2	4	0	3	1	1	1	2	9	3	5	4	4	3	4	4	5	5	1	1	1	1	1	1	1	1	3	1	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.7142857	1	4.142857	4	2.7894738	1		2.7894738	1.7142857	1	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT523DFX
2081	8976	NDAR_INVFT695GH1	1832			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	3	3	4	4	2	3	3	0	0	0	9	2	5	5	2	6	5	2	3	3	1	1	1	1	1	1	1	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	2	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	0	3.7142856	3.5	2.95	1		2.95	3.25	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT695GH1
2081	8976	NDAR_INVFT695GH1	1832			M	5200	EndofPhase1_1a	1	Phase 1/1A	31	1	0	0	0	0	0	0	6	4	4	4	6	4	6	4	0	0	0	9	3	3	4	5	0	4	4	5	5	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.75	0	3.5714285	4	3.55		1	2.95	3.25	0	3.7142856	3.5	0.6	1.5	0	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT695GH1
2081	8976	NDAR_INVFT695GH1	1832			M	5800	EndofPhase2	6	Phase 2	169	0	0	0	0	0	0	1	0	2	2	2	2	1	2	4	2	3	4	9	2	2	2	5	4	4	4	4	4	0	1	0	1	1	1	1	1	1	1	0	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.875	2.25	3.2857144	4	2.75			2.95	3.25	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFT695GH1
2081	8976	NDAR_INVFU277HDV	1841			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	1	1	0	1	2	0	0	1	9	2	2	2	1	1	1	1	2	4	2	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	5	0		0		1	25	0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	6	1.125	0.25	2	1	1.3	1		1.3	1.125	0.25	2	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU277HDV
2081	8976	NDAR_INVFU434HRE	1988			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	1	0	1	1	1	0	0	0	9	0	0	0	2	1	2	2	0	2	1	1	2	2	1	1	2	2	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	7	0		0		1	24	0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	3	0.5	0	0.71428573	2	0.65	1		0.65	0.5	0	0.71428573	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU434HRE
2081	8976	NDAR_INVFU434HRE	1988			M	1600	Visit6	6	Phase 1/1A	198	0	0	0	0	0	0	1	4	0	0	2	2	0	1	2	1	3	0	9	0	2	2	4	5	3	4	4	5	1	1	1	1	1	1	1	1	3	1	0	4	1	4	4	1	0	0	0	0	1	0	0	1	0	1	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	1	3.142857	3.5	2.2			0.65	0.5	0	0.71428573	2	1.55	0.875	1	2.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU434HRE
2081	8976	NDAR_INVFU434HRE	1988			M	2800	Visit12	12	Phase 1/1A	365	0	0	0	0	0	0	1	0	0	0	0	1	0	2	2	0	0	0	9	0	1	0	2	2	3	3	4	4	1	1	1	0	1	1	0	1	3		0	4	2	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	0.625	0	1.8571428	3	1.2			0.65	0.5	0	0.71428573	2	0.55	0.125	0	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU434HRE
2081	8976	NDAR_INVFU434HRE	1988			M	5200	EndofPhase1_1a	18	Phase 1/1A	540	0	0	0	0	0	1	0	1	0	0	0	1	0	1	2	0	0	0	9	0	0	4	3	2	4	2	2	4	1	0	1	0	1	1	2	1	3		0	4	2	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	0.625	0	2.142857	3	1.3		1	0.65	0.5	0	0.71428573	2	0.65	0.125	0	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU434HRE
2081	8976	NDAR_INVFU536JPY	2347			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	1	2	1	3	2	2	1	1	2	1	9	2	2	3	3	4	5	3	4	2	1	0	1	1	1	1	1	1	2	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1.625	1	2.857143	4	2.25	1		2.25	1.625	1	2.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU536JPY
2081	8976	NDAR_INVFU741DDC	1526			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	3	2	2	2	4	0	3	1	9	4	0	3	2	1	6	4	5	5	1	1	1	1	1	1	1	1	1	1	0	4	3	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	1	2.857143	5	2.65	1		2.65	2.375	1	2.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU741DDC
2081	8976	NDAR_INVFU741DDC	1526			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	4	4	4	4	4	3	4	4	2	2	0	9	2	2	4	4	6	6	5	4	6	1	1	0	1	1	1	1	1	1	1	1	3	3	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.875	1	4	5.5	3.7			2.65	2.375	1	2.857143	5	1.05	1.5	0	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU741DDC
2081	8976	NDAR_INVFU741DDC	1526			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	4	4	4	4	4	3	4	4	2	2	0	9	2	2	4	4	6	6	5	4	6	1	1	0	1	1	1	1	1	1	1	1	3	3	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.875	1	4	5.5	3.7			2.65	2.375	1	2.857143	5	1.05	1.5	0	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU741DDC
2081	8976	NDAR_INVFU741DDC	1526			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	1	0	0	0	0	0	5	5	6	5	6	6	6	5	4	4	4	6	5	5	6	6	6	6	4	5	6	1	1	1	1	1	1	1	1	1	2	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	5	5.5	4.5	5.571429	5	5.285714		1	2.65	2.375	1	2.857143	5	2.6357143	3.125	3.5	2.7142856	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFU741DDC
2081	8976	NDAR_INVFV244VJY	2646			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	1	0	0	6	4	3	3	4	4	4	6	1	2	1	9	4	2	5	6	5	4	4	4	6	1	1	1	0	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	1	4.571429	4	3.9	1		3.9	4.25	1	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV244VJY
2081	8976	NDAR_INVFV244VJY	2646			M	5200	EndofPhase1_1a	2	Phase 1/1A	40	0	1	0	0	1	0	0	6	4	3	3	4	5	4	6	1	2	0	9	4	3	5	6	5	4	4	5	5	1	1	0	0	1	1	1	1	1	1	1	4	4	4	4	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	0.75	4.714286	4	3.95		1	3.9	4.25	1	4.571429	4	0.05	0.125	-0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV244VJY
2081	8976	NDAR_INVFV469UJQ	2498			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	0	4	2	4	1	1	0	0	0	0	9	4	0	0	2	0	4	1	4	4	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	0	2	2.5	1.75	1		1.75	2	0	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV469UJQ
2081	8976	NDAR_INVFV469UJQ	2498			F	1600	Visit6	6	Phase 1/1A	171	1	0	1	0	0	0	0	6	0	3	2	6	2	3	0	0	0	4	9	4	4	4	5	2	4	3	6	6	1	1	1	0	1	1	1	1	1	3	0	4	2	1	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1	4.428571	3.5	3.2			1.75	2	0	2	2.5	1.45	0.75	1	2.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV469UJQ
2081	8976	NDAR_INVFV469UJQ	2498			F	2800	Visit12	12	Phase 1/1A	339	1	0	1	0	0	0	0	6	2	0	2	6	2	3	0	0	0	0	9	3	3	2	2	4	4	4	6	6	1	1	1	0	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0	3.7142856	4	2.75			1.75	2	0	2	2.5	1	0.625	0	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV469UJQ
2081	8976	NDAR_INVFV469UJQ	2498			F	5200	EndofPhase1_1a	18	Phase 1/1A	508	1	0	1	0	0	0	0	5	2	3	5	5	6	6	5	5	4	5	6	3	6	4	6	6	6	3	4	6	1	1	1	1	1	1	1	1	2	1	1	4	4	2	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.625	5	5	4.5	4.8095236		1	1.75	2	0	2	2.5	3.0595238	2.625	5	3	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV469UJQ
2081	8976	NDAR_INVFV746EA1	1875			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	1	0	2	2	0	0	0	0	1	0	0	0	2	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.875	0	0.5714286	0.5	0.6	1		0.6	0.875	0	0.5714286	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV746EA1
2081	8976	NDAR_INVFV746EA1	1875			M	1600	Visit6	6	Phase 2	175	0	1	0	0	0	0	0	4	3	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	1	0	2	2	0	0	0	0	1	0	0	0	2	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.875	0	0.5714286	0.5	0.6			0.6	0.875	0	0.5714286	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV746EA1
2081	8976	NDAR_INVFV746EA1	1875			M	2800	Visit12	12	Phase 3	357	0	1	0	0	0	0	0	4	4	2	2	2	1	2	4	1	2	0	9	1	4	3	4	2	5	5	3	3	1	1	1	1	1	2	0	1	1	1	0	4	2	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	0.75	2.857143	5	2.7			0.6	0.875	0	0.5714286	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV746EA1
2081	8976	NDAR_INVFV746EA1	1875			M	4000	Visit18	18	Phase 3	539	0	1	0	0	0	0	0	6	4	5	3	4	3	1	4	1	3	1	4	2	2	3	2	2	6	6	4	5	1	1	0	0	1	1	1	0	3	1	1	3	2	2	2	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	2.25	2.857143	6	3.3809524			0.6	0.875	0	0.5714286	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV746EA1
2081	8976	NDAR_INVFV746EA1	1875			M	5200	EndofPhase1_1a	2	Phase 1/1A	59	0	1	0	0	0	0	0	4	3	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	1	0	2	2	0	0	0	0	1	0	0	0	2	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.875	0	0.5714286	0.5	0.6		1	0.6	0.875	0	0.5714286	0.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV746EA1
2081	8976	NDAR_INVFV746EA1	1875			M	5800	EndofPhase2	8	Phase 2	233	0	1	0	0	0	0	0	4	3	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	0	1	2	2	0	0	0	0	1	0	0	0	2	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.875	0	0.5714286	0.5	0.6			0.6	0.875	0	0.5714286	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFV746EA1
2081	8976	NDAR_INVFW120DLR	2645			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	1	2	1	2	1	1	2	4	9	1	2	2	2	4	2	2	3	5	0	0	1	0	1	0	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	4	3.125	1.75	2.7142856	2	2.75	1		2.75	3.125	1.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW120DLR
2081	8976	NDAR_INVFW120DLR	2645			M	2800	Visit12	12	Phase 2	337	1	0	0	0	0	0	0	6	4	4	3	3	3	3	0	0	1	1	9	1	2	3	3	2	2	2	3	3	0	0	1	0	1	1	1	1	1	2	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	0.5	2.4285715	2	2.45			2.75	3.125	1.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW120DLR
2081	8976	NDAR_INVFW120DLR	2645			M	5200	EndofPhase1_1a	4	Phase 1/1A	113	1	0	0	0	0	0	0	6	3	3	3	4	4	5	3	3	3	4	9	3	4	4	4	4			5	5																	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		3.875	2.5	4.142857		3.8888888		1	2.75	3.125	1.75	2.7142856	2	1.1388888	0.75	0.75	1.4285715																																																																																																																						Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW120DLR
2081	8976	NDAR_INVFW120DLR	2645			M	5400	EndofPhase1b	6	Phase 1B	162	1	0	0	0	0	0	0	6	4	4	3	3	3	3	1	3	2	1	9	3	3	3	4	1	2	2	6	4	0	0	1	0	0	1	1	1	1	2	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	3.375	1.5	3.4285715	2	3.05			2.75	3.125	1.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW120DLR
2081	8976	NDAR_INVFW120DLR	2645			M	5800	EndofPhase2	13	Phase 2	365	1	0	0	0	0	0	0	6	3	0	2	5	4	6	3	0	2	1	9	2	2	3	4	0	1	2	5	4	0	0	0	0	1	1	1	1	1	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.625	0.75	2.857143	1.5	2.75			2.75	3.125	1.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW120DLR
2081	8976	NDAR_INVFW120DLR	2645			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	5	3	2	1	2	1	3	1	1	3	1	9	1	2	3	3	2	1	2	4	4	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	1.25	2.7142856	1.5	2.25			2.75	3.125	1.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW120DLR
2081	8976	NDAR_INVFW298YL1	2256			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	0	3	3	2	3	3	2	2	3	2	9	3	3	3	3	3	3	3	4	5	0	0	1	0	1	1	1	1	2	1	0	4	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.75	1.75	3.4285715	3	2.95	1		2.95	2.75	1.75	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW298YL1
2081	8976	NDAR_INVFW298YL1	2256			M	1600	Visit6	6	Phase 3	159	0	0	0	0	0	0	1	5	3	4	3	3	3	5	2	2	5	5	9	5	4	5	3	4	4	4	4	5	1	0	1	0	1	1	1	1	2	1	1	2	2	2	2	1	0	0	0	0	1	0	0	0	0	0	0	0		1	30	0		0		0		0	1	1	0	0	1	1	0	0	0	0	0	1	1	1	1	4	3.5	3	4.285714	4	3.9			2.95	2.75	1.75	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW298YL1
2081	8976	NDAR_INVFW298YL1	2256			M	5200	EndofPhase1_1a	2	Phase 1/1A	47	0	0	0	0	0	0	1	5	5	2	3	3	3	5	6	3	5	3	9	5	5	2	4	4	4	3	4	5	1	1	1	0	1	1	1	1	2	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	1	1	0	4	4	2.75	4.142857	3.5	3.95		1	2.95	2.75	1.75	3.4285715	3	1	1.25	1	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW298YL1
2081	8976	NDAR_INVFW298YL1	2256			M	5800	EndofPhase2	3	Phase 2	58	0	0	0	0	0	0	1	5	4	2	4	4	3	6	3	3	6	4	9	5	5	5	6	4	4	2	5	6	1	0	1	0	1	1	1	1	2	1	1	2	1	2	1	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	3.875	3.25	5.142857	3	4.3			2.95	2.75	1.75	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW298YL1
2081	8976	NDAR_INVFW298YL1	2256			M	6000	EndofPhase3	15	Phase 3	408	0	0	0	0	0	0	1	6	4	3	4	3	5	4	2	4	4	6	5	5	5	6	5	5	4	4	4	5	1	1	1	0	1	1	1	1	2	1	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.875	4.75	5	4	4.428571			2.95	2.75	1.75	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW298YL1
2081	8976	NDAR_INVFW318LE5	2697			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	0	4	4	2	1	4	2	0	0	0	9	4	2	4	4	2	5	3	5	5	0	1	2	0	1	1	2	0	1	1	1	4	2	4	2	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.875	0	3.7142856	4	2.85	1		2.85	2.875	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW318LE5
2081	8976	NDAR_INVFW318LE5	2697			M	5200	EndofPhase1_1a	1	Phase 1/1A	20	0	0	1	0	0	0	0	0	4	4	4	2	0	4	0	2	1	1	9	3	1	2	3	2	5	4	6	5	1	1	1	1	1	1	0	1	1	1	1	3	2	4	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	1	3.142857	4.5	2.65		1	2.85	2.875	0	3.7142856	4	-0.2	-0.625	1	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFW318LE5
2081	8976	NDAR_INVFX031DT7	1487			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	2	4	3	4	5	4	2	0	0	9	1	2	5	4	5	4	4	4	4	0	1	0	1	1	0	0	0	1	1	1	2	1	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	0.5	3.5714285	4	3.35	1		3.35	4	0.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX031DT7
2081	8976	NDAR_INVFX031DT7	1487			M	5200	EndofPhase1_1a	2	Phase 1/1A	75	1	0	0	0	0	0	0	1	1	1	2	2	1	2	2	0	0	0	9	0	1	4	2	3	5	4	4	4	0	0	0	1	1	1	1	1	2	1	1	4	2	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0	2.5714285	4.5	1.95		1	3.35	4	0.5	3.5714285	4	-1.4	-2.5	-0.5	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX031DT7
2081	8976	NDAR_INVFX031DT7	1487			M	5800	EndofPhase2	4	Phase 2	141	1	0	0	0	0	0	0	6	6	2	5	5	5	6	2	4	4	1	5	2	2	6	1	5	5	4	4	6	0	1	0	1	1	1	1	1	2	1	1	3	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	14	1	6	0		1	10	0		0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	1	5	4.625	3.5	3.7142856	4.5	4.095238			3.35	4	0.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX031DT7
2081	8976	NDAR_INVFX309XU6	1488			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	2	2	2	3	4	2	0	0	0	9	1	1	2	3	1	4	3	4	4	1	1	1	1	1	1	1	1	3	2	1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.625	0	2.2857144	3.5	2.2	1		2.2	2.625	0	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX309XU6
2081	8976	NDAR_INVFX309XU6	1488			M	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	0	1	9	4	4	4	3	3	3	2	0	0	0	9	2	2	2	2	1	4	2	2	4	1	1	1	0	1	1	1	1	3		1	3	2	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.2857144	0	2.142857	3	2.3157895			2.2	2.625	0	2.2857144	3.5	0.11578947	0.66071427	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX309XU6
2081	8976	NDAR_INVFX309XU6	1488			M	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	0	0	1	4	2	3	2	3	3	3	0	0	4	3	9	3	3	2	4	4	3	2	3	3	1	0	1	0	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	2.5	1.75	3.142857	2.5	2.7			2.2	2.625	0	2.2857144	3.5	0.5	-0.125	1.75	0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX309XU6
2081	8976	NDAR_INVFX309XU6	1488			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	0	0	0	0	0	0	1	3	2	3	4	3	4	3	0	0	4	3	9	3	4	2	2	4	4	1	3	3	1	0	1	0	1	0	0	0	2	3	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.75	3	2.5	2.75		1	2.2	2.625	0	2.2857144	3.5	0.55	0.125	1.75	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX309XU6
2081	8976	NDAR_INVFX734PNM	2203			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	6	6	6	6	4	0	4	5	9	4	6	6	5	6	4	3	4	5	1	1	2	1	1	1	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	2	2	1	0	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	5.75	2.25	5.142857	3.5	4.9	1		4.9	5.75	2.25	5.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX734PNM
2081	8976	NDAR_INVFX734PNM	2203			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	6	6	6	6	6	6	6	4	4	4	4	2	4	6	4	6	6	5	3	4	6	1	1	2	1	1	1	0	0	2	1	1	3	2	2	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	5.75	3.5	5.142857	4	4.952381			4.9	5.75	2.25	5.142857	3.5	0.052380953	0	1.25	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX734PNM
2081	8976	NDAR_INVFX734PNM	2203			M	2800	Visit12	12	Phase 1/1A	342	0	0	0	0	0	0	1	6	5	5	6	6	5	6	4	3	3	5	6	3	6	3	6	6	1	4	5	6	1	1	1	1	1	1	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	1	0	0	0	0	0	1	0	1	1	6	5.375	4.25	5	2.5	4.7619047			4.9	5.75	2.25	5.142857	3.5	-0.13809524	-0.375	2	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX734PNM
2081	8976	NDAR_INVFX734PNM	2203			M	5200	EndofPhase1_1a	18	Phase 1/1A	495	0	0	0	0	0	1	0	6	6	6	6	6	6	6	3	4	4	3	2	4	4	4	6	5	4	4	5	4	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	6	5.625	3.25	4.571429	4	4.6666665		1	4.9	5.75	2.25	5.142857	3.5	-0.23333333	-0.125	1	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX734PNM
2081	8976	NDAR_INVFX938WMQ	1440			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	1	0	2	2	2	1	2	4	4	9	6	6	5	5	4	5	5	4	5	1	1	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	1	1	0	0	0	1	0	0	1	1	1	1	4	1.1428572	2.5	5	5	3.3157895	1		3.3157895	1.1428572	2.5	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX938WMQ
2081	8976	NDAR_INVFX938WMQ	1440			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	4	0	0	0	0	2	2	2	2	1	2	9	3	5	6	4	1	6	4	3	5	1	1	1	1	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	1	0	0	0	0	0	1	1	1	1	3	1.25	1.25	3.857143	5	2.6			3.3157895	1.1428572	2.5	5	5	-0.7157895	0.10714286	-1.25	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX938WMQ
2081	8976	NDAR_INVFX938WMQ	1440			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	9	2	2	4	2	2	3	3	2	3	3	9	5	4	5	4	4	6	4	4	5	1	1	1	1	1	1	1	1	3	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.5714285	2	4.428571	5	3.5263157			3.3157895	1.1428572	2.5	5	5	0.21052632	1.4285715	-0.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX938WMQ
2081	8976	NDAR_INVFX938WMQ	1440			M	5200	EndofPhase1_1a	18	Phase 1/1A	501	0	0	0	0	0	0	1	6	3	3	2	2	2	2	2	2	3	2	9	5	5	5	4	4	6	4	4	4	1	1	1	1	1	1	1	1	2	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	4	2.75	1.75	4.428571	5	3.5		1	3.3157895	1.1428572	2.5	5	5	0.18421052	1.6071428	-0.75	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFX938WMQ
2081	8976	NDAR_INVFY588YCY	1426			F	400	Baseline	0	Pre-Rand	1	1	0	1	1	1	0	0	1	2	0	0	0	2	2	3	5	4	4	6	2	2	1	2	4	4	3	2	4	1	0	1	1	0	1	1	1	1	2	1	4	3	2	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	5	1.25	4.75	2.4285715	3.5	2.5238094	1		2.5238094	1.25	4.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFY588YCY
2081	8976	NDAR_INVFY588YCY	1426			F	1600	Visit6	6	Phase 2	155	1	0	1	1	0	0	0	0	0	1	2	2	0	4	3	4	4	6	5	3	2	2	2	4	5	2	4	5	1	1	0	1	1	1	1	1	1	2	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4	1.5	4.75	3.142857	3.5	2.857143			2.5238094	1.25	4.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFY588YCY
2081	8976	NDAR_INVFY588YCY	1426			F	5200	EndofPhase1_1a	5	Phase 1/1A	122	1	0	1	1	0	0	0	2	3	4	3	2	2	2	3	3	3	5	6	3	3	1	4	5	5	2	4	5	1	0	1	1	0	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	1	6	2.625	4.25	3.5714285	3.5	3.3333333		1	2.5238094	1.25	4.75	2.4285715	3.5	0.8095238	1.375	-0.5	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFY588YCY
2081	8976	NDAR_INVFY588YCY	1426			F	5800	EndofPhase2	11	Phase 2	318	1	0	0	1	0	0	0	6	6	3	6	6	4	6	6	4	6	6	6	2	4	5	4	6	4	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	3	2	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	5.375	5.5	4.714286	4	5.047619			2.5238094	1.25	4.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFY588YCY
2081	8976	NDAR_INVFY588YCY	1426			F	6000	EndofPhase3	12	Phase 3	361	1	0	1	1	0	0	0	4	4	4	3	2	2	3	5	4	4	2	5	5	4	2	6	6	4	4	5	6	1	1	1	1	1	1	1	1	1	1	1	4	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.375	3.75	4.857143	4	4			2.5238094	1.25	4.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFY588YCY
2081	8976	NDAR_INVFY880WZZ	1996			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	0	2	0	2	0	3	3	2	2	2	2	2	2	1	4	2	3	3	0	1	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	2.5	2.142857	3	1.8571428	1		1.8571428	1	2.5	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFY880WZZ
2081	8976	NDAR_INVFZ214BJY	2231			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	2	0	4	3	3	1	3	4	4	2	2	2	3	0	1	4	1	2	6	0	0	1	1	1	0	0	0	3	1	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.5	3.25	2.2857144	2.5	2.5714285	1		2.5714285	2.5	3.25	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ214BJY
2081	8976	NDAR_INVFZ214BJY	2231			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	0	0	0	0	1	0	4	2	0	1	5	0	2	1	4	2	4	4	3	3	4	3	4	4	4	4	5	1	1	1	1	1	1	0	0	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	4	1.875	3.5	3.7142856	4	3		1	2.5714285	2.5	3.25	2.2857144	2.5	0.42857143	-0.625	0.25	1.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ214BJY
2081	8976	NDAR_INVFZ430VY8	1332			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	0	1	1	2	1	2	2	0	0	1	9	1	2	2	2	1	1	1	1	5	2	2	2	2	1	1	0	1	3	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	0		1	5	0		1	25	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.375	0.25	2	1	1.4	1		1.4	1.375	0.25	2	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ430VY8
2081	8976	NDAR_INVFZ895JUJ	1956			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	2	4	4	2	2	1	1	3	1	9	3	4	5	5	4	6	6	4	5	1	1	1	1	1	1	1	1	3	1	1	3	2	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	5	2.875	1.25	4.285714	6	3.5	1		3.5	2.875	1.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ895JUJ
2081	8976	NDAR_INVFZ895JUJ	1956			M	1600	Visit6	6	Phase 2	170	0	0	0	0	0	0	1	4	4	4	3	3	3	4	2	6	4	5	4	3	5	4	4	5	5	4	5	4	1	1	1	0	1	1	1	1	3	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	0	4	3.375	4.75	4.285714	4.5	4.047619			3.5	2.875	1.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ895JUJ
2081	8976	NDAR_INVFZ895JUJ	1956			M	2800	Visit12	12	Phase 2	343	0	0	0	0	0	0	1	2	2	3	4	4	3	4	2	1	1	1	9	4	4	4	4	2	5	5	5	5	1	1	1	1	1	1	1	1	3	1	1	4	2	3	4	1	0	1	0	0	0	0	0	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	1	0	0	1	1	1	1	5	3	0.75	4	5	3.25			3.5	2.875	1.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ895JUJ
2081	8976	NDAR_INVFZ895JUJ	1956			M	5200	EndofPhase1_1a	1	Phase 1/1A	28	0	0	0	0	0	0	1	4	3	2	3	3	2	3	1	2	4	1	9	5	4	4	3	2	6	6	4	6	1	1	1	0	1	0	1	1	3	1	1	3	3	3	4	1	0	1	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	5	2.625	1.75	4	6	3.4		1	3.5	2.875	1.25	4.285714	6	-0.1	-0.25	0.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ895JUJ
2081	8976	NDAR_INVFZ895JUJ	1956			M	5800	EndofPhase2	15	Phase 2	425	0	0	0	0	0	0	1	4	1	3	3	3	2	3	1	4	4	5	3	4	4	5	4	1	5	4	4	4	1	1	1	0	1	1	0	1	1	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	4	3.7142856	4.5	3.3809524			3.5	2.875	1.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ895JUJ
2081	8976	NDAR_INVFZ972MUM	2534			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	0	2	1	0	0	1	9	0	2	1	6	4	6	4	5	6	0	1	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.25	3.4285715	5	2.4	1		2.4	1.625	0.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ972MUM
2081	8976	NDAR_INVFZ972MUM	2534			M	1600	Visit6	6	Phase 3	169	1	0	1	0	0	0	0	6	0	0	1	2	0	0	1	0	0	0	9	0	2	0	4	0	6	3	2	3	1	1	0	0	1	0	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0	1.5714285	4.5	1.5			2.4	1.625	0.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ972MUM
2081	8976	NDAR_INVFZ972MUM	2534			M	5200	EndofPhase1_1a	1	Phase 1/1A	33	1	0	1	0	0	0	0	6	0	0	2	2	0	6	1	0	0	4	9	0	2	0	6	1	6	4	4	5	0	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.125	1	2.5714285	5	2.45		1	2.4	1.625	0.25	3.4285715	5	0.05	0.5	0.75	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ972MUM
2081	8976	NDAR_INVFZ972MUM	2534			M	5800	EndofPhase2	2	Phase 2	46	1	0	1	0	0	0	0	6	0	0	2	2	2	1	1	0	0	6	9	0	2	0	6	4	6	3	3	3	1	1	0	0	1	1	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1.5	2.5714285	4.5	2.35			2.4	1.625	0.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ972MUM
2081	8976	NDAR_INVFZ972MUM	2534			M	6000	EndofPhase3	10	Phase 3	269	1	0	1	0	0	0	0	5	0	1	2	2	3	6	1	0	0	5	9	2	2	2	6	0	6	4	4	6	0	1	0	0	1	0	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	1.25	3.142857	5	2.85			2.4	1.625	0.25	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVFZ972MUM
2081	8976	NDAR_INVGA266WDV	2324			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	4	3	4	4	4	4	3	4	3	5	6	5	4	4	6	5	4	4	5	4	1	0	0	0	1	1	0	1	2	2	1	3	3	3	4	1	0	1	0	0	0	0	0	0	0	1	0	0		0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4	4.5	4.714286	4	4.3333335	1		4.3333335	4	4.5	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA266WDV
2081	8976	NDAR_INVGA266WDV	2324			M	5200	EndofPhase1_1a	1	Phase 1/1A	8	1	0	1	0	0	0	0	6	4	3	4	4	4	4	3	4	3	5	6	5	4	4	6	5	4	4	3	3	1	1	0	1	1	2	0	1	2	1	1	3	3	3	3	1	0	1	0	0	0	0	0	0	1	1	0	0		0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4	4.5	4.285714	4	4.1904764		1	4.3333335	4	4.5	4.714286	4	-0.14285715	0	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA266WDV
2081	8976	NDAR_INVGA436AXV	2487			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	0	0	2	3	2	2	1	2	2	1	1	3	3	2	2	2	5	5	3	4	0	2	2	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	1.5	2.7142856	5	2.3809524	1		2.3809524	1.875	1.5	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA436AXV
2081	8976	NDAR_INVGA436AXV	2487			F	1600	Visit6	6	Phase 1/1A	164	0	0	0	1	0	0	0	3	4	3	3	3	3	2	0	0	0	0	9	2	0	2	1	1	5	5	2	1	1	1	1	1	1	1	1	1	1	1	0	4	3	3	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	2	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	0	1.2857143	5	2			2.3809524	1.875	1.5	2.7142856	5	-0.3809524	0.75	-1.5	-1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA436AXV
2081	8976	NDAR_INVGA436AXV	2487			F	2800	Visit12	12	Phase 2	338	0	0	0	1	0	0	0	3	4	3	3	3	2	3	0	1	0	1	9	2	0	2	2	1	5	6	2	1	1	1	1	0	1	1	1	1	1	1	0	4	3	3	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	0.5	1.4285715	5.5	2.2			2.3809524	1.875	1.5	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA436AXV
2081	8976	NDAR_INVGA436AXV	2487			F	4000	Visit18	18	Phase 2	509	0	0	0	0	0	0	1	3	4	3	3	3	3	2	0	0	0	0	9	2	0	2	2	2	5	5	3	2	1	1	1	1	1	1	1	1	1	1	0	4	3	3	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.625	0	1.8571428	5	2.2			2.3809524	1.875	1.5	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA436AXV
2081	8976	NDAR_INVGA436AXV	2487			F	5200	EndofPhase1_1a	10	Phase 1/1A	288	0	0	0	1	0	0	0	5	0	1	3	1	2	2	0	1	2	1	9	1	3	2	0	0	5	5	4	2	1	1	1	1	1	2	2	1	1	2	0	4	3	2	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		2	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	1	1.7142857	5	2		1	2.3809524	1.875	1.5	2.7142856	5	-0.3809524	-0.125	-0.5	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA436AXV
2081	8976	NDAR_INVGA561LML	2367			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	4	6	2	5	2	0	4	5	6	6	0	2	0	6	6	4	3	6	5	1	1	0	0	1	1	1	1	1	2	1	4	2	3	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	5.25	3.5714285	3.5	3.952381	1		3.952381	3.75	5.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA561LML
2081	8976	NDAR_INVGA561LML	2367			M	5200	EndofPhase1_1a	1	Phase 1/1A	15	1	0	0	0	0	0	0	6	5	4	4	2	5	2	0	4	5	6	6	0	2	0	6	6	4	1	6	5	0	0	0	0	1	1	0	0	1	2	1	4	2	3	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	5.25	3.5714285	2.5	3.7619047		1	3.952381	3.75	5.25	3.5714285	3.5	-0.1904762	-0.25	0	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA561LML
2081	8976	NDAR_INVGA783TCP	2239			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	0	0	0	0	0	2	2	1	1	1	9	0	1	0	3	1	4	2	4	4	1	0	0	0	1	1	1	1	1	2	0	4	4	2	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.125	0.75	1.8571428	3	1.55	1		1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA783TCP
2081	8976	NDAR_INVGA783TCP	2239			F	1600	Visit6	6	Phase 1B	170	1	0	0	1	0	0	0	2	4	2	2	2	4	3	4	5	1	2	4	4	4	3	1	3	3	1	5	5	1	0	1	0	1	1	1	1	2	3	1	4	2	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.875	3	3.5714285	2	3.047619			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA783TCP
2081	8976	NDAR_INVGA783TCP	2239			F	5200	EndofPhase1_1a	3	Phase 1/1A	80	0	0	0	1	1	0	0	4	0	0	0	0	1	2	3	0	0	0	9	1	0	0	0	0	2	0	3	2	0	0	0	0	1	0	1	0	1	1	0	4	2	4	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	1.25	0	0.85714287	1	0.9		1	1.55	1.125	0.75	1.8571428	3	-0.65	0.125	-0.75	-1	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA783TCP
2081	8976	NDAR_INVGA783TCP	2239			F	5400	EndofPhase1b	9	Phase 1B	240	0	0	0	0	0	0	1	4	0	0	0	0	0	0	3	0	0	0	9	1	0	1	1	1	3	1	4	4	1	0	1	1	1	1	1	0	1	3	0	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.875	0	1.7142857	2	1.15			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA783TCP
2081	8976	NDAR_INVGA783TCP	2239			F	5800	EndofPhase2	11	Phase 2	296	0	0	0	0	0	0	1	4	4	2	1	1	2	1	3	2	1	1	9	1	2	3	2	1	4	4	4	4	1	0	1	0	1	1	1	1	1	3	1	4	4	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.25	1	2.4285715	4	2.35			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGA783TCP
2081	8976	NDAR_INVGB277FD7	2573			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	4	2	5	3	2	6	1	0	0	9	3	2	4	5	3	2	2	0	3	1	0	1	0	1	0	0	0	1	1	1	3	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	0.25	2.857143	2	2.85	1		2.85	4	0.25	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB277FD7
2081	8976	NDAR_INVGB277FD7	2573			F	1600	Visit6	6	Phase 2	169	0	1	0	0	0	0	0	4	1	1	0	3	0	2	3	0	0	0	9	2	3	2	1	0	5	2	4	2	1	0	1	0	1	0	0	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.75	0	2	3.5	1.75			2.85	4	0.25	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB277FD7
2081	8976	NDAR_INVGB277FD7	2573			F	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	1	0	0	0	0	0	4	4	3	3	3	2	2	4	2	2	1	9	2	4	2	3	2	4	2	3	2	1	0	1	0	1	1	1	0	2	1	1	3	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.25	2.5714285	3	2.7		1	2.85	4	0.25	2.857143	2	-0.15	-0.875	1	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB277FD7
2081	8976	NDAR_INVGB507BG6	1304			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	0	3	2	2	2	3	0	0	0	9	0	2	2	3	3	4	3	4	4	1	1	1	1	1	1	1	1	1	2	0	4	2	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2	0	2.5714285	3.5	2.05	1		2.05	2	0	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB507BG6
2081	8976	NDAR_INVGB507BG6	1304			M	5200	EndofPhase1_1a	3	Phase 1/1A	106	0	1	0	0	0	0	0	5	3	3	2	2	2	3	4	0	0	0	9	0	2	2	4	2	3	2	4	3	1	1	1	1	1	1	1	1	1	2	1	4	2	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	26	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3	0	2.4285715	2.5	2.3		1	2.05	2	0	2.5714285	3.5	0.25	1	0	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB507BG6
2081	8976	NDAR_INVGB626CFZ	2044			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	3	4	5	5	3	0	6	6	5	5	1	0	5	4	5	5	3	5	6	1	0	1	1	1	1	1	1	3		1	3	2	3	4	1	0	0	0	0	1	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	5.5	3.7142856	4	4.1904764	1		4.1904764	4	5.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB626CFZ
2081	8976	NDAR_INVGB626CFZ	2044			F	1600	Visit6	6	Phase 2	168	0	0	0	0	0	1	0	6	5	5	5	4	5	4	0	2	4	5	9	3	3	4	4	4	5	5	4	5	1	1	1	0	1	1	1	1	3	3	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	4.25	2.75	3.857143	5	4.1			4.1904764	4	5.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB626CFZ
2081	8976	NDAR_INVGB626CFZ	2044			F	2800	Visit12	12	Phase 2	332	0	0	0	0	0	1	0	6	4	3	2	3	2	3	1	0	3	3	9	3	4	4	3	4	6	4	3	4	1	1	1	0	1	1	1	1	3	3	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3	1.5	3.5714285	5	3.25			4.1904764	4	5.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB626CFZ
2081	8976	NDAR_INVGB626CFZ	2044			F	5200	EndofPhase1_1a	3	Phase 1/1A	82	0	0	0	0	0	1	0	6	4	2	3	2	1	3	0	1	4	4	9	2	3	5	2	2	5	3	1	3	1	0	1	0	1	1	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	23	0		0		1	7	0		1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	7	2.625	2.25	2.5714285	4	2.8		1	4.1904764	4	5.5	3.7142856	4	-1.3904762	-1.375	-3.25	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB626CFZ
2081	8976	NDAR_INVGB626CFZ	2044			F	5800	EndofPhase2	18	Phase 2	495	0	0	0	0	0	1	0	6	3	4	5	4	5	5	0	3	4	5	9	4		6	5	5	6	6	4	5	1	1	1	1	1	1	1	1	2	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1										0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4	3	4.8333335	6	4.4736843			4.1904764	4	5.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB626CFZ
2081	8976	NDAR_INVGB837GF0	1684			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	2	2	1	9	2	2	0	1	2	6	4	2	3	1	1	1	1	1	1	1	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	0.375	1.25	1.7142857	5	1.5	1		1.5	0.375	1.25	1.7142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB837GF0
2081	8976	NDAR_INVGB837GF0	1684			M	1600	Visit6	6	Phase 1/1A	162	0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	2	2	1	9	2	2	1	1	2	6	4	2	3	1	1	1	1	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	0.625	1.25	1.8571428	5	1.65			1.5	0.375	1.25	1.7142857	5	0.15	0.25	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB837GF0
2081	8976	NDAR_INVGB837GF0	1684			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	3	4	5	4	2	2	1	1	1	5	3	1	2	1	1	1	1	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	0.25	4	1.4285715	4	1.7142857			1.5	0.375	1.25	1.7142857	5	0.21428572	-0.125	2.75	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB837GF0
2081	8976	NDAR_INVGB837GF0	1684			M	5200	EndofPhase1_1a	18	Phase 1/1A	483	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	2	2	3	9	2	2	2	1	2	6	4	1	2	1	1	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	0.125	1.75	1.7142857	5	1.5		1	1.5	0.375	1.25	1.7142857	5	0	-0.25	0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGB837GF0
2081	8976	NDAR_INVGC368ZBX	2056			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	1	1	4	5	4	3	5	5	6	2	2	5	5	5	5	6	5	5	5	5	1	1	1	1	1	1	1	1	1	1	1	3	4	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	0	0	0	1	1	1	1	2	3.375	3.75	5.142857	5	4.1904764	1		4.1904764	3.375	3.75	5.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGC368ZBX
2081	8976	NDAR_INVGC370XVE	2746			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	2	2	2	2	2	2	2	2	2	2	9	1	2	2	2	2	3	1	3	3	1	2	2	0	1	0	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1		0		0		1		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	1.5	2.142857	2	2.05	1		2.05	2	1.5	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGC370XVE
2081	8976	NDAR_INVGD188VYU	1473			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	5	5	5	5	5	5	5	5	5	6	5	4	5	5	5	6	4	6	5	1	0	1	1	1	1	1	1	1	2	1	2	1	1	1	1	0	1	0	0	1	0	0	1	0	2	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	5.25	5	5	5.142857	1		5.142857	5.25	5.25	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD188VYU
2081	8976	NDAR_INVGD295DGB	2121			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	0	2	2	2	2	1	9	0	2	4	3	2	5	3	2	4	0	1	1	0	1	0	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1.75	1.25	2.4285715	4	2.2	1		2.2	1.75	1.25	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD295DGB
2081	8976	NDAR_INVGD295DGB	2121			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	5	0	0	2	2	2	2	2	2	2	1	9	0	0	2	4	2	3	3	4	4	0	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	1.25	2.2857144	3	2.1			2.2	1.75	1.25	2.4285715	4	-0.1	0.125	0	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD295DGB
2081	8976	NDAR_INVGD295DGB	2121			M	2800	Visit12	12	Phase 1/1A	351	1	0	0	0	0	0	0	6	0	0	2	2	2	3	1	0	1	1	9	1	2	2	5	3	3	2	5	4	1	1	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2	0.5	3.142857	2.5	2.25			2.2	1.75	1.25	2.4285715	4	0.05	0.25	-0.75	0.71428573	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD295DGB
2081	8976	NDAR_INVGD295DGB	2121			M	5200	EndofPhase1_1a	18	Phase 1/1A	524	1	0	0	0	0	0	0	6	4	2	4	2	4	4	2	1	2	0	9	0	0	0	3	3	3	2	4	4	1	1	1	0	1	1	1	1	1	1	1	4	4	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	3.5	0.75	2	2.5	2.5		1	2.2	1.75	1.25	2.4285715	4	0.3	1.75	-0.5	-0.42857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD295DGB
2081	8976	NDAR_INVGD726PWP	2403			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	1	0	0	0	2	2	3	2	3	6	9	3	6	4	4	4	2	4	4	6	1	1	1	1	1	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.1428572	2.75	4.428571	3	2.9473684	1		2.9473684	1.1428572	2.75	4.428571	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD726PWP
2081	8976	NDAR_INVGD726PWP	2403			M	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	0	1	9	0	0	1	1	0	1	1	0	0	0	9	1	2	4	4	2	3	5	2	2	1	1	1	1	1	1	1	1	3		0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.5714286	0	2.4285715	4	1.5263158			2.9473684	1.1428572	2.75	4.428571	3	-1.4210526	-0.5714286	-2.75	-2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD726PWP
2081	8976	NDAR_INVGD726PWP	2403			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	9	0	2	2	2	2	2	1	0	0	4	9	0	6	4	3	4	3	6	2	4	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.5714285	1	3.2857144	4.5	2.4736843			2.9473684	1.1428572	2.75	4.428571	3	-0.47368422	0.42857143	-1.75	-1.1428572	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD726PWP
2081	8976	NDAR_INVGD726PWP	2403			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	0	1	9	0	4	2	1	2	2	0	0	0	0	9	1	4	4	3	4	4	4	3	4	1	1	1	1	1	1	1	1	3		0	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5714285	0	3.2857144	4	2.2105262		1	2.9473684	1.1428572	2.75	4.428571	3	-0.7368421	0.42857143	-2.75	-1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD726PWP
2081	8976	NDAR_INVGD984LDX	2627			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	1	3	6	5	5	5	1	4	0	9	0	2	3	4	1	3	2	4	6	0	0	1	1	1	0	0	1	1	2	1	3	1	1	1	1	1	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	1	1	0	0	0	0	4	4.25	1.25	2.857143	2.5	3.2	1		3.2	4.25	1.25	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGD984LDX
2081	8976	NDAR_INVGE627LK8	2022			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	4	1	3	3	2	3	5	1	2	3	9	4	3	0	3	2	1	2	3	2	0	0	0	0	0	1	0	1	3		1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.5	2.4285715	1.5	2.4	1		2.4	2.75	1.5	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGE627LK8
2081	8976	NDAR_INVGE627LK8	2022			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	6	0	4	4	2	2	6	1	4	2	9	6	4	4	6	4	1	2	6	4	0	1	1	0	0	1	1	1	3		1	4	2	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	3.75	1.75	4.857143	1.5	3.7			2.4	2.75	1.5	2.4285715	1.5	1.3	1	0.25	2.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGE627LK8
2081	8976	NDAR_INVGE627LK8	2022			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	5	3	0	2	2	1	3	4	1	0	2	9	3	2	0	1	3	2	1	2	2	0	0	0	0	1	1	1	1	3	3	1	3	2	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	2.5	0.75	1.8571428	1.5	1.95			2.4	2.75	1.5	2.4285715	1.5	-0.45	-0.25	-0.75	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGE627LK8
2081	8976	NDAR_INVGE627LK8	2022			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	0	0	1	0	0	1	5	4	1	2	5	9	2	5	2	3	1	0	0	2	2	0	0	1	0	1	1	0	2	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.375	2	2.4285715	0	1.8		1	2.4	2.75	1.5	2.4285715	1.5	-0.6	-1.375	0.5	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGE627LK8
2081	8976	NDAR_INVGF264JYH	2550			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	1	2	2	3	1	1	2	1	3	1	3	2	3	1	1	2	5	3	0	0	2	0	0	1	0	1	1	1	1	1	3	0	4	4	4	1	1	0	1	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.625	2.25	2	1.5	1.8571428	1		1.8571428	1.625	2.25	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF264JYH
2081	8976	NDAR_INVGF264JYH	2550			F	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	3	2	2	3	3	2	3	2	5	3	4	5	2	1	1	3	5	3	0	2	3	0	0	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.5	4.25	2.4285715	1.5	2.7142856			1.8571428	1.625	2.25	2	1.5	0.85714287	0.875	2	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF264JYH
2081	8976	NDAR_INVGF264JYH	2550			F	5200	EndofPhase1_1a	12	Phase 1/1A	352	0	1	0	1	0	0	0	3	1	1	1	3	2	2	2	5	4	5	4	3	2	1	2	5	3	2	2	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.875	4.5	2.7142856	2.5	2.7142856		1	1.8571428	1.625	2.25	2	1.5	0.85714287	0.25	2.25	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF264JYH
2081	8976	NDAR_INVGF423NNG	2429			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	0	1	2	2	5	1	0	4	2	9	2	2	2	2	1	1	1	4	4	2	1	1	0	1	1	1	1	3	1	1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2.25	1.5	2.4285715	1	2.15	1		2.15	2.25	1.5	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF423NNG
2081	8976	NDAR_INVGF724XM4	1267			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	2	0	0	2	0	0	4	9	2	2	3	2	2	2	0	4	3	0	0	0	1	1	1	1	1	1	1	1	4	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	0.75	1	2.5714285	1	1.5	1		1.5	0.75	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF724XM4
2081	8976	NDAR_INVGF724XM4	1267			M	1600	Visit6	6	Phase 2	157	1	0	0	0	0	0	0	2	1	0	0	2	2	1	1	2	2	1	9	2	1	2	2	1	3	1	4	4	1	1	1	0	1	1	1	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	5	1.125	1.25	2.2857144	2	1.7			1.5	0.75	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF724XM4
2081	8976	NDAR_INVGF724XM4	1267			M	2800	Visit12	12	Phase 2	338	1	0	0	0	0	0	0	4	3	3	2	3	3	3	2	3	2	2	3	3	1	2	3	2	3	0	4	3	0	0	0	0	1	1	1	1	1	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2.875	2.5	2.5714285	1.5	2.5714285			1.5	0.75	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF724XM4
2081	8976	NDAR_INVGF724XM4	1267			M	5200	EndofPhase1_1a	2	Phase 1/1A	50	1	0	0	0	0	0	0	2	1	1	1	2	1	1	1	1	3	2	9	2	2	2	1	2	2	2	3	4	0	0	1	1	1	1	1	1	3	1	1	4	1	1	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.25	1.5	2.2857144	2	1.8		1	1.5	0.75	1	2.5714285	1	0.3	0.5	0.5	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF724XM4
2081	8976	NDAR_INVGF724XM4	1267			M	5800	EndofPhase2	18	Phase 2	505	1	0	0	0	0	0	0	1	3	4	3	3	2	2	1	4	1	1	3	3	1	1	3	3	1	1	2	3	0	1	1	0	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.375	2.25	2.2857144	1	2.1904762			1.5	0.75	1	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF724XM4
2081	8976	NDAR_INVGF972PJA	1719			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	2	2	2	2	2	2	3	2	2	9	2	2	2	2	2	4	4	3	2	2	2	2	1	1	2	2	2	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	10	0		0		1	20	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.75	2.142857	4	2.3	1		2.3	2	1.75	2.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF972PJA
2081	8976	NDAR_INVGF972PJA	1719			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	3	2	1	1	1	1	1	1	2	1	1	9	1	1	1	1	1	3	2	1	1	0	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	1	1	2.5	1.35			2.3	2	1.75	2.142857	4	-0.95	-0.625	-0.75	-1.1428572	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF972PJA
2081	8976	NDAR_INVGF972PJA	1719			M	5200	EndofPhase1_1a	9	Phase 1/1A	267	1	0	0	0	0	0	0	3	2	2	2	2	2	2	4	2	2	2	9	2	2	2	2	2	5	3	4	2	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	1.5	2.2857144	4	2.45		1	2.3	2	1.75	2.142857	4	0.15	0.375	-0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGF972PJA
2081	8976	NDAR_INVGG222FPL	1812			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	0	0	0	6	0	1	0	0	0	0	9	1	0	2	1	0	5	2	3	5	1	1	0	0	1	1	0	2	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	21	0		0		1	9	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.625	0	1.7142857	3.5	1.6	1		1.6	1.625	0	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG222FPL
2081	8976	NDAR_INVGG222FPL	1812			M	1600	Visit6	6	Phase 2	171	0	0	0	0	0	1	0	6	0	0	0	0	0	0	0	0	0	0	9	0	2	4	2	1	5	2	2	3	1	1	1	0	1	1	1	0	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.75	0	2	3.5	1.35			1.6	1.625	0	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG222FPL
2081	8976	NDAR_INVGG222FPL	1812			M	2800	Visit12	12	Phase 2	338	0	0	0	0	0	1	0	2	0	2	4	2	0	3	0	1	0	0	9	0	3	4	4	4	3	3	5	5	1	1	0	0	1	1	0	1	2	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.25	3.5714285	3	2.25			1.6	1.625	0	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG222FPL
2081	8976	NDAR_INVGG222FPL	1812			M	5200	EndofPhase1_1a	2	Phase 1/1A	33	0	0	0	0	0	0	1	6	0	0	0	6	0	1	0	0	0	0	9	1	0	2	1	0	5	2	3	5	1	1	0	0	1	1	0	2	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.625	0	1.7142857	3.5	1.6		1	1.6	1.625	0	1.7142857	3.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG222FPL
2081	8976	NDAR_INVGG222FPL	1812			M	5800	EndofPhase2	18	Phase 2	507	0	0	0	0	0	1	0	5	3	5	5	2	3	5	2	2	4	5	9	4	4	4	3	2	4	3	4	6	1	1	0	1	1	1	2	1	2	1	0	4	4	2	4	1	0	0	0	0	0	1	0	1	1	0	1	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.75	2.75	3.857143	3.5	3.75			1.6	1.625	0	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG222FPL
2081	8976	NDAR_INVGG654MFF	1281			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	1	2	1	1	1	1	1	1	9	1	2	2	2	2	3	4	3	5	1	1	1	1	1	1	1	0	2	2	1	3	3	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	0.75	2.4285715	3.5	1.95	1		1.95	1.5	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG654MFF
2081	8976	NDAR_INVGG654MFF	1281			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	0	0	0	0	0	1	0	0	2	0	0	2	0	0	0	0	0	0	9	2	1	2	2	1	3	2	3	3	1	1	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.5	0	2	2.5	1.15		1	1.95	1.5	0.75	2.4285715	3.5	-0.8	-1	-0.75	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG654MFF
2081	8976	NDAR_INVGG739HTG	1133			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	0	1	0	2	0	1	3	1	9	2	2	4	2	1	5	4	5	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1	1.25	2.857143	4.5	2.1578948	1		2.1578948	1	1.25	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG739HTG
2081	8976	NDAR_INVGG739HTG	1133			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	0	1	1	0	0	1	2	0	1	0	1	2	3	9	1	3	2	1	3	5	4	1	1	1	1	1	0	1	1	1	1	3		0	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	0.625	1.5	1.7142857	4.5	1.6			2.1578948	1	1.25	2.857143	4.5	-0.55789477	-0.375	0.25	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG739HTG
2081	8976	NDAR_INVGG739HTG	1133			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	0	1	9	0	0	0	2	0	2	0	1	3	2	9	1	2	3	2	1	5	4	4	3	1	1	0	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	0.5714286	1.5	2.2857144	4.5	1.8421053			2.1578948	1	1.25	2.857143	4.5	-0.31578946	-0.42857143	0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG739HTG
2081	8976	NDAR_INVGG739HTG	1133			M	4000	Visit18	18	Phase 1/1A	522	0	0	0	0	0	0	1	2	0	1	0	2	1	2	0	2	3	2	9	1	2	2	2	1	5	4	4	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1	1.75	2.2857144	4.5	2		1	2.1578948	1	1.25	2.857143	4.5	-0.15789473	0	0.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGG739HTG
2081	8976	NDAR_INVGH230GEQ	1620			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	4	4	4	2	2	5	4	2	4	6	4	3	4	4	2	6	4	4	5	1	1	1	0	1	1	1	1	3	2	1	3	1	1	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.625	4	3.7142856	5	3.857143	1		3.857143	3.625	4	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH230GEQ
2081	8976	NDAR_INVGH230GEQ	1620			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	4	4	4	4	4	4	4	4	4	2	4	4	4	3	4	4	2	6	4	4	4	1	1	1	1	1	1	1	1	3	2	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4	3.5	3.5714285	5	3.857143			3.857143	3.625	4	3.7142856	5	0	0.375	-0.5	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH230GEQ
2081	8976	NDAR_INVGH230GEQ	1620			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	9	5	4	5	5	4	5	4	2	2	1	9	3	4	4	4	5	6	3	5	6	1	1	1	0	1	1	1	1	3	1	1	2	1	2	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.571429	1.25	4.428571	4.5	4.0526314			3.857143	3.625	4	3.7142856	5	0.19548872	0.9464286	-2.75	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH230GEQ
2081	8976	NDAR_INVGH230GEQ	1620			M	5200	EndofPhase1_1a	18	Phase 1/1A	490	0	0	0	0	0	0	1	9	5	5	5	4	6	5	3	2	5	1	9	5	6	6	4	5	6	3	5	6	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		1	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.714286	2	5.285714	4.5	4.5789475		1	3.857143	3.625	4	3.7142856	5	0.7218045	1.0892857	-2	1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH230GEQ
2081	8976	NDAR_INVGH248AVE	2424			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	0	1	0	0	0	0	0	0	0	9	2	4	6	0	4	5	5	4	4	0	1	1	1	1	1	1	1	2	1	1	4	4	3	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.375	0	3.4285715	5	2.25	1		2.25	1.375	0	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH248AVE
2081	8976	NDAR_INVGH248AVE	2424			F	1600	Visit6	6	Phase 1/1A	171	0	0	0	1	0	0	0	6	6	4	6	6	6	6	1	3	5	5	5	6	6	5	1	5	6	5	5	5	1	1	1	0	1	1	1	1	1	2	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	4	5.125	4.5	4.714286	5.5	4.904762			2.25	1.375	0	3.4285715	5	2.6547618	3.75	4.5	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH248AVE
2081	8976	NDAR_INVGH248AVE	2424			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	1	0	0	0	6	6	4	5	6	4	6	2	5	6	6	6	5	6	4	5	5	6	3	6	6	1	0	1	0	1	1	1	1	1	1	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	5.75	5.285714	4.5	5.142857			2.25	1.375	0	3.4285715	5	2.892857	3.5	5.75	1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH248AVE
2081	8976	NDAR_INVGH248AVE	2424			F	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	1	0	0	0	6	4	4	5	4	5	6	2	5	5	6	9	6	5	3	6	5	6	4	6	6	1	1	1	0	1	1	1	1	1	1	1	4	3	2	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	4.5	4	5.285714	5	4.95		1	2.25	1.375	0	3.4285715	5	2.7	3.125	4	1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH248AVE
2081	8976	NDAR_INVGH606WVP	2357			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	4	2	6	3	4	1	6	6	6	6	2	4	3	4	5	6	4	4	6	1	1	1	1	1	0	0	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4	6	4	5	4.4761906	1		4.4761906	4	6	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH606WVP
2081	8976	NDAR_INVGH606WVP	2357			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	3	2	2	2	2	3	2	6	6	6	6	3	3	2	4	5	5	4	4	4	1	1	1	1	1	1	1	1	3	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.2857144	6	3.5714285	4.5	3.7			4.4761906	4	6	4	5	-0.77619046	-1.7142857	0	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH606WVP
2081	8976	NDAR_INVGH606WVP	2357			M	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	0	1	2	2	0	2	0	4	6	2	6	4	6	6	0	2	2	2	4	4	2	4	2	1	0	1	0	1	1	1	1	3	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.25	5.5	2.2857144	3	2.952381			4.4761906	4	6	4	5	-1.5238096	-1.75	-0.5	-1.7142857	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH606WVP
2081	8976	NDAR_INVGH606WVP	2357			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	9	4	2	4	4	1	2	2	6	6	6	6	4	3	4	3	4	4	3	4	6	1	1	1	1	1	0	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	2.7142856	6	4	3.5	3.9		1	4.4761906	4	6	4	5	-0.5761905	-1.2857143	0	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH606WVP
2081	8976	NDAR_INVGH764EWK	1596			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	4	4	3	3	4	1	2	5	4	9	4	5	6	4	5	5	4	6	5	1	1	1	1	1	1	1	1	2	1	1	2	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.75	2.75	5	4.5	3.85	1		3.85	2.75	2.75	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH764EWK
2081	8976	NDAR_INVGH764EWK	1596			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	1	0	4	3	4	3	4	2	4	2	3	5	4	3	1	4	6	5	6	5	4	5	4	1	1	1	1	1	1	1	1	3	1	1	3	2	2	4	0	0	0	0	0	0	0	1					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	3.25	3.75	4.428571	4.5	3.857143		1	3.85	2.75	2.75	5	4.5	0.007142857	0.5	1	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH764EWK
2081	8976	NDAR_INVGH764EWK	1596			M	2800	Visit12	12	Phase 3	367	0	0	0	0	0	1	0	4	1	2	3	2	2	4	1	3	5	4	3	1	5	5	4	4	6	4	5	4	1	1	1	1	1	1	1	1	3		0		3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.375	3.75	4	5	3.4285715			3.85	2.75	2.75	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH764EWK
2081	8976	NDAR_INVGH764EWK	1596			M	4000	Visit18	18	Phase 3	549	0	0	0	0	0	1	0	2	0	0	2	0	1	3	1	2	4	4	9	3	4	5	4	4	6	3	5	5	1	1	1	1	1	1	1	1	3		0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.125	2.5	4.285714	4.5	2.9			3.85	2.75	2.75	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH764EWK
2081	8976	NDAR_INVGH764EWK	1596			M	5200	EndofPhase1_1a	9	Phase 1/1A	279	0	0	0	0	0	1	0									2									6	3		4	1	1	1	0	1	1	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3				4.5				3.85	2.75	2.75	5	4.5					0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGH764EWK
2081	8976	NDAR_INVGJ199ACH	1160			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	1	4	4	4	4	1	0	1	2	9	1	2	4	3	0	6	4	4	4	1	1	0	0	1	1	1	1	3		1	2	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.2857144	0.75	2.5714285	5	2.8421052	1		2.8421052	3.2857144	0.75	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ199ACH
2081	8976	NDAR_INVGJ423FAB	2879			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	1	1	1	1	1	3	1	2	2	4	9	3	3	3	2	0	3	3	4	4	1	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	0	4	1.375	2	2.7142856	3	2.2	1		2.2	1.375	2	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ423FAB
2081	8976	NDAR_INVGJ423FAB	2879			F	1600	Visit6	6	Phase 1/1A	171	0	1	0	0	0	0	0	5	3	2	2	4	2	2	5	2	2	5	9	2	3	3	4	1	2	3	4	4	0	0	1	0	1	1	1	1	1	2	1	2	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	2.25	3	2.5	3			2.2	1.375	2	2.7142856	3	0.8	1.75	0.25	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ423FAB
2081	8976	NDAR_INVGJ423FAB	2879			F	2800	Visit12	12	Phase 1/1A	341	0	1	0	0	0	0	0	3	3	2	2	3	2	2	4	0	2	4	9	2	2	2	3	0	1	1	3	3	1	0	1	0	1	1	1	1	3	2	1	2	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.625	1.5	2.142857	1	2.2			2.2	1.375	2	2.7142856	3	0	1.25	-0.5	-0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ423FAB
2081	8976	NDAR_INVGJ423FAB	2879			F	5200	EndofPhase1_1a	18	Phase 1/1A	501	0	1	0	0	0	0	0	5	4	3	2	2	2	3	4	2	2	2	9	2	2	3	4	1	2	2	4	3	1	0	1	0	1	1	1	1	2	2	1	2	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	1.5	2.7142856	2	2.7		1	2.2	1.375	2	2.7142856	3	0.5	1.75	-0.5	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ423FAB
2081	8976	NDAR_INVGJ830PFP	1519			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	1	0	0	4	4	0	4	4	2	2	2	0	0	1	9	4	3	2	4	4	0	3	2	6	1	0	1	1	1	0	0	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	4	2.75	0.25	3.5714285	1.5	2.55	1		2.55	2.75	0.25	3.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ830PFP
2081	8976	NDAR_INVGJ830PFP	1519			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	3	0	0	0	2	1	1	3	0	0	0	9	4	3	3	3	2	2	2	1	6	1	0	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.25	0	3.142857	2	1.8			2.55	2.75	0.25	3.5714285	1.5	-0.75	-1.5	-0.25	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ830PFP
2081	8976	NDAR_INVGJ830PFP	1519			M	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	4	3	2	1	0	0	2	3	0	0	3	9	3	3	4	2	4	2	2	0	6	1	0	0	0	1	1	0	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.875	0.75	3.142857	2	2.2			2.55	2.75	0.25	3.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ830PFP
2081	8976	NDAR_INVGJ830PFP	1519			M	5200	EndofPhase1_1a	11	Phase 1/1A	309	0	1	0	0	0	0	0	4	2	2	2	2	1	2	2	0	0	2	9	3	4	5	2	3	1	2	4	6	1	0	1	0	1	1	0	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.5	3.857143	1.5	2.45		1	2.55	2.75	0.25	3.5714285	1.5	-0.1	-0.625	0.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ830PFP
2081	8976	NDAR_INVGJ830PFP	1519			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	1	0	0	3	3	3	4	3	4	3	4	0	0	0	9	3	3	3	3	2	2	2	3	5	0	0	0	0	1	1	0	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	5	3.375	0	3.142857	2	2.65			2.55	2.75	0.25	3.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ830PFP
2081	8976	NDAR_INVGJ862KM9	2742			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	2	0	2	0	0	0	0	9	2	0	2	2	1	3	2	2	3	0	1	1	0	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	1	1	1	1	0	1	0	4	0.75	0	1.7142857	2.5	1.15	1		1.15	0.75	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ862KM9
2081	8976	NDAR_INVGJ862KM9	2742			M	1600	Visit6	6	Phase 2	171	0	0	0	0	0	1	0	0	1	1	1	0	0	6	1	0	0	5	9	2	5	2	3	2	3	2	5	6	1	1	1	0	1	1	1	0	2	2	1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	1	0	1	1	0	4	1.25	1.25	3.5714285	2.5	2.25			1.15	0.75	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ862KM9
2081	8976	NDAR_INVGJ862KM9	2742			M	2800	Visit12	12	Phase 3	340	0	0	0	0	0	1	0	4	2	3	3	5	3	5	3	0	1	1	9	2	4	4	4	2	3	4	4	4	1	0	0	1	1	1	1	1	2	2	1	4	2	4	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	0.5	3.4285715	3.5	3.05			1.15	0.75	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ862KM9
2081	8976	NDAR_INVGJ862KM9	2742			M	5200	EndofPhase1_1a	4	Phase 1/1A	117	0	0	0	0	0	1	0	4	3	4	2	3	2	3	3	2	2	2	9	3	4	4	4	2	2	3	3	4	1	1	0	0	1	1	0	1	3	2	1	3	2	4	2	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	4	3	1.5	3.4285715	2.5	2.95		1	1.15	0.75	0	1.7142857	2.5	1.8	2.25	1.5	1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ862KM9
2081	8976	NDAR_INVGJ862KM9	2742			M	5800	EndofPhase2	7	Phase 2	197	0	0	0	0	0	1	0	4	3	2	2	3	2	4	4	1	1	2	9	3	4	4	4	2	1	2	4	4	1	1	0	1	1	1	1	0	2	2	1	4	2	2	3	1	0	0	0	0	0	1	0	0	1	1	1	0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	1	1	1	0	1	0	5	3	1	3.5714285	1.5	2.8			1.15	0.75	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ862KM9
2081	8976	NDAR_INVGJ862KM9	2742			M	6000	EndofPhase3	18	Phase 3	505	0	0	0	0	0	1	0	1	2	3	2	2	3	6	3	0	1	4	9	3	3	4	3	0	4	2	5	5	0	1	0	1	1	1	1	0	2	2	0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	0	1	1	6	2.75	1.25	3.2857144	3	2.8			1.15	0.75	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGJ862KM9
2081	8976	NDAR_INVGL183LE3	2272			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	3	0	2	5	2	9	4	4	5	4	3	6	2	5	5	0	0	1	1	1	1	0	1	1	1	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	1.875	2.25	4.285714	4	3.1	1		3.1	1.875	2.25	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL183LE3
2081	8976	NDAR_INVGL183LE3	2272			M	2800	Visit12	12	Phase 3	338	1	0	0	0	0	0	0	4	2	1	2	2	1	2	1	0	0	0	9	1	4	5	2	3	5	3	1	3	1	1	1	1	1	1	0	1	1	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0	2.7142856	4	2.1			3.1	1.875	2.25	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL183LE3
2081	8976	NDAR_INVGL183LE3	2272			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	2	3	3	9	4	3	5	4	3	6	2	5	5	1	0	1	1	1	1	0	1	1	2	0	4	4	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	2	4.142857	4	2.95		1	3.1	1.875	2.25	4.285714	4	-0.15	-0.125	-0.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL183LE3
2081	8976	NDAR_INVGL183LE3	2272			M	6000	EndofPhase3	18	Phase 3	509	1	0	0	0	0	0	0	4	0	0	2	2	2	2	1	0	1	2	9	3	3	4	2	4	4	3	2	2	0	0	1	1	1	1	0	1	1	2	0	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.625	0.75	2.857143	3.5	2.15			3.1	1.875	2.25	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL183LE3
2081	8976	NDAR_INVGL443VDT	2532			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	1	4	0	4	2	0	0	0	9	1	0	0	6	6	2	2	4	3	0	0	1	1	1	0	1	1	2	2	1	3	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.125	0	2.857143	2	2.45	1		2.45	3.125	0	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL443VDT
2081	8976	NDAR_INVGL533HMF	2092			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	1	1	1	2	2	1	3	1	4	9	2	2	3	4	2	3	3	2	5	1	0	1	0	1	0	1	0	1	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.25	2	2.857143	3	2.2	1		2.2	1.25	2	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL533HMF
2081	8976	NDAR_INVGL533HMF	2092			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	4	0	2	1	1	1	2	1	3	1	4	9	2	2	3	4	2	3	3	2	5	1	0	1	0	1	0	1	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.5	2	2.857143	3	2.3			2.2	1.25	2	2.857143	3	0.1	0.25	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL533HMF
2081	8976	NDAR_INVGL533HMF	2092			M	2800	Visit12	12	Phase 2	356	0	1	0	0	0	0	0	2	2	3	1	3	3	2	4	1	1	2	9	2	2	4	2	3	3	4	4	2	1	1	1	2	1	1	1	1	3	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.5	1	2.7142856	3.5	2.5			2.2	1.25	2	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL533HMF
2081	8976	NDAR_INVGL533HMF	2092			M	5200	EndofPhase1_1a	10	Phase 1/1A	296	0	1	0	0	0	0	0	4	2	4	2	4	2	2	4	0	0	0	9	2	2	4	3	2	2	3	4	6	1	0	1	0	1	1	0	1	1	2	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3	0	3.2857144	2.5	2.6		1	2.2	1.25	2	2.857143	3	0.4	1.75	-2	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL533HMF
2081	8976	NDAR_INVGL533HMF	2092			M	5800	EndofPhase2	18	Phase 2	567	0	1	0	0	0	0	0	2	2	3	1	3	3	2	4	1	1	2	9	2	2	4	2	3	3	4	4	2	1	1	1	2	1	1	1	1	3	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.5	1	2.7142856	3.5	2.5			2.2	1.25	2	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL533HMF
2081	8976	NDAR_INVGL786TZP	1822			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	2	2	2	3	2	3	3	0	0	1	9	2	2	2	2	1	3	1	4	2	0	0	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	0.25	2.142857	2	2	1		2	2.5	0.25	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL786TZP
2081	8976	NDAR_INVGL786TZP	1822			M	1600	Visit6	6	Phase 2	176	1	0	0	0	0	0	0	4	1	1	0	4	0	0	0	0	1	1	9	0	2	0	0	0	0	0	0	4	1	0	0	0	1	1	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.25	0.5	0.85714287	0	0.9			2	2.5	0.25	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL786TZP
2081	8976	NDAR_INVGL786TZP	1822			M	2800	Visit12	12	Phase 3	344	1	0	1	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	9	1	0	0	1	1	2	1	1	2	0	0	0	0	1	0	0	1	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	0.625	0	0.85714287	1.5	0.7			2	2.5	0.25	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL786TZP
2081	8976	NDAR_INVGL786TZP	1822			M	5200	EndofPhase1_1a	4	Phase 1/1A	114	1	0	0	0	0	0	0	1	1	1	2	1	1	1	1	0	0	0	9	1	1	1	1	1	2	1	2	2	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0	1.2857143	1.5	1.05		1	2	2.5	0.25	2.142857	2	-0.95	-1.375	-0.25	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL786TZP
2081	8976	NDAR_INVGL786TZP	1822			M	5800	EndofPhase2	9	Phase 2	268	1	0	1	0	0	0	0	1	1	1	2	1	1	1	1	0	0	0	9	1	1	1	1	1	2	1	2	2	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0	1.2857143	1.5	1.05			2	2.5	0.25	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL786TZP
2081	8976	NDAR_INVGL786TZP	1822			M	6000	EndofPhase3	18	Phase 3	501	1	0	1	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	9	1	0	0	1	1	2	1	1	2	0	0	0	0	1	0	0	1	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	0.625	0	0.85714287	1.5	0.7			2	2.5	0.25	2.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL786TZP
2081	8976	NDAR_INVGL828YXN	1603			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	1	0	0	4	0	0	0	2	0	1	3	0	0	0	9	1	2	2	1	0	2	1	5	5	0	0	0	0	0	1	0	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.25	0	2.2857144	1.5	1.45	1		1.45	1.25	0	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL828YXN
2081	8976	NDAR_INVGL828YXN	1603			M	5200	EndofPhase1_1a	2	Phase 1/1A	61	0	1	0	1	1	0	0	5	0	0	1	2	0	1	3	0	0	0	9	4	2	2	3	0	2	1	5	5	0	0	0	0	1	1	0	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.5	0	3	1.5	1.8		1	1.45	1.25	0	2.2857144	1.5	0.35	0.25	0	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL828YXN
2081	8976	NDAR_INVGL828YXN	1603			M	5400	EndofPhase1b	6	Phase 1B	156	0	1	0	1	1	0	0	4	0	0	0	2	0	1	2	0	0	0	9	3	2	2	3	0	1	1	4	6	1	0	0	0	0	1	0	1	1	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0	2.857143	1	1.55			1.45	1.25	0	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGL828YXN
2081	8976	NDAR_INVGM160JV7	1639			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	1	0	0	0	0	2	2	2	0	2	0	2	4	3	9	1	2	3	3	3	3	2	4	4	1	2	1	1	1	1	1	1	1	2	0		2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	5	1	2.25	2.857143	2.5	2.1	1		2.1	1	2.25	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM160JV7	1639			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	1	0	0	4	0	0	2	2	0	2	0	2	4	3	9	3	4	2	3	1	4	2	3	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	0	6	1.25	2.25	2.857143	3	2.25			2.1	1	2.25	2.857143	2.5	0.15	0.25	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM160JV7	1639			M	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	1	0	0	4	0	2	2	2	0	2	1	1	4	1	9	1	2	2	2	0	3	1	3	4	1	0	1	0	1	1	1	1	2	2	0	4	3	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	1.625	1.5	2	2	1.85			2.1	1	2.25	2.857143	2.5	-0.25	0.625	-0.75	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM160JV7	1639			M	4000	Visit18	18	Phase 2	504	1	0	0	0	0	0	0	5	5	2	2	4	2	3	4	0	0	4	9	4	4	3	4	3	4	1	5	5	1	1	1	1	0	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.375	1	4	2.5	3.2			2.1	1	2.25	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM160JV7	1639			M	5200	EndofPhase1_1a	17	Phase 1/1A	476	1	0	0	0	0	0	0	5	5	2	2	4	2	3	4	0	0	4	9	4	4	3	4	3	4	1	5	5	1	1	1	1	0	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.375	1	4	2.5	3.2		1	2.1	1	2.25	2.857143	2.5	1.1	2.375	-1.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM160JV7	1639			M	5800	EndofPhase2	21	Phase 2	589	1	0	0	0	0	0	0	4	2	2	3	4	1	3	0	0	0	2	9	2	1	2	4	1	3	2	4	5	1	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	2.375	0.5	2.7142856	2.5	2.25			2.1	1	2.25	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM160JV7	1639			M	6000	EndofPhase3	23	Phase 3	637	1	0	0	0	1	0	0	4	3	2	3	4	1	5	2	0	0	4	9	2	3	2	3	3	4	2	5	6	0	0	1	1	1	1	1	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3	1	3.4285715	3	2.9			2.1	1	2.25	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM160JV7
2081	8976	NDAR_INVGM256NLJ	1275			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	2	2	2	3	1	0	0	1	9	1	1	2	3	1	1	4	4	2	1	1	0	0	0	0	0	1	3	2	1	3	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.25	2	2.5	1.6	1		1.6	1.5	0.25	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM256NLJ
2081	8976	NDAR_INVGM256NLJ	1275			M	1600	Visit6	6	Phase 1/1A	180	0	0	0	0	0	1	0	4	3	2	4	2	2	3	0	0	0	0	9	2	2	2	2	2	3	5	3	4	1	1	0	0	1	1	0	0	3		1	4	3	3	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	2.5	0	2.4285715	4	2.25			1.6	1.5	0.25	2	2.5	0.65	1	-0.25	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM256NLJ
2081	8976	NDAR_INVGM256NLJ	1275			M	5200	EndofPhase1_1a	18	Phase 1/1A	530	0	0	0	0	0	1	0	4	4	2	2	2	3	3	0	0	0	0	9	2	1	3	3	1	4	3	3	4	0	1	2	0	1	1	2	2	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	0	2.4285715	3.5	2.2		1	1.6	1.5	0.25	2	2.5	0.6	1	-0.25	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM256NLJ
2081	8976	NDAR_INVGM281VGA	1221			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	2	3	2	3	2	3	0	5	5	6	6	4	6	4	4	5	4	4	4	4	1	1	0	0	1	1	0	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	5.5	4.428571	4	3.857143	1		3.857143	2.5	5.5	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM281VGA
2081	8976	NDAR_INVGM281VGA	1221			M	2800	Visit12	12	Phase 1/1A	425	1	0	0	0	0	0	0	6	2	4	3	5	3	5	4	6	6	6	6	6	6	6	5	6	5	4	5	5	1	1	1	1	1	1	1	1	2	1	0	4	2	4	1	1	0	1	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4	6	5.571429	4.5	4.952381		1	3.857143	2.5	5.5	4.428571	4	1.0952381	1.5	0.5	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM281VGA
2081	8976	NDAR_INVGM281VGA	1221			M	5800	EndofPhase2	18	Phase 2	623	1	0	1	0	0	0	0	6	0	3	2	2	2	4	2	6	5	6	6	4	5	5	4	5	5	4	5	5	1	1	1	1	1	1	1	1	1	1	0	4	3	3	3	1	0	1	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	5.75	4.714286	4.5	4.095238			3.857143	2.5	5.5	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM281VGA
2081	8976	NDAR_INVGM690DLQ	1027			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	4	2	4	2	3	2	4	5	4	6	3	5	2	4	4	3	3	3	4	0	1	0	0	0	2	1	2	3	1	1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	4.75	3.5714285	3	3.5714285	1		3.5714285	3.125	4.75	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM690DLQ
2081	8976	NDAR_INVGM690DLQ	1027			M	2800	Visit12	12	Phase 1/1A	361	0	0	0	0	0	1	0	6	0	2	2	1	2	3	0	6	6	6	6	0	5	5	6	6	3	3	5	6	1	1	0	1	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2	6	4.714286	3	3.7619047			3.5714285	3.125	4.75	3.5714285	3	0.1904762	-1.125	1.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM690DLQ
2081	8976	NDAR_INVGM690DLQ	1027			M	5200	EndofPhase1_1a	14	Phase 1/1A	393	0	0	0	0	0	1	0	5	4	4	2	2	2	3	0	6	5	5	6	2	3	2	6	5	3	3	3	4	1	1	0	1	1	1	1	1	3		1	2	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.75	5.5	3.5714285	3	3.5714285		1	3.5714285	3.125	4.75	3.5714285	3	0	-0.375	0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGM690DLQ
2081	8976	NDAR_INVGN326JHD	2397			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	2	2	0	2	4	2	1	1	9	2	1	2	6	0	3	2	4	6	1	1	0	0	1	1	0	0	3		0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	5	2	1	3	2.5	2.3	1		2.3	2	1	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN326JHD
2081	8976	NDAR_INVGN326JHD	2397			F	1600	Visit6	6	Phase 1/1A	189	0	1	0	0	0	0	0	6	0	2	2	2	1	2	5	2	2	1	9	1	2	3	4	0	5	2	4	6	0	0	1	0	1	1	1	1	3		0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	5	2.5	1.25	2.857143	3.5	2.6			2.3	2	1	3	2.5	0.3	0.5	0.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN326JHD
2081	8976	NDAR_INVGN326JHD	2397			F	2800	Visit12	12	Phase 1/1A	363	0	1	0	0	0	0	0	6	0	2	0	2	0	2	6	0	0	0	9	0	0	3	2	0	4	2	3	4	0	1	0	0	1	0	0	0	3		0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0	1.7142857	3	1.8			2.3	2	1	3	2.5	-0.5	0.25	-1	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN326JHD
2081	8976	NDAR_INVGN326JHD	2397			F	5200	EndofPhase1_1a	16	Phase 1/1A	445	0	1	0	0	0	0	0	6	0	0	2	3	2	2	2	0	0	0	9	2	0	0	2	0	5	3	4	4	0	1	1	0	1	1	1	1	1	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	1.7142857	4	1.85		1	2.3	2	1	3	2.5	-0.45	0.125	-1	-1.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN326JHD
2081	8976	NDAR_INVGN326JHD	2397			F	5800	EndofPhase2	18	Phase 2	503	0	1	0	0	0	0	0	4	0	4	2	4	2	2	4	0	0	0	9	0	0	2	2	2	4	2	6	4	1	1	0	0	1	1	1	1	1	1	0	4				0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	2.75	0	2.2857144	3	2.2			2.3	2	1	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN326JHD
2081	8976	NDAR_INVGN431PHR	1301			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	4	3	3	4	5	2	1	1	1	9	2	2	1	4	5	5	3	5	5	1	1	1	0	1	0	0	0	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	5	3.375	0.75	3.4285715	4	3.1	1		3.1	3.375	0.75	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN431PHR
2081	8976	NDAR_INVGN431PHR	1301			M	5200	EndofPhase1_1a	2	Phase 1/1A	50	0	0	0	0	0	0	1	2	4	0	4	1	5	6	2	0	2	0	9	5	2	2	2	0	5	3	3	5	0	1	1	0	0	1	0	1	2	2	1	3	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	3	0.5	2.7142856	4	2.65		1	3.1	3.375	0.75	3.4285715	4	-0.45	-0.375	-0.25	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN431PHR
2081	8976	NDAR_INVGN431PHR	1301			M	5800	EndofPhase2	3	Phase 2	85	0	0	0	0	0	0	1	4	5	2	4	5	1	1	1	0	0	0	9	2	1	2	2	1	5	2	4	5	1	1	0	0	1	1	0	1	2	2	1	3	2	2	4	1	0	0	1	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	3	2.875	0	2.4285715	3.5	2.35			3.1	3.375	0.75	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGN431PHR
2081	8976	NDAR_INVGP049NL4	2221			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	0	0	0	1	0	0	3	4	9	2	2	0	2	0	3	4	2	3	0	1	0	0	1	1	1	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	1	1	1	1	0	0	2	0.71428573	1.75	1.5714285	3.5	1.5789474	1		1.5789474	0.71428573	1.75	1.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP049NL4
2081	8976	NDAR_INVGP268FVT	2829			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	4	1	1	1	2	4	4	4	4	2	2	2	4	2	6	6	6	4	4	1	1	1	1	1	1	1	1	3		1	4	3	3	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	3	2.375	3.5	3.4285715	6	3.2857144	1		3.2857144	2.375	3.5	3.4285715	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP268FVT
2081	8976	NDAR_INVGP298BP2	1277			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	1	0	0	3	0	0	0	0	1	1	0	1	3	1	9	3	4	1	1	3	4	1	4	2	1	0	0	1	1	1	1	1	2	2	0	4	2	3	4	0	0	0	0	0	0	0	1	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	0.625	1.25	2.5714285	2.5	1.65	1		1.65	0.625	1.25	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP298BP2
2081	8976	NDAR_INVGP298BP2	1277			F	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	5	4	1	2	2	2	2	1	1	1	1	9	3	2	3	5	4	5	4	5	4	1	1	1	1	1	2	1	1	1	1	0	4	1	2	2	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0.75	3.7142856	4.5	2.85			1.65	0.625	1.25	2.5714285	2.5	1.2	1.75	-0.5	1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP298BP2
2081	8976	NDAR_INVGP298BP2	1277			F	2800	Visit12	12	Phase 1/1A	350	1	0	0	0	0	0	0	3	1	0	2	1	1	2	0	1	2	1	9	4	2	2	1	1	5	5	3	2	1	1	1	1	1	0	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.25	1	2.142857	5	1.95			1.65	0.625	1.25	2.5714285	2.5	0.3	0.625	-0.25	-0.42857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP298BP2
2081	8976	NDAR_INVGP298BP2	1277			F	5200	EndofPhase1_1a	18	Phase 1/1A	543	1	0	0	0	0	0	0	6	2	1	2	2	2	3	1	1	1	0	9	3	4	2	4	1	5	4	3	4	1	1	1	0	1	1	1	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	0.5	3	4.5	2.55		1	1.65	0.625	1.25	2.5714285	2.5	0.9	1.75	-0.75	0.42857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP298BP2
2081	8976	NDAR_INVGP692MCH	1820			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	2	1	1	1	2	1	2	2	1	9	3	2	2	2	2	3	3	4	4	1	1	2	0	1	1	2	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	1	0	0	0	0	0	4	1.25	1.25	2.7142856	3	2	1		2	1.25	1.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP692MCH
2081	8976	NDAR_INVGP692MCH	1820			M	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	1	0	2	1	2	2	1	2	2	1	2	2	1	9	2	2	2	3	2	3	3	3	4	1	1	1	1	1	1	0	1	3		0	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	6	1.625	1.25	2.5714285	3	2.1			2	1.25	1.25	2.7142856	3	0.1	0.375	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP692MCH
2081	8976	NDAR_INVGP692MCH	1820			M	2800	Visit12	12	Phase 1/1A	355	0	0	0	0	0	1	0	0	2	2	2	2	3	2	1	2	2	5	9	1	2	2	3	1	4	3	3	4	1	1	1	1	1	1	1	1	3		1	2	4	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.75	2.25	2.2857144	3.5	2.3			2	1.25	1.25	2.7142856	3	0.3	0.5	1	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP692MCH
2081	8976	NDAR_INVGP692MCH	1820			M	5200	EndofPhase1_1a	18	Phase 1/1A	509	0	0	0	0	0	1	0	2	1	2	1	2	3	2	0	2	2	5	9	2	3	2	4	2	4	3	5	4	1	1	0	0	1	1	1	1	3		0	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	1.625	2.25	3.142857	3.5	2.55		1	2	1.25	1.25	2.7142856	3	0.55	0.375	1	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGP692MCH
2081	8976	NDAR_INVGR781MY3	1873			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	3	5	5	4	5	5	6	6	6	6	4	5	5	5	5	6	4	5	6	1	0	1	1	1	1	0	1	1	1	1	3	2	3	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.875	6	5	5	5.142857	1		5.142857	4.875	6	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR781MY3
2081	8976	NDAR_INVGR781MY3	1873			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	6	5	2	2	4	4	5	6	6	4	5	1	6	4	6	2	6	6	6	6	6	1	1	1	1	1	1	2	1	1	1	1	4	4	4	3	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	4	5.142857	6	4.6666665			5.142857	4.875	6	5	5	-0.47619048	-0.625	-2	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR781MY3
2081	8976	NDAR_INVGR781MY3	1873			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	6	6	6	4	4	2	4	5	6	4	6	2	6	4	6	2	6	6	6	6	6	1	1	0	0	1	1	0	1	1	1	1	2	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.625	4.5	5.142857	6	4.904762			5.142857	4.875	6	5	5	-0.23809524	-0.25	-1.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR781MY3
2081	8976	NDAR_INVGR781MY3	1873			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	1	0	0	0	0	0	6	6	4	4	2	2	2	5	0	2	2	9	2	4	2	2	4	4	2	2	2	1	1	1	1	1	1	0	1	2	1	1	4	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.875	1	2.5714285	3	2.95		1	5.142857	4.875	6	5	5	-2.192857	-1	-5	-2.4285715	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR781MY3
2081	8976	NDAR_INVGR926JV1	2641			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	5	0	4	2	4	5	1	2	2	3	9	3	4	4	4	2	4	3	4	4	1	0	0	1	1	1	0	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.75	3.5714285	3.5	3.1	1		3.1	2.875	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR926JV1
2081	8976	NDAR_INVGR926JV1	2641			M	1600	Visit6	6	Phase 1B	190	0	1	0	0	0	0	0	3	2	3	2	2	3	3	1	0	4	5	9	4	4	3	4	4	5	5	5	5	1	1	0	1	1	0	0	1	1	2	1	4	3	4	3	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	2.25	4.142857	5	3.35			3.1	2.875	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR926JV1
2081	8976	NDAR_INVGR926JV1	2641			M	2800	Visit12	12	Phase 1B	372	0	1	0	0	0	0	0	5	4	4	4	4	4	6	3	1	3		9	3	4	3	3	4	5	3	5	4	1	0	0	1	1	1	2	1	1	2	1	3	2	2	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25		3.7142856	4	3.7894738			3.1	2.875	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR926JV1
2081	8976	NDAR_INVGR926JV1	2641			M	5200	EndofPhase1_1a	1	Phase 1/1A	14	0	1	0	0	0	0	0	1	2	4	4	4	4	4	1	2	3	3	9	1	3	2	4	4	5	1	5	4	0	0	0	0	0	1	0	1	2	2	1	3	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	2	3.2857144	3	3.05		1	3.1	2.875	1.75	3.5714285	3.5	-0.05	0.125	0.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR926JV1
2081	8976	NDAR_INVGR926JV1	2641			M	5400	EndofPhase1b	18	Phase 1B	557	0	1	0	0	0	0	0	5	4	4	4	4	5	6	4	4	4	4	5	4	5	4	4	5	5	2	4	4	1	1	0	1	1	1	0	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.5	4.25	4.285714	3.5	4.285714			3.1	2.875	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGR926JV1
2081	8976	NDAR_INVGT086YUT	1712			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	1	6	6	4	1	6	2	5	4	5	4	4	4	2	4	2	4	4	4	5	1	1	1	0	1	1	1	1	2	2	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	3.5	4.5	3.5714285	4	3.7619047	1		3.7619047	3.5	4.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT086YUT
2081	8976	NDAR_INVGT086YUT	1712			M	1600	Visit6	6	Phase 1/1A	183	0	1	0	0	0	0	0	5	3	4	4	4	3	5	4	3	3	3	3	3	3	4	3	4	3	4	3	4	1	1	1	0	1	1	1	1	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	3	3.4285715	3.5	3.5714285			3.7619047	3.5	4.5	3.5714285	4	-0.1904762	0.5	-1.5	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT086YUT
2081	8976	NDAR_INVGT086YUT	1712			M	2800	Visit12	12	Phase 1/1A	351	0	1	0	0	0	0	0	4	4	4	4	4	4	4	5	1	2	1	9	3	4	4	4	3	4	4	5	2	1	1	0	0	1	1	1	1	1	1	1	3	2	2	1	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	4.125	1	3.5714285	4	3.5			3.7619047	3.5	4.5	3.5714285	4	-0.26190478	0.625	-3.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT086YUT
2081	8976	NDAR_INVGT086YUT	1712			M	5200	EndofPhase1_1a	18	Phase 1/1A	485	0	1	0	0	0	0	0	5	5	4	4	4	5	5	4	2	4	1	9	4	5	4	5	4	4	3	4	4	1	1	1	0	1	1	1	1	1	2	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.5	1.75	4.285714	3.5	4		1	3.7619047	3.5	4.5	3.5714285	4	0.23809524	1	-2.75	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT086YUT
2081	8976	NDAR_INVGT145TPG	1085			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	0	0	2	2	2	1	4	3	5	5	4	4	4	5	2	5	3	5	6	1	1	1	2	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	0.875	4.25	4.285714	4	2.952381	1		2.952381	0.875	4.25	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT145TPG
2081	8976	NDAR_INVGT145TPG	1085			M	1600	Visit6	6	Phase 1/1A	178	1	0	0	0	0	0	0	6	6	4	4	4	3	4	3	4	4	5	6	4	4	4	5	1	5	4	4	5	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	4.75	3.857143	4.5	4.2380953			2.952381	0.875	4.25	4.285714	4	1.2857143	3.375	0.5	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT145TPG
2081	8976	NDAR_INVGT145TPG	1085			M	2800	Visit12	12	Phase 1/1A	372	1	0	0	0	0	0	0	6	4	4	3	4	3	4	3	6	5	4	4	4	4	4	5	4	5	3	4	5	1	1	0	1	1	1	1	1	1	2	1	2	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.875	4.75	4.285714	4	4.1904764			2.952381	0.875	4.25	4.285714	4	1.2380953	3	0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT145TPG
2081	8976	NDAR_INVGT145TPG	1085			M	5200	EndofPhase1_1a	18	Phase 1/1A	540	1	0	0	0	0	0	0	6	4	4	3	4	3	4	2	6	4	6	4	0	5	4	4	5	5	5	2	5	1	1	1	1	1	0	0	1	1	1	1	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	1	0	0	0	1	1	1	1	4	3.75	5	3.5714285	5	4.047619		1	2.952381	0.875	4.25	4.285714	4	1.0952381	2.875	0.75	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT145TPG
2081	8976	NDAR_INVGT423PZ6	1185			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	0	1	2	2	1	0	0	0	9	3	2	4	1	1	3	1	4	2	2	2	2	0	1	1	1	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.25	0	2.4285715	2	1.55	1		1.55	1.25	0	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT423PZ6
2081	8976	NDAR_INVGT423PZ6	1185			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	1	0	2	1	2	2	2	2	3	2	2	1	1	9	3	3	1	2	2	4	2	2	3	1	1	1	0	1	1	1	1	3	3	0	4	2	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2	1	2.2857144	3	2.1			1.55	1.25	0	2.4285715	2	0.55	0.75	1	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT423PZ6
2081	8976	NDAR_INVGT423PZ6	1185			M	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	1	0	4	4	2	5	4	3	4	1	2	4	1	9	3	2	4	2	4	5	4	4	4	1	1	1	0	1	1	1	1	3		1	3	4	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	3.375	1.75	3.2857144	4.5	3.3			1.55	1.25	0	2.4285715	2	1.75	2.125	1.75	0.85714287	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT423PZ6
2081	8976	NDAR_INVGT423PZ6	1185			M	4000	Visit18	18	Phase 1/1A	509	0	0	0	0	0	1	0	3	0	0	2	2	1	2	1	1	4	4	9	3	3	4	2	1	5	3	2	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	2.25	2.7142856	4	2.35			1.55	1.25	0	2.4285715	2	0.8	0.125	2.25	0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT423PZ6
2081	8976	NDAR_INVGT423PZ6	1185			M	5200	EndofPhase1_1a	18	Phase 1/1A	509	0	0	0	0	0	1	0	3	0	0	2	2	1	2	1	1	4	4	9	3	3	4	2	1	5	3	2	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	2.25	2.7142856	4	2.35		1	1.55	1.25	0	2.4285715	2	0.8	0.125	2.25	0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT423PZ6
2081	8976	NDAR_INVGT559ECP	2401			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	2	1	2	1	0	0	2	9	2	2	2	2	2	4	4	4	4	1	1	1	0	1	1	1	1	2	1	0	4	3	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.75	0.5	2.5714285	4	2.1	1		2.1	1.75	0.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT559ECP
2081	8976	NDAR_INVGT559ECP	2401			M	1600	Visit6	6	Phase 1/1A	162	0	0	0	0	0	0	0	6	4	6	6	6	6	6	3	5	4	6	6	4	6	6	6	6	3	3	4	4	1	1	1	1	1	1	1	1	2	2	1	3	2	2	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	5.375	5.25	5.142857	3	5.047619			2.1	1.75	0.5	2.5714285	4	2.947619	3.625	4.75	2.5714285	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT559ECP
2081	8976	NDAR_INVGT559ECP	2401			M	2800	Visit12	12	Phase 1/1A	328	0	0	0	0	0	0	1	9	6	4	4	6	6	4	0	2	4	2	9	2	2	4	2	4	2	0	6	6	1	1	1	1	1	1	1	1	3	1	1	2	2	2	4	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.285714	2	3.7142856	1	3.4736843			2.1	1.75	0.5	2.5714285	4	1.3736842	2.5357144	1.5	1.1428572	-3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT559ECP
2081	8976	NDAR_INVGT559ECP	2401			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	0	1	6	5	1	3	2	4	5	1	2	2	3	9	0	2	5	5	2	4	3	2	3	1	1	1	1	1	0	1	1	2	1	1	3	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.375	1.75	2.7142856	3.5	3		1	2.1	1.75	0.5	2.5714285	4	0.9	1.625	1.25	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT559ECP
2081	8976	NDAR_INVGT705GCV	2577			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	1	1	4	3	4	3	0	2	2	9	2	3	3	3	2	5	3	3	3	1	0	1	0	1	1	1	1	2	2	1	3	2	3	2	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1	2.7142856	4	2.55	1		2.55	2.5	1	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT705GCV
2081	8976	NDAR_INVGT705GCV	2577			F	5200	EndofPhase1_1a	1	Phase 1/1A	7	0	0	0	0	0	0	1	2	2	1	1	4	3	4	3	0	2	2	9	2	3	3	3	2	5	3	3	3	1	0	1	0	1	1	1	1	2	2	1	3	2	3	2	1	0	0	0	0	0	1	0	1	1	1	1	1	16	0		0		1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1	2.7142856	4	2.55		1	2.55	2.5	1	2.7142856	4	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT705GCV
2081	8976	NDAR_INVGT982LLZ	2389			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	5	4	2	2	3	2	4	1	2	1	3	2	2	4	2	2	6	5	3	3	1	1	1	1	1	1	1	1	3		1	4	3	3	3	1	0	0	0	0	0	0	1	0	0	0	0	1	28	0		0		0		0		1	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	1.75	2.5714285	5.5	2.7619047	1		2.7619047	2.75	1.75	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT982LLZ
2081	8976	NDAR_INVGT982LLZ	2389			F	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	2	2	1	2	1	1	1	1	1	0	0	9	1	1	0	1	1	3	4	2	2	1	1	1	0	1	1	1	1	3		1	2	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.375	0.25	1.1428572	3.5	1.35			2.7619047	2.75	1.75	2.5714285	5.5	-1.4119048	-1.375	-1.5	-1.4285715	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT982LLZ
2081	8976	NDAR_INVGT982LLZ	2389			F	2800	Visit12	12	Phase 1/1A	351	0	0	0	0	0	0	1	0	0	1	1	1	1	0	0	1	1	0	9	0	0	0	1	1	4	5	1	2	1	0	1	0	0	0	0	0	3		0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0						0	0	0	0	1	1	1	1	4	0.5	0.5	0.71428573	4.5	1			2.7619047	2.75	1.75	2.5714285	5.5	-1.7619047	-2.25	-1.25	-1.8571428	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT982LLZ
2081	8976	NDAR_INVGT982LLZ	2389			F	4000	Visit18	18	Phase 1/1A	526	0	0	0	0	0	0	1	0	2	0	4	3	2	3	0	3	1	1	2	1	3	1	1	2	2	2	2	5	1	1	1	0	1	1	1	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.75	1.75	2.142857	2	1.9047619		1	2.7619047	2.75	1.75	2.5714285	5.5	-0.85714287	-1	0	-0.42857143	-3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGT982LLZ
2081	8976	NDAR_INVGU369CLX	1918			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	1	0	0	0	0	0	1	0	0	0	9	0	0	0	0	0	3	2	0	3	0	1	0	0	0	2	0	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	13	0		0		0		1	17	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0.2857143	0	0.42857143	2.5	0.5263158	1		0.5263158	0.2857143	0	0.42857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU369CLX
2081	8976	NDAR_INVGU369CLX	1918			M	1600	Visit6	6	Phase 2	168	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	0	9	0	2	0	2	0	3	2	0	2	1	0	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.25	0	0.85714287	2.5	0.65			0.5263158	0.2857143	0	0.42857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU369CLX
2081	8976	NDAR_INVGU369CLX	1918			M	2800	Visit12	12	Phase 2	340	0	0	0	0	0	0	1	1	0	0	1	1	1	1	3	0	0	0	9	0	2	1	1	1	4	2	4	2	1	1	1	1	1	0	1	1	2	2	0	4	3	4	2	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	5	1	0	1.5714285	3	1.25			0.5263158	0.2857143	0	0.42857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU369CLX
2081	8976	NDAR_INVGU369CLX	1918			M	5200	EndofPhase1_1a	4	Phase 1/1A	112	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	9	0	1	2	1	0	3	2	0	3	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	6	0.125	0	1	2.5	0.65		1	0.5263158	0.2857143	0	0.42857143	2.5	0.12368421	-0.16071428	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU369CLX
2081	8976	NDAR_INVGU369CLX	1918			M	5400	EndofPhase1b	5	Phase 1B	139	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	9	0	0	0	0	1	3	2	0	1	1	0	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	5	0.125	0	0.2857143	2.5	0.4			0.5263158	0.2857143	0	0.42857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU369CLX
2081	8976	NDAR_INVGU369CLX	1918			M	5800	EndofPhase2	18	Phase 2	502	0	0	0	0	0	0	1	9	4	4	1	1	5	3	4	0	6	4	6	6	1	6	1	2	4	4	4	4	1	0	0	0	1	1	1	1	1	3	0	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	3.142857	4	3.4285715	4	3.5			0.5263158	0.2857143	0	0.42857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU369CLX
2081	8976	NDAR_INVGU563FT1	1466			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	6	3	4	3	2	2	1	0	0	0	9	2	3	4	2	2	6	3	4	4	1	1	1	1	1	0	0	1	1	1	1	4	2	2	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.25	0	3	4.5	2.8	1		2.8	3.25	0	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU563FT1
2081	8976	NDAR_INVGU563FT1	1466			M	1600	Visit6	6	Phase 2	176	1	0	0	0	0	0	0	6	0	0	0	6	0	2	1	0	0	0	9	0	0	0	0	0	6	3	4	4	1	1	1	0	1	1	1	1	1	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.875	0	1.1428572	4.5	1.6			2.8	3.25	0	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU563FT1
2081	8976	NDAR_INVGU563FT1	1466			M	2800	Visit12	12	Phase 2	344	1	0	0	0	0	0	0	5	0	0	2	2	2	2	2	0	2	0	9	1	2	4	3	2	6	4	4	4	1	1	1	0	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1		1.875	0.5	2.857143	5	2.35			2.8	3.25	0	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU563FT1
2081	8976	NDAR_INVGU563FT1	1466			M	4000	Visit18	18	Phase 2	506	1	0	0	0	0	0	0	6	5	6	5	6	6	6	2	2	4	4	9	4	6	5	5	6	6	5	6	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	0	1	1	0	0	0	0	1	1	1	1	5	5.25	2.5	5.285714	5.5	5			2.8	3.25	0	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU563FT1
2081	8976	NDAR_INVGU563FT1	1466			M	5200	EndofPhase1_1a	5	Phase 1/1A	136	1	0	0	0	0	0	0	4	0	0	0	2	0	2	1	0	0	0	9	0	0	0	0	0	5	1	3	2	1	1	0	0	1	1	1	1	1	1	0	4		4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.125	0	0.71428573	3	1		1	2.8	3.25	0	3	4.5	-1.8	-2.125	0	-2.2857144	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU563FT1
2081	8976	NDAR_INVGU638ZYA	1654			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	6	2	0	2	2	0	2	0	1	0	0	9	0	0	4	5	4	5	4	6	4	2	2	2	2	1	1	1	1	1	1	1	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	21	0		0		1	9	0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0.25	3.2857144	4.5	2.35	1		2.35	1.75	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU638ZYA
2081	8976	NDAR_INVGU638ZYA	1654			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	1	0	0	6	6	6	4	6	3	4	2	2	1	0	9	3	2	4	4	5	5	4	6	5	1	1	1	1	1	1	1	1	1	1	1	3	4	4	2	1	0	0	1	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.625	0.75	4.142857	4.5	3.9			2.35	1.75	0.25	3.2857144	4.5	1.55	2.875	0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU638ZYA
2081	8976	NDAR_INVGU638ZYA	1654			F	2800	Visit12	12	Phase 1/1A	337	0	0	1	0	0	0	0	3	3	2	2	3	3	1	0	0	0	0	9	1	1	2	2	0	3	4	4	2	1	0	1	1	1	1	1	0	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.125	0	1.7142857	3.5	1.8		1	2.35	1.75	0.25	3.2857144	4.5	-0.55	0.375	-0.25	-1.5714285	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGU638ZYA
2081	8976	NDAR_INVGV401TKA	1929			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	4	4	4	1	4	1	0	0	0	9	0	2	2	4	0	4	2	4	4	0	1	2	2	1	2	2	0	2	1	1	2	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3	0	2.2857144	3	2.3	1		2.3	3	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV401TKA
2081	8976	NDAR_INVGV401TKA	1929			M	1600	Visit6	6	Phase 1B	161	0	0	0	0	0	1	0	3	2	4	4	4	1	4	3	0	0	0	9	0	2	2	4	0	4	4	4	4	0	1	2	2	1	2	2	2	1	1	1	2	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.125	0	2.2857144	4	2.45			2.3	3	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV401TKA
2081	8976	NDAR_INVGV401TKA	1929			M	2800	Visit12	12	Phase 2	336	0	0	0	0	0	1	0	4	2	1	0	4	2	4	1	1	1	1	9	1	1	1	1	2	4	2	3	4	0	1	2	2	1	1	1	0	1	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	0.75	1.8571428	3	2			2.3	3	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV401TKA
2081	8976	NDAR_INVGV401TKA	1929			M	5200	EndofPhase1_1a	5	Phase 1/1A	127	0	0	0	0	0	1	0	3	2	4	4	4	1	4	3	0	0	0	9	0	2	2	4	0	4	2	4	4	0	1	2	2	1	2	2	2	2	1	1	2	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.125	0	2.2857144	3	2.35		1	2.3	3	0	2.2857144	3	0.05	0.125	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV401TKA
2081	8976	NDAR_INVGV401TKA	1929			M	5400	EndofPhase1b	8	Phase 1B	228	0	0	0	0	0	1	0	3	2	4	4	4	1	4	4	0	0	0	9	0	2	2	4	0	4	2	3	4	0	1	2	2	0	0	0	2	3	2	1	2	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	0	2.142857	3	2.35			2.3	3	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV401TKA
2081	8976	NDAR_INVGV401TKA	1929			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	0	1	0	3	2	4	4	4	1	4	3	0	2	0	9	2	2	2	2	0	5	5	2	3	0	0	0	0	1	0	2	2	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	3.125	0.5	1.8571428	5	2.5			2.3	3	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV401TKA
2081	8976	NDAR_INVGV707XGF	1842			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	2	2	9	1	1	1	1	1	1	1	1	1	2	2	2	1	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	26	0		0		1	4	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	1.5	1	1	1.55	1		1.55	2	1.5	1	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV707XGF
2081	8976	NDAR_INVGV773PAA	1484			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	5	6	6	6	6	6	1	4	6	6	5	4	5	2	4	6	2	4	5	6	1	1	1	1	1	1	1	1	1	2	1	2	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	5	5.25	4.571429	3	4.714286	1		4.714286	5	5.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV773PAA
2081	8976	NDAR_INVGV773PAA	1484			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	5	6	6	6	6	6	0	5	5	5	6	5	5	2	6	6	2	3	5	5	1	1	0	0	1	0	1	1	1	2	1	3	1	1	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	5.125	5.25	4.857143	2.5	4.8095236			4.714286	5	5.25	4.571429	3	0.0952381	0.125	0	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV773PAA
2081	8976	NDAR_INVGV773PAA	1484			M	2800	Visit12	12	Phase 1/1A	331	0	0	0	0	0	0	1	9	6	6	6	6	6	6	2	5	6	5	6	4	6	6	6	6	2	5	5	6	1	2	0	1	1	1	1	1	2	2	1	2	2	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	5.428571	5.5	5.571429	3.5	5.3			4.714286	5	5.25	4.571429	3	0.5857143	0.42857143	0.25	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV773PAA
2081	8976	NDAR_INVGV773PAA	1484			M	5200	EndofPhase1_1a	18	Phase 1/1A	537	0	0	0	0	0	0	1	9	6	6	6	6	6	4	1	6	4	6	6	5	5	6	5	5	3	4	6	6	1	0	0	1	1	1	1	1	2	1	1	2	1	1	4	1	0	0	0	0	1	1	0	0	0	0	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5	5.5	5.428571	3.5	5.1		1	4.714286	5	5.25	4.571429	3	0.3857143	0	0.25	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGV773PAA
2081	8976	NDAR_INVGW298LF4	2750			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	1	1	4	3	2	2	2	1	1	1	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1		0		0		1		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.125	1.5	2.4285715	1	2.1	1		2.1	2.125	1.5	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW298LF4
2081	8976	NDAR_INVGW831EA4	2055			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	3	6	3	3	6	0	0	0	9	4	2	3	6	2	4	3	4	5	1	1	1	1	1	1	1	1	1	1	1	4	4	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	6	4.875	0	3.7142856	3.5	3.6	1		3.6	4.875	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW831EA4
2081	8976	NDAR_INVGW831EA4	2055			M	1600	Visit6	6	Phase 1/1A	171	0	1	0	1	0	0	0	5	4	0	2	3	4	5	2	0	0	0	9	4	3	4	4	4	5	2	4	5	1	1	1	0	1	0	1	1	1	2	1	4	2	3	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.125	0	4	3.5	3			3.6	4.875	0	3.7142856	3.5	-0.6	-1.75	0	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW831EA4
2081	8976	NDAR_INVGW831EA4	2055			M	2800	Visit12	12	Phase 1/1A	344	1	0	0	0	0	0	0	6	6	0	2	2	6	6	0	0	0	0	9	2	2	4	6	2	6	2	4	4	1	1	1	0	1	1	0	1	1	1	1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.5	0	3.4285715	4	3			3.6	4.875	0	3.7142856	3.5	-0.6	-1.375	0	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW831EA4
2081	8976	NDAR_INVGW831EA4	2055			M	5200	EndofPhase1_1a	17	Phase 1/1A	485	1	0	0	0	0	0	0	6	6	6	4	4	4	6	2	0	0	0	9	0	2	4	6	0	6	3	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.75	0	2.857143	4.5	3.35		1	3.6	4.875	0	3.7142856	3.5	-0.25	-0.125	0	-0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW831EA4
2081	8976	NDAR_INVGW951LP7	2045			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	0	1	2	0	2	5	2	4	4	4	3	5	5	4	2	5	3	1	2	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	4	1.7142857	3.5	3.142857	4	2.8	1		2.8	1.7142857	3.5	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW951LP7
2081	8976	NDAR_INVGW951LP7	2045			M	1600	Visit6	6	Phase 1/1A	188	0	0	0	0	0	0	1	9	2	0	3	5	3	5	5	1	1	2	2	3	4	3	4	1	6	5	5	4	1	1	1	1	1	1	0	1	3	1	1	2	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.2857144	1.5	3.4285715	5.5	3.2			2.8	1.7142857	3.5	3.142857	4	0.4	1.5714285	-2	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW951LP7
2081	8976	NDAR_INVGW951LP7	2045			M	2800	Visit12	12	Phase 1/1A	342	0	0	0	0	0	0	1	9	3	0	4	3	3	4	5	0	0	0	9	2	2	5	6	0	5	4	2	5	1	1	0	1	1	1	0	1	3	1	0	4	3	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.142857	0	3.142857	4.5	2.7894738			2.8	1.7142857	3.5	3.142857	4	-0.010526316	1.4285715	-3.5	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW951LP7
2081	8976	NDAR_INVGW951LP7	2045			M	4000	Visit18	18	Phase 1/1A	509	0	0	0	0	0	0	1	9	5	2	1	3	1	3	5	4	4	5	5	2	2	2	5	5	5	4	6	4	1	1	1	0	1	1	0	1	3	1	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	5	2.857143	4.5	3.7142856	4.5	3.65		1	2.8	1.7142857	3.5	3.142857	4	0.85	1.1428572	1	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGW951LP7
2081	8976	NDAR_INVGX058DL5	2328			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	2	1	1	3	1	0	0	0	1	9	4	4	0	2	2	4	2	4	3	0	2	0	0	1	1	1	1	3		1	2	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	2.25	0.25	2.7142856	3	2.2	1		2.2	2.25	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX058DL5
2081	8976	NDAR_INVGX058DL5	2328			F	1600	Visit6	6	Phase 2	171	0	0	0	0	0	0	1	9	3	3	3	2	5	4	1	6	4	5	4	5	6	5	5	1	4	5	2	5	1	1	1	1	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	1	0	0	0	0	0	1	1	1	1	5	3	4.75	4.142857	4.5	3.9			2.2	2.25	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX058DL5
2081	8976	NDAR_INVGX058DL5	2328			F	2800	Visit12	12	Phase 2	342	0	0	1	0	0	0	0	6	6	6	6	4	6	5	0	6	5	6	6	6	6	5	6	6	5	5	5	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.875	5.75	5.714286	5	5.3333335			2.2	2.25	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX058DL5
2081	8976	NDAR_INVGX058DL5	2328			F	5200	EndofPhase1_1a	3	Phase 1/1A	86	0	1	0	0	0	0	0	6	5	0	6	4	4	4	0	0	0	0	9	1	1	2	4	0	2	4	4	2	0	0	1	0	1	1	1	1	2	1	1	2	2	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.625	0	2	3	2.45		1	2.2	2.25	0.25	2.7142856	3	0.25	1.375	-0.25	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX058DL5
2081	8976	NDAR_INVGX058DL5	2328			F	5800	EndofPhase2	18	Phase 2	512	0	0	0	0	0	0	1	9	6	3	6	6	6	2	3	6	6	6	9	6	6	6	6	6	6	4	5	5	1	1	1	1	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	1	0	0	1	1	1	1	6	4.571429	4.5	5.714286	5	5.263158			2.2	2.25	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX058DL5
2081	8976	NDAR_INVGX096VM4	2585			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	2	3	9	1	2	1	2	1	3	1	1	3	1	0	1	0	1	1	1	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	0.375	1.25	1.5714285	2	1.15	1		1.15	0.375	1.25	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX096VM4
2081	8976	NDAR_INVGX096VM4	2585			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	2	3	9	1	2	1	2	1	3	1	1	3	1	0	1	0	1	1	1	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	5	0.375	1.25	1.5714285	2	1.15			1.15	0.375	1.25	1.5714285	2	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX096VM4
2081	8976	NDAR_INVGX096VM4	2585			M	2800	Visit12	12	Phase 1/1A	359	0	0	0	0	0	0	1	1	1	1	2	2	3	3	3	3	4	3	2	1	4	4	6	4	5	3	3	4	1	0	1	0	0	0	1	0	3	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2	3	3.7142856	4	2.952381			1.15	0.375	1.25	1.5714285	2	1.8023809	1.625	1.75	2.142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX096VM4
2081	8976	NDAR_INVGX096VM4	2585			M	5200	EndofPhase1_1a	18	Phase 1/1A	536	0	0	1	0	0	0	0	6	3	3	3	3	2	2	0	1	3	2	2	2	0	0	3	2	1	2	2	2	0	1	0	0	1	1	1	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	0					0		0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	2	1.5714285	1.5	2.0952382		1	1.15	0.375	1.25	1.5714285	2	0.9452381	2.375	0.75	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX096VM4
2081	8976	NDAR_INVGX776WRX	2292			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	0	0	0	2	1	4	6	6	6	0	0	0	2	0	3	4	0	2	1	1	1	0	1	1	1	1	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	6	0.875	5.5	0.5714286	3.5	1.9047619	1		1.9047619	0.875	5.5	0.5714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX776WRX
2081	8976	NDAR_INVGX776WRX	2292			M	5200	EndofPhase1_1a	3	Phase 1/1A	76	0	0	0	0	0	0	1	1	1	1	1	6	5	5	1	1	4	1	9	1	3	3	3		3	2		1	0	0	0	0	0	0	0	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	12	0		0		1	19	0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	6	2.625	1.5		2.5	2.3888888		1	1.9047619	0.875	5.5	0.5714286	3.5	0.48412699	1.75	-4		-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX776WRX
2081	8976	NDAR_INVGX806TUQ	1646			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	4	1	1	3	3	1	2	1	6	5	6	6	4	5	4	3	5	6	3	5	5	0	0	1	1	1	1	1	1	1	1	1	3	4	4	4	1	0	0	0	1	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	1	0	0	1	1	1	1	6	2	5.75	4.428571	4.5	3.7619047	1		3.7619047	2	5.75	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX806TUQ
2081	8976	NDAR_INVGX806TUQ	1646			M	1600	Visit6	6	Phase 1/1A	182	0	0	1	0	0	0	0	6	2	5	4	6	6	4	3	6	6	6	6	6	4	3	6	6	5	4	6	6	1	1	1	1	1	1	1	1	1	2	1	4	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.5	6	5.285714	4.5	5.047619			3.7619047	2	5.75	4.428571	4.5	1.2857143	2.5	0.25	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX806TUQ
2081	8976	NDAR_INVGX806TUQ	1646			M	2800	Visit12	12	Phase 1/1A	352	0	0	1	0	1	0	0	6	3	0	2	6	3	6	4	6	6	6	6	6	6	6	6	6	5	3	6	6	1	1	1	1	1	0	1	1	1	2	1	3	2	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	6	6	4	4.952381			3.7619047	2	5.75	4.428571	4.5	1.1904762	1.75	0.25	1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX806TUQ
2081	8976	NDAR_INVGX806TUQ	1646			M	5200	EndofPhase1_1a	18	Phase 1/1A	527	1	0	0	0	0	0	0	6	4	3	2	4	4	4	2	6	6	6	6	6	6	6	6	6	5	4	6	6	1	1	1	1	1	1	1	1	1	1	1	4	1	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	6	6	4.5	4.952381		1	3.7619047	2	5.75	4.428571	4.5	1.1904762	1.625	0.25	1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGX806TUQ
2081	8976	NDAR_INVGY745AMC	2277			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	1	2	0	0	6	0	0	0	9	5	3	4	4	1	3	2	6	5	0	0	1	0	1	1	1	1	3		0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	3	1.875	0	4	2.5	2.4	1		2.4	1.875	0	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY745AMC
2081	8976	NDAR_INVGY982YB5	2892			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	2	0	2	2	2	0	0	0	5	9	2	2	6	4	2	6	6	4	6	1	0	0	1	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	1.25	3.7142856	6	2.95	1		2.95	2	1.25	3.7142856	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY982YB5
2081	8976	NDAR_INVGY982YB5	2892			F	1600	Visit6	6	Phase 3	170	1	0	0	0	0	0	0	4	0	1	2	2	0	2	0	2	3	2	9	0	0	4	2	2	6	5	6	6	1	0	0	1	1	1	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	1.375	1.75	2.857143	5.5	2.45			2.95	2	1.25	3.7142856	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY982YB5
2081	8976	NDAR_INVGY982YB5	2892			F	2800	Visit12	12	Phase 3	344	1	0	0	0	0	0	0	6	0	1	0	2	0	0	0	2	1	0	9	1	2	1	2	2	6	3	2	3	1	0	0	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	1.125	0.75	1.8571428	4.5	1.7			2.95	2	1.25	3.7142856	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY982YB5
2081	8976	NDAR_INVGY982YB5	2892			F	5200	EndofPhase1_1a	3	Phase 1/1A	88	1	0	0	0	0	0	0	6	0	0	0	2	0	0	0	0	2	2	9	2	6	4	2	4	6	4	4	3	1	0	1	1	1	0	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	2	0	0	1	0	1	0	0	0	0	1	1	1	1	2	1	1	3.5714285	5	2.35		1	2.95	2	1.25	3.7142856	6	-0.6	-1	-0.25	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY982YB5
2081	8976	NDAR_INVGY982YB5	2892			F	5800	EndofPhase2	5	Phase 2	131	1	0	0	0	0	0	0	4	4	0	0	6	0	0	0	2	2	5	9	2	2	2	0	0	6	6	4	5	1	1	1	1	1	0	0	1	3	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	1	1.75	2.25	2.142857	6	2.5			2.95	2	1.25	3.7142856	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY982YB5
2081	8976	NDAR_INVGY982YB5	2892			F	6000	EndofPhase3	18	Phase 3	495	1	0	0	0	0	0	0	5	0	2	2	2	0	2	1	2	2	1	9	0	2	3	2	5	6	5	4	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.75	1.25	3.142857	5.5	2.6			2.95	2	1.25	3.7142856	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGY982YB5
2081	8976	NDAR_INVGZ074ENQ	2687			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	5	4	4	4	4	3	1	1	1	5	9	4	2	1	2	1	3	4	5	5	1	1	1	0	1	1	1	1	3	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.75	1.75	2.857143	3.5	3.2	1		3.2	3.75	1.75	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ074ENQ
2081	8976	NDAR_INVGZ074ENQ	2687			F	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	2	4	5	4	4	3	2	2	2	2	2	5	3	3	2	4	4	6	6	4	5	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	2.75	3.5714285	6	3.5238094			3.2	3.75	1.75	2.857143	3.5	0.32380953	-0.5	1	0.71428573	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ074ENQ
2081	8976	NDAR_INVGZ074ENQ	2687			F	2800	Visit12	12	Phase 1B	348	0	0	0	0	0	0	1	5	6	4	4	4	3	4	2	0	4	2	5	3	3	3	4	6	6	4	5	6	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	1	0	2	2	2	2	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	2.75	4.285714	5	3.952381			3.2	3.75	1.75	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ074ENQ
2081	8976	NDAR_INVGZ074ENQ	2687			F	5200	EndofPhase1_1a	6	Phase 1/1A	180	0	0	0	0	0	0	1	3	4	4	2	4	4	2	1	2	2	2	3	2	2	4	2	3	6	6	5	4	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3	2.25	3.142857	6	3.1904762		1	3.2	3.75	1.75	2.857143	3.5	-0.00952381	-0.75	0.5	0.2857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ074ENQ
2081	8976	NDAR_INVGZ074ENQ	2687			F	5400	EndofPhase1b	18	Phase 1B	508	0	0	0	0	0	0	1	2	3	2	2	2	2	2	2	4	2	4	5	4	3	3	4	4	4	6	5	4	1	1	1	0	1	1	1	1	2	2	1	3	2	2	2	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	3.75	3.857143	5	3.2857144			3.2	3.75	1.75	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ074ENQ
2081	8976	NDAR_INVGZ423YMJ	2471			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	1	2	2	2	2	0	0	1	1	9	1	2	2	2	3	5	3	3	5	1	1	1	0	1	1	2	1	3	2	0	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.5	2.5714285	4	2.05	1		2.05	1.625	0.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ423YMJ
2081	8976	NDAR_INVGZ423YMJ	2471			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	0	1	6	1	0	2	5	2	2	2	2	3	4	9	2	4	4	6	5	6	4	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.5	2.25	4.714286	5	3.6			2.05	1.625	0.5	2.5714285	4	1.55	0.875	1.75	2.142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ423YMJ
2081	8976	NDAR_INVGZ423YMJ	2471			M	2800	Visit12	12	Phase 1/1A	348	0	0	0	0	0	0	1	0	0	0	2	0	0	2	0	3	2	4	1	2	2	4	4	2	6	2	4	6	0	1	1	0	1	0	0	0	2	1	0	4	2	4	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.5	2.5	3.4285715	4	2.1904762			2.05	1.625	0.5	2.5714285	4	0.1404762	-1.125	2	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ423YMJ
2081	8976	NDAR_INVGZ423YMJ	2471			M	4000	Visit18	18	Phase 1/1A	516	0	0	0	0	0	0	1	9	2	1	0	5	2	2	1	1	3	5	9	2	2	3	4	2	5	3	6	6	1	1	1	1	1	1	1	1	2	1	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.8571428	2.25	3.5714285	4	2.8947368		1	2.05	1.625	0.5	2.5714285	4	0.8447368	0.23214285	1.75	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ423YMJ
2081	8976	NDAR_INVGZ545GWT	1635			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	6	4	6	6	5	6	3	3	5	6	5	4	5	3	6	6	5	5	4	4	0	1	1	0	1	0	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	4.75	4.571429	5	4.904762	1		4.904762	5.25	4.75	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ545GWT
2081	8976	NDAR_INVGZ545GWT	1635			M	1600	Visit6	6	Phase 3	166	1	0	1	0	0	0	0	6	5	5	4	5	3	4	3	4	5	5	6	5	6	2	6	4	5	5	5	4	1	1	1	0	1	1	0	1	1	1	1	4	2	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	5	4.571429	5	4.6190476			4.904762	5.25	4.75	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ545GWT
2081	8976	NDAR_INVGZ545GWT	1635			M	2800	Visit12	12	Phase 3	344	1	0	1	0	0	0	0	6	5	5	5	6	6	5	3	1	2	3	9	3	4	4	6	4	5	4	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.125	1.5	4.428571	4.5	4.35			4.904762	5.25	4.75	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ545GWT
2081	8976	NDAR_INVGZ545GWT	1635			M	5200	EndofPhase1_1a	1	Phase 1/1A	23	1	0	1	0	0	0	0	6	6	4	5	6	5	5	3	2	4	4	9	4	5	3	5	5	5	5	4	4	1	1	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5	2.5	4.285714	5	4.5		1	4.904762	5.25	4.75	4.571429	5	-0.4047619	-0.25	-2.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ545GWT
2081	8976	NDAR_INVGZ545GWT	1635			M	5800	EndofPhase2	5	Phase 2	122	1	0	1	0	0	0	0	6	5	5	5	5	6	4	4	3	3	5	4	5	5	4	5	4	5	4	5	5	1	1	1	0	1	0	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5	3.75	4.714286	4.5	4.6190476			4.904762	5.25	4.75	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ545GWT
2081	8976	NDAR_INVGZ545GWT	1635			M	6000	EndofPhase3	18	Phase 3	526	1	0	1	0	0	0	0	6	5	5	3	4	5	4	2	1	2	1	9	5	4	4	5	2	5	3	5	5	1	1	0	0	1	1	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	1	4.285714	4	3.8			4.904762	5.25	4.75	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ545GWT
2081	8976	NDAR_INVGZ856UJ3	1803			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	4	4	5	5	4	3	6	0	0	0	9	0	0	1	2	2	2	2	6	6	1	0	1	0	1	1	0	1	3		1	2	1	2	1	1	0	0	0	0	1	0	0	1	0	1	0	1	7	0		0		0		1	23	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.125	0	2.4285715	2	2.7	1		2.7	4.125	0	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ856UJ3
2081	8976	NDAR_INVGZ856UJ3	1803			M	1600	Visit6	6	Phase 2	171	0	0	0	0	0	0	1	6	6	4	6	5	6	3	4	0	0	1	9	2	2	2	4	0	2	3	6	6	1	1	1	0	1	1	0	1	2	3	1	4	2	3	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5	0.25	3.142857	2.5	3.4			2.7	4.125	0	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ856UJ3
2081	8976	NDAR_INVGZ856UJ3	1803			M	5200	EndofPhase1_1a	2	Phase 1/1A	66	0	0	0	0	0	0	1	0	6	2	3	4	3	4	6	0	0	0	9	0	0	1	1	2	3	3	6	5	1	1	1	0	1	1	1	1	3		1	3	2	1	1	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	3.5	0	2.142857	3	2.45		1	2.7	4.125	0	2.4285715	2	-0.25	-0.625	0	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ856UJ3
2081	8976	NDAR_INVGZ856UJ3	1803			M	5800	EndofPhase2	11	Phase 2	295	0	0	0	0	0	0	1	6	5	0	2	2	5	2	4	0	0	0	9	0	2	0	0	0	1	3	6	6	0	1	1	0	1	1	0	1	2	1	1	2	4	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	3.25	0	2	2	2.2			2.7	4.125	0	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVGZ856UJ3
2081	8976	NDAR_INVHA082YTY	2243			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	3	6	2	6	2	0	1	1	9	6	4	6	6	6	5	4	6	6	1	1	1	1	1	1	0	1	3		1	2	2	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4	0.5	5.714286	4.5	4.15	1		4.15	4	0.5	5.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA082YTY
2081	8976	NDAR_INVHA082YTY	2243			M	1600	Visit6	6	Phase 1B	167	0	0	0	0	0	1	0	1	5	2	2	5	2	2	4	5	2	2	6	3	4	5	5	5	3	3	5	6	1	1	1	1	1	1	1	1	3		1	3	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	3.75	4.714286	3	3.6666667			4.15	4	0.5	5.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA082YTY
2081	8976	NDAR_INVHA082YTY	2243			M	2800	Visit12	12	Phase 1B	349	0	0	0	0	0	1	0	3	2	2	2	4	4	4	2	0	0	2	9	2	2	3	6	5	4	5	4	5	1	1	1	1	1	1	1	1	3		1	4	2	2	3	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.875	0.5	3.857143	4.5	3.05			4.15	4	0.5	5.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA082YTY
2081	8976	NDAR_INVHA082YTY	2243			M	5200	EndofPhase1_1a	3	Phase 1/1A	72	0	0	0	0	0	1	0	6	5	3	4	5	2	4	3	0	0	2	9	3	2	5	4	1	3	5	5	6	1	1	1	1	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4	0.5	3.7142856	4	3.4		1	4.15	4	0.5	5.714286	4.5	-0.75	0	0	-2	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA082YTY
2081	8976	NDAR_INVHA082YTY	2243			M	5400	EndofPhase1b	18	Phase 1B	489	0	0	0	0	0	1	0	4	2	4	5	5	2	5	3	2	4	4	9	5	5	6	6	5	5	4	6	6	1	0	0	1	1	1	1	1	3		1	3	2	4	2	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	2.5	5.571429	4.5	4.4			4.15	4	0.5	5.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA082YTY
2081	8976	NDAR_INVHA106GA4	2593			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	3	3	3	3	3	3	3	4	1	1	1	9	1	1	1	3	1	5	2	4	3	0	1	0	0	1	1	1	1	1	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	0.75	2	3.5	2.45	1		2.45	3.125	0.75	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA106GA4
2081	8976	NDAR_INVHA222JBF	1675			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	2	2	3	1	2	2	2	2	4	9	2	3	3	2	1	1	1	3	2	0	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	4	2.5	2	2.2857144	1	2.3	1		2.3	2.5	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA222JBF
2081	8976	NDAR_INVHA222JBF	1675			M	1600	Visit6	6	Phase 1B	183	0	0	0	0	1	0	0	2	3	1	2	2	1	1	0	1	2	2	9	1	2	1	1	0	0	2	1	2	0	0	1	0	1	0	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	14	0		0		1	16	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1.5	1.25	1.1428572	1	1.35			2.3	2.5	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA222JBF
2081	8976	NDAR_INVHA222JBF	1675			M	5200	EndofPhase1_1a	3	Phase 1/1A	70	1	0	0	0	0	0	0	3	4	2	2	2	3	3	2	2	3	3	9	2	3	2	2	0	0	2	2	2	0	1	1	0	1	0	0	0	1	1	0	4	2	3	4	0	0	0	0	0	0	0	0					1	25	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2	1.8571428	1	2.2		1	2.3	2.5	2	2.2857144	1	-0.1	0.125	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA222JBF
2081	8976	NDAR_INVHA222JBF	1675			M	5400	EndofPhase1b	9	Phase 1B	262	0	0	0	0	1	0	0	2	3	2	3	2	1	3	1	1	2	2	9	2	2	2	2	0	1	2	2	2	1	0	0	0	1	0	0	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	2.125	1.25	1.7142857	1.5	1.85			2.3	2.5	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA222JBF
2081	8976	NDAR_INVHA344XGZ	2373			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	0	2	2	2	2	0	2	2	1	9	1	2	2	3	3	5	5	4	4	1	1	0	1	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1.25	2.7142856	5	2.4	1		2.4	1.75	1.25	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA344XGZ
2081	8976	NDAR_INVHA344XGZ	2373			M	5200	EndofPhase1_1a	4	Phase 1/1A	115	1	0	0	0	0	0	0	6	0	2	2	2	2	2	0	2	1	1	9	0	0	3	0	0	2	2	1	2	2	2	2	2	1	2	2	2	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	2	1	0.85714287	2	1.5		1	2.4	1.75	1.25	2.7142856	5	-0.9	0.25	-0.25	-1.8571428	-3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA344XGZ
2081	8976	NDAR_INVHA344XGZ	2373			M	5800	EndofPhase2	5	Phase 2	145	1	0	0	0	0	0	0	2	2	0	0	2	0	0	0	0	0	0	9	0	0	2	1	0	5	1	2	0	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.75	0	0.71428573	3	0.85			2.4	1.75	1.25	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHA344XGZ
2081	8976	NDAR_INVHB318THQ	2523			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	0	4	4	5	1	4	4	1	2	2	9	1	2	3	4	1	5	3	4	3	1	2	1	2	1	1	1	1	3		1	2	1	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	3	3.375	1.25	2.5714285	4	2.9	1		2.9	3.375	1.25	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHB318THQ
2081	8976	NDAR_INVHC057YL8	2852			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	2	0	2	1	6	3	6	5	2	3	2	3	4	5	3	3	6	1	1	1	0	1	0	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0.875	5	3.2857144	4	2.7619047	1		2.7619047	0.875	5	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC057YL8
2081	8976	NDAR_INVHC382LJ8	2665			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	6	3	4	6	3	3	4	1	2	2	9	3	4	6	4	2	2	3	6	6	0	0	1	0	1	1	1	1	2	1	1	3	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	4.375	1.25	4.428571	2.5	3.8	1		3.8	4.375	1.25	4.428571	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC382LJ8
2081	8976	NDAR_INVHC399WHA	1430			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	0	0	0	3	1	2	6	3	4	5	4	2	2	6	4	4	4	3	5	5	1	1	1	1	1	1	1	0	3	2	0	4	2	4	1	1	1	0	0	0	0	0	0	1	0	2	2	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.25	4	4	3.5	3.2857144	1		3.2857144	2.25	4	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC399WHA
2081	8976	NDAR_INVHC436ZKD	1259			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	1	1	2	2	2	2	1	2	2	2	9	3	3	2	4	1	3	3	4	5	1	1	0	0	1	1	0	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2	1.5	3.142857	3	2.5	1		2.5	2	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC436ZKD
2081	8976	NDAR_INVHC436ZKD	1259			M	1600	Visit6	6	Phase 1/1A	165	1	0	0	0	0	0	0	5	2	1	1	2	0	2	1	0	1	4	9	2	2	1	2	1	3	3	4	5	1	1	0	0	0	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.25	2.4285715	3	2.1			2.5	2	1.5	3.142857	3	-0.4	-0.25	-0.25	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC436ZKD
2081	8976	NDAR_INVHC436ZKD	1259			M	2800	Visit12	12	Phase 1B	331	1	0	0	0	0	0	0	6	2	1	1	2	0	2	1	0	1	4	9	2	2	1	2	1	3	4	4	5	1	0	0	0	1	0	0	1	1	1	0	4	4	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	1.25	2.4285715	3.5	2.2			2.5	2	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC436ZKD
2081	8976	NDAR_INVHC436ZKD	1259			M	5200	EndofPhase1_1a	7	Phase 1/1A	176	1	0	0	0	0	0	0	6	2	0	2	2	2	2	1	1	1	2	9	3	2	2	3	2	3	3	4	6	1	1	0	0	1	0	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2.125	1	3.142857	3	2.45		1	2.5	2	1.5	3.142857	3	-0.05	0.125	-0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC436ZKD
2081	8976	NDAR_INVHC436ZKD	1259			M	5400	EndofPhase1b	18	Phase 1B	502	1	0	0	0	0	0	0	5	0	0	2	2	2	2	2	1	2	2	9	2	2	2	3	1	4	2	4	5	1	0	0	0	1	1	0	1	1	3	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	1.25	2.7142856	3	2.25			2.5	2	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC436ZKD
2081	8976	NDAR_INVHC837FTW	1499			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	2	2	2	3	6	2	3	2	4	9	4	5	5	4	4	5	3	5	5	1	1	2	1	0	0	0	0	3	3	1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	2.25	4.571429	4	3.5	1		3.5	2.625	2.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHC837FTW	1499			M	2800	Visit12	12	Phase 2	344	0	0	0	0	0	1	0	3	2	1	2	4	2	4	2	0	2	0	9	2	2	4	2	2	4	2	4	4	1	2	2	2	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.5	0.5	2.857143	3	2.4			3.5	2.625	2.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHC837FTW	1499			M	4000	Visit18	18	Phase 3	523	0	0	0	0	0	1	0	3	2	1	2	4	2	4	2	0	2	0	9	2	2	4	2	2	4	2	4	4	1	2	2	2	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.5	0.5	2.857143	3	2.4			3.5	2.625	2.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHC837FTW	1499			M	5200	EndofPhase1_1a	2	Phase 1/1A	59	0	0	0	0	0	1	0	3	2	1	2	4	2	4	2	0	2	0	9	2	2	4	2	2	4	2	4	4	1	2	2	2	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.5	0.5	2.857143	3	2.4		1	3.5	2.625	2.25	4.571429	4	-1.1	-0.125	-1.75	-1.7142857	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHC837FTW	1499			M	5400	EndofPhase1b	6	Phase 1B	165	0	0	0	0	0	1	0	3	2	1	2	4	2	4	2	0	2	0	9	2	2	4	2	2	4	2	4	4	1	2	2	2	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.5	0.5	2.857143	3	2.4			3.5	2.625	2.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHC837FTW	1499			M	5800	EndofPhase2	13	Phase 2	368	0	0	0	0	0	1	0	3	1	1	2	4	2	4	1	0	1	0	9	2	1	4	1	2	4	2	3	4	1	1	2	1	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.25	0.25	2.4285715	3	2.1			3.5	2.625	2.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHC837FTW	1499			M	6000	EndofPhase3	18	Phase 3	523	0	0	0	0	0	1	0	3	2	1	2	4	2	4	2	0	2	0	9	2	2	4	2	2	4	2	4	4	1	2	2	2	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.5	0.5	2.857143	3	2.4			3.5	2.625	2.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHC837FTW
2081	8976	NDAR_INVHD868NZ7	1005			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	1	1	0	2	1	0	0	0	9	2	4	4	4	3	1	2	4	4	0	0	0	1	1	2	0	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	4	1.125	0	3.5714285	1.5	1.85	1		1.85	1.125	0	3.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHD868NZ7
2081	8976	NDAR_INVHD868NZ7	1005			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	0	1	0	0	0	1	2	0	1	1	0	0	0	9	2	2	0	2	2	4	1	0	4	0	0	1	0	1	1	1	1	3	3	0		3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	0.625	0	1.7142857	2.5	1.1			1.85	1.125	0	3.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHD868NZ7
2081	8976	NDAR_INVHD868NZ7	1005			M	5200	EndofPhase1_1a	3	Phase 1/1A	91	0	0	0	0	0	0	1	9	0	0	0	2	0	0	1	0	0	0	9	2	2	2	2	3	4	3	1	3	1	0	1	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	29	0		0		1	1	0		0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	5	0.42857143	0	2.142857	3.5	1.3157895		1	1.85	1.125	0	3.5714285	1.5	-0.5342105	-0.6964286	0	-1.4285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHD868NZ7
2081	8976	NDAR_INVHE449RWH	2653			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	0	2	0	2	0	0	0	0	9	0	2	2	2	0	1	1	4	2	0	0	0	0	1	0	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0	1.7142857	1	1.1	1		1.1	1	0	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHE449RWH
2081	8976	NDAR_INVHE449RWH	2653			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	1	0	2	0	2	0	2	0	0	0	0	0	0	9	0	2	2	2	0	1	1	2	2	0	0	2	0	1	0	2	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.75	0	1.4285715	1	0.9			1.1	1	0	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHE449RWH
2081	8976	NDAR_INVHE449RWH	2653			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	1	0	2	0	2	0	2	0	2	0	0	0	0	9	0	2	0	2	0	2	1	2	4	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1	0	1.4285715	1.5	1.05			1.1	1	0	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHE449RWH
2081	8976	NDAR_INVHE449RWH	2653			M	5200	EndofPhase1_1a	5	Phase 1/1A	145	0	0	0	0	0	1	0	2	0	2	0	2	0	2	0	1	1	1	9	0	2	0	2	1	1	0	2	2	0	0	0	0	1	1	0	0	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0.75	1.2857143	0.5	1.05		1	1.1	1	0	1.7142857	1	-0.05	0	0.75	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHE449RWH
2081	8976	NDAR_INVHE449RWH	2653			M	5800	EndofPhase2	18	Phase 2	497	0	0	0	0	0	1	0	1	0	1	1	2	1	2	0	0	0	0	9	0	2	1	1	0	1	2	2	2	0	0	0	0	1	0	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0	1.1428572	1.5	0.95			1.1	1	0	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHE449RWH
2081	8976	NDAR_INVHF055PUY	2758			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	0	3	5	2	0	3	2	1	0	0	9	0	1	0	4	1	4	3	4	2	1	1	0	0	1	2	0	1	1	1	1	4	4	4	2	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	3	2.125	0.25	1.7142857	3.5	1.85	1		1.85	2.125	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF055PUY
2081	8976	NDAR_INVHF055PUY	2758			M	1600	Visit6	6	Phase 3	155	0	0	0	0	1	0	0	4	4	4	4	3	2	4	2	0	0	0	9	3	2	3	3	3	4	3	4	3	1	1	0	0	1	1	1	1	1	2	1	4	2	3	2	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	0	3	3.5	2.75			1.85	2.125	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF055PUY
2081	8976	NDAR_INVHF055PUY	2758			M	2800	Visit12	12	Phase 3	323	0	0	0	0	1	0	0	4	2	2	2	3	3	3	2	0	0	0	9	2	2	4	4	2	4	3	4	4	1	1	0	0	1	1	1	1	1	1	1	4	3	3	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	0	3.142857	3.5	2.5			1.85	2.125	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF055PUY
2081	8976	NDAR_INVHF055PUY	2758			M	5200	EndofPhase1_1a	3	Phase 1/1A	81	0	0	0	0	1	0	0	6	5	4	4	2	2	4	2	0	0	0	9	2	2	3	3	2	3	3	4	2	1	1	0	0	1	1	1	1	1	1	1	4	3	3	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	0	2.5714285	3	2.65		1	1.85	2.125	0.25	1.7142857	3.5	0.8	1.5	-0.25	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF055PUY
2081	8976	NDAR_INVHF055PUY	2758			M	5800	EndofPhase2	4	Phase 2	99	0	0	0	0	1	0	0	6	5	4	4	2	2	4	2	0	0	0	9	2	2	3	3	2	3	3	4	2	1	1	0	0	1	0	1	1	1	2	1	4	3	3	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	0	2.5714285	3	2.65			1.85	2.125	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF055PUY
2081	8976	NDAR_INVHF055PUY	2758			M	6000	EndofPhase3	15	Phase 3	421	0	0	0	0	1	0	0	5	2	3	4	2	2	4	2	0	0	0	9	2	1	1	3	2	4	3	4	4	1	1	0	0	1	1	1	1	1	1	0	4	3	3	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3	0	2.4285715	3.5	2.4			1.85	2.125	0.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF055PUY
2081	8976	NDAR_INVHF073KBJ	1305			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	0	1	2	1	1	2	0	0	2	9	2	2	2	2	1	4	2	2	4	2	2	2	1	1	1	1	2	2	2	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	0.5	2.142857	3	1.55	1		1.55	1	0.5	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF073KBJ
2081	8976	NDAR_INVHF073KBJ	1305			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	3	1	3	2	2	2	3	2	6	5	5	5	3	5	4	5	5	5	4	5	6	1	0	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	0	0	1	0	0	1	1	1	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	5.25	4.714286	4.5	3.857143			1.55	1	0.5	2.142857	3	2.307143	1.25	4.75	2.5714285	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF073KBJ
2081	8976	NDAR_INVHF073KBJ	1305			M	2800	Visit12	12	Phase 2	339	0	0	0	0	0	1	0	4	2	2	2	2	3	4	2	6	5	5	5	3	4	2	6	5	6	3	4	5	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	5.25	4.142857	4.5	3.8095238			1.55	1	0.5	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF073KBJ
2081	8976	NDAR_INVHF073KBJ	1305			M	5200	EndofPhase1_1a	8	Phase 1/1A	212	0	0	0	0	0	0	1	4	1	3	2	2	2	3	2	6	5	5	5	3	5	4	5	5	5	4	5	6	1	0	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	5.25	4.714286	4.5	3.9047618		1	1.55	1	0.5	2.142857	3	2.3547618	1.375	4.75	2.5714285	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF073KBJ
2081	8976	NDAR_INVHF073KBJ	1305			M	5800	EndofPhase2	13	Phase 2	353	0	0	0	0	0	1	0	4	2	2	2	2	3	4	2	6	5	5	5	3	4	2	6	5	6	3	4	5	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	5.25	4.142857	4.5	3.8095238			1.55	1	0.5	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF073KBJ
2081	8976	NDAR_INVHF829WHN	2719			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	1	0	1	0	0	0	2	0	0	0	0	0	0	9	2	0	6	4	0	5	2	6	6	1	0	1	0	1	1	0	1	1	2	1	3	3	3	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.375	0	3.4285715	3.5	1.7	1		1.7	0.375	0	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF829WHN
2081	8976	NDAR_INVHF829WHN	2719			M	1600	Visit6	6	Phase 1B	168	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	9	6	0	4	4	0	5	1	4	5	0	0	1	0	1	0	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0	0	3.2857144	3	1.45			1.7	0.375	0	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF829WHN
2081	8976	NDAR_INVHF829WHN	2719			M	2800	Visit12	12	Phase 1B	330	1	0	1	0	0	0	0	2	2	0	0	2	0	1	1	0	0	0	9	3	0	3	4	0	5	1	5	0	0	0	0	0	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0	2.142857	3	1.45			1.7	0.375	0	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF829WHN
2081	8976	NDAR_INVHF829WHN	2719			M	5200	EndofPhase1_1a	1	Phase 1/1A	48	1	0	1	0	1	1	0	4	1	1	2	2	0	0	0	0	0	0	9	4	2	4	0	0	5	1	4	6	0	0	0	0	1	0	0	0	1	3	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.25	0	2.857143	3	1.8		1	1.7	0.375	0	3.4285715	3.5	0.1	0.875	0	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF829WHN
2081	8976	NDAR_INVHF829WHN	2719			M	5400	EndofPhase1b	18	Phase 1B	493	0	0	0	0	0	1	0	4	5	2	4	4	3	4	0	0	1	1	9	4	5	5	6	2	4	1	4	5	2	2	2	0	1	1	1	1	2	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	6	0		1	24	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	3.25	0.5	4.428571	2.5	3.2			1.7	0.375	0	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF829WHN
2081	8976	NDAR_INVHF978HK7	1763			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	9	4	4	4	2	1	5	4	1	6	1	1	1	0	1	0	1	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.125	0	3.142857	4.5	1.6	1		1.6	0.125	0	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF978HK7
2081	8976	NDAR_INVHF978HK7	1763			M	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	0	0	0	0	0	1	2	0	0	0	0	0	1	1	0	0	0	9	3	3	5	4	2	6	4	1	2	1	1	1	1	1	0	1	2	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.5	0	2.857143	5	1.7		1	1.6	0.125	0	3.142857	4.5	0.1	0.375	0	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF978HK7
2081	8976	NDAR_INVHF978HK7	1763			M	5800	EndofPhase2	4	Phase 2	116	0	0	0	0	0	0	1	0	2	0	0	2	0	1	1	0	0	0	9	3	4	4	5	6	6	4	3	5	1	1	0	0	1	0	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.75	0	4.285714	5	2.3			1.6	0.125	0	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHF978HK7
2081	8976	NDAR_INVHH011APP	2778			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	3	1	1	2	2	2	4	2	0	0	2	2	2	0	0	5	1	4	4	0	0	0	0	1	1	1	1	1	3	1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	1.875	1.5	2	3	1.9523809	1		1.9523809	1.875	1.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH011APP
2081	8976	NDAR_INVHH011APP	2778			F	1600	Visit6	6	Phase 1/1A	174	0	1	0	0	0	0	0	5	4	3	2	2	0	2	1	4	3	4	3	3	4	3	2	3	6	2	4	4	0	0	1	0	1	1	1	1	1	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	3.5	3.2857144	4	3.047619		1	1.9523809	1.875	1.5	2	3	1.0952381	0.5	2	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH011APP
2081	8976	NDAR_INVHH011APP	2778			F	2800	Visit12	12	Phase 1B	352	0	1	0	0	0	0	0	5	5	5	4	4	3	4	4	4	3	3	3	4	4	4	4	4	6	3	4	6	1	1	1	1	1	1	1	1	1	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	1	0	0	0	0	0	0	1	1	1	1	5	4.25	3.25	4.285714	4.5	4.095238			1.9523809	1.875	1.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH011APP
2081	8976	NDAR_INVHH011APP	2778			F	5400	EndofPhase1b	18	Phase 1B	503	0	1	0	0	0	0	0	4	0	1	2	2	2	2	4	3	4	4	4	4	6	4	4	4	6	2	6	6	0	1	1	0	1	1	1	1	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.125	3.75	4.857143	4	3.5238094			1.9523809	1.875	1.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH011APP
2081	8976	NDAR_INVHH401NKC	1483			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	4	3	2	0	0	0	1	9	3	3	3	3	4	4	4	5	6	1	1	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	4	2.125	0.25	3.857143	4	2.65	1		2.65	2.125	0.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH401NKC
2081	8976	NDAR_INVHH401NKC	1483			M	1600	Visit6	6	Phase 3	164	1	0	0	0	0	0	0	5	0	0	0	4	1	3	1	0	0	1	9	2	2	3	4	4	4	3	3	6	1	1	0	1	1	1	0	1	1	2	1	3	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	8	0		0		1	22	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	5	1.75	0.25	3.4285715	3.5	2.3			2.65	2.125	0.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH401NKC
2081	8976	NDAR_INVHH401NKC	1483			M	2800	Visit12	12	Phase 3	330	1	0	0	0	0	0	0	6	4	4	5	5	5	5	3	0	0	0	9	4	3	5	5	2	4	2	5	5	1	1	1	0	1	1	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.625	0	4.142857	3	3.6			2.65	2.125	0.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH401NKC
2081	8976	NDAR_INVHH401NKC	1483			M	5200	EndofPhase1_1a	4	Phase 1/1A	88	1	0	0	0	0	0	0	4	1	1	1	3	2	3	1	0	0	1	9	3	2	2	3	2	4	1	3	6	0	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	2	0.25	3	2.5	2.15		1	2.65	2.125	0.25	3.857143	4	-0.5	-0.125	0	-0.85714287	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH401NKC
2081	8976	NDAR_INVHH401NKC	1483			M	5800	EndofPhase2	5	Phase 2	131	0	0	0	0	0	1	0	4	0	0	0	2	0	0	1	0	0	1	9	1	0	1	0	0	3	2	2	5	1	1	0	0	1	1	1	0	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	0.875	0.25	1.2857143	2.5	1.1			2.65	2.125	0.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH401NKC
2081	8976	NDAR_INVHH401NKC	1483			M	6000	EndofPhase3	18	Phase 3	498	1	0	0	0	0	0	0	6	4	4	5	5	4	5	3	0	0	0	9	4	3	4	4	3	5	4	5	6	1	1	0	0	1	1	0	1	1	1	1	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.5	0	4.142857	4.5	3.7			2.65	2.125	0.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHH401NKC
2081	8976	NDAR_INVHJ306LDB	2191			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	4	0	4	5	3	4	4	1	5	4	9	1	2	5	5	5	4	3	5	6	1	1	1	1	1	1	1	1	2	3	1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.5	2.5	4.142857	3.5	3.7	1		3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ306LDB
2081	8976	NDAR_INVHJ306LDB	2191			M	1600	Visit6	6	Phase 2	232	1	0	0	0	0	0	0	4	3	4	4	4	3	5	0	3	2	1	2	1	3	3	4	4	6	5	4	4	1	1	1	1	1	1	1	1	1	1	1	2	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.375	2	3.2857144	5.5	3.2857144			3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ306LDB
2081	8976	NDAR_INVHJ306LDB	2191			M	5200	EndofPhase1_1a	4	Phase 1/1A	142	1	0	0	0	0	0	0	4	6	4	4	5	4	4	4	2	2	2	9	2	3	2	6	4	6	6	4	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	3	4.375	1.5	3.857143	6	4		1	3.7	3.5	2.5	4.142857	3.5	0.3	0.875	-1	-0.2857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ306LDB
2081	8976	NDAR_INVHJ306LDB	2191			M	5400	EndofPhase1b	5	Phase 1B	190	1	0	0	0	0	0	0	4	3	4	4	4	3	3	1	2	1	1	9	1	2	2	3	3	6	4	4	4	1	1	1	1	1	1	1	1	1	1	1	2	1	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	3.25	1	2.7142856	5	2.95			3.7	3.5	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ306LDB
2081	8976	NDAR_INVHJ472JCP	2545			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	1	0	0	0	2	0	2	3	1	1	6	9	1	1	2	2	0	3	1	3	4	1	1	1	0	1	1	1	1	1	3	0	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1	2	1.8571428	2	1.65	1		1.65	1	2	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ472JCP
2081	8976	NDAR_INVHJ472JCP	2545			F	1600	Visit6	6	Phase 1/1A	170	0	0	0	1	0	0	0	4	0	0	2	2	2	2	0	0	4	6	9	1	2	0	4	0	2	2	2	4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	1.5	2.5	1.8571428	2	1.95			1.65	1	2	1.8571428	2	0.3	0.5	0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ472JCP
2081	8976	NDAR_INVHJ472JCP	2545			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	1	0	0	0	0	0	2	2	0	2	0	0	2	6	9	0	1	0	2	0	2	2	2	2	1	0	1	0	1	1	1	1	2	2	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	0.75	2	1	2	1.25			1.65	1	2	1.8571428	2	-0.4	-0.25	0	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ472JCP
2081	8976	NDAR_INVHJ472JCP	2545			F	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	0	0	1	0	0	0	2	2	2	2	0	0	2	6	9	0	2	0	2	0	1	1	2	2	1	0	0	0	1	1	0	1	1	3	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1	2	1.1428572	1	1.3		1	1.65	1	2	1.8571428	2	-0.35	0	0	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHJ472JCP
2081	8976	NDAR_INVHK159WKT	1971			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	9	0	0	0	2	1	4	1	4	4	1	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	0.25	0	1.5714285	2.5	0.9	1		0.9	0.25	0	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK159WKT
2081	8976	NDAR_INVHK159WKT	1971			M	4000	Visit18	18	Phase 3	418	1	0	0	0	0	0	0	1	1	1	2	1	2	2	1	1	1	1	9	1	1	2	1	1	5	5	1	1	1	1	1	2	1	1	0	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	0.75	1.1428572	5	1.6			0.9	0.25	0	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK159WKT
2081	8976	NDAR_INVHK159WKT	1971			M	5200	EndofPhase1_1a	3	Phase 1/1A	54	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	9	0	0	0	2	1	4	1	4	4	1	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	0.25	0	1.5714285	2.5	0.9		1	0.9	0.25	0	1.5714285	2.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK159WKT
2081	8976	NDAR_INVHK159WKT	1971			M	5800	EndofPhase2	6	Phase 2	131	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	9	0	0	0	2	1	4	1	4	4	1	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	0.25	0	1.5714285	2.5	0.9			0.9	0.25	0	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK159WKT
2081	8976	NDAR_INVHK159WKT	1971			M	6000	EndofPhase3	18	Phase 3	418	0	0	0	0	1	0	0	0	0	1	2	1	1	2	0	0	0	0	9	0	0	1	2	2	4	1	4	5	1	1	0	0	1	1	0	1	2	2	0	4	3	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.875	0	2	2.5	1.3			0.9	0.25	0	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK159WKT
2081	8976	NDAR_INVHK282TD5	2135			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	3	5	5	4	4	6	0	2	6	6	9	4	6	4	5	3	3	2	5	6	0	0	2	0	1	1	1	2	2	1	0	4	2	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4	3.5	4.714286	2.5	4.2	1		4.2	4	3.5	4.714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK282TD5
2081	8976	NDAR_INVHK282TD5	2135			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	6	6	6	5	5	5	6	0	1	5	6	9	5	5	4	6	5	3	3	5	6	1	0	2	1	1	1	1	1	1	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	13	1	17	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.875	3	5.142857	3	4.65			4.2	4	3.5	4.714286	2.5	0.45	0.875	-0.5	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK282TD5
2081	8976	NDAR_INVHK282TD5	2135			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	6	5	6	6	6	6	6	2	0	5	6	9	1	6	1	6	2	3	1	4	3	1	0	2	2	1	1	1	2	3	1	1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.375	2.75	3.2857144	2	4.05			4.2	4	3.5	4.714286	2.5	-0.15	1.375	-0.75	-1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK282TD5
2081	8976	NDAR_INVHK282TD5	2135			F	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	0	1	5	4	4	4	4	6	6	0	1	5	6	9	0	5	0	6	2	4	2	4	6	0	0	2	1	1	1	1	2	3		1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	4.125	3	3.2857144	3	3.7		1	4.2	4	3.5	4.714286	2.5	-0.5	0.125	-0.5	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK282TD5
2081	8976	NDAR_INVHK948JU3	1723			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	4	1	4	1	2	1	1	1	1	9	3	0	2	4	5	1	2	4	4	0	1	0	0	1	1	0	0	1	1	1	3	1	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	0.75	3.142857	1.5	2.4	1		2.4	2.5	0.75	3.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK948JU3
2081	8976	NDAR_INVHK948JU3	1723			M	1600	Visit6	6	Phase 1/1A	166	0	0	0	0	0	1	0	3	1	1	2	2	1	2	1	1	1	1	9	2	3	1	2	1	2	1	4	4	0	1	2	0	1	1	2	2	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	0.75	2.4285715	1.5	1.8			2.4	2.5	0.75	3.142857	1.5	-0.6	-0.875	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK948JU3
2081	8976	NDAR_INVHK948JU3	1723			M	2800	Visit12	12	Phase 1/1A	334	0	0	0	0	0	1	0	3	0	3	3	2	1	2	1	0	1	2	9	0	2	1	2	3	1	1	3	4	0	1	2	0	1	1	2	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.875	0.75	2.142857	1	1.75			2.4	2.5	0.75	3.142857	1.5	-0.65	-0.625	0	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK948JU3
2081	8976	NDAR_INVHK948JU3	1723			M	5200	EndofPhase1_1a	18	Phase 1/1A	496	0	0	0	0	0	1	0	4	0	0	2	2	1	2	1	1	1	4	9	2	2	0	2	2	1	3	3	4	1	1	2	0	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	1.5	2.142857	2	1.85		1	2.4	2.5	0.75	3.142857	1.5	-0.55	-1	0.75	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHK948JU3
2081	8976	NDAR_INVHL002PZ0	1612			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	4	2	2	2	2	0	2	4	2	9	2	2	2	4	2	5	5	4	4	1	1	1	0	1	1	1	1	3		0	4	1	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.7142857	2	2.857143	5	2.631579	1		2.631579	1.7142857	2	2.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL002PZ0
2081	8976	NDAR_INVHL047ML7	1721			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	1	2	2	9	1	1	2	1	1	2	1	3	3	2	2	2	1	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	20	1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	1.25	1.7142857	1.5	1.8	1		1.8	2	1.25	1.7142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL047ML7
2081	8976	NDAR_INVHL047ML7	1721			M	1600	Visit6	6	Phase 1/1A	192	0	0	0	0	0	1	0	2	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	2	1	2	2	0	0	0	0	1	1	0	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.125	0.75	1.2857143	1.5	1.2			1.8	2	1.25	1.7142857	1.5	-0.6	-0.875	-0.5	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL047ML7
2081	8976	NDAR_INVHL047ML7	1721			M	2800	Visit12	12	Phase 1/1A	385	0	0	0	0	0	1	0	3	2	3	3	2	2	3	1	2	1	1	9	1	1	1	1	1	1	2	2	2	1	0	0	0	0	0	0	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.375	1	1.2857143	1.5	1.75		1	1.8	2	1.25	1.7142857	1.5	-0.05	0.375	-0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL047ML7
2081	8976	NDAR_INVHL424YTX	1942			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	2	1	2	1	1	1	2	2	3	9	3	1	1	2	1	5	3	4	5	0	1	1	0	1	1	1	1	1	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	1.75	1.75	2.4285715	4	2.3	1		2.3	1.75	1.75	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL424YTX
2081	8976	NDAR_INVHL424YTX	1942			M	2800	Visit12	12	Phase 1B	337	0	0	0	0	0	0	1	9	3	3	2	3	2	3	2	5	3	3	3	3	2	1	2	4	5	3	4	5	1	0	1	0	1	1	1	1	2	2	1	3	2	3	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	2.5714285	3.5	3	4	3.05			2.3	1.75	1.75	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL424YTX
2081	8976	NDAR_INVHL424YTX	1942			M	5200	EndofPhase1_1a	6	Phase 1/1A	165	0	0	0	0	0	0	1	3	2	4	4	2	2	3	1	2	3	3	9	1	1	1	3	4	6	5	3	5	1	1	1	1	0	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2.625	2	2.5714285	5.5	2.9		1	2.3	1.75	1.75	2.4285715	4	0.6	0.875	0.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL424YTX
2081	8976	NDAR_INVHL424YTX	1942			M	5400	EndofPhase1b	18	Phase 1B	554	0	0	0	0	0	0	1	3	2	2	2	3	3	3	2	3	4	3	3	3	3	2	3	4	3	1	3	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.5	3.25	3.142857	2	2.8095238			2.3	1.75	1.75	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL424YTX
2081	8976	NDAR_INVHL795HZ4	1410			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	1	0	2	0	2	0	1	2	0	9	0	2	0	4	0	5	1	4	2	0	0	2	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	1	0	0	0	0	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	0.75	1.7142857	3	1.6	1		1.6	1.375	0.75	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL795HZ4
2081	8976	NDAR_INVHL795HZ4	1410			F	5800	EndofPhase2	3	Phase 2	56	0	0	0	0	0	0	1	4	5	4	4	5	3	6	2	0	1	1	9	0	1	1	6	1	4	2	4	4	1	0	1	0	1	1	1	1	2	1	1	2	1	4	4	1	0	0	0	1	1	1	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	4.125	0.5	2.4285715	3	2.9			1.6	1.375	0.75	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHL795HZ4
2081	8976	NDAR_INVHM953EC0	1687			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	0	1	0	2	0	2	2	1	1	0	9	2	1	1	5	1	2	2	4	4	0	0	0	0	0	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	1.5	0.5	2.5714285	2	1.8	1		1.8	1.5	0.5	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHM953EC0
2081	8976	NDAR_INVHM953EC0	1687			M	1600	Visit6	6	Phase 1/1A	166	1	0	0	0	0	0	0	6	2	2	3	2	4	3	2	0	1	1	9	1	2	2	4	2	2	2	2	3	1	1	0	0	1	1	0	1	1	1	0	4	2	3	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	0.5	2.2857144	2	2.3			1.8	1.5	0.5	2.5714285	2	0.5	1.5	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHM953EC0
2081	8976	NDAR_INVHM953EC0	1687			M	2800	Visit12	12	Phase 1/1A	336	1	0	0	0	0	0	0	5	2	1	3	2	4	4	2	1	1	0	9	1	2	2	5	2	3	3	4	3	1	0	0	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.875	0.5	2.7142856	3	2.5			1.8	1.5	0.5	2.5714285	2	0.7	1.375	0	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHM953EC0
2081	8976	NDAR_INVHM953EC0	1687			M	5200	EndofPhase1_1a	18	Phase 1/1A	516	1	0	0	0	0	0	0	6	2	4	5	4	4	4	1	0	0	0	9	0	0	1	6	2	3	3	4	4	1	1	0	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	0	2.4285715	3	2.65		1	1.8	1.5	0.5	2.5714285	2	0.85	2.25	-0.5	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHM953EC0
2081	8976	NDAR_INVHN275BW5	2500			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	1	1	1	1	1	3	2	4	4	3	3	3	3	1	4	4	5	3	4	5	1	1	1	1	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	5	1.4285715	3.5	3.4285715	4	2.8	1		2.8	1.4285715	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN275BW5
2081	8976	NDAR_INVHN275BW5	2500			F	1600	Visit6	6	Phase 2	176	0	0	0	0	0	0	1	9	2	4	4	2	1	4	2	5	2	3	9	3	3	1	4	4	4	3	3	5	1	1	1	0	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.7142856	2.5	3.2857144	3.5	3.1052632			2.8	1.4285715	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN275BW5
2081	8976	NDAR_INVHN275BW5	2500			F	2800	Visit12	12	Phase 2	343	0	0	0	0	0	0	1	2	3	3	3	4	2	4	3	4	3	3	4	4	3	2	2	5	4	3	3	5	1	0	1	0	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	5	3	3.5	3.4285715	3.5	3.2857144			2.8	1.4285715	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN275BW5
2081	8976	NDAR_INVHN275BW5	2500			F	5200	EndofPhase1_1a	2	Phase 1/1A	63	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	3	1	1	9	1	1	1	3	1	4	3	0	4	1	0	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	0.25	1.25	1.5714285	3.5	1.25		1	2.8	1.4285715	3.5	3.4285715	4	-1.55	-1.1785715	-2.25	-1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN275BW5
2081	8976	NDAR_INVHN275BW5	2500			F	5800	EndofPhase2	18	Phase 2	569	0	0	0	0	0	0	1	1	1	1	1	3	1	3	1	4	3	3	3	3	2	1	2	3	4	2	1	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	1.5	3.25	2.2857144	3	2.2380953			2.8	1.4285715	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN275BW5
2081	8976	NDAR_INVHN380TAC	2131			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	3	1	2	2	2	1	1	2	4	2	3	4	4	3	2	2	3	4	3	3	2	1	1	1	1	1	1	1	1	1	2	0	4	3	4	2	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	4	1.75	3.25	2.7142856	3.5	2.5238094	1		2.5238094	1.75	3.25	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN380TAC
2081	8976	NDAR_INVHN380TAC	2131			M	1600	Visit6	6	Phase 1/1A	209	0	0	1	0	0	0	0	4	1	1	1	2	1	2	2	4	1	3	4	4	2	1	2	4	3	1	3	4	1	0	1	1	1	1	1	1	1	2	0	4	4	3	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	6	1.75	3	2.857143	2	2.3809524			2.5238094	1.75	3.25	2.7142856	3.5	-0.14285715	0	-0.25	0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN380TAC
2081	8976	NDAR_INVHN380TAC	2131			M	2800	Visit12	12	Phase 1/1A	386	0	0	1	0	0	0	0	4	2	3	3	3	2	3	3	6	5	5	5	4	4	2	3	5	5	3	4	5	1	1	1	0	1	1	1	1	1	2	0	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	1	6	2.875	5.25	3.857143	4	3.7619047			2.5238094	1.75	3.25	2.7142856	3.5	1.2380953	1.125	2	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN380TAC
2081	8976	NDAR_INVHN380TAC	2131			M	5200	EndofPhase1_1a	18	Phase 1/1A	561	0	0	1	0	0	0	0	5	2	2	2	3	2	4	3	4	4	3	4	3	2	2	3	5	4	3	3	5	1	1	1	0	1	1	1	1	1	1	0	4	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	4	2.875	3.75	3.2857144	3.5	3.2380953		1	2.5238094	1.75	3.25	2.7142856	3.5	0.71428573	1.125	0.5	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN380TAC
2081	8976	NDAR_INVHN723KX3	2632			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	1	0	4	6	6	6	6	6	5	4	6	6	6	6	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.375	6	6	6	5.7619047	1		5.7619047	5.375	6	6	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN723KX3
2081	8976	NDAR_INVHN723KX3	2632			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	1	0	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	6	6	6	6	6			5.7619047	5.375	6	6	6	0.23809524	0.625	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN723KX3
2081	8976	NDAR_INVHN723KX3	2632			M	2800	Visit12	12	Phase 1/1A	375	0	0	0	0	0	1	0	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	6	6	6	6	6			5.7619047	5.375	6	6	6	0.23809524	0.625	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN723KX3
2081	8976	NDAR_INVHN723KX3	2632			M	5200	EndofPhase1_1a	18	Phase 1/1A	571	0	1	0	0	0	0	0	6	6	5	4	4	5	4	5	6	6	5	6	5	5	6	5	5	6	6	6	6	1	1	1	1	1	1	1	1	3		1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	5.75	5.428571	6	5.3333335		1	5.7619047	5.375	6	6	6	-0.42857143	-0.5	-0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHN723KX3
2081	8976	NDAR_INVHR247BZT	2170			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	0	2	0	4	3	0	2	3	0	0	0	9	2	2	4	2	2	3	3	6	5	1	0	1	0	1	1	1	1	1	2	1	3	3	2	1	1	0	0	1	0	0	0	0	1	1	1	1	1	22	0		0		1	8	0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	5	1.75	0	3.2857144	3	2.15	1		2.15	1.75	0	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR247BZT
2081	8976	NDAR_INVHR247BZT	2170			M	1600	Visit6	6	Phase 1/1A	169	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	9	2	1	2	2	1	2	1	5	6	0	0	0	0	1	1	1	0	3		1	3	4	1	4	1	0	0	1	0	0	1	0	1	1	1	1	1	16	0		0		1	14	0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	3	0.125	0	2.7142856	1.5	1.15			2.15	1.75	0	3.2857144	3	-1	-1.625	0	-0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR247BZT
2081	8976	NDAR_INVHR247BZT	2170			M	2800	Visit12	12	Phase 1/1A	336	0	1	0	0	0	0	0	6	4	0	4	2	0	4	6	0	0	0	9	2	2	4	5	5	2	2	4	4	1	0	1	0	1	1	1	1	1	1	1	3	4	2	1	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	6	3.25	0	3.7142856	2	2.8			2.15	1.75	0	3.2857144	3	0.65	1.5	0	0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR247BZT
2081	8976	NDAR_INVHR247BZT	2170			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	1	0	1	0	0	0	6	4	6	6	6	6	0	0	0	0	9	6	2	4	4	5	4	4	6	6	1	1	0	1	1	1	1	0	1	1	1	3	1	2	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.25	0	4.714286	4	3.75		1	2.15	1.75	0	3.2857144	3	1.6	2.5	0	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR247BZT
2081	8976	NDAR_INVHR457JBL	1014			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	5	0	0	2	0	1	3	0	0	0	9	4	3	6	2	0	4	4	5	6	1	1	0	1	1	1	1	1	3	2	1	2	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	1.5	0	3.7142856	4	2.3	1		2.3	1.5	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR457JBL
2081	8976	NDAR_INVHR457JBL	1014			M	1600	Visit6	6	Phase 1/1A	163	0	0	0	0	1	0	0	1	1	1	2	1	2	1	3	0	0	0	9	3	3	5	3	2	3	2	5	6	0	0	0	1	1	1	1	1	1	2	1	3	4	4	4	1	0	0	0	1	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.5	0	3.857143	2.5	2.2			2.3	1.5	0	3.7142856	4	-0.1	0	0	0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR457JBL
2081	8976	NDAR_INVHR457JBL	1014			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	4	4	3	3	3	3	3	3	0	0	3	9	3	3	3	3	3	4	3	3	6	1	2	1	1	1	1	1	1	2	3	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	3.25	0.75	3.4285715	3.5	3			2.3	1.5	0	3.7142856	4	0.7	1.75	0.75	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR457JBL
2081	8976	NDAR_INVHR457JBL	1014			M	5200	EndofPhase1_1a	18	Phase 1/1A	569	0	1	0	0	0	0	0	4	0	0	3	2	3	0	3	0	0	0	9	3	0	4	4	1	4	4	5	5	1	1	1	0	1	1	1	1	3	2	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	1	1	1	1	1	0	1	4	1.875	0	3.142857	4	2.25		1	2.3	1.5	0	3.7142856	4	-0.05	0.375	0	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR457JBL
2081	8976	NDAR_INVHR724VGN	2634			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	2	1	2	2	1	2	2	1	2	2	9	3	3	1	3	3	3	2	3	4	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2.125	1.25	2.857143	2.5	2.35	1		2.35	2.125	1.25	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHR724VGN
2081	8976	NDAR_INVHT173RPK	2319			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	1	1	1	0	2	2	0	4	6	9	4	4	4	4	2	3	5	4	4	0	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1	2.5	3.7142856	4	2.6842105	1		2.6842105	1	2.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHT173RPK
2081	8976	NDAR_INVHT173RPK	2319			M	1600	Visit6	6	Phase 1/1A	156	0	0	0	0	0	0	1	9	1	3	4	1	3	4	2	1	4	4	9	3	2	4	5	2	3	4	4	4	1	1	1	0	1	1	1	1	3		1	2	2	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2.5714285	2.25	3.4285715	3.5	3.0526316			2.6842105	1	2.5	3.7142856	4	0.36842105	1.5714285	-0.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHT173RPK
2081	8976	NDAR_INVHT173RPK	2319			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	9	0	2	2	2	2	2	2	1	1	1	9	0	2	2	3	1	3	3	4	4	1	1	1	0	1	0	1	0	3		1	3	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.7142857	0.75	2.2857144	3	1.9473684			2.6842105	1	2.5	3.7142856	4	-0.7368421	0.71428573	-1.75	-1.4285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHT173RPK
2081	8976	NDAR_INVHT173RPK	2319			M	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	0	0	1	0	0	2	4	1	2	6	3	0	3	4	9	1	5	4	3	2	6	5	4	5	1	1	1	0	1	1	1	1	3		1	3	3	2	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	4	2.25	1.75	3.4285715	5.5	3		1	2.6842105	1	2.5	3.7142856	4	0.31578946	1.25	-0.75	-0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHT173RPK
2081	8976	NDAR_INVHT588LEK	2492			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	2	2	1	1	1	2	4	0	1	0	9	2	2	1	3	2	3	1	3	3	0	1	0	0	1	1	0	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	0	1	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5	2	0.25	2.2857144	2	1.85	1		1.85	2	0.25	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHT588LEK
2081	8976	NDAR_INVHT588LEK	2492			F	5200	EndofPhase1_1a	5	Phase 1/1A	179	0	1	0	0	0	0	0	3	2	2	2	1	1	2	2	0	0	0	9	1	2	1	3	1	2	2	2	3	1	0	1	0	0	1	1	1	1	2	0	4	4	4	4	1	1	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	1.875	0	1.8571428	2	1.6		1	1.85	2	0.25	2.2857144	2	-0.25	-0.125	-0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHT588LEK
2081	8976	NDAR_INVHU225AKV	2851			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	5	2	0	2	2	4	2	6	1	4	4	0	3	1	4	0	4	3	4	4	1	0	1	1	1	1	1	1	3	1	1	4	2	3	3	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	5	2.375	3.75	2.2857144	3.5	2.7142856	1		2.7142856	2.375	3.75	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU225AKV
2081	8976	NDAR_INVHU225AKV	2851			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	0	0	0	0	0	1	0	2	2	0	3	2	3	3	3	0	0	2	9	2	2	1	2	3	3	2	2	2	1	1	1	1	1	1	1	1	2	1	0	4	4	3	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0.5	2	2.5	1.95		1	2.7142856	2.375	3.75	2.2857144	3.5	-0.76428574	-0.125	-3.25	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU225AKV
2081	8976	NDAR_INVHU225AKV	2851			M	5800	EndofPhase2	4	Phase 2	98	0	0	0	0	0	1	0	2	2	0	2	2	2	2	2	1	0	1	9	1	2	2	3	1	3	2	2	6	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	16	0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	1	1	1	1	4	1.75	0.5	2.4285715	2.5	1.9			2.7142856	2.375	3.75	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU225AKV
2081	8976	NDAR_INVHU225AKV	2851			M	6000	EndofPhase3	6	Phase 3	165	0	0	0	0	0	1	0	2	2	0	1	1	1	2	0	1	2	1	9	1	2	0	2	2	3	2	2	5	1	0	1	1	1	1	1	1	3	1	0	4	2	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.125	1	2	2.5	1.6			2.7142856	2.375	3.75	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU225AKV
2081	8976	NDAR_INVHU736MPK	1628			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	0	0	0	1	0	2	1	0	0	1	9	2	2	2	2	2	2	2	4	5	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	1	0.25	2.7142856	2	1.6	1		1.6	1	0.25	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU736MPK
2081	8976	NDAR_INVHU912VJ0	2398			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	4	3	3	2	3	0	2	4	4	9	0	3	4	3	2	3	2	4	6	1	1	1	1	1	1	1	1	3	1	0	4	1	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.625	2.5	3.142857	2.5	2.9	1		2.9	2.625	2.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU912VJ0
2081	8976	NDAR_INVHU912VJ0	2398			M	1600	Visit6	6	Phase 2	174	0	0	0	0	0	1	0	5	3	5	4	3	2	4	0	1	2	1	9	3	2	2	2	2	3	3	4	4	1	1	1	0	1	1	1	1	3	1	1	3	2	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	1	2.7142856	3	2.75			2.9	2.625	2.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU912VJ0
2081	8976	NDAR_INVHU912VJ0	2398			M	2800	Visit12	12	Phase 2	342	0	0	0	0	0	1	0	5	4	6	5	4	6	5	1	2	4	4	9	4	3	3	3	4	3	4	3	4	1	1	1	0	0	1	1	1	3	1	1	4	2	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.5	2.5	3.4285715	3.5	3.85			2.9	2.625	2.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU912VJ0
2081	8976	NDAR_INVHU912VJ0	2398			M	5200	EndofPhase1_1a	4	Phase 1/1A	114	0	0	0	0	0	1	0	4	2	5	5	3	5	4	0	2	3	3	9	3	3	2	3	2	4	3	5	5	0	1	1	1	1	1	1	1	3	1	1	2	1	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	2	3.2857144	3.5	3.3		1	2.9	2.625	2.5	3.142857	2.5	0.4	0.875	-0.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU912VJ0
2081	8976	NDAR_INVHU912VJ0	2398			M	5800	EndofPhase2	18	Phase 2	520	0	0	0	0	0	1	0	3	3	4	3	3	4	4	1	2	3	4	9	0	2	2	3	4	2	2	3	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	2.25	2.5714285	2	2.8			2.9	2.625	2.5	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU912VJ0
2081	8976	NDAR_INVHU948UG2	2084			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	4	4	4	4	6	4	6	5	6	6	6	6	6	6	6	6	5	6	5	1	1	1	2	1	1	1	1	2	2	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5.75	5.857143	5.5	5.142857	1		5.142857	4.125	5.75	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU948UG2
2081	8976	NDAR_INVHU948UG2	2084			F	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	4	5	5	4	4	5	2	5	4	3	4	6	3	3	3	4	4	5	5	5	5	1	1	1	0	1	1	1	1	1	2	1	4	2	3	2	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4.25	4.25	3.857143	5	4.1904764			5.142857	4.125	5.75	5.857143	5.5	-0.95238096	0.125	-1.5	-2	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU948UG2
2081	8976	NDAR_INVHU948UG2	2084			F	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	4	5	6	5	4	5	2	5	5	3	5	6	3	4	3	4	4	4	5	5	4	1	1	1	2	1	1	1	1	1	2	1	2	3	4	3	1	0	0	0	0	1	0	0	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	4.5	4.75	3.857143	4.5	4.3333335			5.142857	4.125	5.75	5.857143	5.5	-0.8095238	0.375	-1	-2	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU948UG2
2081	8976	NDAR_INVHU948UG2	2084			F	5200	EndofPhase1_1a	18	Phase 1/1A	538	0	0	0	0	0	0	1	4	5	5	4	4	5	2	5	5	3	5	6	3	4	3	4	4	4	5	5	4	1	1	1	0	1	1	1	1	1	2	1	4	3	4	3	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	4.25	4.75	3.857143	4.5	4.2380953		1	5.142857	4.125	5.75	5.857143	5.5	-0.9047619	0.125	-1	-2	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHU948UG2
2081	8976	NDAR_INVHV131NAU	1730			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	1	0	5	2	3	2	2	3	4	4	4	4	0	1	2	3	5	5	4	2	1	1	1	1	1	1	1	1	1	1	1	4	2	3	2	1	1	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.5	3.75	2.2857144	5	2.9047618	1		2.9047618	2.5	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV131NAU
2081	8976	NDAR_INVHV131NAU	1730			M	1600	Visit6	6	Phase 2	168	0	1	0	1	0	0	0	6	1	2	1	3	1	2	5	4	4	3	3	3	2	1	4	4	5	4	4	5	1	1	1	1	1	1	0	1	1	3	0	4	2	3	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	2.625	3.5	3.2857144	4.5	3.1904762			2.9047618	2.5	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV131NAU
2081	8976	NDAR_INVHV131NAU	1730			M	2800	Visit12	12	Phase 3	345	0	1	0	1	0	0	0	3	3	2	3	3	2	2	2	1	1	1	9	3	2	2	2	1	5	5	2	4	1	1	0	0	1	0	0	0	1	1	0	4	3	3	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.5	0.75	2.2857144	5	2.45			2.9047618	2.5	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV131NAU
2081	8976	NDAR_INVHV131NAU	1730			M	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	1	0	0	0	0	0	5	2	3	3	3	3	2	4	2	2	1	9	2	2	2	2	2	5	4	4	5	1	1	2	1	1	0	0	0	1	1	0	4	2	4	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.125	1.25	2.7142856	4.5	2.9		1	2.9047618	2.5	3.75	2.2857144	5	-0.004761905	0.625	-2.5	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV131NAU
2081	8976	NDAR_INVHV131NAU	1730			M	5800	EndofPhase2	10	Phase 2	288	0	1	0	1	0	0	0	4	1	1	1	2	1	2	2	2	2	2	9	3	1	1	1	4	6	5	3	4	1	1	1	1	1	1	0	1	1	2	0	4	3	4	1	1	1	0	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1.5	2.4285715	5.5	2.4			2.9047618	2.5	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV131NAU
2081	8976	NDAR_INVHV131NAU	1730			M	6000	EndofPhase3	18	Phase 3	513	0	0	0	1	0	0	0	6	4	3	3	4	2	2	2	2	2	3	9	4	2	1	2	4	5	4	4	5	1	1	1	0	1	1	1	1	1	1	1	3	1	2	1	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1.75	3.142857	4.5	3.2			2.9047618	2.5	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV131NAU
2081	8976	NDAR_INVHV683RTH	1501			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	0	4	2	4	4	2	4	4	5	6	2	4	6	4	5	6	4	4	6	1	1	1	1	1	1	1	1	1	2	1	3	3	3	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.5	4.75	4.428571	5	3.8095238	1		3.8095238	2.5	4.75	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV683RTH
2081	8976	NDAR_INVHV683RTH	1501			M	1600	Visit6	6	Phase 2	204	0	1	0	0	0	0	0	4	4	4	2	4	2	4	2	4	4	0	9	2	2	4	4	4	4	2	4	6	0	0	1	1	1	1	0	1	1	1	1	4	2	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3.25	2	3.7142856	3	3.3			3.8095238	2.5	4.75	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV683RTH
2081	8976	NDAR_INVHV683RTH	1501			M	5200	EndofPhase1_1a	3	Phase 1/1A	104	0	1	0	0	0	0	0	6	4	0	5	0	2	2	3	3	4	4	4	1	3	0	0	1	6	3	0	2	1	0	0	0	1	0	1	1	1	1	0	4	4	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	2.75	3.75	1	4.5	2.5238094		1	3.8095238	2.5	4.75	4.428571	5	-1.2857143	0.25	-1	-3.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV683RTH
2081	8976	NDAR_INVHV683RTH	1501			M	5400	EndofPhase1b	5	Phase 1B	149	0	1	0	0	0	0	0	4	4	2	4	2	2	0	4	6	5	0	9	6	6	4	4	0	6	3	6	6	1	1	1	1	1	1	0	1	1	1	1	4	3	2	1	0	0	0	0	0	0	0	1	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	2.75	4.571429	4.5	3.7			3.8095238	2.5	4.75	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV683RTH
2081	8976	NDAR_INVHV683RTH	1501			M	5800	EndofPhase2	10	Phase 2	283	0	1	0	0	0	0	0	4	4	4	4	4	4	4	4	4	2	0	9	4	4	4	4	4	6	5	6	6	1	1	1	1	1	1	1	1	2	1	1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4	1.5	4.571429	5.5	4.05			3.8095238	2.5	4.75	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV683RTH
2081	8976	NDAR_INVHV683RTH	1501			M	6000	EndofPhase3	11	Phase 3	317	0	1	0	0	0	0	0	6	5	4	4	4	4	3	4	0	0	2	9	4	4	4	4	3	6	3	5	5	1	0	1	0	1	1	1	0	1	2	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	0.5	4.142857	4.5	3.7			3.8095238	2.5	4.75	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV683RTH
2081	8976	NDAR_INVHV997EHA	2048			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	1	0	0	0	2	1	0	0	1	9	0	3	2	2	1	4	3	1	6	1	1	0	1	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					0		1	25	0		1	5	0		0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	1	5	0.5	0.25	2.142857	3.5	1.35	1		1.35	0.5	0.25	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV997EHA
2081	8976	NDAR_INVHV997EHA	2048			M	5200	EndofPhase1_1a	1	Phase 1/1A	27	0	0	0	0	0	1	0	0	0	1	0	0	0	2	2	0	0	1	9	1	6	2	4	2	4	3	2	6	1	1	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	1	1	0	1	1	1	1	5	0.625	0.25	3.2857144	3.5	1.8		1	1.35	0.5	0.25	2.142857	3.5	0.45	0.125	0	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHV997EHA
2081	8976	NDAR_INVHW644GNP	2465			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	4	3	2	3	3	2	0	0	0	9	3	3	4	4	2	5	4	4	5	1	1	1	0	1	1	0	1	3	2	0	4	3	3	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	2.75	0	3.5714285	4.5	2.8	1		2.8	2.75	0	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHW644GNP
2081	8976	NDAR_INVHX172BW6	1867			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	4	3	6	4	3	6	0	3	2	9	6	5	6	6	3	5	2	6	6	1	0	2	0	1	1	1	1	1	1	1	3	3	2	1	1	1	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.5	1.25	5.428571	3.5	4.3	1		4.3	4.5	1.25	5.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX172BW6
2081	8976	NDAR_INVHX172BW6	1867			M	1600	Visit6	6	Phase 3	169	0	1	0	0	0	0	0	6	4	0	2	6	1	2	4	0	0	0	9	4	5	0	3	2	5	2	5	5	0	0	1	1	1	1	1	1	2	3	1	3	4	4	1	1	0	0	1	0	0	0	0	1	0	1	0	1	28	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	0	3.4285715	3.5	2.8			4.3	4.5	1.25	5.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX172BW6
2081	8976	NDAR_INVHX172BW6	1867			M	2800	Visit12	12	Phase 3	351	0	0	0	0	0	0	1	6	6	6	4	6	4	2	6	0	0	2	9	2	2	4	4	2	4	2	6	6	1	0	1	0	1	1	1	1	2	1	1	4	2	2	2	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5	0.5	3.7142856	3	3.7			4.3	4.5	1.25	5.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX172BW6
2081	8976	NDAR_INVHX172BW6	1867			M	4000	Visit18	18	Phase 3	525	0	0	0	0	0	0	1	4	1	4	2	4	2	2	2	0	0	1	9	3	2	2	2	5	1	3	3	6	1	0	1	0	1	1	1	1	2	1	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0.25	3.2857144	2	2.45			4.3	4.5	1.25	5.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX172BW6
2081	8976	NDAR_INVHX172BW6	1867			M	5200	EndofPhase1_1a	1	Phase 1/1A	27	0	1	0	0	0	0	0	6	4	4	3	6	4	3	6	0	3	2	9	6	5	6	6	3	5	2	6	6	1	1	1	2	1	1	1	1	1	1	1	3	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.5	1.25	5.428571	3.5	4.3		1	4.3	4.5	1.25	5.428571	3.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX172BW6
2081	8976	NDAR_INVHX172BW6	1867			M	5800	EndofPhase2	3	Phase 2	84	0	1	0	0	0	0	0	6	2	2	0	2	2	4	4	1	2	2	9	4	2	2	4	2	5	2	5	4	0	0	0	0	1	1	1	1	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	1.25	3.2857144	3.5	2.85			4.3	4.5	1.25	5.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX172BW6
2081	8976	NDAR_INVHX267UED	1512			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	0	2	2	1	2	3	2	3	1	9	2	2	0	4	2	4	2	4	4	1	1	0	1	1	1	1	1	1	3	0	4	4	4	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.75	1.5	2.5714285	3	2.2	1		2.2	1.75	1.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX267UED
2081	8976	NDAR_INVHX267UED	1512			M	1600	Visit6	6	Phase 3	169	0	1	0	1	0	0	0	2	0	0	2	2	2	2	2	1	1	1	9	0	2	2	2	1	4	2	4	3	1	0	1	0	1	1	1	1	2	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	0.75	2	3	1.75			2.2	1.75	1.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX267UED
2081	8976	NDAR_INVHX267UED	1512			M	2800	Visit12	12	Phase 3	336	0	1	0	0	0	0	0	4	0	0	0	2	0	2	1	1	2	3	9	2	2	2	3	1	5	1	4	6	1	0	1	0	1	1	1	1	1	3	0	4	4	4	1	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	1.125	1.5	2.857143	3	2.05			2.2	1.75	1.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX267UED
2081	8976	NDAR_INVHX267UED	1512			M	5800	EndofPhase2	4	Phase 2	105	0	1	0	1	0	0	0	4	0	0	2	2	2	1	2	1	0	0	9	1	1	2	2	2	5	2	2	3	1	0	0	0	1	1	1	1	1	1	0	4	3	4	4	1	1	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.625	0.25	1.8571428	3.5	1.7			2.2	1.75	1.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX267UED
2081	8976	NDAR_INVHX267UED	1512			M	6000	EndofPhase3	18	Phase 3	504	0	1	0	0	0	0	0	1	0	0	2	2	2	2	1	2	2	4	9	1	2	2	4	2	4	2	3	6	1	0	1	0	1	1	1	1	3	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.25	2	2.857143	3	2.2			2.2	1.75	1.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX267UED
2081	8976	NDAR_INVHX284TCW	2189			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	6	6	6	6	6	6	6	3	4	2	3	6	5	6	4	2	3	3	6	6	1	1	1	1	1	1	1	1	1	1	1	4	2	2	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	6	3	5	3	4.8095236	1		4.8095236	6	3	5	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX284TCW
2081	8976	NDAR_INVHX284TCW	2189			F	1600	Visit6	6	Phase 1B	204	0	0	1	0	0	0	0	6	6	6	6	4	5	6	3	6	6	6	5	6	6	6	6	5	3	3	6	6	1	1	1	0	1	1	1	1	1	3	1	4	3	3	4	1	0	0	1	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	5.25	5.75	5.857143	3	5.3333335			4.8095236	6	3	5	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX284TCW
2081	8976	NDAR_INVHX284TCW	2189			F	5200	EndofPhase1_1a	4	Phase 1/1A	162	0	0	1	0	0	0	0	6	6	2	5	6	2	4	2	4	2	4	9	3	3	4	5	2	3	3	6	6	1	0	1	0	1	1	1	1	1	3	1	4	3	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	4.125	2.5	4.142857	3	3.9		1	4.8095236	6	3	5	3	-0.9095238	-1.875	-0.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX284TCW
2081	8976	NDAR_INVHX589YY2	1194			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	4	0	1	0	0	1	1	0	0	9	2	2	2	2	0	3	3	2	3	1	0	0	1	1	1	1	1	2	2	1	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0.75	0.25	1.8571428	3	1.3	1		1.3	0.75	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX589YY2
2081	8976	NDAR_INVHX589YY2	1194			M	1600	Visit6	6	Phase 3	169	0	0	0	0	0	1	0	2	2	1	2	2	2	1	0	0	0	1	9	1	1	1	1	0	3	3	1	2	0	0	0	0	1	1	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1.5	0.25	1	3	1.3			1.3	0.75	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX589YY2
2081	8976	NDAR_INVHX589YY2	1194			M	5200	EndofPhase1_1a	3	Phase 1/1A	66	0	0	0	0	0	1	0	0	0	3	2	2	3	1	2	0	1	1	9	1	2	2	2	3	3	3	1	4	1	1	0	0	1	1	1	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	3	1.625	0.5	2.142857	3	1.8		1	1.3	0.75	0.25	1.8571428	3	0.5	0.875	0.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX589YY2
2081	8976	NDAR_INVHX589YY2	1194			M	5800	EndofPhase2	4	Phase 2	78	0	0	0	0	0	1	0	2	0	3	0	1	0	0	0	0	0	0	9	0	1	2	2	0	2	2	4	4	2	2	2	2	1	1	2	2	3		0	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.75	0	1.8571428	2	1.15			1.3	0.75	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX589YY2
2081	8976	NDAR_INVHX589YY2	1194			M	6000	EndofPhase3	7	Phase 3	176	0	0	0	0	0	1	0	2	2	1	2	2	2	1	0	0	0	1	9	1	1	1	1	0	3	3	1	2	0	0	0	0	1	1	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.5	0.25	1	3	1.3			1.3	0.75	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX589YY2
2081	8976	NDAR_INVHX897ZZ5	1270			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	2	0	1	2	4	4	4	4	4	1	4	6	6	6	6	5	5	4	6	1	1	1	1	1	1	1	1	2	2	1	4	1	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	1	1	0	1	0	1	1	0	0	0	0	4	1.75	3.25	5.428571	5	3.5714285	1		3.5714285	1.75	3.25	5.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX897ZZ5
2081	8976	NDAR_INVHX897ZZ5	1270			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	4	3	3	2	2	3	4	3	1	1	4	9	3	2	4	6	4	5	1	3	5	0	0	1	0	1	1	1	0	2	1	0	4	1	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3	1.5	3.857143	3	3.15		1	3.5714285	1.75	3.25	5.428571	5	-0.42142856	1.25	-1.75	-1.5714285	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHX897ZZ5
2081	8976	NDAR_INVHZ501AVT	2209			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	5	4	1	5	0	1	0	0	0	0	9	3	0	0	2	0	4	5	6	6	0	1	1	0	1	1	1	1	2	1	1	2	3	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.75	0	2.4285715	4.5	2.4	1		2.4	2.75	0	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVHZ501AVT
2081	8976	NDAR_INVJA101FXG	1695			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	3	1	0	2	2	2	2	2	3	4	4	2	2	3	4	4	1	4	6	4	5	1	1	1	1	1	1	1	1	1	2	0	4	1	2	2	1	1	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	1	1	1	0	1	1	4	1.75	3.25	3.2857144	5	2.857143	1		2.857143	1.75	3.25	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA101FXG
2081	8976	NDAR_INVJA101FXG	1695			M	1600	Visit6	6	Phase 1/1A	169	0	0	1	0	1	0	0	6	2	0	1	3	1	3	3	1	1	1	9	2	2	2	2	2	5	5	6	6	1	2	1	1	1	1	1	1	1	3	1	2	1	1	4	1	0	1	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	3	2.375	0.75	3.142857	5	2.7			2.857143	1.75	3.25	3.2857144	5	-0.15714286	0.625	-2.5	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA101FXG
2081	8976	NDAR_INVJA101FXG	1695			M	2800	Visit12	12	Phase 3	337	0	0	0	0	1	0	0	1	4	2	1	2	2	1	3	1	0	0	9	3	3	3	3	1	4	5	4	6	1	1	1	1	1	1	1	1	1	2	1	3	1	2	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	0	0	0	3	2	0.25	3.2857144	4.5	2.45			2.857143	1.75	3.25	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA101FXG
2081	8976	NDAR_INVJA101FXG	1695			M	5200	EndofPhase1_1a	8	Phase 1/1A	225	0	0	0	0	1	0	0	6	4	0	1	2	2	2	1	0	0	0	9	1	0	2	4	5	4	5	5	5	1	1	1	1	1	1	1	1	1	3	1	2	2	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	2.25	0	3.142857	4.5	2.45		1	2.857143	1.75	3.25	3.2857144	5	-0.40714285	0.5	-3.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA101FXG
2081	8976	NDAR_INVJA101FXG	1695			M	5800	EndofPhase2	9	Phase 2	239	0	0	0	0	1	0	0	6	4	0	1	2	2	2	1	0	0	0	9	1	0	2	4	5	4	5	5	5	1	1	1	1	1	1	1	1	1	3	1	2	2	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	2.25	0	3.142857	4.5	2.45			2.857143	1.75	3.25	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA101FXG
2081	8976	NDAR_INVJA299TCN	2072			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	3	0	2	2	3	2	1	0	0	0	9	0	2	3	4	0	5	2	2	3	1	0	1	0	1	1	1	0	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	5	1.75	0	2	3.5	1.75	1		1.75	1.75	0	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA299TCN
2081	8976	NDAR_INVJA426HJF	1198			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	1	2	1	2	2	0	1	1	9	2	2	3	2	2	5	3	5	3	0	1	0	0	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	2	1.75	0.5	2.7142856	4	2.15	1		2.15	1.75	0.5	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA426HJF
2081	8976	NDAR_INVJA426HJF	1198			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	5	0	4	4	2	3	3	1	5	5	5	6	4	5	3	3	5	4	3	6	6	1	1	0	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	7	1	23	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	4	2.75	5.25	4.571429	3.5	3.9047618		1	2.15	1.75	0.5	2.7142856	4	1.7547619	1	4.75	1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA426HJF
2081	8976	NDAR_INVJA941MJQ	1472			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	3	4	2	0	4	1	0	3	1	9	3	2	4	2	2	2	2	4	4	0	0	0	0	1	1	0	0	3	2	0	4	1	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1	3	2	2.25	1		2.25	2	1	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA941MJQ
2081	8976	NDAR_INVJA941MJQ	1472			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	4	0	2	3	2	1	4	0	0	2	4	9	2	2	2	4	2	3	2	4	4	1	1	1	1	1	1	1	1	3		1	2	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2	1.5	2.857143	2.5	2.35			2.25	2	1	3	2	0.1	0	0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA941MJQ
2081	8976	NDAR_INVJA941MJQ	1472			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	1	0	2	2	0	2	2	0	2	0	0	2	5	9	2	2	0	2	0	2	2	4	4	1	0	1	1	1	1	1	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.25	1.75	2	2	1.75			2.25	2	1	3	2	-0.5	-0.75	0.75	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA941MJQ
2081	8976	NDAR_INVJA941MJQ	1472			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	1	0	2	2	2	2	1	0	6	1	0	0	0	9	3	4	3	3	5	4	4	4	6	1	1	1	0	1	1	1	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2	0	4	4	2.6		1	2.25	2	1	3	2	0.35	0	-1	1	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJA941MJQ
2081	8976	NDAR_INVJB090LCJ	1381			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	4	4	3	4	3	3	5	0	0	0	9	1	0	0	2	5	4	2	2	4	2	2	2	2	1	0	1	2	3		1	3	4	4	2	0	0	0	0	0	0	0	0					1	16	0		0		1	15	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3.25	0	2	3	2.3	1		2.3	3.25	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB090LCJ
2081	8976	NDAR_INVJB090LCJ	1381			M	1600	Visit6	6	Phase 3	169	0	0	0	0	0	0	1	5	4	4	3	4	4	5	4	0	0	0	9	0	0	2	5	0	2	3	4	5	1	0	1	0	1	1	1	1	2	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.125	0	2.2857144	2.5	2.7			2.3	3.25	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB090LCJ
2081	8976	NDAR_INVJB090LCJ	1381			M	2800	Visit12	12	Phase 3	334	0	0	0	0	0	1	0	4	4	4	2	3	4	4	4	4	0	0	9	2	2	5	5	5	1	3	5	5	2	2	2	2	1	1	1	1	2	2	1	3	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	6	3.625	1	4.142857	2	3.3			2.3	3.25	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB090LCJ
2081	8976	NDAR_INVJB090LCJ	1381			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	0	0	0	0	0	0	1	2	2	2	1	2	1	2	4	0	0	2	9	0	0	2	1	3	2	2	2	2	2	2	2	2	1	2	2	2	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	2	0.5	1.4285715	2	1.6		1	2.3	3.25	0	2	3	-0.7	-1.25	0.5	-0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB090LCJ
2081	8976	NDAR_INVJB090LCJ	1381			M	5800	EndofPhase2	2	Phase 2	47	0	0	0	0	0	1	0	1	2	2	2	2	0	3	3	2	0	0	9	2	2	2	4	1	3	2	3	4	2	2	2	2	1	1	1	2	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	1	0	0	0	0	0		1.875	0.5	2.5714285	2.5	2			2.3	3.25	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB090LCJ
2081	8976	NDAR_INVJB090LCJ	1381			M	6000	EndofPhase3	18	Phase 3	501	0	0	0	0	0	1	0	3	4	2	2	2	3	2	1	4	4	4	5	4	4	5	4	4	3	3	4	4	2	2	2	0	1	1	1	2	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	5	2.375	4.25	4.142857	3	3.3809524			2.3	3.25	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB090LCJ
2081	8976	NDAR_INVJB091EC5	2060			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	1	2	2	4	2	2	2	4	2	4	9	2	3	3	6	4	6	3	3	4	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	2.5	3.5714285	4.5	3.25	1		3.25	2.625	2.5	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB091EC5
2081	8976	NDAR_INVJB091EC5	2060			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	4	4	3	4	4	2	3	2	3	3	4	9	3	3	4	4	4	5	4	4	4	1	1	1	0	1	1	0	1	2	2	0	3	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.25	2.5	3.7142856	4.5	3.55			3.25	2.625	2.5	3.5714285	4.5	0.3	0.625	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB091EC5
2081	8976	NDAR_INVJB091EC5	2060			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	4	4	3	4	4	2	3	2	3	3	4	4	3	3	4	4	4	2	2	4	4	1	1	1	0	1	1	0	1	2	2	1	3	3	3	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	3.25	3.5	3.7142856	2	3.3333333			3.25	2.625	2.5	3.5714285	4.5	0.083333336	0.625	1	0.14285715	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB091EC5
2081	8976	NDAR_INVJB091EC5	2060			M	5200	EndofPhase1_1a	18	Phase 1/1A	511	1	0	0	0	0	0	0	4	4	3	4	4	2	3	2	3	3	4	9	3	3	4	4	4	5	4	4	4	1	1	1	0	1	1	0	1	2	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.25	2.5	3.7142856	4.5	3.55		1	3.25	2.625	2.5	3.5714285	4.5	0.3	0.625	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB091EC5
2081	8976	NDAR_INVJB260JWP	1452			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	4	6	3	6	5	6	4	4	5	5	5	5	6	5	4	4	2	6	6	0	0	1	1	1	1	1	1	3	3	1	2	1	4	1	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5	4.5	5.285714	3	4.8	1		4.8	5	4.5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB260JWP
2081	8976	NDAR_INVJB260JWP	1452			F	1600	Visit6	6	Phase 3	170	0	0	0	0	0	1	0	4	4	6	6	5	6	6	0	1	1	5	9	4	2	4	5	5	3	2	3	5	1	0	0	1	1	1	2	2	3	1	1	2	3	3	4	1	0	0	0	0	0	1	0	1	1	0	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.625	1.75	4	2.5	3.85			4.8	5	4.5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB260JWP
2081	8976	NDAR_INVJB260JWP	1452			F	2800	Visit12	12	Phase 3	341	0	0	0	0	0	1	0	3	2	3	2	2	3	3	2	0	2	5	9	2	4	0	2	1	3	2	4	3	0	0	2	0	1	1	1	1	3	1	1	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	1.75	2.2857144	2.5	2.4			4.8	5	4.5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB260JWP
2081	8976	NDAR_INVJB260JWP	1452			F	5200	EndofPhase1_1a	3	Phase 1/1A	82	0	0	0	0	0	0	1	6	5	5	5	4	4	5	6	2	4	4	9	4	3	2	5	2	2	1	5	5	1	0	1	0	1	1	0	1	3		1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5	2.5	3.7142856	1.5	3.95		1	4.8	5	4.5	5.285714	3	-0.85	0	-2	-1.5714285	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB260JWP
2081	8976	NDAR_INVJB260JWP	1452			F	5800	EndofPhase2	4	Phase 2	141	0	0	0	0	0	1	0	2	4	4	2	3	4	5	6	2	2	3	9	4	2	4	4	2	1	1	4	6	1	0	1	0	1	1	0	1	2	2	1	4	2	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.75	1.75	3.7142856	1	3.25			4.8	5	4.5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB260JWP
2081	8976	NDAR_INVJB260JWP	1452			F	6000	EndofPhase3	18	Phase 3	516	0	0	0	0	0	1	0	5	5	5	5	5	5	5	0	0	4	4	9	2	2	2	5	1	2	1	5	5	0	0	0	0	1	1	0	0	3		1	2	4	4	4	1	0	0	0	0	0	1	0	0	1	0	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	2	3.142857	1.5	3.4			4.8	5	4.5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB260JWP
2081	8976	NDAR_INVJB370PHG	2355			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	2	5	4	3	4	5	5	4	1	1	3	9	2	2	2	5	5	5	4	5	5	1	1	1	0	1	1	1	1	1	2	1	3	2	2	2	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	4	1.25	3.7142856	4.5	3.6	1		3.6	4	1.25	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB370PHG
2081	8976	NDAR_INVJB370PHG	2355			F	1600	Visit6	6	Phase 1/1A	175	0	0	0	1	0	0	0	2	5	4	3	4	5	5	4	1	1	3	9	2	2	2	5	4	5	4	5	5	1	1	1	0	1	1	1	1	1	2	1	3	2	2	2	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0		4	1.25	3.5714285	4.5	3.55			3.6	4	1.25	3.7142856	4.5	-0.05	0	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB370PHG
2081	8976	NDAR_INVJB370PHG	2355			F	2800	Visit12	12	Phase 1/1A	344	0	0	0	1	0	0	0	6	5	2	4	0	2	6	2	2	2	2	9	1	2	0	2	3	6	3	2	1	0	0	1	0	1	1	1	1	1	2	1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	3.375	1.5	1.5714285	4.5	2.65			3.6	4	1.25	3.7142856	4.5	-0.95	-0.625	0.25	-2.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB370PHG
2081	8976	NDAR_INVJB370PHG	2355			F	4000	Visit18	18	Phase 1/1A	518	0	0	0	1	0	0	0	6	4	3	4	1	2	5	2	0	0	1	9	1	2	1	2	3	6	3	2	1	1	0	1	0	1	1	1	1	1	2	1	3	4	2	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	3.375	0.25	1.7142857	4.5	2.45		1	3.6	4	1.25	3.7142856	4.5	-1.15	-0.625	-1	-2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB370PHG
2081	8976	NDAR_INVJB592TG4	2835			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	2	3	3	3	5	5	0	2	3	4	9	5	6	4	4	2	4	4	4	5	0	1	2	0	1	0	1	1	3	1	1	2	3	3	4	1	0	0	0	0	1	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.375	2.25	4.285714	4	3.7	1		3.7	3.375	2.25	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB592TG4
2081	8976	NDAR_INVJB975MNW	2688			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	2	2	4	6	4	6	4	1	1	1	9	6	6	6	6	4	4	5	6	4	1	1	1	1	1	1	1	1	1	1	1	4	2	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	6	4.25	0.75	5.428571	4.5	4.2	1		4.2	4.25	0.75	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJB975MNW
2081	8976	NDAR_INVJD063WJ9	1090			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	0	4	3	0	1	2	1	0	0	0	9	2	2	0	1	0	1	2	0	4	1	1	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	6	1.625	0	1.2857143	1.5	1.25	1		1.25	1.625	0	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD063WJ9
2081	8976	NDAR_INVJD356ZXP	2255			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	2	2	2	2	3	6	4	4	5	6	6	6	6	6	6	6	5	6	6	1	1	1	1	1	1	0	1	1	1	0	4	2	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	4.75	6	5.5	4.6190476	1		4.6190476	3.125	4.75	6	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD356ZXP
2081	8976	NDAR_INVJD356ZXP	2255			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	2	2	2	4	4	2	4	3	6	4	5	6	4	6	5	6	6	6	6	5	5	1	1	1	0	1	1	0	1	1	1	0	4	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	5.25	5.285714	6	4.428571			4.6190476	3.125	4.75	6	5.5	-0.1904762	-0.25	0.5	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD356ZXP
2081	8976	NDAR_INVJD356ZXP	2255			M	2800	Visit12	12	Phase 1/1A	345	0	1	0	1	0	0	0	6	4	4	4	2	4	4	6	5	4	6	6	6	5	4	3	6	6	4	5	6	1	1	1	0	1	1	0	1	1	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	5.25	5	5	4.7619047			4.6190476	3.125	4.75	6	5.5	0.14285715	1.125	0.5	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD356ZXP
2081	8976	NDAR_INVJD356ZXP	2255			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	1	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	6	6	6	6	6		1	4.6190476	3.125	4.75	6	5.5	1.3809524	2.875	1.25	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD356ZXP
2081	8976	NDAR_INVJD657UJ7	1633			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	1	1	1	0	0	0	0	2	1	9	0	1	1	1	1	1	1	4	2	2	2	2	2	1	2	2	1	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.625	0.75	1.4285715	1	1	1		1	0.625	0.75	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD657UJ7
2081	8976	NDAR_INVJD657UJ7	1633			M	1600	Visit6	6	Phase 2	175	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	3	3	2	2	2	3	3	2	2	2	1	1	1	2	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1	0.75	2.2857144	2	1.55			1	0.625	0.75	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD657UJ7
2081	8976	NDAR_INVJD657UJ7	1633			M	2800	Visit12	12	Phase 3	371	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	1	1	3	3	0	0	0	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0.75	1.5714285	1	1.2			1	0.625	0.75	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD657UJ7
2081	8976	NDAR_INVJD657UJ7	1633			M	5200	EndofPhase1_1a	4	Phase 1/1A	97	0	0	0	0	0	1	0	2	1	1	1	1	1	0	1	1	1	2	9	1	1	2	2	1	4	1	4	2	2	2	0	0	1	1	2	1	3	3	0		4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	1	1.8571428	2.5	1.5		1	1	0.625	0.75	1.4285715	1	0.5	0.375	0.25	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD657UJ7
2081	8976	NDAR_INVJD657UJ7	1633			M	5800	EndofPhase2	7	Phase 2	204	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	3	1	3	1	4	2	0	0	0	0	1	1	2	1	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1	0.75	1.8571428	2	1.4			1	0.625	0.75	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD657UJ7
2081	8976	NDAR_INVJD657UJ7	1633			M	6000	EndofPhase3	18	Phase 3	554	1	0	0	0	0	0	0	4	3	1	1	2	1	1	1	2	2	2	9	2	2	2	2	2	4	3	3	4	1	1	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.5	2.4285715	3.5	2.2			1	0.625	0.75	1.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJD657UJ7
2081	8976	NDAR_INVJE356JMY	2824			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	6	6	6	6	6	4	4	5	6	6	5	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	6	4.75	5.857143	6	5.714286	1		5.714286	6	4.75	5.857143	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJE356JMY
2081	8976	NDAR_INVJE356JMY	2824			M	2800	Visit12	12	Phase 2	337	1	0	0	0	0	0	0	6	1	0	2	2	3	5	1	4	5	3	4	2	2	5	5	4	6	4	6	6	1	1	2	0	1	2	1	0	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	5	2.5	4	4.285714	5	3.6190476			5.714286	6	4.75	5.857143	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJE356JMY
2081	8976	NDAR_INVJE356JMY	2824			M	5200	EndofPhase1_1a	6	Phase 1/1A	161	1	0	0	0	0	0	0	6	6	6	6	6	4	5	6	4	4	5	6	6	4	4	5	6	6		6	6	1		1	1	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	5.625	4.75	5.285714		5.35		1	5.714286	6	4.75	5.857143	6	-0.3642857	-0.375	0	-0.5714286																																																																																																																						Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJE356JMY
2081	8976	NDAR_INVJE356JMY	2824			M	5800	EndofPhase2	18	Phase 2	512	1	0	0	0	0	0	0	6	6	6	6	6	6	6	6	4	6	6	6	6	6	6	6	4	6	6	6	6	1	1	0	1	1	1	1	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	6	5.5	5.714286	6	5.8095236			5.714286	6	4.75	5.857143	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJE356JMY
2081	8976	NDAR_INVJF857RY6	1114			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	3	4	4	2	3	3	0	0	0	9	0	0	0	0	4	3	4	1	4	1	1	1	0	1	1	1	1	3	1	1	2	1	2	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	0	1.2857143	3.5	2.1	1		2.1	3.25	0	1.2857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJF857RY6
2081	8976	NDAR_INVJF857RY6	1114			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	2	3	4	2	2	4	3	1	0	0	0	9	2	2	0	3	2	4	3	4	5	0	0	1	0	1	0	1	1	2	1	1	2	1	2	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.625	0	2.5714285	3.5	2.3			2.1	3.25	0	1.2857143	3.5	0.2	-0.625	0	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJF857RY6
2081	8976	NDAR_INVJF857RY6	1114			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	0	1	9	2	6	6	4	2	6	0	0	4	6	9	2	2	3	6	6	4	4	4	6	1	1	1	0	1	1	1	1	3		1	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.7142856	2.5	4.142857	4	3.8421052			2.1	3.25	0	1.2857143	3.5	1.7421052	0.4642857	2.5	2.857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJF857RY6
2081	8976	NDAR_INVJF857RY6	1114			M	5200	EndofPhase1_1a	14	Phase 1/1A	393	0	0	0	0	0	0	1	0	0	4	2	0	0	2	0	0	0	0	9	1	0	0	4	2	5	3	4	6	1	1	1	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1	0	2.4285715	4	1.65		1	2.1	3.25	0	1.2857143	3.5	-0.45	-2.25	0	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJF857RY6
2081	8976	NDAR_INVJG168UD9	1599			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	4	3	3	4	4	5	5	4	4	5	4	5	4	5	5	4	5	5	6	1	0	1	1	1	1	1	1	1	2	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.125	4.5	4.857143	4.5	4.4761906	1		4.4761906	4.125	4.5	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG168UD9
2081	8976	NDAR_INVJG168UD9	1599			F	1600	Visit6	6	Phase 1/1A	216	0	0	0	0	0	1	0	0	5	0	2	4	4	1	4	4	3	3	6	2	5	5	5	5	5	5	5	5	1	1	1	1	1	1	1	1	3	3	1	2	1	1	1	1	1	0	0	0	0	1	0	1	0	0	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.5	4	4.571429	5	3.7142856			4.4761906	4.125	4.5	4.857143	4.5	-0.7619048	-1.625	-0.5	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG168UD9
2081	8976	NDAR_INVJG168UD9	1599			F	2800	Visit12	12	Phase 2	399	0	0	0	0	0	1	0	6	6	6	4	6	6	6	4	4	4	2	4	3	4	4	6	4	5	5	5	5	1	0	1	1	1	1	1	1	3		1	3	2	2	1	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5.5	3.5	4.428571	5	4.714286			4.4761906	4.125	4.5	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG168UD9
2081	8976	NDAR_INVJG168UD9	1599			F	4000	Visit18	18	Phase 2	553	0	0	0	0	0	0	1	9	5	6	6	6	6	6	6	4	4	2	4	4	5	2	6	6	5	4	4	6	1	0	1	1	1	1	1	1	3		1	2	2	3	1	1	1	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	5.857143	3.5	4.714286	4.5	4.85			4.4761906	4.125	4.5	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG168UD9
2081	8976	NDAR_INVJG168UD9	1599			F	5200	EndofPhase1_1a	9	Phase 1/1A	314	0	0	0	0	0	1	0	1	4	5	4	4	5	4	4	3	4	5	4	2	5	4	5	6	5	5	5	6	1	1	1	1	1	1	1	1	3	1	1	3	1	2	2	1	1	0	0	0	0	0	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.875	4	4.714286	5	4.285714		1	4.4761906	4.125	4.5	4.857143	4.5	-0.1904762	-0.25	-0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG168UD9
2081	8976	NDAR_INVJG234YM4	1810			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	6	6	3	6	3	4	4	4	5	6	6	6	6	5	6	4	4	4	1	1	1	1	1	1	1	1	3	1	1	3	3	3	4	1	0	0	1	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	5.25	4.25	5.285714	5	5.047619	1		5.047619	5.25	4.25	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG234YM4
2081	8976	NDAR_INVJG234YM4	1810			F	1600	Visit6	6	Phase 1/1A	197	0	0	0	0	0	0	1	6	4	2	2	2	0	2	2	4	4	6	6	4	4	4	3	2	6	6	4	3	1	1	1	1	1	1	1	1	3	1	1	4	3	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	7	2.5	5	3.4285715	6	3.6190476			5.047619	5.25	4.25	5.285714	5	-1.4285715	-2.75	0.75	-1.8571428	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG234YM4
2081	8976	NDAR_INVJG234YM4	1810			F	2800	Visit12	12	Phase 1/1A	373	0	0	0	0	0	0	1	3	4	2	4	3	3	5	2	4	4	4	6	4	4	4	6	5	4	5	4	4	1	1	1	1	1	1	1	1	3	1	1	2	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	1	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	3.25	4.5	4.428571	4.5	4			5.047619	5.25	4.25	5.285714	5	-1.0476191	-2	0.25	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG234YM4
2081	8976	NDAR_INVJG234YM4	1810			F	5200	EndofPhase1_1a	18	Phase 1/1A	553	0	0	0	0	0	0	1	6	0	3	2	4	0	6	2	2	3	4	9	4	3	3	4	2	6	6	3	4	1	1	1	1	1	1	1	1	3	1	0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	1	1	0	1	0	0	0	0	0	0	0	1	1	1	1	7	2.875	2.25	3.2857144	6	3.35		1	5.047619	5.25	4.25	5.285714	5	-1.6976191	-2.375	-2	-2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG234YM4
2081	8976	NDAR_INVJG428NKA	2611			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	5	4	2	2	2	3	4	4	4	6	6	3	2	3	3	4	6	5	6	5	0	0	1	0	1	0	0	0	1	1	1	3	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	5	3.7142856	5.5	4	1		4	3.375	5	3.7142856	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG428NKA
2081	8976	NDAR_INVJG428NKA	2611			M	1600	Visit6	6	Phase 1/1A	167	0	1	0	0	0	0	0	4	4	2	2	4	1	2	3	2	2	3	9	2	1	3	1	1	6	2	4	2	1	0	1	0	1	1	0	1	3	1	1	4	1	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	3	2.75	1.75	2	4	2.55			4	3.375	5	3.7142856	5.5	-1.45	-0.625	-3.25	-1.7142857	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG428NKA
2081	8976	NDAR_INVJG428NKA	2611			M	2800	Visit12	12	Phase 3	335	0	1	0	0	0	0	0	5	4	4	2	3	3	4	5	1	1	1	9	1	2	3	1	1	6	3	4	3	1	1	1	1	1	1	0	1	1	1	1	4	1	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	0	3	3.75	0.75	2.142857	4.5	2.85			4	3.375	5	3.7142856	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG428NKA
2081	8976	NDAR_INVJG428NKA	2611			M	5200	EndofPhase1_1a	7	Phase 1/1A	195	0	1	0	0	0	0	0	4	6	1	0	5	0	1	3	1	1	1	9	3	0	1	1	1	6	3	4	3	1	1	1	0	1	1	0	1	2	1	1	3	2	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	3	2.5	0.75	1.8571428	4.5	2.25		1	4	3.375	5	3.7142856	5.5	-1.75	-0.875	-4.25	-1.8571428	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG428NKA
2081	8976	NDAR_INVJG428NKA	2611			M	5800	EndofPhase2	9	Phase 2	251	0	1	0	0	0	0	0	4	2	1	2	3	2	2	3	0	0	0	9	1	1	1	1	1	6	3	3	2	1	1	1	1	1	1	0	1	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.375	0	1.4285715	4.5	1.9			4	3.375	5	3.7142856	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG428NKA
2081	8976	NDAR_INVJG428NKA	2611			M	6000	EndofPhase3	18	Phase 3	489	0	1	0	0	0	0	0	5	5	3	2	4	3	4	5	4	2	3	1	2	3	0	1	2	5	1	4	3	1	0	1	0	1	0	0	1	1	2	1	2	1	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	1	3	3.875	2.5	2.142857	3	2.952381			4	3.375	5	3.7142856	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG428NKA
2081	8976	NDAR_INVJG621KB1	2737			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	4	4	4	0	1	2	0	0	2	9	2	2	3	2	2	2	2	3	4	0	0	0	0	1	0	1	0	1	2	0	4	3	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.625	0.5	2.5714285	2	2.25	1		2.25	2.625	0.5	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG621KB1
2081	8976	NDAR_INVJG621KB1	2737			F	2800	Visit12	12	Phase 1B	388	1	0	0	0	0	0	0	4	2	4	3	4	0	1	2	0	0	2	9	2	2	3	2	2	2	2	3	4	0	0	0	0	1	0	1	0	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.5	0.5	2.5714285	2	2.2			2.25	2.625	0.5	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG621KB1
2081	8976	NDAR_INVJG621KB1	2737			F	5200	EndofPhase1_1a	6	Phase 1/1A	196	1	0	0	0	0	0	0	4	2	4	3	4	0	1	2	0	0	2	9	2	2	3	2	2	2	2	3	4	0	0	0	0	1	0	1	0	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.5	0.5	2.5714285	2	2.2		1	2.25	2.625	0.5	2.5714285	2	-0.05	-0.125	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG621KB1
2081	8976	NDAR_INVJG621KB1	2737			F	5400	EndofPhase1b	18	Phase 1B	561	0	0	1	0	0	0	0	4	2	3	3	3	2	2	1	0	2	2	4	3	3	2	3	3	4	4	2	2	1	0	1	0	1	1	1	1	1	2	1	4	4	4	4	1	0	0	1	0	0	0	0	1	1	0	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	5	2.5	2	2.5714285	4	2.5714285			2.25	2.625	0.5	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG621KB1
2081	8976	NDAR_INVJG908GB7	1155			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	5	4	4	5	4	4	4	4	4	4	5	2	3	3	4	3	4	4	4	6	0	1	0	0	1	1	0	1	2	1	1	3	2	4	2	1	0	1	0	0	0	0	0	1	0	0	0	0		0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	4.25	3.5714285	4	4	1		4	4.25	4.25	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG908GB7
2081	8976	NDAR_INVJG908GB7	1155			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	5	0	4	4	4	4	4	4	4	4	4	5	2	4	3	3	2	4	3	1	4	0	1	1	1	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	7	3.625	4.25	2.7142856	3.5	3.4285715			4	4.25	4.25	3.5714285	4	-0.5714286	-0.625	0	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG908GB7
2081	8976	NDAR_INVJG908GB7	1155			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	4	4	4	4	4	4	4	2	4	5	4	5	4	4	4	5	4	4	4	3	5	1	1	0	1	1	1	1	1	2	1	1	4	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1		3.75	4.5	4.142857	4	4.047619			4	4.25	4.25	3.5714285	4	0.04761905	-0.5	0.25	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG908GB7
2081	8976	NDAR_INVJG908GB7	1155			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	6	5	5	5	5	4	5	5	4	4	5	6	4	4	4	5	4	4	4	5	5	1	1	1	1	1	1	1	1	2	1	1	2	1	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	3	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	6	5	4.75	4.428571	4	4.6666665		1	4	4.25	4.25	3.5714285	4	0.6666667	0.75	0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJG908GB7
2081	8976	NDAR_INVJH420AHL	1922			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	5	0	3	4	3	4	4	4	3	4	4	0	2	1	3	1	6	3	2	4	1	0	1	1	1	1	1	1	2	1	1	3	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.875	3.75	1.8571428	4.5	2.857143	1		2.857143	2.875	3.75	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH420AHL
2081	8976	NDAR_INVJH420AHL	1922			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	4	6	0	4	4	5	4	4	3	3	3	4	4	4	0	6	3	5	4	4	4	1	1	1	1	1	1	1	1	3		1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	1	1	1	1	1	1	5	3.875	3.25	3.5714285	4.5	3.7142856			2.857143	2.875	3.75	1.8571428	4.5	0.85714287	1	-0.5	1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH420AHL
2081	8976	NDAR_INVJH420AHL	1922			M	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	0	1	9	4	3	2	4	0	4	3	1	2	3	9	1	3	4	5	1	5	3	4	5	1	0	1	0	1	1	1	1	3		1	3	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	6	2.857143	1.5	3.2857144	4	3			2.857143	2.875	3.75	1.8571428	4.5	0.14285715	-0.017857144	-2.25	1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH420AHL
2081	8976	NDAR_INVJH420AHL	1922			M	5200	EndofPhase1_1a	15	Phase 1/1A	421	0	0	0	0	0	0	1	9	4	0	3	4	0	4	4	1	2	1	9	4	4	0	4	1	6	4	1	6	1	0	1	0	1	1	1	1	3		1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.7142856	1	2.857143	5	2.7894738		1	2.857143	2.875	3.75	1.8571428	4.5	-0.067669176	-0.16071428	-2.75	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH420AHL
2081	8976	NDAR_INVJH922YHA	2739			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	1	0	0	2	0	0	4	0	0	0	9	3	2	2	2	1	3	1	4	2	0	0	2	0	1	0	2	2	1	2	0	4	4	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	0	2.2857144	2	1.65	1		1.65	1.625	0	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH922YHA
2081	8976	NDAR_INVJH922YHA	2739			M	1600	Visit6	6	Phase 1B	169	0	1	0	0	0	0	0	6	0	0	0	2	0	0	4	2	1	1	9	2	2	2	2	2	2	2	4	4	0	0	2	0	1	2	2	2	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.5	1	2.5714285	2	1.9			1.65	1.625	0	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH922YHA
2081	8976	NDAR_INVJH922YHA	2739			M	5200	EndofPhase1_1a	3	Phase 1/1A	90	0	1	0	0	0	0	0	6	0	1	2	2	0	2	4	0	2	0	9	2	2	2	1	2	3	2	6	2	0	1	2	0	1	0	0	1	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	2.125	0.5	2.4285715	2.5	2.05		1	1.65	1.625	0	2.2857144	2	0.4	0.5	0.5	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH922YHA
2081	8976	NDAR_INVJH922YHA	2739			M	5400	EndofPhase1b	12	Phase 1B	334	0	1	0	1	0	0	0	2	0	1	0	2	0	0	2	0	0	0	9	2	0	0	2	0	3	1	4	4	0	0	0	0	0	0	0	1	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	0.875	0	1.7142857	2	1.15			1.65	1.625	0	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH922YHA
2081	8976	NDAR_INVJH922YHA	2739			M	5800	EndofPhase2	18	Phase 2	512	0	0	0	1	1	0	0	6	2	0	2	2	2	0	4	0	0	0	9	2	2	2	2	2	3	2	2	4	1	1	0	0	1	0	0	0	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.25	0	2.2857144	2.5	1.95			1.65	1.625	0	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJH922YHA
2081	8976	NDAR_INVJK329CNL	2253			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	4	3	2	2	3	4	0	0	0	9	2	2	4	4	1	3	4	1	3	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	5	3.5	0	2.4285715	3.5	2.6	1		2.6	3.5	0	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJK329CNL
2081	8976	NDAR_INVJK329CNL	2253			F	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	6	4	3	2	4	1	3	4	4	4	6	4	1	0	5	4	4	3	3	5	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	4.5	3.2857144	3	3.5238094			2.6	3.5	0	2.4285715	3.5	0.9238095	-0.125	4.5	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJK329CNL
2081	8976	NDAR_INVJK329CNL	2253			F	2800	Visit12	12	Phase 1/1A	336	0	1	0	0	0	0	0	6	6	2	6	4	6	6	6	6	6	5	6	3	4	6	6	6	4	4	6	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	5.75	5	4	5.142857			2.6	3.5	0	2.4285715	3.5	2.5428572	1.75	5.75	2.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJK329CNL
2081	8976	NDAR_INVJK329CNL	2253			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	0	0	6	4	4	6	6	6	6	6	6	4	6	6	6	6	4	6	6	4	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5.5	5.5	5.714286	4	5.428571		1	2.6	3.5	0	2.4285715	3.5	2.8285713	2	5.5	3.2857144	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJK329CNL
2081	8976	NDAR_INVJL870DZR	1109			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	1	1	0	1	0	3	2	3	2	9	4	4	2	2	1	2	6	2	4	0	1	1	1	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	1	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	1.5	1.75	2.7142856	4	2.3	1		2.3	1.5	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJL870DZR
2081	8976	NDAR_INVJL870DZR	1109			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	1	0	0	0	0	0	0	0	2	3	4	4	2	1	2	3	2	2	6	3	3	3	2	2	4	1	3	3	0	1	1	1	1	1	1	1	2	3	1	3	4	3	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	3	2.25	3.25	2.7142856	2.5	2.6190476		1	2.3	1.5	1.75	2.7142856	4	0.31904763	0.75	1.5	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJL870DZR
2081	8976	NDAR_INVJM274VYR	1534			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	5	4	4	3	2	3	2	4	4	4	4	4	5	4	6	5	4	3	3	6	1	1	1	0	1	1	1	1	2	1	1	2	2	3	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	1	0	0	1	1	1	0	4	3.25	4	4.714286	3.5	3.9047618	1		3.9047618	3.25	4	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM274VYR
2081	8976	NDAR_INVJM274VYR	1534			M	1600	Visit6	6	Phase 3	169	0	1	0	0	0	0	0	4	3	6	4	4	4	4	3	1	3	3	9	3	4	4	5	3	4	4	4	4	1	1	1	1	1	1	1	1	2	1	1	2	2	2	1	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	1	0	0	0	1	1	1	1	6	4	1.75	3.857143	4	3.7			3.9047618	3.25	4	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM274VYR
2081	8976	NDAR_INVJM274VYR	1534			M	5200	EndofPhase1_1a	4	Phase 1/1A	99	0	1	0	0	0	0	0	3	5	4	4	3	2	3	2	4	4	4	4	4	5	4	5	4	3	3	3	4	1	1	0	0	1	0	1	1	3	1	1	2	2	3	1	1	1	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	0	5	3.25	4	4.142857	3	3.6666667		1	3.9047618	3.25	4	4.714286	3.5	-0.23809524	0	0	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM274VYR
2081	8976	NDAR_INVJM274VYR	1534			M	5800	EndofPhase2	5	Phase 2	121	0	1	0	0	0	0	0	5	5	4	4	4	4	4	4	1	2	4	9	4	4	3	4	1	4	3	4	5	1	1	1	1	1	0	1	1	2	1	1	2	2	3	1	1	1	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.25	1.75	3.5714285	3.5	3.65			3.9047618	3.25	4	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM274VYR
2081	8976	NDAR_INVJM274VYR	1534			M	6000	EndofPhase3	10	Phase 3	261	0	1	0	0	0	0	0	6	2	2	2	3	1	3	4	1	3	1	9	2	2	3	3	2	4	3	5	6	0	1	1	1	1	1	1	1	3	1	1	3	2	2	1	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	6	2.875	1.25	3.2857144	3.5	2.9			3.9047618	3.25	4	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM274VYR
2081	8976	NDAR_INVJM518XET	1322			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	4	2	2	3	4	3	1	2	3	9	4	3	3	4	5	2	3	5	6	1	1	0	0	1	1	1	1	3	1	0	4	2	4	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	7	3	1.5	4.285714	2.5	3.25	1		3.25	3	1.5	4.285714	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM518XET
2081	8976	NDAR_INVJM518XET	1322			M	1600	Visit6	6	Phase 1/1A	180	0	0	0	0	0	1	0	3	3	4	4	5	4	5	4	2	4	1	9	5	4	4	4	5	3	3	5	6	1	0	2	1	1	1	1	1	3		1	2	1	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4	1.75	4.714286	3	3.9			3.25	3	1.5	4.285714	2.5	0.65	1	0.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM518XET
2081	8976	NDAR_INVJM518XET	1322			M	2800	Visit12	12	Phase 1/1A	375	0	0	0	0	0	1	0	5	3	4	2	4	4	3	4	4	4	3	5	3	3	4	4	5	4	3	5	5	1	1	2	2	1	1	2	1	3	1	1	3	2	2	2	1	0	0	0	0	0	1	0	1	2	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.625	4	4.142857	3.5	3.857143		1	3.25	3	1.5	4.285714	2.5	0.60714287	0.625	2.5	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM518XET
2081	8976	NDAR_INVJM518XET	1322			M	4000	Visit18	18	Phase 1/1A	528	0	0	0	0	0	1	0	6	5	5	5	4	4	6	2	2	4	1	9	4																																																															4.625	1.75						3.25	3	1.5	4.285714	2.5		1.625	0.25																																																																																																																							Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM518XET
2081	8976	NDAR_INVJM531LCL	1592			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	0	0	2	0	1	2	0	0	0	9	2	0	3	0	0	4	3	4	5	2	2	2	2	0	0	1	0	3	3	1	4	2	2	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0.875	0	2	3.5	1.4	1		1.4	0.875	0	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM531LCL
2081	8976	NDAR_INVJM531LCL	1592			M	5200	EndofPhase1_1a	1	Phase 1/1A	38	0	0	0	0	0	0	1	0	3	0	0	2	0	1	2	0	1	0	9	2	1	0	1	0	4	1	2	6	0	0	0	0	1	0	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	21	0		0		1	10	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1	0.25	1.7142857	2.5	1.3		1	1.4	0.875	0	2	3.5	-0.1	0.125	0.25	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM531LCL
2081	8976	NDAR_INVJM531LCL	1592			M	6000	EndofPhase3	5	Phase 3	145	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	9	1	0	0	0	0	4	1	0	3	0	0	0	0	1	0	1	0	3		1	3	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	10	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0.25	0	0.5714286	2.5	0.55			1.4	0.875	0	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM531LCL
2081	8976	NDAR_INVJM981PYD	1912			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0	4	3	4	4	2	3	0	2	0	5	2	4	4	1	1	0	0	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	18	0		0		1	12	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	3	0.25	3.75	2.142857	3.5	1.8571428	1		1.8571428	0.25	3.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM981PYD
2081	8976	NDAR_INVJM981PYD	1912			M	2800	Visit12	12	Phase 2	327	1	0	0	0	0	0	0	6	0	3	2	2	2	5	1	4	2	5	4	1	3	0	2	4	5	4	3	6	1	1	0	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.625	3.75	2.7142856	4.5	3.047619			1.8571428	0.25	3.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM981PYD
2081	8976	NDAR_INVJM981PYD	1912			M	5200	EndofPhase1_1a	6	Phase 1/1A	171	1	0	0	0	0	0	0	2	1	0	0	2	2	2	0	4	3	4	5	0	0	1	0	2	4	3		4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	1.125	4	1.1666666	3.5	1.95		1	1.8571428	0.25	3.75	2.142857	3.5	0.092857145	0.875	0.25	-0.97619045	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM981PYD
2081	8976	NDAR_INVJM981PYD	1912			M	5400	EndofPhase1b	10	Phase 1B	267	1	0	0	0	0	0	0	6	1	2	2	2	1	4	2	3	2	2	6	2	2	2	2	1	4	3	4	4	1	1	0	0	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	2.5	3.25	2.4285715	3.5	2.7142856			1.8571428	0.25	3.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM981PYD
2081	8976	NDAR_INVJM981PYD	1912			M	5800	EndofPhase2	18	Phase 2	495	1	0	1	0	0	0	0	5	0	0	0	1	0	2	0	3	3	6	6	1	4	2	2	4	4	3	4	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	3	1	4.5	3.2857144	3.5	2.6666667			1.8571428	0.25	3.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM981PYD
2081	8976	NDAR_INVJM997GKH	2706			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	1	6	4	4	3	4	0	1	0	2	9	2	4	4	4	3	4	5	5	4	1	1	1	0	1	1	1	1	2	1	0	4	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	7	3.25	0.75	3.7142856	4.5	3.2	1		3.2	3.25	0.75	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM997GKH
2081	8976	NDAR_INVJM997GKH	2706			M	1600	Visit6	6	Phase 1/1A	182	0	0	0	0	0	1	0	1	1	6	2	2	2	3	0	1	3	2	9	2	4	2	3	4	4	4	5	4	1	1	0	0	1	1	1	1	2	1	0	4	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.125	1.5	3.4285715	4	2.75			3.2	3.25	0.75	3.7142856	4.5	-0.45	-1.125	0.75	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM997GKH
2081	8976	NDAR_INVJM997GKH	2706			M	2800	Visit12	12	Phase 1/1A	365	0	0	0	0	0	1	0	1	1	4	2	2	3	3	0	1	4	2	9	3	4	3	2	4	2	4	5	4	1	1	1	0	1	1	1	1	2	1	0	4	2	4	4	1	0	0	1	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2	1.75	3.5714285	3	2.7			3.2	3.25	0.75	3.7142856	4.5	-0.5	-1.25	1	-0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM997GKH
2081	8976	NDAR_INVJM997GKH	2706			M	5200	EndofPhase1_1a	18	Phase 1/1A	561	0	0	0	0	0	1	0	1	1	4	2	2	3	3	0	3	4	3	4	3	4	4	3	4	4	4	5	4	1	1	0	1	1	1	1	1	2	1	0	4	2	2	4	1	0	0	1	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2	3.5	3.857143	4	3.0952382		1	3.2	3.25	0.75	3.7142856	4.5	-0.104761906	-1.25	2.75	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJM997GKH
2081	8976	NDAR_INVJN081PA5	1972			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	0	0	0	0	0	1	9	2	2	2	0	2	6	4	4	5	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.25	0.25	2.4285715	5	1.9	1		1.9	1.25	0.25	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJN081PA5
2081	8976	NDAR_INVJN081PA5	1972			M	5200	EndofPhase1_1a	6	Phase 1/1A	166	1	0	0	0	0	0	0	2	0	0	2	2	0	2	0	0	0	0	9	0	2	0	0	0	5	4	2	2	1	1	1	0	1	1	1	1	1	2	0	4	1	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0	0.85714287	4.5	1.15		1	1.9	1.25	0.25	2.4285715	5	-0.75	-0.25	-0.25	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJN081PA5
2081	8976	NDAR_INVJP154RFB	1432			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	0	1	2	0	4	3	2	2	5	9	2	2	2	3	4	3	3	3	4	0	1	2	1	1	1	1	1	3	1	1	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	2.25	2.857143	3	2.45	1		2.45	1.75	2.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJP154RFB
2081	8976	NDAR_INVJP159MZ9	2350			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	0	2	2	0	1	1	9	1	2	0	3	2	3	1	2	2	0	0	1	0	1	0	1	0	3		1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	0.5	0.5	1.7142857	2	1.1	1		1.1	0.5	0.5	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJP159MZ9
2081	8976	NDAR_INVJP159MZ9	2350			M	5200	EndofPhase1_1a	3	Phase 1/1A	79	0	0	0	0	0	0	1	2	2	3	1	2	0	0	2	0	1	1	9	2	0	0	3	1	3	2	3	3	0	0	1	0	1	1	1	1	3	3	1	3	2	4	2	1	0	0	0	0	0	1	0	1	0	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	6	1.5	0.5	1.7142857	2.5	1.55		1	1.1	0.5	0.5	1.7142857	2	0.45	1	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJP159MZ9
2081	8976	NDAR_INVJP159MZ9	2350			M	5800	EndofPhase2	5	Phase 2	136	0	0	0	0	0	0	1	2	2	3	2	2	2	2	2	0	2	1	9	1	3	1	3	0	2	2	1	2	0	0	1	0	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.125	0.75	1.5714285	2	1.75			1.1	0.5	0.5	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJP159MZ9
2081	8976	NDAR_INVJR064RZC	1132			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	9	0	0	2	0	1	5	3	4	4	1	1	0	1	1	0	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	0	0	1.5714285	4	0.95	1		0.95	0	0	1.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR064RZC
2081	8976	NDAR_INVJR064RZC	1132			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	0	0	0	1	2	2	1	0	0	0	0	9	2	1	0	1	0	4	3	0	2	0	0	1	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	0.75	0	0.85714287	3.5	0.95			0.95	0	0	1.5714285	4	0	0.75	0	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR064RZC
2081	8976	NDAR_INVJR064RZC	1132			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	0	1	0	0	1	1	2	1	2	1	0	0	0	9	0	0	1	2	0	3	3	0	2	0	1	0	0	1	1	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0.71428573	3	0.95			0.95	0	0	1.5714285	4	0	1	0	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR064RZC
2081	8976	NDAR_INVJR064RZC	1132			M	4000	Visit18	18	Phase 1B	506	0	0	0	0	0	0	1	0	0	2	0	3	4	5	1	0	0	0	9	3	2	4	2	2	4	2	4	2	0	0	1	0	1	1	0	1	2	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1.875	0	2.7142856	3	2			0.95	0	0	1.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR064RZC
2081	8976	NDAR_INVJR064RZC	1132			M	5200	EndofPhase1_1a	15	Phase 1/1A	421	0	0	0	0	0	0	1	2	0	0	2	2	2	2	0	0	0	0	9	1	0	2	1	2	3	2	3	2	0	0	1	0	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	1.25	0	1.5714285	2.5	1.3		1	0.95	0	0	1.5714285	4	0.35	1.25	0	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR064RZC
2081	8976	NDAR_INVJR064RZC	1132			M	5400	EndofPhase1b	21	Phase 1B	589	0	0	0	0	0	0	1	0	1	0	0	2	2	0	0	0	0	0	9	2	2	1	2	2	4	3	0	4	1	1	1	1	1	1	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	0.625	0	1.8571428	3.5	1.25			0.95	0	0	1.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR064RZC
2081	8976	NDAR_INVJR389GUV	1527			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	0	2	2	2	2	3	6	2	2	4	9	0	2	0	4	2	5	5	4	5	1	1	1	0	1	1	1	1	0	1	1	4	3	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	2	2.4285715	5	2.85	1		2.85	2.75	2	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR389GUV
2081	8976	NDAR_INVJR389GUV	1527			F	2800	Visit12	12	Phase 3	331	0	1	0	0	0	0	0	6	3	5	4	3	4	5	6	1	2	1	9	3	4	2	3	2	4	3	5	6	1	1	1	0	1	1	1	1	3	3	1	2	1	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.5	1	3.5714285	3.5	3.6			2.85	2.75	2	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR389GUV
2081	8976	NDAR_INVJR389GUV	1527			F	5200	EndofPhase1_1a	2	Phase 1/1A	40	0	1	0	0	0	0	0	6	4	2	1	2	2	1	5	0	2	1	9	2	1	0	1	0	5	2	2	4	1	0	0	0	1	0	0	0	3		0	4	4	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	0.75	1.4285715	3.5	2.15		1	2.85	2.75	2	2.4285715	5	-0.7	0.125	-1.25	-1	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR389GUV
2081	8976	NDAR_INVJR389GUV	1527			F	5800	EndofPhase2	6	Phase 2	162	0	1	0	0	0	0	0	6	5	2	2	2	2	4	4	1	1	1	9	1	1	2	2	1	6	3	5	2	1	1	1	0	1	1	1	1	3		1	2	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.375	0.75	2	4.5	2.65			2.85	2.75	2	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR389GUV
2081	8976	NDAR_INVJR389GUV	1527			F	6000	EndofPhase3	18	Phase 3	524	0	0	0	0	0	0	1	4	2	2	2	2	2	3	4	3	3	4	9	3	2	3	3	4	4	3	4	4	1	1	1	0	1	1	1	1	3	2	1	2	4	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2.5	3.2857144	3.5	3.05			2.85	2.75	2	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR389GUV
2081	8976	NDAR_INVJR448AWR	1889			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	1	0	2	3	0	0	0	3	9	2	2	2	4	3	3	1	5	1	0	0	2	0	1	1	2	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	1	0.75	2.7142856	2	1.7	1		1.7	1	0.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR448AWR
2081	8976	NDAR_INVJR448AWR	1889			M	1600	Visit6	6	Phase 2	175	0	0	0	0	0	1	0	4	0	0	4	2	3	5	0	1	4	4	9	0	2	2	3	3	4	2	4	5	1	1	1	0	1	1	1	1	2	2	1	3	2	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	0	4	2.25	2.25	2.7142856	3	2.6			1.7	1	0.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR448AWR
2081	8976	NDAR_INVJR448AWR	1889			M	2800	Visit12	12	Phase 2	351	0	0	0	0	0	1	0	3	3	4	4	2	2	3	2	1	4	3	9	0	3	2	4	1	3	1	2	4	1	0	2	0	1	1	2	2	3	1	1	2	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.875	2	2.2857144	2	2.55			1.7	1	0.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR448AWR
2081	8976	NDAR_INVJR448AWR	1889			M	5200	EndofPhase1_1a	2	Phase 1/1A	43	0	0	0	0	0	1	0	3	0	2	2	2	0	2	0	1	2	6	9	0	2	0	2	2	3	1	1	0	0	0	2	0	1	1	2	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	28	0		1	2	0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	4	1.375	2.25	1	2	1.55		1	1.7	1	0.75	2.7142856	2	-0.15	0.375	1.5	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR448AWR
2081	8976	NDAR_INVJR448AWR	1889			M	5800	EndofPhase2	18	Phase 2	512	0	0	0	0	0	1	0	4	4	2	4	4	5	6	0	0	4	3	9	1	3	3	4	2	3	2	4	5	1	1	2	0	1	1	2	1	3	1	1	3	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.625	1.75	3.142857	2.5	3.15			1.7	1	0.75	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR448AWR
2081	8976	NDAR_INVJR663ATG	1019			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	2	0	0	0	0	0	0	9	2	1	4	4	0	4	2	0	0	0	0	0	1	0	0	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0.25	0	1.5714285	3	0.95	1		0.95	0.25	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR663ATG
2081	8976	NDAR_INVJR663ATG	1019			M	1600	Visit6	6	Phase 2	177	0	0	0	0	0	0	1	0	0	0	0	2	0	1	0	0	0	2	9	1	0	2	4	0	1	3	2	4	1	1	1	1	1	0	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.375	0.5	1.8571428	2	1.1			0.95	0.25	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR663ATG
2081	8976	NDAR_INVJR663ATG	1019			M	2800	Visit12	12	Phase 2	339	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	3	9	0	1	3	3	0	1	3	0	3	1	1	0	0	0	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	0.25	0.75	1.4285715	2	0.95			0.95	0.25	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR663ATG
2081	8976	NDAR_INVJR663ATG	1019			M	5200	EndofPhase1_1a	1	Phase 1/1A	17	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	9	1	1	2	4	0	3	2	0	3	1	1	0	1	0	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	0	0	1.5714285	2.5	0.8		1	0.95	0.25	0	1.5714285	3	-0.15	-0.25	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR663ATG
2081	8976	NDAR_INVJR663ATG	1019			M	5800	EndofPhase2	18	Phase 2	515	0	0	0	0	0	0	1	2	0	0	0	2	0	2	0	0	0	6	9	2	1	0	6	0	2	2	1	6	1	1	0	0	0	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.75	1.5	2.2857144	2	1.6			0.95	0.25	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR663ATG
2081	8976	NDAR_INVJR912BGW	1579			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	1	0	2	0	0	0	2	3	2	3	0	2	3	9	1	2	2	2	0	1	2	2	5	0	0	0	0	1	1	0	1	1	3	0	4	4	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.5	1.25	2	1.5	1.7	1		1.7	1.5	1.25	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR912BGW
2081	8976	NDAR_INVJR928MXM	2143			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	1	3	4	3	5	2	1	2	1	9	1	3	4	5	2	4	2	4	4	0	0	1	1	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	1	3.2857144	3	3	1		3	3.375	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR928MXM
2081	8976	NDAR_INVJR928MXM	2143			F	1600	Visit6	6	Phase 2	162	1	0	0	0	0	0	0	6	4	0	3	4	3	3	4	1	1	1	9	1	2	4	4	2	4	3	5	4	0	0	1	1	1	1	0	1	1	1	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	0.75	3.142857	3.5	2.95			3	3.375	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR928MXM
2081	8976	NDAR_INVJR928MXM	2143			F	2800	Visit12	12	Phase 2	332	1	0	0	0	0	0	0	6	5	4	4	4	5	4	3	0	1	0	9	2	3	4	4	3	4	4	5	4	1	0	1	1	1	1	0	1	1	1	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	0.25	3.5714285	4	3.45			3	3.375	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR928MXM
2081	8976	NDAR_INVJR928MXM	2143			F	5200	EndofPhase1_1a	5	Phase 1/1A	135	1	0	0	0	0	0	0	6	4	2	3	3	4	4	4	2	2	1	9	3	3	4	4	4	5	4	5	4	1	1	1	1	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	1.25	3.857143	4.5	3.55		1	3	3.375	1	3.2857144	3	0.55	0.375	0.25	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR928MXM
2081	8976	NDAR_INVJR928MXM	2143			F	5800	EndofPhase2	18	Phase 2	514	1	0	0	0	0	0	0	6	4	4	5	4	5	4	2	1	1	0	9	1	4	4	4	2	5	4	5	3	1	1	0	1	1	1	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	4.25	0.5	3.2857144	4.5	3.4			3	3.375	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJR928MXM
2081	8976	NDAR_INVJT481LN0	1362			F	400	Baseline	0	Pre-Rand	1	1	0	0	1	0	0	0	6	0	0	0	2	0	0	4	1	0	0	9	3	1	0	1	0	3	1	5	2	0	0	0	0	0	0	0	0	1	1	1	4	4	4	3	1	1	1	0	0	0	0	0	1	1	0	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.25	1.7142857	2	1.45	1		1.45	1.5	0.25	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJT481LN0
2081	8976	NDAR_INVJT774WLE	1847			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	1	1	0	1	0	2	0	0	0	0	9	0	1	0	1	2	3	3	0	0	1	1	1	0	1	1	1	1	2	3	1	4	1	4	4	1	0	0	0	1	0	0	0	1	0	2	0	1	22	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.875	0	0.5714286	3	0.85	1		0.85	0.875	0	0.5714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJT774WLE
2081	8976	NDAR_INVJT774WLE	1847			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	4	2	2	0	1	1	2	2	0	0	0	9	0	1	0	2	2	2	2	0	4	0	1	1	0	1	1	1	1	1	2	1	3	2	4	4	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1.75	0	1.2857143	2	1.35			0.85	0.875	0	0.5714286	3	0.5	0.875	0	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJT774WLE
2081	8976	NDAR_INVJT774WLE	1847			M	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	0	1	3	1	1	1	2	0	2	1	0	0	0	9	1	0	0	1	1	4	3	3	3	0	1	1	0	1	1	1	1	2	2	0	4	2	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	1.375	0	1.2857143	3.5	1.35			0.85	0.875	0	0.5714286	3	0.5	0.5	0	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJT774WLE
2081	8976	NDAR_INVJT774WLE	1847			M	5200	EndofPhase1_1a	18	Phase 1/1A	527	0	0	0	0	0	0	1	2	0	0	1	2	0	2	1	0	0	0	9	0	0	0	2	1	3	2	2	4	1	1	1	0	1	1	0	1	2	3	0	4	2	3	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1	0	1.2857143	2.5	1.1		1	0.85	0.875	0	0.5714286	3	0.25	0.125	0	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJT774WLE
2081	8976	NDAR_INVJU227NL8	1978			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	0	4	2	2	0	2	2	2	9	3	2	2	4	3	5	3	4	6	1	1	2	1	1	1	2	1	3	2	0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	0	2	1.5	1.5	3.4285715	4	2.5	1		2.5	1.5	1.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU227NL8
2081	8976	NDAR_INVJU644BL9	1464			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	1	2	1	4	1	2	1	2	2	1	9	2	3	3	5	2	2	2	5	2	1	0	0	0	0	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	1.25	3.142857	2	2.45	1		2.45	2.25	1.25	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU644BL9
2081	8976	NDAR_INVJU644BL9	1464			F	5200	EndofPhase1_1a	1	Phase 1/1A	26	1	0	0	0	0	0	0	6	1	1	1	1	1	1	0	2	2	1	9	4	4	4	5	4	3	2	4	4	0	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	1.25	4.142857	2.5	2.55		1	2.45	2.25	1.25	3.142857	2	0.1	-0.75	0	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU644BL9
2081	8976	NDAR_INVJU644BL9	1464			F	5800	EndofPhase2	3	Phase 2	117	1	0	0	0	0	0	0	2	2	1	2	2	2	2	2	2	1	6	9	1	2	3	2	2	1	1	5	2	0	0	1	0	1	1	1	1	1	1	0	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.875	2.25	2.4285715	1	2.15			2.45	2.25	1.25	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU644BL9
2081	8976	NDAR_INVJU652FDQ	2093			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	2	3	2	2	1	1	2	3	3	2	3	3	1	3	3	3	4	4	4	4	1	1	1	0	1	1	1	1	1	1	1	4	3	3	3	1	0	0	1	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	1	1	2.125	2.75	3	4	2.7142856	1		2.7142856	2.125	2.75	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU652FDQ
2081	8976	NDAR_INVJU652FDQ	2093			M	1600	Visit6	6	Phase 2	190	0	0	1	0	0	0	0	2	2	2	3	3	2	2	1	4	4	4	4	3	4	3	2	4	4	4	3	4	1	1	1	0	1	1	1	1	1	3	0	4	3	3	4	1	0	0	1	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	1	4	2.125	4	3.2857144	4	3.047619			2.7142856	2.125	2.75	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU652FDQ
2081	8976	NDAR_INVJU652FDQ	2093			M	2800	Visit12	12	Phase 3	356	0	0	1	0	0	0	0	5	3	3	2	2	2	2	2	5	4	5	5	3	3	2	2	5	4	6	4	5	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	4.75	3.4285715	5	3.5238094			2.7142856	2.125	2.75	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU652FDQ
2081	8976	NDAR_INVJU652FDQ	2093			M	5200	EndofPhase1_1a	5	Phase 1/1A	162	0	0	1	0	0	0	0	3	2	2	1	3	1	2	3	4	4	4	4	2	3	3	3	4	5	4	4	4	1	1	1	1	1	1	1	1	1	2	1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	0	5	2.125	4	3.2857144	4.5	3.0952382		1	2.7142856	2.125	2.75	3	4	0.3809524	0	1.25	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU652FDQ
2081	8976	NDAR_INVJU652FDQ	2093			M	5800	EndofPhase2	8	Phase 2	244	0	0	1	0	1	0	0	3	3	3	1	3	2	2	2	5	4	4	3	2	2	1	2	5	5	5	3	5	1	1	1	0	1	1	1	1	1	1	1	4	3	3	3	1	0	0	1	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	3	2.375	4	2.857143	5	3.0952382			2.7142856	2.125	2.75	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU652FDQ
2081	8976	NDAR_INVJU652FDQ	2093			M	6000	EndofPhase3	18	Phase 3	524	0	0	1	0	0	0	0	5	2	2	2	3	2	2	1	3	3	3	2	3	3	1	3	3	4	4	3	5	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	7	2.375	2.75	3	4	2.8095238			2.7142856	2.125	2.75	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU652FDQ
2081	8976	NDAR_INVJU694ATC	1928			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	2	2	2	2	2	1	2	2	2	9	1	1	1	1	1	3	1	3	3	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	24	0		0		1	6	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1.5	1.5714285	2	1.9	1		1.9	2.125	1.5	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU694ATC
2081	8976	NDAR_INVJU694ATC	1928			M	1600	Visit6	6	Phase 1/1A	210	1	0	0	0	0	0	0	3	3	3	3	2	2	2	1	2	2	2	9	2	2	2	2	2	3	2	4	3	1	0	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.375	1.5	2.4285715	2.5	2.35			1.9	2.125	1.5	1.5714285	2	0.45	0.25	0	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU694ATC
2081	8976	NDAR_INVJU694ATC	1928			M	2800	Visit12	12	Phase 1/1A	366	1	0	0	1	0	0	0	3	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	3	1	3	3	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.125	1.5	2.2857144	2	2.15			1.9	2.125	1.5	1.5714285	2	0.25	0	0	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU694ATC
2081	8976	NDAR_INVJU694ATC	1928			M	5200	EndofPhase1_1a	18	Phase 1/1A	516	1	0	0	0	0	0	0	3	3	3	3	2	2	2	2	2	2	2	9	2	2	2	2	2	5	2	4	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.5	1.5	2.5714285	3.5	2.55		1	1.9	2.125	1.5	1.5714285	2	0.65	0.375	0	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU694ATC
2081	8976	NDAR_INVJU768RVU	1405			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	1	2	2	2	0	0	0	9	2	0	0	2	0	4	4	2	4	1	1	1	0	0	0	1	0	3	3	0	4	2	3	4	1	0	0	0	0	0	1	0	0	1	0	0	1	7	0		0		1	23	0		0	0	0	0	0	0	0	0	1	1	1	0	1	1	1	0	3	0.875	0	1.4285715	4	1.25	1		1.25	0.875	0	1.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU768RVU
2081	8976	NDAR_INVJU768RVU	1405			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	0	1	0	0	1	2	2	1	2	0	0	0	0	9	3	3	4	4	3	5	3	4	5	1	1	1	0	0	1	0	1	3	2	1	4	2	3	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1	0	3.7142856	4	2.1			1.25	0.875	0	1.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU768RVU
2081	8976	NDAR_INVJU768RVU	1405			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0	9	2	2	1	2	0	5	3	4	3	1	1	1	1	0	1	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0.25	0	2	4	1.2		1	1.25	0.875	0	1.4285715	4	-0.05	-0.625	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU768RVU
2081	8976	NDAR_INVJU768RVU	1405			M	5800	EndofPhase2	17	Phase 2	477	0	0	0	0	0	0	1	0	0	0	1	2	1	2	0	0	0	0	9	2	1	4	2	0	5	5	2	5	1	1	1	1	0	1	0	1	3	1	1	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	0.75	0	2.2857144	5	1.6			1.25	0.875	0	1.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU768RVU
2081	8976	NDAR_INVJU768RVU	1405			M	6000	EndofPhase3	18	Phase 3	505	0	0	0	0	0	0	1	0	0	1	1	2	1	2	2	0	0	0	9	2	2	2	4	4	5	4	4	5	1	0	1	1	0	0	0	1	2	2	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	4	1.125	0	3.2857144	4.5	2.05			1.25	0.875	0	1.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU768RVU
2081	8976	NDAR_INVJU962AD5	2730			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	1	0	2	1	2	2	2	9	2	2	2	4	4	5	3	5	6	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	1	0	0	0	1	0	0	1	1	1	1	4	0.75	1.5	3.5714285	4	2.25	1		2.25	0.75	1.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU962AD5
2081	8976	NDAR_INVJU962AD5	2730			F	5200	EndofPhase1_1a	2	Phase 1/1A	57	0	0	0	0	0	1	0	2	2	2	2	1	1	2	0	0	2	2	9	2	2	2	4	3	5	3	5	6	2	2	2	2	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	4	1.5	1	3.4285715	4	2.4		1	2.25	0.75	1.5	3.5714285	4	0.15	0.75	-0.5	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJU962AD5
2081	8976	NDAR_INVJV239ZFU	1076			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	0	2	0	1	3	2	2	4	9	3	2	4	2	2	5	3	4	5	1	1	1	0	1	1	2	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	2	3.142857	4	2.5	1		2.5	1.5	2	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV239ZFU	1076			M	1600	Visit6	6	Phase 3	172	1	0	0	0	0	0	0	2	0	0	0	2	0	2	0	1	1	4	9	2	2	2	2	1	4	3	4	4	1	0	1	0	1	1	1	1	1	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	0.75	1.5	2.4285715	3.5	1.8			2.5	1.5	2	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV239ZFU	1076			M	2800	Visit12	12	Phase 3	345	1	0	0	0	0	0	0	1	0	0	1	1	0	1	0	1	1	1	1	2	2	0	2	0	4	2	4	3	0	0	1	0	1	0	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	0.5	1	1.8571428	3	1.2857143			2.5	1.5	2	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV239ZFU	1076			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	0	0	0	0	0	1	5	4	2	2	2	2	2	2	2	2	4	9	4	4	4	2	1	4	2	6	5	1	0	1	0	1	1	1	1	1	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2	3.7142856	3	3.05		1	2.5	1.5	2	3.142857	4	0.55	1.125	0	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV239ZFU	1076			M	5400	EndofPhase1b	2	Phase 1B	61	1	0	0	0	0	0	0	4	3	3	4	2	3	1	1	1	1	1	9	4	2	4	4	0	3	1	4	5	1	0	1	0	1	1	1	1	1	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.625	0.75	3.2857144	2	2.55			2.5	1.5	2	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV239ZFU	1076			M	5800	EndofPhase2	3	Phase 2	86	0	0	0	0	0	0	1	5	2	1	0	2	2	1	1	2	2	4	9	4	4	4	2	0	3	2	4	6	1	0	1	0	1	1	1	1	1	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	2	3.4285715	2.5	2.55			2.5	1.5	2	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV239ZFU	1076			M	6000	EndofPhase3	18	Phase 3	514	1	0	0	0	0	0	0	2	0	0	0	0	2	6	1	0	0	1	9	2	4	3	2	0	5	4	4	4	1	1	1	0	1	0	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.375	0.25	2.7142856	4.5	2			2.5	1.5	2	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV239ZFU
2081	8976	NDAR_INVJV255EVD	2847			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	4	1	3	2	2	0	1	5	3	9	3	2	2	1	2	2	2	3	3	0	0	1	0	1	0	0	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1		2.2857144	2.25	2.2857144	2	2.368421	1		2.368421	2.2857144	2.25	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV255EVD
2081	8976	NDAR_INVJV255EVD	2847			M	5200	EndofPhase1_1a	2	Phase 1/1A	127	0	0	0	0	0	0	1	9	4	4	4	4	3	3	4	2	3	3	9	1	3	4	0	2	1	2	1	1	0	0	1	0	1	1	1	1	3		0	4	1	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0	2	3.7142856	2	1.7142857	1.5	2.5789473		1	2.368421	2.2857144	2.25	2.2857144	2	0.21052632	1.4285715	-0.25	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV255EVD
2081	8976	NDAR_INVJV255EVD	2847			M	5800	EndofPhase2	8	Phase 2	214	0	0	0	0	0	0	1	9	0	6	4	0	6	6	3	0	0	4	9	0	0	2	2	2	0	0	2	1	0	0	1	0	1	1	1	1	3		0	4	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	0	1	1	1	0		3.5714285	1	1.2857143	0	2			2.368421	2.2857144	2.25	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV255EVD
2081	8976	NDAR_INVJV571NV3	1827			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	1	1	0	4	5	3	0	0	1	9	4	4	2	5	6	3	3	5	6	0	1	0	1	1	2	1	2	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	2	2	0	0	0	0	0	1	0	0	0	0	1	1	0	1	5	1.75	0.25	4.571429	3	2.65	1		2.65	1.75	0.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV571NV3
2081	8976	NDAR_INVJV726LZH	1756			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	0	2	1	5	1	1	0	4	3	3	9	2	2	3	1	1	6	4	4	5	0	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	0	0	1	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	1.875	2.5	2.5714285	5	2.65	1		2.65	1.875	2.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV726LZH
2081	8976	NDAR_INVJV726LZH	1756			F	1600	Visit6	6	Phase 2	170	0	0	0	0	1	0	0	5	0	2	1	5	1	1	0	0	3	3	9	4	3	4	2	3	6	4	5	5	1	0	1	1	1	1	1	1	2	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.875	1.5	3.7142856	5	2.85			2.65	1.875	2.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV726LZH
2081	8976	NDAR_INVJV726LZH	1756			F	2800	Visit12	12	Phase 2	331	0	0	1	0	0	0	0	2	2	1	3	5	1	2	0	5	4	5	9	5	4	4	4	3	6	6	5	5	1	1	1	1	1	1	1	1	2	1	0	4	3	3	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	5	2	3.5	4.285714	6	3.6			2.65	1.875	2.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV726LZH
2081	8976	NDAR_INVJV726LZH	1756			F	4000	Visit18	18	Phase 2	485	0	0	1	0	0	0	0	5	2	2	3	4	4	4	0	0	5	3	9	4	3	4	4	4	5	5	5		1	1	1	1	1	1	1	1	2	2	0	4	2	2	4	0	0	0	0	0	0	0	0					1										0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	3	2	4	5	3.4736843			2.65	1.875	2.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV726LZH
2081	8976	NDAR_INVJV726LZH	1756			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	0	1	0	0	0	0	6	3	2	2	4	2	0	3	4	3	3	9	1	2	3	2	3	5	4	2	4	1	1	1	1	1	1	1	1	2	1	1	4	4	3	4	1	0	0	1	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	2.75	2.5	2.4285715	4.5	2.9		1	2.65	1.875	2.5	2.5714285	5	0.25	0.875	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV726LZH
2081	8976	NDAR_INVJV726LZH	1756			F	5800	EndofPhase2	18	Phase 2	485	0	0	1	0	0	0	0	5	2	2	3	4	4	4	0	0	5	3	9	4	3	4	4	4	5	5	5	3	1	1	1	1	1	1	1	1	2	2	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	3	2	3.857143	5	3.45			2.65	1.875	2.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV726LZH
2081	8976	NDAR_INVJV977BFE	1913			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	4	3	2	5	2	1	2	5	9	2	2	2	2	2	1	2	4	3	0	1	0	0	1	0	1	0	3	1	1	4	2	4	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	25	0		1	5	0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.625	2	2.4285715	1.5	2.85	1		2.85	3.625	2	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV977BFE
2081	8976	NDAR_INVJV977BFE	1913			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	5	4	5	5	3	3	5	3	2	4	3	9	3	3	4	5	4	4	4	3	5	1	1	1	0	1	1	1	1	2	2	1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.125	2.25	3.857143	4	3.85			2.85	3.625	2	2.4285715	1.5	1	0.5	0.25	1.4285715	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV977BFE
2081	8976	NDAR_INVJV977BFE	1913			M	2800	Visit12	12	Phase 1/1A	329	0	0	0	0	0	1	0	5	3	5	4	4	4	5	4	3	3	3	4	2	3	3	4	4	4	3	4	4	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	0	0	0	0	1	0	1	0	1	0	0		1	28	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.25	3.25	3.4285715	3.5	3.7142856			2.85	3.625	2	2.4285715	1.5	0.8642857	0.625	1.25	1	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV977BFE
2081	8976	NDAR_INVJV977BFE	1913			M	5200	EndofPhase1_1a	18	Phase 1/1A	483	0	0	0	0	0	1	0	4	4	4	4	3	3	4	3	4	4	3	4	3	3	4	3	4	4	4	3	3	1	1	1	0	1	1	1	1	2	2	1	3	2	3	2	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.625	3.75	3.2857144	4	3.5714285		1	2.85	3.625	2	2.4285715	1.5	0.7214286	0	1.75	0.85714287	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJV977BFE
2081	8976	NDAR_INVJW411UUK	1448			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	2	0	1	1	0	2	2	9	2	1	0	4	1	4	3	4	4	1	1	1	1	1	1	0	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	1	1	1	2	2	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3	0.75	1	2.2857144	3.5	1.65	1		1.65	0.75	1	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW411UUK
2081	8976	NDAR_INVJW411UUK	1448			M	1600	Visit6	6	Phase 1/1A	182	1	0	0	0	0	0	0	4	2	4	2	2	1	4	1	0	0	2	9	2	2	2	2	0	4	2	5	5	0	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2.5	0.5	2.5714285	3	2.3			1.65	0.75	1	2.2857144	3.5	0.65	1.75	-0.5	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW411UUK
2081	8976	NDAR_INVJW411UUK	1448			M	2800	Visit12	12	Phase 2	353	1	0	0	0	0	0	0	6	4	2	2	2	0	2	2	2	6	4	9	4	4	4	4	2	6	3	4	6	0	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	4	2.5	3	4	4.5	3.45			1.65	0.75	1	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW411UUK
2081	8976	NDAR_INVJW411UUK	1448			M	5200	EndofPhase1_1a	9	Phase 1/1A	268	1	0	0	0	0	0	0	4	4	1	1	4	2	4	1	3	4	4	6	2	4	4	2	3	5	3	5	4	0	1	1	1	1	1	1	1	1	1	1	3	4	2	4	1	0	1	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	5	2.625	4.25	3.4285715	4	3.3333333		1	1.65	0.75	1	2.2857144	3.5	1.6833333	1.875	3.25	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW411UUK
2081	8976	NDAR_INVJW411UUK	1448			M	5800	EndofPhase2	17	Phase 2	518	1	0	0	0	0	0	0	4	2	0	2	2	0	1	1	0	0	0	9	0	2	1	4	2	4	3	6	4	1	0	1	1	1	1	1	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	1.5	0	2.7142856	3.5	1.9			1.65	0.75	1	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW411UUK
2081	8976	NDAR_INVJW716RBX	1412			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	2	3	2	2	1	2	0	1	3	2	9	5	4	4	3	2	6	3	5	6	1	1	1	0	1	1	0	1	3	2	1	4	4	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	1	0	0	0	0	0	1	1	1	1	2	2.125	1.5	4.142857	4.5	3.05	1		3.05	2.125	1.5	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW716RBX
2081	8976	NDAR_INVJW716RBX	1412			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	5	6	6	6	6	6	1	1	4	2	9	5	6	6	6	2	6	4	6	6	1	0	1	1	1	1	0	1	3		1	3	2	2	4	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	5.142857	1.75	5.285714	5	4.736842			3.05	2.125	1.5	4.142857	4.5	1.6868421	3.017857	0.25	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW716RBX
2081	8976	NDAR_INVJW716RBX	1412			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	9	5	6	5	4	3	6	1	1	1	1	9	5	2	6	4	3	5	3	6	6	1	0	1	0	1	0	1	1	3		1	4	2	2	4	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.285714	0.75	4.571429	4	3.8421052			3.05	2.125	1.5	4.142857	4.5	0.79210526	2.1607144	-0.75	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW716RBX
2081	8976	NDAR_INVJW716RBX	1412			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	6	6	6	5	6	6	1	1	4	1	9	3	3	6	5	4	5	4	6	6	1	1	1	0	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.142857	1.5	4.714286	4.5	4.4210525		1	3.05	2.125	1.5	4.142857	4.5	1.3710526	3.017857	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW716RBX
2081	8976	NDAR_INVJW840YA6	1128			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	4	4	3	2	4	2	5	6	9	4	6	5	6	2	5	4	4	5	1	1	1	1	1	1	1	1	2	1	1	4	2	2	1	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	1	0	0	1	1	0	0	0	0	0	1	1	1	0	6	3.875	3.25	4.571429	4.5	4.25	1		4.25	3.875	3.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW840YA6
2081	8976	NDAR_INVJW840YA6	1128			F	1600	Visit6	6	Phase 2	173	0	0	0	0	0	0	1	3	3	3	2	2	2	2	2	2	2	4	9	1	5	4	4	2	4	4	2	4	1	1	1	0	1	1	1	1	3	1	1	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	0	4	2.375	2	3.142857	4	2.85			4.25	3.875	3.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW840YA6
2081	8976	NDAR_INVJW840YA6	1128			F	5200	EndofPhase1_1a	3	Phase 1/1A	86	0	0	0	0	0	0	1	2	2	1	2	2	2	2	0	2	4	2	9	2	6	4	4	4	4	3	4	4	1	1	1	0	1	1	1	1	3		0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.625	2	4	3.5	2.8		1	4.25	3.875	3.25	4.571429	4.5	-1.45	-2.25	-1.25	-0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW840YA6
2081	8976	NDAR_INVJW840YA6	1128			F	5800	EndofPhase2	7	Phase 2	198	0	0	0	0	0	0	1	9	0	2	2	3	2	2	0	1	2	2	9	2	6	4	4	5	4	3	4	4	1	1	1	1	1	1	1	1	3		0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5714285	1.25	4.142857	3.5	2.7368422			4.25	3.875	3.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW840YA6
2081	8976	NDAR_INVJW840YA6	1128			F	6000	EndofPhase3	18	Phase 3	542	0	0	0	0	0	0	1	2	2	2	4	2	3	4	3	4	5	5	6	5	5	4	3	4	4	3	4	6	1	1	1	2	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.75	5	4.428571	3.5	3.8095238			4.25	3.875	3.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJW840YA6
2081	8976	NDAR_INVJX042TML	2467			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	3	2	1	2	2	0	1	0	0	0	2	2	2	2	1	2	2	3	4	0	0	0	0	1	0	0	0	3		0	4	4	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.25	2.2857144	2	1.6190476	1		1.6190476	1.625	0.25	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX042TML
2081	8976	NDAR_INVJX753JPC	2279			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	6	5	5	6	6	5	4	2	6	4	6	6	6	5	5	4	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	0	1	0	4	5.75	4.25	5.571429	4.5	5.285714	1		5.285714	5.75	4.25	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX753JPC
2081	8976	NDAR_INVJX753JPC	2279			F	1600	Visit6	6	Phase 2	169	0	1	0	0	0	0	0	6	6	6	6	6	6	5	6	4	4	4	4	6	6	6	6	4	5	5	6	6	1	1	1	1	1	1	1	1	1	2	1	3	2	3	1	1	1	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	5	5.875	4	5.714286	5	5.3809524			5.285714	5.75	4.25	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX753JPC
2081	8976	NDAR_INVJX753JPC	2279			F	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	6	4	1	4	4	2	4	5	4	3	4	2	3	4	3	4	5	5	5	5	5	1	1	1	1	1	1	1	1	1	2	1	3	2	2	1	1	1	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	5	3.75	3.25	4.142857	5	3.9047618			5.285714	5.75	4.25	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX753JPC
2081	8976	NDAR_INVJX753JPC	2279			F	5200	EndofPhase1_1a	4	Phase 1/1A	116	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	4	5	4	6	6	6	6	6	4	4	6	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	6	4.75	5.714286	5	5.571429		1	5.285714	5.75	4.25	5.571429	4.5	0.2857143	0.25	0.5	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX753JPC
2081	8976	NDAR_INVJX753JPC	2279			F	5800	EndofPhase2	18	Phase 2	507	0	1	0	0	0	0	0	6	6	6	4	5	4	6	6	3	6	6	6	5	5	4	6	5	5	5	6	6	1	1	1	1	1	1	1	1	3	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	5.375	5.25	5.285714	5	5.285714			5.285714	5.75	4.25	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX753JPC
2081	8976	NDAR_INVJX900VAM	1145			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	5	3	4	4	3	4	4	1	4	4	9	4	4	5	4	2	5	3	5	5	0	1	0	0	1	1	1	1	3	1	1	2	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	1	4	3.875	2.25	4.142857	4	3.85	1		3.85	3.875	2.25	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX900VAM
2081	8976	NDAR_INVJX900VAM	1145			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	5	0	0	2	3	2	2	1	1	4	5	9	2	4	6	5	4	5	4	5	4	0	0	1	0	1	1	1	1	3	1	1	2	4	4	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	1.875	2.5	4.285714	4.5	3.2		1	3.85	3.875	2.25	4.142857	4	-0.65	-2	0.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJX900VAM
2081	8976	NDAR_INVJY447NMK	2184			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	2	4	4	2	1	3	0	0	2	9	4	2	3	6	5	5	3	5	6	1	1	0	0	0	0	0	0	1	1	1	4	3	3	2	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	1	0	0	1	1	1	1	6	3.25	0.5	4.428571	4	3.35	1		3.35	3.25	0.5	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJY447NMK
2081	8976	NDAR_INVJY447NMK	2184			F	1600	Visit6	6	Phase 1/1A	168	1	0	0	0	0	0	0	6	5	4	2	6	2	4	4	3	4	4	6	3	5	2	6	2	5	3	6	6	1	1	0	1	0	0	1	0	1	1	1	4	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.125	4.25	4.285714	4	4.1904764			3.35	3.25	0.5	4.428571	4	0.8404762	0.875	3.75	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJY447NMK
2081	8976	NDAR_INVJY447NMK	2184			F	2800	Visit12	12	Phase 1/1A	336	1	0	0	0	0	0	0	4	6	4	4	5	2	6	4	2	6	6	9	4	5	0	6	6	5	3	4	4	1	1	0	1	0	0	1	1	1	2	1	3	2	4	3	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.375	3.5	4.142857	4	4.3			3.35	3.25	0.5	4.428571	4	0.95	1.125	3	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJY447NMK
2081	8976	NDAR_INVJY447NMK	2184			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	1	0	0	0	0	0	0	3	3	0	4	4	2	6	1	2	4	5	9	1	1	3	4	4	5	5	5	6	1	1	0	1	1	0	1	0	1	2	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	1	5	2.875	2.75	3.4285715	5	3.4		1	3.35	3.25	0.5	4.428571	4	0.05	-0.375	2.25	-1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJY447NMK
2081	8976	NDAR_INVJZ140NX8	1379			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	4	4	2	4	3	4	0	0	0	0	9	2	4	2	6	1	4	4	5	5	1	1	1	0	1	0	0	1	2	2	1	3	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.75	0	3.5714285	4	2.75	1		2.75	2.75	0	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJZ140NX8
2081	8976	NDAR_INVJZ140NX8	1379			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	0	0	4	4	4	4	6	0	0	0	0	9	4	4	0	4	1	3	3	4	5	1	1	1	1	1	0	0	1	3	3	1	3	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	0	3.142857	3	2.5			2.75	2.75	0	3.5714285	4	-0.25	0	0	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJZ140NX8
2081	8976	NDAR_INVJZ140NX8	1379			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	9	3	4	4	6	5	6	0	0	4	6	9	4	6	4	4	6	6	4	4	6	1	1	1	1	1	1	1	1	3		1	3	2	2	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	2.5	4.857143	5	4.3157897			2.75	2.75	0	3.5714285	4	1.5657895	1.25	2.5	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJZ140NX8
2081	8976	NDAR_INVJZ140NX8	1379			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	0	0	4	5	4	0	6	1	0	0	0	9	4	4	4	5	1	4	3	5	6	1	1	1	1	1	0	1	1	3		1	3	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	0	4.142857	3.5	2.8		1	2.75	2.75	0	3.5714285	4	0.05	-0.25	0	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVJZ140NX8
2081	8976	NDAR_INVKA464PP4	2698			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	2	2	2	4	3	3	0	2	1	3	9	3	2	5	4	3	6	2	5	6	1	1	0	0	1	1	1	1	3	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	2.375	1.5	4	4	3.05	1		3.05	2.375	1.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKA464PP4
2081	8976	NDAR_INVKA464PP4	2698			M	1600	Visit6	6	Phase 2	174	0	0	0	0	0	0	1	2	2	2	4	4	3	3	0	3	3	1	3	3	4	4	3	2	5	5	6	6	1	1	1	0	1	1	1	1	3	2	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.5	2.5	4	5	3.2380953			3.05	2.375	1.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKA464PP4
2081	8976	NDAR_INVKA464PP4	2698			M	2800	Visit12	12	Phase 2	344	0	0	0	0	0	0	1	2	2	2	3	5	2	3	0	3	4	4	4	3	5	5	5	4	6	4	5	6	1	1	1	0	1	1	1	1	3	2	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	3.75	4.714286	5	3.6666667			3.05	2.375	1.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKA464PP4
2081	8976	NDAR_INVKA464PP4	2698			M	5200	EndofPhase1_1a	3	Phase 1/1A	88	0	0	0	0	0	0	1	4	2	3	4	4	3	3	0	4	4	1	1	2	3	4	4	4	5	4	5	4	1	1	1	1	1	1	1	1	2	2	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.875	2.5	3.7142856	4.5	3.2380953		1	3.05	2.375	1.5	4	4	0.18809524	0.5	1	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKA464PP4
2081	8976	NDAR_INVKC015LFK	2435			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	2	2	4	3	4	4	6	6	6	5	5	4	4	4	6	6	5	5	4	1	1	1	0	1	1	1	1	2	1	0	4	2	2	2	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	3.375	5.75	4.571429	5.5	4.428571	1		4.428571	3.375	5.75	4.571429	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC015LFK
2081	8976	NDAR_INVKC015LFK	2435			F	1600	Visit6	6	Phase 3	183	0	1	0	1	0	0	0	6	4	4	2	3	2	5	4	6	6	6	6	4	4	0	6	6	6	5	5	6	1	1	1	1	1	1	1	1	1	1	1	4	4	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	6	4.428571	5.5	4.571429			4.428571	3.375	5.75	4.571429	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC015LFK
2081	8976	NDAR_INVKC015LFK	2435			F	5200	EndofPhase1_1a	4	Phase 1/1A	125	0	1	0	1	0	0	0	6	4	0	4	6	6	4	6	6	6	6	6	4	6	0	6	4	6	5	3	4	1	1	0	0	1	1	1	1	1	1	1	3	4	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.5	6	3.857143	5.5	4.6666665		1	4.428571	3.375	5.75	4.571429	5.5	0.23809524	1.125	0.25	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC015LFK
2081	8976	NDAR_INVKC020KTM	1022			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	0	5	5	6	5	6	0	0	0	9	2	2	0	3	3	4	3	5	6	1	1	0	1	1	1	0	1	3	1	1	3	4	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	0	3	3.5	3.35	1		3.35	4.875	0	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC020KTM
2081	8976	NDAR_INVKC086XZB	2765			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	4	4	2	4	2	2	2	0	2	0	9	2	3	4	6	2	2	3	4	3	1	1	0	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.25	0.5	3.4285715	2.5	2.85	1		2.85	3.25	0.5	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC086XZB
2081	8976	NDAR_INVKC086XZB	2765			M	5200	EndofPhase1_1a	1	Phase 1/1A	33	0	0	1	0	1	0	0	6	0	1	2	2	2	2	1	0	0	0	9	2	2	3	5	2	2	2	4	4	0	1	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2	0	3.142857	2	2.1		1	2.85	3.25	0.5	3.4285715	2.5	-0.75	-1.25	-0.5	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC086XZB
2081	8976	NDAR_INVKC462WF8	2893			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	4	1	2	1	1	1	0	2	1	9	1	2	0	2	2	4	5	4	3	1	1	1	0	1	1	1	1	2	2	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0.75	2	4.5	2.1	1		2.1	2	0.75	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC462WF8
2081	8976	NDAR_INVKC462WF8	2893			F	1600	Visit6	6	Phase 1/1A	143	0	0	1	0	0	0	0	1	0	0	2	0	3	2	1	0	3	5	9	1	2	4	4	2	4	1	4	4	0	0	0	0	1	1	1	1	2	2	1	3	2	2	4	1	0	0	1	1	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1.125	2	3	2.5	2.15		1	2.1	2	0.75	2	4.5	0.05	-0.875	1.25	1	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC462WF8
2081	8976	NDAR_INVKC617GT6	2531			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	4	3	3	3	3	3	3	1	2	2	9	2	3	3	3	2	5	4	4	4	2	2	2	1	1	1	2	2	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1		0		0		1		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1.25	3	4.5	3.05	1		3.05	3.25	1.25	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC617GT6
2081	8976	NDAR_INVKC621FX1	2781			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	6	0	2	0	2	2	0	0	0	0	9	0	0	0	0	2	5	1	4	4	0	0	1	0	1	0	0	0	1	2	1	3	2	2	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	2	0	1.4285715	3	1.6	1		1.6	2	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC621FX1
2081	8976	NDAR_INVKC621FX1	2781			F	1600	Visit6	6	Phase 3	175	0	1	0	0	0	0	0	6	4	4	4	4	2	3	5	2	4	6	9	0	2	3	3	4	4	1	6	4	0	0	0	0	1	0	0	0	1	1	1	2	3	2	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	4	3	3.142857	2.5	3.55			1.6	2	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC621FX1
2081	8976	NDAR_INVKC621FX1	2781			F	2800	Visit12	12	Phase 3	337	0	1	0	0	0	0	0	5	4	4	2	2	0	1	4	1	2	6	9	1	0	4	3	2	5	3	3	2	1	1	0	0	1	0	1	0	1	1	1	3	2	2	1	1	0	0	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2.75	2.25	2.142857	4	2.7			1.6	2	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC621FX1
2081	8976	NDAR_INVKC621FX1	2781			F	5200	EndofPhase1_1a	1	Phase 1/1A	17	0	1	0	0	0	0	0	4	6	0	2	0	2	2	0	0	0	0	9	0	0	0	0	2	5	0	5	5	0	0	1	0	1	0	0	0	1	2	1	3	2	2	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2	0	1.7142857	2.5	1.65		1	1.6	2	0	1.4285715	3	0.05	0	0	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC621FX1
2081	8976	NDAR_INVKC621FX1	2781			F	5800	EndofPhase2	4	Phase 2	99	0	1	0	0	0	0	0	6	6	0	0	1	4	1	4	3	4	6	3	2	2	2	1	3	5	1	5	5	0	0	1	0	1	1	0	1	3	1	1	3	4	3	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2.75	4	2.857143	3	3.047619			1.6	2	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC621FX1
2081	8976	NDAR_INVKC621FX1	2781			F	6000	EndofPhase3	18	Phase 3	513	0	1	0	0	0	0	0	5	4	1	4	4	2	3	3	1	1	6	9	2	1	0	1	2	5	2	5	3	1	0	1	0	1	0	1	0	1	1	1	3	2	2	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.25	2	2	3.5	2.75			1.6	2	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKC621FX1
2081	8976	NDAR_INVKD155AP4	1056			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	0	0	2	0	6	4	0	0	0	9	5	2	6	5	0	5	2	6	6	0	2	1	0	1	1	1	1	1	1	1	4	2	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	2	2.375	0	4.285714	3.5	2.8	1		2.8	2.375	0	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD155AP4
2081	8976	NDAR_INVKD155AP4	1056			M	1600	Visit6	6	Phase 2	167	1	0	0	0	0	0	0	4	3	2	2	3	0	4	4	3	4	6	3	4	3	4	2	3	4	2	5	6	0	0	1	0	1	0	1	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4	2.75	4	3.857143	3	3.3809524			2.8	2.375	0	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD155AP4
2081	8976	NDAR_INVKD155AP4	1056			M	2800	Visit12	12	Phase 2	337	1	0	0	0	0	0	0	6	0	2	2	2	0	2	4	2	2	4	9	4	3	4	3	2	4	2	5	6	1	1	1	0	1	0	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	0	1	0	4	2.25	2	3.857143	3	2.95			2.8	2.375	0	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD155AP4
2081	8976	NDAR_INVKD155AP4	1056			M	5200	EndofPhase1_1a	5	Phase 1/1A	128	1	0	0	0	0	0	0	4	3	2	2	3	1	4	4	1	3	2	9	3	3	2	2	1	4	1	5	6	0	0	1	0	1	0	1	1	1	2	1	4	2	3	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	4	2.875	1.5	3.142857	2.5	2.8		1	2.8	2.375	0	4.285714	3.5	0	0.5	1.5	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD155AP4
2081	8976	NDAR_INVKD155AP4	1056			M	5800	EndofPhase2	18	Phase 2	499	1	0	1	0	0	0	0	6	0	1	2	2	0	3	4	0	0	0	9	3	2	4	4	1	4	1	5	6	1	0	1	0	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	4	2.25	0	3.5714285	2.5	2.4			2.8	2.375	0	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD155AP4
2081	8976	NDAR_INVKD981KMB	1169			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	0	0	4	0	2	1	1	2		9	0	0	2	1	0	5	3	1	2	1	0	1	0	1	1	2	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	8	0		0		1	22	0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	7	1.125		0.85714287	4	1.3684211	1		1.3684211	1.125		0.85714287	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD981KMB
2081	8976	NDAR_INVKD981KMB	1169			M	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	0	0	1	9	0	0	0	4	2	2	0	0	1	1	9	0	0	1	0	2	4	2	5	5	1	1	1	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	29	0		0		1	1	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1.1428572	0.5	1.8571428	3	1.5263158		1	1.3684211	1.125		0.85714287	4	0.15789473	0.017857144		1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKD981KMB
2081	8976	NDAR_INVKE116DA7	1391			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	2	2	2	0	2	4	2	2	4	9	3	4	4	3	3	4	2	5	5	0	1	0	0	1	1	0	1	1	1	1	4	4	3	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	2	3.857143	3	2.95	1		2.95	2.25	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE116DA7
2081	8976	NDAR_INVKE116DA7	1391			M	1600	Visit6	6	Phase 1/1A	166	1	0	1	0	0	0	0	6	0	0	2	2	2	2	2	0	0	4	9	2	2	0	3	1	5	4	5	4	1	0	0	0	1	1	0	1	1	1	1	3	1	2	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2	1	2.4285715	4.5	2.3			2.95	2.25	2	3.857143	3	-0.65	-0.25	-1	-1.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE116DA7
2081	8976	NDAR_INVKE116DA7	1391			M	2800	Visit12	12	Phase 1/1A	343	1	0	1	0	0	0	0	4	0	0	1	2	0	1	0	0	1	5	4	2	2	0	3	1	5	3	4	4	1	0	0	1	1	1	0	1	1	1	0	4	2	4	4	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	2.5	2.2857144	4	2			2.95	2.25	2	3.857143	3	-0.95	-1.25	0.5	-1.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE116DA7
2081	8976	NDAR_INVKE116DA7	1391			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	1	0	0	0	0	0	0	4	1	0	1	2	1	4	0	0	2	3	9	2	3	0	4	1	5	5	4	4	0	0	0	1	1	1	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.625	1.25	2.5714285	5	2.3		1	2.95	2.25	2	3.857143	3	-0.65	-0.625	-0.75	-1.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE116DA7
2081	8976	NDAR_INVKE220URD	2853			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	3	3	4	6	6	4	3	2	1	2	9	2	1	5	6	5	5	4	4	6	1	1	1	1	0	1	1	1	1	1	1	3	2	1	4	1	0	0	1	0	0	0	0	1	0	0	0	1	6	1	14	1	3	1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	3.625	1.25	4.142857	4.5	3.6	1		3.6	3.625	1.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE220URD
2081	8976	NDAR_INVKE220URD	2853			M	5200	EndofPhase1_1a	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	2	2	4	2	4	4	2	0	2	0	9	1	1	2	3	1	4	4	4	5	1	1	1	1	1	1	0	1	2	1	1	3	2	2	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	3	2.857143	0.5	2.4285715	4	2.4736843		1	3.6	3.625	1.25	4.142857	4.5	-1.1263158	-0.76785713	-0.75	-1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE220URD
2081	8976	NDAR_INVKE220URD	2853			M	5800	EndofPhase2	7	Phase 2	205	0	0	0	0	0	0	1	9	2	0	5	5	5	6	1	1	2	1	9	2	2	5	4	5	4	4	2	6	1	1	1	1	1	1	0	2	2	2	1	4	2	2	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	2	3.4285715	1	3.7142856	4	3.2631578			3.6	3.625	1.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE220URD
2081	8976	NDAR_INVKE360AEG	1807			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	6	5	4	4	5	5	2	2	4	2	9	4	4	4	4	4	4	3	5	3	1	1	1	1	1	1	1	1	2	1	1	3	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	2	1	14	1	14	0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	5	4.25	2	4	3.5	3.85	1		3.85	4.25	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE360AEG
2081	8976	NDAR_INVKE360AEG	1807			M	1600	Visit6	6	Phase 1/1A	192	1	0	0	0	0	0	0	2	6	5	4	6	5	5	4	2	4	3	9	4	3	4	5	2	4	4	5	4	1	1	1	1	0	0	1	1	1	1	1	2	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	6	4.625	2.25	3.857143	4	4.05			3.85	4.25	2	4	3.5	0.2	0.375	0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE360AEG
2081	8976	NDAR_INVKE360AEG	1807			M	5200	EndofPhase1_1a	12	Phase 1/1A	394	1	0	0	0	0	0	0	0	6	6	5	5	6	6	4	3	4	5	4	3	6	4	6	4	4	4	4	4	0	0	1	1	1	0	0	0	3		1	2	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.75	4	4.428571	4	4.428571		1	3.85	4.25	2	4	3.5	0.57857144	0.5	2	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE360AEG
2081	8976	NDAR_INVKE460WG2	2126			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	2	1	2	2	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1	0.75	1.2857143	1.5	1.15	1		1.15	1	0.75	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE460WG2
2081	8976	NDAR_INVKE613TKP	2524			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	0	0	0	4	0	0	0	1	0	2	9	2	5	1	2	0	3	2	5	4	1	0	1	1	1	1	1	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1	0.75	2.7142856	2.5	1.75	1		1.75	1	0.75	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE613TKP
2081	8976	NDAR_INVKE613TKP	2524			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	5	1	1	1	2	2	2	1	1	2	2	9	2	3	4	4	5	4	4	4	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	14	1	14	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.875	1.25	3.857143	4	2.75			1.75	1	0.75	2.7142856	2.5	1	0.875	0.5	1.1428572	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE613TKP
2081	8976	NDAR_INVKE613TKP	2524			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	4	1	1	2	3	1	1	1	1	3	2	9	2	4	4	4	6	3	2	5	6	1	0	1	1	1	1	1	1	1	2	0	4	2	2	4	1	0	1	0	0	0	0	0	0	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.75	1.5	4.428571	2.5	2.8			1.75	1	0.75	2.7142856	2.5	1.05	0.75	0.75	1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE613TKP
2081	8976	NDAR_INVKE613TKP	2524			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	0	0	1	5	1	5	2	2	1	2	1	2	4	3	9	2	4	2	5	5	3	3	5	6	1	0	1	1	1	1	1	1	2	1	1	3	2	1	4	1	0	1	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	2.25	4.142857	3	3.15		1	1.75	1	0.75	2.7142856	2.5	1.4	1.375	1.5	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE613TKP
2081	8976	NDAR_INVKE738GKM	1012			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	2	2	3	2	2	1	6	5	6	6	4	6	2	6	6	5	3	6	5	0	1	0	0	1	1	1	1	2	1	1	3	3	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	1	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	2.75	5.75	5	4	4.1904764	1		4.1904764	2.75	5.75	5	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE738GKM
2081	8976	NDAR_INVKE738GKM	1012			F	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	1	0	6	5	6	6	6	6	6	6	6	6	6	6	6	5	6	6	6	3	4	6	6	1	1	1	1	1	1	1	1	2	2	1	3	3	3	1	1	0	0	0	0	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	5.875	6	5.857143	3.5	5.6666665			4.1904764	2.75	5.75	5	4	1.4761904	3.125	0.25	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE738GKM
2081	8976	NDAR_INVKE738GKM	1012			F	2800	Visit12	12	Phase 1/1A	342	0	0	0	0	0	1	0	6	6	4	6	6	4	6	6	6	6	6	6	4	6	2	6	6	3	3	6	6	1	0	1	0	1	1	1	1	2	1	1	2	3	3	1	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	5.5	6	5.142857	3	5.2380953		1	4.1904764	2.75	5.75	5	4	1.0476191	2.75	0.25	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE738GKM
2081	8976	NDAR_INVKE958KXT	1449			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	1	4	4	4	4	5	0	2	2	3	9	3	2	4	4	3	6	6	4	5	1	1	2	1	1	1	1	1	3	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	27	0		0		1	3	0		0	2	0	0	0	1	0	0	0	0	1	0	1	1	1	1	7	3.5	1.75	3.5714285	6	3.6	1		3.6	3.5	1.75	3.5714285	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE958KXT
2081	8976	NDAR_INVKE958KXT	1449			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	6	4	2	4	5	3	6	1	2	4	6	9	3	5	4	4	5	6	4	5	5	1	1	1	1	1	1	0	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.875	3	4.428571	5	4.2			3.6	3.5	1.75	3.5714285	6	0.6	0.375	1.25	0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE958KXT
2081	8976	NDAR_INVKE958KXT	1449			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	4	6	6	6	4	6	6	4	0	3	2	9	3	5	6	5	4	6	6	4	4	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	5.25	1.25	4.428571	6	4.5			3.6	3.5	1.75	3.5714285	6	0.9	1.75	-0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE958KXT
2081	8976	NDAR_INVKE958KXT	1449			M	5200	EndofPhase1_1a	18	Phase 1/1A	529	0	0	0	0	0	0	1	5	6	6	6	6	6	6	4	1	0	4	9	3	4	4	6	4	6	6	4	4	1	1	1	1	1	1	1	1	2	2	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.625	1.25	4.142857	6	4.55		1	3.6	3.5	1.75	3.5714285	6	0.95	2.125	-0.5	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKE958KXT
2081	8976	NDAR_INVKF668XU5	1825			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	4	2	2	6	4	1	2	1	9	2	2	3	6	2	3	2	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	3	3	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4	1	3.857143	2.5	3.4	1		3.4	4	1	3.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF668XU5
2081	8976	NDAR_INVKF668XU5	1825			M	1600	Visit6	6	Phase 1/1A	181	1	0	0	0	0	0	0	2	4	3	2	3	2	2	1	2	0	0	9	0	0	2	2	2	3	1	4	4	0	0	0	0	1	1	1	0	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	0.5	2	2	1.95			3.4	4	1	3.857143	2.5	-1.45	-1.625	-0.5	-1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF668XU5
2081	8976	NDAR_INVKF668XU5	1825			M	2800	Visit12	12	Phase 1/1A	328	1	0	0	0	0	0	0	6	4	4	4	4	2	4	3	4	4	1	4	2	2	4	5	6	4	4	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	3.25	4.142857	4	3.857143		1	3.4	4	1	3.857143	2.5	0.45714286	-0.125	2.25	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF668XU5
2081	8976	NDAR_INVKF908NM7	2538			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	2	2	3	2	2	1	2	2	1	1	2	3	1	2	2	2	3	4	4	0	1	0	0	1	0	0	0	3	2	1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	1.5	2.5714285	2.5	2.047619	1		2.047619	1.75	1.5	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF908NM7
2081	8976	NDAR_INVKF908NM7	2538			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	0	1	2	2	3	2	2	1	2	2	1	9	2	3	1	2	2	2	2	4	3	0	1	0	0	1	0	0	0	3	2	0	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	1.25	2.4285715	2	1.95			2.047619	1.75	1.5	2.5714285	2.5	-0.09761905	-0.125	-0.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF908NM7
2081	8976	NDAR_INVKF908NM7	2538			M	5200	EndofPhase1_1a	8	Phase 1/1A	239	0	0	0	0	0	1	0	2	0	1	2	1	2	1	1	1	1	1	2	1	1	1	2	1	4	5	2	2	1	1	0	0	1	0	0	0	3	3	0	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	1.25	1.4285715	4.5	1.6190476		1	2.047619	1.75	1.5	2.5714285	2.5	-0.42857143	-0.5	-0.25	-1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF908NM7
2081	8976	NDAR_INVKF983CB0	2111			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	4	0	0	2	0	2	2	0	0	1	9	0	0	0	3	0	1	2	2	4	1	1	1	0	1	0	0	1	1	1	1	4	1	4	4	1	0	0	0	1	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	5	1.875	0.25	1.2857143	1.5	1.4	1		1.4	1.875	0.25	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF983CB0
2081	8976	NDAR_INVKF983CB0	2111			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	1	0	0	4	4	2	2	2	2	2	0	0	1	5	9	0	2	0	4	0	5	2	5	4	1	0	0	0	1	1	0	1	1	1	1	4	3	3	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.25	1.5	2.142857	3.5	2.3			1.4	1.875	0.25	1.2857143	1.5	0.9	0.375	1.25	0.85714287	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF983CB0
2081	8976	NDAR_INVKF983CB0	2111			M	2800	Visit12	12	Phase 3	336	0	0	0	0	1	0	0	6	4	0	4	2	2	4	0	0	4	5	9	0	4	2	5	1	1	2	5	6	0	0	1	0	1	1	2	1	1	1	1	3	2	2	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2.75	2.25	3.2857144	1.5	2.85			1.4	1.875	0.25	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF983CB0
2081	8976	NDAR_INVKF983CB0	2111			M	5200	EndofPhase1_1a	7	Phase 1/1A	204	0	0	0	0	1	0	0	5	0	2	2	2	2	2	0	1	2	6	9	0	0	2	4	0	2	2	4	3	1	1	1	0	1	1	0	1	1	1	0	4	3	4	4	1	0	0	0	1	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1.875	2.25	1.8571428	2	2.05		1	1.4	1.875	0.25	1.2857143	1.5	0.65	0	2	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF983CB0
2081	8976	NDAR_INVKF983CB0	2111			M	5800	EndofPhase2	8	Phase 2	235	0	0	0	0	1	0	0	6	0	2	2	2	2	2	0	0	3	6	9	0	2	0	4	0	3	3	4	5	1	1	0	0	1	1	0	1	1	1	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2	2.25	2.142857	3	2.3			1.4	1.875	0.25	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF983CB0
2081	8976	NDAR_INVKF983CB0	2111			M	6000	EndofPhase3	18	Phase 3	497	0	0	0	0	1	0	0	6	4	4	3	3	3	5	0	0	6	4	9	0	2	1	5	2	3	3	5	6	1	0	1	0	1	1	1	1	1	1	1	3	2	4	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	3.5	2.5	3	3	3.25			1.4	1.875	0.25	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF983CB0
2081	8976	NDAR_INVKF991AAQ	2364			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	9	3	1	4	1	0	2	3	4	3	0	1	1	0	1	1	1	1	3	3	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	6	0.25	0	2.2857144	2.5	1.15	1		1.15	0.25	0	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKF991AAQ
2081	8976	NDAR_INVKG034VZ1	1591			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	2	2	2	2	2	3	2	2	2	9	2	2	2	2	2	4	2	5	3	0	0	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.2857144	1.5	2.5714285	3	2.4210527	1		2.4210527	2.2857144	1.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG034VZ1
2081	8976	NDAR_INVKG034VZ1	1591			M	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	0	0	1	3	3	3	3	3	3	2	2	2	2	2	9	1	1	1	1	1	4	3	4	3	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	1.5	1.7142857	3.5	2.35			2.4210527	2.2857144	1.5	2.5714285	3	-0.07105263	0.4642857	0	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG034VZ1
2081	8976	NDAR_INVKG034VZ1	1591			M	2800	Visit12	12	Phase 1/1A	413	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	3	2	2	2	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2	1.5	2	2.5	2.05			2.4210527	2.2857144	1.5	2.5714285	3	-0.37105262	-0.2857143	0	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG034VZ1
2081	8976	NDAR_INVKG034VZ1	1591			M	5200	EndofPhase1_1a	18	Phase 1/1A	549	0	0	0	0	0	0	1	2	2	3	2	3	2	2	2	2	2	3	9	2	2	2	2	2	4	2	4	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.25	1.75	2.5714285	3	2.45		1	2.4210527	2.2857144	1.5	2.5714285	3	0.028947368	-0.035714287	0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG034VZ1
2081	8976	NDAR_INVKG133MC0	2674			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	3	3	3	3	3	4	0	2	6	9	0	2	0	2	0	4	4	4	3	1	0	1	0	1	1	1	1	1	1	1	2	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3.25	2	1.5714285	4	2.65	1		2.65	3.25	2	1.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG133MC0
2081	8976	NDAR_INVKG133MC0	2674			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	9	3	2	4	4	3	3	0	0	2	6	9	2	2	2	2	0	3	4	3	4	1	0	1	0	1	1	1	1	2	1	1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.7142856	2	2.142857	3.5	2.5789473			2.65	3.25	2	1.5714285	4	-0.07105263	-0.53571427	0	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG133MC0
2081	8976	NDAR_INVKG133MC0	2674			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	4	2	0	0	2	0	2	0	0	1	6	9	0	1	0	0	0	2	2	1	2	1	0	1	0	1	1	1	1	2	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1.25	1.75	0.5714286	2	1.25			2.65	3.25	2	1.5714285	4	-1.4	-2	-0.25	-1	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG133MC0
2081	8976	NDAR_INVKG133MC0	2674			M	5200	EndofPhase1_1a	18	Phase 1/1A	510	0	0	0	0	0	0	1	9	3	2	4	4	3	3	0	0	2	6	9	2	2	2	2	0	3	3	3	4	1	0	1	0	1	1	1	1	2	2	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.7142856	2	2.142857	3	2.5263157		1	2.65	3.25	2	1.5714285	4	-0.12368421	-0.53571427	0	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG133MC0
2081	8976	NDAR_INVKG251TP1	1523			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	2	1	0	3	2	2	1	1	3	9	2	1	2	4	1	1	2	3	4	2	2	2	2	1	0	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	5	1.5	1.25	2.4285715	1.5	1.85	1		1.85	1.5	1.25	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG251TP1
2081	8976	NDAR_INVKG251TP1	1523			M	1600	Visit6	6	Phase 1/1A	203	0	0	0	0	0	1	0	2	4	1	1	1	2	2	2	1	3	3	9	1	2	2	5	1	2	1	4	5	0	0	0	1	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.875	1.75	2.857143	1.5	2.25			1.85	1.5	1.25	2.4285715	1.5	0.4	0.375	0.5	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG251TP1
2081	8976	NDAR_INVKG251TP1	1523			M	2800	Visit12	12	Phase 1/1A	385	0	0	0	0	0	1	0	0	2	0	1	1	1	2	1	2	2	3	9	2	3	4	4	1	2	1	4	4	1	0	0	0	1	1	1	1	3		1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	1	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1	1.75	3.142857	1.5	2			1.85	1.5	1.25	2.4285715	1.5	0.15	-0.5	0.5	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG251TP1
2081	8976	NDAR_INVKG251TP1	1523			M	5200	EndofPhase1_1a	18	Phase 1/1A	574	0	0	0	0	0	1	0	3	0	3	2	1	0	4	1	1	3	3	9	0	4	3	4	1	2	2	3	5	1	0	1	1	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.75	1.75	2.857143	2	2.25		1	1.85	1.5	1.25	2.4285715	1.5	0.4	0.25	0.5	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG251TP1
2081	8976	NDAR_INVKG543MEA	2630			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	1	2	2	2	2	0	6	3	5	3	3	3	3	2	3	4	4	4	4	1	1	1	0	1	0	1	1	3	2	1	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1.625	4.25	3.142857	4	2.857143	1		2.857143	1.625	4.25	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG543MEA
2081	8976	NDAR_INVKG543MEA	2630			M	1600	Visit6	6	Phase 2	198	0	0	0	0	0	1	0	5	4	0	3	4	3	4	1	4	3	5	4	4	2	3	5	5	5	4	5	5	1	1	1	0	1	1	1	1	2	2	1	3	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3	4	4.142857	4.5	3.7142856			2.857143	1.625	4.25	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG543MEA
2081	8976	NDAR_INVKG543MEA	2630			M	2800	Visit12	12	Phase 2	380	0	0	0	0	0	1	0	3	4	4	4	4	4	4	3	5	4	5	6	4	2	4	3	5	6	4	5	6	1	1	1	1	1	1	1	1	3	2	1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	5	4.142857	5	4.2380953			2.857143	1.625	4.25	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG543MEA
2081	8976	NDAR_INVKG543MEA	2630			M	4000	Visit18	18	Phase 2	555	0	0	0	0	0	0	1	5	4	1	4	4	4	5	1	4	4	5	4	3	4	5	4	5	6	4	5	5	1	1	1	1	1	1	1	1	2	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	4.25	4.428571	5	4.095238			2.857143	1.625	4.25	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG543MEA
2081	8976	NDAR_INVKG543MEA	2630			M	5200	EndofPhase1_1a	3	Phase 1/1A	98	0	0	0	0	0	1	0	4	4	4	3	4	3	5	4	5	3	5	3	4	4	3	2	4	5	4	5	4	1	1	1	0	1	1	1	1	2	2	1	3	3	2	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.875	4	3.7142856	4.5	3.9047618		1	2.857143	1.625	4.25	3.142857	4	1.0476191	2.25	-0.25	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG543MEA
2081	8976	NDAR_INVKG589DUB	2530			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0	0	1	6	9	0	0	0	2	0	3	2	3	2	0	0	1	0	0	1	0	1	1	1	1	3	2	4	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	0.25	1.75	1	2.5	1.05	1		1.05	0.25	1.75	1	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG589DUB
2081	8976	NDAR_INVKG832ZDP	2883			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	4	4	3	2	4	1	4	4	4	6	0	2	2	4	4	3	3	4	4	1	0	1	0	1	1	1	1	2	1	1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.25	4.5	2.857143	3	3.3333333	1		3.3333333	3.25	4.5	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG832ZDP
2081	8976	NDAR_INVKG832ZDP	2883			M	2800	Visit12	12	Phase 3	339	0	0	0	0	0	1	0	4	4	4	4	2	3	5	2	2	1	2	9	2	2	2	4	1	4	4	4	4	1	0	0	1	1	1	0	1	3	2	1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	1.25	2.7142856	4	3			3.3333333	3.25	4.5	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG832ZDP
2081	8976	NDAR_INVKG832ZDP	2883			M	5200	EndofPhase1_1a	6	Phase 1/1A	184	0	0	0	0	0	1	0	4	4	4	2	2	2	2	1	3	2	5	4	1	2	2	4	3	4	4	4	4	0	0	1	1	1	1	1	1	3	2	1	3	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	2.625	3.5	2.857143	4	3		1	3.3333333	3.25	4.5	2.857143	3	-0.33333334	-0.625	-1	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG832ZDP
2081	8976	NDAR_INVKG832ZDP	2883			M	5800	EndofPhase2	11	Phase 2	295	0	0	0	0	0	1	0	4	4	4	2	2	2	2	2	2	2	1	9	1	2	4	3	1	4	4	4	4	1	1	1	1	1	1	0	1	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	2	2.75	1.25	2.7142856	4	2.7			3.3333333	3.25	4.5	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG832ZDP
2081	8976	NDAR_INVKG832ZDP	2883			M	6000	EndofPhase3	18	Phase 3	512	0	0	0	0	0	1	0	2	2	4	4	4	3	6	2	0	1	6	9	0	0	3	5	4	5	6	4	3	1	1	1	1	1	1	0	1	3	1	1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.375	1.75	2.7142856	5.5	3.2			3.3333333	3.25	4.5	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG832ZDP
2081	8976	NDAR_INVKG874DX2	2897			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	2	0	2	4	0	2	0	4	6	4	6	6	2	4	2	4	6	2	4	6	1	0	1	1	1	1	1	1	2	3	1	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1		0		0		0		0		1	0	0	0	0	1	0	1	0	0	0	0	1	0	1	1	2	2	5	4	4	3.4285715	1		3.4285715	2	5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG874DX2
2081	8976	NDAR_INVKG874DX2	2897			F	1600	Visit6	6	Phase 2	172	0	0	0	0	0	0	1	9	4	2	0	4	2	2	0	6	4	5	4	6	2	4	4	6	6	2	6	6	1	0	1	1	1	0	1	1	1	2	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	3	2	4.75	4.857143	4	3.75			3.4285715	2	5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG874DX2
2081	8976	NDAR_INVKG874DX2	2897			F	2800	Visit12	12	Phase 2	339	0	0	0	0	0	0	1	2	1	2	2	2	2	1	0	1	0	2	9	2	2	3	3	4	5	4	4	5	1	1	1	0	1	1	1	1	2	3	0	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.75	3.2857144	4.5	2.35			3.4285715	2	5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG874DX2
2081	8976	NDAR_INVKG874DX2	2897			F	5200	EndofPhase1_1a	1	Phase 1/1A	28	0	0	0	0	0	0	1	1	2	1	0	2	0	0	0	0	4	6	9	6	6	6	6	4	2	4	6	6	1	0	1	1	1	1	1	1	2	2	1	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.75	2.5	5.714286	3	3.1		1	3.4285715	2	5	4	4	-0.32857144	-1.25	-2.5	1.7142857	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG874DX2
2081	8976	NDAR_INVKG874DX2	2897			F	5800	EndofPhase2	16	Phase 2	459	0	0	0	0	0	0	1	2	6	2	2	2	2	2	2	4	4	5	6	5	5	5	6	6	5	2	5	6	1	0	1	1	1	1	0	1	3	2	1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	4.75	5.428571	3.5	4			3.4285715	2	5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG874DX2
2081	8976	NDAR_INVKG874DX2	2897			F	6000	EndofPhase3	18	Phase 3	501	0	0	0	0	0	0	1	5	3	2	1	3	2	2	2	6	5	6	6	4	5	4	4	6	5	4	5	6	1	1	1	1	1	1	0	1	2	1	1	4	3	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	5	2.5	5.75	4.857143	4.5	4.095238			3.4285715	2	5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG874DX2
2081	8976	NDAR_INVKG986HC7	2263			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	0	3	3	1	1	3	5	6	3	3	5	5	4	4	3	3	6	3	5	5	1	0	0	0	1	0	0	1	1	1	0	4	2	3	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	4.25	4.142857	4.5	3.6190476	1		3.6190476	2.625	4.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG986HC7
2081	8976	NDAR_INVKG986HC7	2263			M	1600	Visit6	6	Phase 2	156	0	1	0	0	0	0	0	6	1	3	1	1	2	3	6	6	3	6	5	4	3	5	5	5	6	3	4	4	1	1	0	0	1	1	0	1	1	1	0	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6	2.875	5	4.285714	4.5	3.9047618			3.6190476	2.625	4.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG986HC7
2081	8976	NDAR_INVKG986HC7	2263			M	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	6	1	5	4	4	3	3	5	6	6	6	6	6	6	6	6	6	6	4	5	5	1	1	0	1	1	1	0	1	1	1	0	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.875	6	5.714286	5	5			3.6190476	2.625	4.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG986HC7
2081	8976	NDAR_INVKG986HC7	2263			M	5200	EndofPhase1_1a	3	Phase 1/1A	74	0	1	0	0	0	0	0	2	2	2	2	2	2	4	4	5	4	5	5	4	4	4	4	5	6	3	5	5	1	1	0	0	1	0	0	1	1	1	0	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	4.75	4.428571	4.5	3.7619047		1	3.6190476	2.625	4.25	4.142857	4.5	0.14285715	-0.125	0.5	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG986HC7
2081	8976	NDAR_INVKG986HC7	2263			M	5800	EndofPhase2	15	Phase 2	410	0	1	0	0	0	0	0	3	2	5	2	3	2	3	5	6	2	6	3	4	5	4	5	2	6	3	3	4	0	0	0	0	1	1	0	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	4.25	3.857143	4.5	3.7142856			3.6190476	2.625	4.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG986HC7
2081	8976	NDAR_INVKG986HC7	2263			M	6000	EndofPhase3	18	Phase 3	506	0	1	0	0	0	0	0	6	2	6	4	4	2	5	6	6	6	6	6	6	6	4	6	6	6	5	6	6	1	1	0	1	1	1	0	1	1	1	0	4	3	3	1	1	1	0	0	0	0	0	0	0	0	0	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.375	6	5.714286	5.5	5.2380953			3.6190476	2.625	4.25	4.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKG986HC7
2081	8976	NDAR_INVKH175HP3	1360			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	1	0	1	1	0	1	0	0	1	1	9	2	1	0	1	0	2	1	4	2	0	0	1	0	1	0	0	0	1	2	1	2	2	2	4	0	0	0	0	0	0	0	1	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	1	0.5	1.4285715	1.5	1.15	1		1.15	1	0.5	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKH175HP3
2081	8976	NDAR_INVKH175HP3	1360			F	1600	Visit6	6	Phase 2	161	0	0	0	1	0	0	0	3	4	0	2	3	2	2	0	2	2	2	9	1	2	2	2	2	3	1	5	5	0	0	1	1	1	0	0	0	2	3	1	3	2	2	3	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2	1.5	2.7142856	2	2.25			1.15	1	0.5	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKH175HP3
2081	8976	NDAR_INVKH175HP3	1360			F	2800	Visit12	12	Phase 3	337	0	0	0	1	0	0	0	5	4	2	2	2	1	2	0	3	2	5	2	0	2	1	2	0	1	1	3	2	0	0	1	0	1	0	0	0	1	1	1	3	2	3	4	1	0	0	0	0	1	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.25	3	1.4285715	1	2			1.15	1	0.5	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKH175HP3
2081	8976	NDAR_INVKH175HP3	1360			F	5200	EndofPhase1_1a	4	Phase 1/1A	102	0	0	0	0	0	0	1	9	4	0	0	0	0	0	0	2	2	0	9	0	0	0	0	0	2	1	4	2	0	0	0	0	1	0	0	1	3	3	1	3	2	2	2	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	0.5714286	1	0.85714287	1.5	0.8947368		1	1.15	1	0.5	1.4285715	1.5	-0.25526315	-0.42857143	0.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKH175HP3
2081	8976	NDAR_INVKH175HP3	1360			F	5800	EndofPhase2	7	Phase 2	183	0	0	0	1	0	0	0	5	4	2	2	2	2	3	2	4	2	5	2	2	2	1	1	1	1	2	5	2	1	0	0	0	1	0	0	0	1	3	1	3	3	3	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	1	2.75	3.25	2	1.5	2.4761906			1.15	1	0.5	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKH175HP3
2081	8976	NDAR_INVKH175HP3	1360			F	6000	EndofPhase3	18	Phase 3	504	0	0	0	0	0	0	1	5	2	0	1	2	1	2	0	3	2	3	2	2	1	2	2	1	1	2	4	3	1	0	1	0	1	0	1	1	1	3	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	3	1.625	2.5	2.142857	1.5	1.9523809			1.15	1	0.5	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKH175HP3
2081	8976	NDAR_INVKJ548HBB	2887			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	0	0	0	4	0	1	0	0	0	0	9	2	1	0	2	0	1	0	4	4	0	0	0	0	1	1	1	0	1	3	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	5	1.375	0	1.8571428	0.5	1.25	1		1.25	1.375	0	1.8571428	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKJ548HBB
2081	8976	NDAR_INVKJ827ZBA	1638			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	0	4	3	3	6	1	0	0	0	9	1	2	2	2	1	4	1	2	5	0	0	0	0	1	1	0	0	3	2	0	4	4	3	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	0	2.142857	2.5	2.4	1		2.4	3.5	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKJ827ZBA
2081	8976	NDAR_INVKJ827ZBA	1638			M	1600	Visit6	6	Phase 2	173	1	0	0	0	0	0	0	6	2	0	1	2	0	1	1	0	0	0	9	2	2	4	1	0	5	2	5	5	0	0	0	1	1	0	0	0	1	1	1	4	4	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0	2.7142856	3.5	1.95			2.4	3.5	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKJ827ZBA
2081	8976	NDAR_INVKJ827ZBA	1638			M	2800	Visit12	12	Phase 2	335	1	0	0	0	0	0	0	6	0	0	4	6	0	2	0	0	0	0	9	2	0	3	2	3	5	2	4	6	1	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	26	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0	2.857143	3.5	2.25			2.4	3.5	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKJ827ZBA
2081	8976	NDAR_INVKJ827ZBA	1638			M	4000	Visit18	18	Phase 2	515	1	0	0	0	0	0	0	4	0	0	0	3	0	0	0	0	0	0	9	0	2	3	3	0	4	2	5	5	1	0	0	0	1	0	2	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.875	0	2.5714285	3	1.55			2.4	3.5	0	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKJ827ZBA
2081	8976	NDAR_INVKJ827ZBA	1638			M	5200	EndofPhase1_1a	3	Phase 1/1A	76	1	0	0	0	0	0	0	4	2	2	1	2	0	2	1	0	0	0	9	2	2	4	2	1	3	1	2	2	0	0	2	0	1	0	2	2	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	0	2.142857	2	1.65		1	2.4	3.5	0	2.142857	2.5	-0.75	-1.75	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKJ827ZBA
2081	8976	NDAR_INVKK036DX9	1556			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	1	0	6	0	0	2	2	2	2	5	0	4	5	9	3	0	4	3	0	5	2	4	6	1	1	0	0	1	0	1	1	1	1	0	4	2	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	2.25	2.857143	3.5	2.75	1		2.75	2.375	2.25	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKK036DX9
2081	8976	NDAR_INVKK036DX9	1556			F	1600	Visit6	6	Phase 1/1A	165	0	1	0	1	0	1	0	6	0	0	5	6	2	2	5	1	2	5	9	3	3	5	4	5	5	4	6	6	1	1	1	1	1	0	0	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	2	4.571429	4.5	3.75			2.75	2.375	2.25	2.857143	3.5	1	0.875	-0.25	1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKK036DX9
2081	8976	NDAR_INVKK036DX9	1556			F	2800	Visit12	12	Phase 1/1A	341	0	1	0	1	0	1	0	6	0	3	2	2	1	4	5	0	0	1	9	5	1	4	4	1	4	3	6	6	1	1	1	0	1	0	0	0	1	1	0	4	2	3	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	0.25	3.857143	3.5	2.9			2.75	2.375	2.25	2.857143	3.5	0.15	0.5	-2	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKK036DX9
2081	8976	NDAR_INVKK036DX9	1556			F	5200	EndofPhase1_1a	18	Phase 1/1A	502	0	1	0	1	0	0	0	6	0	2	2	2	2	3	6	0	0	3	9	6	4	5	3	3	6	3	5	6	1	1	0	0	1	0	1	0	1	1	0	4	1	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	25	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	0.75	4.571429	4.5	3.35		1	2.75	2.375	2.25	2.857143	3.5	0.6	0.5	-1.5	1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKK036DX9
2081	8976	NDAR_INVKL043UXP	1919			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	6	0	4	2	2	3	1	2	5	1	9	1	5	4	4	5	6	3	6	6	1	1	1	2	1	1	1	1	1	1	1	3	2	3	4	1	0	0	0	1	0	0	0	2	2	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.75	2	4.428571	4.5	3.5	1		3.5	2.75	2	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL043UXP
2081	8976	NDAR_INVKL043UXP	1919			F	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	6	6	5	5	5	4	6	1	2	3	4	9	6	4	6	6	5	6	5	6	6	1	1	1	1	1	1	1	1	2	1	1	3	3	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	2.25	5.571429	5.5	4.85			3.5	2.75	2	4.428571	4.5	1.35	2	0.25	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL043UXP
2081	8976	NDAR_INVKL043UXP	1919			F	5200	EndofPhase1_1a	9	Phase 1/1A	244	0	0	0	0	0	0	1	0	2	4	2	2	6	5	0	6	6	3	6	3	5	5	4	3	6	6	6	6	1	0	1	1	1	1	1	1	2	1	1	3	2	2	4	1	1	0	0	0	1	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	5.25	4.571429	6	4.095238		1	3.5	2.75	2	4.428571	4.5	0.5952381	-0.125	3.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL043UXP
2081	8976	NDAR_INVKL043UXP	1919			F	5800	EndofPhase2	12	Phase 2	327	0	0	0	0	0	0	1	6	6	6	4	6	4	6	1	1	3	4	9	4	4	5	6	5	6	4	6	6	1	0	1	0	1	0	1	1	2	1	1	3	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	1	1	1	1	4	4.875	2	5.142857	5	4.65			3.5	2.75	2	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL043UXP
2081	8976	NDAR_INVKL337YGU	2041			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	2	1	1	1	0	3	0	1	2	9	2	1	1	1	1	2	3	1	1	1	1	0	1	1	0	1	0	3		1	2	4	4	1	0	0	0	0	0	0	0	0					0		0		0		1	10	1	20	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.375	0.75	1.1428572	2.5	1.35	1		1.35	1.375	0.75	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL337YGU
2081	8976	NDAR_INVKL650REQ	2082			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	1	1	1	9	3	3	3	3	3	4	2	2	2	2	2	2	1	1	1	0	1	2	2	1	3	4	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2	0.75	2.7142856	3	2.2	1		2.2	2	0.75	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL650REQ
2081	8976	NDAR_INVKL650REQ	2082			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	1	0	4	5	2	2	4	4	4	4	1	4	6	9	2	3	4	3	3	3	2	3	4	1	0	2	0	1	1	2	1	1	2	1	4	2	4	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	2.75	3.142857	2.5	3.35			2.2	2	0.75	2.7142856	3	1.15	1.625	2	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL650REQ
2081	8976	NDAR_INVKL650REQ	2082			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	1	0	4	3	2	2	3	3	4	2	1	1	1	9	0	3	2	3	4	4	2	5	5	1	0	2	0	1	1	2	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	0.75	3.142857	3	2.7			2.2	2	0.75	2.7142856	3	0.5	0.875	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL650REQ
2081	8976	NDAR_INVKL650REQ	2082			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	4	3	3	3	4	4	4	3	0	3	6	9	3	3	2	4	4	4	3	3	3	1	0	2	0	1	1	2	1	2	2	1	4	2	4	4	1	0	0	1	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.5	2.25	3.142857	3.5	3.3		1	2.2	2	0.75	2.7142856	3	1.1	1.5	1.5	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL650REQ
2081	8976	NDAR_INVKL952FVJ	1866			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	2	4	3	4	2	1	0	0	0	9	2	2	3	0	0	5	4	4	2	1	1	1	1	1	1	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	1	4	2.75	0	1.8571428	4.5	2.2	1		2.2	2.75	0	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL952FVJ
2081	8976	NDAR_INVKL952FVJ	1866			M	1600	Visit6	6	Phase 2	183	1	0	0	0	0	0	0	6	3	4	4	3	3	5	1	6	5	6	5	5	6	6	6	5	5	3	6	4	0	1	0	1	1	1	0	1	1	2	1	3	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.625	5.5	5.428571	4	4.6190476			2.2	2.75	0	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL952FVJ
2081	8976	NDAR_INVKL952FVJ	1866			M	2800	Visit12	12	Phase 2	372	1	0	0	0	0	0	0	5	2	0	6	2	4	5	2	0	0	0	9	2	0	3	6	4	4	5	4	6	1	0	1	1	1	1	0	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	2	1	5	1	21	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.25	0	3.5714285	4.5	3			2.2	2.75	0	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL952FVJ
2081	8976	NDAR_INVKL952FVJ	1866			M	5200	EndofPhase1_1a	3	Phase 1/1A	90	1	0	0	0	0	0	0	3	2	2	2	4	2	4	2	1	1	1	9	3	2	4	6	2	6	5	3	1	0	0	1	1	1	1	0	1	1	2	1	3	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.625	0.75	3	5.5	2.8		1	2.2	2.75	0	1.8571428	4.5	0.6	-0.125	0.75	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL952FVJ
2081	8976	NDAR_INVKL952FVJ	1866			M	5800	EndofPhase2	18	Phase 2	541	0	0	0	0	0	1	0	2	0	0	6	2	2	6		0	0	1	9	3	3	3	4	6	1	0	4	4	2	2	2	0	1	1	1	1	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	3	2.5714285	0.25	3.857143	0.5	2.4736843			2.2	2.75	0	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKL952FVJ
2081	8976	NDAR_INVKM003VDY	2315			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	1	1	1	2	0	2	2	0	0	0	9	2	2	1	2	1	4	2	1	2	1	2	1	2	1	0	0	0	3	2	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	1.5	0	1.5714285	3	1.45	1		1.45	1.5	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM003VDY
2081	8976	NDAR_INVKM003XT8	1099			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	2	2	1	2	2	2	1	4	3	3	4	0	0	0	3	5	5	3	4	5	2	2	2	2	1	1	1	0	1	1	1	3	3	3	3	1	0	0	0	1	0	0	0	0	0	1	1	1	19	0		0		1	13	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.75	3.5	2.4285715	4	2.5238094	1		2.5238094	1.75	3.5	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM003XT8
2081	8976	NDAR_INVKM003XT8	1099			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	1	0	0	5	3	3	4	4	3	4	2	3	4	5	6	2	3	1	4	5	5	1	4	5	0	0	1	1	1	1	1	1	1	1	1	4	2	4	4	1	0	0	0	1	0	0	0	0	0	1	1	1	28	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	3.5	4.5	3.4285715	3	3.6190476			2.5238094	1.75	3.5	2.4285715	4	1.0952381	1.75	1	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM003XT8
2081	8976	NDAR_INVKM003XT8	1099			M	2800	Visit12	12	Phase 1/1A	332	0	0	0	0	1	0	0	5	5	5	4	5	5	5	4	4	4	5	6	3	3	3	4	4	5	3	5	5	1	1	1	0	1	1	1	1	1	1	1	3	3	1	1	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.75	4.75	3.857143	4	4.3809524			2.5238094	1.75	3.5	2.4285715	4	1.8571428	3	1.25	1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM003XT8
2081	8976	NDAR_INVKM003XT8	1099			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	0	1	3	4	4	2	2	2	2	0	5	4	6	6	0	5	0	3	4	5	3	4	5	0	1	1	1	1	1	1	1	3	1	1	4	3	4	3	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.375	5.25	3	4	3.2857144		1	2.5238094	1.75	3.5	2.4285715	4	0.7619048	0.625	1.75	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM003XT8
2081	8976	NDAR_INVKM486MPF	1507			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	4	2	3	3	3	0	1	1	1	9	0	2	0	2	1	4	3	3	3	1	1	0	0	1	0	1	0	2	1	1	3	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.4285715	0.75	1.5714285	3.5	2	1		2	2.4285715	0.75	1.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM486MPF
2081	8976	NDAR_INVKM486MPF	1507			M	1600	Visit6	6	Phase 1/1A	181	0	0	0	0	0	0	1	9	2	2	2	2	2	2	0	1	1	0	9	0	2	0	4	0	4	2	2	3	1	1	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.7142857	0.5	1.5714285	3	1.6315789			2	2.4285715	0.75	1.5714285	3.5	-0.36842105	-0.71428573	-0.25	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM486MPF
2081	8976	NDAR_INVKM486MPF	1507			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	6	0	2	2	2	3	5	0	2	3	6	9	1	2	4	4	6	5	2	2	3	1	1	0	0	1	1	1	1	1	2	0	4	3	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	2.75	3.142857	3.5	3			2	2.4285715	0.75	1.5714285	3.5	1	0.071428575	2	1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM486MPF
2081	8976	NDAR_INVKM486MPF	1507			M	5200	EndofPhase1_1a	18	Phase 1/1A	510	0	0	0	0	0	0	1	9	2	2	2	2	2	3	1	1	2	1	9	2	2	2	4	2	4	2	2	4	1	1	1	0	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	1	2.5714285	3	2.2105262		1	2	2.4285715	0.75	1.5714285	3.5	0.21052632	-0.42857143	0.25	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM486MPF
2081	8976	NDAR_INVKM632LXZ	1549			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	0	2	5	2	0	2	2	1	4	4	9	5	4	2	2	6	6	4	5	5	1	1	0	0	1	0	0	0	2	1	0	4	1	2	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	1.75	2.25	4.142857	5	3.1	1		3.1	1.75	2.25	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM632LXZ
2081	8976	NDAR_INVKM632LXZ	1549			M	1600	Visit6	6	Phase 1/1A	193	1	0	0	0	0	0	0	2	0	4	6	4	2	6	0	6	6	6	6	6	5	4	4	6	6	4	4	4	1	1	0	0	1	0	0	0	1	2	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	6	4.714286	5	4.3333335			3.1	1.75	2.25	4.142857	5	1.2333333	1.25	3.75	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM632LXZ
2081	8976	NDAR_INVKM632LXZ	1549			M	2800	Visit12	12	Phase 1/1A	364	1	0	0	0	0	0	0	6	4	4	6	4	2	4	1	4	6	6	6	4	6	6	3	4	6	4	4	4	1	1	0	1	1	1	0	0	1	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	5.5	4.428571	5	4.4761906			3.1	1.75	2.25	4.142857	5	1.3761904	2.125	3.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM632LXZ
2081	8976	NDAR_INVKM632LXZ	1549			M	5200	EndofPhase1_1a	18	Phase 1/1A	533	1	0	0	0	0	0	0	6	0	4	4	2	2	4	0	4	4	4	3	3	3	4	3	2	6	3	4	4	1	1	1	0	1	0	0	0	1	1	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	3.75	3.2857144	4.5	3.2857144		1	3.1	1.75	2.25	4.142857	5	0.18571429	1	1.5	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM632LXZ
2081	8976	NDAR_INVKM736RNK	1072			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	2	2	4	3	6	5	4	3	5	6	2	4	2	4	4	5	3	4	5	1	1	1	1	1	1	1	1	3	3	1	2	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	4.5	3.5714285	4	3.9047618	1		3.9047618	3.875	4.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM736RNK
2081	8976	NDAR_INVKM736RNK	1072			F	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	9	5	5	4	5	4	6	1	5	4	5	6	6	5	4	4	5	5	4	6	5	1	1	1	0	1	1	0	1	2	2	1	2	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.285714	5	5	4.5	4.7			3.9047618	3.875	4.5	3.5714285	4	0.7952381	0.4107143	0.5	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM736RNK
2081	8976	NDAR_INVKM736RNK	1072			F	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	0	1	9	5	5	4	5	4	4	2	1	4	5	9	5	2	2	4	0	6	3	6	5	1	0	1	1	1	0	1	1	3		1	3	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.142857	2.5	3.4285715	4.5	3.7894738			3.9047618	3.875	4.5	3.5714285	4	-0.11528822	0.26785713	-2	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM736RNK
2081	8976	NDAR_INVKM736RNK	1072			F	5200	EndofPhase1_1a	18	Phase 1/1A	523	0	0	0	0	0	0	1	5	6	6	4	4	5	5	4	0	0	2	9	5	2	3	6	0	5	3	4	5	1	1	1	1	1	1	1	1	3	2	1	2	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	0.5	3.5714285	4	3.7		1	3.9047618	3.875	4.5	3.5714285	4	-0.20476191	1	-4	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM736RNK
2081	8976	NDAR_INVKM926NJU	1066			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	4	4	4	1	5	4	2	2	6	9	2	2	2	3	2	3	3	4	4	1	1	2	0	1	1	1	0	3	3	1	3	1	2	4	1	0	0	0	0	0	1	0	2	2	2	2	0		1	15	0		1	15	0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.875	2.5	2.7142856	3	2.9	1		2.9	2.875	2.5	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM926NJU
2081	8976	NDAR_INVKM926NJU	1066			M	5200	EndofPhase1_1a	2	Phase 1/1A	42	0	0	0	0	0	1	0	0	0	0	0	0	0	2	2	1	0	0	9	2	2	2	1	1	4	3	0	0	1	1	2	0	1	0	1	1	3	1	0	4	3	4	3	0	0	0	0	0	0	0	1	0	0	0	0	0		1	29	0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	0.5	0.25	1.1428572	3.5	1		1	2.9	2.875	2.5	2.7142856	3	-1.9	-2.375	-2.25	-1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKM926NJU
2081	8976	NDAR_INVKN096DXL	1179			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	0	2	2	2	0	1	2	1	9	0	2	0	1	0	4	2	4	1	0	0	1	0	1	1	1	1	2	1	1	2	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	2	1.25	1	1.1428572	3	1.4	1		1.4	1.25	1	1.1428572	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKN096DXL
2081	8976	NDAR_INVKN096DXL	1179			M	1600	Visit6	6	Phase 1/1A	164	0	0	0	0	0	1	0	3	0	0	0	2	0	2	0	1	4	4	9	0	2	0	2	1	3	1	2	2	0	0	0	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.875	2.25	1.2857143	2	1.45			1.4	1.25	1	1.1428572	3	0.05	-0.375	1.25	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKN096DXL
2081	8976	NDAR_INVKN096DXL	1179			M	2800	Visit12	12	Phase 1/1A	346	1	0	0	0	0	0	0	4	4	0	0	4	0	0	0	2	2	4	9	2	4	0	2	1	4	3	4	2	1	1	0	0	1	1	1	1	1	1	0	4	2	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4	1.5	2	2.142857	3.5	2.1			1.4	1.25	1	1.1428572	3	0.7	0.25	1	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKN096DXL
2081	8976	NDAR_INVKN096DXL	1179			M	5200	EndofPhase1_1a	18	Phase 1/1A	513	0	1	0	0	0	0	0	4	0	0	1	2	2	1	5	2	2	1	9	0	2	2	1	0	4	2	4	2	1	0	1	0	1	1	1	1	1	1	1	2	4	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.875	1.25	1.5714285	3	1.85		1	1.4	1.25	1	1.1428572	3	0.45	0.625	0.25	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKN096DXL
2081	8976	NDAR_INVKP474ELA	1232			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	6	6	6	6	1	6	6	5	4	5	4	4	4	6	5	3	3	4	3	0	1	0	0	1	1	1	1	2	2	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	4	4.125	5	4.285714	3	4.2380953	1		4.2380953	4.125	5	4.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKP474ELA
2081	8976	NDAR_INVKR261AJG	1511			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	0	0	0	2	0	2	2	5	9	0	2	2	2	1	3	2	4	4	1	1	1	0	1	0	1	1	2	2	0		4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	0.75	2.25	2.142857	2.5	1.75	1		1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR261AJG
2081	8976	NDAR_INVKR261AJG	1511			M	1600	Visit6	6	Phase 1B	174	0	0	0	0	0	0	1	6	0	0	0	2	0	0	0	1	4	5	9	0	1	2	1	0	3	2	5	3	1	1	1	0	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	2.5	1.7142857	2.5	1.75			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR261AJG
2081	8976	NDAR_INVKR261AJG	1511			M	2800	Visit12	12	Phase 1B	343	0	0	0	0	0	0	1	5	0	1	2	2	0	0	0	1	0	0	9	0	0	0	2	0	4	3	2	2	1	1	1	0	1	1	1	1	2	2	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.25	0.25	0.85714287	3.5	1.2			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR261AJG
2081	8976	NDAR_INVKR261AJG	1511			M	5200	EndofPhase1_1a	5	Phase 1/1A	146	0	0	0	0	0	0	1	5	0	0	0	2	0	0	0	2	3	4	9	1	0	0	0	0	4	2	6	4	1	0	0	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	0.875	2.25	1.5714285	3	1.65		1	1.75	0.75	2.25	2.142857	2.5	-0.1	0.125	0	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR261AJG
2081	8976	NDAR_INVKR261AJG	1511			M	5400	EndofPhase1b	16	Phase 1B	439	0	0	0	0	0	0	1	2	0	0	1	2	0	0	0	1	1	4	9	0	0	2	0	0	4	2	2	2	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	0.625	1.5	0.85714287	3	1.15			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR261AJG
2081	8976	NDAR_INVKR261AJG	1511			M	5800	EndofPhase2	18	Phase 2	504	0	0	0	0	0	0	1	5	0	0	0	2	0	0	0	1	0	6	9	0	1	0	0	0	3	2	2	3	1	1	0	0	1	0	1	1	2	2	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	0.875	1.75	0.85714287	2.5	1.25			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR261AJG
2081	8976	NDAR_INVKR320TJX	2405			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	4	4	5	5	5	3	5	4	4	6	4	5	3	6	6	6	4	5	6	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.375	4.75	5	5	4.714286	1		4.714286	4.375	4.75	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR320TJX
2081	8976	NDAR_INVKR375VWT	1817			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	1	0	0	1	0	0	0	0	9	0		3		1	3	3	3	2	1	1	1	1	1	1	0	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0		0	0	1	0	1	0	4	1	0		3	1.2777778	1		1.2777778	1	0		3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR375VWT
2081	8976	NDAR_INVKR375VWT	1817			M	2800	Visit12	12	Phase 3	339	0	0	0	0	0	0	1	9	0	0	2	0	0	2	0	0	0	1	9	0	2	4	3	2	3	3	3	2	1	1	1	1	1	1	1	1	3		0	4	4	2	4	1	0	0	0	0	0	1	0	0	0	0	1	1	29	0		1	1	0		0		2	2	0	0	0	0	0	1	0	1	0	0	1	0	1	1	4	0.5714286	0.25	2.2857144	3	1.4210526			1.2777778	1	0		3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR375VWT
2081	8976	NDAR_INVKR375VWT	1817			M	5200	EndofPhase1_1a	3	Phase 1/1A	78	0	0	0	0	0	0	1	9	0	0	0	0	0	2	1	0	0	0	9	0	0	1	2	1	3	3	1	2	1	0	1	1	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	1	0	0	1	0	1	0		0.42857143	0	1	3	0.84210527		1	1.2777778	1	0		3	-0.43567252	-0.5714286	0		0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR375VWT
2081	8976	NDAR_INVKR375VWT	1817			M	5400	EndofPhase1b	4	Phase 1B	125	0	0	0	0	0	0	1	9	0	2	2	1	0	2	1	0	0	0	9	2	2	3	3	2	3	4	2	3	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	1	0	0	1	0	1	0	5	1.1428572	0	2.4285715	3.5	1.6842105			1.2777778	1	0		3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR375VWT
2081	8976	NDAR_INVKR375VWT	1817			M	5800	EndofPhase2	6	Phase 2	170	0	0	0	0	0	0	1	0	0	2	4	0	0	3	3	0	0	1	9	4	2	4	2	4	3	2	2	2	1	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	1.5	0.25	2.857143	2.5	1.9			1.2777778	1	0		3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR375VWT
2081	8976	NDAR_INVKR375VWT	1817			M	6000	EndofPhase3	17	Phase 3	489	0	0	0	0	0	1	0	0	1	1	2	1	1	1	1	0	2	0	9	0	1	1	2	1	3	1	1	2	0	1	0	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	3	0		0		1	27	0		2	2	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1	0.5	1.1428572	2	1.1			1.2777778	1	0		3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR375VWT
2081	8976	NDAR_INVKR422MM7	2308			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	3	2	3	3	4	4	5	3	4	3	4	6	3	5	5	4	6	6	6	6	6	1	1	0	1	1	1	0	0	1	2	0	3	2	3	4	0	0	0	0	0	0	0	0					0		0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	4.25	5	6	4.3333335	1		4.3333335	3.375	4.25	5	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR422MM7
2081	8976	NDAR_INVKR422MM7	2308			M	1600	Visit6	6	Phase 1/1A	169	1	0	1	0	0	0	0	4	3	3	4	3	3	4	3	6	4	3	4	5	4	4	4	4	2	2	4	5	1	1	1	1	1	1	1	1	3		1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	4.25	4.285714	2	3.7142856			4.3333335	3.375	4.25	5	6	-0.61904764	0	0	-0.71428573	-4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR422MM7
2081	8976	NDAR_INVKR422MM7	2308			M	2800	Visit12	12	Phase 1/1A	365	1	0	1	0	0	0	0	4	2	3	4	3	3	4	3	6	4	3	4	5	4	4	4	4	2	2	4	5	1	1	1	1	1	1	1	1	2	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5	3.25	4.25	4.285714	2	3.6666667		1	4.3333335	3.375	4.25	5	6	-0.6666667	-0.125	0	-0.71428573	-4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR422MM7
2081	8976	NDAR_INVKR857UYD	1634			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	9	3	2	0	1	0	4	1	3	3	0	0	0	0	1	0	0	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	0.125	0.5	1.7142857	2.5	1	1		1	0.125	0.5	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR857UYD
2081	8976	NDAR_INVKR857UYD	1634			M	5200	EndofPhase1_1a	3	Phase 1/1A	77	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	9	2	1	0	0	0	1	1	0	2	0	0	0	0	0	1	0	0	3		0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	29	0		0		1	1	0		0	0	0	0	0	0	0	1	0	1	0	0	0	1	1	1	1	0	0	0.71428573	1	0.35		1	1	0.125	0.5	1.7142857	2.5	-0.65	-0.125	-0.5	-1	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR857UYD
2081	8976	NDAR_INVKR857UYD	1634			M	5800	EndofPhase2	6	Phase 2	177	1	0	0	0	1	1	0	0	0	0	0	2	0	0	0	0	0	0	9	2	0	0	0	0	0	1	0	4	0	0	0	0	1	0	0	0	3		0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.25	0	0.85714287	0.5	0.45			1	0.125	0.5	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKR857UYD
2081	8976	NDAR_INVKT226ZH3	1078			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	2	2	3	3	1	3	1	1	4	3	3	4	4	4	4	4	2	5	1	1	1	0	1	1	1	1	1	1	1	2	4	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	12	1	18	0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	3	3	2.25	3.5714285	4	3.142857	1		3.142857	3	2.25	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT226ZH3
2081	8976	NDAR_INVKT226ZH3	1078			M	5200	EndofPhase1_1a	3	Phase 1/1A	74	0	0	0	0	0	1	0	4	4	0	0	0	2	2	1	0	1	0	9	2	3	0	4	4	3	4	3	5	1	0	0	0	1	1	1	1	2	2	1	2	4	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	6	0		1	24	0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	1	1	0	5	1.625	0.25	3	3.5	2.1		1	3.142857	3	2.25	3.5714285	4	-1.0428572	-1.375	-2	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT226ZH3
2081	8976	NDAR_INVKT226ZH3	1078			M	5800	EndofPhase2	6	Phase 2	169	0	0	0	0	0	1	0	4	0	1	0	2	1	1	1	0	0	0	9	2	1	2	3	1	2	1	3	5	1	0	0	0	1	1	1	0	2	2	0	4	4	4	4	1	0	1	0	1	0	0	0	1	1	1	1	1	4	0		1	26	0		0		0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	5	1.25	0	2.4285715	1.5	1.5			3.142857	3	2.25	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT226ZH3
2081	8976	NDAR_INVKT303FNU	2447			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	4	2	4	4	3	2	0	1	3	9	2	2	2	2	2	3	2	4	4	1	1	0	0	1	1	1	1	3	2	0	4	3	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	2.625	1	2.5714285	2.5	2.4	1		2.4	2.625	1	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT303FNU
2081	8976	NDAR_INVKT303FNU	2447			M	5200	EndofPhase1_1a	6	Phase 1/1A	170	0	0	0	0	0	1	0	1	2	1	1	1	1	1	2	2	2	4	9	2	3	3	4	1	2	2	5	4	1	1	0	0	0	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1.25	2	3.142857	2	2.2		1	2.4	2.625	1	2.5714285	2.5	-0.2	-1.375	1	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT303FNU
2081	8976	NDAR_INVKT596WVU	1046			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	4	2	0	3	6	2	4	4	4	6	2	6	6	6	6	6	3	6	6	1	0	1	1	1	0	1	1	3	1	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.125	4.5	5.428571	4.5	3.9047618	1		3.9047618	2.125	4.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT596WVU
2081	8976	NDAR_INVKT596WVU	1046			F	2800	Visit12	12	Phase 3	344	0	0	0	0	0	0	1	6	0	4	4	4	6	6	3	4	6	4	3	0	6	6	6	6	6	3	6	6	1	0	1	0	1	1	1	1	3	1	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.125	4.25	5.142857	4.5	4.5238094			3.9047618	2.125	4.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT596WVU
2081	8976	NDAR_INVKT596WVU	1046			F	5200	EndofPhase1_1a	6	Phase 1/1A	192	0	0	0	0	0	0	1	6	5	1	2	2	2	2	2	4	4	6	4	2	4	4	6	5	6	3	6	6	1	1	1	1	1	1	1	1	2	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.75	4.5	4.714286	4.5	3.9047618		1	3.9047618	2.125	4.5	5.428571	4.5	0	0.625	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT596WVU
2081	8976	NDAR_INVKT596WVU	1046			F	5800	EndofPhase2	11	Phase 2	318	0	0	0	0	0	0	1	6	0	4	4	4	4	4	2	4	6	4	6	0	4	4	6	5	6	4	6	6	1	1	1	0	1	1	1	1	3	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.5	5	4.428571	5	4.2380953			3.9047618	2.125	4.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT596WVU
2081	8976	NDAR_INVKT596WVU	1046			F	6000	EndofPhase3	18	Phase 3	507	0	0	0	0	0	0	1	6	0	5	5	6	6	6	2	5	4	4	6	0	6	6	6	6	6	3	6	6	1	0	1	0	1	1	1	1	3	1	1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	1	0	0	0	0	0	0	0	1	1	1	1	7	4.5	4.75	5.142857	4.5	4.7619047			3.9047618	2.125	4.5	5.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKT596WVU
2081	8976	NDAR_INVKU250FT8	2282			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	2	2	2	0	2	1	1	2	0	9	0	0	0	3	3	1	3	2	3	1	1	1	1	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.75	1.5714285	2	1.75	1		1.75	2.125	0.75	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU250FT8
2081	8976	NDAR_INVKU250FT8	2282			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	6	1	0	2	2	2	2	2	0	1	0	9	2	1	1	4	3	2	3	2	3	1	1	0	1	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.125	0.25	2.2857144	2.5	1.95		1	1.75	2.125	0.75	1.5714285	2	0.2	0	-0.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU250FT8
2081	8976	NDAR_INVKU841WRT	1863			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	4	4	4	4	4	5	4	3	4	4	3	2	4	2	5	4	4	5	4	5	0	0	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4.125	3.5	3.7142856	4.5	3.9047618	1		3.9047618	4.125	3.5	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU841WRT
2081	8976	NDAR_INVKU841WRT	1863			F	1600	Visit6	6	Phase 1/1A	171	0	0	0	1	0	0	0	6	6	5	5	6	6	5	6	5	6	6	9	4	4	3	6	4	6	4	6	5	1	0	1	1	1	1	1	1	1	1	1	2	1	4	1	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.625	4.25	4.571429	5	5.2			3.9047618	4.125	3.5	3.7142856	4.5	1.2952381	1.5	0.75	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU841WRT
2081	8976	NDAR_INVKU841WRT	1863			F	2800	Visit12	12	Phase 1/1A	339	0	0	0	1	0	0	0	6	6	5	5	5	5	5	4	4	4	4	2	3	4	2	5	2	4	2	5	5	1	1	1	0	1	1	1	1	1	1	1	2	1	4	1	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.125	3.5	3.7142856	3	4.142857			3.9047618	4.125	3.5	3.7142856	4.5	0.23809524	1	0	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU841WRT
2081	8976	NDAR_INVKU841WRT	1863			F	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	4	4	2	4	4	1	3	0	0	0	0	9	0	0	0	4	0	2	2	4	6	1	0	1	0	1	1	1	1	2	1	1	3	4	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	5	2.75	0	2	2	2		1	3.9047618	4.125	3.5	3.7142856	4.5	-1.9047619	-1.375	-3.5	-1.7142857	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU841WRT
2081	8976	NDAR_INVKU947CLP	2011			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	3	2	2	2	2	2	0	0	1	9	1	1	0	2	2	2	2	2	3	1	1	1	0	1	1	1	1	2	2	1	3	2	3	4	1	0	0	0	0	1	0	0	1	1	0	0	1	19	0		0		1	11	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.375	0.25	1.5714285	2	1.75	1		1.75	2.375	0.25	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU947CLP
2081	8976	NDAR_INVKU947CLP	2011			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	3	4	4	3	3	3	4	3	0	0	1	9	3	3	3	4	3	3	2	3	4	0	0	1	0	1	1	1	1	2	2	1	3	2	3	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.375	0.25	3.2857144	2.5	2.8			1.75	2.375	0.25	1.5714285	2	1.05	1	0	1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU947CLP
2081	8976	NDAR_INVKU947CLP	2011			M	2800	Visit12	12	Phase 2	353	0	0	0	0	0	0	1	3	4	4	3	3	3	3	3	0	1	1	9	3	3	3	4	2	3	3	3	5	1	1	1	0	1	1	1	1	3	2	1	3	2	2	2	1	0	0	0	0	0	1	0	1	0	1	0	1	15	0		1	15	0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	4	3.25	0.5	3.2857144	3	2.85			1.75	2.375	0.25	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU947CLP
2081	8976	NDAR_INVKU947CLP	2011			M	5200	EndofPhase1_1a	8	Phase 1/1A	241	0	0	0	0	0	0	1	3	3	3	2	2	2	2	1	0	0	0	9	1	2	2	2	2	1	1	1	3	0	1	1	0	1	1	1	1	3	2	1	3	3	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	16	0		0		1	14	0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	3	2.25	0	1.8571428	1	1.65		1	1.75	2.375	0.25	1.5714285	2	-0.1	-0.125	-0.25	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU947CLP
2081	8976	NDAR_INVKU947CLP	2011			M	5800	EndofPhase2	18	Phase 2	512	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	0	2	0	9	2	2	4	3	2	3	3	2	5	1	1	0	0	1	1	1	2	3	2	1	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	0.5	2.857143	3	2.2			1.75	2.375	0.25	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKU947CLP
2081	8976	NDAR_INVKV233CBM	2724			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	5	3	4	4	5	4	2	5	4	9	4	3	4	5	5	6	6	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.375	2.75	4.571429	6	4.5	1		4.5	4.375	2.75	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKV233CBM
2081	8976	NDAR_INVKV233CBM	2724			F	1600	Visit6	6	Phase 3	161	0	1	0	0	0	0	0	5	4	3	4	4	4	2	4	0	4	4	4	4	4	2	4	2	6	6	5	5	1	1	1	0	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	3.75	3	3.7142856	6	3.8095238			4.5	4.375	2.75	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKV233CBM
2081	8976	NDAR_INVKV233CBM	2724			F	2800	Visit12	12	Phase 3	335	0	1	0	0	0	0	0	4	2	2	2	2	2	2	3	2	2	2	9	2	2	2	2	2	4	4	4	2	1	0	1	0	1	1	0	1	3	2	1	4	3	3	3	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.375	1.5	2.2857144	4	2.45			4.5	4.375	2.75	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKV233CBM
2081	8976	NDAR_INVKV233CBM	2724			F	5200	EndofPhase1_1a	1	Phase 1/1A	5	0	1	0	0	0	0	0	6	4	4	2	4	4	4	4	2	4	2	9	4	3	4	5	4	6	6	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	2	4.428571	6	4.15		1	4.5	4.375	2.75	4.571429	6	-0.35	-0.375	-0.75	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKV233CBM
2081	8976	NDAR_INVKV233CBM	2724			F	5800	EndofPhase2	1	Phase 2	12	0	1	0	0	0	0	0	5	4	4	4	4	4	2	3	3	3	2	9	4	2	4	3	4	6	6	4	4	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	2	3.5714285	6	3.75			4.5	4.375	2.75	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKV233CBM
2081	8976	NDAR_INVKV233CBM	2724			F	6000	EndofPhase3	18	Phase 3	502	1	0	0	0	0	0	0	5	4	3	4	4	4	2	4	0	4	4	9	4	4	2	4	2	6	6	5	5	1	1	1	0	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.75	2	3.7142856	6	3.8			4.5	4.375	2.75	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKV233CBM
2081	8976	NDAR_INVKW099DZA	2186			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	3	3	2	3	2	2	2	4	3	4	3	2	2	0	1	2	5	2	4	1	1	0	1	0	1	1	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.125	3.5	1.7142857	3.5	2.3809524	1		2.3809524	2.125	3.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW099DZA
2081	8976	NDAR_INVKW099DZA	2186			F	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	0	3	1	1	2	2	2	2	2	2	4	9	1	2	4	3	1	5	3	3	3	1	1	1	0	0	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.625	2	2.4285715	4	2.3			2.3809524	2.125	3.5	1.7142857	3.5	-0.08095238	-0.5	-1.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW099DZA
2081	8976	NDAR_INVKW099DZA	2186			F	2800	Visit12	12	Phase 1/1A	331	0	0	0	0	0	0	1	0	4	0	4	4	2	4	1	2	2	4	9	0	2	2	3	2	5	3	5	3	1	1	1	0	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.375	2	2.4285715	4	2.6			2.3809524	2.125	3.5	1.7142857	3.5	0.21904762	0.25	-1.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW099DZA
2081	8976	NDAR_INVKW099DZA	2186			F	4000	Visit18	18	Phase 2	503	0	0	0	0	0	0	1	9	5	4	4	2	2	2	2	3	2	1	2	1	2	0	2	3	5	3	4	2	1	1	1	0	1	0	1	1	3		1	3	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3	2	2	4	2.55			2.3809524	2.125	3.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW099DZA
2081	8976	NDAR_INVKW099DZA	2186			F	5200	EndofPhase1_1a	15	Phase 1/1A	411	0	0	0	0	0	0	1	9	4	2	3	2	1	2	1	2	3	2	9	1	2	3	2	2	5	3	4	4	1	1	1	1	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.142857	1.75	2.5714285	4	2.5263157		1	2.3809524	2.125	3.5	1.7142857	3.5	0.1453634	0.017857144	-1.75	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW099DZA
2081	8976	NDAR_INVKW099DZA	2186			F	5800	EndofPhase2	23	Phase 2	636	0	0	0	0	0	0	1	9	4	3	2	2	1	3	4	3	2	1	2	1	2	0	1	2	5	3	4	2	1	0	1	0	1	1	1	1	3		1	4	4	4	2	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.7142856	2	1.7142857	4	2.35			2.3809524	2.125	3.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW099DZA
2081	8976	NDAR_INVKW756PRT	1428			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	3	2	2	2	1	1	0	0	0	9	0	0	1	0	0	2	6	5	4	0	1	1	1	1	1	1	1	2	1	1	4	2	2	2	1	0	0	0	0	0	1	0	1	0	0	1	0		1	2	0		1	28	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	7	2.125	0	1.4285715	4	1.75	1		1.75	2.125	0	1.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW756PRT
2081	8976	NDAR_INVKW756PRT	1428			M	5200	EndofPhase1_1a	2	Phase 1/1A	48	1	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	9	0	0	0	1	0	2	1	0	1	2	2	2	2	1	1	1	2	2	1	1	4	4	4	4	1	0	1	0	1	0	0	0	1	1	1	0	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.25	0	0.2857143	1.5	0.35		1	1.75	2.125	0	1.4285715	4	-1.4	-1.875	0	-1.1428572	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKW756PRT
2081	8976	NDAR_INVKX100LBG	1784			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	1	2	4	4	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0.375	0	1.1428572	1.5	0.7	1		0.7	0.375	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX100LBG
2081	8976	NDAR_INVKX100LBG	1784			M	1600	Visit6	6	Phase 1/1A	184	1	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	9	0	0	0	0	2	1	1	2	4	0	1	0	1	1	0	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	0.375	0	1.1428572	1	0.65			0.7	0.375	0	1.1428572	1.5	-0.05	0	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX100LBG
2081	8976	NDAR_INVKX100LBG	1784			M	2800	Visit12	12	Phase 1/1A	380	1	0	0	0	0	0	0	3	0	0	2	2	0	1	0	1	0	6	9	1	0	0	1	0	1	2	3	4	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	1	1.75	1.2857143	1.5	1.35		1	0.7	0.375	0	1.1428572	1.5	0.65	0.625	1.75	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX100LBG
2081	8976	NDAR_INVKX282CC6	1237			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	2	2	2	2	2	0	0	0	9	0	2	2	4	2	4	1	4	4	0	1	0	1	1	1	2	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	24	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.75	0	2.5714285	2.5	1.85	1		1.85	1.75	0	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX282CC6
2081	8976	NDAR_INVKX282CC6	1237			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	1	0	1	2	3	1	1	2	1	2	0	0	0	9	2	3	5	3	5	3	4	4	4	1	1	1	2	1	1	1	1	3		1	2	2	2	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.625	0	3.7142856	3.5	2.3			1.85	1.75	0	2.5714285	2.5	0.45	-0.125	0	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX282CC6
2081	8976	NDAR_INVKX282CC6	1237			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	1	0	0	1	0	1	1	1	1	2	0	0	0	9	0	1	2	1	2	3	3	4	4	1	1	2	2	1	1	1	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	3	0.875	0	2	3	1.35		1	1.85	1.75	0	2.5714285	2.5	-0.5	-0.875	0	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX282CC6
2081	8976	NDAR_INVKX897UXC	1227			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	5	4	4	3	4	2	1	2	1	9	3	4	4	4	2	3	1	4	5	2	2	2	2	1	1	1	1	3	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	7	4.25	1	3.7142856	2	3.4	1		3.4	4.25	1	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX897UXC
2081	8976	NDAR_INVKX897UXC	1227			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	3	3	2	4	1	6	2	0	1	2	9	3	3	4	6	5	3	2	3	5	1	0	1	1	1	1	0	1	3		1	4	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.375	0.75	4.142857	2.5	3.2		1	3.4	4.25	1	3.7142856	2	-0.2	-0.875	-0.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKX897UXC
2081	8976	NDAR_INVKY125NUT	2066			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	1	1	2	2	1	1	3	2	2	2	2	2	1	1	2	4	3	2	2	0	1	0	0	1	0	0	1	1	3	1	3	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	2.25	1.7142857	3.5	1.9523809	1		1.9523809	1.625	2.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY125NUT
2081	8976	NDAR_INVKY125NUT	2066			M	1600	Visit6	6	Phase 2	184	1	0	1	0	0	0	0	2	1	1	1	2	1	2	1	1	1	1	9	3	1	1	2	1	3	0	2	2	0	0	0	0	0	0	0	0	1	3	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	7	0		0		1	23	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	1.375	0.75	1.7142857	1.5	1.45			1.9523809	1.625	2.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY125NUT
2081	8976	NDAR_INVKY125NUT	2066			M	5200	EndofPhase1_1a	3	Phase 1/1A	72	1	0	1	0	0	0	0	2	1	1	1	2	1	1	1	1	1	1	9	1	1	1	1	1	5	2	1	1	0	1	0	0	1	0	0	0	1	3	1	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1.25	0.75	1	3.5	1.35		1	1.9523809	1.625	2.25	1.7142857	3.5	-0.60238093	-0.375	-1.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY125NUT
2081	8976	NDAR_INVKY125NUT	2066			M	5800	EndofPhase2	8	Phase 2	280	1	0	1	0	0	0	0	4	1	1	1	2	1	1	0	1	1	1	9	3	1	1	1	1	4	3	1	3	1	1	0	0	1	1	0	0	1	2	0	4	3	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.375	0.75	1.5714285	3.5	1.6			1.9523809	1.625	2.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY125NUT
2081	8976	NDAR_INVKY460GX8	2728			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	4	3	2	1	5	0	0	0	0	9	0	1	1	6	4	3	3	1	5	0	0	0	0	1	1	0	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2	0	2.5714285	3	2	1		2	2	0	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY460GX8
2081	8976	NDAR_INVKY460GX8	2728			M	1600	Visit6	6	Phase 1/1A	184	0	0	0	0	0	1	0	4	2	0	0	0	2	2	2	0	0	0	9	0	2	4	4	4	4	3	4	3	1	1	2	2	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	0	3	3.5	2			2	2	0	2.5714285	3	0	-0.5	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY460GX8
2081	8976	NDAR_INVKY460GX8	2728			M	2800	Visit12	12	Phase 1/1A	357	0	0	0	0	0	1	0	4	4	0	2	1	2	2	2	0	0	0	9	0	2	4	4	5	5	3	4	3	1	1	0	0	1	1	1	1	3		1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	0	3.142857	4	2.35			2	2	0	2.5714285	3	0.35	0.125	0	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY460GX8
2081	8976	NDAR_INVKY460GX8	2728			M	5200	EndofPhase1_1a	18	Phase 1/1A	545	0	0	0	0	0	1	0	4	4	1	3	2	2	3	2	0	0	0	9	0	2	3	3	4	5	3	4	3	1	1	1	0	1	1	1	1	3		1	4	4	2	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.625	0	2.7142856	4	2.4		1	2	2	0	2.5714285	3	0.4	0.625	0	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKY460GX8
2081	8976	NDAR_INVKZ112BLF	2365			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	5	6	4	5	6	0	5	5	6	6	6	5	5	3	5	6	5	6	5	0	0	1	1	1	0	1	1	2	1	1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	6	4.285714	5.5	5	5.5	4.9	1		4.9	4.285714	5.5	5	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ112BLF
2081	8976	NDAR_INVKZ112BLF	2365			F	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	0	1	9	4	5	4	4	5	6	1	5	6	6	6	6	6	6	6	6	6	5	6	5	1	0	1	1	1	1	0	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.142857	5.75	5.857143	5.5	5.2			4.9	4.285714	5.5	5	5.5	0.3	-0.14285715	0.25	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ112BLF
2081	8976	NDAR_INVKZ112BLF	2365			F	2800	Visit12	12	Phase 1/1A	346	0	0	0	0	0	0	1	6	4	5	6	4	4	5	2	6	6	6	6	6	5	6	6	4	6	5	5	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	7	4.5	6	5.428571	5.5	5.1904764			4.9	4.285714	5.5	5	5.5	0.2904762	0.21428572	0.5	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ112BLF
2081	8976	NDAR_INVKZ112BLF	2365			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	5	5	5	5	5	6	2	6	6	6	6	4	6	6	5	5	6	5	5	5	1	0	1	1	1	1	1	1	2	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.714286	6	5.142857	5.5	5.2		1	4.9	4.285714	5.5	5	5.5	0.3	0.42857143	0.5	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ112BLF
2081	8976	NDAR_INVKZ215BBD	1001			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	1	2	2	1	0	5	4	4	5	3	3	3	4	4	5	3	4	4	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.25	4.5	3.5714285	4	2.9047618	1		2.9047618	1.25	4.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ215BBD
2081	8976	NDAR_INVKZ215BBD	1001			F	1600	Visit6	6	Phase 1B	184	0	0	0	0	0	0	1	5	0	0	0	2	2	2	0	5	4	4	5	2	3	3	4	6	4	3	5	5	1	0	1	1	1	1	1	1	2	1	0	4	2	4	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	4.5	4	3.5	3.047619			2.9047618	1.25	4.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ215BBD
2081	8976	NDAR_INVKZ215BBD	1001			F	2800	Visit12	12	Phase 1B	358	0	0	0	1	0	0	0	5	0	0	2	2	2	2	1	3	4	5	5	1	3	2	4	4	4	3	4	4	1	1	1	1	1	1	1	1	1	1	0	4	3	2	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	4.25	3.142857	3.5	2.857143			2.9047618	1.25	4.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ215BBD
2081	8976	NDAR_INVKZ215BBD	1001			F	5200	EndofPhase1_1a	1	Phase 1/1A	42	0	0	0	0	0	0	1	4	0	0	2	1	0	0	0	0	1	0	9	1	0	2	4	5	2	2	4	5	0	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.875	0.25	3	2	1.65		1	2.9047618	1.25	4.5	3.5714285	4	-1.2547619	-0.375	-4.25	-0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ215BBD
2081	8976	NDAR_INVKZ215BBD	1001			F	5400	EndofPhase1b	18	Phase 1B	511	0	0	0	1	0	0	0	4	4	2	2	2	2	2	1	5	3	5	5	3	2	2	3	4	3	3	4	5	1	0	1	1	1	1	1	1	1	1	0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	4.5	3.2857144	3	3.142857			2.9047618	1.25	4.5	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ215BBD
2081	8976	NDAR_INVKZ365ZLA	1418			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	4	4	3	2	2	3	0	0	0	9	0	2	2	1	1	2	1	2	4	0	0	0	0	1	1	1	1	2	2	1	3	4	4	3	1	0	0	0	0	0	1	0	1	1	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3	0	1.7142857	1.5	1.95	1		1.95	3	0	1.7142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ365ZLA
2081	8976	NDAR_INVKZ377XMU	1533			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	2	1	2	2	4	1	2	2	2	0	0	0	0	2	2	4	3	1	1	0	0	1	1	2	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	4	1	12	0		1	15	0		0	0	0	0	0	1	0	0	1	1	1	1	1	0	1	0	1	1.125	2.25	1.2857143	2	1.4761904	1		1.4761904	1.125	2.25	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ377XMU
2081	8976	NDAR_INVKZ377XMU	1533			M	2800	Visit12	12	Phase 2	339	0	0	0	0	0	1	0	2	2	0	0	2	1	2	2	0	0	0	9	2	0	2	2	0	2	3	3	3	1	1	2	1	0	1	2	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	1.375	0	1.7142857	2.5	1.4			1.4761904	1.125	2.25	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ377XMU
2081	8976	NDAR_INVKZ377XMU	1533			M	5200	EndofPhase1_1a	7	Phase 1/1A	169	0	0	0	0	0	1	0	2	2	0	0	2	1	2	2	0	0	0	9	2	0	2	2	0	2	1	3	3	1	0	0	1	1	1	0	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	1.375	0	1.7142857	1.5	1.3		1	1.4761904	1.125	2.25	1.2857143	2	-0.17619048	0.25	-2.25	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ377XMU
2081	8976	NDAR_INVKZ377XMU	1533			M	5800	EndofPhase2	18	Phase 2	506	0	0	0	0	0	1	0	4	5	2	2	2	3	4	4	2	4	4	9	4	4	4	5	4	4	3	4	5	1	1	0	0	1	1	1	0	3		1	3	2	2	2	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	3.25	2.5	4.285714	3.5	3.65			1.4761904	1.125	2.25	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ377XMU
2081	8976	NDAR_INVKZ575RWH	2599			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	3	5	2	3	2	2	4	4	1	3	2	3	2	4	5	3	5	4	4	4	1	1	1	1	1	1	1	1	3	2	1	2	2	3	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.25	2.5	3.5714285	4.5	3.3333333	1		3.3333333	3.25	2.5	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ575RWH
2081	8976	NDAR_INVKZ575RWH	2599			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	0	0	0	0	0	1	4	2	3	4	1	3	3	4	2	2	1	9	2	1	2	2	2	4	3	1	2	0	0	1	0	1	1	1	1	3		1	2	1	4	1	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	1.25	1.7142857	3.5	2.4		1	3.3333333	3.25	2.5	3.5714285	4.5	-0.93333334	-0.25	-1.25	-1.8571428	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ575RWH
2081	8976	NDAR_INVKZ575RWH	2599			M	5800	EndofPhase2	2	Phase 2	38	0	0	0	0	0	0	1	4	3	3	2	2	1	2	2	2	1	0	9	2	0	0	1	1	5	2	2	3	1	0	1	0	1	0	0	1	2	3	1	4	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0.75	1.2857143	3.5	1.9			3.3333333	3.25	2.5	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ575RWH
2081	8976	NDAR_INVKZ749DHX	2623			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	6	0	6	4	6	6	1	2	4	3	9	4	5	2	6	4	4	3	5	6	1	0	0	1	1	1	1	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	2.25	4.571429	3.5	4.1	1		4.1	4.25	2.25	4.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ749DHX
2081	8976	NDAR_INVKZ749DHX	2623			M	2800	Visit12	12	Phase 1B	338	1	0	1	0	1	0	0	4	3	2	3	2	3	6	2	6	4	5	4	1	4	2	5	6	4	4	2	4	1	1	1	0	1	0	1	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.125	4.75	3.4285715	4	3.6190476			4.1	4.25	2.25	4.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ749DHX
2081	8976	NDAR_INVKZ749DHX	2623			M	5200	EndofPhase1_1a	6	Phase 1/1A	175	1	0	1	0	0	0	0	2	1	1	2	2	2	3	2	0	0	0	9	2	2	2	3	1	4	3	1	2	1	0	1	0	1	1	1	1	1	2	1	3	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.875	0	1.8571428	3.5	1.75		1	4.1	4.25	2.25	4.571429	3.5	-2.35	-2.375	-2.25	-2.7142856	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ749DHX
2081	8976	NDAR_INVKZ749DHX	2623			M	5400	EndofPhase1b	18	Phase 1B	521	1	0	1	0	0	0	0	4	3	5	4	4	6	6	2	0	0	0	9	3	2	2	4	4	4	3	2	5	1	0	0	0	1	1	1	0	1	3	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4.25	0	3.142857	3.5	3.15			4.1	4.25	2.25	4.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ749DHX
2081	8976	NDAR_INVKZ899BRA	1124			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	5	6	6	6	5	6	6	3	5	6	5	6	5	6	6	6	4	4	5	1	1	1	0	1	1	1	1	1	1	1	2	1	2	1	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	5.75	5	5.285714	5	5.3809524	1		5.3809524	5.75	5	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ899BRA
2081	8976	NDAR_INVKZ899BRA	1124			M	2800	Visit12	12	Phase 2	365	0	1	0	0	0	0	0	6	4	4	4	4	1	5	4	6	6	6	6	5	5	4	5	5	5	5	5	6	1	1	1	0	1	1	1	1	1	1	1	2	1	2	1	1	0	0	0	0	1	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4	6	5	5	4.8095236			5.3809524	5.75	5	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ899BRA
2081	8976	NDAR_INVKZ899BRA	1124			M	4000	Visit18	18	Phase 2	565	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	6	4	6	6	4	5	6	4	5	5	5	6	6	1	1	1	1	1	1	0	1	1	2	1	2	2	2	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	6	5.5	5.142857	5	5.5238094			5.3809524	5.75	5	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ899BRA
2081	8976	NDAR_INVKZ899BRA	1124			M	5200	EndofPhase1_1a	1	Phase 1/1A	54	0	1	0	0	0	0	0	6	6	5	4	4	4	4	5	4	4	4	5	5	5	4	4	5	6	5	5	5	1	1	1	0	1	1	1	1	1	1	1	3	3	3	1	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	4.25	4.714286	5.5	4.714286		1	5.3809524	5.75	5	5.285714	5	-0.6666667	-1	-0.75	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ899BRA
2081	8976	NDAR_INVKZ899BRA	1124			M	5400	EndofPhase1b	6	Phase 1B	200	0	1	0	0	0	0	0	6	5	6	6	6	6	6	6	4	5	3	6	5	6	6	6	3	5	3	6	6	1	1	1	0	1	1	1	1	1	2	1	3	1	2	1	1	1	1	1	0	1	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.875	4.5	5.428571	4	5.285714			5.3809524	5.75	5	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVKZ899BRA
2081	8976	NDAR_INVLA282ARY	2624			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	3	2	3	3	2	3	5	2	2	1	3	9	2	3	2	3	1	2	2	3	3	2	2	2	1	1	1	1	2	2	1	1	3	2	2	4	1	0	1	1	0	0	0	0	1	1	1	1	1	22	0		0		1	8	0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	4	2.875	1.5	2.4285715	2	2.5	1		2.5	2.875	1.5	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLA282ARY
2081	8976	NDAR_INVLA282ARY	2624			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	1	0	2	3	3	3	2	3	3	2	2	3	4	9	3	4	3	5	4	1	4	2	4	1	1	0	1	1	1	0	1	2	2	1	2	1	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.625	2.25	3.5714285	2.5	3			2.5	2.875	1.5	2.4285715	2	0.5	-0.25	0.75	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLA282ARY
2081	8976	NDAR_INVLA282ARY	2624			M	2800	Visit12	12	Phase 1B	317	0	0	0	0	0	1	0	3	2	3	1	2	3	2	2	1	2	3	9	2	3	3	4	5	1	2	2	2	0	1	0	0	1	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	1.5	3	1.5	2.4			2.5	2.875	1.5	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLA282ARY
2081	8976	NDAR_INVLA282ARY	2624			M	5200	EndofPhase1_1a	11	Phase 1/1A	289	0	0	0	0	0	1	0	4	2	2	1	2	2	3	2	1	1	4	9	2	3	3	3	2	2	2	2	2	1	0	0	0	0	0	0	0																																															2.25	1.5	2.4285715	2	2.25		1	2.5	2.875	1.5	2.4285715	2	-0.25	-0.625	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLA282ARY
2081	8976	NDAR_INVLA282ARY	2624			M	5400	EndofPhase1b	15	Phase 1B	409	0	0	0	0	0	1	0	2	2	2	2	2	2	3	2	2	1	4	9	1	2	3	3	2	1	2	2	3	0	0	0	0	1	1	0	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	4	2.125	1.75	2.2857144	1.5	2.15			2.5	2.875	1.5	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLA282ARY
2081	8976	NDAR_INVLB128HEX	1127			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	3	2	2	1	2	0	1	0	0	9	0	0	0	2	4	2	3	2	3	1	1	0	0	1	1	1	1	1	2	1	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	2	2.375	0.25	1.5714285	2.5	1.8	1		1.8	2.375	0.25	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB128HEX
2081	8976	NDAR_INVLB128HEX	1127			M	1600	Visit6	6	Phase 1/1A	177	1	0	0	0	0	0	0	6	2	0	2	2	3	3	2	0	0	0	9	2	0	3	3	1	4	2	0	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.5	0	2	3	2			1.8	2.375	0.25	1.5714285	2.5	0.2	0.125	-0.25	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB128HEX
2081	8976	NDAR_INVLB128HEX	1127			M	2800	Visit12	12	Phase 1/1A	344	1	0	0	0	0	0	0	6	6	5	4	6	6	4	6	3	3	2	0	0	0	4	0	2	6	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	0	1	0	1	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	5.375	2	2.5714285	5	3.7619047			1.8	2.375	0.25	1.5714285	2.5	1.9619048	3	1.75	1	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB128HEX
2081	8976	NDAR_INVLB128HEX	1127			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	1	0	0	0	0	0	0	5	5	5	3	4	5	5	4	4	0	2	9	5	5	5	4	5	5	4	4	5	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	0	1	0	1	1	14	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.5	1.5	4.714286	4.5	4.2		1	1.8	2.375	0.25	1.5714285	2.5	2.4	2.125	1.25	3.142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB128HEX
2081	8976	NDAR_INVLB355YV8	1033			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	1	5	5	4	4	4	4	1	1	1	9	1	1	0	4	0	4	2	1	2	2	2	1	0	1	1	1	1	3	3	1	2	1	4	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	3.5	0.75	1.2857143	3	2.3	1		2.3	3.5	0.75	1.2857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB355YV8
2081	8976	NDAR_INVLB355YV8	1033			F	5200	EndofPhase1_1a	2	Phase 1/1A	42	0	0	0	0	0	0	1	2	2	2	2	4	2	4	2	1	3	4	9	3	2	3	3	1	3	1	3	2	0	0	0	2	1	1	0	1	2	2	0		4	4	4	0	0	0	0	0	0	0	1	1	0	1	0	1	14	0		0		1	16	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2.5	2	2.4285715	2	2.45		1	2.3	3.5	0.75	1.2857143	3	0.15	-1	1.25	1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB355YV8
2081	8976	NDAR_INVLB538EZT	2443			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	2	4	4	3	3	6	0	3	4	5	9	3	3	2	3	3	2	2	3	4	1	1	0	0	1	1	0	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.125	3	3	2	3.1	1		3.1	3.125	3	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB538EZT
2081	8976	NDAR_INVLB538EZT	2443			M	5200	EndofPhase1_1a	3	Phase 1/1A	100	0	0	0	0	0	1	0	5	0	2	2	2	2	2	1	2	3	6	9	2	2	4	1	2	2	2	5	3	0	0	0	0	0	0	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	2.75	2.7142856	2	2.5		1	3.1	3.125	3	3	2	-0.6	-1.125	-0.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB538EZT
2081	8976	NDAR_INVLB538EZT	2443			M	5800	EndofPhase2	12	Phase 2	370	0	0	0	0	0	1	0	4	0	3	2	2	3	6	0	1	1	5	9	2	0	2	3	2	1	1	3	4	0	0	0	0	0	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		2.5	1.75	2.2857144	1	2.25			3.1	3.125	3	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB538EZT
2081	8976	NDAR_INVLB982ZWN	2281			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	1	0	4	2	1	2	0	4	2	3	3	2	2	6	5	6	4	2	4	3	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	3	4	3	2.952381	1		2.952381	2	3	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB982ZWN
2081	8976	NDAR_INVLB982ZWN	2281			M	2800	Visit12	12	Phase 3	337	1	0	0	0	0	0	0	4	0	0	2	2	2	2	0	0	0	0	9	2	2	2	0	0	4	1	4	4	0	0	0	0	0	1	0	0	1	2	0	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.5	0	2	2.5	1.55			2.952381	2	3	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB982ZWN
2081	8976	NDAR_INVLB982ZWN	2281			M	5200	EndofPhase1_1a	6	Phase 1/1A	151	1	0	0	0	0	0	0	2	2	0	3	3	2	3	2	0	1	4	9	2	0	2	1	4	4	0	3	4	0	0	0	0	1	0	0	0	3	2	1	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1.25	2.2857144	2	2.1		1	2.952381	2	3	4	3	-0.85238093	0.125	-1.75	-1.7142857	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB982ZWN
2081	8976	NDAR_INVLB982ZWN	2281			M	5800	EndofPhase2	8	Phase 2	218	1	0	0	0	0	0	0	3	2	2	3	3	2	1	1	1	1	4	9	2	1	2	1	1	4	1	3	4	0	0	0	0	1	0	0	0	3	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.125	1.5	2	2.5	2.1			2.952381	2	3	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB982ZWN
2081	8976	NDAR_INVLB982ZWN	2281			M	6000	EndofPhase3	12	Phase 3	354	1	0	0	0	0	0	0	4	0	0	2	2	2	2	0	0	0	0	9	2	2	2	0	0	4	1	4	4	0	0	0	0	0	1	0	0	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.5	0	2	2.5	1.55			2.952381	2	3	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLB982ZWN
2081	8976	NDAR_INVLC113LWB	2696			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	0	0	6	4	5	0	1	4	0	9	2	4	0	2	6	4	3	5	5	1	1	0	0	1	1	1	1	2	1	1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.857143	1.25	3.4285715	3.5	2.9473684	1		2.9473684	2.857143	1.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC113LWB
2081	8976	NDAR_INVLC113LWB	2696			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	2	2	0																																																																																2.9473684	2.857143	1.25	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC113LWB
2081	8976	NDAR_INVLC164MAC	1208			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	3	2	3	3	5	5	3	5	4	5	6	2	2	1	5	4	2	1	2	3	0	0	0	0	0	1	1	0	3	3	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	20	0		0		1	10	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	3.625	5	2.7142856	1.5	3.3809524	1		3.3809524	3.625	5	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC164MAC
2081	8976	NDAR_INVLC164MAC	1208			M	5200	EndofPhase1_1a	5	Phase 1/1A	136	0	0	0	0	0	0	1	2	0	0	0	2	2	2	2	0	1	1	9	2	2	1	2	0	1	1	4	4	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	0.5	2.142857	1	1.45		1	3.3809524	3.625	5	2.7142856	1.5	-1.9309524	-2.375	-4.5	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC164MAC
2081	8976	NDAR_INVLC500ER7	1871			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	0	3	5	3	3	0	2	1	2	9	4	2	2	2	2	5	1	4	4	0	0	0	1	1	1	0	0	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3.125	1.25	2.857143	3	2.8	1		2.8	3.125	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC500ER7
2081	8976	NDAR_INVLC500ER7	1871			M	1600	Visit6	6	Phase 2	185	1	0	0	0	0	0	0	6	5	2	4	6	4	4	4	1	1	1	9	4	2	3	4	3	4	3	4	4	1	1	0	0	1	1	0	0	1	1	1	3	4	4	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.375	0.75	3.4285715	3.5	3.45			2.8	3.125	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC500ER7
2081	8976	NDAR_INVLC500ER7	1871			M	5200	EndofPhase1_1a	3	Phase 1/1A	106	1	0	0	0	0	0	0	6	1	1	4	5	3	2	1	1	1	2	9	4	4	3	2	3	5	4	5	5	1	0	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.875	1	3.7142856	4.5	3.1		1	2.8	3.125	1.25	2.857143	3	0.3	-0.25	-0.25	0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC500ER7
2081	8976	NDAR_INVLC500ER7	1871			M	5800	EndofPhase2	11	Phase 2	338	1	0	0	0	0	0	0	5	4	4	4	4	3	3	2	3	4	3	4	4	3	4	4	3	5	3	4	4	2	2	2	2	1	2	2	2	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	21	0		0		1	9	0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.625	3.5	3.7142856	4	3.6666667			2.8	3.125	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC500ER7
2081	8976	NDAR_INVLC738JBL	2248			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	4	6	4	4	2	6	4	4	4	6	5	2	2	4	6	3	6	6	1	1	0	0	1	0	0	1	1	1	1	3	3	4	1	0	0	0	0	0	0	0	0					1	19	0		0		1	11	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	4.5	4.428571	4.5	4.571429	1		4.571429	4.75	4.5	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738JBL
2081	8976	NDAR_INVLC738JBL	2248			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	6	4	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	1	0	0	0	0	0	0	1	1	1	1	5	5.625	6	6	5	5.7619047			4.571429	4.75	4.5	4.428571	4.5	1.1904762	0.875	1.5	1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738JBL
2081	8976	NDAR_INVLC738JBL	2248			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	6	6	5	6	6	6	6	0	6	6	6	9	6	6	6	6	6	6	5	6	6	1	1	0	1	1	1	1	1	1	1	1	3	2	2	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5.125	4.5	6	5.5	5.6			4.571429	4.75	4.5	4.428571	4.5	1.0285715	0.375	0	1.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738JBL
2081	8976	NDAR_INVLC738JBL	2248			M	5200	EndofPhase1_1a	18	Phase 1/1A	525	0	1	0	0	0	0	0	6	6	4	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	4	6	6	1	1	1	0	1	1	0	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	5.75	6	6	5	5.8095236		1	4.571429	4.75	4.5	4.428571	4.5	1.2380953	1	1.5	1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738JBL
2081	8976	NDAR_INVLC738TNV	2013			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	1	1	2	1	2	2	0	1	1	9	2	1	1	1	2	3	2	2	2	0	0	0	0	1	1	1	1	3		0	4	2	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5	1.375	0.5	1.5714285	2.5	1.45	1		1.45	1.375	0.5	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738TNV
2081	8976	NDAR_INVLC738TNV	2013			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	1	1	1	2	2	1	2	2	0	1	1	9	2	1	1	1	2	3	2	2	2	0	0	0	0	1	1	1	1	3		0	4	2	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1.5	0.5	1.5714285	2.5	1.5			1.45	1.375	0.5	1.5714285	2.5	0.05	0.125	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738TNV
2081	8976	NDAR_INVLC738TNV	2013			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	1	0	2	1	2	2	2	2	3	3	0	1	2	9	2	2	2	3	3	3	2	2	3	0	1	0	0	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.125	0.75	2.4285715	2.5	2.1			1.45	1.375	0.5	1.5714285	2.5	0.65	0.75	0.25	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738TNV
2081	8976	NDAR_INVLC738TNV	2013			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	1	0	1	2	2	3	2	2	2	0	2	2	3	4	3	3	2	2	4	3	3	3	4	1	0	0	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0									1	30					0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.75	2.75	3	3	2.4761906		1	1.45	1.375	0.5	1.5714285	2.5	1.0261905	0.375	2.25	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLC738TNV
2081	8976	NDAR_INVLD134LEG	1575			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	2	2	2	2	0	0	0	9	0	2	2	4	0	4	2	0	2	1	1	0	0	0	1	0	0	2	2	0	4	4	4	4	1	0	1	0	0	0	1	0	1	1	1	1	0		1	10	0		1	20	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.25	0	1.4285715	3	1.3	1		1.3	1.25	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLD134LEG
2081	8976	NDAR_INVLD134LEG	1575			M	5200	EndofPhase1_1a	1	Phase 1/1A	37	0	0	0	0	0	1	0	1	0	0	0	4	0	3	0	0	0	0	9	0	1	0	4	0	3	0	2	3	2	2	0	0	0	1	2	2	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		1	15	0		1	15	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1	0	1.4285715	1.5	1.05		1	1.3	1.25	0	1.4285715	3	-0.25	-0.25	0	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLD134LEG
2081	8976	NDAR_INVLD572XB3	2783			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	2	2	2	3	1	1	2	9	2	2	2	2	2	2	2	3	3	2	1	2	1	1	1	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1		0		0		1		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	2.125	1	2.2857144	2	2.05	1		2.05	2.125	1	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLD572XB3
2081	8976	NDAR_INVLE131NYP	2759			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4																																																																																1																																																																																																																																Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLE131NYP
2081	8976	NDAR_INVLE131NYP	2759			F	1600	Visit6	6	Phase 2	167	0	0	0	0	0	0	1	6	6	0	2	6	1	6	3	3	5	6	5	5	6	5	6	6	5	4	4	3	1	0	1	1	1	1	1	1	3		1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.75	4.75	5	4.5	4.428571																																																																																																																																	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLE131NYP
2081	8976	NDAR_INVLE131NYP	2759			F	2800	Visit12	12	Phase 2	336	0	0	0	0	0	0	1	4	4	2	2	2	3	4	6	4	2	5	6	4	5	3	6	6	5	2	3	3	0	0	1	0	1	1	1	1	3		1	3	1	3	2	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	5	3.375	4.25	4.285714	3.5	3.857143																																																																																																																																	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLE131NYP
2081	8976	NDAR_INVLE131NYP	2759			F	5200	EndofPhase1_1a	1	Phase 1/1A	9	0	0	0	0	0	0	1	4	0	4	1	2	2	2	0	2	2	4	9	4	3	2	0	6	5	2	4	4	1	0	1	0	1	1	0	1	3	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	1	0	0	0	1	0	0	1	0	1	1	4	1.875	2	3.2857144	3.5	2.65		1																																																																																																																															Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLE131NYP
2081	8976	NDAR_INVLF125KA8	1349			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	0	1	2	0	2	0	1	1	6	9	1	1	0	1	1	1	3	0	0	0	1	0	1	0	0	0	1	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	0.625	2	0.5714286	2	1.05	1		1.05	0.625	2	0.5714286	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLF125KA8
2081	8976	NDAR_INVLG113LD8	1769			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	1	1	2	2	2	2	2	0	2	0	9	0	0	1	3	1	2	1	3	3	1	0	1	0	1	1	1	1	3		1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.75	0.5	1.5714285	1.5	1.5	1		1.5	1.75	0.5	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG113LD8
2081	8976	NDAR_INVLG113LD8	1769			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	2	1	1	1	1	2	2	2	0	2	0	9	0	0	1	3	1	2	1	3	3	1	0	1	0	1	1	1	1	3		1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.5	0.5	1.5714285	1.5	1.4			1.5	1.75	0.5	1.5714285	1.5	-0.1	-0.25	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG113LD8
2081	8976	NDAR_INVLG113LD8	1769			M	2800	Visit12	12	Phase 2	359	0	0	0	0	0	0	1	3	3	2	2	1	2	2	3	0	2	1	3	1	1	2	2	2	1	2	1	3	1	1	2	0	1	0	1	1	3	2	0	4	3	4	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		2	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	1.5	1.7142857	1.5	1.8571428			1.5	1.75	0.5	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG113LD8
2081	8976	NDAR_INVLG113LD8	1769			M	5200	EndofPhase1_1a	7	Phase 1/1A	184	0	0	0	0	0	0	1	2	1	1	1	1	2	2	2	0	2	0	9	0	0	1	3	1	2	1	3	3	1	0	1	0	1	1	1	1	3		1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.5	0.5	1.5714285	1.5	1.4		1	1.5	1.75	0.5	1.5714285	1.5	-0.1	-0.25	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG113LD8
2081	8976	NDAR_INVLG113LD8	1769			M	5800	EndofPhase2	18	Phase 2	541	0	0	0	0	0	0	1	2	3	3	5	4	4	3	2	4	3	5	5	4	4	4	3	2	5	5	3	3	1	1	1	1	1	1	1	1	2	3	1	4	3	3	3	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	1	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	4.25	3.2857144	5	3.6190476			1.5	1.75	0.5	1.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG113LD8
2081	8976	NDAR_INVLG609WBM	1605			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	0	0	0	0	1	2	3	4	2	1	4	2	2	5	4	2	5	4	5	6	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1.5	2.75	3.7142856	4.5	2.7619047	1		2.7619047	1.5	2.75	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG609WBM
2081	8976	NDAR_INVLG609WBM	1605			F	1600	Visit6	6	Phase 1/1A	186	0	1	0	1	0	0	0	4	0	4	4	4	2	2	4	6	5	5	4	3	4	6	4	5	5	4	5	6	1	1	1	1	1	1	1	1	1	1	0	4	2	2	1	1	1	0	0	0	1	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	3	5	4.714286	4.5	4.095238			2.7619047	1.5	2.75	3.7142856	4.5	1.3333334	1.5	2.25	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG609WBM
2081	8976	NDAR_INVLG609WBM	1605			F	2800	Visit12	12	Phase 1/1A	358	0	1	0	0	0	0	0	6	5	0	0	0	2	5	6	4	4	5	4	4	5	4	3	5	6	4	6	5	1	1	1	0	1	1	1	1	1	1	1	2	1	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	5	3	4.25	4.571429	5	3.952381			2.7619047	1.5	2.75	3.7142856	4.5	1.1904762	1.5	1.5	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG609WBM
2081	8976	NDAR_INVLG609WBM	1605			F	5200	EndofPhase1_1a	18	Phase 1/1A	526	0	1	0	0	0	0	0	6	4	4	4	4	4	5	5	5	5	4	4	3	4	4	4	4	6	5	5	5	1	1	1	1	1	1	1	1	1	3	1	3	2	3	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	4.5	4.5	4.142857	5.5	4.4761906		1	2.7619047	1.5	2.75	3.7142856	4.5	1.7142857	3	1.75	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG609WBM
2081	8976	NDAR_INVLG948HKH	2888			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	5	6	3	4	4	3	0	0	0	9	3	6	3	1	3	3	4	5	6	1	0	1	1	1	1	0	2	3		1	2	1	1	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	2	2	2	0	0	0	0	0	0	1	0	0	1	0	0	1	3	4	0	3.857143	3.5	3.2631578	1		3.2631578	4	0	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG948HKH
2081	8976	NDAR_INVLG948HKH	2888			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	4	4	3	5	5	4	4	5	5	3	5	5	4	5	4	5	5	5	3	4	6	1	1	1	0	1	1	1	1	3		1	3	2	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	4	4.25	4.5	4.714286	4	4.428571			3.2631578	4	0	3.857143	3.5	1.1654135	0.25	4.5	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG948HKH
2081	8976	NDAR_INVLG948HKH	2888			M	5200	EndofPhase1_1a	9	Phase 1/1A	260	0	0	0	0	0	1	0	0	4	4	5	6	5	2	3	6	6	6	6	3	3	5	5	4	3	5	6	6	1	1	0	1	1	0	1	1	2	1	1	3	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	5	3.625	6	4.571429	4	4.428571		1	3.2631578	4	0	3.857143	3.5	1.1654135	-0.375	6	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLG948HKH
2081	8976	NDAR_INVLH277HFT	2474			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	2	4	2	4	6	0	6	2	6	6	4	6	6	4	5	3	1	6	6	2	2	1	1	1	1	1	1	2	1	1	4	4	4	4	1	0	0	1	0	0	0	0	2	2	0	2	0		0		0		0		1	18	0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3.2857144	5	5.285714	2	4.2	1		4.2	3.2857144	5	5.285714	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH277HFT
2081	8976	NDAR_INVLH277HFT	2474			M	5200	EndofPhase1_1a	5	Phase 1/1A	176	0	0	1	0	0	0	0	6	4	5	4	2	5	5	0	2	2	2	9	2	4	4	6	4	5	5	6	6	1	1	1	1	1	1	1	1	1	1	0	4	2	2	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3.875	1.5	4.571429	5	3.95		1	4.2	3.2857144	5	5.285714	2	-0.25	0.58928573	-3.5	-0.71428573	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH277HFT
2081	8976	NDAR_INVLH348NRN	1649			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	6	6	6	5	3	0	5	5	9	6	6	6	6	5	6	5	5	6	1	1	1	1	1	1	1	1	3	1	1	3	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	5.5	2.5	5.714286	5.5	5.25	1		5.25	5.5	2.5	5.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH348NRN
2081	8976	NDAR_INVLH348NRN	1649			M	1600	Visit6	6	Phase 2	170	0	0	0	0	0	0	1	6	6	6	6	6	6	6	3	0	3	3	9	5	6	4	6	5	6	3	6	6	1	1	1	2	1	1	1	1	2	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.625	1.5	5.428571	4.5	4.9			5.25	5.5	2.5	5.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH348NRN
2081	8976	NDAR_INVLH348NRN	1649			M	2800	Visit12	12	Phase 2	332	0	0	0	0	0	0	1	6	2	4	2	4	4	6	3	0	0	0	9	2	6	4	4	4	6	4	4	4	1	1	1	0	1	1	1	1	3	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.875	0	4	5	3.45			5.25	5.5	2.5	5.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH348NRN
2081	8976	NDAR_INVLH348NRN	1649			M	4000	Visit18	18	Phase 2	518	0	0	0	0	0	0	1	2	0	0	4	2	1	6	2	0	0	2	9	4	2	0	2	4	1	3	0	6	1	1	1	1	1	1	1	1	2	1	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	0.5	2.5714285	2	2.05			5.25	5.5	2.5	5.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH348NRN
2081	8976	NDAR_INVLH348NRN	1649			M	5200	EndofPhase1_1a	5	Phase 1/1A	135	0	0	0	0	0	0	1	6	6	6	6	6	6	6	3	0	3	3	9	5	6	4	6	5	6	3	5	6	1	1	1	1	1	1	1	1	3		1	4	3	3	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	5.625	1.5	5.285714	4.5	4.85		1	5.25	5.5	2.5	5.714286	5.5	-0.4	0.125	-1	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH348NRN
2081	8976	NDAR_INVLH411AZH	1571			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	1	0	0	6	6	0	4	4	5	4	6	6	5	6	6	6	6	6	6	6	5	2	6	6	1	0	1	1	1	1	1	1	1	1	1	3	3	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.375	5.75	6	3.5	5.095238	1		5.095238	4.375	5.75	6	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH411AZH
2081	8976	NDAR_INVLH411AZH	1571			M	5200	EndofPhase1_1a	3	Phase 1/1A	109	0	1	0	1	1	0	0	6	4	4	4	4	5	6	6	6	5	6	6	6	6	6	6	6	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	7	4.875	5.75	6	5	5.428571		1	5.095238	4.375	5.75	6	3.5	0.33333334	0.5	0	0	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH411AZH
2081	8976	NDAR_INVLH471MZY	1246			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	4	4	4	2	4	4	3	3	2	3	9	2	2	2	6	3	1	3	2	4	0	0	1	1	1	1	1	1	3	3	1	2	3	3	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.625	2	3	2	3.1	1		3.1	3.625	2	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLH471MZY
2081	8976	NDAR_INVLJ244MAY	2727			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	9	0	0	0	0	2	2	3	2	4	1	0	1	0	1	1	0	0	3		0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	4	0.25	0	1.1428572	2.5	0.75	1		0.75	0.25	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ244MAY
2081	8976	NDAR_INVLJ704BGG	2232			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	0	0	2	2	2	1	5	2	2	1	9	0	0	2	2	4	6	3	2	2	1	1	1	0	1	1	1	1	1	2	0	4	2	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.25	1.25	1.7142857	4.5	2.2	1		2.2	2.25	1.25	1.7142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ704BGG
2081	8976	NDAR_INVLJ704BGG	2232			F	1600	Visit6	6	Phase 2	176	0	1	0	1	0	0	0	6	0	0	2	2	2	2	4	2	1	0	9	0	0	3	1	4	5	3	2	2	1	1	1	0	1	1	1	1	1	2	0	4	3	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.25	0.75	1.7142857	4	2.05			2.2	2.25	1.25	1.7142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ704BGG
2081	8976	NDAR_INVLJ704BGG	2232			F	2800	Visit12	12	Phase 2	345	0	1	0	1	0	0	0	6	0	0	2	2	0	2	5	3	4	6	2	0	1	0	2	1	5	2	6	5	0	0	1	0	1	0	1	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2.125	3.75	2.142857	3.5	2.5714285			2.2	2.25	1.25	1.7142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ704BGG
2081	8976	NDAR_INVLJ704BGG	2232			F	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	1	0	1	0	0	0	6	0	0	2	2	2	1	5	2	2	1	9	0	0	2	2	4	5	2	2	2	1	0	1	0	1	1	1	1	1	2	0	4	2	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.25	1.25	1.7142857	3.5	2.1		1	2.2	2.25	1.25	1.7142857	4.5	-0.1	0	0	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ704BGG
2081	8976	NDAR_INVLJ704BGG	2232			F	5800	EndofPhase2	18	Phase 2	507	0	1	0	1	0	0	0	6	0	2	4	2	2	3	4	4	4	6	6	3	6	5	5	5	5	3	5	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.875	5	4.714286	4	4			2.2	2.25	1.25	1.7142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ704BGG
2081	8976	NDAR_INVLJ804HFZ	1823			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	3	0	1	0	2	0	3	0	0	0	0	9	0	0	0	1	0	2	3	2	1	1	1	0	0	1	1	0	0	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.125	0	0.5714286	2.5	0.9	1		0.9	1.125	0	0.5714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ804HFZ
2081	8976	NDAR_INVLJ804HFZ	1823			M	1600	Visit6	6	Phase 1/1A	167	1	0	1	0	0	0	0	4	0	1	2	2	3	2	1	5	3	3	2	6	5	5	4	2	5	4	4	3	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	3.25	4.142857	4.5	3.142857			0.9	1.125	0	0.5714286	2.5	2.2428572	0.75	3.25	3.5714285	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ804HFZ
2081	8976	NDAR_INVLJ804HFZ	1823			M	2800	Visit12	12	Phase 1/1A	335	1	0	1	0	0	0	0	5	0	1	2	2	2	2	2	3	3	2	5	4	4	1	5	2	4	3	2	4	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		1	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	4	2	3.25	3.142857	3.5	2.7619047			0.9	1.125	0	0.5714286	2.5	1.8619047	0.875	3.25	2.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ804HFZ
2081	8976	NDAR_INVLJ804HFZ	1823			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	1	0	1	0	0	0	0	6	0	0	2	2	2	3	1	4	4	6	6	3	4	6	4	4	4	3	4	4	1	1	1	0	1	1	0	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2	5	4.142857	3.5	3.4285715		1	0.9	1.125	0	0.5714286	2.5	2.5285714	0.875	5	3.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLJ804HFZ
2081	8976	NDAR_INVLK310ZV1	2171			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	0	0	0	0	3	0	0	0	0	9	1	0	2	3	0	3	3	3	5	0	1	0	1	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.5	0	2	3	1.2	1		1.2	0.5	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK310ZV1
2081	8976	NDAR_INVLK310ZV1	2171			M	1600	Visit6	6	Phase 2	177	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	9	0	1	2	3	2	3	2	4	4	1	1	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0.5	2.2857144	2.5	1.15			1.2	0.5	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK310ZV1
2081	8976	NDAR_INVLK310ZV1	2171			M	2800	Visit12	12	Phase 2	345	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	1	0	9	1	0	3	4	0	3	3	3	4	0	1	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.125	0.5	2.142857	3	1.2			1.2	0.5	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK310ZV1
2081	8976	NDAR_INVLK310ZV1	2171			M	4000	Visit18	18	Phase 2	512	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	9	1	3	3	4	2	3	2	4	4	1	1	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.125	0.25	3	2.5	1.4			1.2	0.5	0	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK310ZV1
2081	8976	NDAR_INVLK310ZV1	2171			M	5200	EndofPhase1_1a	2	Phase 1/1A	63	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0	1	0	0	9	0	0	2	3	1	4	2	4	5	0	1	0	0	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.25	0.25	2.142857	3	1.2		1	1.2	0.5	0	2	3	0	-0.25	0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK310ZV1
2081	8976	NDAR_INVLK368KRY	2708			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	5	4	4	5	4	4	1	3	2	1	2	2	3	4	2	4	6	6	4	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	2	3.4285715	6	3.6190476	1		3.6190476	4	2	3.4285715	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK368KRY
2081	8976	NDAR_INVLK409XVG	2862			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	3	3	1	4	3	4	1	1	1	1	9	3	3	3	2	3	0	2	4	3	2	2	1	2	1	1	1	1	1	2	1	4	1	3	4	1	0	0	0	1	0	0	0	1	1	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0.75	3	1	2.5	1		2.5	3	0.75	3	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK409XVG
2081	8976	NDAR_INVLK409XVG	2862			M	1600	Visit6	6	Phase 1B	200	0	0	0	0	1	0	0	5	2	2	3	4	2	3	1	3	1	2	9	2	2	4	2	2	2	3	4	4	1	1	0	0	1	1	1	1	1	3	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	23	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.75	1.5	2.857143	2.5	2.65			2.5	3	0.75	3	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK409XVG
2081	8976	NDAR_INVLK409XVG	2862			M	5200	EndofPhase1_1a	3	Phase 1/1A	92	1	0	0	0	0	0	0	4	4	1	1	4	1	2	1	1	2	2	9	2	1	3	2	2	1	3	4	3	0	0	0	0	1	1	2	1	2	3	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	2.25	1.25	2.4285715	2	2.2		1	2.5	3	0.75	3	1	-0.3	-0.75	0.5	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK409XVG
2081	8976	NDAR_INVLK409XVG	2862			M	5400	EndofPhase1b	8	Phase 1B	271	1	0	0	0	0	0	0	4	3	3	4	3	2	4	1	1	1	1	9	3	2	4	3	5	1	3	3	4	0	0	0	0	1	0	0	1	1	3	1	3	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	25	0		0		1	5	0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	4	3	0.75	3.4285715	2	2.75			2.5	3	0.75	3	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK409XVG
2081	8976	NDAR_INVLK667RA5	1016			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	3	3	2	2	3	2	4	4	2	3	2	6	3	5	6	4	5	6	6	1	1	1	0	1	1	1	1	2	2	1	3	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	4	2.5714285	3.25	4.857143	4.5	3.7	1		3.7	2.5714285	3.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK667RA5
2081	8976	NDAR_INVLK667RA5	1016			M	1600	Visit6	6	Phase 3	186	0	0	0	0	0	0	1	4	3	4	3	3	4	4	3	2	2	2	9	3	4	4	4	2	4	3	4	4	1	1	1	0	1	1	1	1	3	1	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	0	4	3.5	1.5	3.5714285	3.5	3.3			3.7	2.5714285	3.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK667RA5
2081	8976	NDAR_INVLK667RA5	1016			M	2800	Visit12	12	Phase 3	425	0	0	0	0	0	0	1	2	6	1	2	4	0	6	6	1	0	2	9	3	2	2	4	4	4	4	6	6	1	1	1	0	1	1	1	1	3	2	1	2	1	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	4	3.375	0.75	3.857143	4	3.25			3.7	2.5714285	3.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK667RA5
2081	8976	NDAR_INVLK667RA5	1016			M	5200	EndofPhase1_1a	1	Phase 1/1A	27	0	0	0	0	0	0	1	9	2	4	1	1	1	1	1	2	2	2	9	2	5	2	2	2	4	3	3	4	1	1	1	2	1	1	1	1	3		0			4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	1	4	1.5714285	1.5	2.857143	3.5	2.3157895		1	3.7	2.5714285	3.25	4.857143	4.5	-1.3842105	-1	-1.75	-2	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK667RA5
2081	8976	NDAR_INVLK667RA5	1016			M	5800	EndofPhase2	2	Phase 2	56	0	0	0	0	0	0	1	9	3	4	4	4	4	4	3	1	2	2	9	3	4	3	4	2	4	3	4	5	1	1	1	1	1	1	1	1	3	3	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	0	4	3.7142856	1.25	3.5714285	3.5	3.3157895			3.7	2.5714285	3.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK667RA5
2081	8976	NDAR_INVLK667RA5	1016			M	6000	EndofPhase3	16	Phase 3	564	0	0	0	0	0	0	1	5	4	4	3	4	3	4	5	1	3	4	9	3	4	4	4	4	5	5	4	5	1	1	1	2	1	1	1	1	2	2	1	2	2	2	1	1	1	0	0	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	4	4	2	4	5	3.9			3.7	2.5714285	3.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK667RA5
2081	8976	NDAR_INVLK707KDG	2105			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	0	2	0	0	0	0	0	0	9	0	0	0	0	0	4	1	5	5	0	2	2	0	0	0	1	1	3	1	1	4	3	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	5	1	25	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	0.75	0	1.4285715	2.5	1.05	1		1.05	0.75	0	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK707KDG
2081	8976	NDAR_INVLK707KDG	2105			F	1600	Visit6	6	Phase 2	164	0	0	0	0	0	1	0	6	1	4	4	2	0	2	2	0	0	0	9	1	0	2	2	4	3	1	4	2	1	1	2	1	0	1	1	2	3	1	1	4	1	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	0	2.142857	2	2			1.05	0.75	0	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK707KDG
2081	8976	NDAR_INVLK707KDG	2105			F	2800	Visit12	12	Phase 2	333	0	0	0	0	0	1	0	4	4	3	2	2	0	2	4	0	0	0	9	2	0	0	4	2	4	2	4	4	2	1	2	1	0	1	1	1	3	1	1	4	3	3	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.625	0	2.2857144	3	2.15			1.05	0.75	0	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK707KDG
2081	8976	NDAR_INVLK707KDG	2105			F	5200	EndofPhase1_1a	3	Phase 1/1A	65	0	0	0	0	0	1	0	5	0	2	2	2	1	3	2	0	0	0	9	2	2	0	2	0	4	2	4	3	2	2	2	0	1	0	1	0	3	1	1	4	4	4	1	1	0	1	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2.125	0	1.8571428	3	1.8		1	1.05	0.75	0	1.4285715	2.5	0.75	1.375	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK707KDG
2081	8976	NDAR_INVLK707KDG	2105			F	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	0	1	0	6	2	1	2	2	2	2	2	0	0	0	9	1	2	0	2	2	4	2	4	4	1	0	1	1	0	1	1	1	2	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	2	2	0		1	27	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	2	2.375	0	2.142857	3	2			1.05	0.75	0	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLK707KDG
2081	8976	NDAR_INVLL215JLR	2732			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	4	3	1	3	0	2	0	2	2	3	9	4	3	2	2	1	2	1	4	3	0	0	0	0	1	0	0	0	2	2	0	4	3	3	4	1	0	0	0	0	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	3	2.125	1.75	2.7142856	1.5	2.3	1		2.3	2.125	1.75	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL215JLR
2081	8976	NDAR_INVLL215JLR	2732			M	1600	Visit6	6	Phase 2	167	0	0	0	0	0	1	0	2	1	1	2	2	1	2	2	2	2	2	9	2	2	2	2	1	1	1	4	2	0	0	0	0	0	0	0	0	3		0	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	1.625	1.5	2.142857	1	1.8			2.3	2.125	1.75	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL215JLR
2081	8976	NDAR_INVLL215JLR	2732			M	2800	Visit12	12	Phase 2	341	0	0	0	0	0	1	0	1	1	1	2	2	2	1	2	3	2	4	3	4	2	2	2	2	2	1	2	3	0	0	0	0	0	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	1.5	3	2.4285715	1.5	2.0952382			2.3	2.125	1.75	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL215JLR
2081	8976	NDAR_INVLL215JLR	2732			M	5200	EndofPhase1_1a	2	Phase 1/1A	53	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	9	1	1	1	2	0	1	1	2	3	0	0	0	0	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	1	1	1	0	0	0	3	0	1	1.4285715	1	0.8		1	2.3	2.125	1.75	2.7142856	1.5	-1.5	-2.125	-0.75	-1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL215JLR
2081	8976	NDAR_INVLL215JLR	2732			M	5800	EndofPhase2	18	Phase 2	509	0	0	0	0	0	0	1	4	3	2	2	2	2	2	2	4	4	5	4	4	3	2	4	3	3	2	4	4	1	0	1	0	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	1	1	1	0	4	2.375	4.25	3.4285715	2.5	3.0952382			2.3	2.125	1.75	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL215JLR
2081	8976	NDAR_INVLL288KNC	2042			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	4	2	2	2	2	2	1	2	2	9	2	2	4	2	2	4	2	4	4	0	1	0	0	1	0	1	1	1	2	1	3	1	4	4	1	0	1	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.75	1.25	2.857143	3	2.65	1		2.65	2.75	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL288KNC
2081	8976	NDAR_INVLL288KNC	2042			M	1600	Visit6	6	Phase 1B	175	1	0	0	0	0	0	0	0	2	3	4	3	0	6	1	0	0	6	9	0	0	2	2	1	6	4	4	4	1	1	1	1	1	0	2	1	1	2	1	3	1	2	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	2.375	1.5	1.8571428	5	2.4			2.65	2.75	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL288KNC
2081	8976	NDAR_INVLL288KNC	2042			M	2800	Visit12	12	Phase 1B	335	1	0	0	0	0	0	0	2	1	2	2	2	3	6	3	0	0	0	9	2	2	2	4	2	5	3	3	4	0	0	1	0	1	0	0	1	1	2	1	3	2	4	3	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	1	2	2.625	0	2.7142856	4	2.4			2.65	2.75	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL288KNC
2081	8976	NDAR_INVLL288KNC	2042			M	5200	EndofPhase1_1a	4	Phase 1/1A	102	1	0	0	0	0	0	0	4	0	2	4	1	0	4	2	0	0	0	9	0	0	0	2	2	6	2	4	4	1	1	1	0	1	1	2	2	3	3	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2.125	0	1.7142857	4	1.85		1	2.65	2.75	1.25	2.857143	3	-0.8	-0.625	-1.25	-1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL288KNC
2081	8976	NDAR_INVLL288KNC	2042			M	5400	EndofPhase1b	18	Phase 1B	503	0	1	0	0	0	0	0	6	2	4	4	4	6	6	2	0	0	0	9	1	1	0	4	2	4	2	4	4	0	1	1	0	1	0	1	0	3	3	1	2	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	4.25	0	2.2857144	3	2.8			2.65	2.75	1.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL288KNC
2081	8976	NDAR_INVLL614WJ7	1500			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	3	4	6	6	6	6	4	2	5	3	9	3	4	2	5	4	5	5	5	5	1	1	1	1	0	1	1	1	3	3	1	3	2	2	1	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	3	4.75	2.5	4	5	4.3	1		4.3	4.75	2.5	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL614WJ7
2081	8976	NDAR_INVLL765HV9	1505			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	0	2	2	2	0	3	3	4	4	3	2	2	3	4	6	2	6	4	1	0	1	0	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	5	0.85714287	3.5	3.4285715	4	2.6	1		2.6	0.85714287	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL765HV9
2081	8976	NDAR_INVLL765HV9	1505			M	1600	Visit6	6	Phase 2	170	0	0	0	0	0	0	1	9	0	2	0	2	2	2	0	4	4	6	6	0	3	0	3	6	6	4	4	4	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.1428572	5	2.857143	5	2.9			2.6	0.85714287	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL765HV9
2081	8976	NDAR_INVLL765HV9	1505			M	2800	Visit12	12	Phase 2	330	0	0	0	0	0	0	1	9	1	2	2	2	2	2	1	4	4	6	6	0	2	0	2	4	6	2	1	2	1	0	1	0	1	1	0	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	1.7142857	5	1.5714285	4	2.55			2.6	0.85714287	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL765HV9
2081	8976	NDAR_INVLL765HV9	1505			M	4000	Visit18	18	Phase 2	497	0	0	0	0	0	0	1	5	0	0	2	2	2	2	1	4	4	6	5	2	2	4	2	4	6	2	4	4	1	0	1	0	1	1	0	1	2	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	1.75	4.75	3.142857	4	3			2.6	0.85714287	3.5	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL765HV9
2081	8976	NDAR_INVLL765HV9	1505			M	5200	EndofPhase1_1a	0	Phase 1/1A	8	0	0	0	0	0	0	1	9	0	0	0	2	2	2	0	3	3	4	4	3	2	2	3	4	6	3	6	4	1	0	1	0	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	0.85714287	3.5	3.4285715	4.5	2.65		1	2.6	0.85714287	3.5	3.4285715	4	0.05	0	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL765HV9
2081	8976	NDAR_INVLL816KXF	2026			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	6	6	6	6	6	0	0	5	5	9	2	6	4	6	3	6	3	6	6	1	0	1	0	1	1	1	1	2	1	1	2	2	2	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5	2.5	4.714286	4.5	4.6	1		4.6	5	2.5	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL816KXF
2081	8976	NDAR_INVLL816KXF	2026			F	1600	Visit6	6	Phase 1/1A	192	0	0	0	0	0	0	1	6	6	6	6	6	6	6	0	0	4	5	9	6	6	6	6	6	6	4	6	6	1	0	1	0	1	1	1	1	3	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.25	2.25	6	5	5.15			4.6	5	2.5	4.714286	4.5	0.55	0.25	-0.25	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL816KXF
2081	8976	NDAR_INVLL816KXF	2026			F	2800	Visit12	12	Phase 1/1A	373	0	0	0	0	0	0	1	9	4	5	4	4	3	6	0	0	1	1	9	3	3	3	6	3	5	4	5	5	1	1	1	0	1	1	1	1	3	1	1	4	3	3	4	1	0	0	1	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.7142856	0.5	4	4.5	3.4210527			4.6	5	2.5	4.714286	4.5	-1.1789473	-1.2857143	-2	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL816KXF
2081	8976	NDAR_INVLL816KXF	2026			F	5200	EndofPhase1_1a	18	Phase 1/1A	555	0	0	0	0	0	0	1	9	3	4	5	4	3	5	3	0	4	1	9	3	6	4	6	6	6	3	5	5	0	0	1	0	1	1	1	1	3	1	1	3	2	3	4	1	0	0	1	1	1	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	3.857143	1.25	5	4.5	4		1	4.6	5	2.5	4.714286	4.5	-0.6	-1.1428572	-1.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL816KXF
2081	8976	NDAR_INVLL921FKT	1064			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	1	1	3	5	3	3	5	0	0	0	9	3	4	5	3	3	4	2	4	5	1	0	1	1	2	1	2	1	2	1	1	3	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	3.375	0	3.857143	3	3	1		3	3.375	0	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL921FKT
2081	8976	NDAR_INVLL921FKT	1064			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	6	2	4	4	4	3	4	4	2	0	0	9	0	0	2	3	0	4	1	2	3	0	0	0	0	1	1	1	0	1	1	0	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.875	0.5	1.4285715	2.5	2.4			3	3.375	0	3.857143	3	-0.6	0.5	0.5	-2.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL921FKT
2081	8976	NDAR_INVLL921FKT	1064			M	2800	Visit12	12	Phase 1/1A	338	0	1	0	0	0	0	0	5	1	2	1	4	2	2	4	0	1	2	9	5	4	0	3	1	5	2	4	5	1	1	1	0	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	0.75	3.142857	3.5	2.65		1	3	3.375	0	3.857143	3	-0.35	-0.75	0.75	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLL921FKT
2081	8976	NDAR_INVLM190MXJ	1762			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	4	4	5	4	4	2	0	4	4	9	2	4	0	4	0	3	5	3	4	1	1	0	0	1	1	1	1	3		1	2	2	2	4	1	0	0	1	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	4.375	2	2.4285715	4	3.4	1		3.4	4.375	2	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLM190MXJ
2081	8976	NDAR_INVLM190MXJ	1762			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	6	6	5	4	4	4	3	0	4	6	9	2	4	0	4	4	4	3	4	6	1	1	1	1	1	1	1	0	3		1	2	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	4	4.75	2.5	3.4285715	3.5	3.95			3.4	4.375	2	2.4285715	4	0.55	0.375	0.5	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLM190MXJ
2081	8976	NDAR_INVLM190MXJ	1762			M	2800	Visit12	12	Phase 1/1A	367	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	2	2	2	2	1	1	1	1	1	2	1	4	4	1	1	1	0	0	0	0	0	0	1	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0.5	0	0	0.0952381			3.4	4.375	2	2.4285715	4	-3.304762	-4.375	-1.5	-2.4285715	-4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLM190MXJ
2081	8976	NDAR_INVLM190MXJ	1762			M	4000	Visit18	18	Phase 1/1A	540	0	0	0	0	0	1	0	0	2	2	1	1	1	1	0	1	1	0	0	1	1	1	1	0	1	1	2	1	0	0	1	0	1	1	1	0	1	2	1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0.5	1	1	0.9047619		1	3.4	4.375	2	2.4285715	4	-2.495238	-3.375	-1.5	-1.4285715	-3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLM190MXJ
2081	8976	NDAR_INVLM361KWN	1494			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	5	4	4	4	4	5	2	2	0	9	2	3	4	4	4	4	2	5	4	0	0	1	0	1	1	2	1	1	1	1	3	2	3	2	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	4.75	1	3.7142856	3	3.7	1		3.7	4.75	1	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLM361KWN
2081	8976	NDAR_INVLM361KWN	1494			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	6	4	4	3	5	3	2	2	4	2	2	4	3	4	5	0	1	4	2	0	5	1	0	1	0	1	1	2	1	1	1	1	3	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	6	3.625	3	2.5714285	3	3.0952382		1	3.7	4.75	1	3.7142856	3	-0.6047619	-1.125	2	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLM361KWN
2081	8976	NDAR_INVLN140DEQ	2407			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	0	2	2	0	4	4	0	0	2	9	2	4	0	6	2	4	5	4	0	1	1	1	1	1	1	1	1	3	2	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.5	0.5	2.5714285	4.5	2.45	1		2.45	2.5	0.5	2.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN140DEQ
2081	8976	NDAR_INVLN538UKX	1389			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	1	0	4	5	4	6	2	0	0	4	9	2	2	2	6	1	5	3	4	5	1	1	1	1	1	1	0	1	1	1	0	4	2	4	4	1	0	0	1	1	0	0	0	1	1	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.5	1	3.142857	4	3.1	1		3.1	3.5	1	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN538UKX
2081	8976	NDAR_INVLN538UKX	1389			M	1600	Visit6	6	Phase 1B	134	1	0	0	0	0	0	0	4	2	1	2	2	2	4	1	0	2	6	9	2	2	3	3	4	3	3	5	5	1	1	0	0	1	0	0	1	3	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	2	3.4285715	3	2.8			3.1	3.5	1	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN538UKX
2081	8976	NDAR_INVLN538UKX	1389			M	2800	Visit12	12	Phase 1B	299	1	0	0	0	0	0	0	5	4	4	4	4	4	5	2	1	1	2	6	2	2	2	3	2	3	3	6	4	1	1	1	2	1	1	1	1	1	1	1	4	2	3	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	2.5	3	3	3.2857144			3.1	3.5	1	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN538UKX
2081	8976	NDAR_INVLN538UKX	1389			M	5400	EndofPhase1b	18	Phase 1B	477	0	0	0	0	0	0	0	6	4	4	2	2	2	4	4	4	4	4	6	2	3	4	4	2	3	4	5	5	1	1	1	1	1	1	1	1	2	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.5	4.5	3.5714285	3.5	3.7142856			3.1	3.5	1	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN538UKX
2081	8976	NDAR_INVLN961YU6	2147			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	1	0	1	2	0	2	0	0	0	1	9	1	1	0	6	6	1	2	1	3	1	1	2	1	1	1	1	1	2	1	1	3	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0.25	2.5714285	1.5	1.5	1		1.5	1	0.25	2.5714285	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN961YU6
2081	8976	NDAR_INVLN961YU6	2147			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	6	4	4	4	0	0	6	0	0	0	5	9	0	2	2	6	4	1	2	2	3	1	1	1	0	1	1	1	1	3	1	1	2	2	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	1.25	2.7142856	1.5	2.55			1.5	1	0.25	2.5714285	1.5	1.05	2	1	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN961YU6
2081	8976	NDAR_INVLN961YU6	2147			M	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	0	1	5	4	4	2	2	0	6	1	1	1	6	9	0	1	0	6	3	1	2	1	1	1	1	1	0	1	1	1	1	3	1	1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3	2	1.7142857	1.5	2.35			1.5	1	0.25	2.5714285	1.5	0.85	2	1.75	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN961YU6
2081	8976	NDAR_INVLN961YU6	2147			M	5200	EndofPhase1_1a	18	Phase 1/1A	511	0	0	0	0	0	0	1	4	0	2	2	2	2	6	0	2	4	6	9	2	2	0	6	5	1	1	4	4	0	1	1	0	1	1	1	1	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.25	3	3.2857144	1	2.75		1	1.5	1	0.25	2.5714285	1.5	1.25	1.25	2.75	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLN961YU6
2081	8976	NDAR_INVLP321TBN	1485			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	1	2	5	0	1	0	2	1	2	9	3	4	3	6	6	6	3	6	6	1	1	1	1	1	0	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.375	1.25	4.857143	4.5	3.35	1		3.35	2.375	1.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLP321TBN
2081	8976	NDAR_INVLP321TBN	1485			M	1600	Visit6	6	Phase 1/1A	214	1	0	0	0	0	0	0	6	6	3	4	4	1	2	5	6	4	5	6	4	4	5	5	3	5	4	4	6	1	0	1	1	1	1	1	0	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.875	5.25	4.428571	4.5	4.3809524		1	3.35	2.375	1.25	4.857143	4.5	1.0309523	1.5	4	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLP321TBN
2081	8976	NDAR_INVLP321TBN	1485			M	4000	Visit18	18	Phase 2	477	1	0	0	0	0	0	0	6	6	4	6	5	6	4	1	4	3	4	1	4	6	2	4	6	5	5	6	5	1	1	1	1	1	0	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	2	4.75	3	4.714286	5	4.428571			3.35	2.375	1.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLP321TBN
2081	8976	NDAR_INVLP321TBN	1485			M	5800	EndofPhase2	23	Phase 2	620	1	0	0	0	0	0	0	6	6	4	6	5	6	4	1	4	3	4	1	4	6	2	4	6	5	5	6	5	1	1	1	1	1	0	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2	4.75	3	4.714286	5	4.428571			3.35	2.375	1.25	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLP321TBN
2081	8976	NDAR_INVLR186ZGE	1819			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	4	4	4	3	4	1	0	1	0	9	3	3	2	4	4	3	2	5	5	1	2	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	0	0	1	0	0	0	2	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	0.25	3.7142856	2.5	3.05	1		3.05	3.625	0.25	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR186ZGE
2081	8976	NDAR_INVLR186ZGE	1819			M	5200	EndofPhase1_1a	0	Phase 1/1A	7	1	0	0	0	0	0	0	6	3	3	2	2	2	3	3	0	2	2	9	2	2	2	3	2	2	2	3	3	2	2	1	2	1	1	0	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	1	2.4285715	2	2.45		1	3.05	3.625	0.25	3.7142856	2.5	-0.6	-0.625	0.75	-1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR186ZGE
2081	8976	NDAR_INVLR186ZGE	1819			M	5800	EndofPhase2	6	Phase 2	168	1	0	0	0	0	0	0	6	6	6	6	5	2	3	2	0	1	1	9	2	1	2	4	0	2	0	2	2	0	0	0	0	1	1	0	1	2	2	1	3	2	2	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4.5	0.5	1.8571428	1	2.65			3.05	3.625	0.25	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR186ZGE
2081	8976	NDAR_INVLR341AGJ	1153			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	0	0	1	2	0	2	4	0	0	1	9	3	1	3	3	1	4	3	4	6	0	0	1	1	1	1	1	0	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	1.875	0.25	3	3.5	2.2	1		2.2	1.875	0.25	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR341AGJ
2081	8976	NDAR_INVLR341AGJ	1153			M	1600	Visit6	6	Phase 2	169	0	1	0	0	0	0	0	6	1	4	2	4	2	5	4	2	2	1	9	2	3	3	5	3	5	2	4	5	1	0	1	1	1	1	2	1	1	1	1	2	2	3	1	1	1	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	3.5	1.25	3.5714285	3.5	3.25			2.2	1.875	0.25	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR341AGJ
2081	8976	NDAR_INVLR341AGJ	1153			M	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	5	2	2	1	6	2	1	5	1	1	1	9	1	4	2	5	2	3	3	3	5	0	0	1	1	1	1	0	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0.75	3.142857	3	2.75			2.2	1.875	0.25	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR341AGJ
2081	8976	NDAR_INVLR341AGJ	1153			M	5200	EndofPhase1_1a	3	Phase 1/1A	92	0	1	0	1	0	0	0	5	0	2	1	5	0	1	4	0	0	1	9	2	2	2	4	1	5	2	4	5	1	0	1	1	1	0	2	0	1	2	1	2	1	1	1	1	1	0	0	0	0	0	0	1	1	1	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	0.25	2.857143	3.5	2.3		1	2.2	1.875	0.25	3	3.5	0.1	0.375	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR341AGJ
2081	8976	NDAR_INVLR359HJE	2621			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	4	4	5	5	5	2	3	1	4	2	9	1	2	4	5	5	3	4	6	6	1	1	1	1	1	1	1	1	1	2	1	3	3	3	4	1	0	0	1	0	0	0	0	0	1	0	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	4	4.25	1.75	4.142857	3.5	3.85	1		3.85	4.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR359HJE
2081	8976	NDAR_INVLR359HJE	2621			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	2	5	0	4	4	4	6	2	2	4	4	3	2	4	5	4	6	2	3	5	6	1	0	0	0	1	1	1	0	3	2	1	3	1	1	4	1	0	0	1	0	0	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5	3.375	3.25	4.571429	2.5	3.6666667			3.85	4.25	1.75	4.142857	3.5	-0.18333334	-0.875	1.5	0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR359HJE
2081	8976	NDAR_INVLR359HJE	2621			M	2800	Visit12	12	Phase 3	288	0	0	0	0	0	1	0	4	0	2	4	5	2	4	2	0	0	0	9	2	4	5	5	3	2	5	4	4	0	0	0	0	1	1	1	1	2	2	1	3	2	2	4	1	0	0	1	0	0	0	0	1	1	1	1	1	14	0		0		1	14	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	0	3.857143	3.5	2.85			3.85	4.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR359HJE
2081	8976	NDAR_INVLR359HJE	2621			M	5200	EndofPhase1_1a	8	Phase 1/1A	204	0	0	0	0	0	1	0	6	5	5	5	3	3	4	3	2	6	4	6	4	6	6	5	4	3	3	6	6	1	1	1	0	1	1	1	1	3	2	1	4	3	4	3	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.25	4.5	5.285714	3	4.5238094		1	3.85	4.25	1.75	4.142857	3.5	0.6738095	0	2.75	1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR359HJE
2081	8976	NDAR_INVLR359HJE	2621			M	5800	EndofPhase2	9	Phase 2	212	0	0	0	0	0	1	0	6	5	5	5	3	3	4	3	2	6	4	9	4	6	6	5	4	3	3	6	6	1	1	1	0	1	1	1	1	3	2	1	4	3	4	3	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.25	3	5.285714	3	4.45			3.85	4.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR359HJE
2081	8976	NDAR_INVLR359HJE	2621			M	6000	EndofPhase3	18	Phase 3	441	0	0	0	0	0	1	0	5	2	0	2	4	2	6	2	0	0	0	9	2	6	4	3	0	2	1	4	4	1	0	0	0	1	1	0	1	3		1	2	1	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.875	0	3.2857144	1.5	2.45			3.85	4.25	1.75	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR359HJE
2081	8976	NDAR_INVLR806ZAL	1630			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	5	0	4	3	4	1	2	5	3	9	2	2	1	2	2	4	1	4	4	1	0	1	0	1	1	1	1	3	3	1	4	1	4	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	3	2.125	2.5	2.4285715	2.5	2.45	1		2.45	2.125	2.5	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR806ZAL
2081	8976	NDAR_INVLR806ZAL	1630			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	0	0	2	1	2	2	5	2	4	3	5	6	1	2	0	2	3	5	3	2	5	1	1	1	1	1	1	1	1	3		0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	0	1	1	30	0		0		0		0		2	2	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	4.5	2.142857	4	2.6190476			2.45	2.125	2.5	2.4285715	2.5	0.16904762	-0.375	2	-0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR806ZAL
2081	8976	NDAR_INVLR806ZAL	1630			M	2800	Visit12	12	Phase 1/1A	350	0	0	0	0	0	0	1	1	5	1	1	4	2	1	1	0	1	1	9	2	2	2	2	5	4	2	4	5	0	0	1	0	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2	0.5	3.142857	3	2.3			2.45	2.125	2.5	2.4285715	2.5	-0.15	-0.125	-2	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR806ZAL
2081	8976	NDAR_INVLR806ZAL	1630			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	0	1	1	2	3	4	1	3	3	0	0	1	3	9	2	2	1	2	4	5	3	4	5	1	0	0	0	1	0	1	1	3		0	4	2	4	4	1	0	0	0	0	0	1	0	0	0	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	4	2.125	1	2.857143	4	2.45		1	2.45	2.125	2.5	2.4285715	2.5	0	0	-1.5	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLR806ZAL
2081	8976	NDAR_INVLT848KRW	1714			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	4	0	0	0	0	1	0	0	0	5	9	0	1	1	2	0	2	4	4	2	1	1	0	0	1	1	0	1	1	1	1	3	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	4	0.75	1.25	1.4285715	3	1.35	1		1.35	0.75	1.25	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLT848KRW
2081	8976	NDAR_INVLT848KRW	1714			F	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	6	4	0	0	2	0	2	0	6	4	6	5	2	6	0	4	3	5	5	5	6	1	1	1	1	1	1	1	1	1	2	1	3	2	4	2	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	1.75	5.25	3.7142856	5	3.3809524			1.35	0.75	1.25	1.4285715	3	2.0309525	1	4	2.2857144	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLT848KRW
2081	8976	NDAR_INVLT848KRW	1714			F	2800	Visit12	12	Phase 1/1A	350	1	0	0	0	0	0	0	5	2	2	0	2	2	4	4	2	4	4	9	3	6	0	6	4	5	5	2	4	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	1	1	1	1	1	1	5	2.625	2.5	3.5714285	5	3.3			1.35	0.75	1.25	1.4285715	3	1.95	1.875	1.25	2.142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLT848KRW
2081	8976	NDAR_INVLT848KRW	1714			F	5200	EndofPhase1_1a	18	Phase 1/1A	540	1	0	0	0	0	0	0	6	4	0	4	6	4	6	6	2	4	4	9	3	4	4	5	6	5	4	6	6	1	1	1	1	1	1	1	1	2	1	1	4	2	2	2	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	1	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.5	2.5	4.857143	4.5	4.45		1	1.35	0.75	1.25	1.4285715	3	3.1	3.75	1.25	3.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLT848KRW
2081	8976	NDAR_INVLU090ZX3	2161			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	4	2	4	4	6	1	2	3	3	9	0	4	2	4	4	5	5	2	2	1	1	0	0	1	0	0	1	3		1	2	3	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3.625	2	2.5714285	5	3.25	1		3.25	3.625	2	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU090ZX3
2081	8976	NDAR_INVLU090ZX3	2161			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	1	0	6	4	4	2	3	3	3	1	2	4	4	9	0	4	3	4	1	5	3	4	3	1	1	0	1	1	0	0	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.25	2.5	2.7142856	4	3.15			3.25	3.625	2	2.5714285	5	-0.1	-0.375	0.5	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU090ZX3
2081	8976	NDAR_INVLU090ZX3	2161			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	1	0	4	3	3	2	2	3	3	0	2	4	4	9	0	4	2	4	5	4	3	4	3	1	1	2	0	1	0	0	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.5	2.5	3.142857	3.5	2.95			3.25	3.625	2	2.5714285	5	-0.3	-1.125	0.5	0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU090ZX3
2081	8976	NDAR_INVLU090ZX3	2161			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	1	0	2	2	4	2	2	2	2	1	2	2	4	9	0	2	2	4	2	5	2	4	4	1	1	1	0	1	0	0	0	3		1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	2	2.5714285	3.5	2.5		1	3.25	3.625	2	2.5714285	5	-0.75	-1.5	0	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU090ZX3
2081	8976	NDAR_INVLU137ERT	1328			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	1	2	2	5	2	1	0	0	9	2	2	3	4	1	1	1	3	2	2	2	2	2	1	1	0	2	2	1	1	4	4	4	2	1	0	0	1	0	0	0	0	0	0	0	0	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2	0.25	2.4285715	1	1.8	1		1.8	2	0.25	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU137ERT
2081	8976	NDAR_INVLU137ERT	1328			M	1600	Visit6	6	Phase 2	168	0	0	0	0	0	1	0	1	0	0	1	2	0	2	2	0	0	0	9	1	1	6	3	2	1	3	2	2	0	0	0	0	1	1	1	0	3	1	1	2	2	2	1	1	0	0	0	0	0	1	0	1	2	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1	0	2.4285715	2	1.45			1.8	2	0.25	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU137ERT
2081	8976	NDAR_INVLU137ERT	1328			M	2800	Visit12	12	Phase 2	334	0	0	0	0	0	1	0	0	0	0	2	2	0	0	2	0	0	0	9	2	0	4	2	3	1	1	3	3	2	2	2	1	1	0	0	2	2	1	0	4	1	4	1	0	0	0	0	0	0	0	0					0		0		0		1	25	0		2	0	2	0	0	0	0	0	0	0	0	0	1	1	1	0	4	0.75	0	2.4285715	1	1.25			1.8	2	0.25	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU137ERT
2081	8976	NDAR_INVLU137ERT	1328			M	5200	EndofPhase1_1a	3	Phase 1/1A	89	0	0	0	0	0	1	0	2	0	1	1	2	1	2	2	0	2	5	9	2	2	4	4	1	2	0	4	2	2	2	2	2	0	1	2	2	3	1	1	2	3	4	4	1	0	0	1	0	0	0	0	2	0	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.375	1.75	2.7142856	1	1.95		1	1.8	2	0.25	2.4285715	1	0.15	-0.625	1.5	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU137ERT
2081	8976	NDAR_INVLU137ERT	1328			M	5800	EndofPhase2	18	Phase 2	504	0	0	0	0	0	1	0	1	1	1	2	2	2	6	2	0	0	0	9	2	2	4	4	3	3	3	1	1	2	2	2	1	0	1	2	2	3		1	2	4	3	2	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	1	0	0	1	0	0	1	0	1	0	6	2.125	0	2.4285715	3	2			1.8	2	0.25	2.4285715	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU137ERT
2081	8976	NDAR_INVLU425AN3	2876			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	2	2	2	2	2	2	1	2	3	3	4	2	2	3	2	1	4	2	2	4	1	1	1	1	1	0	1	0	1	1	1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	2.375	3	2.2857144	3	2.5238094	1		2.5238094	2.375	3	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU425AN3
2081	8976	NDAR_INVLU425AN3	2876			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	0	1	6	2	2	2	2	2	3	1	2	4	3	4	2	2	3	2	2	4	5	2	4	1	1	0	0	1	0	1	0	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	3.25	2.4285715	4.5	2.8095238		1	2.5238094	2.375	3	2.2857144	3	0.2857143	0.125	0.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU425AN3
2081	8976	NDAR_INVLU534TP0	2553			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	6	6	6	6	6	6	6	6	5	5	9	6	6	6	6	6	4	6	6	6	1	0	1	1	1	1	1	1	1	2	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	6	4	6	5	5.8	1		5.8	6	4	6	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU534TP0
2081	8976	NDAR_INVLU534TP0	2553			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	6	6	5	9	6	6	6	6	6	5	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	1	1	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	6	4.25	6	5.5	5.9			5.8	6	4	6	5	0.1	0	0.25	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU534TP0
2081	8976	NDAR_INVLU534TP0	2553			F	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	6	4	5	9	4	4	5	6	6	5	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	6	3.75	5.285714	5.5	5.55			5.8	6	4	6	5	-0.25	0	-0.25	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU534TP0
2081	8976	NDAR_INVLU534TP0	2553			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	6	6	6	6	6	6	6	4	5	5	4	9	3	5	4	6	5	4	5	6	6	1	1	1	1	1	1	1	1	1	1	1	2	1	1	4	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.75	3.5	5	4.5	5.2		1	5.8	6	4	6	5	-0.6	-0.25	-0.5	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU534TP0
2081	8976	NDAR_INVLU800FDD	2664			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	2	1	3	1	2	3	0	0	1	9	1	2	2	2	1	3	2	2	3	0	0	0	0	1	2	1	2	3		1	3	2	2	2	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.75	0.25	1.8571428	2.5	1.65	1		1.65	1.75	0.25	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU800FDD
2081	8976	NDAR_INVLU800FDD	2664			F	5200	EndofPhase1_1a	1	Phase 1/1A	37	0	0	0	0	0	1	0	0	2	2	1	3	1	2	3	0	0	1	9	1	2	2	1	1	2	2	2	3	0	0	0	0	1	1	2	2	3		1	3	2	2	2	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.75	0.25	1.7142857	2	1.55		1	1.65	1.75	0.25	1.8571428	2.5	-0.1	0	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU800FDD
2081	8976	NDAR_INVLU883HM0	2414			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	5	4	2	5	5	4	4	6	5	5	3	6	3	5	6	5	5	6	6	1	1	1	1	1	1	1	1	3	1	1	3	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	1	1	0	0	1	1	1	1	7	4.25	5	5	5	4.714286	1		4.714286	4.25	5	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU883HM0
2081	8976	NDAR_INVLU883HM0	2414			M	5200	EndofPhase1_1a	3	Phase 1/1A	81	0	1	0	0	0	0	0	4	0	3	4	1	3	4	4	4	4	6	3	4	5	2	5	6	5	4	5	5	1	1	1	1	1	1	1	1	3		0	4	3	1	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	1	1	0	0	1	1	1	1	6	2.875	4.25	4.571429	4.5	3.857143		1	4.714286	4.25	5	5	5	-0.85714287	-1.375	-0.75	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU883HM0
2081	8976	NDAR_INVLU883HM0	2414			M	5800	EndofPhase2	5	Phase 2	143	0	1	0	0	0	0	0	2	1	4	5	1	2	2	4	4	4	6	4	4	6	2	5	6	5	5	5	5	1	1	1	1	1	1	1	1	3	2	0	4	2	2	2	0	0	0	0	0	0	0	0					1	14	0		0		0		1	14	0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.625	4.5	4.714286	5	3.9047618			4.714286	4.25	5	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU883HM0
2081	8976	NDAR_INVLU985JW3	2602			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	2	4	2	4	4	4	0	4	4	5	6	4	4	4	4	5	5	2	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	4.75	4.571429	3.5	4	1		4	3.25	4.75	4.571429	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU985JW3
2081	8976	NDAR_INVLU985JW3	2602			F	1600	Visit6	6	Phase 1/1A	196	0	0	0	1	0	0	0	5	4	2	2	4	4	4	0	4	4	4	5	4	2	4	3	4	4	3	4	4	1	1	1	0	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	4.25	3.5714285	3.5	3.5238094			4	3.25	4.75	4.571429	3.5	-0.47619048	-0.125	-0.5	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU985JW3
2081	8976	NDAR_INVLU985JW3	2602			F	2800	Visit12	12	Phase 1/1A	387	0	0	0	1	0	0	0	6	4	2	4	4	4	4	4	4	4	5	6	4	4	5	4	5	5	4	5	5	1	1	1	1	1	1	1	1	1	1	1	4	2	2	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4	4.75	4.571429	4.5	4.3809524			4	3.25	4.75	4.571429	3.5	0.3809524	0.75	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU985JW3
2081	8976	NDAR_INVLU985JW3	2602			F	4000	Visit18	18	Phase 1/1A	560	0	0	0	1	0	0	0	6	2	4	2	6	4	2	2	4	6	6	6	4	6	6	6	6	6	4	6	6	1	1	1	0	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.5	5.5	5.714286	5	4.7619047		1	4	3.25	4.75	4.571429	3.5	0.7619048	0.25	0.75	1.1428572	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLU985JW3
2081	8976	NDAR_INVLV570TXE	1193			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	2	0	0	2	2	0	0	4	4	9	2	2	4	6	2	3	3	4	2	1	1	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	0.75	2	3.142857	3	2.1	1		2.1	0.75	2	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLV570TXE
2081	8976	NDAR_INVLV570TXE	1193			F	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	0	1	1	0	1	1	1	1	2	1	1	4	4	9	2	2	4	6	2	3	3	3	2	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	3	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	1	2.25	3	3	2.2			2.1	0.75	2	3.142857	3	0.1	0.25	0.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLV570TXE
2081	8976	NDAR_INVLV570TXE	1193			F	2800	Visit12	12	Phase 1/1A	359	0	0	0	0	0	0	1	2	1	2	3	2	2	2	1	0	1	2	9	3	4	2	6	2	1	1	2	2	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.875	0.75	3	1	2.05		1	2.1	0.75	2	3.142857	3	-0.05	1.125	-1.25	-0.14285715	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLV570TXE
2081	8976	NDAR_INVLW132VAR	2035			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	6	2	3	5	6	6	6	5	5	6	6	5	6	5	5	6	5	5	6	6	1	0	1	1	1	1	1	1	3	1	1	3	2	2	2	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	1	0	0	0	0	0	1	1	1	1	5	4.857143	5.5	5.571429	5	5.25	1		5.25	4.857143	5.5	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW132VAR
2081	8976	NDAR_INVLW132VAR	2035			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	6	4	4	5	6	6	6	5	5	6	6	4	6	4	5	6	5	3	6	6	1	0	1	1	1	1	1	1	1	1	1	2	4	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	5	5.285714	5.5	5.285714	4	5.2		1	5.25	4.857143	5.5	5.571429	5	-0.05	0.42857143	0	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW132VAR
2081	8976	NDAR_INVLW210WH8	2404			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	2	4	2	2	3	0	2	2	4	9	2	1	4	5	1	4	3	4	5	1	0	1	0	0	1	0	1	1	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	10	0		0		1	13	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	2	3.142857	3.5	2.7	1		2.7	2.125	2	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW210WH8
2081	8976	NDAR_INVLW210WH8	2404			M	1600	Visit6	6	Phase 2	200	0	0	0	0	0	0	1	5	2	0	2	3	2	2	0	0	0	1	9	2	2	0	1	1	4	3	2	2	1	1	1	0	1	1	1	1	1	1	1	3	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	2	0.25	1.4285715	3.5	1.7			2.7	2.125	2	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW210WH8
2081	8976	NDAR_INVLW210WH8	2404			M	2800	Visit12	12	Phase 2	339	0	0	0	0	0	0	1	9	4	3	3	2	2	4	1	2	1	2	9	2	2	2	3	1	4	5	2	4	1	1	1	1	0	1	1	1	2	1	1	2	1	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	4	2.7142856	1.25	2.2857144	4.5	2.5789473			2.7	2.125	2	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW210WH8
2081	8976	NDAR_INVLW210WH8	2404			M	5200	EndofPhase1_1a	5	Phase 1/1A	136	0	0	0	0	0	0	1	4	0	4	4	2	3	4	0	1	2	5	9	4	3	3	4	4	4	4	4	5	1	1	1	0	0	0	0	0	1	1	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2	3.857143	4	3.2		1	2.7	2.125	2	3.142857	3.5	0.5	0.5	0	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW210WH8
2081	8976	NDAR_INVLW210WH8	2404			M	5800	EndofPhase2	18	Phase 2	507	0	0	0	0	0	0	1	5	3	4	4	4	3	2	1	0	0	0	9	3	3	2	4	2	4	5	2	4	1	1	1	1	1	1	0	1	1	1	1	3	1	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	3.25	0	2.857143	4.5	2.75			2.7	2.125	2	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW210WH8
2081	8976	NDAR_INVLW305RHQ	1219			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	2	4	2	2	3	0	0	0	9	2	1	2	4	4	5	3	6	4	1	1	1	0	1	1	1	1	1	1	1	4	2	3	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	6	3.875	0	3.2857144	4	3.1	1		3.1	3.875	0	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW305RHQ
2081	8976	NDAR_INVLW305RHQ	1219			M	1600	Visit6	6	Phase 1/1A	163	0	0	0	0	0	0	1	0	2	0	1	2	1	2	0	0	0	0	9	2	2	2	4	2	5	4	4	4	1	1	1	0	1	1	1	1	2	1	1	4	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0	2.857143	4.5	1.85			3.1	3.875	0	3.2857144	4	-1.25	-2.875	0	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW305RHQ
2081	8976	NDAR_INVLW305RHQ	1219			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	0	4	2	2	4	0	3	2	0	0	0	9	3	2	4	4	4	5	3	4	5	0	1	1	0	1	1	1	1	3	2	1	4	4	2	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0	3.7142856	4	2.55			3.1	3.875	0	3.2857144	4	-0.55	-1.75	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW305RHQ
2081	8976	NDAR_INVLW305RHQ	1219			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	0	1	2	2	1	1	2	0	4	0	0	0	0	9	2	2	3	5	4	5	4	6	5	1	1	1	0	1	1	1	1	2	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0	3.857143	4.5	2.4		1	3.1	3.875	0	3.2857144	4	-0.7	-2.375	0	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW305RHQ
2081	8976	NDAR_INVLW894CPZ	1754			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	0	0	2	0	0	4	0	0	0	9	2	0	2	2	2	3	4	3	5	1	0	1	0	1	2	1	2	3		1	2	1	4	1	1	1	0	0	0	0	0	0	1	0	1	0	0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	4	1.4285715	0	2.2857144	3.5	1.7368422	1		1.7368422	1.4285715	0	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW894CPZ
2081	8976	NDAR_INVLW894CPZ	1754			M	5200	EndofPhase1_1a	3	Phase 1/1A	114	0	1	0	0	0	0	0	4	0	0	2	1	0	0	2	0	0	0	9	2	2	4	4	4	3	3	2	1	1	0	0	1	0	1	0	1	3	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	10	0		0		0		1	20	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	5	1.125	0	2.7142856	3	1.7		1	1.7368422	1.4285715	0	2.2857144	3.5	-0.036842104	-0.30357143	0	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLW894CPZ
2081	8976	NDAR_INVLX086NPR	1906			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	0	0	4	4	0	5	6	2	4	6	4	2	6	2	1	4	5	6	4	1	1	1	0	1	1	1	1	3	1	1	2	2	2	2	1	0	0	1	0	0	0	0	1	0	1	0	1	16	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5714285	4.5	3.5714285	4.5	3.5	1		3.5	2.5714285	4.5	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX086NPR
2081	8976	NDAR_INVLX373BC8	1388			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	3	2	2	2	1	1	1	0	9	1	2	1	5	1	6	2	4	4	0	1	0	0	1	1	1	1	3	1	0	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0.5	2.5714285	4	2.1	1		2.1	1.75	0.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX373BC8
2081	8976	NDAR_INVLX373BC8	1388			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	4	0	0	1	2	2	3	1	2	3	1	9	4	3	2	4	1	6	3	4	5	1	1	1	0	1	1	0	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	4	1.625	1.5	3.2857144	4.5	2.55			2.1	1.75	0.5	2.5714285	4	0.45	-0.125	1	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX373BC8
2081	8976	NDAR_INVLX373BC8	1388			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	4	0	0	0	2	1	3	1	4	4	4	6	5	4	3	4	4	6	3	5	5	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	5	1.375	4.5	4.285714	4.5	3.2380953			2.1	1.75	0.5	2.5714285	4	1.1380953	-0.375	4	1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX373BC8
2081	8976	NDAR_INVLX373BC8	1388			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	0	1	4	0	0	2	2	2	3	1	5	6	5	5	5	5	3	4	5	6	3	5	4	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1.75	5.25	4.428571	4.5	3.5714285		1	2.1	1.75	0.5	2.5714285	4	1.4714285	0	4.75	1.8571428	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX373BC8
2081	8976	NDAR_INVLX459CXH	2227			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	2	2	2	2	1	2	6	4	5	3	4	5	5	3	6	6	2	6	6	1	0	1	1	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	4.5	5	4	3.8095238	1		3.8095238	2.375	4.5	5	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX459CXH
2081	8976	NDAR_INVLX459CXH	2227			M	1600	Visit6	6	Phase 1B	161	1	0	1	0	0	0	0	4	2	1	1	2	1	0	2	3	2	1	3	4	2	4	2	4	6	3	4	4	1	1	0	1	1	0	0	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	2.25	3.4285715	4.5	2.6190476			3.8095238	2.375	4.5	5	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX459CXH
2081	8976	NDAR_INVLX459CXH	2227			M	5200	EndofPhase1_1a	4	Phase 1/1A	105	1	0	1	0	0	0	0	4	4	2	0	4	2	3	2	6	3	4	2	2	4	4	4	4	6	3	4	2	0	1	0	0	1	1	1	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.625	3.75	3.4285715	4.5	3.2857144		1	3.8095238	2.375	4.5	5	4	-0.52380955	0.25	-0.75	-1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX459CXH
2081	8976	NDAR_INVLX459CXH	2227			M	5400	EndofPhase1b	7	Phase 1B	245	1	0	0	0	0	0	0	4	4	5	5	5	4	5	5	0	4	4	9	4	4	4	4	4	5	5	5	5	1	1	0	1	1	0	0	1	1	2	1	2	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.625	2	4.285714	5	4.25			3.8095238	2.375	4.5	5	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX459CXH
2081	8976	NDAR_INVLX620WTX	1538			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	2	2	4	3	1	2	3	1	2	1	9	3	2	2	4	3	2	3	2	2	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.75	1	2.5714285	2.5	2.45	1		2.45	2.75	1	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX620WTX
2081	8976	NDAR_INVLX620WTX	1538			M	1600	Visit6	6	Phase 1B	175	1	0	0	0	0	0	0	5	2	0	1	3	2	2	2	1	2	1	9	2	2	1	4	3	4	1	2	2	0	0	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	1	2.2857144	2.5	2.1			2.45	2.75	1	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX620WTX
2081	8976	NDAR_INVLX620WTX	1538			M	2800	Visit12	12	Phase 1B	356	1	0	0	0	0	0	0	4	1	4	4	4	4	4	3	2	2	4	9	3	4	4	4	4	3	3	3	3	1	1	0	0	1	1	1	0	1	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	2	3.5714285	3	3.35			2.45	2.75	1	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX620WTX
2081	8976	NDAR_INVLX620WTX	1538			M	5200	EndofPhase1_1a	1	Phase 1/1A	33	1	0	1	0	0	0	0	5	2	2	4	3	4	3	3	1	1	1	9	3	2	2	6	3	2	3	2	2	1	1	1	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.25	0.75	2.857143	2.5	2.7		1	2.45	2.75	1	2.5714285	2.5	0.25	0.5	-0.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX620WTX
2081	8976	NDAR_INVLX620WTX	1538			M	5400	EndofPhase1b	18	Phase 1B	544	1	0	0	0	0	0	0	4	6	4	4	4	2	2	4	0	2	2	9	2	2	4	4	3	2	2	4	2	1	1	1	0	1	1	1	1	3	2	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.75	1	3	2	2.95			2.45	2.75	1	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLX620WTX
2081	8976	NDAR_INVLY453LT5	2755			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	1	1	2	1	1	1	0	2	0	9	4	4	3	5	4	4	6	4	4	1	1	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	5	1.125	0.5	4	5	2.45	1		2.45	1.125	0.5	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY453LT5
2081	8976	NDAR_INVLY453LT5	2755			M	1600	Visit6	6	Phase 2	194	0	0	0	0	0	1	0	0	3	2	4	2	1	1	2	0	1	0	9	3	4	4	5	4	4	5	5	3	1	1	1	1	1	1	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	7	1	20	0		0		1	3	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0	1	5	1.875	0.25	4	4.5	2.65			2.45	1.125	0.5	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY453LT5
2081	8976	NDAR_INVLY453LT5	2755			M	5200	EndofPhase1_1a	1	Phase 1/1A	32	0	0	0	0	0	1	0	2	0	1	0	2	1	1	1	1	2	1	9	3	3	3	5	1	4	5	4	4	1	1	0	0	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1	1	3.2857144	4.5	2.2		1	2.45	1.125	0.5	4	5	-0.25	-0.125	0.5	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY453LT5
2081	8976	NDAR_INVLY733BF3	2744			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	3	1	2	3	3	2	0	2	1	9	1	2	2	3	3	2	4	3	4	1	2	2	2	1	1	2	1	2	2	1	4	2	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2.5	0.75	2.5714285	3	2.35	1		2.35	2.5	0.75	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY733BF3
2081	8976	NDAR_INVLY733BF3	2744			M	1600	Visit6	6	Phase 1/1A	178	0	0	0	0	0	1	0	3	3	3	2	2	3	3	2	0	2	1	9	0	2	3	4	4	2	4	3	4	1	2	2	2	1	1	2	1	2	2	1	4	2	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.625	0.75	2.857143	3	2.5		1	2.35	2.5	0.75	2.5714285	3	0.15	0.125	0	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY733BF3
2081	8976	NDAR_INVLY933FNK	2240			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	0	0	0	2	2	2	1	0	3	5	9	0	2	1	1	0	3	2	3	3	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	1.5	2	1.4285715	2.5	1.75	1		1.75	1.5	2	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY933FNK
2081	8976	NDAR_INVLY933FNK	2240			F	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	4	0	0	0	2	2	2	0	0	3	5	9	0	2	0	3	0	4	3	4	5	0	0	1	0	1	1	0	1	2	1	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	7	1.25	2	2	3.5	1.95			1.75	1.5	2	1.4285715	2.5	0.2	-0.25	0	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY933FNK
2081	8976	NDAR_INVLY933FNK	2240			F	2800	Visit12	12	Phase 1/1A	337	0	0	1	0	0	0	0	4	0	0	0	2	2	2	0	0	2	6	9	0	2	0	3	0	4	3	4	4	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	7	1.25	2	1.8571428	3.5	1.9			1.75	1.5	2	1.4285715	2.5	0.15	-0.25	0	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY933FNK
2081	8976	NDAR_INVLY933FNK	2240			F	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	6	0	0	2	2	0	2	0	0	3	4	9	0	3	0	4	0	3	3	4	4	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	1.5	1.75	2.142857	3	2		1	1.75	1.5	2	1.4285715	2.5	0.25	0	-0.25	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVLY933FNK
2081	8976	NDAR_INVMA045MTH	1239			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	0	0	4	2	0	2	0	0	1	1	9	2	3	3	3	1	2	3	3	4	1	1	0	0	1	1	0	1	1	2	1	3	4	2	4	1	0	0	1	1	0	0	0	1	1	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	0.5	2.7142856	2.5	1.8	1		1.8	1.25	0.5	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA045MTH
2081	8976	NDAR_INVMA045MTH	1239			F	1600	Visit6	6	Phase 1/1A	172	0	0	1	0	0	0	0	5	0	0	0	6	3	2	1	0	0	0	9	6	3	2	2	1	2	2	4	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.125	0	3.142857	2	2.15			1.8	1.25	0.5	2.7142856	2.5	0.35	0.875	-0.5	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA045MTH
2081	8976	NDAR_INVMA045MTH	1239			F	2800	Visit12	12	Phase 1/1A	333	0	0	1	0	0	0	0	5	0	0	0	4	2	3	2	0	0	0	9	6	3	3	2	1	2	1	4	4	0	0	0	0	1	1	1	1	1	1	0	4	1	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0	3.2857144	1.5	2.1			1.8	1.25	0.5	2.7142856	2.5	0.3	0.75	-0.5	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA045MTH
2081	8976	NDAR_INVMA045MTH	1239			F	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	1	0	0	0	0	5	2	2	3	4	3	4	3	1	2	1	9	6	3	3	2	1	2	2	4	4	0	0	0	0	1	1	1	1	1	1	0	4	1	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1	3.2857144	2	2.85		1	1.8	1.25	0.5	2.7142856	2.5	1.05	2	0.5	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA045MTH
2081	8976	NDAR_INVMA894CMY	1535			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	1	2	4	6	2	2	1	0	5	3	9	4	5	5	5	6	5	4	6	5	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5714285	2	5.142857	4.5	3.7368422	1		3.7368422	2.5714285	2	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA894CMY
2081	8976	NDAR_INVMA894CMY	1535			M	1600	Visit6	6	Phase 1/1A	184	0	0	0	0	0	0	1	6	0	1	2	2	5	3	0	0	0	0	9	2	3	4	6	1	5	4	6	6	1	0	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0	4	4.5	2.8			3.7368422	2.5714285	2	5.142857	4.5	-0.9368421	-0.19642857	-2	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA894CMY
2081	8976	NDAR_INVMA894CMY	1535			M	2800	Visit12	12	Phase 1/1A	359	0	0	0	0	0	0	1	6	0	4	4	2	6	2	0	0	0	1	9	4	5	5	6	0	5	4	6	6	1	0	1	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0.25	4.571429	4.5	3.3			3.7368422	2.5714285	2	5.142857	4.5	-0.4368421	0.42857143	-1.75	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA894CMY
2081	8976	NDAR_INVMA894CMY	1535			M	5200	EndofPhase1_1a	16	Phase 1/1A	456	0	0	0	0	0	0	1	9	0	4	6	2	6	3	0	0	0	1	9	3	5	4	6	2	5	3	6	6	1	0	1	1	1	1	1	1	2	1	0	4	3	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0.25	4.571429	4	3.2631578		1	3.7368422	2.5714285	2	5.142857	4.5	-0.47368422	0.42857143	-1.75	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA894CMY
2081	8976	NDAR_INVMA927FD1	2792			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	0	2	2	2	4	5	3	0	1	0	9	2	5	6	5	5	5	5	3	1	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	4	3	0.25	3.857143	5	3.1	1		3.1	3	0.25	3.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA927FD1
2081	8976	NDAR_INVMA927FD1	2792			M	5200	EndofPhase1_1a	1	Phase 1/1A	15	0	0	1	0	0	0	0	6	0	1	2	2	4	4	3	0	0	0	9	0	3	5	5	4	5	5	5	3	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	0	3.5714285	5	2.85		1	3.1	3	0.25	3.857143	5	-0.25	-0.25	-0.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA927FD1
2081	8976	NDAR_INVMA954KEF	2579			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	2	2	2	2	2	2	3	3	2	2	9	2	2	2	3	3	4	4	3	3	1	1	1	0	1	1	0	1	1	2	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2	2.25	1.75	2.5714285	4	2.55	1		2.55	2.25	1.75	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA954KEF
2081	8976	NDAR_INVMA954KEF	2579			M	1600	Visit6	6	Phase 1/1A	179	0	1	0	0	0	0	0	3	2	3	2	2	2	2	2	3	3	1	2	1	2	1	2	2	2	2	3	2	0	0	0	0	1	1	1	1	2	2	0	4	3	3	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2.25	2.25	1.8571428	2	2.0952382			2.55	2.25	1.75	2.5714285	4	-0.4547619	0	0.5	-0.71428573	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA954KEF
2081	8976	NDAR_INVMA954KEF	2579			M	2800	Visit12	12	Phase 1/1A	337	1	1	0	1	0	0	0	5	4	3	2	2	2	2	5	1	2	2	9	2	2	3	2	4	4	4	5	6	1	1	1	0	1	1	1	1	2	2	1	4	2	2	1	1	1	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	1.25	3.4285715	4	3.1			2.55	2.25	1.75	2.5714285	4	0.55	0.875	-0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA954KEF
2081	8976	NDAR_INVMA954KEF	2579			M	5200	EndofPhase1_1a	18	Phase 1/1A	523	1	0	1	0	1	0	0	4	3	3	3	2	2	2	3	1	3	4	9	4	4	3	4	4	4	5	4	5	1	1	1	0	1	1	1	1																																															2.75	2	4	4.5	3.35		1	2.55	2.25	1.75	2.5714285	4	0.8	0.5	0.25	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMA954KEF
2081	8976	NDAR_INVMB096BEU	1351			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	3	1	1	2	6	6	1	0	2	2	9	0	0	0	4	4	3	3	3	6	0	0	1	0	1	1	1	1	3	1	0	4	2	3	2	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.875	1	2.4285715	3	2.5	1		2.5	2.875	1	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB096BEU
2081	8976	NDAR_INVMB096BEU	1351			F	1600	Visit6	6	Phase 1/1A	156	0	0	0	0	0	0	1	5	1	2	1	4	0	4	2	0	2	4	9	4	4	4	3	0	3	5	4	6	0	1	0	1	1	1	0	1	3	2	0	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	1.5	3.5714285	4	2.9			2.5	2.875	1	2.4285715	3	0.4	-0.5	0.5	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB096BEU
2081	8976	NDAR_INVMB096BEU	1351			F	2800	Visit12	12	Phase 1/1A	331	0	0	0	0	0	0	1	5	1	2	1	4	0	4	2	0	2	4	9	4	4	4	3	0	3	4	4	6	0	0	0	1	1	1	0	1	2	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	1.5	3.5714285	3.5	2.85		1	2.5	2.875	1	2.4285715	3	0.35	-0.5	0.5	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB096BEU
2081	8976	NDAR_INVMB605HZ1	1011			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	5	5	6	6	6	6	2	0	4	4	9	2	3	6	6	6	5	5	6	4	1	1	1	1	1	1	1	1	3	3	1	2	3	1	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5.25	2	4.714286	5	4.65	1		4.65	5.25	2	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB605HZ1
2081	8976	NDAR_INVMB605HZ1	1011			M	2800	Visit12	12	Phase 2	333	0	0	0	0	0	1	0	4	4	3	5	4	6	6	0	2	2	0	9	4	5	4	6	3	5	5	5	4	1	1	1	1	1	1	1	1	3		1	3	2	2	4	1	0	0	0	0	0	1	0	1	2	1	2	0		1	30	0		0		0		2	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	4	1	4.428571	5	3.85			4.65	5.25	2	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB605HZ1
2081	8976	NDAR_INVMB605HZ1	1011			M	5200	EndofPhase1_1a	6	Phase 1/1A	158	0	0	0	0	0	1	0	4	5	5	6	5	6	6	1	1	2	1	9	2	2	4	6	5	5	5	4	4	1	1	0	1	1	1	1	1	3		1	2	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.75	1	3.857143	5	3.95		1	4.65	5.25	2	4.714286	5	-0.7	-0.5	-1	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB605HZ1
2081	8976	NDAR_INVMB605HZ1	1011			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	0	1	0	5	4	4	4	4	5	6	0	1	2	1	9	3	4	4	5	4	4	5	4	3	1	1	1	1	1	1	1	1	3		1	2	2	2	2	1	0	0	0	0	1	0	0	1	0	1	0	0		1	30	0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4	1	3.857143	4.5	3.6			4.65	5.25	2	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMB605HZ1
2081	8976	NDAR_INVMC042WD0	1522			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	6	4	6	6	2	4	2	0	0	6	9	4	4	5	6	6	3	3	3	6	0	1	0	0	1	1	1	0	3	2	1	3	4	3	4	0	0	0	0	0	0	0	1	0	1	1	0	0		0		1	30	0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	0	5	3.75	1.5	4.857143	3	3.8	1		3.8	3.75	1.5	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMC042WD0
2081	8976	NDAR_INVMC295GDH	2353			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	5	6	6	6	6	6	0	3	4	5	5	4	6	5	5	6	5	3	6	6	1	0	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	1	0	1	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	5.125	4.25	5.428571	4	4.952381	1		4.952381	5.125	4.25	5.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMC295GDH
2081	8976	NDAR_INVMC295GDH	2353			M	5200	EndofPhase1_1a	1	Phase 1/1A	28	1	0	1	0	0	0	0	6	5	6	6	6	6	6	0	3	4	5	5	4	6	5	5	6	5	3	6	6	1	0	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	1	0	1	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	5.125	4.25	5.428571	4	4.952381		1	4.952381	5.125	4.25	5.428571	4	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMC295GDH
2081	8976	NDAR_INVMD025EN0	2382			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	2	2	2	4	3	2	2	1	1	2	9	2	2	4	4	2	3	2	2	4	1	0	0	1	1	1	0	2	1	2	1	2	2	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	1	5	2.625	1	2.857143	2.5	2.5	1		2.5	2.625	1	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD025EN0
2081	8976	NDAR_INVMD025EN0	2382			M	5200	EndofPhase1_1a	1	Phase 1/1A	19	1	0	1	0	0	0	0	4	3	2	2	4	2	4	2	2	4	4	9	2	4	4	4	3	3	3	4	4	1	1	0	0	1	1	1	1	1	1	1	3	2	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.875	2.5	3.5714285	3	3.2		1	2.5	2.625	1	2.857143	2.5	0.7	0.25	1.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD025EN0
2081	8976	NDAR_INVMD062XMR	1793			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	2	6	4	4	6	4	4	2	0	2	2	9	4	4	6	2	6	4	3	4	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	0	0	0	1	0	0	0	0	0	0	1	24	0		0		1	6	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	4	1	4.428571	3.5	3.7	1		3.7	4	1	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD062XMR
2081	8976	NDAR_INVMD062XMR	1793			F	1600	Visit6	6	Phase 2	175	0	0	0	1	0	0	0	6	4	2	3	4	0	2	0	0	0	2	9	4	3	4	4	0	4	4	4	6	1	0	1	0	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.625	0.5	3.5714285	4	2.8			3.7	4	1	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD062XMR
2081	8976	NDAR_INVMD062XMR	1793			F	2800	Visit12	12	Phase 2	350	0	0	0	0	0	0	1	9	5	2	1	2	2	2	2	0	2	1	9	3	2	2	4	4	5	4	5	3	1	1	1	0	1	1	1	1	3	1	1	3	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.2857144	0.75	3.2857144	4.5	2.6842105			3.7	4	1	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD062XMR
2081	8976	NDAR_INVMD062XMR	1793			F	4000	Visit18	18	Phase 2	505	0	1	0	0	0	0	0	4	5	4	4	4	4	5	5	4	4	3	3	3	3	2	4	4	4	5	4	4	1	1	1	0	1	1	1	1	2	2	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	4.375	3.5	3.4285715	4.5	3.9047618			3.7	4	1	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD062XMR
2081	8976	NDAR_INVMD062XMR	1793			F	5200	EndofPhase1_1a	4	Phase 1/1A	107	0	0	0	1	0	0	0	4	6	0	5	5	5	2	0	0	0	3	9	3	2	0	4	2	4	2	4	4	1	1	1	0	1	1	1	1	1	3	1	3	2	2	4	0	0	0	0	0	0	0	0					1	22	0		0		1	8	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	3.375	0.75	2.7142856	3	2.75		1	3.7	4	1	4.428571	3.5	-0.95	-0.625	-0.25	-1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD062XMR
2081	8976	NDAR_INVMD062XMR	1793			F	5800	EndofPhase2	18	Phase 2	505	0	1	0	0	0	0	0	4	5	4	4	4	4	5	5	4	4	3	3	3	3	2	4	4	4	5	4	4	1	1	1	0	1	1	1	1	2	2	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	4.375	3.5	3.4285715	4.5	3.9047618			3.7	4	1	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD062XMR
2081	8976	NDAR_INVMD277JEA	2503			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	3	3	2	2	2	3	2	2	1	4	0	1	2	2	0	2	2	2	1	1	0	1	0	0	1	0	0	1	1	3	1	4	2	2	2	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	1	1	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.875	1.75	1.2857143	2	2.047619	1		2.047619	2.875	1.75	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD277JEA
2081	8976	NDAR_INVMD277JEA	2503			F	2800	Visit12	12	Phase 1/1A	345	0	1	0	0	0	0	0	2	2	2	1	2	1	2	2	0	1	1	5	1	2	1	0	1	2	2	0	0	1	1	0	0	1	1	1	1	1	3	0	4	2	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	16	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.75	0.71428573	2	1.4285715			2.047619	2.875	1.75	1.2857143	2	-0.61904764	-1.125	0	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD277JEA
2081	8976	NDAR_INVMD277JEA	2503			F	4000	Visit18	18	Phase 1/1A	524	0	0	0	0	1	0	0	6	4	4	5	2	2	4	4	0	0	0	9	0	4	0	4	4	4	4	6	6	1	1	0	1	1	1	1	1	2	1	1	2	3	3	2	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.875	0	3.4285715	4	3.15		1	2.047619	2.875	1.75	1.2857143	2	1.102381	1	-1.75	2.142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD277JEA
2081	8976	NDAR_INVMD336MA2	2388			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	0	2	3	2	3	3	1	2	2	4	9	3	3	3	3	2	6	4	4	5	0	0	1	1	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.375	2	3.2857144	5	3	1		3	2.375	2	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD336MA2
2081	8976	NDAR_INVMD336MA2	2388			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	4	0	3	3	2	2	4	1	2	4	4	9	3	3	4	4	3	5	2	4	6	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	2.5	3.857143	3.5	3.15			3	2.375	2	3.2857144	5	0.15	0	0.5	0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD336MA2
2081	8976	NDAR_INVMD336MA2	2388			M	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	0	0	1	2	0	1	2	2	2	2	0	1	1	1	9	0	1	1	2	1	4	3	4	3	0	0	1	0	0	1	0	1	2	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.375	0.75	1.7142857	3.5	1.65			3	2.375	2	3.2857144	5	-1.35	-1	-1.25	-1.5714285	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD336MA2
2081	8976	NDAR_INVMD336MA2	2388			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	0	1	4	1	3	3	2	1	3	1	1	1	1	9	1	2	2	3	4	4	3	4	3	1	0	1	1	0	1	1	1	2	1	0	4	3	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.25	0.75	2.7142856	3.5	2.35		1	3	2.375	2	3.2857144	5	-0.65	-0.125	-1.25	-0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD336MA2
2081	8976	NDAR_INVMD516KE3	1970			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	1	2	2	2	0	0	1	0	0	0	9	1	2	2	4	3	4	3	5	3	1	1	1	1	1	0	1	0	2	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	14	1	7	0		1	10	0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1.25	0	2.857143	3.5	1.85	1		1.85	1.25	0	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD516KE3
2081	8976	NDAR_INVMD516KE3	1970			M	1600	Visit6	6	Phase 1/1A	167	1	0	0	0	0	0	0	4	0	2	3	2	4	2	2	0	0	0	9	2	3	3	6	3	5	5	5	2	1	1	1	1	1	1	1	0	1	3	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2.375	0	3.4285715	5	2.65		1	1.85	1.25	0	2.857143	3.5	0.8	1.125	0	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD516KE3
2081	8976	NDAR_INVMD543CVT	1689			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	2	2	2	2	2	0	2	3	1	9	2	2	2	3	2	4	3	4	4	0	1	1	0	1	1	1	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	1.5	2.7142856	3.5	2.45	1		2.45	2.125	1.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD543CVT
2081	8976	NDAR_INVMD704EJQ	2820			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	0	1	2	0	2	2	0	1	1	9	2	1	0	3	0	3	2	2	3	1	0	0	0	0	0	0	0	3		0	4	1	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	0	1	1	7	2	0.5	1.5714285	2.5	1.7	1		1.7	2	0.5	1.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD704EJQ
2081	8976	NDAR_INVMD704EJQ	2820			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	9	0	0	0	0	0	6	3	0	0	0	9	0	1	1	3	0	4	3	4	6	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	1	0	0	1	0	1	1	4	1.2857143	0	2.142857	3.5	1.6315789		1	1.7	2	0.5	1.5714285	2.5	-0.06842105	-0.71428573	-0.5	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMD704EJQ
2081	8976	NDAR_INVME016TKT	2074			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	1	0	2	2	1	2	1	2	9	3	2	0	0	1	4	3	0	2	2	1	2	2	1	1	0	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	16	0		1	14	0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.75	1.25	1.1428572	3.5	1.3	1		1.3	0.75	1.25	1.1428572	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME016TKT
2081	8976	NDAR_INVME483GC4	2344			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	6	3	2	6	6	1	3	4	2	9	6	4	6	6	4	4	4	6	6	1	1	1	1	1	1	1	1	2	1	1	4	2	2	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	3.75	2.25	5.428571	4	4.25	1		4.25	3.75	2.25	5.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME483GC4
2081	8976	NDAR_INVME483GC4	2344			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	1	0	5	3	5	5	3	5	6	1	3	3	2	9	3	5	6	6	5	4	4	5	6	1	1	1	1	1	1	1	1	3	1	1	3	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.125	2	5.142857	4	4.25			4.25	3.75	2.25	5.428571	4	0	0.375	-0.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME483GC4
2081	8976	NDAR_INVME483GC4	2344			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	1	0	4	5	5	5	4	3	6	3	4	3	4	9	3	2	6	5	4	3	5	5	5	1	0	1	1	1	1	1	1	3	1	1	3	2	3	4	1	0	1	1	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.375	2.75	4.285714	4	4.2		1	4.25	3.75	2.25	5.428571	4	-0.05	0.625	0.5	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME483GC4
2081	8976	NDAR_INVME607JXP	2751			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	0	2	2	2	2	2	0	0	0	9	2	0	2	2	0	3	3	2	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0	1.7142857	3	1.6	1		1.6	1.75	0	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME607JXP
2081	8976	NDAR_INVME607JXP	2751			M	5200	EndofPhase1_1a	1	Phase 1/1A	20	0	0	0	0	0	1	0	4	4	2	2	1	3	6	0	0	0	0	9	2	2	2	6	4	2	3	3	4	0	1	1	1	1	1	1	1	3		1	3	3	4	3	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	23	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	0	3.2857144	2.5	2.5		1	1.6	1.75	0	1.7142857	3	0.9	1	0	1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME607JXP
2081	8976	NDAR_INVME957NEB	2122			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	4	4	5	3	4	1	0	0	4	9	2	3	4	1	5	3	3	4	5	1	0	0	0	1	1	1	0	3		1	3	2	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	7	3.875	1	3.4285715	3	3.25	1		3.25	3.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVME957NEB
2081	8976	NDAR_INVMF053DR2	2420			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	4	2	2	2	4	2	6	0	0	2	9	6	6	2	6	0	4	4	4	4	0	1	0	0	1	1	1	0	3		1	2	1	3	1	1	1	0	0	0	0	0	0	1	1	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	6	2.75	0.5	4	4	3	1		3	2.75	0.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF053DR2
2081	8976	NDAR_INVMF053DR2	2420			F	1600	Visit6	6	Phase 2	176	0	0	0	0	0	0	1	6	5	3	4	3	6	4	6	0	0	1	9	2	1	4	6	0	5	5	5	5	1	1	1	0	1	1	1	1	1	2	1	4	3	2	2	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	2	4.625	0.25	3.2857144	5	3.55			3	2.75	0.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF053DR2
2081	8976	NDAR_INVMF053DR2	2420			F	5200	EndofPhase1_1a	5	Phase 1/1A	152	0	0	0	0	1	0	0	6	4	5	5	6	6	6	6	0	0	3	9	4	6	0	6	3	4	6	5	6	1	1	1	0	1	1	1	1	2	1	1	4	2	3	3	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.5	0.75	4.285714	5	4.35		1	3	2.75	0.5	4	4	1.35	2.75	0.25	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF053DR2
2081	8976	NDAR_INVMF053DR2	2420			F	5800	EndofPhase2	7	Phase 2	197	0	0	0	0	0	0	1	0	4	0	2	5	6	2	4	0	0	6	9	6	4	1	4	1	4	5	6	6	1	1	1	0	1	1	0	1	2	2	1	4	2	3	2	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.5	4	4.5	3.3			3	2.75	0.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF053DR2
2081	8976	NDAR_INVMF919JJ4	1870			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	4	5	5	4	4	5	6	5	5	5	5	4	5	5	5	5	3	4	5	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	5.25	4.714286	4	4.7619047	1		4.7619047	4.75	5.25	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF919JJ4
2081	8976	NDAR_INVMF919JJ4	1870			M	1600	Visit6	6	Phase 2	162	1	0	0	0	0	0	0	6	0	3	1	4	2	4	1	4	4	5	6	4	4	2	4	6	5	3	6	6	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	4.75	4.571429	4	3.8095238			4.7619047	4.75	5.25	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF919JJ4
2081	8976	NDAR_INVMF919JJ4	1870			M	2800	Visit12	12	Phase 2	330	1	0	0	0	0	0	0	6	0	0	1	0	2	1	2	1	2	1	9	4	2	4	5	4	6	4	5	5	1	1	1	1	1	1	1	1	3		1	2	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	1	4.142857	5	2.75			4.7619047	4.75	5.25	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF919JJ4
2081	8976	NDAR_INVMF919JJ4	1870			M	5200	EndofPhase1_1a	2	Phase 1/1A	52	1	0	0	0	0	0	0	6	1	4	2	4	2	1	1	0	0	0	9	6	2	5	4	5	4	1	4	5	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	2.625	0	4.428571	2.5	2.85		1	4.7619047	4.75	5.25	4.714286	4	-1.9119048	-2.125	-5.25	-0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF919JJ4
2081	8976	NDAR_INVMF919JJ4	1870			M	5800	EndofPhase2	18	Phase 2	508	1	0	0	0	0	0	0	0	0	2	2	2	0	2	2	2	2	4	9	2	4	4	4	6	6	4	4	6	1	0	1	0									4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		1		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.25	2	4.285714	5	2.9			4.7619047	4.75	5.25	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMF919JJ4
2081	8976	NDAR_INVMG586PFK	1963			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	3	0	4	4	2	5	2	3	2	2	1	9	3	2	6	3	3	4	5	2	6	0	1	0	1	1	1	0	0	1	3	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	4	2.875	1.25	3.5714285	4.5	3.1	1		3.1	2.875	1.25	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMG586PFK
2081	8976	NDAR_INVMG586PFK	1963			M	1600	Visit6	6	Phase 1/1A	182	0	0	0	0	0	0	1	9	0	4	5	0	6	4	0	2	2	2	9	3	3	6	4	4	4	3	4	6	0	1	0	1	1	1	0	1	3	3	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	1	1	1	1	1	1	2	2.7142856	1.5	4.285714	3.5	3.2631578			3.1	2.875	1.25	3.5714285	4.5	0.1631579	-0.16071428	0.25	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMG586PFK
2081	8976	NDAR_INVMG586PFK	1963			M	5200	EndofPhase1_1a	12	Phase 1/1A	331	0	0	0	0	0	0	1	9	0	4	2	2	2	4	1	1	2	1	9	5	2	4	2	0	4	2	4	4	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.142857	1	3	3	2.4210527		1	3.1	2.875	1.25	3.5714285	4.5	-0.6789474	-0.73214287	-0.25	-0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMG586PFK
2081	8976	NDAR_INVMG756CWR	1459			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	1	0	1	2	2	2	2	6	9	0	2	0	3	2	3	2	4	5	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30									0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.4285715	2.5	2.2857144	2.5	2.1578948	1		2.1578948	1.4285715	2.5	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMG756CWR
2081	8976	NDAR_INVMG756CWR	1459			M	1600	Visit6	6	Phase 1/1A	204	0	0	0	0	0	0	1	9	2	2	2	2	2	2	2	4	3	4	4	2	3	4	2	3	4	3	4	4	1	0	1	0	1	1	1	1	3		1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	2	3.75	3.142857	3.5	2.9			2.1578948	1.4285715	2.5	2.2857144	2.5	0.74210525	0.5714286	1.25	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMG756CWR
2081	8976	NDAR_INVMG756CWR	1459			M	2800	Visit12	12	Phase 1/1A	351	0	0	0	0	0	0	1	4	2	4	4	4	4	4	4	5	4	6	6	4	4	4	4	4	4	5	4	5	1	1	1	0	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	3	3.75	5.25	4.142857	4.5	4.2380953		1	2.1578948	1.4285715	2.5	2.2857144	2.5	2.0802004	2.3214285	2.75	1.8571428	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMG756CWR
2081	8976	NDAR_INVMH212WWB	2489			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	0	0	0	2	2	2	0	1	2	6	9	2	2	0	1	1	5	2	2	4	0	0	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	1.375	2.25	1.7142857	3.5	1.95	1		1.95	1.375	2.25	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH212WWB
2081	8976	NDAR_INVMH533VPM	2133			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	0	1	3	6	2	2	1	1	0	0	9	1	2	2	3	0	1	3	4	4	1	0	0	1	1	1	0	1	1	1	0	4	3	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.625	0.25	2.2857144	2	2.1	1		2.1	2.625	0.25	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH533VPM
2081	8976	NDAR_INVMH533VPM	2133			M	1600	Visit6	6	Phase 1/1A	161	1	0	1	0	0	0	0	3	0	0	0	6	0	2	0	1	1	1	9	3	2	2	0	0	4	3	3	4	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.375	0.75	2	3.5	1.75			2.1	2.625	0.25	2.2857144	2	-0.35	-1.25	0.5	-0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH533VPM
2081	8976	NDAR_INVMH533VPM	2133			M	2800	Visit12	12	Phase 1/1A	329	1	0	1	0	1	0	0	4	6	0	5	6	6	6	2	2	6	6	9	2	6	4	6	2	5	6	4	6	1	1	0	1	1	1	0	0	1	1	1	3	2	2	4	1	0	1	1	0	1	0	0	1	1	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	3.5	4.285714	5.5	4.5			2.1	2.625	0.25	2.2857144	2	2.4	1.75	3.25	2	3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH533VPM
2081	8976	NDAR_INVMH533VPM	2133			M	5200	EndofPhase1_1a	18	Phase 1/1A	483	1	0	1	0	1	0	0	2	4	4	3	6	4	4	2	0	0	0	9	2	4	0	6	0	5	5	4	6	1	1	0	1	1	1	0	1	1	3	1	3	1	4	4	1	0	1	1	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.625	0	3.142857	5	3.05		1	2.1	2.625	0.25	2.2857144	2	0.95	1	-0.25	0.85714287	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH533VPM
2081	8976	NDAR_INVMH706BG3	1879			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	0	6	6	6	6	6	2	4	5	4	6	4	3	4	6	4	4	4	5	5	0	1	0	1	1	1	1	1	1	1	1	3	2	2	4	1	0	0	0	1	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	4.75	4.75	4.428571	4	4.571429	1		4.571429	4.75	4.75	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH706BG3
2081	8976	NDAR_INVMH706BG3	1879			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	1	0	0	6	4	4	5	4	4	5	3	4	4	5	9	5	4	5	5	5	5	5	4	5	1	1	0	1	1	1	1	1	1	1	1	3	3	3	4	1	0	0	0	0	0	1	0	1	0	1	0	0		0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	4.375	3.25	4.714286	5	4.55			4.571429	4.75	4.75	4.428571	4	-0.02142857	-0.375	-1.5	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH706BG3
2081	8976	NDAR_INVMH706BG3	1879			F	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	1	0	0	6	4	4	5	4	4	5	4	4	4	5	6	5	4	5	5	5	5	4	5	5	0	1	0	0	1	1	1	1	1	1	1	3	4	2	2	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.5	4.75	4.857143	4.5	4.6666665			4.571429	4.75	4.75	4.428571	4	0.0952381	-0.25	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH706BG3
2081	8976	NDAR_INVMH706BG3	1879			F	5200	EndofPhase1_1a	18	Phase 1/1A	601	0	0	0	0	1	0	0	6	4	4	5	4	4	5	4	4	4	5	6	5	4	5	5	5	5	4	5	5	0	1	0	0	1	1	1	1	1	1	1	3	4	2	2	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.5	4.75	4.857143	4.5	4.6666665		1	4.571429	4.75	4.75	4.428571	4	0.0952381	-0.25	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMH706BG3
2081	8976	NDAR_INVMJ584WWU	1238			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	2	2	2	2	2	1	0	1	0	9	2	2	1	2	1	4	2	2	3	0	0	0	1	1	1	1	1	3	2	1	3	3	3	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	0.25	1.8571428	3	1.95	1		1.95	2.375	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ584WWU
2081	8976	NDAR_INVMJ584WWU	1238			M	5200	EndofPhase1_1a	2	Phase 1/1A	57	1	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	0	9	0	2	2	2	2	3	1	1	2	0	1	2	1	1	1	0	1	1	2	0		4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.625	0	1.5714285	2	1		1	1.95	2.375	0.25	1.8571428	3	-0.95	-1.75	-0.25	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ584WWU
2081	8976	NDAR_INVMJ584WWU	1238			M	5800	EndofPhase2	3	Phase 2	90	1	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	0	9	0	2	2	2	2	3	1	1	2	0	1	2	2	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.625	0	1.5714285	2	1			1.95	2.375	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ584WWU
2081	8976	NDAR_INVMJ584WWU	1238			M	6000	EndofPhase3	6	Phase 3	175	1	0	0	0	0	0	0	4	2	2	1	3	3	4	2	0	0	1	9	3	1	3	3	3	3	2	4	3	1	0	1	1	1	1	1	1	3	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0.25	2.857143	2.5	2.35			1.95	2.375	0.25	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ584WWU
2081	8976	NDAR_INVMJ694HNA	2057			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	0	2	2	0	2	0	0	0	0	9	0	2	5	4	2	5	3	4	4	1	2	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	27	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	1.25	0	3	4	1.95	1		1.95	1.25	0	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ694HNA
2081	8976	NDAR_INVMJ694HNA	2057			M	1600	Visit6	6	Phase 1/1A	167	0	0	1	0	0	0	0	5	0	0	2	2	1	2	0	0	0	0	9	2	3	5	6	3	5	3	4	5	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.5	0	4	4	2.4			1.95	1.25	0	3	4	0.45	0.25	0	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ694HNA
2081	8976	NDAR_INVMJ694HNA	2057			M	2800	Visit12	12	Phase 1/1A	335	0	0	1	0	0	0	0	6	0	0	4	2	2	2	0	0	0	3	9	0	4	4	2	2	5	4	2	4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2	0.75	2.5714285	4.5	2.3			1.95	1.25	0	3	4	0.35	0.75	0.75	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ694HNA
2081	8976	NDAR_INVMJ694HNA	2057			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	1	0	0	0	0	6	0	0	2	2	2	2	0	0	0	0	9	0	4	6	6	2	5	3	4	5	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	5	1.75	0	3.857143	4	2.45		1	1.95	1.25	0	3	4	0.5	0.5	0	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMJ694HNA
2081	8976	NDAR_INVMK102EKH	1862			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	2	4	1	9	2	3	4	2	1	5	4	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	1.75	3.4285715	4.5	2.7	1		2.7	1.75	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK102EKH
2081	8976	NDAR_INVMK102EKH	1862			M	1600	Visit6	6	Phase 2	184	1	0	0	0	0	0	0	6	0	1	2	2	2	2	0	0	0	0	9	0	2	4	2	0	4	2	3	4	1	1	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	0	2.142857	3	1.8			2.7	1.75	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK102EKH
2081	8976	NDAR_INVMK102EKH	1862			M	2800	Visit12	12	Phase 2	338	1	0	0	0	0	0	0	6	2	4	2	4	3	2	0	1	1	0	9	1	2	4	2	1	3	3	4	5	1	1	0	0	1	1	1	1	1	1	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	0.5	2.7142856	3	2.5			2.7	1.75	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK102EKH
2081	8976	NDAR_INVMK102EKH	1862			M	5200	EndofPhase1_1a	2	Phase 1/1A	59	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	0	0	0	9	1	1	4	2	1	2	2	4	4	0	0	0	1	1	0	0	1	1	1	0	4	2	4	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.75	0	2.4285715	2	1.75		1	2.7	1.75	1.75	3.4285715	4.5	-0.95	0	-1.75	-1	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK102EKH
2081	8976	NDAR_INVMK102EKH	1862			M	5800	EndofPhase2	18	Phase 2	505	1	0	0	0	0	0	0	6	0	1	2	2	1	2	0	0	0	1	9	0	2	6	6	2	4	2	3	6	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		1.75	0.25	3.5714285	3	2.3			2.7	1.75	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK102EKH
2081	8976	NDAR_INVMK446URG	2798			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	6	1	2	3	1	1	0	2	1	1	9	4	2	1	2	2	6	2	2	4	1	0	1	0	1	1	1	1	1	3	1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.5	1	2.4285715	4	2.45	1		2.45	2.5	1	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK446URG
2081	8976	NDAR_INVMK750CV9	1749			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	3	2	2	2	1	2	4	0	0	1	9	3	3	3	2	3	2	1	3	2	1	0	1	0	1	1	1	1	2	2	1	4	2	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	0.25	2.7142856	1.5	2.2	1		2.2	2.625	0.25	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK750CV9
2081	8976	NDAR_INVMK750CV9	1749			F	1600	Visit6	6	Phase 3	169	0	1	0	0	0	0	0	5	3	2	2	2	1	2	4	0	0	1	9	3	3	3	2	3	2	1	3	2	1	0	1	0	1	1	1	1	2	2	1	4	2	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	0.25	2.7142856	1.5	2.2			2.2	2.625	0.25	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK750CV9
2081	8976	NDAR_INVMK750CV9	1749			F	5200	EndofPhase1_1a	4	Phase 1/1A	114	0	1	0	0	0	0	0	5	3	2	2	2	1	2	4	0	0	1	9	3	3	3	2	3	2	1	3	2	1	0	1	0	1	1	1	1	2	2	1	4	2	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	0.25	2.7142856	1.5	2.2		1	2.2	2.625	0.25	2.7142856	1.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK750CV9
2081	8976	NDAR_INVMK750CV9	1749			F	5800	EndofPhase2	5	Phase 2	128	0	1	0	0	0	0	0	5	3	2	2	2	1	2	4	0	0	1	9	3	3	3	2	3	2	1	3	2	1	0	1	0	1	1	1	1	2	2	1	4	2	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	2.625	0.25	2.7142856	1.5	2.2			2.2	2.625	0.25	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK750CV9
2081	8976	NDAR_INVMK750CV9	1749			F	6000	EndofPhase3	7	Phase 3	233	0	1	0	0	0	0	0	2	3	2	2	2	1	2	4	1	0	2	9	3	3	3	2	3	2	1	3	2	1	0	1	0	1	1	1	1	2	2	1	4	2	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	0.75	2.7142856	1.5	2.15			2.2	2.625	0.25	2.7142856	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMK750CV9
2081	8976	NDAR_INVML149YRX	2269			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	0	0	4	4	2	4	4	0	0	0	9	4	4	4	6	4	1	1	4	4	0	0	1	0	1	1	1	1	1	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	7	2.75	0	4.285714	1	2.7	1		2.7	2.75	0	4.285714	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML149YRX
2081	8976	NDAR_INVML199FN8	1717			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	4	0	0	4	2	3	2	0	0	3	9	2	2	3	3	5	3	3	3	2	1	0	1	0	1	1	0	1	2	2	1	4	4	4	4	1	0	0	1	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	5	2.125	0.75	2.857143	3	2.3	1		2.3	2.125	0.75	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML199FN8
2081	8976	NDAR_INVML199FN8	1717			M	1600	Visit6	6	Phase 1/1A	202	0	0	1	0	0	0	0	2	2	4	3	2	2	1	1	0	0	1	9	0	2	2	4	2	3	2	2	4	1	0	1	0	0	0	0	0	3	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2.125	0.25	2.2857144	2.5	1.95			2.3	2.125	0.75	2.857143	3	-0.35	0	-0.5	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML199FN8
2081	8976	NDAR_INVML199FN8	1717			M	5200	EndofPhase1_1a	6	Phase 1/1A	222	0	0	1	0	0	0	0	2	1	0	2	0	1	2	0	0	0	1	9	1	0	0	2	1	3	2	2	2	0	0	1	0	0	0	0	0	3	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	1	0.25	1.1428572	2.5	1.1		1	2.3	2.125	0.75	2.857143	3	-1.2	-1.125	-0.5	-1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML199FN8
2081	8976	NDAR_INVML843GMU	1887			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	6	5	2	4	5	5	5	6	6	6	6	5	4	6	4	2	6	3	6	6	1	1	1	0	1	1	2	1	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.5	6	4.714286	4.5	4.857143	1		4.857143	4.5	6	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML843GMU
2081	8976	NDAR_INVML843GMU	1887			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	4	6	5	2	4	5	5	5	6	6	6	6	5	4	6	4	2	6	3	6	6	1	1	1	0	1	1	2	1	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.5	6	4.714286	4.5	4.857143			4.857143	4.5	6	4.714286	4.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML843GMU
2081	8976	NDAR_INVML843GMU	1887			M	2800	Visit12	12	Phase 2	325	0	1	0	0	0	0	0	6	6	6	6	6	6	4	6	0	4	2	9	6	6	6	4	4	6	6	6	4	1	1	1	1	1	1	1	1	1	1	1	2	3	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.75	1.5	5.142857	6	5			4.857143	4.5	6	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML843GMU
2081	8976	NDAR_INVML843GMU	1887			M	5200	EndofPhase1_1a	11	Phase 1/1A	290	0	1	0	0	0	0	0	6	5	3	2	4	3	4	4	0	2	2	9	4	4	4	3	3	6	4	4	4	1	1	1	1	1	1	1	1	1	1	1	4	3	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	3.875	1	3.7142856	5	3.55		1	4.857143	4.5	6	4.714286	4.5	-1.3071429	-0.625	-5	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML843GMU
2081	8976	NDAR_INVML843GMU	1887			M	5800	EndofPhase2	18	Phase 2	501	0	1	0	0	0	0	0	6	2	2	1	6	2	6	6	6	4	0	9	4	2	4	2	2	6	2	4	6	1	0	1	1	1	1	1	1	1	1	1	4	4	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		1	0	0	1	1	1	1	0	0	0	0	0	1	1	1	1	4	3.875	2.5	3.4285715	4	3.65			4.857143	4.5	6	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML843GMU
2081	8976	NDAR_INVML850AYA	1800			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	5	3	6	5	6	4	2	1	4	0	9	2	4	4	4	2	4	5	4	5	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.5	1.25	3.5714285	4.5	3.75	1		3.75	4.5	1.25	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML850AYA
2081	8976	NDAR_INVML850AYA	1800			M	1600	Visit6	6	Phase 2	175	0	0	1	0	0	0	0	4	2	0	1	2	2	2	2	0	0	0	9	0	1	2	2	2	4	3	4	4	1	1	1	0	0	1	1	1	1	2	1	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	0	2.142857	3.5	1.85			3.75	4.5	1.25	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML850AYA
2081	8976	NDAR_INVML850AYA	1800			M	2800	Visit12	12	Phase 2	352	0	0	1	0	0	0	0	6	2	3	3	2	2	3	2	0	0	0	9	0	2	3	3	2	4	4	2	4	1	1	1	0	1	1	1	1	1	2	1	3	1	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	0	2.2857144	4	2.35			3.75	4.5	1.25	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML850AYA
2081	8976	NDAR_INVML850AYA	1800			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	0	1	0	0	0	0	6	2	2	1	3	3	4	2	0	0	0	9	2	2	1	2	2	3	3	4	3	1	1	1	0	1	1	1	1	1	2	1	3	2	2	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	5	2.875	0	2.2857144	3	2.25		1	3.75	4.5	1.25	3.5714285	4.5	-1.5	-1.625	-1.25	-1.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML850AYA
2081	8976	NDAR_INVML850AYA	1800			M	5800	EndofPhase2	18	Phase 2	520	0	0	0	0	1	0	0	4	2	2	2	2	2	2	2	0	0	0	9	0	1	1	2	2	4	3	2	4	1	1	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	0	1.7142857	3.5	1.85			3.75	4.5	1.25	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVML850AYA
2081	8976	NDAR_INVMM478ERT	2039			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	5	5	4	4	2	4	3	0	2	2	9	4	4	4	4	5	6	4	5	5	1	1	1	0	1	1	1	1	2	1	1	3	2	4	4	1	0	0	1	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.875	1	4.428571	5	3.8	1		3.8	3.875	1	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM478ERT
2081	8976	NDAR_INVMM478ERT	2039			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	1	0	0	4	1	4	2	4	2	4	1	0	4	4	9	3	4	5	4	3	6	5	6	6	1	1	1	1	1	1	1	1	1	2	0	4	2	4	4	1	0	0	1	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	2	4.428571	5.5	3.6			3.8	3.875	1	4.428571	5	-0.2	-1.125	1	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM478ERT
2081	8976	NDAR_INVMM478ERT	2039			M	2800	Visit12	12	Phase 1/1A	335	1	0	0	0	0	0	0	4	4	2	4	4	1	3	2	4	6			4	3	4	4	6	6	4	5	4	1	1	1	1	1	1	1	1		1	1	3	1	2	2	1	0	0	0	0	1	0	0	0	1	0	0	1																		0	0	0	0	0	0	0	0	4	3		4.285714	5	3.8947368			3.8	3.875	1	4.428571	5	0.094736844	-0.875		-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM478ERT
2081	8976	NDAR_INVMM478ERT	2039			M	5200	EndofPhase1_1a	18	Phase 1/1A	495	0	0	0	0	1	0	0	5	5	4	2	5	2	4	0	1	5	5	9	5	5	5	5	4	6	6	5	5	1	1	1	1	1	1	1	1	2	3	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	4	3.375	2.75	4.857143	6	4.2		1	3.8	3.875	1	4.428571	5	0.4	-0.5	1.75	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM478ERT
2081	8976	NDAR_INVMM496CMP	2270			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	0	2	0	1	0	1	0	2	2	2	9	2	2	4	2	1	4	3	2	1	1	1	1	0	1	0	1	0	3	3	0	4	4	3	4	1	0	1	0	0	0	0	0	1	0	0	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	6	0.875	1.5	2	3.5	1.7	1		1.7	0.875	1.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM496CMP
2081	8976	NDAR_INVMM496CMP	2270			M	1600	Visit6	6	Phase 2	162	0	0	0	0	0	0	1	4	2	2	3	3	2	4	1	0	2	0	9	2	3	4	4	2	6	3	4	4	0	0	1	0	1	1	1	1	2	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	4	2.625	0.5	3.2857144	4.5	2.75			1.7	0.875	1.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM496CMP
2081	8976	NDAR_INVMM496CMP	2270			M	2800	Visit12	12	Phase 3	330	0	0	0	0	1	0	0	4	3	4	4	4	4	4	2	2	3	0	9	4	4	5	4	5	6	6	4	5	1	1	1	1	1	1	1	1	1	2	1	2	2	2	1	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.625	1.25	4.428571	6	3.85			1.7	0.875	1.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM496CMP
2081	8976	NDAR_INVMM496CMP	2270			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	0	0	0	0	0	0	1	9	0	0	0	0	0	0	0	0	0	0	9	1	1	1	2	0	5	2	2	1	0	0	1	1	1	1	0	0	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	4	0	0	1.1428572	3.5	0.7894737		1	1.7	0.875	1.5	2	3.5	-0.91052634	-0.875	-1.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM496CMP
2081	8976	NDAR_INVMM496CMP	2270			M	5800	EndofPhase2	8	Phase 2	204	0	0	0	0	0	0	1	4	2	2	2	2	2	3	0	2	0	0	9	2	1	3	2	2	5	4	3	4	0	1	1	0	1	1	1	1	2	2	1	4	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.125	0.5	2.4285715	4.5	2.25			1.7	0.875	1.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM496CMP
2081	8976	NDAR_INVMM730HYM	1643			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	2	0	0	0	1	1	1	0	0	1	1	9	2	2	2	1	1	4	3	1	1	1	1	1	1	1	0	0	1	1	2	0	4	3	3	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.625	0.5	1.4285715	3.5	1.2	1		1.2	0.625	0.5	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM730HYM
2081	8976	NDAR_INVMM730HYM	1643			F	5200	EndofPhase1_1a	1	Phase 1/1A	35	1	0	0	0	0	0	0	2	0	0	0	0	1	1	0	0	1	1	9	1	2	2	2	1	3	3	1	1	1	1	1	0	1	0	0	1	0	2	0	4	4	3	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.5	0.5	1.4285715	3	1.1		1	1.2	0.625	0.5	1.4285715	3.5	-0.1	-0.125	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM730HYM
2081	8976	NDAR_INVMM849FA7	1745			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	1	0	6	6	3	6	6	5	5	3	1	1	2	9	4	6	4	5	5	4	5	6	6	1	1	1	1	1	1	1	1	1	1	1	2	3	2	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	1	5.142857	4.5	4.45	1		4.45	5	1	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM849FA7
2081	8976	NDAR_INVMM849FA7	1745			M	1600	Visit6	6	Phase 1B	169	1	0	0	0	0	0	0	6	4	5	5	4	6	6	5	5	5	5	5	3	4	4	6	5	6	3	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5.125	5	4.857143	4.5	4.952381			4.45	5	1	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM849FA7
2081	8976	NDAR_INVMM849FA7	1745			M	2800	Visit12	12	Phase 1B	335	1	0	0	0	0	0	0	5	3	3	4	4	3	6	5	6	5	6	6	5	5	6	6	6	6	5	5	6	0	0	0	0	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5.75	5.571429	5.5	5.047619			4.45	5	1	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM849FA7
2081	8976	NDAR_INVMM849FA7	1745			M	5400	EndofPhase1b	18	Phase 1B	482	0	1	0	0	0	0	0	5	6	6	6	6	6	4	5	6	4	6	6	4	3	5	5	5	6	5	5	6	0	1	1	1	1	1	1	1	1	2	1	3	2	3	3	0	0	0	0	0	0	0	0					0		0		0		0		0		1	0	0	1	0	0	0	0	0	1	0	0	1	1	1	1	5	5.5	5.5	4.714286	5.5	5.2380953			4.45	5	1	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM849FA7
2081	8976	NDAR_INVMM981NC6	1036			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	3	4	2	2	2	4	1	1	2	9	4	2	4	5	4	3	3	4	3	0	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	1	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	4	3.125	1	3.7142856	3	3.05	1		3.05	3.125	1	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMM981NC6
2081	8976	NDAR_INVMN366CGG	1899			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	6	3	2	3	6	3	1	1	2	3	9	3	4	1	4	5	1	1	5	4	0	0	1	0	1	0	1	1	2	3	1	4	2	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	5	3.625	1.5	3.7142856	1	3.15	1		3.15	3.625	1.5	3.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN366CGG
2081	8976	NDAR_INVMN366CGG	1899			M	5200	EndofPhase1_1a	3	Phase 1/1A	91	0	0	0	0	0	1	0		2	3	4	1	3	3	1	1	0	0	9	0	2	3	4	6	1	2	5	5	0	0	1	1	1	1	1	1	3	3	0	4	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	2.4285715	0.25	3.5714285	1.5	2.4210527		1	3.15	3.625	1.5	3.7142856	1	-0.72894734	-1.1964285	-1.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN366CGG
2081	8976	NDAR_INVMN574PY7	1855			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	1	0	2	2	2	0	2	1	1	9	0	3	3	2	1	3	2	4	2	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	1	2.142857	2.5	1.85	1		1.85	1.625	1	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN574PY7
2081	8976	NDAR_INVMN574PY7	1855			F	2800	Visit12	12	Phase 2	339	1	0	0	0	0	0	0	6	0	0	2	2	1	2	0	1	2	4	9	3	2	2	2	2	2	1	5	3	1	0	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.625	1.75	2.7142856	1.5	2.1			1.85	1.625	1	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN574PY7
2081	8976	NDAR_INVMN574PY7	1855			F	5200	EndofPhase1_1a	6	Phase 1/1A	178	1	0	0	0	0	0	0	6	0	0	2	2	1	2	0	1	2	1	9	1	2	2	2	1	4	2	4	3	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	1	2.142857	3	1.9		1	1.85	1.625	1	2.142857	2.5	0.05	0	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN574PY7
2081	8976	NDAR_INVMN574PY7	1855			F	5800	EndofPhase2	18	Phase 2	505	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	2	4	5	9	6	2	2	2	3	3	2	5	5	1	0	1	1	1	1	1	1	1	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	2.75	3.5714285	2.5	2.75			1.85	1.625	1	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN574PY7
2081	8976	NDAR_INVMN585DN6	1378			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	5	2	5	6	6	6	5	3	4	4	6	6	6	6	6	6	3	4	6	6	1	1	1	1	1	1	1	1	3	1	1	3	2	2	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	5	4.875	4.25	6	3.5	5	1		5	4.875	4.25	6	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN585DN6
2081	8976	NDAR_INVMN585DN6	1378			F	1600	Visit6	6	Phase 1/1A	192	0	0	0	0	0	1	0	6	6	2	6	6	6	6	4	4	6	6	6	6	6	3	6	6	4	5	6	6	1	1	1	1	1	1	1	1	2	1	1	3	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	5.5	5.571429	4.5	5.3333335			5	4.875	4.25	6	3.5	0.33333334	0.375	1.25	-0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN585DN6
2081	8976	NDAR_INVMN585DN6	1378			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	6	6	3	5	6	6	6	4	2	4	5	9	4	6	4	6	6	5	5	6	6	1	1	1	1	1	1	1	1	3	1	1	3	2	2	3	1	0	0	0	0	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0	5	5.25	2.75	5.428571	5	5.05			5	4.875	4.25	6	3.5	0.05	0.375	-1.5	-0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN585DN6
2081	8976	NDAR_INVMN585DN6	1378			F	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	1	0	6	6	3	4	6	6	6	4	1	1	2	9	6	4	4	6	6	5	5	6	6	1	1	1	1	1	1	1	1	2	1	1	2	1	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	5.125	1	5.428571	5	4.65		1	5	4.875	4.25	6	3.5	-0.35	0.25	-3.25	-0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN585DN6
2081	8976	NDAR_INVMN616AN6	2018			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	9	1	0	0	1	0	3	1	0	1	2	2	2	2	0	2	2	2	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	4	0.125	0	0.42857143	2	0.4	1		0.4	0.125	0	0.42857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMN616AN6
2081	8976	NDAR_INVMP244UNM	1806			F	400	Baseline	0	Pre-Rand	1	1	1	0	0	0	0	0	6	0	0	0	5	4	1	4	3	3	3	1	3	1	0	3	1	5	4	4	2	1	1	1	0	1	1	1	1	1	1	0	4	4	4	1	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2.5	2.5	2	4.5	2.5238094	1		2.5238094	2.5	2.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP244UNM
2081	8976	NDAR_INVMP324WRF	1908			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	0	4	6	5	6	3	0	2	0	9	0	2	0	3	4	3	1	5	4	0	0	1	0	1	2	0	1	1	1	1	4	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.5	0.5	2.5714285	2	3	1		3	4.5	0.5	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP324WRF
2081	8976	NDAR_INVMP324WRF	1908			F	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	5	4	0	4	2	2	2	4	0	0	0	9	2	2	0	2	2	3	2	4	4	0	0	0	0	1	0	0	0	3	1	1	4	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	0	2.2857144	2.5	2.2			3	4.5	0.5	2.5714285	2	-0.8	-1.625	-0.5	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP324WRF
2081	8976	NDAR_INVMP324WRF	1908			F	2800	Visit12	12	Phase 1/1A	334	1	0	0	0	0	0	0	4	2	0	0	2	0	2	3	0	2	0	9	2	2	0	2	0	3	2	4	4	0	1	0	0	1	0	0	0	2	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.5	2	2.5	1.7			3	4.5	0.5	2.5714285	2	-1.3	-2.875	0	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP324WRF
2081	8976	NDAR_INVMP324WRF	1908			F	5200	EndofPhase1_1a	18	Phase 1/1A	510	1	0	0	0	0	0	0	2	2	0	2	2	0	2	2	0	0	0	9	2	2	0	0	0	3	3	4	4	0	0	1	0	1	1	1	1	1	1	1	3	3	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	0	1.7142857	3	1.5		1	3	4.5	0.5	2.5714285	2	-1.5	-3	-0.5	-0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP324WRF
2081	8976	NDAR_INVMP410HW5	1496			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	3	4	5	4	3	4	1	2	1	9	3	3	3	4	4	5	4	5	5	1	1	1	1	1	1	1	1	1	1	1	3	1	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.125	1	3.857143	4.5	3.65	1		3.65	4.125	1	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP410HW5
2081	8976	NDAR_INVMP410HW5	1496			M	5200	EndofPhase1_1a	4	Phase 1/1A	106	0	0	0	0	0	0	1	5	4	0	4	3	5	4	2	0	0	1	9	3	1	0	2	1	5	3	4	5	1	1	0	0	1	1	1	1	1	3	1	2	1	2	1	1	0	1	0	0	0	0	0	1	1	1	1	1	28	0		1	2	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	3.375	0.25	2.2857144	4	2.6		1	3.65	4.125	1	3.857143	4.5	-1.05	-0.75	-0.75	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP410HW5
2081	8976	NDAR_INVMP715ZYC	1371			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	0	1	2	2	0	2	4	0	0	1	9	0	2	4	2	0	4	2	4	2	0	1	0	0	1	0	1	0	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.25	2	3	1.9	1		1.9	2.125	0.25	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP715ZYC
2081	8976	NDAR_INVMP715ZYC	1371			F	1600	Visit6	6	Phase 2	168	0	0	0	0	0	0	1	4	0	0	0	2	0	3	1	2	1	1	9	1	4	2	2	1	6	3	3	4	0	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	1	2.4285715	4.5	2			1.9	2.125	0.25	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP715ZYC
2081	8976	NDAR_INVMP715ZYC	1371			F	5200	EndofPhase1_1a	4	Phase 1/1A	131	0	0	0	0	0	0	1	4	0	1	2	2	2	2	1	0	0	1	9	2	0	2	5	3	2	1	2	2	2	2	2	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	23	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	0.25	2.2857144	1.5	1.7		1	1.9	2.125	0.25	2	3	-0.2	-0.375	0	0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP715ZYC
2081	8976	NDAR_INVMP715ZYC	1371			F	5800	EndofPhase2	10	Phase 2	273	0	0	0	0	0	1	0	2	0	0	0	2	2	2	0	1	1	4	9	1	2	4	2	1	6	4	3	4	0	1	2	1	1	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	8	0		0		1	22	0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	1	1.5	2.4285715	5	2.05			1.9	2.125	0.25	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP715ZYC
2081	8976	NDAR_INVMP988HLB	2736			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	3	4	3	3	4	0	0	0	9	2	2	3	4	0	5	6	4	5	1	1	1	1	1	0	1	1	2	1	1	2	4	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4.375	0	2.857143	5.5	3.3	1		3.3	4.375	0	2.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP988HLB
2081	8976	NDAR_INVMP988HLB	2736			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	6	4	6	0	2	2	2	2	0	0	0	9	2	2	4	4	4	4	3	4	6	1	1	1	1	1	0	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	3	0	3.7142856	3.5	2.85			3.3	4.375	0	2.857143	5.5	-0.45	-1.375	0	0.85714287	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP988HLB
2081	8976	NDAR_INVMP988HLB	2736			M	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	0	1	6	2	4	2	3	2	6	2	0	0	0	9	3	3	4	4	5	4	3	4	5	1	0	1	1	1	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.375	0	4	3.5	3.1			3.3	4.375	0	2.857143	5.5	-0.2	-1	0	1.1428572	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP988HLB
2081	8976	NDAR_INVMP988HLB	2736			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	0	0	0	0	1	6	0	2	2	2	2	2	0	2	2	2	9	2	2	4	2	2	4	4	4	5	1	0	1	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	2	2	1.5	3	4	2.55		1	3.3	4.375	0	2.857143	5.5	-0.75	-2.375	1.5	0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMP988HLB
2081	8976	NDAR_INVMR416APU	2864			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	0	2	0	2	2	6	4	4	6	4	4	2	3	4	4	3	2	2	1	1	0	0	1	0	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	0.85714287	5	3	3.5	2.7	1		2.7	0.85714287	5	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR416APU
2081	8976	NDAR_INVMR416APU	2864			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	9	0	4	2	2	2	2	0	4	3	4	5	5	4	2	3	4	4	4	4	2	1	1	1	0	1	0	1	1	1	3	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	1.7142857	4	3.4285715	4	3			2.7	0.85714287	5	3	3.5	0.3	0.85714287	-1	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR416APU
2081	8976	NDAR_INVMR416APU	2864			M	2800	Visit12	12	Phase 1/1A	329	0	0	0	0	0	0	1	5	0	0	0	2	2	2	1	1	2	3	9	3	2	2	2	2	5	2	4	2	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.5	1.5	2.4285715	3.5	2.1			2.7	0.85714287	5	3	3.5	-0.6	0.64285713	-3.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR416APU
2081	8976	NDAR_INVMR416APU	2864			M	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	0	0	1	5	4	4	2	2	2	4	2	2	2	2	9	6	4	4	4	4	4	3	4	4	1	1	1	0	1	1	1	1	1	2	1	3	2	2	2	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.125	1.5	4.285714	3.5	3.4		1	2.7	0.85714287	5	3	3.5	0.7	2.267857	-3.5	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR416APU
2081	8976	NDAR_INVMR670JTD	1744			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	1	3	3	4	4	4	3	5	0	0	0	9	1	1	3	2	0	3	3	5	4	0	0	0	0	1	1	1	1	1	3	1	2	1	2	1	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	5	3.375	0	2.2857144	3	2.45	1		2.45	3.375	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR670JTD
2081	8976	NDAR_INVMR670JTD	1744			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	2	2	2	2	2	2	2	3	0	0	0	9	1	2	1	2	1	3	3	2	2	1	0	1	0	1	1	1	1	2	2	1	2	1	1	1	1	0	0	0	1	0	0	0	1	1	1	1	1	16	0		1	14	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	0	1.5714285	3	1.7			2.45	3.375	0	2.2857144	3	-0.75	-1.25	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR670JTD
2081	8976	NDAR_INVMR670JTD	1744			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	9	2	5	4	3	6	3	4	0	0	0	9	1	1	4	4	1	3	2	4	2	1	0	1	0	1	1	1	1	2	2	1	2	1	4	1	1	0	0	0	0	1	0	0	0	0	1	0	1	21	0		0		0		1	9	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.857143	0	2.4285715	2.5	2.5789473			2.45	3.375	0	2.2857144	3	0.12894736	0.48214287	0	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR670JTD
2081	8976	NDAR_INVMR670JTD	1744			M	4000	Visit18	18	Phase 1/1A	513	0	0	0	0	0	1	0	5	5	0	4	5	6	4	4	1	1	1	4	2	3	3	6	1	3	5	4	5	1	1	0	1	1	1	1	1	2	2	1	3	2	1	1	1	0	0	0	0	0	1	0	1	1	1	0	0		0		0		0		1	30	0	0	0	0	1	0	0	0	0	0	1	1	1	1	1	0	5	4.125	1.75	3.4285715	4	3.4285715		1	2.45	3.375	0	2.2857144	3	0.9785714	0.75	1.75	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMR670JTD
2081	8976	NDAR_INVMT158VH7	1936			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	2	3	2	2	2	1	3	4	6	4	3	5	3	5	6	4	3	1	6	0	0	1	1	1	1	1	1	2	1	1	3	1	4	4	1	0	1	0	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	7	2.75	4.25	4.142857	3.5	3.5714285	1		3.5714285	2.75	4.25	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT158VH7
2081	8976	NDAR_INVMT158VH7	1936			F	1600	Visit6	6	Phase 2	171	0	0	0	0	0	0	1	6	5	2	5	5	1	2	1	2	2	6	9	3	3	3	4	3	5	3	4	6	1	0	1	1	1	1	1	1	2	1	1	3	2	3	4	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	3.375	2.5	3.7142856	4	3.55			3.5714285	2.75	4.25	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT158VH7
2081	8976	NDAR_INVMT158VH7	1936			F	2800	Visit12	12	Phase 2	352	0	0	0	0	0	0	1	4	3	4	3	4	3	2	1	4	4	5	6	3	4	3	1	3	4	4	4	5	1	0	1	1	1	1	1	1	3	2	1	3	4	2	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	4	3	4.75	3.2857144	4	3.5238094			3.5714285	2.75	4.25	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT158VH7
2081	8976	NDAR_INVMT158VH7	1936			F	5200	EndofPhase1_1a	3	Phase 1/1A	94	0	0	0	0	0	0	1	6	3	0	1	5	1	2	1	0	0	0	9	1	1	1	1	1	5	3	3	5	1	0	1	1	1	1	1	1	3	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	4	2.375	0	1.8571428	4	2		1	3.5714285	2.75	4.25	4.142857	3.5	-1.5714285	-0.375	-4.25	-2.2857144	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT158VH7
2081	8976	NDAR_INVMT158VH7	1936			F	5800	EndofPhase2	18	Phase 2	498	0	0	0	0	0	0	1	5	2	3	4	4	1	2	2	1	1	4	9	2	1	3	3	1	6	5	2	6	1	0	1	1	1	1	0	1	3	1	1	2	2	1	1	1	0	1	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5	2.875	1.5	2.5714285	5.5	2.9			3.5714285	2.75	4.25	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT158VH7
2081	8976	NDAR_INVMT304FZL	2460			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	6	0	0	0	2	0	0	0	0	9	0	0	0	2	0	4	2	1	2	0	0	0	0	1	1	0	0	3		1	3	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	1.5	0	0.71428573	3	1.15	1		1.15	1.5	0	0.71428573	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT304FZL
2081	8976	NDAR_INVMT304FZL	2460			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	0	0	4	2	0	3	1	1	4	5	9	4	6	0	4	5	4	3	5	2	0	0	0	0	1	1	0	1	2	1	1	2	2	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	2.5	3.7142856	3.5	2.95			1.15	1.5	0	0.71428573	3	1.8	0.5	2.5	3	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT304FZL
2081	8976	NDAR_INVMT304FZL	2460			F	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	1	0	6	4	2	2	2	0	1	2	3	5	6	6	2	2	1	2	3	3	1	2	3	1	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	5	2.142857	2	2.7619047			1.15	1.5	0	0.71428573	3	1.6119047	0.875	5	1.4285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT304FZL
2081	8976	NDAR_INVMT304FZL	2460			F	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	1	0	6	4	4	4	1	1	3	2	5	4	6	9	4	4	4	4	4	4	2	4	5	1	0	1	0	1	1	1	1	1	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.125	3.75	4.142857	3	3.75		1	1.15	1.5	0	0.71428573	3	2.6	1.625	3.75	3.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT304FZL
2081	8976	NDAR_INVMT617RXB	1724			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	2	2	2	2	3	2	3	2	1	2	2	4	1	2	3	2	4	1	5	1	0	1	1	1	1	1	1	3		0	4	1	1	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2.5	2	2.5714285	3	2.4761906	1		2.4761906	2.5	2	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT617RXB
2081	8976	NDAR_INVMT617RXB	1724			M	1600	Visit6	6	Phase 1/1A	168	1	0	0	0	0	0	0	5	5	1	1	3	2	2	2	5	4	3	3	3	1	1	3	2	4	2	4	5	1	1	1	2	1	1	1	1	1	1	1	3	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	6	2.625	3.75	2.7142856	3	2.9047618			2.4761906	2.5	2	2.5714285	3	0.42857143	0.125	1.75	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT617RXB
2081	8976	NDAR_INVMT617RXB	1724			M	2800	Visit12	12	Phase 1/1A	335	1	0	0	0	0	0	0	5	1	1	2	2	2	3	2	2	2	2	9	3	2	2	2	1	4	2	3	4	1	1	0	0	0	0	1	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	2.25	1.5	2.4285715	3	2.35			2.4761906	2.5	2	2.5714285	3	-0.12619047	-0.25	-0.5	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT617RXB
2081	8976	NDAR_INVMT617RXB	1724			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	1	0	0	0	0	0	0	2	1	1	1	1	1	1	1	1	1	1	9	2	2	1	2	2	4	1	2	4	0	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5	1.125	0.75	2.142857	2.5	1.6		1	2.4761906	2.5	2	2.5714285	3	-0.8761905	-1.375	-1.25	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT617RXB
2081	8976	NDAR_INVMT746DTV	1111			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	2	2	2	9	2	2	4	2	1	3	3	3	3	2	2	2	1	1	2	2	2	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	20	1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.5	2.4285715	3	2.25	1		2.25	2	1.5	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT746DTV
2081	8976	NDAR_INVMT746DTV	1111			M	1600	Visit6	6	Phase 2	185	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	1	1	1	1	0	0	0	0	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1	0.75	1	1	1			2.25	2	1.5	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT746DTV
2081	8976	NDAR_INVMT746DTV	1111			M	5200	EndofPhase1_1a	4	Phase 1/1A	104	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	2	1	1	1	0	0	0	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	1	0.75	1	1.5	1.05		1	2.25	2	1.5	2.4285715	3	-1.2	-1	-0.75	-1.4285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMT746DTV
2081	8976	NDAR_INVMU034UAX	2321			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	0	0	0	2	1	1	0	0	5	2	9	1	0	4	0	0	4	3	2	4	1	1	1	0	1	1	1	1	2	1	1	3	3	4	3	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	4	1.125	1.75	1.5714285	3.5	1.7	1		1.7	1.125	1.75	1.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU034UAX
2081	8976	NDAR_INVMU034UAX	2321			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	1	0	6	4	2	2	2	0	4	0	0	0	0	9	0	0	0	3	0	2	2	6	5	1	0	1	0	1	1	1	1	2	1	0	2	2	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.5	0	2	2	1.9			1.7	1.125	1.75	1.5714285	3.5	0.2	1.375	-1.75	0.42857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU034UAX
2081	8976	NDAR_INVMU034UAX	2321			F	2800	Visit12	12	Phase 1/1A	336	0	0	0	1	0	0	0	4	0	0	0	4	0	0	0	0	0	0	9	0	0	2	4	0	3	2	6	6	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1	0	2.5714285	2.5	1.55		1	1.7	1.125	1.75	1.5714285	3.5	-0.15	-0.125	-1.75	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU034UAX
2081	8976	NDAR_INVMU755UN3	2426			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	1	0	2	4	1	1	2	2	0	0	9	1	0	2	1	1	5	3	4	3	0	1	1	0	0	0	1	0	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	3	1.625	0.5	1.7142857	4	1.75	1		1.75	1.625	0.5	1.7142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU755UN3
2081	8976	NDAR_INVMU755UN3	2426			M	1600	Visit6	6	Phase 1B	172	0	1	0	0	0	0	0	4	0	3	2	3	4	2	5	1	1	1	9	3	1	4	4	2	6	3	4	6	1	1	1	1	1	1	0	1	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	5	2.875	0.75	3.4285715	4.5	2.95			1.75	1.625	0.5	1.7142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU755UN3
2081	8976	NDAR_INVMU755UN3	2426			M	2800	Visit12	12	Phase 1B	340	0	1	0	0	0	0	0	6	2	2	2	2	2	2	5	0	0	0	9	3	3	0	5	2	5	3	4	4	1	0	1	0	1	1	1	1	1	1	0	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	2.875	0	3	4	2.6			1.75	1.625	0.5	1.7142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU755UN3
2081	8976	NDAR_INVMU755UN3	2426			M	5200	EndofPhase1_1a	2	Phase 1/1A	47	0	1	0	0	0	0	0	6	0	2	0	2	0	1	4	0	0	0	9	1	2	2	2	0	4	2	3	4	0	0	0	0	1	0	1	1	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	1	1	0	0	3	1.875	0	2	3	1.75		1	1.75	1.625	0.5	1.7142857	4	0	0.25	-0.5	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU755UN3
2081	8976	NDAR_INVMU755UN3	2426			M	5400	EndofPhase1b	18	Phase 1B	505	0	1	0	0	0	0	0	6	1	4	3	2	2	2	3	0	0	0	9	2	4	4	6	5	5	4	4	5	1	1	1	1	1	1	1	1	1	2	1	3	1	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	0	4.285714	4.5	3.1			1.75	1.625	0.5	1.7142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMU755UN3
2081	8976	NDAR_INVMW132XC8	2304			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	5	5	2	2	3	2	1	2	5	9	3	2	4	3	0	4	4	6	6	0	0	0	1	1	0	0	0	3		1	3	4	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	0	0	0	0	1	3.625	2	3.4285715	4	3.45	1		3.45	3.625	2	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW132XC8
2081	8976	NDAR_INVMW376RY0	1365			M	400	Baseline	0	Pre-Rand	1	1	0	0	1	0	0	0	6	5	4	4	4	4	4	0	3	4	6	6	4	4	4	5	4	5	3	5	3	1	1	1	0	0	1	1	1	2	3	1	3	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.875	4.75	4.142857	4	4.142857	1		4.142857	3.875	4.75	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW376RY0
2081	8976	NDAR_INVMW376RY0	1365			M	5200	EndofPhase1_1a	6	Phase 1/1A	195	1	0	0	1	0	0	0	6	4	5	4	5	6	4	0	2	4	5	9	0	0	3	5	0	4	3	4	3	1	0	1	0	1	1	1	1	1	1	1	3	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	2.75	2.142857	3.5	3.35		1	4.142857	3.875	4.75	4.142857	4	-0.79285717	0.375	-2	-2	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW376RY0
2081	8976	NDAR_INVMW376RY0	1365			M	5800	EndofPhase2	12	Phase 2	351	1	0	0	1	0	0	0	6	4	5	4	5	6	4	0	2	4	5	9	0	0	3	5	0	4	3	4	3	1	0	1	0	1	1	1	1	1	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	2.75	2.142857	3.5	3.35			4.142857	3.875	4.75	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW376RY0
2081	8976	NDAR_INVMW376RY0	1365			M	6000	EndofPhase3	16	Phase 3	491	1	0	0	1	0	0	0	6	5	2	1	2	6	6	0	4	4	6	5	4	4	2	6	6	6	4	5	6	1	1	0	0	1	1	1	1	2	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	6	3.5	4.75	4.714286	5	4.285714			4.142857	3.875	4.75	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW376RY0
2081	8976	NDAR_INVMW502BHK	1797			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	1	2	2	1	0	0	0	0	9	0	0	2	2	1	2	1	3	2	0	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.5	0	1.4285715	1.5	1.25	1		1.25	1.5	0	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW502BHK
2081	8976	NDAR_INVMW502BHK	1797			M	1600	Visit6	6	Phase 1/1A	174	1	0	0	0	0	0	0	6	0	0	2	2	0	2	0	1	4	1	9	3	3	1	2	2	4	1	4	5	0	0	1	0	1	1	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.5	1.5	2.857143	2.5	2.15			1.25	1.5	0	1.4285715	1.5	0.9	0	1.5	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW502BHK
2081	8976	NDAR_INVMW502BHK	1797			M	2800	Visit12	12	Phase 1/1A	340	1	0	0	0	0	0	0	5	0	0	2	2	2	2	0	1	4	1	9	1	3	4	2	2	3	2	3	2	0	1	0	0	0	1	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	1.5	2.4285715	2.5	2.05			1.25	1.5	0	1.4285715	1.5	0.8	0.125	1.5	1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW502BHK
2081	8976	NDAR_INVMW502BHK	1797			M	5200	EndofPhase1_1a	18	Phase 1/1A	496	1	0	0	0	0	0	0	6	0	0	2	2	0	2	0	1	4	1	9	1	2	3	1	2	2	2	4	3	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	1.5	2.2857144	2	1.9		1	1.25	1.5	0	1.4285715	1.5	0.65	0	1.5	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW502BHK
2081	8976	NDAR_INVMW940NN6	1283			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	2	2	2	2	3	2	2	0	6	5	9	0	2	4	4	6	5	4	5	6	1	1	1	0	1	1	1	1	3	3	1	4	3	3	3	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	2.75	3.857143	4.5	3.2	1		3.2	2.125	2.75	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMW940NN6
2081	8976	NDAR_INVMX035XL5	1168			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	2	1	2	0	2	2	1	2	2	9	3	2	5	2	1	1	3	4	3	1	1	2	0	1	1	1	1	3	2	1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.5	1.25	2.857143	2	2.05	1		2.05	1.5	1.25	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX035XL5
2081	8976	NDAR_INVMX035XL5	1168			M	1600	Visit6	6	Phase 2	178	0	0	0	0	0	1	0	2	1	0	1	1	1	2	2	2	2	2	9	2	3	3	2	3	1	3	4	5	0	1	0	0	1	1	1	1	3	3	0	4	3	4	3	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	1.5	3.142857	2	2.1			2.05	1.5	1.25	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX035XL5
2081	8976	NDAR_INVMX035XL5	1168			M	2800	Visit12	12	Phase 2	358	0	0	0	0	0	1	0	2	2	2	3	4	2	3	2	0	0	0	9	2	0	2	4	2	0	4	4	4	0	1	0	0	1	1	0	1	3	1	1	3	2	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0	2.5714285	2	2.1			2.05	1.5	1.25	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX035XL5
2081	8976	NDAR_INVMX035XL5	1168			M	5200	EndofPhase1_1a	2	Phase 1/1A	37	0	0	0	0	0	1	0	2	1	1	2	0	1	2	0	2	3	1	9	1	2	4	1	2	0	3	4	4	0	0	2	1	1	1	1	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	1.125	1.5	2.5714285	1.5	1.8		1	2.05	1.5	1.25	2.857143	2	-0.25	-0.375	0.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX035XL5
2081	8976	NDAR_INVMX035XL5	1168			M	5800	EndofPhase2	18	Phase 2	530	0	0	0	0	0	1	0	0	4	4	4	5	0	2	2	0	0	0	9	2	0	2	6	2	1	3	5	6	0	1	0	1	1	0	0	1	3	2	1	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0	3.2857144	2	2.4			2.05	1.5	1.25	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX035XL5
2081	8976	NDAR_INVMX250HHH	2017			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	2	2	2	2	2	2	1	1	1	9	2	2	3	6	2	3	3	4	4	1	0	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.5	0.75	3.2857144	3	2.6	1		2.6	2.5	0.75	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX250HHH
2081	8976	NDAR_INVMX250HHH	2017			M	5200	EndofPhase1_1a	3	Phase 1/1A	90	1	0	0	0	0	0	0	5	2	1	1	1	1	1	1	0	0	0	9	1	0	1	3	2	3	3	2	1	2	2	2	2	2	2	2	2	3	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.625	0	1.4285715	3	1.45		1	2.6	2.5	0.75	3.2857144	3	-1.15	-0.875	-0.75	-1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX250HHH
2081	8976	NDAR_INVMX356EZX	2747			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	2	2	0	3	2	1	1	3	0	0	0	9	0	0	0	0	0	2	0	2	0	1	0	0	0	1	1	0	1	2	2	1	3	2	4	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	4	1.75	0	0.2857143	1	0.9	1		0.9	1.75	0	0.2857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX356EZX
2081	8976	NDAR_INVMX356EZX	2747			M	1600	Visit6	6	Phase 1B	168	1	0	0	0	0	0	0	4	2	0	2	2	0	3	2	0	0	6	9	0	2	0	2	0	3	1	3	2	1	0	0	0	1	1	0	0	1	1	1	3	2	4	1	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	1.5	1.2857143	2	1.7			0.9	1.75	0	0.2857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX356EZX
2081	8976	NDAR_INVMX356EZX	2747			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	4	2	0	0	2	1	0	2	0	0	5	9	0	1	0	0	0	3	2	1	1	1	0	0	0	1	1	0	0	1	3	0	4	2	4	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1.375	1.25	0.42857143	2.5	1.2		1	0.9	1.75	0	0.2857143	1	0.3	-0.375	1.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX356EZX
2081	8976	NDAR_INVMX575ZTU	1450			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	3	1	1	1	9	1	1	2	2	1	5	2	3	3	0	0	2	2	1	1	2	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.125	0.75	1.8571428	3.5	2	1		2	2.125	0.75	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX575ZTU
2081	8976	NDAR_INVMX734LGR	1479			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	0	2	2	2	5	5	1	0	0	0	9	2	2	3	4	3	4	3	4	3	1	1	1	0	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.75	0	3	3.5	2.5	1		2.5	2.75	0	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX734LGR
2081	8976	NDAR_INVMX734LGR	1479			F	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	0	0	0	0	0	1	5	0	3	2	2	4	2	0	0	0	1	9	2	5	3	5	2	4	4	4	2	1	1	1	0	1	1	1	1	2	2	0	4	1	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0.25	3.2857144	4	2.5		1	2.5	2.75	0	3	3.5	0	-0.5	0.25	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMX734LGR
2081	8976	NDAR_INVMY137MTN	1002			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	2	1	2	6	0	0	0	0	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0	0	1.1428572	1.5	0.55	1		0.55	0	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY137MTN
2081	8976	NDAR_INVMY137MTN	1002			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	2	2	1	4	4	2	3	0	0	0	1	9	2	2	2	2	2	3	2	2	3	1	0	2	0	1	2	2	2	3		0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	0.25	2.142857	2.5	1.95			0.55	0	0	1.1428572	1.5	1.4	2.25	0.25	1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY137MTN
2081	8976	NDAR_INVMY137MTN	1002			M	2800	Visit12	12	Phase 3	353	0	0	0	0	0	1	0	2	1	1	2	2	1	2	1	0	0	1	9	2	2	2	2	2	3	2	2	2	1	0	2	2	1	2	2	2	3		0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.25	2	2.5	1.6			0.55	0	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY137MTN
2081	8976	NDAR_INVMY137MTN	1002			M	5200	EndofPhase1_1a	8	Phase 1/1A	221	0	0	0	0	0	1	0	2	1	1	2	2	1	2	1	0	0	1	9	2	2	2	2	2	3	2	2	2	1	0	2	2	1	2	2	2	3		0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.25	2	2.5	1.6		1	0.55	0	0	1.1428572	1.5	1.05	1.5	0.25	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY137MTN
2081	8976	NDAR_INVMY137MTN	1002			M	5800	EndofPhase2	9	Phase 2	234	0	0	0	0	0	1	0	2	1	1	2	2	1	2	1	0	0	1	9	2	2	2	2	2	3	2	2	2	1	0	2	2	1	2	2	2	3		0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.25	2	2.5	1.6			0.55	0	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY137MTN
2081	8976	NDAR_INVMY137MTN	1002			M	6000	EndofPhase3	18	Phase 3	546	0	0	0	0	0	1	0	2	2	2	1	1	1	1	1	1	1	1	9	1	1	1	1	0	2	2	1	2	2	2	2	2	1	1	2	2	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	0.75	1	2	1.25			0.55	0	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY137MTN
2081	8976	NDAR_INVMY530MF1	1142			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	9	1	0	3	1	4	6	4	4	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.125	0	2.4285715	5	1.4	1		1.4	0.125	0	2.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY530MF1
2081	8976	NDAR_INVMY530MF1	1142			M	5200	EndofPhase1_1a	2	Phase 1/1A	91	0	0	0	0	0	0	1	1	0	4	0	0	1	2	2	0	0	3	9	1	0	4	0	4	6	4	4	4	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.25	0.75	2.4285715	5	2		1	1.4	0.125	0	2.4285715	5	0.6	1.125	0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY530MF1
2081	8976	NDAR_INVMY622GTW	2496			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	1	1	2	2	2	3	6	4	5	6	4	3	6	2	4	2	4	3	4	5	1	1	1	0	1	1	1	1	2	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	4.75	3.7142856	3.5	3.5714285	1		3.5714285	2.875	4.75	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY622GTW
2081	8976	NDAR_INVMY622GTW	2496			F	1600	Visit6	6	Phase 1B	171	0	1	0	1	0	0	0	6	5	4	4	6	3	4	5	4	5	6	2	2	6	0	3	2	4	3	5	5	1	1	1	0	1	1	1	1	1	2	1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	4.625	4.25	3.2857144	3.5	4			3.5714285	2.875	4.75	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY622GTW
2081	8976	NDAR_INVMY622GTW	2496			F	2800	Visit12	12	Phase 1B	346	1	0	0	1	0	0	0	6	5	2	2	6	2	3	5	6	5	6	5	4	6	3	3	4	4	4	5	5	1	1	1	0	1	1	1	1	1	2	1	4	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.875	5.5	4.285714	4	4.3333335			3.5714285	2.875	4.75	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY622GTW
2081	8976	NDAR_INVMY622GTW	2496			F	5200	EndofPhase1_1a	2	Phase 1/1A	57	0	1	0	1	0	0	0	6	1	1	2	2	2	3	4	4	5	6	4	3	6	2	5	5	4	3	5	6	1	1	1	0	1	1	1	1	2	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	4.75	4.571429	3.5	3.7619047		1	3.5714285	2.875	4.75	3.7142856	3.5	0.1904762	-0.25	0	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY622GTW
2081	8976	NDAR_INVMY622GTW	2496			F	5400	EndofPhase1b	16	Phase 1B	456	1	0	0	1	0	0	0	6	4	2	2	2	2	5	5	4	5	5	5	3	6	3	3	3	5	4	4	5	1	1	1	0	1	1	1	1	1	2	0	4	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.5	4.75	3.857143	4.5	3.952381			3.5714285	2.875	4.75	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMY622GTW
2081	8976	NDAR_INVMZ005TXY	1576			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	4	2	4	4	4	5	0	6	5	6	4	4	3	4	4	2	6	3	4	6	0	1	0	0	1	0	0	0	3	1	1	3	2	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	5.25	3.857143	4.5	3.9047618	1		3.9047618	3.125	5.25	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ005TXY
2081	8976	NDAR_INVMZ005TXY	1576			F	1600	Visit6	6	Phase 1/1A	173	0	1	0	0	0	0	0	0	6	3	0	4	0	4	3	0	1	3	9	4	4	3	5	4	6	2	5	6	1	1	1	0	1	1	1	1	2	2	1	3	3	4	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1	4.428571	4	3.15			3.9047618	3.125	5.25	3.857143	4.5	-0.75476193	-0.625	-4.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ005TXY
2081	8976	NDAR_INVMZ005TXY	1576			F	2800	Visit12	12	Phase 1/1A	366	0	1	0	0	0	0	0	0	4	3	0	1	0	4	2	0	1	3	9	4	4	3	5	4	6	3	5	6	1	1	1	0	1	1	1	1	2	2	1	3	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	1	4.428571	4.5	2.9			3.9047618	3.125	5.25	3.857143	4.5	-1.0047619	-1.375	-4.25	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ005TXY
2081	8976	NDAR_INVMZ005TXY	1576			F	4000	Visit18	18	Phase 1/1A	543	0	0	0	0	0	0	1	5	5	6	0	2	2	3	1	6	4	3	6	3	4	4	5	4	6	2	5	4	1	1	2	0	1	0	2	2	3	2	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	4.75	4.142857	4	3.8095238		1	3.9047618	3.125	5.25	3.857143	4.5	-0.0952381	-0.125	-0.5	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ005TXY
2081	8976	NDAR_INVMZ197RTC	1023			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	5	5	5	4	5	3	6	5	6	6	5	5	6	5	6	5	5	5	6	1	1	1	0	1	1	1	1	1	1	1	3	2	3	2	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.75	5.75	5.428571	5	5.1904764	1		5.1904764	4.75	5.75	5.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ197RTC
2081	8976	NDAR_INVMZ197RTC	1023			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	6	5	2	4	5	4	3	3	6	6	5	6	5	6	6	5	6	4	5	4	5	1	1	1	1	1	1	1	1	1	1	1	2	1	1	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	4	5.75	5.285714	4.5	4.8095236			5.1904764	4.75	5.75	5.428571	5	-0.3809524	-0.75	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ197RTC
2081	8976	NDAR_INVMZ197RTC	1023			M	2800	Visit12	12	Phase 1/1A	339	1	0	0	0	0	0	0	5	5	2	4	4	4	5	4	5	6	6	6	3	5	1	5	5	5	5	4	6	1	1	1	2	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.125	5.75	4.142857	5	4.5238094			5.1904764	4.75	5.75	5.428571	5	-0.6666667	-0.625	0	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ197RTC
2081	8976	NDAR_INVMZ197RTC	1023			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	1	0	0	0	0	0	0	6	4	4	4	4	4	5	4	6	6	6	6	5	6	4	5	6	5	5	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	6	5.285714	5	5.047619		1	5.1904764	4.75	5.75	5.428571	5	-0.14285715	-0.375	0.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ197RTC
2081	8976	NDAR_INVMZ915JRK	1581			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	0	0	0	2	1	1	1		9	1	2	1	2	1	1	1	2	2	0	0	2	0	1	0	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		1	30	0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	3	0.625		1.5714285	1	1.0526316	1		1.0526316	0.625		1.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ915JRK
2081	8976	NDAR_INVMZ935JR6	2375			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	2	2	2	2	2	0	1	2	0	9	0	1	2	5	2	5	3	5	5	1	1	2	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.625	0.75	2.857143	4	2.2	1		2.2	1.625	0.75	2.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ935JR6
2081	8976	NDAR_INVMZ935JR6	2375			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	3	0	4	4	4	4	4	0	1	2	1	9	2	4	2	5	3	5	2	5	5	0	1	1	1	1	1	1	1	3		0	4	3	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	1	3.7142856	3.5	3			2.2	1.625	0.75	2.857143	4	0.8	1.25	0.25	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ935JR6
2081	8976	NDAR_INVMZ935JR6	2375			F	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	1	0	3	4	3	2	3	3	2	0	1	1	1	9	2	4	3	5	4	5	3	5	6	1	1	0	1	1	1	1	1	3		1	4	1	1	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.5	0.75	4.142857	4	3			2.2	1.625	0.75	2.857143	4	0.8	0.875	0	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ935JR6
2081	8976	NDAR_INVMZ935JR6	2375			F	5200	EndofPhase1_1a	13	Phase 1/1A	372	0	0	0	0	0	1	0	2	3	2	4	4	4	4	1	1	1	0	9	2	4	2	5	2	5	3	5	5	1	1	0	1	1	1	1	1	3		0	4	3	3	3	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3	0.5	3.5714285	4	2.95		1	2.2	1.625	0.75	2.857143	4	0.75	1.375	-0.25	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ935JR6
2081	8976	NDAR_INVMZ935JR6	2375			F	5800	EndofPhase2	18	Phase 2	513	0	0	0	0	0	1	0	4	4	1	2	3	4	4	1	2	2	1	9	2	2	2	6	4	6	4	5	5	1	1	0	1	1	1	1	1	3		1	4	3	3	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	1.25	3.7142856	5	3.2			2.2	1.625	0.75	2.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVMZ935JR6
2081	8976	NDAR_INVNA619PWB	2254			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	2	0	2	0	0	2	2	2	2	9	1	0	1	4	1	5	2	4	3	1	0	1	1	0	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1.5	2	3.5	2.05	1		2.05	1.75	1.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNA619PWB
2081	8976	NDAR_INVNA619PWB	2254			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	0	0	0	1	1	1	2	1	5	5	1	2	1	2	1	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	2	2	1	2	1	30	0		0		0		0		1	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0.25	1.2857143	5	1.3333334			2.05	1.75	1.5	2	3.5	-0.71666664	-0.75	-1.25	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNA619PWB
2081	8976	NDAR_INVNA619PWB	2254			M	2800	Visit12	12	Phase 1/1A	350	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	0	0	9	1	1	1	2	1	5	5	1	2	1	2	1	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	2	2	1	2	1	30	0		0		0		0		1	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0.25	1.2857143	5	1.4			2.05	1.75	1.5	2	3.5	-0.65	-0.75	-1.25	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNA619PWB
2081	8976	NDAR_INVNA619PWB	2254			M	4000	Visit18	18	Phase 1/1A	518	1	0	0	0	0	0	0	1	1	1	1	2	3	1	0	1	1	1	2	2	1	3	2	1	4	4	4	2	1	1	1	0	1	1	1	1	2	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	1.25	2.142857	4	1.8095238		1	2.05	1.75	1.5	2	3.5	-0.24047619	-0.5	-0.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNA619PWB
2081	8976	NDAR_INVNB024ART	1138			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	1	0	2	6	1	4	2	1	0	0	9	2	2	2	5	1	6	4	4	4	1	1	1	0	1	1	1	1	2	1	1	3	4	2	1	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	7	2.625	0.25	2.857143	5	2.6	1		2.6	2.625	0.25	2.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB024ART
2081	8976	NDAR_INVNB024ART	1138			M	1600	Visit6	6	Phase 1/1A	171	0	1	0	0	0	0	0	5	1	0	2	6	1	4	2	1	0	0	9	2	2	2	5	1	6	4	4	4	1	1	1	0	1	1	1	1	3	1	1	3	4	2	1	1	0	1	0	0	0	0	0	0	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.625	0.25	2.857143	5	2.6			2.6	2.625	0.25	2.857143	5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB024ART
2081	8976	NDAR_INVNB024ART	1138			M	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	0	1	0	3	0	3	1	2	2	3	2	1	1	1	9	2	3	3	2	2	5	5	5	4	1	1	1	0	1	1	1	1	1	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2	0.75	3	5	2.5			2.6	2.625	0.25	2.857143	5	-0.1	-0.625	0.5	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB024ART
2081	8976	NDAR_INVNB024ART	1138			M	4000	Visit18	18	Phase 1/1A	513	1	0	0	0	0	0	0	2	2	1	3	1	2	3	3	1	1	1	9	2	2	2	3	1	5	5	3	2	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.75	2.142857	5	2.25			2.6	2.625	0.25	2.857143	5	-0.35	-0.5	0.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB024ART
2081	8976	NDAR_INVNB024ART	1138			M	5200	EndofPhase1_1a	19	Phase 1/1A	572	0	0	0	0	0	0	1	2	2	1	2	1	2	3	2	1	0	1	9	2	2	2	3	1	5	5	4	3	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.875	0.5	2.4285715	5	2.2		1	2.6	2.625	0.25	2.857143	5	-0.4	-0.75	0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB024ART
2081	8976	NDAR_INVNB856FVM	1606			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	5	6	5	5	4	6	4	4	3	9	4	4	3	6	2	0	1	5	4	1	0	0	0	1	1	2	2	3	2	1	2	1	2	1	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.375	2.75	4	0.5	4.15	1		4.15	5.375	2.75	4	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB856FVM
2081	8976	NDAR_INVNB856FVM	1606			M	1600	Visit6	6	Phase 3	169	0	0	0	0	0	1	0	4	4	2	2	2	1	2	0	4	2	6	5	2	2	2	4	4	6	5	6	4	0	1	1	1	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	2.125	4.25	3.4285715	5.5	3.2857144			4.15	5.375	2.75	4	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB856FVM
2081	8976	NDAR_INVNB856FVM	1606			M	2800	Visit12	12	Phase 3	343	0	0	0	0	0	1	0	0	0	0	1	0	1	1	0	2	2	6	4	1	1	0	3	2	2	1	0	0	1	0	1	1	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	0.375	3.5	1	1.5	1.2857143			4.15	5.375	2.75	4	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB856FVM
2081	8976	NDAR_INVNB856FVM	1606			M	5200	EndofPhase1_1a	1	Phase 1/1A	42	0	0	0	0	0	1	0	5	6	5	2	3	2	4	5	3	2	4	3	2	2	3	4	2	1	2	4	4	0	0	0	0	1	0	0	0	3		1	2	1	2	1	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4	3	3	1.5	3.2380953		1	4.15	5.375	2.75	4	0.5	-0.91190475	-1.375	0.25	-1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB856FVM
2081	8976	NDAR_INVNB856FVM	1606			M	5800	EndofPhase2	2	Phase 2	70	0	0	0	0	0	1	0	4	4	2	4	1	3	4	6	2	2	4	9	2	3	2	3	2	1	0	2	2	0	0	0	0	1	1	0	0	3		1	2	1	1	1	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3.5	2	2.2857144	0.5	2.65			4.15	5.375	2.75	4	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB856FVM
2081	8976	NDAR_INVNB856FVM	1606			M	6000	EndofPhase3	18	Phase 3	511	0	0	0	0	0	1	0	0	0	0	0	1	0	2	0	4	2	6	4	1	2	0	2	2	0	3	2	2	1	1	1	1	1	1	1	1	3		0	4	2	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	0.375	4	1.5714285	1.5	1.5714285			4.15	5.375	2.75	4	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB856FVM
2081	8976	NDAR_INVNB954NDU	1211			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	4	4	4	3	4	1	6	4	5	6	2	2	2	4	4	5	4	4	4	1	1	1	1	1	0	0	1	3	1	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.4285715	5.25	3.142857	4.5	3.8	1		3.8	3.4285715	5.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNB954NDU
2081	8976	NDAR_INVNC577CL7	1740			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	1	0	1	0	0	3	4	4	0	1	2	9	2	3	3	2	2	4	5	4	5	1	1	1	0	1	1	1	1	2	3	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	4	1.625	0.75	3	4.5	2.3	1		2.3	1.625	0.75	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC577CL7
2081	8976	NDAR_INVNC577CL7	1740			M	1600	Visit6	6	Phase 1/1A	220	0	0	0	0	0	0	1	1	1	1	1	1	1	2	1	1	1	1	9	3	2	4	1	2	4	2	4	6	1	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	1.125	0.75	3.142857	3	2		1	2.3	1.625	0.75	3	4.5	-0.3	-0.5	0	0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC577CL7
2081	8976	NDAR_INVNC943RHV	1226			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	3	1	3	4	4	3	1	1	1	0	3	2	3	4	5	5	5	4	5	1	1	0	0	1	1	0	1	2	1	0	4	1	2	1	1	0	0	0	1	0	1	0	1	1	1	1	0		1	15	0		1	15	0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	5	3.125	0.75	3.7142856	5	3.047619	1		3.047619	3.125	0.75	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC943RHV
2081	8976	NDAR_INVNC943RHV	1226			F	1600	Visit6	6	Phase 1/1A	182	0	1	0	0	0	0	0	5	5	4	4	4	4	4	5	5	3	4	5	5	5	6	5	5	5	5	5	5	1	1	1	1	1	1	1	1	2	1	1	4	3	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	6	4.375	4.25	5.142857	5	4.6666665			3.047619	3.125	0.75	3.7142856	5	1.6190476	1.25	3.5	1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC943RHV
2081	8976	NDAR_INVNC943RHV	1226			F	2800	Visit12	12	Phase 1/1A	356	0	0	0	0	0	0	1	9	5	4	5	5	4	4	5	4	4	4	5	4	4	5	5	4	6	6	5	5	1	1	1	1	1	1	1	1	2	2	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.571429	4.25	4.571429	6	4.65			3.047619	3.125	0.75	3.7142856	5	1.602381	1.4464285	3.5	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC943RHV
2081	8976	NDAR_INVNC943RHV	1226			F	4000	Visit18	18	Phase 1/1A	517	0	0	0	0	0	0	1	5	4	4	3	4	3	4	2	5	3	5	4	4	4	4	4	4	6	3	4	4	1	1	1	1	1	1	1	1	2	2	1	3	2	2	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.625	4.25	4	4.5	3.952381		1	3.047619	3.125	0.75	3.7142856	5	0.9047619	0.5	3.5	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC943RHV
2081	8976	NDAR_INVNC994CGK	1125			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	2	0	0	0	0	0	0	9	0	0	4	2	0	4	0	1	2	0	0	1	0	0	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0.25	0	1.2857143	2	0.75	1		0.75	0.25	0	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNC994CGK
2081	8976	NDAR_INVND139LTG	2514			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	1	1	1	0	1	1	1	1	2	1	9	3	1	1	2	1	4	3	0	2	1	1	1	1	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	3	0.75	1	1.4285715	3.5	1.35	1		1.35	0.75	1	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND139LTG
2081	8976	NDAR_INVND139LTG	2514			M	1600	Visit6	6	Phase 1/1A	166	0	0	0	0	0	0	1	1	1	1	3	2	1	4	1	1	1	2	9	1	2	1	1	2	4	2	1	2	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	1.75	1	1.4285715	3	1.7			1.35	0.75	1	1.4285715	3.5	0.35	1	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND139LTG
2081	8976	NDAR_INVND139LTG	2514			M	5200	EndofPhase1_1a	12	Phase 1/1A	330	0	0	0	0	0	0	1	0	0	0	1	1	1	1	0	4	4	3	4	2	3	1	2	4	4	3	1	2	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	4	0.5	3.75	2.142857	3.5	1.9523809		1	1.35	0.75	1	1.4285715	3.5	0.60238093	-0.25	2.75	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND139LTG
2081	8976	NDAR_INVND139LTG	2514			M	5400	EndofPhase1b	18	Phase 1B	515	0	0	0	0	0	0	1	1	0	1	1	1	0	1	0	1	2	2	9	2	2	1	2	1	4	4	1	2	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	2	0.625	1.25	1.5714285	4	1.45			1.35	0.75	1	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND139LTG
2081	8976	NDAR_INVND168CHY	2782			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	0	0	2	0	0	5	3	3	2	2	0	2	4	4	1	4	3	4	4	1	0	1	1	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	1	0	1	0	0	1	3	1.625	2.5	2.7142856	3.5	2.3333333	1		2.3333333	1.625	2.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND168CHY
2081	8976	NDAR_INVND401LPF	1119			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	4	4	4	0	5	2	0	0	0	9	1	2	3	5	4	2	1	4	5	0	0	0	1	0	0	0	0	3	3	1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	7	2.875	0	3.4285715	1.5	2.5	1		2.5	2.875	0	3.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND401LPF
2081	8976	NDAR_INVND812FZH	1590			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	2	3	3	3	6	5	4	6	2	2	3	4	4	6	4	3	5	5	6	1	1	1	0	1	1	1	1	1	1	1	2	2	2	1	1	1	1	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	3.5	4.571429	4	4.047619	1		4.047619	3.875	3.5	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND812FZH
2081	8976	NDAR_INVND812FZH	1590			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	4	2	2	3	5	3	5	5	5	5	6	6	5	6	5	6	6	5	5	4	6	1	1	1	1	1	1	1	1	1	1	1	4	2	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	1	7	3.625	5.5	5.428571	5	4.714286			4.047619	3.875	3.5	4.571429	4	0.6666667	-0.25	2	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND812FZH
2081	8976	NDAR_INVND812FZH	1590			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	5	2	4	4	2	5	5	3	0	2	1	9	4	3	3	6	2	3	3	4	5	1	0	1	1	1	1	1	1	2	1	0	4	3	3	2	1	1	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	1	1	0	1	0	5	3.75	0.75	3.857143	3	3.3			4.047619	3.875	3.5	4.571429	4	-0.74761903	-0.125	-2.75	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND812FZH
2081	8976	NDAR_INVND812FZH	1590			M	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	1	0	0	6	2	3	4	2	6	6	3	0	0	0	9	3	4	5	6	5	2	6	4	6	1	1	1	0	1	1	1	1	1	2	1	3	3	4	4	1	0	0	0	1	0	0	0	0	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	7	4	0	4.714286	4	3.65		1	4.047619	3.875	3.5	4.571429	4	-0.39761904	0.125	-3.5	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND812FZH
2081	8976	NDAR_INVND882AAF	1419			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	1	0	2	2	1	0	0	1	9	2	2	2	4	2	6	5	4	6	1	1	1	1	1	1	1	1	3	3	1	3	2	4	2	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0.85714287	0.25	3.142857	5.5	2.1052632	1		2.1052632	0.85714287	0.25	3.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND882AAF
2081	8976	NDAR_INVND882AAF	1419			F	2800	Visit12	12	Phase 2	349	0	0	0	0	0	0	1	9	2	2	2	2	1	2	2	0	2	0	9	2	2	2	2	2	4	4	4	6	1	1	1	0	1	1	1	1	3	2	1	3	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.8571428	0.5	2.857143	4	2.2631578			2.1052632	0.85714287	0.25	3.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND882AAF
2081	8976	NDAR_INVND882AAF	1419			F	4000	Visit18	18	Phase 2	524	0	0	0	0	0	0	1	9	2	2	2	2	2	2	0	0	2	0	9	2	2	2	2	2	6	3	4	6	1	1	1	0	1	1	1	1	3	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.7142857	0.5	2.857143	4.5	2.2631578			2.1052632	0.85714287	0.25	3.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND882AAF
2081	8976	NDAR_INVND882AAF	1419			F	5200	EndofPhase1_1a	6	Phase 1/1A	174	0	0	0	0	0	0	1	9	2	2	3	2	2	2	2	0	2	2	9	2	2	4	4	2	6	4	4	5	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.142857	1	3.2857144	5	2.7368422		1	2.1052632	0.85714287	0.25	3.142857	5.5	0.6315789	1.2857143	0.75	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVND882AAF
2081	8976	NDAR_INVNE716GN4	2695			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	1	0	1	0	1	3	1	3	2	5	6	2	1	2	1	1	1	1	4	4	0	0	0	0	1	1	1	2	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		1	15	0		1	15	0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4	0.875	4	2.142857	1	1.9047619	1		1.9047619	0.875	4	2.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE716GN4
2081	8976	NDAR_INVNE716GN4	2695			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	9	2	3	4	1	1	3	1	4	3	5	4	1	5	3	4	4	4	3	2	2	0	1	0	0	1	2	0	2	3		1	3	2	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.142857	4	3	3.5	2.95			1.9047619	0.875	4	2.142857	1	1.0452381	1.2678572	0	0.85714287	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE716GN4
2081	8976	NDAR_INVNE716GN4	2695			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	0	1	1	1	0	0	2	1	6	4	6	3	2	3	2	1	5	4	2	1	1	0	1	0	0	1	0	0	0	3		0	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	0.75	4.75	2.142857	3	2.1904762			1.9047619	0.875	4	2.142857	1	0.2857143	-0.125	0.75	0	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE716GN4
2081	8976	NDAR_INVNE716GN4	2695			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	0	0	0	0	0	1	0	0	1	1	2	1	1	2	2	6	4	5	2	1	2	1	2	6	4	3	1	2	1	1	2	0	1	1	0	2	3		1	4	1	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	4.25	2.142857	3.5	2.3333333		1	1.9047619	0.875	4	2.142857	1	0.42857143	0.375	0.25	0	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE716GN4
2081	8976	NDAR_INVNE811NJ2	1844			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	4	2	3	2	1	3	0	2	2	6	9	2	2	4	4	2	5	2	3	2	1	0	1	1	1	1	0	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	2.5	2.7142856	3.5	2.75	1		2.75	2.375	2.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE811NJ2
2081	8976	NDAR_INVNE811NJ2	1844			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	2	2	2	2	2	1	2	2	0	3	6	9	2	2	2	2	0	3	2	2	2	1	0	1	0	1	1	0	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	2.25	1.7142857	2.5	2.05			2.75	2.375	2.5	2.7142856	3.5	-0.7	-0.5	-0.25	-1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE811NJ2
2081	8976	NDAR_INVNE811NJ2	1844			M	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	5	2	1	2	3	2	2	0	3	2	5	2	3	3	4	2	1	3	2	4	3	1	0	0	0	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	3	2.857143	2.5	2.5714285			2.75	2.375	2.5	2.7142856	3.5	-0.17857143	-0.25	0.5	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE811NJ2
2081	8976	NDAR_INVNE811NJ2	1844			M	4000	Visit18	18	Phase 2	506	1	0	0	0	0	0	0	4	1	2	2	2	1	3	1	2	2	4	9	3	3	3	3	1	4	2	3	3	0	0	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	2	2.7142856	3	2.45			2.75	2.375	2.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE811NJ2
2081	8976	NDAR_INVNE811NJ2	1844			M	5200	EndofPhase1_1a	15	Phase 1/1A	429	1	0	0	0	0	0	0	4	0	0	0	2	0	2	0	2	1	2	9	0	2	0	3	0	3	1	4	4	1	0	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1	1.25	1.8571428	2	1.5		1	2.75	2.375	2.5	2.7142856	3.5	-1.25	-1.375	-1.25	-0.85714287	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE811NJ2
2081	8976	NDAR_INVNE811NJ2	1844			M	5800	EndofPhase2	21	Phase 2	620	1	0	0	0	0	0	0	4	4	2	3	3	2	3	3	1	3	4	9	3	2	2	3	2	3	3	4	3	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3	2	2.7142856	3	2.85			2.75	2.375	2.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNE811NJ2
2081	8976	NDAR_INVNF019HLW	2038			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1		0	0	3	6	2	4	0	0	4	4	9	5	6	4	4	5	6	4	3	5	1	1	0	1	1	1	1	0	2	1	0	4	2	2	4	1	0	0	0	1	0	0	0	2	1	2	2	0		0		0		1	30	0		0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	1	2	2.142857	2	4.571429	5	3.4210527	1		3.4210527	2.142857	2	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNF019HLW
2081	8976	NDAR_INVNF019HLW	2038			F	1600	Visit6	6	Phase 3	152	0	0	0	0	0	1	0	2	0	0	4	2	0	4	1	0	0	0	9	1	4	0	6	6	5	2	6	5	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.625	0	4	3.5	2.4			3.4210527	2.142857	2	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNF019HLW
2081	8976	NDAR_INVNF019HLW	2038			F	2800	Visit12	12	Phase 3	312	0	0	0	0	0	1	0	5	0	2	2	3	2	2	0	0	0	0	9	2	4	3	3	4	5	2	5	4	1	1	1	0	1	1	1	1	2	1	0	4	2	2	4	1	0	0	0	1	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	0	3.5714285	3.5	2.4			3.4210527	2.142857	2	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNF019HLW
2081	8976	NDAR_INVNF019HLW	2038			F	5200	EndofPhase1_1a	1	Phase 1/1A	12	0	0	0	0	0	1	0	4	0	0	2	5	3	4	0	0	4	4	9	4	4	4	2	4	5	4	4	5	1	1	0	1	0	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	2.25	2	3.857143	4.5	3.1		1	3.4210527	2.142857	2	4.571429	5	-0.32105264	0.10714286	0	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNF019HLW
2081	8976	NDAR_INVNF019HLW	2038			F	5800	EndofPhase2	3	Phase 2	64	0	0	0	0	0	1	0	2	0	0	3	4	1	3	0	1	1	3	9	5	5	2	3	3	5	3	5	3	2	2	2	2	1	1	1	1	2	1	0	4	4	3	4	1	0	0	0	1	0	0	0	1	0	0	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	1.25	3.7142856	4	2.6			3.4210527	2.142857	2	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNF019HLW
2081	8976	NDAR_INVNF019HLW	2038			F	6000	EndofPhase3	18	Phase 3	470	0	0	0	0	0	1	0	5	3	4	4	5	4	4	0	3	4	4	9	4	4	5	4	4	5	5	5	4	1	1	1	1	1	1	1	1	2	2	0	4	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	2.75	4.285714	5	4			3.4210527	2.142857	2	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNF019HLW
2081	8976	NDAR_INVNG526BWY	2678			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	0	1	1	1	5	0	0	0	9	0	2	3	4	0	3	3	0	6	1	0	1	0	1	1	1	1	2	3	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.75	0	2.142857	3	1.75	1		1.75	1.75	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG526BWY
2081	8976	NDAR_INVNG526BWY	2678			F	2800	Visit12	12	Phase 2	338	0	1	0	0	0	0	0	5	4	0	0	5	0	4	2	2	2	5	9	0	2	6	6	1	4	2	2	4	0	0	0	0	1	1	1	1	3	1	1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	2.5	2.25	3	3	2.8			1.75	1.75	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG526BWY
2081	8976	NDAR_INVNG526BWY	2678			F	5200	EndofPhase1_1a	6	Phase 1/1A	175	0	1	0	0	0	0	0	6	4	0	2	2	1	3	2	0	0	0	9	4	4	6	3	1	4	2	5	6	1	0	1	0	1	1	1	1	2	1	1	2	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	0	4.142857	3	2.75		1	1.75	1.75	0	2.142857	3	1	0.75	0	2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG526BWY
2081	8976	NDAR_INVNG526BWY	2678			F	5800	EndofPhase2	18	Phase 2	510	0	0	0	0	0	0	1	2	0	0	0	3	0	5	1	0	0	0	9	1	3	3	5	1	2	1	3	4	0	0	0	0	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.375	0	2.857143	1.5	1.7			1.75	1.75	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG526BWY
2081	8976	NDAR_INVNG882ZDF	2361			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	1	0	4	4	2	5	0	2	5	5	9	4	6	2	6	5	5	4	5	6	1	1	1	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	0	1	0	4	2.5	3	4.857143	4.5	3.75	1		3.75	2.5	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG882ZDF
2081	8976	NDAR_INVNG882ZDF	2361			F	5200	EndofPhase1_1a	3	Phase 1/1A	91	0	0	0	0	0	0	1	6	4	4	5	5	4	5	3	4	4	3	5	3	4	4	5	5	5	4	5	4	1	1	1	0	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.5	4	4.285714	4.5	4.3333335		1	3.75	2.5	3	4.857143	4.5	0.5833333	2	1	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG882ZDF
2081	8976	NDAR_INVNG882ZDF	2361			F	5400	EndofPhase1b	4	Phase 1B	113	1	0	0	0	0	0	0	5	2	1	1	2	1	5	4	4	6	6	4	2	5	6	6	5	3	3	4	5	1	0	0	0	1	1	1	1	1	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.625	5	4.714286	3	3.8095238			3.75	2.5	3	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNG882ZDF
2081	8976	NDAR_INVNH072URL	1559			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	6	6	6	6	6	6	2	1	1	2	9	4	3	5	5	4	5	5	5	4	1	1	1	1	1	0	0	0	1	1	1	2	2	2	1	1	0	0	0	0	1	0	0	0	0	0	0	0		1	28	0		0		1	2	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	4	4.75	1	4.285714	5	4.1	1		4.1	4.75	1	4.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH072URL
2081	8976	NDAR_INVNH466HXW	1263			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	0	1	2	0	0	0	0	0	2	9	2	1	0	0	2	3		1	1	1	1		1	1	1	1	0	3	1		4	1	4	4	0	0	0	0	0	0	0	0					0		1				0		0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	4	0.5	0.5	1		0.84210527	1		0.84210527	0.5	0.5	1																																																																																																																											Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH466HXW
2081	8976	NDAR_INVNH466HXW	1263			M	5200	EndofPhase1_1a	1	Phase 1/1A	42	0	0	0	0	0	1	0	2	2	4	3	2	1	2	0	0	0	6	9	0	0	0	2	4	3	3	2	4	1	1	0	0	1	1	1	1	1	1	1	4	1	4	4	1	0	0	1	0	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	5	2	1.5	1.7142857	3	2		1	0.84210527	0.5	0.5	1		1.1578947	1.5	1	0.71428573																																																																																																																						Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH466HXW
2081	8976	NDAR_INVNH506JW4	1272			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	0	0	0	0	3	0	0	1	9	6	2	2	2	0	4	2	3	4	0	1	0	0	1	0	0	0	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.125	0.25	2.7142856	3	1.75	1		1.75	1.125	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH506JW4
2081	8976	NDAR_INVNH506JW4	1272			M	2800	Visit12	12	Phase 3	345	1	0	0	0	0	0	0	6	1	2	2	2	2	2	1	0	3	3	9	1	3	4	4	3	5	4	5	3	1	1	1	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.25	1.5	3.2857144	4.5	2.8			1.75	1.125	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH506JW4
2081	8976	NDAR_INVNH506JW4	1272			M	5200	EndofPhase1_1a	4	Phase 1/1A	100	1	0	1	0	0	0	0	2	1	2	2	2	0	2	1	2	3	3	9	3	2	3	2	2	3	3	3	3	0	1	1	0	1	1	1	1	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	29	0		0		1	1	0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.5	2	2.5714285	3	2.2		1	1.75	1.125	0.25	2.7142856	3	0.45	0.375	1.75	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH506JW4
2081	8976	NDAR_INVNH506JW4	1272			M	5800	EndofPhase2	6	Phase 2	168	1	0	0	0	0	0	0	6	0	0	2	2	2	2	1	0	0	1	9	2	2	3	4	2	5	2	4	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.875	0.25	3	3.5	2.2			1.75	1.125	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH506JW4
2081	8976	NDAR_INVNH506JW4	1272			M	6000	EndofPhase3	18	Phase 3	525	1	0	0	0	0	0	0	5	1	3	3	3	2	3	1	2	2	2	9	2	3	6	4	2	5	4	3	4	1	1	1	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.625	1.5	3.4285715	4.5	3			1.75	1.125	0.25	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH506JW4
2081	8976	NDAR_INVNH580AGC	2393			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	3	4	3	4	3	4	4	1	1	1	9	3	3	5	4	2	2	3	5	4	1	1	0	0	1	1	0	1	1	3	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	1	7	0		0		1	11	1	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.625	0.75	3.7142856	2.5	3.15	1		3.15	3.625	0.75	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH580AGC
2081	8976	NDAR_INVNH580AGC	2393			M	5200	EndofPhase1_1a	1	Phase 1/1A	33	1	0	0	0	0	0	0	5	4	2	4	5	3	3	2	2	2	2	9	2	2	4	2	2	2	3	4	4	1	1	2	0	1	1	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	3.5	1.5	2.857143	2.5	2.95		1	3.15	3.625	0.75	3.7142856	2.5	-0.2	-0.125	0.75	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH580AGC
2081	8976	NDAR_INVNH580AGC	2393			M	5400	EndofPhase1b	2	Phase 1B	86	0	0	0	0	0	1	0	4	4	3	3	4	3	4	1	1	1	1	9	2	2	3	2	2	3	1	4	4	2	1	2	0	1	2	1	2	2	1	1	4	4	3	4	1	0	1	0	0	0	1	0	2	2	1	0	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	3.25	0.75	2.7142856	2	2.6			3.15	3.625	0.75	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH580AGC
2081	8976	NDAR_INVNH676VKJ	1031			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	3	4	0	2	4	5	2	0	0	1	9	3	3	4	4	0	1	2	5	5	2	1	2	0	1	1	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	2	2.75	0.25	3.4285715	1.5	2.5	1		2.5	2.75	0.25	3.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNH676VKJ
2081	8976	NDAR_INVNJ023ZUZ	1692			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	2	1	3	4	4	0	0	0	9	2	2	4	4	2	2	2	4	2	1	0	2	2	1	1	1	2	3	3	1	3	4	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	2.25	0	2.857143	2	2.1	1		2.1	2.25	0	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNJ023ZUZ
2081	8976	NDAR_INVNJ356WBD	2099			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	1	2	3	3	3	2	0	3	2	2	3	2	2	1	2	1	2	2	4	4	1	0	1	0	1	1	0	1	1	1	0	4	3	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2.25	2.5	2.2857144	2	2.2857144	1		2.2857144	2.25	2.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNJ356WBD
2081	8976	NDAR_INVNJ356WBD	2099			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	4	1	2	3	2	2	3	2	3	2	3	9	3	3	2	3	3	1	3	3	5	0	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.375	2	3.142857	2	2.65			2.2857144	2.25	2.5	2.2857144	2	0.3642857	0.125	-0.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNJ356WBD
2081	8976	NDAR_INVNJ356WBD	2099			M	2800	Visit12	12	Phase 1/1A	342	0	0	0	0	0	0	1	9	2	2	2	3	2	2	4	4	2	5	4	3	2	2	3	4	2	3	4	5	1	0	1	1	1	1	1	1	1	1	1	3	2	3	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.4285715	3.75	3.2857144	2.5	3			2.2857144	2.25	2.5	2.2857144	2	0.71428573	0.17857143	1.25	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNJ356WBD
2081	8976	NDAR_INVNJ356WBD	2099			M	5200	EndofPhase1_1a	18	Phase 1/1A	524	0	0	0	0	0	0	1	5	5	1	1	3	1	2	2	2	2	2	9	3	2	1	2	4	2	2	3	5	1	0	1	1	1	1	0	1	2	1	1	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	5	2.5	1.5	2.857143	2	2.5		1	2.2857144	2.25	2.5	2.2857144	2	0.21428572	0.25	-1	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNJ356WBD
2081	8976	NDAR_INVNL402JND	1271			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	1	0	3	0	1	1	0	0	0	9	2	1	1	1	1	5	4	5	6	0	1	0	0	1	0	0	0	1	1	1	4	1	4	4	1	0	1	1	1	0	0	0	1	1	1	1	1	23	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	4	1.5	0	2.4285715	4.5	1.9	1		1.9	1.5	0	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL402JND
2081	8976	NDAR_INVNL402JND	1271			M	1600	Visit6	6	Phase 2	172	1	0	0	0	0	0	0	6	0	1	2	2	2	1	1	0	0	1	9	3	3	5	5	3	4	4	5	5	1	0	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0.25	4.142857	4	2.65			1.9	1.5	0	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL402JND
2081	8976	NDAR_INVNL402JND	1271			M	2800	Visit12	12	Phase 3	344	1	0	0	0	0	0	0	6	1	1	2	2	2	2	1	0	0	0	9	2	2	4	4	2	5	3	4	4	0	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.125	0	3.142857	4	2.35			1.9	1.5	0	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL402JND
2081	8976	NDAR_INVNL402JND	1271			M	5200	EndofPhase1_1a	4	Phase 1/1A	116	1	0	0	0	0	0	0	6	2	2	0	2	2	2	1	0	0	0	9	1	2	3	3	2	5	4	5	5	1	1	1	1	1	1	1	1	1	2	0	4	3	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	3	4.5	2.35		1	1.9	1.5	0	2.4285715	4.5	0.45	0.625	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL402JND
2081	8976	NDAR_INVNL402JND	1271			M	5800	EndofPhase2	9	Phase 2	260	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	0	0	0	9	1	2	4	3	2	4	5	4	5	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0	3	4.5	2.2			1.9	1.5	0	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL402JND
2081	8976	NDAR_INVNL402JND	1271			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	4	0	0	2	1	0	2	0	0	0	1	9	1	1	4	3	2	5	4	4	3	1	1	1	0	1	1	1	1	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0.25	2.5714285	4.5	1.85			1.9	1.5	0	2.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL402JND
2081	8976	NDAR_INVNL917LKX	1490			F	400	Baseline	0	Pre-Rand	1	1	1	0	1	0	0	0	4	4	3	2	3	3	2	3	3	3	2	4	2	2	2	4	2	4	3	4	5	1	1	1	0	1	1	1	1	1	2	0	4	3	3	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3	3	3	3.5	3.047619	1		3.047619	3	3	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNL917LKX
2081	8976	NDAR_INVNM416KDL	2358			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	0	1	0	0	0	0	1	6	9	2	0	0	2	0	2	0	3	4	0	0	0	0	1	1	1	1	3	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	4	0.71428573	1.75	1.5714285	1	1.3157895	1		1.3157895	0.71428573	1.75	1.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM416KDL
2081	8976	NDAR_INVNM416KDL	2358			M	1600	Visit6	6	Phase 1/1A	167	0	0	1	0	0	0	0	1	0	0	0	2	0	2	0	6	4	6	5	3	4	0	3	6	2	1	3	3	0	1	0	0	1	1	1	0	2	1	0	4	4	4	4	1	0	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	0.625	5.25	3.142857	1.5	2.4285715			1.3157895	0.71428573	1.75	1.5714285	1	1.112782	-0.08928572	3.5	1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM416KDL
2081	8976	NDAR_INVNM416KDL	2358			M	2800	Visit12	12	Phase 1/1A	342	0	0	0	0	1	0	0	4	0	0	0	0	0	2	0	6	3	6	4	0	4	0	4	6	2	1	2	1	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	6	0.75	4.75	2.4285715	1.5	2.142857		1	1.3157895	0.71428573	1.75	1.5714285	1	0.8270677	0.035714287	3	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM416KDL
2081	8976	NDAR_INVNM694RM7	2813			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	1	2	4	3	2	3	1	0	1	0	9	3	2	6	4	5	6	4	6	6	1	0	1	1	1	1	1	1	1	1	1	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	0.25	4.571429	5	3.25	1		3.25	2.75	0.25	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM694RM7
2081	8976	NDAR_INVNM694RM7	2813			M	2800	Visit12	12	Phase 3	344	1	0	1	0	0	0	0	3	0	2	4	3	2	5	3	4	4	4	5	4	6	4	5	4	5	4	5	6	1	1	1	1	1	1	1	1	1	1	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.75	4.25	4.857143	4.5	3.9047618			3.25	2.75	0.25	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM694RM7
2081	8976	NDAR_INVNM694RM7	2813			M	5200	EndofPhase1_1a	2	Phase 1/1A	63	1	0	0	0	0	0	0	6	6	6	6	6	2	6	3	0	0	4	9	2	6	4	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.125	1	5.142857	6	4.65		1	3.25	2.75	0.25	4.571429	5	1.4	2.375	0.75	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM694RM7
2081	8976	NDAR_INVNM694RM7	2813			M	5800	EndofPhase2	6	Phase 2	181	1	0	1	0	0	0	0	6	4	4	4	4	2	5	2	1	4	5	9	2	4	2	6	5	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	2.5	4.428571	5	4.1			3.25	2.75	0.25	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM694RM7
2081	8976	NDAR_INVNM694RM7	2813			M	6000	EndofPhase3	18	Phase 3	503	1	0	1	0	0	0	0	6	0	0	2	2	1	2	3	3	2	4	5	3	6	4	4	4	6	3	4	5	1	1	1	1	1	1	1	1	1	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2	3.5	4.285714	4.5	3.2857144			3.25	2.75	0.25	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM694RM7
2081	8976	NDAR_INVNM903PYC	1188			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	2	2	2	2	2	3	2	2	1	9	1	2	1	3	1	6	3	3	3	1	1	1	0	1	1	0	1	3	1	1	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	1.25	2	4.5	2.25	1		2.25	2.125	1.25	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM903PYC
2081	8976	NDAR_INVNM903PYC	1188			F	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	0	6	4	5	4	2	4	0	1	2	4	9	2	2	2	2	2	6	5	3	2	1	1	1	0	1	1	0	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	1.75	2.142857	5.5	2.9			2.25	2.125	1.25	2	4.5	0.65	1	0.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM903PYC
2081	8976	NDAR_INVNM903PYC	1188			F	2800	Visit12	12	Phase 1/1A	334	0	1	0	0	0	0	0	2	4	3	4	3	3	4	2	0	0	0	9	3	2	3	2	2	6	2	3	2	1	1	1	0	1	2	2	0	1	1	1	3	2	2	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.125	0	2.4285715	4	2.5			2.25	2.125	1.25	2	4.5	0.25	1	-1.25	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM903PYC
2081	8976	NDAR_INVNM903PYC	1188			F	4000	Visit18	18	Phase 1/1A	502	0	1	0	0	0	0	0	4	2	2	4	3	4	5	0	0	0	0	9	2	0	3	3	2	6	6	2	3	1	1	1	1	1	1	2	1	1	1	1	3	2	2	4	1	1	0	0	0	0	0	0	1	1	1	1	1	17	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0	2.142857	6	2.55		1	2.25	2.125	1.25	2	4.5	0.3	0.875	-1.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNM903PYC
2081	8976	NDAR_INVNN264HR6	1212			F	400	Baseline	0	Pre-Rand	1	1	0	0	1	0	0	0	5	1	1	0	2	1	2	3	0	0	1	9	1	1	1	6	1	3	1	4	5	0	0	1	0	1	1	1	1	1	2	0	4	4	4	2	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.875	0.25	2.7142856	2	1.95	1		1.95	1.875	0.25	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNN264HR6
2081	8976	NDAR_INVNN264HR6	1212			F	1600	Visit6	6	Phase 1/1A	178	1	0	0	1	0	0	0	6	4	0	2	3	3	3	4	2	1	2	9	3	2	1	4	1	3	1	4	5	0	0	0	0	1	0	1	1	1	2	0	4	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	0	1	4	3.125	1.25	2.857143	2	2.7			1.95	1.875	0.25	2.7142856	2	0.75	1.25	1	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNN264HR6
2081	8976	NDAR_INVNN264HR6	1212			F	2800	Visit12	12	Phase 1/1A	346	1	0	0	1	0	0	0	4	1	0	2	2	1	2	5	0	0	0	9	1	2	0	6	2	3	1	3	5	0	0	0	0	0	0	1	1	1	2	1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.125	0	2.7142856	2	2			1.95	1.875	0.25	2.7142856	2	0.05	0.25	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNN264HR6
2081	8976	NDAR_INVNN264HR6	1212			F	5200	EndofPhase1_1a	15	Phase 1/1A	430	1	0	0	1	0	0	0	6	4	0	2	4	3	3	4	1	2	4	9	2	2	4	6	1	4	2	2	3	0	0	0	1	1	1	1	1	1	2	0	4	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	5	3.25	1.75	2.857143	3	2.95		1	1.95	1.875	0.25	2.7142856	2	1	1.375	1.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNN264HR6
2081	8976	NDAR_INVNN289GHU	1830			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	1	0	2	5	4	3	4	0	0	0	9	4	2	4	2	4	3	1	6	6	0	1	0	0	1	1	1	0	1	1	1	3	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	11	1	19	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0	4	2	2.8	1		2.8	3	0	4	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNN289GHU
2081	8976	NDAR_INVNP114APU	2537			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	4	2	4	2	3	3	3	0	4	2	9	4	6	4	4	0	6	2	6	5	0	1	1	0	1	0	1	0	1	1	1	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	3	1.5	4.142857	4	3.35	1		3.35	3	1.5	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP114APU
2081	8976	NDAR_INVNP114APU	2537			F	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	4	4	2	4	2	3	3	3	0	4	2	9	4	6	4	4	0	6	2	6	5	0	1	1	0	1	0	1	0	1	1	1	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	3.125	1.5	4.142857	4	3.4			3.35	3	1.5	4.142857	4	0.05	0.125	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP114APU
2081	8976	NDAR_INVNP114APU	2537			F	2800	Visit12	12	Phase 1/1A	348	0	0	0	0	0	0	1	6	6	6	5	5	4	0	4	4	3	3	5	4	4	4	6	4	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	1	1	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	1	0	0	0	0	0	0	0	1	1	5	4.5	3.75	4.857143	6	4.6190476			3.35	3	1.5	4.142857	4	1.2690476	1.5	2.25	0.71428573	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP114APU
2081	8976	NDAR_INVNP114APU	2537			F	5200	EndofPhase1_1a	18	Phase 1/1A	509	0	0	0	0	0	0	1	4	1	1	1	3	1	4	3	2	3	2	9	3	3	5	5	3	6	4	6	6	1	1	1	0	1	1	1	1	3		1	4	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5	2.25	1.75	4.428571	5	3.3		1	3.35	3	1.5	4.142857	4	-0.05	-0.75	0.25	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP114APU
2081	8976	NDAR_INVNP663AY9	2562			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	4	2	2	2	0	2	0	0	0	0	9	0	0	0	2	0	4	1	4	2	0	0	0	0	1	1	1	1	1	1	1	3	2	2	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.25	0	1.1428572	2.5	1.55	1		1.55	2.25	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP663AY9
2081	8976	NDAR_INVNP663AY9	2562			M	1600	Visit6	6	Phase 2	170	0	0	1	0	0	0	0	6	4	2	2	2	2	2	0	0	0	0	9	0	0	1	2	0	4	2	3	1	0	0	0	0	1	1	1	1	1	2	1	3	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0	1	3	1.65			1.55	2.25	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP663AY9
2081	8976	NDAR_INVNP663AY9	2562			M	5200	EndofPhase1_1a	5	Phase 1/1A	154	0	0	1	0	0	0	0	6	4	2	2	2	0	2	0	0	0	0	9	0	0	0	2	0	4	3	4	2	0	0	1	0	1	1	1	1	1	2	1	3	2	2	4	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.25	0	1.1428572	3.5	1.65		1	1.55	2.25	0	1.1428572	2.5	0.1	0	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNP663AY9
2081	8976	NDAR_INVNR566KRC	1790			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	1	0	1	1	0	2	4	4	4	3	1	2	0	4	2	6	4	4	3	1	1	1	1	1	1	1	1	1	2	1	4	2	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.375	3.75	2.2857144	5	2.4761906	1		2.4761906	1.375	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR566KRC
2081	8976	NDAR_INVNR566KRC	1790			M	1600	Visit6	6	Phase 2	174	1	0	0	0	0	0	0	4	0	4	3	2	0	4	1	1	4	4	9	1	2	2	6	2	6	4	4	5	1	0	1	1	1	0	1	1	1	2	0	4	3	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	2.25	3.142857	5	2.95			2.4761906	1.375	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR566KRC
2081	8976	NDAR_INVNR566KRC	1790			M	2800	Visit12	12	Phase 2	341	1	0	0	0	0	0	0	1	2	2	3	1	2	3	1	4	4	4	5	0	2	3	4	4	6	3	3	5	1	0	1	1	1	1	1	1	1	3	0	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	4.25	3	4.5	2.952381			2.4761906	1.375	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR566KRC
2081	8976	NDAR_INVNR566KRC	1790			M	5200	EndofPhase1_1a	3	Phase 1/1A	96	1	0	0	0	0	0	0	5	0	3	0	2	0	2	1	1	2	4	9	1	2	0	3	1	6	3	6	6	1	0	1	1	1	1	1	1	1	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.625	1.75	2.7142856	4.5	2.4		1	2.4761906	1.375	3.75	2.2857144	5	-0.07619048	0.25	-2	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR566KRC
2081	8976	NDAR_INVNR566KRC	1790			M	5800	EndofPhase2	17	Phase 2	469	1	0	0	0	0	0	0	2	2	5	3	1	0	2	0	2	2	3	9	0	1	0	4	4	6	3	0	4	1	0	1	1	1	1	1	1	2	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	1.75	1.8571428	4.5	2.2			2.4761906	1.375	3.75	2.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR566KRC
2081	8976	NDAR_INVNR964HE4	2107			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	2	0	4	0	1	1	0	0	1	9	0	2	0	4	3	4	1	6	6	1	0	0	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	25	0		0		0		1	5	0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	7	1.8571428	0.25	3	2.5	2.1052632	1		2.1052632	1.8571428	0.25	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR964HE4
2081	8976	NDAR_INVNR964HE4	2107			F	1600	Visit6	6	Phase 2	177	0	0	0	0	0	0	1	2	4	3	1	5	3	3	1	0	0	0	9	2	2	0	4	0	4	2	6	6	0	0	1	0	1	1	0	1	3	1	1	4	3	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	2.75	0	2.857143	3	2.4			2.1052632	1.8571428	0.25	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR964HE4
2081	8976	NDAR_INVNR964HE4	2107			F	2800	Visit12	12	Phase 2	326	0	1	0	0	0	0	0	4	2	1	0	2	1	1	0	2	3	4	2	1	3	2	2	3	5	2	5	6	0	0	1	0	1	1	0	0	2	2	1	4	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	4	1.375	2.75	3.142857	3.5	2.4285715			2.1052632	1.8571428	0.25	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR964HE4
2081	8976	NDAR_INVNR964HE4	2107			F	4000	Visit18	18	Phase 3	501	0	0	0	0	0	0	1	9	1	2	1	2	1	1	0	1	2	1	9	1	1	0	1	1	5	2	4	5	0	0	1	0	1	1	1	1	2	2	1	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	0	1	1	2	1.1428572	1	1.8571428	3.5	1.6842105			2.1052632	1.8571428	0.25	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR964HE4
2081	8976	NDAR_INVNR964HE4	2107			F	5200	EndofPhase1_1a	1	Phase 1/1A	37	0	0	0	0	0	1	0	3	5	2	2	3	1	1	1	0	0	0	9	0	3	2	1	1	3	3	1	3	1	0	0	0	1	1	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	1	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	4	2.25	0	1.5714285	3	1.75		1	2.1052632	1.8571428	0.25	3	2.5	-0.35526314	0.39285713	-0.25	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR964HE4
2081	8976	NDAR_INVNR964HE4	2107			F	5800	EndofPhase2	13	Phase 2	367	0	0	0	0	0	0	1	2	5	0	1	5	1	1	1	2	2	3	2	1	3	2	4	2	4	2	4	4	0	0	1	0	1	1	0	0	2	2	1	4	3	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	4	2	2.25	2.857143	3	2.4285715			2.1052632	1.8571428	0.25	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNR964HE4
2081	8976	NDAR_INVNT123TT7	1821			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	4	2	3	2	2	1	6	5	6	6	5	5	4	4	4	5	3	4	3	1	1	1	0	1	2	2	2	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	5.75	4.142857	4	3.952381	1		3.952381	2.875	5.75	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT123TT7
2081	8976	NDAR_INVNT123TT7	1821			M	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	0	0	1	1	0	1	1	1	1	1	1	6	6	6	6	2	4	2	2	6	4	3	4	5	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	0.875	6	3.5714285	3.5	3			3.952381	2.875	5.75	4.142857	4	-0.95238096	-2	0.25	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT123TT7
2081	8976	NDAR_INVNT123TT7	1821			M	2800	Visit12	12	Phase 1/1A	373	0	0	0	0	0	0	1	4	2	2	3	3	6	4	0	6	0	3	6	4	4	4	2	6	4	4	1	2	1	0	0	0	1	1	1	1	1	1	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3	3.75	3.2857144	4	3.3333333		1	3.952381	2.875	5.75	4.142857	4	-0.61904764	0.125	-2	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT123TT7
2081	8976	NDAR_INVNT464YZK	2169			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	5	5	6	4	4	4	4	5	5	4	3	4	4	4	5	5	4	5	5	1	1	1	1	1	1	1	1	3	1	1	3	1	2	2	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1		5	4.5	4.285714	4.5	4.6190476	1		4.6190476	5	4.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT464YZK
2081	8976	NDAR_INVNT464YZK	2169			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	9	5	3	4	2	3	4	3	0	0	2	9	2	3	4	3	3	5	3	5	5	1	1	1	1	0	1	1	1	2	1	1	2	1	3	2	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.4285715	0.5	3.5714285	4	3.1052632			4.6190476	5	4.5	4.285714	4.5	-1.5137844	-1.5714285	-4	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT464YZK
2081	8976	NDAR_INVNT464YZK	2169			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	9	4	4	4	4	4	4	5	2	2	2	9	4	4	2	4	1	5	4	5	5	1	1	1	1	1	1	1	1	3		1	3	2	2	1	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.142857	1.5	3.5714285	4.5	3.631579			4.6190476	5	4.5	4.285714	4.5	-0.98746866	-0.85714287	-3	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT464YZK
2081	8976	NDAR_INVNT464YZK	2169			M	4000	Visit18	18	Phase 2	505	0	0	0	0	0	1	0	0	4	0	4	3	2	6	3	1	2	5	9	2	3	3	3	4	4	1	5	5	0	1	0	0	0	2	2	0	3	1	1	2	1		2	1	0	0	1	0	1	0	0	1	1	1	0	0		1	15	0		1	15	0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	2	3.5714285	2.5	3			4.6190476	5	4.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT464YZK
2081	8976	NDAR_INVNT464YZK	2169			M	5200	EndofPhase1_1a	15	Phase 1/1A	432	0	0	0	0	0	0	1	9	1	1	1	4	0	2	4	1	1	1	9	0	3	2	3	2	5	3	5	4	1	1	1	1	1	1	1	1	3		1	4	1	4	1	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.8571428	0.75	2.7142856	4	2.2631578		1	4.6190476	5	4.5	4.285714	4.5	-2.3558898	-3.142857	-3.75	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT464YZK
2081	8976	NDAR_INVNT464YZK	2169			M	5800	EndofPhase2	22	Phase 2	624	0	0	0	0	0	1	0	6	5	5	5	6	6	4	4	4	4	4	5	5	5	5	5	4	5	3	5	5	0	1	2	1	1	1	2	1	3	1	1	3	1	2	1	1	1	0	1	0	0	1	0	1	1	1	1	0		1	30	0		0		0		2	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	5.125	4.25	4.857143	4	4.7619047			4.6190476	5	4.5	4.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNT464YZK
2081	8976	NDAR_INVNU008CCX	1013			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	0	0	2	2	2	2	2	5	5	5	9	5	4	4	5	5	6	2	5	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	1.875	3.75	4.714286	4	3.55	1		3.55	1.875	3.75	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU008CCX
2081	8976	NDAR_INVNU008CCX	1013			F	1600	Visit6	6	Phase 1/1A	179	0	1	0	0	0	0	0	5	0	0	2	2	4	2	3	4	4	5	9	4	5	4	6	5	6	4	6	5	1	0	1	0	1	0	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	3.25	5	5	3.8			3.55	1.875	3.75	4.714286	4	0.25	0.375	-0.5	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU008CCX
2081	8976	NDAR_INVNU008CCX	1013			F	2800	Visit12	12	Phase 2	339	0	1	0	1	0	0	0	6	0	2	2	2	2	3	3	4	4	4	5	4	4	4	5	4	6	4	5	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.5	4.25	4.428571	5	3.7142856			3.55	1.875	3.75	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU008CCX
2081	8976	NDAR_INVNU008CCX	1013			F	4000	Visit18	18	Phase 2	508	0	0	1	1	0	0	0	5	0	0	2	2	2	2	3	3	4	3	5	1	4	4	5	4	5	3	5	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	3.75	3.857143	4	3.142857			3.55	1.875	3.75	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU008CCX
2081	8976	NDAR_INVNU008CCX	1013			F	5200	EndofPhase1_1a	7	Phase 1/1A	206	0	1	0	1	0	0	0	4	0	0	2	2	2	2	3	5	4	1	9	3	5	6	5	6	6	5	6	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	2.5	5.142857	5.5	3.6		1	3.55	1.875	3.75	4.714286	4	0.05	0	-1.25	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU008CCX
2081	8976	NDAR_INVNU008CCX	1013			F	5800	EndofPhase2	20	Phase 2	570	1	0	0	1	0	0	0	6	0	0	2	2	2	2	3	4	3	5	5	1	4	4	5	4	6	4	5	5	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.125	4.25	4	5	3.4285715			3.55	1.875	3.75	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU008CCX
2081	8976	NDAR_INVNU946AFG	2555			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	1	1	1	2	2	2	4	1	1	0	9	2	1	0	2	0	2	2	2	2	1	0	0	0	0	0	0	0	3		1	3	2	4	4	0	0	0	0	0	0	0	0					0		0		0		1	10	1	20	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	3	2.125	0.5	1.2857143	2	1.6	1		1.6	2.125	0.5	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU946AFG
2081	8976	NDAR_INVNU972TNA	1608			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	6	6	0	5	1	4	4	6	6	6	4	6	5	6	6	4	6	6	1	1	0	1	1	0	0	1	1	2	1	3	2	2	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	4.5	5	5.571429	5	5	1		5	4.5	5	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU972TNA
2081	8976	NDAR_INVNU972TNA	1608			M	1600	Visit6	6	Phase 3	196	1	0	0	0	0	0	0	6	4	6	3	3	2	3	2	0	0	4	9	6	4	4	5	2	6	4	6	6	1	1	1	0	1	0	0	1	1	2	1	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.625	1	4.714286	5	3.8			5	4.5	5	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU972TNA
2081	8976	NDAR_INVNU972TNA	1608			M	2800	Visit12	12	Phase 3	336	1	0	0	0	0	0	0	6	4	4	4	3	2	4	1	0	0	4	9	0	2	6	4	2	6	4	6	6	1	1	1	0	1	0	0	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.5	1	3.7142856	5	3.4			5	4.5	5	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU972TNA
2081	8976	NDAR_INVNU972TNA	1608			M	5200	EndofPhase1_1a	2	Phase 1/1A	57	1	0	0	0	0	0	0	4	6	6	6	6	0	6	2	2	5	6	9	6	5	6	6	2	6	4	6	6	1	1	1	1	1	0	1	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	2	4.5	3.25	5.285714	5	4.8		1	5	4.5	5	5.571429	5	-0.2	0	-1.75	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU972TNA
2081	8976	NDAR_INVNU972TNA	1608			M	5800	EndofPhase2	4	Phase 2	99	1	0	0	0	0	0	0	4	6	6	6	6	1	6	2	2	5	6	9	6	5	6	5	2	6	4	6	6	1	1	1	1	1	0	0	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	4.625	3.25	5.142857	5	4.8			5	4.5	5	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU972TNA
2081	8976	NDAR_INVNU972TNA	1608			M	6000	EndofPhase3	18	Phase 3	504	1	0	0	0	0	0	0	6	4	4	3	4	2	4	1	0	0	4	9	2	1	4	4	2	6	4	6	6	1	1	1	0	1	1	0	1	1	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.5	1	3.5714285	5	3.35			5	4.5	5	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNU972TNA
2081	8976	NDAR_INVNV699KD6	2148			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	4	0	4	2	2	2	6	0	0	0	2	0	2	2	0	2	6	6	6	2	2	2	2	0	0	0	0	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.5	1.5	2.5714285	4	2.4761906	1		2.4761906	2.5	1.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV699KD6
2081	8976	NDAR_INVNV699KD6	2148			M	1600	Visit6	6	Phase 2	194	0	1	0	0	0	0	0	4	0	0	0	4	0	0	1	0	0	0	9	0	0	0	0	0	3	4	3	2	1	1	1	1	1	0	0	0	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.125	0	0.71428573	3.5	1.05			2.4761906	2.5	1.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV699KD6
2081	8976	NDAR_INVNV699KD6	2148			M	2800	Visit12	12	Phase 3	420	0	1	0	0	0	0	0	3	1	2	2	2	2	2	2	0	0	1	9	1	1	2	2	3	3	3	2	3	1	0	1	0	1	1	0	1	2	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2	0.25	2	3	1.85			2.4761906	2.5	1.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV699KD6
2081	8976	NDAR_INVNV699KD6	2148			M	5200	EndofPhase1_1a	3	Phase 1/1A	89	0	1	0	0	0	0	0	5	2	1	2	4	2	2	3	0	0	1	9	3	1	0	3	0	3	3	2	4	1	1	0	0	1	0	0	0	1	2	1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2.625	0.25	1.8571428	3	2.05		1	2.4761906	2.5	1.5	2.5714285	4	-0.42619047	0.125	-1.25	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV699KD6
2081	8976	NDAR_INVNV699KD6	2148			M	5800	EndofPhase2	7	Phase 2	225	0	1	0	0	0	0	0	4	5	4	3	3	2	2	2	0	0	1	9	0	0	2	0	0	2	3	2	3	1	1	0	0	1	0	0	1	2	1	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.125	0.25	1	2.5	1.9			2.4761906	2.5	1.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV699KD6
2081	8976	NDAR_INVNV699KD6	2148			M	6000	EndofPhase3	18	Phase 3	603	0	1	0	0	0	0	0	3	3	2	2	4	1	2	3	0	0	1	9	1	1	1	1	1	2	3	1	3	1	1	1	0	1	1	0	0	1	2	0	4	4	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	0.25	1.2857143	2.5	1.75			2.4761906	2.5	1.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV699KD6
2081	8976	NDAR_INVNV838LPV	1896			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	1	0	0	2	0	0	0	0	9	0	0	2	0	0	3	2	4	2	0	1	0	0	1	1	1	0	1	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.875	0	1.1428572	2.5	1	1		1	0.875	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV838LPV
2081	8976	NDAR_INVNV838LPV	1896			M	5200	EndofPhase1_1a	1	Phase 1/1A	47	0	0	0	0	0	0	1	0	0	0	1	2	0	2	0	0	0	1	9	2	0	0	4	0	4	3	1	0	0	0	0	0	1	1	1	1	2	1	0	4	2	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.625	0.25	1	3.5	1		1	1	0.875	0	1.1428572	2.5	0	-0.25	0.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV838LPV
2081	8976	NDAR_INVNV847MZ6	1107			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	0	4	4	2	1	1	2	1	2	1	9	1	1	1	3	2	1	2	3	3	1	0	1	0	0	1	1	1	2	2	1	3	2	3	4	1	0	0	0	0	1	0	0	1	1	0	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	2.375	1	2	1.5	2	1		2	2.375	1	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV847MZ6
2081	8976	NDAR_INVNV847MZ6	1107			F	5200	EndofPhase1_1a	1	Phase 1/1A	38	0	0	0	1	0	0	0	2	4	1	2	2	0	2	1	2	2	1	9	1	1	1	3	2	1	6	3	3	1	1	1	0	1	1	1	1	2	2	1	3	2	2	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1.75	1.25	2	3.5	2		1	2	2.375	1	2	1.5	0	-0.625	0.25	0	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV847MZ6
2081	8976	NDAR_INVNV847MZ6	1107			F	5400	EndofPhase1b	4	Phase 1B	116	0	0	0	0	0	0	1	4	4	0	1	4	0	1	2	1	1	1	9	1	1	0	2	1	2	3	4	5	1	0	1	0	0	1	1	1	1	2	1	3	2	2	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	2	0.75	2	2.5	1.9			2	2.375	1	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNV847MZ6
2081	8976	NDAR_INVNW240YGQ	2352			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	2	2	2	2	2	0	3	4	9	2	4	4	3	4	5	3	6	6	1	0	1	0	1	1	0	1	2	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.4285715	1.75	4.142857	4	2.8421052	1		2.8421052	1.4285715	1.75	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW240YGQ
2081	8976	NDAR_INVNW240YGQ	2352			M	1600	Visit6	6	Phase 1/1A	156	0	0	0	0	0	0	1	5	4	0	4	4	2	5	1	3	4	4	6	5	5	5	4	4	6	5	5	5	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	3.125	4.25	4.714286	5.5	4.095238			2.8421052	1.4285715	1.75	4.142857	4	1.2531328	1.6964285	2.5	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW240YGQ
2081	8976	NDAR_INVNW240YGQ	2352			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	9	2	4	2	2	2	2	1	4	4	4	6	2	2	1	4	2	6	4	4	4	1	1	1	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	2.142857	4.5	2.7142856	5	3.1			2.8421052	1.4285715	1.75	4.142857	4	0.25789472	0.71428573	2.75	-1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW240YGQ
2081	8976	NDAR_INVNW240YGQ	2352			M	5200	EndofPhase1_1a	18	Phase 1/1A	513	0	0	0	0	0	0	1	6	0	0	2	2	2	2	1	3	3	5	6	4	4	3	3	4	5	3	5	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	1.875	4.25	3.857143	4	3.1904762		1	2.8421052	1.4285715	1.75	4.142857	4	0.34837094	0.44642857	2.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW240YGQ
2081	8976	NDAR_INVNW268FA1	1214			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	2	2	2	2	1	4	0	0	0	9	0	0	0	0	2	5	3	3	4	1	1	1	1	1	1	1	1	2	3	1	4	2	4	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	6	3.125	0	1.2857143	4	2.1	1		2.1	3.125	0	1.2857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW268FA1
2081	8976	NDAR_INVNW747THY	2472			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	3	3	3	5	0	0	0	0	9	2	1	2	5	2	3	3	4	5	1	0	1	0	1	1	1	1	2	1	1	3	2	4	4	1	0	0	1	0	0	1	0	1	1	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.5	0	3	3	2.75	1		2.75	3.5	0	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW747THY
2081	8976	NDAR_INVNW747THY	2472			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	4	2	4	4	2	0	2	2	0	0	0	9	1	0	2	4	0	3	2	3	4	1	0	1	0	1	0	0	1	2	1	1	4	4	3	4	1	0	0	1	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0	2	2.5	1.95			2.75	3.5	0	3	3	-0.8	-1	0	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW747THY
2081	8976	NDAR_INVNW747THY	2472			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	4	2	4	4	2	1	2	2	0	0	0	9	1	0	2	4	0	3	2	3	4	1	0	1	0	1	1	0	1	2	1	1	3	2	2	2	1	0	0	1	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.625	0	2	2.5	2			2.75	3.5	0	3	3	-0.75	-0.875	0	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW747THY
2081	8976	NDAR_INVNW747THY	2472			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	5	4	4	4	5	4	5	4	2	2	2	9	2	2	2	6	4	3	2	4	6	1	1	0	0	1	1	1	1	2	1	1	3	2	2	2	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.375	1.5	3.7142856	2.5	3.6		1	2.75	3.5	0	3	3	0.85	0.875	1.5	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW747THY
2081	8976	NDAR_INVNW814NK7	2166			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	3	1	2	2	3	4	5	0	4	9	2	3	3	6	5	3	5	5	5	1	1	1	1	1	1	1	1	1	2	1	2	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	1	3	0		1	7	1	23	0		0	0	0	0	0	0	1	0	0	1	0	0	1	1	1	1	4	2.625	2.25	4.142857	4	3.35	1		3.35	2.625	2.25	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW814NK7
2081	8976	NDAR_INVNW814NK7	2166			M	1600	Visit6	6	Phase 2	175	0	0	0	0	0	0	1	6	6	6	6	6	6	5	5	4	4	3	4	3	3	4	5	4	4	4	5	6	1	0	1	0	1	1	1	1	2	1	1	2	1	2	2	0	0	0	0	0	0	0	0					1	27	0		1	3	0		0		0	2	0	0	0	1	0	0	0	0	0	0	0	0	1	0	4	5.75	3.75	4.285714	4	4.714286			3.35	2.625	2.25	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW814NK7
2081	8976	NDAR_INVNW814NK7	2166			M	5200	EndofPhase1_1a	5	Phase 1/1A	152	0	0	0	0	0	1	0	6	6	6	6	6	6	4	6	2	2	2	9	4	2	3	5	2	1	4	4	6	1	1	1	1	1	1	1	1	3	1	1	4	3	3	2	1	0	0	1	0	0	0	0	0	0	0	0	0		0		1	3	1	27	0		0	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	5.75	1.5	3.7142856	2.5	4.15		1	3.35	2.625	2.25	4.142857	4	0.8	3.125	-0.75	-0.42857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW814NK7
2081	8976	NDAR_INVNW862WRN	2262			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	4	2	1	6	2	0	0	4	4	9	2	2	0	4	6	2	2	4	4	0	0	0	0	1	0	1	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.375	2	3.142857	2	2.65	1		2.65	2.375	2	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNW862WRN
2081	8976	NDAR_INVNX003UKH	1737			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	3	1	3	6	6	2	0	0	0	9	2	3	6	6	6	3	6	6	4	1	1	0	0	1	2	0	1	3		1	2	1	1	4	1	0	0	0	0	0	1	0	1	1	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	1	0	0	1	1	0	1	5	3.4285715	0	4.714286	4.5	3.4736843	1		3.4736843	3.4285715	0	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX003UKH
2081	8976	NDAR_INVNX003UKH	1737			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	9	0	4	4	5	6	5	3	6	6	6	6	2	6	5	6	6	4	3	4	5	1	1	1	1	1	1	1	1	3		0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.857143	6	4.857143	3.5	4.6			3.4736843	3.4285715	0	4.714286	4.5	1.1263158	0.42857143	6	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX003UKH
2081	8976	NDAR_INVNX003UKH	1737			M	2800	Visit12	12	Phase 2	340	0	0	0	0	0	0	1	9	0	0	2	1	1	3	5	1	1	1	9	2	2	1	4	2	4	4	1	5	1	1	1	1	1	1	1	1	3		0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.7142857	0.75	2.4285715	4	2.1052632			3.4736843	3.4285715	0	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX003UKH
2081	8976	NDAR_INVNX003UKH	1737			M	5200	EndofPhase1_1a	9	Phase 1/1A	239	0	0	0	0	0	0	1	9	0	4	4	1	6	6	3	3	2	2	2	2	4	3	5	4	5	4	2	2	1	1	1	1	1	0	1	1	3		0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.4285715	2.25	3.142857	4.5	3.2		1	3.4736843	3.4285715	0	4.714286	4.5	-0.2736842	0	2.25	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX003UKH
2081	8976	NDAR_INVNX003UKH	1737			M	5800	EndofPhase2	16	Phase 2	452	0	0	0	0	0	0	1	9	4	4	6	4	6	6	5	4	4	4	4	6	6	4	6	4	4	4	5	4	1	1	1	1	1	1	1	1	3		1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5	4	5	4	4.7			3.4736843	3.4285715	0	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX003UKH
2081	8976	NDAR_INVNX003UKH	1737			M	6000	EndofPhase3	17	Phase 3	465	0	0	0	0	0	0	1	4	1	2	6	6	1	4	4	4	2	1	4	2	1	2	4	6	5	4	1	6	1	0	1	1	0	0	0	1	3		1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	2.75	3.142857	4.5	3.3333333			3.4736843	3.4285715	0	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX003UKH
2081	8976	NDAR_INVNX257JV8	2490			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	2	4	3	2	2	2	1	0	1	1	9	2	3	4	3	1	2	1	4	4	1	0	0	1	1	1	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	15	0		0		1	15	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.625	0.5	3	1.5	2.35	1		2.35	2.625	0.5	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX257JV8
2081	8976	NDAR_INVNX320YH1	2140			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	2	4	3	1	4	1	6	6	4	6	5	5	1	5	6	2	4	5	3	0	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	7	0		1	23	0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	5.5	4.285714	3	3.6666667	1		3.6666667	2.375	5.5	4.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX320YH1
2081	8976	NDAR_INVNX684YL2	1089			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	6	4	4	4	6	6	5	6	9	4	6	4	6	6	4	3	5	6	1	1	1	1	1	1	1	1	1	1	1	3	4	2	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	4.25	5.285714	3.5	5.15	1		5.15	5.25	4.25	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX684YL2
2081	8976	NDAR_INVNX755ZTW	2427			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	3	3	4	3	3	2	2	3	2	3	9	4	4	4	4	4	4	3	2	5	1	1	2	1	1	2	1	2	2	2	1	4	4	3	1	0	0	0	0	0	0	0	0					1	4	0		1	8	0		1	18	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	5	3	2	3.857143	3.5	3.3	1		3.3	3	2	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX755ZTW
2081	8976	NDAR_INVNX755ZTW	2427			M	5200	EndofPhase1_1a	5	Phase 1/1A	188	0	0	0	0	0	0	1	3	2	3	3	4	3	5	4	4	4	3	4	3	3	4	4	3	3	4	4	4	1	1	1	0	1	1	1	0	2	1	0	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	3.75	3.5714285	3.5	3.5238094		1	3.3	3	2	3.857143	3.5	0.22380953	0.375	1.75	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNX755ZTW
2081	8976	NDAR_INVNY212JAC	1424			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	3	3	2	2	2	2	4	0	1	1	9	2	3	3	3	1	4	0	4	3	2	2	2	2	1	1	1	1	2	2	1	4	2	2	4	1	0	0	1	0	0	0	0	1	0	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0.5	2.7142856	2	2.25	1		2.25	2.5	0.5	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY212JAC
2081	8976	NDAR_INVNY212JAC	1424			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	0	1	9	2	4	0	4	6	0	2	2	0	1	9	4	2	4	4	0	5	4	4	4	1	1	1	1	1	1	1	1	2	1	1	2	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.5714285	0.75	3.142857	4.5	2.7368422		1	2.25	2.5	0.5	2.7142856	2	0.4868421	0.071428575	0.25	0.42857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY212JAC
2081	8976	NDAR_INVNY605WYR	1710			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	1	1	4	2	0	3	0	0	0	1	9	1	0	2	2	0	2	2	0	2	1	1	0	1	1	1	2	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.375	0.25	1	2	1.15	1		1.15	1.375	0.25	1	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY605WYR
2081	8976	NDAR_INVNY605WYR	1710			M	2800	Visit12	12	Phase 2	337	1	0	0	0	1	0	0	6	4	4	4	2	1	5	1	0	0	0	9	2	3	3	4	2	2	3	6	3	0	0	2	0	1	1	2	1	1	1	1	2	2	2	4	1	0	1	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	0	3.2857144	2.5	2.75			1.15	1.375	0.25	1	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY605WYR
2081	8976	NDAR_INVNY605WYR	1710			M	5200	EndofPhase1_1a	6	Phase 1/1A	172	1	0	0	0	1	0	0	4	0	1	4	2	0	2	0	3	4	4	4	0	0	2	1	4	2	2	5	2	0	0	2	1	1	1	2	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	1	0	0	0	0	1	1	1	1	5	1.625	3.75	2	2	2.1904762		1	1.15	1.375	0.25	1	2	1.0404762	0.25	3.5	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY605WYR
2081	8976	NDAR_INVNY605WYR	1710			M	5800	EndofPhase2	18	Phase 2	515	1	0	0	0	1	0	0	6	4	4	2	2	0	5	0	4	4	6	6	4	4	6	6	6	3	2	4	4	2	1	2	0	1	1	2	2	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.875	5	4.857143	2.5	3.9047618			1.15	1.375	0.25	1	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY605WYR
2081	8976	NDAR_INVNY606BKA	1648			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	2	2	2	2	2	1	1	0	9	2	1	4	3	0	6	5	4	4	0	1	1	0	1	0	0	1	3	2	0	4	3	3	3	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2	0.5	2.5714285	5.5	2.35	1		2.35	2	0.5	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY606BKA	1648			M	1600	Visit6	6	Phase 2	176	0	1	0	0	0	0	0	4	0	0	0	1	1	0	2	1	0	1	9	2	1	2	2	1	5	2	2	4	0	1	2	1	1	2	2	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0.5	2	3.5	1.55			2.35	2	0.5	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY606BKA	1648			M	2800	Visit12	12	Phase 3	337	0	1	0	0	0	0	0	4	0	0	0	1	1	0	2	1	0	1	9	2	1	2	2	1	5	2	2	4	0	1	2	1	1	2	2	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0.5	2	3.5	1.55			2.35	2	0.5	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY606BKA	1648			M	4000	Visit18	18	Phase 3	505	0	1	0	0	0	0	0	4	0	0	0	1	1	0	2	1	0	1	9	2	1	2	2	1	5	2	2	4	0	1	2	1	1	2	2	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0.5	2	3.5	1.55			2.35	2	0.5	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY606BKA	1648			M	5200	EndofPhase1_1a	2	Phase 1/1A	57	0	1	0	0	0	0	0	6	0	0	2	2	2	2	2	1	1	0	9	2	1	4	3	1	6	4	4	4	0	1	1	0	1	1	1	1	1	2	0	4	3	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	0.5	2.7142856	5	2.35		1	2.35	2	0.5	2.5714285	5.5	0	0	0	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY606BKA	1648			M	5800	EndofPhase2	9	Phase 2	246	0	1	0	0	0	0	0	5	1	1	1	3	1	1	4	1	1	1	9	3	2	3	2	3	5	4	3	2	1	1	1	0	1	0	0	1	1	1	0	4	3	3	1	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.75	2.5714285	4.5	2.35			2.35	2	0.5	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY606BKA	1648			M	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	4	0	0	0	1	1	0	2	1	0	1	9	2	1	2	2	1	5	2	2	4	0	1	2	1	1	2	2	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0.5	2	3.5	1.55			2.35	2	0.5	2.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY606BKA
2081	8976	NDAR_INVNY959THN	1766			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	5	5	5	5	4	3	5	1	0	0	9	1	0	3	4	2	6	5	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.625	0.25	2.857143	5.5	3.45	1		3.45	4.625	0.25	2.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY959THN
2081	8976	NDAR_INVNY959THN	1766			M	5200	EndofPhase1_1a	3	Phase 1/1A	88	1	0	0	0	0	0	0	6	6	4	4	6	3	4	2	1	0	1	9	2	2	3	4	4	6	4	6	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.375	0.5	3.5714285	5	3.6		1	3.45	4.625	0.25	2.857143	5.5	0.15	-0.25	0.25	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY959THN
2081	8976	NDAR_INVNY959THN	1766			M	5800	EndofPhase2	6	Phase 2	158	1	0	0	0	0	0	0	4	5	6	4	6	3	4	3	0	0	0	9	0	2	3	4	2	5	4	6	4	0	1	1	1	1	1	1	1	1	1	1	3	2	2	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.375	0	3	4.5	3.25			3.45	4.625	0.25	2.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY959THN
2081	8976	NDAR_INVNY959THN	1766			M	6000	EndofPhase3	8	Phase 3	213	1	0	0	0	0	0	0	6	6	5	6	6	4	5	4	0	0	0	9	2	0	3	4	1	6	3	4	6	0	1	1	1	1	0	1	1	1	1	1	3	2	2	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.25	0	2.857143	4.5	3.55			3.45	4.625	0.25	2.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVNY959THN
2081	8976	NDAR_INVPA179JJH	2563			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	0	2	0	2	0	4	3	3	3	2	2	1	2	3	5	3	2	3	1	1	1	0	1	1	1	1	3		0	4	4	1	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1	3.25	2.142857	4	2.0952382	1		2.0952382	1	3.25	2.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA179JJH
2081	8976	NDAR_INVPA179JJH	2563			M	1600	Visit6	6	Phase 3	150	0	0	0	0	0	1	0	3	4	4	2	2	2	4	2	4	3	4	4	2	4	1	2	4	5	4	4	4	1	1	1	0	1	1	0	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.875	3.75	3	4.5	3.2380953			2.0952382	1	3.25	2.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA179JJH
2081	8976	NDAR_INVPA179JJH	2563			M	5200	EndofPhase1_1a	1	Phase 1/1A	19	0	0	0	0	0	1	0	2	2	2	0	2	0	2	2	4	3	3	3	1	2	1	2	3	3	4	2	3	1	1	1	0	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.5	3.25	2	3.5	2.1904762		1	2.0952382	1	3.25	2.142857	4	0.0952381	0.5	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA179JJH
2081	8976	NDAR_INVPA225WJC	2796			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	3	3	1	2	3	4	2	5	3	4	9	3	3	4	6	1	4	2	4	5	2	2	2	2	1	1	1	1	2	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	22	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	5	2.75	3	3.7142856	3	3.3	1		3.3	2.75	3	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA225WJC
2081	8976	NDAR_INVPA225WJC	2796			M	1600	Visit6	6	Phase 3	165	1	0	0	0	0	0	0	6	5	5	5	5	5	5	3	2	1	1	9	1	3	3	3	3	4	3	3	4	1	0	1	0	1	1	0	1	1	1	1	2	1	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	1	2.857143	3.5	3.5			3.3	2.75	3	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA225WJC
2081	8976	NDAR_INVPA225WJC	2796			M	2800	Visit12	12	Phase 3	333	1	0	0	0	0	0	0	5	4	4	3	3	3	5	3	1	1	1	9	1	1	2	3	1	3	2	3	3	1	0	1	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	0.75	2	2.5	2.6			3.3	2.75	3	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA225WJC
2081	8976	NDAR_INVPA225WJC	2796			M	5200	EndofPhase1_1a	1	Phase 1/1A	39	1	0	0	0	0	0	0	6	1	1	2	2	1	3	1	0	1	1	9	3	2	4	3	2	5	2	4	5	1	0	1	1	0	1	1	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0.5	3.2857144	3.5	2.45		1	3.3	2.75	3	3.7142856	3	-0.85	-0.625	-2.5	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA225WJC
2081	8976	NDAR_INVPA225WJC	2796			M	5800	EndofPhase2	3	Phase 2	85	1	0	0	0	0	0	0	4	4	4	2	2	2	2	2	4	3	4	9	4	3	4	3	3	3	1	4	5	2	2	2	2	1	0	1	2	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	2.75	3.7142856	2	3.15			3.3	2.75	3	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA225WJC
2081	8976	NDAR_INVPA225WJC	2796			M	6000	EndofPhase3	18	Phase 3	502	1	0	0	0	0	0	0	4	3	3	3	3	3	4	3	0	1	1	9	2	2	3	3	0	4	3	2	5	1	0	1	1	1	1	1	1	1	1	1	2	1	1	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	0.5	2.4285715	3.5	2.6			3.3	2.75	3	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA225WJC
2081	8976	NDAR_INVPA430NJX	2325			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	9	0	0	2	4	0	5	2	2	5	1	0	1	1	1	1	1	1	3	3	1	4	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		2	0	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.5	0	1.8571428	3.5	1.2	1		1.2	0.5	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA430NJX
2081	8976	NDAR_INVPA507AW3	2475			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	6	4	4	6	5	6	6	6	6	5	6	5	6	4	6	6	5	2	5	5	1	0	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	5.25	5.75	5.285714	3.5	5.1904764	1		5.1904764	5.25	5.75	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA507AW3
2081	8976	NDAR_INVPA507AW3	2475			M	1600	Visit6	6	Phase 3	177	1	0	0	0	0	0	0	6	4	5	5	5	6	6	5	3	5	4	5	5	5	5	6	5	4	3	4	5	1	0	1	0	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	5.25	4.25	5	3.5	4.8095236			5.1904764	5.25	5.75	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA507AW3
2081	8976	NDAR_INVPA507AW3	2475			M	2800	Visit12	12	Phase 3	337	1	0	0	0	0	0	0	6	4	4	4	3	4	4	3	5	4	4	6	3	4	3	6	6	5	3	5	6	1	1	1	1	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4	4.75	4.714286	4	4.3809524			5.1904764	5.25	5.75	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA507AW3
2081	8976	NDAR_INVPA507AW3	2475			M	5200	EndofPhase1_1a	3	Phase 1/1A	92	1	0	0	0	0	0	0	5	5	4	6	4	4	6	5	6	6	6	6	5	6	5	6	4	5	3	4	6	1	1	1	0	1	1	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	1	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.875	6	5.142857	4	5.095238		1	5.1904764	5.25	5.75	5.285714	3.5	-0.0952381	-0.375	0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA507AW3
2081	8976	NDAR_INVPA507AW3	2475			M	5800	EndofPhase2	4	Phase 2	113	1	0	0	0	0	0	0	6	5	2	2	4	5	6	3	2	3	3	9	5	4	4	5	4	4	3	3	5	1	1	1	0	1	1	1	1	1	2	1	3	3	2	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.125	2	4.285714	3.5	3.9			5.1904764	5.25	5.75	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA507AW3
2081	8976	NDAR_INVPA507AW3	2475			M	6000	EndofPhase3	18	Phase 3	507	1	0	0	0	0	0	0	6	6	4	2	4	3	5	2	2	3	3	9	3	4	3	6	5	5	3	6	6	1	1	1	1	1	1	1	1	1	2	1	3	2	2	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4	2	4.714286	4	4.05			5.1904764	5.25	5.75	5.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPA507AW3
2081	8976	NDAR_INVPB385LEZ	1140			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	3	3	2	1	3	1	0	1	1	9	2	2	4	4	4	4	5	3	2	1	1	1	1	1	0	0	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	4	1.875	0.5	3	4.5	2.35	1		2.35	1.875	0.5	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB385LEZ
2081	8976	NDAR_INVPB385LEZ	1140			M	1600	Visit6	6	Phase 3	164	0	0	0	0	0	0	1	6	2	2	2	4	2	3	2	1	1	2	9	4	3	5	6	5	6	6	5	5	0	1	1	1	1	0	0	1	2	1	1	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	2.875	1	4.714286	6	3.6			2.35	1.875	0.5	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB385LEZ
2081	8976	NDAR_INVPB385LEZ	1140			M	2800	Visit12	12	Phase 3	332	0	0	0	0	0	0	1	6	0	1	2	2	2	1	1	3	3	1	2	1	1	6	4	5	6	5	4	6	1	0	1	1	1	0	1	1	2	1	1	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	2.25	3.857143	5.5	2.952381			2.35	1.875	0.5	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB385LEZ
2081	8976	NDAR_INVPB385LEZ	1140			M	5200	EndofPhase1_1a	1	Phase 1/1A	10	0	0	0	0	0	0	1	2	0	3	3	2	1	3	1	0	1	1	9	2	2	4	4	4	4	5	3	2	1	1	1	1	1	0	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	0	1	1	4	1.875	0.5	3	4.5	2.35		1	2.35	1.875	0.5	3	4.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB385LEZ
2081	8976	NDAR_INVPB385LEZ	1140			M	5800	EndofPhase2	2	Phase 2	44	0	0	0	0	0	0	1	2	0	3	3	2	1	3	1	0	1	1	9	2	2	4	4	4	4	5	3	2	1	1	1	1	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	4	1.875	0.5	3	4.5	2.35			2.35	1.875	0.5	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB385LEZ
2081	8976	NDAR_INVPB385LEZ	1140			M	6000	EndofPhase3	18	Phase 3	500	0	0	0	0	0	0	1	3	2	1	2	2	2	2	1	0	0	0	9	2	2	6	4	2	5	4	4	4	1	0	1	1	1	1	1	1	3	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	3	1.875	0	3.4285715	4.5	2.4			2.35	1.875	0.5	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB385LEZ
2081	8976	NDAR_INVPB479HY6	1329			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	5	3	3	4	6	5	0	4	4	4	6	6	6	6	6	6	5	4	6	5	1	1	1	1	1	0	1	1	3	1	1	3	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	4	3.625	4.5	5.857143	4.5	4.6190476	1		4.6190476	3.625	4.5	5.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB479HY6
2081	8976	NDAR_INVPB479HY6	1329			M	5200	EndofPhase1_1a	1	Phase 1/1A	8	0	0	0	0	0	1	0	3	5	3	3	4	6	5	0	4	4	4	6	6	6	6	6	6	5	4	6	5	1	1	1	1	1	0	1	1	3	1	1	3	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4	3.625	4.5	5.857143	4.5	4.6190476		1	4.6190476	3.625	4.5	5.857143	4.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB479HY6
2081	8976	NDAR_INVPB479HY6	1329			M	5800	EndofPhase2	2	Phase 2	27	0	0	0	0	0	1	0	3	5	3	3	4	6	5	0	4	4	4	6	6	6	6	6	6	5	3	6	5	1	1	1	1	1	1	1	1	3	1	1	3	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	4	3.625	4.5	5.857143	4	4.571429			4.6190476	3.625	4.5	5.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB479HY6
2081	8976	NDAR_INVPB479HY6	1329			M	6000	EndofPhase3	3	Phase 3	60	0	0	0	0	0	1	0	2	5	3	3	4	6	5	0	4	4	4	6	6	6	6	6	6	5	3	6	5	1	1	1	0	1	1	1	1	3	1	1	3	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	4	3.5	4.5	5.857143	4	4.5238094			4.6190476	3.625	4.5	5.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPB479HY6
2081	8976	NDAR_INVPC098RAV	1951			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	2	2	2	3	2	4	4	3	3	2	2	3	4	4	4	4	4	3	4	5	1	1	1	1	1	1	1	1	1	1	1	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	26	0		0		1	4	0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	6	3	2.5	4	3.5	3.2857144	1		3.2857144	3	2.5	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC098RAV
2081	8976	NDAR_INVPC098RAV	1951			M	1600	Visit6	6	Phase 1/1A	167	0	0	1	0	1	0	0	6	5	5	5	6	6	4	4	3	2	4	2	6	4	4	6	5	5	4	6	6	0	0	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	6	5.125	2.75	5.285714	4.5	4.6666665			3.2857144	3	2.5	4	3.5	1.3809524	2.125	0.25	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC098RAV
2081	8976	NDAR_INVPC098RAV	1951			M	2800	Visit12	12	Phase 1/1A	336	0	0	1	0	0	0	0	5	3	3	2	6	0	2	4	2	2	0	9	3	3	4	6	3	5	2	6	6	1	1	1	0	1	1	1	1	1	2	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.125	1	4.428571	3.5	3.35			3.2857144	3	2.5	4	3.5	0.06428571	0.125	-1.5	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC098RAV
2081	8976	NDAR_INVPC098RAV	1951			M	5200	EndofPhase1_1a	18	Phase 1/1A	513	0	0	1	0	0	0	0	6	4	4	5	6	2	6	5	0	0	2	9	4	4	4	6	2	4	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	3	3	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	0.5	4.571429	4	4		1	3.2857144	3	2.5	4	3.5	0.71428573	1.75	-2	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC098RAV
2081	8976	NDAR_INVPC246WXU	2439			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	4	4	4	4	4	5	0	1	1	0	9	4	5	4	4	2	0	2	4	6	0	1	0	0	0	1	0	0	3	1	1	4	3	3	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	6	3.875	0.5	4.142857	1	3.2	1		3.2	3.875	0.5	4.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC246WXU
2081	8976	NDAR_INVPC246WXU	2439			M	5200	EndofPhase1_1a	1	Phase 1/1A	126	0	0	0	0	1	0	0	4	4	2	2	4	1	2	1	0	0	0	9	2	1	3	3	2	1	1	2	2	2	2	2	2	1	1	1	1	1	1	1	2	2	3	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	6	2.5	0	2.142857	1	1.85		1	3.2	3.875	0.5	4.142857	1	-1.35	-1.375	-0.5	-2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC246WXU
2081	8976	NDAR_INVPC258DP7	2626			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	0	5	2	2	1	0	0	0	9	2	2	4	2	1	4	3	4	5	2	2	2	2	1	1	1	2	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	20	0		0		1	10	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1.75	0	2.857143	3.5	2.05	1		2.05	1.75	0	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC258DP7
2081	8976	NDAR_INVPC258DP7	2626			M	1600	Visit6	6	Phase 3	169	0	0	0	0	0	0	1	0	4	0	1	0	0	0	2	0	1	2	3	4	4	6	2	2	5	2	5	3	1	1	1	1	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.875	1.5	3.7142856	3.5	2.1904762			2.05	1.75	0	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC258DP7
2081	8976	NDAR_INVPC258DP7	2626			M	2800	Visit12	12	Phase 3	346	0	0	0	0	0	0	1	2	3	0	1	0	0	0	2	2	2	2	9	2	4	5	4	2	5	3	4	5	1	0	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	2	1	1.5	3.7142856	4	2.4			2.05	1.75	0	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC258DP7
2081	8976	NDAR_INVPC258DP7	2626			M	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	0	0	0	0	0	1	6	0	0	2	0	0	2	2	2	4	0	9	6	2	4	4	4	4	3	4	4	1	0	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	17	0		0		1	13	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	1.5	4	3.5	2.65		1	2.05	1.75	0	2.857143	3.5	0.6	-0.25	1.5	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC258DP7
2081	8976	NDAR_INVPC258DP7	2626			M	5800	EndofPhase2	4	Phase 2	113	0	0	0	0	0	0	1	4	0	0	4	0	1	2	2	1	1	2	9	2	3	4	2	2	5	2	4	3	1	1	1	1	1	0	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1.625	1	2.857143	3.5	2.2			2.05	1.75	0	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC258DP7
2081	8976	NDAR_INVPC258DP7	2626			M	6000	EndofPhase3	18	Phase 3	505	0	0	0	0	0	0	1	0	0	0	2	2	0	2	2	3	2	0	2	2	4	5	4	3	4	4	6	6	1	1	1	1	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	1	1.75	4.285714	4	2.5238094			2.05	1.75	0	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC258DP7
2081	8976	NDAR_INVPC499XAF	1504			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	4	2	3	1	2	2	2	3	3	9	2	2	2	2	2	2	5	4	2	1	1	1	1	1	1	1	1	3	1	1	2	2	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	7	2.2857144	2	2.2857144	3.5	2.4736843	1		2.4736843	2.2857144	2	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC499XAF
2081	8976	NDAR_INVPC499XAF	1504			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	4	4	2	2	2	4	4	0	3	2	9	0	2	0	4	2	4	4	4	2	1	1	1	1	0	1	1	1	3	1	1	3	3	3	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.142857	1.25	2	4	2.5789473			2.4736843	2.2857144	2	2.2857144	3.5	0.10526316	0.85714287	-0.75	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC499XAF
2081	8976	NDAR_INVPC499XAF	1504			M	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	0	1	9	6	6	4	6	6	6	5	1	4	3	9	2	4	4	4	2	5	4	4	2	1	1	1	0	1	1	1	1	2	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.571429	2	3.142857	4.5	4.105263			2.4736843	2.2857144	2	2.2857144	3.5	1.6315789	3.2857144	0	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC499XAF
2081	8976	NDAR_INVPC499XAF	1504			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	0	1	0	0	0	0	0	6	6	6	4	6	6	6	3	0	2	4	9	0	2	3	4	2	3	4	4	3	1	1	1	1	1	1	1	1	3	1	1	3	2	3	2	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.375	1.5	2.5714285	3.5	3.7		1	2.4736843	2.2857144	2	2.2857144	3.5	1.2263157	3.0892856	-0.5	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC499XAF
2081	8976	NDAR_INVPC979YRX	2390			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	4	3	5	3	5	5	2	2	4	3	9	5	5	3	4	5	3	3	5	6	1	1	1	1	1	1	1	1	2	1	1	2	1	1	4	1	0	1	0	0	0	0	0	1	0	1	1	1	17	0		0		1	13	0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	5	3.875	2.25	4.714286	3	3.95	1		3.95	3.875	2.25	4.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC979YRX
2081	8976	NDAR_INVPC979YRX	2390			F	5200	EndofPhase1_1a	4	Phase 1/1A	142	1	0	0	0	0	0	0	3	1	2	2	4	3	4	2	1	1	1	9	1	3	2	5	1	5	3	2	4	1	2	2	0	1	0	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	6	0		0		1	24	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.625	0.75	2.5714285	4	2.5		1	3.95	3.875	2.25	4.714286	3	-1.45	-1.25	-1.5	-2.142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPC979YRX
2081	8976	NDAR_INVPD031PDP	1315			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	4	3	4	3	2	2	0	0	0	9	1	2	2	3	2	5	3	4	4	1	1	1	0	1	1	1	1	1	2	1	4	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	3.125	0	2.5714285	4	2.55	1		2.55	3.125	0	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD031PDP
2081	8976	NDAR_INVPD031PDP	1315			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	4	2	4	4	2	0	4	2	0	0	0	9	0	1	2	2	2	5	3	4	4	1	1	1	0	1	1	1	1	2	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	0	2.142857	4	2.25			2.55	3.125	0	2.5714285	4	-0.3	-0.375	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD031PDP
2081	8976	NDAR_INVPD031PDP	1315			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	5	2	4	2	3	2	2	0	0	0	0	9	0	0	4	4	2	5	4	4	4	1	0	1	0	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	0	2.5714285	4.5	2.35			2.55	3.125	0	2.5714285	4	-0.2	-0.625	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD031PDP
2081	8976	NDAR_INVPD031PDP	1315			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	0	0	0	0	1	6	2	2	4	4	2	3	0	0	0	0	9	0	4	5	6	4	5	4	4	4	1	1	1	0	1	1	1	1	2	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	2.875	0	3.857143	4.5	2.95		1	2.55	3.125	0	2.5714285	4	0.4	-0.25	0	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD031PDP
2081	8976	NDAR_INVPD304CM4	2525			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	2	2	2	2	2	1	0	0	1	9	2	2	2	2	0	4	2	3	3	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	0.25	2	3	1.9	1		1.9	2.125	0.25	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD304CM4
2081	8976	NDAR_INVPD304CM4	2525			M	1600	Visit6	6	Phase 1/1A	168	1	0	0	0	0	0	0	4	4	5	3	3	3	2	1	0	0	0	9	2	2	3	4	2	4	3	3	3	1	1	1	0	1	1	1	1	1	2	1	3	2	2	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	3	3.125	0	2.7142856	3.5	2.55			1.9	2.125	0.25	2	3	0.65	1	-0.25	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD304CM4
2081	8976	NDAR_INVPD304CM4	2525			M	2800	Visit12	12	Phase 2	330	0	0	0	0	0	0	1	3	3	4	4	4	4	3	1	0	1	1	9	2	2	3	3	3	5	3	2	4	1	1	0	0	1	0	0	0	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	0.5	2.7142856	4	2.75			1.9	2.125	0.25	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD304CM4
2081	8976	NDAR_INVPD304CM4	2525			M	5200	EndofPhase1_1a	10	Phase 1/1A	259	0	0	0	0	0	0	1	3	4	2	3	3	3	3	1	0	2	1	9	2	2	3	2	2	4	2	3	3	1	0	1	0	1	1	1	1	2	2	1	2	1	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.75	0.75	2.4285715	3	2.4		1	1.9	2.125	0.25	2	3	0.5	0.625	0.5	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD304CM4
2081	8976	NDAR_INVPD304CM4	2525			M	5800	EndofPhase2	18	Phase 2	498	0	0	0	0	0	0	1	4	3	3	3	2	3	3	1	0	0	0	9	3	2	3	3	2	5	2	3	3	1	1	0	0	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.75	0	2.7142856	3.5	2.4			1.9	2.125	0.25	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD304CM4
2081	8976	NDAR_INVPD448NJC	1152			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	1	2	2	2	2	2	2	2	9	3	2	3	2	0	1	2	1	1	1	1	0	0	1	1	1	1	2	3	1	3	4	4	2	1	0	1	0	0	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	2	1.375	1.5	1.7142857	1.5	1.6	1		1.6	1.375	1.5	1.7142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD448NJC
2081	8976	NDAR_INVPD448NJC	1152			F	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	5	4	2	2	4	4	2	2	2	3	0	9	3	5	4	4	2	4	4	4	5	1	1	0	1	1	0	1	1	1	2	0		2	4	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3.125	1.25	3.857143	4	3.25			1.6	1.375	1.5	1.7142857	1.5	1.65	1.75	-0.25	2.142857	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD448NJC
2081	8976	NDAR_INVPD448NJC	1152			F	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	4	4	4	4	4	4	4	2	3	4	4	6	4	4	4	4	4	3	5	5	4	1	1	1	1	1	1	1	1	1	1	0	4	1	2	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.75	4.25	4.142857	4	4			1.6	1.375	1.5	1.7142857	1.5	2.4	2.375	2.75	2.4285715	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD448NJC
2081	8976	NDAR_INVPD448NJC	1152			F	4000	Visit18	18	Phase 1/1A	512	1	0	0	0	0	0	0	6	0	0	1	2	1	1	2	0	4	1	9	1	2	4	2	2	5	5	4	4	1	1	1	0	1	1	1	1	1	3	0	4	4	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.625	1.25	2.7142856	5	2.35		1	1.6	1.375	1.5	1.7142857	1.5	0.75	0.25	-0.25	1	3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD448NJC
2081	8976	NDAR_INVPD821GTR	1261			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	0	0	2	3	0	0	0	0	0	0	9	2	0	0	0	0	2	1	4	1	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0	1	1.5	0.95	1		0.95	1.125	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD821GTR
2081	8976	NDAR_INVPD821GTR	1261			M	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	9	0	0	0	1	0	2	2	4	4	1	0	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.125	0	1.2857143	2	0.7			0.95	1.125	0	1	1.5	-0.25	-1	0	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD821GTR
2081	8976	NDAR_INVPD821GTR	1261			M	4000	Visit18	18	Phase 1/1A	513	1	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	9	1	1	1	0	2	2	0	0	1	0	0	0	0	1	0	0	0	3		0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.375	0	0.85714287	1	0.55		1	0.95	1.125	0	1	1.5	-0.4	-0.75	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPD821GTR
2081	8976	NDAR_INVPE952HKV	1949			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	0	6	9	0	0	0	2	0	1	1	0	1	0	0	0	0	0	0	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.5	1.5	0.42857143	1	0.75	1		0.75	0.5	1.5	0.42857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE952HKV
2081	8976	NDAR_INVPE952HKV	1949			M	1600	Visit6	6	Phase 1/1A	180	0	0	0	0	0	1	0	2	0	0	2	2	2	2	0	0	1	6	9	0	1	0	2	0	2	2	1	1	1	1	2	0	1	1	2	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.25	1.75	0.71428573	2	1.3			0.75	0.5	1.5	0.42857143	1	0.55	0.75	0.25	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE952HKV
2081	8976	NDAR_INVPE952HKV	1949			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	4	0	0	2	2	2	2	0	0	2	6	9	0	2	2	3	0	2	2	5	5	0	0	1	0	1	1	1	1	3	1	1	2	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	7	1.5	2	2.4285715	2	2.05			0.75	0.5	1.5	0.42857143	1	1.3	1	0.5	2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE952HKV
2081	8976	NDAR_INVPE952HKV	1949			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	0	0	0	0	0	1	0	2	0	0	2	2	2	2	0	0	2	6	9	0	1	0	4	1	2	2	1	2	0	0	1	0	1	1	0	1	3	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.25	2	1.2857143	2	1.55		1	0.75	0.5	1.5	0.42857143	1	0.8	0.75	0.5	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE952HKV
2081	8976	NDAR_INVPE961ZJ2	2448			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	1	1	3	2	2	2	4	2	1	1	9	3	3	4	2	2	6	3	5	5	1	1	0	0	1	1	1	0	1	2	0	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	2.25	1	3.4285715	4.5	2.75	1		2.75	2.25	1	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE961ZJ2
2081	8976	NDAR_INVPE961ZJ2	2448			M	1600	Visit6	6	Phase 1/1A	176	0	1	0	1	0	0	0	4	3	0	2	2	0	2	0	1	2	4	9	0	0	0	2	1	3	1	3	3	0	0	1	0	1	1	0	1	1	3	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1.625	1.75	1.2857143	2	1.65			2.75	2.25	1	3.4285715	4.5	-1.1	-0.625	0.75	-2.142857	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE961ZJ2
2081	8976	NDAR_INVPE961ZJ2	2448			M	2800	Visit12	12	Phase 1/1A	370	0	1	0	1	0	0	0	2	4	0	2	2	0	2	1	1	2	1	9	0	1	2	2	0	2	1	4	4	0	0	0	0	1	1	0	1	2	2	0	4	3	3	2	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	1	1.8571428	1.5	1.65			2.75	2.25	1	3.4285715	4.5	-1.1	-0.625	0	-1.5714285	-3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE961ZJ2
2081	8976	NDAR_INVPE961ZJ2	2448			M	5200	EndofPhase1_1a	18	Phase 1/1A	537	0	1	0	0	0	0	0	2	1	0	0	0	0	2	0	0	0	0	9	0	0	2	1	0	4	2	2	2	1	1	0	0	1	1	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	0.625	0	1	3	0.9		1	2.75	2.25	1	3.4285715	4.5	-1.85	-1.625	-1	-2.4285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPE961ZJ2
2081	8976	NDAR_INVPF339DKJ	2233			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	2	2	3	3	3	0	2	5	2	9	5	5	5	6	2	3	3	4	5	1	0	1	1	1	1	0	1	1	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	2.875	2.25	4.571429	3	3.5	1		3.5	2.875	2.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF339DKJ
2081	8976	NDAR_INVPF539UGK	1672			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	2	2	2	6	6	4	0	4	6	9	4	2	2	6	6	4	4	6	4	1	1	1	1	1	1	1	1	1	1	0	4	1	1	1	1	1	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.75	2.5	4.285714	4	3.9	1		3.9	3.75	2.5	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF539UGK
2081	8976	NDAR_INVPF539UGK	1672			M	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	1	0	0	0	0	0	6	3	1	2	3	2	5	3	0	0	1	9	3	2	2	3	4	3	3	5	5	1	1	1	1	1	1	1	1	1	1	1	3	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	0.25	3.4285715	3	2.8		1	3.9	3.75	2.5	4.285714	4	-1.1	-0.625	-2.25	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF539UGK
2081	8976	NDAR_INVPF539UGK	1672			M	5800	EndofPhase2	3	Phase 2	82	0	1	0	0	0	0	0	5	2	2	2	2	2	4	4	0	0	0	9	5	4	4	5	5	4	3	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.875	0	4.428571	3.5	3.05			3.9	3.75	2.5	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF539UGK
2081	8976	NDAR_INVPF672TKA	1667			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	3	1	3	1	1	2	1	0	0	9	2	0	4	2	3	4	4	2	2	1	1	1	1	1	1	0	1	3	2	1	2	3	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	1	0	0	1	0	1	0	3	2.25	0.25	2.142857	4	2.1	1		2.1	2.25	0.25	2.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF672TKA
2081	8976	NDAR_INVPF672TKA	1667			F	5200	EndofPhase1_1a	6	Phase 1/1A	174	0	0	0	0	0	1	0	4	3	2	1	2	1	1	2	0	0	0	9	1	0	3	2	2	5	3	2	2	1	1	1	1	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	23	0		1	7	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0	1.7142857	4	1.8		1	2.1	2.25	0.25	2.142857	4	-0.3	-0.25	-0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF672TKA
2081	8976	NDAR_INVPF672TKA	1667			F	5800	EndofPhase2	7	Phase 2	208	0	0	0	0	0	1	0	4	2	2	1	1	1	1	2	0	0	0	9	0	0	3	2	2	5	3	2	2	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	28	0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.75	0	1.5714285	4	1.65			2.1	2.25	0.25	2.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF672TKA
2081	8976	NDAR_INVPF944NW4	1098			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	5	3	5	4	5	2	4	5	5	5	5	5	4	3	5	4	4	4	5	1	1	1	2	1	1	1	1	1	2	1	3	2	2	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4	4.75	4.428571	4	4.285714	1		4.285714	4	4.75	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF944NW4
2081	8976	NDAR_INVPF944NW4	1098			F	1600	Visit6	6	Phase 1/1A	190	0	1	0	0	0	0	0	3	4	3	2	1	3	2	4	4	4	4	5	4	3	5	3	5	5	4	4	4	1	1	1	2	1	1	1	1	1	2	1	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	4.25	4	4.5	3.6190476			4.285714	4	4.75	4.428571	4	-0.6666667	-1.25	-0.5	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF944NW4
2081	8976	NDAR_INVPF944NW4	1098			F	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	4	4	4	5	4	5	5	4	4	4	4	5	5	5	5	5	2	4	4	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	4	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.375	4.25	4.571429	4	4.3809524			4.285714	4	4.75	4.428571	4	0.0952381	0.375	-0.5	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF944NW4
2081	8976	NDAR_INVPF944NW4	1098			F	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	1	0	0	0	0	0	5	5	4	5	5	4	3	5	5	5	4	6	5	5	5	5	5	5	5	5	5	1	1	1	0	1	1	1	1	1	2	1	3	2	2	1	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	1	0	0	0	1	1	1	1	4	4.5	5	5	5	4.8095236		1	4.285714	4	4.75	4.428571	4	0.52380955	0.5	0.25	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPF944NW4
2081	8976	NDAR_INVPG391RB6	2681			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	2	2	0	6	6	0	0	0	9	2	4	4	6	6	5	3	5	4	0	0	1	1	1	1	1	1	1	1	1	2	1	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	4.25	0	4.428571	4	3.65	1		3.65	4.25	0	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG391RB6
2081	8976	NDAR_INVPG391RB6	2681			F	1600	Visit6	6	Phase 1/1A	165	0	1	0	0	0	0	0	6	6	2	2	5	1	4	6	4	6	6	6	6	6	6	6	6	4	3	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	0	0	0	0	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4	5.5	6	3.5	4.904762			3.65	4.25	0	4.428571	4	1.2547619	-0.25	5.5	1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG391RB6
2081	8976	NDAR_INVPG391RB6	2681			F	2800	Visit12	12	Phase 1/1A	338	0	1	0	0	0	0	0	6	6	6	6	6	0	6	6	4	6	6	9	5	6	4	6	5	5	2	6	6	1	1	1	0	1	1	1	1	1	1	1	3	1	2	1	1	1	0	1	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.25	4	5.428571	3.5	5.15			3.65	4.25	0	4.428571	4	1.5	1	4	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG391RB6
2081	8976	NDAR_INVPG391RB6	2681			F	4000	Visit18	18	Phase 1/1A	506	0	1	0	0	0	0	0	6	6	6	6	6	5	6	5	5	6	6	9	5	6	5	6	5	5	3	6	6	1	1	1	0	1	1	1	1	1	1	1	3	1	2	1	1	1	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	7	5.75	4.25	5.571429	4	5.5			3.65	4.25	0	4.428571	4	1.85	1.5	4.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG391RB6
2081	8976	NDAR_INVPG391RB6	2681			F	5200	EndofPhase1_1a	18	Phase 1/1A	506	1	0	1	0	0	0	0	6	6	6	6	6	5	6	5	5	6	6	9	5	6	5	6	5	5	3	6	6	1	1	1	1	1	1	1	1	1	1	1	3	1	2	2	1	1	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	7	5.75	4.25	5.571429	4	5.5		1	3.65	4.25	0	4.428571	4	1.85	1.5	4.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG391RB6
2081	8976	NDAR_INVPG997KG7	1985			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	4	0	0	2	1	2	2	2	2	1	9	0	0	0	0	0	4	1	2	4	0	0	1	0	1	1	1	1	1	1	1	2	4	2	4	1	0	0	0	1	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	7	1.875	1.25	0.85714287	2.5	1.55	1		1.55	1.875	1.25	0.85714287	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG997KG7
2081	8976	NDAR_INVPG997KG7	1985			F	5200	EndofPhase1_1a	4	Phase 1/1A	109	0	0	0	1	0	0	0	5	4	0	2	2	1	4	1	4	4	1	5	0	2	0	3	3	4	1	4	4	0	0	1	0	1	0	1	1	1	1	1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	2.375	3.5	2.2857144	2.5	2.5714285		1	1.55	1.875	1.25	0.85714287	2.5	1.0214286	0.5	2.25	1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG997KG7
2081	8976	NDAR_INVPG997KG7	1985			F	5800	EndofPhase2	5	Phase 2	151	0	0	0	1	0	0	0	5	4	0	2	2	1	4	1	4	4	1	5	0	2	0	3	3	3	2	4	4	1	1	1	0	1	1	1	1	1	1	1	2	1	4	4	0	0	0	0	0	0	0	0					1	29	0		0		1	2	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	2.375	3.5	2.2857144	2.5	2.5714285			1.55	1.875	1.25	0.85714287	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG997KG7
2081	8976	NDAR_INVPG997KG7	1985			F	6000	EndofPhase3	6	Phase 3	186	0	0	0	1	0	0	0	5	4	0	2	1	1	3	0	4	4	1	5	0	1	0	3	2	4	2	4	4	0	0	1	0	1	1	1	1	1	1	1	2	4	4	4	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	1	2	3.5	2	3	2.3809524			1.55	1.875	1.25	0.85714287	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPG997KG7
2081	8976	NDAR_INVPH326TWU	1531			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	0	1	1	1	3	1	1	1	1	9	2	2	0	2	2	2	1	2	3	2	2	2	0	1	2	2	2	3	3	1	4	2	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		1	7	1	21	0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	1	4	1.375	0.75	1.8571428	1.5	1.5	1		1.5	1.375	0.75	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH326TWU
2081	8976	NDAR_INVPH813KHF	2513			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	0	2	3	2	4	4	2	2	1	9	1	2	2	5	4	4	4	2	4	1	1	1	1	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	17	0		0		1	13	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	1.25	2.857143	4	2.8	1		2.8	2.875	1.25	2.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH813KHF
2081	8976	NDAR_INVPH868ELE	1041			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	2	4	4	2	2	4	0	2	2	2	9	2	2	2	4	3	2	2	4	4	0	0	0	0	1	1	1	1	1	2	1	3	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.25	1.5	3	2	2.45	1		2.45	2.25	1.5	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH868ELE
2081	8976	NDAR_INVPH877JXE	2817			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	1	2	1	1	1	2	2	6	3	5	3	4	3	2	2	5	5	4	4	4	1	1	1	0	1	1	1	1	3	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	0	3	1.5	4.25	3.4285715	4.5	2.952381	1		2.952381	1.5	4.25	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH877JXE
2081	8976	NDAR_INVPH877JXE	2817			M	1600	Visit6	6	Phase 3	141	0	0	0	0	0	0	1	1	4	3	4	3	2	2	1	1	1	1	9	1	2	2	2	1	6	3	4	4	0	0	1	0	1	1	1	1	1	1	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.5	0.75	2.2857144	4.5	2.4			2.952381	1.5	4.25	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH877JXE
2081	8976	NDAR_INVPH877JXE	2817			M	2800	Visit12	12	Phase 3	343	0	0	0	0	0	0	1	1	3	1	1	1	1	1	1	5	1	4	2	2	1	2	2	1	5	1	3	3	1	0	1	0	1	1	1	1	3	3	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	1.25	3	2	3	2			2.952381	1.5	4.25	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH877JXE
2081	8976	NDAR_INVPH877JXE	2817			M	5200	EndofPhase1_1a	4	Phase 1/1A	90	0	0	0	0	0	0	1	1	2	1	2	1	1	2	2	3	3	2	3	2	2	2	2	2	4	4	4	3	1	1	1	0	1	1	1	1	3	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	1.5	2.75	2.4285715	4	2.2857144		1	2.952381	1.5	4.25	3.4285715	4.5	-0.6666667	0	-1.5	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH877JXE
2081	8976	NDAR_INVPH877JXE	2817			M	5800	EndofPhase2	5	Phase 2	113	0	0	0	0	0	0	1	0	4	1	2	1	3	2	2	2	2	2	9	2	2	2	2	1	5	2	3	3	0	1	1	0	1	1	1	1	2	3	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.875	1.5	2.142857	3.5	2.15			2.952381	1.5	4.25	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPH877JXE
2081	8976	NDAR_INVPJ126DL1	1333			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	3	4	3	4	4	2	3	4	2	5	2	3	4	4	5	5	5	4	4	1	1	1	1	1	1	1	1	1	3	1	4	1	2	2	1	0	1	1	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	1	4	2.875	3.5	3.7142856	5	3.4761906	1		3.4761906	2.875	3.5	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ126DL1
2081	8976	NDAR_INVPJ126DL1	1333			M	1600	Visit6	6	Phase 2	196	0	0	0	0	0	1	0	6	6	3	4	4	4	1	2	0	2	1	9	1	2	5	6	4	5	5	5	5	1	1	1	1	1	1	1	1	2	2	1	2	2	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	0	4	3.75	0.75	4	5	3.55			3.4761906	2.875	3.5	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ126DL1
2081	8976	NDAR_INVPJ126DL1	1333			M	5200	EndofPhase1_1a	1	Phase 1/1A	42	0	0	0	0	0	1	0	0	1	1	1	0	4	3	1	3	4	5	5	3	4	5	5	4	5	5	5	6	1	0	1	0	1	1	1	1	3	3	1	3	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	0	1	4	1.375	4.25	4.571429	5	3.3333333		1	3.4761906	2.875	3.5	3.7142856	5	-0.14285715	-1.5	0.75	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ126DL1
2081	8976	NDAR_INVPJ126DL1	1333			M	5800	EndofPhase2	7	Phase 2	222	0	0	0	0	0	1	0	0	6	6	6	6	6	6	3	2	2	2	9	3	4	6	1	5	4	6	4	6	1	1	1	1	1	1	1	1	3	2	1	3	2	3	3	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	4	4.875	1.5	4.142857	5	4.2			3.4761906	2.875	3.5	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ126DL1
2081	8976	NDAR_INVPJ185HDR	2866			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	3	2	3	0	1	2	0	0	0	9	3	1	3	1	5	3	5	3	5	1	0	0	0	1	1	1	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0	3	4	2.45	1		2.45	2.5	0	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ185HDR
2081	8976	NDAR_INVPJ185HDR	2866			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	1	1	2	2	2	1	2	2	0	0	1	9	1	0	2	1	0	2	5	1	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.625	0.25	1.2857143	3.5	1.5			2.45	2.5	0	3	4	-0.95	-0.875	0.25	-1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ185HDR
2081	8976	NDAR_INVPJ185HDR	2866			M	2800	Visit12	12	Phase 1/1A	353	1	0	0	0	0	0	0	1	1	1	1	2	1	1	1	0	0	0	9	1	1	1	1	4	3	5	3	3	1	0	1	0	1	1	1	1	1	2	1	3	2	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.125	0	2	4	1.55			2.45	2.5	0	3	4	-0.9	-1.375	0	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ185HDR
2081	8976	NDAR_INVPJ185HDR	2866			M	5200	EndofPhase1_1a	18	Phase 1/1A	540	1	0	0	0	0	0	0	5	0	3	3	2	2	1	1	0	0	0	9	1	0	1	1	6	2	5	3	6	1	1	0	0	1	1	1	1	1	1	0	4	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	2.5714285	3.5	2.1		1	2.45	2.5	0	3	4	-0.35	-0.375	0	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ185HDR
2081	8976	NDAR_INVPJ342TDK	2775			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	6	0	0	2	2	3	6	0	3	4	6	4	4	6	2	4	3	3	3	5	5	0	1	0	1	1	1	1	1	1	1	0	4	4	3	4	1	0	0	1	0	0	1	0	1	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	4.25	4.142857	3	3.3809524	1		3.3809524	2.375	4.25	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ342TDK
2081	8976	NDAR_INVPJ342TDK	2775			M	1600	Visit6	6	Phase 1/1A	172	1	0	1	0	1	0	0	6	0	0	2	2	2	6	0	3	4	6	3	3	6	5	4	2	3	3	5	6	0	0	0	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	4	4.428571	3	3.3809524			3.3809524	2.375	4.25	4.142857	3	0	-0.125	-0.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ342TDK
2081	8976	NDAR_INVPJ342TDK	2775			M	2800	Visit12	12	Phase 1/1A	335	1	0	1	0	1	0	0	6	0	0	2	2	2	6	0	3	4	6	6	3	6	4	5	2	3	4	5	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	5	2.25	4.75	4.428571	3.5	3.5714285			3.3809524	2.375	4.25	4.142857	3	0.1904762	-0.125	0.5	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ342TDK
2081	8976	NDAR_INVPJ342TDK	2775			M	5200	EndofPhase1_1a	18	Phase 1/1A	510	1	0	1	0	1	0	0	6	0	0	2	2	2	6	0	3	4	6	6	3	6	4	6	2	4	4	5	6	0	1	0	1	1	1	1	1	1	1	0	4	3	3	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	4.75	4.571429	4	3.6666667		1	3.3809524	2.375	4.25	4.142857	3	0.2857143	-0.125	0.5	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ342TDK
2081	8976	NDAR_INVPJ466WRF	2582			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	0	0	1	1	9	1	1	1	1	1	3	2	2	2	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.875	0.5	1.2857143	2.5	1.15	1		1.15	0.875	0.5	1.2857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ466WRF
2081	8976	NDAR_INVPJ466WRF	2582			M	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	4	2	3	3	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	1.5	2.2857144	3	2.2			1.15	0.875	0.5	1.2857143	2.5	1.05	1.125	1	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ466WRF
2081	8976	NDAR_INVPJ466WRF	2582			M	2800	Visit12	12	Phase 1/1A	368	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	3	2	4	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2	1.5	2.5714285	2.5	2.25			1.15	0.875	0.5	1.2857143	2.5	1.1	1.125	1	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ466WRF
2081	8976	NDAR_INVPJ466WRF	2582			M	5200	EndofPhase1_1a	18	Phase 1/1A	530	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	1	2	9	1	1	1	1	1	3	3	3	3	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.25	1.5714285	3	1.9		1	1.15	0.875	0.5	1.2857143	2.5	0.75	1.125	0.75	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ466WRF
2081	8976	NDAR_INVPJ476PFK	2410			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	4	2	3	2	2	4	3	2	2	2	2	4	4	4	5	3	5	4	4	1	1	1	1	1	1	1	1	2	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.375	2.25	3.857143	4	3.3809524	1		3.3809524	3.375	2.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ476PFK
2081	8976	NDAR_INVPJ476PFK	2410			F	1600	Visit6	6	Phase 1/1A	148	0	0	0	1	0	0	0	6	4	4	6	6	4	4	4	5	5	3	6	6	4	4	4	3	4	4	4	4	1	1	1	0	1	1	1	1	1	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.75	4.75	4.142857	4	4.4761906		1	3.3809524	3.375	2.25	3.857143	4	1.0952381	1.375	2.5	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ476PFK
2081	8976	NDAR_INVPJ476PFK	2410			F	5800	EndofPhase2	18	Phase 2	523	0	0	0	1	0	0	0	0	5	0	0	0	0	0	0	0	2	0	9	0	1	0	0	0	3	2	0	0	0	0	0	0	0	0	0	0	3		0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	3	0.625	0.5	0.14285715	2.5	0.65			3.3809524	3.375	2.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ476PFK
2081	8976	NDAR_INVPJ561VBB	1122			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	0	3	0	0	0	4	5	5	3	4	2	2	4	5	4	4	5	5	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	1	0	0	0	0	1	1	1	1	5	0.875	4.25	3.857143	4	2.8095238	1		2.8095238	0.875	4.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ561VBB
2081	8976	NDAR_INVPJ650TTA	1311			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	3	3	4	2	4	3	2	5	4	3	2	3	3	5	3	4	3	4	4	3	1	1	1	1	1	1	0	1	3	1	0	4	2	2	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	2.875	3.5	3.5714285	3.5	3.2857144	1		3.2857144	2.875	3.5	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ650TTA
2081	8976	NDAR_INVPJ746TN7	1861			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	0	0	0	6	0	3	1	1	2	1	9	1	2	1	3	2	2	1	5	3	0	0	0	0	1	1	1	1	1	1	0	4	1	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1	2.4285715	1.5	2	1		2	2	1	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ746TN7
2081	8976	NDAR_INVPJ746TN7	1861			M	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	1	0	0	6	0	0	5	4	2	3	0	0	0	1	9	1	1	1	2	1	2	2	6	5	0	0	0	0	1	0	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	0.25	2.4285715	2	2.1			2	2	1	2.4285715	1.5	0.1	0.5	-0.75	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ746TN7
2081	8976	NDAR_INVPJ746TN7	1861			M	2800	Visit12	12	Phase 1/1A	351	0	0	1	0	0	0	0	6	1	1	3	6	3	4	1	3	3	1	9	1	3	3	5	2	3	1	6	6	0	0	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.75	3.7142856	2	3.1			2	2	1	2.4285715	1.5	1.1	1.125	0.75	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ746TN7
2081	8976	NDAR_INVPJ746TN7	1861			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	1	0	0	0	0	6	2	1	2	2	2	3	3	3	2	4	9	3	3	3	2	2	4	0	4	5	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	2.25	3.142857	2	2.8		1	2	2	1	2.4285715	1.5	0.8	0.625	1.25	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPJ746TN7
2081	8976	NDAR_INVPK027RUY	2546			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	3	0	4	3	4	4	0	3	4	9	3	2	4	3	4	5	3	6	6	1	0	1	0	1	1	1	1	1	1	1	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.375	1.75	4	4	3.5	1		3.5	3.375	1.75	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK027RUY
2081	8976	NDAR_INVPK140BW5	2218			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	1	2	2	2	1	0	2	5	9	0	2	0	2	0	3	2	2	2	1	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	1.75	1.1428572	2.5	1.6	1		1.6	1.5	1.75	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK140BW5
2081	8976	NDAR_INVPK140BW5	2218			M	1600	Visit6	6	Phase 3	170	1	0	0	0	0	0	0	6	0	0	0	2	0	2	0	0	2	5	9	0	4	0	4	0	3	2	3	5	1	0	1	0	1	1	2	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	1.25	1.75	2.2857144	2.5	1.9			1.6	1.5	1.75	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK140BW5
2081	8976	NDAR_INVPK140BW5	2218			M	2800	Visit12	12	Phase 3	337	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	0	4	3	9	0	3	0	2	0	3	2	5	5	1	1	1	0	1	1	2	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	1.75	2.142857	2.5	2.05			1.6	1.5	1.75	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK140BW5
2081	8976	NDAR_INVPK140BW5	2218			M	5200	EndofPhase1_1a	2	Phase 1/1A	64	1	0	0	0	0	0	0	4	0	0	2	2	2	2	0	0	2	6	9	2	2	0	3	0	3	3	3	4	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	2	2	3	2		1	1.6	1.5	1.75	1.1428572	2.5	0.4	0	0.25	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK140BW5
2081	8976	NDAR_INVPK140BW5	2218			M	5800	EndofPhase2	3	Phase 2	93	1	0	0	0	0	0	0	5	0	0	2	2	2	2	0	2	2	5	9	0	1	0	2	2	3	2	4	3	1	1	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.625	2.25	1.7142857	2.5	1.95			1.6	1.5	1.75	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK140BW5
2081	8976	NDAR_INVPK140BW5	2218			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	5	4	0	2	2	2	2	0	0	2	6	9	0	1	0	2	0	3	2	5	3	1	1	0	0	1	1	2	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.125	2	1.5714285	2.5	2.05			1.6	1.5	1.75	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK140BW5
2081	8976	NDAR_INVPK185YLP	1402			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	2	2	2	1	2	4	2	4	1	3	3	3	1	0	2	1	4	5	4	3	1	1	0	1	1	1	0	1	3	2	1	4	4	3	4	0	0	0	0	0	0	0	0					1	15	0		0		0		0		2	2	1	1	0	0	0	0	0	0	0	0	1	1	0	1	3	2.125	2.75	2	4.5	2.4285715	1		2.4285715	2.125	2.75	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK185YLP
2081	8976	NDAR_INVPK185YLP	1402			M	1600	Visit6	6	Phase 3	167	1	0	0	0	0	0	0	3	0	1	3	3	0	2	1	1	1	2	9	3	2	4	3	2	5	5	3	3	1	1	2	0	1	1	1	2	1	2	0	4	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	17	0		0		1	13	0		2	0	1	0	0	1	0	0	0	0	0	0	1	1	1	0	3	1.625	1	2.857143	5	2.35			2.4285715	2.125	2.75	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK185YLP
2081	8976	NDAR_INVPK185YLP	1402			M	5200	EndofPhase1_1a	2	Phase 1/1A	50	0	0	0	0	0	1	0	1	0	1	1	2	1	3	0	2	4	4	9	3	4	1	3	2	4	4	4	1	1	1	2	1	1	1	1	2	2	1	0	4	4	2	4	1	0	1	0	0	0	0	0	2	2	2	2	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	5	1.125	2.5	2.5714285	4	2.25		1	2.4285715	2.125	2.75	2	4.5	-0.17857143	-1	-0.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK185YLP
2081	8976	NDAR_INVPK185YLP	1402			M	5800	EndofPhase2	5	Phase 2	141	1	0	0	0	0	0	0	3	0	3	3	2	0	4	0	2	2	3	9	3	5	0	5	1	6	5	5	3	1	1	1	1	1	1	0	1	1	2	0		2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		2	2	2	0	0	1	1	0	0	0	0	0	1	1	1	1	4	1.875	1.75	3.142857	5.5	2.75			2.4285715	2.125	2.75	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK185YLP
2081	8976	NDAR_INVPK185YLP	1402			M	6000	EndofPhase3	8	Phase 3	223	1	0	0	0	0	0	0	5	2	1	2	5	2	5	2	4	4	3	5	5	6	5	5	1	5	4	4	5	1	1	1	1	1	1	1	1	1	1	0	4	2	2	2	1	0	1	0	0	0	0	0	0	1	2	2	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	5	3	4	4.428571	4.5	3.8095238			2.4285715	2.125	2.75	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK185YLP
2081	8976	NDAR_INVPK187JR6	2351			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	1	0	3	0	1	4	2	4	2	1	0	1	0	1	0	1	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	1.5714285	3	0.85	1		0.85	0	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK187JR6
2081	8976	NDAR_INVPK187JR6	2351			M	2800	Visit12	12	Phase 2	333	0	0	0	0	0	1	0	2	3	3	1	3	0	0	4	6	4	5	4	3	2	4	4	5	5	4	6	3	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2	4.75	3.857143	4.5	3.3809524			0.85	0	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK187JR6
2081	8976	NDAR_INVPK187JR6	2351			M	5200	EndofPhase1_1a	6	Phase 1/1A	175	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	6	3	3	2		0	0	1	5	5	5	5	1	1	1	1	0	1	1	1	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4	0	3.5	2	5	1.8		1	0.85	0	0	1.5714285	3	0.95	0	3.5	0.42857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK187JR6
2081	8976	NDAR_INVPK187JR6	2351			M	5800	EndofPhase2	18	Phase 2	522	0	0	0	0	0	1	0	6	0	1	0	0	0	1	2	6	4	6	4	2	4	0	4	6	6	4	5	5	0	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	5	3.7142856	5	3.142857			0.85	0	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK187JR6
2081	8976	NDAR_INVPK392ZU3	2076			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	1	3	1	2	2	1	1	1	1	2	1	9	2	2	1	2	1	2	2	2	2	1	1	1	0	1	0	0	0	1	3	1	4	3	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1.5	1	1.7142857	2	1.6	1		1.6	1.5	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK392ZU3
2081	8976	NDAR_INVPK392ZU3	2076			M	2800	Visit12	12	Phase 3	371	1	0	0	0	0	0	0	3	2	2	1	2	2	2	1	1	1	2	9	2	2	1	1	1	2	1	3	4	1	1	0	0	1	0	0	0	1	2	0	4	4	3	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.875	1	2	1.5	1.8			1.6	1.5	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK392ZU3
2081	8976	NDAR_INVPK392ZU3	2076			M	5200	EndofPhase1_1a	6	Phase 1/1A	168	1	0	0	0	0	0	0	1	2	3	2	2	1	3	1	2	1	1	9	2	1	1	2	2	2	2	2	3	0	1	1	1	1	1	0	1	1	3	0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	4	1.875	1	1.8571428	2	1.8		1	1.6	1.5	1	1.7142857	2	0.2	0.375	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK392ZU3
2081	8976	NDAR_INVPK392ZU3	2076			M	5800	EndofPhase2	10	Phase 2	315	0	0	1	0	0	0	0	1	2	1	1	1	2	2	2	1	1	1	9	1	1	1	1	1	2	2	1	2	1	1	1	0	1	1	0	0	1	3	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.5	0.75	1.1428572	2	1.35			1.6	1.5	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK392ZU3
2081	8976	NDAR_INVPK392ZU3	2076			M	6000	EndofPhase3	13	Phase 3	393	1	0	0	0	0	0	0	1	1	1	1	2	1	2	1	1	0	1	9	2	1	1	1	1	2	0	2	2	0	0	1	0	1	0	0	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.25	0.5	1.4285715	1	1.2			1.6	1.5	1	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPK392ZU3
2081	8976	NDAR_INVPL724GG5	1097			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	2	2	1	4	1	0	0	0	9	0	2	3	2	0	4	3	5	4	1	1	1	1	1	0	0	1	3	1	0		4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	0	2.2857144	3.5	1.65	1		1.65	1.25	0	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPL724GG5
2081	8976	NDAR_INVPL724GG5	1097			M	1600	Visit6	6	Phase 1/1A	186	0	0	0	0	0	0	1	9	0	0	1	2	2	2	0	1	0	1	9	3	1	3	4	4	5	5	5	5	1	1	1	1	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0.5	3.5714285	5	2.3157895			1.65	1.25	0	2.2857144	3.5	0.6657895	-0.25	0.5	1.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPL724GG5
2081	8976	NDAR_INVPL724GG5	1097			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	9	2	2	4	2	1	4	0	0	0	0	9	3	2	4	2	1	5	4	6	6	1	1	1	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.142857	0	3.4285715	4.5	2.5263157			1.65	1.25	0	2.2857144	3.5	0.8763158	0.89285713	0	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPL724GG5
2081	8976	NDAR_INVPL724GG5	1097			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	0	0	2	2	2	2	0	0	0	0	9	2	2	4	4	0	5	4	4	4	0	0	1	1	1	1	1	1	3	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	1.1428572	0	2.857143	4.5	1.9473684		1	1.65	1.25	0	2.2857144	3.5	0.2973684	-0.10714286	0	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPL724GG5
2081	8976	NDAR_INVPM144DLP	1652			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	2	5	5	6	6	6	5	0	0	1	9	4	2	4	6	6	3	2	5	6	0	0	0	0	1	1	1	1	2	2	1	4	4	4	2	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	0.25	4.714286	2.5	3.85	1		3.85	4.75	0.25	4.714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM144DLP
2081	8976	NDAR_INVPM144DLP	1652			M	1600	Visit6	6	Phase 1/1A	165	0	0	0	0	0	1	0	6	5	6	6	6	6	6	4	3	4	5	6	5	5	6	5	6	3	3	6	6	1	1	0	0	1	1	1	1	3	3	1	2	1	2	2	1	0	0	0	0	1	0	0	1	1	1	1	1	19	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.625	4.5	5.571429	3	5.142857			3.85	4.75	0.25	4.714286	2.5	1.2928572	0.875	4.25	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM144DLP
2081	8976	NDAR_INVPM144DLP	1652			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	1	0	6	5	5	5	4	4	4	5	0	4	6	9	3	5	5	5	5	5	3	5	6	1	1	1	1	1	1	0	1	3		1	2	1	4	1	1	0	0	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	2.5	4.857143	4	4.5			3.85	4.75	0.25	4.714286	2.5	0.65	0	2.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM144DLP
2081	8976	NDAR_INVPM144DLP	1652			M	5200	EndofPhase1_1a	18	Phase 1/1A	523	0	0	0	0	0	1	0	6	6	6	6	6	6	6	6	4	4	6	9	5	6	6	6	5	4	3	6	6	1	1	0	1	0	1	0	1	3		1	2	1	1	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	6	6	3.5	5.714286	3.5	5.45		1	3.85	4.75	0.25	4.714286	2.5	1.6	1.25	3.25	1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM144DLP
2081	8976	NDAR_INVPM276XAV	2332			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	4	4	2	0	0	4	0	0	4	0	2	2	4	2	2	0	2	6	1	0	0	1	1	1	0	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.75	2	2.5714285	1	2	1		2	1.75	2	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM276XAV
2081	8976	NDAR_INVPM276XAV	2332			M	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	1	0	2	1	1	3	4	2	0	1	4	0	0	4	0	2	1	4	2	2	0	2	5	1	1	0	1	1	0	0	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.75	2	2.2857144	1	1.9047619			2	1.75	2	2.5714285	1	-0.0952381	0	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM276XAV
2081	8976	NDAR_INVPM276XAV	2332			M	2800	Visit12	12	Phase 1/1A	328	0	0	0	0	0	1	0	2	1	2	3	2	2	1	0	1	2	1	3	1	2	1	4	1	4	4	3	4	1	1	0	1	1	0	0	0	3		1	4	2	3	3	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	1.75	2.2857144	4	2.0952382			2	1.75	2	2.5714285	1	0.0952381	-0.125	-0.25	-0.2857143	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM276XAV
2081	8976	NDAR_INVPM276XAV	2332			M	4000	Visit18	18	Phase 1/1A	489	0	0	0	0	0	1	0	2	1	2	2	1	2	2	0	2	2	1	9	1	2	1	1	3	5	5	1	1	1	1	0	1	1	0	0	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	1	1	0	1	0	0	0	0	1	1	1	1	4	1.5	1.25	1.4285715	5	1.85		1	2	1.75	2	2.5714285	1	-0.15	-0.25	-0.75	-1.1428572	4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM276XAV
2081	8976	NDAR_INVPM595JJ5	2234			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	2	4	4	3	3	3	1	1	1	9	3	2	3	4	4	2	1	4	2	0	1	1	0	1	1	0	1	1	2	1	2	1	2	2	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	0.75	3.142857	1.5	2.8	1		2.8	3.5	0.75	3.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM595JJ5
2081	8976	NDAR_INVPM595JJ5	2234			M	1600	Visit6	6	Phase 1/1A	177	0	1	0	1	0	0	0	5	2	2	4	5	3	3	1	1	1	1	9	1	1	4	3	2	2	3	3	3	2	2	0	0	1	1	1	1	1	2	1	3	2	2	1	1	1	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	0.75	2.4285715	2.5	2.5			2.8	3.5	0.75	3.142857	1.5	-0.3	-0.375	0	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM595JJ5
2081	8976	NDAR_INVPM595JJ5	2234			M	4000	Visit18	18	Phase 2	561	0	1	0	0	0	0	0	3	2	4	3	4	3	3	2	3	2	1	1	2	3	4	3	2	2	3	3	4	1	1	2	0	1	1	0	1	1	2	1	4	3	3	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3	1.75	3	2.5	2.7142856			2.8	3.5	0.75	3.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM595JJ5
2081	8976	NDAR_INVPM595JJ5	2234			M	5200	EndofPhase1_1a	13	Phase 1/1A	414	0	1	0	0	0	0	0	4	3	2	4	4	3	4	2	2	2	2	9	3	2	3	4	3	2	3	4	4	1	1	1	0	1	1	0	1	1	2	1	3	2	3	2	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3.25	1.5	3.2857144	2.5	3		1	2.8	3.5	0.75	3.142857	1.5	0.2	-0.25	0.75	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM595JJ5
2081	8976	NDAR_INVPM595JJ5	2234			M	5800	EndofPhase2	19	Phase 2	603	0	1	0	0	0	0	0	4	4	4	3	4	3	4	3	1	2	2	9	3	2	3	4	4	1	2	4	4	2	1	2	0	1	1	1	1	1	2	1	4	3	3	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	6	3.625	1.25	3.4285715	1.5	3.05			2.8	3.5	0.75	3.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM595JJ5
2081	8976	NDAR_INVPM595JJ5	2234			M	6000	EndofPhase3	21	Phase 3	659	0	0	0	1	0	0	0	2	2	2	2	2	2	2	4	0	0	0	9	2	1	0	3	2	1	1	0	2	0	0	1	0	1	1	0	1	1	2	1	2	1	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	2.25	0	1.4285715	1	1.5			2.8	3.5	0.75	3.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPM595JJ5
2081	8976	NDAR_INVPN069RVU	2463			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	4	2	4	4	4	2	3	2	2	3	9	3	3	3	3	4	6	4	4	5	1	1	1	2	1	1	1	1	3	1	1	3	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.375	1.75	3.5714285	5	3.45	1		3.45	3.375	1.75	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPN069RVU
2081	8976	NDAR_INVPN560VKP	1542			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	1	1	1	2	2	2	0	1	4	1	9	1	1	0	2	1	3	4	5	3	1	0	1	0	1	1	1	1	3	1	0		4	4	4	0	0	0	0	0	0	0	1	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	1.5	1.8571428	3.5	2	1		2	1.75	1.5	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPN560VKP
2081	8976	NDAR_INVPN750HUN	1826			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	6	6	6	4	5	3	1	1	1	9	4	2	5	4	0	4	2	6	6	0	0	0	0	1	1	1	0	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	5.25	0.75	3.857143	3	3.9	1		3.9	5.25	0.75	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPN750HUN
2081	8976	NDAR_INVPN750HUN	1826			F	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	0	1	0	4	1	2	1	2	2	3	1	1	2	1	9	2	2	3	3	2	3	2	5	3	0	0	0	1	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	10	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1	2.857143	2.5	2.25			3.9	5.25	0.75	3.857143	3	-1.65	-3.25	0.25	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPN750HUN
2081	8976	NDAR_INVPN750HUN	1826			F	5200	EndofPhase1_1a	15	Phase 1/1A	415	0	0	0	0	0	1	0	3	3	3	3	2	3	3	1	3	1	1	9	3	3	3	3	2	4	1	5	4	0	0	0	1	1	1	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	1.25	3.2857144	2.5	2.7		1	3.9	5.25	0.75	3.857143	3	-1.2	-2.625	0.5	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPN750HUN
2081	8976	NDAR_INVPN750HUN	1826			F	5800	EndofPhase2	18	Phase 2	513	0	0	0	0	0	1	0	6	6	6	5	4	5	5	3	3	2	4	9	3	4	4	5	2	3	4	3	6	1	0	0	0	1	1	1	0	3	3	1	3	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5	2.25	3.857143	3.5	4.15			3.9	5.25	0.75	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPN750HUN
2081	8976	NDAR_INVPP627DZR	1777			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	0	2	2	2	2	2	0	4	3	5	4	5	4	6	4	5	4	2	6	6	0	0	1	0	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	1	0	0	0	0	0	0	0	0	0	1	1	1	3	1.875	4	5.142857	3	3.4761906	1		3.4761906	1.875	4	5.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP627DZR
2081	8976	NDAR_INVPP627DZR	1777			M	5200	EndofPhase1_1a	2	Phase 1/1A	50	1	0	0	0	0	0	0	6	2	2	2	2	2	2	0	2	4	5	9	5	5	4	4	4	4	3	6	6	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	2.75	4.857143	3.5	3.5		1	3.4761906	1.875	4	5.142857	3	0.023809524	0.375	-1.25	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP627DZR
2081	8976	NDAR_INVPP627DZR	1777			M	5400	EndofPhase1b	3	Phase 1B	78	1	0	0	0	0	0	0	6	0	2	2	2	2	2	0	4	4	5	3	3	6	6	3	4	4	4	6	6	1	1	1	0	1	0	0	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	1	0	0	1	0	1	1	5	2	4	4.857143	4	3.5238094			3.4761906	1.875	4	5.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP627DZR
2081	8976	NDAR_INVPP829MJ2	1960			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	1	0	2	1	2	2	0	0	0	0	9	2	2	0	2	1	2	1	0	2	1	0	1	0	1	1	2	1	3	3	1	3	2	3	1	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	4	1	0	1.2857143	1.5	1	1		1	1	0	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP829MJ2
2081	8976	NDAR_INVPP829MJ2	1960			M	2800	Visit12	12	Phase 2	343	0	1	0	1	0	0	0	2	4	4	2	4	2	3	4	0	0	0	9	4	2	2	2	2	2	3	4	5	2	1	2	2	1	1	2	1	1	2	1	2	1	2	1	1	1	0	0	0	1	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	4	3.125	0	3	2.5	2.55			1	1	0	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP829MJ2
2081	8976	NDAR_INVPP829MJ2	1960			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	0	0	0	0	0	0	1	2	1	1	1	0	2	0	0	0	0	0	9	2	0	2	0	2	3	2	3	4	1	0	0	0	1	1	1	1	2	2	1	2	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	0.875	0	1.8571428	2.5	1.25		1	1	1	0	1.2857143	1.5	0.25	-0.125	0	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP829MJ2
2081	8976	NDAR_INVPP829MJ2	1960			M	5800	EndofPhase2	16	Phase 2	451	0	1	0	1	0	0	0	0	2	2	0	2	0	2	0	0	0	0	9	2	2	2	1	0	2	2	4	4	0	0	2	2	1	0	1	0	1	2	1	2	1	4	1	1	1	0	0	0	1	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1	0	2.142857	2	1.35			1	1	0	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP829MJ2
2081	8976	NDAR_INVPP829MJ2	1960			M	6000	EndofPhase3	18	Phase 3	507	0	0	0	0	0	0	1	4	4	4	4	4	2	2	4	0	2	4	9	3	2	2	4	2	3	3	4	5	1	1	0	0	1	0	1	1	1	2	1	3	2	4	1	1	1	0	0	0	1	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	1.5	3.142857	3	3.1			1	1	0	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPP829MJ2
2081	8976	NDAR_INVPR029WPX	1984			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	0	2	0	1	4	6	4	4	4	3	2	2	3	1	5	3	4	3	1	1	0	0	1	1	1	1	3		0	4	4	4	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	1	1	0	0	0	0	0	0	1	1	1	1	4	1.5714285	4.5	2.5714285	4	2.75	1		2.75	1.5714285	4.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR029WPX
2081	8976	NDAR_INVPR029WPX	1984			M	1600	Visit6	6	Phase 2	191	0	0	0	0	0	0	1	9	2	4	2	2	2	2	2	6	4	6	6	3	2	0	4	4	5	2	6	4	0	0	1	1	1	1	0	1	3	3	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	4	2.2857144	5.5	3.2857144	3.5	3.4			2.75	1.5714285	4.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR029WPX
2081	8976	NDAR_INVPR029WPX	1984			M	2800	Visit12	12	Phase 3	368	0	0	0	0	0	0	1	9	4	4	4	3	4	4	4	3	4	6	4	3	3	2	3	2	5	3	4	6	1	0	1	0	1	1	1	1	1	1	1	4	3	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1	4	3.857143	4.25	3.2857144	4	3.75			2.75	1.5714285	4.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR029WPX
2081	8976	NDAR_INVPR029WPX	1984			M	5200	EndofPhase1_1a	1	Phase 1/1A	15	0	0	0	0	0	0	1	9	0	3	1	2	0	2	3	6	4	4	6	3	2	2	4	1	5	3	4	3	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	3	1.5714285	5	2.7142856	4	2.9		1	2.75	1.5714285	4.5	2.5714285	4	0.15	0	0.5	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR029WPX
2081	8976	NDAR_INVPR029WPX	1984			M	5800	EndofPhase2	10	Phase 2	326	0	0	0	0	0	0	1	9	4	4	0	4	4	4	4	4	4	6	6	3	6	0	6	4	4	5	4	6	1	1	1	1	1	1	1	1	3	2	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	3.4285715	5	4.142857	4.5	4.1			2.75	1.5714285	4.5	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR029WPX
2081	8976	NDAR_INVPR066AUZ	1905			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	0	0	2	0	4	4	6	2	0	3	0	1	5	2	1	0	4	0	0	1	1	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	4	0.5	4	1.8571428	1.5	1.7142857	1		1.7142857	0.5	4	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR066AUZ
2081	8976	NDAR_INVPR066AUZ	1905			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	0	0	0	2	1	0	1	1	5	4	5	4	4	4	2	4	5	4	3	4	5	1	1	1	1	1	0	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	0.625	4.5	4	3.5	2.7619047			1.7142857	0.5	4	1.8571428	1.5	1.0476191	0.125	0.5	2.142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR066AUZ
2081	8976	NDAR_INVPR066AUZ	1905			M	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	1	0	2	2	2	3	3	3	3	3	5	5	6	5	5	5	5	5	5	3	3	3	5	1	0	1	1	1	1	1	1	3		1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	5.25	4.714286	3	3.857143			1.7142857	0.5	4	1.8571428	1.5	2.142857	2.125	1.25	2.857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR066AUZ
2081	8976	NDAR_INVPR066AUZ	1905			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	1	0	2	0	0	0	2	0	4	2	6	4	5	3	1	2	0	0	5	3	2	2	4	0	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	1.25	4.5	2	2.5	2.2380953		1	1.7142857	0.5	4	1.8571428	1.5	0.52380955	0.75	0.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPR066AUZ
2081	8976	NDAR_INVPU108GD2	1771			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	2	2	2	2	1	2	1	2	1	9	3	3	3	3	2	4	2	5	5	1	1	1	1	1	1	0	1	1	1	1	2	2	2	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	1.875	1	3.4285715	3	2.45	1		2.45	1.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU108GD2
2081	8976	NDAR_INVPU108GD2	1771			M	1600	Visit6	6	Phase 1B	169	0	1	0	0	0	0	0	3	1	2	3	4	2	2	2	3	2	2	2	2	2	2	2	3	4	2	3	2	1	1	1	1	1	1	1	1	1	2	1	4	2	3	4	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	2.375	2.25	2.2857144	3	2.3809524			2.45	1.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU108GD2
2081	8976	NDAR_INVPU108GD2	1771			M	2800	Visit12	12	Phase 3	359	0	1	0	0	0	0	0	4	3	2	2	2	2	2	3	2	2	3	9	4	2	2	3	3	4	3	3	4	1	1	1	1	1	1	1	1	1	2	1	4	2	3	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.5	1.75	3	3.5	2.75			2.45	1.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU108GD2
2081	8976	NDAR_INVPU108GD2	1771			M	5200	EndofPhase1_1a	3	Phase 1/1A	86	0	1	0	1	0	0	0	4	1	0	2	2	2	2	1	1	2	2	9	2	1	0	2	2	4	3	3	4	0	1	1	1	1	1	1	1	1	2	0	4	2	4	1	1	1	0	0	1	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	1.25	2	3.5	2		1	2.45	1.875	1	3.4285715	3	-0.45	-0.125	0.25	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU108GD2
2081	8976	NDAR_INVPU108GD2	1771			M	5400	EndofPhase1b	9	Phase 1B	254	0	1	0	0	0	0	0	2	1	1	2	2	1	2	2	1	1	2	9	2	1	2	1	2	4	3	2	2	1	1	1	1	1	1	0	1	1	2	0	4	3	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1.625	1	1.7142857	3.5	1.8			2.45	1.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU108GD2
2081	8976	NDAR_INVPU108GD2	1771			M	6000	EndofPhase3	18	Phase 3	505	0	0	0	1	0	0	0	4	2	2	2	3	1	2	0	1	1	2	9	2	1	1	1	1	3	4	2	3	1	1	1	1	1	1	0	1	1	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2	1	1.5714285	3.5	1.9			2.45	1.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU108GD2
2081	8976	NDAR_INVPU149HBG	2552			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	6	0	0	2	3	1	4	0	0	4	9	1	2	1	1	4	4	4	4	3	0	0	1	0	1	1	1	1	1	2	1	4	4	4	3	1	1	1	0	1	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	2.5	1	2.2857144	4	2.4	1		2.4	2.5	1	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU149HBG
2081	8976	NDAR_INVPU149HBG	2552			F	5200	EndofPhase1_1a	2	Phase 1/1A	50	0	1	0	0	0	0	0	4	1	1	2	1	2	4	2	4	2	4	9	3	2	0	1	3	4	3	3	4	1	0	1	0	1	1	1	1	1	2	1	4	4	4	4	1	1	0	0	1	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	2.125	2.5	2.2857144	3.5	2.5		1	2.4	2.5	1	2.2857144	4	0.1	-0.375	1.5	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPU149HBG
2081	8976	NDAR_INVPV052MMJ	1650			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	2	1	1	1	2	2	1	2	4	9	1	1	4	3	2	3	2	2	3	0	1	0	0	1	0	1	0	3	2	0	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.5	1.75	2.2857144	2.5	2	1		2	1.5	1.75	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPV052MMJ
2081	8976	NDAR_INVPV053EPK	2266			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	2	2	2	5	2	2	5	4	4	4	3	4	4	4	4	3	4	2	4	5	2	1	2	2	1	2	2	2	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	3.75	4	3	3.5238094	1		3.5238094	3.125	3.75	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPV053EPK
2081	8976	NDAR_INVPV625NAY	1569			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	5	0	5	2	2	6	1	0	1	1	9	0	4	2	6	2	1	4	5	6	1	1	1	2	1	0	0	0	3	1	1	3	2	2	1	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	3.375	0.5	3.5714285	2.5	2.95	1		2.95	3.375	0.5	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPV625NAY
2081	8976	NDAR_INVPV867DYH	1498			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	3	1	2	2	1	2	4	1	1	1	9	1	3	4	3	2	4	2	4	4	1	1	1	1	1	1	0	1	1	2	0	4	3	4	4	1	1	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	2.25	0.75	3	3	2.4	1		2.4	2.25	0.75	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPV867DYH
2081	8976	NDAR_INVPW301XMW	1057			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	4	2	1	4	0	0	0	9	0	0	0	2	2	6	5	4	2	0	0	0	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	0	4	2.375	0	1.4285715	5.5	2	1		2	2.375	0	1.4285715	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPW301XMW
2081	8976	NDAR_INVPX136VZJ	1070			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	3	4	3	3	2	2	1	0	4	4	9	2	2	4	4	5	3	3	5	5	0	1	0	0	1	0	0	0	1	1	1	2	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2.25	2	3.857143	3	2.95	1		2.95	2.25	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX136VZJ
2081	8976	NDAR_INVPX136VZJ	1070			M	1600	Visit6	6	Phase 3	119	0	0	0	0	0	1	0	6	3	4	2	6	2	6	1	2	4	1	9	0	4	4	5	2	3	4	5	6	1	1	0	0	1	1	1	0	2	2	1	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	3.75	1.75	3.7142856	3.5	3.5			2.95	2.25	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX136VZJ
2081	8976	NDAR_INVPX136VZJ	1070			M	2800	Visit12	12	Phase 3	288	0	0	0	0	0	1	0	0	1	1	1	2	0	0	0	0	1	0	9	0	4	1	3	2	3	3	3	3	1	0	1	0	1	1	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.625	0.25	2.2857144	3	1.4			2.95	2.25	2	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX136VZJ
2081	8976	NDAR_INVPX136VZJ	1070			M	5200	EndofPhase1_1a	3	Phase 1/1A	66	0	0	0	0	0	1	0	0	3	2	2	2	2	3	1	0	4	4	9	2	2	4	3	3	3	2	4	4	1	1	1	0	1	1	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	1					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	2	3.142857	2.5	2.5		1	2.95	2.25	2	3.857143	3	-0.45	-0.375	0	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX136VZJ
2081	8976	NDAR_INVPX161BHY	2040			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	2	3	4	0	1	6	0	0	0	9	6	4	6	4	5	5	6	5	6	1	1	1	0	1	1	2	1	1	1	1	3	4	1	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	0	5.142857	5.5	3.65	1		3.65	3.25	0	5.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX161BHY
2081	8976	NDAR_INVPX675GWU	2363			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	6	5	5	4	5	5	4	5	5	5	5	5	5	6	4	4	4	4	5	0	0	1	0	1	1	1	1	2	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.875	4.75	4.857143	4	4.7619047	1		4.7619047	4.875	4.75	4.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX675GWU
2081	8976	NDAR_INVPX675GWU	2363			M	5200	EndofPhase1_1a	9	Phase 1/1A	291	0	0	0	0	0	0	1	6	6	6	4	4	4	4	3	4	5	6	6	5	4	3	4	4	2	3	3	3	1	1	1	0	1	1	1	1																																															4.625	5.25	3.7142856	2.5	4.2380953		1	4.7619047	4.875	4.75	4.857143	4	-0.52380955	-0.25	0.5	-1.1428572	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX675GWU
2081	8976	NDAR_INVPX748YLP	2091			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	2	2	3	0	2	2	0	0	6	9	2	2	2	2	1	3	2	4	4	1	0	1	1	1	1	0	1	2	1	1	3	1	2	1	1	0	1	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.375	1.5	2.4285715	2.5	2.35	1		2.35	2.375	1.5	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX748YLP
2081	8976	NDAR_INVPX748YLP	2091			M	5200	EndofPhase1_1a	2	Phase 1/1A	60	0	0	0	0	0	1	0	4	0	0	2	2	2	2	1	0	2	4	9	3	2	3	3	1	5	3	4	4	1	1	1	1	1	1	0	1	2	1	1	2	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.625	1.5	2.857143	4	2.35		1	2.35	2.375	1.5	2.4285715	2.5	0	-0.75	0	0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX748YLP
2081	8976	NDAR_INVPX769HMJ	1562			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	1	1	2	2	2	4	0	0	1	9	2	2	2	4	1	3	3	3	2	1	1	1	0	1	0	1	1	1	3	0	4	2	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	3	2.25	0.25	2.2857144	3	2.05	1		2.05	2.25	0.25	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX769HMJ
2081	8976	NDAR_INVPX769HMJ	1562			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	1	0	4	4	3	2	2	3	3	2	2	4	5	9	3	2	2	4	2	1	1	4	3	1	1	1	0	1	1	1	1	3	3	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	2.75	2.857143	1	2.8		1	2.05	2.25	0.25	2.2857144	3	0.75	0.625	2.5	0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX769HMJ
2081	8976	NDAR_INVPX877FZ2	1623			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	2	6	0	2	0	0	3	4	9	3	2	3	1	2	1	2	3	3	1	1	1	0	0	1	0	1	1	1	0	4	4	4	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	1.75	2.4285715	1.5	2.05	1		2.05	1.75	1.75	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX877FZ2
2081	8976	NDAR_INVPX877FZ2	1623			M	1600	Visit6	6	Phase 1/1A	191	0	0	0	0	0	0	1	9	0	0	2	1	0	1	0	0	0	0	9	2	0	0	4	0	2	2	5	4	1	1	1	0	1	0	0	0	3		0	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.5714286	0	2.142857	2	1.2105263			2.05	1.75	1.75	2.4285715	1.5	-0.83947366	-1.1785715	-1.75	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX877FZ2
2081	8976	NDAR_INVPX877FZ2	1623			M	2800	Visit12	12	Phase 1/1A	350	0	0	0	0	0	0	1	9	0	0	2	1	0	1	0	0	0	0	9	2	0	0	4	0	2	2	5	4	1	1	1	0	1	0	0	0	3		1	4	4	4	4	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.5714286	0	2.142857	2	1.2105263			2.05	1.75	1.75	2.4285715	1.5	-0.83947366	-1.1785715	-1.75	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX877FZ2
2081	8976	NDAR_INVPX877FZ2	1623			M	4000	Visit18	18	Phase 1/1A	538	0	0	0	0	0	0	1	0	1	0	0	2	0	0	0	0	0	1	9	0	0	0	4	0	1	2	3	4	1	1	1	0	1	1	1	2	3		1	3	2	4	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.375	0.25	1.5714285	1.5	0.9		1	2.05	1.75	1.75	2.4285715	1.5	-1.15	-1.375	-1.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX877FZ2
2081	8976	NDAR_INVPX890WTY	1460			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	0	0	0	0	0	2	2	6	4	6	2	0	2	0	0	2	1	2	2	0	0	0	0	0	1	1	1	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	1	0	1	6	0		0		1	21	0		0	0	0	1	1	0	0	0	0	0	0	0	1	1	1	1	6	0.625	4.5	0.85714287	1.5	1.5238096	1		1.5238096	0.625	4.5	0.85714287	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX890WTY
2081	8976	NDAR_INVPX890WTY	1460			M	5200	EndofPhase1_1a	2	Phase 1/1A	28	1	0	0	0	0	0	0	0	0	0	1	0	0	2	2	2	2	6	9	2	1	0	2	1	2	1	2	0	1	1	0	0	1	1	1	0	2	3	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	0.625	2.5	1.1428572	1.5	1.3		1	1.5238096	0.625	4.5	0.85714287	1.5	-0.22380953	0	-2	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPX890WTY
2081	8976	NDAR_INVPY547PGZ	1658			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	0	3	4	5	4	3	0	0	3	9	2	2	2	4	4	2	3	3	3	0	1	0	0	1	1	0	1	1	2	1	2	1	2	4	1	0	0	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		3.375	0.75	2.857143	2.5	2.75	1		2.75	3.375	0.75	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPY547PGZ
2081	8976	NDAR_INVPY547PGZ	1658			M	5200	EndofPhase1_1a	6	Phase 1/1A	177	0	0	0	0	0	1	0	1	0	0	1	2	0	2	2	0	0	3	9	2	2	0	2	1	1	1	4	3	0	1	0	0	1	0	1	1	1	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	28	0		1	2	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		1	0.75	2	1	1.35		1	2.75	3.375	0.75	2.857143	2.5	-1.4	-2.375	0	-0.85714287	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPY547PGZ
2081	8976	NDAR_INVPZ071XF1	1417			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	2	2	0	0	0	0	0	0	9	2	2	0	2	2	0	3	2	4	2	1	2	2	1	2	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		1	30	1	30	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	6	0.5	0	2	1.5	1.05	1		1.05	0.5	0	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ071XF1
2081	8976	NDAR_INVPZ071XF1	1417			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	0	0	0	0	1	2	2	0	0	0	1	9	2	2	2	1	2	3	2	0	5	1	1	1	0	1	1	1	1	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	0.625	0.25	2	2.5	1.25			1.05	0.5	0	2	1.5	0.2	0.125	0.25	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ071XF1
2081	8976	NDAR_INVPZ071XF1	1417			M	2800	Visit12	12	Phase 1/1A	349	0	0	0	0	0	0	1	9	0	0	0	1	0	0	0	0	0	0	9	2	1	2	0	0	4	2	0	5	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.14285715	0	1.4285715	3	0.8947368			1.05	0.5	0	2	1.5	-0.15526316	-0.35714287	0	-0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ071XF1
2081	8976	NDAR_INVPZ071XF1	1417			M	4000	Visit18	18	Phase 1/1A	540	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	9	0	0	0	0	0	4	1	2	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.125	0	0.85714287	2.5	0.6		1	1.05	0.5	0	2	1.5	-0.45	-0.375	0	-1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ071XF1
2081	8976	NDAR_INVPZ329HCK	1470			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	0	3	2	5	2	2	3	1	9	2	5	4	4	5	1	4	4	5	1	0	1	1	1	1	1	1	3	1	0	4	3	4	4	1	0	0	1	0	0	0	0	0	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	1.5	4.142857	2.5	2.8	1		2.8	2	1.5	4.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ329HCK
2081	8976	NDAR_INVPZ329HCK	1470			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	4	0	0	0	3	2	5	2	2	3	1	9	2	4	4	4	4	1	4	4	4	1	0	1	1	1	1	1	1	2	1	0	4	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.5	3.7142856	2.5	2.65			2.8	2	1.5	4.142857	2.5	-0.15	0	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ329HCK
2081	8976	NDAR_INVPZ329HCK	1470			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	1	0	4	0	0	1	2	2	5	2	2	3	1	9	2	2	4	4	3	3	2	4	4	1	0	1	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.5	3.2857144	2.5	2.5			2.8	2	1.5	4.142857	2.5	-0.3	0	0	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ329HCK
2081	8976	NDAR_INVPZ329HCK	1470			M	4000	Visit18	18	Phase 1/1A	504	0	0	0	0	0	1	0	4	0	0	0	3	2	5	2	2	3	1	9	2	4	4	4	4	1	4	4	4	1	0	1	1	1	1	1	1	2	1	0	4	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	1.5	3.7142856	2.5	2.65			2.8	2	1.5	4.142857	2.5	-0.15	0	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ329HCK
2081	8976	NDAR_INVPZ329HCK	1470			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	1	0	4	0	0	0	0	3	2	5	2	3	1	9	2	4	4	4	4	1	4	4	4	1	0	1	1	1	1	1	1	2	1	0	4	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	1.5	3.7142856	2.5	2.55		1	2.8	2	1.5	4.142857	2.5	-0.25	-0.25	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ329HCK
2081	8976	NDAR_INVPZ348JR1	2504			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	3	3	2	4	3	3	5	6	5	5	6	5	2	2	4	5	4	3	3	5	1	1	1	0	0	0	1	0	1	1	0	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3	3.5	5.5	3.7142856	3.5	3.952381	1		3.952381	3.5	5.5	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ348JR1
2081	8976	NDAR_INVPZ348JR1	2504			M	5200	EndofPhase1_1a	6	Phase 1/1A	185	0	1	0	0	0	0	0	5	1	2	2	2	2	4	3	4	4	3	4	2	1	1	2	4	4	2	4	4	1	0	1	0	0	0	0	0	1	2	0	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3	2.625	3.75	2.5714285	3	2.857143		1	3.952381	3.5	5.5	3.7142856	3.5	-1.0952381	-0.875	-1.75	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ348JR1
2081	8976	NDAR_INVPZ348JR1	2504			M	5800	EndofPhase2	12	Phase 2	346	0	1	0	0	0	0	0	4	2	2	2	2	2	3	4	4	4	4	3	3	4	2	3	4	5	4	3	4	1	1	1	0	1	0	0	1	1	2	0	4	4	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	3	2.625	3.75	3.2857144	4.5	3.2380953			3.952381	3.5	5.5	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ348JR1
2081	8976	NDAR_INVPZ384MUC	1268			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	2	4	5	3	4	6	2	1	1	1	9	1	2	0	6	2	3	2	2	2	1	1	1	0	1	0	1	1	1	2	1	2	1	1	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	7	3.75	0.75	2.142857	2.5	2.65	1		2.65	3.75	0.75	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ384MUC
2081	8976	NDAR_INVPZ384MUC	1268			M	1600	Visit6	6	Phase 1/1A	199	1	0	0	0	1	0	0	6	5	5	5	5	4	5	5	1	2	2	9	2	2	5	5	2	2	3	4	6	1	0	0	0	1	1	1	1	1	1	1	2	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	1.25	3.7142856	2.5	3.8		1	2.65	3.75	0.75	2.142857	2.5	1.15	1.25	0.5	1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ384MUC
2081	8976	NDAR_INVPZ384MUC	1268			M	2800	Visit12	12	Phase 2	409	0	0	0	0	0	0	1	4	6	4	4	6	6	5	6	0	0	0	9	2	2	2	6	2	5	5	4	4	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30									0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.125	0	3.142857	5	3.65			2.65	3.75	0.75	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ384MUC
2081	8976	NDAR_INVPZ384MUC	1268			M	5800	EndofPhase2	16	Phase 2	514	0	0	0	0	0	0	0	4	3	4	4	2	4	5	4	0	2	1	9	0	1	2	2	2	2	2	2	2	0	0	0	0	1	1	1	1	2	2	1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	6	3.75	0.75	1.5714285	2	2.4			2.65	3.75	0.75	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVPZ384MUC
2081	8976	NDAR_INVRA369MTG	2712			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	1	2	2	3	2	4	4	0	4	0	9	1	2	3	4	6	4	2	4	4	1	0	0	0	1	1	1	1	2	3	1	2	3	1	1	1	0	0	0	0	0	1	0	1	0	1	1	1	16	0		0		1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	2.875	1	3.4285715	3	2.85	1		2.85	2.875	1	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA369MTG
2081	8976	NDAR_INVRA369MTG	2712			F	5200	EndofPhase1_1a	2	Phase 1/1A	57	1	0	0	0	0	0	0	6	4	2	2	3	4	4	5	0	1	0	9	2	2	4	0	2	5	2	4	4	0	0	1	0	1	1	1	1	1	1	1	3	3	4	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.75	0.25	2.5714285	3.5	2.8		1	2.85	2.875	1	3.4285715	3	-0.05	0.875	-0.75	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA369MTG
2081	8976	NDAR_INVRA703VPM	1702			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	5	5	5	5	5	5	4	4	6	5	5	5	5	5	5	5	2	3	5	6	0	0	0	0	1	1	1	1	3	2	1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	4	4.875	5	5.142857	2.5	4.7619047	1		4.7619047	4.875	5	5.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA703VPM
2081	8976	NDAR_INVRA703VPM	1702			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	3	3	3	3	3	4	3	3	4	5	5	5	4	5	5	5	5	4	4	5	6	1	1	1	0	1	1	1	1	3		1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.125	4.75	5	4	4.142857			4.7619047	4.875	5	5.142857	2.5	-0.61904764	-1.75	-0.25	-0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA703VPM
2081	8976	NDAR_INVRA703VPM	1702			F	2800	Visit12	12	Phase 1/1A	334	0	0	0	0	0	1	0	4	4	4	5	4	4	5	5	6	5	5	5	5	5	5	5	5	5	4	4	5	1	1	1	0	1	1	1	1	3	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.375	5.25	4.857143	4.5	4.714286			4.7619047	4.875	5	5.142857	2.5	-0.04761905	-0.5	0.25	-0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA703VPM
2081	8976	NDAR_INVRA703VPM	1702			F	5200	EndofPhase1_1a	18	Phase 1/1A	511	0	0	0	0	0	0	1	5	5	5	5	4	5	6	5	6	6	6	6	5	6	4	5	5	4	4	5	5	1	1	1	1	1	1	1	1	3		1	4	3	3	3	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5	6	5	4	5.095238		1	4.7619047	4.875	5	5.142857	2.5	0.33333334	0.125	1	-0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA703VPM
2081	8976	NDAR_INVRA742CA4	1252			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	6	4	2	6	2	2	0	0	0	0	9	0	1	2	4	3	4	3	2	1	1	1	1	0	1	1	0	0	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	0	1.8571428	3.5	2.4	1		2.4	3.5	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA742CA4
2081	8976	NDAR_INVRA784VZA	1671			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	4	0	0	4	1	2	1	0	6	1	9	1	2	0	2	0	5	1	3	4	0	0	0	0	0	1	1	1	2	3	1	4	2	3	4	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	1.5	1.75	1.7142857	3	1.85	1		1.85	1.5	1.75	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA784VZA
2081	8976	NDAR_INVRA784VZA	1671			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	9	0	1	2	5	0	1	0	4	5	5	9	4	3	2	4	2	5	4	4	5	1	1	1	0	0	1	1	1	2	2	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.2857143	3.5	3.4285715	4.5	2.9473684			1.85	1.5	1.75	1.7142857	3	1.0973685	-0.21428572	1.75	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA784VZA
2081	8976	NDAR_INVRA784VZA	1671			M	2800	Visit12	12	Phase 1/1A	330	0	0	0	0	0	0	1	9	0	0	0	2	0	2	0	0	0	4	9	4	3	5	3	2	6	6	5	5	1	1	1	1	1	1	1	1	2	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.5714286	1	3.857143	6	2.4736843			1.85	1.5	1.75	1.7142857	3	0.6236842	-0.9285714	-0.75	2.142857	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA784VZA
2081	8976	NDAR_INVRA784VZA	1671			M	4000	Visit18	18	Phase 1/1A	494	1	0	0	0	0	0	0	1	0	0	2	2	0	3	1	3	4	2	6	4	3	3	3	3	6	5	5	2	1	1	1	0	1	1	1	1	1	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		1.125	3.75	3.2857144	5.5	2.7619047		1	1.85	1.5	1.75	1.7142857	3	0.91190475	-0.375	2	1.5714285	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA784VZA
2081	8976	NDAR_INVRA991HCL	1158			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	1	1	2	0	1	0	1	2	1	9	2	2	0	3	2	6	2	2	2	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	1	1.8571428	4	1.7	1		1.7	1.125	1	1.8571428	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA991HCL
2081	8976	NDAR_INVRA991HCL	1158			M	1600	Visit6	6	Phase 1/1A	167	0	0	1	0	0	0	0	4	0	0	0	4	0	1	1	1	1	0	9	1	2	2	4	1	5	2	3	4	0	1	1	0	0	1	0	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		1.25	0.5	2.4285715	3.5	1.8			1.7	1.125	1	1.8571428	4	0.1	0.125	-0.5	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA991HCL
2081	8976	NDAR_INVRA991HCL	1158			M	5200	EndofPhase1_1a	7	Phase 1/1A	182	0	0	1	0	0	0	0	4	0	1	1	2	0	1	0	1	2	1	9	2	2	0	3	2	6	2	2	2	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	1	1.8571428	4	1.7		1	1.7	1.125	1	1.8571428	4	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRA991HCL
2081	8976	NDAR_INVRB027RJ8	2114			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	2	2	2	2	2	0	0	0	0	9	0	0	0	2	0	2	2	0	2	1	0	1	0	1	1	1	1	3	2	0	4	4	4	4	1	0	0	1	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	0	0.5714286	2	1	1		1	1.5	0	0.5714286	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB027RJ8
2081	8976	NDAR_INVRB027RJ8	2114			M	1600	Visit6	6	Phase 1B	197	0	0	0	0	0	1	0	2	0	1	2	2	0	2	0	0	0	0	9	0	2	0	2	0	2	1	0	4	0	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.125	0	1.1428572	1.5	1			1	1.5	0	0.5714286	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB027RJ8
2081	8976	NDAR_INVRB027RJ8	2114			M	2800	Visit12	12	Phase 1B	367	0	0	0	0	0	1	0	0	0	0	2	2	0	2	0	0	0	0	9	2	2	2	2	0	4	5	2	4	1	1	1	1	1	1	1	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.75	0	2	4.5	1.45			1	1.5	0	0.5714286	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB027RJ8
2081	8976	NDAR_INVRB027RJ8	2114			M	4000	Visit18	18	Phase 1B	542	0	0	0	0	0	1	0	0	0	2	2	2	2	2	0	0	2	0	9	0	2	2	2	0	3	2	2	2	1	0	1	1	1	1	1	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	0.5	1.4285715	2.5	1.35			1	1.5	0	0.5714286	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB027RJ8
2081	8976	NDAR_INVRB027RJ8	2114			M	5200	EndofPhase1_1a	2	Phase 1/1A	71	0	0	0	0	0	1	0	0	0	0	1	2	1	1	0	0	0	0	9	0	0	0	2	0	1	1	2	2	1	0	1	0	1	1	0	0	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.625	0	0.85714287	1	0.65		1	1	1.5	0	0.5714286	2	-0.35	-0.875	0	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB027RJ8
2081	8976	NDAR_INVRB221EYA	1028			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	2	1	0	2	5	2	0	0	0	9	0	0	0	4	0	2	3	4	4	1	1	1	0	1	1	1	1	3	2	1	2	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.2857144	0	1.7142857	2.5	1.7368422	1		1.7368422	2.2857144	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB221EYA
2081	8976	NDAR_INVRB221EYA	1028			M	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	0	1	1	2	4	4	3	5	5	2	4	4	4	4	1	4	4	4	4	5	3	4	6	1	1	1	0	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	4	3.857143	4	3.6666667			1.7368422	2.2857144	0	1.7142857	2.5	1.9298246	0.96428573	4	2.142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB221EYA
2081	8976	NDAR_INVRB221EYA	1028			M	2800	Visit12	12	Phase 1/1A	371	0	0	0	0	0	0	1	9	6	5	6	5	6	6	4	2	4	4	9	1	2	4	6	4	5	4	5	6	1	1	1	0	1	1	1	1	3	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.428571	2.5	4	4.5	4.4736843			1.7368422	2.2857144	0	1.7142857	2.5	2.7368422	3.142857	2.5	2.2857144	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB221EYA
2081	8976	NDAR_INVRB221EYA	1028			M	4000	Visit18	18	Phase 1/1A	512	0	0	0	0	0	1	0	3	4	3	4	4	3	5	3	0	4	0	9	0	2	0	5	0	5	4	5	6	1	1	1	0	1	1	1	1	3		1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.625	1	2.5714285	4.5	3		1	1.7368422	2.2857144	0	1.7142857	2.5	1.2631578	1.3392857	1	0.85714287	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB221EYA
2081	8976	NDAR_INVRB231DC2	1574			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	5	5	5	2	5	4	5	5	5	6	3	5	4	4	6	5	3	5	6	1	1	0	1	1	1	1	2	3	3	1	3	3	2	2	1	0	0	0	0	0	1	0	0	0	0	0	0		1		0		0		0		0	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	5	3.75	5.25	4.714286	4	4.3809524	1		4.3809524	3.75	5.25	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB231DC2
2081	8976	NDAR_INVRB231DC2	1574			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	1	0	5	0	5	5	5	5	5	1	0	1	1	9	1	1	2	5	3	5	5	5	4	1	1	1	1	1	1	1	2	3		1	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	5	3.875	0.5	3	5	3.2			4.3809524	3.75	5.25	4.714286	4	-1.1809524	0.125	-4.75	-1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB231DC2
2081	8976	NDAR_INVRB231DC2	1574			M	2800	Visit12	12	Phase 1/1A	355	0	0	0	0	0	0	1	9	5	4	4	2	4	5	1	1	2	1	9	0	3	3	3	4	5	4	5	6	1	1	1	1	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	1	0	0	0	1	0	0	1	1	1	1	6	3.5714285	1	3.4285715	4.5	3.2631578			4.3809524	3.75	5.25	4.714286	4	-1.1177945	-0.17857143	-4.25	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB231DC2
2081	8976	NDAR_INVRB231DC2	1574			M	5200	EndofPhase1_1a	18	Phase 1/1A	511	0	0	0	0	0	0	1	9	5	4	4	3	4	5	1	1	4	6	9	4	5	3	4	4	5	4	5	6	1	1	0	0	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.7142856	2.75	4.428571	4.5	4.0526314		1	4.3809524	3.75	5.25	4.714286	4	-0.3283208	-0.035714287	-2.5	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB231DC2
2081	8976	NDAR_INVRB602HCL	2163			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	0	0	2	0	2	3	0	0	1	9	0	0	0	0	0	2	1	2	1	0	0	1	2	1	2	1	2	2	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	4	0		0		0		1	26	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	4	1.625	0.25	0.42857143	1.5	1	1		1	1.625	0.25	0.42857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB602HCL
2081	8976	NDAR_INVRB602HCL	2163			M	2800	Visit12	12	Phase 1/1A	309	0	0	0	0	1	0	0	6	0	2	4	2	2	1	1	0	1	1	9	2	2	2	3	1	2	3	3	4	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	0.5	2.4285715	2.5	2.1			1	1.625	0.25	0.42857143	1.5	1.1	0.625	0.25	2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB602HCL
2081	8976	NDAR_INVRB602HCL	2163			M	4000	Visit18	18	Phase 1/1A	463	1	0	0	0	0	0	0	6	0	1	4	3	2	1	2	0	1	2	9	2	2	2	3	2	2	2	3	4	0	1	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	5	2.375	0.75	2.5714285	2	2.2		1	1	1.625	0.25	0.42857143	1.5	1.2	0.75	0.5	2.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB602HCL
2081	8976	NDAR_INVRB990VNF	1068			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	3	3	0	2	2	2	2	2	4	4	4	4	4	2	6	1	4	4	4	5	5	0	0	1	1	1	1	1	1	1	1	1	4	3	3	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2	4	3.857143	4	3.1904762	1		3.1904762	2	4	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB990VNF
2081	8976	NDAR_INVRB990VNF	1068			M	1600	Visit6	6	Phase 1/1A	179	0	0	1	0	0	0	0	6	6	0	2	6	0	1	5	0	0	0	9	5	6	5	5	4	3	3	1	6	1	0	1	0	1	1	1	1	1	1	1	4	3	3	3	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	4	3.25	0	4.571429	3	3.2			3.1904762	2	4	3.857143	4	0.00952381	1.25	-4	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB990VNF
2081	8976	NDAR_INVRB990VNF	1068			M	2800	Visit12	12	Phase 1/1A	334	0	0	1	0	0	0	0	6	0	2	4	5	0	2	2	0	0	0	9	0	3	2	2	6	4	3	0	3	0	0	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.625	0	2.2857144	3.5	2.2			3.1904762	2	4	3.857143	4	-0.9904762	0.625	-4	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB990VNF
2081	8976	NDAR_INVRB990VNF	1068			M	4000	Visit18	18	Phase 1/1A	516	0	0	1	0	0	0	0	6	4	2	1	2	2	2	4	4	3	2	4	4	4	4	4	4	6	5	6	6	0	1	1	1	1	1	1	1	1	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	2.875	3.25	4.571429	5.5	3.7619047			3.1904762	2	4	3.857143	4	0.5714286	0.875	-0.75	0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB990VNF
2081	8976	NDAR_INVRB990VNF	1068			M	5200	EndofPhase1_1a	18	Phase 1/1A	516	0	0	1	0	0	0	0	6	4	2	1	2	2	2	4	4	3	2	4	4	4	4	4	4	6	5	6	6	0	1	1	1	1	1	1	1	1	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	2.875	3.25	4.571429	5.5	3.7619047		1	3.1904762	2	4	3.857143	4	0.5714286	0.875	-0.75	0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRB990VNF
2081	8976	NDAR_INVRC235DXR	1642			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	2	2	2	2	2	6	4	0	2	4	9	0	2	0	4	5	1	1	5	6	1	1	0	0	1	2	1	2	2	1	1	4	2	2	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	7	2.875	1.5	3.142857	1	2.65	1		2.65	2.875	1.5	3.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC235DXR
2081	8976	NDAR_INVRC235DXR	1642			M	1600	Visit6	6	Phase 2	181	0	0	0	0	0	0	1	2	1	1	3	3	0	6	0	0	0	0	9	0	0	0	1		1	1	0	2	0	0	0	0	1	2	2	2	3		1	4	2	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	2	0	0.5	1	1.1052631			2.65	2.875	1.5	3.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC235DXR
2081	8976	NDAR_INVRC235DXR	1642			M	2800	Visit12	12	Phase 2	335	0	0	0	0	0	0	1	9	0	0	0	0	0	2	1	0	0	0	9	0	0	0	0	0	0	1	0	0	0	1	0	0	1	2	2	2	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	7	0.42857143	0	0	0.5	0.21052632			2.65	2.875	1.5	3.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC235DXR
2081	8976	NDAR_INVRC235DXR	1642			M	5200	EndofPhase1_1a	2	Phase 1/1A	82	0	0	0	0	0	1	0	3	4	3	3	2	3	4	1	0	2	1	9	2	2	0	2	4	1	2	2	4	0	0	0	0	0	0	0	0	3		1	3	2	2	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	2.875	0.75	2.2857144	1.5	2.25		1	2.65	2.875	1.5	3.142857	1	-0.4	0	-0.75	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC235DXR
2081	8976	NDAR_INVRC235DXR	1642			M	5800	EndofPhase2	15	Phase 2	418	0	0	0	0	0	1	0	0	4	4	1	2	0	3	1	0	0	0	9	1	4	0	5	5	1	1	2	2	1	1	1	0	1	2	1	2	3		1	3	2	2	2	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	4	1.875	0	2.7142856	1	1.8			2.65	2.875	1.5	3.142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC235DXR
2081	8976	NDAR_INVRC494GT7	2601			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	3	0	2	2	2	1	1	2	4	1	9	1	2	3	2	2	4	3	4	3	1	0	1	1	0	1	0	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	1.875	1.75	2.4285715	3.5	2.3	1		2.3	1.875	1.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC494GT7
2081	8976	NDAR_INVRC494GT7	2601			M	1600	Visit6	6	Phase 2	176	1	0	0	0	0	0	0	2	3	3	4	3	4	5	2	3	4	3	4	3	2	2	4	3	3	3	5	5	1	0	1	1	0	1	0	1	1	2	1	4	4		4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.25	3.5	3.4285715	3	3.3333333			2.3	1.875	1.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC494GT7
2081	8976	NDAR_INVRC494GT7	2601			M	2800	Visit12	12	Phase 3	344	1	0	0	0	0	0	0	3	3	2	2	4	4	4	2	3	4	4	4	3	3	4	2	3	3	2	3	3	1	0	1	0	0	1	0	0	1	1	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3	3.75	3	2.5	3.0952382			2.3	1.875	1.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC494GT7
2081	8976	NDAR_INVRC494GT7	2601			M	5200	EndofPhase1_1a	1	Phase 1/1A	18	1	0	0	0	0	0	0	3	3	2	2	2	1	1	1	1	1	1	9	2	2	0	2	2	4	3	4	3	1	0	1	1	0	1	1	1	1	2	1	3	2	2	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0.75	2.142857	3.5	2		1	2.3	1.875	1.75	2.4285715	3.5	-0.3	0	-1	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC494GT7
2081	8976	NDAR_INVRC494GT7	2601			M	5800	EndofPhase2	11	Phase 2	310	1	0	0	0	0	0	0	4	1	1	2	2	2	6	1	3	3	3	3	3	4	2	2	1	4	2	4	5	1	0	1	1	1	1	0	0	1	2	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	3	3	3	2.7619047			2.3	1.875	1.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC494GT7
2081	8976	NDAR_INVRC494GT7	2601			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	2	3	0	1	3	2	5	1	3	5	1	3	1	4	3	4	3	5	3	5	3	1	1	1	1	1	1	0	1	1	2	1	3	2	2	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	1	0	0	1	1	1	0	4	2.125	3	3.2857144	4	2.857143			2.3	1.875	1.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC494GT7
2081	8976	NDAR_INVRC968YZA	1195			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	3	2	1	3	2	1	1	2	1	9	1	2	1	2	1	2	1	1	1	1	0	1	0	1	1	1	1	1	2	1	2	2	4	2	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.75	1	1.2857143	1.5	1.5	1		1.5	1.75	1	1.2857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC968YZA
2081	8976	NDAR_INVRC968YZA	1195			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	2	2	2	2	2	1	2	2	1	1	1	9	2	2	2	3	3	1	2	2	2	1	0	1	1	1	1	1	1	2	1	1	3	2	4	1	1	0	0	1	0	0	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.875	0.75	2.2857144	1.5	1.85			1.5	1.75	1	1.2857143	1.5	0.35	0.125	-0.25	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC968YZA
2081	8976	NDAR_INVRC968YZA	1195			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	1	0	6	4	5	5	5	3	5	2	0	0	0	9	0	1	3	4	4	2	2	0	1	1	1	1	0	1	1	1	1	2	1	1	2	1	1	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	0	1.8571428	2	2.6			1.5	1.75	1	1.2857143	1.5	1.1	2.625	-1	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC968YZA
2081	8976	NDAR_INVRC968YZA	1195			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	1	0	5	3	3	6	4	2	3	1	0	0	0	9	1	1	0	2	2	2	3	5	0	1	1	1	1	1	1	1	1	2	1	1	2	2	2	1	1	0	0	0	0	0	1	0	1	0	1	1	0		1	25	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	7	3.375	0	1.5714285	2.5	2.15		1	1.5	1.75	1	1.2857143	1.5	0.65	1.625	-1	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRC968YZA
2081	8976	NDAR_INVRD299KAL	1601			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	0	1	2	2	1	1	3	4	4	5	6	4	4	5	5	4	4	3	5	6	1	0	1	2	1	1	1	1	1	3	0	4	4	3	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1.75	4.75	4.714286	3.5	3.4761906	1		3.4761906	1.75	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD299KAL
2081	8976	NDAR_INVRD299KAL	1601			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	1	0	0	4	2	1	2	1	0	1	1	1	3	3	9	3	3	2	1	5	4	2	4	5	2	2	1	2	1	1	1	1	2	2	1	3	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.5	1.75	3.2857144	3	2.4			3.4761906	1.75	4.75	4.714286	3.5	-1.0761905	-0.25	-3	-1.4285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD299KAL
2081	8976	NDAR_INVRD299KAL	1601			M	2800	Visit12	12	Phase 1/1A	333	0	0	0	0	1	0	0	0	2	0	0	0	2	3	4	1	4	5	9	4	4	5	4	6	6	3	5	6	1	1	1	0	1	1	1	1	2	2	1	3	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	2.5	4.857143	4.5	3.2			3.4761906	1.75	4.75	4.714286	3.5	-0.2761905	-0.375	-2.25	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD299KAL
2081	8976	NDAR_INVRD299KAL	1601			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	1	0	0	2	2	2	2	2	4	4	1	2	4	2	9	3	5	2	4	4	5	2	5	6	0	0	1	0	1	1	1	1	1	2	1	4	2	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	2.375	2	4.142857	3.5	3.15		1	3.4761906	1.75	4.75	4.714286	3.5	-0.32619047	0.625	-2.75	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD299KAL
2081	8976	NDAR_INVRD358PKH	1354			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	4	3	2	0	3	0	2	1	1	4	0	9	3	3	2	2	0	2	0	4	5	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	5	1.875	1.25	2.7142856	1	2.05	1		2.05	1.875	1.25	2.7142856	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD358PKH
2081	8976	NDAR_INVRD358PKH	1354			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	6	1	1	2	2	3	3	2	0	0	0	9	2	2	4	4	2	4	3	5	5	1	1	0	0	1	1	1	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	0	3.4285715	3.5	2.55		1	2.05	1.875	1.25	2.7142856	1	0.5	0.625	-1.25	0.71428573	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD358PKH
2081	8976	NDAR_INVRD425RRA	1390			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	2	0	4	0	2	5	2	2	1	9	2	0	4	3	4	5	1	4	4	0	0	1	0	1	1	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	25	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	1.25	3	3	2.55	1		2.55	2.375	1.25	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD425RRA
2081	8976	NDAR_INVRD440WC0	2016			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	2	0	4	4	4	4	5	3	0	2	6	6	6	6	5	6	3	4	6	6	1	1	0	0	1	1	1	1	2	1	1	2	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		1	30	0		0		0		1	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.625	2.75	5.857143	3.5	4.1904764	1		4.1904764	3.625	2.75	5.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD440WC0
2081	8976	NDAR_INVRD551ED7	1063			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	3	4	1	2	2	2	2	2	1	1	9	2	2	4	3	1	4	3	2	5	0	0	1	1	1	1	0	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	1	2.7142856	3.5	2.4	1		2.4	2.25	1	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD551ED7
2081	8976	NDAR_INVRD551ED7	1063			F	5200	EndofPhase1_1a	6	Phase 1/1A	169	1	0	1	0	0	0	0	3	3	1	1	4	3	2	3	1	2	1	9	2	1	1	3	1	5	3	3	2	2	1	1	1	1	1	0	1	1	2	1	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	1	1.8571428	4	2.25		1	2.4	2.25	1	2.7142856	3.5	-0.15	0.25	0	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD551ED7
2081	8976	NDAR_INVRD551ED7	1063			F	5800	EndofPhase2	9	Phase 2	233	1	0	0	0	0	0	0	5	1	1	1	4	2	2	1	2	2	1	9	2	1	1	1	1	6	2	3	4	2	1	0	1	1	0	0	0	1	2	1	4	4	4	3	1	0	1	1	0	0	0	0	1	1	1	0	1	24	0		0		1	6	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	1.25	1.8571428	4	2.15			2.4	2.25	1	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD551ED7
2081	8976	NDAR_INVRD714ZWG	1845			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	5	4	1	4	2	2	1	0	0	0	9	2	3	2	2	0	4	2	2	2	0	1	1	1	1	1	0	1	3	1	1	4	4	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	3	0	1.8571428	3	2.15	1		2.15	3	0	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD714ZWG
2081	8976	NDAR_INVRD714ZWG	1845			F	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	0	1	6	4	2	2	5	2	3	2	3	3	4	6	3	4	3	4	6	4	3	5	6	1	1	1	1	1	1	1	1	2	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.25	4	4.428571	3.5	3.8095238			2.15	3	0	1.8571428	3	1.6595238	0.25	4	2.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD714ZWG
2081	8976	NDAR_INVRD714ZWG	1845			F	2800	Visit12	12	Phase 1/1A	332	0	0	0	0	0	0	1	5	3	3	3	5	3	6	3	1	4	3	9	3	4	4	4	5	4	4	4	6	1	0	1	0	1	1	1	1	1	2	1	4	1	3	4	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	3.875	2	4.285714	4	3.85		1	2.15	3	0	1.8571428	3	1.7	0.875	2	2.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD714ZWG
2081	8976	NDAR_INVRD780DMD	1403			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	5	4	4	4	4	2	3	6	4	4	3	5	4	6	5	5	6	6	6	4	1	1	1	1	1	1	1	1	3	1	1	4	4	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	21	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	4.25	5	6	4.571429	1		4.571429	4	4.25	5	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD780DMD
2081	8976	NDAR_INVRD780DMD	1403			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	5	5	2	4	2	2	2	3	6	3	4	4	3	5	4	3	4	6	5	6	6	1	1	1	1	1	1	1	1	2	1	1	2	1	2	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.125	4.25	4.428571	5.5	4			4.571429	4	4.25	5	6	-0.5714286	-0.875	0	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD780DMD
2081	8976	NDAR_INVRD780DMD	1403			F	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	9	4	6	6	6	4	4	6	6	6	6	6	5	6	6	4	6	6	6	6	6	1	1	1	1	1	0	1	1	3	1	1	2	1	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5.142857	6	5.571429	6	5.55			4.571429	4	4.25	5	6	0.9785714	1.1428572	1.75	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD780DMD
2081	8976	NDAR_INVRD780DMD	1403			F	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	0	0	1	2	4	5	2	2	2	4	2	6	5	6	6	6	5	6	4	6	6	6	6	6	0	1	1	1	1	1	1	1	3	2	1	2	3	4	1	1	1	0	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	5.75	5.571429	6	4.6190476		1	4.571429	4	4.25	5	6	0.04761905	-1.125	1.5	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD780DMD
2081	8976	NDAR_INVRD974LTH	2019			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	6	1	6	1	6	2	0	0	6	9	2	2	0	6	0	2	2	2	4	0	0	1	0	1	1	1	0	1	2	1	2	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	7	4.25	1.5	2.2857144	2	3	1		3	4.25	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD974LTH
2081	8976	NDAR_INVRD974LTH	2019			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	4	0	2	2	3	0	1	2	0	0	0	9	0	0	0	2	0	4	5	2	2	1	1	1	0	1	1	1	1	1	2	0	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.75	0	0.85714287	4.5	1.45			3	4.25	1.5	2.2857144	2	-1.55	-2.5	-1.5	-1.4285715	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD974LTH
2081	8976	NDAR_INVRD974LTH	2019			M	2800	Visit12	12	Phase 1/1A	360	1	0	0	0	0	0	0	3	4	3	2	3	1	2	2	0	0	0	9	0	0	0	2	5	5	5	1	2	0	0	1	0	1	1	1	1	2	2	1	2	2	4	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.5	0	1.4285715	5	2			3	4.25	1.5	2.2857144	2	-1	-1.75	-1.5	-0.85714287	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD974LTH
2081	8976	NDAR_INVRD974LTH	2019			M	5200	EndofPhase1_1a	18	Phase 1/1A	539	1	0	0	0	0	0	0	2	0	0	2	2	1	2	0	0	0	0	9	0	0	1	2	3	4	4	1	1	0	1	0	0	1	1	1	0	1	2	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1.125	0	1.1428572	4	1.25		1	3	4.25	1.5	2.2857144	2	-1.75	-3.125	-1.5	-1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRD974LTH
2081	8976	NDAR_INVRE239FFW	2112			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	3	4	4	2	3	3	4	4	5	5	2	2	4	4	3	4	2	5	5	1	1	1	0	1	1	2	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		0		1	30	0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3	4.5	3.5714285	3	3.5	1		3.5	3	4.5	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRE239FFW
2081	8976	NDAR_INVRE326MLP	2285			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	2	2	3	3	3	3	0	0	0	9	1	4	2	4	3	4	4	2	4	0	1	0	0	0	2	0	1	3		1	2	2	2	1	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	2	2.857143	0	2.857143	4	2.5263157	1		2.5263157	2.857143	0	2.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRE326MLP
2081	8976	NDAR_INVRF963KRF	2830			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	2	2	3	4	4	6	1	2	4	4	3	2	4	0	3	3	6	5	1	1	0	0	1	1	2	1	3	2	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.375	3.25	3.4285715	3	2.952381	1		2.952381	2.375	3.25	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRF963KRF
2081	8976	NDAR_INVRF963KRF	2830			M	5200	EndofPhase1_1a	2	Phase 1/1A	64	0	0	0	0	0	1	0	4	3	0	3	2	3	4	0	1	4	5	9	2	3	3	4	0	3	3	4	5	0	1	2	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.375	2.5	3	3	2.8		1	2.952381	2.375	3.25	3.4285715	3	-0.15238096	0	-0.75	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRF963KRF
2081	8976	NDAR_INVRG415MDR	1163			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	3	4	5	4	3	3	2	0	1	1	9	3	2	4	5	2	4	3	3	3	1	0	1	1	1	1	1	1	3		1	3	1	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	0.5	3.142857	3.5	3.05	1		3.05	3.75	0.5	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG415MDR
2081	8976	NDAR_INVRG500UP9	1374			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	0	2	2	2	2	4	4	2	4	4	3	4	3	3	5	4	2	4	6	1	0	1	0	1	1	1	1	3	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	26	0		0		1	4	0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.2857144	3.5	4	3	3.2	1		3.2	2.2857144	3.5	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG500UP9
2081	8976	NDAR_INVRG500UP9	1374			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	4	4	2	1	2	2	2	4	1	1	1	9	4	1	2	3	3	4	2	5	2	1	0	1	0	1	1	1	1	3	2	1	2	1	1	1	1	0	0	0	0	1	0	0	0	0	0	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.625	0.75	2.857143	3	2.5			3.2	2.2857144	3.5	4	3	-0.7	0.3392857	-2.75	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG500UP9
2081	8976	NDAR_INVRG500UP9	1374			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	4	4	2	2	2	1	2	4	2	3	4	9	2	2	3	4	2	4	3	4	4	1	0	1	0	1	1	1	1	3	2	1	3	2	2	2	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	5	2.625	2.25	3	3.5	2.9			3.2	2.2857144	3.5	4	3	-0.3	0.3392857	-1.25	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG500UP9
2081	8976	NDAR_INVRG500UP9	1374			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	0	1	9	2	2	4	4	3	2	5	0	0	2	9	3	4	1	4	4	5	3	5	5	1	1	1	1	1	1	1	1	2	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	1	1	1	1	1	1	5	3.142857	0.5	3.7142856	4	3.0526316		1	3.2	2.2857144	3.5	4	3	-0.14736842	0.85714287	-3	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG500UP9
2081	8976	NDAR_INVRG612HJ9	1456			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	2	1	1	4	4	2	1	1	3	2	9	1	0	2	2	2	3	1	4	2	1	0	1	0	1	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.625	1.5	1.8571428	2	2.2	1		2.2	2.625	1.5	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG612HJ9
2081	8976	NDAR_INVRG612HJ9	1456			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	1	1	0	0	6	4	4	4	4	4	4	4	0	4	4	9	2	4	4	4	4	3	3	4	4	1	1	1	0	1	1	1	1	1	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	2	3.7142856	3	3.7			2.2	2.625	1.5	1.8571428	2	1.5	1.625	0.5	1.8571428	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG612HJ9
2081	8976	NDAR_INVRG612HJ9	1456			F	2800	Visit12	12	Phase 1/1A	348	0	0	0	0	1	0	0	6	0	0	0	2	0	1	0	0	2	1	9	0	2	2	4	0	4	2	2	2	0	0	1	0	1	0	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	1.125	0.75	1.7142857	3	1.5		1	2.2	2.625	1.5	1.8571428	2	-0.7	-1.5	-0.75	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRG612HJ9
2081	8976	NDAR_INVRH091VC4	1187			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	0	4	2	1	1	0	1	1	9	1	1	2	2	1	4	3	1	4	0	1	1	1	1	1	1	1	3	3	1	3	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	1.5	0.5	1.7142857	3.5	1.65	1		1.65	1.5	0.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH091VC4
2081	8976	NDAR_INVRH091VC4	1187			M	1600	Visit6	6	Phase 1B	163	1	0	0	0	0	0	0	3	1	1	3	2	1	1	2	0	0	1	9	2	2	1	2	1	2	1	3	2	0	0	1	1	1	1	0	0	3	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	0.25	1.8571428	1.5	1.55			1.65	1.5	0.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH091VC4
2081	8976	NDAR_INVRH091VC4	1187			M	5200	EndofPhase1_1a	3	Phase 1/1A	85	1	0	0	0	0	0	0	1	2	1	2	2	2	2	1	1	1	1	9	1	1	2	2	1	2	3	2	2	1	0	1	0	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.625	0.75	1.5714285	2.5	1.6		1	1.65	1.5	0.5	1.7142857	3.5	-0.05	0.125	0.25	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH091VC4
2081	8976	NDAR_INVRH091VC4	1187			M	5400	EndofPhase1b	7	Phase 1B	191	1	0	0	0	0	0	0	2	0	2	1	2	0	2	1	0	0	0	9	1	1	2	1	0	2	1	2	1	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	0	1.1428572	1.5	1.05			1.65	1.5	0.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH091VC4
2081	8976	NDAR_INVRH091VC4	1187			M	6000	EndofPhase3	12	Phase 3	359	1	0	0	0	0	0	0	4	0	0	0	0	0	1	1	0	0	0	9	0	0	1	0	0	4	2	0	1	1	1	1	1	1	0	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	16	0		0		1	14	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	0.75	0	0.2857143	3	0.7			1.65	1.5	0.5	1.7142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH091VC4
2081	8976	NDAR_INVRH974JMB	2030			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	4	0	1	2	1	3	4	4	4	2	2	3	3	3	5	3	4	5	1	1	2	0	1	1	0	1	3		1	4	2	3	4	0	0	0	0	0	0	0	0					0		1		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	5	1.5	3.75	3.142857	4	2.7142856	1		2.7142856	1.5	3.75	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH974JMB
2081	8976	NDAR_INVRH974JMB	2030			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	1	0	3	3	2	2	2	2	3	1	3	2	5	4	3	2	2	4	3	5	3	4	4	0	0	2	0	1	1	0	1	3		1	3	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.25	3.5	3.142857	4	2.952381			2.7142856	1.5	3.75	3.142857	4	0.23809524	0.75	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH974JMB
2081	8976	NDAR_INVRH974JMB	2030			M	2800	Visit12	12	Phase 2	323	0	0	0	0	0	1	0	3	1	4	3	2	3	4	3	4	4	4	4	4	3	4	4	4	5	2	5	5	1	0	2	0	1	1	0	1	3		1	3	2	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.875	4	4.142857	3.5	3.5714285			2.7142856	1.5	3.75	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH974JMB
2081	8976	NDAR_INVRH974JMB	2030			M	5200	EndofPhase1_1a	9	Phase 1/1A	232	0	0	0	0	0	1	0	2	4	4	3	2	2	4	4	2	2	5	9	2	2	3	4	3	4	4	4	5	1	1	2	1	1	1	2	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	6	3.125	2.25	3.2857144	4	3.25		1	2.7142856	1.5	3.75	3.142857	4	0.53571427	1.625	-1.5	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH974JMB
2081	8976	NDAR_INVRH974JMB	2030			M	5800	EndofPhase2	18	Phase 2	499	0	0	0	0	0	1	0	3	3	3	2	3	2	3	1	2	2	4	9	2	2	2	4	5	5	2	5	4	1	1	2	1	1	1	2	1	3	2	1	4	3	4	4	1	0	0	0	0	1	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.5	2	3.4285715	3.5	2.95			2.7142856	1.5	3.75	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH974JMB
2081	8976	NDAR_INVRH976HXT	1183			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	2	4	4	4	4	4	1	2	2	3	9	2	2	2	2	1	2	3	4	4	1	0	1	0	1	1	1	1	1	3	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	3	3.125	1.75	2.4285715	2.5	2.7	1		2.7	3.125	1.75	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH976HXT
2081	8976	NDAR_INVRH976HXT	1183			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	4	2	2	2	2	0	3	1	0	0	2	9	1	2	2	2	0	3	1	1	3	0	0	1	1	1	1	0	0	1	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	1	1	1	1	1	1	3	2	0.5	1.5714285	2	1.65			2.7	3.125	1.75	2.4285715	2.5	-1.05	-1.125	-1.25	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH976HXT
2081	8976	NDAR_INVRH976HXT	1183			M	2800	Visit12	12	Phase 1/1A	336	1	0	0	0	0	0	0	4	0	2	2	2	2	2	1	2	2	5	9	2	2	4	2	1	3	1	4	3	0	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	2.25	2.5714285	2	2.3			2.7	3.125	1.75	2.4285715	2.5	-0.4	-1.25	0.5	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH976HXT
2081	8976	NDAR_INVRH976HXT	1183			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	1	0	0	0	0	0	0	4	0	0	0	2	0	2	1	1	2	2	9	1	2	2	4	0	3	2	4	2	0	0	1	1	1	1	0	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	1	0	1	1	1	1	5	1.125	1.25	2.142857	2.5	1.7		1	2.7	3.125	1.75	2.4285715	2.5	-1	-2	-0.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRH976HXT
2081	8976	NDAR_INVRJ980WLC	2481			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	3	3	3	3	3	3	4	4	1	1	1	9	2	2	3	4	2	5	4	4	4	1	1	1	0	1	1	1	1	1	2	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	0.75	3	4.5	2.95	1		2.95	3.25	0.75	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRJ980WLC
2081	8976	NDAR_INVRK125MRZ	1336			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	1	1	1	1	1	1	2	2	2	3	9	2	2	2	3	3	4	2	3	3	0	0	1	0	1	1	2	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	4	1.375	1.75	2.5714285	3	2.1	1		2.1	1.375	1.75	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK125MRZ
2081	8976	NDAR_INVRK380CZB	1181			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	2	2	2	2	4	0	1	3	5	9	2	4	4	4	1	6	5	6	6	0	0	0	0	1	1	1	1	1	1	1	2	2	3	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.25	2.25	3.857143	5.5	3.25	1		3.25	2.25	2.25	3.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK380CZB
2081	8976	NDAR_INVRK380CZB	1181			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	6	4	3	4	4	4	6	3	0	0	1	9	0	2	4	6	2	5	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	4	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	0.25	3.7142856	4.5	3.5			3.25	2.25	2.25	3.857143	5.5	0.25	2	-2	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK380CZB
2081	8976	NDAR_INVRK380CZB	1181			F	5200	EndofPhase1_1a	12	Phase 1/1A	347	0	0	0	0	0	0	1	9	0	2	2	2	2	4	1	0	0	0	9	2	1	2	2	2	4	2	6	6	1	1	1	0	1	1	1	1	2	1	1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	1.8571428	0	3	3	2.1052632		1	3.25	2.25	2.25	3.857143	5.5	-1.1447369	-0.39285713	-2.25	-0.85714287	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK380CZB
2081	8976	NDAR_INVRK842RN5	1780			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	2	5	5	6	6	6	5	5	5	5	6	2	6	3	6	6	6	2	4	4	1	1	1	0	0	1	1	1	2	1	1	3	2	1	3	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	1	0	0	0	0	1	1	1	1	5	5.125	5.25	4.428571	4	4.8095236	1		4.8095236	5.125	5.25	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK842RN5
2081	8976	NDAR_INVRK842RN5	1780			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	6	4	5	5	5	6	6	5	5	4	5	6	1	6	3	6	6	4	2	4	4	1	0	1	0	1	1	1	1	2	1	1	3	2	2	3	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	5	4.285714	3	4.6666665			4.8095236	5.125	5.25	4.428571	4	-0.14285715	0.125	-0.25	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK842RN5
2081	8976	NDAR_INVRK842RN5	1780			F	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	3	4	3	3	3	3	3	3	1	1	3	9	1	1	2	3	2	4	1	4	5	1	0	1	0	1	1	1	1	3		0	4	1	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.125	1.25	2.5714285	2.5	2.65			4.8095236	5.125	5.25	4.428571	4	-2.1595237	-2	-4	-1.8571428	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK842RN5
2081	8976	NDAR_INVRK842RN5	1780			F	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	0	0	1	4	4	4	3	3	3	5	4	0	0	0	9	3	4	4	4	4	5	2	5	5	1	1	1	0	1	1	1	1	1	3	0	4	2	4	3	1	0	0	0	0	0	1	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	0	4.142857	3.5	3.3		1	4.8095236	5.125	5.25	4.428571	4	-1.5095239	-1.375	-5.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRK842RN5
2081	8976	NDAR_INVRL545XJY	1761			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	3	0	4	4	6	1	2	0	0	0	0	9	0	1	0	2	0	4	2	4	4	1	1	0	1	1	0	0	1	1	2	1	4	1	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2.5	0	1.5714285	3	1.85	1		1.85	2.5	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRL545XJY
2081	8976	NDAR_INVRL545XJY	1761			M	1600	Visit6	6	Phase 1/1A	165	0	0	0	0	1	0	0	5	0	0	1	5	0	1	0	2	3	3	9	0	2	0	2	0	3	2	6	6	0	1	0	0	1	0	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	2	1.5	2	2.2857144	2.5	2.05			1.85	2.5	0	1.5714285	3	0.2	-1	2	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRL545XJY
2081	8976	NDAR_INVRL545XJY	1761			M	5200	EndofPhase1_1a	12	Phase 1/1A	338	0	0	0	0	1	0	0	6	0	2	4	2	4	2	0	0	0	1	9	0	2	0	2	0	3	3	5	6	1	1	0	1	1	1	0	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0.25	2.142857	3	2.1		1	1.85	2.5	0	1.5714285	3	0.25	0	0.25	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRL545XJY
2081	8976	NDAR_INVRL545XJY	1761			M	5800	EndofPhase2	13	Phase 2	361	0	0	0	0	1	0	0	5	0	2	0	2	0	1	0	0	0	1	9	0	2	0	2	0	3	2	6	5	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.25	0.25	2.142857	2.5	1.55			1.85	2.5	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRL545XJY
2081	8976	NDAR_INVRL545XJY	1761			M	6000	EndofPhase3	18	Phase 3	502	0	0	0	0	1	0	0	5	0	4	2	3	3	4	1	1	3	4	9	2	1	1	4	2	5	3	6	6	1	0	1	1	1	1	0	1	1	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	2	3.142857	4	3			1.85	2.5	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRL545XJY
2081	8976	NDAR_INVRM037MVX	2770			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	1	0	1	4	1	1	2	1	1	1	9	1	2	4	3	1	6	5	1	1	1	1	1	1	1	0	0	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1.5	0.75	1.8571428	5.5	1.95	1		1.95	1.5	0.75	1.8571428	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM037MVX
2081	8976	NDAR_INVRM037MVX	2770			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	1	0	0	0	0	0	2	2	1	1	3	2	2	2	1	2	2	9	2	1	2	1	1	5	4	1	2	1	1	1	1	1	1	1	1	2	3	0	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	2	1.875	1.25	1.4285715	4.5	1.95		1	1.95	1.5	0.75	1.8571428	5.5	0	0.375	0.5	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM037MVX
2081	8976	NDAR_INVRM037MVX	2770			F	5800	EndofPhase2	4	Phase 2	94	0	1	0	0	0	0	0	5	1	1	1	2	1	1	4	1	1	1	9	1	1	1	1	1	4	4	2	2	1	1	1	0	1	1	1	1	2	2	1	4	4	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	0.75	1.2857143	4	1.8			1.95	1.5	0.75	1.8571428	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM037MVX
2081	8976	NDAR_INVRM051ZTR	2195			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	4	6	6	6	6	1	2	4	6	9	3	3	4	5	4	3	2	6	6	0	0	0	1	1	1	1	1	2	1	1	2	4	4	4	1	0	0	1	0	1	1	0	0	0	0	0	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	3	4.428571	2.5	4.35	1		4.35	4.875	3	4.428571	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM051ZTR
2081	8976	NDAR_INVRM051ZTR	2195			M	5200	EndofPhase1_1a	1	Phase 1/1A	25	0	0	0	0	0	1	0	6	4	4	6	6	6	6	1	2	4	6	9	3	3	4	5	4	3	2	6	6	1	1	0	1	1	1	1	0	2	1	1	2	4	4	4	1	0	0	1	0	0	1	0	0	1	1	1	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.875	3	4.428571	2.5	4.35		1	4.35	4.875	3	4.428571	2.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM051ZTR
2081	8976	NDAR_INVRM395MTG	1029			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	4	0	0	0	0	1	1	0	2	2	4	9	3	1	3	3	2	6	3	6	6	1	0	1	1	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	1	1	1	1	6	0.75	2	3.4285715	4.5	2.35	1		2.35	0.75	2	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM395MTG
2081	8976	NDAR_INVRM395MTG	1029			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	4	1	4	2	4	2	2	2	3	3	2	2	4	2	1	2	2	5	4	4	5	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	2.5	2.857143	4.5	2.857143			2.35	0.75	2	3.4285715	4.5	0.50714284	1.875	0.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM395MTG
2081	8976	NDAR_INVRM395MTG	1029			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	1	0	0	0	0	4	1	2	3	1	2	3	5	2	2	3	2	2	2	3	4	5	3	3	2	1	1	1	1	1	1	1	1	1	2	1	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2	3	2.5714285	4	2.5714285			2.35	0.75	2	3.4285715	4.5	0.22142857	1.25	1	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM395MTG
2081	8976	NDAR_INVRM395MTG	1029			F	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	1	0	0	0	3	1	1	1	2	2	2	1	5	3	3	3	4	3	2	2	3	5	3	3	4	1	1	1	1	1	1	1	1	1	1	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	5	1.625	3.5	3	4	2.6666667		1	2.35	0.75	2	3.4285715	4.5	0.31666666	0.875	1.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM395MTG
2081	8976	NDAR_INVRM608VCY	2182			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	2	4	4	4	2	4	6	3	4	3	9	3	4	5	5	4	2	1	4	5	0	0	0	0	1	1	1	1	3		1	2	2	4	2	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	4	2.5	4.285714	1.5	3.75	1		3.75	4	2.5	4.285714	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM608VCY
2081	8976	NDAR_INVRM608VCY	2182			M	1600	Visit6	6	Phase 3	176	0	0	0	0	0	1	0	5	4	5	5	4	5	4	5	4	4	3	3	3	4	3	3	3	3	3	5	5	0	0	0	0	1	1	1	1	3		1	2	1	3	2	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	4.625	3.5	3.7142856	3	3.952381			3.75	4	2.5	4.285714	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM608VCY
2081	8976	NDAR_INVRM608VCY	2182			M	2800	Visit12	12	Phase 3	340	0	0	0	0	0	0	1	9	4	5	4	2	3	4	5	3	3	1	9	4	2	3	4	4	2	3	4	5	1	1	1	0	1	1	1	1	3	1	0	4	4	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	4	3.857143	1.75	3.7142856	2.5	3.4210527			3.75	4	2.5	4.285714	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM608VCY
2081	8976	NDAR_INVRM608VCY	2182			M	5200	EndofPhase1_1a	1	Phase 1/1A	26	0	0	0	0	0	1	0	6	2	6	4	2	3	3	6	3	4	4	9	4	3	2	4	3	2	1	4	5	0	0	0	0	1	1	1	1	3		1	2	2	4	2	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	2.75	3.5714285	1.5	3.55		1	3.75	4	2.5	4.285714	1.5	-0.2	0	0.25	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM608VCY
2081	8976	NDAR_INVRM608VCY	2182			M	5800	EndofPhase2	2	Phase 2	53	0	0	0	0	0	1	0	6	3	6	5	5	6	6	6	4	4	1	3	3	3	3	4	4	3	1	4	5	0	0	0	0	1	1	1	1	3		1	2	1	4	1	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	5.375	3	3.7142856	2	4.047619			3.75	4	2.5	4.285714	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM608VCY
2081	8976	NDAR_INVRM608VCY	2182			M	6000	EndofPhase3	18	Phase 3	508	0	0	0	0	0	0	1	9	5	5	5	4	4	4	5	2	4	3	9	4	5	4	5	4	3	2	5	6	1	0	1	0	1	1	1	1	3		1	2	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	4.571429	2.25	4.714286	2.5	4.1578946			3.75	4	2.5	4.285714	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM608VCY
2081	8976	NDAR_INVRM666PPN	1285			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	0	1	2	0	4	0	4	4	5	1	2	2	4	5	3	5	4	4	4	1	1	1	0	1	1	1	1	2	1	1	3	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.75	3.5	3.4285715	4.5	2.9047618	1		2.9047618	1.75	3.5	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM666PPN
2081	8976	NDAR_INVRM666PPN	1285			M	1600	Visit6	6	Phase 1/1A	161	0	0	0	0	0	1	0	4	0	0	1	1	1	1	0	4	4	5	3	3	2	2	3	4	5	2	2	3	0	0	1	0	1	1	2	1	2	1	0	4	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1	4	2.7142856	3.5	2.3809524			2.9047618	1.75	3.5	3.4285715	4.5	-0.52380955	-0.75	0.5	-0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM666PPN
2081	8976	NDAR_INVRM666PPN	1285			M	2800	Visit12	12	Phase 1/1A	386	0	0	0	0	0	1	0	2	0	3	2	2	2	2	1	4	2	4	4	2	2	2	2	4	4	3	4	4	1	1	1	2	1	1	1	1	2	1	1	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	3.5	2.857143	3.5	2.6190476			2.9047618	1.75	3.5	3.4285715	4.5	-0.2857143	0	0	-0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM666PPN
2081	8976	NDAR_INVRM666PPN	1285			M	4000	Visit18	18	Phase 1/1A	582	0	0	0	0	0	0	1	9	3	3	1	4	1	4	3	4	4	5	5	2	5	4	2	4	5	3	6	5	1	1	1	0	1	1	1	1																																															2.7142856	4.5	4	4	3.65			2.9047618	1.75	3.5	3.4285715	4.5	0.74523807	0.96428573	1	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM666PPN
2081	8976	NDAR_INVRM666PPN	1285			M	5200	EndofPhase1_1a	18	Phase 1/1A	582	0	0	0	0	0	0	1	9	3	3	1	4	1	4	3	4	4	5	5	2	5	4	2	4	5	3	6	5	1	1	1	0	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.7142856	4.5	4	4	3.65		1	2.9047618	1.75	3.5	3.4285715	4.5	0.74523807	0.96428573	1	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM666PPN
2081	8976	NDAR_INVRM730UMJ	2637			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	4	2	5	5	6	4	2	4	5	9	4	5	5	4	4	5	5	5	6	1	1	1	0	1	1	1	1	1	1	1	2	2	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.25	2.75	4.714286	5	4.4	1		4.4	4.25	2.75	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM730UMJ
2081	8976	NDAR_INVRM730UMJ	2637			M	5200	EndofPhase1_1a	4	Phase 1/1A	99	0	0	0	0	0	0	1	4	6	5	4	4	4	4	2	1	2	2	9	4	4	4	4	4	5	5	5	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.125	1.25	4.428571	5	3.95		1	4.4	4.25	2.75	4.714286	5	-0.45	-0.125	-1.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRM730UMJ
2081	8976	NDAR_INVRN277AA6	1156			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	2	1	1	9	1	1	1	2	1	3	3	2	2	1	1	0	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1.4285715	3	1.4	1		1.4	1	1	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN277AA6
2081	8976	NDAR_INVRN277AA6	1156			F	5200	EndofPhase1_1a	4	Phase 1/1A	108	0	0	0	0	0	0	1	2	0	0	0	0	0	1	0	0	1	0	9	0	1	2	1	2	3	3	2	2	1	1	0	0	1	1	1	0	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.375	0.25	1.4285715	3	1		1	1.4	1	1	1.4285715	3	-0.4	-0.625	-0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN277AA6
2081	8976	NDAR_INVRN291KNC	2517			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	2	1	1	2	2	1	4	2	3	5	0	2	0	1	0	6	0	4	1	0	0	0	0	0	0	0	0	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	1.875	3.5	1.1428572	3	2.047619	1		2.047619	1.875	3.5	1.1428572	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN291KNC
2081	8976	NDAR_INVRN291KNC	2517			M	1600	Visit6	6	Phase 2	176	0	0	0	0	0	1	0	3	1	1	2	2	2	2	0	4	2	3	2	1	2	1	2	1	3	3	3	2	1	0	1	0	1	1	1	1	3	3	0	4	4	4	3	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.625	2.75	1.7142857	3	2			2.047619	1.875	3.5	1.1428572	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN291KNC
2081	8976	NDAR_INVRN291KNC	2517			M	5200	EndofPhase1_1a	2	Phase 1/1A	62	0	0	0	0	0	0	1	5	4	4	4	4	4	4	4	4	4	4	5	4	4	4	5	4	4	5	4	5	0	0	0	0	1	0	0	0	2	2	1	4	3	3	3	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.125	4.25	4.285714	4.5	4.2380953		1	2.047619	1.875	3.5	1.1428572	3	2.1904762	2.25	0.75	3.142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN291KNC
2081	8976	NDAR_INVRN291KNC	2517			M	5800	EndofPhase2	12	Phase 2	342	0	0	0	0	0	0	1	9	4	4	3	5	4	5	1	5	4	5	5	4	2	1	4	5	2	1	2	4	0	1	0	0	1	0	0	0	3		1	3	4	3	4	0	0	0	0	0	0	0	0					1	23	0		0		1	7	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	3.7142856	4.75	3.142857	1.5	3.5			2.047619	1.875	3.5	1.1428572	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN291KNC
2081	8976	NDAR_INVRN352YFF	1045			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	2	0	2	3	4	4	1	6	6	6	6	5	6	6	5	6	6	3	6	5	1	1	1	0	1	1	1	1	2	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.625	6	5.571429	4.5	4.428571	1		4.428571	2.625	6	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN352YFF
2081	8976	NDAR_INVRN352YFF	1045			M	1600	Visit6	6	Phase 3	143	0	0	0	0	0	1	0	4	3	1	2	2	2	2	1	4	6	6	2	5	6	5	4	5	6	3	5	5	1	1	1	1	1	0	1	1	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.125	4.5	5	4.5	3.7619047			4.428571	2.625	6	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN352YFF
2081	8976	NDAR_INVRN352YFF	1045			M	2800	Visit12	12	Phase 3	325	0	0	0	0	0	1	0	4	2	0	2	2	2	3	0	6	6	6	6	6	6	6	4	6	6	5	5	5	1	1	1	1	1	1	1	1	2	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	6	5.428571	5.5	4.1904764			4.428571	2.625	6	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN352YFF
2081	8976	NDAR_INVRN352YFF	1045			M	5200	EndofPhase1_1a	1	Phase 1/1A	20	0	0	0	0	0	1	0	4	4	0	1	2	2	3	0	6	6	6	3	6	6	4	3	5	6	3	4	3	1	0	1	0	1	1	1	1	3	1	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2	5.25	4.428571	4.5	3.6666667		1	4.428571	2.625	6	5.571429	4.5	-0.7619048	-0.625	-0.75	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN352YFF
2081	8976	NDAR_INVRN352YFF	1045			M	5800	EndofPhase2	2	Phase 2	37	0	0	0	0	0	1	0	4	3	1	1	2	2	3	1	2	4	6	9	6	6	4	3	5	6	3	5	5	1	0	1	1	1	1	1	1	2	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.125	3	4.857143	4.5	3.6			4.428571	2.625	6	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN352YFF
2081	8976	NDAR_INVRN352YFF	1045			M	6000	EndofPhase3	18	Phase 3	513	0	0	0	0	0	1	0	2	2	0	2	2	0	2	0	6	6	6	6	5	6	6	4	6	6	4	4	5	1	1	1	1	1	1	1	1	2	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1.25	6	5.142857	5	3.8095238			4.428571	2.625	6	5.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN352YFF
2081	8976	NDAR_INVRN403NDD	2052			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	0	2	2	2	0	2	2	5	9	2	1	0	2	2	5	2	2	4	1	0	2	0	0	1	2	1	1	3	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2	1	2.25	1.8571428	3.5	1.85	1		1.85	1	2.25	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN403NDD
2081	8976	NDAR_INVRN403NDD	2052			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	4	0	0	2	2	2	2	0	3	2	4	0	2	2	2	2	2	4	4	2	4	1	1	1	0	1	1	1	1	2	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.5	2.25	2.2857144	4	2.142857		1	1.85	1	2.25	1.8571428	3.5	0.29285714	0.5	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN403NDD
2081	8976	NDAR_INVRN459NF2	2875			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	3	0	0	0	2	0	0	0	0	2	6	9	0	1	0	2	0	3	4	2	3	0	1	1	1	1	1	1	1	2	3	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	7	0.625	2	1.1428572	3.5	1.4	1		1.4	0.625	2	1.1428572	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN459NF2
2081	8976	NDAR_INVRN513EXN	2338			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	4	0	0	2	2	2	4	5	4	4	3	0	2	2	2	6	4	1	2	2	0	0	2	0	1	1	2	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	3	1.75	4	2.2857144	2.5	2.4285715	1		2.4285715	1.75	4	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN513EXN
2081	8976	NDAR_INVRN808RGP	2685			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	1	1	1	2	1	1	0	1	2	5	9	2	2	2	2	2	4	3	2	3	1	1	0	0	1	1	1	1	2	1	1	2	2	2	3	1	0	0	1	0	0	0	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.375	2	2.142857	3.5	2.05	1		2.05	1.375	2	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN808RGP
2081	8976	NDAR_INVRN808RGP	2685			M	2800	Visit12	12	Phase 3	337	0	0	0	0	0	0	1	6	3	3	4	6	4	4	0	0	4	5	4	4	3	4	4	4	6	6	5	5	1	0	1	0	1	1	1	1	2	1	0	4	2	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1										0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.75	3.25	4.142857	6	4			2.05	1.375	2	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN808RGP
2081	8976	NDAR_INVRN808RGP	2685			M	5200	EndofPhase1_1a	6	Phase 1/1A	151	0	0	0	0	0	0	1	6	4	3	4	5	4	2	0				9	4	4	3	2	2	4	5	3	4	1	1	1	0	1	1	1	1	2	1	1	4	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.5		3.142857	4.5	3.4705882		1	2.05	1.375	2	2.142857	3.5	1.4205883	2.125		1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN808RGP
2081	8976	NDAR_INVRN808RGP	2685			M	5800	EndofPhase2	6	Phase 2	170	0	0	0	0	0	0	1	6	5	4	5	5	5	3	2	0	3	4	9	4	3	4	4	4	5	5	3	5	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	1	0	1	1	0	1	1	0	1	0	0	0	1	8	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	4.375	1.75	3.857143	5	3.95			2.05	1.375	2	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN808RGP
2081	8976	NDAR_INVRN808RGP	2685			M	6000	EndofPhase3	18	Phase 3	498	0	0	0	0	0	0	1	6	3	3	4	6	4	4	0	0	4	5	9	4	3	4	4	4	6	6	5	5	1	0	1	0	1	1	1	1	2	1	0	4	2	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.75	2.25	4.142857	6	4			2.05	1.375	2	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN808RGP
2081	8976	NDAR_INVRN931LV6	1677			F	400	Baseline	0	Pre-Rand	1	1	0	1	1	1	0	0	4	3	0	0	0	1	1	2	3	2	1	9	3	2	4	4	4	2	4	2	5	1	0	1	1	1	1	1	1	1	2	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	3	1.375	1.5	3.4285715	3	2.35	1		2.35	1.375	1.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN931LV6
2081	8976	NDAR_INVRN931LV6	1677			F	1600	Visit6	6	Phase 1/1A	172	1	0	0	0	0	0	0	2	0	2	0	2	1	3	1	2	2	1	9	3	4	2	5	1	4	3	5	5	1	0	1	1	1	1	1	1	2	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	5	1.375	1.25	3.5714285	3.5	2.4		1	2.35	1.375	1.5	3.4285715	3	0.05	0	-0.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRN931LV6
2081	8976	NDAR_INVRP318LJG	1201			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	4	4	1	0	1	1	6	5	5	2	3	6	4	4	5	6	3	3	6	0	1	0	1	1	0	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.8571428	4.5	4.428571	4.5	3.55	1		3.55	1.8571428	4.5	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP318LJG
2081	8976	NDAR_INVRP485GWJ	2451			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	0	6	6	6	6	4	0	0	0	9	2	4	6	3	4	6	5	6	6	1	1	1	1	1	1	0	1	2	1	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4.75	0	4.428571	5.5	4	1		4	4.75	0	4.428571	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP485GWJ
2081	8976	NDAR_INVRP485GWJ	2451			M	5200	EndofPhase1_1a	1	Phase 1/1A	8	0	0	0	0	0	0	1	6	4	3	6	6	6	6	3	0	0	0	9	3	4	6	4	4	6	5	6	6	1	1	1	1	1	1	1	1	2	1	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	0	4.714286	5.5	4.2		1	4	4.75	0	4.428571	5.5	0.2	0.25	0	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP485GWJ
2081	8976	NDAR_INVRP589CD1	1297			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	2	4	4	2	2	2	3	1	2	0	0	9	2	2	2	2	2	2	1	2	2	0	0	0	0	1	0	0	1	2	3	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	28	0		0		1	2	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.5	0.5	2	1.5	1.95	1		1.95	2.5	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP589CD1
2081	8976	NDAR_INVRP589CD1	1297			M	1600	Visit6	6	Phase 2	179	1	0	1	0	0	0	0	5	2	0	0	2	1	1	1	0	0	0	9	1	1	1	3	0	2	2	2	4	0	0	0	0	1	0	0	0	1	2	1	3	2	3	1	1	0	1	0	0	0	0	0	1	1	1	1	1	18	0		0		1	12	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	0	5	1.5	0	1.7142857	2	1.4			1.95	2.5	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP589CD1
2081	8976	NDAR_INVRP589CD1	1297			M	2800	Visit12	12	Phase 2	358	1	0	0	0	0	0	0	4	4	3	3	2	2	2	1	0	0	0	9	1	1	1	2	1	1	1	3	2	0	1	1	0	1	1	0	0	1	2	1	4	3	3	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0	1.5714285	1	1.7			1.95	2.5	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP589CD1
2081	8976	NDAR_INVRP589CD1	1297			M	5200	EndofPhase1_1a	5	Phase 1/1A	146	1	0	1	0	0	0	0	2	3	2	1	2	2	1	1	0	0	1	9	2	2	0	2	0	2	1	2	3	0	0	0	0	1	0	0	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	21	0		0		1	9	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	5	1.75	0.25	1.5714285	1.5	1.45		1	1.95	2.5	0.5	2	1.5	-0.5	-0.75	-0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP589CD1
2081	8976	NDAR_INVRP589CD1	1297			M	5800	EndofPhase2	15	Phase 2	441	1	0	0	0	0	0	0	3	2	2	2	2	2	2	1	0	0	0	9	2	2	2	2	1	2	2	3	3	1	1	1	0	1	1	0	1	1	2	1	4	3	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2	0	2.142857	2	1.75			1.95	2.5	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP589CD1
2081	8976	NDAR_INVRP589CD1	1297			M	6000	EndofPhase3	18	Phase 3	525	0	0	0	0	0	1	0	4	2	2	2	2	2	3	1	0	0	1	9	2	1	2	4	0	2	1	2	2	0	1	0	0	1	1	1	0	2	2	0	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.25	0.25	1.8571428	1.5	1.75			1.95	2.5	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP589CD1
2081	8976	NDAR_INVRP764XAF	1478			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	0	1	2	0	0	2	1	2	0	9	3	2	2	5	2	2	3	4	5	1	1	0	0	1	1	1	1	2	2	1	3	2	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	1.875	0.75	3.2857144	2.5	2.3	1		2.3	1.875	0.75	3.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP764XAF
2081	8976	NDAR_INVRP764XAF	1478			F	2800	Visit12	12	Phase 1/1A	345	0	0	0	1	0	0	0	2	0	2	0	2	0	2	1	1	2	1	9	2	2	4	3	2	1	2	4	5	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.125	1	3.142857	1.5	1.9		1	2.3	1.875	0.75	3.2857144	2.5	-0.4	-0.75	0.25	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP764XAF
2081	8976	NDAR_INVRP824KUD	2807			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	4	4	4	1	5	4	3	4	5	4	4	5	5	2	3	4	3	5	3	3	1	1	1	0	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.5	4.25	3.5714285	4	3.7142856	1		3.7142856	3.5	4.25	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP824KUD
2081	8976	NDAR_INVRP824KUD	2807			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	4	0	2	3	0	4	2	2	1	1	1	9	2	2	2	4	1	4	3	3	2	1	1	1	0	1	1	1	1	3	3	0	4	2		3	1	0	1	0	0	0	0	0	1	1	1	0	1	22	0		0		1	8	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.125	0.75	2.2857144	3.5	2.15			3.7142856	3.5	4.25	3.5714285	4	-1.5642858	-1.375	-3.5	-1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP824KUD
2081	8976	NDAR_INVRP824KUD	2807			F	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	9	5	6	6	5	5	5	6	4	4	4	4	5	5	2	5	4	3	4	4	5	1	1	1	0	1	1	1	1	2	1	1	3	2	2	1	1	1	0	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.428571	4	4.285714	3.5	4.55			3.7142856	3.5	4.25	3.5714285	4	0.8357143	1.9285715	-0.25	0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP824KUD
2081	8976	NDAR_INVRP824KUD	2807			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	5	2	3	3	3	3	5	2	2	4	9	6	4	0	5	2	3	4	5	5	1	1	1	1	1	1	1	1	2	1	1	4	1	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	6	3.4285715	2	3.857143	3.5	3.4736843		1	3.7142856	3.5	4.25	3.5714285	4	-0.24060151	-0.071428575	-2.25	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP824KUD
2081	8976	NDAR_INVRP989LBV	1134			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	1	0	0	2	1	0	0	2	0	0	0	9	0	1	0	2	0	4	1	0	5	0	0	1	0	1	1	1	1	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	0.75	0	1.1428572	2.5	0.95	1		0.95	0.75	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP989LBV
2081	8976	NDAR_INVRP989LBV	1134			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	0	0	0	2	1	0	0	2	0	0	0	9	0	2	0	0	0	4	2	1	4	1	1	1	0	1	1	1	1	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	1	0.625	0	1	3	0.9			0.95	0.75	0	1.1428572	2.5	-0.05	-0.125	0	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP989LBV
2081	8976	NDAR_INVRP989LBV	1134			M	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	3	0	0	0	2	0	0	3	0	0	0	9	0	0	0	0	0	2	1	2	4	0	0	0	0	1	0	0	0	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1	0	0.85714287	1.5	0.85			0.95	0.75	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP989LBV
2081	8976	NDAR_INVRP989LBV	1134			M	5200	EndofPhase1_1a	11	Phase 1/1A	309	0	1	0	0	0	0	0	3	0	0	0	2	0	0	3	0	0	0	9	0	2	0	0	0	3	1	2	4	0	0	1	0	1	1	0	1	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1	0	1.1428572	2	1		1	0.95	0.75	0	1.1428572	2.5	0.05	0.25	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP989LBV
2081	8976	NDAR_INVRP989LBV	1134			M	5800	EndofPhase2	13	Phase 2	365	0	1	0	0	0	0	0	2	0	0	0	2	0	0	3	0	0	0	9	0	0	0	0	0	2	1	2	3	0	0	0	0	1	0	0	0	1	3	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.875	0	0.71428573	1.5	0.75			0.95	0.75	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP989LBV
2081	8976	NDAR_INVRP989LBV	1134			M	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	2	0	0	0	2	0	0	3	0	0	0	9	0	0	0	2	0	2	1	2	3	1	0	1	0	1	0	0	0	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	1	0.875	0	1	1.5	0.85			0.95	0.75	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRP989LBV
2081	8976	NDAR_INVRR007EHH	2805			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	6	2	2	4	2	4	2	3	6	4	6	4	4	0	2	0	5	3	5	4	1	1	0	0	1	0	1	1	2	3	1	3	2	2	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		1	2	0		0		0	0	0	0	1	0	0	0	0	0	1	0	1	1	4	3.5	4.75	2.7142856	4	3.5238094	1		3.5238094	3.5	4.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR007EHH
2081	8976	NDAR_INVRR007EHH	2805			M	5200	EndofPhase1_1a	3	Phase 1/1A	110	0	0	0	1	0	0	0	6	6	2	2	4	2	4	2	5	6	2	5	3	4	1	3	2	5	3	5	4	1	1	0	0	1	0	1	1	2	3	1	3	2	2	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30			0		1	2	0		0	0	0	1	0	0	1		0	0	0	0	1	0	1	0	3	3.5	4.5	3.142857	4	3.6190476		1	3.5238094	3.5	4.75	2.7142856	4	0.0952381	0	-0.25	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR007EHH
2081	8976	NDAR_INVRR350XWG	2029			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	4	5	6	3	2	1	1	2	9	3	4	5	4	3	4	3	5	4	1	0	0	0	1	1	1	1	1	1	1	3	1	1	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	1	4	3.5	3.65	1		3.65	4.25	1	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR350XWG
2081	8976	NDAR_INVRR350XWG	2029			M	1600	Visit6	6	Phase 1/1A	157	1	0	0	0	0	0	0	6	4	4	4	4	4	4	4	4	4	2	4	2	2	2	2	3	4	4	4	4	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	4.25	3.5	2.7142856	4	3.5714285			3.65	4.25	1	4	3.5	-0.07857143	0	2.5	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR350XWG
2081	8976	NDAR_INVRR350XWG	2029			M	2800	Visit12	12	Phase 1/1A	339	1	0	0	0	0	0	0	6	0	2	2	2	2	2	1	0	0	0	9	2	2	4	4	3	3	3	5	6	1	0	1	1	1	1	0	1	1	1	1	3	4	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.125	0	3.7142856	3	2.45		1	3.65	4.25	1	4	3.5	-1.2	-2.125	-1	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR350XWG
2081	8976	NDAR_INVRR350XWG	2029			M	6000	EndofPhase3	18	Phase 3	486	1	0	0	0	0	0	0	0	0	3	3	2	2	2	0	0	2	2	9	4	2	2	2	2	4	3	2	4	1	0	0	1	1	1	0	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	2	0		0	1	0	0	0	0	0	0	1	0	1	0	1	1	1	1	1	1.5	1	2.5714285	3.5	2.05			3.65	4.25	1	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR350XWG
2081	8976	NDAR_INVRR355DDG	1699			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	5	2	3	5	4	4	2	1	2	1	9	1	4	0	4	3	5	4	4	5	1	1	1	0	1	1	1	1	2	1	1	4	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.75	1	3	4.5	3.2	1		3.2	3.75	1	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR355DDG
2081	8976	NDAR_INVRR355DDG	1699			M	5200	EndofPhase1_1a	2	Phase 1/1A	66	0	0	0	0	0	0	1	5	5	0	3	5	5	4	2	0	0	1	9	2	1	0	2	1	6	4	5	5	1	1	1	0	1	1	1	1	2	1	1	3	2	3	2	1	0	0	0	1	0	0	0	0	0	1	0	1	21	0		0		1	9	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.625	0.25	2.2857144	5	2.8		1	3.2	3.75	1	3	4.5	-0.4	-0.125	-0.75	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRR355DDG
2081	8976	NDAR_INVRT708URG	1713			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	4	4	4	4	6	2	3	4	4	4	3	2	4	6	5	6	4	4	6	1	0	1	1	1	1	1	1	2	1	1	2	2	3	2	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	3.5	3.75	4.285714	5	3.952381	1		3.952381	3.5	3.75	4.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT708URG
2081	8976	NDAR_INVRT708URG	1713			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	1	2	2	2	2	2	6	2	6	4	4	4	4	4	4	6	6	6	5	4	6	1	0	1	0	0	1	1	1	2	1	1	3	2	3	2	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	2.375	4.5	4.857143	5.5	3.9047618			3.952381	3.5	3.75	4.285714	5	-0.04761905	-1.125	0.75	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT708URG
2081	8976	NDAR_INVRT708URG	1713			M	2800	Visit12	12	Phase 1/1A	352	0	0	0	0	0	1	0	4	0	3	1	1	0	4	2	6	6	6	6	4	4	4	4	6	6	3	6	6	1	1	1	1	1	1	1	1	2	1	1	2	1	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	6	4.857143	4.5	3.9047618			3.952381	3.5	3.75	4.285714	5	-0.04761905	-1.625	2.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT708URG
2081	8976	NDAR_INVRT708URG	1713			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	0	0	2	2	3	4	2	4	6	2	0	0	1	9	2	4	4	6	6	6	5	4	4	1	0	1	1	1	0	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	0	6	3.125	0.25	4.285714	5.5	3.35		1	3.952381	3.5	3.75	4.285714	5	-0.60238093	-0.375	-3.5	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT708URG
2081	8976	NDAR_INVRT825DG0	2119			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	2	2	2	2	0	0	2	0	9	1	1	0	2	1	2	1	4	5	1	0	0	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	1	1	1	1	0	0	0	0	0	1	1	1	1	4	1.25	0.5	2	1.5	1.45	1		1.45	1.25	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT825DG0
2081	8976	NDAR_INVRT825DG0	2119			F	5200	EndofPhase1_1a	2	Phase 1/1A	66	0	0	0	0	0	1	0	2	2	2	2	2	1	2	0	0	0	0	9	0	0	0	1	0	3	1	0	4	1	2	2	2	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.625	0	0.71428573	2	1.1		1	1.45	1.25	0.5	2	1.5	-0.35	0.375	-0.5	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT825DG0
2081	8976	NDAR_INVRT825DG0	2119			F	5800	EndofPhase2	2	Phase 2	81	0	0	0	0	0	1	0	9	0	0	2	2	0	2	0	0	0	0	9	2	0	0	2	2	3	2	0	4	1	0	0	0	1	1	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.85714287	0	1.4285715	2.5	1.1052631			1.45	1.25	0.5	2	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT825DG0
2081	8976	NDAR_INVRT964RXC	1399			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	0	4	3	2	2	2	1	6	6	6	6	3	4	2	1	5	5	4	4	2	0	1	1	0	1	1	0	1	1	1	1	3	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	6	3	4.5	3.3809524	1		3.3809524	2.125	6	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT964RXC
2081	8976	NDAR_INVRT964RXC	1399			F	5200	EndofPhase1_1a	1	Phase 1/1A	116	0	0	0	0	0	0	1	0	0	2	0	1	1	2	0	6	2	4	6	2	4	4	0	5	4	3	4	5	1	1	1	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	0.75	4.5	3.4285715	3.5	2.6190476		1	3.3809524	2.125	6	3	4.5	-0.7619048	-1.375	-1.5	0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRT964RXC
2081	8976	NDAR_INVRU923XE7	2603			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	4	0	0	0	2	5	3	1	2	6	9	3	4	2	4	4	5	4	5	6	1	1	1	0	1	1	1	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2	2.25	4	4.5	3.1	1		3.1	2	2.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRU923XE7
2081	8976	NDAR_INVRU923XE7	2603			F	1600	Visit6	6	Phase 1/1A	167	1	0	0	0	0	0	0	4	4	0	2	2	2	2	3	6	4	6	4	2	5	0	4	6	6	5	5	6	1	1	1	0	1	1	1	1	1	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	5	4	5.5	3.7142856			3.1	2	2.25	4	4.5	0.6142857	0.375	2.75	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRU923XE7
2081	8976	NDAR_INVRU923XE7	2603			F	2800	Visit12	12	Phase 1/1A	335	1	0	0	0	0	0	0	2	4	0	0	2	3	2	3	5	4	6	5	2	4	1	4	6	6	4	4	6	1	1	0	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	5	3.857143	5	3.4761906			3.1	2	2.25	4	4.5	0.37619048	0	2.75	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRU923XE7
2081	8976	NDAR_INVRU923XE7	2603			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	1	0	0	0	0	0	0	0	2	4	0	2	2	3	0	4	4	6	4	1	2	2	4	6	6	4	4	6	1	1	0	0	1	1	1	1	1	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.625	4.5	3.5714285	5	3.142857		1	3.1	2	2.25	4	4.5	0.042857144	-0.375	2.25	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRU923XE7
2081	8976	NDAR_INVRV108KBU	2556			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	3	0	2	2	3	2	3	1	3	3	9	3	2	2	4	5	3	1	4	5	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.5	1.75	3.5714285	2	2.8	1		2.8	2.5	1.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRV108KBU
2081	8976	NDAR_INVRV108KBU	2556			M	1600	Visit6	6	Phase 1/1A	177	1	0	0	0	0	0	0	5	4	4	3	4	3	3	4	6	4	6	6	5	5	2	4	6	5	4	4	4	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	5.5	4.285714	4.5	4.3333335			2.8	2.5	1.75	3.5714285	2	1.5333333	1.25	3.75	0.71428573	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRV108KBU
2081	8976	NDAR_INVRV108KBU	2556			M	2800	Visit12	12	Phase 1/1A	344	1	0	0	0	0	0	0	5	5	4	4	3	4	4	4	1	1	2	3	4	4	2	4	2	4	5	4	3	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.125	1.75	3.2857144	4.5	3.4285715		1	2.8	2.5	1.75	3.5714285	2	0.62857145	1.625	0	-0.2857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRV108KBU
2081	8976	NDAR_INVRW270ZCY	2004			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	4	2	1	2	2	0	2	4	6	4	6	5	3	1	2	3	6	4	3	4	6	1	0	1	0	1	1	1	1	1	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	28	0		1	2	0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	4	2.125	5.25	3.5714285	3.5	3.3333333	1		3.3333333	2.125	5.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW270ZCY
2081	8976	NDAR_INVRW270ZCY	2004			F	1600	Visit6	6	Phase 3	155	0	1	0	1	0	0	0	5	0	2	1	2	3	2	5	6	5	6	4	3	4	3	4	5	4	2	4	6	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	5.25	4.142857	3	3.6190476			3.3333333	2.125	5.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW270ZCY
2081	8976	NDAR_INVRW270ZCY	2004			F	2800	Visit12	12	Phase 3	335	0	1	0	1	0	0	0	4	2	1	1	2	1	1	5	3	2	2	3	0	2	1	2	2	4	1	4	5	0	0	1	0	0	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	24	0		1	2	1	4	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	2.5	2.2857144	2.5	2.2857144			3.3333333	2.125	5.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW270ZCY
2081	8976	NDAR_INVRW270ZCY	2004			F	5200	EndofPhase1_1a	1	Phase 1/1A	41	0	1	0	1	0	0	0	6	0	4	4	2	1	2	3	5	3	6	3	4	1	2	4	2	4	3	4	6	1	1	0	1	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	4.25	3.2857144	3.5	3.2857144		1	3.3333333	2.125	5.25	3.5714285	3.5	-0.04761905	0.625	-1	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW270ZCY
2081	8976	NDAR_INVRW270ZCY	2004			F	5800	EndofPhase2	2	Phase 2	48	0	1	0	1	0	0	0	4	0	4	4	2	2	2	4	2	4	6	9	0	2	3	3	4	4	2	5	6	1	0	1	1	1	1	1	1	2	1	0	4	4	4	2	0	0	0	0	0	0	0	0					1	5	0		1	3	0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	3	3.2857144	3	3.15			3.3333333	2.125	5.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW270ZCY
2081	8976	NDAR_INVRW270ZCY	2004			F	6000	EndofPhase3	15	Phase 3	428	0	1	0	1	0	0	0	5	3	1	0	2	0	2	5	1	1	2	9	5	0	0	1	1	3	2	5	5	1	0	0	0	1	0	1	0	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	0	0	1	0	1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.25	1	2.4285715	2.5	2.2			3.3333333	2.125	5.25	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW270ZCY
2081	8976	NDAR_INVRW381BEH	2106			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	6	6	1	4	1	2	2	5	9	6	6	6	4	3	6	4	5	6	1	0	1	1	1	1	1	1	3	3	1	2	3	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4.5	2.25	5.142857	5	4.55	1		4.55	4.5	2.25	5.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW381BEH
2081	8976	NDAR_INVRW381BEH	2106			F	5200	EndofPhase1_1a	4	Phase 1/1A	92	0	0	0	0	0	0	1	6	6	6	4	5	2	4	4	0	3	6	9	5	5	6	6	3	6	4	6	6	1	0	1	0	1	1	0	1	3		1	4	3	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	4.625	2.25	5.285714	5	4.65		1	4.55	4.5	2.25	5.142857	5	0.1	0.125	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW381BEH
2081	8976	NDAR_INVRW400JTH	1783			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	4	4	3	4	5	4	2	4	4	4	9	3	4	4	5	5	6	5	4	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	3	4.285714	5.5	4.2	1		4.2	3.875	3	4.285714	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW400JTH
2081	8976	NDAR_INVRW400JTH	1783			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	1	0	0	0	5	1	1	2	4	3	4	2	4	4	4	3	4	4	3	5	4	6	3	5	6	1	0	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	4	2.75	3.75	4.428571	4.5	3.6666667			4.2	3.875	3	4.285714	5.5	-0.53333336	-1.125	0.75	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW400JTH
2081	8976	NDAR_INVRW400JTH	1783			F	2800	Visit12	12	Phase 1/1A	343	0	0	0	1	0	0	0	4	4	4	3	3	2	4	3	3	4	3	3	4	4	4	4	3	6	2	4	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.375	3.25	4	4	3.6190476			4.2	3.875	3	4.285714	5.5	-0.5809524	-0.5	0.25	-0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW400JTH
2081	8976	NDAR_INVRW400JTH	1783			F	5200	EndofPhase1_1a	15	Phase 1/1A	413	0	0	0	1	0	0	0	5	3	2	2	4	3	4	3	3	4	4	4	4	4	2	5	5	6	4	5	5	1	1	1	0	1	1	1	1	1	1	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	5	3.25	3.75	4.285714	5	3.857143		1	4.2	3.875	3	4.285714	5.5	-0.34285715	-0.625	0.75	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW400JTH
2081	8976	NDAR_INVRW540GAG	1789			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	0	2	4	4	4	1	0	0	0	9	2	4	2	4	4	3	3	5	4	1	1	1	1	1	1	1	0	2	3	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.375	0	3.5714285	3	2.9	1		2.9	3.375	0	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW540GAG
2081	8976	NDAR_INVRW540GAG	1789			M	5200	EndofPhase1_1a	1	Phase 1/1A	21	1	0	0	0	0	0	0	5	4	0	2	4	2	3	1	0	0	0	9	1	1	0	2	2	3	1	2	1	1	1	2	1	1	1	1	0	2	2	1	4	4	4	4	1	0	1	0	0	0	0	0	2	0	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0	1.2857143	2	1.7		1	2.9	3.375	0	3.5714285	3	-1.2	-0.75	0	-2.2857144	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW540GAG
2081	8976	NDAR_INVRW540GAG	1789			M	5800	EndofPhase2	6	Phase 2	170	1	0	0	0	0	0	0				0					0	0		9									0																	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1									2.9	3.375	0	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW540GAG
2081	8976	NDAR_INVRW963CR1	1525			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	3	2	2	2	2	2	1	5	4	4	3	2	3	4	3	5	6	3	2	4	1	1	0	1	1	1	1	0	2	1	1	3	2	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	4	3.2857144	4.5	3.1904762	1		3.1904762	2.375	4	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRW963CR1
2081	8976	NDAR_INVRX445HZ4	2581			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	3	2	4	6	6	4	0	6	6	9	3	4	4	6	6	3	3	5	6	1	1	2	1	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	3	4.857143	3	4.15	1		4.15	3.875	3	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRX445HZ4
2081	8976	NDAR_INVRX445HZ4	2581			F	1600	Visit6	6	Phase 2	145	0	0	0	0	0	0	1	9	4	5	4	3	4	6	1	0	5	6	9	4	6	6	6	6	4	4	6	6	1	1	1	1	1	1	1	1	3		1	3	2	3	4	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.857143	2.75	5.714286	4	4.5263157			4.15	3.875	3	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRX445HZ4
2081	8976	NDAR_INVRX445HZ4	2581			F	5200	EndofPhase1_1a	3	Phase 1/1A	75	0	0	0	0	0	0	1	9	6	5	5	5	5	5	1	5	4	6	6	4	5	5	4	5	5	4	6	6	1	1	1	1	1	1	1	1	3		1	4	1	2	4	0	0	0	0	0	0	0	0					1	15	1	15	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	4.571429	5.25	5	4.5	4.85		1	4.15	3.875	3	4.857143	3	0.7	0.6964286	2.25	0.14285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRX445HZ4
2081	8976	NDAR_INVRX445HZ4	2581			F	5800	EndofPhase2	6	Phase 2	145	0	0	0	0	0	0	1	9	4	5	4	3	4	6	1	0	5	6	9	4	6	6	6	6	4	4	6	6	1	1	1	1	1	1	1	1	3		1	3	2	3	4	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.857143	2.75	5.714286	4	4.5263157			4.15	3.875	3	4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRX445HZ4
2081	8976	NDAR_INVRY026GJK	2768			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	3	3	3	3	3	3	3	2	3	3	9	2	3	3	3	3	5	2	4	3	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3.125	2	3	3.5	3.05	1		3.05	3.125	2	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY026GJK
2081	8976	NDAR_INVRY026GJK	2768			M	5200	EndofPhase1_1a	5	Phase 1/1A	150	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	4	1	4	4	2	2	2	1	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1		0		0		1		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2	1.5	2.5714285	2.5	2.25		1	3.05	3.125	2	3	3.5	-0.8	-1.125	-0.5	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY026GJK
2081	8976	NDAR_INVRY242VU4	1741			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	3	3	3	4	4	5	2	2	3	4	9	2	2	2	4	2	6	4	4	4	1	1	1	1	1	0	1	1	2	1	1	3	3	3	4	1	0	0	1	0	0	0	0	1	1	0	0	1	28	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	2.25	2.857143	5	3.45	1		3.45	3.75	2.25	2.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY242VU4
2081	8976	NDAR_INVRY242VU4	1741			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	6	4	4	4	4	4	5	2	4	4	4	4	3	4	4	6	6	6	4	4	6	1	1	1	1	1	1	1	1	3	2	1	3	2	3	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.125	4	4.714286	5	4.3809524			3.45	3.75	2.25	2.857143	5	0.93095237	0.375	1.75	1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY242VU4
2081	8976	NDAR_INVRY242VU4	1741			M	2800	Visit12	12	Phase 1/1A	357	0	0	0	0	0	0	1	6	6	6	6	6	3	6	2	3	4	3	5	2	3	4	6	4	6	4	4	5	1	1	1	0	1	1	1	1	3	1	1	3	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	5.125	3.75	4	5	4.4761906			3.45	3.75	2.25	2.857143	5	1.0261905	1.375	1.5	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY242VU4
2081	8976	NDAR_INVRY242VU4	1741			M	5200	EndofPhase1_1a	18	Phase 1/1A	527	0	0	0	0	0	0	1	6	3	4	4	4	4	5	0	4	4	4	4	4	4	4	6	2	6	4	4	4	1	1	1	0	1	1	1	1	3	1	1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.75	4	4	5	4		1	3.45	3.75	2.25	2.857143	5	0.55	0	1.75	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY242VU4
2081	8976	NDAR_INVRY395DYP	1597			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	4	4	6	6	6	6	3	6	6	4	4	4	4	6	5	6	6	4	6	6	1	1	1	1	1	0	1	1	1		1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	4.625	5	5.285714	5	4.952381	1		4.952381	4.625	5	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY395DYP
2081	8976	NDAR_INVRY395DYP	1597			M	1600	Visit6	6	Phase 1/1A	177	1	0	1	0	0	0	0	0	1	2	1	2	0	1	1	6	3	4	3	3	3	2	3	5	6	5	4	6	1	1	1	1	1	1	1	1	2	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1	4	3.7142856	5.5	2.9047618			4.952381	4.625	5	5.285714	5	-2.047619	-3.625	-1	-1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY395DYP
2081	8976	NDAR_INVRY395DYP	1597			M	5200	EndofPhase1_1a	7	Phase 1/1A	212	1	0	1	0	0	0	0	0	1	2	1	2	0	1	1	0	0	0	9	3	3	3	2	4	6	4	5	5	1	1	1	1	1	1	1	0	1	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0	3.5714285	5	2.15		1	4.952381	4.625	5	5.285714	5	-2.802381	-3.625	-5	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY395DYP
2081	8976	NDAR_INVRY503YTT	2588			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	3	2	3	2	3	3	0	0	0	9	0	1	2	2	2	4	3	2	2	0	1	0	0	1	0	0	0	3	2	1	4	2	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	0	1.5714285	3.5	1.9	1		1.9	2.5	0	1.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY503YTT
2081	8976	NDAR_INVRY503YTT	2588			M	1600	Visit6	6	Phase 1/1A	163	0	0	0	0	0	0	1	1	0	0	1	1	0	2	0	0	0	0	9	1	1	3	2	0	4	3	3	5	1	1	0	1	0	1	0	2	3		0	4	1	4	4	1	0	1	0	0	0	0	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	1	0	1	1	1	0	7	0.625	0	2.142857	3.5	1.35			1.9	2.5	0	1.5714285	3.5	-0.55	-1.875	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY503YTT
2081	8976	NDAR_INVRY503YTT	2588			M	2800	Visit12	12	Phase 1/1A	324	0	0	0	0	0	1	0	2	1	1	1	1	1	2	1	0	0	0	9	0	0	0	2	0	1	2	4	6	1	1	2	2	0	1	1	0	3	3	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.25	0	1.7142857	1.5	1.25			1.9	2.5	0	1.5714285	3.5	-0.65	-1.25	0	0.14285715	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY503YTT
2081	8976	NDAR_INVRY503YTT	2588			M	5200	EndofPhase1_1a	15	Phase 1/1A	408	0	0	0	0	0	0	1	4	3	3	2	2	2	2	0	0	0	0	9	0	0	0	3	1	3	3	4	6	1	1	0	0	1	1	1	0	3	3	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	0	2	3	1.9		1	1.9	2.5	0	1.5714285	3.5	0	-0.25	0	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY503YTT
2081	8976	NDAR_INVRY623JA7	1808			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	1	2	2	0	1	3	0	0	0	9	3	2	2	2	0	5	3	5	5	2	2	2	2	1	1	0	2	1	1	0	4	4	4	1	1	0	1	0	0	0	0	0	1	1	1	1	1	11	0		0		1	19	0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	2	1.875	0	2.7142856	4	2.1	1		2.1	1.875	0	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY623JA7
2081	8976	NDAR_INVRY623JA7	1808			F	1600	Visit6	6	Phase 3	169	1	0	0	0	0	0	0	6	0	0	0	2	0	0	3	0	0	0	9	3	2	4	4	0	3	5	4	3	1	1	0	0	1	1	0	0	1	2	1	4	3	4	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.375	0	2.857143	4	1.95			2.1	1.875	0	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY623JA7
2081	8976	NDAR_INVRY623JA7	1808			F	5200	EndofPhase1_1a	1	Phase 1/1A	33	1	0	0	0	0	0	0	0	0	0	1	2	2	4	0	0	0	0	9	4	5	6	3	0	5	5	6	6	1	0	1	0	1	1	1	1	1	2	1	4	4	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	7	0		0		1	21	0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	1.125	0	4.285714	5	2.45		1	2.1	1.875	0	2.7142856	4	0.35	-0.75	0	1.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY623JA7
2081	8976	NDAR_INVRY623JA7	1808			F	5800	EndofPhase2	4	Phase 2	112	1	0	0	0	0	0	0	6	2	0	0	0	0	2	2	0	0	1	9	2	2	2	4	0	6	4	4	4	2	2	2	2	1	1	1	2	1	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	20	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.5	0.25	2.5714285	5	2.05			2.1	1.875	0	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY623JA7
2081	8976	NDAR_INVRY623JA7	1808			F	6000	EndofPhase3	11	Phase 3	299	1	0	0	0	0	0	0	0	0	0	2	2	0	0	2	0	0	0	9	2	2	2	3	0	5	4	4	3	0	0	0	0	1	1	0	0	1	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	23	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	0.75	0	2.2857144	4.5	1.55			2.1	1.875	0	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY623JA7
2081	8976	NDAR_INVRY734LZ3	1731			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	4	2	2	2	2	2	4	4	4	6	2	3	2	4	4	4	3	4	5	2	1	1	0	1	0	1	0	3	2	1	3	4	3	3	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	2.5	4.5	3.4285715	3.5	3.2857144	1		3.2857144	2.5	4.5	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY734LZ3
2081	8976	NDAR_INVRY734LZ3	1731			M	1600	Visit6	6	Phase 1/1A	149	0	0	0	0	0	0	1	6	0	2	2	4	3	4	3	2	4	6	4	3	3	2	4	4	4	2	2	5	1	0	1	0	1	1	1	1	1	1	0	4	4	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	5	3	4	3.2857144	3	3.2857144			3.2857144	2.5	4.5	3.4285715	3.5	0	0.5	-0.5	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY734LZ3
2081	8976	NDAR_INVRY734LZ3	1731			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	4	1	4	2	2	4	3	0	2	3	5	5	3	5	0	3	4	5	3	5	5	1	1	1	0	1	1	1	1	2	1	0	4	2	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.5	3.75	3.5714285	4	3.2380953			3.2857144	2.5	4.5	3.4285715	3.5	-0.04761905	0	-0.75	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY734LZ3
2081	8976	NDAR_INVRY734LZ3	1731			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	0	0	0	0	1	5	4	3	4	3	3	5	4	3	2	1	2	3	4	4	4	3	4	3	6	6	0	0	0	1	0	1	1	0	3	1	1	4	4	4	1	1	0	1	1	0	0	0	0	1	0	1	0	1	21	0		1	9	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	7	3.875	2	4.285714	3.5	3.6190476		1	3.2857144	2.5	4.5	3.4285715	3.5	0.33333334	1.375	-2.5	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRY734LZ3
2081	8976	NDAR_INVRZ581ADK	1393			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	4	4	5	5	6	6	5	4	5	4	9	5	4	4	6	5	3	3	4	4	0	0	0	1	1	1	0	1	1	1	1	4	4	3	4	1	0	1	1	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	6	4.875	3.25	4.571429	3	4.5	1		4.5	4.875	3.25	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ581ADK
2081	8976	NDAR_INVRZ581ADK	1393			M	1600	Visit6	6	Phase 1/1A	178	1	0	0	0	0	0	0	4	5	4	4	5	5	4	3	4	4	5	9	4	4	4	6	6	3	5	4	3	0	0	0	0	1	1	0	1	1	1	1	4	4	3	4	1	0	1	1	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	6	4.25	3.25	4.428571	4	4.3			4.5	4.875	3.25	4.571429	3	-0.2	-0.625	0	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ581ADK
2081	8976	NDAR_INVRZ581ADK	1393			M	2800	Visit12	12	Phase 1/1A	351	1	0	1	0	0	0	0	4	5	4	4	5	5	4	3	4	4	5	9	4	4	4	6	4	4	4	4	3	0	0	1	1	1	1	0	1	1	1	1	4	2	3	4	1	0	1	1	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	4	4.25	3.25	4.142857	4	4.2			4.5	4.875	3.25	4.571429	3	-0.3	-0.625	0	-0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ581ADK
2081	8976	NDAR_INVRZ581ADK	1393			M	4000	Visit18	18	Phase 1/1A	511	1	0	1	0	0	0	0	6	1	3	4	3	3	2	2	5	5	5	6	4	4	4	4	4	3	3	4	4	1	0	1	2	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	1	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3	5.25	4	3	3.7619047		1	4.5	4.875	3.25	4.571429	3	-0.7380952	-1.875	2	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ581ADK
2081	8976	NDAR_INVRZ825LE0	2406			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	0	4	5	3	4	1	1	0	1	9	2	4	5	2	3	2	2	6	6	1	0	1	0	1	1	1	1	2	2	0	4	1	1	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.375	0.5	4	2	2.65	1		2.65	2.375	0.5	4	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ825LE0
2081	8976	NDAR_INVRZ970GTH	2598			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	3	1	3	3	3	3	5	0	1	0	9	1	0	2	2	1	2	1	4	5	0	1	1	1	1	0	1	1	1	3	1	2	1	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	0.25	2.142857	1.5	2.3	1		2.3	3.375	0.25	2.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ970GTH
2081	8976	NDAR_INVRZ970GTH	2598			F	1600	Visit6	6	Phase 2	154	0	1	0	0	0	0	0	5	4	4	5	5	5	5	5	5	5	4	5	4	5	5	1	2	5	1	5	4	0	1	1	1	1	1	1	1	2	1	1	2	2	4	1	1	1	0	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	4.75	4.75	3.7142856	3	4.2380953			2.3	3.375	0.25	2.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ970GTH
2081	8976	NDAR_INVRZ970GTH	2598			F	5200	EndofPhase1_1a	3	Phase 1/1A	70	0	1	0	0	0	0	0	5	3	2	1	2	1	3	4	2	1	1	9	2	2	3	3	2	2	2	4	4	1	0	1	1	0	1	1	1	3	2	1	3	2	4	1	1	1	0	0	0	0	0	0	1	1	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.625	1	2.857143	2	2.45		1	2.3	3.375	0.25	2.142857	1.5	0.15	-0.75	0.75	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ970GTH
2081	8976	NDAR_INVRZ970GTH	2598			F	5800	EndofPhase2	12	Phase 2	323	0	1	0	0	0	0	0	5	4	1	4	3	2	2	5	2	3	2	9	2	3	4	5	2	5	2	5	5	1	0	0	0	1	1	1	1	2	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	3.25	1.75	3.7142856	3.5	3.3			2.3	3.375	0.25	2.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ970GTH
2081	8976	NDAR_INVRZ970GTH	2598			F	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	5	4	2	2	4	2	4	4	4	5	4	5	4	4	5	5	5	4	3	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	2	1	1	1	0	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	3.375	4.5	5	3.5	4.142857			2.3	3.375	0.25	2.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVRZ970GTH
2081	8976	NDAR_INVTA976EWX	2615			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	2	2	4	0	0	2	0	3	0	9	1	2	2	3	0	6	2	5	5	0	0	1	0	1	1	0	1	3		1	4	3	3	4	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2	0.75	2.5714285	4	2.2631578	1		2.2631578	2	0.75	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTA976EWX
2081	8976	NDAR_INVTA976EWX	2615			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	1	4	4	2	4	1	4	3	2	4	3	9	2	2	3	4	2	5	2	4	5	0	0	1	0	1	1	1	1	3		1	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2.875	2.25	3.142857	3.5	3.05			2.2631578	2	0.75	2.5714285	4	0.7868421	0.875	1.5	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTA976EWX
2081	8976	NDAR_INVTA976EWX	2615			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	9	1	3	0	1	0	2	1	1	0	0	9	1	2	1	3	0	6	3	5	5	1	1	1	1	1	1	1	1	3		1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.1428572	0.25	2.4285715	4.5	1.8421053			2.2631578	2	0.75	2.5714285	4	-0.42105263	-0.85714287	-0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTA976EWX
2081	8976	NDAR_INVTA976EWX	2615			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	4	1	3	2	1	2	2	0	4	1	9	2	2	2	3	5	5	2	5	5	1	0	1	1	1	1	1	1	3		1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.142857	1.25	3.4285715	3.5	2.6842105		1	2.2631578	2	0.75	2.5714285	4	0.42105263	0.14285715	0.5	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTA976EWX
2081	8976	NDAR_INVTB464CY0	1073			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	1	2	2	2	3	4	3	4	1	0	1	1	0	1	2	0	5	0	0	0	1	0	1	1	1	1	3	3	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.5	3	1.1428572	1	1.6190476	1		1.6190476	1.5	3	1.1428572	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB464CY0
2081	8976	NDAR_INVTB501WZJ	2235			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	4	6	6	4	2	1	6	6	9	2	2	5	4	4	4	4	5	4	1	1	1	0	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	2	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	5	3.25	3.7142856	4	4.35	1		4.35	5	3.25	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB501WZJ
2081	8976	NDAR_INVTB954BPP	2549			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	1	2	2	2	2	1	0	2	1	9	2	1	1	1	1	6	6	4	2	0	0	0	0	1	1	1	1	2	1	1	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	0.75	1.7142857	6	2.1	1		2.1	1.875	0.75	1.7142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB954BPP
2081	8976	NDAR_INVTB954BPP	2549			M	1600	Visit6	6	Phase 2	153	1	0	1	0	0	0	0	6	4	1	2	6	3	2	2	4	2	4	9	4	3	4	4	4	4	3	6	6	1	0	0	1	1	2	0	1	1	1	1	4	2	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	3.25	2.5	4.428571	3.5	3.7			2.1	1.875	0.75	1.7142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB954BPP
2081	8976	NDAR_INVTB954BPP	2549			M	2800	Visit12	12	Phase 2	324	1	0	1	0	0	0	0	5	6	4	6	6	6	4	1	0	0	0	9	5	3	4	5	3	6	4	5	6	1	1	1	1	1	1	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	4.75	0	4.428571	5	3.95			2.1	1.875	0.75	1.7142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB954BPP
2081	8976	NDAR_INVTB954BPP	2549			M	5200	EndofPhase1_1a	1	Phase 1/1A	23	1	0	0	0	0	0	0	4	2	2	3	3	2	2	2	0	2	2	9	3	2	2	2	3	6	6	5	3	0	0	0	0	1	1	0	1	1	2	0	4	4	3	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	1	2.857143	6	2.8		1	2.1	1.875	0.75	1.7142857	6	0.7	0.625	0.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB954BPP
2081	8976	NDAR_INVTB954BPP	2549			M	5400	EndofPhase1b	3	Phase 1B	76	1	0	1	0	0	0	0	6	5	1	1	4	2	2	3	2	2	1	9	2	2	0	3	0	5	2	4	4	0	0	0	0	1	1	0	1	1	1	1	2	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	2	3	1.25	2.142857	3.5	2.55			2.1	1.875	0.75	1.7142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB954BPP
2081	8976	NDAR_INVTB954BPP	2549			M	5800	EndofPhase2	18	Phase 2	503	1	0	1	0	0	0	0	5	6	6	6	6	4	4	4	2	3	4	9	6	6	5	6	5	5	6	4	6	1	1	1	1	1	1	1	1	2	2	1	3	2	3	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	5	5.125	2.25	5.428571	5.5	4.95			2.1	1.875	0.75	1.7142857	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTB954BPP
2081	8976	NDAR_INVTC102HJM	1697			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	0	2	2	1	1	0	0	1	1	9	1	1	2	4	1	4	2	3	5	1	1	0	0	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.5	0.5	2.4285715	3	1.85	1		1.85	1.5	0.5	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTC102HJM
2081	8976	NDAR_INVTC102HJM	1697			F	1600	Visit6	6	Phase 1/1A	168	1	0	0	0	0	0	0	2	0	2	1	2	1	1	2	0	1	1	2	2	2	1	2	1	5	3	6	3	1	1	1	0	1	1	1	1	1	2	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.375	1	2.4285715	4	1.9047619			1.85	1.5	0.5	2.4285715	3	0.054761905	-0.125	0.5	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTC102HJM
2081	8976	NDAR_INVTC102HJM	1697			F	5200	EndofPhase1_1a	11	Phase 1/1A	294	1	0	0	0	0	0	0	4	3	0	2	3	0	1	0	0	0	0	9	2	2	0	4	1	5	2	4	4	1	1	0	0	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	1	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0	2.4285715	3.5	1.85		1	1.85	1.5	0.5	2.4285715	3	0	0.125	-0.5	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTC102HJM
2081	8976	NDAR_INVTD401LZX	2028			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	0	0	0	1	0	0	3	1	2	5	9	2	2	1	1	0	3	1	2	2	1	0	0	0	1	0	1	0	3	3	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0.75	2	1.4285715	2	1.4	1		1.4	0.75	2	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD401LZX
2081	8976	NDAR_INVTD401LZX	2028			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	5	4	2	2	3	2	2	4	2	2	4	9	3	2	1	2	1	4	1	3	4	0	0	0	0	1	0	0	1	1	2	1	2	3	4	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3	2	2.2857144	2.5	2.65			1.4	0.75	2	1.4285715	2	1.25	2.25	0	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD401LZX
2081	8976	NDAR_INVTD401LZX	2028			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	5	4	4	3	4	3	4	4	4	4	5	4	3	4	3	4	3	4	3	4	5	0	0	1	0	0	1	1	1	1	1	1	3	2	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.875	4.25	3.7142856	3.5	3.857143			1.4	0.75	2	1.4285715	2	2.4571428	3.125	2.25	2.2857144	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD401LZX
2081	8976	NDAR_INVTD401LZX	2028			M	5200	EndofPhase1_1a	18	Phase 1/1A	530	0	1	0	0	0	0	0	4	3	2	3	3	4	2	3	3	2	5	4	2	4	2	2	3	2	1	3	2	1	0	1	0	1	1	0	1	3	2	1	2	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3	3	3.5	2.5714285	1.5	2.8095238		1	1.4	0.75	2	1.4285715	2	1.4095238	2.25	1.5	1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD401LZX
2081	8976	NDAR_INVTD430AFA	2001			F	400	Baseline	0	Pre-Rand	1	1	0	0	1	1	0	0	4	4	0	2	3	4	2	3	0	0	0	9	3	2	3	2	0	4	3	5	6	1	2	0	0	1	1	1	0	1	2	1	3	2	3	2	0	0	0	0	0	0	0	0					1	28	0		0		1	2	0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	4	2.75	0	3	3.5	2.5	1		2.5	2.75	0	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD430AFA
2081	8976	NDAR_INVTD430AFA	2001			F	2800	Visit12	12	Phase 2	344	1	0	0	0	0	0	0	6	5	0	0	4	5	2	0	0	0	0	9	2	1	0	1	0	5	1	2	4	0	0	1	0	1	1	1	1	3		1	4	2	3	4	0	0	0	0	0	0	0	0					1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	0	4	2.75	0	1.4285715	3	1.9			2.5	2.75	0	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD430AFA
2081	8976	NDAR_INVTD430AFA	2001			F	4000	Visit18	18	Phase 2	507	0	0	0	1	0	0	0	6	4	5	4	4	1	5	1	1	5	6	9	4	2	0	6	6	4	5	5	6	1	1	1	0	1	1	1	1	1	1	1	2	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	4	3.75	3	4.142857	4.5	4			2.5	2.75	0	3	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD430AFA
2081	8976	NDAR_INVTD510EY1	2535			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	6	6	6	6	5	4	6	6	5	4	5	4	6	5	6	6	5	5	1	0	1	1	0	1	2	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6	5.875	5.25	4.857143	6	5.428571	1		5.428571	5.875	5.25	4.857143	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD510EY1
2081	8976	NDAR_INVTD510EY1	2535			F	1600	Visit6	6	Phase 1/1A	169	0	1	0	1	0	0	0	6	6	6	6	5	6	6	6	6	6	6	6	5	6	0	6	6	6	6	6	6	0	0	1	1	1	1	1	1	1	2	1	3	2	2	1	1	1	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	5.875	6	5	6	5.6190476			5.428571	5.875	5.25	4.857143	6	0.1904762	0	0.75	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD510EY1
2081	8976	NDAR_INVTD510EY1	2535			F	2800	Visit12	12	Phase 1/1A	338	0	1	0	1	0	0	0	6	6	6	6	6	6	6	6	6	4	6	6	4	5	3	6	5	5	5	4	4	0	0	1	1	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	7	6	5.5	4.428571	5	5.285714			5.428571	5.875	5.25	4.857143	6	-0.14285715	0.125	0.25	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD510EY1
2081	8976	NDAR_INVTD510EY1	2535			F	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	1	0	1	0	0	0	4	2	4	3	5	4	5	6	4	4	5	6	4	4	2	5	5	4	4	5	4	1	0	1	0	1	1	1	1	1	2	1	4	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	4	4.125	4.75	4.142857	4	4.2380953		1	5.428571	5.875	5.25	4.857143	6	-1.1904762	-1.75	-0.5	-0.71428573	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTD510EY1
2081	8976	NDAR_INVTE625VPB	1770			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	1	0	0	4	2	6	4	2	6	6	4	2	2	2	9	4	4	4	6	2	5	3	5	6	1	0	1	1	1	1	1	1	1	1	1	4	1	2	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	1	6	4.25	1.5	4.428571	4	3.95	1		3.95	4.25	1.5	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE625VPB
2081	8976	NDAR_INVTE784XUQ	2276			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	2	2	0	2	0	0	0	0	9	5	2	1	2	0	4	4	0	2	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	0	1.7142857	4	1.4	1		1.4	1	0	1.7142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE784XUQ
2081	8976	NDAR_INVTE784XUQ	2276			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	4	4	0	2	2	2	2	0	2	3	6	9	2	3	2	2	2	3	2	2	3	0	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	2.75	2.2857144	2.5	2.4			1.4	1	0	1.7142857	4	1	1	2.75	0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE784XUQ
2081	8976	NDAR_INVTE784XUQ	2276			M	2800	Visit12	12	Phase 1/1A	347	1	0	0	0	0	0	0	6	0	4	2	2	4	2	2	0	4	6	9	2	4	3	6	4	4	3	4	4	1	0	1	1	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	2.5	3.857143	3.5	3.3			1.4	1	0	1.7142857	4	1.9	1.75	2.5	2.142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE784XUQ
2081	8976	NDAR_INVTE784XUQ	2276			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	1	0	0	0	0	0	0	6	0	0	4	2	2	5	2	4	4	6	4	2	5	2	4	4	5	4	4	5	0	1	1	1	1	1	1	1	1	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	4.5	3.7142856	4.5	3.5238094		1	1.4	1	0	1.7142857	4	2.1238096	1.625	4.5	2	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE784XUQ
2081	8976	NDAR_INVTE920FV2	2265			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	4	3	0	4	1	2	3	5	3	5	5	2	2	2	2	3	3	2	5	4	0	1	1	0	1	1	1	1	1	2	1	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	19	0		0		1	11	0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	2.625	4.5	2.857143	2.5	3.047619	1		3.047619	2.625	4.5	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE920FV2
2081	8976	NDAR_INVTE920FV2	2265			M	1600	Visit6	6	Phase 1B	174	0	1	0	0	0	0	0	6	4	4	3	3	3	5	4	0	0	1	9	4	4	3	5	2	3	3	5	4	1	1	0	0	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	4	4	0.25	3.857143	3	3.3			3.047619	2.625	4.5	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE920FV2
2081	8976	NDAR_INVTE920FV2	2265			M	2800	Visit12	12	Phase 1B	342	0	1	0	0	0	0	0	4	1	2	2	2	2	2	3	0	0	1	9	2	2	2	2	1	3	2	3	3	1	1	0	0	1	1	1	1	1	2	0	4	2	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	28	0		0		1	2	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.25	0.25	2.142857	2.5	1.95			3.047619	2.625	4.5	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE920FV2
2081	8976	NDAR_INVTE920FV2	2265			M	5200	EndofPhase1_1a	5	Phase 1/1A	146	0	1	0	0	1	0	0	5	2	2	2	2	2	2	4	0	0	1	9	3	2	3	3	1	3	2	4	3	2	1	1	0	1	1	1	1	1	1	1	4	3	3	1	1	1	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	4	2.625	0.25	2.7142856	2.5	2.3		1	3.047619	2.625	4.5	2.857143	2.5	-0.74761903	0	-4.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE920FV2
2081	8976	NDAR_INVTE920FV2	2265			M	5400	EndofPhase1b	18	Phase 1B	517	0	0	0	0	0	1	0	4	4	4	4	4	4	4	5	4	4	3	5	4	4	4	4	4	5	3	4	4	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	1	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	1	1	1	1	1	1	1	1	6	4.125	4	4	4	4.047619			3.047619	2.625	4.5	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTE920FV2
2081	8976	NDAR_INVTF185EEF	2145			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	1	4	1	0	2	2	0	1	3	1	9	3	3	2	3	1	2	2	3	3	0	1	1	0	1	1	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	5	1.4285715	1.25	2.5714285	2	1.9473684	1		1.9473684	1.4285715	1.25	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTF185EEF
2081	8976	NDAR_INVTF185EEF	2145			F	1600	Visit6	6	Phase 1/1A	178	0	0	0	0	0	1	0	1	2	4	2	1	3	2	0	2	3	2	9	2	2	3	2	2	1	2	1	1	1	0	1	0	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.875	1.75	1.8571428	1.5	1.9		1	1.9473684	1.4285715	1.25	2.5714285	2	-0.047368422	0.44642857	0.5	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTF185EEF
2081	8976	NDAR_INVTF243FFY	2777			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	4	3	2	2	2	4	0	0	0	9	0	2	4	5	1	3	2	4	6	0	1	2	0	1	2	0	2	3		1	2	3	4	1	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.25	0	3.142857	2.5	2.65	1		2.65	3.25	0	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTF243FFY
2081	8976	NDAR_INVTF243FFY	2777			M	5200	EndofPhase1_1a	3	Phase 1/1A	112	0	0	0	0	0	0	1	3	2	2	3	3	2	3	2	0	0	0	9	0	2	3	3	1	4	3	2	6	1	1	1	0	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0	2.4285715	3.5	2.2		1	2.65	3.25	0	3.142857	2.5	-0.45	-0.75	0	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTF243FFY
2081	8976	NDAR_INVTG142GEA	1437			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	2	5	3	2	2	2	4	2	2	4	3	2	4	5	4	4	3	5	5	1	0	0	1	1	0	1	1	1	2	0	4	2	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	6	3	3	4	3.5	3.3809524	1		3.3809524	3	3	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG142GEA
2081	8976	NDAR_INVTG142GEA	1437			M	1600	Visit6	6	Phase 1/1A	175	0	1	0	0	0	0	0	3	2	1	2	2	3	5	3	0	2	5	9	2	3	4	4	5	3	3	5	3	1	0	0	0	1	0	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.625	1.75	3.7142856	3	3			3.3809524	3	3	4	3.5	-0.3809524	-0.375	-1.25	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG142GEA
2081	8976	NDAR_INVTG142GEA	1437			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	6	4	4	4	4	1	3	5	5	3	5	3	4	4	4	2	4	4	4	5	5	1	1	0	1	1	1	1	1	1	1	1	4	2	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.875	4	4	4	3.952381			3.3809524	3	3	4	3.5	0.5714286	0.875	1	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG142GEA
2081	8976	NDAR_INVTG142GEA	1437			M	5200	EndofPhase1_1a	18	Phase 1/1A	496	0	1	0	0	0	0	0	6	4	4	5	4	3	5	5	5	5	5	5	5	4	4	5	5	3	2	5	5	1	0	1	0	1	1	1	1	1	2	0	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.5	5	4.714286	2.5	4.4761906		1	3.3809524	3	3	4	3.5	1.0952381	1.5	2	0.71428573	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG142GEA
2081	8976	NDAR_INVTG213HAZ	2236			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	3	2	4	4	1	2	0	1	1	0	9	2	4	5	6	2	1	4	5	5	0	1	1	1	1	1	0	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	2	2.25	0.5	4.142857	2.5	2.7	1		2.7	2.25	0.5	4.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG213HAZ
2081	8976	NDAR_INVTG828ZF9	1801			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	0	2	2	2	1	0	0	1	9	2	2	0	1	0	3	2	3	2	0	0	0	0	1	1	1	1	1	3	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	4	1.375	0.25	1.4285715	2.5	1.35	1		1.35	1.375	0.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG828ZF9
2081	8976	NDAR_INVTG828ZF9	1801			M	1600	Visit6	6	Phase 2	177	1	0	0	0	0	0	0	3	3	2	2	2	2	2	2	0	0	4	9	2	0	0	2	0	3	1	4	4	0	0	1	0	1	1	0	0	1	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	3	2.25	1	1.7142857	2	1.9			1.35	1.375	0.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG828ZF9
2081	8976	NDAR_INVTG828ZF9	1801			M	2800	Visit12	12	Phase 2	352	1	0	0	0	0	0	0	5	4	4	3	2	5	4	5	6	6	6	4	2	4	2	4	6	3	1	4	4	0	1	1	0	1	0	1	1	1	1	1	3	2	4	1	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	5	4	5.5	3.7142856	2	4			1.35	1.375	0.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG828ZF9
2081	8976	NDAR_INVTG828ZF9	1801			M	5200	EndofPhase1_1a	4	Phase 1/1A	121	1	0	0	0	0	0	0	3	2	2	2	2	2	2	1	1	1	1	9	2	1	0	2	0	3	2	2	3	0	0	0	0	1	1	0	1	1	2	0	4	1	4	1	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	0.75	1.4285715	2.5	1.7		1	1.35	1.375	0.25	1.4285715	2.5	0.35	0.625	0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG828ZF9
2081	8976	NDAR_INVTG828ZF9	1801			M	5800	EndofPhase2	17	Phase 2	483	0	1	0	0	0	0	0	6	5	3	5	4	4	4	4	0	3	4	9	2	3	1	2	1	2	2	4	4	0	0	1	0	1	1	1	1	1	2	1	2	4	2	1	1	1	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	4.375	1.75	2.4285715	2	3.15			1.35	1.375	0.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG828ZF9
2081	8976	NDAR_INVTG828ZF9	1801			M	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	4	2	0	0	2	2	2	3	0	2	2	9	0	2	0	4	0	1	2	3	3	1	0	1	0	1	1	1	1	2	2	1	2	4	4	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.875	1	1.7142857	1.5	1.7			1.35	1.375	0.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTG828ZF9
2081	8976	NDAR_INVTH044CDG	2548			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	0	0	0	2	0	0	0	0	0	0	9	0	0	0	4	0	6	6	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	1	0	2.2857144	6	1.8	1		1.8	1	0	2.2857144	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH044CDG
2081	8976	NDAR_INVTH044CDG	2548			M	5200	EndofPhase1_1a	4	Phase 1/1A	141	0	0	0	0	0	0	1	4	2	2	2	2	2	3	2	0	0	0	9	2	0	2	2	1	5	3	2	3	1	1	1	1	1	1	1	1	1	1	1	4	3	4	4	1	0	0	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0	1.7142857	4	1.95		1	1.8	1	0	2.2857144	6	0.15	1.375	0	-0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH044CDG
2081	8976	NDAR_INVTH171FTE	1454			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	6	6	6	4	6	3	5	2	1	1	1	9	4	4	3	5	4	1	2	5	3	1	1	0	1	1	0	1	0	1	1	1	3	2	3	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	0.75	4	1.5	3.6	1		3.6	4.75	0.75	4	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH171FTE
2081	8976	NDAR_INVTH171FTE	1454			F	1600	Visit6	6	Phase 1/1A	168	0	0	1	0	0	0	0	4	3	2	4	2	1	2	1	3	2	1	2	1	2	4	3	4	5	5	2	6	1	1	0	0	1	1	0	1	1	1	1	3	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	2	3.142857	5	2.8095238			3.6	4.75	0.75	4	1.5	-0.7904762	-2.375	1.25	-0.85714287	3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH171FTE
2081	8976	NDAR_INVTH171FTE	1454			F	2800	Visit12	12	Phase 2	336	0	0	1	0	0	0	0	4	1	4	4	2	2	3	1	1	2	1	9	0	2	4	3	2	4	4	3	2	1	1	1	2	1	0	0	1	1	1	1	3	4	4	4	1	0	0	1	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	1	2.2857144	4	2.45			3.6	4.75	0.75	4	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH171FTE
2081	8976	NDAR_INVTH171FTE	1454			F	4000	Visit18	18	Phase 3	502	0	0	1	0	0	0	0	6	3	3	1	1	0	0	1	0	0	0	9	0	0	0	0	0	4	2	0	0	1	0	0	0	1	0	0	0	1	1	1	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	0	0	3	1.05			3.6	4.75	0.75	4	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH171FTE
2081	8976	NDAR_INVTH171FTE	1454			F	5200	EndofPhase1_1a	7	Phase 1/1A	208	0	0	1	0	0	0	0	6	5	6	4	4	1	5	2	1	1	1	9	1	2	3	4	2	4	4	4	3	1	1	1	0	1	1	1	2	1	1	1	3	3	3	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.125	0.75	2.7142856	4	3.15		1	3.6	4.75	0.75	4	1.5	-0.45	-0.625	0	-1.2857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH171FTE
2081	8976	NDAR_INVTH171FTE	1454			F	5800	EndofPhase2	13	Phase 2	364	0	0	1	0	0	0	0	5	5	4	4	2	3	5	2	2	1	1	9	2	2	5	5	4	4	4	5	4	1	1	0	0	1	0	0	1	1	1	1	3	3	3	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	1	3.857143	4	3.45			3.6	4.75	0.75	4	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH171FTE
2081	8976	NDAR_INVTH370TJA	2200			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	2	2	2	4	6	1	4	5	5	3	5	6	6	3	5	3	3	6	6	1	0	1	0	0	1	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	4	2.375	4.25	5.285714	3	3.7619047	1		3.7619047	2.375	4.25	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH370TJA
2081	8976	NDAR_INVTH370TJA	2200			M	1600	Visit6	6	Phase 3	211	1	0	1	0	0	0	0	4	0	0	1	2	1	2	1	4	5	6	1	4	6	6	2	5	4	2	5	6	0	0	1	0	1	1	1	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	1	0	0	0	0	0	0	0	1	1	1	0	2	1.375	4	4.857143	3	3.1904762			3.7619047	2.375	4.25	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH370TJA
2081	8976	NDAR_INVTH370TJA	2200			M	2800	Visit12	12	Phase 3	363	1	0	1	0	0	0	0	1	0	1	3	2	6	2	0	5	6	6	3	5	6	6	1	5	4	3	4	6	1	1	1	0	1	0	1	0	2	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	1	0	0	0	0	0	1	0	1	1	3	1.875	5	4.714286	3.5	3.5714285			3.7619047	2.375	4.25	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH370TJA
2081	8976	NDAR_INVTH370TJA	2200			M	5200	EndofPhase1_1a	1	Phase 1/1A	8	1	0	1	0	0	0	0	6	0	1	2	2	3	6	1	4	4	5	3	5	5	6	2	3	3	2	6	6	1	0	1	0	0	1	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.625	4	4.714286	2.5	3.5714285		1	3.7619047	2.375	4.25	5.285714	3	-0.1904762	0.25	-0.25	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH370TJA
2081	8976	NDAR_INVTH370TJA	2200			M	5800	EndofPhase2	2	Phase 2	19	1	0	1	0	0	0	0	4	0	0	1	2	3	6	1	4	4	6	2	5	6	6	3	4	3	2	4	6	1	0	1	0	0	1	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.125	4	4.857143	2.5	3.4285715			3.7619047	2.375	4.25	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH370TJA
2081	8976	NDAR_INVTH370TJA	2200			M	6000	EndofPhase3	18	Phase 3	517	1	0	1	0	0	0	0	1	0	3	3	2	6	2	1	4	3	6	1	6	6	6	2	5	2	2	4	6	1	0	1	1	0	1	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	1	0	1	0	0	0	0	0	1	0	1	1	4	2.25	3.5	5	2	3.3809524			3.7619047	2.375	4.25	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH370TJA
2081	8976	NDAR_INVTH715NPJ	1669			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	1	0	1	4	6	6	6	5	6	4	1	5	4	9	1	2	4	4	4	4	5	5	3	1	1	1	0	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	4.75	2.5	3.2857144	4.5	4																																																																																																																																	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH715NPJ
2081	8976	NDAR_INVTH715NPJ	1669			F	2800	Visit12	12	Phase 1/1A	351	0	0	0	0	0	1	0	2	3	5	4	4	3	4	2	0	1	2	9	4	4	4	5	6	2	3	4	6	1	1	1	1	1	1	1	1	3	1	1	4	3	2	4	1	0	0	0	0	1	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.375	0.75	4.714286	2.5	3.4																																																																																																																																	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH715NPJ
2081	8976	NDAR_INVTH715NPJ	1669			F	5200	EndofPhase1_1a	18	Phase 1/1A	510	0	0	0	0	0	1	0	5	5	5	5	5	4	5	1	1	4	4	9	4	5	4	5	6	4	4	6	6	1	1	0	1	1	1	1	1	3		1	3	3	3	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	4.375	2.25	5.142857	4	4.4		1																																																																																																																															Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH715NPJ
2081	8976	NDAR_INVTH861CHX	1540			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	5	4	6	6	6	4	0	0	1	0	9	4	5	1	6	2	3	2	4	3	1	0	1	0	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	22	1	8	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4.375	0.25	3.5714285	2.5	3.3	1		3.3	4.375	0.25	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH861CHX
2081	8976	NDAR_INVTH861CHX	1540			F	1600	Visit6	6	Phase 2	172	0	0	0	0	0	1	0	5	4	5	4	5	6	4	4	0	3	0	9	2	4	1	4	1	3	3	5	4	1	1	1	0	1	1	1	1	3	2	1	2	1	2	1	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.625	0.75	3	3	3.35			3.3	4.375	0.25	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH861CHX
2081	8976	NDAR_INVTH861CHX	1540			F	5200	EndofPhase1_1a	1	Phase 1/1A	19	0	0	0	0	0	1	0	5	5	1	5	5	5	2	0	0	0	0	9	2	0	0	5	2	2	3	2	2	1	1	0	0	1	1	1	1	1	2	1	3	1	3	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	0	1.8571428	2.5	2.3		1	3.3	4.375	0.25	3.5714285	2.5	-1	-0.875	-0.25	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH861CHX
2081	8976	NDAR_INVTH861CHX	1540			F	5800	EndofPhase2	12	Phase 2	326	0	0	0	0	0	1	0	4	0	2	2	1	0	1	0	0	0	0	9	1	2	0	0	0	3	1	2	2	1	0	1	0	1	1	1	1	3	3	0	4	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	2	1.25	0	1	2	1.05			3.3	4.375	0.25	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH861CHX
2081	8976	NDAR_INVTH861CHX	1540			F	6000	EndofPhase3	15	Phase 3	417	0	0	1	0	0	0	0	5	0	0	2	2	0	1	0	0	1	1	9	2	0	0	2	1	1	2	2	2	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	13	1	14	0		0		1	3	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.5	1.2857143	1.5	1.2			3.3	4.375	0.25	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH861CHX
2081	8976	NDAR_INVTH945VDB	2648			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	0	2	0	0	0	0	0	0	9	1	1	1	1	0	3	3	1	1	1	1	0	1	1	2	2	2	2	2	0	4	4	4	4	1	0	0	1	0	0	1	0	1	1	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	0.75	0	0.85714287	3	0.9	1		0.9	0.75	0	0.85714287	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH945VDB
2081	8976	NDAR_INVTH945VDB	2648			F	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	1	1	0	9	6	2	2	2	0	5	2	6	6	1	1	1	0	1	1	1	1	2	2	0	4	4	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0.5	3.4285715	3.5	2.35			0.9	0.75	0	0.85714287	3	1.45	1	0.5	2.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH945VDB
2081	8976	NDAR_INVTH945VDB	2648			F	5200	EndofPhase1_1a	8	Phase 1/1A	224	1	0	0	0	0	0	0	4	2	0	2	2	2	2	2	0	2	0	9	2	2	0	4	2	3	2	4	4	0	0	1	0	1	1	1	1	1	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.5	2.5714285	2.5	2.05		1	0.9	0.75	0	0.85714287	3	1.15	1.25	0.5	1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH945VDB
2081	8976	NDAR_INVTH945VDB	2648			F	5800	EndofPhase2	12	Phase 2	344	1	0	0	0	0	0	0	2	0	0	2	2	2	2	0	2	2	0	9	2	2	0	2	2	3	2	4	2	0	0	1	0	1	1	1	1	1	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	24	0		0		1	6	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	1	2	2.5	1.65			0.9	0.75	0	0.85714287	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH945VDB
2081	8976	NDAR_INVTH949LW5	2175			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	0	0	0	0	1	1	0	0	0	9	2	0	1	0	0	3	2	1	2	0	0	0	0	0	0	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	18	0		0		1	12	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	0.375	0	0.85714287	2.5	0.7	1		0.7	0.375	0	0.85714287	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH949LW5
2081	8976	NDAR_INVTH949LW5	2175			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	0	0	0	1	2	2	2	1	0	1	0	9	2	2	3	2	0	3	2	2	4	1	1	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1	0.25	2.142857	2.5	1.45			0.7	0.375	0	0.85714287	2.5	0.75	0.625	0.25	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH949LW5
2081	8976	NDAR_INVTH949LW5	2175			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	9	0	0	1	0	0	3	3	2	3	1	1	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.125	0	0.85714287	3	0.65			0.7	0.375	0	0.85714287	2.5	-0.05	-0.25	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH949LW5
2081	8976	NDAR_INVTH949LW5	2175			M	5200	EndofPhase1_1a	18	Phase 1/1A	501	0	0	0	0	0	0	1	0	0	1	1	0	0	1	1	0	0	0	9	2	1	2	0	0	3	3	2	2	1	1	1	0	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.5	0	1.2857143	3	0.95		1	0.7	0.375	0	0.85714287	2.5	0.25	0.125	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTH949LW5
2081	8976	NDAR_INVTJ006LZN	2619			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	6	6	5	1	4	0	2	0	9	4	4	3	2	4	6	6	4	5	1	1	1	1	1	1	1	1	1	2	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5	0.5	3.7142856	6	4	1		4	5	0.5	3.7142856	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ006LZN
2081	8976	NDAR_INVTJ188JGA	2834			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	0	2	0	0	0	0	0	0	9	0	0	2	2	0	2	1	2	2	2	2	2	2	1	2	2	2	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	0.75	0	1.1428572	1.5	0.85	1		0.85	0.75	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ188JGA
2081	8976	NDAR_INVTJ188JGA	2834			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	4	5	0	4	2	5	6	2	0	0	0	9	0	0	0	6	0	2	1	4	4	0	0	0	0	1	1	1	1	1	1	1	2	3	2	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	0	2	1.5	2.25			0.85	0.75	0	1.1428572	1.5	1.4	2.75	0	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ188JGA
2081	8976	NDAR_INVTJ188JGA	2834			M	5200	EndofPhase1_1a	8	Phase 1/1A	225	1	0	0	0	0	0	0	4	2	0	2	2	0	2	0	0	0	0	9	2	2	0	4	0	3	1	4	4	0	1	0	0	1	1	1	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.5	0	2.2857144	2	1.6		1	0.85	0.75	0	1.1428572	1.5	0.75	0.75	0	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ188JGA
2081	8976	NDAR_INVTJ188JGA	2834			M	5400	EndofPhase1b	12	Phase 1B	340	1	0	0	0	0	0	0	4	2	0	2	2	0	2	2	0	0	0	9	2	2	2	4	0	3	1	4	5	0	0	0	0	1	0	0	1	1	1	0	4	1	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	0	2.7142856	2	1.85			0.85	0.75	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ188JGA
2081	8976	NDAR_INVTJ188JGA	2834			M	5800	EndofPhase2	14	Phase 2	396	1	0	0	0	0	0	0	6	4	0	4	4	2	4	4	0	0	0	9	0	2	2	6	0	3	1	4	6	0	0	0	0	1	1	1	1	1	1	1	4	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	0	2.857143	2	2.6			0.85	0.75	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ188JGA
2081	8976	NDAR_INVTJ188JGA	2834			M	6000	EndofPhase3	18	Phase 3	512	1	0	0	0	0	0	0	4	2	0	2	2	2	2	2	0	0	0	9	0	2	0	4	0	1	0	4	4	0	0	0	0	1	1	1	1	2	1	0	4	4	4	3	1	0	1	0	0	0	0	0	1	1	1	0	1	25	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	0	2	0.5	1.55			0.85	0.75	0	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ188JGA
2081	8976	NDAR_INVTJ200BRH	2217			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	0	2	2	0	2	2	6	6	6	5	3	3	4	5	6	4	3	4	3	1	2	1	2	1	2	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	5	1.5	5.75	4	3.5	3.3333333	1		3.3333333	1.5	5.75	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ200BRH
2081	8976	NDAR_INVTJ913FZB	2152			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	0	1	4	1	2	0	3	4	3	3	4	5	4	2	4	4	2	3	0	5	0	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	4	0		1	26	0		2	2	2	0	1	0	0	0	1	1	1	1	1	1	1	1	2	2	3.5	3.4285715	2.5	2.8095238	1		2.8095238	2	3.5	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTJ913FZB
2081	8976	NDAR_INVTK224VJP	1694			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	0	3	2	0	4	4	1	4	3	9	2	4	2	4	4	5	3	3	5	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	23	0		0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	2	3.4285715	4	3.05	1		3.05	2.625	2	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK224VJP
2081	8976	NDAR_INVTK224VJP	1694			M	1600	Visit6	6	Phase 1/1A	169	1	0	1	0	0	0	0	0	2	0	0	2	6	5	4	1	0	0	9	2	2	0	3	2	4	4	4	4	0	0	1	1	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	7	2.375	0.25	2.4285715	4	2.25			3.05	2.625	2	3.4285715	4	-0.8	-0.25	-1.75	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK224VJP
2081	8976	NDAR_INVTK224VJP	1694			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	1	0	2	2	2	2	2	0	6	2	1	1	0	9	2	2	2	2	2	3	3	0	2	0	0	2	0	1	1	1	1	3		0	4	3	3	3	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	2.25	0.5	1.7142857	3	1.9			3.05	2.625	2	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK224VJP
2081	8976	NDAR_INVTK224VJP	1694			M	5200	EndofPhase1_1a	9	Phase 1/1A	254	1	0	1	0	0	0	0	4	0	2	1	2	2	2	1	0	0	0	9	2	2	2	4	2	4	2	4	1	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.75	0	2.4285715	3	1.85		1	3.05	2.625	2	3.4285715	4	-1.2	-0.875	-2	-1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK224VJP
2081	8976	NDAR_INVTK224VJP	1694			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	0	1	0	0	2	4	4	3	6	4	5	0	0	0	9	3	2	3	5	1	4	4	4	1	0	1	2	0	1	0	1	2	3	2	1	3	1	2	2	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	1	0	0	0	1	0	0	0	0	0	1	1	0	0	5	3.5	0	2.7142856	4	2.75			3.05	2.625	2	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK224VJP
2081	8976	NDAR_INVTK504DTZ	1392			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	3	3	2	2	2	3	0	2	1	1	9	4	2	3	4	1	2	1	3	4	2	2	2	0	1	0	2	2	3	2	1	2	3	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1	3	1.5	2.25	1		2.25	2.125	1	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK504DTZ
2081	8976	NDAR_INVTK504DTZ	1392			M	1600	Visit6	6	Phase 1/1A	166	0	0	0	0	0	1	0	1	2	2	1	2	2	2	0	0	2	5	9	2	2	0	3	0	2	2	4	4	0	1	0	0	1	0	1	1	3	1	1	4	4	3	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	1.75	2.142857	2	1.9			2.25	2.125	1	3	1.5	-0.35	-0.625	0.75	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK504DTZ
2081	8976	NDAR_INVTK504DTZ	1392			M	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	1	0	5	3	2	2	2	2	4	0	0	4	6	9	4	5	2	4	2	2	3	6	5	0	0	0	0	1	1	1	1	2	1	0	4	2	4	4	1	0	0	0	0	0	0	1	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2.5	2.5	4	2.5	3.15			2.25	2.125	1	3	1.5	0.9	0.375	1.5	1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK504DTZ
2081	8976	NDAR_INVTK504DTZ	1392			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	2	1	2	2	1	2	5	0	3	4	6	9	4	4	3	4	5	3	3	4	6	1	1	0	0	1	1	1	0	2	2	1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.875	3.25	4.285714	3	3.2		1	2.25	2.125	1	3	1.5	0.95	-0.25	2.25	1.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTK504DTZ
2081	8976	NDAR_INVTL188VAX	2078			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	1	0	2	2	2	2	5	1	1	1	9	1	2	2	2	1	4	3	4	5	1	1	1	0	1	1	1	1	1	1	0	4	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	0.75	2.4285715	3.5	2.3	1		2.3	2.375	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL188VAX
2081	8976	NDAR_INVTL188VAX	2078			F	1600	Visit6	6	Phase 2	169	0	1	1	0	0	0	0	6	0	0	2	2	2	4	4	2	2	0	9	0	2	0	5	0	6	2	4	4	1	0	1	0	1	1	0	1	1	1	0	4	4	4	1	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1	2.142857	4	2.35			2.3	2.375	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL188VAX
2081	8976	NDAR_INVTL188VAX	2078			F	2800	Visit12	12	Phase 2	337	0	1	0	1	0	0	0	5	0	0	2	5	1	2	4	2	3	4	9	1	1	0	2	1	6	3	4	4	0	0	1	0	1	1	0	1	1	1	0	4	3	3	1	1	1	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	2.25	1.8571428	4.5	2.5			2.3	2.375	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL188VAX
2081	8976	NDAR_INVTL188VAX	2078			F	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	1	0	1	0	0	0	5	0	0	2	2	2	2	4	4	3	1	3	1	2	2	3	1	6	1	4	5	0	0	1	0	1	1	0	1	1	1	0	4	4	4	1	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.125	2.75	2.5714285	3.5	2.5238094		1	2.3	2.375	0.75	2.4285715	3.5	0.22380953	-0.25	2	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL188VAX
2081	8976	NDAR_INVTL188VAX	2078			F	5800	EndofPhase2	18	Phase 2	512	0	1	0	0	0	0	0	6	0	0	1	2	2	3	4	0	4	0	9	0	0	0	4	0	6	2	5	6	0	0	1	0	1	1	0	1	2	1	1	2	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	1	2.142857	4	2.25			2.3	2.375	0.75	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL188VAX
2081	8976	NDAR_INVTL217WDX	1186			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	4	2	1	2	4	2	2	4	2	9	4	3	3	4	4	4	4	5	6	0	0	0	0	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	1	0	1	0	0	0	0	0	1	1	1	1	5	2.375	2	4.142857	4	3.2	1		3.2	2.375	2	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL217WDX
2081	8976	NDAR_INVTL217WDX	1186			M	1600	Visit6	6	Phase 3	160	0	0	0	0	0	1	0	0	0	2	0	1	1	2	2	6	4	5	4	4	4	2	4	5	5	4	3	3	1	1	2	0	0	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1	4.75	3.5714285	4.5	2.9047618			3.2	2.375	2	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL217WDX
2081	8976	NDAR_INVTL217WDX	1186			M	5200	EndofPhase1_1a	2	Phase 1/1A	48	0	0	0	0	0	1	0	1	1	2	2	2	3	3	2	5	3	4	4	3	3	3	2	4	4	4	3	3	1	1	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		1	30	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	6	2	4	3	4	2.9047618		1	3.2	2.375	2	4.142857	4	-0.2952381	-0.375	2	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL217WDX
2081	8976	NDAR_INVTL217WDX	1186			M	6000	EndofPhase3	7	Phase 3	202	0	0	0	0	0	0	1	0	1	2	1	1	1	2	2	6	4	5	4	2	3	3	4	5	4	3	3	3	1	1	1	0	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	20	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	1.25	4.75	3.2857144	3.5	2.8095238			3.2	2.375	2	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL217WDX
2081	8976	NDAR_INVTL259EMD	1317			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	4	2	1	4	2	2	4	0	0	2	9	4	3	2	4	0	3	1	4	4	2	2	0	0	1	0	0	1	3	3	1	2	4	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	2.875	0.5	3	2	2.5	1		2.5	2.875	0.5	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL259EMD
2081	8976	NDAR_INVTL259EMD	1317			M	1600	Visit6	6	Phase 1/1A	175	0	1	0	0	0	0	0	4	0	4	2	2	3	3	4	0	0	2	9	4	4	2	4	1	3	3	4	4	1	0	1	1	1	1	1	1	2	1	1	2	2	4	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	4	2.75	0.5	3.2857144	3	2.65			2.5	2.875	0.5	3	2	0.15	-0.125	0	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL259EMD
2081	8976	NDAR_INVTL259EMD	1317			M	2800	Visit12	12	Phase 1/1A	387	0	1	0	0	0	0	0	6	0	4	2	2	3	2	4	0	0	2	9	2	2	2	4	2	3	2	4	4	1	0	1	0	1	1	1	1	2	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	2.875	0.5	2.857143	2.5	2.5			2.5	2.875	0.5	3	2	0	0	0	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL259EMD
2081	8976	NDAR_INVTL259EMD	1317			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	9	3	4	3	3	3	2	1	0	0	1	9	1	1	0	2	0	2	2	4	2	0	0	1	0	1	1	0	1	3	2	1	2	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.7142856	0.25	1.4285715	2	1.7894737		1	2.5	2.875	0.5	3	2	-0.7105263	-0.16071428	-0.25	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL259EMD
2081	8976	NDAR_INVTL952YZZ	1703			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	1	0	1	0	2	6	3	2	0	6	2	4	4	5	5	4	2	4	4	1	0	1	0	1	1	1	1	1	1	1	3	2	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	2.75	4	3	3.1904762	1		3.1904762	2.75	2.75	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL952YZZ
2081	8976	NDAR_INVTL952YZZ	1703			F	1600	Visit6	6	Phase 1/1A	181	1	0	0	0	0	0	0	6	0	2	4	4	2	4	6	1	0	0	9	0	2	4	6	0	4	3	6	6	0	0	1	0	1	1	1	1	1	1	1	3	2	3	1	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3.5	0.25	3.4285715	3.5	3			3.1904762	2.75	2.75	4	3	-0.1904762	0.75	-2.5	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL952YZZ
2081	8976	NDAR_INVTL952YZZ	1703			F	2800	Visit12	12	Phase 1/1A	342	1	0	0	0	0	0	0	6	4	4	4	4	4	3	6	1	0	0	9	3	4	0	6	1	5	3	5	5	1	1	1	0	1	0	1	1	1	1	1	4	3	3	1	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.375	0.25	3.4285715	4	3.4			3.1904762	2.75	2.75	4	3	0.20952381	1.625	-2.5	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL952YZZ
2081	8976	NDAR_INVTL952YZZ	1703			F	5200	EndofPhase1_1a	18	Phase 1/1A	499	1	0	0	1	0	0	0	6	6	4	4	4	4	4	6	0	0	0	9	0	2	2	6	1	5	3	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	0	3.2857144	4	3.45		1	3.1904762	2.75	2.75	4	3	0.2595238	2	-2.75	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTL952YZZ
2081	8976	NDAR_INVTM586DVN	1397			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	2	1	1	0	5	4	0	0	0	9	5	4	1	5	0	3	3	6	5	1	1	0	0	1	1	1	1	3	1	1	4	2	2	2	1	0	0	0	0	0	1	0	0	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.75	0	3.7142856	3	2.7	1		2.7	2.75	0	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM586DVN
2081	8976	NDAR_INVTM586DVN	1397			F	1600	Visit6	6	Phase 3	176	0	0	0	0	0	0	1	9	1	0	0	2	2	3	0	5	3	3	5	3	5	0	4	2	3	3	4	5	0	0	1	0	1	1	1	1	2	1	1	2	1	2	4	1	0	0	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.1428572	4	3.2857144	3	2.65			2.7	2.75	0	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM586DVN
2081	8976	NDAR_INVTM586DVN	1397			F	2800	Visit12	12	Phase 3	345	0	0	0	1	0	0	0	2	2	1	2	1	2	1	1	0	1	1	9	0	0	1	1	1	2	2	1	2	1	0	1	0	1	1	1	1	1	2	1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	0.5	0.85714287	2	1.2			2.7	2.75	0	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM586DVN
2081	8976	NDAR_INVTM586DVN	1397			F	6000	EndofPhase3	18	Phase 3	512	0	0	0	1	1	0	0	5	5	5	4	5	3	3	5	0	0	0	9	3	3	5	3	2	2	1	4	5	1	1	1	0	1	1	1	1	1	1	1	4	4	3	3	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	0	3.5714285	1.5	3.15			2.7	2.75	0	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM586DVN
2081	8976	NDAR_INVTM724FW4	2178			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	3	2	3	3	2	3	6	5	5	3	4	5	4	4	6	5	2	4	6	0	0	0	0	1	1	0	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	4.75	4.714286	3.5	3.7619047	1		3.7619047	2.5	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTM724FW4	2178			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	6	2	2	2	6	3	4	2	5	4	4	4	5	6	6	5	5	5	4	6	6	1	1	0	0	1	0	1	1	1	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	6	3.375	4.25	5.571429	4.5	4.3809524			3.7619047	2.5	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTM724FW4	2178			M	2800	Visit12	12	Phase 3	338	1	0	0	0	0	0	0	4	4	2	2	4	3	4	2	2	1	2	9	5	4	4	4	2	6	3	5	6	2	0	0	0	1	0	0	1	1	3	1	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4	3.125	1.25	4.285714	4.5	3.45			3.7619047	2.5	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTM724FW4	2178			M	4000	Visit18	18	Phase 3	515	1	0	0	0	0	0	0	5	4	4	3	5	4	5	3	3	4	4	5	4	4	4	5	5	5	5	5	6	1	1	0	1	1	1	0	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	1	1	0	0	0	0	0	1	1	1	1	5	4.125	4	4.714286	5	4.3809524			3.7619047	2.5	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTM724FW4	2178			M	5200	EndofPhase1_1a	4	Phase 1/1A	99	1	0	0	0	0	0	0	4	4	2	4	4	4	4	2	5	4	4	0	3	4	0	4	5	5	2	2	5	1	1	1	0	1	1	0	1	1	2	1	4	4	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	3.25	3.2857144	3.5	3.3809524		1	3.7619047	2.5	4.75	4.714286	3.5	-0.3809524	1	-1.5	-1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTM724FW4	2178			M	5800	EndofPhase2	10	Phase 2	269	1	0	0	0	0	0	0	4	3	2	1	4	2	4	2	2	1	2	9	1	1	4	4	2	5	1	4	5	0	0	0	0	1	0	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	25	0		0		1	5	0		0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	4	2.75	1.25	3	3	2.7			3.7619047	2.5	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTM724FW4	2178			M	6000	EndofPhase3	18	Phase 3	515	1	0	0	0	0	0	0	5	4	4	3	5	4	5	3	3	4	4	5	4	4	4	5	5	5	5	5	6	1	1	0	1	1	1	0	1	1	2	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	1	1	0	0	0	0	0	1	1	1	1	5	4.125	4	4.714286	5	4.3809524			3.7619047	2.5	4.75	4.714286	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTM724FW4
2081	8976	NDAR_INVTN147RB8	1279			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	2	5	4	6	2	0	0	3	9	2	2	2	6	3	4	2	5	6	1	2	1	1	1	1	2	1	3	2	1	4	2	4	4	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	0.75	3.7142856	3	3.35	1		3.35	4	0.75	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN147RB8
2081	8976	NDAR_INVTN147RB8	1279			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	2	0	2	1	2	0	4	1	0	0	0	9	2	3	2	2	1	4	3	1	3	1	0	0	1	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0	2	3.5	1.65			3.35	4	0.75	3.7142856	3	-1.7	-2.5	-0.75	-1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN147RB8
2081	8976	NDAR_INVTN147RB8	1279			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	1	0	3	4	3	1	2	0	3	1	0	0	1	9	1	1	4	2	1	3	3	2	3	1	1	1	1	1	1	1	1	3		1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0.25	2	3	1.9			3.35	4	0.75	3.7142856	3	-1.45	-1.875	-0.5	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN147RB8
2081	8976	NDAR_INVTN147RB8	1279			M	5200	EndofPhase1_1a	18	Phase 1/1A	509	0	0	0	0	0	1	0	4	5	3	6	5	5	6	1	1	2	1	9	2	1	3	5	5	4	2	2	4	0	0	0	0	1	1	1	1	3		1	3	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	4	4.375	1	3.142857	3	3.35		1	3.35	4	0.75	3.7142856	3	0	0.375	0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN147RB8
2081	8976	NDAR_INVTN318ZVD	2682			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	2	6	6	3	3	6	4	5	3	6	1	0	0	3	3	6	3	3	4	1	1	1	1	1	1	1	1	1	2	1	4	3	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4.75	4.5	2	4.5	3.7619047	1		3.7619047	4.75	4.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN318ZVD
2081	8976	NDAR_INVTN318ZVD	2682			F	1600	Visit6	6	Phase 2	175	0	1	0	1	0	0	0	6	0	2	0	2	0	6	4	3	5	1	6	0	6	4	3	6	3	3	4	6	1	1	1	1	1	1	0	1	1	2	0	4	4	4	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.5	3.75	4.142857	3	3.3333333			3.7619047	4.75	4.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN318ZVD
2081	8976	NDAR_INVTN318ZVD	2682			F	2800	Visit12	12	Phase 3	338	0	1	0	0	0	0	0	5	0	0	4	3	2	3	3	5	5	4	6	3	3	2	4	5	6	4	5	5	1	1	1	1	1	1	1	1	1	1	0	4	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.5	5	3.857143	5	3.6666667			3.7619047	4.75	4.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN318ZVD
2081	8976	NDAR_INVTN318ZVD	2682			F	5200	EndofPhase1_1a	3	Phase 1/1A	94	0	1	0	0	0	0	0	6	2	3	1	2	2	0	5	2	2	1	9	2	2	4	4	3	6	4	5	4	1	1	1	1	1	1	1	1	1	1	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	1.25	3.4285715	5	3		1	3.7619047	4.75	4.5	2	4.5	-0.7619048	-2.125	-3.25	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN318ZVD
2081	8976	NDAR_INVTN318ZVD	2682			F	5800	EndofPhase2	8	Phase 2	224	0	1	0	1	0	0	0	6	4	1	2	2	2	5	4	4	4	5	6	1	6	5	6	1	6	4	5	6	0	1	1	1	1	1	1	1	1	1	0	4	4	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	3	3.25	4.75	4.285714	5	4.047619			3.7619047	4.75	4.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN318ZVD
2081	8976	NDAR_INVTN318ZVD	2682			F	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	6	0	2	2	2	2	3	5	3	5	6	6	4	6	2	4	6	5	3	4	6	1	1	1	1	1	1	2	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.75	5	4.571429	4	3.9047618			3.7619047	4.75	4.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN318ZVD
2081	8976	NDAR_INVTN355DAZ	2208			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	1	0	6	5	5	5	5	4	6	6	0	3	3	9	1	2	4	6	2	4	3	6	6	1	0	1	0	1	1	0	1	1	1	1	2	4	4	1	1	1	0	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	1	0	0	0	0	1	0	5	5.25	1.5	3.857143	3.5	4.1	1		4.1	5.25	1.5	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN355DAZ
2081	8976	NDAR_INVTN355DAZ	2208			F	1600	Visit6	6	Phase 1/1A	167	0	1	0	0	0	1	0	6	6	6	4	4	0	5	6	0	0	0	9	3	2	2	2	4	3	2	3	5	1	1	1	0	1	0	0	0	2	1	1	2	4	4	1	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	4.625	0	3	2.5	3.15			4.1	5.25	1.5	3.857143	3.5	-0.95	-0.625	-1.5	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN355DAZ
2081	8976	NDAR_INVTN355DAZ	2208			F	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	1	0	4	4	0	2	3	4	6	6	0	0	0	9	2	2	2	6	2	4	1	5	6	0	0	1	1	1	1	0	1	1	1	1	2	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	0		0		0		0		1	30	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3.625	0	3.5714285	2.5	2.95			4.1	5.25	1.5	3.857143	3.5	-1.15	-1.625	-1.5	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN355DAZ
2081	8976	NDAR_INVTN355DAZ	2208			F	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	1	0	0	0	1	0	6	6	6	6	6	6	6	5	0	0	0	9	2	2	4	6	0	3	2	5	6	1	0	1	0	1	0	0	1	3		1	3	2	4	1	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	5.875	0	3.5714285	2.5	3.85		1	4.1	5.25	1.5	3.857143	3.5	-0.25	0.625	-1.5	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN355DAZ
2081	8976	NDAR_INVTN556PKJ	2692			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	1	1	4	2	4	2	1	0	1	9	3	2	0	4	1	3	2	4	4	1	0	0	0	1	1	1	2	2	2	1	4	4	4	4	1	0	0	1	0	0	0	0	1	1	0	0	0		0		0		1	30	0		0	0	1	0	1	0	0	0	0	0	1	1	0	0	1	0	4	2.625	0.5	2.5714285	2.5	2.3	1		2.3	2.625	0.5	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN556PKJ
2081	8976	NDAR_INVTN649KVP	1486			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	1	0	2	0	2	1	1	1	2	9	3	3	4	1	1	1	3	3	3	1	1	0	1	0	0	1	0	3	1	1	3	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		0		0		0		1	30	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	1	3	1.25	1	2.5714285	2	1.8	1		1.8	1.25	1	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN649KVP
2081	8976	NDAR_INVTN649KVP	1486			M	1600	Visit6	6	Phase 1/1A	201	0	0	0	0	0	0	1	4	4	1	1	2	0	2	1	2	2	4	9	3	2	3	1	3	2	5	2	2	1	1	0	0	1	2	1	0	3		1	4	2	2	4	0	0	0	0	0	0	0	0					1	2	0		0		0		1	28	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	1	5	1.875	2	2.2857144	3.5	2.3			1.8	1.25	1	2.5714285	2	0.5	0.625	1	-0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN649KVP
2081	8976	NDAR_INVTN649KVP	1486			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	0	0	1	4	4	1	2	2	1	0	1	0	0	0	9	2	0	3	3	0	2	3	4	3	1	1	0	0	1	0	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1	5	1.875	0	2.142857	2.5	1.75			1.8	1.25	1	2.5714285	2	-0.05	0.625	-1	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN649KVP
2081	8976	NDAR_INVTN649KVP	1486			M	5200	EndofPhase1_1a	14	Phase 1/1A	405	0	0	0	0	0	0	1	1	2	2	0	0	3	5	2	0	0	0	9	1	2	4	2	2	2	3	4	4	1	1	1	0	1	2	1	2	3		1	3	4	4	4	1	0	0	0	0	1	0	0	1	0	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	5	1.875	0	2.7142856	2.5	1.95		1	1.8	1.25	1	2.5714285	2	0.15	0.625	-1	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN649KVP
2081	8976	NDAR_INVTN649KVP	1486			M	5800	EndofPhase2	17	Phase 2	460	0	0	0	0	0	0	1	4	3	2	0	2	1	5	1	0	0	1	9	3	1	0	2	2	1	4	2	2	1	1	0	0	1	2	1	2	3	1	1	4	2	2	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	3	2.25	0.25	1.7142857	2.5	1.8			1.8	1.25	1	2.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN649KVP
2081	8976	NDAR_INVTN831JWE	1091			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	2	2	2	2	2	1	2	4	9	2	2	2	4	2	3	3	3	4	1	0	0	0	1	1	1	1	2	1	1	3	4	4	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	5	2.875	1.75	2.7142856	3	2.75	1		2.75	2.875	1.75	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN831JWE
2081	8976	NDAR_INVTN831JWE	1091			F	1600	Visit6	6	Phase 2	184	0	0	0	0	0	1	0	5	4	3	4	2	3	5	2	0	0	0	9	3	3	3	5	2	4	3	2	5	1	1	1	1	1	1	1	1	3	2	1	4	3	3	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.5	0	3.2857144	3.5	2.9			2.75	2.875	1.75	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN831JWE
2081	8976	NDAR_INVTN831JWE	1091			F	5200	EndofPhase1_1a	2	Phase 1/1A	63	0	0	0	0	0	1	0	6	6	4	3	5	4	4	2	0	0	0	9	0	2	4	4	2	5	3	2	5	1	1	2	1	1	1	1	1	3	3	1	2	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	0	2.7142856	4	3.05		1	2.75	2.875	1.75	2.7142856	3	0.3	1.375	-1.75	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN831JWE
2081	8976	NDAR_INVTN831JWE	1091			F	5800	EndofPhase2	11	Phase 2	340	0	0	0	0	0	1	0	5	4	2	2	2	2	4	2	0	2	4	9	2	1	4	4	2	5	5	4	6	1	1	2	1	1	1	1	1	3	2	1	4	3	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	1.5	3.2857144	5	3.1			2.75	2.875	1.75	2.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTN831JWE
2081	8976	NDAR_INVTP339NHK	2699			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	9	1	0	0	1	0	2	2	2	3	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	0	0	1	2	0.55	1		0.55	0	0	1	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP339NHK
2081	8976	NDAR_INVTP339NHK	2699			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	0	0	0	3	0	0	0	0	0	0	0	9	2	3	6	1	0	3	2	4	6	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.375	0	3.142857	2.5	1.5		1	0.55	0	0	1	2	0.95	0.375	0	2.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP339NHK
2081	8976	NDAR_INVTP957PKK	2291			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	4	0	2	2	2	2	2	0	0	1	9	2	4	4	1	2	1	4	6	3	0	1	1	1	1	1	1	1	2	2	1	3	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	0.25	3.142857	2.5	2.2	1		2.2	2	0.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP957PKK
2081	8976	NDAR_INVTP957PKK	2291			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	9	4	1	2	2	1	2	2	1	1	2	9	3	1	4	1	4	1	5	4	4	1	0	1	1	1	1	1	1	2	2	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	2	1	3	3	2.368421			2.2	2	0.25	3.142857	2.5	0.16842106	0	0.75	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP957PKK
2081	8976	NDAR_INVTP957PKK	2291			M	2800	Visit12	12	Phase 3	389	0	0	0	0	0	0	1	2	2	2	2	2	1	2	1	0	0	4	9	1	1	1	2	5	1	3	2	3	1	1	1	0	1	1	1	1	2	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1	2.142857	2	1.85			2.2	2	0.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP957PKK
2081	8976	NDAR_INVTP957PKK	2291			M	5200	EndofPhase1_1a	7	Phase 1/1A	211	0	0	0	0	0	0	1	9	4	2	2	3	2	2	2	1	1	3	9	3	2	2	2	5	1	4	4	4	0	1	0	0	1	1	1	1	1	2	0	4	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2.4285715	1.25	3.142857	2.5	2.5789473		1	2.2	2	0.25	3.142857	2.5	0.37894738	0.42857143	1	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP957PKK
2081	8976	NDAR_INVTP957PKK	2291			M	5800	EndofPhase2	7	Phase 2	227	0	0	0	0	0	0	1	9	4	2	2	3	2	2	2	3	2	5	2	2	1	2	1	4	1	5	2	4	1	0	1	0	1	1	1	1	1	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.4285715	3	2.2857144	3	2.55			2.2	2	0.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP957PKK
2081	8976	NDAR_INVTP957PKK	2291			M	6000	EndofPhase3	18	Phase 3	577	0	0	0	0	0	0	1	2	1	2	2	2	2	1	1	1	1	3	9	1	1	0	1	3	1	3	2	2	1	0	1	0	1	1	1	1	2	2	1	3	2	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	1	1.625	1.25	1.4285715	2	1.6			2.2	2	0.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTP957PKK
2081	8976	NDAR_INVTR115VUV	1372			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	1	0	0	3	0	2	1	1	2	1	1	1	2	4	4	1	6	2	6	6	1	1	1	1	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	1	1	0	0	0	0	1	0	1	1	4	1.5	1.25	3.4285715	4	2.3333333	1		2.3333333	1.5	1.25	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR115VUV
2081	8976	NDAR_INVTR115VUV	1372			M	5200	EndofPhase1_1a	1	Phase 1/1A	12	1	0	0	0	0	0	0	6	0	0	2	2	0	3	1	1	2	1	9	1	2	4	4	1	6	2	6	6	1	1	1	1	1	1	0	1	0	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	0	1	1	4	1.75	1	3.4285715	4	2.5		1	2.3333333	1.5	1.25	3.4285715	4	0.16666667	0.25	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR115VUV
2081	8976	NDAR_INVTR690DVD	2012			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	5	4	3	2	4	3	0	2	2	1	9	3	5	0	4	1	3	2	4	5	1	1	0	0	1	2	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	24	0		0		0		1	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3.125	1.25	3.142857	2.5	2.85	1		2.85	3.125	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR690DVD
2081	8976	NDAR_INVTR690DVD	2012			F	1600	Visit6	6	Phase 1/1A	195	0	0	0	0	0	0	1	5	0	2	1	2	1	2	0	3	4	1	5	5	5	5	3	4	5	3	5	6	1	1	1	0	1	1	1	1	2	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	14	0		0		0		1	16	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	5	1.625	3.25	4.714286	4	3.1904762			2.85	3.125	1.25	3.142857	2.5	0.34047619	-1.5	2	1.5714285	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR690DVD
2081	8976	NDAR_INVTR690DVD	2012			F	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	5	0	2	1	3	1	2	3	3	4	1	5	5	4	5	4	4	6	3	5	5	1	1	1	0	1	1	1	1	2	1	1	3	3	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.125	3.25	4.571429	4.5	3.3809524			2.85	3.125	1.25	3.142857	2.5	0.5309524	-1	2	1.4285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR690DVD
2081	8976	NDAR_INVTR690DVD	2012			F	4000	Visit18	18	Phase 1/1A	499	0	0	0	0	0	0	1	5	1	2	2	3	2	1	3	2	4	2	9	3	4	4	5	3	5	3	5	5	1	1	1	0	1	1	1	1	2	1	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.375	2	4.142857	4	3.2		1	2.85	3.125	1.25	3.142857	2.5	0.35	-0.75	0.75	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR690DVD
2081	8976	NDAR_INVTR972AEA	1319			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	1	2	2	2	2	0	0	0	9	1	0	1	4	0	3	4	4	3	1	1	1	1	1	1	0	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	2	1.875	0	1.8571428	3.5	1.75	1		1.75	1.875	0	1.8571428	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR972AEA
2081	8976	NDAR_INVTR972AEA	1319			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	0	4	1	9	2	2	2	3	3	4	3	5	5	1	1	1	1	1	1	1	1	3	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.25	3.142857	3.5	2.5			1.75	1.875	0	1.8571428	3.5	0.75	0.125	1.25	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR972AEA
2081	8976	NDAR_INVTR972AEA	1319			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	4	0	2	2	2	2	2	1	0	3	4	9	2	2	2	2	1	5	3	2	4	0	0	0	0	1	1	0	1	2	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	1.75	2.142857	4	2.25			1.75	1.875	0	1.8571428	3.5	0.5	0	1.75	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR972AEA
2081	8976	NDAR_INVTR972AEA	1319			M	4000	Visit18	18	Phase 1/1A	514	0	0	0	0	0	1	0	0	2	2	4	2	1	3	1	2	2	2	2	2	2	1	1	2	2	2	2	3	2	2	2	2	1	1	1	2	2	2	1	3	3	3	2	1	0	0	0	0	0	1	0	0	0	1	1	1	3	1	1	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.875	2	1.8571428	2	1.9047619		1	1.75	1.875	0	1.8571428	3.5	0.15476191	0	2	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTR972AEA
2081	8976	NDAR_INVTT302PMN	2197			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	4	1	1	1	9	1	1	1	1	1	3	3	3	3	1	0	0	0	1	1	1	2	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	0.75	1.5714285	3	1.9	1		1.9	2.25	0.75	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT302PMN
2081	8976	NDAR_INVTT302PMN	2197			M	5200	EndofPhase1_1a	1	Phase 1/1A	37	0	1	0	0	0	0	0	3	3	3	4	3	3	3	4	2	2	1	9	1	1	1	1	1	3	3	3	3	1	1	1	0	1	1	1	1	3		1	3	2	2	2	0	0	0	0	0	0	0	0					1	20	1	10	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	1.25	1.5714285	3	2.4		1	1.9	2.25	0.75	1.5714285	3	0.5	1	0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT302PMN
2081	8976	NDAR_INVTT495DDA	2454			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	3	3	3	2	1	6	4	1	2	3	9	1	6	6	3	2	3	2	6	4	1	1	1	1	1	0	1	1	1	3	0	4	4	4	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	1.5	4	2.5	3.35	1		3.35	3.5	1.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT495DDA
2081	8976	NDAR_INVTT495DDA	2454			M	1600	Visit6	6	Phase 1B	166	0	0	0	0	0	1	0	4	2	0	4	3	4	6	4	4	4	6	4	3	4	3	6	4	2	4	6	4	0	1	0	0	1	1	1	1	1	2	1	2	2	1	1	1	0	0	0	0	1	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	4.5	4.285714	3	3.857143			3.35	3.5	1.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT495DDA
2081	8976	NDAR_INVTT495DDA	2454			M	5200	EndofPhase1_1a	3	Phase 1/1A	79	1	0	0	0	0	0	0	6	3	3	3	5	3	3	2	2	2	1	9	1	3	3	5	3	3	1	4	4	2	2	2	2	1	0	1	0	2	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.5	1.25	3.2857144	2	3		1	3.35	3.5	1.5	4	2.5	-0.35	0	-0.25	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT495DDA
2081	8976	NDAR_INVTT495DDA	2454			M	5400	EndofPhase1b	12	Phase 1B	348	0	0	0	0	0	1	0	4	2	2	2	4	0	5	2	2	4	3	9	2	4	2	4	4	3	2	5	6	0	0	0	0	1	1	0	1	2	1	1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	2.625	2.25	3.857143	2.5	3.1			3.35	3.5	1.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT495DDA
2081	8976	NDAR_INVTT495DDA	2454			M	5800	EndofPhase2	18	Phase 2	516	0	0	0	0	0	1	0	6	2	2	4	6	2	4	2	2	4	6	9	6	6	4	6	4	3	2	5	6	0	1	0	0	1	1	1	1	2	3	1	3	2	4	4	1	0	0	0	0	0	1	0	0	0	1	0	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	3	5.285714	2.5	4.1			3.35	3.5	1.5	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT495DDA
2081	8976	NDAR_INVTT567HV6	1230			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	0	2	3	0	0	2	0	0	0	9	2	1	0	2	0	3	3	2	4	2	2	2	2	1	0	1	2	1	3	1	3	4	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	19	0		1	2	1	9	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.625	0	1.5714285	3	1.5	1		1.5	1.625	0	1.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT567HV6
2081	8976	NDAR_INVTT567HV6	1230			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	6	6	4	6	6	6	6	4	0	0	0	9	4	5	5	6	5	3	3	5	6	0	1	1	0	1	1	1	1	1	1	1	2	2	2	1	1	1	0	0	1	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.5	0	5.142857	3	4.3			1.5	1.625	0	1.5714285	3	2.8	3.875	0	3.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT567HV6
2081	8976	NDAR_INVTT567HV6	1230			F	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	0	0	0	6	1	2	6	2	2	5	6	0	0	0	9	5	5	6	6	4	3	5	6	6	1	0	1	2	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.75	0	5.428571	4	3.8			1.5	1.625	0	1.5714285	3	2.3	2.125	0	3.857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT567HV6
2081	8976	NDAR_INVTT567HV6	1230			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	6	5	6	6	6	6	6	6	0	4	1	9	3	6	4	6	6	5	4	6	6	1	0	1	0	1	1	1	1	1	1	1	3	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5.875	1.25	5.285714	4.5	4.9		1	1.5	1.625	0	1.5714285	3	3.4	4.25	1.25	3.7142856	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT567HV6
2081	8976	NDAR_INVTT723NPW	2110			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	1	0	4	0	4	5	5	5	5	6	4	5	1	4	5	3	1	6	6	0	0	2	1	1	0	2	0	3	1	1	3	2	2	1	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	1	0	1	0	0	1	0	0	1	1	1	0	4	2.875	5.25	4.428571	2	3.7619047	1		3.7619047	2.875	5.25	4.428571	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT723NPW
2081	8976	NDAR_INVTT723NPW	2110			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	6	2	4	4	3	4	5	4	4	5	4	5	0	2	3	4	2	3	1	5	6	1	0	2	1	1	1	1	2	2	1	1	4	4	4	1	1	0	0	0	0	0	1	0	1	1	0	2	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4	4.5	3.142857	2	3.6190476			3.7619047	2.875	5.25	4.428571	2	-0.14285715	1.125	-0.75	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT723NPW
2081	8976	NDAR_INVTT723NPW	2110			F	2800	Visit12	12	Phase 2	336	0	0	0	0	0	1	0	5	5	2	2	4	3	4	4	2	2	3	9	3	1	2	3	3	4	1	4	4	0	0	2	1	1	1	2	2	2	1	1	2	3	2	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	4	3.625	1.75	2.857143	2.5	3.05			3.7619047	2.875	5.25	4.428571	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT723NPW
2081	8976	NDAR_INVTT723NPW	2110			F	5200	EndofPhase1_1a	10	Phase 1/1A	278	0	0	0	0	0	1	0	6	5	4	2	2	3	3	4	3	3	5	5	4	4	2	5	3	4	0	5	6	0	0	2	1	1	1	2	2	3	2	1	3	3	4	1	0	0	0	0	0	0	0	0					0		1	23	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.625	4	4.142857	2	3.7142856		1	3.7619047	2.875	5.25	4.428571	2	-0.04761905	0.75	-1.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT723NPW
2081	8976	NDAR_INVTT723NPW	2110			F	5800	EndofPhase2	18	Phase 2	504	0	0	0	0	0	1	0	5	5	2	4	4	3	4	5	5	5	4	6	0	4	4	5	5	4	2	4	6	1	1	2	1	1	1	2	2	3	1	1	3	4	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	1	0	0	1	1	1	1	4	4	5	4	3	4.095238			3.7619047	2.875	5.25	4.428571	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT723NPW
2081	8976	NDAR_INVTT995AZV	2425			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	2	2	2	3	2	0	2	0	9	2	4	4	4	3	5	3	5	4	1	0	0	1	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	0.5	3.7142856	4	2.55	1		2.55	1.875	0.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT995AZV
2081	8976	NDAR_INVTT995AZV	2425			M	1600	Visit6	6	Phase 1B	164	1	0	0	0	0	0	0	6	1	4	3	2	4	2	2	0	1	1	9	3	4	4	3	3	5	4	6	4	1	1	0	1	1	1	0	0	1	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	3	0.5	3.857143	4.5	3.1			2.55	1.875	0.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT995AZV
2081	8976	NDAR_INVTT995AZV	2425			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	1	0	0	0	0	0	0	4	0	0	2	2	2	3	1	0	0	1	9	1	3	3	2	0	4	1	4	3	0	0	0	0	1	1	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	0.25	2.2857144	2.5	1.8		1	2.55	1.875	0.5	3.7142856	4	-0.75	-0.125	-0.25	-1.4285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT995AZV
2081	8976	NDAR_INVTT995AZV	2425			M	5400	EndofPhase1b	6	Phase 1B	172	1	0	0	0	0	0	0	6	0	4	3	2	4	2	2	0	1	0	9	2	3	3	3	3	6	4	4	5	1	1	0	1	1	1	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2.875	0.25	3.2857144	5	2.85			2.55	1.875	0.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT995AZV
2081	8976	NDAR_INVTT995AZV	2425			M	5800	EndofPhase2	9	Phase 2	262	1	0	0	0	0	0	0	6	0	2	2	2	2	4	3	3	2	4	3	2	5	4	4	3	4	4	4	3	1	1	0	0	1	1	0	0	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	1	2.625	3	3.5714285	4	3.142857			2.55	1.875	0.5	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTT995AZV
2081	8976	NDAR_INVTU970LL0	1999			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	0	0	2	4	2	2	2	0	0	0	9	0	0	1	2	1	5	2	3	3	0	1	1	0	1	1	0	1	1	2	0	4	3	4	4	1	0	0	1	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	1.4285715	3.5	1.7	1		1.7	2.125	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTU970LL0
2081	8976	NDAR_INVTU970LL0	1999			M	1600	Visit6	6	Phase 3	186	1	0	0	0	1	0	0	3	2	2	3	3	0	2	1	0	1	1	9	3	0	4	2	3	5	3	3	4	1	1	1	0	1	1	0	1	1	2	1	4	3	3	4	1	0	0	0	0	0	1	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		2	0.5	2.7142856	4	2.25			1.7	2.125	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTU970LL0
2081	8976	NDAR_INVTU970LL0	1999			M	2800	Visit12	12	Phase 3	343	1	0	0	0	0	0	0	4	3	4	3	3	3	6	2	2	4	5	9	2	3	4	4	5	5	3	4	4	0	0	1	0	1	1	2	1	1	1	1	4	2	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.5	2.75	3.7142856	4	3.65			1.7	2.125	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTU970LL0
2081	8976	NDAR_INVTU970LL0	1999			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	4	2	0	1	2	2	4	0	0	0	1	9	2	0	1	0	2	4	2	3	2	1	1	1	1	1	1	1	1	1	1	1	4	2	4	4	1	0	0	1	0	0	1	0	1	1	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		1.875	0.25	1.4285715	3	1.6		1	1.7	2.125	0	1.4285715	3.5	-0.1	-0.25	0.25	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTU970LL0
2081	8976	NDAR_INVTU970LL0	1999			M	5800	EndofPhase2	4	Phase 2	120	1	0	0	0	0	0	0	4	1	1	0	2	0	1	0	0	0	1	9	0	0	2	2	1	4	1	2	1	0	0	1	0	1	1	0	1	1	1	0	4	1	4	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.125	0.25	1.1428572	2.5	1.15			1.7	2.125	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTU970LL0
2081	8976	NDAR_INVTU970LL0	1999			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	3	4	4	5	4	3	6	2	4	5	4	5	2	5	3	3	4	5	3	4	3	1	1	1	0	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	3	3.875	4.5	3.4285715	4	3.857143			1.7	2.125	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTU970LL0
2081	8976	NDAR_INVTV288JZP	2246			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	1	1	1	0	1	2	0	0	1	9	2	3	4	2	4	2	3	4	4	1	1	2	2	1	1	1	2	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	3	0.875	0.25	3.2857144	2.5	1.8	1		1.8	0.875	0.25	3.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTV288JZP
2081	8976	NDAR_INVTV346DJY	2204			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	0	0	0	1	0	2	0	2	4	5	4	3	3	3	3	2	5	3	3	6	1	1	1	0	1	1	1	1	3	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	4	0.875	3.75	3.2857144	4	2.5238094	1		2.5238094	0.875	3.75	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTV346DJY
2081	8976	NDAR_INVTW092YYY	2371			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	6	5	6	2	5	6	5	2	0	2	0	9	2	2	2	6	4	1	3	1	4	1	0	1	0	1	0	1	1	1	1	1	3	3	3	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	6	4.625	0.5	3	2	3.2	1		3.2	4.625	0.5	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW092YYY
2081	8976	NDAR_INVTW092YYY	2371			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	2	6	2	3	4	2	4	6	5	4	6	9	2	2	1	2	3	2	4	3	4	1	1	1	1	1	1	1	1	1	1	1	2	2	4	4	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.625	3.75	2.4285715	3	3.35			3.2	4.625	0.5	3	2	0.15	-1	3.25	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW092YYY
2081	8976	NDAR_INVTW092YYY	2371			M	2800	Visit12	12	Phase 1/1A	344	1	0	0	0	0	0	0	4	2	1	0	3	2	2	2	0	1	1	9	1	2	2	3	3	2	3	0	3	0	0	1	1	1	1	1	1	2	2	1	2	1	1	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	0.5	2	2.5	1.85			3.2	4.625	0.5	3	2	-1.35	-2.625	0	-1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW092YYY
2081	8976	NDAR_INVTW092YYY	2371			M	5200	EndofPhase1_1a	13	Phase 1/1A	373	1	0	0	0	0	0	0	5	4	2	2	4	2	4	2	0	0	0	9	2	2	6	2	0	2	5	0	4	0	0	0	0	1	1	1	1	3	1	1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.125	0	2.2857144	3.5	2.4		1	3.2	4.625	0.5	3	2	-0.8	-1.5	-0.5	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW092YYY
2081	8976	NDAR_INVTW121PX2	1893			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	6	6	4	2	4	3	6	6	6	3	5	5	3	2	5	5	5	3	4	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.625	5.25	3.857143	5	4.142857	1		4.142857	3.625	5.25	3.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW121PX2
2081	8976	NDAR_INVTW121PX2	1893			F	5200	EndofPhase1_1a	1	Phase 1/1A	21	0	1	0	0	0	0	0	6	0	4	5	4	3	2	4	6	2	6	6	3	4	6	2	5	5	5	2	5	1	1	1	0	1	1	1	1	1	1	0	4	1	2	4	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	5	3.857143	5	4.047619		1	4.142857	3.625	5.25	3.857143	5	-0.0952381	-0.125	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW121PX2
2081	8976	NDAR_INVTW121PX2	1893			F	5800	EndofPhase2	3	Phase 2	72	0	1	0	0	0	0	0	2	5	6	6	6	6	5	2	4	2	4	0	3	4	3	5	5	5	4	4	6	1	1	1	1	1	1	1	1	3	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	1	4	4.75	2.5	4.285714	4.5	4.142857			4.142857	3.625	5.25	3.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW121PX2
2081	8976	NDAR_INVTW558ZHT	2372			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	2	2	2	2	2	1	0	0	0	9	3	2	4	3	1	2	2	3	4	0	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	2.125	0	2.857143	2	2.05	1		2.05	2.125	0	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW558ZHT
2081	8976	NDAR_INVTW558ZHT	2372			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	4	4	3	3	2	3	3	4	0	0	0	9	3	3	3	3	3	4	2	3	4	1	1	0	0	1	1	1	1	1	2	1	4	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	0	3.142857	3	2.7			2.05	2.125	0	2.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW558ZHT
2081	8976	NDAR_INVTW558ZHT	2372			M	5200	EndofPhase1_1a	4	Phase 1/1A	115	0	0	1	0	0	0	0	4	1	1	2	2	2	2	1	0	2	1	9	2	2	2	2	2	3	1	2	2	0	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	0.75	2	2	1.8		1	2.05	2.125	0	2.857143	2	-0.25	-0.25	0.75	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTW558ZHT
2081	8976	NDAR_INVTX844XU6	2694			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	4	1	4	4	4	2	2	5	4	5	3	3	2	4	2	6	5	6	4	4	1	1	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	4.25	3.5714285	5.5	3.7142856	1		3.7142856	3.125	4.25	3.5714285	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTX844XU6
2081	8976	NDAR_INVTX844XU6	2694			M	5200	EndofPhase1_1a	1	Phase 1/1A	12	1	0	1	0	0	0	0	4	4	1	4	4	5	2	2	5	4	5	3	3	2	4	2	6	5	6	4	5	1	1	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	4.25	3.7142856	5.5	3.8095238		1	3.7142856	3.125	4.25	3.5714285	5.5	0.0952381	0.125	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTX844XU6
2081	8976	NDAR_INVTY425KG4	2438			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	4	4	6	6	6	0	4	5	6	6	3	3	4	6	6	6	5	6	6	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.5	5.25	4.857143	5.5	4.857143	1		4.857143	4.5	5.25	4.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY425KG4
2081	8976	NDAR_INVTY425KG4	2438			F	1600	Visit6	6	Phase 3	131	0	0	0	0	0	1	0	6	4	4	6	6	6	6	1	3	5	6	4	3	4	5	6	6	5	6	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	0	1	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	4.875	4.5	5.142857	5.5	4.952381			4.857143	4.5	5.25	4.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY425KG4
2081	8976	NDAR_INVTY425KG4	2438			F	2800	Visit12	12	Phase 3	306	0	0	0	0	0	1	0	6	6	5	6	6	6	6	4	4	5	6	4	3	4	6	6	6	6	5	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	6	5.625	4.75	5.285714	5.5	5.3333335			4.857143	4.5	5.25	4.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY425KG4
2081	8976	NDAR_INVTY425KG4	2438			F	5200	EndofPhase1_1a	2	Phase 1/1A	37	0	0	0	0	0	1	0	6	4	4	4	6	6	6	1	3	5	6	6	3	4	5	6	4	5	6	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	0	1	0	1	0	0	2	2	2	2	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.625	5	4.857143	5.5	4.857143		1	4.857143	4.5	5.25	4.857143	5.5	0	0.125	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY425KG4
2081	8976	NDAR_INVTY425KG4	2438			F	5800	EndofPhase2	3	Phase 2	42	0	0	0	0	0	1	0	6	4	4	4	6	6	6	1	3	5	6	6	3	4	5	6	4	5	6	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	0	1	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.625	5	4.857143	5.5	4.857143			4.857143	4.5	5.25	4.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY425KG4
2081	8976	NDAR_INVTY425KG4	2438			F	6000	EndofPhase3	18	Phase 3	485	0	0	0	0	0	1	0	6	6	6	6	6	6	6	0	4	6	6	1	5	6	5	6	6	6	4	5	6	1	1	1	0	1	1	1	1	2	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	1	1	0	1	0	1	0	0	0	0	0	1	1	1	1	5	5.25	4.25	5.571429	5	5.142857			4.857143	4.5	5.25	4.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY425KG4
2081	8976	NDAR_INVTY650WF3	2286			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	1	2	0	0	1	1	0	0	0	0	0	9	4	2	4	2	0	3	3	0	4	1	0	1	1	1	1	1	1	3		1	2	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	0.625	0	2.2857144	3	1.35	1		1.35	0.625	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY650WF3
2081	8976	NDAR_INVTY650WF3	2286			F	1600	Visit6	6	Phase 1/1A	203	1	1	0	0	0	0	0	6	0	0	2	2	0	2	1	0	0	0	9	1	0	0	4	0	4	2	6	6	0	0	0	0	1	2	2	2	1	1	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.625	0	2.4285715	3	1.8			1.35	0.625	0	2.2857144	3	0.45	1	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY650WF3
2081	8976	NDAR_INVTY650WF3	2286			F	2800	Visit12	12	Phase 3	341	1	0	0	0	0	0	0	2	2	2	0	2	1	5	0	0	0	0	9	3	0	3	6	0	4	3	4	6	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	6	1.75	0	3.142857	3.5	2.15			1.35	0.625	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY650WF3
2081	8976	NDAR_INVTY650WF3	2286			F	5200	EndofPhase1_1a	9	Phase 1/1A	275	1	1	0	0	0	0	0	6	6	2	0	4	0	2	0	0	0	0	9	2	0	0	6	0	4	3	6	6	0	0	1	0	1	1	1	1	1	1	0	4	4	4	1	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	2.5	0	2.857143	3.5	2.35		1	1.35	0.625	0	2.2857144	3	1	1.875	0	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY650WF3
2081	8976	NDAR_INVTY650WF3	2286			F	5800	EndofPhase2	11	Phase 2	317	1	1	0	0	0	0	0	3	1	2	1	2	2	2	0	0	0	0	9	4	2	4	3	0	3	4	4	6	0	0	1	1	0	1	1	0	1	1	0	4	4	4	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0	3.2857144	3.5	2.15			1.35	0.625	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY650WF3
2081	8976	NDAR_INVTY650WF3	2286			F	6000	EndofPhase3	18	Phase 3	509	1	0	1	0	1	0	0	4	2	0	0	6	0	2	0	0	0	0	9	2	0	3	4	0	4	2	0	0	0	0	1	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.75	0	1.2857143	3	1.45			1.35	0.625	0	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY650WF3
2081	8976	NDAR_INVTY982LJM	1859			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	3	2	2	2	2	2	1	0	0	1	9	3	2	3	3	1	3	3	4	5	1	1	1	1	1	1	1	1	1	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	2.5	0.25	3	3	2.4	1		2.4	2.5	0.25	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY982LJM
2081	8976	NDAR_INVTY982LJM	1859			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	5	4	3	2	2	2	2	3	0	1	1	9	2	2	4	3	2	4	3	3	4	1	1	0	1	1	1	0	1	1	2	1	4	3	4	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	0.5	2.857143	3.5	2.6			2.4	2.5	0.25	3	3	0.2	0.375	0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY982LJM
2081	8976	NDAR_INVTY982LJM	1859			M	5200	EndofPhase1_1a	12	Phase 1/1A	344	1	0	0	0	0	0	0	4	2	2	2	2	3	3	2	0	0	1	9	4	2	3	4	1	5	3	4	4	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	0.25	3.142857	4	2.55		1	2.4	2.5	0.25	3	3	0.15	0	0	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY982LJM
2081	8976	NDAR_INVTY982LJM	1859			M	5800	EndofPhase2	15	Phase 2	428	1	0	0	0	0	0	0	4	3	3	3	3	2	2	1	0	1	1	9	2	2	3	3	1	4	2	3	4	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0.5	2.5714285	3	2.35			2.4	2.5	0.25	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY982LJM
2081	8976	NDAR_INVTY982LJM	1859			M	6000	EndofPhase3	18	Phase 3	512	1	0	0	0	0	0	0	5	3	2	2	2	2	2	1	0	0	1	9	2	2	4	4	2	5	3	3	3	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0.25	2.857143	4	2.4			2.4	2.5	0.25	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTY982LJM
2081	8976	NDAR_INVTZ070VDK	1987			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	0	0	0	0	2	2	0	0	0	0	9	2	1	0	4	1	3	1	4	5	1	0	0	0	1	0	1	1	3		0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	0.75	0	2.4285715	2	1.35	1		1.35	0.75	0	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ070VDK
2081	8976	NDAR_INVTZ070VDK	1987			M	1600	Visit6	6	Phase 1/1A	263	0	1	0	0	0	0	0	4	2	0	0	2	0	0	2	0	0	0	9	0	2	2	4	0	3	2	4	4	1	0	1	0	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	0	2.2857144	2.5	1.55			1.35	0.75	0	2.4285715	2	0.2	0.5	0	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ070VDK
2081	8976	NDAR_INVTZ070VDK	1987			M	2800	Visit12	12	Phase 1/1A	459	0	1	0	0	0	0	0	2	2	1	2	2	2	2	2	0	0	0	9	0	2	2	2	1	3	2	2	2	1	1	1	0	1	1	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0	1.5714285	2.5	1.55			1.35	0.75	0	2.4285715	2	0.2	1.125	0	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ070VDK
2081	8976	NDAR_INVTZ070VDK	1987			M	4000	Visit18	18	Phase 1/1A	646	0	1	0	0	0	0	0	4	4	0	4	2	0	2	2	0	2	0	9	2	2	2	2	0	3	3	4	4	1	1	1	0	1	0	1	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	4	2.25	0.5	2.2857144	3	2.1		1	1.35	0.75	0	2.4285715	2	0.75	1.5	0.5	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ070VDK
2081	8976	NDAR_INVTZ560RN5	1613			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	2	2	2	2	2	0	6	4	4	5	4	4	4	4	6	6	4	5	6	1	0	1	0	1	1	1	1	3	2	0	4	3	2	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	1	30	1	30	1	30	1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2.75	4.75	4.714286	5	4	1		4	2.75	4.75	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ560RN5
2081	8976	NDAR_INVTZ560RN5	1613			F	1600	Visit6	6	Phase 3	190	0	0	0	0	0	0	1	3	3	4	4	4	4	4	2	4	2	6	6	5	5	4	6	6	5	5	6	6	1	1	1	1	1	1	1	1	2	2	1	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	3.5	4.5	5.428571	5	4.4761906			4	2.75	4.75	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ560RN5
2081	8976	NDAR_INVTZ560RN5	1613			F	5200	EndofPhase1_1a	1	Phase 1/1A	14	0	0	0	0	0	0	1	6	6	2	2	2	2	2	0	3	3	4	5	4	4	4	6	6	5	3	5	6	0	1	1	1	1	1	1	1	3	2	0	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	3.75	5	4	3.8095238		1	4	2.75	4.75	4.714286	5	-0.1904762	0	-1	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ560RN5
2081	8976	NDAR_INVTZ560RN5	1613			F	5400	EndofPhase1b	2	Phase 1B	43	0	0	0	0	0	0	1	4	4	2	2	2	2	2	0	6	4	4	5	4	4	4	4	6	6	4	4	6	1	0	1	2	1	1	1	1	3	2	0	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.25	4.75	4.571429	5	3.7619047			4	2.75	4.75	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ560RN5
2081	8976	NDAR_INVTZ560RN5	1613			F	5800	EndofPhase2	3	Phase 2	71	0	0	0	0	0	0	1	6	3	2	2	2	2	3	1	4	3	5	5	5	6	5	6	6	4	3	6	6	1	1	1	0	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.625	4.25	5.714286	3.5	4.047619			4	2.75	4.75	4.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVTZ560RN5
2081	8976	NDAR_INVUA055LUX	2709			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	4	3	1	6	0	2	2	6	6	0	0	0	0	1	1	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	5	0	0	3.7142856	2	1.5	1		1.5	0	0	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA055LUX
2081	8976	NDAR_INVUA055LUX	2709			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	1	0	6	6	6	6	6	2	6	4	0	2	1	9	4	5	6	6	4	4	2	5	6	1	0	1	0	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	5.25	0.75	5.142857	3	4.35			1.5	0	0	3.7142856	2	2.85	5.25	0.75	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA055LUX
2081	8976	NDAR_INVUA055LUX	2709			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	0	1	1	9	1	6	6	6	2	4	3	6	6	0	0	1	0	1	1	1	1	3	1	1	3	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	6	0.5	4.714286	3.5	4.5			1.5	0	0	3.7142856	2	3	6	0.5	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA055LUX
2081	8976	NDAR_INVUA055LUX	2709			M	4000	Visit18	18	Phase 1/1A	513	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	9	1	2	2	0	0	4	2	4	5	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	0.125	0	2	3	1.05		1	1.5	0	0	3.7142856	2	-0.45	0.125	0	-1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA055LUX
2081	8976	NDAR_INVUA710TN3	1343			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	4	4	4	2	4	2	2	2	3	9	3	4	4	3	2	6	4	1	2	1	1	1	0	1	1	0	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.25	1.75	2.7142856	5	3.1	1		3.1	3.25	1.75	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA710TN3
2081	8976	NDAR_INVUA871GZA	1400			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	3	3	2	2	2	4	2	4	1	2	2	3	3	2	6	4	3	4	1	1	1	1	1	1	1	1	2	2	1	4	2	2	3	1	0	1	0	0	0	0	0	1	2	2	2	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	3	2.2857144	2.75	2.7142856	5	2.8	1		2.8	2.2857144	2.75	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA871GZA
2081	8976	NDAR_INVUA871GZA	1400			M	1600	Visit6	6	Phase 3	169	0	0	0	0	0	0	1	3	2	2	2	2	2	1	1	2	1	2	9	2	1	2	2	3	3	3	4	4	1	1	1	1	1	1	1	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.875	1.25	2.5714285	3	2.2			2.8	2.2857144	2.75	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA871GZA
2081	8976	NDAR_INVUA871GZA	1400			M	2800	Visit12	12	Phase 3	344	0	0	0	0	0	0	1	3	2	2	2	2	2	1	1	2	1	2	9	2	1	2	2	3	3	3	4	4	1	1	1	1	1	1	1	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.875	1.25	2.5714285	3	2.2			2.8	2.2857144	2.75	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA871GZA
2081	8976	NDAR_INVUA871GZA	1400			M	4000	Visit18	18	Phase 3	505	0	0	0	0	0	0	1	3	2	2	2	2	2	1	1	2	1	2	9	2	1	2	2	3	3	3	4	4	1	1	1	1	1	1	1	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.875	1.25	2.5714285	3	2.2			2.8	2.2857144	2.75	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA871GZA
2081	8976	NDAR_INVUA871GZA	1400			M	5200	EndofPhase1_1a	2	Phase 1/1A	47	0	0	0	0	0	0	1	9	2	2	3	3	2	2	2	4	2	4	1	2	2	3	3	2	6	4	3	4	1	1	1	1	1	1	1	1	2	2	1	4	2	2	3	1	0	1	0	0	0	0	0	1	2	2	2	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	3	2.2857144	2.75	2.7142856	5	2.8		1	2.8	2.2857144	2.75	2.7142856	5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA871GZA
2081	8976	NDAR_INVUA871GZA	1400			M	5800	EndofPhase2	5	Phase 2	128	0	0	0	0	0	0	1	3	2	2	2	2	2	1	1	2	1	2	9	2	1	2	2	3	3	3	4	4	1	1	1	1	1	1	1	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	3	1.875	1.25	2.5714285	3	2.2			2.8	2.2857144	2.75	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUA871GZA
2081	8976	NDAR_INVUB021BHY	1416			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	4	0	4	1	4	6	3	4	2	9	4	4	4	5	6	5	4	6	6	1	0	1	0	1	1	1	1	1	1	1	3	3	3	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	1	1	0	1	1	4	3.125	2.25	5	4.5	3.9	1		3.9	3.125	2.25	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB021BHY
2081	8976	NDAR_INVUB021BHY	1416			F	1600	Visit6	6	Phase 3	170	1	0	0	1	1	0	0	6	2	0	3	2	4	3	3	0	0	0	9	5	3	4	5	4	3	4	6	6	1	0	1	0	1	1	1	1	1	1	1	3	2	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	2.875	0	4.714286	3.5	3.15			3.9	3.125	2.25	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB021BHY
2081	8976	NDAR_INVUB021BHY	1416			F	2800	Visit12	12	Phase 3	360	0	0	0	0	0	1	0	4	3	4	2	3	4	3	3	0	0	0	9	2	2	2	5	1	3	2	4	6	1	0	1	0	1	1	1	1	3	1	1	2	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	6	3.25	0	3.142857	2.5	2.65			3.9	3.125	2.25	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB021BHY
2081	8976	NDAR_INVUB021BHY	1416			F	5200	EndofPhase1_1a	1	Phase 1/1A	37	1	0	0	0	0	0	0	6	1	4	2	4	1	4	4	2	3	2	9	3	3	4	5	4	3	3	6	4	1	0	1	0	1	1	1	1	1	1	1	3	2	3	3	1	0	1	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	4	3.25	1.75	4.142857	3	3.4		1	3.9	3.125	2.25	5	4.5	-0.5	0.125	-0.5	-0.85714287	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB021BHY
2081	8976	NDAR_INVUB021BHY	1416			F	5800	EndofPhase2	4	Phase 2	134	1	0	0	1	1	0	0	5	2	4	3	2	4	3	3	0	0	0	9	5	3	4	5	4	4	4	6	6	1	1	1	0	1	1	1	1	1	1	1	4	3	4	3	1	0	1	0	0	0	0	0	1	0	1	0	1	28	0		1	2	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	3.25	0	4.714286	4	3.35			3.9	3.125	2.25	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB021BHY
2081	8976	NDAR_INVUB021BHY	1416			F	6000	EndofPhase3	18	Phase 3	501	1	0	1	0	1	0	0	4	4	3	4	4	2	4	4	0	0	0	9	3	2	2	5	2	4	4	4	6	1	2	1	0	1	1	1	1	1	1	1	4	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	0	4	3.625	0	3.4285715	4	3.05			3.9	3.125	2.25	5	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB021BHY
2081	8976	NDAR_INVUB027UJG	1228			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	4	4	4	2	4	0	1	6	5	9	3	5	5	2	4	4	4	5	6	1	1	1	1	1	0	0	1	3	3	1	4	3	3	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	3.142857	3	4.285714	4	3.7894738	1		3.7894738	3.142857	3	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB027UJG
2081	8976	NDAR_INVUB027UJG	1228			M	1600	Visit6	6	Phase 1/1A	144	0	0	0	0	0	1	0	2	4	3	3	4	3	3	2	1	1	2	9	2	2	3	2	2	5	2	3	2	1	1	0	0	1	1	1	1	3		1	2	4	4	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	4	3	1	2.2857144	3.5	2.55			3.7894738	3.142857	3	4.285714	4	-1.2394737	-0.14285715	-2	-2	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB027UJG
2081	8976	NDAR_INVUB027UJG	1228			M	2800	Visit12	12	Phase 1/1A	326	0	0	0	0	0	1	0	6	2	2	2	4	2	2	1	2	3	0	9	6	4	4	5	2	4	4	6	6	1	1	0	0	1	1	1	1	3	2	1	4	4	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	2.625	1.25	4.714286	4	3.35			3.7894738	3.142857	3	4.285714	4	-0.4394737	-0.51785713	-1.75	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB027UJG
2081	8976	NDAR_INVUB027UJG	1228			M	5200	EndofPhase1_1a	18	Phase 1/1A	484	0	0	0	0	0	1	0	5	1	1	0	0	1	1	1	0	2	1	9	1	1	0	1	2	5	3	2	4	0	1	0	0	0	1	1	0	3		0	4	3	2	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.25	0.75	1.5714285	4	1.6		1	3.7894738	3.142857	3	4.285714	4	-2.1894736	-1.8928572	-2.25	-2.7142856	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB027UJG
2081	8976	NDAR_INVUB219AKB	2009			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	9	0	1	0	2	0	2	1	1	3	1	0	2	0	1	2	2	0	3	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.25	0	1	1.5	0.6	1		0.6	0.25	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB219AKB
2081	8976	NDAR_INVUB219AKB	2009			M	1600	Visit6	6	Phase 2	176	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	9	0	1	0	2	2	2	1	0	4	0	0	0	0	1	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	5	0.25	0	1.2857143	1.5	0.7			0.6	0.25	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB219AKB
2081	8976	NDAR_INVUB219AKB	2009			M	2800	Visit12	12	Phase 2	344	0	0	0	0	0	1	0	1	1	0	1	2	0	1	0	0	0	0	9	1	1	0	2	0	2	1	1	3	0	0	0	0	1	0	0	0	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.75	0	1.1428572	1.5	0.85			0.6	0.25	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB219AKB
2081	8976	NDAR_INVUB219AKB	2009			M	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	9	2	0	0	0	0	2	0	0	2	0	0	0	0	0	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0	0.25	0.5714286	1	0.35		1	0.6	0.25	0	1	1.5	-0.25	-0.25	0.25	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB219AKB
2081	8976	NDAR_INVUB219AKB	2009			M	5800	EndofPhase2	18	Phase 2	508	0	0	0	0	0	1	0	0	0	0	0	2	3	1	1	0	0	1	9	1	0	0	2	0	2	1	2	3	2	2	2	0	1	0	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	0.875	0.25	1.1428572	1.5	0.95			0.6	0.25	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB219AKB
2081	8976	NDAR_INVUB310RU6	1935			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	0	1	2	0	1	1	1	1	4	9	2	1	3	2	2	2	2	2	4	2	2	2	2	1	2	2	2	3		1	4	3	4	4	1	0	0	0	0	1	0	0	0	0	0	0	0		0		0		1	28	1	2	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	3	1	1.5	2.2857144	2	1.7368422	1		1.7368422	1	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB310RU6
2081	8976	NDAR_INVUB310RU6	1935			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	1	0	6	5	3	2	4	3	4	2	6	6	5	6	6	5	5	6	5	2	2	5	6	0	0	2	1	1	1	1	2	3	1	1	3	3	4	4	1	0	0	0	0	1	0	0	1	2	1	2	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.625	5.75	5.428571	2	4.4761906			1.7368422	1	1.5	2.2857144	2	2.7393484	2.625	4.25	3.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB310RU6
2081	8976	NDAR_INVUB310RU6	1935			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	5	3	4	4	2	4	5	1	5	5	4	6	5	6	4	6	5	3	2	6	6	1	1	2	1	1	1	0	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	22	1	8	0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	5	5.428571	2.5	4.3333335			1.7368422	1	1.5	2.2857144	2	2.5964913	2.5	3.5	3.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB310RU6
2081	8976	NDAR_INVUB310RU6	1935			M	4000	Visit18	18	Phase 1B	505	0	0	0	0	0	1	0	4	5	4	2	4	5	6	2	1	5	3	9	5	5	3	6	6	3	2	5	6	1	0	1	0	1	1	1	1	3		1	3	2	2	4	1	0	0	0	0	1	0	0	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4	2.25	5.142857	2.5	4.1			1.7368422	1	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB310RU6
2081	8976	NDAR_INVUB310RU6	1935			M	5200	EndofPhase1_1a	16	Phase 1/1A	454	0	0	0	0	0	1	0	5	4	2	3	4	4	4	1	1	5	2	9	2	4	3	6	6	3	3	4	6	1	1	1	0	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	3.375	2	4.428571	3	3.6		1	1.7368422	1	1.5	2.2857144	2	1.8631579	2.375	0.5	2.142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB310RU6
2081	8976	NDAR_INVUB310RU6	1935			M	5400	EndofPhase1b	22	Phase 1B	616	0	0	0	0	0	1	0	5	4	4	5	4	4	4	1	2	6	2	9	6	6	5	4	6	4	4	5	5	1	0	1	1	1	1	1	1	3		1	3	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	6	3.875	2.5	5.285714	4	4.3			1.7368422	1	1.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB310RU6
2081	8976	NDAR_INVUB416EL5	1327			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	3	2	4	1	2	1	2	1	9	4	5	4	6	4	5	2	2	2	1	0	1	0	1	1	1	1	3	2	0	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	29	0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1.5	1	3.857143	3.5	2.5	1		2.5	1.5	1	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB416EL5
2081	8976	NDAR_INVUB416EL5	1327			M	2800	Visit12	12	Phase 3	324	0	0	0	0	0	1	0	3	2	2	3	3	4	2	4	3	4	6	6	2	4	4	5	4	3	3	5	5	1	1	0	1	1	1	1	0	3		1	2	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	4.75	4.142857	3	3.6666667			2.5	1.5	1	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB416EL5
2081	8976	NDAR_INVUB416EL5	1327			M	5200	EndofPhase1_1a	3	Phase 1/1A	89	0	0	0	0	0	1	0	5	0	4	1	2	2	2	1	2	4	6	9	4	3	0	2	3	5	2	3	4	1	0	1	0	1	1	1	1	3		0	3	4	4	1	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	3	2.7142856	3.5	2.75		1	2.5	1.5	1	3.857143	3.5	0.25	0.625	2	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB416EL5
2081	8976	NDAR_INVUB416EL5	1327			M	5800	EndofPhase2	6	Phase 2	215	0	0	0	0	0	1	0	4	4	4	5	3	4	5	4	6	5	6	5	3	5	3	5	4	5	4	4	5	1	1	0	0	1	1	1	1	1	1	1	2	1	1	1	1	1	0	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5.5	4.142857	4.5	4.428571			2.5	1.5	1	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB416EL5
2081	8976	NDAR_INVUB416EL5	1327			M	6000	EndofPhase3	18	Phase 3	505	1	0	0	0	0	0	0	5	5	4	4	3	4	4	4	5	6	4	5	4	4	4	5	5	6	3	4	5	1	0	0	0	1	1	1	0	1	2	1	2	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.125	5	4.428571	4.5	4.428571			2.5	1.5	1	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB416EL5
2081	8976	NDAR_INVUB526MFT	1998			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	6	6	5	4	6	6	0	0	1	9	0	6	6	4	2	3	2	6	6	1	1	1	0	1	0	1	1	1	2	1	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	5.375	0.25	4.285714	2.5	3.95	1		3.95	5.375	0.25	4.285714	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB526MFT
2081	8976	NDAR_INVUB526MFT	1998			M	1600	Visit6	6	Phase 1/1A	170	0	1	0	0	0	0	0	6	0	0	2	2	2	2	6	0	0	1	9	0	2	2	2	0	6	2	2	2	1	0	0	0	1	0	0	0	1	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0.25	1.4285715	4	1.95			3.95	5.375	0.25	4.285714	2.5	-2	-2.875	0	-2.857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB526MFT
2081	8976	NDAR_INVUB526MFT	1998			M	2800	Visit12	12	Phase 1/1A	333	0	1	0	0	0	0	0	6	2	2	2	2	2	2	6	0	0	0	9	1	4	4	6	3	4	3	1	0	1	0	1	1	1	1	0	1	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	0	2.7142856	3.5	2.5			3.95	5.375	0.25	4.285714	2.5	-1.45	-2.375	-0.25	-1.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB526MFT
2081	8976	NDAR_INVUB526MFT	1998			M	5200	EndofPhase1_1a	12	Phase 1/1A	344	0	1	0	0	0	0	0	6	2	2	2	2	2	2	6	0	0	0	9	1	6	5	6	6	4	3	4	0	0	0	1	1	1	1	0	1	1	1	1	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	0	4	3.5	2.95		1	3.95	5.375	0.25	4.285714	2.5	-1	-2.375	-0.25	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB526MFT
2081	8976	NDAR_INVUB526MFT	1998			M	5800	EndofPhase2	12	Phase 2	353	0	1	0	0	0	0	0	6	2	2	2	2	2	2	6	0	0	0	9	1	6	5	6	6	4	3	4	0	0	0	1	1	1	1	0	1	1	1	1	4	3	3	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0	4	3.5	2.95			3.95	5.375	0.25	4.285714	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB526MFT
2081	8976	NDAR_INVUB941WTK	1894			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	3	0	2	2	2	2	4	0	0	1	9	2	0	0	3	0	2	2	4	2	1	0	2	0	1	1	2	1	3	1	1	2	4	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	6	2.125	0.25	1.5714285	2	1.65	1		1.65	2.125	0.25	1.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB941WTK
2081	8976	NDAR_INVUB941WTK	1894			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	1	0	4	4	0	2	4	3	3	4	0	0	3	9	3	3	0	5	0	2	0	2		0	0	2	0	1	1	2	0	3	1	1	2	2	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	5	3	0.75	2.1666667	1	2.2105262			1.65	2.125	0.25	1.5714285	2	0.5605263	0.875	0.5	0.5952381	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB941WTK
2081	8976	NDAR_INVUB941WTK	1894			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	1	0	5	4	4	2	2	4	6	1	0	4	2	9	2	5	2	3	0	1	0	3	3	0	0	2	0	1	1	2	1	3	1	1	2	1	1	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	3.5	1.5	2.5714285	0.5	2.65			1.65	2.125	0.25	1.5714285	2	1	1.375	1.25	1	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB941WTK
2081	8976	NDAR_INVUB941WTK	1894			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	0	1	0	5	4	2	2	3	2	4	4	2	0	3	9	0	2	2	3	1	1	1	3	4	0	0	2	0	1	1	2	2	3	1	1	3	4	4	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.25	1.25	2.142857	1	2.4		1	1.65	2.125	0.25	1.5714285	2	0.75	1.125	1	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB941WTK
2081	8976	NDAR_INVUB974LTM	2155			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	1	2	1	2	1	2	2	4	9	3	3	3	3	2	4	3	4	5	0	0	1	0	1	1	0	0	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	0	4	1.625	2	3.2857144	3.5	2.55	1		2.55	1.625	2	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB974LTM
2081	8976	NDAR_INVUB974LTM	2155			M	5200	EndofPhase1_1a	2	Phase 1/1A	31	1	0	0	0	0	0	0	5	1	1	2	2	2	2	2	2	1	5	9	3	3	3	2	1	3	2	4	5	0	0	0	1	1	1	0	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	0	0	0	1	1	0	0	0	0	0	1	1	1	1	4	2.125	2	3	2.5	2.55		1	2.55	1.625	2	3.2857144	3.5	0	0.5	0	-0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB974LTM
2081	8976	NDAR_INVUB974LTM	2155			M	5800	EndofPhase2	3	Phase 2	38	1	0	0	0	0	0	0	5	1	1	2	2	2	2	2	2	1	5	9	3	3	3	2	1	3	2	4	5	0	0	0	1	1	1	0	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	0	0	0	1	1	0	0	0	0	0	1	1	1	1	4	2.125	2	3	2.5	2.55			2.55	1.625	2	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB974LTM
2081	8976	NDAR_INVUB986DER	2333			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	2	1	1	2	0	1	0	1	0	1	2	1	1	1	0	3	4	3	2	0	0	2	1	1	1	2	2	3	3	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.625	0.5	1.4285715	3.5	1.5238096	1		1.5238096	1.625	0.5	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB986DER
2081	8976	NDAR_INVUB986DER	2333			M	5200	EndofPhase1_1a	5	Phase 1/1A	140	0	0	0	0	0	1	0	2	3	2	1	1	2	1	1	0	1	0	9	2	1	1	1	0	2	3	2	2	0	2	2	1	1	1	2	2	3	3	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.625	0.25	1.2857143	2.5	1.4		1	1.5238096	1.625	0.5	1.4285715	3.5	-0.123809524	0	-0.25	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUB986DER
2081	8976	NDAR_INVUC008PTG	1293			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	4	2	2	3	2	5	6	4	6	6	5	5	4	5	5	6	2	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	5.5	5.142857	4	4.571429	1		4.571429	3.75	5.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUC008PTG	1293			F	1600	Visit6	6	Phase 1B	173	0	1	0	0	0	0	0	6	5	4	2	3	2	5	4	6	6	6	6	5	6	3	5	5	5	3	5	5	1	1	1	0	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.875	6	4.857143	4	4.6190476			4.571429	3.75	5.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUC008PTG	1293			F	2800	Visit12	12	Phase 3	338	0	1	0	0	0	0	0	6	4	2	1	2	2	2	4	6	4	4	6	3	4	2	4	4	4	2	5	6	1	1	1	0	1	1	1	1	3	2	1	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	1	0	0	0	1	1	1	1	5	2.875	5	4	3	3.6666667			4.571429	3.75	5.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUC008PTG	1293			F	5200	EndofPhase1_1a	3	Phase 1/1A	81	0	1	0	0	0	0	0	6	4	2	1	3	1	4	3	4	4	5	6	3	3	2	4	5	6	3	5	5	1	1	1	1	1	1	1	1	3	2	1	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3	4.75	3.857143	4.5	3.7619047		1	4.571429	3.75	5.5	5.142857	4	-0.8095238	-0.75	-0.75	-1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUC008PTG	1293			F	5400	EndofPhase1b	7	Phase 1B	199	0	1	0	0	0	0	0	6	2	1	0	4	0	1	3	6	4	5	4	4	2	2	4	5	5	3	5	5	1	1	1	0	1	1	1	1	3	2	0	4	3	4	1	1	1	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	4.75	3.857143	4	3.3809524			4.571429	3.75	5.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUC008PTG	1293			F	5800	EndofPhase2	8	Phase 2	205	0	1	0	0	0	0	0	6	2	1	0	4	0	1	3	6	4	5	4	4	3	3	4	4	5	3	5	5	1	1	1	0	1	1	1	1	3	2	0	4	4	4	1	1	1	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	4.75	4	4	3.4285715			4.571429	3.75	5.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUC008PTG	1293			F	6000	EndofPhase3	18	Phase 3	499	0	1	0	0	0	0	0	5	2	2	2	2	2	3	4	6	5	6	6	4	5	3	4	5	5	4	5	6	1	1	1	0	1	1	1	1	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.75	5.75	4.571429	4.5	4.095238			4.571429	3.75	5.5	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUC008PTG
2081	8976	NDAR_INVUD454MFH	2843			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	0	2	4	5	1	0	0	2	9	2	5	2	1	2	5	2	0	6	1	0	1	0	1	1	1	1	3		1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0.5	2.5714285	3.5	2.25	1		2.25	2.25	0.5	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD454MFH
2081	8976	NDAR_INVUD478NWA	1560			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	4	5	5	5	4	2	2	4	9	2	4	4	4	5	4	5	4	4	1	1	1	0	0	1	0	0	3	3	1	2	2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	6	5.125	2	3.857143	4.5	4.25	1		4.25	5.125	2	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD478NWA
2081	8976	NDAR_INVUD478NWA	1560			M	1600	Visit6	6	Phase 1/1A	162	0	0	0	0	0	0	1	6	5	5	6	6	6	6	4	0	2	2	9	2	2	2	3	2	3	5	4	5	0	1	0	0	1	1	1	1	1	2	1	2	1	2	1	1	0	0	0	0	1	0	0	1	0	1	0	1	29	0		0		0		1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	5.5	1	2.857143	4	3.8		1	4.25	5.125	2	3.857143	4.5	-0.45	0.375	-1	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD478NWA
2081	8976	NDAR_INVUD692PHD	2831			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	2	4	2	3	4	0	0	0	9	2	3	4	3	1	3	3	5	2	0	0	1	1	1	1	1	1	1	2	1	3	2	4	1	1	0	1	1	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.625	0	2.857143	3	2.75	1		2.75	3.625	0	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD692PHD
2081	8976	NDAR_INVUD692PHD	2831			M	1600	Visit6	6	Phase 1B	169	0	0	0	0	0	0	1	9	4	4	5	4	6	3	5	0	0	1	9	4	4	4	5	5	5	6	5	5	1	1	1	1	1	1	1	1	2	2	1	3	2	3	2	1	1	1	1	0	0	0	0	1	1	1	0	1	14	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.428571	0.25	4.571429	5.5	3.9473684			2.75	3.625	0	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD692PHD
2081	8976	NDAR_INVUD692PHD	2831			M	2800	Visit12	12	Phase 1B	337	0	0	0	0	0	0	1	9	6	6	4	4	2	2	5	2	1	0	9	2	3	5	2	4	4	4	6	5	1	0	1	0	1	1	1	1	2	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.142857	0.75	3.857143	4	3.5263157			2.75	3.625	0	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD692PHD
2081	8976	NDAR_INVUD692PHD	2831			M	5200	EndofPhase1_1a	1	Phase 1/1A	19	1	0	0	0	0	0	0	6	5	0	3	3	0	3	5	0	0	0	9	1	2	4	4	1	3	3	6	5	1	0	1	0	1	1	1	1	1	2	1	3	4	4	1	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	0	3.2857144	3	2.7		1	2.75	3.625	0	2.857143	3	-0.05	-0.5	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD692PHD
2081	8976	NDAR_INVUD692PHD	2831			M	5400	EndofPhase1b	18	Phase 1B	510	0	0	0	0	0	0	1	6	5	5	6	6	4	6	5	1	2	6	9	3	4	3	5	3	4	4	5	5	1	0	1	0	1	1	1	1	2	1	1	4	1	2	1	1	1	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.375	2.25	4	4	4.4			2.75	3.625	0	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUD692PHD
2081	8976	NDAR_INVUE115PGE	2149			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	5	4	5	3	4	4	5	2	2	1	9	4	5	6	5	2	4	4	5	5	1	1	1	0	1	0	1	1	1	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	4.25	1.25	4.571429	4	3.95	1		3.95	4.25	1.25	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUE115PGE
2081	8976	NDAR_INVUE115PGE	2149			M	1600	Visit6	6	Phase 1/1A	170	0	0	1	0	0	0	0	6	4	2	0	4	4	5	3	1	2	1	9	0	3	4	4	2	5	5	5	5	1	1	0	0	1	0	1	0	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	1	3.2857144	5	3.25			3.95	4.25	1.25	4.571429	4	-0.7	-0.75	-0.25	-1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUE115PGE
2081	8976	NDAR_INVUE115PGE	2149			M	2800	Visit12	12	Phase 1/1A	338	0	0	1	0	0	0	0	4	5	4	4	4	4	4	4	2	0	1	9	2	4	4	4	3	2	3	4	5	0	1	1	0	1	0	1	1	1	3	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	4.125	0.75	3.7142856	2.5	3.35			3.95	4.25	1.25	4.571429	4	-0.6	-0.125	-0.5	-0.85714287	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUE115PGE
2081	8976	NDAR_INVUE115PGE	2149			M	5200	EndofPhase1_1a	18	Phase 1/1A	513	0	0	0	0	0	1	0	2	4	3	4	4	2	3	3	0	0	0	9	1	2	2	5	3	3	4	5	5	1	1	1	0	1	1	1	1	3	3	0	4	3	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.125	0	3.2857144	3.5	2.75		1	3.95	4.25	1.25	4.571429	4	-1.2	-1.125	-1.25	-1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUE115PGE
2081	8976	NDAR_INVUF960VT8	1888			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	0	0	1	2	2	2	1	0	2	2	9	3	2	0	2	0	2	1	4	2	0	0	0	0	1	1	1	1	2	3	1	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.125	1	1.8571428	1.5	1.45	1		1.45	1.125	1	1.8571428	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUF960VT8
2081	8976	NDAR_INVUF960VT8	1888			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	1	0	0	1	1	1	1	1	2	2	0	0	2	4	9	3	4	2	2	1	2	1	2	3	0	0	0	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	6	1.125	1.5	2.4285715	1.5	1.75			1.45	1.125	1	1.8571428	1.5	0.3	0	0.5	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUF960VT8
2081	8976	NDAR_INVUF960VT8	1888			M	2800	Visit12	12	Phase 1/1A	342	1	0	0	0	0	0	0	2	0	0	0	1	2	1	1	0	0	0	9	1	1	0	3	4	1	0	4	4	2	0	0	0	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	0.875	0	2.4285715	0.5	1.25			1.45	1.125	1	1.8571428	1.5	-0.2	-0.25	-1	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUF960VT8
2081	8976	NDAR_INVUF960VT8	1888			M	5200	EndofPhase1_1a	18	Phase 1/1A	516	1	0	0	0	0	0	0	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	5	3	4	4	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4	4	4	4	4		1	1.45	1.125	1	1.8571428	1.5	2.55	2.875	3	2.142857	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUF960VT8
2081	8976	NDAR_INVUG103THW	2786			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	3	0	2	2	2	2	2	2	3	4	9	3	3	3	4	2	4	3	3	5	1	0	1	1	1	1	0	1	1	2	1	3	2	3	1	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.25	2.25	3.2857144	3.5	2.85	1		2.85	2.25	2.25	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG103THW
2081	8976	NDAR_INVUG103THW	2786			M	5200	EndofPhase1_1a	1	Phase 1/1A	7	0	0	0	0	1	0	0	5	3	0	2	2	2	2	2	2	3	3	9	3	3	2	4	1	3	2	3	4	1	0	1	1	1	1	1	1	1	2	1	3	2	3	1	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.25	2	2.857143	2.5	2.55		1	2.85	2.25	2.25	3.2857144	3.5	-0.3	0	-0.25	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG103THW
2081	8976	NDAR_INVUG201FYP	2162			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	4	2	2	2	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0.75	1.2857143	3	1.35	1		1.35	1.125	0.75	1.2857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG201FYP
2081	8976	NDAR_INVUG201FYP	2162			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	4	4	3	4	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	1.5	2.4285715	4	2.35		1	1.35	1.125	0.75	1.2857143	3	1	0.875	0.75	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG201FYP
2081	8976	NDAR_INVUG573DWR	1331			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	2	2	2	2	2	2	2	1	2	2	9	2	2	1	3	1	2	4	4	5	1	1	0	1	1	0	0	0	2	1	1	4	4	2	2	1	0	1	1	0	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	2	2.125	1.25	2.5714285	3	2.3	1		2.3	2.125	1.25	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG573DWR
2081	8976	NDAR_INVUG573DWR	1331			M	5800	EndofPhase2	10	Phase 2	297	0	0	0	0	0	1	0	3	3	2	3	4	3	3	3	2	2	2	9	2	0	2	2	1	1	4																																																									3	1.5		2.5	2.3333333			2.3	2.125	1.25	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG573DWR
2081	8976	NDAR_INVUG573DWR	1331			M	6000	EndofPhase3	14	Phase 3	393	0	0	0	0	0	1	0	2	2	2	2	2	1	2	1	0	0	0	9	1	1	2	2	2	2	2	2	2	1	1	0	0	1	0	0	0	3	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	15	0		1	15	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	3	1.75	0	1.7142857	2	1.5			2.3	2.125	1.25	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG573DWR
2081	8976	NDAR_INVUG930AA9	1518			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	1	0	0	6	6	6	6	6	1	6	6	0	0	1	9	0	4	2	6	4	6	5	5	2	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.375	0.25	3.2857144	5.5	3.9	1		3.9	5.375	0.25	3.2857144	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG930AA9
2081	8976	NDAR_INVUG930AA9	1518			M	1600	Visit6	6	Phase 1/1A	173	0	1	0	0	0	0	0	6	6	6	6	6	5	6	6	5	4	6	4	5	4	4	5	5	6	4	5	4	1	1	1	1	1	1	1	1	1	1	1	4	2	2	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.875	4.75	4.571429	5	5.142857			3.9	5.375	0.25	3.2857144	5.5	1.2428571	0.5	4.5	1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG930AA9
2081	8976	NDAR_INVUG930AA9	1518			M	2800	Visit12	12	Phase 1/1A	341	0	1	0	0	0	0	0	6	6	6	4	4	4	6	6	4	4	4	9	2	4	6	6	6	6	4	6	5	0	1	1	0	1	0	1	1	1	1	1	2	2	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.25	3	5	5	4.95			3.9	5.375	0.25	3.2857144	5.5	1.05	-0.125	2.75	1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG930AA9
2081	8976	NDAR_INVUG930AA9	1518			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	1	0	0	0	0	0	6	6	6	6	6	6	6	5	0	0	0	9	6	6	6	6	6	6	4	6	6	1	1	1	0	1	1	1	1	1	1	1	3	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.875	0	6	5	4.95		1	3.9	5.375	0.25	3.2857144	5.5	1.05	0.5	-0.25	2.7142856	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUG930AA9
2081	8976	NDAR_INVUH274GFE	2741			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	3	2	3	4	3	3	4	3	3	3	4	3	3	3	3	4	5	2	2	4	5	0	0	1	0	1	1	1	1	1	3	1	3	2	3	2	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	3.125	3.25	3.857143	2	3.2857144	1		3.2857144	3.125	3.25	3.857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH274GFE
2081	8976	NDAR_INVUH274GFE	2741			M	1600	Visit6	6	Phase 1/1A	173	0	0	1	0	0	0	0	2	2	2	3	3	2	2	3	2	2	2	9	3	3	2	4	2	0	2	2	2	0	1	0	0	1	0	1	0	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	24	0		0		1	6	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	1.5	2.5714285	1	2.25			3.2857144	3.125	3.25	3.857143	2	-1.0357143	-0.75	-1.75	-1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH274GFE
2081	8976	NDAR_INVUH274GFE	2741			M	2800	Visit12	12	Phase 1/1A	338	0	0	1	0	0	0	0	4	4	4	3	3	2	2	4	2	2	2	9	2	2	2	2	2	1	2	3	3	1	0	1	0	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1.5	2.2857144	1.5	2.55		1	3.2857144	3.125	3.25	3.857143	2	-0.73571426	0.125	-1.75	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH274GFE
2081	8976	NDAR_INVUH466KFZ	2381			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	6	5	2	4	0	1	2	4	4	3	6	2	2	2	1	2	2	2	2	2	1	0	1	0	1	1	0	1	1	2	1	2	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	6	2.857143	4.25	1.8571428	2	2.7	1		2.7	2.857143	4.25	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH466KFZ
2081	8976	NDAR_INVUH466KFZ	2381			M	1600	Visit6	6	Phase 1/1A	166	0	0	0	0	0	0	1	4	4	4	4	4	3	4	3	0	0	1	9	0	2	2	3	0	4	4	2	2	1	0	1	1	1	1	0	1	1	1	1	2	4	4	1	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.75	0.25	1.5714285	4	2.5			2.7	2.857143	4.25	1.8571428	2	-0.2	0.89285713	-4	-0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH466KFZ
2081	8976	NDAR_INVUH466KFZ	2381			M	5200	EndofPhase1_1a	12	Phase 1/1A	334	0	0	0	0	0	0	1	4	4	4	4	2	1	2	2	2	2	3	9	0	2	1	2	2	4	5	2	2	1	0	1	0	1	1	0	1	2	2	1	2	2	4	1	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	1	3	2.875	1.75	1.5714285	4.5	2.5		1	2.7	2.857143	4.25	1.8571428	2	-0.2	0.017857144	-2.5	-0.2857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH466KFZ
2081	8976	NDAR_INVUH466KFZ	2381			M	5800	EndofPhase2	18	Phase 2	516	0	0	0	0	0	0	1	2	2	2	2	2	2	4	2	0	2	2	9	0	2	0	2	1	4	3	2	2	1	0	1	0	1	1	0	1	3	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.25	1	1.2857143	3.5	1.9			2.7	2.857143	4.25	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH466KFZ
2081	8976	NDAR_INVUH736LXX	2339			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	2	4	2	4	2	1	1	1	9	2	2	1	4	3	3	1	4	5	2	2	2	2	1	1	1	2	2	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	5	0		0		1	25	0		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	4	1.75	0.75	3	2	2.1	1		2.1	1.75	0.75	3	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH736LXX
2081	8976	NDAR_INVUH736LXX	2339			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	1	0	0	0	0	0	0	2	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	4	0	0	2	2	2	2	2	0	0	0	2	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0.5	0	0.2857143	2	0.47619048		1	2.1	1.75	0.75	3	2	-1.6238096	-1.25	-0.75	-2.7142856	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUH736LXX
2081	8976	NDAR_INVUJ276BZJ	2436			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	4	5	5	6	6	6	5	4	6	4	4	4	4	4	2	4	2	6	5	1	0	1	0	1	1	1	1	1	2	1	2	4	2	2	1	1	1	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5.142857	4.75	4.142857	3	4.5	1		4.5	5.142857	4.75	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ276BZJ
2081	8976	NDAR_INVUJ397VYA	2392			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	4	4	2	5	6	6	2	4	0	9	4	4	3	5	5	6	5	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	0	1	1	0	1	9	0		0		1	21	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	1.5	4.714286	5.5	4.45	1		4.45	4.875	1.5	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ397VYA	2392			F	1600	Visit6	6	Phase 1B	168	0	1	0	0	0	0	0	6	6	4	4	6	4	4	6	4	3	5	4	6	4	4	5	2	6	4	6	6	1	0	1	0	1	1	1	1	1	1	1	4	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5	4	4.714286	5	4.714286			4.45	4.875	1.5	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ397VYA	2392			F	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	6	3	6	4	4	4	6	2	5	4	4	4	5	4	4	5	2	6	3	6	6	1	1	1	1	1	1	1	1	1	2	1	4	4	3	1	1	1	0	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	6	4.375	4.25	4.571429	4.5	4.428571			4.45	4.875	1.5	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ397VYA	2392			F	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	1	0	0	0	0	0	6	4	6	6	6	4	5	2	1	2	1	9	4	2	0	4	0	6	4	6	6	0	0	1	0	1	0	1	0	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	1	3.142857	5	3.75		1	4.45	4.875	1.5	4.714286	5.5	-0.7	0	-0.5	-1.5714285	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ397VYA	2392			F	5400	EndofPhase1b	10	Phase 1B	284	0	1	0	0	0	0	0	2	4	4	4	6	0	6	2	4	2	3	4	4	4	0	4	2	6	4	6	4	1	1	1	1	1	1	1	1	1	1	1	2	2	2	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.5	3.25	3.4285715	5	3.5714285			4.45	4.875	1.5	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ397VYA	2392			F	5800	EndofPhase2	15	Phase 2	416	0	1	0	0	0	0	0	0	2	0	0	2	0	2	0	0	1	1	9	1	1	1	0	0	5	0	2	2	0	0	0	0	1	0	0	0	1	1	1	4	4	4	1	1	1	0	0	0	0	1	0	1	1	1	1	1	24	0		1	6	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0.75	0.5	1	2.5	1			4.45	4.875	1.5	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ397VYA	2392			F	6000	EndofPhase3	16	Phase 3	449	0	1	0	0	0	0	0	1	2	2	2	3	2	2	1	0	0	0	9	2	0	2	0	0	3	1	2	4	1	0	0	0	1	0	0	0	1	2	1	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	8	0		0		1	22	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	0	1.4285715	2	1.45			4.45	4.875	1.5	4.714286	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ397VYA
2081	8976	NDAR_INVUJ589MX0	1708			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	0	2	0	0	6	4	4	1	6	4	6	4	6	4	3	1	3	3	0	0	2	2	1	1	1	2	2	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	4	1.75	3.75	4.285714	2	3	1		3	1.75	3.75	4.285714	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ589MX0
2081	8976	NDAR_INVUJ589MX0	1708			M	1600	Visit6	6	Phase 1/1A	170	0	1	0	0	0	0	0	5	3	1	2	4	2	3	4	5	4	3	4	4	2	2	5	4	4	2	4	3	0	0	1	0	1	1	0	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3	4	3.4285715	3	3.3333333			3	1.75	3.75	4.285714	2	0.33333334	1.25	0.25	-0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ589MX0
2081	8976	NDAR_INVUJ589MX0	1708			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	1	1	0	0	5	0	2	2	3	2	3	4	4	4	4	5	4	3	2	4	4	4	3	4	2	0	0	1	1	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.625	4.25	3.2857144	3.5	3.2380953			3	1.75	3.75	4.285714	2	0.23809524	0.875	0.5	-1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ589MX0
2081	8976	NDAR_INVUJ589MX0	1708			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	1	0	0	0	0	0	4	3	3	2	2	0	2	3	3	1	4	5	0	2	3	5	4	5	3	4	4	1	0	1	0	1	1	1	1	1	1	1	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	3.25	3.142857	4	2.952381		1	3	1.75	3.75	4.285714	2	-0.04761905	0.625	-0.5	-1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUJ589MX0
2081	8976	NDAR_INVUK248FD1	1931			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	3	0	3	0	2	3	0	1	3	3	3	2	4	3	1	4	5	4	3	1	1	1	2	1	1	1	1	2	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		1	7	0		1	23	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.125	1.75	2.857143	4.5	2.5238094	1		2.5238094	2.125	1.75	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK248FD1
2081	8976	NDAR_INVUK248FD1	1931			M	2800	Visit12	12	Phase 2	357	0	0	0	0	0	1	0	0	0	1	2	1	0	2	1	6	3	3	4	3	5	3	2	4	4	4	4	5	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		1	30	0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	0.875	4	3.7142856	4	2.7142856			2.5238094	2.125	1.75	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK248FD1
2081	8976	NDAR_INVUK248FD1	1931			M	5200	EndofPhase1_1a	2	Phase 1/1A	35	0	0	0	0	0	0	1	4	2	3	0	3	0	2	3	0	1	3	9	3	2	4	3	1	4	5	4	5	1	1	2	2	1	1	1	1	2	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		1	30	0		0	0	0	0	1	0	1	0	0	0	0	0	1	1	1	0	4	2.125	1	3.142857	4.5	2.6		1	2.5238094	2.125	1.75	2.857143	4.5	0.07619048	0	-0.75	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK248FD1
2081	8976	NDAR_INVUK248FD1	1931			M	5400	EndofPhase1b	6	Phase 1B	155	1	0	0	0	0	0	0	4	0	0	1	0	0	2	2	0	0	0	9	2	2	4	0	5	4	5	4	4	1	1	2	1	1	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	2	2	1	1	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0	3	4.5	1.95			2.5238094	2.125	1.75	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK248FD1
2081	8976	NDAR_INVUK248FD1	1931			M	5800	EndofPhase2	16	Phase 2	442	0	0	0	0	0	1	0	3	2	1	1	1	0	1	2	2	3	1	9	3	4	2	2	5	4	3	3	3	1	1	2	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	1	0	0	0	1	0	0	0	1	1	1	1	4	1.375	1.5	3.142857	3.5	2.3			2.5238094	2.125	1.75	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK248FD1
2081	8976	NDAR_INVUK248FD1	1931			M	6000	EndofPhase3	18	Phase 3	506	0	0	0	0	0	1	0	5	2	3	2	3	2	2	2	2	4	3	4	4	3	4	4	4	4	3	4	5	1	1	0	0	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.625	3.25	4	3.5	3.2857144			2.5238094	2.125	1.75	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK248FD1
2081	8976	NDAR_INVUK356VZW	2167			F	400	Baseline	0	Pre-Rand	1	0	0	1	1	0	0	0	6	6	6	6	6	6	6	6	3	1	1	5	5	5	4	6	2	5	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	1	4	1	0	1	0	1	0	0	0	1	1	1	0	1	26	0		0		1	4	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	6	2.5	4.857143	4.5	4.8095236	1		4.8095236	6	2.5	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK356VZW
2081	8976	NDAR_INVUK356VZW	2167			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	1	0	0	0	6	6	1	6	6	2	6	2	3	5	6	9	3	4	6	6	2	3	4	6	6	1	1	1	1	1	1	1	1	1	1	1	4	2	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	3.5	4.714286	3.5	4.45			4.8095236	6	2.5	4.857143	4.5	-0.3595238	-1.625	1	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK356VZW
2081	8976	NDAR_INVUK356VZW	2167			F	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	5	4	4	9	5	4	4	6	2	4	3	6	6	1	0	1	1	1	1	1	1	1	2	1	3	1	2	1	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	6	3.25	4.714286	3.5	5.05			4.8095236	6	2.5	4.857143	4.5	0.24047619	0	0.75	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK356VZW
2081	8976	NDAR_INVUK356VZW	2167			F	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	4	6	5	9	5	5	6	6	4	4	3	6	6	1	0	1	0	1	1	1	1	1	1	1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	6	3.75	5.428571	3.5	5.4		1	4.8095236	6	2.5	4.857143	4.5	0.5904762	0	1.25	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK356VZW
2081	8976	NDAR_INVUK526BWA	2499			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	6	4	2	4	4	4	6	6	4	5	2	6	6	6	4	6	4	5	6	6	1	1	1	1	1	0	0	2	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	1	1	1	1	1	1	3	4.375	4.25	5.714286	4.5	4.8095236	1		4.8095236	4.375	4.25	5.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK526BWA
2081	8976	NDAR_INVUK526BWA	2499			M	1600	Visit6	6	Phase 1/1A	176	0	1	0	0	0	0	0	6	6	5	6	5	6	5	6	6	5	6	4	4	4	2	2	4	6	5	5	5	1	1	1	0	1	1	0	1	2	2	1	3	4	2	2	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	1	0	0	0	0	0	0	0	1	1	1	1	4	5.625	5.25	3.7142856	5.5	4.904762			4.8095236	4.375	4.25	5.714286	4.5	0.0952381	1.25	1	-2	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK526BWA
2081	8976	NDAR_INVUK526BWA	2499			M	5200	EndofPhase1_1a	12	Phase 1/1A	327	0	1	0	0	0	0	0	6	4	4	4	4	4	4	3	6	3	3	4	4	4	4	4	5	5	2	4	4	1	0	0	0	1	1	1	1	1	1	1	4	4	4	4	1	1	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	4.125	4	4.142857	3.5	4.047619		1	4.8095236	4.375	4.25	5.714286	4.5	-0.7619048	-0.25	-0.25	-1.5714285	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK526BWA
2081	8976	NDAR_INVUK788TFH	2108			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	5	2	4	5	6	6	6	6	5	5	6	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	3	1	1	1	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	6	4	5.857143	5.5	5.5238094	1		5.5238094	6	4	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK788TFH
2081	8976	NDAR_INVUK788TFH	2108			F	2800	Visit12	12	Phase 3	316	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	6	5	5	9	6	6	6	6	6	5	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	6	4	6	4.5	5.75			5.5238094	6	4	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK788TFH
2081	8976	NDAR_INVUK788TFH	2108			F	5200	EndofPhase1_1a	7	Phase 1/1A	197	0	0	0	0	0	0	1	6	6	4	6	6	6	6	3	5	5	6	9	6	6	6	6	6	4	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	5.375	4	6	4	5.45		1	5.5238094	6	4	5.857143	5.5	-0.07380953	-0.625	0	0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK788TFH
2081	8976	NDAR_INVUK788TFH	2108			F	5800	EndofPhase2	9	Phase 2	245	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	5	4	5	9	6	5	6	5	4	4	3	6	6	0	1	1	0	1	1	1	1	2	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	6	3.5	5.428571	3.5	5.35			5.5238094	6	4	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK788TFH
2081	8976	NDAR_INVUK788TFH	2108			F	6000	EndofPhase3	18	Phase 3	477	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	6	5	5	9	6	5	5	5	5	4	3	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	6	4	5.428571	3.5	5.45			5.5238094	6	4	5.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUK788TFH
2081	8976	NDAR_INVUL035KZQ	1705			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	2	5	4	4	4	2	6	3	4	2	2	9	3	2	2	2	2	5	2	5	4	0	1	1	1	1	1	1	1	1	2	1	3	2	4	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	3.75	2	2.857143	3.5	3.25	1		3.25	3.75	2	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUL035KZQ
2081	8976	NDAR_INVUL650JV6	2007			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	2	2	1	1	2	2	2	1	1	1	2	2	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	16	0		0		1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1	0.75	1	2	1.1	1		1.1	1	0.75	1	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUL650JV6
2081	8976	NDAR_INVUM121BFD	1235			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	4	3	2	0	2	0	2	3	2	9	3	5	6	4	5	5	4	4	6	1	1	1	1	1	1	1	1	3		0	4	4	2	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	1	7	1.625	1.75	4.714286	4.5	3.1	1		3.1	1.625	1.75	4.714286	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUM121BFD
2081	8976	NDAR_INVUM121BFD	1235			F	1600	Visit6	6	Phase 1/1A	197	0	0	0	0	0	0	1	2	0	2	0	4	1	1	2	1	2	2	9	3	4	5	6	6	5	4	3	6	1	1	1	1	1	1	1	1	3		0	4	4	4	3	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	1.5	1.25	4.714286	4.5	2.95			3.1	1.625	1.75	4.714286	4.5	-0.15	-0.125	-0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUM121BFD
2081	8976	NDAR_INVUM121BFD	1235			F	5200	EndofPhase1_1a	12	Phase 1/1A	365	0	0	0	0	0	0	1	3	4	2	4	2	0	0	4	0	0	0	9	2	3	2	6	6	3	3	1	3	1	1	0	1	1	1	1	1	2	1	1	4	4	4	3	0	0	0	0	0	0	0	0					1	26	0		0		0		1	4	2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	0	3.2857144	3	2.4		1	3.1	1.625	1.75	4.714286	4.5	-0.7	0.75	-1.75	-1.4285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUM121BFD
2081	8976	NDAR_INVUM967YBV	1657			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	2	2	2	2	3	2	1	1	1	9	1	3	6	4	1	3	4	3	4	1	1	1	1	1	1	0	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	2.142857	0.75	3.142857	3.5	2.4736843	1		2.4736843	2.142857	0.75	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUM967YBV
2081	8976	NDAR_INVUN188JYV	2491			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	2	1	2	2	2	0	2	1	1	9	0	1	1	1	2	2	1	3	2	1	0	1	0	1	1	0	1	1	2	0	4	3	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	1	1.4285715	1.5	1.5	1		1.5	1.625	1	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN188JYV
2081	8976	NDAR_INVUN188JYV	2491			M	1600	Visit6	6	Phase 1/1A	174	0	0	1	0	0	0	0	0	0	4	3	0	0	6	0	2	2	4	9	1	2	2	2	3	2	3	3	4	0	0	1	0	1	1	1	1	1	2	1	4	4	4	4	1	0	0	1	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	1.625	2	2.4285715	2.5	2.15			1.5	1.625	1	1.4285715	1.5	0.65	0	1	1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN188JYV
2081	8976	NDAR_INVUN188JYV	2491			M	2800	Visit12	12	Phase 1/1A	354	0	0	0	0	0	0	1	2	0	2	2	2	2	6	1	2	2	6	9	0	2	1	2	2	2	2	4	4	1	0	1	1	1	1	1	1	2	2	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	6	2.125	2.5	2.142857	2	2.3			1.5	1.625	1	1.4285715	1.5	0.8	0.5	1.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN188JYV
2081	8976	NDAR_INVUN188JYV	2491			M	5200	EndofPhase1_1a	18	Phase 1/1A	508	0	0	0	0	0	0	1	1	0	1	2	2	0	2	0	2	1	6	9	0	2	0	2	2	1	2	3	3	0	1	0	0	1	1	1	1	3		1	3	2	2	3	1	0	1	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1	2.25	1.7142857	1.5	1.6		1	1.5	1.625	1	1.4285715	1.5	0.1	-0.625	1.25	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN188JYV
2081	8976	NDAR_INVUN857PW0	1921			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	2	2	4	3	4	3	0	2	2	5	9	2	2	4	5	2	5	4	5	6	1	0	1	0	1	1	1	1	3	1	1	2	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	2.25	3.7142856	4.5	3.25	1		3.25	2.625	2.25	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN857PW0
2081	8976	NDAR_INVUN857PW0	1921			F	1600	Visit6	6	Phase 2	169	0	0	0	0	0	0	1	6	2	2	3	3	1	1	0	1	2	2	9	2	2	2	3	4	5	3	4	5	0	0	0	0	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	1	4	2.25	1.25	3.142857	4	2.65			3.25	2.625	2.25	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN857PW0
2081	8976	NDAR_INVUN857PW0	1921			F	2800	Visit12	12	Phase 3	336	0	0	0	0	0	0	1	2	1	3	2	2	1	2	0	1	2	3	9	1	1	3	3	2	4	3	5	5	1	1	1	0	1	0	1	0	3	3	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.625	1.5	2.857143	3.5	2.3			3.25	2.625	2.25	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN857PW0
2081	8976	NDAR_INVUN857PW0	1921			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	0	0	0	0	0	1	4	2	2	3	3	4	2	0	2	4	4	9	4	2	4	4	3	5	3	4	6	1	2	1	1	1	1	1	1	3	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.5	2.5	3.857143	4	3.25		1	3.25	2.625	2.25	3.7142856	4.5	0	-0.125	0.25	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN857PW0
2081	8976	NDAR_INVUN857PW0	1921			F	5800	EndofPhase2	7	Phase 2	183	0	0	0	0	0	0	1	6	2	2	1	4	1	1	0	1	2	1	9	1	2	2	4	2	5	3	5	6	0	1	1	0	1	1	1	1	2	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.125	1	3.142857	4	2.55			3.25	2.625	2.25	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN857PW0
2081	8976	NDAR_INVUN857PW0	1921			F	6000	EndofPhase3	18	Phase 3	499	0	0	0	0	0	0	1	4	2	3	3	3	1	3	0	0	4	1	9	1	2	2	5	2	4	3	5	6	1	1	1	0	1	1	1	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	1.25	3.2857144	3.5	2.7			3.25	2.625	2.25	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUN857PW0
2081	8976	NDAR_INVUP593HYD	2578			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	2	0	2	2	2	2	2	0	0	0	9	2	2	2	4	4	3	0	2	4	0	0	1	0	1	1	1	1	1	1	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.875	0	2.857143	1.5	1.9	1		1.9	1.875	0	2.857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUP593HYD
2081	8976	NDAR_INVUP593HYD	2578			M	1600	Visit6	6	Phase 2	180	1	0	0	0	0	0	0	4	2	0	2	2	2	2	3	0	0	1	9	2	2	2	6	4	3	2	2	4	0	0	1	0	1	1	0	1	3	1	1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.125	0.25	3.142857	2.5	2.25			1.9	1.875	0	2.857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUP593HYD
2081	8976	NDAR_INVUP593HYD	2578			M	2800	Visit12	12	Phase 2	354	1	0	0	0	0	0	0	4	2	6	4	2	4	4	2	0	0	1	9	1	2	0	2	2	4	1	3	4	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	4	3.5	0.25	2	2.5	2.4			1.9	1.875	0	2.857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUP593HYD
2081	8976	NDAR_INVUP593HYD	2578			M	5200	EndofPhase1_1a	4	Phase 1/1A	124	1	0	0	0	0	0	0	3	2	4	2	3	4	3	3	0	0	0	9	2	2	2	4	2	3	2	3	4	0	0	1	0	1	1	0	1	1	1	1	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3	0	2.7142856	2.5	2.4		1	1.9	1.875	0	2.857143	1.5	0.5	1.125	0	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUP593HYD
2081	8976	NDAR_INVUP593HYD	2578			M	5800	EndofPhase2	18	Phase 2	509	1	0	1	0	0	0	0	6	2	4	2	2	2	2	0	1	1	0	9	2	0	0	4	2	3	0	2	2	0	0	0	0	1	1	1	1	1	1	1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0.5	1.7142857	1.5	1.85			1.9	1.875	0	2.857143	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUP593HYD
2081	8976	NDAR_INVUR760AYF	2878			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	1	2	3	2	2	5	2	1	0	1	9	2	1	2	2	1	3	1	4	4	0	0	1	0	1	1	0	0	3	3	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	0.5	2.2857144	2	2.05	1		2.05	2.375	0.5	2.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR760AYF
2081	8976	NDAR_INVUR760AYF	2878			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	5	3	2	4	3	3	5	2	4	3	5	5	2	3	4	4	1	3	1	4	5	0	0	0	0	1	1	0	1	1	2	1	4	2	4	4	1	0	1	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.375	4.25	3.2857144	2	3.3809524			2.05	2.375	0.5	2.2857144	2	1.3309524	1	3.75	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR760AYF
2081	8976	NDAR_INVUR760AYF	2878			M	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	4	1	3	4	3	3	5	1	0	0	1	9	1	2	4	5	2	4	3	5	6	1	0	1	0	1	0	1	1	1	1	1	4	2	1	4	1	0	1	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3	0.25	3.5714285	3.5	2.85			2.05	2.375	0.5	2.2857144	2	0.8	0.625	-0.25	1.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR760AYF
2081	8976	NDAR_INVUR760AYF	2878			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	1	0	1	0	0	0	0	3	3	2	3	3	3	3	3	1	1	3	9	2	2	4	4	1	4	3	5	6	1	0	1	0	1	0	1	1	1	1	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.25	3.4285715	3.5	2.95		1	2.05	2.375	0.5	2.2857144	2	0.9	0.5	0.75	1.1428572	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR760AYF
2081	8976	NDAR_INVUR840DMM	1444			M	400	Baseline	0	Pre-Rand	1	1	1	0	1	0	0	0	4	0	0	1	2	0	2	4	5	2	4	2	1	0	0	0	5	4	2	6	5	0	1	0	0	1	0	0	0	1	1	0	4	3	4	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	1.625	3.25	2.4285715	3	2.3333333	1		2.3333333	1.625	3.25	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR840DMM
2081	8976	NDAR_INVUR840DMM	1444			M	1600	Visit6	6	Phase 1/1A	170	1	1	0	0	0	0	0	6	3	1	2	4	2	2	2	6	4	4	6	3	4	4	3	1	4	3	3	4	0	0	0	0	1	0	1	1	1	2	1	3	4	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	2.75	5	3.142857	3.5	3.3809524			2.3333333	1.625	3.25	2.4285715	3	1.0476191	1.125	1.75	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR840DMM
2081	8976	NDAR_INVUR840DMM	1444			M	2800	Visit12	12	Phase 1/1A	347	0	1	0	0	0	0	0	4	2	0	0	2	1	2	4	6	3	4	4	4	3	3	4	4	5	4	5	6	1	0	0	0	1	1	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	4.25	4.142857	4.5	3.3333333			2.3333333	1.625	3.25	2.4285715	3	1	0.25	1	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR840DMM
2081	8976	NDAR_INVUR840DMM	1444			M	5200	EndofPhase1_1a	18	Phase 1/1A	511	0	1	0	0	0	0	0	6	3	4	5	5	5	5	5	6	5	6	6	5	5	6	6	5	6	6	4	5	1	1	0	1	1	1	1	1	1	3	1	3	2	3	1	1	1	1	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	5.75	5.142857	6	5.1904764		1	2.3333333	1.625	3.25	2.4285715	3	2.857143	3.125	2.5	2.7142856	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUR840DMM
2081	8976	NDAR_INVUT333DJ2	2655			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	1	2	2	2	0	0	0	1	9	1	1	2	2	2	2	1	2	2	0	1	0	0	1	0	0	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.375	0.25	1.7142857	1.5	1.35	1		1.35	1.375	0.25	1.7142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT333DJ2
2081	8976	NDAR_INVUT333DJ2	2655			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	4	1	3	2	1	1	1	0	0	0	0	9	1	1	0	2	1	1	0	2	2	0	0	0	0	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	1.625	0	1.2857143	0.5	1.15			1.35	1.375	0.25	1.7142857	1.5	-0.2	0.25	-0.25	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT333DJ2
2081	8976	NDAR_INVUT333DJ2	2655			F	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	1	0	2	1	3	2	1	2	2	0	1	2	2	9	2	1	1	2	1	1	1	2	2	0	1	0	0	1	0	0	0	3	3	1	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	1.25	1.5714285	1	1.55			1.35	1.375	0.25	1.7142857	1.5	0.2	0.25	1	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT333DJ2
2081	8976	NDAR_INVUT333DJ2	2655			F	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	1	0	2	2	2	2	2	1	3	2	0	0	1	9	1	2	1	1	1	2	3	2	2	1	1	0	0	1	1	0	2	3	2	1	3	3	2	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	0.25	1.4285715	2.5	1.6		1	1.35	1.375	0.25	1.7142857	1.5	0.25	0.625	0	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT333DJ2
2081	8976	NDAR_INVUT835XPV	1008			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	1	1	1	4	2	1	4	1	1	3	9	3	2	2	3	3	3	3	4	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	1.25	3.142857	3	2.65	1		2.65	2.5	1.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT835XPV
2081	8976	NDAR_INVUT835XPV	1008			M	1600	Visit6	6	Phase 2	182	0	0	0	0	1	0	0	5	0	0	2	2	0	2	2	0	0	4	9	2	4	1	2	2	3	1	2	2	1	0	0	0	1	1	1	1	2	1	1	3	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		1	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	1	2.142857	2	1.8			2.65	2.5	1.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT835XPV
2081	8976	NDAR_INVUT835XPV	1008			M	4000	Visit18	18	Phase 2	519	1	0	0	0	0	0	0	6	3	0	3	2	1	2	1	0	2	4	9	2	2	2	4	0	1	1	4	4	0	0	1	0	1	1	1	1	2	1	1	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	1.5	2.5714285	1	2.2			2.65	2.5	1.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT835XPV
2081	8976	NDAR_INVUT835XPV	1008			M	5200	EndofPhase1_1a	1	Phase 1/1A	44	1	0	0	0	0	0	0	6	4	2	3	3	1	2	2	1	2	2	9	3	2	2	3	2	3	3	4	5	1	1	1	0	1	1	1	1	1	1	0		4	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	1.25	3	3	2.75		1	2.65	2.5	1.25	3.142857	3	0.1	0.375	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT835XPV
2081	8976	NDAR_INVUT835XPV	1008			M	5800	EndofPhase2	18	Phase 2	519	1	0	0	0	0	0	0	6	3	0	3	2	1	2	1	0	2	4	9	2	2	2	4	0	1	1	4	4	0	0	1	0	1	1	1	1	2	1	1	4	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	1.5	2.5714285	1	2.2			2.65	2.5	1.25	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUT835XPV
2081	8976	NDAR_INVUU592YVL	2015			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	2	0	0	2	0	1	0	1	1	5	9	2	2	3	2	3	5	3	4	3	1	1	0	0	1	1	0	1	1	3	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	4	0.75	1.75	2.7142856	4	2	1		2	0.75	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU592YVL
2081	8976	NDAR_INVUU592YVL	2015			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	2	3	0	2	2	2	2	1	2	2	3	9	2	3	4	3	2	5	3	3	4	1	1	0	1	1	1	0	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	4	1.75	1.75	3	4	2.5			2	0.75	1.75	2.7142856	4	0.5	1	0	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU592YVL
2081	8976	NDAR_INVUU592YVL	2015			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	0	1	9	0	0	2	2	1	2	0	0	3	4	9	1	3	3	5	3	6	4	2	5	1	0	1	1	1	1	1	1	1	1	0	4	2	3	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1	1.75	3.142857	5	2.4210527			2	0.75	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU592YVL
2081	8976	NDAR_INVUU592YVL	2015			M	5200	EndofPhase1_1a	9	Phase 1/1A	253	0	0	0	0	0	0	1	2	2	2	0	2	2	2	0	0	2	4	9	2	2	2	2	1	6	4	2	4	1	1	1	1	1	1	1	1	2	2	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	4	1.5	1.5	2.142857	5	2.15		1	2	0.75	1.75	2.7142856	4	0.15	0.75	-0.25	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU592YVL
2081	8976	NDAR_INVUU592YVL	2015			M	5800	EndofPhase2	18	Phase 2	506	0	0	0	0	0	0	1	4	0	0	2	2	2	2	0	0	2	6	9	0	2	4	2	0	6	4	1	4	1	1	1	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	4	1.5	2	1.8571428	5	2.15			2	0.75	1.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU592YVL
2081	8976	NDAR_INVUU693RD0	1173			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	1	0	0	4	0	0	2	2	0	2	2	4	2	5	6	1	2	0	2	3	3	2	2	4	1	1	1	0	1	1	0	1	1	1	1	4	4	4	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	4.25	2	2.5	2.2857144	1		2.2857144	1.5	4.25	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU693RD0
2081	8976	NDAR_INVUU693RD0	1173			F	1600	Visit6	6	Phase 3	176	0	0	0	1	1	0	0	4	1	1	2	2	2	2	0	4	4	6	6	0	2	0	3	2	4	3	4	4	1	0	1	0	1	1	1	1	2	1	1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5	1.75	5	2.142857	3.5	2.6666667			2.2857144	1.5	4.25	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU693RD0
2081	8976	NDAR_INVUU693RD0	1173			F	2800	Visit12	12	Phase 3	335	0	0	0	0	0	0	1	3	1	0	2	2	2	2	0	0	4	6	9	1	2	2	1	2	3	3	3	4	1	1	1	0	1	1	2	1	1	1	0	4	2	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	2.5	2.142857	3	2.15			2.2857144	1.5	4.25	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU693RD0
2081	8976	NDAR_INVUU693RD0	1173			F	5200	EndofPhase1_1a	2	Phase 1/1A	58	0	0	0	1	0	0	0	4	0	1	1	2	1	2	2	0	2	6	9	0	2	0	4	0	3	3	1	1	1	1	1	0	1	1	1	1	2	2	1	2	1	1	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.625	2	1.1428572	3	1.75		1	2.2857144	1.5	4.25	2	2.5	-0.53571427	0.125	-2.25	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU693RD0
2081	8976	NDAR_INVUU693RD0	1173			F	5800	EndofPhase2	3	Phase 2	104	0	0	0	1	0	0	0	2	0	0	0	2	0	0	0	1	1	4	9	2	1	0	2	0	3	2	1	1	1	1	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	0.5	1.5	1	2.5	1.1			2.2857144	1.5	4.25	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU693RD0
2081	8976	NDAR_INVUU693RD0	1173			F	6000	EndofPhase3	18	Phase 3	509	0	0	0	0	0	0	1	0	0	0	1	2	2	2	0	0	2	6	9	2	2	0	2	0	4	4	2	2	1	0	1	0	1	1	1	1	1	2	0	4	2	4	4	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	0.875	2	1.4285715	4	1.65			2.2857144	1.5	4.25	2	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU693RD0
2081	8976	NDAR_INVUU926DVN	1184			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	1	2	2	2	2	3	1	1	1	9	1	2	4	4	2	5	2	2	5	1	0	1	0	1	0	1	1	1	2	0		2	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	0.75	2.857143	3.5	2.3	1		2.3	2	0.75	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU926DVN
2081	8976	NDAR_INVUU926DVN	1184			F	1600	Visit6	6	Phase 1/1A	166	0	1	0	0	0	0	0	5	1	1	2	2	2	2	4	1	2	4	9	1	3	3	4	2	4	3	4	6	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	1.75	3.2857144	3.5	2.8			2.3	2	0.75	2.857143	3.5	0.5	0.375	1	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU926DVN
2081	8976	NDAR_INVUU926DVN	1184			F	2800	Visit12	12	Phase 1/1A	342	0	1	0	0	0	0	0	5	0	1	2	2	2	2	4	2	2	3	9	0	2	3	3	2	4	3	4	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	1.75	2.857143	3.5	2.6			2.3	2	0.75	2.857143	3.5	0.3	0.25	1	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU926DVN
2081	8976	NDAR_INVUU926DVN	1184			F	5200	EndofPhase1_1a	18	Phase 1/1A	487	0	1	0	0	0	0	0	5	0	0	2	2	2	2	2	2	4	4	9	1	2	4	4	2	4	3	3	6	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	2.5	3.142857	3.5	2.7		1	2.3	2	0.75	2.857143	3.5	0.4	-0.125	1.75	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUU926DVN
2081	8976	NDAR_INVUV426DUR	1159			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	3	3	3	3	3	3	2	3	1	1	3	9	2	1	1	1	1	3	3	3	3	1	1	1	0	1	1	1	1	3	2	1	4	3	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.25	1.7142857	3	2.3	1		2.3	2.875	1.25	1.7142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUV426DUR
2081	8976	NDAR_INVUV426DUR	1159			M	1600	Visit6	6	Phase 1/1A	199	0	1	0	0	0	0	0	3	3	3	3	3	3	3	4	1	1	1	9	2	2	2	2	2	5	3	3	4	1	0	1	0	1	1	1	1	1	2	1	3	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	0.75	2.4285715	4	2.65			2.3	2.875	1.25	1.7142857	3	0.35	0.25	-0.5	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUV426DUR
2081	8976	NDAR_INVUV426DUR	1159			M	2800	Visit12	12	Phase 1/1A	373	0	1	0	0	0	0	0	3	2	3	4	3	4	3	3	2	3	2	9	3	3	3	3	3	4	3	3	4	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.125	1.75	3.142857	3.5	3.05		1	2.3	2.875	1.25	1.7142857	3	0.75	0.25	0.5	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUV426DUR
2081	8976	NDAR_INVUW044NT0	2354			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	2	1	1	1	0	1	1	0	0	1	1	1	3	2	2	2	1	3	0	1	0	0	1	0	0	0	1	2	0	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.125	0.5	1.7142857	2	1.2857143	1		1.2857143	1.125	0.5	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUW044NT0
2081	8976	NDAR_INVUW044NT0	2354			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	1	0	1	1	2	1	1	2	2	0	1	1	1	9	2	2	2	2	1	3	3	4	5	0	1	0	0	1	0	0	0	3	1	0	2	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.25	0.75	2.5714285	3	1.85			1.2857143	1.125	0.5	1.7142857	2	0.5642857	0.125	0.25	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUW044NT0
2081	8976	NDAR_INVUW044NT0	2354			M	2800	Visit12	12	Phase 1/1A	328	0	0	0	0	0	1	0	1	2	1	1	2	4	2	0	1	1	0	2	2	1	2	2	1	3	3	2	1	1	1	0	0	1	1	0	0	3	3	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	1	1.5714285	3	1.6190476			1.2857143	1.125	0.5	1.7142857	2	0.33333334	0.5	0.5	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUW044NT0
2081	8976	NDAR_INVUW044NT0	2354			M	4000	Visit18	18	Phase 1/1A	489	0	0	0	0	0	1	0	0	2	1	1	2	3	2	1	1	1	1	2	2	1	1	2	1	2	3	2	1	1	1	0	0	1	0	0	0	3	3	0	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	1.25	1.4285715	2.5	1.5238096		1	1.2857143	1.125	0.5	1.7142857	2	0.23809524	0.375	0.75	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUW044NT0
2081	8976	NDAR_INVUW838LVT	1980			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	4	6	5	4	5	6	5	4	2	4	2	9	4	2	1	4	2	3	2	5	6	1	1	0	0	1	1	0	1	1	1	1	3	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	0	4	4.875	2	3.4285715	2.5	3.8	1		3.8	4.875	2	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUW838LVT
2081	8976	NDAR_INVUW838LVT	1980			F	5200	EndofPhase1_1a	0	Phase 1/1A	7	0	1	0	1	0	0	0	4	6	5	4	5	6	5	4	2	4	2	9	4	2	1	4	2	3	2	5	6	1	1	0	0	1	1	0	1	1	1	1	3	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4.875	2	3.4285715	2.5	3.8		1	3.8	4.875	2	3.4285715	2.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUW838LVT
2081	8976	NDAR_INVUX108UFL	1075			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	1	2	2	4	4	3	5	3	2	2	2	2	2	1	2	1	2	1	4	4	1	1	0	0	1	1	1	1	3	1	1	4	3	3	3	1	0	1	0	0	0	0	0	2	2	2	2	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.375	2.25	2.2857144	1.5	2.6190476	1		2.6190476	3.375	2.25	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUX108UFL
2081	8976	NDAR_INVUX108UFL	1075			M	1600	Visit6	6	Phase 1/1A	166	0	0	0	0	0	1	0	6	5	6	6	6	6	6	3	0	3	4	9	2	3	2	5	4	1	5	6	6	0	1	1	1	1	1	1	0	3	1	1	3	3	3	4	1	0	0	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	1	0	1	0	1	1	1	1	4	5.5	1.75	4	3	4.25		1	2.6190476	3.375	2.25	2.2857144	1.5	1.6309524	2.125	-0.5	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUX108UFL
2081	8976	NDAR_INVUX203MV4	1088			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	2	1	2	0	2	3	4	4	6	3	1	2	0	3	1	4	3	5	2	1	0	1	0	1	1	1	1	1	1	1	4	4	3	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	2.25	4.25	2	3.5	2.6666667	1		2.6666667	2.25	4.25	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUX203MV4
2081	8976	NDAR_INVUX225WRB	1052			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	4	4	2	4	6	4	4	0	0	2	9	3	2	0	4	1	2	1	4	2	0	0	1	0	1	1	1	1	1	3	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	0	7	3.875	0.5	2.2857144	1.5	2.6	1		2.6	3.875	0.5	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUX225WRB
2081	8976	NDAR_INVUX562PYR	1570			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	2	2	2	3	0	0	0	9	4	3	3	2	0	2	2	3	4	2	1	2	0	1	1	1	1	2	1	1	4	2	4	2	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	3	1.375	0	2.7142856	2	1.7	1		1.7	1.375	0	2.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUX562PYR
2081	8976	NDAR_INVUX562PYR	1570			F	5200	EndofPhase1_1a	1	Phase 1/1A	38	0	0	0	0	0	1	0	5	0	3	4	2	2	2	2	1	2	0	9	4	4	4	4	5	2	2	5	6	2	2	2	1	1	1	1	1	3	1	1	2	4	4	4	1	0	0	0	0	1	0	0	2	2	2	2	0		0		1	30	0		0		0	1	0	0	0	0	1	0	1	1	0	0	1	0	0	0	4	2.5	0.75	4.571429	2	2.95		1	1.7	1.375	0	2.7142856	2	1.25	1.125	0.75	1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUX562PYR
2081	8976	NDAR_INVUY313LVY	2516			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	5	2	3	4	4	0	2	5	1	9	4	5	5	2	3	3	4	4	5	0	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.125	2	4	3.5	3.4	1		3.4	3.125	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY313LVY
2081	8976	NDAR_INVUY313LVY	2516			M	1600	Visit6	6	Phase 2	164	0	0	0	0	0	1	0	0	0	3	3	1	1	4	0	2	3	5	9	4	4	4	1	3	3	2	2	4	0	0	0	0	0	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.5	2.5	3.142857	2.5	2.45			3.4	3.125	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY313LVY
2081	8976	NDAR_INVUY313LVY	2516			M	2800	Visit12	12	Phase 3	321	0	0	0	0	0	1	0	1	0	0	2	0	0	2	1	2	2	5	9	2	2	4	3	2	4	2	3	4	0	0	0	0	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	0.75	2.25	2.857143	3	2.05			3.4	3.125	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY313LVY
2081	8976	NDAR_INVUY313LVY	2516			M	5200	EndofPhase1_1a	3	Phase 1/1A	94	0	0	0	0	0	1	0	1	2	3	3	1	3	5	0	2	2	5	9	1	3	4	2	3	3	2	3	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	2.25	2.857143	2.5	2.6		1	3.4	3.125	2	4	3.5	-0.8	-0.875	0.25	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY313LVY
2081	8976	NDAR_INVUY313LVY	2516			M	5800	EndofPhase2	10	Phase 2	265	0	0	0	0	0	1	0	1	0	0	2	1	0	2	1	2	2	5	9	0	2	3	1	2	4	2	1	4	0	0	0	0	0	1	1	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	0.875	2.25	1.8571428	3	1.75			3.4	3.125	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY313LVY
2081	8976	NDAR_INVUY313LVY	2516			M	6000	EndofPhase3	18	Phase 3	500	0	0	0	0	0	1	0	0	0	3	3	0	2	2	1	1	1	4	9	2	6	6	0	2	3	2	1	6	1	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1		1.375	1.5	3.2857144	2.5	2.25			3.4	3.125	2	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY313LVY
2081	8976	NDAR_INVUY327NL4	1234			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	5	5	2	4	4	6	5	2	2	1	9	3	4	3	5	2	4	3	5	5	0	0	1	0	0	1	0	1	1	1	1	3	2	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.625	1.25	3.857143	3.5	3.8	1		3.8	4.625	1.25	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY327NL4
2081	8976	NDAR_INVUY327NL4	1234			M	1600	Visit6	6	Phase 2	169	0	1	0	1	0	0	0	5	5	6	4	6	6	6	6	2	3	0	9	3	5	2	6	2	4	3	6	6	1	0	0	0	1	1	0	0	1	1	1	3	2	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.5	1.25	4.285714	3.5	4.3			3.8	4.625	1.25	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY327NL4
2081	8976	NDAR_INVUY327NL4	1234			M	2800	Visit12	12	Phase 2	342	0	0	0	0	0	1	0	5	6	6	2	6	4	4	0	0	0	0	9	4	4	3	6	2	3	2	5	6	0	1	1	0	1	1	0	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	1	5	4.125	0	4.285714	2.5	3.4			3.8	4.625	1.25	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY327NL4
2081	8976	NDAR_INVUY327NL4	1234			M	5200	EndofPhase1_1a	3	Phase 1/1A	88	0	1	0	1	0	0	0	6	6	5	4	5	6	6	6	1	1	1	9	0	1	5	6	2	4	2	6	6	0	0	1	0	0	1	0	1	1	1	1	4	3	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.5	0.75	3.7142856	3	3.95		1	3.8	4.625	1.25	3.857143	3.5	0.15	0.875	-0.5	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY327NL4
2081	8976	NDAR_INVUY327NL4	1234			M	5800	EndofPhase2	18	Phase 2	497	0	1	0	0	0	0	0	3	5	4	3	3	5	5	1	0	0	1	9	4	2	4	4	3	4	2	5	6	1	1	1	0	1	1	1	1	3		1	3	1	2	4	0	0	0	0	0	0	0	0					1	27	0		0		1	3	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	5	3.625	0.25	4	3	3.2			3.8	4.625	1.25	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY327NL4
2081	8976	NDAR_INVUY836FAR	1253			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	6	4	6	6	6	3	4	3		2	9	5	5	5	6	3	3	3	4	6	2	1	0	0	1	1	1	1	2	1	1	3	2	4	2	1	0	1	0	0	0	0	0	1	2	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875		4.857143	3	4.4210525	1		4.4210525	4.875		4.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY836FAR
2081	8976	NDAR_INVUY836FAR	1253			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	6	2	1	3	3	3	3	3	2	6	2	9	4	4	4	3	2	5	5	5	6	0	0	0	0	1	1	1	1	1	1	1	4	2	3	3	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	3	2.5	4	5	3.6			4.4210525	4.875		4.857143	3	-0.8210526	-1.875		-0.85714287	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY836FAR
2081	8976	NDAR_INVUY836FAR	1253			M	2800	Visit12	12	Phase 1/1A	337	1	0	1	0	1	0	0	6	5	3	5	4	4	5	1	3	4	3	5	3	4	3	5	3	4	4	5	6	1	1	0	1	1	1	1	1	1	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5	4.125	3.75	4.142857	4	4.047619			4.4210525	4.875		4.857143	3	-0.3734336	-0.75		-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY836FAR
2081	8976	NDAR_INVUY836FAR	1253			M	5200	EndofPhase1_1a	18	Phase 1/1A	520	1	0	0	0	1	0	0	4	6	4	4	2	4	2	2	4	4	4	2	6	5	4	5	6	4	4	6	6	1	0	1	1	1	1	1	1	1	1	1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	3.5	5.428571	4	4.1904764		1	4.4210525	4.875		4.857143	3	-0.23057644	-1.375		0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUY836FAR
2081	8976	NDAR_INVUZ032ZR1	2423			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	5	4	4	3	2	2	4	2	2	3	2	9	2	3	2	3	2	4	3	5	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	6	3.25	1.75	3.2857144	3.5	3.15	1		3.15	3.25	1.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ032ZR1	2423			M	1600	Visit6	6	Phase 2	181	1	0	1	0	0	0	0	5	2	4	5	2	3	5	2	2	4	2	9	3	4	3	4	3	4	4	5	5	1	0	1	0	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.5	2	3.857143	4	3.55			3.15	3.25	1.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ032ZR1	2423			M	2800	Visit12	12	Phase 3	349	0	0	1	0	0	0	0	6	3	3	6	2	3	4	1	1	4	3	9	2	4	2	5	5	5	3	5	5	0	0	1	1	1	1	1	1	1	1	0	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	3.5	2	4	4	3.6			3.15	3.25	1.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ032ZR1	2423			M	4000	Visit18	18	Phase 3	502	1	0	1	0	0	0	0	5	4	6	4	5	4	5	2	6	4	6	5	4	4	4	4	6	4	3	5	6	1	2	1	1	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	5.25	4.714286	3.5	4.571429			3.15	3.25	1.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ032ZR1	2423			M	5200	EndofPhase1_1a	1	Phase 1/1A	34	1	0	1	0	0	0	0	6	1	1	1	2	1	2	1	2	1	1	9	2	3	4	4	5	4	2	4	5	1	1	1	1	1	1	0	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.875	1	3.857143	3	2.6		1	3.15	3.25	1.75	3.2857144	3.5	-0.55	-1.375	-0.75	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ032ZR1	2423			M	5800	EndofPhase2	8	Phase 2	224	1	0	0	0	0	0	0	6	2	2	6	5	3	3	2	2	1	2	9	3	4	3	4	4	4	3	5	6	1	0	1	0	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	4	3.625	1.25	4.142857	3.5	3.5			3.15	3.25	1.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ032ZR1	2423			M	6000	EndofPhase3	18	Phase 3	502	1	0	1	0	0	0	0	5	4	6	4	5	4	5	2	6	4	6	5	4	4	4	4	6	4	3	5	6	1	2	1	1	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	5.25	4.714286	3.5	4.571429			3.15	3.25	1.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ032ZR1
2081	8976	NDAR_INVUZ101HJH	2118			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	4	2	4	0	4	5	6	2	2	4	2	2	0	4	6	3	5	2	4	1	1	1	1	1	1	1	1	2	1	1	2	2	2	2	1	1	1	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		0	0	1	1	0	0	1	0	0	1	0	0	1	1	1	1	4	2.375	3.5	2.857143	4	2.9047618	1		2.9047618	2.375	3.5	2.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ101HJH
2081	8976	NDAR_INVUZ199FKW	2215			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	4	2	3	1	3	0	0	2	1	9	2	2	2	2	2	5	5	3	5	0	0	1	1	0	1	1	1	2	3	0	4	2	2	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	0.75	2.5714285	5	2.5	1		2.5	2.375	0.75	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ199FKW
2081	8976	NDAR_INVUZ199FKW	2215			F	5200	EndofPhase1_1a	1	Phase 1/1A	28	0	0	0	0	0	0	1	2	2	3	3	1	1	1	0	0	1	1	9	3	2	3	4	4	4	3	3	6	0	1	1	1	0	1	1	1	2	3	1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.625	0.5	3.5714285	3.5	2.35		1	2.5	2.375	0.75	2.5714285	5	-0.15	-0.75	-0.25	1	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVUZ199FKW
2081	8976	NDAR_INVVA110JVY	1968			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	4	4	2	2	2	2	2	3	4	6	5	3	4	1	2	2	2	2	5	5	1	1	1	1	1	0	1	0	3		1	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2.625	4.5	3.142857	2	3.0952382	1		3.0952382	2.625	4.5	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA110JVY
2081	8976	NDAR_INVVA110JVY	1968			M	1600	Visit6	6	Phase 2	190	0	0	0	0	0	1	0	2	0	1	4	0	2	4	1	2	4	4	9	4	4	2	6	2	2	2	4	6	1	0	1	0	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	1.75	2.5	4	2	2.8			3.0952382	2.625	4.5	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA110JVY
2081	8976	NDAR_INVVA110JVY	1968			M	2800	Visit12	12	Phase 2	365	0	0	0	0	0	1	0	2	0	4	4	2	4	5	0	2	5	5	9	5	6	1	4	3	3	2	4	6	1	0	1	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	4	2.625	3	4.142857	2.5	3.35			3.0952382	2.625	4.5	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA110JVY
2081	8976	NDAR_INVVA110JVY	1968			M	5200	EndofPhase1_1a	3	Phase 1/1A	79	0	0	0	0	0	1	0	3	3	2	3	1	3	3	1	2	4	4	9	4	4	1	4	3	2	2	4	0	1	0	1	1	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	2.5	2.857143	2	2.65		1	3.0952382	2.625	4.5	3.142857	2	-0.44523808	-0.25	-2	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA110JVY
2081	8976	NDAR_INVVA529WUA	1116			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	1	2	2	2	2	1	3	3	2	1	3	3	4	2	2	4	1	4	4	2	2	2	2	1	1	1	2	3	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	1	1	1	1	1	1	3	1.875	2.25	3.142857	2.5	2.4285715	1		2.4285715	1.875	2.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA529WUA
2081	8976	NDAR_INVVA529WUA	1116			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	1	2	4	1	2	2	3	2	2	3	1	9	1	2	0	2	5	5	3	3	4	1	1	1	0	1	1	2	1	2	2	1	4	2	3	4	1	0	0	1	0	0	1	0	1	1	1	0	1	7	0		0		1	23	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2.125	1.5	2.4285715	4	2.4			2.4285715	1.875	2.25	3.142857	2.5	-0.028571429	0.25	-0.75	-0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA529WUA
2081	8976	NDAR_INVVA529WUA	1116			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	4	3	4	2	3	2	3	1	1	2	1	9	3	3	2	3	2	4	3	4	4	1	1	1	0	1	0	0	1	2	2	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	1	3	3.5	2.7			2.4285715	1.875	2.25	3.142857	2.5	0.27142859	0.875	-1.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA529WUA
2081	8976	NDAR_INVVA529WUA	1116			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	1	0	1	0	0	0	0	4	2	2	2	3	2	4	1	3	2	2	9	3	5	4	2	4	5	2	5	4	0	1	0	0	1	0	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	1	0	0	1	1	1	1	4	2.5	1.75	3.857143	3.5	3.05		1	2.4285715	1.875	2.25	3.142857	2.5	0.62142855	0.625	-0.5	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA529WUA
2081	8976	NDAR_INVVA539WZ0	2377			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	3	1	4	4	4	1	1	2	5	9	1	2	3	3	4	3	3	2	6	1	1	1	0	1	1	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.625	2	3	3	3.2	1		3.2	3.625	2	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA539WZ0
2081	8976	NDAR_INVVA539WZ0	2377			M	1600	Visit6	6	Phase 1/1A	171	1	0	0	0	0	0	0	6	4	4	2	5	3	3	3	3	3	4	9	3	3	3	4	2	3	2	6	6	1	0	0	0	1	1	0	1	1	2	1	4	3	4	3	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.75	2.5	3.857143	2.5	3.6			3.2	3.625	2	3	3	0.4	0.125	0.5	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA539WZ0
2081	8976	NDAR_INVVA539WZ0	2377			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	6	6	6	6	6	4	6	3	3	2	4	9	2	3	4	4	3	4	3	6	6	0	0	0	0	1	1	0	1	1	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	5.375	2.25	4	3.5	4.35			3.2	3.625	2	3	3	1.15	1.75	0.25	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA539WZ0
2081	8976	NDAR_INVVA539WZ0	2377			M	5200	EndofPhase1_1a	18	Phase 1/1A	520	1	0	0	0	0	0	0	4	2	1	2	2	0	2	0	0	0	0	9	0	2	4	2	0	3	3	4	2	0	0	0	0	1	1	0	1	1	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	0	2	3	1.65		1	3.2	3.625	2	3	3	-1.55	-2	-2	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA539WZ0
2081	8976	NDAR_INVVA655XDP	2605			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	5	4	2	2	2	2	4	1	2	1	9	1	2	2	4	2	4	3	4	5	0	1	0	0	1	0	1	0	2	2	0	4	4	2	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	4	3.125	1	2.857143	3.5	2.8	1		2.8	3.125	1	2.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVA655XDP
2081	8976	NDAR_INVVB140MCL	2138			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	5	4	3	4	3	4	3	0	4	6	9	6	6	3	4	2	4	3	4	4	1	1	1	0	1	1	1	1	3		1	3	3	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	2.5	4.142857	3.5	3.9	1		3.9	4	2.5	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB140MCL
2081	8976	NDAR_INVVB364LJN	2763			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	0	1	2	1	2	0	1	1	0	9	0	1	2	1	2	4	2	4	4	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	2	1.625	0.5	2	3	1.75	1		1.75	1.625	0.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB364LJN
2081	8976	NDAR_INVVB364LJN	2763			F	5200	EndofPhase1_1a	2	Phase 1/1A	54	0	0	0	0	0	0	1	4	3	0	1	2	1	2	0	1	2	1	9	2	1	2	2	1	4	3	4	5	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	2	1.625	1	2.4285715	3.5	2.05		1	1.75	1.625	0.5	2	3	0.3	0	0.5	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB364LJN
2081	8976	NDAR_INVVB364LJN	2763			F	5800	EndofPhase2	4	Phase 2	104	0	0	0	0	0	0	1	4	3	0	1	2	2	2	0	1	2	1	9	2	1	4	2	1	4	1	4	5	0	0	1	1	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	3	1.75	1	2.7142856	2.5	2.1			1.75	1.625	0.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB364LJN
2081	8976	NDAR_INVVB610CEC	1229			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	4	2	2	2	4	4	6	6	6	6	6	6	4	4	6	4	4	6	4	1	2	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	2	0	0	0	1	30	0		0		0		0		0	0	1	1	0	0	0	1	0	0	0	0	1	1	1	1	6	3.75	6	5.142857	4	4.6666665	1		4.6666665	3.75	6	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB610CEC
2081	8976	NDAR_INVVB610CEC	1229			M	1600	Visit6	6	Phase 1/1A	179	1	0	0	0	0	0	0	6	4	4	5	6	6	6	3	6	6	6	6	5	6	6	6	6	5	3	5	5	1	0	1	1	1	1	2	1	1	1	1	3	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5	6	5.571429	4	5.285714			4.6666665	3.75	6	5.142857	4	0.61904764	1.25	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB610CEC
2081	8976	NDAR_INVVB610CEC	1229			M	2800	Visit12	12	Phase 1/1A	340	1	0	0	0	0	0	0	6	6	6	4	4	6	6	2	6	6	6	9	6	6	6	6	6	4	2	6	6	1	0	1	1	1	1	2	1	1	1	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5	4.5	6	3	5.3			4.6666665	3.75	6	5.142857	4	0.6333333	1.25	-1.5	0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB610CEC
2081	8976	NDAR_INVVB610CEC	1229			M	5200	EndofPhase1_1a	18	Phase 1/1A	515	1	0	0	0	0	0	0	4	4	5	6	6	6	6	3	6	6	6	6	6	6	6	6	6	6	3	6	6	1	1	1	1	1	1	2	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5	6	6	4.5	5.4761906		1	4.6666665	3.75	6	5.142857	4	0.8095238	1.25	0	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB610CEC
2081	8976	NDAR_INVVB880NL1	1053			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	1	2	2	2	3	1	2	4	5	9	0	2	2	5	4	2	1	5	3	1	0	1	0	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	5	2.125	2.75	3	1.5	2.6	1		2.6	2.125	2.75	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB880NL1
2081	8976	NDAR_INVVB880NL1	1053			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	6	3	4	2	2	3	4	2	1	6	6	9	3	3	3	6	4	3	1	5	5	1	0	1	1	1	1	1	1	1	2	1	3	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.25	3.25	4.142857	2	3.6			2.6	2.125	2.75	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB880NL1
2081	8976	NDAR_INVVB880NL1	1053			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	0	1	5	3	2	0	2	2	4	0	2	4	5	9	3	5	5	4	4	3	2	5	5	0	0	1	1	1	1	1	1	1	2	1	2	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.25	2.75	4.428571	2.5	3.25			2.6	2.125	2.75	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB880NL1
2081	8976	NDAR_INVVB880NL1	1053			M	5200	EndofPhase1_1a	4	Phase 1/1A	106	1	0	0	0	0	0	0	5	1	0	1	2	2	3	0	2	5	4	9	3	2	2	4	3	3	1	5	5	1	0	1	0	1	1	1	1	1	2	0		2	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	1.75	2.75	3.4285715	2	2.65		1	2.6	2.125	2.75	3	1.5	0.05	-0.375	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB880NL1
2081	8976	NDAR_INVVB880NL1	1053			M	5800	EndofPhase2	18	Phase 2	505	1	0	0	0	0	0	0	5	3	2	1	2	1	2	0	4	4	5	2	0	2	0	4	2	3	2	4	4	0	0	1	1	1	1	0	1	1	3	1	3	2	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2	3.75	2.2857144	2.5	2.4761906			2.6	2.125	2.75	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVB880NL1
2081	8976	NDAR_INVVD104GP4	2811			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	3	3	2	2	0	2	2	6	4	5	4	4	5	6	2	6	5	3	4	6	0	0	1	1	1	1	1	1	1	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	1	2.5	4.75	4.714286	4	3.8095238	1		3.8095238	2.5	4.75	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD104GP4
2081	8976	NDAR_INVVD142RTF	2473			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	1	2	0	1	0	1	3	5	9	1	2	2	2	1	4	1	3	4	0	0	2	0	1	0	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	0.75	2.25	2.142857	2.5	1.75	1		1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD142RTF
2081	8976	NDAR_INVVD142RTF	2473			M	1600	Visit6	6	Phase 3	167	0	0	0	0	0	1	0	1	0	0	0	1	0	2	2	0	0	0	9	0	2	3	4	0	2	2	2	4	0	1	0	0	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	1	1	29	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	7	0.75	0	2.142857	2	1.25			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD142RTF
2081	8976	NDAR_INVVD142RTF	2473			M	2800	Visit12	12	Phase 3	336	0	0	0	0	0	1	0	3	0	4	3	2	4	4	2	1	1	1	9	3	4	3	4	2	2	2	4	3	1	1	0	1	1	0	0	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	0	5	2.75	0.75	3.2857144	2	2.6			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD142RTF
2081	8976	NDAR_INVVD142RTF	2473			M	5200	EndofPhase1_1a	1	Phase 1/1A	35	0	0	0	0	0	1	0	2	0	2	2	2	0	2	0	2	3	4	9	1	2	2	3	2	4	2	3	3	1	1	2	0	1	1	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	5	1.25	2.25	2.2857144	3	2.05		1	1.75	0.75	2.25	2.142857	2.5	0.3	0.5	0	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD142RTF
2081	8976	NDAR_INVVD142RTF	2473			M	5800	EndofPhase2	5	Phase 2	133	0	0	0	0	0	1	0	2	0	0	0	0	0	1	1	1	2	5	9	0	2	1	5	3	4	2	1	3	0	1	0	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	0		1	6	0		1	15	0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	7	0.5	2	2.142857	3	1.65			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD142RTF
2081	8976	NDAR_INVVD142RTF	2473			M	6000	EndofPhase3	18	Phase 3	496	0	0	0	0	0	1	0	1	0	2	1	1	0	3	2	0	0	0	9	0	2	2	4	1	2	2	3	4	1	0	0	1	1	0	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.25	0	2.2857144	2	1.5			1.75	0.75	2.25	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD142RTF
2081	8976	NDAR_INVVD436LLK	1564			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	0	0	0	3	0	2	4	0	0	0	9	1	2	0	0	1	3	1	2	4	0	1	0	0	1	1	0	1	1	3	0	4	3	1	1	1	1	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	2	1.75	0	1.4285715	2	1.4	1		1.4	1.75	0	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD436LLK
2081	8976	NDAR_INVVD436LLK	1564			F	5200	EndofPhase1_1a	2	Phase 1/1A	62	0	1	0	1	0	0	0	3	0	0	0	2	0	1	1	0	0	0	9	0	1	0	1	0	2	2	4	2	1	1	0	0	1	1	0	1	1	2	0	4	4	4	1	1	1	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.875	0	1.1428572	2	0.95		1	1.4	1.75	0	1.4285715	2	-0.45	-0.875	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD436LLK
2081	8976	NDAR_INVVD715VTJ	1747			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	1	0	1	0	0	0	2	0	1	0	0	0	0	9	0	0	0	1	0	0	1	0	2	0	0	0	0	1	0	0	1	3		1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	0.5	0	0.42857143	0.5	0.4	1		0.4	0.5	0	0.42857143	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD715VTJ
2081	8976	NDAR_INVVD715VTJ	1747			M	1600	Visit6	6	Phase 1/1A	163	1	0	0	0	0	0	0	5	3	0	4	2	0	5	1	0	0	0	9	2	4	4	6	2	0	2	2	2	0	0	0	0	0	1	0	1	1	1	1	2	2	2	1	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.5	0	3.142857	1	2.2			0.4	0.5	0	0.42857143	0.5	1.8	2	0	2.7142856	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD715VTJ
2081	8976	NDAR_INVVD715VTJ	1747			M	2800	Visit12	12	Phase 2	337	1	0	0	0	0	0	0	1	0	2	1	2	1	4	0	1	0	0	9	0	2	1	2	0	2	1	0	1	0	0	0	0	1	0	0	1	1	1	1	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.375	0.25	0.85714287	1.5	1.05			0.4	0.5	0	0.42857143	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD715VTJ
2081	8976	NDAR_INVVD715VTJ	1747			M	5200	EndofPhase1_1a	7	Phase 1/1A	184	1	0	0	0	0	0	0	2	3	4	4	2	0	4	2	1	0	0	9	0	1	2	3	2	0	2	2	1	0	0	2	0	0	0	0	2	1	1	1	2	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	17	0		0		1	13	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	0.25	1.5714285	1	1.75		1	0.4	0.5	0	0.42857143	0.5	1.35	2.125	0.25	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD715VTJ
2081	8976	NDAR_INVVD715VTJ	1747			M	5800	EndofPhase2	18	Phase 2	504	1	0	0	0	0	0	0	4	1	5	1	2	3	3	0	0	0	4	9	2	1	0	5	1	1	1	4	2	0	0	0	0	0	1	0	1	2	2	1	2	3	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	6	2.375	1	2.142857	1	2			0.4	0.5	0	0.42857143	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVD715VTJ
2081	8976	NDAR_INVVE801YDM	2812			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	2	0	2	3	4	0	1	0	3	9	1	2	0	6	2	4	2	2	3	1	1	1	0	1	0	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	1.375	1	2.2857144	3	1.85	1		1.85	1.375	1	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVE801YDM
2081	8976	NDAR_INVVE801YDM	2812			M	1600	Visit6	6	Phase 2	177	0	0	0	0	0	0	1	0	3	0	2	2	2	5	0	0	0	6	9	0	1	0	2	0	4	1	3	3	0	0	0	0	1	1	1	1	3		1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.5	1.2857143	2.5	1.7			1.85	1.375	1	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVE801YDM
2081	8976	NDAR_INVVE801YDM	2812			M	5200	EndofPhase1_1a	5	Phase 1/1A	145	0	0	0	0	0	0	1	0	4	4	2	1	3	1	2	0	0	6	9	2	1	0	0	0	4	2	1	4	0	0	1	0	1	1	1	1	3		1	2	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1.5	1.1428572	3	1.85		1	1.85	1.375	1	2.2857144	3	0	0.75	0.5	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVE801YDM
2081	8976	NDAR_INVVE801YDM	2812			M	6000	EndofPhase3	11	Phase 3	298	0	0	0	0	0	0	1	0	0	2	2	2	1	6	0	0	0	6	9	1	2	2	0	0	4	2	4	5	1	1	1	0	1	0	0	1	3		0	4	4	4	3	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	6	1.625	1.5	2	3	1.95			1.85	1.375	1	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVE801YDM
2081	8976	NDAR_INVVF107RA8	1733			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	3	0	0	2	2	0	0	0	9	0	0	2	1	3	4	2	0	1	1	0	0	0	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	6	1.125	0	1	3	1.1	1		1.1	1.125	0	1	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF107RA8
2081	8976	NDAR_INVVF107RA8	1733			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	1	0	1	2	2	2	1	0	2	1	0	0	1	9	0	2	2	3	2	4	0	1	1	0	0	1	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.375	0.25	1.5714285	2	1.35			1.1	1.125	0	1	3	0.25	0.25	0.25	0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF107RA8
2081	8976	NDAR_INVVF107RA8	1733			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	4	0	0	2	3	2	3	1	0	2	1	9	2	1	2	3	4	3	2	3	4	0	1	1	0	1	1	1	1	3		1	2	4	2	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.875	0.75	2.7142856	2.5	2.1			1.1	1.125	0	1	3	1	0.75	0.75	1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF107RA8
2081	8976	NDAR_INVVF107RA8	1733			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	0	0	0	2	3	2	6	1	0	0	0	9	2	5	4	6	0	6	1	0	0	0	1	0	0	1	1	1	1	1	1	1	2	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0	2.4285715	3.5	1.9		1	1.1	1.125	0	1	3	0.8	0.625	0	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF107RA8
2081	8976	NDAR_INVVF208VR0	1753			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	1	1	4	2	3	4	0	0	0	0	9	1	3	5	5	4	5	3	3	5	1	0	1	0	1	1	1	1	1	3	1	3	1	3	4	0	0	0	0	0	0	0	0					1	10	0		1	21	0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	2.625	0	3.7142856	4	2.75	1		2.75	2.625	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF208VR0
2081	8976	NDAR_INVVF208VR0	1753			F	5200	EndofPhase1_1a	2	Phase 1/1A	45	0	0	0	0	0	0	1	5	6	4	4	2	6	6	1	2	4	1	9	2	4	4	6	5	5	3	5	6	1	0	1	0	1	1	1	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	1.75	4.571429	4	4.05		1	2.75	2.625	0	3.7142856	4	1.3	1.625	1.75	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF208VR0
2081	8976	NDAR_INVVF208VR0	1753			F	5800	EndofPhase2	3	Phase 2	71	0	0	0	0	0	0	1	6	2	2	2	3	5	5	0	1	4	5	9	2	3	4	5	4	5	5	3	6	1	1	1	1	1	0	1	1	2	1	1	4	1	2	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	2.5	3.857143	5	3.6			2.75	2.625	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF208VR0
2081	8976	NDAR_INVVF208VR0	1753			F	6000	EndofPhase3	7	Phase 3	183	0	0	1	0	0	0	0	5	2	2	4	5	3	2	1	1	1	1	9	4	4	4	5	1	5	4	4	6	1	0	1	0	1	1	1	1	1	3	1	4	2	2	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	0.75	4	4.5	3.2			2.75	2.625	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF208VR0
2081	8976	NDAR_INVVF407WXG	1224			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	2	0	0	5	2	1	0	6	1	3	1	3	4	2	4	3	5	5	4	5	1	0	1	1	1	1	0	1	1	2	1	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.75	2.75	3.5714285	5	2.857143	1		2.857143	1.75	2.75	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF407WXG
2081	8976	NDAR_INVVF407WXG	1224			M	1600	Visit6	6	Phase 1/1A	178	1	0	0	0	0	0	0	5	2	1	2	2	2	2	1	1	2	1	9	2	2	4	4	3	5	2	4	5	1	0	1	0	1	1	1	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	1	3.4285715	3.5	2.6			2.857143	1.75	2.75	3.5714285	5	-0.25714287	0.375	-1.75	-0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF407WXG
2081	8976	NDAR_INVVF407WXG	1224			M	2800	Visit12	12	Phase 1/1A	373	1	0	0	0	0	0	0	3	0	0	0	2	0	0	1	0	0	0	9	2	2	4	4	3	6	4	4	4	0	1	0	1	1	1	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	3	0.75	0	3.2857144	5	1.95			2.857143	1.75	2.75	3.5714285	5	-0.9071429	-1	-2.75	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF407WXG
2081	8976	NDAR_INVVF407WXG	1224			M	4000	Visit18	18	Phase 1/1A	562	1	0	1	0	1	0	0	4	0	1	1	4	0	1	1	2	5	2	9	3	2	2	4	3	5	2	4	3	0	0	1	1	1	1	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.5	2.25	3	3.5	2.45		1	2.857143	1.75	2.75	3.5714285	5	-0.40714285	-0.25	-0.5	-0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF407WXG
2081	8976	NDAR_INVVF508CU8	1306			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	0	2	0	2	0	1	0	0	1	1	9	3	2	2	1	0	5	2	4	2	1	1	1	0	1	0	1	1	2	3	0	4	3	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0.75	0.5	2	3.5	1.45	1		1.45	0.75	0.5	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF508CU8
2081	8976	NDAR_INVVF554CZ1	1199			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	0	2	2	2	6	2	1	1	9	0	2	0	6	2	5	4	6	5	1	0	0	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	1	3	4.5	2.6	1		2.6	2.25	1	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF554CZ1
2081	8976	NDAR_INVVF554CZ1	1199			M	1600	Visit6	6	Phase 1/1A	189	0	1	0	1	0	0	0	6	0	0	2	2	2	2	6	0	0	0	9	0	3	4	6	2	5	4	5	2	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0	3.142857	4.5	2.55		1	2.6	2.25	1	3	4.5	-0.05	0.25	-1	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF554CZ1
2081	8976	NDAR_INVVF571NX5	2312			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	3	0	0	4	0	1	0	0	0	0	9	2	0	0	0	0	5	2	4	5	1	1	1	0	1	1	1	1	3	1	1	2	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0	1.5714285	3.5	1.6	1		1.6	1.75	0	1.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF571NX5
2081	8976	NDAR_INVVF571NX5	2312			M	5200	EndofPhase1_1a	1	Phase 1/1A	9	0	0	0	0	0	0	1	9	3	0	0	4	0	1	0	0	0	0	9	2	0	0	0	0	5	2	4	5	1	0	1	0	1	1	1	1	2	1	1	2	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.1428572	0	1.5714285	3.5	1.3684211		1	1.6	1.75	0	1.5714285	3.5	-0.23157895	-0.60714287	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF571NX5
2081	8976	NDAR_INVVF571NX5	2312			M	5800	EndofPhase2	2	Phase 2	19	0	0	0	0	0	0	1	6	3	0	0	4	0	1	0	0	0	0	9	2	0	0	0	0	5	2	4	5	0	0	1	0	1	0	1	1	2	1	1	2	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0	1.5714285	3.5	1.6			1.6	1.75	0	1.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF571NX5
2081	8976	NDAR_INVVF703LVQ	2612			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	0	0	0	2	2	0	0	0	9	1	1	0	1	2	1	0	2	3	0	0	0	0	0	0	0	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	1	0	1.4285715	0.5	0.95	1		0.95	1	0	1.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF703LVQ
2081	8976	NDAR_INVVF703LVQ	2612			M	1600	Visit6	6	Phase 2	186	0	0	0	0	0	1	0	0	0	0	0	0	1	2	0	0	0	0	9	0	1	0	6	2	2	0	4	4	0	0	0	0	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	0.375	0	2.4285715	1	1.1			0.95	1	0	1.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF703LVQ
2081	8976	NDAR_INVVF703LVQ	2612			M	5200	EndofPhase1_1a	4	Phase 1/1A	124	0	0	0	0	0	1	0	0	0	4	0	0	0	2	2	0	0	0	9	0	2	0	3	0	2	0	2	4	0	0	0	0	1	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	7	1	0	1.5714285	1	1.05		1	0.95	1	0	1.4285715	0.5	0.1	0	0	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF703LVQ
2081	8976	NDAR_INVVF703LVQ	2612			M	5800	EndofPhase2	9	Phase 2	278	0	0	0	0	0	1	0	2	0	0	1	2	0	2	1	0	0	0	9	0	0	0	2	2	3	1	0	4	0	0	0	0	1	1	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0	1.1428572	2	1			0.95	1	0	1.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF703LVQ
2081	8976	NDAR_INVVF703LVQ	2612			M	6000	EndofPhase3	12	Phase 3	361	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	0	2	0	2	0	2	0	0	2	0	0	0	0	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0	0	0.85714287	1	0.4			0.95	1	0	1.4285715	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVF703LVQ
2081	8976	NDAR_INVVG401NFK	2583			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	4	4	6	4	5	5	6	5	5	5	5	4	4	4	6	6	6	4	5	1	1	1	1	1	1	1	1	1	2	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5	5.25	4.571429	6	5	1		5	5	5.25	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG401NFK
2081	8976	NDAR_INVVG401NFK	2583			M	5200	EndofPhase1_1a	2	Phase 1/1A	53	0	1	0	0	0	0	0	5	2	4	2	2	6	6	5	6	2	3	2	4	5	3	5	6	6	5	5	6	1	1	0	2	1	1	0	1	1	2	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4	3.25	4.857143	5.5	4.285714		1	5	5	5.25	4.571429	6	-0.71428573	-1	-2	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG401NFK
2081	8976	NDAR_INVVG481HB4	1609			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	2	0	2	2	1	1	1	1	1	9	3	4	3	3	2	3	3	5	5	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.1428572	0.75	3.5714285	3	2.2105262	1		2.2105262	1.1428572	0.75	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG481HB4
2081	8976	NDAR_INVVG481HB4	1609			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	5	4	5	4	5	4	5	2	1	2	4	9	6	4	4	5	4	3	3	6	6	1	1	1	1	1	1	1	1	2	2	1	3	2	3	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	1.75	5	3	4.1			2.2105262	1.1428572	0.75	3.5714285	3	1.8894737	3.107143	1	1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG481HB4
2081	8976	NDAR_INVVG481HB4	1609			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	0	1	4	0	3	2	2	3	3	0	0	1	4	9	2	2	1	3	0	4	3	3	4	1	0	1	0	1	1	1	1	2	2	0	4	1	2	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1.25	2.142857	3.5	2.2			2.2105262	1.1428572	0.75	3.5714285	3	-0.010526316	0.98214287	0.5	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG481HB4
2081	8976	NDAR_INVVG481HB4	1609			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	0	0	0	0	1	4	0	0	3	2	1	2	1	2	4	6	9	4	3	2	2	1	5	3	5	5	1	1	1	1	1	1	1	1	2	2	1	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.625	3	3.142857	4	2.75		1	2.2105262	1.1428572	0.75	3.5714285	3	0.5394737	0.48214287	2.25	-0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG481HB4
2081	8976	NDAR_INVVG792GC3	1200			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	3	0	2	2	2	2	0	0	2	1	9	0	2	4	2	1	2	3	4	4	1	1	1	2	1	0	1	1	2	2	1	2	1	1	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.75	0.75	2.4285715	2.5	1.95	1		1.95	1.75	0.75	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG792GC3
2081	8976	NDAR_INVVG792GC3	1200			M	1600	Visit6	6	Phase 1/1A	163	0	0	0	0	0	1	0	4	2	4	2	2	2	2	2	1	2	4	9	2	3	6	4	4	4	3	4	4	1	1	1	1	1	1	1	1	3		1	2	1	4	3	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.5	1.75	3.857143	3.5	3.05			1.95	1.75	0.75	2.4285715	2.5	1.1	0.75	1	1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG792GC3
2081	8976	NDAR_INVVG792GC3	1200			M	5200	EndofPhase1_1a	9	Phase 1/1A	253	0	0	0	0	0	1	0	3	2	2	2	2	2	4	2	4	4	4	4	0	4	5	4	6	5	4	5	5	1	1	1	0	1	1	1	1	3		1	2	1	1	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	1	0	0	0	1	0	1	1	0	0	1	1	1	1	4	2.375	4	4.142857	4.5	3.4761906		1	1.95	1.75	0.75	2.4285715	2.5	1.5261905	0.625	3.25	1.7142857	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVG792GC3
2081	8976	NDAR_INVVH072TUT	2102			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	0	0	2	2	0	2	1	0	1	6	9	2	2	3	4	3	2	1	4	4	0	1	0	1	1	0	2	1	2	2	1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	1.25	1.75	3.142857	1.5	2.1	1		2.1	1.25	1.75	3.142857	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH072TUT
2081	8976	NDAR_INVVH072TUT	2102			M	1600	Visit6	6	Phase 1/1A	182	1	0	0	0	0	0	0	5	3	3	2	2	2	2	1	0	3	4	9	4	4	2	4	4	5	2	4	5	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	0	7	2.5	1.75	3.857143	3.5	3.05			2.1	1.25	1.75	3.142857	1.5	0.95	1.25	0	0.71428573	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH072TUT
2081	8976	NDAR_INVVH072TUT	2102			M	2800	Visit12	12	Phase 1/1A	336	1	0	0	0	0	0	0	6	5	4	5	5	4	5	0	0	4	4	9	2	2	2	4	2	3	4	4	5	1	1	1	1	1	1	1	1	1	1	1	2	1	3	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.25	2	3	3.5	3.5			2.1	1.25	1.75	3.142857	1.5	1.4	3	0.25	-0.14285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH072TUT
2081	8976	NDAR_INVVH072TUT	2102			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	1	0	0	0	0	0	0	5	2	4	3	3	2	5	0	2	4	6	9	3	3	3	4	2	4	2	3	6	1	1	1	1	1	1	1	1	1	1	1	4	2	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	1	0	0	0	0	1	0	0	0	0	1	0	1	0	6	3	3	3.4285715	3	3.3		1	2.1	1.25	1.75	3.142857	1.5	1.2	1.75	1.25	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH072TUT
2081	8976	NDAR_INVVH361WEZ	2558			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	2	1	1	0	2	2	3	2	4	5	9	0	1	2	4	6	5	3	2	3	1	1	1	1	0	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	2.125	2.75	2.5714285	4	2.7	1		2.7	2.125	2.75	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH361WEZ
2081	8976	NDAR_INVVH568CGZ	2320			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	4	3	5	4	3	4	5	4	5	6	6	2	6	6	5	6	6	5	5	6	1	1	1	1	1	1	1	1	2	3	1	2	1	1	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	1	0	1	0	0	0	1	0	0	5	4.125	5.25	5.142857	5.5	4.8095236	1		4.8095236	4.125	5.25	5.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH568CGZ
2081	8976	NDAR_INVVH568CGZ	2320			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	0	1	4	4	4	4	4	2	4	5	3	4	6	6	1	5	4	5	4	5	4	5	6	0	1	0	1	1	1	1	1	2	3	1	2	1	1	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	4	3.875	4.75	4.285714	4.5	4.2380953			4.8095236	4.125	5.25	5.142857	5.5	-0.5714286	-0.25	-0.5	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH568CGZ
2081	8976	NDAR_INVVH568CGZ	2320			M	5200	EndofPhase1_1a	18	Phase 1/1A	506	0	0	0	0	0	0	1	6	4	5	4	3	3	4	6	4	4	5	6	3	3	2	4	5	6	3	5	4	0	1	1	1	1	1	1	1	2	1	1	3	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	4.375	4.75	3.7142856	4.5	4.2380953		1	4.8095236	4.125	5.25	5.142857	5.5	-0.5714286	0.25	-0.5	-1.4285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH568CGZ
2081	8976	NDAR_INVVH747VD2	1632			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	2	4	4	4	4	3	4	1	1	0	9	3	3	2	4	4	3	2	5	5	1	2	1	0	1	1	1	1	2	1	1	3	2	2	2	1	0	0	0	1	0	0	0	2	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	0.5	3.7142856	2.5	3.15	1		3.15	3.75	0.5	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH747VD2
2081	8976	NDAR_INVVH747VD2	1632			M	1600	Visit6	6	Phase 3	174	0	0	0	0	0	0	1	5	3	4	3	3	3	4	2	1	1	1	9	4	4	4	4	3	3	2	4	4	1	0	1	2	1	1	1	1	2	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.375	0.75	3.857143	2.5	3.1			3.15	3.75	0.5	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH747VD2
2081	8976	NDAR_INVVH747VD2	1632			M	2800	Visit12	12	Phase 3	338	0	0	0	0	0	0	1	9	5	3	1	2	1	2	2	0	0	1	9	2	2	2	4	1	3	2	4	5	1	0	1	0	0	1	1	1	3	3	1	2	2	4	3	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.2857144	0.25	2.857143	2.5	2.2105262			3.15	3.75	0.5	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH747VD2
2081	8976	NDAR_INVVH747VD2	1632			M	4000	Visit18	18	Phase 3	506	0	0	0	0	0	0	1	9	4	1	2	4	0	2	2	0	0	1	9	2	5	2	6	6	3	4	6	5	1	0	1	0	1	0	1	1	2	2	1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.142857	0.25	4.571429	3.5	2.8947368			3.15	3.75	0.5	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH747VD2
2081	8976	NDAR_INVVH747VD2	1632			M	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	0	0	0	0	0	1	2	3	3	2	2	2	1	1	1	1	1	9	2	2	2	2	1	4	2	3	4	1	2	1	2	1	1	1	1	2	2	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	3	2	0.75	2.2857144	3	2.05		1	3.15	3.75	0.5	3.7142856	2.5	-1.1	-1.75	0.25	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH747VD2
2081	8976	NDAR_INVVH747VD2	1632			M	5800	EndofPhase2	2	Phase 2	44	0	0	0	0	0	0	1	2	2	1	2	3	1	2	1	1	1	1	9	3	2	2	3	1	3	2	4	4	1	2	1	2	1	1	1	1	2	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.75	0.75	2.7142856	2.5	2.05			3.15	3.75	0.5	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVH747VD2
2081	8976	NDAR_INVVJ275WD8	1660			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	5	2	2	5	3	3	4	4	4	5	5	4	5	3	5	3	4	3	4	6	0	0	1	0	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	2	2	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	5	3.75	4.5	4.285714	3.5	4.047619	1		4.047619	3.75	4.5	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVJ275WD8
2081	8976	NDAR_INVVJ500HJN	2387			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	0	0	0	0	2	2	0	0	0	2	9	2	3	1	2	4	4	3	2	1	1	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5	0.75	0.5	2.142857	3.5	1.5	1		1.5	0.75	0.5	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVJ500HJN
2081	8976	NDAR_INVVJ500HJN	2387			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	1	0	0	2	0	0	0	0	2	2	0	1	0	2	9	2	3	1	2	4	4	3	2	1	1	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4	0.75	0.75	2.142857	3.5	1.55			1.5	0.75	0.5	2.142857	3.5	0.05	0	0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVJ500HJN
2081	8976	NDAR_INVVJ500HJN	2387			M	2800	Visit12	12	Phase 1/1A	333	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	2	2	1	9	1	2	0	3	2	3	1	2	2	0	0	1	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	1	1	0	0	0	0	3	0.125	1.25	1.7142857	2	1.1			1.5	0.75	0.5	2.142857	3.5	-0.4	-0.625	0.75	-0.42857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVJ500HJN
2081	8976	NDAR_INVVJ500HJN	2387			M	4000	Visit18	18	Phase 1/1A	508	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	1	1	9	1	1	0	2	1	3	2	2	1	1	0	1	0	1	1	1	1	2	3	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	3	0.25	0.5	1.1428572	2.5	0.85		1	1.5	0.75	0.5	2.142857	3.5	-0.65	-0.5	0	-1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVJ500HJN
2081	8976	NDAR_INVVJ896WAY	1436			M	400	Baseline	0	Pre-Rand	1	0	1	1	0	0	0	0	0	6	0	0	0	0	2	2	0	0	0	9	3	4	6	1	5	5	4	6	6	1	1	1	1	0	0	1	1	1	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	3	1.25	0	4.428571	4.5	2.5	1		2.5	1.25	0	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVJ896WAY
2081	8976	NDAR_INVVK617FB3	1274			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	4	2	4	0	2	4	3	3	4	6	0	4	4	2	2	6	4	4	3	1	1	1	0	1	1	1	1	3		1	2	4	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.75	4	2.7142856	5	3.1904762	1		3.1904762	2.75	4	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK617FB3
2081	8976	NDAR_INVVK617FB3	1274			M	1600	Visit6	6	Phase 1/1A	177	0	1	0	0	0	0	0	6	6	6	6	6	6	6	4	2	6	2	9	4	5	6	6	2	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	2	4	1	1	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.75	2.5	5	5.5	5.1			3.1904762	2.75	4	2.7142856	5	1.9095238	3	-1.5	2.2857144	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK617FB3
2081	8976	NDAR_INVVK617FB3	1274			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	9	4	2	4	3	3	4	1	1	3	2	9	2	3	6	4	0	5	5	4	5	1	0	1	1	1	1	1	1	3		1	3	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	3	1.5	3.4285715	5	3.2105262			3.1904762	2.75	4	2.7142856	5	0.020050125	0.25	-2.5	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK617FB3
2081	8976	NDAR_INVVK617FB3	1274			M	5200	EndofPhase1_1a	18	Phase 1/1A	519	0	0	0	0	0	0	1	9	4	2	4	3	3	4	4	1	3	2	9	2	3	6	4	2	5	4	4	5	1	1	1	1	1	1	1	1	3		1	2	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	7	3.4285715	1.5	3.7142856	4.5	3.4210527		1	3.1904762	2.75	4	2.7142856	5	0.23057644	0.6785714	-2.5	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK617FB3
2081	8976	NDAR_INVVK650PGC	2303			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	3	4	3	4	3	3	2	0	1	1	9	2	2	2	4	2	6	2	0	0	0	0	1	0	1	0	1	1	1				3	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	0.5	1.7142857	4	2.3	1		2.3	3	0.5	1.7142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK650PGC
2081	8976	NDAR_INVVK650PGC	2303			M	1600	Visit6	6	Phase 1/1A	190	1	0	0	0	0	0	0	4	1	2	2	2	2	2	2	0	2	4	9	2	2	2	4	0	2	5	2	2	0	1	1	0	1	0	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.125	1.5	2	3.5	2.2			2.3	3	0.5	1.7142857	4	-0.1	-0.875	1	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK650PGC
2081	8976	NDAR_INVVK650PGC	2303			M	2800	Visit12	12	Phase 1/1A	384	1	0	0	0	0	0	0	4	4	4	2	4	2	2	3	1	1	3	9	3	2	1	2	0	4	1	2	4	0	1	1	1	1	0	0	0	1	2	1	3	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	1.25	2	2.5	2.45			2.3	3	0.5	1.7142857	4	0.15	0.125	0.75	0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK650PGC
2081	8976	NDAR_INVVK650PGC	2303			M	5200	EndofPhase1_1a	18	Phase 1/1A	589	1	0	0	0	0	0	0	2	0	2	2	2	2	2	2	0	2	4	9	1	2	2	2	0	4	2	1	1	0	0	1	1	1	0	1	1	1	3	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.75	1.5	1.2857143	3	1.75		1	2.3	3	0.5	1.7142857	4	-0.55	-1.25	1	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVK650PGC
2081	8976	NDAR_INVVM176XUZ	1130			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	4	4	4	4	3	6	2	0	0	2	9	0	2	3	4	0	4	3	4	4	2	1	2	2	1	2	2	2	3		1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.875	0.5	2.4285715	3.5	2.85	1		2.85	3.875	0.5	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVM176XUZ
2081	8976	NDAR_INVVM607JZM	2187			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	1	1	1	2	2	0	2	1	0	1	5	9	1	1	0	2	0	3	2	2	4	1	0	1	0	1	1	1	1	1	1	0	4	3	4	4	1	1	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	2	1.25	1.5	1.4285715	2.5	1.55	1		1.55	1.25	1.5	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVM607JZM
2081	8976	NDAR_INVVM607JZM	2187			M	1600	Visit6	6	Phase 1/1A	166	0	1	0	0	0	0	0	3	0	0	0	2	2	2	2	0	1	6	9	0	0	3	3	0	5	2	4	5	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.375	1.75	2.142857	3.5	2			1.55	1.25	1.5	1.4285715	2.5	0.45	0.125	0.25	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVM607JZM
2081	8976	NDAR_INVVM607JZM	2187			M	2800	Visit12	12	Phase 2	339	0	0	0	0	0	0	1	0	0	0	0	2	1	2	0	0	1	6	9	2	2	0	3	0	2	1	4	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	0.625	1.75	2.142857	1.5	1.5			1.55	1.25	1.5	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVM607JZM
2081	8976	NDAR_INVVM607JZM	2187			M	5200	EndofPhase1_1a	10	Phase 1/1A	290	0	1	0	0	0	0	0	0	0	0	0	2	2	2	0	0	2	6	9	0	1	0	4	0	4	2	4	5	1	0	1	0	1	1	1	1	1	2	0	4	3	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	0.75	2	2	3	1.7		1	1.55	1.25	1.5	1.4285715	2.5	0.15	-0.5	0.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVM607JZM
2081	8976	NDAR_INVVM607JZM	2187			M	5800	EndofPhase2	18	Phase 2	501	0	1	0	0	0	0	0	2	0	0	0	2	0	2	0	0	2	6	9	3	2	0	4	0	4	2	4	4	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	4	0.75	2	2.4285715	3	1.85			1.55	1.25	1.5	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVM607JZM
2081	8976	NDAR_INVVN663FU9	1060			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	6	3	3	5	3	3	0	6	4	5	9	0	3	3	5	4	4	3	4	6	0	1	1	0	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3.5	3.75	3.5714285	3.5	3.75	1		3.75	3.5	3.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVN663FU9
2081	8976	NDAR_INVVN763VKE	1118			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	4	2	3	2	3	3	2	0	0	0	9	3	3	3	4	1	1	1	5	6	0	0	0	0	1	0	1	0	3	1	1	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.875	0	3.5714285	1	2.5	1		2.5	2.875	0	3.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVN763VKE
2081	8976	NDAR_INVVN763VKE	1118			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	1	0	2	2	3	3	3	3	3	5	3	0	1	9	3	3	3	3	3	2	1	3	6	2	2	2	2	1	1	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	1	0	1	1	1	1	7	3	1	3.4285715	1.5	2.75			2.5	2.875	0	3.5714285	1	0.25	0.125	1	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVN763VKE
2081	8976	NDAR_INVVN763VKE	1118			M	2800	Visit12	12	Phase 1/1A	354	0	0	0	0	0	1	0	4	4	3	4	3	3	3	3	3	4	5	5	3	3	4	4	3	2	2	4	5	2	2	2	2	1	1	1	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		0		1	30	0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.375	4.25	3.7142856	2	3.5238094			2.5	2.875	0	3.5714285	1	1.0238096	0.5	4.25	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVN763VKE
2081	8976	NDAR_INVVN763VKE	1118			M	5200	EndofPhase1_1a	18	Phase 1/1A	507	0	0	0	0	0	1	0	2	2	2	3	2	3	3	3	3	3	3	4	3	3	3	3	4	3	2	4	5	2	2	2	2	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		0		0		1	30	0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.5	3.25	3.5714285	2.5	3		1	2.5	2.875	0	3.5714285	1	0.5	-0.375	3.25	0	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVN763VKE
2081	8976	NDAR_INVVN784HEY	1992			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	3	0	1	1	2	2	2	0	1	1	9	2	2	1	1	1	0	2	3	3	0	0	0	1	0	1	0	1	1	1	1	4	4	2	4	0	0	0	0	0	0	0	0					1	8	0		1	7	1	15	0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	3	1.75	0.5	1.8571428	1	1.55	1		1.55	1.75	0.5	1.8571428	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVN784HEY
2081	8976	NDAR_INVVP107DUU	2827			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	0	2	2	3	4	4	0	0	0	9	0	6	3	6	4	4	4	4	6	1	0	0	0	1	1	1	1	3	1	1	2	2	3	2	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.857143	0	4.142857	4	3	1		3	2.857143	0	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVP107DUU
2081	8976	NDAR_INVVP372CTZ	2014			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	0	2	2	2	2	2	4	4	1	9	2	1	0	1	2	1	3	1	2	1	0	0	0	1	1	1	1	3	1	0	4	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.375	2.25	1.2857143	2	1.65	1		1.65	1.375	2.25	1.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVP372CTZ
2081	8976	NDAR_INVVP372CTZ	2014			M	5200	EndofPhase1_1a	2	Phase 1/1A	34	0	0	0	0	0	1	0	0	0	0	0	0	2	2	0	0	1	1	9	1	0	3	2	2	2	2	0	4	2	2	2	2	1	1	1	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	6	0.5	0.5	1.7142857	2	1.1		1	1.65	1.375	2.25	1.2857143	2	-0.55	-0.875	-1.75	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVP372CTZ
2081	8976	NDAR_INVVR205GBF	1503			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	4	3	3	4	2	3	3	3	5	3	3	4	4	3	3	3	5	3	1	1	1	1	1	1	1	1	2	2	1	3	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.625	3.5	3.5714285	3	3.5238094	1		3.5238094	3.625	3.5	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVR205GBF
2081	8976	NDAR_INVVR205GBF	1503			M	5200	EndofPhase1_1a	1	Phase 1/1A	20	0	0	0	0	0	1	0	5	4	1	1	5	4	4	2	1	2	3	9	2	3	2	4	2	3	2	4	2	1	1	1	1	1	1	1	1	3	2	1	3	3	3	4	1	0	1	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.25	1.5	2.7142856	2.5	2.8		1	3.5238094	3.625	3.5	3.5714285	3	-0.72380954	-0.375	-2	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVR205GBF
2081	8976	NDAR_INVVR460GLQ	2156			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	1	1	3	3	4	3	1	3	2	1	2	2	3	4	3	4	5	3	4	4	1	0	1	1	1	1	1	1	2	2	0	4	4	4	4	1	0	1	1	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.5	2	3.4285715	4	2.857143	1		2.857143	2.5	2	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVR460GLQ
2081	8976	NDAR_INVVR460GLQ	2156			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	1	0	3	1	1	2	3	4	3	1	2	2	1	9	2	3	4	3	4	5	3	4	4	1	0	1	1	1	1	1	1	2	2	0	4	4	4	4	1	0	1	1	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.25	1.25	3.4285715	4	2.75			2.857143	2.5	2	3.4285715	4	-0.10714286	-0.25	-0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVR460GLQ
2081	8976	NDAR_INVVR460GLQ	2156			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	1	0	3	1	1	2	3	4	3	1	2	2	1	9	2	3	4	3	4	5	3	4	4	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.25	1.25	3.4285715	4	2.75			2.857143	2.5	2	3.4285715	4	-0.10714286	-0.25	-0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVR460GLQ
2081	8976	NDAR_INVVR460GLQ	2156			M	5200	EndofPhase1_1a	18	Phase 1/1A	537	0	0	0	0	0	1	0	3	1	1	2	3	4	3	1	2	2	1	9	2	3	4	3	4	5	3	4	4	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	1	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.25	1.25	3.4285715	4	2.75		1	2.857143	2.5	2	3.4285715	4	-0.10714286	-0.25	-0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVR460GLQ
2081	8976	NDAR_INVVT288FAM	2206			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	4	4	3	3	2	3	1	6	3	4	3	3	4	3	2	5	4	4	4	3	1	1	2	1	1	0	1	2	3	1	1	2	1	2	4	1	0	1	0	0	0	0	0	1	0	1	1	0		0		1	30	0		0		2	0	1	0	1	0	1	0	0	0	0	0	0	0	1	1	4	3	4	3.4285715	4	3.4285715	1		3.4285715	3	4	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT288FAM
2081	8976	NDAR_INVVT288FAM	2206			M	1600	Visit6	6	Phase 2	166	0	0	0	0	0	1	0	1	4	4	4	4	5	4	2	1	3	1	9	3	4	4	4	4	4	3	4	4	1	0	2	0	1	1	2	1	2	1	1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.5	1.25	3.857143	3.5	3.35			3.4285715	3	4	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT288FAM
2081	8976	NDAR_INVVT288FAM	2206			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	0	0	0	0	0	1	0	4	2	2	3	2	1	3	0	2	2	4	9	1	1	3	2	2	5	4	3	1	1	1	2	0	1	1	0	2	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		2	2	1	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2.125	2	1.8571428	4.5	2.35		1	3.4285715	3	4	3.4285715	4	-1.0785714	-0.875	-2	-1.5714285	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT288FAM
2081	8976	NDAR_INVVT288FAM	2206			M	5800	EndofPhase2	10	Phase 2	287	0	0	0	0	0	1	0	3	4	4	4	4	5	5	0	4	4	3	4	3	4	0	4	2	4	3	5	2	0	0	0	0	1	1	2	0	1	1	1	3	2	2	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	16	0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.625	3.75	2.857143	3.5	3.3809524			3.4285715	3	4	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT288FAM
2081	8976	NDAR_INVVT288FAM	2206			M	6000	EndofPhase3	11	Phase 3	310	0	0	0	0	0	1	0	5	4	2	4	3	2	3	0	4	3	3	4	1	4	4	4	3	5	2	3	2	0	1	2	0	1	1	1	2	3	1	1	3	3	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.875	3.5	3	3.5	3.0952382			3.4285715	3	4	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT288FAM
2081	8976	NDAR_INVVT668DYK	1853			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	9	0	1	1	0	0	3	2	1	1	0	1	0	0	1	0	1	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0.375	0	0.5714286	2.5	0.6	1		0.6	0.375	0	0.5714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT668DYK
2081	8976	NDAR_INVVT668DYK	1853			M	1600	Visit6	6	Phase 3	189	1	0	0	0	0	0	0	2	0	0	0	0	0	1	1	0	0	0		4	2	4	3	2	5	3	4	4	1	1	1	1	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	0.5		3.2857144	4	1.75			0.6	0.375	0	0.5714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT668DYK
2081	8976	NDAR_INVVT668DYK	1853			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	0	0	0	0	2	1	2	1	0	0	0	9	2	2	1	1	0	5	2	2	2	0	0	1	1	1	1	1	1	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	0.75	0	1.4285715	3.5	1.15		1	0.6	0.375	0	0.5714286	2.5	0.55	0.375	0	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT668DYK
2081	8976	NDAR_INVVT668DYK	1853			M	5800	EndofPhase2	5	Phase 2	161	1	0	0	0	0	0	0	2	1	0	0	0	2	3	1	0	0	1	9	2	0	2	2	0	4	2	2	4	1	1	1	1	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	3	1.125	0.25	1.7142857	3	1.4			0.6	0.375	0	0.5714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT668DYK
2081	8976	NDAR_INVVT668DYK	1853			M	6000	EndofPhase3	9	Phase 3	275	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	9	1	1	1	2	0	4	1	2	1	1	0	0	0	1	0	1	1	2	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	0.125	0	1.1428572	2.5	0.7			0.6	0.375	0	0.5714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVT668DYK
2081	8976	NDAR_INVVU532MM4	2797			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	4	4	3	3	3	1	1	1	1	9	0	2	2	4	1	5	3	4	3	1	1	0	0	1	1	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	0.75	2.2857144	4	2.6	1		2.6	3.125	0.75	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVU532MM4
2081	8976	NDAR_INVVU532MM4	2797			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	3	4	4	2	2	2	2	1	1	2	4	9	0	0	2	4	1	4	3	2	4	0	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.5	1.75	1.8571428	3.5	2.35			2.6	3.125	0.75	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVU532MM4
2081	8976	NDAR_INVVU532MM4	2797			M	2800	Visit12	12	Phase 2	337	0	1	0	0	0	0	0	4	2	2	2	2	2	4	2	2	3	1	9	0	2	2	3	2	5	3	2	4	1	1	0	0	1	1	0	1	1	2	1	3	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.5	1.5	2.142857	4	2.45			2.6	3.125	0.75	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVU532MM4
2081	8976	NDAR_INVVU532MM4	2797			M	5200	EndofPhase1_1a	2	Phase 1/1A	50	1	0	0	0	0	0	0	4	2	4	2	2	2	2	2	2	2	3	9	0	2	2	2	4	4	3	4	2	0	1	0	0	1	1	0	1	1	1	1	3	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1.75	2.2857144	3.5	2.5		1	2.6	3.125	0.75	2.2857144	4	-0.1	-0.625	1	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVU532MM4
2081	8976	NDAR_INVVU532MM4	2797			M	5800	EndofPhase2	18	Phase 2	504	1	0	0	0	0	0	0	4	0	4	2	2	2	3	2	1	1	1	9	0	2	3	4	4	5	3	4	4	1	1	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.375	0.75	3	4	2.55			2.6	3.125	0.75	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVU532MM4
2081	8976	NDAR_INVVV432PZQ	1967			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	4	4	2	1	2	1	3	3	2	4	4	2	4	3	4	5	3	3	3	4	1	1	1	0	1	1	1	1	2	1	1	3	2	4	2	1	0	0	0	0	0	1	0	1	1	0	0	1	10	0		0		0		1	20	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	2.625	3.25	3.5714285	3	3.0952382	1		3.0952382	2.625	3.25	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV432PZQ
2081	8976	NDAR_INVVV623ZFA	2250			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	1	1	0	6	1	2	1	3	4	3	5	3	5	4	4	3	3	2	4	6	0	0	0	0	1	0	0	1	1	1	1	3	2	4	4	1	0	1	0	1	0	0	0	1	1	1	1	1	27	0		0		1	3	0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	2	3.75	4.142857	2.5	3.0952382	1		3.0952382	2	3.75	4.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV623ZFA
2081	8976	NDAR_INVVV623ZFA	2250			M	1600	Visit6	6	Phase 1/1A	170	1	0	1	0	0	0	0	6	0	2	2	6	0	3	1	3	6	6	6	4	6	5	6	6	3	2	5	6	1	0	1	0	1	0	0	1	1	1	0	4	3	3	4	1	0	1	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	7	2.5	5.25	5.428571	2.5	4			3.0952382	2	3.75	4.142857	2.5	0.9047619	0.5	1.5	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV623ZFA
2081	8976	NDAR_INVVV623ZFA	2250			M	2800	Visit12	12	Phase 1/1A	338	1	0	1	0	0	0	0	6	4	2	2	6	0	3	1	4	4	4	6	3	4	2	2	2	3	2	5	5	0	0	0	1	1	1	0	1	1	1	1	2	4	4	4	1	0	1	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3	4.5	3.2857144	2.5	3.3333333			3.0952382	2	3.75	4.142857	2.5	0.23809524	1	0.75	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV623ZFA
2081	8976	NDAR_INVVV623ZFA	2250			M	4000	Visit18	18	Phase 1/1A	492	1	0	1	0	0	0	0	6	6	4	6	6	6	6	3	4	4	4	0	4	5	4	4	6	3	2	4	6	0	0	0	1	1	0	0	1	1	1	1	2	1	2	3	1	0	1	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	1	0	1	0	0	0	0	0	1	1	1	1	5	5.375	3	4.714286	2.5	4.428571			3.0952382	2	3.75	4.142857	2.5	1.3333334	3.375	-0.75	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV623ZFA
2081	8976	NDAR_INVVV623ZFA	2250			M	5200	EndofPhase1_1a	18	Phase 1/1A	492	1	0	1	0	0	0	0	6	6	4	6	6	6	6	3	4	4	4	0	4	5	4	4	6	3	2	4	6	0	0	0	1	1	0	0	1	1	1	1	2	1	2	3	1	0	1	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	1	0	1	0	0	0	0	0	1	1	1	1	5	5.375	3	4.714286	2.5	4.428571		1	3.0952382	2	3.75	4.142857	2.5	1.3333334	3.375	-0.75	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV623ZFA
2081	8976	NDAR_INVVV805DAH	1067			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	4	4	4	6	6	3	5	4	5	5	6	5	4	6	6	6	4	4	6	0	1	1	1	1	1	1	1	3		1	2	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.571429	4.75	5.285714	5	4.9	1		4.9	4.571429	4.75	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV805DAH
2081	8976	NDAR_INVVV805DAH	1067			M	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	0	1	9	6	6	6	6	4	6	2	1	0	2	9	4	4	4	4	4	5	3	4	4	0	1	0	1	1	1	1	1	3	1	1	2	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.142857	0.75	4	4	3.9473684			4.9	4.571429	4.75	5.285714	5	-0.9526316	0.5714286	-4	-1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV805DAH
2081	8976	NDAR_INVVV805DAH	1067			M	2800	Visit12	12	Phase 1/1A	332	0	0	0	0	0	1	0	6	5	5	6	5	4	5	2	0	0	4	9	2	2	4	6	2	6	4	4	5	1	1	1	1	1	1	0	1	3		1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	4.75	1	3.5714285	5	3.85			4.9	4.571429	4.75	5.285714	5	-1.05	0.17857143	-3.75	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV805DAH
2081	8976	NDAR_INVVV805DAH	1067			M	5200	EndofPhase1_1a	18	Phase 1/1A	514	0	0	0	0	0	1	0	6	6	6	6	6	3	5	2	1	2	1	9	3	2	4	5	2	6	4	5	5	1	1	0	0	1	1	1	1	3		1	2	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	1	3.7142856	5	4		1	4.9	4.571429	4.75	5.285714	5	-0.9	0.42857143	-3.75	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVV805DAH
2081	8976	NDAR_INVVW240HY0	1209			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	0	0	3	2	3	2	1	0	1	0	9	4	4	4	3	1	5	3	5	4	1	1	1	0	0	1	1	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	0.25	3.5714285	4	2.45	1		2.45	1.875	0.25	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW240HY0
2081	8976	NDAR_INVVW240HY0	1209			M	1600	Visit6	6	Phase 1/1A	168	1	0	0	0	0	0	0	4	0	0	4	4	0	3	1	0	0	0	9	4	4	5	5	2	6	3	5	5	1	1	1	0	1	0	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0	4.285714	4.5	2.75			2.45	1.875	0.25	3.5714285	4	0.3	0.125	-0.25	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW240HY0
2081	8976	NDAR_INVVW240HY0	1209			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	6	2	3	4	3	3	4	2	0	1	2	9	2	2	5	5	2	6	4	5	5	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	0.75	3.7142856	5	3.3			2.45	1.875	0.25	3.5714285	4	0.85	1.5	0.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW240HY0
2081	8976	NDAR_INVVW240HY0	1209			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	1	0	0	0	0	0	0	5	0	0	3	5	3	3	2	1	1	1	9	4	5	6	4	1	6	3	5	6	1	1	1	1	1	0	1	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	0.75	4.428571	4.5	3.2		1	2.45	1.875	0.25	3.5714285	4	0.75	0.75	0.5	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW240HY0
2081	8976	NDAR_INVVW428CKB	2856			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	3	5	4	4	4	5	4	4	1	2	1	9	2	4	4	4	4	3	4	4	5	1	1	1	1	1	1	1	1	1	2	1	2	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.125	1	3.857143	3.5	3.55	1		3.55	4.125	1	3.857143	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW428CKB
2081	8976	NDAR_INVVW428CKB	2856			M	5200	EndofPhase1_1a	3	Phase 1/1A	103	1	0	1	0	0	0	0	0	1	2	2	2	4	4	3	3	2	3	1	0	1	2	4	4	3	4	1	4	1	1	1	1	1	0	1	0	1	3	1	3	2	3	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.25	2.25	2.2857144	3.5	2.3809524		1	3.55	4.125	1	3.857143	3.5	-1.1690476	-1.875	1.25	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW428CKB
2081	8976	NDAR_INVVW567UKB	1917			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	2	0	1	3	1	1	1	1	1	6	9	2	2	2	3	2	6	2	3	4	1	0	1	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.5	2	2.5714285	4	2.3	1		2.3	1.5	2	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW567UKB
2081	8976	NDAR_INVVW567UKB	1917			M	1600	Visit6	6	Phase 2	178	0	0	0	0	0	0	1	2	2	2	2	2	2	3	2	3	3	1	2	3	3	4	2	3	5	3	3	5	1	0	1	0	1	1	1	1	3		0	4	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.125	2.25	3.2857144	4	2.7142856			2.3	1.5	2	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW567UKB
2081	8976	NDAR_INVVW567UKB	1917			M	2800	Visit12	12	Phase 2	346	0	0	0	0	0	0	1	3	2	2	2	2	2	2	0	1	3	1	9	1	2	2	4	3	5	2	3	3	1	0	1	0	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	1.25	2.5714285	3.5	2.25			2.3	1.5	2	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW567UKB
2081	8976	NDAR_INVVW567UKB	1917			M	5200	EndofPhase1_1a	4	Phase 1/1A	119	0	0	0	0	0	0	1	2	2	1	2	2	3	2	2	1	2	6	9	3	3	3	3	3	4	3	3	4	1	0	1	0	1	1	1	1	3		0	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2	2.25	3.142857	3.5	2.7		1	2.3	1.5	2	2.5714285	4	0.4	0.5	0.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW567UKB
2081	8976	NDAR_INVVW567UKB	1917			M	5800	EndofPhase2	18	Phase 2	501	0	0	0	0	0	0	1	3	2	3	3	3	3	4	2	1	4	1	9	3	3	4	3	4	5	2	5	6	1	0	1	1	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	1.5	4	3.5	3.2			2.3	1.5	2	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW567UKB
2081	8976	NDAR_INVVW581CZH	2485			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	3	4	2	2	2	2	3	2	0	1	0	9	0	0	1	3	2	5	5	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	3	2	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0					0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	0.25	2	5	2.25	1		2.25	2.5	0.25	2	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW581CZH
2081	8976	NDAR_INVVW581CZH	2485			F	1600	Visit6	6	Phase 2	173	0	1	0	0	0	0	0	3	4	2	2	2	2	2	2	0	1	0	9	0	0	1	3	2	4	4	5	4	1	1	1	1	1	1	1	1	1	1	1	3	2	3	2	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	0.25	2.142857	4	2.15			2.25	2.5	0.25	2	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW581CZH
2081	8976	NDAR_INVVW581CZH	2485			F	2800	Visit12	12	Phase 2	334	0	1	0	0	0	0	0	3	4	2	2	2	2	2	2	0	1	0	9	0	0	0	3	2	4	4	5	4	1	1	1	1	1	1	1	1	1	1	1	2	2	3	2	1	0	0	0	1	0	0	0	1	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	0.25	2	4	2.1			2.25	2.5	0.25	2	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW581CZH
2081	8976	NDAR_INVVW581CZH	2485			F	4000	Visit18	18	Phase 2	518	0	1	0	0	0	0	0	6	6	6	6	6	5	5	6	4	2	2	9	3	5	4	5	4	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	5.75	2	4.714286	5	4.85			2.25	2.5	0.25	2	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW581CZH
2081	8976	NDAR_INVVW581CZH	2485			F	5200	EndofPhase1_1a	5	Phase 1/1A	148	0	0	0	0	0	1	0	2	1	2	1	1	1	4	0	1	1	0	9	0	1	2	1	2	3	2	2	4	0	1	0	0	1	0	0	0	3		0	3	4	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.5	1.7142857	2.5	1.55		1	2.25	2.5	0.25	2	5	-0.7	-1	0.25	-0.2857143	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW581CZH
2081	8976	NDAR_INVVW592FA3	2690			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	3	2	3	3	2	4	4	0	0	1	9	3	2	2	3	4	5	5	4	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	0.25	3.2857144	5	3	1		3	3.25	0.25	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW592FA3
2081	8976	NDAR_INVVW592FA3	2690			M	5200	EndofPhase1_1a	2	Phase 1/1A	64	0	0	0	0	0	0	1	4	3	2	3	3	2	4	3	0	0	1	9	3	2	2	3	4	4	5	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	0.25	3.142857	4.5	2.8		1	3	3.25	0.25	3.2857144	5	-0.2	-0.25	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW592FA3
2081	8976	NDAR_INVVW592FA3	2690			M	5400	EndofPhase1b	18	Phase 1B	77	0	0	0	0	0	0	1	4	3	2	3	3	2	4	3	0	0	1	9	3	2	2	3	4	4	5	4	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1		3	0.25	3.142857	4.5	2.8			3	3.25	0.25	3.2857144	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW592FA3
2081	8976	NDAR_INVVW632GC2	2700			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	2	0	0	0	0	9	4	6	6	4	0	2	2	4	4	1	0	1	1	1	1	1	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	1	1	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.75	0	4	2	2.3	1		2.3	1.75	0	4	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW632GC2
2081	8976	NDAR_INVVW632GC2	2700			F	1600	Visit6	6	Phase 1/1A	183	1	0	1	0	0	0	0	6	0	0	0	4	0	1	1	3	4	6	4	0	5	6	4	6	3	2	4	4	1	1	1	1	1	1	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.5	4.25	4.142857	2.5	3			2.3	1.75	0	4	2	0.7	-0.25	4.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW632GC2
2081	8976	NDAR_INVVW632GC2	2700			F	2800	Visit12	12	Phase 1/1A	348	1	0	1	0	0	0	0	6	0	0	2	2	2	2	0	4	5	6	6	4	4	4	4	5	3	3	5	4	1	1	1	1	1	1	1	1	1	1	0	4	4	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	5.25	4.285714	3	3.3809524		1	2.3	1.75	0	4	2	1.0809524	0	5.25	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW632GC2
2081	8976	NDAR_INVVW653NEP	1030			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	4	1	2	4	3	3	0	2	4	1	9	3	5	4	2	6	6	2	5	2	0	0	0	0	1	0	0	1	1	3	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	3	2.375	1.75	3.857143	4	3.05	1		3.05	2.375	1.75	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW653NEP
2081	8976	NDAR_INVVW653NEP	1030			F	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	6	6	4	1	6	6	5	1	2	4	4	9	2	1	4	6	6	6	2	4	5	0	0	0	0	1	0	0	0	3	3	1	3	2	2	4	1	0	1	0	0	0	0	0	2	0	0	0	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	3	4.375	2.5	4	4	4.05			3.05	2.375	1.75	3.857143	4	1	2	0.75	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW653NEP
2081	8976	NDAR_INVVW653NEP	1030			F	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	6	5	4	5	4	2	4	0	5	2	6	4	2	5	4	4	4	5	4	3	4	0	1	0	0	1	0	0	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	4	3.75	4.25	3.7142856	4.5	3.9047618			3.05	2.375	1.75	3.857143	4	0.8547619	1.375	2.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW653NEP
2081	8976	NDAR_INVVW653NEP	1030			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	1	0	0	0	0	0	0	4	4	0	0	2	0	2	2	2	3	6	4	2	4	4	6	6	2	2	4	4	0	1	0	0	0	0	0	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	3	1.75	3.75	4.285714	2	3		1	3.05	2.375	1.75	3.857143	4	-0.05	-0.625	2	0.42857143	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW653NEP
2081	8976	NDAR_INVVW686WX6	2844			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	2	2	1	1	2	2	3	5	4	4	4	5	5	4	6	6	5	4	3	1	1	1	1	1	0	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.4285715	4	4.428571	5.5	3.4	1		3.4	1.4285715	4	4.428571	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW686WX6
2081	8976	NDAR_INVVW686WX6	2844			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	9	0	1	2	2	2	5	3	3	4	4	6	3	6	5	6	5	6	4	5	5	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.142857	4.25	5	5	3.85			3.4	1.4285715	4	4.428571	5.5	0.45	0.71428573	0.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW686WX6
2081	8976	NDAR_INVVW686WX6	2844			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	0	1	5	2	3	4	4	4	5	3	4	5	6	5	5	4	4	6	5	6	4	5	5	1	1	1	1	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.75	5	4.857143	5	4.4761906			3.4	1.4285715	4	4.428571	5.5	1.0761905	2.3214285	1	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW686WX6
2081	8976	NDAR_INVVW686WX6	2844			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	9	0	4	2	2	0	5	3	4	5	4	6	1	6	5	5	5	6	4	5	5	1	0	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	2.2857144	4.75	4.571429	5	3.85		1	3.4	1.4285715	4	4.428571	5.5	0.45	0.85714287	0.75	0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVW686WX6
2081	8976	NDAR_INVVX155EC5	1678			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	3	4	4	4	4	4	2	0	1	1	9	2	2	2	3	1	3	3	3	3	1	1	0	0	1	0	1	1	3		1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	0		0		1	30	0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	1	4	3.625	0.5	2.2857144	3	2.65	1		2.65	3.625	0.5	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX155EC5
2081	8976	NDAR_INVVX245FM3	2440			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	0	1	0	0	1	3	3	4	4	2	3	2	2	4	4	3	5	4	0	0	1	0	1	1	0	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.75	3.5	3.142857	3.5	2.3333333	1		2.3333333	0.75	3.5	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX245FM3
2081	8976	NDAR_INVVX245FM3	2440			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	1	0	3	4	1	0	3	2	2	0	3	3	3	4	2	3	4	2	3	5	2	5	4	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	1.875	3.25	3.2857144	3.5	2.7619047			2.3333333	0.75	3.5	3.142857	3.5	0.42857143	1.125	-0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX245FM3
2081	8976	NDAR_INVVX245FM3	2440			F	2800	Visit12	12	Phase 1/1A	349	0	0	0	0	0	1	0	2	2	0	1	3	2	2	0	3	3	4	2	3	4	4	4	4	5	3	5	4	0	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	1.5	3	4	4	2.857143			2.3333333	0.75	3.5	3.142857	3.5	0.52380955	0.75	-0.5	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX245FM3
2081	8976	NDAR_INVVX245FM3	2440			F	5200	EndofPhase1_1a	18	Phase 1/1A	535	0	0	0	0	0	1	0	4	0	0	0	2	2	2	0	2	2	1	9	1	1	4	2	2	5	2	5	3	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	1.25	2.5714285	3.5	2		1	2.3333333	0.75	3.5	3.142857	3.5	-0.33333334	0.5	-2.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX245FM3
2081	8976	NDAR_INVVX356ZJX	2267			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0	0	9	2	2	3	3	2	2	3	2	2	1	1	1	0	1	0	0	0	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	0.25	0	2.2857144	2.5	1.15	1		1.15	0.25	0	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX356ZJX
2081	8976	NDAR_INVVX356ZJX	2267			M	1600	Visit6	6	Phase 1/1A	171	0	0	0	0	0	0	1	0	2	2	2	2	2	2	3	0	0	2	9	2	2	2	2	2	2	2	2	2	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.875	0.5	2	2	1.75		1	1.15	0.25	0	2.2857144	2.5	0.6	1.625	0.5	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX356ZJX
2081	8976	NDAR_INVVX658RT4	2526			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	0	4	2	1	2	0	1	2	0	0	2	9	4	4	1	2	0	3	3	5	5	0	1	0	0	1	1	1	1	1	3	1	3	3	4	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.5	0.5	3	3	2.05	1		2.05	1.5	0.5	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX658RT4
2081	8976	NDAR_INVVX658RT4	2526			F	1600	Visit6	6	Phase 3	176	1	0	1	0	0	0	0	6	6	4	4	6	4	5	6	6	5	6	6	5	4	0	6	5	5	4	6	6	1	1	1	1	0	1	1	1	1	1	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	6	5.125	5.75	4.571429	4.5	5			2.05	1.5	0.5	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX658RT4
2081	8976	NDAR_INVVX658RT4	2526			F	5200	EndofPhase1_1a	1	Phase 1/1A	15	1	0	1	0	0	0	0	6	4	5	5	5	4	3	3	6	2	5	3	3	5	0	5	5	4	2	6	5	0	1	0	0	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	4	4.375	4	4.142857	3	4.095238		1	2.05	1.5	0.5	3	3	2.045238	2.875	3.5	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX658RT4
2081	8976	NDAR_INVVX658RT4	2526			F	5800	EndofPhase2	2	Phase 2	44	1	0	0	0	0	0	0	0	2	4	3	3	2	3	4	0	0	2	9	2	0	0	3	0	4	1	5	5	0	1	0	0	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	2.625	0.5	2.142857	2.5	2.15			2.05	1.5	0.5	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX658RT4
2081	8976	NDAR_INVVX658RT4	2526			F	6000	EndofPhase3	7	Phase 3	198	1	0	1	0	0	0	0	6	6	5	5	6	6	5	4	5	3	5	6	5	5	5	6	6	5	3	5	6	0	1	1	1	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	5	5.375	4.75	5.428571	4	5.142857			2.05	1.5	0.5	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX658RT4
2081	8976	NDAR_INVVX715XJ0	1824			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	4	5	4	2	4	4	4	3	6	5	3	3	3	5	5	5	3	5	4	1	0	1	0	1	1	1	1	2	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	4.5	4	4	4.095238	1		4.095238	4	4.5	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX715XJ0
2081	8976	NDAR_INVVX715XJ0	1824			F	2800	Visit12	12	Phase 1/1A	349	0	1	0	0	0	0	0	6	5	6	6	6	6	6	6	1	6	6	9	2	4	4	5	5	4	4	6	6	1	1	1	0	1	1	1	0	3	2	1	3	2	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.875	3.25	4.571429	4	5			4.095238	4	4.5	4	4	0.9047619	1.875	-1.25	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX715XJ0
2081	8976	NDAR_INVVX715XJ0	1824			F	5200	EndofPhase1_1a	18	Phase 1/1A	562	0	0	0	0	0	0	1	9	6	4	2	2	4	4	2	4	2	6	2	0	0	0	0	6	0	0	4	2	1	0	1	0	1	1	1	1	3	2	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	3.4285715	3.5	1.7142857	0	2.5		1	4.095238	4	4.5	4	4	-1.5952381	-0.5714286	-1	-2.2857144	-4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX715XJ0
2081	8976	NDAR_INVVX955KYT	1334			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	0	0	2	0	0	0	3	0	0	1	0	0	0	0	3	6	2	0	3	0	0	0	0	1	1	0	1	1	1	0	4	4	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	7	1.25	1	0.85714287	4	1.3333334	1		1.3333334	1.25	1	0.85714287	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX955KYT
2081	8976	NDAR_INVVX955KYT	1334			M	1600	Visit6	6	Phase 2	177	1	0	0	0	0	0	0	6	1	0	0	1	0	1	1	5	1	0	2	0	1	2	1	2	4	2	2	3	1	1	1	2	1	1	1	1	1	1	0		4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.25	2	1.5714285	3	1.6666666			1.3333334	1.25	1	0.85714287	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX955KYT
2081	8976	NDAR_INVVX955KYT	1334			M	2800	Visit12	12	Phase 2	325	1	0	0	0	0	0	0	6	5	5	4	4	4	4	4	0	0	1	9	2	1	2	2	3	5	2	4	5	1	1	1	0	1	2	2	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.5	0.25	2.7142856	3.5	3.15			1.3333334	1.25	1	0.85714287	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX955KYT
2081	8976	NDAR_INVVX955KYT	1334			M	4000	Visit18	18	Phase 2	511	1	0	0	0	0	0	0	6	5	5	4	4	4	4	4	0	0	1	9	2	1	2	2	3	5	2	4	5	1	1	0	0	1	2	2	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	4.5	0.25	2.7142856	3.5	3.15			1.3333334	1.25	1	0.85714287	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX955KYT
2081	8976	NDAR_INVVX955KYT	1334			M	5200	EndofPhase1_1a	2	Phase 1/1A	60	1	0	0	0	0	0	0	6	0	0	0	6	0	2	0	3	2	0	2	0	0	0	3	3	4	1	4	3	0	0	0	0	1	0	0	0	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.75	1.75	1.8571428	2.5	1.8571428		1	1.3333334	1.25	1	0.85714287	4	0.52380955	0.5	0.75	1	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX955KYT
2081	8976	NDAR_INVVX955KYT	1334			M	5800	EndofPhase2	18	Phase 2	511	1	0	0	0	0	0	0	6	5	5	4	4	4	4	4	0	0	1	9	2	1	2	2	3	5	2	4	5	1	1	0	0	1	2	2	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	4.5	0.25	2.7142856	3.5	3.15			1.3333334	1.25	1	0.85714287	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVX955KYT
2081	8976	NDAR_INVVY594WPX	2080			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	1	0	2	2	2	2	1	1	1	1	9	1	2	2	2	0	2	2	2	3	0	1	1	0	0	0	0	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.625	0.75	1.7142857	2	1.6	1		1.6	1.625	0.75	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY594WPX
2081	8976	NDAR_INVVY594WPX	2080			M	1600	Visit6	6	Phase 3	160	1	0	0	0	0	0	0	4	0	2	1	2	3	2	1	0	1	1	9	1	2	4	3	0	2	2	5	4	1	1	1	0	0	0	0	1	1	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1.875	0.5	2.7142856	2	2			1.6	1.625	0.75	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY594WPX
2081	8976	NDAR_INVVY594WPX	2080			M	5200	EndofPhase1_1a	4	Phase 1/1A	105	1	0	0	0	0	0	0	4	0	3	2	2	2	3	2	1	1	2	9	1	1	2	2	1	1	2	3	2	1	0	1	0	0	0	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2.25	1	1.7142857	1.5	1.85		1	1.6	1.625	0.75	1.7142857	2	0.25	0.625	0.25	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY594WPX
2081	8976	NDAR_INVVY594WPX	2080			M	6000	EndofPhase3	8	Phase 3	218	1	0	0	0	0	0	0	3	0	2	1	1	2	2	1	1	1	1	9	3	1	3	2	1	3	3	3	3	1	1	1	0	0	0	0	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1.5	0.75	2.2857144	3	1.85			1.6	1.625	0.75	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY594WPX
2081	8976	NDAR_INVVY623WFW	2669			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	5	5	5	4	5	3	1	0	0	0	4	4	3	4	5	4	5	6	6	1	0	0	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.875	0.25	4.571429	4.5	3.857143	1		3.857143	4.875	0.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY623WFW
2081	8976	NDAR_INVVY623WFW	2669			M	1600	Visit6	6	Phase 1/1A	177	1	0	0	0	0	0	0	6	6	4	4	6	5	4	3	3	4	3	5	4	3	3	5	3	4	4	6	3	1	0	0	1	1	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.75	3.75	3.857143	4	4.1904764			3.857143	4.875	0.25	4.571429	4.5	0.33333334	-0.125	3.5	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY623WFW
2081	8976	NDAR_INVVY623WFW	2669			M	5200	EndofPhase1_1a	12	Phase 1/1A	343	1	0	0	0	0	0	0	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5	5	5	5	5		1	3.857143	4.875	0.25	4.571429	4.5	1.1428572	0.125	4.75	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY623WFW
2081	8976	NDAR_INVVY623WFW	2669			M	5800	EndofPhase2	13	Phase 2	363	1	0	0	0	0	0	0	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	4	4	4	4			3.857143	4.875	0.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY623WFW
2081	8976	NDAR_INVVY623WFW	2669			M	6000	EndofPhase3	17	Phase 3	467	1	0	0	0	0	0	0	4	4	4	4	5	4	4	5	4	4	4	3	3	3	4	4	3	5	5	5	4	1	1	1	1	1	1	1	1	1	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	3.75	3.7142856	5	4.047619			3.857143	4.875	0.25	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVY623WFW
2081	8976	NDAR_INVVZ416YDT	2370			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	5	5	4	4	5	4	2	5	2	9	5	4	3	4	1	4	3	4	5	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	3	3.875	2.25	3.7142856	3.5	3.65	1		3.65	3.875	2.25	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVZ416YDT
2081	8976	NDAR_INVVZ416YDT	2370			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	5	4	4	3	3	3	4	4	1	4	2	9	6	5	6	4	2	5	4	6	5	1	1	1	1	1	1	1	1	2	1	1	4	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	1	4	3.75	1.75	4.857143	4.5	4			3.65	3.875	2.25	3.7142856	3.5	0.35	-0.125	-0.5	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVZ416YDT
2081	8976	NDAR_INVVZ416YDT	2370			M	5200	EndofPhase1_1a	9	Phase 1/1A	253	0	0	0	0	0	0	1	6	5	4	4	6	3	4	4	2	5	2	9	6	5	5	4	2	5	3	5	6	1	1	1	0	1	1	1	1	2	1	1	4	3	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.5	2.25	4.714286	4	4.3		1	3.65	3.875	2.25	3.7142856	3.5	0.65	0.625	0	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVZ416YDT
2081	8976	NDAR_INVVZ418LZN	1129			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	1	1	1	2	2	0	2	2	4	9	3	2	2	5	2	4	1	5	4	0	0	0	0	1	1	1	1	3	3	0	4	4	3	4	1	0	0	0	0	0	1	0	0	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.875	2	3.2857144	2.5	2.15	1		2.15	0.875	2	3.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVZ418LZN
2081	8976	NDAR_INVVZ418LZN	1129			M	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	0	0	0	0	0	0	2	1	2	2	2	2	0	0	0	5	9	0	0	1	4	0	4	2	2	4	2	2	2	2	1	1	1	2	2	2	0	4	3	3	4	1	0	1	0	0	0	0	0	0	1	0	0	1	7	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1.375	1.25	1.5714285	3	1.65		1	2.15	0.875	2	3.2857144	2.5	-0.5	0.5	-0.75	-1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVZ418LZN
2081	8976	NDAR_INVVZ562UC6	1475			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	2	0	2	2	1	2	2	1	1	1	9	2	2	4	4	4	6	3	5	5	1	1	1	1	1	1	1	1	2	2	0	4	2	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	2.125	0.75	3.7142856	4.5	2.75	1		2.75	2.125	0.75	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVVZ562UC6
2081	8976	NDAR_INVWA295TC2	1120			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	6	4	2	4	4	4	4	1	1	2	9	5	5	4	4	4	3	3	4	4	1	0	1	1	1	1	1	1	2	1	1	3	2	2	3	1	0	0	0	0	0	1	0	1	1	0	0	1	28	0		0		1	2	0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1	7	4.125	1	4.285714	3	3.65	1		3.65	4.125	1	4.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA295TC2
2081	8976	NDAR_INVWA295TC2	1120			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	0	1	0	2	2	2	0	0	0	0	0	9	2	2	0	4	0	3	1	3	2	0	0	1	0	1	1	1	1	2	1	1	3	2	3	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.875	0	1.8571428	2	1.2			3.65	4.125	1	4.285714	3	-2.45	-3.25	-1	-2.4285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA295TC2
2081	8976	NDAR_INVWA295TC2	1120			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	9	0	5	4	2	5	5	0	0	0	0	9	4	6	2	5	4	3	3	6	6	1	0	1	1	1	1	0	1	3	1	1	3	2	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3	0	4.714286	3	3.1578948			3.65	4.125	1	4.285714	3	-0.49210528	-1.125	-1	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA295TC2
2081	8976	NDAR_INVWA295TC2	1120			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	6	4	1	5	2	5	3	1	0	0	0	9	4	3	4	4	5	3	2	6	6	1	0	1	1	1	1	2	1	2	1	1	3	1	4	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3.375	0	4.571429	2.5	3.2		1	3.65	4.125	1	4.285714	3	-0.45	-0.75	-1	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA295TC2
2081	8976	NDAR_INVWA551WF8	2077			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	3	2	2	2	1	4	2	0	3	3	9	4	2	3	4	4	3	3	4	5	1	1	1	0	1	1	0	1	1	1	1	2	1	3	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	1.5	3.7142856	3	2.95	1		2.95	2.625	1.5	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA551WF8
2081	8976	NDAR_INVWA662ZFP	2734			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	3	4	4	4	6	4	0	0	0	9	0	2	3	6	5	3	3	4	5	2	1	1	0	1	1	1	1	1	2	1	2	1	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	4	4.375	0	3.5714285	3	3.3	1		3.3	4.375	0	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA662ZFP
2081	8976	NDAR_INVWA662ZFP	2734			M	1600	Visit6	6	Phase 1/1A	183	1	0	0	0	0	0	0	5	5	4	4	5	4	5	4	1	1	1	9	2	1	4	4	0	4	4	5	6	1	1	1	2	1	1	1	1	1	1	1	2	1	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	4	4.5	0.75	3.142857	4	3.45		1	3.3	4.375	0	3.5714285	3	0.15	0.125	0.75	-0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWA662ZFP
2081	8976	NDAR_INVWB158FFZ	1813			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	1	5	0	0	1	0	1	0	1	0	9	0	0	0	0	0	4	1	1	3	0	0	0	0	1	0	0	1	3		0	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	1.5	0.25	0.5714286	2.5	1.1	1		1.1	1.5	0.25	0.5714286	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB158FFZ
2081	8976	NDAR_INVWB262MKH	2445			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	1	2	5	1	6	1	0	1	4	9	6	6	6	1	2	3	3	6	6	1	0	1	1	1	1	1	1	2	3	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	0	0	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	0	1	3	2.75	1.25	4.714286	3	3.3	1		3.3	2.75	1.25	4.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB262MKH	2445			F	1600	Visit6	6	Phase 1/1A	152	1	0	0	0	0	0	0	2	4	0	3	2	1	2	2	1	1	1	9	3	4	4	4	4	5	3	4	3	0	1	1	0	1	1	1	1	1	1	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0.75	3.7142856	4	2.65			3.3	2.75	1.25	4.714286	3	-0.65	-0.75	-0.5	-1	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB262MKH	2445			F	2800	Visit12	12	Phase 1B	299	0	0	0	0	0	0	1	4	0	0	1	1	1	2	3	3	4	6	6	0	5	4	4	4	5	4	4	6	1	1	1	1	1	1	1	1	2	1	0	4				1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	1.5	4.75	3.857143	4.5	3.1904762			3.3	2.75	1.25	4.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB262MKH	2445			F	4000	Visit18	18	Phase 2	460	0	0	0	0	0	0	1	6	0	0	4	6	4	5	2	4	5	6	4	2	6	4	6	5	6	5	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.375	4.75	5	5.5	4.3809524			3.3	2.75	1.25	4.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB262MKH	2445			F	5200	EndofPhase1_1a	10	Phase 1/1A	243	0	0	0	0	0	0	1	5	4	2	4	4	3	6	3	4	4	6	6	0	4	4	4	4	6	4	6	3	1	1	1	1	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	3.875	5	3.5714285	5	4.095238		1	3.3	2.75	1.25	4.714286	3	0.7952381	1.125	3.75	-1.1428572	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB262MKH	2445			F	5400	EndofPhase1b	16	Phase 1B	404	0	0	0	0	0	0	1	2	2	1	4	1	4	4	2	4	5	6	4	4	6	4	6	3	6	4	6	5	0	1	0	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	2.5	4.75	4.857143	5	3.952381			3.3	2.75	1.25	4.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB262MKH	2445			F	5800	EndofPhase2	23	Phase 2	601	0	0	0	0	0	0	1	6	0	0	0	6	4	4	3	4	4	6	6	4	4	4	4	4	6	3	6	6	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	5	4.571429	4.5	4			3.3	2.75	1.25	4.714286	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB262MKH
2081	8976	NDAR_INVWB586DLN	1203			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	0	2	2	0	1	1	9	2	2	1	2	2	5	1	4	5	0	0	0	0	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	15	0		0		0		1	15	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	0.5	0.5	2.5714285	3	1.5	1		1.5	0.5	0.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB586DLN
2081	8976	NDAR_INVWB586DLN	1203			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	0	1	9	0	1	0	4	4	4	3	3	3	2	2	2	2	3	4	3	4	5	1	5	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.2857144	2.5	2.857143	4.5	2.75			1.5	0.5	0.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB586DLN
2081	8976	NDAR_INVWB586DLN	1203			M	2800	Visit12	12	Phase 3	337	0	0	0	0	0	0	1	9	4	3	3	4	3	4	5	3	3	3	3	4	4	4	4	4	6	6	5	5	1	1	1	1	1	1	1	1	3		1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.7142856	3	4.285714	6	4			1.5	0.5	0.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB586DLN
2081	8976	NDAR_INVWB586DLN	1203			M	4000	Visit18	18	Phase 3	512	0	0	0	0	0	0	1	3	3	2	3	4	4	4	4	3	3	3	4	3	3	5	4	3	6	5	4	5	1	1	1	1	1	1	1	1	3	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.375	3.25	3.857143	5.5	3.7142856			1.5	0.5	0.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB586DLN
2081	8976	NDAR_INVWB586DLN	1203			M	5200	EndofPhase1_1a	3	Phase 1/1A	78	0	0	0	0	0	0	1	9	0	0	1	4	1	2	2	0	0	0	9	3	3	3	2	4	4	3	2	5	1	1	0	0	1	1	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		1	16	0		1	14	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	3	1.4285715	0	3.142857	3.5	2.0526316		1	1.5	0.5	0.5	2.5714285	3	0.55263156	0.9285714	-0.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB586DLN
2081	8976	NDAR_INVWB586DLN	1203			M	5800	EndofPhase2	9	Phase 2	261	0	0	0	0	0	0	1	9	2	2	4	4	3	2	4	3	2	2	9	4	3	4	4	4	6	4	4	5	1	1	1	1	1	1	1	1	3		0	4	3	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	1.75	4	5	3.4736843			1.5	0.5	0.5	2.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB586DLN
2081	8976	NDAR_INVWB748NJW	1291			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	2	2	2	0	1	1	6	0	2	1	9	2	0	2	6	0	2	1	5	2	0	0	0	0	1	2	1	0	3	3	0	4	2	4	2	0	0	0	0	0	0	0	1					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.875	0.75	2.4285715	1.5	1.9	1		1.9	1.875	0.75	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB748NJW
2081	8976	NDAR_INVWB748NJW	1291			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	1	0	1	3	1	1	0	1	2	3	1	1	1	9	2	2	2	3	1	2	2	4	6	1	1	0	0	1	0	1	0	3		0	4	2	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	0	0	1	0	2	1.5	0.75	2.857143	2	1.95			1.9	1.875	0.75	2.4285715	1.5	0.05	-0.375	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB748NJW
2081	8976	NDAR_INVWB748NJW	1291			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	1	0	2	2	1	1	2	0	2	3	1	2	1	9	0	2	2	2	0	2	1	4	5	0	1	0	2	1	0	0	0	3		1	3	4	4	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.625	1	2.142857	1.5	1.75			1.9	1.875	0.75	2.4285715	1.5	-0.15	-0.25	0.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB748NJW
2081	8976	NDAR_INVWB748NJW	1291			M	5200	EndofPhase1_1a	18	Phase 1/1A	498	0	0	0	0	0	1	0	5	0	0	0	2	0	2	3	0	1	5	9	0	2	4	2	0	2	2	4	5	1	1	0	0	1	1	1	0	3		0	4	4	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.5	1.5	2.4285715	2	1.95		1	1.9	1.875	0.75	2.4285715	1.5	0.05	-0.375	0.75	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB748NJW
2081	8976	NDAR_INVWB974EBQ	2795			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	3	3	2	2	2	1	2	2	2	9	2	2	0	0	1	2	0	5	6					1	1	0	1	1	2	0	4	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	2	2.375	1.5	2.2857144	1	2.15	1		2.15	2.375	1.5	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB974EBQ
2081	8976	NDAR_INVWB974EBQ	2795			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	6	5	5	4	4	5	4	3	3	4	5	6	2	2	0	5	2	2	4	6	6	1	1	1	1	1	1	1	1	1	1	1	2	3	2	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4.5	4.5	3.2857144	3	3.952381			2.15	2.375	1.5	2.2857144	1	1.8023809	2.125	3	1	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB974EBQ
2081	8976	NDAR_INVWB974EBQ	2795			M	2800	Visit12	12	Phase 1/1A	344	1	0	0	0	0	0	0	1	0	1	4	0	0	6	3	4	3	3	0	0	2	1	1	3	4	2	4	4	1	1	0	1	1	1	1	1	1	3	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	2.5	2.142857	3	2.1904762			2.15	2.375	1.5	2.2857144	1	0.04047619	-0.5	1	-0.14285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB974EBQ
2081	8976	NDAR_INVWB974EBQ	2795			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	1	0	0	0	0	0	0	4	0	4	3	1	3	3	3	1	1	2	9	3	0	2	3	1	5	2	4	6	1	1	1	0	1	1	1	1	1	3	0	4	2	4	2	1	0	1	0	0	0	0	0	1	2	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	1	0	0	0	1	1	1	1	4	2.625	1	2.7142856	3.5	2.55		1	2.15	2.375	1.5	2.2857144	1	0.4	0.25	-0.5	0.42857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWB974EBQ
2081	8976	NDAR_INVWC888DBE	1149			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	4	3	3	4	5	2	2	0	0	1	9	2	0	0	2	4	5	4	4	4	0	1	0	0	1	1	0	1	1	2	1	4	2	2	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	0	1	0	0	4	3.375	0.25	2.2857144	4.5	2.65	1		2.65	3.375	0.25	2.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWC888DBE
2081	8976	NDAR_INVWC888DBE	1149			M	1600	Visit6	6	Phase 3	169	0	1	0	1	1	0	0	4	0	0	0	2	0	0	2	0	0	0	9	1	0	1	2	2	6	3	2	2	1	1	2	1	1	1	2	1	1	2	0	4	3	4	1	1	1	0	0	0	0	0	0	1	2	1	2	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1	0	1.4285715	4.5	1.35			2.65	3.375	0.25	2.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWC888DBE
2081	8976	NDAR_INVWC888DBE	1149			M	2800	Visit12	12	Phase 3	337	0	1	0	1	1	0	0	6	4	2	0	2	0	2	2	0	0	0	9	0	0	2	4	4	6	3	6	6	1	0	2	0	1	1	0	1	1	2	1	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	2.25	0	3.142857	4.5	2.45			2.65	3.375	0.25	2.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWC888DBE
2081	8976	NDAR_INVWC888DBE	1149			M	5200	EndofPhase1_1a	1	Phase 1/1A	27	0	1	0	0	0	0	0	5	2	2	2	2	0	2	4	0	0	0	9	2	0	2	4	4	5	3	6	4	1	1	0	1	1	0	2	1	1	1	1	3	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.375	0	3.142857	4	2.45		1	2.65	3.375	0.25	2.2857144	4.5	-0.2	-1	-0.25	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWC888DBE
2081	8976	NDAR_INVWC888DBE	1149			M	5800	EndofPhase2	3	Phase 2	85	0	1	0	0	0	0	0	4	1	2	0	0	2	1	3	0	0	0	9	2	1	2	2	2	5	3	0	2	0	0	0	1	1	1	0	1	1	2	1	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	6	1.625	0	1.5714285	4	1.6			2.65	3.375	0.25	2.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWC888DBE
2081	8976	NDAR_INVWC888DBE	1149			M	6000	EndofPhase3	18	Phase 3	505	0	1	0	1	1	0	0	6	2	4	2	2	2	4	5	0	0	0	9	4	4	5	6	2	5	3	6	6	1	1	2	1	1	1	2	1	1	2	1	3	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	6	3.375	0	4.714286	4	3.4			2.65	3.375	0.25	2.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWC888DBE
2081	8976	NDAR_INVWD860CRF	2199			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	4	0	2	2	0	2	1	0	0	6	9	3	1	0	2	0	3	1	4	2	0	0	0	0	1	1	0	0	3	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	3	2.125	1.5	1.7142857	2	1.95	1		1.95	2.125	1.5	1.7142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWD860CRF
2081	8976	NDAR_INVWE201KX2	2743			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	5	4	5	5	5	5	6	4	5	3	5	5	5	3	4	3	6	5	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.125	4.25	4.571429	5.5	4.8095236	1		4.8095236	5.125	4.25	4.571429	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE201KX2
2081	8976	NDAR_INVWE201KX2	2743			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	6	4	4	5	6	4	5	5	4	5	4	4	5	3	2	5	4	6	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.875	4.25	4.428571	5	4.6190476			4.8095236	5.125	4.25	4.571429	5.5	-0.1904762	-0.25	0	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE201KX2
2081	8976	NDAR_INVWE201KX2	2743			M	2800	Visit12	12	Phase 1/1A	347	0	1	0	0	0	0	0	6	5	4	5	5	3	5	6	5	5	4	6	5	5	3	5	3	6	5	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.875	5	4.571429	5.5	4.857143			4.8095236	5.125	4.25	4.571429	5.5	0.04761905	-0.25	0.75	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE201KX2
2081	8976	NDAR_INVWE201KX2	2743			M	5200	EndofPhase1_1a	14	Phase 1/1A	408	0	1	0	0	0	0	0	6	5	4	4	4	3	4	5	4	4	4	4	4	2	2	4	4	6	5	4	6	1	1	1	1	1	0	1	1	1	1	1	4	3	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.375	4	3.7142856	5.5	4.1904764		1	4.8095236	5.125	4.25	4.571429	5.5	-0.61904764	-0.75	-0.25	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE201KX2
2081	8976	NDAR_INVWE201KX2	2743			M	5800	EndofPhase2	18	Phase 2	527	0	1	0	0	0	0	0	5	5	2	3	4	3	4	5	4	4	4	5	4	4	3	4	4	6	3	4	5	1	1	1	1	1	1	1	1	1	1	1	3	2	3	1	0	0	0	0	0	0	0	0					1	26	0		0		1	4	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	4.25	4	4.5	4.047619			4.8095236	5.125	4.25	4.571429	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE201KX2
2081	8976	NDAR_INVWE336ZRH	2644			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	2	0	3	2	4	4	2	2	1	1	9	1	2	0	3	1	3	4	5	5	1	1	1	0	1	0	1	1	1	2	1	4	2	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	5	2.875	1	2.4285715	3.5	2.55	1		2.55	2.875	1	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE336ZRH
2081	8976	NDAR_INVWE336ZRH	2644			M	1600	Visit6	6	Phase 1/1A	176	0	0	1	0	0	0	0	5	3	4	4	5	2	6	2	2	2	4	9	4	5	5	6	5	5	3	6	6	1	0	1	1	1	0	0	1	1	2	1	4	2	3	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	5	3.875	2	5.285714	4	4.2			2.55	2.875	1	2.4285715	3.5	1.65	1	1	2.857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE336ZRH
2081	8976	NDAR_INVWE336ZRH	2644			M	2800	Visit12	12	Phase 1/1A	346	0	0	0	0	0	1	0	4	5	5	4	5	5	5	3	2	3	2	9	2	4	3	5	3	4	2	4	5	0	0	1	1	1	1	0	1	2	2	1	3	2	3	3	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	5	4.5	1.75	3.7142856	3	3.75			2.55	2.875	1	2.4285715	3.5	1.2	1.625	0.75	1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE336ZRH
2081	8976	NDAR_INVWE336ZRH	2644			M	5200	EndofPhase1_1a	18	Phase 1/1A	526	0	0	0	0	0	1	0	6	5	6	4	4	4	5	4	2	2	1	9	2	5	4	4	4	4	3	6	6	1	0	1	1	1	1	0	1	2	2	1	3	2	3	2	1	0	0	0	0	0	1	0	1	0	1	1	1	5	1	25	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	6	4.75	1.25	4.428571	3.5	4.05		1	2.55	2.875	1	2.4285715	3.5	1.5	1.875	0.25	2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE336ZRH
2081	8976	NDAR_INVWE337XNR	2656			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	4	3	4	5	4	4	1	3	3	3	3	3	2	4	3	3	5	1	4	4	0	0	2	1	1	1	1	1	1	2	1	3	4	4	4	1	0	0	0	1	0	0	0	1	2	1	2	1	9	0		0		1	21	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	3.75	3	3.2857144	3	3.3809524	1		3.3809524	3.75	3	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE337XNR
2081	8976	NDAR_INVWE337XNR	2656			M	1600	Visit6	6	Phase 1/1A	189	0	0	0	0	0	0	1	4	4	2	2	4	3	3	2	2	2	3	9	4	3	5	4	3	5	3	4	4	1	1	1	0	1	1	1	1	2	2	1	4	3	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	3	1.75	3.857143	4	3.3			3.3809524	3.75	3	3.2857144	3	-0.08095238	-0.75	-1.25	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE337XNR
2081	8976	NDAR_INVWE337XNR	2656			M	2800	Visit12	12	Phase 1/1A	371	0	0	0	0	0	0	1	9	0	0	0	0	0	1	0	0	0	0	9	4	0	2	2	2	6	3	1	1	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	0.14285715	0	1.7142857	4.5	1.1578947		1	3.3809524	3.75	3	3.2857144	3	-2.2230577	-3.607143	-3	-1.5714285	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE337XNR
2081	8976	NDAR_INVWE449JD2	1552			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	1	1	0	1	2	1	1	1	9	1	1	1	3	1	3	3	4	2	1	1	0	1	1	1	2	1	1	2	0		4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	1.125	0.75	1.8571428	3	1.55	1		1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE449JD2
2081	8976	NDAR_INVWE449JD2	1552			M	1600	Visit6	6	Phase 3	169	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	2	2	2	2	1	1	1	2	3	0	1	2	0	1	1	2	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1	0.75	2	1	1.35			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE449JD2
2081	8976	NDAR_INVWE449JD2	1552			M	2800	Visit12	12	Phase 3	336	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	2	2	2	2	0	1	0	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	1	0.75	1.2857143	2	1.2			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE449JD2
2081	8976	NDAR_INVWE449JD2	1552			M	5200	EndofPhase1_1a	4	Phase 1/1A	112	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	9	1	1	1	1	1	1	1	3	3	0	1	2	0	1	1	2	1	3	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1	0.75	1.5714285	1	1.2		1	1.55	1.125	0.75	1.8571428	3	-0.35	-0.125	0	-0.2857143	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE449JD2
2081	8976	NDAR_INVWE449JD2	1552			M	5800	EndofPhase2	5	Phase 2	127	0	0	0	0	0	1	0	2	2	2	2	2	1	1	1	1	1	1	9	1	1	1	1	1	1	1	3	2	2	2	2	0	1	2	2	2	3	3	0		4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		1	16	1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	1.625	0.75	1.4285715	1	1.4			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE449JD2
2081	8976	NDAR_INVWE449JD2	1552			M	6000	EndofPhase3	18	Phase 3	510	0	0	0	0	0	1	0	2	2	1	2	2	2	1	1	1	1	2	9	1	2	2	2	2	2	4	3	2	1	0	0	0	1	1	0	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	1.625	1	2	3	1.85			1.55	1.125	0.75	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE449JD2
2081	8976	NDAR_INVWE493FHM	2274			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	1	3	2	5	2	5	1	2	5	3	9	4	6	4	5	4	3	3	5	4	1	1	1	0	1	1	1	1	2	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.125	2.5	4.571429	3	3.65	1		3.65	3.125	2.5	4.571429	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE493FHM
2081	8976	NDAR_INVWE493FHM	2274			M	5200	EndofPhase1_1a	1	Phase 1/1A	33	0	0	0	0	0	0	1	6	1	2	2	5	2	5	1	2	5	3	9	4	6	4	5	4	3	5	5	4	1	1	1	0	1	1	1	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3	2.5	4.571429	4	3.7		1	3.65	3.125	2.5	4.571429	3	0.05	-0.125	0	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWE493FHM
2081	8976	NDAR_INVWF045RC4	2073			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	4	2	0	2	2	1	1	2	2	2	9	1	2	2	4	1	6	4	4	4	0	1	0	0	1	1	1	1	2	1	1	3	4	4	4	1	0	1	0	0	1	0	0	0	0	0	2	1	30	0		0		0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	4	1.75	1.5	2.5714285	5	2.4	1		2.4	1.75	1.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF045RC4
2081	8976	NDAR_INVWF045RC4	2073			M	5200	EndofPhase1_1a	6	Phase 1/1A	178	1	0	0	0	0	0	0	4	3	4	4	4	3	6	3	2	4	4	9	3	2	0	6	6	5	4	4	4	1	1	0	0	1	0	1	0	1	1	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.875	2.5	3.5714285	4.5	3.75		1	2.4	1.75	1.5	2.5714285	5	1.35	2.125	1	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF045RC4
2081	8976	NDAR_INVWF045RC4	2073			M	5400	EndofPhase1b	7	Phase 1B	191	1	0	0	0	0	0	0	4	4	2	3	3	2	3	2	2	3	4	9	2	2	3	6	2	6	3	5	6	0	1	1	0	1	0	1	0	1	2	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.875	2.25	3.7142856	4.5	3.35			2.4	1.75	1.5	2.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF045RC4
2081	8976	NDAR_INVWF505PV5	2528			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	4	1	4	2	3	3	4	4	3	4	3	4	3	4	4	3	3	3	4	4	1	1	1	2	1	1	1	1	1	2	0	4	4	4	3	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	3.5	3.7142856	3	3.3809524	1		3.3809524	3.125	3.5	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF505PV5
2081	8976	NDAR_INVWF505PV5	2528			F	1600	Visit6	6	Phase 3	164	1	0	1	0	0	0	0	4	2	0	2	2	2	2	2	2	1	3	9	2	2	2	3	3	3	3	4	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	2	1.5	2.857143	3	2.4			3.3809524	3.125	3.5	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF505PV5
2081	8976	NDAR_INVWF505PV5	2528			F	2800	Visit12	12	Phase 3	351	1	0	1	0	0	0	0	3	2	1	3	2	1	2	2	1	2	0	9	2	2	2	2	2	2	3	3	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2	0.75	2.4285715	2.5	2.05			3.3809524	3.125	3.5	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF505PV5
2081	8976	NDAR_INVWF505PV5	2528			F	5200	EndofPhase1_1a	3	Phase 1/1A	88	1	0	1	0	0	0	0	4	4	1	4	2	3	3	4	4	3	4	3	3	3	3	4	3	3	3	4	4	1	1	1	2	1	1	2	1	1	2	0	4	4	4	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.125	3.5	3.4285715	3	3.2857144		1	3.3809524	3.125	3.5	3.7142856	3	-0.0952381	0	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF505PV5
2081	8976	NDAR_INVWF505PV5	2528			F	5800	EndofPhase2	5	Phase 2	142	1	0	1	0	0	0	0	4	2	0	2	2	2	2	2	2	1	3	9	2	2	2	3	3	3	3	4	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	3	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2	1.5	2.857143	3	2.4			3.3809524	3.125	3.5	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF505PV5
2081	8976	NDAR_INVWF505PV5	2528			F	6000	EndofPhase3	18	Phase 3	530	1	0	0	0	0	0	0	4	4	3	4	3	3	4	4	3	3	2	3	3	3	4	2	2	4	4	4	4	1	1	1	2	1	1	1	1	1	2	1	2	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	3.625	2.75	3.142857	4	3.3333333			3.3809524	3.125	3.5	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF505PV5
2081	8976	NDAR_INVWF823YW7	1583			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	5	2	6	6	6	5	2	1	1	1	9	4	4	4	6	2	4	3	5	5	1	1	1	0	0	1	0	1	2	1	1	2	2	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	6	4.75	0.75	4.285714	3.5	3.9	1		3.9	4.75	0.75	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF823YW7
2081	8976	NDAR_INVWF823YW7	1583			M	1600	Visit6	6	Phase 2	168	0	1	0	0	0	0	0	6	5	1	5	4	5	5	2	2	4	1	9	3	2	4	5	2	4	2	5	6	1	0	1	0	1	1	0	1	2	1	1	4	2	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.125	1.75	3.857143	3	3.65			3.9	4.75	0.75	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF823YW7
2081	8976	NDAR_INVWF823YW7	1583			M	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	0	0	0	0	0	1	4	2	2	2	2	3	6	2	1	1	1	9	3	2	3	6	1	4	3	4	6	1	0	1	1	1	0	1	1	2	1	1	2	2	2	3	1	0	1	1	0	1	1	0	1	1	1	0	1	29	0		0		1	1	0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	2.875	0.75	3.5714285	3.5	2.9		1	3.9	4.75	0.75	4.285714	3.5	-1	-1.875	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF823YW7
2081	8976	NDAR_INVWF871JW9	2705			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	0	2	2	2	2	2	2	0	0	9	2	2	2	2	4	3	2	4	4	2	2	2	2	0	1	2	2	3	2	1	3	3	4	3	1	0	1	1	0	0	1	0	1	1	1	1	1	11	0		0		1	19	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.7142857	0.5	2.857143	2.5	2.0526316	1		2.0526316	1.7142857	0.5	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF871JW9
2081	8976	NDAR_INVWF871JW9	2705			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	0	1	9	2	0	3	1	2	3	3	4	2	5	5	3	2	2	5	6	4	4	4	2	1	1	1	1	1	1	0	1	2	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	2	4	3.4285715	4	3.1			2.0526316	1.7142857	0.5	2.857143	2.5	1.0473684	0.2857143	3.5	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF871JW9
2081	8976	NDAR_INVWF871JW9	2705			M	2800	Visit12	12	Phase 1/1A	331	0	0	0	0	0	0	1	9	4	2	3	4	2	3	2	3	3	5	4	2	2	4	4	2	3	3	4	2	1	0	1	1	1	1	1	1	2	2	1	3	4	4	1	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	7	2.857143	3.75	2.857143	3	3.05			2.0526316	1.7142857	0.5	2.857143	2.5	0.9973684	1.1428572	3.25	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF871JW9
2081	8976	NDAR_INVWF871JW9	2705			M	5200	EndofPhase1_1a	18	Phase 1/1A	499	0	0	0	0	0	0	1	9	0	2	3	3	2	3	3	0	0	1	9	2	1	2	3	4	3	4	4	4	1	1	1	0	1	1	1	1	1	1	1	4	2	4	2	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	2.2857144	0.25	2.857143	3.5	2.3157895		1	2.0526316	1.7142857	0.5	2.857143	2.5	0.2631579	0.5714286	-0.25	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWF871JW9
2081	8976	NDAR_INVWG522NPA	1477			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	3	2	4	3	3	4	1	1	2	1	9	1	2	2	3	2	4	2	4	3	1	0	0	0	1	1	0	1	3	1	1	4	3	3	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	28	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3	1	2.4285715	3	2.55	1		2.55	3	1	2.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG522NPA
2081	8976	NDAR_INVWG522NPA	1477			M	1600	Visit6	6	Phase 1/1A	161	0	0	0	0	0	1	0	4	0	2	2	2	2	6	0	0	0	0	9	0	2	1	4	4	3	1	3	4	1	1	0	0	1	1	0	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.25	0	2.5714285	2	2			2.55	3	1	2.4285715	3	-0.55	-0.75	-1	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG522NPA
2081	8976	NDAR_INVWG522NPA	1477			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	1	0	3	0	0	2	2	3	3	1	1	0	0	9	1	2	3	3	2	5	3	3	3	1	1	0	0	1	1	0	1	3	2	1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.75	0.25	2.4285715	4	2			2.55	3	1	2.4285715	3	-0.55	-1.25	-0.75	0	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG522NPA
2081	8976	NDAR_INVWG522NPA	1477			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	1	0	3	1	0	2	3	2	3	0	1	2	1	9	3	3	5	3	4	5	2	3	4	1	1	0	0	1	1	0	1	3	1	1	3	3	4	4	1	0	0	0	0	0	0	1	0	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	1	3.5714285	3.5	2.5		1	2.55	3	1	2.4285715	3	-0.05	-1.25	0	1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG522NPA
2081	8976	NDAR_INVWG774AVD	2100			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	4	2	2	3	4	1	0	3	4	9	4	3	4	4	2	6	3	5	5	1	1	1	1	1	1	1	1	3	2	1	2	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	5	2.857143	1.75	3.857143	4.5	3.3157895	1		3.3157895	2.857143	1.75	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG774AVD
2081	8976	NDAR_INVWG774AVD	2100			M	1600	Visit6	6	Phase 3	170	0	0	0	0	0	0	1	2	2	2	2	2	2	2	0	0	3	5	9	1	2	1	3	2	6	3	4	4	1	1	1	0	1	1	1	1	2	2	1	2	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.75	2	2.4285715	4.5	2.4			3.3157895	2.857143	1.75	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG774AVD
2081	8976	NDAR_INVWG774AVD	2100			M	5200	EndofPhase1_1a	1	Phase 1/1A	36	0	0	0	0	0	0	1	2	4	3	2	3	3	3	0	0	3	5	9	2	3	2	4	2	5	2	4	4	1	0	1	0	1	1	1	1	3	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.5	2	3	3.5	2.8		1	3.3157895	2.857143	1.75	3.857143	4.5	-0.51578945	-0.35714287	0.25	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG774AVD
2081	8976	NDAR_INVWG774AVD	2100			M	5800	EndofPhase2	3	Phase 2	79	0	0	0	0	0	0	1	4	4	2	2	2	2	2	1	0	2	5	9	3	3	4	3	1	6	3	4	5	1	0	1	1	1	1	1	1	2	1	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	25	0		1	5	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	2.375	1.75	3.2857144	4.5	2.9			3.3157895	2.857143	1.75	3.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG774AVD
2081	8976	NDAR_INVWG956VA4	1663			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	1	0	2	0	2	1	0	0	0	9	3	2	4	2	0	5	2	4	4	1	1	1	1	0	1	0	1	3	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.2857143	0	2.7142856	3.5	1.8421053	1		1.8421053	1.2857143	0	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG956VA4
2081	8976	NDAR_INVWG956VA4	1663			F	1600	Visit6	6	Phase 3	167	0	0	0	0	0	0	1	5	5	2	2	4	2	3	1	0	0	0	9	1	0	2	6	0	4	2	6	6	1	0	1	0	0	0	0	1	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	0	3	3	2.55			1.8421053	1.2857143	0	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG956VA4
2081	8976	NDAR_INVWG956VA4	1663			F	2800	Visit12	12	Phase 3	337	0	0	0	0	0	0	1	6	4	0	0	4	3	4	4	0	0	5	9	2	2	2	6	2	5	3	4	6	1	1	1	0	0	1	0	1	3	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	1.25	3.4285715	4	3.1			1.8421053	1.2857143	0	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG956VA4
2081	8976	NDAR_INVWG956VA4	1663			F	5200	EndofPhase1_1a	1	Phase 1/1A	42	0	0	0	0	0	0	1	5	3	2	1	3	0	5	1	0	0	1	9	3	2	3	2	0	4	4	4	4	1	1	1	1	1	1	0	1	3	1	1	4	3	4	4	1	0	1	0	1	0	0	0	1	0	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.5	0.25	2.5714285	4	2.35		1	1.8421053	1.2857143	0	2.7142856	3.5	0.50789475	1.2142857	0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG956VA4
2081	8976	NDAR_INVWG956VA4	1663			F	5800	EndofPhase2	3	Phase 2	83	0	0	0	0	0	0	1	6	3	0	0	2	2	2	2	0	0	0	9	1	0	2	3	0	4	2	5	5	1	1	2	0	0	0	0	1	3	1	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0	2.2857144	3	1.95			1.8421053	1.2857143	0	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG956VA4
2081	8976	NDAR_INVWG956VA4	1663			F	6000	EndofPhase3	18	Phase 3	499	0	0	0	0	0	0	1	6	4	2	2	2	3	1	3	0	0	6	9	4	4	3	6	0	3	2	5	6	1	0	1	1	1	1	0	1	3	1	1	3	3	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	1.5	4	2.5	3.1			1.8421053	1.2857143	0	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWG956VA4
2081	8976	NDAR_INVWH509PJR	1856			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	3	4	4	6	6	2	6	6	6	3	6	6	6	6	6	4	4	4	6	0	1	1	0	1	1	1	0	2	3	1	4	1	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	20	0		0		1	10	0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.625	5.25	5.714286	4	5.047619	1		5.047619	4.625	5.25	5.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH509PJR
2081	8976	NDAR_INVWH509PJR	1856			F	5200	EndofPhase1_1a	1	Phase 1/1A	6	0	0	0	0	0	1	0	6	6	3	4	4	6	6	2	6	6	6	3	6	6	6	6	6	4	4	4	6	1	0	1	0	1	0	0	1	1	3	1	4	1	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	20	0		0		1	10	0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.625	5.25	5.714286	4	5.047619		1	5.047619	4.625	5.25	5.714286	4	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH509PJR
2081	8976	NDAR_INVWH904FGL	2722			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	2	4	4	2	2	2	1	2	2	3	9	2	4	4	4	2	5	4	4	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	1.75	3.4285715	4.5	3.15	1		3.15	2.875	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH904FGL
2081	8976	NDAR_INVWH904FGL	2722			M	1600	Visit6	6	Phase 2	168	1	0	0	0	0	0	0	6	0	0	2	2	2	2	1	4	4	5	6	3	5	2	6	4	6	4	5	6	1	1	1	1	1	1	1	1	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.875	4.75	4.428571	5	3.5714285			3.15	2.875	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH904FGL
2081	8976	NDAR_INVWH904FGL	2722			M	2800	Visit12	12	Phase 3	334	1	0	0	0	0	0	0	6	0	2	2	2	2	2	1	2	3	5	9	5	3	4	4	2	5	3	4	3	1	1	1	1	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2.125	2.5	3.5714285	4	3			3.15	2.875	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH904FGL
2081	8976	NDAR_INVWH904FGL	2722			M	5200	EndofPhase1_1a	2	Phase 1/1A	63	1	0	0	0	0	0	0	6	2	4	4	2	2	2	0	2	2	3	9	2	4	4	4	2	5	4	4	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.75	3.4285715	4.5	3.1		1	3.15	2.875	1.75	3.4285715	4.5	-0.05	-0.125	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH904FGL
2081	8976	NDAR_INVWH904FGL	2722			M	5800	EndofPhase2	9	Phase 2	245	1	0	0	0	0	0	0	6	1	3	0	2	2	2	0	6	4	5	6	3	4	4	4	4	5	4	4	5	1	1	1	1	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2	5.25	4	4.5	3.5238094			3.15	2.875	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH904FGL
2081	8976	NDAR_INVWH904FGL	2722			M	6000	EndofPhase3	18	Phase 3	512	1	0	0	0	0	0	0	6	0	3	4	2	3	2	1	2	3	4	9	3	3	4	4	2	5	4	4	3	1	1	1	1	1	1	1	1	1	1	0	4	4	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	2.25	3.2857144	4.5	3.1			3.15	2.875	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH904FGL
2081	8976	NDAR_INVWH949JKC	1350			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	0	2	0	2	2	2	2	3	2	4	2	2	4	2	2	3	6	2	4	2	1	1	1	1	0	1	1	1	1	3	0	4	1	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1.25	2.75	2.7142856	4	2.2857144	1		2.2857144	1.25	2.75	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH949JKC
2081	8976	NDAR_INVWH949JKC	1350			M	5200	EndofPhase1_1a	1	Phase 1/1A	35	0	1	0	0	0	0	0	0	0	2	4	4	2	4	3	4	2	6	4	2	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	1	0		3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2.375	4	0.2857143	0	1.7619047		1	2.2857144	1.25	2.75	2.7142856	4	-0.52380955	1.125	1.25	-2.4285715	-4																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWH949JKC
2081	8976	NDAR_INVWJ007FDD	1422			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	0	3	2	4	3	4	4	3	1	9	1	2	1	2	5	6	2	6	4	1	0	1	0	1	1	1	1	1	1	1	3	4	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	2	3	4	3.15	1		3.15	3.25	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ007FDD
2081	8976	NDAR_INVWJ007FDD	1422			F	2800	Visit12	12	Phase 3	357	1	0	1	0	0	0	0	4	0	2	1	2	0	2	4	2	2	1	9	1	2	2	4	4	4	2	5	2	1	0	1	0	1	1	1	1	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	1.25	2.857143	3	2.3			3.15	3.25	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ007FDD
2081	8976	NDAR_INVWJ007FDD	1422			F	5200	EndofPhase1_1a	2	Phase 1/1A	57	1	0	0	0	0	0	0	5	5	4	3	4	4	5	6	3	3	4	9	2	2	3	5	5	5	4	6	5	1	1	0	0	1	1	1	1	1	1	1	2	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	4.5	2.5	4	4.5	4.15		1	3.15	3.25	2	3	4	1	1.25	0.5	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ007FDD
2081	8976	NDAR_INVWJ007FDD	1422			F	5800	EndofPhase2	5	Phase 2	148	1	0	0	0	0	0	0	4	5	0	3	4	5	5	5	4	3	4	4	2	4	2	4	3	6	3	6	5	1	0	0	0	1	1	1	1	1	1	1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.875	3.75	3.7142856	4.5	3.857143			3.15	3.25	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ007FDD
2081	8976	NDAR_INVWJ096ZPM	2660			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	2	4	4	3	3	5	4	4	5	6	4	4	3	6	4	4	2	3	4	5	1	0	1	0	1	0	0	1	3	1	1	3	4	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	4	3.75	4.75	4.285714	2.5	4	1		4	3.75	4.75	4.285714	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ096ZPM
2081	8976	NDAR_INVWJ096ZPM	2660			M	1600	Visit6	6	Phase 1/1A	184	0	0	0	0	0	1	0	4	4	4	3	3	3	5	5	3	5	6	9	5	4	4	5	4	3	2	6	6	1	0	1	1	1	1	1	1	3		1	3	2	4	2	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	0	1	0	7	3.875	3.5	4.857143	2.5	4.2			4	3.75	4.75	4.285714	2.5	0.2	0.125	-1.25	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ096ZPM
2081	8976	NDAR_INVWJ096ZPM	2660			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	0	0	1	0	4	0	2	3	4	3	6	6	2	3	2	5	2	3	3	5	5	0	0	0	0	0	0	1	1	3	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	0	0	0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.25	4.75	3.4285715	3	2.8095238			4	3.75	4.75	4.285714	2.5	-1.1904762	-2.5	0	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ096ZPM
2081	8976	NDAR_INVWJ096ZPM	2660			M	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	0	0	1	0	3	4	6	2	4	2	6	3	2	1	1	9	0	2	3	2	2	3	2	3	4	1	0	1	1	1	1	1	1	3	1	0	4	4	3	4	1	0	0	1	0	0	0	0	0	0	0	0	0		0		1	30	0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	0	1	0	4	3.75	1	2.2857144	2.5	2.75		1	4	3.75	4.75	4.285714	2.5	-1.25	0	-3.75	-2	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ096ZPM
2081	8976	NDAR_INVWJ587VB6	1489			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	0	2	3	2	0	2	3	0	0	1	9	0	2	3	6	0	1	4	2	4	1	1	1	0	1	1	1	1	1	1	1	3	2	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.75	0.25	2.4285715	2.5	1.85	1		1.85	1.75	0.25	2.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ587VB6
2081	8976	NDAR_INVWJ587VB6	1489			M	5200	EndofPhase1_1a	3	Phase 1/1A	73	0	1	0	1	1	0	0	6	0	0	2	2	0	2	4	0	0	0	9	0	2	0	2	0	3	1	2	4	2	0	0	0	1	2	2	0	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	2	0	1.4285715	2	1.5		1	1.85	1.75	0.25	2.4285715	2.5	-0.35	0.25	-0.25	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ587VB6
2081	8976	NDAR_INVWJ809GRR	1144			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	1	3	4	5	2	1	1	3	3	9	2	2	5	3	3	6	3	5	5	1	1	1	1	1	0	1	1	1	1	1	3	4	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.75	1.75	3.5714285	4.5	3.15	1		3.15	2.75	1.75	3.5714285	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ809GRR
2081	8976	NDAR_INVWJ809GRR	1144			M	5200	EndofPhase1_1a	2	Phase 1/1A	57	1	0	0	0	0	0	0	5	0	0	1	2	0	1	0	1	1	3	9	0	2	4	4	4	6	4	4	4	1	1	1	1	1	1	1	1	1	1	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.125	1.25	3.142857	5	2.3		1	3.15	2.75	1.75	3.5714285	4.5	-0.85	-1.625	-0.5	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ809GRR
2081	8976	NDAR_INVWJ939AKX	2207			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	4	2	4	2	4	2	4	2	1	2	1	9	2	2	4	3	1	3	2	4	4	1	1	2	1	1	0	1	2	2	1	1	2	2	3	4	1	0	1	0	0	0	0	0	1	1	2	2	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	7	3	1	2.857143	2.5	2.65	1		2.65	3	1	2.857143	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWJ939AKX
2081	8976	NDAR_INVWK468BDC	1074			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	4	1	2	2	4	2	1	1	1	9	0	2	2	5	0	3	2	4	3	0	0	0	0	1	1	0	0	3	1	1	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.125	0.75	2.2857144	2.5	2.05	1		2.05	2.125	0.75	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWK468BDC
2081	8976	NDAR_INVWK468BDC	1074			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	1	0	2	2	3	1	2	2	3	0	0	0	1	9	0	2	0	2	3	4	3	4	2	1	1	2	0	1	0	0	0	3	1	1	3	4	4	4	0	0	0	0	0	0	0	1					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	7	1.875	0.25	1.8571428	3.5	1.8			2.05	2.125	0.75	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWK468BDC
2081	8976	NDAR_INVWK468BDC	1074			M	2800	Visit12	12	Phase 2	336	0	0	0	0	0	1	0	1	2	3	2	2	2	4	2	0	0	4	9	0	2	2	2	3	3	3	3	3	1	0	0	0	1	0	0	0	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.25	1	2.142857	3	2.15			2.05	2.125	0.75	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWK468BDC
2081	8976	NDAR_INVWK468BDC	1074			M	5200	EndofPhase1_1a	2	Phase 1/1A	44	0	0	0	0	0	1	0	0	1	2	0	2	0	1	0	0	0	1	9	0	1	1	0	0	3	2	4	1	1	0	0	0	1	0	0	0	1	2	1	3	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	6	0.75	0.25	1	2.5	0.95		1	2.05	2.125	0.75	2.2857144	2.5	-1.1	-1.375	-0.5	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWK468BDC
2081	8976	NDAR_INVWK468BDC	1074			M	5800	EndofPhase2	18	Phase 2	504	0	0	0	0	0	1	0	1	1	1	0	1	0	3	0	0	0	6	9	0	2	0	1	0	4	2	3	2	1	1	0	0	1	2	2	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	0	1	1	6	0.875	1.5	1.1428572	3	1.35			2.05	2.125	0.75	2.2857144	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWK468BDC
2081	8976	NDAR_INVWK758BB0	2068			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	1	0	3	0	0	0	2	0	0	1	9	3	0	0	2	2	1	2	0	1	0	1	0	1	0	0	0	0	3	3	0	4	1	2	4	1	0	1	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.875	0.25	1.1428572	1.5	0.95	1		0.95	0.875	0.25	1.1428572	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWK758BB0
2081	8976	NDAR_INVWL604YP7	2898			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	4	2	3	3	0	0	1	0	9	2	2	3	3	2	5	4	5	6	1	2	1	0	1	1	1	1	2	2	0	4	3	3	3	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	0.25	3.2857144	4.5	2.95	1		2.95	3.25	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWL604YP7
2081	8976	NDAR_INVWL604YP7	2898			F	1600	Visit6	6	Phase 1/1A	164	0	0	0	0	0	0	1	9	2	4	4	4	2	4	4	4	2	4	2	2	4	2	1	4	4	2	5	6	1	2	1	1	1	0	0	1	3		1	3	3	4	2	1	0	0	1	0	0	0	0	1	0	1	0	1	28	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.4285715	3	3.4285715	3	3.3		1	2.95	3.25	0.25	3.2857144	4.5	0.35	0.17857143	2.75	0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWL604YP7
2081	8976	NDAR_INVWM052HDK	1892			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	4	3	4	4	4	4	4	5	3	6	5	6	6	5	5	2	4	4	6	1	0	2	1	1	1	2	0	2	1	1	3	3	3	2	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.375	4.5	5.285714	3	4.571429	1		4.571429	4.375	4.5	5.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM052HDK
2081	8976	NDAR_INVWM052HDK	1892			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	1	0	6	6	4	4	5	6	6	6	2	6	4	9	6	6	6	6	5	4	5	6	6	1	1	0	1	1	1	2	2	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	12	1	18	0		0		0		0	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	6	5.375	3	5.857143	4.5	5.25			4.571429	4.375	4.5	5.285714	3	0.6785714	1	-1.5	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM052HDK
2081	8976	NDAR_INVWM052HDK	1892			M	2800	Visit12	12	Phase 1/1A	334	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	2	6	2	9	3	6	6	6	6	5	5	4	5	1	1	1	1	1	1	1	1	2	1	1	3	2	2	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	1	0	0	1	0	0	1	1	1	1	6	6	2.5	5.142857	5	5.2			4.571429	4.375	4.5	5.285714	3	0.62857145	1.625	-2	-0.14285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM052HDK
2081	8976	NDAR_INVWM052HDK	1892			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	0	0	0	0	0	0	1	6	6	6	6	6	6	6	4	2	6	3	9	4	6	5	6	5	5	6	4	6	1	1	1	1	1	1	0	1	2	2	1	3	2	2	1	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	1	0	0	1	0	0	1	1	1	1	6	5.75	2.75	5.142857	5.5	5.2		1	4.571429	4.375	4.5	5.285714	3	0.62857145	1.375	-1.75	-0.14285715	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM052HDK
2081	8976	NDAR_INVWM802BEV	1050			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	2	2	2	0	2	4	0	0	0	9	0	0	0	0	0	3	3	2	4	1	0	1	0	1	1	0	1	2	1	1	4	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	14	0		1	16	0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	1	0	5	2	0	0.85714287	3	1.4	1		1.4	2	0	0.85714287	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM802BEV
2081	8976	NDAR_INVWM868JXL	2882			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	6	4	4	0	2	4	0	9	1	2	1	2	5	2	1	4	2	1	0	1	2	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	16	1	2	1	3	1	9	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.5	2.4285715	1.5	2	1		2	1.75	1.5	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM868JXL
2081	8976	NDAR_INVWM868JXL	2882			M	5200	EndofPhase1_1a	2	Phase 1/1A	54	0	0	0	0	0	1	0	2	0	0	0	2	0	2	2	0	0	0	9	0	0	0	2	2	2	2	0	0	2	2	2	2	1	1	1	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	22	0		1	6	1	2	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1	0	0.5714286	2	0.8		1	2	1.75	1.5	2.4285715	1.5	-1.2	-0.75	-1.5	-1.8571428	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM868JXL
2081	8976	NDAR_INVWM868JXL	2882			M	5400	EndofPhase1b	2	Phase 1B	96	0	0	0	0	0	1	0	0	0	0	0	2	2	2	2	4	2	5	5	1	1	1	4	5	5	6	5	3	1	1	1	1	1	1	1	1	1	1	0	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	4	2.857143	5.5	2.6190476			2	1.75	1.5	2.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWM868JXL
2081	8976	NDAR_INVWN355NBL	2369			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	2	2	2	2	3	1	1	1	3	9	3	2	3	1	2	2	3	4	4	1	1	2	0	1	1	0	1	2	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	7	1.75	1.25	2.7142856	2.5	2.15	1		2.15	1.75	1.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWN355NBL
2081	8976	NDAR_INVWN355NBL	2369			M	1600	Visit6	6	Phase 1B	160	0	0	0	0	0	1	0	2	1	1	2	2	2	2	0	0	2	1	9	0	2	2	2	1	1	0	3	3	0	0	2	0	1	0	0	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	7	1.5	0.75	1.8571428	0.5	1.45			2.15	1.75	1.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWN355NBL
2081	8976	NDAR_INVWN355NBL	2369			M	2800	Visit12	12	Phase 1B	335	0	0	0	0	0	1	0	1	1	0	1	0	0	1	2	0	2	1	9	0	2	0	1	0	0	0	0	2	0	0	0	1	1	1	0	0	3	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		1	1	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	0.75	0.75	0.71428573	0	0.7			2.15	1.75	1.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWN355NBL
2081	8976	NDAR_INVWN355NBL	2369			M	5200	EndofPhase1_1a	4	Phase 1/1A	99	0	0	0	0	0	1	0	3	0	0	2	2	0	2	0	0	0	2	9	2	2	1	4	0	0	2	2	3	0	0	2	0	1	1	0	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		1	30	0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	1	1.125	0.5	2	1	1.35		1	2.15	1.75	1.25	2.7142856	2.5	-0.8	-0.625	-0.75	-0.71428573	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWN355NBL
2081	8976	NDAR_INVWN355NBL	2369			M	5400	EndofPhase1b	18	Phase 1B	496	0	0	0	0	0	1	0	3	2	2	2	2	2	2	1	0	0	0	9	1	1	2	3	1	2	2	1	1	0	1	0	0	0	1	0	0	3	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	0	1.4285715	2	1.5			2.15	1.75	1.25	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWN355NBL
2081	8976	NDAR_INVWP163WP6	1547			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	0	0	4	0	0	4	0	0	1	9	2	0	4	4	2	5	4	6	5	1	1	1	1	1	1	1	1	2	2	1	2	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	1.7142857	0.25	3.2857144	4.5	2.368421	1		2.368421	1.7142857	0.25	3.2857144	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP163WP6
2081	8976	NDAR_INVWP163WP6	1547			F	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	5	2	0	0	0	0	1	4	0	2	1	9	3	4	4	2	2	4	3	5	5	1	0	1	1	1	1	1	1	2	1	1	2	3	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.5	0.75	3.5714285	3.5	2.35			2.368421	1.7142857	0.25	3.2857144	4.5	-0.018421054	-0.21428572	0.5	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP163WP6
2081	8976	NDAR_INVWP163WP6	1547			F	2800	Visit12	12	Phase 1/1A	351	0	1	0	0	0	0	0	6	6	5	3	4	2	4	4	0	2	1	9	1	2	3	2	2	4	4	6	5	1	0	1	1	1	1	1	1	3		1	4	2	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	4.25	0.75	3	4	3.3		1	2.368421	1.7142857	0.25	3.2857144	4.5	0.93157893	2.5357144	0.5	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP163WP6
2081	8976	NDAR_INVWP198XXF	2772			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	2	2	2	1	3	1	2	1	1	1	2	9	4	3	4	2	2	2	4	5	6	1	1	1	1	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	5	1.75	1	3.7142856	3	2.5	1		2.5	1.75	1	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP198XXF
2081	8976	NDAR_INVWP198XXF	2772			F	2800	Visit12	12	Phase 3	340	0	0	0	0	0	0	1	6	0	2	2	2	2	2	0	3	6	4	9	4	6	6	3	4	5	4	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	1	1	0	0	0	0	0	1	1	1	1	6	2	3.25	5	4.5	3.65			2.5	1.75	1	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP198XXF
2081	8976	NDAR_INVWP198XXF	2772			F	5200	EndofPhase1_1a	3	Phase 1/1A	95	0	0	0	0	0	0	1	6	4	2	2	3	3	5	0	1	1	2	9	5	4	4	5	2	1	4	6	6	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	5	3.125	1	4.571429	2.5	3.3		1	2.5	1.75	1	3.7142856	3	0.8	1.375	0	0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP198XXF
2081	8976	NDAR_INVWP198XXF	2772			F	5800	EndofPhase2	6	Phase 2	200	0	0	0	0	0	0	1	6	0	1	2	2	3	3	0	2	5	2	9	4	6	6	3	3	5	4	6	6	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	1	0	1	1	1	0	0	0	0	0	1	1	1	1	5	2.125	2.25	4.857143	4.5	3.45			2.5	1.75	1	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP198XXF
2081	8976	NDAR_INVWP198XXF	2772			F	6000	EndofPhase3	18	Phase 3	530	0	0	0	0	0	0	1	6	0	2	2	2	2	2	0	4	6	4	3	4	5	4	4	5	3	4	6	6	1	1	1	1	1	1	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	5	2	4.25	4.857143	3.5	3.5238094			2.5	1.75	1	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWP198XXF
2081	8976	NDAR_INVWR380PJN	1530			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	4	4	5	5	5	4	2	1	3	6	9	4	3	2	4	4	5	5	6	5	1	1	1	1	1	1	1	1	3	1	1	3	1	2	2	1	0	0	0	0	1	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.25	2.5	4	5	4.1	1		4.1	4.25	2.5	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWR380PJN
2081	8976	NDAR_INVWR380PJN	1530			F	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	1	0	0	5	5	5	6	6	6	3	4	3	5	5	4	5	6	6	5	3	3	6	6	1	1	1	1	1	1	1	1	2	1	1	2	1	2	2	1	0	0	0	0	0	1	0	0	1	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	4.5	4.25	5.428571	3	4.6190476			4.1	4.25	2.5	4	5	0.5190476	0.25	1.75	1.4285715	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWR380PJN
2081	8976	NDAR_INVWR380PJN	1530			F	5200	EndofPhase1_1a	9	Phase 1/1A	234	0	0	0	0	0	1	0	6	4	6	4	4	4	4	0	0	4	6	9	4	6	4	4	4	6	4	4	6	1	0	1	1	1	1	1	1	3		1	4	2	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	18	0		1	12	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4	2.5	4.571429	5	4.2		1	4.1	4.25	2.5	4	5	0.1	-0.25	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWR380PJN
2081	8976	NDAR_INVWR380PJN	1530			F	5800	EndofPhase2	12	Phase 2	329	0	0	0	0	0	1	0	2	4	3	4	4	2	5	1	0	0	0	9	4	3	4	4	5	4	0	4	6	2	2	2	2	1	1	1	1	3		1	2	2	3	4	1	0	0	0	0	0	1	0	0	1	1	1	0		1	14	0		1	16	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	0	4.285714	2	2.95			4.1	4.25	2.5	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWR380PJN
2081	8976	NDAR_INVWR380PJN	1530			F	6000	EndofPhase3	18	Phase 3	507	0	0	0	0	0	1	0	9	0	2	0	1	1	0	0	0	0	0	9	1	2	0	0	0	1	1	0	2	2	2	2	2	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	0	1	0	0	0	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0.5714286	0	0.71428573	1	0.57894737			4.1	4.25	2.5	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWR380PJN
2081	8976	NDAR_INVWT182JWM	2194			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	0	0	0	2	2	2	0	1	0	1	9	0	0	2	2	2	4	1	2	2	1	1	1	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	1.375	0.5	1.4285715	2.5	1.4	1		1.4	1.375	0.5	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT182JWM
2081	8976	NDAR_INVWT182JWM	2194			M	2800	Visit12	12	Phase 1B	352	0	0	0	0	0	0	1	4	4	1	4	4	2	4	2	1	2	1	9	0	2	2	3	4	5	3	3	4	1	1	0	1	1	1	1	1	1	1	1	2	1	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.125	1	2.5714285	4	2.75			1.4	1.375	0.5	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT182JWM
2081	8976	NDAR_INVWT182JWM	2194			M	5200	EndofPhase1_1a	6	Phase 1/1A	162	0	0	0	0	0	0	1	2	0	1	2	2	2	2	0	2	2	3	9	0	2	2	2	2	4	1	1	2	1	1	0	0	1	0	1	0	1	1	0	4	1	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.375	1.75	1.5714285	2.5	1.7		1	1.4	1.375	0.5	1.4285715	2.5	0.3	0	1.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT182JWM
2081	8976	NDAR_INVWT182JWM	2194			M	5400	EndofPhase1b	18	Phase 1B	537	0	0	0	0	0	0	1	4	3	0	2	4	2	3	1	3	1	0	0	2	3	3	2	2	4	4	3	3	1	1	1	0	1	1	1	1	2	1	1	4	2	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.375	1	2.5714285	4	2.3333333			1.4	1.375	0.5	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT182JWM
2081	8976	NDAR_INVWT265WW6	1233			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	1	0	1	2	1	2	0	0	0	0	9	0	1	0	2	0	2	2	0	0	2	2	2	2	1	1	1	1	3	3	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	14	0		0		1	14	0		0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	7	1.375	0	0.42857143	2	0.9	1		0.9	1.375	0	0.42857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT265WW6
2081	8976	NDAR_INVWT265WW6	1233			M	1600	Visit6	6	Phase 1B	165	0	0	0	0	0	0	1	1	4	2	2	0	2	0	0	0	0	0	9	2	1	2	2	0	3	2	2	2	1	0	1	0	1	1	1	1	3	3	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.375	0	1.5714285	2.5	1.35			0.9	1.375	0	0.42857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT265WW6
2081	8976	NDAR_INVWT265WW6	1233			M	2800	Visit12	12	Phase 1B	337	0	0	0	0	0	0	1	9	4	4	4	4	0	6	2	1	2	0	9	2	2	0	6	4	4	4	5	6	1	1	1	1	1	1	1	1	2	2	1	3	2	4	4	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	5	3.4285715	0.75	3.5714285	4	3.1578948			0.9	1.375	0	0.42857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT265WW6
2081	8976	NDAR_INVWT265WW6	1233			M	5200	EndofPhase1_1a	1	Phase 1/1A	24	1	0	0	0	0	0	0	5	2	0	2	2	2	0	0	0	0	0	9	2	2	1	3	1	2	2	2	1	1	1	0	0	1	0	1	2	2	3	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	4	0		0		1	26	0		2	2	2	0	0	0	0	0	0	0	1	1	0	0	1	1	5	1.625	0	1.7142857	2	1.45		1	0.9	1.375	0	0.42857143	2	0.55	0.25	0	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT265WW6
2081	8976	NDAR_INVWT265WW6	1233			M	5400	EndofPhase1b	18	Phase 1B	506	0	0	0	0	0	0	1	4	2	4	4	2	4	3	0	0	0	0	9	3	2	3	6	2	3	2	6	4	0	1	1	0	1	1	1	1	2	3	1	2	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	0	3.7142856	2.5	2.7			0.9	1.375	0	0.42857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT265WW6
2081	8976	NDAR_INVWT712VKA	2659			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	5	0	4	5	6	4	0	2	3	6	9	0	3	0	2	2	3	1	4	6	0	0	0	0	1	1	1	1	3	1	1	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.75	2.75	2.4285715	2	3.1	1		3.1	3.75	2.75	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT712VKA
2081	8976	NDAR_INVWT712VKA	2659			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	1	0	6	1	0	2	3	4	4	0	2	2	6	9	0	3	0	2	3	3	3	4	4	1	1	0	0	1	1	1	1	3	1	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	2.5	2.2857144	3	2.6			3.1	3.75	2.75	2.4285715	2	-0.5	-1.25	-0.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT712VKA
2081	8976	NDAR_INVWT712VKA	2659			F	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	1	0	6	1	0	2	2	4	4	0	2	2	6	9	2	3	0	2	3	3	3	4	6	1	0	0	0	1	1	1	1	3	1	1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	2.375	2.5	2.857143	3	2.75			3.1	3.75	2.75	2.4285715	2	-0.35	-1.375	-0.25	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT712VKA
2081	8976	NDAR_INVWT712VKA	2659			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	6	4	4	3	3	2	4	0	2	2	6	9	2	3	0	2	4	3	3	3	6	1	1	0	0	1	1	1	1	3	2	1	4	3	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	2.5	2.857143	3	3.1		1	3.1	3.75	2.75	2.4285715	2	0	-0.5	-0.25	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT712VKA
2081	8976	NDAR_INVWT826NYV	2271			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	0	2	2	1	4	1	2	2	0	0	2	9	2	3	5	4	2	5	2	4	4	1	0	1	1	1	1	1	1	1	2	1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0			0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0.5	3.4285715	3.5	2.35	1		2.35	1.75	0.5	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT826NYV
2081	8976	NDAR_INVWT826NYV	2271			M	1600	Visit6	6	Phase 1/1A	177	1	0	1	0	0	0	0	6	4	4	4	5	4	4	4	2	2	2	9	4	3	4	4	5	6	6	5	6	0	1	1	1	1	1	0	1	2	3	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	1.5	4.428571	6	4.2			2.35	1.75	0.5	3.4285715	3.5	1.85	2.625	1	1	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT826NYV
2081	8976	NDAR_INVWT826NYV	2271			M	5200	EndofPhase1_1a	7	Phase 1/1A	229	1	0	1	0	0	0	0	4	4	2	4	4	4	4	4	1	0	0	9	4	4	4	4	4	6	5	5	6	1	1	1	1	1	1	0	1	2	1	1	2	2	2	2	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	1	0	0	1	1	1	1	6	3.75	0.25	4.428571	5.5	3.65		1	2.35	1.75	0.5	3.4285715	3.5	1.3	2	-0.25	1	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWT826NYV
2081	8976	NDAR_INVWU491FFH	1043			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	6	2	1	4	0	2	2	0	0	0	9	2	0	2	1	1	5	0	1	6	0	0	1	0	1	1	1	1	0	2	1	2	2	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	25	0		0		1	5	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2.125	0	1.8571428	2.5	1.75	1		1.75	2.125	0	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWU491FFH
2081	8976	NDAR_INVWU491FFH	1043			F	1600	Visit6	6	Phase 1/1A	179	0	1	0	0	0	0	0	1	6	5	4	5	6	5	3	6	5	4	9	3	3	0	3	2	5	3	4	6	1	0	1	1	1	1	1	1	1	1	1	2	2	2	4	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	4.375	3.75	3	4	3.95			1.75	2.125	0	1.8571428	2.5	2.2	2.25	3.75	1.1428572	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWU491FFH
2081	8976	NDAR_INVWU491FFH	1043			F	2800	Visit12	12	Phase 3	333	0	1	0	0	0	0	0	1	6	5	5	5	6	2	1	2	2	4	9	0	3	2	4	1	5	2	4	5	0	0	1	0	1	1	1	1	2	1	1	2	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.875	2	2.7142856	3.5	3.25			1.75	2.125	0	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWU491FFH
2081	8976	NDAR_INVWU491FFH	1043			F	5200	EndofPhase1_1a	8	Phase 1/1A	229	0	1	0	0	0	0	0	1	6	5	4	5	6	5	1	6	2	4	9	3	3	0	2	2	3	1	4	6	2	2	2	2	1	2	1	1	1	1	1	2	2	2	4	1	0	0	0	0	1	0	0	1	0	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	4.125	3	2.857143	2	3.45		1	1.75	2.125	0	1.8571428	2.5	1.7	2	3	1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWU491FFH
2081	8976	NDAR_INVWU491FFH	1043			F	5800	EndofPhase2	11	Phase 2	299	0	1	0	0	0	0	0	1	6	5	3	5	6	2	1	6	2	4	9	3	3	0	3	2	5	2	4	4	1	0	1	0	1	1	1	1	1	1	1	3	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	3.625	3	2.7142856	3.5	3.35			1.75	2.125	0	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWU491FFH
2081	8976	NDAR_INVWU491FFH	1043			F	6000	EndofPhase3	18	Phase 3	512	0	1	0	0	0	0	0	2	1	2	2	3	0	1	0	0	3	0	9	0	2	0	2	2	5	2	5	5	1	0	1	0	1	1	1	1	1	1	1	4	4	2	1	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.375	0.75	2.2857144	3.5	1.85			1.75	2.125	0	1.8571428	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWU491FFH
2081	8976	NDAR_INVWV068RYW	1828			M	1600	Visit6	6	Phase 1/1A	190	1	0	0	0	0	0	0	4	2	4	3	2	2	3	1	2	2	4	9	3	2	2	3	0	3	1	5	5	0	0	1	0	1	1	1	1	1	1	0	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2	2.857143	2	2.65		1																																																																																																																															Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV068RYW
2081	8976	NDAR_INVWV686ED9	1548			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	5	2	3	4	3	4	1	3	3	2	3	4	3	4	5	2	5	3	4	4	1	1	1	0	1	1	0	1	1	1	1	2	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	3.25	2.75	3.7142856	4	3.3809524	1		3.3809524	3.25	2.75	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV686ED9
2081	8976	NDAR_INVWV686ED9	1548			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	4	5	3	4	5	4	4	1	2	4	3	9	3	3	3	4	2	5	3	4	4	0	1	1	1	1	0	1	1	1	3	1	2	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	5	3.75	2.25	3.2857144	4	3.5			3.3809524	3.25	2.75	3.7142856	4	0.11904762	0.5	-0.5	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV686ED9
2081	8976	NDAR_INVWV686ED9	1548			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	3	4	2	3	3	3	3	1	2	4	4	9	3	2	2	4	1	6	3	4	5	0	1	1	0	1	1	0	1	1	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.75	2.5	3	4.5	3.1			3.3809524	3.25	2.75	3.7142856	4	-0.2809524	-0.5	-0.25	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV686ED9
2081	8976	NDAR_INVWV686ED9	1548			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	0	1	4	2	2	1	3	2	4	1	3	4	5	9	2	3	2	4	2	6	2	4	5	1	1	1	0	1	0	0	1	1	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.375	3	3.142857	4	3.05		1	3.3809524	3.25	2.75	3.7142856	4	-0.33095238	-0.875	0.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV686ED9
2081	8976	NDAR_INVWV744AC3	2867			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	6	4	4	5	5	5	3	4	4	5	9	6	6	4	6	4	5	3	6	5	1	2	1	0	1	1	1	1	1	1	1	3	4	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	6	4.75	3.25	5.285714	4	4.8	1		4.8	4.75	3.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV744AC3
2081	8976	NDAR_INVWV744AC3	2867			F	1600	Visit6	6	Phase 3	171	1	0	1	0	0	0	0	6	2	1	1	6	0	5	0	0	0	2	9	4	5	3	6	1	4	1	6	6	0	0	0	0	1	0	0	0	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4	2.625	0.5	4.428571	2.5	2.95			4.8	4.75	3.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV744AC3
2081	8976	NDAR_INVWV744AC3	2867			F	2800	Visit12	12	Phase 3	340	1	0	1	0	1	0	0	6	2	2	2	2	2	4	0	0	2	2	9	3	4	4	6	2	4	3	6	6	0	0	0	1	1	1	0	1	1	3	0	4	4	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4	2.5	1	4.428571	3.5	3.1			4.8	4.75	3.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV744AC3
2081	8976	NDAR_INVWV744AC3	2867			F	5200	EndofPhase1_1a	1	Phase 1/1A	29	1	0	1	0	1	0	0	5	5	1	1	6	6	6	1	3	4	4	5	5	5	0	6	4	5	4	6	6	2	0	1	0	1	1	0	1	1	1	1	3	4	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	0	6	3.875	4	4.571429	4.5	4.1904764		1	4.8	4.75	3.25	5.285714	4	-0.60952383	-0.875	0.75	-0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV744AC3
2081	8976	NDAR_INVWV744AC3	2867			F	5800	EndofPhase2	3	Phase 2	85	1	0	1	0	0	0	0	6	4	4	2	6	6	6	2	1	3	2	9	6	4	0	6	2	6	5	6	6	1	1	2	0	1	0	1	0	3		1	4	4	3	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	5	4.5	1.5	4.285714	5.5	4.15			4.8	4.75	3.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV744AC3
2081	8976	NDAR_INVWV744AC3	2867			F	6000	EndofPhase3	16	Phase 3	452	1	0	1	0	1	0	0	6	6	5	4	6	6	6	2	3	4	5	6	6	5	5	6	4	5	3	6	6	0	1	0	0	1	0	0	0	1	2	1	4	4	2	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	5.125	4.5	5.428571	4	5			4.8	4.75	3.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWV744AC3
2081	8976	NDAR_INVWW220XN4	2179			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	2	1	3	3	3	3	5	4	3	4	3	3	3	3	4	2	3	2	5	4	1	0	1	0	1	0	1	1	1	1	1	4	3	3	1	1	0	1	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	3.125	3.5	3.4285715	2.5	3.2380953	1		3.2380953	3.125	3.5	3.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWW220XN4
2081	8976	NDAR_INVWW220XN4	2179			F	5200	EndofPhase1_1a	1	Phase 1/1A	9	0	1	0	0	0	0	0	4	2	1	2	3	3	3	5	4	3	4	3	3	3	3	4	2	3	2	5	4	1	1	1	0	1	1	1	1	1	1	1	4	3	3	1	1	1	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.875	3.5	3.4285715	2.5	3.142857		1	3.2380953	3.125	3.5	3.4285715	2.5	-0.0952381	-0.25	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWW220XN4
2081	8976	NDAR_INVWX000YP0	1897			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	0	2	2	2	2	5	6	4	6	4	2	4	2	3	5	4	2	4	4	1	1	1	1	1	1	1	1	1	2	1	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	29	0		0		1	1	0		0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	5	2.75	5	3.4285715	3	3.4285715	1		3.4285715	2.75	5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX000YP0
2081	8976	NDAR_INVWX000YP0	1897			M	5200	EndofPhase1_1a	1	Phase 1/1A	36	0	1	0	0	0	0	0	4	0	2	0	2	1	2	4	3	1	2	0	4	2	2	4	1	4	1	2	5	0	1	1	0	1	1	1	1	1	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1	5	1.875	1.5	2.857143	2.5	2.1904762		1	3.4285715	2.75	5	3.4285715	3	-1.2380953	-0.875	-3.5	-0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX000YP0
2081	8976	NDAR_INVWX379RGM	1645			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	2	2	4	0	0	2	0	9	2	2	4	4	2	4	2	4	6	1	0	0	1	1	0	0	0	2	2	0	4	2	4	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2	0.5	3.4285715	3	2.4	1		2.4	2	0.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX379RGM
2081	8976	NDAR_INVWX388WVU	2043			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	2	2	2	2	3	1	2	3	2	4	6	4	6	6	6	4	4	1	1	1	1	1	1	1	1	2	2	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	2.25	4.285714	6	3.1904762	1		3.1904762	2	2.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX388WVU
2081	8976	NDAR_INVWX388WVU	2043			M	2800	Visit12	12	Phase 2	352	0	0	0	0	0	0	1	2	1	1	2	3	3	2	1	1	2	3	9	4	3	4	4	3	6	4	4	5	1	0	1	1	1	1	0	1	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	0	1	1	1	0	0	0	0	0	1	1	1	0	4	1.875	1.5	3.857143	5	2.9			3.1904762	2	2.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX388WVU
2081	8976	NDAR_INVWX388WVU	2043			M	5800	EndofPhase2	18	Phase 2	531	0	0	0	0	0	0	1	2	2	0	1	2	2	3	1	1	2	2	3	2	4	4	3	2	6	3	4	6	1	2	1	1	1	1	0	1	2	1	1	4	3	3	4	1	0	1	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	4	1.625	2	3.5714285	4.5	2.6190476			3.1904762	2	2.25	4.285714	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX388WVU
2081	8976	NDAR_INVWX599CYL	1566			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	0	3	3	3	3	0	0	4	2	9	3	4	3	3	4	5	4	5	4	1	1	0	0	1	1	0	1	1	3	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2	1.5	3.7142856	4.5	2.85	1		2.85	2	1.5	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX599CYL
2081	8976	NDAR_INVWX599CYL	1566			M	1600	Visit6	6	Phase 1/1A	175	0	0	1	0	0	0	0	5	4	0	6	5	2	6	0	4	4	4	6	5	5	6	6	6	5	5	5	3	1	1	1	1	1	1	2	1	1	2	1	3	2	3	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.5	4.5	5.142857	5	4.3809524			2.85	2	1.5	3.7142856	4.5	1.5309523	1.5	3	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX599CYL
2081	8976	NDAR_INVWX599CYL	1566			M	2800	Visit12	12	Phase 2	350	0	0	1	0	0	0	0	6	6	4	6	4	2	5	0	2	4	5	9	4	6	4	6	4	4	4	6	6	1	1	1	1	1	1	0	1	1	1	1	3	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.125	2.75	5.142857	4	4.4			2.85	2	1.5	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX599CYL
2081	8976	NDAR_INVWX599CYL	1566			M	4000	Visit18	18	Phase 2	539	0	0	1	0	0	0	0	6	6	6	6	1	6	5	0	1	4	1	9	2	5	5	4	1	4	2	6	6	1	0	1	1	1	1	2	1	2	1	1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.5	1.5	4.142857	3	3.85			2.85	2	1.5	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX599CYL
2081	8976	NDAR_INVWX599CYL	1566			M	5200	EndofPhase1_1a	8	Phase 1/1A	223	0	0	1	0	0	0	0	6	5	4	4	0	5	5	0	2	1	5	9	0	3	5	5	4	5	5	2	3	1	1	1	1	1	1	0	1	1	2	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	3.625	2	3.142857	5	3.45		1	2.85	2	1.5	3.7142856	4.5	0.6	1.625	0.5	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWX599CYL
2081	8976	NDAR_INVWY161EP2	2462			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	2	2	2	1	1	1	1	9	2	2	2	2	2	3	1	2	2	2	2	2	1	1	2	2	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	17	0		0		1	13	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0.75	2	2	1.8	1		1.8	1.875	0.75	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY161EP2
2081	8976	NDAR_INVWY161EP2	2462			M	5200	EndofPhase1_1a	2	Phase 1/1A	44	0	0	0	0	0	1	0	3	2	2	2	2	1	1	0	1	1	1	9	1	1	1	2	1	4	2	3	2	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	0.75	1.5714285	3	1.65		1	1.8	1.875	0.75	2	2	-0.15	-0.25	0	-0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY161EP2
2081	8976	NDAR_INVWY161EP2	2462			M	5800	EndofPhase2	3	Phase 2	57	0	0	0	0	0	1	0	2	2	2	2	2	2	2	2	2	2	2	9	2	2	1	2	2	4	2	2	2	1	2	0	1	1	1	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0		1		0		0		1		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.5	1.8571428	3	2.05			1.8	1.875	0.75	2	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY161EP2
2081	8976	NDAR_INVWY835VCC	2402			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	1	0	2	2	0	2	1	1	1	1	9	0	2	2	2	3	5	2	1	5	2	0	1	1	1	1	1	1	1	3	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	0	1	1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	0	3	1.375	0.75	2.142857	3.5	1.8	1		1.8	1.375	0.75	2.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY835VCC
2081	8976	NDAR_INVWY945VJF	2359			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	2	2	2	2	2	2	0	0	0	9	2	2	6	4	1	3	1	4	5	1	0	0	0	0	0	0	0	3		1	2	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	1	2.25	0	3.4285715	2	2.3	1		2.3	2.25	0	3.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY945VJF
2081	8976	NDAR_INVWY945VJF	2359			M	1600	Visit6	6	Phase 1/1A	175	0	0	0	0	0	0	1	9	3	3	2	2	2	2	2	0	0	0	9	1	2	4	4	1	3	2	4	4	0	0	1	0	0	0	0	1	3		1	2	2	4	4	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	2	2.2857144	0	2.857143	2.5	2.1578948			2.3	2.25	0	3.4285715	2	-0.14210527	0.035714287	0	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY945VJF
2081	8976	NDAR_INVWY945VJF	2359			M	2800	Visit12	12	Phase 1/1A	343	0	0	0	0	0	0	1	5	4	4	0	2	0	2	0	1	1	1	9	0	2	2	2	0	3	2	4	4	1	0	1	0	0	0	0	1	3		1	2	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	2.125	0.75	2	2.5	1.95			2.3	2.25	0	3.4285715	2	-0.35	-0.125	0.75	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY945VJF
2081	8976	NDAR_INVWY945VJF	2359			M	5200	EndofPhase1_1a	18	Phase 1/1A	539	0	1	0	0	0	0	0	6	4	0	0	2	0	2	2	0	0	0	9	0	0	2	2	0	4	2	2	0	0	1	0	0	0	1	0	0	3		1	3	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2	0	0.85714287	3	1.4		1	2.3	2.25	0	3.4285715	2	-0.9	-0.25	0	-2.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVWY945VJF
2081	8976	NDAR_INVXA288NGN	2456			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	0	0	1	2	0	0	0	0	0	0	9	0	0	0	3	1	1	1	2	2	1	1	0	1	1	0	1	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.625	0	1.1428572	1	0.75	1		0.75	0.625	0	1.1428572	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA288NGN
2081	8976	NDAR_INVXA288NGN	2456			M	2800	Visit12	12	Phase 3	381	1	0	0	0	0	0	0	4	0	0	0	2	2	2	1	0	1	1	9	2	2	4	4	4	3	4	5	3	0	1	1	1	1	1	1	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.375	0.5	3.4285715	3.5	2.2			0.75	0.625	0	1.1428572	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA288NGN
2081	8976	NDAR_INVXA288NGN	2456			M	5200	EndofPhase1_1a	7	Phase 1/1A	217	1	0	0	0	0	0	0	2	0	0	2	2	0	0	1	0	0	0	9	2	2	4	2	2	3	3	4	1	0	0	0	0	1	0	0	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0.875	0	2.4285715	3	1.5		1	0.75	0.625	0	1.1428572	1	0.75	0.25	0	1.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA288NGN
2081	8976	NDAR_INVXA288NGN	2456			M	5800	EndofPhase2	11	Phase 2	346	1	0	0	0	0	0	0	2	0	0	2	2	2	2	0	0	0	0	9	2	1	2	2	2	3	3	4	2	1	1	0	0	1	1	0	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	0	2.142857	3	1.55			0.75	0.625	0	1.1428572	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA288NGN
2081	8976	NDAR_INVXA288NGN	2456			M	6000	EndofPhase3	18	Phase 3	578	1	0	0	0	1	0	0	2	0	0	1	2	0	4	2	0	0	0	9	1	1	4	5	2	3	3	1	2	1	0	0	1	1	0	1	0	1	3	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.375	0	2.2857144	3	1.65			0.75	0.625	0	1.1428572	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA288NGN
2081	8976	NDAR_INVXA574EBZ	1255			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	0	6	2	2	1	6	4	1	9	2	2	6	6	6	3	1	4	6	0	0	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.125	2.75	4.571429	2	3.2	1		3.2	2.125	2.75	4.571429	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA574EBZ
2081	8976	NDAR_INVXA574EBZ	1255			M	1600	Visit6	6	Phase 1/1A	176	1	0	0	0	0	0	0	6	1	1	1	3	2	2	1	5	4	3	9	2	3	6	6	6	4	2	5	6	1	0	1	0	1	1	1	1	1	1	0	4	2	3	4	1	0	1	0	0	0	0	0	0	1	1	0	0		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.125	3	4.857143	3	3.45			3.2	2.125	2.75	4.571429	2	0.25	0	0.25	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA574EBZ
2081	8976	NDAR_INVXA574EBZ	1255			M	2800	Visit12	12	Phase 1/1A	337	1	0	0	0	0	0	0	2	3	4	4	3	2	3	4	0	0	5	9	4	3	2	4	5	4	3	3	5	1	1	1	1	1	1	0	1	2	2	1	3	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	1.25	3.7142856	3.5	3.15			3.2	2.125	2.75	4.571429	2	-0.05	1	-1.5	-0.85714287	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA574EBZ
2081	8976	NDAR_INVXA574EBZ	1255			M	4000	Visit18	18	Phase 1/1A	510	1	0	0	0	0	0	0	6	1	2	4	2	2	3	4	4	3	2	2	4	4	4	6	6	3	4	4	6	1	1	1	2	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3	2.75	4.857143	3.5	3.6190476		1	3.2	2.125	2.75	4.571429	2	0.41904762	0.875	0	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA574EBZ
2081	8976	NDAR_INVXA578PJQ	1377			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	3	2	4	3	4	2	1	1	1	9	3	3	2	3	2	1	3	6	6	1	1	2	0	1	1	1	1	3	2	0	4	3	3	4	1	0	0	1	0	0	0	0	1	0	1	2	0		1	30	0		0		0		0	2	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	0.75	3.5714285	2	3	1		3	3.5	0.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA578PJQ	1377			F	1600	Visit6	6	Phase 3	127	0	0	0	0	0	1	0	5	4	3	2	3	3	0	3	0	1	1	9	2	3	2	3	1	2	2	5	3	1	1	1	0	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.875	0.5	2.7142856	2	2.4			3	3.5	0.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA578PJQ	1377			F	2800	Visit12	12	Phase 3	317	1	0	0	0	0	0	0	6	0	0	2	2	2	2	2	0	2	1	9	1	1	1	2	0	3	2	4	4	1	0	0	0	1	0	1	1	1	3	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2	0.75	1.8571428	2.5	1.85			3	3.5	0.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA578PJQ	1377			F	4000	Visit18	18	Phase 3	518	1	0	0	0	0	0	0	5	0	0	2	3	1	0	1	0	0	1	9	1	1	2	1	0	2	3	4	5	1	1	0	0	1	1	1	1	1	2	0	4	4	3	4	1	0	1	0	0	0	0	0	1	2	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.5	0.25	2	2.5	1.6			3	3.5	0.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA578PJQ	1377			F	5200	EndofPhase1_1a	2	Phase 1/1A	38	0	0	0	0	0	1	0	6	4	5	3	3	2	2	3	1	2	1	9	2	3	2	4	1	2	2	4	3	1	1	2	2	1	1	1	1	2	1	1	4	3	4	3	1	0	0	1	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	3.5	1	2.7142856	2	2.75		1	3	3.5	0.75	3.5714285	2	-0.25	0	0.25	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA578PJQ	1377			F	5400	EndofPhase1b	3	Phase 1B	51	0	0	0	0	0	1	0	5	3	5	3	3	2	2	3	0	1	1	9	2	2	2	3	1	1	2	4	3	0	0	0	0	1	1	1	1	2	2	0	4	3	4	3	1	0	0	1	0	0	0	0	1	1	1	1	0		1	28	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	3.25	0.5	2.4285715	1.5	2.4			3	3.5	0.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA578PJQ	1377			F	5800	EndofPhase2	4	Phase 2	71	0	0	0	0	0	1	0	6	4	3	2	3	2	3	2	1	1	1	9	2	2	2	3	1	1	3	5	3	1	1	2	0	1	1	1	1	3	2	0	4	3	3	4	1	0	0	1	0	0	1	0	1	1	1	1	0		1	30	0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.125	0.75	2.5714285	2	2.5			3	3.5	0.75	3.5714285	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA578PJQ
2081	8976	NDAR_INVXA592ED6	1044			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	2	2	2	2	2	2	3	0	0	2	9	2	2	2	4	2	4	3	3	4	1	1	1	0	1	1	1	1	1	2	0	4	4	4	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	6	2.5	0.5	2.7142856	3.5	2.4	1		2.4	2.5	0.5	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA592ED6
2081	8976	NDAR_INVXA592ED6	1044			F	1600	Visit6	6	Phase 1/1A	275	0	0	0	0	0	0	1	4	4	3	4	4	4	4	4	2	2	2	9	2	1	5	6	4	4	4	4	4	1	1	1	1	1	1	1	1	3	2	1	2	1	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	1.5	3.7142856	4	3.55			2.4	2.5	0.5	2.7142856	3.5	1.15	1.375	1	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA592ED6
2081	8976	NDAR_INVXA592ED6	1044			F	2800	Visit12	12	Phase 1/1A	404	0	0	0	0	0	0	1	6	5	6	6	6	6	6	6	5	4	4	6	4	4	4	4	6	5	5	4	4	1	1	1	0	1	1	1	1	1	1	1	3	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.875	4.75	4.285714	5	5.047619			2.4	2.5	0.5	2.7142856	3.5	2.647619	3.375	4.25	1.5714285	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA592ED6
2081	8976	NDAR_INVXA592ED6	1044			F	5200	EndofPhase1_1a	18	Phase 1/1A	561	0	0	0	0	0	0	1	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	1	1	1	2	1	1	1	1	2	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	6	6	6	6	6		1	2.4	2.5	0.5	2.7142856	3.5	3.6	3.5	5.5	3.2857144	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXA592ED6
2081	8976	NDAR_INVXB092YZA	1266			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	5	5	4	5	6	4	4	6	5	6	6	4	4	4	5	5	5	4	4	5	1	0	1	1	1	1	1	1	1	1	1	2	2	3	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.875	5.75	4.428571	4.5	4.857143	1		4.857143	4.875	5.75	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB092YZA
2081	8976	NDAR_INVXB092YZA	1266			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	5	2	3	4	3	2	4	5	6	5	5	6	3	4	3	4	6	5	4	6	5	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	1	0	0	1	1	1	1	6	3.5	5.5	4.428571	4.5	4.285714			4.857143	4.875	5.75	4.428571	4.5	-0.5714286	-1.375	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB092YZA
2081	8976	NDAR_INVXB092YZA	1266			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	1	0	0	0	6	6	4	6	5	4	4	5	6	4	4	4	4	5	3	4	6	6	4	4	6	1	1	1	1	1	1	1	1	1	1	1	2	3	3	4	0	0	0	0	0	0	0	0					1	24	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5	4.5	4.571429	5	4.7619047			4.857143	4.875	5.75	4.428571	4.5	-0.0952381	0.125	-1.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB092YZA
2081	8976	NDAR_INVXB092YZA	1266			M	4000	Visit18	18	Phase 1/1A	512	0	1	0	0	0	0	0	6	5	4	6	6	5	6	5	6	4	5	3	3	5	3	6	6	6	4	4	6	1	1	1	0	1	1	1	1	1	2	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5.375	4.5	4.714286	5	4.952381		1	4.857143	4.875	5.75	4.428571	4.5	0.0952381	0.5	-1.25	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB092YZA
2081	8976	NDAR_INVXB261TTZ	2761			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	3	2	5	3	3	4	1	1	1	9	3	2	3	2	3	4	1	4	4	2	1	2	0	1	0	0	0	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.625	0.75	3	2.5	2.9	1		2.9	3.625	0.75	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB261TTZ
2081	8976	NDAR_INVXB261TTZ	2761			M	5200	EndofPhase1_1a	0	Phase 1/1A	77	0	1	0	0	0	0	0	4	3	2	2	4	2	2	1	2	1	1	9	2	2	2	2	2	4	2	4	4	1	0	0	0	1	0	0	1	1	3	1	4	4	4	4	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.5	1	2.5714285	3	2.4		1	2.9	3.625	0.75	3	2.5	-0.5	-1.125	0.25	-0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB261TTZ
2081	8976	NDAR_INVXB267UT7	1137			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	2	1	2	2	5	3	4	1	2	2	1	2	3	2	3	5	3	4	4	0	0	1	1	1	0	1	1	2	3	0	4	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	3	2.625	2.25	2.7142856	4	2.7142856	1		2.7142856	2.625	2.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB267UT7
2081	8976	NDAR_INVXB267UT7	1137			M	1600	Visit6	6	Phase 2	175	0	0	0	0	0	0	1	9	2	2	4	3	3	4	1	0	0	1	9	2	2	2	2	0	3	5	4	4	1	1	1	1	1	1	1	1	2	3	1	3	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	6	2.7142856	0.25	2.2857144	4	2.3157895			2.7142856	2.625	2.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB267UT7
2081	8976	NDAR_INVXB267UT7	1137			M	2800	Visit12	12	Phase 2	337	0	0	0	0	0	0	1	4	2	4	4	4	2	4	1	1	2	1	9	2	2	4	4	4	4	5	4	6	1	1	1	1	1	1	1	1	3	3	1	3	2	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	6	3.125	1	3.7142856	4.5	3.2			2.7142856	2.625	2.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB267UT7
2081	8976	NDAR_INVXB267UT7	1137			M	5200	EndofPhase1_1a	3	Phase 1/1A	93	0	0	0	0	0	0	1	2	2	0	0	2	2	2	1	0	1	1	9	0	0	2	0	0	1	4	5	4	0	1	1	0	1	0	0	1	2	1	0	4	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	3	1.375	0.5	1.5714285	2.5	1.45		1	2.7142856	2.625	2.25	2.7142856	4	-1.2642857	-1.25	-1.75	-1.1428572	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB267UT7
2081	8976	NDAR_INVXB267UT7	1137			M	5800	EndofPhase2	18	Phase 2	493	0	0	0	0	0	0	1	9	2	5	4	3	2	4	1	0	0	2	9	2	2	3	2	3	6	4	4	6	1	1	1	1	1	1	0	1	2	2	1	3	1	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	2	3	0.5	3.142857	5	2.8947368			2.7142856	2.625	2.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB267UT7
2081	8976	NDAR_INVXB267UT7	1137			M	6000	EndofPhase3	21	Phase 3	568	0	0	0	0	0	0	1	4	2	4	2	2	4	2	2	0	2	1	9	0	2	3	2	3	4	4	4	5	1	1	1	1	1	1	1	1	2	2	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.75	0.75	2.7142856	4	2.6			2.7142856	2.625	2.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB267UT7
2081	8976	NDAR_INVXB750UM2	2050			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	9	0	2	2	2	0	3	3	4	5	1	0	0	1	1	1	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	0.375	0	2.142857	3	1.2	1		1.2	0.375	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB750UM2
2081	8976	NDAR_INVXB750UM2	2050			M	1600	Visit6	6	Phase 2	184	0	0	0	0	0	1	0	2	2	0	0	4	3	3	1	0	0	0	9	1	1	0	6	2	2	2	3	5	1	0	0	0	1	1	0	0	3		1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.875	0	2.5714285	2	1.85			1.2	0.375	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB750UM2
2081	8976	NDAR_INVXB750UM2	2050			M	2800	Visit12	12	Phase 2	332	0	0	0	0	0	1	0	2	1	4	4	0	3	6	0	0	0	2	9	1	3	4	6	3	3	3	4	6	1	0	0	1	1	0	0	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.5	0.5	3.857143	3	2.75			1.2	0.375	0	2.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB750UM2
2081	8976	NDAR_INVXB750UM2	2050			M	5200	EndofPhase1_1a	3	Phase 1/1A	73	0	0	0	0	0	1	0	1	1	4	4	3	2	4	2	0	0	5	9	2	6	5	6	6	2	4	5	6	1	1	0	1	1	1	0	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	23	0		1	7	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	2.625	1.25	5.142857	3	3.4		1	1.2	0.375	0	2.142857	3	2.2	2.25	1.25	3	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB750UM2
2081	8976	NDAR_INVXB788BB9	2710			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	2	2	2	2	2	2	1	2	3	2	9	4	3	3	4	2	6	3	4	4	1	1	1	1	1	1	1	1	1	2	0	4	1	3	4	1	0	1	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	2.25	1.75	3.4285715	4.5	2.9	1		2.9	2.25	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB788BB9
2081	8976	NDAR_INVXB788BB9	2710			F	1600	Visit6	6	Phase 2	174	0	0	0	0	0	1	0	6	4	3	3	3	3	3	2	0	0	3	9	3	3	3	4	2	6	3	3	4	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	1	0	1	1	1	1	0		1	25	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.375	0.75	3.142857	4.5	3.05			2.9	2.25	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB788BB9
2081	8976	NDAR_INVXB788BB9	2710			F	5200	EndofPhase1_1a	2	Phase 1/1A	41	0	0	0	0	0	0	1	5	3	4	2	2	2	2	1	1	3	4	9	3	3	4	4	3	6	3	4	4	1	1	1	1	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	1	3	2.625	2	3.5714285	4.5	3.15		1	2.9	2.25	1.75	3.4285715	4.5	0.25	0.375	0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB788BB9
2081	8976	NDAR_INVXB788BB9	2710			F	5800	EndofPhase2	11	Phase 2	309	0	0	0	0	0	1	0	4	3	3	2	2	2	2	1	1	2	4	9	1	2	3	2	2	4	2	4	4	1	1	0	0	1	0	0	0	1	1	1	3	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	21	0		1	9	0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	2.375	1.75	2.5714285	3	2.5			2.9	2.25	1.75	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXB788BB9
2081	8976	NDAR_INVXC182HF0	2566			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	0	2	3	2	1	3	0	2	3	4	9	3	2	4	3	2	4	4	5	4	1	1	1	0	1	1	1	1	3	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	2.25	3.2857144	4	2.65	1		2.65	1.625	2.25	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC182HF0
2081	8976	NDAR_INVXC182HF0	2566			M	1600	Visit6	6	Phase 1/1A	197	0	0	0	0	0	0	1	2	0	4	3	3	2	6	0	1	2	6	9	6	1	2	3	1	3	2	5	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	2.25	3.142857	2.5	2.8			2.65	1.625	2.25	3.2857144	4	0.15	0.875	0	-0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC182HF0
2081	8976	NDAR_INVXC182HF0	2566			M	2800	Visit12	12	Phase 1/1A	390	0	0	0	0	0	0	1	9	0	2	0	0	0	2	1	1	0	0	9	0	2	4	2	1	2	2	4	4	0	0	1	0	0	0	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.71428573	0.25	2.4285715	2	1.4210526			2.65	1.625	2.25	3.2857144	4	-1.2289474	-0.91071427	-2	-0.85714287	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC182HF0
2081	8976	NDAR_INVXC182HF0	2566			M	5200	EndofPhase1_1a	18	Phase 1/1A	508	0	0	0	0	0	0	1	9	0	2	1	0	1	1	0	1	1	0	9	0	0	3	1	1	3	2	5	4																0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1										0.71428573	0.5	2	2.5	1.3684211		1	2.65	1.625	2.25	3.2857144	4	-1.2815789	-0.91071427	-1.75	-1.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC182HF0
2081	8976	NDAR_INVXC730ZZK	2211			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	0	0	0	2	0	2	4	0	0	0	9	2	2	4	5	3	5	2	5	5	1	1	1	1	1	1	0	1	1	2	1	4	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	1.25	0	3.7142856	3.5	2.15	1		2.15	1.25	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC730ZZK
2081	8976	NDAR_INVXC730ZZK	2211			F	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	2	2	4	4	1	4	4	0	0	0	0	9	6	4	6	6	1	5	4	6	5	1	1	1	0	1	1	1	1	3		1	3	4	4	1	1	1	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	2.625	0	4.857143	4.5	3.2			2.15	1.25	0	3.7142856	3.5	1.05	1.375	0	1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC730ZZK
2081	8976	NDAR_INVXC730ZZK	2211			F	2800	Visit12	12	Phase 2	344	0	0	0	0	0	0	1	0	1	2	4	1	2	2	0	1	0	0	9	2	2	4	4	2	4	3	6	4	1	1	1	0	1	1	1	1	3		1	3	4	2	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.25	3.4285715	3.5	2.2			2.15	1.25	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC730ZZK
2081	8976	NDAR_INVXC730ZZK	2211			F	5200	EndofPhase1_1a	9	Phase 1/1A	247	0	0	0	0	0	0	1	0	1	2	4	2	2	0	1	1	1	0	9	0	1	4	4	2	2	3	1	5	1	0	2	1	1	1	1	1	3		1	3	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	1.5	0.5	2.4285715	2.5	1.8		1	2.15	1.25	0	3.7142856	3.5	-0.35	0.25	0.5	-1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC730ZZK
2081	8976	NDAR_INVXC730ZZK	2211			F	5800	EndofPhase2	13	Phase 2	364	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	9	2	0	2	0	0	3	1	4	0	0	0	1	0	0	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0	0	1.1428572	2	0.6			2.15	1.25	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC730ZZK
2081	8976	NDAR_INVXC730ZZK	2211			F	6000	EndofPhase3	18	Phase 3	507	0	0	0	0	0	0	1	4	4	4	2	2	3	6	2	0	0	0	9	2	2	6	5	4	4	3	6	4	1	0	1	1	1	1	1	1	1	1	1	4	3	2	1	1	0	0	0	1	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	7	3.375	0	4.142857	3.5	3.15			2.15	1.25	0	3.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXC730ZZK
2081	8976	NDAR_INVXD210MY4	2340			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	3	0	2	1	2	2	1	4	2	3	2	1	5	4	4	2	2	5	4	4	5	1	1	1	1	1	1	1	1	3	2	1	3	3	3	3	1	1	0	0	0	0	0	0	1	0	1	0	1		0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	2	3.7142856	4.5	2.7619047	1		2.7619047	1.875	2	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXD210MY4
2081	8976	NDAR_INVXD210MY4	2340			F	1600	Visit6	6	Phase 1/1A	163	0	1	0	0	0	0	0	4	4	4	4	4	3	4	4	2	4	4	9	3	4	4	3	3	5	5	4	4	1	1	1	1	1	1	1	1	2	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	1	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3.875	2.5	3.5714285	5	3.8			2.7619047	1.875	2	3.7142856	4.5	1.0380952	2	0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXD210MY4
2081	8976	NDAR_INVXD210MY4	2340			F	2800	Visit12	12	Phase 1/1A	358	0	1	0	0	0	0	0	2	2	2	1	2	1	2	2	0	1	1	5	1	2	1	0	1	2	2	0	0	1	1	0	0	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1.75	0.71428573	2	1.4285715			2.7619047	1.875	2	3.7142856	4.5	-1.3333334	-0.125	-0.25	-3	-2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXD210MY4
2081	8976	NDAR_INVXD210MY4	2340			F	4000	Visit18	18	Phase 1/1A	561	0	1	0	1	0	0	0	6	4	4	3	5	4	4	4	4	2	4	5	4	4	2	3	5	5	4	5	5	1	1	1	1	1	1	1	1	1	1	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	3.75	4	4.5	4.095238		1	2.7619047	1.875	2	3.7142856	4.5	1.3333334	2.375	1.75	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXD210MY4
2081	8976	NDAR_INVXD772LJ0	2597			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	6	0	2	3	4	0	0	0	0	9	0	2	4	4	4	3	4	4	4	1	1	0	1	1	0	1	1	2	1	1	2	1	1	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	6	3.375	0	3.142857	3.5	2.8	1		2.8	3.375	0	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXD772LJ0
2081	8976	NDAR_INVXE202FDR	1772			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	2	4	0	1	2	1	2	1	0	0	0	9	0	2	2	3	1	2	2	1	1	1	0	1	0	1	0	0	0	2	2	1	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	1.625	0	1.4285715	2	1.35	1		1.35	1.625	0	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXE202FDR
2081	8976	NDAR_INVXE202FDR	1772			M	5200	EndofPhase1_1a	2	Phase 1/1A	50	1	0	1	0	0	0	0	2	4	0	1	2	1	2	1	0	0	0	9	0	2	2	3	1	2	1	1	1	1	0	1	0	1	0	0	0	2	2	1	4	3	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	12	0		0		0		1	18	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	1.625	0	1.4285715	1.5	1.3		1	1.35	1.625	0	1.4285715	2	-0.05	0	0	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXE202FDR
2081	8976	NDAR_INVXF265FDL	1536			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	5	1	3	6	4	5	1	2	5	3	9	4	5	4	4	5			5	5	1	1	1	1	1	1	1	1	1	1	1	3	1	1	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	3.75	2.5	4.571429		4	1		4	3.75	2.5	4.571429																																																																																																																											Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXF265FDL
2081	8976	NDAR_INVXF265FDL	1536			M	6000	EndofPhase3	7	Phase 3	187	0	0	0	0	0	0	1	4								1	3	4	9						6	5			1	1	1	1	1	1	1	1	1	2	1	3	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	6		2		5.5				4	3.75	2.5	4.571429																																																																																																																											Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXF265FDL
2081	8976	NDAR_INVXF276WCM	2649			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	2	2	3	5	3	3	1	2	2	1	9	3	3	4	3	4	6	4	4	4	1	1	1	0	1	1	0	1	1	2	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3	1.25	3.5714285	5	3.2	1		3.2	3	1.25	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXF276WCM
2081	8976	NDAR_INVXF276WCM	2649			M	1600	Visit6	6	Phase 2	159	1	0	0	0	0	0	0	5	4	3	4	5	3	3	2	1	1	1	9	3	3	4	4	4	6	3	4	4	1	1	2	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	8	0		1	22	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	3.625	0.75	3.7142856	4.5	3.35			3.2	3	1.25	3.5714285	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXF276WCM
2081	8976	NDAR_INVXF276WCM	2649			M	5200	EndofPhase1_1a	4	Phase 1/1A	107	1	0	0	0	0	0	0	5	4	4	4	5	3	3	2	3	3	3	3	3	3	4	4	3	6	5	4	4	1	1	0	0	1	1	0	2	2	2	1	3	3	4	4	1	0	1	0	0	0	0	0	1	1	0	0	1	8	0		1	22	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	3	3.5714285	5.5	3.7142856		1	3.2	3	1.25	3.5714285	5	0.51428574	0.75	1.75	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXF276WCM
2081	8976	NDAR_INVXG204PYC	1664			M	1600	Visit6	6	Phase 1/1A	170	1	0	1	0	0	0	0	6	6	1	2	6	6	4	3	4	6	6	6	6	6	6	6	3	6	4	6	6	1	1	0	0	1	0	0	0	1	2	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	1	0	0	0	0	1	0	0	0	0	1	1	1	0	4	4.25	5.5	5.571429	5	5																																																																																																																																	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG204PYC
2081	8976	NDAR_INVXG204PYC	1664			M	2800	Visit12	12	Phase 1/1A	344	1	0	0	0	0	0	0	6	4	0	4	5	2	3	2	2	4	5	9	6	4	6	6	2	6	4	6	6	1	1	1	1	1	1	0	0	1	1	1	4	2	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.25	2.75	5.142857	5	4.15																																																																																																																																	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG204PYC
2081	8976	NDAR_INVXG204PYC	1664			M	4000	Visit18	18	Phase 1/1A	489	1	0	0	0	0	0	0	6	4	3	6	3	6	2	2	6	5	6	6	6	6	6	6	4	5	4	6	6	1	1	1	0	1	1	0	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4	5.75	5.714286	4.5	4.952381		1																																																																																																																															Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG204PYC
2081	8976	NDAR_INVXG904XGE	2476			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	0	2	0	0	0	0	0	0	9	0	0	2	2	0	4	3	2	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	0.2857143	0	1.4285715	3.5	1	1		1	0.2857143	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG904XGE
2081	8976	NDAR_INVXG904XGE	2476			M	1600	Visit6	6	Phase 2	189	0	0	0	0	0	0	1	9	0	0	0	2	0	2	0	0	0	0	9	0	2	2	2	2	3	3	2	4	1	1	1	0	1	1	1	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.5714286	0	2	3	1.2631578			1	0.2857143	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG904XGE
2081	8976	NDAR_INVXG904XGE	2476			M	5200	EndofPhase1_1a	4	Phase 1/1A	133	0	0	0	0	0	0	1	9	4	0	0	2	0	2	0	0	0	0	9	2	2	2	4	0	5	2	2	4	2	1	1	2	1	1	1	1	3	2	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.1428572	0	2.2857144	3.5	1.6315789		1	1	0.2857143	0	1.4285715	3.5	0.6315789	0.85714287	0	0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG904XGE
2081	8976	NDAR_INVXG904XGE	2476			M	5800	EndofPhase2	7	Phase 2	229	0	0	0	0	0	0	1	9	1	1	1	2	0	1	0	0	0	0	9	2	2	2	2	1	3	3	3	5	1	1	1	2	1	1	1	1	3		1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.85714287	0	2.4285715	3	1.5263158			1	0.2857143	0	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXG904XGE
2081	8976	NDAR_INVXH101CXX	2249			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	4	0	0	0	2	0	0	3	6	2	4	0	2	3	0	2	4	4	2	2	3	0	0	0	0	1	0	0	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	3	1.125	3	2.2857144	3	2.047619	1		2.047619	1.125	3	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH101CXX
2081	8976	NDAR_INVXH101CXX	2249			M	5200	EndofPhase1_1a	4	Phase 1/1A	124	0	1	0	1	0	0	0	3	0	0	0	2	0	0	2	6	2	6	2	2	2	0	2	5	4	1	4	3	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	4	0.875	4	2.5714285	2.5	2.1904762		1	2.047619	1.125	3	2.2857144	3	0.14285715	-0.25	1	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH101CXX
2081	8976	NDAR_INVXH101CXX	2249			M	5800	EndofPhase2	6	Phase 2	181	0	1	0	1	0	0	0	2	0	0	0	2	0	0	2	0	0	2	9	2	2	0	0	0	4	1	2	2	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.75	0.5	1.1428572	2.5	1.05			2.047619	1.125	3	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH101CXX
2081	8976	NDAR_INVXH101CXX	2249			M	6000	EndofPhase3	9	Phase 3	273	0	1	0	1	0	0	0	3	0	0	0	2	0	0	2	0	0	0	9	2	2	0	0	0	4	1	4	3	1	0	0	0	1	0	0	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	0.875	0	1.5714285	2.5	1.15			2.047619	1.125	3	2.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH101CXX
2081	8976	NDAR_INVXH192GCR	1299			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	4	4	2	2	3	4	4	1	6	4	4	5	1	5	4	4	5	6	4	5	4	0	1	1	0	0	1	1	1	0	1	1	3	3	3	4	1	0	1	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	5	3	4.75	4	5	3.857143	1		3.857143	3	4.75	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH192GCR
2081	8976	NDAR_INVXH192GCR	1299			M	1600	Visit6	6	Phase 1B	170	1	0	1	0	0	0	0	5	1	3	4	4	4	4	0	5	5	6	6	2	6	3	4	5	5	4	6	6	1	1	1	2	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	5.5	4.571429	4.5	4.1904764			3.857143	3	4.75	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH192GCR
2081	8976	NDAR_INVXH192GCR	1299			M	2800	Visit12	12	Phase 1B	345	1	0	1	0	0	0	0	4	2	4	2	2	2	4	0	5	4	5	6	2	4	3	4	5	4	3	5	6	1	1	1	0	1	1	1	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	5	4.142857	3.5	3.6190476			3.857143	3	4.75	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH192GCR
2081	8976	NDAR_INVXH192GCR	1299			M	5200	EndofPhase1_1a	5	Phase 1/1A	130	1	0	1	0	0	0	0	6	1	4	4	3	4	4	0	4	4	5	4	2	6	2	3	4	4	3	5	5	1	1	0	0	1	1	0	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	4.25	3.857143	3.5	3.6666667		1	3.857143	3	4.75	4	5	-0.1904762	0.25	-0.5	-0.14285715	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH192GCR
2081	8976	NDAR_INVXH192GCR	1299			M	5400	EndofPhase1b	18	Phase 1B	543	1	0	0	0	0	0	0	6	4	4	2	5	1	4	2	6	5	6	6	2	4	2	4	5	6	5	3	6	0	1	1	0	1	1	1	1	2	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.5	5.75	3.7142856	5.5	4.1904764			3.857143	3	4.75	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH192GCR
2081	8976	NDAR_INVXH305UKL	2245			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	3	4	4	2	2	3	4	3	4	5	4	5	5	3	4	4	2	5	4	1	1	1	0	1	1	1	1	2	2	1	2	4	4	1	1	0	1	1	0	0	0	0	0	0	1	0	0		0		1	30	0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.142857	4	4.285714	3	3.7	1		3.7	3.142857	4	4.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH305UKL
2081	8976	NDAR_INVXH305UKL	2245			M	5200	EndofPhase1_1a	2	Phase 1/1A	99																																													0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	1	3								3.7	3.142857	4	4.285714	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH305UKL
2081	8976	NDAR_INVXH328AN2	2574			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	2	2	3	2	3	3	2	1	3	2	9	1	2	4	3	1	3	2	4	4	0	0	0	0	1	1	0	1	2	1	1	4	2	3	4	0	0	0	0	0	0	0	0					1	17	0		0		1	13	0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.625	1.5	2.7142856	2.5	2.55	1		2.55	2.625	1.5	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH328AN2
2081	8976	NDAR_INVXH328AN2	2574			M	1600	Visit6	6	Phase 3	165	0	0	0	0	0	1	0	2	3	2	1	2	2	3	2	0	0	3	9	3	4	4	3	0	4	1	4	6	0	0	2	0	1	1	1	2	2	2	0	4	4	3	4	0	0	0	0	0	0	0	0					0		1	30	0		1	8	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.125	0.75	3.4285715	2.5	2.45			2.55	2.625	1.5	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH328AN2
2081	8976	NDAR_INVXH328AN2	2574			M	5200	EndofPhase1_1a	3	Phase 1/1A	71	0	0	0	0	0	0	1	4	0	3	2	2	2	3	1	1	6	5	9	1	3	3	4	1	3	2	4	6	2	2	2	2	1	1	2	2	2	1	1	4	1	4	4	0	0	0	0	0	0	0	0					1	72	0		1	8	1		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	5	2.125	3	3.142857	2.5	2.8		1	2.55	2.625	1.5	2.7142856	2.5	0.25	-0.5	1.5	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH328AN2
2081	8976	NDAR_INVXH328AN2	2574			M	5800	EndofPhase2	5	Phase 2	123	0	0	0	0	0	1	0	3	4	3	2	2	3	4	2	1	3	4	9	4	3	3	4	4	3	1	5	6	2	2	2	2	1	2	2	2	3		1	4	3	4	3	0	0	0	0	0	0	0	0					0		0		1	8	1	6	0		0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	4	2.875	2	4.142857	2	3.2			2.55	2.625	1.5	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH328AN2
2081	8976	NDAR_INVXH328AN2	2574			M	6000	EndofPhase3	12	Phase 3	331	0	0	0	0	0	1	0	3	3	4	4	2	2	3	2	0	3	3	9	0	2	3	3	2	4	1	5	6	1	0	2	0	1	1	1	0	2	3	1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	1.5	3	2.5	2.75			2.55	2.625	1.5	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH328AN2
2081	8976	NDAR_INVXH667DBR	2466			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	0	3	2	5	3	4	2	2	4	5	9	3	5	2	4	4	4	1	4	6	0	0	1	1	1	1	1	1	1	2	0	4	2	3	4	1	0	1	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	6	2.875	2.75	4	2.5	3.35	1		3.35	2.875	2.75	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH667DBR
2081	8976	NDAR_INVXH667DBR	2466			M	1600	Visit6	6	Phase 1/1A	172	0	0	1	0	0	0	0	4	4	5	4	5	6	5	0	0	0	4	9	4	5	3	6	4	4	2	4	6	1	0	1	1	1	1	1	1	1	1	1	3	1	1	4	1	0	1	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.125	1	4.571429	3	3.75		1	3.35	2.875	2.75	4	2.5	0.4	1.25	-1.75	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH667DBR
2081	8976	NDAR_INVXH786JCF	2434			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	5	4	6	5	5	5	0	0	2	1	9	5	5	5	6	4	5	5	6	5	1	1	2	1	1	1	1	2	2	1	1	2	4	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	0.75	5.142857	5	4.2	1		4.2	4.375	0.75	5.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH786JCF
2081	8976	NDAR_INVXH910TVL	2415			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	5	6	6	4	6	2	6	5	6	6	4	5	6	4	5	6	4	6	5	0	0	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	1	1	1	1	1	1	1	5	5	5.75	5	5	5.142857	1		5.142857	5	5.75	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH910TVL
2081	8976	NDAR_INVXH910TVL	2415			M	5200	EndofPhase1_1a	12	Phase 1/1A	355	1	0	0	0	0	0	0	6	5	4	4	5	4	4	2	6	5	5	5	4	4	6	5	5	5	3	6	5	1	1	0	0	1	1	1	1	1	1	1	3	3	3	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4.25	5.25	5	4	4.6666665		1	5.142857	5	5.75	5	5	-0.47619048	-0.75	-0.5	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH910TVL
2081	8976	NDAR_INVXH910TVL	2415			M	5800	EndofPhase2	18	Phase 2	505	1	0	0	0	0	0	0	6	6	6	6	6	6	6	4	2	6	2	9	6	6	6	6	6	6	6	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.75	2.5	6	6	5.5			5.142857	5	5.75	5	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXH910TVL
2081	8976	NDAR_INVXJ148ADL	1691			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	1	2	4	4	2	0	2	1	1	2	9	2	4	4	5	4	4	4	3	4	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.5	1	3.7142856	4	2.9	1		2.9	2.5	1	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ148ADL
2081	8976	NDAR_INVXJ148ADL	1691			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	5	3	1	4	3	2	4	3	2	4	1	9	3	5	4	6	2	5	3	4	4	0	1	1	1	1	1	1	1	1	2	1	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.125	1.75	4	4	3.4			2.9	2.5	1	3.7142856	4	0.5	0.625	0.75	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ148ADL
2081	8976	NDAR_INVXJ148ADL	1691			M	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	5	2	0	2	2	2	6	3	0	0	0	9	2	6	6	6	5	5	3	5	5	1	1	1	1	1	1	1	1	1	1	1	4	3	4	3	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.75	0	5	4	3.25			2.9	2.5	1	3.7142856	4	0.35	0.25	-1	1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ148ADL
2081	8976	NDAR_INVXJ148ADL	1691			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	0	1	4	0	0	2	2	2	4	3	1	1	2	9	3	3	4	5	2	5	3	4	4	1	1	1	1	1	1	1	1	2	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	1	3.5714285	4	2.7		1	2.9	2.5	1	3.7142856	4	-0.2	-0.375	0	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ148ADL
2081	8976	NDAR_INVXJ223PJ2	2287			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	6	6	4	5	6	6	6	2	5	1	9	3	4	4	6	4	4	4	6	6	1	1	1	0	1	0	1	1	1	1	1	4	1	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.625	2	4.714286	4	4.7	1		4.7	5.625	2	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ223PJ2
2081	8976	NDAR_INVXJ223PJ2	2287			M	2800	Visit12	12	Phase 3	343	1	0	1	0	0	0	0	6	5	6	5	5	4	6	0	2	6	3	9	2	6	6	6	4	3	4	6	6	1	1	1	1	1	1	1	1	1	2	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.625	2.75	5.142857	3.5	4.55			4.7	5.625	2	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ223PJ2
2081	8976	NDAR_INVXJ223PJ2	2287			M	5200	EndofPhase1_1a	5	Phase 1/1A	152	1	0	1	0	0	0	0	6	4	4	3	3	4	4	0	1	2	2	9	2	3	5	6	3	4	4	4	6	1	1	1	1	1	1	1	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	1.25	4.142857	4	3.5		1	4.7	5.625	2	4.714286	4	-1.2	-2.125	-0.75	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ223PJ2
2081	8976	NDAR_INVXJ223PJ2	2287			M	5800	EndofPhase2	6	Phase 2	169	1	0	1	0	0	0	0	6	2	4	3	4	6	4	0	1	1	2	9	0	6	6	6	2	4	4	6	6	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.625	1	4.571429	4	3.65			4.7	5.625	2	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ223PJ2
2081	8976	NDAR_INVXJ223PJ2	2287			M	6000	EndofPhase3	18	Phase 3	520	1	0	1	0	0	0	0	6	4	4	3	4	5	5	4	5	5	4	5	3	6	6	6	5	4	4	6	6	1	1	1	1	1	1	1	1	1	3	1	4	2	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.375	4.75	5.428571	4	4.7619047			4.7	5.625	2	4.714286	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ223PJ2
2081	8976	NDAR_INVXJ640TP1	1205			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	1	0	2	2	1	2	1	4	4	5	2	4	4	3	3	5	4	2	4	5	1	0	1	0	1	1	0	1	3	2	1	2	3	4	4	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.5	3.75	4	3	2.9047618	1		2.9047618	1.5	3.75	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ640TP1
2081	8976	NDAR_INVXJ640TP1	1205			M	1600	Visit6	6	Phase 1/1A	163	0	0	0	0	0	1	0	6	0	0	0	2	0	2	0	2	4	5	9	2	4	0	4	4	4	3	4	4	1	1	1	0	1	0	0	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	1.25	2.75	3.142857	3.5	2.5			2.9047618	1.5	3.75	4	3	-0.4047619	-0.25	-1	-0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ640TP1
2081	8976	NDAR_INVXJ640TP1	1205			M	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	1	0	6	0	0	2	0	0	2	1	3	5	5	4	4	2	1	6	6	4	3	5	6	1	1	1	0	1	1	1	1	3	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.375	4.25	4.285714	3.5	3.0952382			2.9047618	1.5	3.75	4	3	0.1904762	-0.125	0.5	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ640TP1
2081	8976	NDAR_INVXJ640TP1	1205			M	5200	EndofPhase1_1a	18	Phase 1/1A	520	0	0	0	0	0	1	0	4	0	0	0	2	0	2	1	5	4	6	6	0	2	0	6	6	4	3	2	4	1	1	1	1	1	0	0	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1.125	5.25	2.857143	3.5	2.7142856		1	2.9047618	1.5	3.75	4	3	-0.1904762	-0.375	1.5	-1.1428572	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXJ640TP1
2081	8976	NDAR_INVXK326HCD	2144			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	0	2	2	0	2	1	1	2	1	9	0	2	0	2	1	1	1	3	3	0	1	2	1	0	0	0	2	2	1	0	4	3	3	4	1	0	1	0	0	0	0	0	2	2	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1	1	1.5714285	1	1.25	1		1.25	1	1	1.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXK326HCD
2081	8976	NDAR_INVXK326HCD	2144			M	5200	EndofPhase1_1a	1	Phase 1/1A	32	0	0	0	0	0	1	0	2	0	1	1	3	2	3	1	1	1	1	9	0	2	0	3	0	3	1	2	3	1	1	2	1	1	1	1	0	3	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	26	0		1	4	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.625	0.75	1.4285715	2	1.5		1	1.25	1	1	1.5714285	1	0.25	0.625	-0.25	-0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXK326HCD
2081	8976	NDAR_INVXK451YLG	2278			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	1	0	0	1	0	1	0	2	0	0	0	1	2	0	9	1	0	0	2	4	3	2	4	4	1	0	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	0.5	0.75	2.142857	2.5	1.35	1		1.35	0.5	0.75	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXK451YLG
2081	8976	NDAR_INVXK451YLG	2278			F	2800	Visit12	12	Phase 1B	343	0	0	0	1	0	0	0	4	2	0	1	1	1	2	2	2	4	3	9	1	2	3	2	5	4	3	3	5	1	0	1	0	1	1	0	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	5	1.625	2.25	3	3.5	2.5			1.35	0.5	0.75	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXK451YLG
2081	8976	NDAR_INVXK451YLG	2278			F	5200	EndofPhase1_1a	6	Phase 1/1A	195	0	0	0	1	0	0	0	3	0	0	0	0	0	0	2	0	2	1	9	2	1	2	0	2	2	2	1	4	1	1	1	0	1	1	0	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	2	0.625	0.75	1.7142857	2	1.2		1	1.35	0.5	0.75	2.142857	2.5	-0.15	0.125	0	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXK451YLG
2081	8976	NDAR_INVXK715BHZ	2501			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	4	0	0	2	0	0	0	0	9	0	0	0	2	0	2	2	0	4	0	0	0	0	1	0	0	0	3		0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1	0	0.85714287	2	0.9	1		0.9	1	0	0.85714287	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXK715BHZ
2081	8976	NDAR_INVXL106AEQ	2670			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	0	4	2	2	2	1	2	2	1	9	3	2	2	1	1	4	3	2	3	1	1	1	0	1	1	1	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	1.5	1.25	2	3.5	1.9	1		1.9	1.5	1.25	2	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL106AEQ
2081	8976	NDAR_INVXL106AEQ	2670			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	1	0	2	1	2	1	2	2	3	4	4	4	6	6	4	1	3	4	5	4	4	5	4	1	1	0	1	1	1	1	0	3	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	2.125	5	3.7142856	4	3.3809524			1.9	1.5	1.25	2	3.5	1.4809524	0.625	3.75	1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL106AEQ
2081	8976	NDAR_INVXL106AEQ	2670			M	2800	Visit12	12	Phase 1/1A	337	0	0	0	0	0	0	1	2	1	2	2	3	1	2	1	1	1	5	9	1	2	2	2	1	3	4	2	3	1	1	1	0	1	0	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1.75	1.8571428	3.5	2.05			1.9	1.5	1.25	2	3.5	0.15	0.25	0.5	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL106AEQ
2081	8976	NDAR_INVXL106AEQ	2670			M	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	1	0	2	2	4	4	4	3	2	2	1	1	1	9	1	3	2	2	2	4	4	4	5	1	1	0	0	1	1	0	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	0.75	2.7142856	4	2.65		1	1.9	1.5	1.25	2	3.5	0.75	1.375	-0.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL106AEQ
2081	8976	NDAR_INVXL394HGK	1471			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	1	1	2	2	2	2	3	2	3	1	9	2	1	0	1	2	4	2	4	4	1	1	0	0	1	1	0	1	1	2	1	3	2	4	2	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.25	1.5	2	3	2.2	1		2.2	2.25	1.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL394HGK
2081	8976	NDAR_INVXL394HGK	1471			F	2800	Visit12	12	Phase 1B	348	0	1	0	0	0	0	0	6	2	2	2	2	2	2	4	2	4	6	9	3	2	0	3	2	4	2	4	4	1	0	0	1	1	1	0	1	1	3	0	4	2	4	4	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.75	3	2.5714285	3	2.9			2.2	2.25	1.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL394HGK
2081	8976	NDAR_INVXL394HGK	1471			F	5200	EndofPhase1_1a	6	Phase 1/1A	186	0	1	0	1	0	0	0	6	2	2	2	2	0	2	3	2	2	4	9	2	2	1	4	2	4	2	3	4	1	1	0	0	1	0	0	1	1	2	1	3	4	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.375	2	2.5714285	3	2.55		1	2.2	2.25	1.5	2	3	0.35	0.125	0.5	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL394HGK
2081	8976	NDAR_INVXL394HGK	1471			F	5400	EndofPhase1b	18	Phase 1B	508	0	1	0	0	0	0	0	4	0	4	2	2	2	2	3	3	3	4	9	3	3	0	3	2	4	4	3	4	1	1	1	0	1	1	1	1	1	2	0	4	2	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	2.375	2.5	2.5714285	4	2.75			2.2	2.25	1.5	2	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL394HGK
2081	8976	NDAR_INVXL556MPF	1704			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	9	0	0	0	0	0	3	1	0	0	0	0	0	0	1	1	1	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	0.125	0	0	2	0.25	1		0.25	0.125	0	0	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL556MPF
2081	8976	NDAR_INVXL556MPF	1704			M	5200	EndofPhase1_1a	2	Phase 1/1A	63	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	2	2	2	2	0	3	2	0	4	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	4	0	0	1.7142857	2.5	0.85		1	0.25	0.125	0	0	2	0.6	-0.125	0	1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL556MPF
2081	8976	NDAR_INVXL630DDW	2571			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	1	1	1	1	1	1	2	0	0	0	9	0	1	2	1	1	5	3	2	2	1	1	1	0	1	1	1	1	3		1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.125	0	1.2857143	4	1.3	1		1.3	1.125	0	1.2857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXL630DDW
2081	8976	NDAR_INVXM711GLX	1035			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	3	0	4	6	4	4	0	5	2	3	5	4	5	4	4	6	6	4	4	4	1	1	1	1	0	1	2	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.375	3.75	4.428571	5	3.952381	1		3.952381	3.375	3.75	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXM711GLX
2081	8976	NDAR_INVXM711GLX	1035			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	6	3	2	2	1	1	3	3	6	4	6	3	5	5	5	6	5	6	4	3	5	1	1	0	1	1	1	0	1	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	4.75	4.857143	5	4			3.952381	3.375	3.75	4.428571	5	0.04761905	-0.75	1	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXM711GLX
2081	8976	NDAR_INVXM711GLX	1035			M	5200	EndofPhase1_1a	10	Phase 1/1A	280	1	0	0	0	0	0	0	6	1	2	3	5	3	4	2	4	5	6	6	6	4	4	3	4	6	5	6	6	1	1	2	1	1	0	1	1	1	1	1	4	4	3	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	3.25	5.25	4.714286	5.5	4.3333335		1	3.952381	3.375	3.75	4.428571	5	0.3809524	-0.125	1.5	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXM711GLX
2081	8976	NDAR_INVXN758CUX	1627			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	3	1	0	0	2	0	1	2	0	1	1	9	2	2	6	3	3	3	3	5	6	0	0	0	0	1	1	0	0	3	3	1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.125	0.5	3.857143	3	2.2	1		2.2	1.125	0.5	3.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN758CUX
2081	8976	NDAR_INVXN758CUX	1627			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	0	1	0	2	0	3	2	2	0	2	2	0	1	1	9	1	1	4	4	3	3	3	4	5	0	0	0	0	1	1	0	1	3	3	1	2	4	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	0.5	3.142857	3	2.15			2.2	1.125	0.5	3.857143	3	-0.05	0.5	0	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN758CUX
2081	8976	NDAR_INVXN758CUX	1627			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	2	2	0	1	3	1	2	0	0	1	1	9	2	2	4	4	2	3	3	5	6	1	0	0	0	1	1	0	1	3		1	2	4	4	4	1	0	0	0	0	0	1	0	1	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.375	0.5	3.5714285	3	2.2			2.2	1.125	0.5	3.857143	3	0	0.25	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN758CUX
2081	8976	NDAR_INVXN758CUX	1627			M	5200	EndofPhase1_1a	18	Phase 1/1A	511	0	0	0	0	0	1	0	4	0	1	0	3	1	2	2	0	0	0	9	2	3	4	4	5	5	3	5	6	1	0	0	1	1	0	0	1	3	1	1	4	3	3	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0	4.142857	4	2.5		1	2.2	1.125	0.5	3.857143	3	0.3	0.5	-0.5	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN758CUX
2081	8976	NDAR_INVXN941TKH	1458			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	6	6	6	5	6	5	6	5	4	6	6	5	5	5	5	5	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5.75	5.25	5.285714	5	5.428571	1		5.428571	5.75	5.25	5.285714	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN941TKH
2081	8976	NDAR_INVXN941TKH	1458			M	1600	Visit6	6	Phase 1/1A	170	0	0	0	0	1	0	0	6	5	6	5	5	5	5	2	6	6	5	6	4	6	4	5	5	6	5	5	6	1	1	1	1	1	1	1	1	2	1	1	3	3	2	3	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6	4.875	5.75	5	5.5	5.142857			5.428571	5.75	5.25	5.285714	5	-0.2857143	-0.875	0.5	-0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN941TKH
2081	8976	NDAR_INVXN941TKH	1458			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	1	0	0	4	5	5	6	4	5	5	2	6	6	6	6	5	6	6	6	5	6	5	5	6	1	1	1	1	1	1	1	1	2	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.5	6	5.571429	5.5	5.2380953			5.428571	5.75	5.25	5.285714	5	-0.1904762	-1.25	0.75	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN941TKH
2081	8976	NDAR_INVXN941TKH	1458			M	5200	EndofPhase1_1a	18	Phase 1/1A	535	0	0	0	0	0	0	1	3	3	3	3	3	4	5	0	6	6	6	4	4	6	4	5	6	6	5	5	6	1	1	1	1	1	1	1	1	2	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	14	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3	5.5	5.142857	5.5	4.428571		1	5.428571	5.75	5.25	5.285714	5	-1	-2.75	0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXN941TKH
2081	8976	NDAR_INVXP042YFP	1610			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	3	3	2	3	4	3	3	2	6	5	4	6	4	3	4	4	3	3	3	5	5	0	1	0	1	1	0	1	0	1	2	1	2	2	2	2	1	0	1	1	0	0	0	0	0	1	0	0	1	22	0		0		1	8	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	5.25	4	3	3.7142856	1		3.7142856	2.875	5.25	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP042YFP
2081	8976	NDAR_INVXP042YFP	1610			M	1600	Visit6	6	Phase 1/1A	170	0	0	1	0	0	0	0	4	2	2	1	2	1	4	3	6	4	5	2	1	2	0	3	4	2	4	6	6	1	1	0	1	1	0	1	0	2	2	0	4	3	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	4.25	3.142857	3	3.047619			3.7142856	2.875	5.25	4	3	-0.6666667	-0.5	-1	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP042YFP
2081	8976	NDAR_INVXP042YFP	1610			M	2800	Visit12	12	Phase 1/1A	341	0	0	1	0	0	0	0	4	3	2	3	3	2	2	2	6	4	4	4	2	4	2	4	3	5	3	5	4	0	1	0	1	1	0	1	0	3	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	1	1	1	1	1	1	4	2.625	4.5	3.4285715	4	3.3809524			3.7142856	2.875	5.25	4	3	-0.33333334	-0.25	-0.75	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP042YFP
2081	8976	NDAR_INVXP042YFP	1610			M	5200	EndofPhase1_1a	17	Phase 1/1A	465	0	0	1	0	0	0	0	5	2	3	2	2	2	2	1	6	4	4	4	2	3	3	3	4	3	3	3	3	1	1	0	0	1	1	1	1	2	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	27	0		0		1	3	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	4.5	3	3	3.047619		1	3.7142856	2.875	5.25	4	3	-0.6666667	-0.5	-0.75	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP042YFP
2081	8976	NDAR_INVXP458GJD	1411			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	1	4	0	2	5	1	2	1	0	3	0	9	0	0	0	0	0	2	2	0	4	0	0	1	0	1	0	1	1	1	3	1	3	2	3	2	1	0	0	0	0	1	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	1	0	1	1	1	1	4	2	0.75	0.5714286	2	1.35	1		1.35	2	0.75	0.5714286	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP458GJD
2081	8976	NDAR_INVXP458GJD	1411			F	1600	Visit6	6	Phase 1/1A	163	1	0	0	0	0	0	0	0	4	0	4	4	0	4	0	2	3	0	9	0	0	2	3	0	2	3	4	4	1	0	1	0	1	1	1	0	1	3	1	2	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2	1.25	1.8571428	2.5	1.95			1.35	2	0.75	0.5714286	2	0.6	0	0.5	1.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP458GJD
2081	8976	NDAR_INVXP458GJD	1411			F	2800	Visit12	12	Phase 1/1A	331	1	0	0	0	0	0	0	2	2	0	0	2	2	2	0	2	2	0	9	2	2	0	2	2	3	2	4	4	0	0	0	0	1	1	1	1	1	3	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.25	1	2.2857144	2.5	1.75			1.35	2	0.75	0.5714286	2	0.4	-0.75	0.25	1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP458GJD
2081	8976	NDAR_INVXP458GJD	1411			F	4000	Visit18	18	Phase 1/1A	506	0	0	1	0	1	0	0	0	6	6	6	6	6	4	6	0	0	0	9	0	2	0	4	2	3	4	4	6	1	1	1	1	1	1	1	1	1	2	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	5	0	2.5714285	3.5	3.25		1	1.35	2	0.75	0.5714286	2	1.9	3	-0.75	2	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP458GJD
2081	8976	NDAR_INVXP616CEB	1751			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	5	4	5	5	5	5	5	2	5	1	9	4	4	4	5	1	3	3	4	6	1	1	0	1	1	1	1	1	3	1	1	4	3	3	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	4	4.875	2	4	3	4.05	1		4.05	4.875	2	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP616CEB
2081	8976	NDAR_INVXP616CEB	1751			F	1600	Visit6	6	Phase 3	172	0	0	0	0	0	1	0	6	6	6	5	4	6	6	4	3	3	4	4	4	4	3	3	4	5	4	5	6	1	1	0	1	1	1	1	1	3	1	1	3	2	2	2	1	0	0	1	0	1	0	0	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	1	1	0	1	0	0	1	0	1	0	4	5.375	3.5	4.142857	4.5	4.5238094			4.05	4.875	2	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP616CEB
2081	8976	NDAR_INVXP616CEB	1751			F	2800	Visit12	12	Phase 3	336	0	0	0	0	0	0	1	5	5	4	5	5	5	5	2	2	3	5	9	4	4	2	4	4	4	3	5	5	1	1	1	1	1	1	1	1	3	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	27	1	3	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.5	2.5	4	3.5	4.05			4.05	4.875	2	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP616CEB
2081	8976	NDAR_INVXP616CEB	1751			F	5200	EndofPhase1_1a	5	Phase 1/1A	144	0	0	0	0	0	1	0	5	4	4	5	5	5	4	5	2	4	2	9	5	5	4	5	5	3	3	5	6	1	1	1	1	1	1	1	1	3	1	1	4	3	3	3	0	0	0	0	0	0	0	0					0		1	30	0		0		0		2	0	0	0	0	0	1	1	0	0	0	0	1	0	1	1	4	4.625	2	5	3	4.3		1	4.05	4.875	2	4	3	0.25	-0.25	0	1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP616CEB
2081	8976	NDAR_INVXP616CEB	1751			F	6000	EndofPhase3	17	Phase 3	492	0	0	0	0	0	0	1	4	4	2	4	2	4	4	0	2	4	5	9	3	3	4	4	6	6	2	4	5	1	1	0	1	1	1	1	1	3		1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3	2.75	4.142857	4	3.6			4.05	4.875	2	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXP616CEB
2081	8976	NDAR_INVXR112YLZ	1572			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	1	2	3	2	3	3	0	2	4	4	9	4	6	6	3	3	5	4	6	6	1	0	1	0	1	1	1	1	1	2	0		4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	2.5	4.857143	4.5	3.6	1		3.6	2.375	2.5	4.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR112YLZ
2081	8976	NDAR_INVXR112YLZ	1572			F	5200	EndofPhase1_1a	1	Phase 1/1A	44	0	0	0	0	0	0	1	5	0	1	2	2	2	2	0	1	4	5	9	4	6	5	4	4	5	4	6	6	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	1.75	2.5	5	4.5	3.4		1	3.6	2.375	2.5	4.857143	4.5	-0.2	-0.625	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR112YLZ
2081	8976	NDAR_INVXR353XA4	1406			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	5	4	6	6	6	6	1	1	1	9	6	2	4	6	2	4	3	5	6	1	1	1	0	1	1	0	1	3		1	3	2	2	1	0	0	0	0	0	0	0	1	2	2	2	2	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	5.375	0.75	4.428571	3.5	4.2	1		4.2	5.375	0.75	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR353XA4
2081	8976	NDAR_INVXR353XA4	1406			F	1600	Visit6	6	Phase 1/1A	179	0	0	0	0	0	0	1	6	6	2	5	6	2	6	6	2	3	3	9	0	0	3	6	6	5	4	6	5	1	1	0	0	1	0	1	1	3		1	2	1	2	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	7	4.875	2	3.7142856	4.5	4.1			4.2	5.375	0.75	4.428571	3.5	-0.1	-0.5	1.25	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR353XA4
2081	8976	NDAR_INVXR353XA4	1406			F	5200	EndofPhase1_1a	6	Phase 1/1A	179	0	0	0	0	0	0	1	6	6	2	5	6	2	6	6	2	3	3	9	0	0	3	6	6	5	4	6	5	1	1	0	0	1	0	1	1	3		1	2	1	2	1	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	7	4.875	2	3.7142856	4.5	4.1		1	4.2	5.375	0.75	4.428571	3.5	-0.1	-0.5	1.25	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR353XA4
2081	8976	NDAR_INVXR766RLV	2711			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	4	2	1	2	2	2	2	2	2	2	4	9	2	2	2	3	2	1	1	3	2	0	0	1	0	1	0	1	0	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	2	2.125	2	2.2857144	1	2.15	1		2.15	2.125	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR766RLV
2081	8976	NDAR_INVXR766RLV	2711			F	1600	Visit6	6	Phase 1B	169	0	0	1	0	0	0	0	4	2	2	3	2	2	3	2	3	2	4	4	2	3	1	2	0	1	2	3	3	0	1	1	0	0	0	1	0	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	4	2.5	3.25	2	1.5	2.3809524			2.15	2.125	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR766RLV
2081	8976	NDAR_INVXR766RLV	2711			F	2800	Visit12	12	Phase 1B	339	0	1	0	0	0	0	0	3	2	2	2	3	3	3	4	2	2	5	9	3	3	1	3	1	0	0	2	2	0	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	2.25	2.142857	0	2.3			2.15	2.125	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR766RLV
2081	8976	NDAR_INVXR766RLV	2711			F	5200	EndofPhase1_1a	4	Phase 1/1A	128	0	0	1	0	0	0	0	4	3	2	2	2	3	3	2	2	4	4	9	3	4	4	4	1	2	3	4	3	1	0	1	0	1	1	0	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2.5	3.2857144	2.5	2.95		1	2.15	2.125	2	2.2857144	1	0.8	0.5	0.5	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR766RLV
2081	8976	NDAR_INVXR766RLV	2711			F	5400	EndofPhase1b	18	Phase 1B	520	0	0	1	0	0	0	0	4	3	2	2	2	1	2	1	1	2	4	9	2	2	2	3	1	2	2	2	3	1	0	0	0	1	1	0	1	1	2	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.125	1.75	2.142857	2	2.15			2.15	2.125	2	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXR766RLV
2081	8976	NDAR_INVXT013LMB	2418			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	1	1	2	6	2	3	1	2	2	3	9	2	4	2	4	2	5	5	6	4	0	0	0	1	1	1	0	1	1	1	0	4	4	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.75	3.4285715	5	3.15	1		3.15	2.75	1.75	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT013LMB
2081	8976	NDAR_INVXT013LMB	2418			F	5200	EndofPhase1_1a	2	Phase 1/1A	42	1	0	1	0	0	0	0	6	2	2	2	4	2	2	1	2	2	4	9	2	2	2	4	2	2	1	4	3	1	1	0	0	1	1	0	1	0	1	0	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.625	2	2.7142856	1.5	2.55		1	3.15	2.75	1.75	3.4285715	5	-0.6	-0.125	0.25	-0.71428573	-3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT013LMB
2081	8976	NDAR_INVXT174RYM	2639			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	1	1	2	2	2	3	1	0	0	1	9	2	2	2	3	2	3	3	4	5	0	1	0	0	1	1	2	1	2	2	1	3	4	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	6	1.75	0.25	2.857143	3	2.05	1		2.05	1.75	0.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT174RYM
2081	8976	NDAR_INVXT174RYM	2639			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	2	2	0	9	2	2	2	2	0	5	1	2	1	1	1	1	1	1	1	1	1	3	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	2	0		0		1	28	0		0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	4	0.375	1	1.5714285	3	1.2		1	2.05	1.75	0.25	2.857143	3	-0.85	-1.375	0.75	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT174RYM
2081	8976	NDAR_INVXT430HG3	1180			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	0	2	4	3	3	2	3	0	0	1	9	4	2	0	4	2	3	3	4	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	2	1	0	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	2.875	0.25	2.857143	3	2.5	1		2.5	2.875	0.25	2.857143	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT430HG3
2081	8976	NDAR_INVXT430HG3	1180			M	1600	Visit6	6	Phase 1/1A	166	0	0	0	0	1	0	0	4	4	4	4	4	4	4	4	0	4	4	9	2	4	4	3	4	3	3	5	6	1	1	0	0	1	1	1	0	1	2	1	3	1	2	2	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		1	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4	2	4	3	3.7			2.5	2.875	0.25	2.857143	3	1.2	1.125	1.75	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT430HG3
2081	8976	NDAR_INVXT430HG3	1180			M	2800	Visit12	12	Phase 1/1A	335	0	0	0	0	1	0	0	4	4	2	2	2	2	2	2	0	2	4	9	2	4	4	4	2	3	1	2	2	0	0	0	0	1	1	0	1	1	2	1	3	2	2	1	1	0	0	0	1	0	0	0	1	1	0	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	1.5	2.857143	2	2.5		1	2.5	2.875	0.25	2.857143	3	0	-0.375	1.25	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT430HG3
2081	8976	NDAR_INVXT740AX1	2814			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	1	0	1	0	2	1	1	0	1	9	1	0	2	2	1	1	1	0	2	0	1	0	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	5	0.625	0.5	1.1428572	1	0.85	1		0.85	0.625	0.5	1.1428572	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT740AX1
2081	8976	NDAR_INVXT740AX1	2814			M	5200	EndofPhase1_1a	1	Phase 1/1A	19	0	0	0	0	0	1	0	2	1	1	1	1	0	0	2	0	0	0	9	0	0	0	0	0	1	3	0	2	1	1	0	1	1	1	1	0	3		1	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	1	0	0.2857143	2	0.7		1	0.85	0.625	0.5	1.1428572	1	-0.15	0.375	-0.5	-0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT740AX1
2081	8976	NDAR_INVXT836FR8	1909			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	1	2	2	2	1	4	4	1	1	1	9	4	2	4	6	2	4	3	6	6	1	0	1	0	1	1	1	1	1	2	0	4	2	4	1	0	0	0	0	0	0	0	0					1		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	2.75	0.75	4.285714	3.5	3.1	1		3.1	2.75	0.75	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT836FR8
2081	8976	NDAR_INVXT836FR8	1909			M	2800	Visit12	12	Phase 2	325	0	1	0	0	0	0	0	5	0	2	2	5	1	2	3	0	0	2	9	4	2	4	2	3	1	4	6	5	0	0	0	1	1	1	1	1	1	1	1	2	2	4	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.5	0.5	3.7142856	2.5	2.65			3.1	2.75	0.75	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT836FR8
2081	8976	NDAR_INVXT836FR8	1909			M	5200	EndofPhase1_1a	2	Phase 1/1A	44	1	0	0	0	0	0	0	6	6	6	6	6	3	5	6	1	1	1	9	6	6	6	4	4	6	4	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	4	5.5	0.75	5.285714	5	4.7		1	3.1	2.75	0.75	4.285714	3.5	1.6	2.75	0	1	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT836FR8
2081	8976	NDAR_INVXT836FR8	1909			M	5400	EndofPhase1b	6	Phase 1B	148	0	1	0	0	0	0	0	6	0	0	0	4	2	2	2	0	0	0	9	2	0	4	4	2	5	4	4	4	1	0	1	0	1	1	1	1	1	1	0	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2	0	2.857143	4.5	2.25			3.1	2.75	0.75	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXT836FR8
2081	8976	NDAR_INVXU187EDV	2680			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	2	2	6	2	0	2	6	2	4	6	9	3	2	4	4	4	3	5	4	6	1	1	1	1	1	1	1	1	3		0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	3.25	3	3.857143	4	3.65	1		3.65	3.25	3	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU187EDV
2081	8976	NDAR_INVXU201XFE	1750			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	4	4	2	6	5	6	6	1	1	2	9	5	5	2	4	3	4	3	5	5	1	1	1	0	1	1	1	1	2	1	1	2	2	4	2	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	2	4.375	1	4.142857	3.5	3.75	1		3.75	4.375	1	4.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU201XFE
2081	8976	NDAR_INVXU201XFE	1750			M	1600	Visit6	6	Phase 1/1A	178	0	0	0	0	1	0	0	2	4	2	2	1	2	6	6	2	4	4	9	4	2	4	1	4	4	5	2	4	1	1	1	0	1	1	1	1	3	3	1	3	2	2	1	1	0	0	1	0	0	0	0	1	2	1	1	1		0		0		0		0		0	1	0	0	1	1	0	0	0	0	0	0	1	1	1	1	7	3.125	2.5	3	4.5	3.25			3.75	4.375	1	4.142857	3.5	-0.5	-1.25	1.5	-1.1428572	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU201XFE
2081	8976	NDAR_INVXU201XFE	1750			M	2800	Visit12	12	Phase 1/1A	352	0	1	0	0	0	0	0	6	6	6	0	0	1	5	6	6	3	3	6	3	6	5	6	6	6	6	5	4	1	1	0	1	1	1	1	1	2	2	1	4	3	3	1	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	5	3.75	4.5	5	6	4.5238094			3.75	4.375	1	4.142857	3.5	0.77380955	-0.625	3.5	0.85714287	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU201XFE
2081	8976	NDAR_INVXU201XFE	1750			M	4000	Visit18	18	Phase 1/1A	547	0	1	0	0	0	0	0	6	6	4	1	1	4	3	5	5	5	6	6	5	6	6	6	6	6	6	4	5	1	1	1	0	1	0	0	1	2	2	0	4	1	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.75	5.5	5.428571	6	4.857143		1	3.75	4.375	1	4.142857	3.5	1.1071428	-0.625	4.5	1.2857143	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU201XFE
2081	8976	NDAR_INVXU370CAA	1674			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	4	2	3	3	2	3	3	3	4	3	9	3	3	4	4	4	2	3	3	4	1	1	1	0	1	1	1	1	1	1	1	2	1	4	1	1	1	0	0	0	0	0	0	1	0	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	0	4	3.125	2.5	3.5714285	2.5	3.25	1		3.25	3.125	2.5	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU370CAA
2081	8976	NDAR_INVXU934NRA	1920			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	4	2	4	5	5	6	6	3	4	4	4	3	5	4	4	4	6	4	4	4	1	1	1	1	1	1	1	1	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	3.75	4	5	4.3333335	1		4.3333335	4.75	3.75	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU934NRA
2081	8976	NDAR_INVXU934NRA	1920			F	5200	EndofPhase1_1a	4	Phase 1/1A	130	0	1	0	1	0	0	0	4	4	3	3	5	4	4	3	5	4	4	9	3	2	3	4	3	5	3	5	5	1	1	1	1	1	1	1	1	1	1	1	4	3	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	5	3.75	3.25	3.5714285	4	3.8		1	4.3333335	4.75	3.75	4	5	-0.53333336	-1	-0.5	-0.42857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU934NRA
2081	8976	NDAR_INVXU990CJK	2848			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	1	1	3	1	5	3	4	4	5	6	4	5	3	5	5	5	3	5	5	1	2	2	1	1	1	1	1	2	1	1	4	4	2	1	1	0	1	1	1	1	0	0	1	1	1	2	1	6	0		0		1	24	0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	2.75	4.75	4.571429	4	3.857143	1		3.857143	2.75	4.75	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU990CJK
2081	8976	NDAR_INVXU990CJK	2848			F	1600	Visit6	6	Phase 1/1A	168	1	0	0	0	0	0	0	5	5	5	3	4	5	6	2	2	2	1	9	0	3	2	4	4	4	3	2	4	0	0	0	0	1	2	1	1	1	1	0	4	2	3	3	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.375	1.25	2.7142856	3.5	3.3			3.857143	2.75	4.75	4.571429	4	-0.55714285	1.625	-3.5	-1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU990CJK
2081	8976	NDAR_INVXU990CJK	2848			F	2800	Visit12	12	Phase 1/1A	336	1	0	0	0	0	0	0	5	5	4	4	4	3	5	4	2	5	1	9	1	2	0	4	3	5	4	2	3	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4.25	2	2.142857	4.5	3.3			3.857143	2.75	4.75	4.571429	4	-0.55714285	1.5	-2.75	-2.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU990CJK
2081	8976	NDAR_INVXU990CJK	2848			F	5200	EndofPhase1_1a	18	Phase 1/1A	503	1	0	0	0	0	0	0	6	4	1	5	4	5	6	0	0	2	0	9	3	2	2	6	3	4	4	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.875	0.5	4	4	3.45		1	3.857143	2.75	4.75	4.571429	4	-0.40714285	1.125	-4.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXU990CJK
2081	8976	NDAR_INVXV106FT9	2799			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	1	0	0	0	0	1	3	1	2	4	9	5	2	4	3	4	5	3	5	5	1	1	1	1	1	1	1	1	3	3	1	4	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	0.625	1.75	4	4	2.4	1		2.4	0.625	1.75	4	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV106FT9
2081	8976	NDAR_INVXV106FT9	2799			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	0	0	0	0	0	1	5	2	0	3	3	0	3	0	2	2	3	9	3	3	4	1	1	4	3	4	5	1	0	0	0	1	0	1	1	2	3	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	1	2	1.75	3	3.5	2.55		1	2.4	0.625	1.75	4	4	0.15	1.375	0	-1	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV106FT9
2081	8976	NDAR_INVXV605VZJ	2086			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	1	3	1	0	4	3	4	4	2	1	2	1	3	2	5	3	4	6	1	1	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	3.25	2.7142856	4	2.6190476	1		2.6190476	1.875	3.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV605VZJ
2081	8976	NDAR_INVXV605VZJ	2086			F	1600	Visit6	6	Phase 1/1A	170	0	1	0	0	0	0	0	3	1	1	2	2	1	1	4	2	2	1	9	2	4	1	2	4	5	5	5	6	1	0	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	2	1.875	1.25	3.4285715	5	2.7			2.6190476	1.875	3.25	2.7142856	4	0.08095238	0	-2	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV605VZJ
2081	8976	NDAR_INVXV605VZJ	2086			F	2800	Visit12	12	Phase 2	343	0	1	0	0	0	0	0	4	1	1	2	2	2	2	3	4	3	5	3	2	4	3	4	1	5	3	5	6	1	0	1	0	1	1	1	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	3	2.125	3.75	3.5714285	4	3.0952382			2.6190476	1.875	3.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV605VZJ
2081	8976	NDAR_INVXV605VZJ	2086			F	5200	EndofPhase1_1a	7	Phase 1/1A	196	0	1	0	0	0	0	0	5	1	2	2	2	1	2	4	0	0	1	9	2	3	3	2	2	5	5	4	6	1	1	1	0	1	1	1	1	1	2	0	4	4	3	1	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.375	0.25	3.142857	5	2.6		1	2.6190476	1.875	3.25	2.7142856	4	-0.01904762	0.5	-3	0.42857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV605VZJ
2081	8976	NDAR_INVXV605VZJ	2086			F	5800	EndofPhase2	15	Phase 2	429	0	1	0	0	0	0	0	5	0	0	2	2	2	0	3	0	4	5	9	2	2	2	2	2	5	4	3	5	1	1	1	0	1	1	1	1	3	3	0	4	4	4	1	1	1	0	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	3	1.75	2.25	2.5714285	4.5	2.5			2.6190476	1.875	3.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV605VZJ
2081	8976	NDAR_INVXV605VZJ	2086			F	6000	EndofPhase3	18	Phase 3	497	0	1	0	0	0	0	0	4	0	0	2	2	2	1	5	0	4	6	9	3	3	0	4	4	5	3	4	6	1	0	1	0	1	1	1	1	1	1	0	4	4	4	4	1	1	0	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	3	2	2.5	3.4285715	4	2.9			2.6190476	1.875	3.25	2.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV605VZJ
2081	8976	NDAR_INVXV817DG6	2008			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	1	2	0	2	1	1	1	4	9	0	2	3	2	1	6	3	2	4	1	1	1	1	1	1	1	1	3	1	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.25	1.5	2	4.5	1.95	1		1.95	1.25	1.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV817DG6
2081	8976	NDAR_INVXV817DG6	2008			M	6000	EndofPhase3	12	Phase 3	338	0	0	0	0	0	0	1	4	0	0	0	2	0	1	0	0	0	5	9	1	3	4	2	1	5	4	3	3	1	0	1	0	1	1	1	1	2	1	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	0.875	1.25	2.4285715	4.5	1.9			1.95	1.25	1.5	2	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV817DG6
2081	8976	NDAR_INVXV903GLK	2675			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	0	0	0	2	2	0	0	0	0	9	3	4	0	2	1	2	1	1	5	0	1	0	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	1	0	0	1	0	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0.75	0	2.2857144	1.5	1.25	1		1.25	0.75	0	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV903GLK
2081	8976	NDAR_INVXV903GLK	2675			M	5200	EndofPhase1_1a	4	Phase 1/1A	99	0	1	0	0	0	0	0	6	2	0	3	2	4	5	4	0	2	3	9	5	3	3	4	0	2	1	5	4	1	0	0	0	1	1	0	1	3		1	2	4	1	1	1	0	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.25	1.25	3.4285715	1.5	2.9		1	1.25	0.75	0	2.2857144	1.5	1.65	2.5	1.25	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV903GLK
2081	8976	NDAR_INVXV903GLK	2675			M	5400	EndofPhase1b	8	Phase 1B	188	0	0	0	0	0	0	0	9	2	2	3	3	3	3	3	2	2	1	9	3	3	0	3	0	3	2	5	6	1	0	1	0	1	1	1	1	3		1	3	2	2	2	1	0	0	0	0	0	1	0	1	1	1	0	1	27	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.7142856	1.25	2.857143	2.5	2.5789473			1.25	0.75	0	2.2857144	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXV903GLK
2081	8976	NDAR_INVXW062TX9	2590			M	5200	EndofPhase1_1a	11	Phase 1/1A	315	1	0	1	0	0	1	0	1	0	0	2	2	2	2	1	0	0	0	9		2	0	1	0	1	1	3	1	0	0	1	1	0	1	0	0	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.25	0	1.1666666	1	1		1																																																																																																																															Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXW062TX9
2081	8976	NDAR_INVXW131AAK	2633			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	0	0	0	0	4	0	0	0	9	4	2	3	6	0	2	3	2	2	0	1	1	0	1	1	1	1	3	2	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.25	0	2.7142856	2.5	1.7	1		1.7	1.25	0	2.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXW131AAK
2081	8976	NDAR_INVXW292EP7	1589			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	2	2	0	1	2	2	2	3	2	9	5	5	3	2	2	4	4	3	5	0	1	1	1	1	1	1	1	3	3	0	4	2	3	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	1.375	1.75	3.5714285	4	2.55	1		2.55	1.375	1.75	3.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXW292EP7
2081	8976	NDAR_INVXW476UYR	2002			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	1	2	3	3	0	0	0	0	9	4	3	6	4	6	6	5	5	6	1	1	0	0	1	0	1	0	3	1	1	4	3	2	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	2	0	0	0	0	1	1	0	0	0	0	0	1	1	0	1	4	1.375	0	4.857143	5.5	2.8	1		2.8	1.375	0	4.857143	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXW476UYR
2081	8976	NDAR_INVXX208GER	2604			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	6	6	6	6	6	4	0	4	0	9	3	4	1	2	4	6	4	6	6	1	1	1	1	1	1	1	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.428571	1	3.7142856	5	4.105263	1		4.105263	5.428571	1	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX208GER
2081	8976	NDAR_INVXX208GER	2604			M	2800	Visit12	12	Phase 3	343	0	0	0	0	0	0	1	9	2	5	5	4	5	5	0	0	0	1	9	4	4	6	6	5	6	4	5	6	1	1	1	1	1	0	0	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	3.7142856	0.25	5.142857	5	3.8421052			4.105263	5.428571	1	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX208GER
2081	8976	NDAR_INVXX208GER	2604			M	5200	EndofPhase1_1a	4	Phase 1/1A	126	0	0	0	0	0	0	1	4	4	4	4	3	3	2	3	0	0	0	9	2	2	5	5	4	5	5	4	6	1	1	0	1	1	1	1	1	3	3	1	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	0	4	5	3.25		1	4.105263	5.428571	1	3.7142856	5	-0.8552632	-2.0535715	-1	0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX208GER
2081	8976	NDAR_INVXX208GER	2604			M	5800	EndofPhase2	6	Phase 2	178	0	0	0	0	0	0	1	9	6	4	5	5	6	5	0	0	0	0	9	5	3	6	6	3	6	5	5	6	1	1	1	1	1	1	1	1	3		1	3	1	2	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.428571	0	4.857143	5.5	4			4.105263	5.428571	1	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX208GER
2081	8976	NDAR_INVXX208GER	2604			M	6000	EndofPhase3	18	Phase 3	524	0	0	0	0	0	0	1	9	6	2	5	4	5	5	0	0	0	1	9	4	4	6	6	5	6	4	5	6	1	1	1	1	1	0	0	1	3		1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.857143	0.25	5.142857	5	3.8947368			4.105263	5.428571	1	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX208GER
2081	8976	NDAR_INVXX227MDF	1816			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	0	1	3	1	0	6	4	2	3	5	9	5	4	0	5	5	5	4	0	5	1	1	1	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	2	2.5	3.4285715	4.5	2.95	1		2.95	2	2.5	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX227MDF
2081	8976	NDAR_INVXX227MDF	1816			F	1600	Visit6	6	Phase 3	141	0	0	0	0	0	0	1	2	1	1	2	1	2	5	1	1	1	4	9	3	2	2	5	5	6	5	2	5	1	0	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.875	1.5	3.4285715	5.5	2.8			2.95	2	2.5	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX227MDF
2081	8976	NDAR_INVXX227MDF	1816			F	2800	Visit12	12	Phase 3	323	0	0	0	0	0	0	1	0	0	1	1	2	1	2	0	1	2	1	9	2	2	1	3	4	6	4	2	5	1	0	0	0	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	0.875	1	2.7142856	5	2			2.95	2	2.5	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX227MDF
2081	8976	NDAR_INVXX227MDF	1816			F	4000	Visit18	18	Phase 3	519	0	0	0	0	0	0	1	9	0	0	2	2	0	2	2	1	2	1	9	2	2	1	3	4	6	4	1	5	1	1	1	0	1	1	1	1	3		0	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	1.1428572	1	2.5714285	5	2.1052632			2.95	2	2.5	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX227MDF
2081	8976	NDAR_INVXX227MDF	1816			F	5200	EndofPhase1_1a	1	Phase 1/1A	22	0	0	0	0	0	0	1	2	0	0	1	1	0	6	2	2	2	6	9	3	3	2	6	5	5	4	4	5	1	0	1	0	1	1	1	1	3		0	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	1.5	2.5	4	4.5	2.95		1	2.95	2	2.5	3.4285715	4.5	0	-0.5	0	0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX227MDF
2081	8976	NDAR_INVXX227MDF	1816			F	5800	EndofPhase2	2	Phase 2	36	0	0	0	0	0	0	1	1	0	1	1	1	0	1	1	1	0	1	9	1	1	0	1	5	5	4	0	3	1	0	1	0	1	1	1	1	3		0	4	4	4	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	7	0.75	0.5	1.5714285	4.5	1.4			2.95	2	2.5	3.4285715	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX227MDF
2081	8976	NDAR_INVXX278VNH	2089			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	1	0	4	1	0	0	5	5	2	5	1	1	0	2	0	3	2	3	3	0	1	0	0	1	0	0	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	1.875	4.25	1.4285715	2.5	2.2380953	1		2.2380953	1.875	4.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX278VNH
2081	8976	NDAR_INVXX278VNH	2089			M	1600	Visit6	6	Phase 1/1A	178	0	0	1	0	0	0	0	6	6	6	4	5	6	6	6	6	5	5	6	6	6	4	6	5	4	3	6	6	1	1	2	0	1	1	0	1	1	1	1	3	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.625	5.5	5.571429	3.5	5.3809524			2.2380953	1.875	4.25	1.4285715	2.5	3.142857	3.75	1.25	4.142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX278VNH
2081	8976	NDAR_INVXX278VNH	2089			M	2800	Visit12	12	Phase 2	339	1	0	0	0	0	0	0	6	2	1	2	2	2	2	2	2	2	2	9	3	4	2	2	2	4	2	2	2	0	0	1	0	1	1	1	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.375	1.5	2.4285715	3	2.4			2.2380953	1.875	4.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX278VNH
2081	8976	NDAR_INVXX278VNH	2089			M	5200	EndofPhase1_1a	7	Phase 1/1A	197	1	0	0	0	0	0	0	6	6	6	4	5	6	6	6	6	5	5	6	6	6	4	6	5	4	4	6	6	1	1	2	0	1	1	0	1	1	1	1	3	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	3	5.625	5.5	5.571429	4	5.428571		1	2.2380953	1.875	4.25	1.4285715	2.5	3.1904762	3.75	1.25	4.142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX278VNH
2081	8976	NDAR_INVXX278VNH	2089			M	5800	EndofPhase2	15	Phase 2	435	1	0	1	0	0	0	0	4	2	0	2	2	0	4	0	0	0	1	9	0	3	0	2	0	3	2	1	4	0	0	0	0	1	1	1	1	1	1	1	3	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	5	0		0		1	25	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	6	1.75	0.25	1.4285715	2.5	1.5			2.2380953	1.875	4.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX278VNH
2081	8976	NDAR_INVXX278VNH	2089			M	6000	EndofPhase3	18	Phase 3	508	1	0	1	0	0	0	0	4	4	2	4	4	2	3	1	6	4	4	6	4	4	2	3	4	4	4	3	5	1	1	0	0	1	0	0	0	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3	5	3.5714285	4	3.6666667			2.2380953	1.875	4.25	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX278VNH
2081	8976	NDAR_INVXX284NYD	1368			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	1	0	1	1	0	0	2	0	0	0	3	2	4	0	3	3	2	3	3	4	1	4	3	0	0	1	0	1	1	1	1	1	2	0	4	3	4	4	1	0	0	0	1	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	0.5	2.25	3	2.5	1.8571428	1		1.8571428	0.5	2.25	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX284NYD
2081	8976	NDAR_INVXX511REB	1447			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	2	2	2	0	4	4	0	0	0	9	0	2	4	4	4	4	4	4	5	1	1	0	0	0	0	0	1	2	2	1	2	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	2.5	0	3.2857144	4	2.55	1		2.55	2.5	0	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX511REB
2081	8976	NDAR_INVXX511REB	1447			F	1600	Visit6	6	Phase 3	162	0	1	0	0	0	0	0	6	0	0	0	4	0	2	2	0	0	0	9	1	0	2	6	4	4	2	1	2	1	1	0	1	0	0	0	0	3	1	1	2	3	4	1	1	0	0	0	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	0	2.2857144	3	1.8			2.55	2.5	0	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX511REB
2081	8976	NDAR_INVXX511REB	1447			F	2800	Visit12	12	Phase 3	352	0	1	0	0	0	0	0	5	3	0	1	3	2	3	2	1	1	1	9	2	0	1	6	4	4	3	1	2	1	1	0	0	0	1	1	1	3	2	1	2	1	4	3	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.375	0.75	2.2857144	3.5	2.25			2.55	2.5	0	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX511REB
2081	8976	NDAR_INVXX511REB	1447			F	5200	EndofPhase1_1a	3	Phase 1/1A	72	0	1	0	0	0	0	0	6	4	0	6	4	4	4	4	0	0	0	9	0	0	4	6	5	4	2	4	6	1	1	0	0	0	0	0	0	2	2	1	2	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	4	0	3.5714285	3	3.15		1	2.55	2.5	0	3.2857144	4	0.6	1.5	0	0.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX511REB
2081	8976	NDAR_INVXX511REB	1447			F	5800	EndofPhase2	5	Phase 2	135	0	1	0	0	0	0	0	6	4	0	6	4	4	4	4	0	0	0	9	0	0	4	6	5	3	1	2	4	1	1	0	1	0	0	0	0	2	2	1	3	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	4	4	0	3	2	2.85			2.55	2.5	0	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX511REB
2081	8976	NDAR_INVXX511REB	1447			F	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	6	0	0	2	2	2	2	0	0	0	0	9	0	0	0	6	0	4	3	2	2	1	1	0	0	0	0	0	0	1	1	0	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	0	1.4285715	3.5	1.55			2.55	2.5	0	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX511REB
2081	8976	NDAR_INVXX793AFN	1062			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	0	0	2	4	4	3	2	6	6	3	6	5	6	6	4	6	5	5	6	6	1	1	0	1	1	1	1	1	2	2	1	4	3	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		1	0	0	1	0	0	1	0	0	0	0	0	1	1	1	1	4	2.625	5.25	5.571429	5	4.3333335	1		4.3333335	2.625	5.25	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX793AFN
2081	8976	NDAR_INVXX793AFN	1062			M	5200	EndofPhase1_1a	3	Phase 1/1A	131	0	0	0	0	0	0	1	9	2	6	5	6	0	2	2	6	5	2	4	6	6	6	4	5	4	5	4	6	0	1	1	1	1	1	2	1	3	1	1	2	4	4	4	1	0	1	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		1	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	2	3.2857144	4.25	5.285714	4.5	4.3		1	4.3333335	2.625	5.25	5.571429	5	-0.03333333	0.66071427	-1	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXX793AFN
2081	8976	NDAR_INVXY139LUK	2880			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	5	5	2	4	3	5	1	1	1	1	9	3	5	4	4	4	5	4	6	6	1	1	0	0	1	1	0	1	1	1	1	4	3	3	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	6	3.875	0.75	4.571429	4.5	3.75	1		3.75	3.875	0.75	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY139LUK
2081	8976	NDAR_INVXY139LUK	2880			M	5200	EndofPhase1_1a	1	Phase 1/1A	28	1	0	1	0	0	0	0	6	5	6	4	5	4	5	1	0	0	0	9	3	2	5	6	1	5	4	4	5	1	1	0	1	1	1	1	0	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.5	0	3.7142856	4.5	3.55		1	3.75	3.875	0.75	4.571429	4.5	-0.2	0.625	-0.75	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY139LUK
2081	8976	NDAR_INVXY139LUK	2880			M	5800	EndofPhase2	2	Phase 2	67	1	0	1	0	0	0	0	5	4	5	3	4	4	4	1	0	0	0	9	0	2	4	3	2	5	6	4	4	1	1	1	1	1	1	0	0	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	0	2.7142856	5.5	3			3.75	3.875	0.75	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY139LUK
2081	8976	NDAR_INVXY139LUK	2880			M	6000	EndofPhase3	18	Phase 3	530	1	0	1	0	0	0	0	5	4	5	3	4	4	5	0	0	0	0	9	2	2	6	4	1	5	4	2	4	1	1	1	1	1	1	0	0	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.75	0	3	4.5	3			3.75	3.875	0.75	4.571429	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY139LUK
2081	8976	NDAR_INVXY472UVR	2309			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	3	3	3	3	3	2	6	4	0	6	5	6	4	5	6	5	5	4	4	1	1	1	1	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	4	4.857143	5	4.047619	1		4.047619	3.125	4	4.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY472UVR
2081	8976	NDAR_INVXY641YZD	1250			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	1	1	3	2	3	2	0	2	4	9	2	2	2	4	5	5	5	4	5	1	1	1	1	1	1	1	0	1	1	1	4	3	4	4	1	0	0	1	1	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	1.5	3.4285715	5	3	1		3	2.5	1.5	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY641YZD
2081	8976	NDAR_INVXY641YZD	1250			M	5200	EndofPhase1_1a	1	Phase 1/1A	9	1	0	1	0	0	0	0	5	2	1	1	3	2	3	3	0	2	4	9	2	2	2	4	5	5	5	4	5	1	1	1	1	1	1	1	2	1	1	1	4	3	4	4	1	0	0	1	1	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2.5	1.5	3.4285715	5	3		1	3	2.5	1.5	3.4285715	5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY641YZD
2081	8976	NDAR_INVXY641YZD	1250			M	5400	EndofPhase1b	2	Phase 1B	14	1	0	1	0	0	0	0	5	2	1	1	3	2	3	3	0	2	4	9	2	2	2	4	5	5	5	4	5	1	1	1	1	1	1	1	0	1	1	1	4	3	3	4	1	0	0	1	1	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	5	2.5	1.5	3.4285715	5	3			3	2.5	1.5	3.4285715	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY641YZD
2081	8976	NDAR_INVXY828FPT	1880			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	1	0	0	6	0	0	1	2	1	3	2	4	3	1	9	2	2	2	4	3	3	1	2	2	1	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.875	2	2.4285715	2	2.2	1		2.2	1.875	2	2.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY828FPT
2081	8976	NDAR_INVXY828FPT	1880			F	1600	Visit6	6	Phase 1/1A	162	1	0	0	1	0	0	0	4	2	3	2	2	2	2	1	3	2	2	3	2	2	2	3	3	3	2	2	2	1	0	1	0	1	1	1	1	1	2	1	3	2	3	3	1	1	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.25	2.5	2.2857144	2.5	2.3333333			2.2	1.875	2	2.4285715	2	0.13333334	0.375	0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY828FPT
2081	8976	NDAR_INVXY828FPT	1880			F	5200	EndofPhase1_1a	9	Phase 1/1A	245	1	0	0	0	0	0	0	2	2	2	2	2	2	3	0	2	3	3	9	3	3	4	3	3	4	3	2	4	1	0	1	0	1	1	1	1	3	2	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1.875	2	3.142857	3.5	2.6		1	2.2	1.875	2	2.4285715	2	0.4	0	0	0.71428573	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY828FPT
2081	8976	NDAR_INVXY858UYV	2753			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	1	2	1	2	1	2	4	1	2	2	9	3	0	4	1	2	2	0	5	5	0	0	1	0	1	0	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	2	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2.375	1.25	2.857143	1	2.3	1		2.3	2.375	1.25	2.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY858UYV
2081	8976	NDAR_INVXY858UYV	2753			M	1600	Visit6	6	Phase 2	168	1	0	1	0	0	0	0	6	5	4	1	3	1	3	1	0	0	0	9	2	2	2	5	0	2	3	3	2	0	0	1	0	1	0	0	1	1	2	1	4	4	4	4	1	0	1	0	0	0	0	0	0	2	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0	2.2857144	2.5	2.25			2.3	2.375	1.25	2.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY858UYV
2081	8976	NDAR_INVXY858UYV	2753			M	5200	EndofPhase1_1a	3	Phase 1/1A	86	1	0	0	0	0	0	0	6	2	2	2	2	2	5	2	1	1	1	9	0	1	1	6	3	1	1	3	4	0	0	1	0	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	3	2.875	0.75	2.5714285	1	2.3		1	2.3	2.375	1.25	2.857143	1	0	0.5	-0.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY858UYV
2081	8976	NDAR_INVXY858UYV	2753			M	5800	EndofPhase2	10	Phase 2	282	1	0	0	0	0	0	0	5	1	2	1	1	1	2	1	1	2	2	9	2	1	1	1	1	2	1	2	4	0	0	0	0	1	1	1	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	1	1	1	1	1	1	0	4	1.75	1.25	1.7142857	1.5	1.7			2.3	2.375	1.25	2.857143	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXY858UYV
2081	8976	NDAR_INVXZ398RJA	1945			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	4	2	3	2	2	1	6	5	5	4	4	4	2	4	6	4	3	4	4	1	1	0	0	1	1	1	1	1	1	0	4	3	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.5	5	4	3.5	3.5714285	1		3.5714285	2.5	5	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ398RJA
2081	8976	NDAR_INVXZ418ZBP	1143			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	1	1	0	2	0	1	0	0	0	0	9	3	3	5	3	1	2	3	5	6	1	0	1	1	1	1	0	1	2	1	1	3	1	1	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	6	1.25	0	3.7142856	2.5	2.05	1		2.05	1.25	0	3.7142856	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ418ZBP
2081	8976	NDAR_INVXZ418ZBP	1143			M	1600	Visit6	6	Phase 1/1A	170	1	0	0	0	0	0	0	6	3	3	3	6	3	3	3	5	5	5	5	5	5	4	5	5	4	3	5	6	1	1	1	1	1	0	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.75	5	5	3.5	4.3809524			2.05	1.25	0	3.7142856	2.5	2.3309524	2.5	5	1.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ418ZBP
2081	8976	NDAR_INVXZ418ZBP	1143			M	2800	Visit12	12	Phase 1/1A	345	1	0	0	0	0	0	0	6	2	2	3	4	4	4	4	6	6	6	6	6	6	6	6	6	5	4	6	6	1	1	0	1	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		2	2	2	1	0	0	0	0	0	0	0	0	1	1	1	1	7	3.625	6	6	4.5	4.952381			2.05	1.25	0	3.7142856	2.5	2.902381	2.375	6	2.2857144	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ418ZBP
2081	8976	NDAR_INVXZ418ZBP	1143			M	5200	EndofPhase1_1a	15	Phase 1/1A	408	1	0	0	0	0	0	0	5	2	0	4	5	4	5	5	4	5	5	6	4	5	5	5	5	4	4	5	5	0	1	1	0	1	0	1	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	3.75	5	4.857143	4	4.3809524		1	2.05	1.25	0	3.7142856	2.5	2.3309524	2.5	5	1.1428572	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ418ZBP
2081	8976	NDAR_INVXZ419RXZ	1594			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	3	0	4	5	4	2	0	3	3	4	6	3	4	3	4	1	5	4	5	6	1	1	1	1	1	0	1	1	2	1	1	3	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.875	4	3.7142856	4.5	3.5238094	1		3.5238094	2.875	4	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ419RXZ
2081	8976	NDAR_INVXZ419RXZ	1594			F	1600	Visit6	6	Phase 2	166	0	0	0	0	0	0	1	6	0	4	2	2	0	2	0	2	2	4	9	4	1	1	4	4	5	5	4	6	1	1	1	0	1	1	0	1	2	3	0	4	1	4	4	1	0	1	0	0	0	0	0	1	0	1	0	0		1	30	0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	2	2	3.4285715	5	2.9			3.5238094	2.875	4	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ419RXZ
2081	8976	NDAR_INVXZ419RXZ	1594			F	2800	Visit12	12	Phase 3	338	1	0	0	0	0	0	0	6	4	4	2	6	2	2	0	0	1	0	9	3	1	2	2	1	5	5	5	6	1	1	0	1	1	1	0	1	1	1	1	4	4	3	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	3.25	0.25	2.857143	5	2.85			3.5238094	2.875	4	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ419RXZ
2081	8976	NDAR_INVXZ419RXZ	1594			F	5200	EndofPhase1_1a	5	Phase 1/1A	133	0	0	0	0	0	0	1	6	5	4	4	6	4	3	0	3	3	5	4	1	2	4	2	5	5	5	5	6	1	1	1	1	1	1	1	1	2	2	1	2	1	4	4	1	0	0	0	0	1	1	0	1	0	0	0	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	2	4	3.75	3.5714285	5	3.9047618		1	3.5238094	2.875	4	3.7142856	4.5	0.3809524	1.125	-0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ419RXZ
2081	8976	NDAR_INVXZ419RXZ	1594			F	5800	EndofPhase2	11	Phase 2	287	0	0	0	0	0	0	1	5	4	5	3	6	2	2	1	3	3	4	0	3	5	4	6	4	5	6	5	5	1	1	2	1	1	1	0	1	1	1	1	4	2	2	4	1	0	1	1	1	0	0	0	1	1	1	0	0		1	17	1	13	0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	3.5	2.5	4.571429	5.5	3.857143			3.5238094	2.875	4	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ419RXZ
2081	8976	NDAR_INVXZ419RXZ	1594			F	6000	EndofPhase3	18	Phase 3	510	0	0	0	0	0	0	1	5	3	3	2	2	0	1	0	1	1	1	9	0	1	2	5	1	5	5	6	6	1	1	0	1	1	0	1	1	2	2	0	4	1	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	17	1	13	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.75	3	5	2.5			3.5238094	2.875	4	3.7142856	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ419RXZ
2081	8976	NDAR_INVXZ493DN1	2417			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	0	0	0	2	2	2	2	0	0	2	6	9	0	1	0	1	0	4	1	3	3	0	0	0	0	1	0	1	1	2	3	1	4	3	4	4	1	0	0	0	0	1	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1	2	1.1428572	2.5	1.45	1		1.45	1	2	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ493DN1
2081	8976	NDAR_INVXZ493DN1	2417			F	1600	Visit6	6	Phase 3	173	0	1	0	0	0	0	0	0	0	0	0	2	0	2	0	0	2	6	9	0	1	0	2	0	4	1	2	4	1	0	0	0	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	6	0.5	2	1.2857143	2.5	1.3			1.45	1	2	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ493DN1
2081	8976	NDAR_INVXZ493DN1	2417			F	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	6	9	0	1	0	1	0	4	1	3	3	0	0	0	0	1	1	1	1	2	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	2	0.25	2	1.1428572	2.5	1.15		1	1.45	1	2	1.1428572	2.5	-0.3	-0.75	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ493DN1
2081	8976	NDAR_INVXZ493DN1	2417			F	5800	EndofPhase2	5	Phase 2	141	0	0	0	0	0	1	0	0	0	0	2	2	0	2	0	0	2	6	9	0	2	0	2	0	4	2	2	4	1	0	0	0	1	1	0	1	2	3	0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0.75	2	1.4285715	3	1.5			1.45	1	2	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ493DN1
2081	8976	NDAR_INVXZ493DN1	2417			F	6000	EndofPhase3	11	Phase 3	307	0	0	0	0	0	1	0	0	0	0	1	2	0	2	0	0	2	6	9	0	2	0	3	0	4	2	3	6	1	0	0	0	1	1	1	1	3	2	0	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	5	0.625	2	2	3	1.65			1.45	1	2	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ493DN1
2081	8976	NDAR_INVXZ560ELT	1151			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	3	3	5	2	4	4	6	2	6	3	4	6	4	2	4	3	3	2	4	2	2	2	2	1	1	1	1	1	1	1	3	2	3	1	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	4	3.75	4.25	3.7142856	3	3.7619047	1		3.7619047	3.75	4.25	3.7142856	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ560ELT
2081	8976	NDAR_INVXZ560ELT	1151			M	1600	Visit6	6	Phase 1/1A	211	1	0	0	0	0	0	0	6	4	5	4	4	3	5	4	5	4	5	2	4	4	3	2	5	6	5	4	4	0	1	1	0	1	1	1	1	1	1	1	3	2	1	1	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5	4.375	4	3.7142856	5.5	4.1904764			3.7619047	3.75	4.25	3.7142856	3	0.42857143	0.625	-0.25	0	2.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ560ELT
2081	8976	NDAR_INVXZ560ELT	1151			M	2800	Visit12	12	Phase 1/1A	394	1	0	0	0	0	0	0	4	4	4	4	4	1	3	2	5	2	5	2	4	4	2	2	5	6	4	4	4	1	1	1	0	1	1	1	1	1	1	1	4	2	4	1	1	0	1	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	3.5	3.5714285	5	3.5714285			3.7619047	3.75	4.25	3.7142856	3	-0.1904762	-0.5	-0.75	-0.14285715	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ560ELT
2081	8976	NDAR_INVXZ560ELT	1151			M	4000	Visit18	18	Phase 1/1A	568	1	0	0	0	0	0	0	2	2	4	4	4	3	4	3	4	4	6	2	3	2	2	4	4	5	4	4	4	1	1	0	0	1	1	1	1	1	2	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.25	4	3.2857144	4.5	3.5238094		1	3.7619047	3.75	4.25	3.7142856	3	-0.23809524	-0.5	-0.25	-0.42857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ560ELT
2081	8976	NDAR_INVXZ661HM2	2587			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	5	5	5	5	4	3	6	6	6	5	6	3	4	2	4	6	5	3	6	6	1	0	1	0	1	1	1	1	1	1	1	4	1	3	1	1	1	0	1	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.875	5.75	4.428571	4	4.8095236	1		4.8095236	4.875	5.75	4.428571	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ661HM2
2081	8976	NDAR_INVXZ661HM2	2587			F	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	6	4	4	4	5	3	4	6	6	6	4	0	5	4	4	4	6	5	5	6	6	1	1	1	0	1	1	1	1	3		1	4	4	2	1	1	1	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	4.5	4	5	5	4.6190476			4.8095236	4.875	5.75	4.428571	4	-0.1904762	-0.375	-1.75	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ661HM2
2081	8976	NDAR_INVXZ661HM2	2587			F	2800	Visit12	12	Phase 1/1A	344	0	1	0	0	0	0	0	6	4	4	3	5	3	3	6	6	6	5	6	5	4	2	4	6	4	5	6	6	1	1	1	0	1	1	1	1	1	1	1	4	2	3	1	1	0	0	1	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	4.25	5.75	4.714286	4.5	4.714286			4.8095236	4.875	5.75	4.428571	4	-0.0952381	-0.625	0	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ661HM2
2081	8976	NDAR_INVXZ661HM2	2587			F	5200	EndofPhase1_1a	16	Phase 1/1A	442	0	1	0	0	0	0	0	6	4	4	2	3	2	4	5	6	6	5	6	4	3	3	6	6	4	5	6	6	1	1	1	1	1	0	1	1	1	1	1	4	1	3	1	1	1	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3.75	5.75	4.857143	4.5	4.571429		1	4.8095236	4.875	5.75	4.428571	4	-0.23809524	-1.125	0	0.42857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVXZ661HM2
2081	8976	NDAR_INVYA067HP5	2049			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	4	6	4	4	2	2	3	1	9	3	2	3	3	2	4	2	4	5	1	1	1	0	1	1	0	0	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	3	4.25	1.5	3.142857	3	3.4	1		3.4	4.25	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA067HP5
2081	8976	NDAR_INVYA067HP5	2049			M	1600	Visit6	6	Phase 3	176	0	0	0	0	0	0	1	6	4	4	2	3	2	2	2	1	2	0	9	3	2	4	2	2	6	3	4	5	1	1	1	0	1	1	0	1	3	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	3.125	0.75	3.142857	4.5	2.95			3.4	4.25	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA067HP5
2081	8976	NDAR_INVYA067HP5	2049			M	2800	Visit12	12	Phase 3	353	0	0	0	0	0	0	1	6	6	6	2	6	4	4	2	2	0	0	9	3	2	2	2	2	4	3	4	5	1	1	1	0	1	0	0	1	2	1	1	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	3	4.5	0.5	2.857143	3.5	3.25			3.4	4.25	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA067HP5
2081	8976	NDAR_INVYA067HP5	2049			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	0	0	0	0	0	0	1	6	2	4	4	4	2	2	0	1	2	1	9	2	2	2	4	2	4	3	3	3	1	1	1	0	1	0	0	1	2	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	3	3	1	2.5714285	3.5	2.65		1	3.4	4.25	1.5	3.142857	3	-0.75	-1.25	-0.5	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA067HP5
2081	8976	NDAR_INVYA067HP5	2049			M	5800	EndofPhase2	2	Phase 2	36	0	0	0	0	0	0	1	6	2	4	4	4	2	2	0	1	2	1	9	2	2	2	4	2	4	3	3	3	1	1	1	0	1	0	0	1	2	1	1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	3	3	1	2.5714285	3.5	2.65			3.4	4.25	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA067HP5
2081	8976	NDAR_INVYA067HP5	2049			M	6000	EndofPhase3	18	Phase 3	519	0	0	0	0	0	0	1	6	6	4	2	2	2	3	1	0	2	0	9	2	2	4	4	2	5	2	4	6	1	0	1	0	1	1	0	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	3.25	0.5	3.4285715	3.5	2.95			3.4	4.25	1.5	3.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA067HP5
2081	8976	NDAR_INVYA343DNP	1973			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	0	0	2	2	2	4	5	4	2	5	3	4	0	2	2	2	3	3	4	1	0	0	0	1	1	0	1	3		1	4	4	2	2	1	1	0	0	0	0	0	0	1	0	0	0	0		0		1	30	0		0		0	0	0	0	0	0	1	1	0	0	0	0	1	1	1	0	3	1.75	4	2.5714285	2.5	2.5238094	1		2.5238094	1.75	4	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA343DNP
2081	8976	NDAR_INVYA343DNP	1973			M	1600	Visit6	6	Phase 1/1A	180	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	2	2	1	9	2	2	0	2	2	2	1	0	4	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	1	1	1	1	4	0.375	1.25	1.7142857	1.5	1.15			2.5238094	1.75	4	2.5714285	2.5	-1.3738096	-1.375	-2.75	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA343DNP
2081	8976	NDAR_INVYA343DNP	1973			M	2800	Visit12	12	Phase 1/1A	339	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	2	2	1	9	2	2	0	2	2	3	1	0	4	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	4	0.375	1.25	1.7142857	2	1.2			2.5238094	1.75	4	2.5714285	2.5	-1.3238095	-1.375	-2.75	-0.85714287	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA343DNP
2081	8976	NDAR_INVYA343DNP	1973			M	4000	Visit18	18	Phase 1/1A	509	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	1	2	0	9	1	2	3	1	2	4	2	4	4	0	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	6	0.375	0.75	2.4285715	3	1.45		1	2.5238094	1.75	4	2.5714285	2.5	-1.0738095	-1.375	-3.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA343DNP
2081	8976	NDAR_INVYA403LF9	2647			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	5	2	2	3	5	0	4	4	4	4	4	5	5	5	5	5	3	5	3	1	1	1	0	1	1	1	1	2	1	1	4	2	2	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.857143	4	4.571429	4	3.8	1		3.8	2.857143	4	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA403LF9
2081	8976	NDAR_INVYA403LF9	2647			F	1600	Visit6	6	Phase 1/1A	190	0	0	0	0	0	0	1	3	1	4	2	3	1	3	2	0	4	5	9	3	0	1	2	1	5	3	4	6	1	1	1	0	1	1	1	1	3	3	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.375	2.25	2.4285715	4	2.65			3.8	2.857143	4	4.571429	4	-1.15	-0.48214287	-1.75	-2.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA403LF9
2081	8976	NDAR_INVYA403LF9	2647			F	2800	Visit12	12	Phase 2	373	0	0	0	0	0	0	1	9	3	2	2	2	3	5	1	0	3	1	9	3	2	4	4	2	6	4	4	4	1	1	1	0	1	1	1	1	3	1	1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5714285	1	3.2857144	5	2.8947368			3.8	2.857143	4	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA403LF9
2081	8976	NDAR_INVYA403LF9	2647			F	5200	EndofPhase1_1a	9	Phase 1/1A	276	0	0	0	0	0	0	1	9	2	2	0	4	2	3	2	1	3	1	9	3	2	4	2	1	4	2	5	5	1	1	1	0	1	0	1	1	3	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2.142857	1.25	3.142857	3	2.5263157		1	3.8	2.857143	4	4.571429	4	-1.2736843	-0.71428573	-2.75	-1.4285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA403LF9
2081	8976	NDAR_INVYA403LF9	2647			F	5800	EndofPhase2	14	Phase 2	424	0	0	0	0	0	0	1	5	4	5	4	5	6	5	0	0	0	1	9	0	1	3	1	1	5	2	5	5	1	1	1	0	1	0	1	1	3		1	3	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4.25	0.25	2.2857144	3.5	2.9			3.8	2.857143	4	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA403LF9
2081	8976	NDAR_INVYA403LF9	2647			F	6000	EndofPhase3	15	Phase 3	450	0	0	0	0	0	0	1	3	4	4	1	4	2	3	0	0	1	1	9	0	2	1	1	1	5	2	4	5	1	1	1	0	1	1	1	1	3	2	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	3	2.625	0.5	2	3.5	2.2			3.8	2.857143	4	4.571429	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA403LF9
2081	8976	NDAR_INVYA994XHT	2658			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	4	5	4	4	3	4	1	5	4	2	9	3	3	4	4	5	6	4	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	3	4	1	0	0	0	1	0	1	0	1	1	1	0	1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	2.75	4.142857	5	4.05	1		4.05	3.875	2.75	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA994XHT
2081	8976	NDAR_INVYA994XHT	2658			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	1	0	0	0	4	3	4	3	4	3	4	1	5	3	2	9	3	3	4	4	4	6	4	4	4	1	1	1	0	1	1	1	1	1	1	1	3	2	3	4	1	0	0	0	1	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	2.5	3.7142856	5	3.6			4.05	3.875	2.75	4.142857	5	-0.45	-0.625	-0.25	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA994XHT
2081	8976	NDAR_INVYA994XHT	2658			F	2800	Visit12	12	Phase 1/1A	344	0	0	0	1	0	0	0	6	4	5	4	4	3	4	1	5	4	2	9	3	3	4	4	5	6	4	5	5	1	1	1	0	1	1	1	1	2	2	1	4	3	3	4	1	0	0	0	1	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.875	2.75	4.142857	5	4.05		1	4.05	3.875	2.75	4.142857	5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA994XHT
2081	8976	NDAR_INVYA994XHT	2658			F	5800	EndofPhase2	18	Phase 2	517	0	0	0	1	0	0	0	4	4	4	2	5	3	4	1	5	4	2	9	3	3	4	4	5	6	4	5	5	1	1	0	1	1	1	1	1	1	2	1	3	2	3	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.375	2.75	4.142857	5	3.85			4.05	3.875	2.75	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYA994XHT
2081	8976	NDAR_INVYB087YTU	1683			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	2	3	2	2	0	0	0	0	9	2	2	1	3	2	4	4	3	3	2	1	2	0	1	2	2	1	3	2	0	4	3	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.375	0	2.2857144	4	1.75	1		1.75	1.375	0	2.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB087YTU
2081	8976	NDAR_INVYB087YTU	1683			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	1	0	0	6	5	5	5	4	3	2	0	0	0	9	1	3	3	3	2	4	1	3	4	0	0	0	1	0	1	0	1	3		1	4	3	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	3.75	0	2.7142856	2.5	2.7			1.75	1.375	0	2.2857144	4	0.95	2.375	0	0.42857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB087YTU
2081	8976	NDAR_INVYB087YTU	1683			M	2800	Visit12	12	Phase 1/1A	387	0	0	0	0	0	1	0	1	0	2	2	2	1	2	1	0	0	0	1	1	1	1	1	0	2	2	2	3	2	2	2	1	1	1	2	2	3	3	0	4	4	4	4	1	0	0	1	1	0	0	0	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.375	0.25	1.2857143	2	1.1904762			1.75	1.375	0	2.2857144	4	-0.5595238	0	0.25	-1	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB087YTU
2081	8976	NDAR_INVYB087YTU	1683			M	5200	EndofPhase1_1a	18	Phase 1/1A	558	0	0	0	0	0	1	0	1	0	2	2	2	1	2	1	1	0	0	9	0	1	2	1	0	2	2	2	2	2	2	2	1	1	1	2	2	3	3	0	4	4	4	4	1	0	0	1	1	0	0	0	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.375	0.25	1.1428572	2	1.2		1	1.75	1.375	0	2.2857144	4	-0.55	0	0.25	-1.1428572	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB087YTU
2081	8976	NDAR_INVYB380LYZ	1962			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	0	0	1	1	1	2	0	0	0	9	2	0	3	2	1	1	1	2	2	2	2	2	2	1	2	1	2	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	4	0.75	0	1.7142857	1	1	1		1	0.75	0	1.7142857	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB380LYZ
2081	8976	NDAR_INVYB394WDJ	1260			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	1	4	4	3	3	5	5	4	0	0	0	9	2	2	2	4	2	1	1	0	4	1	0	1	0	1	1	0	1	3	2	1	4	4	4	1	0	0	0	0	0	0	0	1	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	6	3.625	0	2.2857144	1	2.35	1		2.35	3.625	0	2.2857144	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB394WDJ
2081	8976	NDAR_INVYB693UTW	1110			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	3	0	2	2	2	2	3	2	5	4	2	6	1	4	2	3	5	6	2	5	4	0	1	1	0	1	1	1	1	1	1	1	2	1	1	4	1	0	0	1	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	2	4.25	3.4285715	4	3.0952382	1		3.0952382	2	4.25	3.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB693UTW
2081	8976	NDAR_INVYB693UTW	1110			M	5200	EndofPhase1_1a	1	Phase 1/1A	17	0	0	1	0	0	0	0	6	4	2	2	2	2	5	2	4	4	6	4	0	4	2	5	4	4	3	4	5	1	1	1	0	1	1	1	1	1	1	0	4	2	4	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	3.125	4.5	3.4285715	3.5	3.5238094		1	3.0952382	2	4.25	3.4285715	4	0.42857143	1.125	0.25	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYB693UTW
2081	8976	NDAR_INVYD654DNE	2450			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	2	3	2	5	2	0	0	0	0	9	0	0	0	4	0	1	2	0	3	0	1	0	0	0	0	0	0	3		0	4	2	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		1	20	1	5	1	5	0		2	2	2	0	0	0	0	1	0	1	1	1	1	0	1	1	3	1.75	0	1	1.5	1.2	1		1.2	1.75	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYD654DNE
2081	8976	NDAR_INVYD654DNE	2450			M	5200	EndofPhase1_1a	3	Phase 1/1A	84	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9	0	0	0	2	1	1	1	0	2	0	0	0	0	1	2	2	2	3		0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	0	0		1	15	0		1	15	0		0	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0	2	0	0	0.71428573	1	0.35		1	1.2	1.75	0	1	1.5	-0.85	-1.75	0	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYD654DNE
2081	8976	NDAR_INVYD724AHZ	1225			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	0	2	4	2	2	4	0	4	2	2	9	4	2	2	6	2	5	3	4	6	1	1	1	1	1	1	0	1	1	2	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	5	2.25	2	3.7142856	4	3	1		3	2.25	2	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYD724AHZ
2081	8976	NDAR_INVYE038KR1	1881			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	2	2	3	5	4	6	6	6	4	6	6	6	6	6	6	6	6	4	5	6	0	0	1	1	1	0	1	1	1	1	1	4	2	3	1	0	0	0	0	0	0	0	0					1	26	0		0		1	4	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	4.25	5.5	5.857143	5	5.095238	1		5.095238	4.25	5.5	5.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE038KR1
2081	8976	NDAR_INVYE038KR1	1881			M	1600	Visit6	6	Phase 2	171	0	1	0	1	0	0	0	6	2	0	3	3	2	3	6	2	3	3	9	0	2	0	6	2	6	4	5	4	1	1	1	0	1	0	1	1	1	1	0	4	3	2	1	1	1	0	0	1	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.125	2	2.7142856	5	3.1			5.095238	4.25	5.5	5.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE038KR1
2081	8976	NDAR_INVYE038KR1	1881			M	2800	Visit12	12	Phase 2	342	0	1	0	1	0	0	0	6	6	5	4	5	4	6	6	6	4	6	6	4	4	0	6	4	6	3	5	4	1	1	1	0	1	0	1	1	1	1	1	3	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	5.25	5.5	3.857143	4.5	4.7619047			5.095238	4.25	5.5	5.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE038KR1
2081	8976	NDAR_INVYE038KR1	1881			M	5200	EndofPhase1_1a	2	Phase 1/1A	62	0	1	0	1	0	0	0	6	0	4	4	2	0	6	4	1	4	2	9	2	4	4	6	0	6	4	6	6	1	0	1	1	1	0	1	1	1	1	1	4	3	3	1	1	1	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	1.75	4	5	3.55		1	5.095238	4.25	5.5	5.857143	5	-1.5452381	-1	-3.75	-1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE038KR1
2081	8976	NDAR_INVYE038KR1	1881			M	5800	EndofPhase2	15	Phase 2	426	0	1	0	1	0	0	0	3	1	2	2	6	2	6	4	1	3	2	9	3	0	0	4	1	6	2	6	4	1	0	1	0	1	1	1	1	1	1	1	4	4	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.25	1.5	2.5714285	4	2.9			5.095238	4.25	5.5	5.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE038KR1
2081	8976	NDAR_INVYE038KR1	1881			M	6000	EndofPhase3	18	Phase 3	513	0	1	0	1	0	0	0	4	4	4	2	4	3	4	3	6	4	6	6	3	3	0	6	6	6	3	4	4	1	0	1	1	1	0	1	1	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.5	5.5	3.7142856	4.5	4.047619			5.095238	4.25	5.5	5.857143	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE038KR1
2081	8976	NDAR_INVYE479NCG	1243			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	2	2	4	6	1	2	0	2	1	1	9	4	3	2	5	4	6	4	6	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	1	4.142857	5	3.3	1		3.3	2.875	1	4.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE479NCG
2081	8976	NDAR_INVYE479NCG	1243			M	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	0	1	0	0	0	0	2	2	1	2	2	0	2	0	1	0	0	9	0	4	1	1	1	6	2	2	4	1	1	0	0	1	0	0	0	1	3	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1.375	0.25	1.8571428	4	1.65		1	3.3	2.875	1	4.142857	5	-1.65	-1.5	-0.75	-2.2857144	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE479NCG
2081	8976	NDAR_INVYE536UAJ	2756			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	2	3	3	3	3	3	4	3	2	2	9	3	3	3	3	2	5	3	4	3	0	0	2	1	1	1	2	2	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1		0		0		1		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	1.75	3	4	3.05	1		3.05	3.125	1.75	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE536UAJ
2081	8976	NDAR_INVYE536UAJ	2756			M	1600	Visit6	6	Phase 1/1A	182	0	1	0	0	0	0	0	3	3	2	3	3	2	3	4	2	2	2	9	2	2	3	2	2	4	2	3	3	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	2.875	1.5	2.4285715	3	2.6			3.05	3.125	1.75	3	4	-0.45	-0.25	-0.25	-0.5714286	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE536UAJ
2081	8976	NDAR_INVYE536UAJ	2756			M	2800	Visit12	12	Phase 1/1A	360	0	1	0	0	0	0	0	3	2	2	2	1	2	2	2	2	2	2	9	2	2	2	2	2	4	3	3	3	1	0	0	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	2	1.5	2.2857144	3.5	2.25			3.05	3.125	1.75	3	4	-0.8	-1.125	-0.25	-0.71428573	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE536UAJ
2081	8976	NDAR_INVYE536UAJ	2756			M	5200	EndofPhase1_1a	17	Phase 1/1A	500	0	1	0	0	0	0	0	2	2	2	2	2	2	2	3	2	2	2	9	2	2	2	2	2	3	3	2	3	1	1	1	0	1	1	1	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	25	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.125	1.5	2.142857	3	2.2		1	3.05	3.125	1.75	3	4	-0.85	-1	-0.25	-0.85714287	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYE536UAJ
2081	8976	NDAR_INVYG383FDB	1943			F	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	0	0	0	0	0	6	0	1	2	2	9	3	2	2	4	1	2	2	6	5	1	1	1	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	6	1.5	1.25	3.2857144	2	2.2	1		2.2	1.5	1.25	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYG383FDB
2081	8976	NDAR_INVYG383FDB	1943			F	1600	Visit6	6	Phase 2	191	1	0	0	0	0	0	0	6	0	0	0	5	0	2	0	5	4	5	5	4	5	1	4	4	4	2	4	4	0	1	1	1	1	1	1	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	1	20	0		1	8	0		0		0	1	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.625	4.75	3.7142856	3	3.047619			2.2	1.5	1.25	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYG383FDB
2081	8976	NDAR_INVYG383FDB	1943			F	2800	Visit12	12	Phase 2	366	1	0	0	0	0	0	0	5	1	1	2	5	1	3	0	3	3	3	4	4	4	1	4	3	4	3	4	4	1	1	1	0	1	1	1	1	2	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	1	0	0	1	0	0	0	0	0	0	0	1	1	1	1	5	2.25	3.25	3.4285715	3.5	2.952381			2.2	1.5	1.25	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYG383FDB
2081	8976	NDAR_INVYG383FDB	1943			F	5200	EndofPhase1_1a	2	Phase 1/1A	62	1	0	1	0	0	0	0	3	0	4	2	2	2	4	1	1	5	5	9	4	2	0	2	1	3	3	2	2	0	0	0	1	1	0	0	0	2	1	0	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	26	0		0		1	4	0		0	1	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	2.25	2.75	1.8571428	3	2.4		1	2.2	1.5	1.25	3.2857144	2	0.2	0.75	1.5	-1.4285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYG383FDB
2081	8976	NDAR_INVYG383FDB	1943			F	5800	EndofPhase2	13	Phase 2	393	1	0	0	0	0	0	0	5	3	2	3	5	3	4	1	3	3	3	4	4	4	3	4	4	5	4	4	4	1	1	1	1	1	1	1	1	1	1	1	3	1	2	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	3.25	3.25	3.857143	4.5	3.5714285			2.2	1.5	1.25	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYG383FDB
2081	8976	NDAR_INVYG383FDB	1943			F	6000	EndofPhase3	18	Phase 3	569	0	0	0	0	0	0	1	5	4	3	5	5	4	5	0	5	4	4	5	5	5	4	4	5	5	4	4	5	1	1	1	1	1	1	1	1	2	1	1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	4.5	4.571429	4.5	4.285714			2.2	1.5	1.25	3.2857144	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYG383FDB
2081	8976	NDAR_INVYH349AMR	2453			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	6	4	4	4	1	2	6	3	2	4	9	4	3	5	4	3	4	3	6	6	0	0	0	1	0	1	0	1	1	1	1	3	2	4	4	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	4.125	2.25	4.428571	3.5	4	1		4	4.125	2.25	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYH349AMR
2081	8976	NDAR_INVYH349AMR	2453			M	5200	EndofPhase1_1a	6	Phase 1/1A	174	0	1	0	0	0	0	0	6	6	6	6	6	6	6	6	6	4	4	9	5	5	6	6	5	4	2	6	6	0	0	0	1	1	1	0	1	1	1	1	3	1	2		1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	6	3.5	5.571429	3	5.35		1	4	4.125	2.25	4.428571	3.5	1.35	1.875	1.25	1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYH349AMR
2081	8976	NDAR_INVYH938UUA	1356			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	2	0	2	0	2	1	2	1	2	2	9	6	2	3	4	4	3	3	4	6	1	1	1	1	1	1	1	1	3		1	4	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	5	1.125	1.25	4.142857	3	2.45	1		2.45	1.125	1.25	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYH938UUA
2081	8976	NDAR_INVYH938UUA	1356			M	1600	Visit6	6	Phase 1/1A	176	0	0	0	0	0	0	1	0	1	0	0	0	0	1	3	0	0	1	9	3	1	3	2	1	3	1	5	6	0	0	0	0	1	2	0	2	3	3	1	3	4	4	4	1	0	0	0	0	1	0	0	1	1	1	0	0		0		0		1	30	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	5	0.625	0.25	3	2	1.55			2.45	1.125	1.25	4.142857	3	-0.9	-0.5	-1	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYH938UUA
2081	8976	NDAR_INVYH938UUA	1356			M	2800	Visit12	12	Phase 1/1A	338	0	0	0	0	0	1	0	6	5	2	2	1	0	1	2	3	2	3	2	1	2	2	1	2	4	2	6	6	1	0	1	0	1	1	0	1	3		1	4	2	4	4	1	0	0	0	0	0	0	1	1	0	1	0	1	30	0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	0	4	2.375	2.5	2.857143	3	2.6190476		1	2.45	1.125	1.25	4.142857	3	0.16904762	1.25	1.25	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYH938UUA
2081	8976	NDAR_INVYJ068NM9	2288			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	2	2	4	2	3	2	2	1	1	9	3	3	4	3	2	5	1	4	4	2	2	2	2	1	2	2	2	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	16	0		1	14	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.625	1	3.2857144	3	2.7	1		2.7	2.625	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ068NM9
2081	8976	NDAR_INVYJ068NM9	2288			M	5200	EndofPhase1_1a	2	Phase 1/1A	49	0	0	0	0	0	0	1	9	3	4	3	4	3	3	1	3	3	2	3	1	1	1	2	2	5	1	4	4	2	2	2	1	1	2	2	2	2	1	1	4	2	2	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	3	2.75	2.142857	3	2.65		1	2.7	2.625	1	3.2857144	3	-0.05	0.375	1.75	-1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ068NM9
2081	8976	NDAR_INVYJ068NM9	2288			M	5800	EndofPhase2	2	Phase 2	86	1	0	0	0	0	0	0	4	3	4	4	4	3	3	1	3	1	2	1	1	2	2	2	2	5	3	4	4	0	1	2	0	1	1	0	1	1	1	0	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	2	1	8	0		1	22	0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	3.25	1.75	2.4285715	4	2.7619047			2.7	2.625	1	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ068NM9
2081	8976	NDAR_INVYJ087RDW	2300			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	2	4	4	6	3	1	2	4	9	6	4	6	6	6	6	4	5	6	0	0	1	1	1	1	1	1	1	1	1	4	2	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	4.125	1.75	5.571429	5	4.45	1		4.45	4.125	1.75	5.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ087RDW
2081	8976	NDAR_INVYJ087RDW	2300			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	6	0	2	5	4	0	6	1	0	1	1	9	5	6	4	6	6	5	4	5	6	1	1	1	1	1	1	0	1	1	1	0	4	4	4	4	1	0	1	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	3	0.5	5.428571	4.5	3.65			4.45	4.125	1.75	5.571429	5	-0.8	-1.125	-1.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ087RDW
2081	8976	NDAR_INVYJ087RDW	2300			M	2800	Visit12	12	Phase 1/1A	336	1	0	0	0	0	0	0	6	1	3	2	3	2	6	3	3	4	6	9	3	6	4	6	6	6	3	5	6	1	1	1	1	1	1	1	1	1	1	0	4	1	3	2	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.25	3.25	5.142857	4.5	4.2			4.45	4.125	1.75	5.571429	5	-0.25	-0.875	1.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ087RDW
2081	8976	NDAR_INVYJ087RDW	2300			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	1	0	0	0	0	0	0	6	6	5	6	5	5	5	4	1	4	3	9	5	6	5	6	4	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	1	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	6	5.25	2	5.428571	5.5	4.95		1	4.45	4.125	1.75	5.571429	5	0.5	1.125	0.25	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ087RDW
2081	8976	NDAR_INVYJ090NRQ	1626			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	0	0	2	2	2	2	3	5	2	6	4	3	2	3	4	4	6	4	4	2	1	1	1	0	1	1	1	1	1	1	0	4	4	3	1	1	1	0	0	0	0	0	0	1	1	0	0	1		0		0		0		0		0	0	0	1					0	0	0	0	1	1	1	1	5	2	4.25	3.142857	5	3.0952382	1		3.0952382	2	4.25	3.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ090NRQ
2081	8976	NDAR_INVYJ090NRQ	1626			M	1600	Visit6	6	Phase 2	181	0	1	0	1	0	0	0	6	6	4	2	2	3	6	5	4	5	5	6	4	4	2	5	5	6	2	4	5	1	1	1	0	1	1	1	1	1	1	1	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	5	4.142857	4	4.3333335			3.0952382	2	4.25	3.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ090NRQ
2081	8976	NDAR_INVYJ090NRQ	1626			M	2800	Visit12	12	Phase 2	386	0	1	0	1	0	0	0	4	5	4	2	4	2	4	4	6	4	6	4	5	4	2	4	5	6	5	4	4	1	1	1	0	1	1	1	1	1	1	0	4	2	2	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.625	5	4	5.5	4.1904764			3.0952382	2	4.25	3.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ090NRQ
2081	8976	NDAR_INVYJ090NRQ	1626			M	4000	Visit18	18	Phase 2	554	0	1	0	0	0	0	0	6	6	2	2	2	1	4	4	6	4	6	6	5	4	4	5	6	6	6	5	3	1	1	1	0	1	1	1	1	1	1	0	4	4	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	3.375	5.5	4.571429	6	4.428571			3.0952382	2	4.25	3.142857	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ090NRQ
2081	8976	NDAR_INVYJ090NRQ	1626			M	5200	EndofPhase1_1a	4	Phase 1/1A	111	0	1	0	0	0	0	0	4	0	2	2	0	2	2	4	4	3	6	4	3	4	2	4	4	6	5	4	3	1	1	1	0	1	1	1	1	1	1	0	4	3	4	4	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	1	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2	4.25	3.4285715	5.5	3.2380953		1	3.0952382	2	4.25	3.142857	5	0.14285715	0	0	0.2857143	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ090NRQ
2081	8976	NDAR_INVYJ108JZB	1651			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	2	2	4	3	2	4	3	0	3	2	9	4	4	0	0	2	4	3	4	5	1	2	1	0	1	1	1	1	1	1	1	4	3	3	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		1	2	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.125	1.25	2.7142856	3.5	2.8	1		2.8	3.125	1.25	2.7142856	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYJ108JZB
2081	8976	NDAR_INVYK381JU2	2395			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	5	4	4	4	4	4	2	0	1	1	9	1	3	1	4	1	1	1	4	4	0	1	1	0	1	1	0	1	1	2	1	4	3	3	3	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.125	0.5	2.5714285	1	2.75	1		2.75	4.125	0.5	2.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYK381JU2
2081	8976	NDAR_INVYK381JU2	2395			M	1600	Visit6	6	Phase 1/1A	173	1	0	0	0	0	0	0	6	6	6	5	6	3	4	1	2	1	1	9	1	2	3	4	2	1	2	2	4	0	1	0	0	0	1	0	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.625	1	2.5714285	1.5	3.1			2.75	4.125	0.5	2.5714285	1	0.35	0.5	0.5	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYK381JU2
2081	8976	NDAR_INVYK381JU2	2395			M	5200	EndofPhase1_1a	8	Phase 1/1A	227	1	0	0	0	0	0	0	6	4	3	3	3	1	3	1	1	2	3	9	2	3	3	3	1	1	0	4	4	0	0	0	0	1	0	0	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	1.5	2.857143	0.5	2.55		1	2.75	4.125	0.5	2.5714285	1	-0.2	-1.125	1	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYK381JU2
2081	8976	NDAR_INVYK747DF1	1300			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	0	4	4	3	4	2	3	3	1	0	1	1	9	1	2	3	3	2	4	3	3	2	1	1	2	1	1	1	1	2	2	1	1	2	1	2	1	1	0	1	0	0	0	0	0	0	1	0	0	1	13	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	0	1	1	1	0	6	3	0.5	2.2857144	3.5	2.45	1		2.45	3	0.5	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYK747DF1
2081	8976	NDAR_INVYK747DF1	1300			M	5200	EndofPhase1_1a	1	Phase 1/1A	14	0	0	0	0	0	0	0	4	4	3	4	2	3	3	1	0	1	1	9	1	2	3	3	2	4	3	3	2	1	1	2	1	1	1	1	2	2	1	1	2	1	2	1	1	0	1	0	0	0	0	0	0	1	0	0	0		0		0		1	30	0		0	0	0	0	0	0	1	0	0	0	1	0	1	1	1	0	5	3	0.5	2.2857144	3.5	2.45		1	2.45	3	0.5	2.2857144	3.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYK747DF1
2081	8976	NDAR_INVYK747DF1	1300			M	5800	EndofPhase2	2	Phase 2	46	0	0	0	0	0	1	0	4	1	4	4	4	3	4	2	3	4	3	4	2	4	0	2	6	5	3	3	3	1	1	2	1	1	1	1	2	2	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	1	1	0	0		0		0		1	30	0		2	0	1	0	1	0	1	0	0	0	0	0	1	1	0	0	6	3.25	3.5	2.857143	4	3.2380953			2.45	3	0.5	2.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYK747DF1
2081	8976	NDAR_INVYL125WYU	2484			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	3	2	0	2	1	2	4	6	4	6	4	2	4	4	4	2	6	6	4	5	1	1	1	1	1	1	1	1	3	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	1	1	1	1	0	0	0	0	0	1	1	1	1	5	2.25	5	3.5714285	6	3.5714285	1		3.5714285	2.25	5	3.5714285	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL125WYU
2081	8976	NDAR_INVYL125WYU	2484			M	5200	EndofPhase1_1a	2	Phase 1/1A	81	0	0	0	0	0	0	1	4	4	2	1	3	1	2	3	5	3	5	9	2	3	3	2	2	6	6	4	4	1	1	1	1	1	1	1	1	3	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	1	1	1	1	0	0	0	0	0	1	1	1	1	4	2.5	3.25	2.857143	6	3.25		1	3.5714285	2.25	5	3.5714285	6	-0.32142857	0.25	-1.75	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL125WYU
2081	8976	NDAR_INVYL125WYU	2484			M	5400	EndofPhase1b	6	Phase 1B	186	0	1	0	0	0	0	0	4	4	2	1	3	1	2	3	5	3	5	9	2	3	3	2	2	6	6	4	4	1	1	1	1	1	1	1	1	3	2	1	4	3	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	1	1	1	1	0	0	0	0	0	1	1	1	1	4	2.5	3.25	2.857143	6	3.25			3.5714285	2.25	5	3.5714285	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL125WYU
2081	8976	NDAR_INVYL522DTK	2180			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	2	0	1	3	1	1	1	2	3	4	9	2	0	3	2	5	5	3	5	4	1	0	1	0	0	0	0	1	3		1	4	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	1.125	2.25	3	4	2.35	1		2.35	1.125	2.25	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL522DTK
2081	8976	NDAR_INVYL522DTK	2180			M	1600	Visit6	6	Phase 1/1A	155	0	0	0	0	0	0	1	9	4	6	6	6	4	6	1	1	1	1	9	2	2	4	4	1	5	3	4	4	1	1	1	1	1	1	0	1	2	1	1	3	2	2	4	1	0	0	1	0	1	0	0	2	2	2	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.714286	0.75	3	4	3.4210527			2.35	1.125	2.25	3	4	1.0710527	3.5892856	-1.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL522DTK
2081	8976	NDAR_INVYL522DTK	2180			M	2800	Visit12	12	Phase 2	354	0	0	0	0	0	0	1	9	2	2	2	2	2	3	1	3	3	1	2	3	2	3	3	2	4	2	4	3	1	1	1	1	0	1	1	1	3	3	1	3	2	2	4	1	0	0	1	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	5	2	2.25	2.857143	3	2.45			2.35	1.125	2.25	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL522DTK
2081	8976	NDAR_INVYL522DTK	2180			M	4000	Visit18	18	Phase 3	549	0	0	0	0	0	0	1	9	2	1	1	2	2	2	1	2	1	1	9	2	2	3	2	1	4	2	3	3	1	0	1	1	0	0	0	1	3		1	4	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	1.5714285	1	2.2857144	3	1.9473684			2.35	1.125	2.25	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL522DTK
2081	8976	NDAR_INVYL522DTK	2180			M	5200	EndofPhase1_1a	7	Phase 1/1A	192	0	0	0	0	0	0	1	9	2	2	2	2	2	3	1	1	1	1	9	3	2	3	3	1	5	2	3	4	1	1	1	1	1	1	0	1	2	1	1	3	2	2	4	1	0	0	1	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2	0.75	2.7142856	3.5	2.2631578		1	2.35	1.125	2.25	3	4	-0.086842105	0.875	-1.5	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL522DTK
2081	8976	NDAR_INVYL522DTK	2180			M	5800	EndofPhase2	16	Phase 2	481	0	0	0	0	0	0	1	9	3	2	2	2	3	3	1	3	3	1	2	3	2	4	3	3	6	3	4	3	1	1	1	1	0	0	0	1	3	2	1	3	2	3	4	1	0	0	1	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	1	4	2.2857144	2.25	3.142857	4.5	2.8			2.35	1.125	2.25	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL522DTK
2081	8976	NDAR_INVYL820KJT	1413			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	6	6	5	6	3	6	0	2	4	5	9	0	4	1	6	2	3	2	6	6	1	1	1	0	1	1	1	1	1	1	1	2	2	4	4	1	0	0	1	0	0	0	0	1	0	1	0	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	4.75	2.75	3.5714285	2.5	3.95	1		3.95	4.75	2.75	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL820KJT
2081	8976	NDAR_INVYL820KJT	1413			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	6	4	4	4	6	6	6	0					4	5	3	6	6			5	6	1	1	1	0	1	1	1	1	2	1	1	3	1	2	4	1	0	0	1	0	0	0	0	1	0	1	0											0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	5	4.5		5					3.95	4.75	2.75	3.5714285	2.5		-0.25		1.4285715																																																																																																																						Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL820KJT
2081	8976	NDAR_INVYL820KJT	1413			F	2800	Visit12	12	Phase 1/1A	336	0	0	0	0	0	0	1	6	6	1	6	4	5	6	2	0	0	1	9	3	2	0	6	6	4	3	6	6	1	1	1	0	1	1	1	1	2	1	1	2	1	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	5	4.5	0.25	4.142857	3.5	3.65			3.95	4.75	2.75	3.5714285	2.5	-0.3	-0.25	-2.5	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL820KJT
2081	8976	NDAR_INVYL820KJT	1413			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	6	6	6	6	6	6	6	0	0	0	0	9	0	2	2	6	6	4	4	5	6	1	1	1	0	1	1	1	1	2	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	5.25	0	3.857143	4	3.85		1	3.95	4.75	2.75	3.5714285	2.5	-0.1	0.5	-2.75	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYL820KJT
2081	8976	NDAR_INVYM059HFY	1006			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	0	0	2	0	0	4	2	3	3	9	0	3	6	4	0	5	3	4	4	1	0	1	0	1	0	0	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	1.5	2	3	4	2.45	1		2.45	1.5	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM059HFY
2081	8976	NDAR_INVYM059HFY	1006			M	1600	Visit6	6	Phase 1/1A	175	0	1	0	1	0	0	0	6	0	0	2	2	2	2	6	2	2	1	9	3	6	5	6	5	6	3	6	5	1	0	1	0	1	1	0	1	1	2	0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.5	1.25	5.142857	4.5	3.5			2.45	1.5	2	3	4	1.05	1	-0.75	2.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM059HFY
2081	8976	NDAR_INVYM059HFY	1006			M	2800	Visit12	12	Phase 1B	343	0	1	0	1	0	0	0	6	0	0	2	2	0	0	4	1	2	4	9	2	2	6	4	4	5	2	2	5	0	0	1	0	1	1	0	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	1.75	1.75	3.5714285	3.5	2.65			2.45	1.5	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM059HFY
2081	8976	NDAR_INVYM059HFY	1006			M	5200	EndofPhase1_1a	8	Phase 1/1A	218	0	1	0	1	0	0	0	6	0	4	1	2	2	0	3	1	2	3	9	2	0	0	0	0	4	1	2	2	0	0	0	0	1	0	0	0	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	3	2.25	1.5	0.85714287	2.5	1.75		1	2.45	1.5	2	3	4	-0.7	0.75	-0.5	-2.142857	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM059HFY
2081	8976	NDAR_INVYM059HFY	1006			M	5400	EndofPhase1b	18	Phase 1B	503	0	1	0	0	0	0	0	5	1	0	2	2	1	1	1	5	4	1	5	2	4	4	3	5	5	3	2	5	1	0	1	0	1	0	0	1	1	2	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	3.75	3.5714285	4	2.9047618			2.45	1.5	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM059HFY
2081	8976	NDAR_INVYM362BU4	1686			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	5	0	0	2	4	3	5	4	0	0	2	9	2	3	2	4	2	5	4	4	4	1	1	1	1	1	1	1	1	2	2	1	3	2	4	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.875	0.5	3	4.5	2.75	1		2.75	2.875	0.5	3	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM362BU4
2081	8976	NDAR_INVYM362BU4	1686			M	1600	Visit6	6	Phase 1/1A	176	0	1	0	0	0	0	0	5	1	2	2	2	3	3	4	0	1	5	9	2	2	1	4	1	5	4	1	5	1	0	1	0	1	0	1	1	2	1	0	4	2	4	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.75	1.5	2.2857144	4.5	2.65			2.75	2.875	0.5	3	4.5	-0.1	-0.125	1	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM362BU4
2081	8976	NDAR_INVYM362BU4	1686			M	2800	Visit12	12	Phase 1/1A	355	0	1	0	0	0	0	0	4	2	0	2	2	3	3	4	1	0	1	9	2	2	0	4	2	5	4	4	4	1	1	1	0	1	1	1	1	2	2	1	4	2	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	2.5	0.5	2.5714285	4.5	2.45			2.75	2.875	0.5	3	4.5	-0.3	-0.375	0	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM362BU4
2081	8976	NDAR_INVYM362BU4	1686			M	4000	Visit18	18	Phase 1/1A	549	0	1	0	0	0	0	0	5	2	2	3	2	3	4	4	2	1	1	9	2	2	2	4	2	4	3	4	5	1	0	1	1	1	1	1	1	3		1	4	2	3	1	1	1	0	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.125	1	3	3.5	2.85		1	2.75	2.875	0.5	3	4.5	0.1	0.25	0.5	0	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM362BU4
2081	8976	NDAR_INVYM492GB6	1551			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	4	2	2	2	3	1	2	0	5	3	5	3	1	2	3	2	4	4	4	5	4	1	1	1	0	1	2	1	1	1	1	0	4	1	4	4	1	0	1	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	3	2	4	3	4	2.9047618	1		2.9047618	2	4	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM492GB6
2081	8976	NDAR_INVYM492GB6	1551			M	1600	Visit6	6	Phase 1/1A	173	1	0	0	0	0	0	0	2	0	0	0	0	2	2	0	6	2	6	6	4	3	4	2	2	2	3	4	4	1	0	0	0	1	0	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	1	0	1	1	1	1	2	0.75	5	3.2857144	2.5	2.5714285			2.9047618	2	4	3	4	-0.33333334	-1.25	1	0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM492GB6
2081	8976	NDAR_INVYM492GB6	1551			M	5200	EndofPhase1_1a	12	Phase 1/1A	324	1	0	0	0	0	0	0	0	0	0	0	2	0	2	0	0	0	1	9	0	2	2	2	0	4	4	4	4	1	1	1	1	1	1	1	1	2	2	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	5	0.5	0.25	2	4	1.35		1	2.9047618	2	4	3	4	-1.5547619	-1.5	-3.75	-1	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM492GB6
2081	8976	NDAR_INVYM492GB6	1551			M	5800	EndofPhase2	18	Phase 2	509	1	0	0	0	0	0	0	4	0	1	2	2	2	4	1	0	0	0	9	1	2	1	4	1	3	3	4	4	1	1	1	0	1	0	1	0	1	2	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0	2.4285715	3	1.95			2.9047618	2	4	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM492GB6
2081	8976	NDAR_INVYM825RX9	2047			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	5	0	3	0	1	1	1	1	0	1	9	4	6	0	3	6	6	4	3	4	1	1	1	0	0	1	1	1	2	3	1	4	3	3	4	0	0	0	0	0	0	0	0					0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	1.5714285	0.5	3.7142856	5	2.5789473	1		2.5789473	1.5714285	0.5	3.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM825RX9
2081	8976	NDAR_INVYM856XE8	1565			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	5	6	4	4	6	6	0	0	0	0	9	1	4	4	0	4	3	4	6	6	1	1	1	0	1	1	1	1	2	1	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.625	0	3.5714285	3.5	3.45	1		3.45	4.625	0	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM856XE8
2081	8976	NDAR_INVYM856XE8	1565			F	1600	Visit6	6	Phase 1B	169	0	0	0	0	0	0	1	6	5	4	6	6	5	6	0	2	4	5	9	3	4	3	6	5	3	4	6	6	1	1	1	2	1	1	1	1	2	1	1	3	2	2	4	1	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	4	4.75	2.75	4.714286	3.5	4.45			3.45	4.625	0	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM856XE8
2081	8976	NDAR_INVYM856XE8	1565			F	5200	EndofPhase1_1a	2	Phase 1/1A	42	0	0	0	0	0	0	1	6	5	5	5	5	6	6	0	1	0	0	9	1	4	4	0	3	3	3	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.75	0.25	3.4285715	3	3.45		1	3.45	4.625	0	3.5714285	3.5	0	0.125	0.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYM856XE8
2081	8976	NDAR_INVYN214KFZ	2762			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	5	5	6	6	6	6	0	5	4	4	6	4	6	6	6	4	6	4	6	6	1	1	1	1	1	1	1	1	2	1	1	4	3	2	4	1	0	1	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	5	4.75	5.428571	5	5.095238	1		5.095238	5	4.75	5.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN214KFZ
2081	8976	NDAR_INVYN214KFZ	2762			F	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	0	6	6	6	6	6	6	0	4	6	5	9	6	6	6	6	6	5	4	4	6	0	0	1	1	1	1	0	1	2	1	1	3	1	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	4.5	3.75	5.714286	4.5	5			5.095238	5	4.75	5.428571	5	-0.0952381	-0.5	-1	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN214KFZ
2081	8976	NDAR_INVYN214KFZ	2762			F	2800	Visit12	12	Phase 1/1A	347	0	0	0	0	0	0	1	0	6	6	6	5	6	6	2	4	4	5	6	6	5	6	6	6	5	4	6	6	1	1	1	1	1	1	1	1	2	2	1	3	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.625	4.75	5.857143	4.5	5.047619			5.095238	5	4.75	5.428571	5	-0.04761905	-0.375	0	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN214KFZ
2081	8976	NDAR_INVYN214KFZ	2762			F	5200	EndofPhase1_1a	18	Phase 1/1A	505	0	0	0	0	0	0	1	6	6	4	6	6	6	6	6	4	4	5	6	6	6	4	6	5	6	4	6	6	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	0	0	0	0	0	1	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5.75	4.75	5.571429	5	5.428571		1	5.095238	5	4.75	5.428571	5	0.33333334	0.75	0	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN214KFZ
2081	8976	NDAR_INVYN551CY5	1925			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	2	3	0	0	2	1	2	3	2	4	2	4	4	4	6	6	5	6	3	6	6	1	0	1	1	1	1	1	1	1	1	1	2	1	2	1	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	6	1.625	3	5.285714	4.5	3.3809524	1		3.3809524	1.625	3	5.285714	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN551CY5
2081	8976	NDAR_INVYN551CY5	1925			F	1600	Visit6	6	Phase 1/1A	169	0	0	0	1	0	0	0	6	4	5	5	4	5	6	5	6	6	6	6	6	6	6	6	6	6	3	6	6	1	1	1	0	1	1	1	1	1	2	1	2	2	2	1	1	0	0	0	0	0	1	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	5	6	6	4.5	5.4761906			3.3809524	1.625	3	5.285714	4.5	2.0952382	3.375	3	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN551CY5
2081	8976	NDAR_INVYN551CY5	1925			F	2800	Visit12	12	Phase 1/1A	343	0	0	0	1	0	0	0	6	6	6	6	6	6	6	6	4	6	6	6	6	6	6	6	6	6	5	6	6	1	0	1	1	1	1	1	1	1	1	1	2	1	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	6	5.5	6	5.5	5.857143			3.3809524	1.625	3	5.285714	4.5	2.4761906	4.375	2.5	0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN551CY5
2081	8976	NDAR_INVYN551CY5	1925			F	5200	EndofPhase1_1a	18	Phase 1/1A	503	0	0	0	1	0	0	0	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	3	6	6	1	0	1	1	1	1	1	1	1	1	1	2	1	2	1	1	0	0	0	0	0	1	0	1	0	0	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	7	6	6	6	4.5	5.857143		1	3.3809524	1.625	3	5.285714	4.5	2.4761906	4.375	3	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYN551CY5
2081	8976	NDAR_INVYP256TU1	2749			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	5	2	2	4	2	0	2	0	0	0	0	9	0	0	0	0	0	3	2	4	4	1	1	2	2	1	1	2	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2.125	0	1.1428572	2.5	1.5	1		1.5	2.125	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP256TU1
2081	8976	NDAR_INVYP256TU1	2749			M	2800	Visit12	12	Phase 2	365	0	0	1	0	0	0	0	6	6	6	4	4	2	2	2	0	3	0	9	2	3	4	4	2	3	4	6	4	1	1	1	0	1	1	1	1	1	2	1	2	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	4	0.75	3.5714285	3.5	3.35			1.5	2.125	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP256TU1
2081	8976	NDAR_INVYP256TU1	2749			M	5200	EndofPhase1_1a	6	Phase 1/1A	195	0	0	0	0	1	0	0	5	5	2	1	2	3	4	1	0	1	0	9	1	2	0	4	2	3	3	4	5	1	1	1	0	1	1	0	1	1	2	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	0.25	2.5714285	3	2.4		1	1.5	2.125	0	1.1428572	2.5	0.9	0.75	0.25	1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP256TU1
2081	8976	NDAR_INVYP256TU1	2749			M	5800	EndofPhase2	18	Phase 2	561	0	0	0	0	1	0	0	6	5	5	4	4	3	3	2	0	0	0	9	3	2	3	4	2	4	3	5	6	1	1	1	0	1	1	1	1	1	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	0	3.5714285	3.5	3.2			1.5	2.125	0	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP256TU1
2081	8976	NDAR_INVYP894MM3	1092			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	1	0	6	0	0	5	6	4	6	6	5	6	6	6	6	6	6	6	6	4	3	6	6	1	1	1	1	1	1	1	1	2	1	1	2	4	4	1	0	0	0	0	0	0	0	1	0	0	0	0	1	25	0		0		0		1	5	0	0	1	0	0	0	0	1	0	0	0	0	1	1	1	1	6	4.125	5.75	6	3.5	5	1		5	4.125	5.75	6	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP894MM3
2081	8976	NDAR_INVYP894MM3	1092			F	5200	EndofPhase1_1a	1	Phase 1/1A	34	0	1	0	0	0	1	0	4	0	0	4	6	2	6	6	4	4	6	4	4	6	4	6	6	5	2	6	6	1	0	1	0	1	1	0	1	2	2	1	3	2	2	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5	4.5	5.428571	3.5	4.3333335		1	5	4.125	5.75	6	3.5	-0.6666667	-0.625	-1.25	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP894MM3
2081	8976	NDAR_INVYP894MM3	1092			F	5800	EndofPhase2	3	Phase 2	77	0	1	0	0	0	1	0	4	3	0	4	6	2	6	6	4	4	6	4	4	5	4	6	6	5	3	6	5	1	1	1	0	1	1	1	1	3	1	1	2	4	4	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.875	4.5	5.142857	4	4.428571			5	4.125	5.75	6	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP894MM3
2081	8976	NDAR_INVYP933BN2	1814			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	5	1	4	3	5	2	2	5	2	2	1	9	1	1	4	3	3	3	2	5	5	1	0	1	1	1	1	1	1	1	2	0	4	3	3	3	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	5	3.375	1.25	3.142857	2.5	2.95	1		2.95	3.375	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYP933BN2	1814			M	1600	Visit6	6	Phase 1B	172	0	1	0	1	0	0	0	5	3	2	2	5	3	3	5	2	2	2	9	3	4	4	3	4	5	3	5	5	0	0	1	0	1	1	1	1	1	2	1	3	3	3	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	3.5	1.5	4	4	3.5			2.95	3.375	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYP933BN2	1814			M	2800	Visit12	12	Phase 1B	337	0	1	0	0	0	0	0	5	4	2	3	5	4	3	4	2	2	1	9	2	2	3	3	3	5	3	4	4	1	1	1	0	1	1	0	1	1	2	1	4	3	3	4	1	1	1	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	3.75	1.25	3	4	3.2			2.95	3.375	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYP933BN2	1814			M	4000	Visit18	18	Phase 2	512	0	1	0	0	0	0	0	5	5	3	3	5	3	3	3	3	3	3	3	2	3	4	3	4	5	3	5	4	1	1	1	1	1	1	1	1	1	2	1	4	3	4	4	1	1	0	0	0	0	0	0	1	2	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	3.75	3	3.5714285	4	3.5714285			2.95	3.375	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYP933BN2	1814			M	5200	EndofPhase1_1a	3	Phase 1/1A	86	0	1	0	0	0	0	0	5	2	2	2	5	3	3	4	2	3	3	9	3	3	4	3	3	4	3	5	5	0	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	4	3.25	2	3.7142856	3.5	3.35		1	2.95	3.375	1.25	3.142857	2.5	0.4	-0.125	0.75	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYP933BN2	1814			M	5400	EndofPhase1b	15	Phase 1B	435	0	1	0	0	0	0	0	6	4	2	2	5	4	3	5	4	3	3	3	2	2	4	3	2	4	3	4	5	1	1	1	0	1	1	1	1	1	2	1	3	2	3	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	3.875	3.25	3.142857	3.5	3.4761906			2.95	3.375	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYP933BN2	1814			M	5800	EndofPhase2	23	Phase 2	659	0	1	0	1	0	0	0	6	4	4	4	5	3	3	3	2	3	2	9	3	2	4	3	3	5	3	5	4	1	1	1	0	1	1	2	1	1	2	1	3	2	3	4	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4	1.75	3.4285715	4	3.55			2.95	3.375	1.25	3.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYP933BN2
2081	8976	NDAR_INVYR189BCW	2684			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	0	1	0	0	2	0	0	0	2	9	1	0	1	2	2	2	2	3	1	1	0	1	0	1	1	1	1	3		0	4	4	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	0.42857143	0.5	1.4285715	2	1	1		1	0.42857143	0.5	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR189BCW
2081	8976	NDAR_INVYR189BCW	2684			M	1600	Visit6	6	Phase 2	174	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	2	3	3	9	2	0	1	1	2	2	1	3	3	0	0	1	0	1	1	0	1	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	1	0	0	0	1	0	1	1	1	1	4	0.125	2	1.7142857	1.5	1.2			1	0.42857143	0.5	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR189BCW
2081	8976	NDAR_INVYR189BCW	2684			M	2800	Visit12	12	Phase 2	338	0	0	0	0	0	1	0	0	0	3	2	1	0	2	1	0	0	2	9	1	3	2	1	2	3	2	2	1	0	0	1	0	1	1	1	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	3	1.125	0.5	1.7142857	2.5	1.4			1	0.42857143	0.5	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR189BCW
2081	8976	NDAR_INVYR189BCW	2684			M	5200	EndofPhase1_1a	2	Phase 1/1A	48	0	0	0	0	0	0	1	9	0	0	1	0	0	0	1	0	0	1	9	0	1	1	2	1	2	1	2	2	0	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	0.2857143	0.25	1.2857143	1.5	0.7894737		1	1	0.42857143	0.5	1.4285715	2	-0.21052632	-0.14285715	-0.25	-0.14285715	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR189BCW
2081	8976	NDAR_INVYR189BCW	2684			M	5400	EndofPhase1b	5	Phase 1B	134	0	0	0	0	0	0	1	9	0	2	2	0	0	2	0	0	0	0	9	2	0	4	3	0	3	2	4	3	1	0	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	0	3	0.85714287	0	2.2857144	2.5	1.4210526			1	0.42857143	0.5	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR189BCW
2081	8976	NDAR_INVYR189BCW	2684			M	5800	EndofPhase2	18	Phase 2	505	0	0	0	0	0	0	1	9	0	0	0	0	0	2	1	0	0	5	9	1	1	2	1	0	3	1	3	3	0	0	1	0	1	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	4	0.42857143	1.25	1.5714285	2	1.2105263			1	0.42857143	0.5	1.4285715	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR189BCW
2081	8976	NDAR_INVYR649KT1	1578			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	1	0	0	0	2	2	2	0	1	1	9	1	2	3	5	2	4	2	5	6	0	0	0	0	1	1	1	1	1	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.625	0.5	3.4285715	3	2.25	1		2.25	1.625	0.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR649KT1
2081	8976	NDAR_INVYR649KT1	1578			F	1600	Visit6	6	Phase 1B	169	1	0	0	0	0	0	0	2	0	1	0	2	1	2	1	0	0	0	9	5	3	4	3	3	3	2	5	6	0	1	0	1	0	1	1	1	1	2	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.125	0	4.142857	2.5	2.15			2.25	1.625	0.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR649KT1
2081	8976	NDAR_INVYR649KT1	1578			F	2800	Visit12	12	Phase 1B	344	1	0	0	0	0	0	0	5	0	0	2	2	3	3	0	0	0	1	9	2	3	2	1	1	3	2	5	6	0	0	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	3	1.875	0.25	2.857143	2.5	2.05			2.25	1.625	0.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR649KT1
2081	8976	NDAR_INVYR649KT1	1578			F	5200	EndofPhase1_1a	4	Phase 1/1A	103	1	0	0	0	0	0	0	6	2	0	4	2	1	2	0	0	2	1	9	2	3	3	4	2	4	4	6	6	0	0	0	0	1	1	1	1	1	1	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	0	1	25	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0.75	3.7142856	4	2.7		1	2.25	1.625	0.5	3.4285715	3	0.45	0.5	0.25	0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR649KT1
2081	8976	NDAR_INVYR649KT1	1578			F	5400	EndofPhase1b	14	Phase 1B	378	1	0	0	0	0	0	0	5	1	1	0	2	0	2	2	0	0	1	9	1	1	0	1	2	1	0	5	4	2	2	2	2	1	1	1	2	2	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		1	29	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1.625	0.25	2	0.5	1.45			2.25	1.625	0.5	3.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYR649KT1
2081	8976	NDAR_INVYT079EX0	2592			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	0	0	2	1	1	0	1	2	1	9	0	2	2	2	1	5	4	4	4	1	1	1	0	1	1	1	1	1	1	1	3	2	2	2	1	0	0	0	0	0	1	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	2	1.1428572	1	2.142857	4.5	1.8947369	1		1.8947369	1.1428572	1	2.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYT079EX0
2081	8976	NDAR_INVYT079EX0	2592			M	5200	EndofPhase1_1a	4	Phase 1/1A	113	0	0	0	0	0	0	1	2	1	0	0	2	2	2	4	0	0	0	9	0	4	4	4	6	6	3	4	4	2	2	2	2	1	1	2	1	2	3	1	2	2	2	4	1	0	0	0	0	1	0	0	1	1	1	1	1	16	0		0		1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.625	0	3.7142856	4.5	2.4		1	1.8947369	1.1428572	1	2.142857	4.5	0.50526315	0.48214287	-1	1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYT079EX0
2081	8976	NDAR_INVYT713VNN	1725			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	1	0	0	5	0	0	0	2	2	2	2	0	3	4	9	2	1	2	2	1	2	0	4	2	0	0	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	1	1	15	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.625	1.75	2	1	1.8	1		1.8	1.625	1.75	2	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYT713VNN
2081	8976	NDAR_INVYT713VNN	1725			M	5200	EndofPhase1_1a	1	Phase 1/1A	22	1	0	0	0	0	0	0	5	1	0	0	2	2	2	2	0	0	4	9	2	1	2	2	1	2	0	4	1	0	0	0	0	1	1	0	0	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	0	1	1	1	1	15	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.75	1	1.8571428	1	1.65		1	1.8	1.625	1.75	2	1	-0.15	0.125	-0.75	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYT713VNN
2081	8976	NDAR_INVYT931KAZ	1434			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	6	2	4	2	2	2	1	1	5	0	9	0	5	4	4	2	5	3	6	6	1	1	1	0	1	1	1	1	2	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	1.5	3.857143	4	3.2	1		3.2	2.875	1.5	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYT931KAZ
2081	8976	NDAR_INVYT931KAZ	1434			M	5200	EndofPhase1_1a	5	Phase 1/1A	128	0	0	0	0	0	0	1	2	0	4	2	2	3	3	1	0	3	0	9	3	5	5	6	4	6	2	4	5	0	0	0	0	1	1	1	1	2	1	1	4	2	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	27	0		0		1	3	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.125	0.75	4.571429	4	3		1	3.2	2.875	1.5	3.857143	4	-0.2	-0.75	-0.75	0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYT931KAZ
2081	8976	NDAR_INVYU332RLR	1831			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	2	2	1	1	2	1	4	2	4	3	2	3	2	4	5	2	3		4	1	1	1	0	1	1	0	1	2	2	0	4	2	4	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	1.625	3.25	3.3333333	2.5	2.55	1		2.55	1.625	3.25	3.3333333	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU332RLR
2081	8976	NDAR_INVYU332RLR	1831			M	1600	Visit6	6	Phase 1/1A	189	0	0	0	0	0	1	0	4	1	1	4	2	1	3	1	3	4	6	6	3	6	1	4	5	1	2	4	4	1	1	1	0	1	1	0	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	1	1	1	1	6	2.125	4.75	3.857143	1.5	3.142857			2.55	1.625	3.25	3.3333333	2.5	0.5928571	0.5	1.5	0.52380955	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU332RLR
2081	8976	NDAR_INVYU332RLR	1831			M	2800	Visit12	12	Phase 3	373	0	0	0	0	0	1	0	4	1	4	5	1	4	5	0	1	4	4	9	3	6	2	4	2	2	2	4	5	0	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3	2.25	3.7142856	2	3.15			2.55	1.625	3.25	3.3333333	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU332RLR
2081	8976	NDAR_INVYU332RLR	1831			M	5200	EndofPhase1_1a	8	Phase 1/1A	268	0	0	0	0	0	1	0	2	1	3	2	1	2	2	1	2	3	6	9	2	5	1	4	4	2	2	4	5	0	1	1	0	1	1	0	1	2	1	0	4	2	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	3	1.75	2.75	3.5714285	2	2.7		1	2.55	1.625	3.25	3.3333333	2.5	0.15	0.125	-0.5	0.23809524	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU332RLR
2081	8976	NDAR_INVYU332RLR	1831			M	5800	EndofPhase2	10	Phase 2	304	0	0	0	0	0	1	0																		2	1			0	1	1	0	1	1	0	1	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4				1.5				2.55	1.625	3.25	3.3333333	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU332RLR
2081	8976	NDAR_INVYU332RLR	1831			M	6000	EndofPhase3	18	Phase 3	521	0	0	0	0	0	1	0	3	1	3	2	1	1	2	0	0	0	0	9	0	2	1	2	1	3	3	0	2	1	1	1	0	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.625	0	1.1428572	3	1.35			2.55	1.625	3.25	3.3333333	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU332RLR
2081	8976	NDAR_INVYU438EL6	1409			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	4	1	2	2	2	1	1	1	1	3	1	9	2	1	2	2	3	3	2	4	4	1	0	1	0	1	1	1	1	1	2	1	4	4	4	1	1	0	1	1	0	1	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	1.75	1.25	2.5714285	2.5	2.1	1		2.1	1.75	1.25	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU438EL6
2081	8976	NDAR_INVYU438EL6	1409			F	1600	Visit6	6	Phase 2	185	0	1	0	1	0	0	0	6	3	1	1	4	2	2	2	3	4	3	4	2	1	1	2	2	0	2	5	3	1	0	1	1	1	1	1	1	1	1	0	4	3	3	1	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.625	3.5	2.2857144	1	2.5238094			2.1	1.75	1.25	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU438EL6
2081	8976	NDAR_INVYU438EL6	1409			F	2800	Visit12	12	Phase 2	344	0	1	0	1	0	0	0	4	2	2	2	3	2	3	2	3	3	1	3	4	3	1	2	4	4	4	3	2	1	1	1	0	1	1	1	1	1	2	0	4	3	4	1	1	0	1	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2.5	2.5	2.7142856	4	2.7142856			2.1	1.75	1.25	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU438EL6
2081	8976	NDAR_INVYU438EL6	1409			F	5200	EndofPhase1_1a	5	Phase 1/1A	162	0	1	0	1	0	0	0	5	3	2	2	2	3	2	2	4	4	4	3	3	4	3	2	4	2	2	3	2	1	0	1	1	1	1	1	1	1	3	0	4	3	4	1	1	0	0	0	1	0	1	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	2.625	3.75	3	2	2.9047618		1	2.1	1.75	1.25	2.5714285	2.5	0.8047619	0.875	2.5	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU438EL6
2081	8976	NDAR_INVYU438EL6	1409			F	5800	EndofPhase2	18	Phase 2	512	0	1	0	1	0	0	0	4	1	1	2	1	1	2	1	3	1	1	9	3	2	1	1	4	2	2	2	3	1	0	1	0	1	1	1	1	1	3	0	4	3	4	1	1	0	1	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.625	1.25	2.2857144	2	1.9			2.1	1.75	1.25	2.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYU438EL6
2081	8976	NDAR_INVYV384BA9	2432			F	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	2	4	5	4	4	4	4	4	0	1	1	9	1	3	2	3	2	4	3	2	4	1	1	1	0	1	1	1	1	1	3	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	2	3.875	0.5	2.4285715	3.5	2.85	1		2.85	3.875	0.5	2.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV384BA9
2081	8976	NDAR_INVYV384BA9	2432			F	1600	Visit6	6	Phase 1/1A	199	0	0	0	0	0	0	1	9	4	3	2	5	1	1	5	1	1	1	9	2	3	3	2	2	5	2	3	3	0	1	1	1	0	1	0	1	2	3	1	3	1	4	1	1	0	1	1	0	1	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	3	0.75	2.5714285	3.5	2.5789473			2.85	3.875	0.5	2.4285715	3.5	-0.27105263	-0.875	0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV384BA9
2081	8976	NDAR_INVYV384BA9	2432			F	4000	Visit18	18	Phase 1/1A	282	0	1	0	0	0	0	0	5	0	0	0	2	2	0	4	2	2	0	9	3	0	0	2	0	6	0	4	5	1	0	1	0	0	0	0	0	1	2	0	4	4	3	1	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1.625	1	2	3	1.85		1	2.85	3.875	0.5	2.4285715	3.5	-1	-2.25	0.5	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV384BA9
2081	8976	NDAR_INVYV558JKN	1617			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	0	0	1	2	1	1	0	0	0	1	9	0	0	0	2	0	2	1	2	2	1	0	0	0	1	0	0	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1.375	0.25	0.85714287	1.5	1.05	1		1.05	1.375	0.25	0.85714287	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV558JKN
2081	8976	NDAR_INVYV558JKN	1617			M	1600	Visit6	6	Phase 1/1A	166	1	0	1	0	0	0	0	4	0	0	2	2	0	2	0	0	2	1	9	2	2	1	0	1	3	1	2	2	1	1	1	0	1	1	0	0	2	2	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	0	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.25	0.75	1.4285715	2	1.35			1.05	1.375	0.25	0.85714287	1.5	0.3	-0.125	0.5	0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV558JKN
2081	8976	NDAR_INVYV558JKN	1617			M	2800	Visit12	12	Phase 1/1A	331	1	0	1	0	0	0	0	4	0	0	2	2	0	2	0	0	2	1	9	2	2	1	0	1	1	1	2	1	0	0	0	0	1	0	0	0	3	2	1	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.25	0.75	1.2857143	1	1.2			1.05	1.375	0.25	0.85714287	1.5	0.15	-0.125	0.5	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV558JKN
2081	8976	NDAR_INVYV558JKN	1617			M	4000	Visit18	18	Phase 1/1A	491	1	0	1	0	0	0	0	4	0	0	2	2	2	2	0	0	2	1	9	2	2	1	0	1	3	1	2	3	1	0	0	0	1	0	0	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.75	1.5714285	2	1.5		1	1.05	1.375	0.25	0.85714287	1.5	0.45	0.125	0.5	0.71428573	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYV558JKN
2081	8976	NDAR_INVYW349DX4	2510			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	2	0	0	2	0	1	0	0	0	2	9	1	2	2	2	0	3	2	4	4	0	1	0	0	1	0	0	0	1	1	1	4	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	1.25	0.5	2.142857	2.5	1.6	1		1.6	1.25	0.5	2.142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW349DX4
2081	8976	NDAR_INVYW349DX4	2510			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	0	0	1	9	4	3	2	2	2	2	2	2	3	3	9	2	4	2	4	1	3	2	5	5	1	1	0	0	1	1	1	1	1	1	1	4	1	3	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2.4285715	2	3.2857144	2.5	2.7894738			1.6	1.25	0.5	2.142857	2.5	1.1894736	1.1785715	1.5	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW349DX4
2081	8976	NDAR_INVYW349DX4	2510			M	2800	Visit12	12	Phase 1/1A	312	0	0	0	0	0	0	1	4	2	0	1	4	0	2	1	0	1	1	9	2	4	2	3	0	4	2	5	6	1	1	0	0	1	1	0	0	1	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	4	1.75	0.5	3.142857	3	2.2			1.6	1.25	0.5	2.142857	2.5	0.6	0.5	0	1	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW349DX4
2081	8976	NDAR_INVYW349DX4	2510			M	5200	EndofPhase1_1a	18	Phase 1/1A	497	0	0	0	0	0	0	1	2	1	0	2	3	1	3	1	1	1	1	9	2	4	4	5	2	4	3	4	6	1	1	0	0	1	1	1	0	3	1	1	3	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.625	0.75	3.857143	3.5	2.5		1	1.6	1.25	0.5	2.142857	2.5	0.9	0.375	0.25	1.7142857	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW349DX4
2081	8976	NDAR_INVYW648YM5	2386			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	0	4	1	2	2	2	0	0	1	1	9	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.625	0.5	0.2857143	0.5	0.9	1		0.9	1.625	0.5	0.2857143	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW648YM5
2081	8976	NDAR_INVYW713NWQ	2468			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	3	2	2	2	2	4	0	0	0	1	9	2	3	5	5	4	6	2	4	6	1	1	0	0	1	0	0	0	3	1	0	3	4	3	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.125	0.25	4.142857	4	2.75	1		2.75	2.125	0.25	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW713NWQ
2081	8976	NDAR_INVYW713NWQ	2468			M	1600	Visit6	6	Phase 1/1A	177	0	0	0	0	0	1	0	2	2	2	2	2	2	4	0	1	1	1	9	2	3	5	5	4	6	2	4	6	1	1	0	0	1	0	0	0	3	1	1	3	4	3	4	1	0	0	1	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.75	4.142857	4	2.8			2.75	2.125	0.25	4.142857	4	0.05	-0.125	0.5	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW713NWQ
2081	8976	NDAR_INVYW713NWQ	2468			M	2800	Visit12	12	Phase 1/1A	345	0	0	0	0	0	1	0	2	2	1	2	2	2	4	0	2	1	2	9	2	2	4	4	4	2	2	4	5	1	1	0	0	1	0	0	0	3	2	1	3	4	3	2	1	0	0	1	0	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.875	1.25	3.5714285	2	2.45			2.75	2.125	0.25	4.142857	4	-0.3	-0.25	1	-0.5714286	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW713NWQ
2081	8976	NDAR_INVYW713NWQ	2468			M	4000	Visit18	18	Phase 1/1A	508	0	0	0	0	0	1	0	2	2	2	2	2	4	2	0	0	1	1	9	2	3	4	5	4	6	2	4	6	1	1	0	0	1	0	0	0	3	1	1	3	4	3	4	1	0	0	1	0	0	0	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	5	2	0.5	4	4	2.7		1	2.75	2.125	0.25	4.142857	4	-0.05	-0.125	0.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYW713NWQ
2081	8976	NDAR_INVYX172DCJ	2058			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	1	2	1	3	3	3	3	3	3	4	3	3	5	2	3	5	0	0	1	1	1	1	1	1	1	3	0	4	4	4	4	1	0	1	1	0	0	0	0	1	0	0	0	1	28	0		0		1	2	0		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4	1.75	3	3.4285715	3.5	2.7142856	1		2.7142856	1.75	3	3.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX172DCJ
2081	8976	NDAR_INVYX172DCJ	2058			M	1600	Visit6	6	Phase 1/1A	172	1	0	0	0	0	0	0	5	2	2	2	2	1	2	2	6	5	5	6	4	4	3	4	6	5	3	5	4	1	1	1	1	1	1	1	1	1	2	0	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	2.25	5.5	4.285714	4	3.7142856			2.7142856	1.75	3	3.4285715	3.5	1	0.5	2.5	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX172DCJ
2081	8976	NDAR_INVYX172DCJ	2058			M	2800	Visit12	12	Phase 1/1A	347	1	0	0	0	0	0	0	6	4	4	4	3	3	3	3	6	5	5	6	4	4	4	4	6	5	4	3	5	1	1	1	1	1	1	1	1	1	2	1	4	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	3.75	5.5	4.285714	4.5	4.3333335			2.7142856	1.75	3	3.4285715	3.5	1.6190476	2	2.5	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX172DCJ
2081	8976	NDAR_INVYX172DCJ	2058			M	5200	EndofPhase1_1a	18	Phase 1/1A	522	1	0	0	0	0	0	0	4	3	2	2	2	2	2	2	6	4	5	6	5	5	4	4	5	6	3	3	4	1	1	1	0	1	1	1	1	1	2	1	3	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.375	5.25	4.285714	4.5	3.7619047		1	2.7142856	1.75	3	3.4285715	3.5	1.0476191	0.625	2.25	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX172DCJ
2081	8976	NDAR_INVYX695ZU9	2168			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	4	0	5	4	5	3	4	0	0	1	9	3	4	2	6	5	4	3	5	6	1	1	1	0	1	0	0	1	3		1	3	2	2	3	1	0	0	0	0	1	0	0	1	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.375	0.25	4.428571	3.5	3.3	1		3.3	3.375	0.25	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX695ZU9
2081	8976	NDAR_INVYX695ZU9	2168			M	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	0	0	0	0	0	1	0	6	5	4	2	6	6	2	0	0	3	9	6	4	0	6	5	4	3	4	4	0	1	1	0	1	0	0	1	2	3	1	2	1	1	1	1	0	0	0	0	0	0	1	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.875	0.75	4.142857	3.5	3.5		1	3.3	3.375	0.25	4.428571	3.5	0.2	0.5	0.5	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX695ZU9
2081	8976	NDAR_INVYX695ZU9	2168			M	5800	EndofPhase2	3	Phase 2	102	0	0	0	0	0	0	1	0	4	0	5	4	1	1	4	0	0	1	9	4	4	2	6	5	4	2	6	6	1	1	1	0	1	0	1	1	3	3	1	2	4	4	2	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	7	2.375	0.25	4.714286	3	2.95			3.3	3.375	0.25	4.428571	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYX695ZU9
2081	8976	NDAR_INVYZ011TV0	1555			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	3	0	3	2	1	2	2	0	0	1	9	2	1	0	2	0	2	1	3	2	1	0	0	0	0	1	0	1	3		1	2	1	4	4	1	0	0	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	1.8571428	0.25	1.4285715	1.5	1.4210526	1		1.4210526	1.8571428	0.25	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ011TV0
2081	8976	NDAR_INVYZ011TV0	1555			M	1600	Visit6	6	Phase 1/1A	173	0	0	0	0	0	0	1	9	0	3	3	2	0	2	1	0	0	0	9	3	0	0	1	1	2	1	2	2	0	0	0	0	1	1	1	1	3		1	3	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.5714285	0	1.2857143	1.5	1.2105263			1.4210526	1.8571428	0.25	1.4285715	1.5	-0.21052632	-0.2857143	-0.25	-0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ011TV0
2081	8976	NDAR_INVYZ011TV0	1555			M	2800	Visit12	12	Phase 1/1A	341	0	0	0	0	0	0	1	0	0	2	1	0	2	2	0	0	0	1	9	0	0	2	1	0	3	1	3	3	1	0	1	0	1	1	1	1	3		1	3	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	0.875	0.25	1.2857143	2	1.05			1.4210526	1.8571428	0.25	1.4285715	1.5	-0.37105262	-0.98214287	0	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ011TV0
2081	8976	NDAR_INVYZ011TV0	1555			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	0	0	1	9	0	2	0	0	0	0	1	0	0	1	9	0	2	2	1	2	1	2	2	4	0	1	0	0	0	0	1	0	3		0	4	3	4	4	0	0	0	0	0	0	0	0					0		0		1	14	1	14	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	0.42857143	0.25	1.8571428	1.5	1.0526316		1	1.4210526	1.8571428	0.25	1.4285715	1.5	-0.36842105	-1.4285715	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ011TV0
2081	8976	NDAR_INVYZ011TV0	1555			M	5800	EndofPhase2	23	Phase 2	644	0	0	0	0	0	1	0	3	0	0	4	2	0	2	0	1	2	1	9	2	1	2	3	4	2	3	2	1	1	1	0	0	1	1	1	1	3		0	4	3	3	4	0	0	0	0	0	0	0	0					0		0		1	30	0		0		0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	1	3	1.375	1	2.142857	2.5	1.75			1.4210526	1.8571428	0.25	1.4285715	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ011TV0
2081	8976	NDAR_INVYZ748FC0	2826			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	2	2	4	1	2	2	2	1	1	0	0	9	0	2	2	2	0	6	3	4	3	1	1	0	1	0	0	0	1	3		1	4	3	3	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	2	0.25	1.8571428	4.5	1.95	1		1.95	2	0.25	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ748FC0
2081	8976	NDAR_INVYZ748FC0	2826			M	2800	Visit12	12	Phase 3	338	0	1	0	0	0	0	0	3	4	1	4	2	2	4	0	2	2	4	9	1	1	4	4	4	5	4	4	2	1	1	1	1	0	0	0	1	1	3	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	0	1	1	30	0		0		0		0		0	0	0	1	1	1	1	0	0	0	0	0	1	1	1	1	7	2.5	2	2.857143	4.5	2.85			1.95	2	0.25	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ748FC0
2081	8976	NDAR_INVYZ748FC0	2826			M	5200	EndofPhase1_1a	2	Phase 1/1A	54	0	1	0	0	0	0	0	2	2	2	0	2	0	0	1	0	0	0	9	0	1	2	2	0	5	3	3	2	1	1	2	1	0	0	0	0	3		0	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	1.125	0	1.4285715	4	1.35		1	1.95	2	0.25	1.8571428	4.5	-0.6	-0.875	-0.25	-0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ748FC0
2081	8976	NDAR_INVYZ748FC0	2826			M	5800	EndofPhase2	6	Phase 2	177	0	1	0	0	0	0	0	4	4	2	2	2	0	2	0	1	0	1	9	2	2	6	4	2	5	3	4	4	1	1	1	1	0	0	0	0	1	2	1	3	3	3	1	1	1	0	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.5	3.4285715	4	2.5			1.95	2	0.25	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ748FC0
2081	8976	NDAR_INVYZ748FC0	2826			M	6000	EndofPhase3	18	Phase 3	515	0	1	0	0	0	0	0	4	4	2	4	3	3	2	0	1	1	2	9	0	3	5	4	1	5	4	2	4	1	1	1	1	0	0	0	0	1	3	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	5	2.75	1	2.7142856	4.5	2.7			1.95	2	0.25	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ748FC0
2081	8976	NDAR_INVYZ979KAE	1004			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	9	0	1	2	1	1	3	0	0	2	0	0	0	0	1	0	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	15	0		1	15	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0.25	0	1	1.5	0.6	1		0.6	0.25	0	1	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVYZ979KAE
2081	8976	NDAR_INVZA315XLU	1982			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	0	2	1	2	4	2	2	4	1	9	2	3	1	6	3	5	2	5	5	1	0	0	0	1	1	1	0	2	2	1	3	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	5	2.625	1.75	3.5714285	3.5	3	1		3	2.625	1.75	3.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA315XLU
2081	8976	NDAR_INVZA315XLU	1982			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	1	0	0	0	0	0	0	3	4	2	1	2	5	2	3	2	3	1	9	2	4	3	6	5	5	1	4	5	1	0	1	0	1	1	1	1	1	2	1	4	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	2	2.75	1.5	4.142857	3	3.15		1	3	2.625	1.75	3.5714285	3.5	0.15	0.125	-0.25	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA315XLU
2081	8976	NDAR_INVZA367GRG	2128			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	2	2	2	2	2	2	2	2	2	2	2	9	2	2	2	2	2	5	1	1	2	1	0	0	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2	1.5	1.8571428	3	2.05	1		2.05	2	1.5	1.8571428	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA367GRG
2081	8976	NDAR_INVZA367GRG	2128			M	5200	EndofPhase1_1a	6	Phase 1/1A	169	1	0	0	0	0	0	0	3	2	2	2	2	2	2	1	1	1	1	9	2	2	2	2	2	6	3	4	3	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2	0.75	2.4285715	4.5	2.25		1	2.05	2	1.5	1.8571428	3	0.2	0	-0.75	0.5714286	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA367GRG
2081	8976	NDAR_INVZA489JDG	2850			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	0	0	2	3	3	3	4	5	2	2	1	4	4	4	4	6	5	6	6	1	1	0	1	1	1	1	1	2	1	1	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	3.25	4.142857	5.5	3.2380953	1		3.2380953	1.875	3.25	4.142857	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA489JDG
2081	8976	NDAR_INVZA489JDG	2850			M	5200	EndofPhase1_1a	1	Phase 1/1A	31	0	0	0	0	0	0	1	2	2	0	1	2	2	3	3	4	4	2	2	1	4	4	4	4	6	5	6	6	1	1	0	0	1	1	1	1	2	1	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.875	3	4.142857	5.5	3.1904762		1	3.2380953	1.875	3.25	4.142857	5.5	-0.04761905	0	-0.25	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA489JDG
2081	8976	NDAR_INVZA947JV5	2280			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	5	5	5	4	4	5	3	0	0	1	9	3	4	5	4	3	3	2	4	5	0	1	0	0	1	2	1	2	2	2	1	2	1	1	2	0	0	0	0	0	0	0	0					0		0		0		1	13	1	17	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	4.5	0.25	4	2.5	3.5	1		3.5	4.5	0.25	4	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA947JV5
2081	8976	NDAR_INVZA947JV5	2280			M	5200	EndofPhase1_1a	2	Phase 1/1A	58	0	0	0	0	0	0	1	3	3	4	3	2	2	4	3	0	0	1	9	3	3	2	3	1	1	2	3	4	1	1	1	0	1	1	1	1	2	2	1	2	1	3	4	1	0	1	0	0	0	0	0	1	0	1	0	1	23	0		0		0		1	7	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	3	0.25	2.7142856	1.5	2.35		1	3.5	4.5	0.25	4	2.5	-1.15	-1.5	0	-1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZA947JV5
2081	8976	NDAR_INVZB079KUC	2757			F	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	1	4	4	1	3	1	5	2	1	2	2	9	2	3	4	4	4	5	3	5	5	1	0	1	1	1	1	1	1	1	1	1	2	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.625	1.25	3.857143	4	3.05	1		3.05	2.625	1.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB079KUC
2081	8976	NDAR_INVZB079KUC	2757			F	1600	Visit6	6	Phase 3	171	0	1	0	0	0	0	0	6	6	6	3	5	2	6	5	2	1	2	9	2	2	5	5	2	5	3	6	6	1	0	1	1	1	1	1	1	1	1	1	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.875	1.25	4	4	4			3.05	2.625	1.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB079KUC
2081	8976	NDAR_INVZB079KUC	2757			F	2800	Visit12	12	Phase 3	339	0	1	0	0	0	0	0	4	6	5	6	6	5	6	2	5	5	6	6	4	5	5	0	5	5	3	6	5	1	1	1	1	1	1	1	1	1	1	1	2	1	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	5	5.5	4.285714	4	4.7619047			3.05	2.625	1.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB079KUC
2081	8976	NDAR_INVZB079KUC	2757			F	5200	EndofPhase1_1a	1	Phase 1/1A	30	0	1	0	0	0	0	0	5	5	3	3	5	3	4	2	1	2	2	9	3	4	5	5	4	6	4	5	5	1	0	1	1	1	1	1	1	1	2	1	4	2	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	4	3.75	1.25	4.428571	5	3.8		1	3.05	2.625	1.25	3.857143	4	0.75	1.125	0	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB079KUC
2081	8976	NDAR_INVZB079KUC	2757			F	5800	EndofPhase2	3	Phase 2	82	0	1	0	0	0	0	0	2	2	1	1	1	1	2	2	5	4	3	5	5	5	5	5	5	4	2	6	6	1	0	1	1	1	1	1	1	1	2	0	4	4	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	1.5	4.25	5.285714	3	3.4285715			3.05	2.625	1.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB079KUC
2081	8976	NDAR_INVZB079KUC	2757			F	6000	EndofPhase3	18	Phase 3	500	0	1	0	0	0	0	0	4	3	4	3	3	2	4	5	2	3	2	9	3	6	6	6	6	5	3	6	6	1	1	1	1	1	1	1	1	1	2	0	4	1	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	3	3.5	1.75	5.571429	4	4.1			3.05	2.625	1.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB079KUC
2081	8976	NDAR_INVZB671CCF	1384			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	4	2	1	2	1	2	0	1	2	0	9	2	1	0	1	0	6	2	4	2	1	0	0	0	1	0	0	1	1	1	1	4	3	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.125	0.75	1.4285715	4	1.9	1		1.9	2.125	0.75	1.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB671CCF
2081	8976	NDAR_INVZB671CCF	1384			F	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	6	6	3	6	5	6	6	3	3	4	5	6	5	6	4	6	4	5	4	6	5	1	1	1	1	1	0	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.125	4.5	5.142857	4.5	4.952381			1.9	2.125	0.75	1.4285715	4	3.052381	3	3.75	3.7142856	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB671CCF
2081	8976	NDAR_INVZB671CCF	1384			F	2800	Visit12	12	Phase 1/1A	330	1	0	0	0	0	0	0	6	6	5	6	5	6	6	4	4	5	5	5	5	6	5	6	5	5	4	6	6	1	1	0	0	1	1	1	1	1	1	1	4	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.5	4.75	5.571429	4.5	5.285714			1.9	2.125	0.75	1.4285715	4	3.3857143	3.375	4	4.142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB671CCF
2081	8976	NDAR_INVZB671CCF	1384			F	4000	Visit18	18	Phase 1/1A	511	1	0	0	0	0	0	0	6	6	6	6	5	5	5	2	3	6	6	6	4	5	5	6	2	6	5	6	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.125	5.25	4.857143	5.5	5.095238			1.9	2.125	0.75	1.4285715	4	3.195238	3	4.5	3.4285715	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB671CCF
2081	8976	NDAR_INVZB671CCF	1384			F	5200	EndofPhase1_1a	20	Phase 1/1A	573	1	0	0	0	0	0	0	6	5	5	6	5	5	6	4	5	4	5	5	3	5	5	6	5	5	5	6	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	5.25	4.75	5	5	5.047619		1	1.9	2.125	0.75	1.4285715	4	3.147619	3.125	4	3.5714285	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZB671CCF
2081	8976	NDAR_INVZC017DAL	2098			M	400	Baseline	0	Pre-Rand	1	1	0	1	0	0	0	0	6	2	1	2	4	2	3	2	4	2	5	6	4	4	4	5	4	2	2	3	2	0	0	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.75	4.25	3.7142856	2	3.2857144	1		3.2857144	2.75	4.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC017DAL	2098			M	1600	Visit6	6	Phase 1B	148	1	0	1	0	0	0	0	1	1	2	2	2	2	2	2	4	2	4	4	2	2	2	2	2	1	1	1	1	0	0	0	0	0	0	0	0	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.75	3.5	1.7142857	1	2			3.2857144	2.75	4.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC017DAL	2098			M	2800	Visit12	12	Phase 3	323	1	0	0	0	0	0	0	4	2	2	1	4	3	2	2	0	0	2	9	2	1	2	2	2	2	2	3	4	1	1	1	1	1	0	1	1	2	2	1	3	3	3	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.5	0.5	2.2857144	2	2.1			3.2857144	2.75	4.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC017DAL	2098			M	5200	EndofPhase1_1a	3	Phase 1/1A	80	1	0	1	0	0	0	0	4	1	1	4	3	1	2	2	4	2	4	9	4	2	2	2	3	1	2	2	2	1	0	0	0	1	0	0	1	1	1	0	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.25	2.5	2.4285715	1.5	2.4		1	3.2857144	2.75	4.25	3.7142856	2	-0.8857143	-0.5	-1.75	-1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC017DAL	2098			M	5400	EndofPhase1b	7	Phase 1B	169	1	0	1	0	0	0	0	1	1	2	2	2	2	2	2	4	2	4	4	2	2	2	2	2	0	1	1	1	0	0	0	0	1	0	0	0	1	1	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.75	3.5	1.7142857	0.5	1.9523809			3.2857144	2.75	4.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC017DAL	2098			M	5800	EndofPhase2	8	Phase 2	177	1	0	1	0	0	0	0	1	1	2	2	2	2	2	2	4	2	4	4	2	2	2	2	2	0	1	1	1	0	0	0	0	0	1	0	0	1	1	0	4	4	4	4	1	1	1	0	0	0	0	0	1	1	1	1	0		0		0		0		0		0	0	1	0	0	1	0	0	0	0	0	0	1	1	1	1	4	1.75	3.5	1.7142857	0.5	1.9523809			3.2857144	2.75	4.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC017DAL	2098			M	6000	EndofPhase3	18	Phase 3	533	1	0	0	0	0	0	0	4	2	2	1	4	3	2	2	0	0	2	9	2	1	2	2	2	2	2	3	4	1	1	1	1	1	0	1	1	2	2	1	3	3	3	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	0	0	0	0	5	2.5	0.5	2.2857144	2	2.1			3.2857144	2.75	4.25	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC017DAL
2081	8976	NDAR_INVZC126XG4	1539			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	3	2	3	3	3	3	4	3	3	3	4	4	2	3	4	2	3	4	3	4	1	0	1	0	1	1	1	1	1	2	1	2	3	3	4	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	3.25	3.142857	3.5	3.142857	1		3.142857	3	3.25	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC126XG4
2081	8976	NDAR_INVZC126XG4	1539			M	1600	Visit6	6	Phase 1/1A	172	1	0	0	0	0	0	0	6	6	6	6	6	4	4	5	0	4	5	9	4	6	4	6	4	5	5	5	5	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.375	2.25	4.857143	5	4.8			3.142857	3	3.25	3.142857	3.5	1.6571429	2.375	-1	1.7142857	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC126XG4
2081	8976	NDAR_INVZC126XG4	1539			M	2800	Visit12	12	Phase 1/1A	334	1	0	0	0	0	0	0	6	6	6	6	6	4	4	5	0	5	5	9	4	6	5	6	5	5	5	5	5	1	1	1	1	1	1	1	1	2	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	5.375	2.5	5.142857	5	4.95			3.142857	3	3.25	3.142857	3.5	1.8071429	2.375	-0.75	2	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC126XG4
2081	8976	NDAR_INVZC126XG4	1539			M	4000	Visit18	18	Phase 1/1A	502	0	0	0	0	0	1	0	5	2	4	4	4	2	3	2	0	2	2	9	1	1	0	2	2	3	2	4	4	1	1	1	0	1	1	0	1	2	2	1	3	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.25	1	2	2.5	2.45			3.142857	3	3.25	3.142857	3.5	-0.69285715	0.25	-2.25	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC126XG4
2081	8976	NDAR_INVZC126XG4	1539			M	5200	EndofPhase1_1a	18	Phase 1/1A	502	0	0	0	0	0	1	0	5	2	4	4	4	2	3	2	0	2	2	9	1	1	0	2	2	3	2	4	4	1	1	1	0	1	1	0	1	2	2	1	3	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	3.25	1	2	2.5	2.45		1	3.142857	3	3.25	3.142857	3.5	-0.69285715	0.25	-2.25	-1.1428572	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC126XG4
2081	8976	NDAR_INVZC132JY9	1815			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	5	5	5	5	5	6	3	1	2	6	9	5	4	4	5	3	5	5	5	6	1	1	1	1	1	1	1	1	3	1	1	4	4	4	4	1	0	1	0	0	0	0	0	2	2	2	2	0		0		0		1	30	0		2	2	2	0	0	0	0	1	0	0	1	0	1	1	1	1	4	4.875	2.25	4.571429	5	4.5	1		4.5	4.875	2.25	4.571429	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC132JY9
2081	8976	NDAR_INVZC132JY9	1815			M	1600	Visit6	6	Phase 1/1A	175	1	0	0	0	0	0	0	4	4	4	3	4	3	3	4	4	4	6	6	4	4	3	4	5	5	5	4	3	1	1	1	1	1	1	1	1	1	2	1	3	1	2	2	1	0	1	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	0	1	5	3.625	5	3.857143	5	4.095238			4.5	4.875	2.25	4.571429	5	-0.4047619	-1.25	2.75	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC132JY9
2081	8976	NDAR_INVZC132JY9	1815			M	2800	Visit12	12	Phase 1/1A	340	1	0	0	0	0	0	0	4	5	4	4	4	5	5	4	2	3	1	9	4	4	5	4	3	5	5	5	5	1	1	1	1	1	1	1	1	1	2	1	3	1	1	2	1	0	1	0	1	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.375	1.5	4.285714	5	4.05			4.5	4.875	2.25	4.571429	5	-0.45	-0.5	-0.75	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC132JY9
2081	8976	NDAR_INVZC132JY9	1815			M	5200	EndofPhase1_1a	18	Phase 1/1A	504	1	0	0	0	0	0	0	4	4	4	4	4	3	3	4	5	4	2	5	3	3	0	4	4	4	6	3	4	1	1	1	1	1	1	0	1	1	2	1	3	4	3	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	3.75	4	3	5	3.6666667		1	4.5	4.875	2.25	4.571429	5	-0.8333333	-1.125	1.75	-1.5714285	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC132JY9
2081	8976	NDAR_INVZC401KAW	2174			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	1	4	1	4	3	4	2	1	2	2	9	2	2	2	5	3	4	2	5	4	1	1	1	1	1	1	1	2	3	1	1	3	2	3	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	1.25	3.2857144	3	2.7	1		2.7	2.5	1.25	3.2857144	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC401KAW
2081	8976	NDAR_INVZC401KAW	2174			M	5200	EndofPhase1_1a	2	Phase 1/1A	43	0	0	0	0	0	1	0	0	0	2	2	2	2	2	2	0	1	1	9	1	2	2	4	2	5	3	4	4	0	1	0	0	1	1	1	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.5	0.5	2.7142856	4	2.05		1	2.7	2.5	1.25	3.2857144	3	-0.65	-1	-0.75	-0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC401KAW
2081	8976	NDAR_INVZC637XPY	2046			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	6	5	4	4	4	0	4	4	0	0	0	9	1	2	1	1	0	4	5	4	4	1	1	1	1	1	1	1	1	1	3	1	2	1	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	3	3.875	0	1.8571428	4.5	2.65	1		2.65	3.875	0	1.8571428	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC637XPY
2081	8976	NDAR_INVZC675ZWV	1768			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	0	4	5	4	5	0	1	4	5	9	3	6	6	0	5	4	2	0	5	1	0	0	1	1	1	1	1	3	1	1	2	1	3	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5	3	2.5	3.5714285	3	3.25	1		3.25	3	2.5	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC675ZWV
2081	8976	NDAR_INVZC675ZWV	1768			F	5200	EndofPhase1_1a	4	Phase 1/1A	110	0	0	0	0	0	1	0	3	2	3	2	2	1	2	2	0	0	1	9	1	1	1	2	1	1	1	2	3	0	0	0	0	1	1	1	0	3		1	2	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	3	2.125	0.25	1.5714285	1	1.55		1	3.25	3	2.5	3.5714285	3	-1.7	-0.875	-2.25	-2	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC675ZWV
2081	8976	NDAR_INVZC675ZWV	1768			F	5800	EndofPhase2	5	Phase 2	124	0	0	0	0	0	1	0	2	1	2	3	3	2	2	1																																																																				2							3.25	3	2.5	3.5714285	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZC675ZWV
2081	8976	NDAR_INVZD259FL1	2863			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	1	1	4	3	0	4	4	0	0	0	9	3	4	5	5	2	5	4	6	6	1	1	1	1	0	0	1	1	1	1	0	4	4	4	1	1	1	0	0	0	0	0	0	1	2	1	1	1	22	0		0		1	8	0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	4	2.875	0	4.428571	4.5	3.15	1		3.15	2.875	0	4.428571	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD259FL1
2081	8976	NDAR_INVZD464XBQ	1352			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	0	2	2	2	0	3	0	0	1	9	3	2	4	2	0	6	3	6	5	0	1	0	0	1	1	1	1	1	2	1	4	3	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		2	0	0	0	0	0	0	1	0	1	0	0	1	1	1	1	4	2.375	0.25	3.142857	4.5	2.55	1		2.55	2.375	0.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD464XBQ
2081	8976	NDAR_INVZD464XBQ	1352			M	1600	Visit6	6	Phase 3	172	0	1	0	0	0	0	0	4	3	2	3	4	0	1	4	4	5	4	5	5	3	2	2	2	6	2	5	4	0	0	0	0	1	0	0	1	1	1	1	4	3	4	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	2.625	4.5	3.2857144	4	3.3333333			2.55	2.375	0.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD464XBQ
2081	8976	NDAR_INVZD464XBQ	1352			M	2800	Visit12	12	Phase 3	345	0	1	0	0	0	0	0	5	2	1	2	3	2	2	3	4	4	5	5	5	4	1	2	4	6	2	4	3	0	1	0	1	1	1	0	1	1	1	1	4	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.5	4.5	3.2857144	4	3.2857144			2.55	2.375	0.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD464XBQ
2081	8976	NDAR_INVZD464XBQ	1352			M	4000	Visit18	18	Phase 3	521	0	1	0	0	0	0	0	5	3	1	2	3	2	2	3	4	5	4	4	3	3	3	4	3	6	2	4	4	0	1	0	0	1	0	1	1	1	1	1	4	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	2	2	0	0	1	0	0	0	0	0	0	1	1	1	1	4	2.625	4.25	3.4285715	4	3.3333333			2.55	2.375	0.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD464XBQ
2081	8976	NDAR_INVZD464XBQ	1352			M	5200	EndofPhase1_1a	2	Phase 1/1A	64	0	1	0	0	0	0	0	6	5	0	4	4	2	3	2	5	3	2	0	6	3	6	3	5	6	3	5	6	1	1	0	1	1	1	0	0	1	1	1	4	2	3	1	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	1	1	0	0	1	1	1	1	3	3.25	2.5	4.857143	4.5	3.7619047		1	2.55	2.375	0.25	3.142857	4.5	1.2119048	0.875	2.25	1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD464XBQ
2081	8976	NDAR_INVZD464XBQ	1352			M	5800	EndofPhase2	3	Phase 2	88	0	1	0	0	0	0	0	6	3	0	2	2	2	3	3	1	2	4	9	1	3	4	2	2	6	3	5	4	0	1	0	1	1	0	0	0	1	1	1	4	3	3	1	0	0	0	0	0	0	0	1	2	2	2	2	1	30	0		0		0		0		1	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	2.625	1.75	3	4.5	2.9			2.55	2.375	0.25	3.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZD464XBQ
2081	8976	NDAR_INVZE002CN1	2104			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	2	0	2	1	2	1	1	3	0	9	0	0	2	3	4	3	2	6	6	1	0	1	1	1	1	1	1	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	0	1	20	0		0		0		1	10	0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	1	5	1	1	3	2.5	1.9	1		1.9	1	1	3	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZE002CN1
2081	8976	NDAR_INVZF004WP5	2273			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	1	0	5	4	2	4	2	4	6	2	4	6	3	6	3	5	1	6	6	2	2	2	3	0	0	1	0	1	1	1	1	1	3	1	2	2	1	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	1	4	3.625	4.75	3.7142856	2	3.7142856	1		3.7142856	3.625	4.75	3.7142856	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF004WP5
2081	8976	NDAR_INVZF004WP5	2273			M	1600	Visit6	6	Phase 1/1A	182	0	0	1	0	0	1	0	4	4	3	4	3	4	5	0	5	4	5	1	5	4	0	4	5	3	1	3	5	0	1	0	0	1	0	0	1	2	1	1	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	1	0	0	0	0	0	0	1	1	1	1	6	3.375	3.75	3.7142856	2	3.4285715			3.7142856	3.625	4.75	3.7142856	2	-0.2857143	-0.25	-1	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF004WP5
2081	8976	NDAR_INVZF004WP5	2273			M	5200	EndofPhase1_1a	12	Phase 1/1A	323	0	0	0	0	0	1	0	4	5	4	4	4	6	4	1	6	4	5	6	3	3	0	6	6	3	2	2	2	1	0	1	0	1	0	1	1	3		1	3	1	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	6	4	5.25	3.142857	2.5	3.8095238		1	3.7142856	3.625	4.75	3.7142856	2	0.0952381	0.375	0.5	-0.5714286	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF004WP5
2081	8976	NDAR_INVZF305EDY	2518			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	0	0	0	0	0	2	0	0	3	0	9	3	2	6	2	3	5	2	4	3	1	0	1	1	1	1	1	1	2	1	0	4	4	4	4	1	0	0	0	1	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	0.75	0.75	3.2857144	3.5	1.95	1		1.95	0.75	0.75	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF305EDY
2081	8976	NDAR_INVZF305EDY	2518			F	1600	Visit6	6	Phase 1/1A	174	0	0	0	0	0	0	1	4	0	0	0	2	0	0	0	0	2	0	9	2	0	0	4	0	5	3	3	4	1	1	1	1	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	5	0.75	0.5	1.8571428	4	1.45			1.95	0.75	0.75	3.2857144	3.5	-0.5	0	-0.25	-1.4285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF305EDY
2081	8976	NDAR_INVZF305EDY	2518			F	5200	EndofPhase1_1a	12	Phase 1/1A	348	0	0	0	0	0	0	1	6	0	0	0	0	0	2	0	0	0	0	9	2	2	0	0	3	4	2	4	4	1	0	1	1	1	0	0	0	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	3	1	0	2.142857	3	1.45		1	1.95	0.75	0.75	3.2857144	3.5	-0.5	0.25	-0.75	-1.1428572	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF305EDY
2081	8976	NDAR_INVZF330CXA	2522			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	5	1	1	2	3	2	2	1	3	3	2	9	4	3	1	2	3	3	3	4	4	1	1	1	0	1	1	1	1	1	1	0	4	3	3	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	6	2.125	2	3	3	2.6	1		2.6	2.125	2	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF330CXA
2081	8976	NDAR_INVZF330CXA	2522			F	5200	EndofPhase1_1a	3	Phase 1/1A	85	0	0	0	1	0	0	0	5	2	2	4	3	2	3	1	3	3	3	3	4	3	1	2	3	3	2	3	5	0	0	1	0	1	1	1	1	1	1	0	4	2	3	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.75	3	3	2.5	2.857143		1	2.6	2.125	2	3	3	0.25714287	0.625	1	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF330CXA
2081	8976	NDAR_INVZF330CXA	2522			F	5800	EndofPhase2	4	Phase 2	113	0	0	0	1	0	0	0	4	1	2	2	2	2	2	1	3	3	3	3	3	1	1	2	3	3	1	4	3	0	0	1	0	1	1	1	1	1	2	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2	3	2.4285715	2	2.3333333			2.6	2.125	2	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZF330CXA
2081	8976	NDAR_INVZG053MM6	1009			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	2	2	2	5	4	3	3	1	2	4	9	5	2	4	1	3	5	3	4	4	0	0	1	0	1	1	0	1	1	1	1	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	3.375	1.75	3.2857144	4	3.25	1		3.25	3.375	1.75	3.2857144	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG053MM6
2081	8976	NDAR_INVZG053MM6	1009			M	1600	Visit6	6	Phase 1/1A	172	0	0	1	0	0	0	0	2	0	1	2	4	3	3	2	1	1	3	9	4	2	4	1	3	5	4	4	4	1	0	1	0	1	1	0	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	1	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	2.125	1.25	3.142857	4.5	2.65			3.25	3.375	1.75	3.2857144	4	-0.6	-1.25	-0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG053MM6
2081	8976	NDAR_INVZG053MM6	1009			M	5200	EndofPhase1_1a	8	Phase 1/1A	219	0	0	1	0	0	0	0	2	1	2	2	4	2	2	2	3	2	4	6	3	3	2	4	4	4	4	2	2	0	0	0	0	1	1	0	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	2.125	3.75	2.857143	4	2.857143		1	3.25	3.375	1.75	3.2857144	4	-0.39285713	-1.25	2	-0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG053MM6
2081	8976	NDAR_INVZG288UA6	2003			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	1	4	3	2	4	1	2	2	1	2	1	9	2	3	3	4	1	2	2	5	4	1	0	0	0	1	1	1	1	3		1	2	3	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	4	2.375	1	3.142857	2	2.45	1		2.45	2.375	1	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG288UA6
2081	8976	NDAR_INVZG288UA6	2003			M	1600	Visit6	6	Phase 2	169	0	0	0	0	0	1	0	0	2	2	1	2	2	2	1	1	2	3	9	2	4	2	3	1	2	2	3	5	0	0	0	0	1	1	1	1	3		0	4	4	3	4	1	0	0	0	0	0	1	0	1	0	0	0	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	5	1.5	1.5	2.857143	2	2.1			2.45	2.375	1	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG288UA6
2081	8976	NDAR_INVZG288UA6	2003			M	2800	Visit12	12	Phase 2	359	0	0	0	0	0	1	0	2	2	4	3	2	3	4	2	1	0	3	9	1	4	2	5	5	3	2	3	4	0	0	2	0	1	1	2	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	1	0	0	0	1	1	0	0	5	2.75	1	3.4285715	2.5	2.75			2.45	2.375	1	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG288UA6
2081	8976	NDAR_INVZG288UA6	2003			M	4000	Visit18	18	Phase 2	547	0	0	0	0	0	1	0	3	1	3	2	3	2	3	2	1	2	2	9	2	3	3	4	1	3	3	3	5	1	0	0	1	1	1	2	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	1.25	3	3	2.55			2.45	2.375	1	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG288UA6
2081	8976	NDAR_INVZG288UA6	2003			M	5200	EndofPhase1_1a	4	Phase 1/1A	121	0	0	0	0	0	1	0	1	1	4	1	0	1	1	0	1	1	3	9	3	2	2	3	1	1	0	3	4	0	0	2	0	1	1	1	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	0	0	0	0		0		0		1	12	1	18	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	1.125	1.25	2.5714285	0.5	1.65		1	2.45	2.375	1	3.142857	2	-0.8	-1.25	0.25	-0.5714286	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG288UA6
2081	8976	NDAR_INVZG288UA6	2003			M	5800	EndofPhase2	19	Phase 2	575	0	0	0	0	0	1	0	3	1	3	2	3	2	3	2	1	2	2	9	2	3	3	4	1	3	3	3	5	1	0	0	1	1	1	2	1	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.375	1.25	3	3	2.55			2.45	2.375	1	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZG288UA6
2081	8976	NDAR_INVZH401DX1	2804			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	3	1	1	2	2	2	0	0	2	1	9	2	2	3	4	3	3	3	3	4	1	0	1	1	1	1	0	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	1.875	0.75	3	3	2.25	1		2.25	1.875	0.75	3	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH401DX1
2081	8976	NDAR_INVZH401DX1	2804			M	1600	Visit6	6	Phase 1/1A	172	0	0	1	0	0	0	0	0	0	2	2	2	2	2	2	4	0	0	6	2	2	2	2	2	2	2	6	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	0		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	6	1.5	2.5	3.142857	2	2.2857144			2.25	1.875	0.75	3	3	0.035714287	-0.375	1.75	0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH401DX1
2081	8976	NDAR_INVZH401DX1	2804			M	2800	Visit12	12	Phase 1/1A	347	0	0	0	0	1	0	0	4	1	1	0	0	0	0	1	0	0	0	9	0	0	0	3	0	4	2	2	3	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	0.875	0	1.1428572	3	1.05			2.25	1.875	0.75	3	3	-1.2	-1	-0.75	-1.8571428	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH401DX1
2081	8976	NDAR_INVZH401DX1	2804			M	5200	EndofPhase1_1a	18	Phase 1/1A	512	0	0	0	0	1	0	0	6	0	0	0	3	0	0	0	0	0	1	9	0	2	2	3	1	3	2	3	1	1	1	1	0	1	0	1	1	2	1	0	4	2	4	4	1	0	0	1	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	1	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.125	0.25	1.7142857	2.5	1.35		1	2.25	1.875	0.75	3	3	-0.9	-0.75	-0.5	-1.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH401DX1
2081	8976	NDAR_INVZH488YFD	1330			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	3	4	4	4	5	4	1	0	0	9	2	4	4	6	2	4	3	5	5	1	1	0	0	1	0	1	0	2	2	1	2	1	4	1	1	0	1	0	0	0	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4.25	0.25	4	3.5	3.5	1		3.5	4.25	0.25	4	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH488YFD
2081	8976	NDAR_INVZH488YFD	1330			M	5200	EndofPhase1_1a	3	Phase 1/1A	86	0	0	0	0	0	1	0	5	4	2	5	6	4	3	2	1	1	1	9	1	3	3	4	3	4	3	3	5	1	1	1	0	1	1	0	1	2	2	1	3	2	2	3	1	0	0	0	0	1	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	1	0	0	1	1	1	1	4	3.875	0.75	3.142857	3.5	3.15		1	3.5	4.25	0.25	4	3.5	-0.35	-0.375	0.5	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH488YFD
2081	8976	NDAR_INVZH723BZD	2470			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	2	3	2	2	2	6	0	4	5	5	6	5	6	4	4	2	4	2	4	6	1	1	2	0	1	1	1	1	3	2	1	3	4	4	4	1	0	0	1	0	0	0	0	1	0	0	2	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	2.375	5	4.428571	3	3.6190476	1		3.6190476	2.375	5	4.428571	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH723BZD
2081	8976	NDAR_INVZH818ULC	2455			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	6	6	6	6	6	4	0	1	2	2	9	5	6	6	6	1	5	4	6	6	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	0	1	1	0	0	4	5	1.25	5.142857	4.5	4.5	1		4.5	5	1.25	5.142857	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH818ULC
2081	8976	NDAR_INVZH818ULC	2455			M	1600	Visit6	6	Phase 1/1A	169	0	1	0	0	0	0	0	6	6	2	6	6	6	6	6	5	6	5	6	6	6	6	6	6	6	4	6	6	1	1	1	1	1	0	1	1	1	2	1	2	1	1	1	1	1	0	0	0	1	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	1	5	5.5	5.5	6	5	5.6190476			4.5	5	1.25	5.142857	4.5	1.1190476	0.5	4.25	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH818ULC
2081	8976	NDAR_INVZH818ULC	2455			M	2800	Visit12	12	Phase 1/1A	337	0	1	0	0	1	0	0	6	2	6	5	4	6	6	6	6	6	6	6	6	6	6	6	6	6	5	6	6	1	1	2	1	1	1	2	1	1	1	1	2	3	1	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	5.125	6	6	5.5	5.6190476			4.5	5	1.25	5.142857	4.5	1.1190476	0.125	4.75	0.85714287	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH818ULC
2081	8976	NDAR_INVZH818ULC	2455			M	5200	EndofPhase1_1a	18	Phase 1/1A	509	0	1	0	0	0	0	0	6	6	1	6	6	6	4	4	6	6	6	6	6	6	6	6	6	5	5	6	6	1	1	1	0	1	1	1	1	1	2	1	2	2	1	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	2	4.875	6	6	5	5.4761906		1	4.5	5	1.25	5.142857	4.5	0.97619045	-0.125	4.75	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZH818ULC
2081	8976	NDAR_INVZJ340TPB	2185			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	2	4	4	4	2	2	4	4	0	0	0	9	2	4	2	2	6	3	2	4	5	1	1	2	0	1	1	1	2	3	1	1	4	2	3	1	0	0	0	0	0	0	0	0					1	19	0		0		1	11	0		0	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	4	3.25	0	3.5714285	2.5	2.8	1		2.8	3.25	0	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ340TPB
2081	8976	NDAR_INVZJ340TPB	2185			F	1600	Visit6	6	Phase 2	169	0	0	0	0	0	0	1	9	0	2	4	3	1	4	3	0	3	1	9	4	6	6	6	6	4	4	6	6	1	1	1	1	1	1	1	1	2	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	1	0	0	0	0	1	1	6	2.4285715	1	5.714286	4	3.631579			2.8	3.25	0	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ340TPB
2081	8976	NDAR_INVZJ340TPB	2185			F	2800	Visit12	12	Phase 3	337	0	0	0	1	0	0	0	6	0	0	2	2	0	2	0	6	6	6	6	4	2	4	4	4	5	4	6	5	1	0	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	1.5	6	4.142857	4.5	3.5238094			2.8	3.25	0	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ340TPB
2081	8976	NDAR_INVZJ340TPB	2185			F	5200	EndofPhase1_1a	4	Phase 1/1A	113	0	0	0	0	0	1	0	0	0	1	2	0	0	2	2	2	3	1	9	4	4	0	4	4	4	3	6	4	1	1	2	0	1	1	0	2	2	1	0	4	4	2	4	1	0	0	0	0	0	1	0	1	1	0	0	1	30	0		0		0		0		0	0	2	0	0	0	0	1	0	0	0	0	1	0	1	1	5	0.875	1.5	3.7142856	3.5	2.3		1	2.8	3.25	0	3.5714285	2.5	-0.5	-2.375	1.5	0.14285715	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ340TPB
2081	8976	NDAR_INVZJ340TPB	2185			F	5800	EndofPhase2	11	Phase 2	303	0	0	0	1	0	0	0	6	0	0	0	2	2	6	0	6	2	1	4	3	2	3	6	4	5	3	5	6	1	1	1	1	1	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	5	2	3.25	4.142857	4	3.142857			2.8	3.25	0	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ340TPB
2081	8976	NDAR_INVZJ340TPB	2185			F	6000	EndofPhase3	18	Phase 3	505	0	0	0	1	0	0	0	2	0	0	1	1	2	2	0	0	0	0	9	2	2	0	2	3	5	2	5	4	1	0	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	1	1	5	1	0	2.5714285	3.5	1.65			2.8	3.25	0	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ340TPB
2081	8976	NDAR_INVZJ551UCZ	2508			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	2	3	0	1	0	1	0	0	0	1	9	2	2	1	4	2	6	4	3	5	1	1	1	0	0	1	1	1	2	2	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0		0	0	0	0	1	1	1	1	5	1	0.25	2.7142856	5	1.9473684	1		1.9473684	1	0.25	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ551UCZ
2081	8976	NDAR_INVZJ551UCZ	2508			M	1600	Visit6	6	Phase 1/1A	169	0	0	0	0	0	0	1	9	2	3	1	1	1	1	0	0	0	1	9	2	2	1	3	2	6	4	3	4	1	1	1	1	0	1	1	1	2	2	0	4	2	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.2857143	0.25	2.4285715	5	1.9473684			1.9473684	1	0.25	2.7142856	5	0	0.2857143	0	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ551UCZ
2081	8976	NDAR_INVZJ551UCZ	2508			M	2800	Visit12	12	Phase 2	345	0	0	0	0	0	0	1	9	2	0	0	2	0	2	0	2	4	1	9	2	2	3	6	3	6	4	6	6	1	1	1	2	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	0.85714287	1.75	4	5	2.6842105			1.9473684	1	0.25	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ551UCZ
2081	8976	NDAR_INVZJ551UCZ	2508			M	4000	Visit18	18	Phase 2	506	0	0	0	0	0	0	1	5	3	3	2	2	2	3	2	1	2	1	9	2	2	5	5	1	6	3	4	5	1	1	1	0	1	0	0	1	3	1	1	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.75	1	3.4285715	4.5	2.95			1.9473684	1	0.25	2.7142856	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ551UCZ
2081	8976	NDAR_INVZJ551UCZ	2508			M	5200	EndofPhase1_1a	8	Phase 1/1A	245	0	0	0	0	0	0	1	4	0	0	0	2	0	2	0	4	4	4	4	3	4	5	4	5	6	6	5	6	1	1	1	1	1	1	1	1	2	2	0	4	4	4	4	1	0	0	1	0	0	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1	4	4.571429	6	3.2380953		1	1.9473684	1	0.25	2.7142856	5	1.2907268	0	3.75	1.8571428	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ551UCZ
2081	8976	NDAR_INVZJ890VAE	1818			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	6	6	2	2	2	5	2	3	3	9	2	4	1	3	2	4	4	4	5	0	1	1	1	1	1	1	1	3		1	4	2	2	2	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	7	3.857143	2	3	4	3.368421	1		3.368421	3.857143	2	3	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ890VAE
2081	8976	NDAR_INVZJ890VAE	1818			M	5200	EndofPhase1_1a	1	Phase 1/1A	69	0	0	0	0	0	0	1	4	6	4	6	4	5	4	5	2	2	4	9	2	2	3	4	0	5	4	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	1	1	0	0		1	30	0		0		0		0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	1	7	4.75	2	3	4.5	3.8		1	3.368421	3.857143	2	3	4	0.43157893	0.89285713	0	0	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZJ890VAE
2081	8976	NDAR_INVZK240HUH	2764			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	5	3	3	1	4	2	4	1	5	5	3	3	3	4	6	6	6	6	2	5	6	1	0	1	0	1	0	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	11	0		0		1	19	0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	2.875	4	5.142857	4	3.952381	1		3.952381	2.875	4	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK240HUH
2081	8976	NDAR_INVZK240HUH	2764			F	1600	Visit6	6	Phase 2	147	0	0	0	0	0	0	1	5	3	3	1	4	2	4	1	5	5	3	3	3	4	6	6	6	6	3	5	6	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	2.875	4	5.142857	4.5	4			3.952381	2.875	4	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK240HUH
2081	8976	NDAR_INVZK240HUH	2764			F	2800	Visit12	12	Phase 2	315	0	0	0	0	0	0	1	5	3	3	1	3	3	5	3	6	5	4	6	3	4	4	6	6	6	2	5	6	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3.25	5.25	4.857143	4	4.2380953			3.952381	2.875	4	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK240HUH
2081	8976	NDAR_INVZK240HUH	2764			F	5200	EndofPhase1_1a	5	Phase 1/1A	111	0	0	0	0	0	0	1	5	2	3	2	4	3	4	1	6	5	5	6	3	5	3	5	5	6	2	5	6	1	0	1	0	1	1	1	1	3		1	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	3	5.5	4.571429	4	4.095238		1	3.952381	2.875	4	5.142857	4	0.14285715	0.125	1.5	-0.5714286	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK240HUH
2081	8976	NDAR_INVZK240HUH	2764			F	5800	EndofPhase2	18	Phase 2	490	0	0	0	0	0	0	1	5	1	0	1	1	0	1	0	6	5	2	5	3	6	0	4	6	6	3	5	4	1	1	1	0	1	1	1	1	3		0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	6	1.125	4.5	4	4.5	3.047619			3.952381	2.875	4	5.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK240HUH
2081	8976	NDAR_INVZK633ZJJ	1760			F	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	3	2	3	2	3	5	4	0	0	0	9	0	2	0	4	0	2	4	2	2	1	1	0	0	1	1	1	1	1	1	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.5	0	1.4285715	3	2.2	1		2.2	3.5	0	1.4285715	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK633ZJJ
2081	8976	NDAR_INVZK633ZJJ	1760			F	1600	Visit6	6	Phase 1/1A	184	1	0	0	0	0	0	0	6	6	1	4	4	6	6	2	1	2	1	9	3	3	1	2	2	2	2	4	4	0	0	1	1	1	1	0	1	1	1	1	3	4	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	3	4.375	1	2.7142856	2	3.1		1	2.2	3.5	0	1.4285715	3	0.9	0.875	1	1.2857143	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK633ZJJ
2081	8976	NDAR_INVZK736AJ2	2097			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	4	4	4	2	4	2	2	0	0	0	9	0	1	1	0	2	3	2	2	4	1	0	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	0	5	3.5	0	1.4285715	2.5	2.15	1		2.15	3.5	0	1.4285715	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK736AJ2
2081	8976	NDAR_INVZK736AJ2	2097			M	1600	Visit6	6	Phase 1/1A	174	1	0	0	0	0	0	0	6	4	4	5	4	4	5	3	2	5	5	9	3	4	4	4	4	5	4	5	4	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	1	7	4.375	3	4	4.5	4.2			2.15	3.5	0	1.4285715	2.5	2.05	0.875	3	2.5714285	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK736AJ2
2081	8976	NDAR_INVZK736AJ2	2097			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	6	5	5	6	5	4	5	3	4	5	5	4	4	5	4	5	4	6	5	5	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	7	4.875	4.5	4.571429	5.5	4.7619047			2.15	3.5	0	1.4285715	2.5	2.6119049	1.375	4.5	3.142857	3																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK736AJ2
2081	8976	NDAR_INVZK736AJ2	2097			M	4000	Visit18	18	Phase 1/1A	495	1	0	0	0	0	0	0	6	5	4	4	6	5	5	0	4	4	5	6	5	4	5	5	5	6	6	4	4	1	0	1	1	1	1	1	1	1	1	1	3	2	2	3	1	0	1	0	0	0	0	0	0	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4.375	4.75	4.571429	6	4.6666665		1	2.15	3.5	0	1.4285715	2.5	2.5166667	0.875	4.75	3.142857	3.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK736AJ2
2081	8976	NDAR_INVZK741LAD	1206			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	6	4	4	2	2	2	4	2	0	0	0	9	2	2	6	4	4	6	4	6	4	1	1	1	1	1	1	1	1	1	1	1	2	3	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	7	3.25	0	4	5	3.2	1		3.2	3.25	0	4	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK741LAD
2081	8976	NDAR_INVZK857MGR	2801			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	2	2	2	2	2	3	3	1	1	0	9	2	3	3	4	2	5	2	4	5	1	0	1	0	1	1	1	1	3	2	1	4	2	3	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	1	1	0	0	1	3	2.5	0.5	3.2857144	3.5	2.6	1		2.6	2.5	0.5	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK857MGR
2081	8976	NDAR_INVZK857MGR	2801			M	2800	Visit12	12	Phase 3	344	0	1	0	0	0	0	0	4	2	2	2	3	2	3	4	1	2	1	9	2	2	2	4	2	5	3	5	5	1	0	0	1	1	1	0	1	2	1	1	3	2	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	2.75	1	3.142857	4	2.8			2.6	2.5	0.5	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK857MGR
2081	8976	NDAR_INVZK857MGR	2801			M	5200	EndofPhase1_1a	4	Phase 1/1A	92	0	0	1	0	0	0	0	4	4	3	3	3	3	3	2	2	1	0	9	3	2	4	3	2	5	3	5	5	1	0	0	1	1	1	1	0	2	2	1	3	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	3.125	0.75	3.4285715	4	3		1	2.6	2.5	0.5	3.2857144	3.5	0.4	0.625	0.25	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK857MGR
2081	8976	NDAR_INVZK857MGR	2801			M	5800	EndofPhase2	6	Phase 2	148	0	1	0	0	0	0	0	4	4	2	3	3	2	3	4	2	2	0	9	3	2	4	4	2	5	2	5	5	1	0	1	0	1	1	1	1	3	1	1	2	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	3.125	1	3.5714285	3.5	3.05			2.6	2.5	0.5	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK857MGR
2081	8976	NDAR_INVZK857MGR	2801			M	6000	EndofPhase3	18	Phase 3	505	0	1	0	0	0	0	0	4	1	2	3	3	2	3	3	6	3	3	2	3	3	4	4	3	5	2	5	5	1	0	1	0	1	1	1	0	2	1	1	4	3	4	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4	2.625	3.5	3.857143	3.5	3.2857144			2.6	2.5	0.5	3.2857144	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZK857MGR
2081	8976	NDAR_INVZL037CT6	2890			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	2	1	1	2	1	2	1	3	1	0	1	9	2	2	0	3	2	1	1	2	0	1	0	1	0	1	1	1	1	2	2	0	4	4	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		1	5	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	4	1.625	0.5	1.5714285	1	1.4	1		1.4	1.625	0.5	1.5714285	1																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZL037CT6
2081	8976	NDAR_INVZL222KFD	2428			M	400	Baseline	0	Pre-Rand	1	1	1	0	0	0	0	0	3	1	2	2	4	2	3	4	1	1	2	9	3	3	2	3	3	6	5	5	5	1	0	1	1	1	1	0	1	3	1	1	3	2	3	1	1	1	1	0	0	0	0	0	0	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	4	2.625	1	3.4285715	5.5	3	1		3	2.625	1	3.4285715	5.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZL222KFD
2081	8976	NDAR_INVZL222KFD	2428			M	5200	EndofPhase1_1a	2	Phase 1/1A	39	1	1	0	0	0	0	0	5	2	2	2	4	4	3	3	2	2	2	9	4	2	2	2	0	5	5	1	1	1	1	1	1	0	1	1	1	1	2	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	3.125	1.5	1.7142857	5	2.65		1	3	2.625	1	3.4285715	5.5	-0.35	0.5	0.5	-1.7142857	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZL222KFD
2081	8976	NDAR_INVZM258APH	2311			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	0	0	0	6	6	6	6	5	6	4	6	2	4	6	9	4	4	4	4	4	6	6	6	6	1	1	1	0	1	1	1	1	1	1	1	3	2	2	4	1	0	0	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	3	5.625	3	4.571429	6	5.05	1		5.05	5.625	3	4.571429	6																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZM258APH
2081	8976	NDAR_INVZM258APH	2311			M	1600	Visit6	6	Phase 1/1A	170	0	1	0	0	0	0	0	6	6	6	2	4	2	4	5	6	6	6	6	6	4	6	5	6	6	4	6	6	1	1	0	0	1	0	0	0	2	1	1	2	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4.375	6	5.571429	5	5.142857			5.05	5.625	3	4.571429	6	0.092857145	-1.25	3	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZM258APH
2081	8976	NDAR_INVZM258APH	2311			M	2800	Visit12	12	Phase 1/1A	337	0	0	1	0	0	0	0	6	6	2	3	5	4	6	6	6	5	6	6	5	4	2	4	5	6	3	6	6	0	1	0	0	1	1	0	0	2	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	5	4.75	5.75	4.571429	4.5	4.857143			5.05	5.625	3	4.571429	6	-0.19285715	-0.875	2.75	0	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZM258APH
2081	8976	NDAR_INVZM258APH	2311			M	5200	EndofPhase1_1a	18	Phase 1/1A	508	0	1	0	0	0	0	0	6	6	6	2	4	2	4	5	6	6	6	6	6	4	6	5	6	6	4	6	6	1	1	0	0	1	0	0	0	2	1	1	2	3	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4.375	6	5.571429	5	5.142857		1	5.05	5.625	3	4.571429	6	0.092857145	-1.25	3	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZM258APH
2081	8976	NDAR_INVZN083WAB	1295			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	0	2	0	0	0	0	0	1	2	1	9	2	2	4	2	2	5	4	4	4	1	1	1	1	1	1	1	1	3	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	5	0.2857143	1	2.857143	4.5	1.8421053	1		1.8421053	0.2857143	1	2.857143	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZN083WAB
2081	8976	NDAR_INVZN083WAB	1295			M	5200	EndofPhase1_1a	3	Phase 1/1A	80	0	0	0	0	0	0	1	9	0	2	0	0	0	0	0	1	2	1	9	2	2	4	2	2	5	4	4	4	1	1	1	0	1	1	1	1	3	2	1	3	2	2	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.2857143	1	2.857143	4.5	1.8421053		1	1.8421053	0.2857143	1	2.857143	4.5	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZN083WAB
2081	8976	NDAR_INVZR336YKJ	2032			M	400	Baseline	0	Pre-Rand	1	0	0	0	1	0	0	0	6	0	0	2	2	0	2	2	4	4	0	4	0	2	2	4	4	5	3	4	2	1	0	1	0	1	1	0	1	1	1	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.75	3	2.5714285	4	2.4761906	1		2.4761906	1.75	3	2.5714285	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR336YKJ
2081	8976	NDAR_INVZR477LH7	2336			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	4	5	5	5	4	5	3	1	3	2	9	2	1	3	4	3	1	2	4	4	1	1	1	1	1	1	1	1	2	2	1	2	2	2	4	1	0	1	0	0	0	0	0	1	1	1	0	1	18	0		0		1	12	0		0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	4	4.625	1.5	3	1.5	3.35	1		3.35	4.625	1.5	3	1.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR477LH7
2081	8976	NDAR_INVZR477LH7	2336			M	1600	Visit6	6	Phase 1/1A	169	1	0	0	0	0	0	0	3	4	4	3	3	3	3	1	0	0	1	9	3	3	3	4	2	4	3	4	5	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3	0.25	3.4285715	3.5	2.8			3.35	4.625	1.5	3	1.5	-0.55	-1.625	-1.25	0.42857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR477LH7
2081	8976	NDAR_INVZR477LH7	2336			M	2800	Visit12	12	Phase 1/1A	338	1	0	0	0	0	0	0	5	4	3	3	3	3	3	2	1	1	3	9	4	3	3	4	4	3	2	3	4	1	1	1	1	1	1	0	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1.25	3.5714285	2.5	3.05			3.35	4.625	1.5	3	1.5	-0.3	-1.375	-0.25	0.5714286	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR477LH7
2081	8976	NDAR_INVZR477LH7	2336			M	5200	EndofPhase1_1a	18	Phase 1/1A	509	1	0	0	0	0	0	0	4	4	4	4	4	4	4	2	2	0	0	9	2	2	3	4	4	4	3	4	4	1	1	1	1	1	1	1	1	1	2	1	3	2	2	4	1	0	1	0	0	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3.75	0.5	3.2857144	3.5	3.1		1	3.35	4.625	1.5	3	1.5	-0.25	-0.875	-1	0.2857143	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR477LH7
2081	8976	NDAR_INVZR518GZB	2176			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	5	6	0	2	2	1	2	3	0	0	1	9	1	3	4	3	4	3	2	5	5	0	0	2	0	1	1	1	0	2	2	1	3	3	3	4	1	1	0	0	0	0	1	0	1	0	1	1	0		1	16	0		1	14	0		0	0	0	0	0	0	0	1	0	1	0	0	1	1	0	0	2	2.625	0.25	3.5714285	2.5	2.6	1		2.6	2.625	0.25	3.5714285	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR518GZB
2081	8976	NDAR_INVZR791ULN	1781			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	3	6	6	5	6	6	4	2	3	3	9	2	4	5	4	2	4	2	6	6	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	5.125	2	4.142857	3	4.2	1		4.2	5.125	2	4.142857	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR791ULN
2081	8976	NDAR_INVZR791ULN	1781			M	1600	Visit6	6	Phase 1/1A	161	1	0	0	0	0	0	0	4	5	2	2	2	0	4	4	0	0	1	9	3	3	2	3	2	2	4	3	3	1	1	1	0	1	1	0	1	1	1	1	2	1	2	1	1	0	1	0	0	0	0	0	1	0	1	0	0		0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.875	0.25	2.7142856	3	2.45			4.2	5.125	2	4.142857	3	-1.75	-2.25	-1.75	-1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR791ULN
2081	8976	NDAR_INVZR791ULN	1781			M	2800	Visit12	12	Phase 1/1A	325	1	0	1	0	1	0	0	5	4	4	2	2	2	3	4	1	2	1	9	3	2	2	6	2	6	4	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	3	2	1	0	1	0	0	0	0	0	1	2	1	2	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.25	1	3.5714285	5	3.25			4.2	5.125	2	4.142857	3	-0.95	-1.875	-1	-0.5714286	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR791ULN
2081	8976	NDAR_INVZR791ULN	1781			M	5200	EndofPhase1_1a	15	Phase 1/1A	396	1	0	1	0	1	0	0	5	5	4	5	2	1	3	3	0	2	1	9		1		6	1	5	4	2	2	1	1	0	0	1	1	1	1	1	3	1	3	2	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	3	3.5	0.75		4.5	2.8888888		1	4.2	5.125	2	4.142857	3	-1.3111111	-1.625	-1.25		1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR791ULN
2081	8976	NDAR_INVZR817KBP	2251			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	5	6	6	5	6	6	6	5	6	4	4	4	1	4	4	5	5	4	4	6	5	1	0	0	0	1	1	0	0	1	1	1	3	2	3	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	5.625	4.5	4.285714	4	4.8095236	1		4.8095236	5.625	4.5	4.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR817KBP
2081	8976	NDAR_INVZR817KBP	2251			M	1600	Visit6	6	Phase 1/1A	177	1	0	0	0	0	0	0	6	5	4	5	4	5	5	4	5	5	5	1	4	5	4	4	5	6	5	5	5	1	1	1	1	1	1	1	1	1	2	1	2	3	2	3	1	1	0	0	1	1	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4.75	4	4.571429	5.5	4.6190476			4.8095236	5.625	4.5	4.285714	4	-0.1904762	-0.875	-0.5	0.2857143	1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR817KBP
2081	8976	NDAR_INVZR817KBP	2251			M	2800	Visit12	12	Phase 1/1A	341	1	0	0	0	0	0	0	4	6	4	3	4	5	3	6	3	2	2	2	1	2	1	4	4	5	4	2	4	1	1	1	0	1	0	0	1	1	1	1	2	2	2	4	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	4.375	2.25	2.5714285	4.5	3.3809524			4.8095236	5.625	4.5	4.285714	4	-1.4285715	-1.25	-2.25	-1.7142857	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR817KBP
2081	8976	NDAR_INVZR817KBP	2251			M	5200	EndofPhase1_1a	18	Phase 1/1A	509	1	0	0	0	0	0	0	6	6	3	5	5	5	5	4	1	1	1	9	3	3	1	6	1	6	6	5	5	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	0	1	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	4	4.875	0.75	3.4285715	6	3.9		1	4.8095236	5.625	4.5	4.285714	4	-0.9095238	-0.75	-3.75	-0.85714287	2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZR817KBP
2081	8976	NDAR_INVZT470LM3	1625			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	5	0	0	3	2	4	0	0	0	0	9	4	6	6	4	4	5	5	4	3	0	1	0	0	1	1	1	1	2	2	1	4	4	4	4	0	0	0	0	0	0	0	1	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.125	0	4.428571	5	2.9	1		2.9	2.125	0	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT470LM3
2081	8976	NDAR_INVZT470LM3	1625			M	1600	Visit6	6	Phase 1/1A	182	1	0	0	0	0	0	0	3	4	0	0	0	0	2	0	4	4	2	5	3	4	6	4	6	5	4	6	6	1	0	0	0	1	1	0	0	3	1	1	4	4	4	4	0	0	0	0	0	0	0	0					1	15	0		0		1	15	0		1	2	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	1.125	3.75	5	4.5	3.2380953			2.9	2.125	0	4.428571	5	0.33809525	-1	3.75	0.5714286	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT470LM3
2081	8976	NDAR_INVZT470LM3	1625			M	5200	EndofPhase1_1a	9	Phase 1/1A	237	1	0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0	9	1	1	1	2	2	0	0	3	4	2	2	2	2	1	2	2	2	2	2	0	4	3	4	4	1	0	1	0	0	0	0	0	0	0	0	0	0		0		0		1	29	0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	4	0.5	0	2	0	0.9		1	2.9	2.125	0	4.428571	5	-2	-1.625	0	-2.4285715	-5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT470LM3
2081	8976	NDAR_INVZT470LM3	1625			M	5800	EndofPhase2	12	Phase 2	329	0	0	0	0	1	0	0	2	0	0	1	4	1	0	1	0	0	0	9	1	2	3	2	2	3	4	4	1	1	1	0	0	1	0	1	1	2	2	1	4	4	4	4	1	0	1	0	0	0	0	0	1	1	1	1	1	23	0		0		1	7	0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	4	1.125	0	2.142857	3.5	1.55			2.9	2.125	0	4.428571	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT470LM3
2081	8976	NDAR_INVZT810LKK	1100			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	3	3	3	3	1	6	2	1	2	6	9	0	2	2	4	0	3	1	1	4	0	0	0	0	1	1	0	1	3		1	4	4	4	4	1	0	0	0	0	0	1	0	1	1	1	1	0		0		0		0		1	30	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4	2.625	2.25	1.8571428	2	2.35	1		2.35	2.625	2.25	1.8571428	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT810LKK
2081	8976	NDAR_INVZT810LKK	1100			M	5200	EndofPhase1_1a	2	Phase 1/1A	72	0	0	1	0	0	0	0	3	3	3	3	3	2	3	2	1	2	5	9	0	2	2	4	0	2	1	1	4	0	0	0	0	1	1	0	1	3	2	1	3	3	4	4	1	0	0	1	0	0	0	0	1	0	0	0	1	15	1	15	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2.75	2	1.8571428	1.5	2.3		1	2.35	2.625	2.25	1.8571428	2	-0.05	0.125	-0.25	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT810LKK
2081	8976	NDAR_INVZT841FC7	2452			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	5	5	5	5	5	4	5	0	0	0	9	3	3	3	4	3	4	4	5	5	1	0	0	0	1	1	1	0	1	2	1	3	2	2	2	1	0	0	0	1	0	0	0	1	0	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	4	4.875	0	3.7142856	4	3.65	1		3.65	4.875	0	3.7142856	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT841FC7
2081	8976	NDAR_INVZT841FC7	2452			M	1600	Visit6	6	Phase 1/1A	167	0	0	0	0	1	0	0	5	4	4	4	3	5	3	4	1	3	4	9	2	4	2	5	3	3	2	4	4	1	0	1	1	1	1	1	1	1	1	1	3	4	2	3	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	4	2	3.4285715	2.5	3.45			3.65	4.875	0	3.7142856	4	-0.2	-0.875	2	-0.2857143	-1.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT841FC7
2081	8976	NDAR_INVZT841FC7	2452			M	5200	EndofPhase1_1a	12	Phase 1/1A	323	0	0	0	0	1	0	0	4	4	4	2	4	2	4	4	0	3	4	9	2	3	2	4	4	3	3	5	5	1	0	1	0	1	1	0	0	2	2	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	3	3.5	1.75	3.5714285	3	3.3		1	3.65	4.875	0	3.7142856	4	-0.35	-1.375	1.75	-0.14285715	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZT841FC7
2081	8976	NDAR_INVZU124ADY	2295			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	4	4	2	2	3	3	3	1	2	1	3	9	3	2	3	6	4	4	5	5	5	1	1	1	0	1	1	1	2	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	1	4	2.75	1.5	4	4.5	3.25	1		3.25	2.75	1.5	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU124ADY
2081	8976	NDAR_INVZU271LFJ	2790			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	4	0	2	4	3	6	6	1	2	2	9	4	5	1	6	6	4	4	6	6	1	1	1	1	1	1	1	1	2	1	1	3	3	2	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	3.5714285	1.25	4.857143	4	3.7894738	1		3.7894738	3.5714285	1.25	4.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU271LFJ
2081	8976	NDAR_INVZU271LFJ	2790			F	1600	Visit6	6	Phase 1/1A	176	0	1	0	0	0	0	0	6	4	5	2	6	4	6	6	6	4	4	5	4	5	4	6	6	5	2	5	6	1	0	1	0	1	1	1	1	2	3	1	4	3	3	1	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	7	4.875	4.75	5.142857	3.5	4.8095236			3.7894738	3.5714285	1.25	4.857143	4	1.0200502	1.3035715	3.5	0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU271LFJ
2081	8976	NDAR_INVZU271LFJ	2790			F	2800	Visit12	12	Phase 1/1A	343	0	1	0	0	0	0	0	6	3	2	2	2	2	4	4	1	1	5	9	3	4	4	4	2	5	3	6	6	0	0	1	0	1	1	1	1	3	1	1	4	4	4	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	1	4	3.125	1.75	4.142857	4	3.45			3.7894738	3.5714285	1.25	4.857143	4	-0.3394737	-0.44642857	0.5	-0.71428573	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU271LFJ
2081	8976	NDAR_INVZU271LFJ	2790			F	5200	EndofPhase1_1a	17	Phase 1/1A	494	0	1	0	0	0	0	0	5	2	2	2	2	4	5	2	6	4	6	6	1	4	3	4	5	6	2	5	6	0	0	1	0	1	0	1	1	2	2	1	4	3	4	2	1	0	0	1	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3	3	5.5	4	4	3.9047618		1	3.7894738	3.5714285	1.25	4.857143	4	0.11528822	-0.5714286	4.25	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU271LFJ
2081	8976	NDAR_INVZU777BMH	1376			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	9	6	6	6	6	6	6	4	0	0	4	9	0	2	2	5	4	4	3	4	5	1	1	1	0	1	1	1	1	3	3	1	2	1	2	2	1	0	0	0	0	1	0	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	5.714286	1	3.142857	3.5	3.8421052	1		3.8421052	5.714286	1	3.142857	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU777BMH
2081	8976	NDAR_INVZU777BMH	1376			F	1600	Visit6	6	Phase 1/1A	182	0	1	0	0	0	0	0	6	4	1	2	2	2	2	3	1	2	2	9	2	2	2	2	2	2	1	4	2	1	0	1	0	1	0	1	0	2	2	1	2	2	3	1	1	1	0	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2.75	1.25	2.2857144	1.5	2.3		1	3.8421052	5.714286	1	3.142857	3.5	-1.5421053	-2.9642856	0.25	-0.85714287	-2																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU777BMH
2081	8976	NDAR_INVZU996DWF	1614			M	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	6	2	2	2	2	2	6	5	2	2	9	4	6	4	4	3	5	3	4	2	1	0	0	2	1	0	0	1	1	1	0	4	4	3	4	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	3.5	2.25	3.857143	4	3.6	1		3.6	3.5	2.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU996DWF
2081	8976	NDAR_INVZU996DWF	1614			M	1600	Visit6	6	Phase 3	155	0	1	0	1	0	0	0	6	6	2	2	2	2	2	6	5	2	3	9	3	5	3	3	3	4	3	4	2	1	1	0	2	1	0	0	1	1	1	0	4	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4	3.5	2.5	3.2857144	3.5	3.4			3.6	3.5	2.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU996DWF
2081	8976	NDAR_INVZU996DWF	1614			M	5200	EndofPhase1_1a	2	Phase 1/1A	41	0	1	0	1	0	0	0	6	4	1	2	2	2	4	4	4	3	4	6	5	6	6	4	5	3	3	4	4	0	0	1	1	0	1	1	1	1	1	0	4	4	4	4	0	0	0	0	0	0	0	1	0	0	0	0	0		0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	0	4	3.125	4.25	4.857143	3	3.9047618		1	3.6	3.5	2.25	3.857143	4	0.30476192	-0.375	2	1	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU996DWF
2081	8976	NDAR_INVZU996DWF	1614			M	5800	EndofPhase2	3	Phase 2	49	0	1	0	0	0	0	0	6	6	1	2	2	2	1	4	4	2	2	9	4	4	6	5	4	4	3	2	2	1	0	1	1	1	1	1	1	1	1	1	4	4	4	4	1	1	0	0	1	0	0	0	1	1	1	1	1	30	0		0		0		0		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	3	2	3.857143	3.5	3.3			3.6	3.5	2.25	3.857143	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZU996DWF
2081	8976	NDAR_INVZW128RLG	1474			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	4	4	4	6	4	6	6	6	6	6	6	6	6	4	6	6	6	4	6	6	1	1	1	1	1	1	1	1	1	1	1	3	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	4	5	6	5.714286	5	5.428571	1		5.428571	5	6	5.714286	5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW128RLG
2081	8976	NDAR_INVZW128RLG	1474			M	1600	Visit6	6	Phase 1/1A	190	0	1	0	0	0	0	0	6	6	4	3	4	2	3	6	6	4	6	6	4	4	3	4	6	5	5	5	5	1	1	1	0	1	1	1	1	1	1	1	3	2	2	1	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	4.25	5.5	4.428571	5	4.6190476			5.428571	5	6	5.714286	5	-0.8095238	-0.75	-0.5	-1.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW128RLG
2081	8976	NDAR_INVZW128RLG	1474			M	2800	Visit12	12	Phase 1/1A	344	0	1	0	1	0	0	0	6	6	6	6	6	6	6	6	6	6	6	6	6	4	6	6	6	5	5	6	6	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	1	1	0	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	6	6	6	5.714286	5	5.8095236		1	5.428571	5	6	5.714286	5	0.3809524	1	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW128RLG
2081	8976	NDAR_INVZW181KNK	1711			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	4	4	5	4	4	5	4	6	3	3	4	3	5	4	2	3	5	5	3	4	6	1	1	2	1	1	1	1	1	1	2	1	3	2	2	2	0	0	0	0	0	0	0	1	0	0	0	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	4	4.5	3.25	4.142857	4	4.095238	1		4.095238	4.5	3.25	4.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW181KNK
2081	8976	NDAR_INVZW181KNK	1711			M	1600	Visit6	6	Phase 1/1A	168	0	0	0	0	0	0	1	4	2	2	2	2	3	2	2	2	2	4	9	2	2	2	2	4	5	4	4	0	0	1	1	1	1	1	1	1	2	2	1	4	2	3	2	1	0	0	0	0	0	1	0	0	1	0	0	1	30	0		0		0		0		0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	0	5	2.375	2	2.2857144	4.5	2.6			4.095238	4.5	3.25	4.142857	4	-1.4952381	-2.125	-1.25	-1.8571428	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW181KNK
2081	8976	NDAR_INVZW181KNK	1711			M	2800	Visit12	12	Phase 1/1A	340	0	0	0	0	0	0	1	9	3	1	2	4	3	2	6	4	4	4	3	4	5	2	4	6	5	4	5	4	0	0	1	1	1	1	1	1	3	1	1	3	2	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		1	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	6	3	3.75	4.285714	4.5	3.75			4.095238	4.5	3.25	4.142857	4	-0.3452381	-1.5	0.5	0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW181KNK
2081	8976	NDAR_INVZW181KNK	1711			M	5200	EndofPhase1_1a	18	Phase 1/1A	508	0	0	0	0	1	0	0	4	0	1	4	4	2	2	4	4	4	5	5	2	2	2	3	4	4	4	1	3	0	0	1	1	1	1	1	1	2	3	0	4	2	2	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	2.625	4.5	2.4285715	4	3.047619		1	4.095238	4.5	3.25	4.142857	4	-1.0476191	-1.875	1.25	-1.7142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW181KNK
2081	8976	NDAR_INVZW704PKP	2543			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	2	0	0	0	1	2	3	9	0	1	0	1	0	3	1	0	0	0	0	1	0	1	1	0	1	2	2	0	4	2	4	4	1	0	0	0	0	0	1	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	0.25	1.5	0.2857143	2	0.7	1		0.7	0.25	1.5	0.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW704PKP
2081	8976	NDAR_INVZW704PKP	2543			M	2800	Visit12	12	Phase 1B	338	0	0	0	0	0	0	1	2	0	0	0	0	1	1	1	1	2	2	9	2	3	3	2	0	4	1	2	3	1	0	1	0	1	1	0	0	3		0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	0	0	0	4	0.625	1.25	2.142857	2.5	1.5			0.7	0.25	1.5	0.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW704PKP
2081	8976	NDAR_INVZW704PKP	2543			M	5200	EndofPhase1_1a	6	Phase 1/1A	171	0	0	0	0	0	0	1	3	0	0	1	1	1	2	1	1	3	2	9	0	3	0	1	0	3	1	3	3	0	0	1	0	1	0	0	0	2	3	0	4	3	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4	1.125	1.5	1.4285715	2	1.45		1	0.7	0.25	1.5	0.2857143	2	0.75	0.875	0	1.1428572	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW704PKP
2081	8976	NDAR_INVZW704PKP	2543			M	5400	EndofPhase1b	14	Phase 1B	379	0	0	0	0	0	0	1	3	0	0	0	1	1	2	0	0	1	4	9	0	0	0	2	0	3	1	1	2	0	0	1	0	1	0	1	0	2	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	1	0	0	0	1	0	0	0	0	0	1	1	0	0	4	0.875	1.25	0.71428573	2	1.05			0.7	0.25	1.5	0.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW704PKP
2081	8976	NDAR_INVZW704PKP	2543			M	5800	EndofPhase2	18	Phase 2	492	0	0	0	0	0	0	1	1	0	0	1	2	0	1	0	1	3	4	9	0	0	0	1	0	3	2	2	2	1	0	1	0	1	0	0	0	2	3	0	4	2	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	4	0.625	2	0.71428573	2.5	1.15			0.7	0.25	1.5	0.2857143	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZW704PKP
2081	8976	NDAR_INVZX006NX8	1655			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	0	3	3	6	3	3	6	1	2	2	9	4	6	6	6	3	6	2	6	6	0	1	0	0	1	0	0	1	1	1	1	4	4	4	1	1	1	0	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	6	3.75	1.25	5.285714	4	4	1		4	3.75	1.25	5.285714	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX006NX8
2081	8976	NDAR_INVZX006NX8	1655			M	5200	EndofPhase1_1a	8	Phase 1/1A	233	0	1	0	0	0	0	0	6	6	6	4	4	4	4	4	2	2	0	9	2	6	4	4	4	6	4	6	6	1	1	0	0	1	0	1	1	1	1	1	4	2	2	1	1	1	0	0	0	0	0	0	0	1	1	0	1	18	0		0		0		0		0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	5	4.75	1	4.571429	5	4.2		1	4	3.75	1.25	5.285714	4	0.2	1	-0.25	-0.71428573	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX006NX8
2081	8976	NDAR_INVZX111CN3	2314			F	400	Baseline	0	Pre-Rand	1	0	1	0	1	0	0	0	6	0	0	0	2	0	2	2	0	1	1	9	2	2	0	2	2	4	3	0	2	1	0	1	1	1	1	1	1	1	1	1	4	4	4	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	1.5	0.5	1.4285715	3.5	1.55	1		1.55	1.5	0.5	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX111CN3
2081	8976	NDAR_INVZX111CN3	2314			F	1600	Visit6	6	Phase 2	170	0	1	0	1	0	0	0	4	4	2	2	4	0	2	3	1	2	1	9	2	2	3	2	2	4	4	4	4	1	1	1	0	1	1	1	1	1	1	1	4	4	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.625	1	2.7142856	4	2.6			1.55	1.5	0.5	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX111CN3
2081	8976	NDAR_INVZX111CN3	2314			F	5200	EndofPhase1_1a	3	Phase 1/1A	87	0	1	0	1	0	0	0	6	4	2	2	2	1	2	4	0	0	0	9	4	2	2	4	2	3	3	5	4	1	1	1	0	1	1	1	1	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.875	0	3.2857144	3	2.6		1	1.55	1.5	0.5	1.4285715	3.5	1.05	1.375	-0.5	1.8571428	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX111CN3
2081	8976	NDAR_INVZX111CN3	2314			F	5400	EndofPhase1b	4	Phase 1B	113	0	1	0	1	0	0	0	4	4	2	2	2	0	2	4	0	0	0	9	2	0	2	2	0	3	3	4	4	1	1	1	0	1	1	1	1	1	1	1	4	3	3	1	1	1	0	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	2.5	0	2	3	2			1.55	1.5	0.5	1.4285715	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX111CN3
2081	8976	NDAR_INVZX445VNF	2160			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	0	0	4	3	2	2	4	2	1	2	0	9	2	2	3	4	1	5	3	5	5	2	1	1	0	1	1	1	1	3		1	3	4	3	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	2.125	0.75	3.142857	4	2.5	1		2.5	2.125	0.75	3.142857	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX445VNF
2081	8976	NDAR_INVZX445VNF	2160			M	1600	Visit6	6	Phase 1/1A	172	0	0	0	0	0	1	0	4	0	2	2	2	4	5	1	2	1	0	9	2	3	4	1	1	5	2	5	4	1	1	1	0	1	1	1	0	3		1	4	4	4	4	1	0	0	0	0	1	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	3	2.5	0.75	2.857143	3.5	2.5			2.5	2.125	0.75	3.142857	4	0	0.375	0	-0.2857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX445VNF
2081	8976	NDAR_INVZX445VNF	2160			M	2800	Visit12	12	Phase 1/1A	346	0	0	0	0	0	1	0	4	0	2	2	3	3	4	1	1	1	0	9	2	3	2	3	3	5	3	5	5	1	1	1	0	1	1	1	0	3		0	4	3	4	4	1	0	0	0	0	1	0	0	0	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2.375	0.5	3.2857144	4	2.6			2.5	2.125	0.75	3.142857	4	0.1	0.25	-0.25	0.14285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX445VNF
2081	8976	NDAR_INVZX445VNF	2160			M	5200	EndofPhase1_1a	18	Phase 1/1A	534	0	0	0	0	0	1	0	4	5	5	4	5	6	5	1	0	2	1	9	4	3	2	6	4	5	4	4	5	1	1	0	1	1	1	1	0	3		1	3	3	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	4.375	0.75	4	4.5	3.75		1	2.5	2.125	0.75	3.142857	4	1.25	2.25	0	0.85714287	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX445VNF
2081	8976	NDAR_INVZX552JRP	2494			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	3	2	1	1	1	1	1	1	1	2	1	9	1	1	1	1	1	3	2	2	1	0	0	2	2	1	1	2	2	2	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	20	0		0		1	10	0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	3	1.375	1	1.1428572	2.5	1.4	1		1.4	1.375	1	1.1428572	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZX552JRP
2081	8976	NDAR_INVZY528EBG	2301			M	400	Baseline	0	Pre-Rand	1	1	0	0	0	0	0	0	6	0	0	2	2	2	4	2	2	1	1	9	3	3	4	6	1	3	3	5	6	1	1	1	1	1	1	1	1	1	1	1	3	3	2	2	1	0	1	0	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.25	1	4	3	2.8	1		2.8	2.25	1	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY528EBG
2081	8976	NDAR_INVZY528EBG	2301			M	1600	Visit6	6	Phase 2	169	1	0	0	0	0	0	0	6	4	0	5	4	1	5	3	2	3	1	9	3	2	5	6	3	4	4	5	6	0	1	1	1	1	1	1	1	1	2	1	3	3	3	2	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	3.5	1.5	4.285714	4	3.6			2.8	2.25	1	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY528EBG
2081	8976	NDAR_INVZY528EBG	2301			M	5200	EndofPhase1_1a	3	Phase 1/1A	84	1	0	0	0	0	0	0	6	4	0	5	2	1	1	3	2	3	1	9	2	2	5	6	1	4	3	5	6	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.75	1.5	3.857143	3.5	3.1		1	2.8	2.25	1	4	3	0.3	0.5	0.5	-0.14285715	0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY528EBG
2081	8976	NDAR_INVZY528EBG	2301			M	5800	EndofPhase2	12	Phase 2	331	1	0	0	0	0	0	0	6	0	3	2	3	3	4	3	4	5	4	5	4	4	4	5	4	4	4	4	5	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	0	1	0	0	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	3	4.5	4.285714	4	3.8095238			2.8	2.25	1	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY528EBG
2081	8976	NDAR_INVZY528EBG	2301			M	6000	EndofPhase3	18	Phase 3	503	1	0	0	0	0	0	0	5	4	4	4	3	4	5	4	3	3	2	5	4	5	4	6	6	6	5	4	5	1	1	1	1	1	1	1	1	1	1	0	4	1	1	2	1	0	1	0	0	0	0	0	1	0	0	0	1	30	0		0		0		0		0	0	0	0	0	0	1	0	0	0	1	0	1	1	1	1	6	4.125	3.25	4.857143	5.5	4.3333335			2.8	2.25	1	4	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY528EBG
2081	8976	NDAR_INVZY642WFE	1930			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	1	0	0	1	1	2	2	1	0	0	0	9	0	0	0	2	2	3	2	4	4	2	1	1	0	1	1	1	1	3	3	1	4	2	3	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	1.7142857	2.5	1.25	1		1.25	1	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY642WFE
2081	8976	NDAR_INVZY642WFE	1930			M	5200	EndofPhase1_1a	3	Phase 1/1A	112	0	0	0	0	0	1	0	0	0	1	1	1	2	1	2	0	0	0	9	0	2	2	2	4	3	2	2	3	1	0	0	0	1	1	1	1	3	2	0	4	2	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	2.142857	2.5	1.4		1	1.25	1	0	1.7142857	2.5	0.15	0	0	0.42857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY642WFE
2081	8976	NDAR_INVZY642WFE	1930			M	5800	EndofPhase2	5	Phase 2	176	0	0	0	0	0	1	0	1	0	0	1	1	1	1	2	0	0	0	9	1	1	1	1	5	5	3	0	4	1	1	1	0	1	1	1	1	3		0	4	2	4	4	0	0	0	0	0	0	0	0					0		0		0		0		1	30	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	4	0.875	0	1.8571428	4	1.4			1.25	1	0	1.7142857	2.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY642WFE
2081	8976	NDAR_INVZY693LFJ	2259			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	1	0	6	0	4	6	6	6	6	2	0	4	6	9	4	3	6	5	6	3	3	5	6	1	1	0	1	1	0	0	1	3	2	0	4	4	4	4	1	0	1	0	0	0	0	0	1	0	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4.5	2.5	5	3	4.35	1		4.35	4.5	2.5	5	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY693LFJ
2081	8976	NDAR_INVZY693LFJ	2259			M	1600	Visit6	6	Phase 1/1A	183	0	0	0	0	0	1	0	1	3	2	1	1	0	2	1	3	3	5	5	3	3	3	3	5	2	4	4	4	1	1	0	0	1	0	0	0	3		0	4	4	4	4	1	0	0	0	0	0	1	0	0	0	0	1	0		1	30	0		0		0		0	0	0	0	1	0	0	0	0	0	0	0	1	1	1	1	6	1.375	4	3.5714285	3	2.7619047			4.35	4.5	2.5	5	3	-1.5880952	-3.125	1.5	-1.4285715	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY693LFJ
2081	8976	NDAR_INVZY693LFJ	2259			M	2800	Visit12	12	Phase 1/1A	344	0	0	0	0	0	1	0	6	3	2	4	3	3	3	3	5	3	4	9	3	4	3	3	3	2	2	3	4	0	1	0	0	1	0	0	0	3	1	0	4	4	4	4	0	0	0	0	0	0	0	0					0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	3.375	3	3.2857144	2	3.3			4.35	4.5	2.5	5	3	-1.05	-1.125	0.5	-1.7142857	-1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY693LFJ
2081	8976	NDAR_INVZY693LFJ	2259			M	5200	EndofPhase1_1a	15	Phase 1/1A	421	0	0	0	0	0	1	0	6	5	4	5	5	5	5	3	5	3	3	9	3	3	5	5	4	2	4	5	4	0	0	0	0	1	0	0	0	3	1	1	2	3	2	4	1	0	0	0	0	0	1	0	1	1	1	1	0		1	30	0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	4.75	2.75	4.142857	3	4.2		1	4.35	4.5	2.5	5	3	-0.15	0.25	0.25	-0.85714287	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY693LFJ
2081	8976	NDAR_INVZY693LFJ	2259			M	5800	EndofPhase2	18	Phase 2	506	0	0	0	0	0	1	0	3	0	0	0	0	0	1	0	2	2	6	9	0	0	0	0	0	1	4	0	0	1	1	1	1	1	1	0	2	3	1	0	4	4	3	3	1	0	0	0	0	0	1	0	1	0	1	1	0		0		0		1	23	0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	0.5	2.5	0	2.5	0.95			4.35	4.5	2.5	5	3																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY693LFJ
2081	8976	NDAR_INVZY740HGN	2378			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	9	3	0	2	0	1	0	1	1	1	1	0	1	1	1	1	0	0	3		0	4	4	4	4	0	0	0	0	0	0	0	0					0		0		0		1	30	0		0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	3	0.125	0	1.1428572	0.5	0.5	1		0.5	0.125	0	1.1428572	0.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY740HGN
2081	8976	NDAR_INVZY888ZC7	2307			F	400	Baseline	0	Pre-Rand	1	0	0	0	1	1	0	0	6	0	0	0	2	0	2	0	2	2	2	9	0	2	2	2	0	4	4	4	4	1	1	1	0	1	1	0	1	1	3	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.25	1.5	2	4	1.9	1		1.9	1.25	1.5	2	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY888ZC7
2081	8976	NDAR_INVZY888ZC7	2307			F	1600	Visit6	6	Phase 3	195	0	0	0	1	0	0	0	5	0	0	2	2	2	2	0	0	2	3	9	2	2	4	3	2	4	3	4	4	1	1	0	0	1	1	1	1	1	1	0	4	4	4	4	1	0	0	0	1	0	0	0	1	1	0	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	5	1.625	1.25	3	3.5	2.3			1.9	1.25	1.5	2	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY888ZC7
2081	8976	NDAR_INVZY888ZC7	2307			F	2800	Visit12	12	Phase 3	362	0	0	0	0	0	0	1	6	0	2	2	2	2	2	0	0	3	0	9	2	2	3	0	0	4	3	4	6	1	1	1	0	1	1	1	1	1	2	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	4	2	0.75	2.4285715	3.5	2.15			1.9	1.25	1.5	2	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY888ZC7
2081	8976	NDAR_INVZY888ZC7	2307			F	5200	EndofPhase1_1a	1	Phase 1/1A	48	0	0	0	1	1	0	0	6	0	0	0	2	0	2	0	2	2	2	9	0	2	2	2	0	4	4	4	4	1	1	1	0	1	1	0	1	1	3	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.25	1.5	2	4	1.9		1	1.9	1.25	1.5	2	4	0	0	0	0	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY888ZC7
2081	8976	NDAR_INVZY888ZC7	2307			F	5800	EndofPhase2	4	Phase 2	123	0	0	0	1	1	0	0	6	0	0	0	2	0	2	0	2	2	2	9	0	2	2	2	0	4	4	4	4	1	1	1	0	1	1	0	1	1	3	0	4	3	4	4	1	0	0	0	1	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	3	1.25	1.5	2	4	1.9			1.9	1.25	1.5	2	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY888ZC7
2081	8976	NDAR_INVZY888ZC7	2307			F	6000	EndofPhase3	18	Phase 3	573	0	0	0	1	0	0	0	6	0	0	2	2	2	2	0	0	0	0	9	0	2	2	4	2	4	3	4	5	1	0	1	0	1	1	0	1	1	1	0	4	2	4	4	1	0	0	0	1	0	0	0	1	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	5	1.75	0	2.7142856	3.5	2			1.9	1.25	1.5	2	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY888ZC7
2081	8976	NDAR_INVZY901AJ9	1779			M	400	Baseline	0	Pre-Rand	1	0	1	0	0	0	0	0	6	5	4	4	4	5	5	6	3	4	5	6	4	6	2	5	1	4	3	6	6	1	1	1	1	1	1	1	1	1	1	1	2	2	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	4.875	4.5	4.285714	3.5	4.4761906	1		4.4761906	4.875	4.5	4.285714	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY901AJ9
2081	8976	NDAR_INVZY901AJ9	1779			M	1600	Visit6	6	Phase 1/1A	165	0	1	0	0	0	0	0	6	5	3	2	2	4	6	6	5	4	5	4	3	5	3	4	1	5	4	6	6	1	1	1	1	1	1	1	1	1	1	1	4	3	4	1	1	1	0	0	0	0	0	0	1	0	1	1	1	30	0		0		0		0		2	2	0	0	0	0	0	1	0	1	0	0	1	1	1	1	7	4.25	4.5	4	4.5	4.2380953			4.4761906	4.875	4.5	4.285714	3.5	-0.23809524	-0.625	0	-0.2857143	1																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY901AJ9
2081	8976	NDAR_INVZY901AJ9	1779			M	5200	EndofPhase1_1a	12	Phase 1/1A	337	0	1	0	0	0	0	0	6	0	0	2	2	3	4	6	4	4	5	4	4	4	3	4	4	3	3	5	6	0	1	0	0	1	1	1	1	1	1	1	4	3	4	1	1	1	0	0	0	0	0	0	1	1	1	1	1	8	1	20	0		0		1	2	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	6	2.875	4.25	4.285714	3	3.6190476		1	4.4761906	4.875	4.5	4.285714	3.5	-0.85714287	-2	-0.25	0	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZY901AJ9
2081	8976	NDAR_INVZZ168GJJ	2816			F	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	2	2	2	2	2	2	2	0	0	0	1	9	4	2	4	4	4	5	4	4	6	1	1	1	1	1	1	1	1	2	1	0	4	2	3	4	1	0	1	0	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1.75	0.25	4	4.5	2.6	1		2.6	1.75	0.25	4	4.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ168GJJ
2081	8976	NDAR_INVZZ168GJJ	2816			F	5200	EndofPhase1_1a	2	Phase 1/1A	43	0	0	0	0	0	0	1	6	0	2	4	4	4	4	0	0	2	0	9	2	4	4	4	2	5	4	5	5	1	1	1	1	1	1	1	1	2	1	0	4	2	2	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	4	3	0.5	3.7142856	4.5	3.05		1	2.6	1.75	0.25	4	4.5	0.45	1.25	0.25	-0.2857143	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ168GJJ
2081	8976	NDAR_INVZZ241YP6	1636			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	0	0	1	3	4	4	2	2	2	2	2	3	2	3	2	2	2	4	2	2	6	2	2	3	0	1	1	1	1	0	0	1	1	1	1	4	1	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2.625	2.5	2.4285715	4	2.6666667	1		2.6666667	2.625	2.5	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ241YP6
2081	8976	NDAR_INVZZ241YP6	1636			M	1600	Visit6	6	Phase 2	189	0	0	0	0	0	0	1	4	4	6	6	6	2	0	0	0	4	6	9	3	3	6	2	2	5	2	5	6	1	1	1	1	1	1	0	1	1	1	1	3	2	2	4	1	0	0	1	0	0	0	0	2	2	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	1	1	1	3	3.5	2.5	3.857143	3.5	3.6			2.6666667	2.625	2.5	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ241YP6
2081	8976	NDAR_INVZZ241YP6	1636			M	2800	Visit12	12	Phase 2	364	0	0	0	0	0	0	1	6	2	4	4	6	2	2	1	4	3	6	9	3	4	4	4	4	5	4	4	6	1	1	1	1	1	1	1	1	2	1	1	4	2	2	4	1	0	1	1	0	0	0	0	0	0	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	3.25	4.142857	4.5	3.9			2.6666667	2.625	2.5	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ241YP6
2081	8976	NDAR_INVZZ241YP6	1636			M	5200	EndofPhase1_1a	4	Phase 1/1A	122	0	0	0	0	0	0	1	6	0	2	4	4	0	2	0	0	0	2	9	2	3	3	2	2	4	3	4	4	1	1	1	1	1	1	1	1	1	2	0	4	4	4	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	0	0	0	0	0	1	0	1	0	4	2.25	0.5	2.857143	3.5	2.35		1	2.6666667	2.625	2.5	2.4285715	4	-0.31666666	-0.375	-2	0.42857143	-0.5																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ241YP6
2081	8976	NDAR_INVZZ241YP6	1636			M	5800	EndofPhase2	16	Phase 2	487	1	0	1	0	0	0	0	6	2	2	4	6	2	4	1	4	6	6	4	4	2	4	3	3	5	4	4	5	1	1	1	1	1	1	1	1	1	1	0	4	4	2	4	1	0	1	1	0	0	0	0	1	1	1	0	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.375	5	3.5714285	4.5	3.857143			2.6666667	2.625	2.5	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ241YP6
2081	8976	NDAR_INVZZ241YP6	1636			M	6000	EndofPhase3	18	Phase 3	546	1	0	1	0	0	0	0	6	4	4	4	6	0	3	1	0	4	6	9	3	3	4	3	2	5	4	4	6	1	1	0	1	1	1	0	1	1	1	1	4	4	2	4	1	0	1	1	0	0	0	0	1	1	1	1	1	30	0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	2.5	3.5714285	4.5	3.6			2.6666667	2.625	2.5	2.4285715	4																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ241YP6
2081	8976	NDAR_INVZZ243NW0	2745			M	400	Baseline	0	Pre-Rand	1	0	0	0	0	1	0	0	5	3	3	4	5	4	4	0	3	2	3	3	3	3	2	2	1	3	4	3	4	1	1	1	1	1	1	1	1	1	2	1	4	2	2	4	1	0	1	0	0	0	0	0	0	0	0	0	1		0		0		0		0		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	4	3.5	2.75	2.5714285	3.5	3.047619	1		3.047619	3.5	2.75	2.5714285	3.5																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ243NW0
2081	8976	NDAR_INVZZ292CU2	1165			M	400	Baseline	0	Pre-Rand	1	0	0	1	0	1	0	0	5	2	0	0	2	0	2	0	0	0	0	9	0	6	4	6	2	3	1	2	2	0	0	0	0	0	1	0	1	1	2	0		4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.375	0	3.142857	2	1.85	1		1.85	1.375	0	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ292CU2
2081	8976	NDAR_INVZZ292CU2	1165			M	2800	Visit12	12	Phase 3	342	0	0	1	0	1	0	0	4	1	0	0	2	0	1	0	0	0	0	9	0	0	2	3	0	3	1	2	3	0	0	0	0	0	1	0	1	1	1	0	4	4	4	4	1	0	0	1	0	0	0	0	0	1	1	0	1	30	0		0		0		0		2	2	2	0	0	0	0	1	0	0	0	0	1	1	1	1	5	1	0	1.4285715	2	1.1			1.85	1.375	0	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ292CU2
2081	8976	NDAR_INVZZ292CU2	1165			M	4000	Visit18	18	Phase 3	505	0	0	1	0	0	0	0	5	0	0	0	4	1	3	0	0	0	1	9	1	2	2	4	0	3	1	3	4	0	0	0	1	0	0	0	0	1	1	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1.625	0.25	2.2857144	2	1.7			1.85	1.375	0	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ292CU2
2081	8976	NDAR_INVZZ292CU2	1165			M	5200	EndofPhase1_1a	3	Phase 1/1A	78	0	0	1	0	0	0	0	3	0	0	0	2	0	0	0	2	2	0	9	0	2	0	2	1	3	1	0	2	0	0	1	0	0	1	0	1	1	3	0	4	4	4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	0.625	1	1	2	1		1	1.85	1.375	0	3.142857	2	-0.85	-0.75	1	-2.142857	0																																																																																																																					Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ292CU2
2081	8976	NDAR_INVZZ292CU2	1165			M	5800	EndofPhase2	6	Phase 2	161	0	0	1	0	0	1	0	3	0	0	0	3	0	2	0	2	1	0	9	0	1	2	3	1	3	1	2	2	0	0	1	0	1	0	0	1	1	3	0	4		4	4	0	0	0	0	0	0	0	0					1	30	0		0		0		0		0	2	0	0	0	0	0	1	0	0	0	0	1	1	1	1	7	1	0.75	1.5714285	2	1.3			1.85	1.375	0	3.142857	2																																																																																																																										Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia	NDAR_INVZZ292CU2
